Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.21.68 - t-Plasminogen activator

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abdominal Abscess
Delayed administration of tissue plasminogen activator reduces intra-abdominal abscess formation.
Effect of recombinant tissue plasminogen activator on intra-abdominal abscess formation in rats with generalized peritonitis.
Gentamycin reduces bacteremia and mortality rates associated with the treatment of experimental peritonitis with recombinant tissue plasminogen activator.
Prevention of intra-abdominal abscesses by fibrinolysis using recombinant tissue plasminogen activator.
Prevention of intra-abdominal abscesses with fibrinolytic agents.
Saline vs Tissue Plasminogen Activator Irrigations after Drain Placement for Appendicitis-Associated Abscess: A Prospective Randomized Trial.
The role of tissue plasminogen activator in the management of complex intra-abdominal abscesses in children.
Tissue-type plasminogen activator prevents formation of intra-abdominal abscesses after surgical treatment of secondary peritonitis in a rat model.
Use of Tissue Plasminogen Activator in Abdominal Abscesses in Children-A Single-Center Randomized Control Trial.
Abortion, Habitual
Aspirin desensitization in a woman with inherited thrombophilia and recurrent miscarriage.
Association between plasminogen activator inhibitor 1 gene mutation and different subgroups of recurrent miscarriage and implantation failure.
Comparison between thrombophilic gene polymorphisms among high risk patients.
Fibrinolytic defects and recurrent miscarriage: a systematic review and meta-analysis.
Genetic factors in fetal growth restriction and miscarriage.
Plasminogen activator inhibitor-1, factor V, factor II and methylenetetrahydrofolate reductase polymorphisms in women with recurrent miscarriage.
Polymorphisms in MTHFR, MTHFD, and PAI-1 and recurrent miscarriage among North Indian women.
Polymorphisms in NOS3, ACE and PAI-1 genes and risk of spontaneous recurrent miscarriage in the Gaza Strip.
Prevalence of coagulation factor XIII and plasminogen activator inhibitor-1 gene polymorphisms among Egyptian women suffering from unexplained primary recurrent miscarriage.
Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis.
Abortion, Spontaneous
Angiotensin-converting enzyme D/I and plasminogen activator inhibitor-1 4G/5G gene polymorphisms are associated with increased risk of spontaneous abortions in polycystic ovarian syndrome.
Association of Plasminogen Activator Inhibitor-1 Gene Polymorphisms and Methylene Tetrahydrofolate Reductase Polymorphisms with Spontaneous Miscarriages.
Comparison of the plasminogen activator inhibitor-1 4G/5G gene polymorphism in females with venous thromboembolism during pregnancy or spontaneous abortion.
Increased Circulating Levels of Tissue-Type Plasminogen Activator Are Associated with the Risk of Spontaneous Abortion During the First Trimester of Pregnancy.
Insulin resistance/hyperinsulinemia and reproductive disorders in infertile women.
Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss.
Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome.
Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome.
Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome.
Plasminogen Activator Inhibitor-1 Polymorphism Confers a Genetic Contribution to the Risk of Recurrent Spontaneous Abortion: An Updated Meta-Analysis.
Polymorphisms of plasminogen activator inhibitor-1, angiotensin converting enzyme and coagulation factor XIII genes in patients with recurrent spontaneous abortion.
The factor V Leiden mutation, high factor VIII, and high plasminogen activator inhibitor activity: etiologies for sporadic miscarriage.
[Association of genetic polymorphisms in plasminogen activator inhibitor-1 gene and 5,10-methylenetetrahydrofolate reductase gene with recurrent early spontaneous abortion]
[Polycystic ovary syndrome and miscarriage].
Abortion, Threatened
[Thrombolytic therapy with rt-PA for thrombosis of tricuspid valve prosthesis during pregnancy]
Abruptio Placentae
Genetic hypofibrinolysis in complicated pregnancies.
Abscess
Adaptive upregulation of Clumping Factor A (ClfA) by S. aureus in the obese, type 2 diabetic host mediates increased virulence.
Both tissue-type plasminogen activator and urokinase prevent intraabdominal abscess formation after surgical treatment of peritonitis in the rat.
Complex abdominal and pelvic abscesses: efficacy of adjunctive tissue-type plasminogen activator for drainage.
Delayed administration of tissue plasminogen activator reduces intra-abdominal abscess formation.
Effect of recombinant tissue plasminogen activator on intra-abdominal abscess formation in rats with generalized peritonitis.
Intracameral recombinant tissue plasminogen activator for refractory glaucoma secondary to a fungal corneal abscess.
Pharmacokinetics of human recombinant tissue-type plasminogen activator, administered intra-abdominally, in a rat peritonitis model.
Plasminogen activator, but not systemic antibiotic therapy, prevents abscess formation in an experimental model of secondary peritonitis.
Prevention of intra-abdominal abscesses by fibrinolysis using recombinant tissue plasminogen activator.
Randomized prospective comparison of alteplase versus saline solution for the percutaneous treatment of loculated abdominopelvic abscesses.
Saline vs Tissue Plasminogen Activator Irrigations after Drain Placement for Appendicitis-Associated Abscess: A Prospective Randomized Trial.
Successful intracavitary tissue plasminogen activator treatment of gastrocnemius intramuscular hematoma in a patient following anticoagulant therapy with warfarin: case report.
Timing and dose of tissue plasminogen activator to prevent abscess formation after surgical treatment of secondary peritonitis in the rat.
Tissue plasminogen activator for the treatment of intraabdominal abscesses in a neonate.
Tissue plasminogen activator in the percutaneous drainage of splenic abscess.
Tissue plasminogen activator reverses the deleterious effect of infection on colonic wound healing.
Tissue-type plasminogen activator prevents abscess formation but does not affect healing of bowel anastomoses and laparotomy wounds in rats with secondary peritonitis.
Tissue-type plasminogen activator prevents formation of intra-abdominal abscesses after surgical treatment of secondary peritonitis in a rat model.
[The immune and fibrinolytic potentials of patients with a postpneumonic lung abscess from the viewpoints of systemic-regional correlations]
Acanthamoeba Keratitis
Effect of immunization with the mannose-induced Acanthamoeba protein and Acanthamoeba plasminogen activator in mitigating Acanthamoeba keratitis.
Protease-activated receptor 2 (PAR2) is upregulated by Acanthamoeba plasminogen activator (aPA) and induces proinflammatory cytokine in human corneal epithelial cells.
Acantholysis
A possible mechanism for phenol-induced pemphigus.
Characterization of keratinocyte plasminogen activator inhibitors and demonstration of the prevention of pemphigus IgG-induced acantholysis by a purified plasminogen activator inhibitor.
Dexamethasone inhibits plasminogen activator activity in experimental pemphigus in vivo but does not block acantholysis.
Imbalance between plasminogen activator and its inhibitors in thiol-induced acantholysis.
Involvement of urokinase-type plasminogen activator in acantholysis induced by pemphigus IgG.
Pemphigus can be induced by topical phenol as well as by foods and drugs that contain phenols or thiols.
Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice.
Penicillamine-induced pemphigus. Immunoglobulin from this patient induces plasminogen activator synthesis by human epidermal cells in culture: mechanism for acantholysis in pemphigus.
Pharmacologic evidence for involvement of phospholipase C in pemphigus IgG-induced inositol 1,4,5-trisphosphate generation, intracellular calcium increase, and plasminogen activator secretion in DJM-1 cells, a squamous cell carcinoma line.
Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis.
Role of plasminogen activator in pemphigus vulgaris.
Vesiculobullous mucocutaneous disease: pemphigus vulgaris.
Acanthosis Nigricans
Cardiometabolic risk among African American women: a pilot study.
Acidosis
Alleviation of methyl isocyanate-induced airway obstruction and mortality by tissue plasminogen activator.
Effect of acidosis on expression of mesothelial cell plasminogen activator inhibitor type-1.
Effects of hypoxia and acidosis on vascular plasminogen activator release in the pig ear perfusion system.
Effects of phorbol ester on contraction, intracellular pH and intracellular Ca2+ in isolated mammalian ventricular myocytes.
Model of trauma-induced coagulopathy including hemodilution, fibrinolysis, acidosis, and hypothermia: Impact on blood coagulation and platelet function.
Prospective evaluation of tissue plasminogen activator in 11 cats with arterial thromboembolism.
Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans.
Recombinant tissue-type plasminogen activator-evoked hyperfibrinolysis is enhanced by acidosis and inhibited by hypothermia but still can be blocked by tranexamic acid.
Should thrombolysis be contraindicated in patients with cerebral arteriovenous malformations?
Toxicological review and oral risk assessment of terephthalic acid (TPA) and its esters: A category approach.
Acidosis, Lactic
Tissue Plasminogen Activator Prevents Mortality from Sulfur Mustard Analog-Induced Airway Obstruction.
Acquired Immunodeficiency Syndrome
Digital necrosis in acquired immune deficiency syndrome vasculopathy treated with recombinant tissue plasminogen activator.
Early Recanalization With Alteplase in Stroke Because of Large Vessel Occlusion in the ESCAPE Trial.
Endothelial cell dysfunction in HIV infection.
Management of a large organized intraatrial catheter-tip thrombus in a child with acquired immunodeficiency syndrome using escalating tissue plasminogen activator infusions.
Plasminogen activator inhibitor-1 aids nerve growth factor-induced differentiation and survival of pheochromocytoma cells by activating both the extracellular signal-regulated kinase and c-Jun pathways.
Plasminogen activator inhibitor-1 aids survival of neurites on neurons derived from pheochromocytoma (PC-12) cells.
Production of plasminogen activator and plasminogen activator inhibitors by alveolar macrophages in control subjects and AIDS patients.
Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulence.
Synthesis, spectroscopic and nonlinear optical properties of multiple [60]fullerene-oligo(p-phenylene ethynylene) hybrids.
Visual Aids for Patient, Family, and Physician Decision Making About Endovascular Thrombectomy for Acute Ischemic Stroke.
[Clinical effects of PSK on esophageal and gastric cancer patients and usefulness of serum levels of glycoproteins and HLA antigens as prognostic indicators]
Acromegaly
Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.
[Treatment of acromegaly. Results in 56 patients]
Activated Protein C Resistance
Alteration of haemostasis in non-metastatic gastric cancer.
Atherogenic, hemostatic, and other potential risk markers in subjects with previous isolated myocardial infarction compared with long-standing uncomplicated stable angina.
Changes in coagulation and fibrinolysis of post-SARS osteonecrosis in a Chinese population.
Coagulation activation after laparoscopic cholecystectomy in spite of thromboembolism prophylaxis.
Coexistence of preeclampsia and inherited thrombophilia in Turkish pregnant women.
Comparison of the effects of two low fat diets with different alpha-linolenic:linoleic acid ratios on coagulation and fibrinolysis.
Effects of vaginally administered high estradiol doses on hormonal pharmacokinetics and hemostasis in postmenopausal women.
Haemocoagulative modifications correlated with pregnancy.
Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17?-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study.
Influence of inherited and acquired thrombophilic defects on the clinical manifestations of mixed cryoglobulinaemia.
Normalization of haemoglobin concentration with recombinant erythropoietin has minimal effect on blood haemostasis.
Plasma resistance to activated protein C regulates the activation of coagulation induced by thrombolysis in patients with ischaemic heart disease.
Prevalence of hypercoagulable disorders in inflammatory bowel disease.
Primary thrombophilia in Mexico III: A prospective study of the sticky platelet syndrome.
Primary thrombophilia in Mexico. V. A comprehensive prospective study indicates that most cases are multifactorial.
Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade.
[Hematological changes and related gene mutation of post-severe acute respiratory syndrome patients with osteonecrosis]
Acute Coronary Syndrome
A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators.
Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
Activated inflammatory cells participate in thrombus size through tissue factor and plasminogen activator inhibitor-1 in acute coronary syndrome: Immunohistochemical analysis.
Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality.
Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction.
Alteplase: descendancy in myocardial infarction, ascendancy in stroke.
Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis.
Conservative management of a large oesophageal haematoma as a complication of systemic thrombolysis.
Defective fibrinolytic states as triggers of myocardial infarction: the cardiologist's view.
Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Substudy. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes.
Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study.
Endothelial tissue-type plasminogen activator release in coronary heart disease: Transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction.
Fibrinogen in relation to degree and composition of coronary plaque on intravascular ultrasound in patients undergoing coronary angiography.
Increased plasminogen activator inhibitor-1 and apolipoprotein (a) in coronary atherectomy specimens in acute coronary syndromes.
Maximal endothelial tissue plasminogen activator release is not impaired in patients with acute coronary syndromes before heparin treatment.
PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting.
Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
Plasminogen activator inhibitor 1 in acute coronary syndromes.
Platelet glycoprotein IIb/IIIa blockade in acute ischemic stroke.
Relationship between myocardial injury and soluble P-selectin in non-ST elevation acute coronary syndromes.
Relationship between tissue type plasminogen activator and coronary vulnerable plaque in patients with acute coronary syndrome: virtual histological study.
Safety and efficacy of tenecteplase versus alteplase in acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes.
The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes.
The potential influence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes.
The Relationship of Plasminogen Activator Inhibitor-1 Levels to the ST Deviation Pattern of Acute Myocardial Infarction.
Therapeutic Implications of a Specific Murine Monoclonal Antibody (7E3) to the Platelet Receptor GPIIb/IIIa.
Thrombus Neutrophil Extracellular Traps Content Impair tPA-Induced Thrombolysis in Acute Ischemic Stroke.
Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: the EPICOR study.
[A study on the reserve capacity of endothelial tissue plasminogen activator in patients with acute coronary syndrome]
[Alteplase in acute coronary syndromes]
[Blood coagulation and fibrinolysis in arteriosclerosis]
[Effect of Puerarin on platelet activating factors CD63 and CD62P, plasminogen activator inhibitor and C-reactive protein in patients with unstable angia pectoris]
[Evolution of fibrinolysis status with D-dimer level and the rate of plasminogen activator inhibitor type-1/D-dimer in acute coronary syndrome patients complicated with impaired glucose tolerance]
[Facilitated revascularisation in myocardial infarction with ST-segment elevation]
[Treatment of acute myocardial infarct with ST segment elevation with a combination of fibrinolytic therapy and abciximab]
[Urokinase-type plasminogen activator and its inhibitor type 1 in the diagnosis of evolving complications in coronary heart disease]
Acute Kidney Injury
Abrogation of plasminogen activator inhibitor-1-vitronectin interaction ameliorates acute kidney injury in murine endotoxemia.
Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats.
Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury*
Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury.
Successful fibrinolytic therapy using tissue plasminogen activator in acute renal failure due to acute thrombosis of bilateral renal arteries.
Transarterial fibrinolysis using tissue plasminogen activator in a patient with acute renal failure due to acute thrombosis of bilateral renal arteries. 3 years' follow-up.
[Massive pulmonary embolism treated with a reduced dose of alteplase in a patient with acute renal failure.]
[Treatment of acute renal insufficiency in intensive care. Current perspectives with TPA and proxazole]
[Type of Thrombolytic Agent and Rate of Acute Kidney Injury in Patients With Myocardial Infarction].
Acute Lung Injury
4G/5G polymorphism of plasminogen activator inhibitor-1 gene is associated with mortality in intensive care unit patients with severe pneumonia.
Aerosolized tissue plasminogen inhibitor improves pulmonary function in sheep with burn and smoke inhalation.
Alveolar epithelial cell plasminogen activator. Characterization and regulation.
Cylindromatosis (CYLD) inhibits Streptococcus pneumonia-induced plasminogen activator inhibitor-1 expression via interacting with TRAF-6.
Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury.
Fusion Expression and Fibrinolytic Activity of rPA/SP-B.
Hyaluronan fragments induce plasminogen activator inhibitor-1 and inhibit urokinase activity in mouse alveolar macrophages: a potential mechanism for impaired fibrinolytic activity in acute lung injury.
Lack of durable protection against cotton smoke-induced acute lung injury in sheep by nebulized single chain urokinase plasminogen activator or tissue plasminogen activator.
Meta-Analysis of Preclinical Studies of Fibrinolytic Therapy for Acute Lung Injury.
Myeloperoxidase instigates proinflammatory responses in a cecal ligation and puncture rat model of sepsis.
Nebulization of Single-Chain Tissue-Type and Single-Chain Urokinase Plasminogen Activator for Treatment of Inhalational Smoke-Induced Acute Lung Injury.
Neither fibrin nor plasminogen activator inhibitor-1 deficiency protects lung function in a mouse model of acute lung injury.
PAI-1 inhibits neutrophil efferocytosis.
Perfluorochemical-facilitated plasminogen activator delivery to the airways: A novel treatment for inhalational smoke-induced acute lung injury.
PLASMA BIOMARKER PROFILES IN ACUTE EXACERBATION OF IDIOPATHIC PULMONARY FIBROSIS.
Plasminogen activator inhibitor type-1 deficiency exaggerates LPS-induced acute lung injury through enhancing Toll-like receptor 4 signaling pathway.
Plasminogen Activator Inhibitor-1 Is Critical in Alcohol-Enhanced Acute Lung Injury in Mice.
Pulmonary net release of tissue-type plasminogen activator during porcine primary and secondary acute lung injury.
Suppression of plasminogen activator inhibitor-1 by inhaled nitric oxide attenuates the adverse effects of hyperoxia in a rat model of acute lung injury.
The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability.
Wood Bark Smoke Induces Lung and Pleural Plasminogen Activator Inhibitor 1 and Stabilizes its mRNA in Porcine Lung Cells.
[Changes of platelet endothelial cell adhesion molecule-1, tissue type plasminogen activator and plasminogen activator inhibitor-1 expression in the lung tissue of neonatal rats after intraperitoneal injection with lipopolysaccharide]
[Effect of hypothermia on TLR2/MyD88 signal pathway in lung tissue in rats with acute lung injury induced by lipopolysaccharide].
Adenocarcinoma
A model system for the in vivo determination of the thrombolytic effect of plasminogen activators.
A two-dimensional model of cell movement. Well differentiated human rectal adenocarcinoma cells move as coherent sheets upon TPA stimulation.
Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
Appearance of plasminogen activator activity during a synchronous cycle of a rat adenocarcinoma cell line, PA-III.
Biological significance of plasminogen activator inhibitor-1 expression in ovarian clear cell adenocarcinoma.
Characterization of epidermal growth factor (EGF) receptor and biological effect of EGF on human uterine cervical adenocarcinoma cell line OMC-4.
Clinical significance of the number of positive tumor markers in assisting the diagnosis of lung cancer with multiple tumor marker assay.
Clinical usefulness of computer-assisted diagnosis using combination assay of tumor markers for pancreatic carcinoma.
Correlation between urokinase-type plasminogen activator production and the metastasizing ability of two murine mammary adenocarcinomas.
Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS.
Detection of cathepsin B, plasminogen activators and plasminogen activator inhibitor in human non-small lung cancer cell lines.
Differential response of premalignant epithelial cell classes to phorbol ester tumor promoters and to deoxycholic acid.
Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
Effects of TNF-alpha and phorbol ester on human surfactant protein and MnSOD gene transcription in vitro.
Efficacy of eight serially measured markers for diagnosis of prostatic carcinoma.
Enhanced plasminogen activator production by highly metastatic variant cell lines of a rat mammary adenocarcinoma.
Establishment and characterization of cell line SFCC from clear cell adenocarcinoma of the uterine cervix.
Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.
Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC).
Expression of tissue-type plasminogen activator, plasminogen activator inhibitor and von Willebrand factor in the supernatant of endothelial cell cultures in response to the seeding of adenocarcinoma cell line HRT-18.
Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue.
Galectin-1 is a novel functional receptor for tissue plasminogen activator in pancreatic cancer.
Helicobacter pylori induces plasminogen activator inhibitor 2 in gastric epithelial cells through nuclear factor-kappaB and RhoA: implications for invasion and apoptosis.
High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma.
Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.
Inhibitory effects of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans retinoic acid on the growth of cultured human pancreas cancer cells and pancreas tumor xenografts in immunodeficient mice.
Investigations of coagulation system and fibrinolysis in patients with disseminated adenocarcinomas and non-Hodgkin's lymphomas.
Involvement of plasminogen activator production with tumor metastasis in a rat model.
Iron-mediated stability of PAI-1 mRNA in adenocarcinoma cells-involvement of a mRNA-binding nuclear protein.
Key contribution of CPEB4-mediated translational control to cancer progression.
Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas.
Modulation of plasminogen activator activity in human endometrial adenocarcinoma cells by basic fibroblast growth factor and transforming growth factor beta.
Modulation of plasminogen activator systems by matrix components in two breast cancer cell lines: MCF-7 and MDA-MB-231.
mRNA expression of adipocytokines and glucocorticoid-related genes are associated with downregulation of E-cadherin mRNA in colorectal adenocarcinomas.
Placental alkaline phosphatase (PLAP)/PLAP-like alkaline phosphatase as tumour marker in relation to CA 125 and TPA for ovarian epithelial tumours.
Plasminogen Activation System in Rectal Adenocarcinoma.
Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma.
Plasminogen Activator Inhibitor Type 1 (PAI-1) A15T Gene Polymorphism Is Associated with Prognosis in Patients with EGFR Mutation Positive Pulmonary Adenocarcinoma.
Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.
Plasminogen activator inhibitors in endometrial adenocarcinoma.
Plasminogen activator profiles in neoplastic tissues of the human colon.
Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
Plasminogen activators in (pre)malignant conditions of the colorectum.
Plasminogen activators in oesophageal carcinoma.
Prediagnostic circulating markers of inflammation and risk of oesophageal adenocarcinoma: a study within the National Cancer Institute Cohort Consortium.
Protein kinase C (PKC) isoenzyme expression pattern as an indicator of proliferative activity in uterine tumor cells.
Purification and characterization of an inhibitor of plasminogen activator released by rat mammary adenocarcinoma cells.
Purification and properties of a plasminogen activator from cultured rat prostate adenocarcinoma cells.
Rapid induction of skin and mammary tumors in human c-Ha-ras proto-oncogene transgenic rats by treatment with 7,12-dimethylbenz[a]anthracene followed by 12-O-tetradecanoylphorbol 13-acetate.
Regulation of thrombin-induced plasminogen activator inhibitor-1 in 4T1 murine breast cancer cells.
Selective loss of TGFbeta Smad-dependent signalling prevents cell cycle arrest and promotes invasion in oesophageal adenocarcinoma cell lines.
Sensitivity of monoclonal antibodies to carcinoembryonic antigen, tissue polypeptide antigen, alpha-fetoprotein, carbohydrate antigen 50, and carbohydrate antigen 19-9 in the diagnosis of colorectal adenocarcinoma.
Serum and tissue levels of CEA, TPA, CA 125 and CA 15.3 in patients with lung cancer.
Serum biomarker panels for the diagnosis of gastric adenocarcinoma.
Sex hormones modulate the synthesis of basic fibroblast growth factor in human endometrial adenocarcinoma cells: implications for the neovascularization of normal and neoplastic endometrium.
Signaling pathways regulating aromatase and cyclooxygenases in normal and malignant breast cells.
Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
Stimulation of CEACAM1 expression by 12-O-tetradecanoylphorbol-13-acetate (TPA) and calcium ionophore A23187 in endometrial carcinoma cells.
Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Tamoxifen exerts oestrogen-agonistic effects on proliferation and plasminogen activation, but not on gelatinase activity, glycogen metabolism and p53 protein expression, in cultures of oestrogen-responsive human endometrial adenocarcinoma cells.
The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells.
The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma.
Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumors and contribution to cancer progression.
Tissue polypeptide antigen--a marker antigen differentiating cholangiolar tumors from other hepatic tumors.
Transcriptional gene expression profiles of oesophageal adenocarcinoma and normal oesophageal tissues.
Tumor markers kinetic in malignant lung neoplasms.
Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.
Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
[Clinical evaluation of combination assay of tumor markers in primary lung cancer patients]
[Fibrinolytic activity and effect of anti-fibrinolytic agents on the growth of cloned cell lines in vitro (author's transl)]
[Serum CA125 and CA19-9 levels in adenocarcinoma of the uterine cervix and endometrial carcinoma]
[Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer]
[Studies on marker substances in cell lines derived from various human gynecologic tumors (author's transl)]
[Tissue polypeptide antigen in serum and tissue in patients with lung cancer]
Adenocarcinoma of Lung
Phorbol ester up-regulates aldose reductase expression in A549 cells: a potential role for aldose reductase in cell cycle modulation.
[Semiquantitative parameters of 18F-FDG PET/CT, gene mutation states of epidermal growth factor receptor and anaplastic lymphoma kinase in prognosis evaluation of patients with lung adenocarcinoma].
[Usefulness of cytosolic tissue-type plasminogen activator levels in lung adenocarcinomas]
Adenocarcinoma, Clear Cell
Biological significance of plasminogen activator inhibitor-1 expression in ovarian clear cell adenocarcinoma.
Establishment and characterization of cell line SFCC from clear cell adenocarcinoma of the uterine cervix.
Adenocarcinoma, Follicular
Increased plasminogen activator and type IV collagenase activity in invasive follicular thyroid carcinoma cells.
Adenocarcinoma, Scirrhous
Correlation between expression of urokinase-type plasminogen activator receptor and metastasis in gastric carcinoma.
Adenoma
12-O-Tetradecanoylphorbol-13-acetate stimulation of DNA synthesis in cultured preneoplastic familial polyposis colonic epithelial cells but not in normal colonic epithelial cells.
A model for human colon carcinoma evolution based on the differential response of cultured preneoplastic, premalignant, and malignant cells to 12-O-tetradecanoylphorbol-13-acetate.
ACTH and phorbol ester stimulated redistribution of protein kinase C in human cortisol-producing adrenal adenoma.
Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas.
Arsenic exposure in utero and nonepidermal proliferative response in adulthood in Tg.AC mice.
Clinical evaluation of serum tissue polypeptide specific antigen in patients with thyroid carcinoma.
Comparative study of plasminogen activator antigens in colonic carcinomas and adenomas.
Detection of the plasmin system in human mammary pathology using immunofluorescence.
Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Growth hormone secretion in human acromegalic pituitary adenomas: cyclic adenosine monophosphate and protein kinase C responses.
In situ stromal expression of the urokinase/plasmin system correlates with epithelial dysplasia in colorectal adenomas.
Phorbol ester, not growth hormone releasing factor, consistently stimulates growth hormone release from somatotroph adenomas in culture.
Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
Rapid induction of skin and mammary tumors in human c-Ha-ras proto-oncogene transgenic rats by treatment with 7,12-dimethylbenz[a]anthracene followed by 12-O-tetradecanoylphorbol 13-acetate.
Role of urokinase in colorectal neoplasia.
The Plasminogen System in Microdissected Colonic Mucosa Distant from an Isolated Adenoma.
Tissue polypeptide antigen (TPA) and prostatic acid phosphatase in serum of prostatic cancer patients.
Tissue polypeptide antigen in thyroid tumours of follicular cell origin: an immunohistochemical re-evaluation for diagnostic purposes.
Tumor-promoter-enhanced destruction of noninvasive human benign colon tumor cells by cocultivated carcinoma cells.
[Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases]
Adenoma, Villous
A model for human colon carcinoma evolution based on the differential response of cultured preneoplastic, premalignant, and malignant cells to 12-O-tetradecanoylphorbol-13-acetate.
Adenomatous Polyposis Coli
Oncogenic potential in fibroblasts from individuals genetically predisposed to cancer.
Adenomatous Polyps
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?
Plasminogen activators in human colorectal neoplasia.
Adenomyosis
Immunoreactivity of Plasminogen Activator Inhibitor 1 and Its Correlation with Dysmenorrhea and Lesional Fibrosis in Adenomyosis.
Adrenocortical Adenoma
Arsenic exposure in utero and nonepidermal proliferative response in adulthood in Tg.AC mice.
Adrenocortical Carcinoma
The steroidogenic acute regulatory protein is induced by angiotensin II and K+ in H295R adrenocortical cells.
Adrenocortical Hyperfunction
Development of a plasminogen activator inhibitor (PAI-1) assay and comparison of plasma PAI-1 activity in hyperlipidemic/dyslipidemic dogs with either hyperadrenocorticism or diabetes mellitus, and healthy dogs.
Aggressive Periodontitis
Evaluation of gingival crevicular fluid levels of tissue plasminogen activator, plasminogen activator inhibitor 2, matrix metalloproteinase-3 and interleukin 1-? in patients with different periodontal diseases.
Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in Turkish patients with generalized aggressive periodontitis.
Short term effects of non-surgical periodontal treatment on gingival crevicular fluid levels of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 2 (PAI-2) in patients with chronic and aggressive periodontitis.
Agranulocytosis
Plasminogen activator and its inhibitor in cancer patients treated with tumor necrosis factor.
Airway Obstruction
Airway tissue plasminogen activator prevents acute mortality due to lethal sulfur mustard inhalation.
Alleviation of methyl isocyanate-induced airway obstruction and mortality by tissue plasminogen activator.
Anaphylactoid reaction to recombinant tissue plasminogen activator.
Management of Plastic Bronchitis With Topical Tissue-type Plasminogen Activator.
PAI-1 gain-of-function genotype, factors increasing PAI-1 levels, and airway obstruction: The GALA II Cohort.
Sulfur mustard inhalation: mechanisms of injury, alteration of coagulation, and fibrinolytic therapy.
Tissue Plasminogen Activator Prevents Mortality from Sulfur Mustard Analog-Induced Airway Obstruction.
[Upper airway obstruction by angioedema following thrombolytic therapy with recombinant tissue plasminogen activator]
Albinism
Characterization of human hairbulb tyrosinase: properties of normal and albino enzyme.
Albuminuria
A PAI-1 mutant retards diabetic nephropathy in db/db mice through protecting podocytes.
Adiponectin retards the progression of diabetic nephropathy in db/db mice by counteracting angiotensin II.
Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.
Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
Apocynin attenuates tubular apoptosis and tubulointerstitial fibrosis in transgenic mice independent of hypertension.
Inhibition of the ERK1/2-mTORC1 axis ameliorates proteinuria and the fibrogenic action of transforming growth factor-? in Adriamycin-induced glomerulosclerosis.
L-arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis.
Low but sustained coagulation activation ameliorates glucose induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy.
Prorenin independently causes hypertension and renal and cardiac fibrosis in cyp1a1-prorenin transgenic rats.
The lost correlation between heat shock protein 70 (HSPA1A) and plasminogen activator inhibitor-1 in patients with type 2 diabetes and albuminuria.
Wnt/?-catenin regulates blood pressure and kidney injury in rats.
Alkalosis
Effects of phorbol ester on contraction, intracellular pH and intracellular Ca2+ in isolated mammalian ventricular myocytes.
Alveolar Bone Loss
Association of gene polymorphisms for plasminogen activators with alveolar bone loss.
Alzheimer Disease
A functional polymorphism within plasminogen activator urokinase (PLAU) is associated with Alzheimer's disease.
A Small Molecule Inhibitor of Plasminogen Activator Inhibitor-1 Reduces Brain Amyloid-? Load and Improves Memory in an Animal Model of Alzheimer's Disease.
Administration of the extra virgin olive oil (EVOO) in mild cognitive impairment (MCI) patients as a therapy for preventing the progress to AD.
Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model.
Analysis of Matrix Metallo-Proteases and the Plasminogen System in Mild Cognitive Impairment and Alzheimer's Disease Cerebrospinal Fluid.
ApoE genotype does not affect plasma tPA and PAI-1 antigen levels.
Association between Plasma Levels of PAI-1, tPA/PAI-1 Molar Ratio, and Mild Cognitive Impairment in Chinese Patients with Type 2 Diabetes Mellitus.
Association between plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and risk of Alzheimer's disease, metabolic syndrome, and female infertility: A meta-analysis.
Beta-amyloidolysis and glutathione in Alzheimer's disease.
Compartment- and context-specific changes in tissue-type plasminogen activator (tPA) activity following brain injury and pharmacological stimulation.
Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer's disease brain.
Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimer's disease.
Microglia express the type 2 plasminogen activator inhibitor in the brain of control subjects and patients with Alzheimer's disease.
Neuroserpin up-regulation in the Alzheimer's disease brain is associated with elevated thyroid hormone receptor-?1 and HuD expression.
Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain.
Plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer's disease.
Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation.
Spousal caregivers of patients with Alzheimer's disease show longitudinal increases in plasma level of tissue-type plasminogen activator antigen.
The Plasminogen Activator Inhibitor 1 4G/5G Polymorphism and the Risk of Alzheimer's Disease.
The possible role of tissue-type plasminogen activator (tPA) and tPA blockers in the pathogenesis and treatment of Alzheimer's disease.
The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration.
Theaflavin digallate inactivates plasminogen activator inhibitor: could tea help in Alzheimer's disease and obesity?
Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy.
Tissue plasminogen activator arrests Alzheimer's disease pathogenesis.
Tissue Plasminogen Activator Expression Is Restricted to Subsets of Excitatory Pyramidal Glutamatergic Neurons.
Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation.
Tissue-type plasminogen activator-mediated plasminogen activation and contact activation, implications in and beyond haemostasis.
tPA deficiency underlies neurovascular coupling dysfunction by amyloid-?.
Amaurosis Fugax
Cerebral hemorrhage after systemic fibrinolysis in a patient with severe carotid artery stenosis.
Amnesia
Acute ischemic stroke as a complication of Stanford type A acute aortic dissection: a review and proposed clinical recommendations for urgent diagnosis.
Amyloidosis
Hemostasis associated with abnormalities of fibrinolysis.
Identification of fibronectin type I domains as amyloid-binding modules on tissue-type plasminogen activator and three homologs.
Plasminogen activator in nephrotic syndrome.
Plasminogen activator inhibitor-1 gene polymorphism in Iranian Azeri Turkish patients with FMF disease and its association with amyloidosis.
Soluble interleukin 2 receptor and tissue polypeptide antigen serum concentrations in end-stage renal failure.
Tissue-type plasminogen activator-mediated plasminogen activation and contact activation, implications in and beyond haemostasis.
[Fibrinolytic activity of the urine during chronic glomerulonephritis and amyloidosis]
[Urokinase as a blood and urine plasminogen activator in chronic glomerulonephritis and amyloidosis]
Amyotrophic Lateral Sclerosis
Collagenase activity in skin fibroblasts of patients with amyotrophic lateral sclerosis.
The urokinase system of plasminogen activator plays a role in amyotrophic lateral sclerosis (ALS) pathogenesis.
Anaphylaxis
A patient with anaphylaxis after alteplase infusion.
A rapid and strong increase of plasminogen activator induced by experimental anaphylaxis in rabbits.
Acute allergic reaction due to the administration of fibrinolytic therapy for ST-segment elevation myocardial infarction: case report and discussion.
Acute myocardial infarction following intravenous tissue plasminogen activator for acute ischemic stroke: An unknown danger.
Anaphylactoid reaction after injection of alteplase.
Anaphylactoid reaction during an infusion of recombinant tissue-type plasminogen activator for acute myocardial infarction.
Anaphylactoid reaction to recombinant tissue plasminogen activator.
Anaphylactoid reactions and angioedema during alteplase treatment of acute ischemic stroke.
Anaphylaxis with tissue plasminogen activator: case report and literature review.
Angioedema: A Life-threatening Complication of Tissue Plasminogen Activator.
Aspirin desensitization in a woman with inherited thrombophilia and recurrent miscarriage.
Evidence of anaphylaxy after alteplase infusion.
Hypersensitivity reactions associated with recombinant tissue-type plasminogen activator and urokinase.
Incidence of orolingual angioedema after intravenous thrombolysis for stroke.
Isolated tongue angioedema after alteplase infusion in acute ischemic stroke.
Life-Threatening Anaphylactoid Reaction in an Acute Ischemic Stroke Patient With Intravenous rt-PA Thrombolysis, Followed by Successful Intra-Arterial Thrombolysis.
Life-threatening anaphylactoid shock caused by recombinant tissue plasminogen activator.
Myocardial infarction following t-PA for acute stroke.
[Anaphylactoid reaction during administration of tissue plasminogen activator (t-PA)]
[Angioneurotic orolingual edema associated with the use of rt-PA following a stroke.]
Anemia
Acute renal failure in African children with Burkitt's lymphoma: A comparison of two treatment regimens.
Acute-phase response and the hypercoagulable state in pulmonary tuberculosis.
Catheter-directed thrombolysis in inflammatory bowel diseases: report of a case.
Current approaches to glycoprotein analysis.
Defective release of tissue plasminogen activator in patients with sickle cell anemia.
Hemostatic changes in active pulmonary tuberculosis.
Prognostic Impact of Baseline Hemoglobin Levels on Long-Term Thrombotic and Bleeding Events After Percutaneous Coronary Interventions.
Regulation of tissue plasminogen activator in sickle cell anemia.
Successful drainage of complex haemoserous malignant pleural effusion with a single modified low-dose intrapleural alteplase and dornase alfa.
The Hemostatic Changes in Active Pulmonary Tuberculosis.
Treatment of post-traumatic trabecular mashwork thrombosis and secondary glaucoma with intracameral tissue plasminogen activator in previously unrecognized sickle cell anemia.
[Thrombolysis with rt-PA in children with arterial and venous thromboses--a new therapy concept]
Anemia, Aplastic
Effect of cyclosporin A on T cell clones from severe aplastic anemia: differential sensitivity of TNF and GM-CSF production.
Properties of urokinase type-plasminogen activator found in chest fluid.
Anemia, Hemolytic, Autoimmune
Plasma levels of endothelial-derived haemostatic factors in autoimmune thrombocytopenia and haemolytic anaemia.
Anemia, Sickle Cell
Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke: Findings From Get With The Guidelines-Stroke.
Defective release of tissue plasminogen activator in patients with sickle cell anemia.
Paracentral Acute Middle Maculopathy as a Presenting Sign of CRAO in Sickle Cell Disease Treated with Tissue Plasminogen Activator.
Peroxisome proliferator-activated receptor-?-mediated transcription of miR-301a and miR-454 and their host gene SKA2 regulates endothelin-1 and PAI-1 expression in sickle cell disease.
Placenta growth factor (PlGF), a novel inducer of plasminogen activator inhibitor-1 (PAI-1) in sickle cell disease (SCD).
Regulation of tissue plasminogen activator in sickle cell anemia.
The role of hypercoagulability in the development of osteonecrosis of the femoral head.
Tissue type plasminogen activator antigen and activity in sickle cell disease.
Treatment of post-traumatic trabecular mashwork thrombosis and secondary glaucoma with intracameral tissue plasminogen activator in previously unrecognized sickle cell anemia.
[Thrombolysis with rt-PA in children with arterial and venous thromboses--a new therapy concept]
Aneurysm
A case of intra-arterial thrombolysis with alteplase in a patient with hypothenar hammer syndrome but without underlying aneurysm.
A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm.
Abnormal levels of urokinase plasminogen activator protein and tissue plasminogen activator activity in human aortic aneurysms.
Acute haemorrhagic stroke.
Acute Thromboembolic Ischemic Stroke From Complex Aortic Arch Plaque.
Adjunctive therapies in the cath lab. Successful thrombolysis using the combination of tissue plasminogen activator and abciximab in an adult with Kawasaki's disease.
Aneurysms at a temporopolar artery origin from the internal carotid artery: report of two cases.
Aortic stent graft leak and aneurysm rupture after alteplase for stroke.
Cohort study of intraventricular thrombolysis with recombinant tissue plasminogen activator for aneurysmal intraventricular hemorrhage.
Failure of intracisternal tissue plasminogen activator to prevent vasospasm in certain patients with aneurysmal subarachnoid hemorrhage.
Fibrillins 1 and 2 perform partially overlapping functions during aortic development.
Gamma knife surgery-induced aneurysm rupture associated with tissue plasminogen activator injection: A case report and literature review.
Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation, and atherosclerosis.
Genetic studies on the role of proteinases and growth factors in atherosclerosis and aneurysm formation.
Influence of intraoperative using of recombinant tissue plasminogen activator on the development of cerebral angiospasm after subarachnoid haemorrhage in patients with ruptured intracranial aneurysms.
Intra-aneurysmal GDC embolization followed by intrathecal tPA administration for poor-grade basilar tip aneurysm.
Intracisternal recombinant tissue plasminogen activator after aneurysmal subarachnoid hemorrhage.
Intracisternal rt-PA during early surgery for aneurysmal subarachnoid hemorrhage: an Italian report.
Intraluminal thrombus enhances proteolysis in abdominal aortic aneurysms.
Intraventricular hemorrhage after aneurysmal subarachnoid hemorrhage: pilot study of treatment with intraventricular tissue plasminogen activator.
Intraventricular hemorrhage secondary to intranidal aneurysm rupture-successful management by arteriovenous malformation embolization followed by intraventricular tissue plasminogen activator: case report.
Intraventricular Hemorrhage Secondary to Intranidal Aneurysm Rupture: Successful management by AVM embolization followed by intraventricular tPA: Case Report.
Phlegmasia cerulea dolens secondary to an aortoiliac aneurysm.
Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1.
Recanalization of previously thrombosed type II endoleak with aneurysm sac expansion after systemic thrombolysis.
Relationship of genetic factors with development of aortic dissection and aneurysm.
Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis evaluation in transgenic animals.
Ruptured saccular aneurysm of distal vertebral artery fenestration managed with Guglielmi detachable coils and intraventricular tissue plasminogen activator.
Safety of tissue plasminogen activator factor in an acute stroke patient with two unruptured cerebral aneurysms.
Stent retriever thrombectomy with aneurysm in target vessel: Technical note.
Successful Thrombolysis despite Having an Incidental Unruptured Cerebral Aneurysm.
The risk of intravenous thrombolysis-induced intracranial hemorrhage in Taiwanese patients with unruptured intracranial aneurysm.
The safety of intravenous thrombolysis for ischemic stroke in patients with pre-existing cerebral aneurysms: a case series and review of the literature.
Thrombolysis for intraventricular hemorrhage after endovascular aneurysmal coiling.
Transpalpebral approach for microsurgical clipping of an unruptured basilar apex aneurysm: case report and literature review.
Treatment of intraventricular hemorrhage with tissue plasminogen activator.
Use of intraventricular tissue plasminogen activator and Guglielmi detachable coiling for the acute treatment of casted ventricles from cerebral aneurysm hemorrhage: two technical case reports.
Vascular aneurysms: a perspective.
[An autopsy case of a ruptured cerebral aneurysm treated with interlocking detachable coils]
[Cerebrovascular malformation revealed during the prethrombolysis workup in acute ischemic stroke. Impact on therapeutic decision making.]
[Comparative assessment of efficacy of tissue plasminogen activator and streptokinase in the treatment of patients with acute myocardial infarction]
[Effects of urokinase type plasminogen activator and plasminogen activator inhibitor-1 expressions on the formation of aneurysm of perimembranous ventricular septal defect].
[Hemostatic factors of endothelial origin in major vascular pathology]
[Radiological interventional procedures for the acute abdomen]
[The diagnosis and treatment of traumatic optic nerve neuropathy combined with carotid artery injury].
Aneurysm, Dissecting
Acute ischemic stroke as a complication of Stanford type A acute aortic dissection: a review and proposed clinical recommendations for urgent diagnosis.
Acute ischemic stroke what is hidden behind?
Acute Thromboembolic Ischemic Stroke From Complex Aortic Arch Plaque.
Administration of recombinant tissue plasminogen activator to a case of cerebral infarction in the setting of painless aortic dissection.
Aortic dissection diagnosed on stroke computed tomography protocol: a case report.
Carotid Artery Dissection and Ischemic Stroke Originating from Localized Aortic Arch Dissection.
Carotid Ultrasonography Can Identify Stroke Patients Ineligible for Intravenous Thrombolysis Therapy due to Acute Aortic Dissection.
Catastrophic Secondary Infarctions with Onset Seizure Following Tissue Plasminogen Activator Therapy.
Full-Dose Thrombolysis for a Right Middle Cerebral Artery Stroke after an Acute Aortic Dissection.
Hyper-acute stroke patients associated with aortic dissection.
Intravenous recombinant tissue plasminogen activator thrombolysis in a patient with acute ischemic stroke secondary to aortic dissection.
Intravenous Thrombolysis in an Elderly Patient With Acute Ischemic Stroke Masking Aortic Dissection.
Intravenous tPA in the treatment of acute stroke related to aortic dissection.
Relationship of genetic factors with development of aortic dissection and aneurysm.
Stroke secondary to aortic dissection treated with a thrombolytic: a successful case.
Stroke treatment with tissue plasminogen activator in the setting of aortic dissection.
Successful Delayed Aortic Surgery for a Patient with Ischemic Stroke Secondary to Aortic Dissection.
Successful Tissue Plasminogen Activator for a Patient with Stroke After Stanford Type A Aortic Dissection Treatment.
Successful treatment of ischemic stroke associated with brachiocephalic artery stenosis using alteplase.
Thrombolytic therapy in a patient with acute ischemic stroke caused by aortic dissection.
Usefulness of Fibrinogen/Fibrin Degradation Products Value in Differential Diagnosis Between Acute Ischemic Stroke and Acute Aortic Dissection.
[A case of brain infarction and thoracic aortic dissection without chest nor back pain diagnosed by carotid duplex ultrasonography]
Aneurysm, False
Pseudoaneurysm after transpedal arterial access for evaluation and treatment of peripheral arterial disease.
Pseudoaneurysm of the inferior gluteal artery: an unusual complication after abdominoperineal resection for rectal cancer. Report of a case.
Surgical treatment achieves better outcome in severe traumatic pericallosal aneurysm: case report and literature review.
Aneurysm, Ruptured
Aneurysms at a temporopolar artery origin from the internal carotid artery: report of two cases.
Early treatment of subarachnoid hemorrhage after preventing rerupture of an aneurysm.
Fibrinolytic treatment of intraventricular haemorrhage preceding surgical repair of ruptured aneurysms and arteriovenous malformations.
Tissue plasminogen activator levels after single intracisternal injection in patients with subarachnoid hemorrhage.
Angina Pectoris
Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-I levels in acute myocardial infarction.
Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis.
Increased plasminogen activator inhibitor activity and diabetes predict subsequent coronary events in patients with angina pectoris.
Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris.
Levels of plasminogen activator inhibitor in patients with angina pectoris.
Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response.
Plasminogen activator inhibitor 1 in thrombotic disease.
Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.
Plasminogen activator inhibitor-1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis.
Residual coronary stenoses and calculated transstenotic gradients after intravenous streptokinase versus tissue plasminogen activator.
Tissue plasminogen activator and leucocyte elastase as predictors of cardiovascular events in subjects with angina pectoris: Edinburgh Artery Study.
Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris.
[Study on early fibrinolytic therapy to avoid acute myocardial infarction]
[Tissue plasminogen activator, its inhibitor and other factors of the blood fibrinolytic system in stable coronary heart disease]
Angina, Stable
Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina.
Circulating thrombotic and haemostatic components in patients with coronary artery disease.
Early changes in local hemostasis activation following percutaneous coronary intervention in stable angina patients: a comparison between drug-eluting and bare metal stents.
Effect of ACE inhibition on the fibrinolytic system in patients requiring coronary artery bypass grafting.
Evidence for reduced fibrinolytic activity in unstable angina at rest. Clinical, biochemical, and angiographic correlates.
Fibrinogen in relation to degree and composition of coronary plaque on intravascular ultrasound in patients undergoing coronary angiography.
Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina.
Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris.
Levels of haemostatic factors, arteriosclerosis and cardiovascular disease.
Plasma soluble P-selectin in acute myocardial infarction: effects of coronary recanalization therapy.
Plasma urokinase antigen and C-reactive protein predict angina recurrence after coronary angioplasty.
Pre-existing anticardiolipin antibodies and development of restenosis after coronary balloon angioplasty: predictive value for a complicated course?
Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina.
Thrombosis-related markers in unstable angina pectoris.
Angina, Unstable
A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction.
A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris.
Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.
Antithrombotic agents from salivary glands of hematophagous animals.
Assessment of left ventricular function by isometric handgrip exercise after thrombolysis in patients with refractory unstable angina.
Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patients with stable and unstable angina.
Circulating thrombotic and haemostatic components in patients with coronary artery disease.
Comparison of plasma tissue factor levels in unstable and stable angina pectoris.
Coronary revascularization after intravenous tissue plasminogen activator for unstable angina pectoris: results of a randomized, double-blind, placebo-controlled trial.
Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1).
Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial.
Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina.
Effectiveness of prolonged low dose recombinant tissue-type plasminogen activator for refractory unstable angina.
Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia.
Endothelial function parameters in patients with unstable angina and infection with Helicobacter pylori and Chlamydia pneumoniae.
Endothelial tissue-type plasminogen activator release in coronary heart disease: Transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction.
Evidence for reduced fibrinolytic activity in unstable angina at rest. Clinical, biochemical, and angiographic correlates.
Fibrinolytic activity in coronary heart disease.
Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial).
Importance of thrombosis and thrombolysis in silent ischaemia: comparison of patients with acute myocardial infarction and unstable angina.
Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation.
Intracoronary recombinant tissue-type plasminogen activator in unstable angina: a pilot angiographic study.
Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled, randomized trial.
Lesion-directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty.
One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction.
Overview: rationale of thrombolysis in treating acute myocardial infarction.
Plasma lipoprotein(a) levels and fibrinolytic activity in patients with unstable angina.
Plasma plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary spastic angina.
Plasminogen activator inhibitor type 1 in adults with Down syndrome and protection against macrovascular disease.
Platelet glycoprotein inhibitors in patients with medically managed acute coronary syndrome: does the enthusiasm exceed the science?
Platelet hyperaggregability persists even after the improvement of increased blood coagulation and impaired fibrinolysis with the stabilization of symptoms in patients with unstable angina.
Platelet polymorphisms: Frequency distribution and association with coronary artery disease in an Indian population.
Prediction of event-free survival after hospital discharge in acute myocardial infarction treated with tissue-plasminogen activator.
Preinfarction angina and improved reperfusion of the infarct-related artery.
Prodromal unstable angina in acute myocardial infarction: prognostic value of short- and long-term outcome and predictor of infarct size.
Randomized, double-blind, placebo-controlled trial of tissue plasminogen activator in unstable angina.
Reactive coagulation induced by plasmin in patients treated with recombinant tissue-type plasminogen activator.
Recombinant tissue-type plasminogen activator followed by heparin compared with heparin alone for refractory unstable angina pectoris.
Results of percutaneous transluminal coronary angioplasty in unstable angina and non-Q-wave myocardial infarction. Observations from the TIMI IIIB Trial.
Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes.
t-Plasminogen activator and von Willebrand factor in patients with unstable angina.
Thrombolysis in unstable angina. Randomized double-blind trial of t-PA and placebo.
Thrombosis-related markers in unstable angina pectoris.
Tissue plasminogen activator and plasminogen activator inhibitor-1 levels in patients with acute myocardial infarction and unstable angina.
Tissue plasminogen activator in refractory unstable angina. A randomized double-blind placebo-controlled trial in patients with refractory unstable angina and subsequent angioplasty.
Tissue plasminogen activator using a rapid-infusion low-dose regimen for unstable angina.
Tissue-type plasminogen activator and plasminogen activator inhibitor activities as predictors of adverse events in unstable angina.
Unstable angina and thrombolysis.
[Antithrombin therapy in acute coronary syndromes]
[Dynamic changes in fibrinolytic system in patients with acute myocardial infarction]
[Effect of Puerarin on platelet activating factors CD63 and CD62P, plasminogen activator inhibitor and C-reactive protein in patients with unstable angia pectoris]
[Intravenous thrombolysis by recombinant plasminogen activator (rt-PA) in unstable angina. A randomized multicenter study versus placebo]
[Newly developed stenocardia: effect of intensive physical training on the indicators of the blood coagulation system and fibrinolysis]
[Pathophysiology of acute coronary syndromes]
[Role of the hemostasis in unstable angina pectoris]
[Unstable angina: tissue plasminogen activator, tissue plasminogen activator inhibitors, protein C and other factors of the blood fibrinolytic system]
[Unstable angina: tissue-type plasminogen activator inhibitor and other hemostatic factors in aspirin and intravenous heparin administration]
Angioedema
A Case of Oropharyngeal Angioedema Following Intravenous Recombinant Tissue Plasminogen Activator (rt-PA) and Mechanical Thrombectomy.
A Case Report of Unilateral Orolingual Angioedema Secondary to Alteplase Administration.
A Novel Approach to the Treatment of Orolingual Angioedema After Tissue Plasminogen Activator Administration.
Analysis of related factors of orolingual angioedema after rt-PA intravenous thrombolytic therapy.
Anaphylactoid reaction to recombinant tissue plasminogen activator.
Anaphylactoid reactions and angioedema during alteplase treatment of acute ischemic stroke.
Angioedema after administration of tPA for ischemic stroke: case report.
Angioedema after rt-PA infusion led to airway emergency: a case report of rescue treatment with fresh frozen plasma.
Angioedema after rt-PA treatment in acute ischemic stroke may be attended by shock and worsening of stroke outcome.
Angioedema after thrombolysis with tissue plasminogen activator: an airway emergency.
Angioedema After tPA: What Neurointensivists Should Know.
Angioedema and Hemorrhage After 4.5-Hour tPA (Tissue-Type Plasminogen Activator) Thrombolysis Ameliorated by T541 via Restoring Brain Microvascular Integrity.
Angioedema during therapy with recombinant tissue plasminogen activator.
Angioedema from recombinant TPA administration: case report and pathophysiology review.
Angioedema in Stroke Patients With Thrombolysis.
Angioedema in the neurointerventional suite.
Angioedema Risk Associated With Central Vascular Access Device Declotting.
Angioedema Secondary to IV Tissue Plasminogen Activator Administration for Treatment of Acute Ischemic Stroke.
Angioedema Secondary to tPA Use in Acute Ischemic Stroke Patient with Hypertension: A Case Report.
Angioedema: A Life-threatening Complication of Tissue Plasminogen Activator.
Angioneurotic orolingual oedema following thrombolysis in acute ischaemic stroke.
Asymmetric angioneurotic edema associated with thrombolysis for acute stroke.
Asymmetric oro-facial angioedema following alteplase for acute ischaemic stroke.
Audit report and systematic review of orolingual angioedema in post-acute stroke thrombolysis.
Benign angioedema after thrombolysis for acute stroke.
Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach.
Cardiovascular Instability Preceded by Orolingual Angioedema after Alteplase Treatment.
Complicated orolingual angioedema after recombinant tissue plasminogen activator treatment in stroke patients under angiotensin converting enzyme inhibitor: Report of two cases.
Facial angioedema and stroke.
Gastrointestinal Angioedema as a Side Effect of Alteplase for Acute Stroke.
Hemi Orolingual Angioedema after tPA Administration for Acute Ischemic Stroke.
Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke.
Hemifacial angioedema following alteplase for acute stroke.
Hemilingual Angioedema after Thrombolysis in a Patient on an Angiotensin II Receptor Blocker.
Hypersensitivity reactions associated with recombinant tissue-type plasminogen activator and urokinase.
Icatibant as a Potential Treatment of Life-Threatening Alteplase-Induced Angioedema.
Icatibant for the treatment of orolingual angioedema following the administration of tissue plasminogen activator.
Impact of Bradykinin Generation During Thrombolysis in Ischemic Stroke.
Incidence of orolingual angioedema after intravenous thrombolysis for stroke.
Incidence of urticaria, angioedema, and type I hypersensitivity reactions associated with fibrinolytic agents in Thailand using the database of the health product vigilance center.
Institutional Incidence of Severe tPA-Induced Angioedema in Ischemic Cerebral Vascular Accidents.
Isolated tongue angioedema after alteplase infusion in acute ischemic stroke.
Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke.
Lingual angioedema after alteplase treatment in a patient with acute ischemic stroke.
Lingual angioedema with macroglossia during the treatment of acute ischemic stroke with alteplase.
Onset of Orolingual Angioedema After Treatment of Acute Brain Ischemia with Alteplase Depends on the Site of Brain Ischemia: A Meta-analysis.
Orolingual angiodema associated with alteplase treatment of acute stroke: a reappraisal.
Orolingual angioedema after alteplase therapy of acute ischaemic stroke: incidence and risk of prior angiotensin-converting enzyme inhibitor use.
Orolingual angioedema after thrombolysis is not associated with insular cortex ischemia on pre-thrombolysis CT.
Orolingual Angioedema After Tissue Plasminogen Activator Administration in Patients Taking Angiotensin-Converting Enzyme Inhibitors.
Orolingual angioedema associated with olmesartan use after recombinant tissue plasminogen activator treatment of acute stroke.
Orolingual angioedema to alteplase. Identify, counsel and monitor at risk patients.
Orolingual angioedema with alteplase administration for treatment of acute ischemic stroke.
Orolingual angioneurotic edema following therapy of acute ischemic stroke with alteplase.
Oropharyngeal angioneurotic edema due to recombinant tissue plasminogen activator following massive pulmonary thromboembolism.
Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.
Related factors with orolingual angioedema after intravenous alteplase in acute ischemic stroke: results from a single-center cohort and meta-analysis.
Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic Stroke.
Safety of thrombolysis in acute ischemic stroke: a review of complications, risk factors, and newer technologies.
Select hyperacute complications of ischemic stroke: cerebral edema, hemorrhagic transformation, and orolingual angioedema secondary to intravenous Alteplase.
Tissue Plasminogen Activator-Induced Angioedema Involving a Posterior Cerebral Artery Infarct: A Case Presentation.
Urticaria, angioedema, and type I hypersensitivity reactions associated with fibrinolytic agents.
[Acute orolingual angioedema associated to recombinant human tissue plasminogen activator treatment].
[Angioneuritic edema in ischaemic stroke patients treated with rt-PA].
[Angioneurotic orolingual edema associated with the use of rt-PA following a stroke.]
[Orolingual angioedema as complication after rt-PA in stroke patient treated with ACE inhibitor]
[Orolingual angioedema secondary to alteplase treatment in cases of stroke]
[Orolingual angioedema under systemic thrombolysis with rt-PA: an underestimated side effect]
[Upper airway obstruction by angioedema following thrombolytic therapy with recombinant tissue plasminogen activator]
Angioedemas, Hereditary
Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels.
Angiomyolipoma
Benefit vs. Risk of a Permanent Inferior Vena Cava Filter in Pulmonary Embolism with Anticoagulation Contraindication.
Anhedonia
Increased ratio of mature BDNF to precursor-BDNF in patients with major depressive disorder with severe anhedonia.
Anisocoria
Isolated Anisocoria as a Presenting Stroke Code Symptom is Unlikely to Result in Alteplase Administration.
Secondary hemorrhage after intraventricular fibrinolysis: a cautionary note: a report of two cases.
Ankylosis
Biological activities of phosphocitrate: a potential meniscal protective agent.
Anterior Spinal Artery Syndrome
Anterior spinal artery syndrome, intravenous alteplase or not.
Anterior Wall Myocardial Infarction
Concurrent nitroglycerin administration reduces the efficacy of recombinant tissue-type plasminogen activator in patients with acute anterior wall myocardial infarction.
Concurrent use of reteplase and lepirudin in the treatment of acute anterior wall myocardial infarction.
Demonstration of reperfusion after thrombolysis with technetium-99m isonitrile myocardial imaging.
Fatal Hemoptysis during Coronary Thrombolysis.
Front-loaded infusion therapy of rT-PA during active menstruation. A case report.
Thrombolytic therapy in spontaneous coronary artery dissection.
Anthrax
A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types.
Activation of plasminogen activator inhibitor implicates protease InhA in the acute-phase response to Bacillus anthracis infection.
Antibody-mediated targeting of the urokinase-type plasminogen activator proteolytic function neutralizes fibrinolysis in vivo.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator (rt-PA) therapy for acute cerebral infarction in a patient with ANCA-associated vasculitis.
Intracerebral hemorrhage after IV tPA for stroke as early symptom of ANCA-associated vasculitis.
Antiphospholipid Syndrome
Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients.
Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome.
Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
Elevated plasminogen activator inhibitor type-1 (PAI-1) as contributing factor in pathogenesis of hypercoagulable state in antiphospholipid syndrome.
Genetic polymorphism of murine tissue plasminogen activator associated with antiphospholipid syndrome.
Hereditary and acquired defects in the fibrinolytic system associated with thrombosis.
Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome.
Modulation of fibrinolysis by the combined action of phospholipids and immunoglobulins.
Prevalence of anti-S100A10 antibodies in antiphospholipid syndrome patients.
Recombinant tissue plasminogen activator for the treatment of cutaneous infarctions in antiphospholipid antibody syndrome: a case report.
Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a review and update.
Recurrent miscarriage syndrome due to blood coagulation protein/platelet defects: prevalence, treatment and outcome results. DRW Metroplex Recurrent Miscarriage Syndrome Cooperative Group.
Seronegative antiphospholipid syndrome associated with plasminogen activator inhibitor.
Successful intravenous thrombolysis in a patient with antiphospholipid syndrome, acute ischemic stroke and severe thrombocytopenia.
The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome.
Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome.
[Plasminogen activator inhibitor type 1 gene polymorphism and thromboses in patients with antiphospholipid syndrome].
[Prognostic value of allelic variants affecting the hemostatic system in the development of antiphospholipid syndrome and kidney lesion in patients with systemic lupus erythematosus].
[Recurrent miscarriage and inherited thrombophilia: diagnostic work-out and therapeutic management]
[Thrombocytopenia in patients with systemic lupus erythematosis as a risk factor for thrombotic complications and its connection with severity and the course of the disease, systemic lupus erythematosis]
Antithrombin III Deficiency
Emergency treatment with recombinant tissue plasminogen activator of pulmonary embolism in a pregnant woman with antithrombin III deficiency.
Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations.
Hematological risk factors for coronary heart disease.
Primary hypercoagulable states in general and vascular surgery.
Anuria
Neonatal renal vein thrombosis: Role of anticoagulation and thrombolysis-An institutional review.
Anus Neoplasms
CEA, TPA, CA 19-9, SCC and CYFRA at diagnosis and in the follow-up of anal canal tumors.
Aortic Aneurysm
Abnormal levels of urokinase plasminogen activator protein and tissue plasminogen activator activity in human aortic aneurysms.
Aortic transgraft hemorrhage after intravenous tissue plasminogen activator therapy in patients with acute ischemic stroke.
Hyperglycemia modulates plasminogen activator inhibitor-1 expression and aortic diameter in experimental aortic aneurysm disease.
Increased plasminogen activator inhibitor-1 levels in patients with isolated coronary artery ectasia.
Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1.
Aortic Aneurysm, Abdominal
Abdominal aortic aneurysm surgery: retroperitoneal or transperitoneal approach?
Association of the 4G/5G polymorphism in the promoter region of plasminogen activator inhibitor-1 with abdominal aortic aneurysms.
Elevated tissue plasminogen activator in patients with screening-detected abdominal aortic aneurysm.
Genotype-phenotype relationships in an investigation of the role of proteases in abdominal aortic aneurysm expansion.
High levels of homocysteine, lipoprotein (a) and plasminogen activator inhibitor-1 are present in patients with abdominal aortic aneurysm.
Plasma Tissue Plasminogen Activator and Abdominal Aortic Aneurysm Presence: A Systematic Review and Meta-analysis.
Systemic thrombolytic therapy after recent abdominal aortic aneurysm repair: an absolute contraindication?
The influence of 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene promoter on the incidence, growth and operative risk of abdominal aortic aneurysm.
[Expression of urokiase-type plasminogen activator and matrix metalloproteinases in human tissue of abdominal aortic aneurysm]
Aortic Aneurysm, Thoracic
Rupture of a thoracic aortic aneurysm: a rare adverse reaction following systemic tissue plasminogen activator infusion.
Aortic Valve Stenosis
Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis.
Psoas muscle size as a frailty measure for open and transcatheter aortic valve replacement.
Aphakia
[Tissue plasminogen activator treatment of postvitrectomy pupillary fibrin membrane]
Aphasia
Acute ischemic stroke as a complication of Stanford type A acute aortic dissection: a review and proposed clinical recommendations for urgent diagnosis.
Acute ischemic stroke successfully treated using sequenced intravenous and intra-arterial thrombolysis and argatroban anticoagulation: a case study.
Dissociation of severity of stroke and aphasia recovery early after intravenous recombinant tissue plasminogen activator thrombolysis.
Endovascular treatment of an acute left middle cerebral artery >6 h post stroke in a patient presenting with dysphasia and dense right hemiplegia.
Factitious stroke presenting for acute treatment.
Factors that influence clinicians' decisions to offer intravenous alteplase in acute ischemic stroke patients with uncertain treatment indication: Results of a discrete choice experiment.
Intermittent Broca's aphasia management in an emergency unit: from theory to practice.
Intravenous thrombolysis in a patient using factor Xa inhibitor.
Prognosis of aphasia in stroke patients early after iv thrombolysis.
Stroke and Cardiac Papillary Fibroelastoma: Mechanical Thrombectomy after Thrombolytic Therapy.
Successful Intravenous Alteplase for a Centenarian Woman with Acute Ischaemic Stroke.
The FAST-ED App: A Smartphone Platform for the Field Triage of Patients With Stroke.
Thrombolysis' benefits on early post-stroke language recovery in aphasia patients.
Unruptured Cerebral Aneurysm Detected after Intravenous Tissue Plasminogen Activator for Stroke.
Use of Emergency department transcranial doppler assessment of reperfusion after intravenous tPA for ischemic stroke.
Vascular Aphasia Outcome after Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis for Ischemic Stroke.
Apnea
Noninvasive ventilatory correction as an adjunct to an experimental systemic reperfusion therapy in acute ischemic stroke.
Appendicitis
Evaluation of a Possible Inflammatory Response after Appendectomy for Non-Perforated Appendicitis in Children.
Local and systemic expressions of MMP-9, TIMP-1 and PAI-1 in patients undergoing surgery for clinically suspected appendicitis.
Treatment of superior mesenteric and portal vein thrombosis with direct thrombolytic infusion via an operatively placed mesenteric catheter.
Arachnoiditis
Prevention of spinal epidural fibrosis by recombinant tissue plasminogen activator in rats.
Arrhythmias, Cardiac
Biological risk factors for sudden death in patients with coronary artery disease and without heart failure.
Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole.
Late ventricular potentials in risk assessment of the occurrence of complex ventricular arrhythmia in patients with myocardial infarction and heart failure.
Prospective evaluation of tissue plasminogen activator in 11 cats with arterial thromboembolism.
Significance of arrhythmias during the first 24 hours of acute myocardial infarction treated with alteplase and effect of early administration of a beta-blocker or a bradycardiac agent on their incidence.
Ventricular arrhythmias during treatment with alteplase (recombinant tissue plasminogen activator) in suspected acute myocardial infarction.
[Animal in vivo model of arrhythmia for genes target identification for 5-amino-exo-3-azatricyclo[5.2.1.0(2,6)]decan-4-one].
Arterial Occlusive Diseases
A simplified procedure for intra-arterial thrombolysis with tissue-type plasminogen activator in peripheral arterial occlusive disease: primary and long-term results.
Clot lysis in a primate model of peripheral arterial occlusive disease with use of systemic or intraarterial reteplase: addition of abciximab results in improved vessel reperfusion.
Coagulation alterations due to local fibrinolytic therapy with recombinant tissue-type plasminogen activator (rt-PA) in patients with peripheral arterial occlusive disease.
D-dimer in local thrombolytic therapy with low doses of recombinant human tissue-type plasminogen activator (rt-PA) in patients with peripheral arterial occlusive disease.
Endothelial marker proteins in hyperhomocysteinemia.
Initial experience with the combination of reteplase and abciximab for thrombolytic therapy in peripheral arterial occlusive disease: a pilot study.
Initial results of reteplase in the treatment of acute lower extremity arterial occlusions.
Relation of haemostatic, fibrinolytic, and rheological variables to the angiographic extent of peripheral arterial occlusive disease.
Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial.
Short- and long-term treatments with iloprost in diabetic patients with peripheral vascular disease: effects on the cardiovascular risk factor plasminogen activator inhibitor type-1.
The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.
Thrombolytic therapy in peripheral arterial occlusive disease: mechanisms of action and drugs available.
Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: review of the clinical literature. The Advisory Panel.
[Local intra-arterial thrombolysis with low dosage rt-PA. Thrombolysis in arterial occlusive disease of the leg]
Arteriosclerosis
Docosahexaenoic acid regulates vascular endothelial cell function and prevents cardiovascular disease.
Elevations of tissue-type plasminogen activator and differential expression of urokinase-type plasminogen activator in diseased aorta.
Fenofibrate ameliorates insulin resistance, hypertension and novel oxidative stress markers in patients with metabolic syndrome.
Green tea polyphenols inhibit plasminogen activator inhibitor-1 expression and secretion in endothelial cells.
Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells.
Levels of haemostatic factors, arteriosclerosis and cardiovascular disease.
Plasminogen activator inhibitor in plasma and arteriosclerosis.
Redox-Induced Src Kinase and Caveolin-1 Signaling in TGF-?1-Initiated SMAD2/3 Activation and PAI-1 Expression.
The TGF-?1/p53/PAI-1 Signaling Axis in Vascular Senescence: Role of Caveolin-1.
Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon.
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site.
[t-PA activity, antigen and PAI-1 antigen levels in blood obtained from the patients with cerebral infarction]
Arteriovenous Fistula
A strategy of aggressive regional therapy for acute iliofemoral venous thrombosis with contemporary venous thrombectomy or catheter-directed thrombolysis.
Local fibrinolysis in native arteriovenous fistulas of haemodialysis patients.
Paradoxical Brain Embolism Caused by Isolated Pulmonary Arteriovenous Fistula Successfully Treated with Recombinant Tissue Plasminogen Activator.
Recombinant tissue plasminogen activator (rt-PA) as first-line therapy for declotting of haemodialysis access.
Recombinant tissue plasminogen activator to declot dialysis fistulas.
The use of tissue plasminogen activator as continuous infusion into an arteriovenous hemodialysis access in the hemodialysis unit: a case series.
Thrombolysis With Alteplase: A Non-Invasive Treatment for Occluded Arteriovenous Fistulas and Grafts.
Time-extended local rtPA infiltration for acutely thrombosed hemodialysis fistulas.
[Qi deficiency and blood stasis and circulatory renin-angiotensin system as well as plasminogen activator inhibitor activity in rats with cardiac qi deficiency syndrome]
Arteriovenous Malformations
Fibrinolytic treatment of intraventricular haemorrhage preceding surgical repair of ruptured aneurysms and arteriovenous malformations.
Intraventricular haemorrhage due to re-ruptured arteriovenous malformation cleared with tissue plasminogen activator administered through a pre-existing ventriculoperitoneal shunt.
Intraventricular hemorrhage secondary to intranidal aneurysm rupture-successful management by arteriovenous malformation embolization followed by intraventricular tissue plasminogen activator: case report.
Intraventricular tissue plasminogen activator for intraventricular hemorrhage caused by an arteriovenous malformation.
Recombinant tissue plasminogen activator in the treatment of intraventricular hemorrhage secondary to periventricular arteriovenous malformation before surgery: case report.
Ruptured arteriovenous malformation complicating thrombolytic therapy with tissue plasminogen activator.
Tissue plasminogen activator thrombolysis of a middle cerebral artery embolus in a patient with an arteriovenous malformation. Case report.
Treatment of intraventricular hemorrhage with tissue plasminogen activator.
Using low-dose tissue plasminogen activator through external ventricular drain and Cerebrolysin for the treatment of severe intraventricular hemorrhage: A case report.
Arteritis
Coagulation and fibrinolysis in inflammatory bowel disease and in giant cell arteritis.
von Willebrand factor antigen and plasminogen activator inhibitor in giant cell arteritis.
Arthritis
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Cytokine modulation of plasminogen activator inhibitor-1 (PAI-1) production by human articular cartilage and chondrocytes. Down-regulation by tumor necrosis factor alpha and up-regulation by transforming growth factor-B basic fibroblast growth factor.
Elimination of arthritis pain and inflammation for over 2 years with a single 90 min, topical 14% gallium nitrate treatment: case reports and review of actions of gallium III.
Plasminogen activator inhibitor type-1 deficiency attenuates murine antigen-induced arthritis.
Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behçet's disease.
Plasminogen activators in synovial fluid and plasma from patients with arthritis.
Recombinant human interleukin-1 stimulates human articular cartilage to undergo resorption and human chondrocytes to produce both tissue- and urokinase-type plasminogen activator.
Role of plasminogen activator inhibitor - 1 (PAI-1) in regulating the pathogenesis of S. aureus arthritis via plasminogen pathway.
Tissue-type plasminogen activator deficiency exacerbates arthritis.
Arthritis, Experimental
Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis.
Arthritis, Gouty
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
Arthritis, Infectious
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Arthritis, Psoriatic
Interleukin-1 beta, plasminogen activator and inhibitor of plasminogen activator in synovial fluid of rheumatoid arthritis, psoriatic arthritis and osteoarthritis.
Arthritis, Rheumatoid
Administration of exogenous tissue plasminogen activator reduces oedema in mice lacking the tissue plasminogen activator gene.
Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model.
Association between plasminogen activator inhibitor?1 (PAI-1) 4G/5G polymorphism and circulating PAI-1 level in systemic lupus erythematosus and rheumatoid arthritis : A meta-analysis.
Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
Cell adhesion molecules and plasminogen activator inhibitor type-1 (PAI-1) in patients with rheumatoid arthritis: influence of metabolic syndrome.
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes.
Determination of metalloproteinases, plasminogen-activators and their inhibitors in the synovial fluids of patients with rheumatoid arthritis during chemical synoviorthesis.
Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis.
Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium.
Elevations in synovial fluid plasminogen activator in patients with rheumatoid arthritis.
Evaluation of t-PA, PAI-2, IL-1beta and PGE(2) in gingival crevicular fluid of rheumatoid arthritis patients with periodontal disease.
Gingival crevicular fluid tissue/blood vessel-type plasminogen activator and plasminogen activator inhibitor-2 levels in patients with rheumatoid arthritis: effects of nonsurgical periodontal therapy.
Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity.
Interleukin-1 beta, plasminogen activator and inhibitor of plasminogen activator in synovial fluid of rheumatoid arthritis, psoriatic arthritis and osteoarthritis.
Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade.
Mobilization of fibrinolytic enzymes in synovial fluid and plasma of rheumatoid arthritis and spondyloarthropathy and their relation to radiological destruction.
Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints.
Plasminogen activator in synovial fluid from patients with rheumatoid arthritis.
Plasminogen activator inhibitor-1 C/G polymorphism in relation to plasma levels in rheumatoid arthritis.
Plasminogen activators in synovial fluid and plasma from patients with arthritis.
Significance of serine proteinase and matrix metalloproteinase systems in the destruction of human articular cartilage.
Streptokinase and human fibronectin share a common epitope: implications for regulation of fibrinolysis and rheumatoid arthritis.
Synoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptors on their surface.
The -844 G/A PAI-1 polymorphism is associated with mRNA expression in rheumatoid arthritis.
The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis.
Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis.
[Detection and significance of plasminogen activator inhibitor in synovial tissue, synovial fluid and plasma from patients with rheumatoid arthritis]
Asbestosis
Biomarker assessments in asbestos-exposed workers as indicators for selective prevention of mesothelioma or bronchogenic carcinoma: rationale and practical implementations.
Increased alveolar plasminogen activator in early asbestosis.
Asthma
An evaluation of tissue polypeptide antigen (TPA) in the two bronchoalveolar lavage fractions of lung cancer patients.
Association of elevated plasminogen activator inhibitor 1 levels with diminished lung function in patients with asthma.
Asthma is associated with reduced fibrinolytic activity, abnormal clot architecture, and decreased clot retraction rate.
Blood Coagulation and Asthma Exacerbation in Children.
Coagulation factors in the airways in moderate and severe asthma and the effect of inhaled steroids.
Concentrations of plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in induced sputum of asthma patients after allergen challenge.
Dysregulated repair in asthmatic paediatric airway epithelial cells: the role of plasminogen activator inhibitor-1.
Effect of secreted lymphocyte antigen-6/urokinase-type plasminogen activator receptor-related peptide-1 (SLURP-1) on airway epithelial cells.
IMD-4690, a novel specific inhibitor for plasminogen activator inhibitor-1, reduces allergic airway remodeling in a mouse model of chronic asthma via regulating angiogenesis and remodeling-related mediators.
Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma model.
Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 attenuates allergic asthma in mice.
Mast cell-derived plasminogen activator inhibitor type 1 promotes airway inflammation and remodeling in a murine model of asthma.
PAI-1 gain-of-function genotype, factors increasing PAI-1 levels, and airway obstruction: The GALA II Cohort.
Plasminogen activator inhibitor type-1 gene 4G/5G polymorphism in Turkish adult patients with asthma.
Plasminogen activator inhibitor-1 (PAI-1) and urokinase plasminogen activator (uPA) in sputum of allergic asthma patients.
Plasminogen activator inhibitor-1 and angiotensin converting enzyme gene polymorphisms in Turkish asthmatic children.
Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation.
Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in Turkish children with asthma and allergic rhinitis.
Plasminogen activator inhibitor-1 in the pathogenesis of asthma.
Plasminogen activator inhibitor-1 plasma concentration in allergic asthma patients during allergen challenge.
Plasminogen activator inhibitor-1, fibrinogen, and lung function in adolescents with asthma and obesity.
Platelet function and fibrinolytic activity in patients with bronchial asthma.
Polymorphism 4G/5G in the plasminogen activator inhibitor-1 (PAI-1) gene is associated with IgE-mediated allergic diseases and asthma in the Czech population.
Polymorphism 4G/5G of the plasminogen activator inhibitor 1 gene as a risk factor for the development of allergic rhinitis symptoms in patients with asthma.
Possible role of the 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene in the development of asthma.
Production of plasminogen activator inhibitor-1 by human mast cells and its possible role in asthma.
Prothrombotic state in patients with severe and prednisolone-dependent asthma.
Pulmonary Embolism and Severe Asthma: Case Report and Literature Review.
Retinol-binding protein 4 and plasminogen activator inhibitor-1 as potential prognostic biomarkers of non-allergic asthma caused by obesity in adolescents.
Soy isoflavones reduce asthma exacerbation in asthmatics with high PAI-1 producing genotypes.
The -675 4G/5G plasminogen activator inhibitor-1 promoter polymorphism in house dust mite-sensitive allergic asthma patients.
The -675 4G/5G polymorphism in plasminogen activator inhibitor-1 gene is associated with risk of asthma: a meta-analysis.
The Role of Pai-1 Gene 4g/5g Polymorphism and Diagnostic Value of Biomarkers in Allergic and Non-Allergic Asthma Phenotype.
The role of vitamin D in asthma.
Therapeutic potential of an orally effective small molecule inhibitor of plasminogen activator inhibitor for asthma.
Up-regulation of the extrinsic coagulation pathway in acute asthma--a case study.
Upstream stimulating factor-1 mediates the E-box-dependent transcriptional repression of the plasminogen activator inhibitor-1 gene in human mast cells.
[Changes in platelet function, activated partial thromboplastin time and plasminogen activator inhibitor in patients with bronchial asthma after prednisone treatment]
[Research advances in association between pediatric obesity and bronchial asthma].
[The fibrinolytic system of bronchial asthma patients in the late terms of pregnancy]
Astrocytoma
Amplification of the epidermal growth factor receptor gene in human gliomas.
Correlation of tumor plasminogen activator with peritumoral cerebral edema. A CT and biochemical study.
CXCL12-mediated induction of plasminogen activator inhibitor-1 expression in human CXCR4 positive astroglioma cells.
Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of plasminogen activation system in U373-MG astrocytoma cells.
Expression and cellular localization of messenger RNA for plasminogen activator inhibitor type 1 in human astrocytomas in vivo.
Growth regulation of human melanocytes: mitogenic factors in extracts of melanoma, astrocytoma, and fibroblast cell lines.
Plasminogen activators and inhibitors in gliomas: an immunohistochemical study.
Prognostic significance of proteolytic enzymes in human brain tumors.
Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation of their expression.
[The expression of plasminogen activator inhibitor-1 (PAI-1) gene in human astrocytomas]
Ataxia
Enhanced induction of tissue-type plasminogen activator in normal human cells compared to cancer-prone cells following ionizing radiation.
Opalski Syndrome Treated with Intravenous Recombinant Tissue Type Plasminogen Activator-Case Report and Review of Literature.
Purkinje neuron degeneration in nervous (nr) mutant mice is mediated by a metabolic pathway involving excess tissue plasminogen activator.
Tissue-type plasminogen activator is an extracellular mediator of Purkinje cell damage and altered gait.
Use of Intra-Arterial Tissue Plasminogen Activator in Acute Stroke: Video Case.
Ataxia Telangiectasia
A protective effect of chromosome 11 against DNA damage by TPA-activated neutrophils but not TPA acting alone.
Atherosclerosis
2-amino-phenoxazine-3-one attenuates glucose-induced augmentation of embryonic form of myosin heavy chain, endothelin-1 and plasminogen activator inhibitor-1 in human umbilical vein endothelial cells.
A basic study on theglobal coagulation and fibrinolysis of hyperlipaemic and atherosclerotic patients.2. Plasminogen activator, plasminogen, a2-macroglobulin in atherosclerosis and endogenous hypertriglyceridaemia.
A common phenotype associated with atherogenesis in diverse mouse models of vascular lipid lesions.
A cross-sectional study of endogenous tissue plasminogen activator, total cholesterol, HDL cholesterol, and apolipoproteins A-I, A-II, and B-100.
A new hypothesis: possible mechanisms in the involvement of the increased plasminogen activator activity in branching regions of the aorta in the initiation of atherosclerosis.
Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke.
Acute psychological stress decreases plasma tissue plasminogen activator (tPA) and tissue plasminogen activator/plasminogen activator inhibitor-1 (tPA/PAI-1) complexes in cardiac patients.
Adipocyte-derived factors potentiate nutrient-induced production of plasminogen activator inhibitor-1 by macrophages.
Antifibrinolytic properties of the vascular wall. Dependence on the history of smooth muscle cell doublings in vitro and in vivo.
Antihypertensive drugs and fibrinolytic function.
Apigenin Attenuates Atherogenesis through Inducing Macrophage Apoptosis via Inhibition of AKT Ser473 Phosphorylation and Downregulation of Plasminogen Activator Inhibitor-2.
Assessment of coronary heart disease risk by combined analysis of coagulation factors.
Association between AMPD1 gene polymorphism and coagulation factors in patients with coronary heart disease.
Association of cardiovascular risk factors and endothelial dysfunction in japanese hypertensive patients: implications for early atherosclerosis.
Association of fibrinolytic parameters with early atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities Study.
Association of increased fibrin turnover and defective fibrinolytic capacity with leg atherosclerosis. The PLAT Group.
Atherosclerosis is associated with plasminogen activator inhibitor type-1 in chronic haemodialysis patients.
Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1.
Atherosclerosis, cigarette smoking, and endogenous fibrinolysis: is there a direct link?
Attenuation by fibrates of plasminogen activator inhibitor type-1 expression in human arterial smooth muscle cells.
Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis.
Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states.
C-type natriuretic peptide (CNP) suppresses plasminogen activator inhibitor-1 (PAI-1) in vivo.
Cardiovascular risk factors in relation to cigarette smoking: a population-based survey among Asians in Singapore.
Changes in arterial expression of fibrinolytic system proteins in atherogenesis.
Changes of serum parameters of TiO? nanoparticle-induced atherosclerosis in mice.
Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease.
Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS).
Contribution of genetic and metabolic syndrome to omental adipose tissue PAI-1 gene mRNA and plasma levels in obesity.
Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression.
Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells.
Dependence of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type 1 by insulin on soluble factors released from vascular smooth muscle cells.
Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome.
Editor's Highlight: PCB126 Exposure Increases Risk for Peripheral Vascular Diseases in a Liver Injury Mouse Model.
Effect of fatty acid chain length and thioesterification on the augmentation of expression of plasminogen activator inhibitor-1.
Effect of renal impairment on atherosclerosis: only partially mediated by homocysteine.
Effects of a diet containing Brazilian propolis on lipopolysaccharide-induced increases in plasma plasminogen activator inhibitor-1 levels in mice.
Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis.
Effects of human tissue plasminogen gene transfer on allograft coronary atherosclerosis.
Effects of Lisinopril, Irbesartan, and Amlodipine on the Thrombogenic Variables in the Early and Late Stages of the Treatment in Hypertensive Patients.
Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Efficacy of nobiletin in improving hypercholesterolemia and nonalcoholic fatty liver disease in high-cholesterol diet-fed mice.
Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study.
Elevated tissue plasminogen activator in patients with screening-detected abdominal aortic aneurysm.
Endogenous tissue-type plasminogen activator and risk of myocardial infarction.
Enhanced plasminogen activator inhibitor-1 expression in transgenic mice with hepatocyte-specific overexpression of superoxide dismutase or glutathione peroxidase.
Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1.
Evaluation of serum 25-hydroxyvitamin d as a predictor of carotid intima-media thickness and carotid total plaque area in nonsmokers: the tromsø study.
Femoral artery wall morphology, hemostatic factors and intermittent claudication: ultrasound study in men at high and low risk for atherosclerotic disease.
Fibrinogen and fibrinolytic activity in CAPD patients with atherosclerosis and its correlation with serum albumin.
Fibrinogen in relation to degree and composition of coronary plaque on intravascular ultrasound in patients undergoing coronary angiography.
Fibrinolysis in chronic renal failure, dialysis and renal transplantation.
Fibrinolytic activity in peripheral atherosclerosis in the elderly.
Fibrinolytic dysfunction after gestation is associated to components of insulin resistance and early type 2 diabetes in latino women with previous gestational diabetes.
Gene expression profiling of resting and activated vascular smooth muscle cells by serial analysis of gene expression and clustering analysis.
Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation, and atherosclerosis.
Genetic deletion of tissue-type plasminogen activator (t-PA) in APOE3-Leiden mice reduces progression of cholesterol-induced atherosclerosis.
Genetic studies on the role of proteinases and growth factors in atherosclerosis and aneurysm formation.
Göttingen minipig model of diet-induced atherosclerosis: influence of mild streptozotocin-induced diabetes on lesion severity and markers of inflammation evaluated in obese, obese and diabetic, and lean control animals.
Headache in Children: Selected Factors of Vascular Changes Involved in Underlying Processes of Idiopathic Headaches.
Hypofibrinolytic and atherogenic risk factors for stroke.
Identification and localization of a fatty acid response region in the human plasminogen activator inhibitor-1 gene.
Impact of bariatric surgery on subclinical atherosclerosis in patients with morbid obesity.
Impaired fasting glucose is not a risk factor for atherosclerosis.
In-vitro effect of oncostatin M on the release by endothelial cells of von Willebrand factor, tissue-type plasminogen activator and plasminogen activator inhibitor-1.
Increased blood plasminogen activator inhibitor-1 and intercellular adhesion molecule-1 as possible risk factors of atherosclerosis in Werner syndrome.
Increased levels of resistin in rotating shift workers: A potential mediator of cardiovascular risk associated with circadian misalignment.
Increased plasminogen activator inhibitor activity in survivors of myocardial infarction is associated with metabolic risk factors of atherosclerosis.
Induction of tissue inhibitor of metalloproteinase and its mitogenic response to endothelial cells in human atherosclerotic and restenotic lesions.
Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion.
Inflammatory aspects of sleep apnea and their cardiovascular consequences.
Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes.
Inhibitor of plasminogen activator in human arterial wall. II. Biochemical characterization.
Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system.
Insulin resistance and thrombosis: a cardiologist's view.
Insulin resistance, inflammation, and the prediabetic state.
Intracellular signal transduction modulating expression of plasminogen activator inhibitor-1 in adipocytes.
Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis.
Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats.
Is the effect of antihypertensive drugs on platelet aggregability and fibrinolysis clinically relevant?
Is There Association between Uric Acid and Inflammation in Hemodialysis Patients?
Large Artery Atherosclerotic Clots are Larger than Clots of other Stroke Etiologies and have Poorer Recanalization rates.
Leptin upregulates the expression of plasminogen activator inhibitor-1 in human vascular endothelial cells.
Lipid-independent effects of an estrogen-statin combination: inhibition of expression of adhesion molecules and plasminogen activator inhibitor--I in human endothelial cell cultures.
Lipoprotein(a) and apolipoproteins B and A-I after acute myocardial infarction.
Local Production of Soluble Urokinase Plasminogen Activator Receptor and Plasminogen Activator Inhibitor-1 in the Coronary Circulation Is Associated With Coronary Endothelial Dysfunction in Humans.
Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study.
Lysophosphatidylcholine induces tPA gene expression through CRE-dependent mechanism.
Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy.
Microinflammation factors in the common diseases of the heart and kidneys.
Moderate alcohol consumption and atherosclerosis : Meta-analysis of effects on lipids and inflammation.
Modulation of expression of monocyte/macrophage plasminogen activator activity and its implications for attenuation of vasculopathy.
Modulators of induction of plasminogen activator inhibitor type-1 in HepG2 cells by transforming growth factor-?.
Morphological Carotid Plaque Area Is Associated With Glomerular Filtration Rate: A Study of South Asian Indian Patients With Diabetes and Chronic Kidney Disease.
Multiple thrombophilia mutations as a possible cause of premature myocardial infarction.
New approaches to insulin resistance in polycystic ovarian syndrome.
New atherosclerosis risk factors in obese, hypertensive and diabetic children and adolescents.
Niacin affects cell adhesion molecules and plasminogen activator inhibitor-1 in HepG2 cells.
Noninvasive detection and localization of vulnerable plaque and arterial thrombosis with computed tomography angiography/positron emission tomography.
Novel bis-arylsulfonamides and aryl sulfonimides as inactivators of plasminogen activator inhibitor-1 (PAI-1).
Obstructive sleep apnea and cardiovascular disease.
On the role of coagulation and fibrinolysis in atherosclerosis.
Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries.
Overweight/obesity, smoking, and heavy alcohol consumption are important determinants of plasma PAI-1 levels in healthy men.
Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression through reactive oxygen species generation and ERK1/2 activation in 3T3-L1 adipocytes.
Physiological consequences of over- or under-expression of fibrinolytic system components in transgenic mice.
Plasma Adiponectin Levels Inversely Correlate to Clinical Parameters in Type 2 Diabetes Mellitus Patients with Macrovascular Diseases.
Plasma Concentration of Endogenous Tissue Plasminogen Activator and the Occurrence of Future Cardiovascular Events.
Plasma fibrinolytic capacity in renal transplant recipients: effect of steroid-free immunosuppression therapy.
Plasma plasminogen activator inhibitor-1 activity in normoglycemic hypertriglyceridemic north Asian Indian subjects: a preliminary case-control study.
Plasma plasminogen activator inhibitor-I is associated with plasma leptin irrespective of body mass index, body fat mass, and plasma insulin and metabolic parameters in premenopausal women.
Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis.
Plasminogen activator expression in human atherosclerotic lesions.
Plasminogen activator inhibitor 1 activity and lipoprotein(a) in nephropathic patients with non-insulin-dependent diabetes mellitus versus patients with nondiabetic nephropathy.
Plasminogen Activator Inhibitor 1 Promotes Immunosuppression in Human Non-Small Cell Lung Cancers by Enhancing TGF-?1 Expression in Macrophage.
Plasminogen activator inhibitor contributes to the coronary wall thickening in patients with angiographically normal coronary.
Plasminogen activator inhibitor type 1 increases neointima formation in balloon-injured rat carotid arteries.
Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects.
Plasminogen activator inhibitor type 1: the two faces of the same coin.
Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery.
Plasminogen activator inhibitor-1 expression in human liver and healthy or atherosclerotic vessel walls.
Plasminogen activator system and vascular disease.
Posttranscriptional regulation of expression of plasminogen activator inhibitor type-1 by cAMP in HepG2 liver cells.
Posttranscriptional regulation of expression of plasminogen activator inhibitor type-1 by sphingosine 1-phosphate in HepG2 liver cells.
Potentiation by hypercholesterolemia of the induction of aortic intramural synthesis of plasminogen activator inhibitor type 1 by endothelial injury.
Predictors of carotid plaque progression over a 4-year follow-up in the Reykjavik REFINE-study.
Preliminary Study of Dynamic Cerebral Autoregulation in Acute Ischemic Stroke: Association With Clinical Factors.
Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes.
Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study.
Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study.
Protein kinase C-beta mediates lipoprotein-induced generation of PAI-1 from vascular endothelial cells.
Quantitative measurement of carotid atherosclerosis in relation to levels of von Willebrand factor and fibrinolytic variables in plasma--a 2-year follow-up study.
Regulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator.
Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins.
Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease.
Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women.
Relationships between fibrinolytic and inflammatory parameters in human adipose tissue: strong contribution of TNFalpha receptors to PAI-1 levels.
Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.
Rho kinase and PAI-1 in Bartter's/Gitelman's syndromes: relationship to angiotensin II signaling.
Role of AGEs-RAGE system in cardiovascular disease.
Role of fibrinolytic parameters and plasminogen activator inhibitor 1 (PAI-1) promoter polymorphism on premature atherosclerosis in SLE patients.
Role of parnaparin in atherosclerosis.
Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis evaluation in transgenic animals.
Salvianolic acid B attenuates plasminogen activator inhibitor type 1 production in TNF-alpha treated human umbilical vein endothelial cells.
Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
Sesamol regulates plasminogen activator gene expression in cultured endothelial cells: a potential effect on the fibrinolytic system.
Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation.
Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome.
Stimulated release of endothelin-converting enzyme is simultaneous with tissue-type plasminogen activator and decrease in coronary heart disease.
Stimulation by proinsulin of expression of plasminogen activator inhibitor type-I in endothelial cells.
Stimulation in vivo of expression of intra-abdominal adipose tissue plasminogen activator inhibitor Type I by proinsulin.
Successful silencing of plasminogen activator inhibitor-1 in human vascular endothelial cells using small interfering RNA.
Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids.
The Angiotensin Receptor Blocker, Azilsartan Medoxomil (TAK-491), Suppresses Vascular Wall Expression of Plasminogen Activator Inhibitor Type-I Protein Potentially Facilitating the Stabilization of Atherosclerotic Plaques.
The effects of the overexpression of recombinant uncoupling protein 2 on proliferation, migration and plasminogen activator inhibitor 1 expression in human vascular smooth muscle cells.
The metabolic syndrome - an ongoing story.
The orphan nuclear receptor Rev-erb alpha regulates circadian expression of plasminogen activator inhibitor type 1.
The relationship between endothelial function and aortic valve calcification: Multi-Ethnic Study of Atherosclerosis.
The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus.
Thrombolysis with recombinant tissue plasminogen activator in atherosclerotic thrombotic occlusion.
Thrombosis and atherosclerosis.
Tissue plasminogen activator inhibits reactive oxygen species production by macrophages.
Transmembrane signaling pathway mediates oxidized low-density lipoprotein-induced expression of plasminogen activator inhibitor-1 in vascular endothelial cells.
Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells.
Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line.
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Variant of PAI-2 gene is associated with coronary artery disease and recurrent coronary event risk in Chinese Han population.
Vascular effects of TZDs: new implications.
Vascular Risk Factors in Patients with Different Subtypes of Ischemic Stroke May Affect Their Outcome after Intravenous tPA.
von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis.
Who Should Receive Hormone Replacement Therapy?
Why is the mammary artery so special and what protects it from atherosclerosis?
[Anti-atherosclerotic actions of HMG-CoA reductase inhibitors]
[Blood coagulation and fibrinolysis in arteriosclerosis]
[Changes in immune and fibrinolytic systems of patients with atherosclerosis and chronic nonspecific pulmonary diseases]
[Effect of estrogen replacement therapy in the early phase on atherosclerosis and PAI-1 in ovariectomized cholesterol-fed rabbit]
[Effect of fibrinogen, fibrin and fibrin (ogen) degradation products on the tissue plasminogen activator and plasminogen activator inhibitor-1 expressions of vascular endothelial cells in coculture system]
[Effects of exercise on markers of hemostatic activation in young survivors of myocardial infarction]
[Efffect of plasminogen activator inhibitor-1 and endothelin-1 on the atherosclerosis in the maintenance hemodialysis patients].
[Genetic predisposition in multiple metabolic syndrome. Part 2. Candidate genes in type II diabetes mellitus]
[Non-traditional atherosclerosis risk factors in patients with renal artery stenosis and hypertension]
[Recent Knowledge of Smoking and Peripheral Arterial Disease in Lower Extremities].
[The insulin resistance syndrome and fibrinolysis disorders]
[Tissue plasminogen activator and diabetes mellitus]
[Tissue plasminogen activator and inhibitor and the severity and extensiveness of vascular lesions in peripheral atherosclerosis of the legs]
[Tissue plasminogen activator and plasminogen activator inhibitor gene polymorphisms: possible relation to atherosclerosis and its complications]
[Tissue plasminogen activator, its inhibitor and other factors of the blood fibrinolytic system in stable coronary heart disease]
Atrial Fibrillation
A case of renal artery embolism treated by selective intra-arterial infusion of tissue plasminogen activator.
Anticoagulant therapy modifies fibrinolytic dysfunction in chronic atrial fibrillation.
Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Atrial fibrillation predicts good functional outcome following intravenous tissue plasminogen activator in patients with severe stroke.
Can catheter-directed thrombolysis be applied to acute lower extremity artery embolism after recent cerebral embolism from atrial fibrillation?
CHADS2 score is associated with 3-month clinical outcomes after intravenous rt-PA therapy in stroke patients with atrial fibrillation: SAMURAI rt-PA Registry.
Clinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial.
Clinical Characteristics, Management, and In-Hospital Outcomes in Patients With Stroke or Transient Ischemic Attack in China.
Clinical outcomes of acute stroke patients with atrial fibrillation.
Correlative Magnetic Resonance Imaging and Autopsy Findings in A Patient with Coagulation Necrosis Treated with Tissue Plasminogen Activator.
Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation.
Determinants of early outcomes in patients with acute ischemic stroke and proximal artery occlusion.
Early recurrent ischemic stroke complicating intravenous thrombolysis for stroke: incidence and association with atrial fibrillation.
Effect of Alteplase Use on Outcomes in Patients With Atrial Fibrillation: Analysis of the Initiation of Anticoagulation After Cardioembolic Stroke Study.
Endovascular therapy for hemodialysis patients with atrial fibrillation and cerebral thromboembolism: A case series.
Endovascular Treatment for Acute Ischemic Stroke in the Setting of Anticoagulation.
Fibrinolytic Deficit and Platelet Activation in Atrial Fibrillation and Their Postablation Modulation.
Gender differences in stroke examined in a 10-year cohort of patients admitted to a Canadian teaching hospital.
Get With the Guidelines-Stroke performance indicators: surveillance of stroke care in the Taiwan Stroke Registry: Get With the Guidelines-Stroke in Taiwan.
Hypercoagulability existing in the local left atrium of patient with mitral stenosis.
Hypofibrinolysis in atrial fibrillation.
Increased levels of tissue plasminogen activator antigen and factor VIII activity in nonvalvular atrial fibrillation: relation to predictors of thromboembolism.
Increased tissue plasminogen activator levels in patients with nonvalvular atrial fibrillation.
Inflammatory and metalloproteinases profiles predict three-month poor outcomes in ischemic stroke treated with thrombolysis.
Intravenous thrombolysis on early recurrent cardioembolic stroke: 'Dr Jekyll' or 'Mr Hyde'?
Involvement of plasminogen activator inhibitor-1 and its related molecules in atrial fibrosis in patients with atrial fibrillation.
Ischemic stroke. Clinical strategies based on mechanisms and risk factors.
IV t-PA therapy in acute stroke patients with atrial fibrillation.
Markers of fibrinolysis as predictors for maintenance of sinus rhythm after electrical cardioversion.
Microcatheter contrast injections during intra-arterial thrombolysis may increase intracranial hemorrhage risk.
Multimode Computed-Tomography-Guided Thrombolysis under a Prolonged Time Window in Acute Ischemic Stroke Patients with Atrial Fibrillation.
Not only the Sugar, Early infarct sign, hyperDense middle cerebral artery, Age, Neurologic deficit score but also atrial fibrillation is predictive for symptomatic intracranial hemorrhage after intravenous recombinant tissue plasminogen activator.
Outcome of patients with atrial fibrillation after intravenous thrombolysis for cerebral ischaemia.
Paul Coverdell National Acute Stroke Registry Surveillance - four states, 2005-2007.
Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass.
Predicting Independence 6 and 18 Months after Ischemic Stroke Considering Differences in 12 Countries: A Secondary Analysis of the IST-3 Trial.
Predictive Factors of Hemorrhage After Thrombolysis in Patients With Acute Ischemic Stroke.
Predictors of poor hospital discharge outcome in acute stroke due to atrial fibrillation.
Prothrombotic state and elevated levels of plasminogen activator inhibitor-1 in mitral stenosis with and without atrial fibrillation.
Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics.
Relationship between chronic atrial fibrillation and worse outcomes in stroke patients after intravenous thrombolysis.
Revascularization for acute ischemic stroke is safe for rivaroxaban users.
Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.
Risk Factors for Early Intracerebral Hemorrhage after Intravenous Thrombolysis with Alteplase.
Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. The Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators.
Safety and efficacy of non-vitamin K oral anticoagulant treatment compared with warfarin in patients with non-valvular atrial fibrillation who develop acute ischemic stroke or transient ischemic attack: a multicenter prospective cohort study (daVinci study).
Safety of early initiation of rivaroxaban or dabigatran after thrombolysis in acute ischemic stroke.
Similar thrombolysis outcomes in acute stroke patients with and without atrial fibrillation if pre-stroke CHA2DS2-VASc score is low: A retrospective study.
Stroke Quality Measures in Mexican Americans and Non-Hispanic Whites.
Successful Tissue Plasminogen Activator for a Patient with Stroke After Stanford Type A Aortic Dissection Treatment.
Ten-Year Evaluation of the TOYOTA Prehospital Stroke Scale for Tissue Plasminogen Activator Intravenous Therapy in the Real World.
The problem of strict image-based inclusion criteria for mechanical thrombectomy - an analysis of stroke patients with an initial low CBV-ASPECTS score.
The Stroke Practice Improvement Network: a quasiexperimental trial of a multifaceted intervention to improve quality.
Thrombolysis with alteplase for acute ischemic stroke patients with atrial fibrillation.
Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab: Case Report and Literature Review.
Thrombosis and occlusion of vascular access in hemodialyzed patients.
Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment.
Types of intraparenchymal hematoma as a predictor after revascularization in patients with anterior circulation acute ischemic stroke.
Utilization of intravenous thrombolysis is increasing in the United States.
Who will benefit more from low-dose alteplase in acute ischemic stroke?
[Examinations to detect left atrial thrombus and blood coagulation test analyses in aged patients with atrial fibrillation]
[Improvement in fibrinolytic function following anticoagulant treatment in chronic rheumatic atrial fibrillation]
[Quantitative study of left auricle endocardial nitric oxide and plasminogen activator inhibitor-1 mRNA expression in auricular fibrillation in dogs]
[The experimental study on changes of endothelial nitric oxide synthase and plasminogen activator inhibitor-1 protein in the canine atrial fibrillation model]
Atrioventricular Block
Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole.
Autoimmune Diseases
Autoantibodies to plasminogen and tissue plasminogen activator in women with recurrent pregnancy loss.
Lysophosphatidylcholine induces tPA gene expression through CRE-dependent mechanism.
Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases.
Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7.
Risk factors of diffuse alveolar hemorrhage after acute ischemic stroke treated with tissue-type plasminogen activator. The effectiveness of activated recombinant factor VII treatment.
Azoospermia
Biomarkers for demographic research: sperm counts and other male infertility biomarkers.
[Source of plasminogen activator in rhesus monkey semen and its possible role in sperm capacitation]
Azotemia
Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.
Prospective evaluation of tissue plasminogen activator in 11 cats with arterial thromboembolism.
Relationship between autonomic function and plasma fibrinogen, viscosity, and elements of fibrinolytic activity in diabetic nephropathy.
The role of obesity and its bioclinical correlates in the progression of chronic kidney disease.
Bacteremia
An Economic Evaluation of rt-PA Locking Solution in Dialysis Catheters.
Effect of recombinant tissue plasminogen activator on intra-abdominal abscess formation in rats with generalized peritonitis.
Effectiveness and Cost of Weekly Recombinant Tissue Plasminogen Activator Hemodialysis Catheter Locking Solution.
Efficacy of local instillation of recombinant tissue plasminogen activator for restoring occluded central venous catheters in neonates.
Gentamycin reduces bacteremia and mortality rates associated with the treatment of experimental peritonitis with recombinant tissue plasminogen activator.
Treatment of catheter-related bacteremia with tissue plasminogen activator antibiotic locks.
Urokinase-containing locking solution in the prevention of dialysis catheter dysfunction: a double blind randomized controlled trial.
Bacterial Infections
CSF and serum inflammatory response and association with outcomes in spontaneous intracerebral hemorrhage with intraventricular extension: an analysis of the CLEAR-III Trial.
Plasminogen activator inhibitor activity in bacterial infection.
Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulence.
Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial.
tPA Alu (I/D) polymorphism associates with bacterial osteomyelitis.
Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis.
Urokinase receptor-deficient mice mount an innate immune response to and clarify respiratory viruses as efficiently as wild-type mice.
Basal Cell Nevus Syndrome
Oncogenic potential in fibroblasts from individuals genetically predisposed to cancer.
Basal Ganglia Hemorrhage
Influence of intraventricular fibrinolytic therapy with rt-PA on the long-term outcome of treated patients with spontaneous basal ganglia hemorrhage: a case-control study.
Spontaneous intracerebral hemorrhage.
Behcet Syndrome
Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behcet's disease.
Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease.
Plasminogen activator activity levels in patients with Behçet's syndrome.
Transvenous Catheter-Based Thrombolysis With Continuous Tissue Plasminogen Activator Infusion for Refractory Thrombosis in a Patient With Behcet's Disease.
beta-Thalassemia
Impact of ?-thalassemia trait carrier state on inflammatory status in patients with newly diagnosed hypertension.
Multifactorial Painful Leg Ulcers Due to Hyperhomocysteinemia, Plasminogen Activator Inhibitor-1 4G/5G Heterozygote Gene Mutation, and Beta Thalassemia Minor: A Case Report.
Bile Duct Neoplasms
[Measurement of serum tissue polypeptide antigen (TPA) in patients with malignant tumor using prolifigen TPA-M "Daiichi" kit]
Blast Crisis
Heterogenous response of primary cultured bone marrow cells of patients with different varieties of leukemia to differentiation inducers.
Blindness
Intravascular lithotripsy facilitated percutaneous endovascular intervention of the aortic arch: A single-center experience.
Blindness, Cortical
Bioccipital Lobe Hypoperfusion and Anton's Syndrome Resolution with Intravenous Thrombolysis.
Blister
Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung.
Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation.
Corneal endothelial permeability in protection glaucoma filter bleb with tissue plasminogen activator.
Effects of tissue plasminogen activator on glaucoma filter blebs in rabbits.
Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes.
Evaluation of a commercial recombinant tissue-type plasminogen activator preparation in the subretinal space of the cat.
Fibrin directs early retinal damage after experimental subretinal hemorrhage.
Filtering bleb thrombolysis with tissue plasminogen activator.
Fluorescein-Assisted Subretinal Tissue Plasminogen Activator (tPA) Delivery For Submacular Hemorrhage.
Intracameral tissue plasminogen activator after glaucoma surgery. Indications, effectiveness, and complications.
PAI-1 inhibits development of chronic otitis media and tympanosclerosis in a mouse model of otitis media.
Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice.
Plasminogen activation in lesional skin of Pemphigus vulgaris type Neumann.
Promotion of glaucoma filter bleb with tissue plasminogen activator after sclerectomy under a clot.
Responses of amphibian embryos and blastomeres to a tumor-promoting phorbol ester.
Subconjunctival high dose plasminogen activator in rabbit filtration surgery.
Tissue plasminogen activator and glaucoma drainage implants.
Treatment of failing glaucoma filtering cystic blebs with tissue plasminogen activator (tPA).
Use of tissue plasminogen activator to revive blebs following intraocular surgery.
[Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients]
[TGF-beta and platelet]
[Therapeutic and prophylactic application of TPA (recombinant tissue plasminogen activator) into the anterior chamber of the eye]
Bloom Syndrome
Biological activities of phosphocitrate: a potential meniscal protective agent.
Enhanced induction of tissue-type plasminogen activator in normal human cells compared to cancer-prone cells following ionizing radiation.
Bone Diseases, Metabolic
Plasminogen activator inhibitor-1 deficiency enhances subchondral osteopenia after induction of osteoarthritis in mice.
Role of Plasminogen Activator Inhibitor-1 in Glucocorticoid-Induced Diabetes and Osteopenia in Mice.
Bone Resorption
Bone resorption induced by 1 alpha,25 dihydroxyvitamin D(3) in vivo is not altered by inactivation of the plasminogen activator inhibitor 1.
Increased expression of tissue plasminogen activator messenger ribonucleic acid is an immediate response to parathyroid hormone in neonatal rat osteoblasts.
Melatonin as adjunctive therapy in the treatment of periodontitis associated with obesity.
Modulation of plasminogen activators and plasminogen activator inhibitors by TGF-beta, IL-1 alpha and EGF in fetal rat calvaria cells at different times of culture.
N-terminal truncation of salmon calcitonin leads to calcitonin antagonists. Structure activity relationship of N-terminally truncated salmon calcitonin fragments in vitro and in vivo.
Regulation of plasminogen activator and plasminogen activator inhibitor production by growth factors and cytokines in rat calvarial cells.
Stimulation of prostaglandin production in bone by phorbol diesters and melittin.
The role of the plasminogen system in bone resorption in vitro.
Tissue and urokinase plasminogen activators in bone tissue and their regulation by parathyroid hormone.
Bradycardia
A Case of Oropharyngeal Angioedema Following Intravenous Recombinant Tissue Plasminogen Activator (rt-PA) and Mechanical Thrombectomy.
Cardiovascular Instability Preceded by Orolingual Angioedema after Alteplase Treatment.
Early tPA treatment and aeromedical transport of patients with acute myocardial infarction.
Brain Concussion
Neuroprotective Effect of Plasminogen Activator Inhibitor-1 Antagonist in the Rat Model of Mild Traumatic Brain Injury.
Plasminogen Activator Inhibitor Type 1: A Possible Novel Biomarker of Late Pituitary Dysfunction after Mild Traumatic Brain Injury.
Brain Death
Activation of hemostasis in brain dead organ donors: An observational study.
Brain Diseases
Association between 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene with stroke or encephalopathy after cardiac surgery.
Chemotherapy induced stroke mimic: 5-Fluorouracil encephalopathy fulfilling criteria for tissue plasminogen activator therapy.
Encephalopathy only stroke codes (EoSC) do not result in rt-PA treatments.
Neurological Emergencies During Pregnancy.
Tissue plasminogen activator in brain tissues infected with transmissible spongiform encephalopathies.
Tissue plasminogen activator prevents white matter damage following stroke.
Brain Edema
A new threshold of apparent diffusion coefficient values in white matter after successful tissue plasminogen activator treatment for acute brain ischemia.
Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.
Albumin ameliorates tissue plasminogen activator-mediated blood-brain barrier permeability and ischemic brain injury in rats.
Application of albumin prior to delayed thrombolysis reduces brain edema and blood brain barrier permeability in an embolic stroke model.
Atrial fibrillation and cardiembolic stroke. Treatment and issue in acute phase.
Biological significance of tissue plasminogen activator content in brain tumors.
Cell permeable HMGB1-binding heptamer peptide ameliorates neurovascular complications associated with thrombolytic therapy in rats with transient ischemic stroke.
Combined Treatment With 2-(2-Benzofu-Ranyl)-2-Imidazoline and Recombinant Tissue Plasminogen Activator Protects Blood-Brain Barrier Integrity in a Rat Model of Embolic Middle Cerebral Artery Occlusion.
Correlation of tumor plasminogen activator with peritumoral cerebral edema. A CT and biochemical study.
Deficiency of plasminogen activator inhibitor type 2 limits brain edema formation after traumatic brain injury.
Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats.
Development of a rat model of photothrombotic ischemia and infarction within the caudoputamen.
Effect of Intravenous Alteplase on Ischemic Lesion Water Homeostasis.
Effects of angiopoietin-1 on hemorrhagic transformation and cerebral edema after tissue plasminogen activator treatment for ischemic stroke in rats.
Effects of erythropoietin combined with tissue plasminogen activator on the rats following cerebral ischemia and reperfusion.
Epigallocatechin Gallate Extends the Therapeutic Window of Recombinant Tissue Plasminogen Activator Treatment in Ischemic Rats.
Exacerbation of perihematomal edema and sterile meningitis with intraventricular administration of tissue plasminogen activator in patients with intracerebral hemorrhage.
Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke.
IMM-H004 prevents toxicity induced by delayed treatment of tPA in a rat model of focal cerebral ischemia involving PKA-and PI3K-dependent Akt activation.
Impact of Bradykinin Generation During Thrombolysis in Ischemic Stroke.
Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke.
Inhibition of tPA-induced hemorrhagic transformation involves adenosine A2b receptor activation after cerebral ischemia.
Matrix Metalloproteinase-9 Expression is Enhanced by Ischemia and Tissue Plasminogen Activator and Induces Hemorrhage, Disability and Mortality in Experimental Stroke.
Microglial low-density lipoprotein receptor-related protein 1 mediates the effect of tissue-type plasminogen activator on matrix metalloproteinase-9 activity in the ischemic brain.
Monoacylglycerol Lipase Inhibitor is Safe when Combined with Delayed r-tPA Administration in Treatment of Stroke.
Neuroserpin extends the time window of tPA thrombolysis in a rat model of middle cerebral artery occlusion.
Neutralizing the neurotoxic effects of exogenous and endogenous tPA.
Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.
Normobaric hyperoxia slows blood-brain barrier damage and expands the therapeutic time window for tissue-type plasminogen activator treatment in cerebral ischemia.
Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA.
Phosphorylated recombinant HSP27 protects the brain and attenuates blood-brain barrier disruption following stroke in mice receiving intravenous tissue-plasminogen activator.
Postoperative venous thromboembolism and brain tumors: Part III. Biochemical profile.
Progesterone attenuates hemorrhagic transformation after delayed tPA treatment in an experimental model of stroke in rats: involvement of the VEGF-MMP pathway.
Recombinant Tissue Plasminogen Activator Induces Neurological Side Effects Independent on Thrombolysis in Mechanical Animal Models of Focal Cerebral Infarction: A Systematic Review and Meta-Analysis.
Safety and Outcome of Decompressive Hemicraniectomy After Recombinant Tissue Plasminogen Activator Thrombolysis for Acute Ischemic Stroke: A Systematic Review.
Safety and Tolerability of Desmoteplase Within 3 to 9 Hours After Symptoms Onset in Japanese Patients With Ischemic Stroke.
Select hyperacute complications of ischemic stroke: cerebral edema, hemorrhagic transformation, and orolingual angioedema secondary to intravenous Alteplase.
Serum S100B indicates successful combination treatment with recombinant tissue plasminogen activator and MK-801 in a rat model of embolic stroke.
Subacute intranasal administration of tissue plasminogen activator increases functional recovery and axonal remodeling after stroke in rats.
Subacute intranasal administration of tissue plasminogen activator promotes neuroplasticity and improves functional recovery following traumatic brain injury in rats.
Timing of Symptomatic Infarct Swelling Following Intravenous Thrombolysis in Acute Middle Cerebral Artery Infarction: A Case-Control Study.
Tissue plasminogen activator mediates deleterious complement cascade activation in stroke.
Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia.
Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain.
Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic.
Urokinase, a promising candidate for fibrinolytic therapy for intracerebral hemorrhage.
Whole body hypothermia extends tissue plasminogen activator treatment window in the rat model of embolic stroke.
[A case of cerebral infarction treated with tissue-plasminogen activator exhibiting prolonged cerebral edema for more than 1 month].
Brain Infarction
A combined treatment with tacrolimus (FK506) and recombinant tissue plasminogen activator for thrombotic focal cerebral ischemia in rats: increased neuroprotective efficacy and extended therapeutic time window.
A Simulation-based Approach for Improving Utilization of Thrombolysis in Acute Brain Infarction.
Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke.
Cognitive and functional outcome after intravenous recombinant tissue plasminogen activator treatment in patients with a first symptomatic brain infarct.
Effects of erythropoietin combined with tissue plasminogen activator on the rats following cerebral ischemia and reperfusion.
Effects of tissue plasminogen activator on cerebral microvessels of rats during focal cerebral ischemia and reperfusion.
Endogenous tissue-type plasminogen activator and cardioembolic brain infarct subtype.
Epigallocatechin Gallate Extends the Therapeutic Window of Recombinant Tissue Plasminogen Activator Treatment in Ischemic Rats.
Evaluation of applied cases of thrombolytic therapy against ultra-acute ischemic stroke. Using the Japanese Standard Stroke Registry Database.
FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
Functional recovery after embolic stroke in rodents by activated protein C.
Low dose tPA plus annexin A2 combination attenuates tPA delayed treatment-associated hemorrhage and improves recovery in rat embolic focal stroke.
Matrix Metalloproteinase-9 Expression is Enhanced by Ischemia and Tissue Plasminogen Activator and Induces Hemorrhage, Disability and Mortality in Experimental Stroke.
Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating ?2-antiplasmin.
NAD replenishment with nicotinamide mononucleotide protects blood-brain barrier integrity and attenuates delayed tissue plasminogen activator-induced haemorrhagic transformation after cerebral ischaemia.
Neuroprotective effect of neuroserpin in rat primary cortical cultures after oxygen and glucose deprivation and tPA.
Neuroprotective effects of human neural stem cells over-expressing choline acetyltransferase in a middle cerebral artery occlusion model.
PAI-1 but Not PAI-2 Gene Deficiency Attenuates Ischemic Brain Injury After Experimental Stroke.
Partial Intra-Aortic Occlusion Improves Perfusion Deficits and Infarct Size Following Focal Cerebral Ischemia.
Plasminogen activator inhibitor genotype and brain infarction.
Protective effects of 2-(2-benzonfuranyl)-2-imidazoline combined with tissue plasminogen activator after embolic stroke in rats.
Protective effects of pamiteplase, a modified t-PA, in a rat model of embolic stroke.
Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CP101,606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats.
Reversing the deleterious effects of ?2-antiplasmin on tissue plasminogen activator therapy improves outcomes in experimental ischemic stroke.
The Kringle-2 domain of tissue plasminogen activator significantly reduces mortality and brain infarction in middle cerebral artery occlusion rats.
Treatment of acute ischemic brain infarction with the assistance of local intraarterial thrombolysis with recombinant tissue-type plasminogen activator.
[A case of brain infarction and thoracic aortic dissection without chest nor back pain diagnosed by carotid duplex ultrasonography]
[Diagnosis and management for acute ischemic stroke]
[Hyperglycemia: a predictor of poor prognosis in acute stroke]
[Mediastinal Hematoma after Intravenous Thrombolytic Therapy for Cerebral Infarction in a Patient with a History of Total Aortic Arch Replacement].
Brain Injuries
2,7-Bis-(4-amidinobenzylidene)-cycloheptan-1-one dihydrochloride, tPA stop, prevents tPA-enhanced excitotoxicity both in vitro and in vivo.
A mouse model of hemorrhagic transformation by delayed tissue plasminogen activator administration after in situ thromboembolic stroke.
Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase.
Alteplase treatment does not increase brain injury after mechanical middle cerebral artery occlusion in the rat.
Altered NO function contributes to impairment of uPA and tPA cerebrovasodilation after brain injury.
Aneurysmal subarachnoid hemorrhage models: do they need a fix?
Blood-Brain Barrier Damage in Ischemic Stroke and Its Regulation by Endothelial Mechanotransduction.
Blood-Brain Barrier Protection as a Therapeutic Strategy for Acute Ischemic Stroke.
Brain capillary tissue plasminogen activator in a diabetes stroke model.
Bryostatin improves survival and reduces ischemic brain injury in aged rats after acute ischemic stroke.
Chronic nicotine treatment enhances focal ischemic brain injury and depletes free pool of brain microvascular tissue plasminogen activator in rats.
Coagulopathy in the Setting of Mild Traumatic Brain Injury: Truths and Consequences.
Compartment- and context-specific changes in tissue-type plasminogen activator (tPA) activity following brain injury and pharmacological stimulation.
Concomitant intracerebral infusion of tissue plasminogen activator and thrombin leads to brain injury.
Danhong Injection Combined With t-PA Improves Thrombolytic Therapy in Focal Embolic Stroke.
Delayed adjuvant therapy with the 21-aminosteroid U74006F and the anion channel blocker L644-711 does not improve outcome following thrombolytic therapy in a rabbit model of thromboembolic stroke.
Effect of intravenous thrombolysis with alteplase on clinical efficacy, inflammatory factors, and neurological function in patients with acute cerebral infarction.
Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats.
Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice.
Enhanced poly(ADP-ribose) polymerase-1 activation contributes to recombinant tissue plasminogen activator-induced aggravation of ischemic brain injury in vivo.
Expression of the plasminogen activator system and the inhibitors PAI-1 and PAI-2 in posttraumatic lesions of the CNS and brain injuries following dramatic circulatory arrests: an immunohistochemical study.
FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
FUNDC1-dependent mitophagy induced by tPA protects neurons against cerebral ischemia-reperfusion injury.
Future Perspectives on the Fibrinolytic Therapy of Intracerebral Hemorrhages.
Glucagon Protects Against Impaired NMDA-Mediated Cerebrovasodilation and Cerebral Autoregulation during Hypotension after Brain Injury by Activating cAMP Protein Kinase A and Inhibiting Upregulation of tPA.
High t-PA release by neonate brain microvascular endothelial cells under glutamate exposure affects neuronal fate.
Hypoxia-ischemia or excitotoxin-induced tissue plasminogen activator- dependent gelatinase activation in mice neonate brain microvessels.
Impact of aging and comorbidities on ischemic stroke outcomes in preclinical animal models: A translational perspective.
Interferon-? alleviates delayed tPA-induced adverse effects via modulation of MMP3/9 production in ischemic stroke.
Intravenously administered recombinant tissue-plasminogen activator attenuates neuronal injury after mild focal cerebral ischemia in mice.
Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator.
Matrix Metalloproteinase-9 Expression is Enhanced by Ischemia and Tissue Plasminogen Activator and Induces Hemorrhage, Disability and Mortality in Experimental Stroke.
Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke.
Microparticles Impair Hypotensive Cerebrovasodilation and Cause Hippocampal Neuronal Cell Injury after Traumatic Brain Injury.
Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating ?2-antiplasmin.
Neuroprotection by urokinase plasminogen activator in the hippocampus.
NOX2 inhibition with apocynin worsens stroke outcome in aged rats.
Pathophysiology of brain edema formation.
Peroxynitrite-Induced Tyrosine Nitration Contributes to Matrix Metalloprotease-3 Activation: Relevance to Hyperglycemic Ischemic Brain Injury and Tissue Plasminogen Activator.
Phosphorylated recombinant HSP27 protects the brain and attenuates blood-brain barrier disruption following stroke in mice receiving intravenous tissue-plasminogen activator.
Phthalide derivative CD21 attenuates tissue plasminogen activator-induced hemorrhagic transformation in ischemic stroke by enhancing macrophage scavenger receptor 1-mediated DAMP (peroxiredoxin 1) clearance.
Plasminogen activator inhibitor-1 induction after experimental intracerebral hemorrhage.
Plasminogen Activator Inhibitor-1 Mitigates Brain Injury in a Rat Model of Infection-Sensitized Neonatal Hypoxia-Ischemia.
Protective role of tuftsin fragment 1-3 in an animal model of intracerebral hemorrhage.
Recombinant tissue-type plasminogen activator transiently enhances blood-brain barrier permeability during cerebral ischemia through vascular endothelial growth factor-mediated endothelial endocytosis in mice.
Reduced cortical injury and edema in tissue plasminogen activator knockout mice after brain trauma.
Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats.
Reversing the deleterious effects of ?2-antiplasmin on tissue plasminogen activator therapy improves outcomes in experimental ischemic stroke.
Role of MC-1 alone and in combination with tissue plasminogen activator in focal ischemic brain injury in rats.
Rosiglitazone alone or in combination with tissue plasminogen activator improves ischemic brain injury in an embolic model in rats.
Stressed neurons protect themselves by a tissue-type plasminogen activator-mediated EGFR-dependent mechanism.
Taming neonatal hypoxic-ischemic brain injury by intranasal delivery of plasminogen activator inhibitor-1.
The novel proteasome inhibitor BSc2118 protects against cerebral ischaemia through HIF1A accumulation and enhanced angioneurogenesis.
Therapeutic administration of plasminogen activator inhibitor-1 prevents hypoxic-ischemic brain injury in newborns.
Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background.
Tissue plasminogen activator deficiency preserves neurological function and protects against murine acute ischemic stroke.
Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia.
Tissue plasminogen activator promotes white matter integrity and functional recovery in a murine model of traumatic brain injury.
Tissue plasminogen activator reduces brain injury in a rabbit model of thromboembolic stroke.
Traumatic intraventricular hemorrhage treated with intraventricular recombinant-tissue plasminogen activator: technical case report.
Treatment for ischemic stroke: From thrombolysis to thrombectomy and remaining challenges.
Vampire bats yield potent clot buster for ischemic stroke.
Worse Outcome in Stroke Patients Treated with rt-PA Without Early Reperfusion: Associated Factors.
[Changes and significance of endogenous tissue plasminogen activators in cerebral hypoxia-ischemia in neonatal rats]
Brain Injuries, Traumatic
Altered NO function contributes to impairment of uPA and tPA cerebrovasodilation after brain injury.
An Outcome Model for Intravenous rt-PA in Acute Ischemic Stroke.
Combination therapy with glucagon and a novel plasminogen activator inhibitor-1-derived peptide enhances protection against impaired cerebrovasodilation during hypotension after traumatic brain injury through inhibition of ERK and JNK MAPK.
Compartment- and context-specific changes in tissue-type plasminogen activator (tPA) activity following brain injury and pharmacological stimulation.
Deficiency of plasminogen activator inhibitor type 2 limits brain edema formation after traumatic brain injury.
Efficacy of Sanqi (Radix Notoginseng) in treating cerebral hemorrhage in rats with traumatic brain injury.
Erythrocyte-bound Tissue Plasminogen Activator (tPA) is Neuroprotective in Experimental Traumatic Brain Injury.
Inhibiting endogenous tissue plasminogen activator enhanced neuronal apoptosis and axonal injury after traumatic brain injury.
Microparticles Impair Hypotensive Cerebrovasodilation and Cause Hippocampal Neuronal Cell Injury after Traumatic Brain Injury.
Neutralizing the neurotoxic effects of exogenous and endogenous tPA.
Optimizing blood pressure in neurological emergencies.
Plasminogen activator inhibitor-1 augments damage by impairing fibrinolysis after traumatic brain injury.
Reduced cortical injury and edema in tissue plasminogen activator knockout mice after brain trauma.
Subacute intranasal administration of tissue plasminogen activator promotes neuroplasticity and improves functional recovery following traumatic brain injury in rats.
Tissue plasminogen activator promotes white matter integrity and functional recovery in a murine model of traumatic brain injury.
tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK.
tPA in the central nervous system: relations between tPA and cell surface LRPs.
tPA-S(481)A Prevents Impairment of Cerebrovascular Autoregulation by Endogenous tPA after Traumatic Brain Injury by Upregulating p38 MAPK and Inhibiting ET-1.
tPA-S481A prevents neurotoxicity of endogenous tPA in traumatic brain injury.
Brain Ischemia
"Brain attack": an indication for thrombolysis?
17?-estradiol attenuates breakdown of blood-brain barrier and hemorrhagic transformation induced by tissue plasminogen activator in cerebral ischemia.
A combined treatment with tacrolimus (FK506) and recombinant tissue plasminogen activator for thrombotic focal cerebral ischemia in rats: increased neuroprotective efficacy and extended therapeutic time window.
A new threshold of apparent diffusion coefficient values in white matter after successful tissue plasminogen activator treatment for acute brain ischemia.
A novel approach to screening for new neuroprotective compounds for the treatment of stroke.
A pilot randomized clinical safety study of sonothrombolysis augmentation with ultrasound-activated perflutren-lipid microspheres for acute ischemic stroke.
A Review of the Mechanisms of Blood-Brain Barrier Permeability by Tissue-Type Plasminogen Activator Treatment for Cerebral Ischemia.
A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator.
Accuracy of National Institutes of Health Stroke Scale Score in Predicting the Site of Arterial Occlusion in Acute Stroke: A Transcranial Doppler Study.
Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke.
Acute spinal cord ischemia during aortography treated with intravenous thrombolytic therapy.
Acute stroke: therapeutic transcranial Doppler sonography.
Administration of Uric Acid in the Emergency Treatment of Acute Ischemic Stroke.
Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase.
Albumin ameliorates tissue plasminogen activator-mediated blood-brain barrier permeability and ischemic brain injury in rats.
Alteplase treatment does not increase brain injury after mechanical middle cerebral artery occlusion in the rat.
Are patients with acutely recovered cerebral ischemia more unstable?
Are the results of intravenous thrombolysis trials reproduced in clinical practice? Comparison of observed and expected outcomes with the stroke-thrombolytic predictive instrument (STPI).
Assessment of suitability of thrombolysis in middle cerebral artery infarction: a proof of concept study of a stereologically-based technique.
Association of pretreatment blood pressure with tissue plasminogen activator-induced arterial recanalization in acute ischemic stroke.
Beneficial Role of Rosuvastatin in Blood-Brain Barrier Damage Following Experimental Ischemic Stroke.
Blockade of Phosphodiesterase-III Protects against Oxygen-Glucose Deprivation in Endothelial Cells by Upregulation of VE-Cadherin.
Bryostatin extends tPA time window to 6 h following middle cerebral artery occlusion in aged female rats.
Bryostatin improves survival and reduces ischemic brain injury in aged rats after acute ischemic stroke.
Cell permeable HMGB1-binding heptamer peptide ameliorates neurovascular complications associated with thrombolytic therapy in rats with transient ischemic stroke.
Circadian rhythms in the efficacy of intravenous alteplase in patients with acute ischemic stroke and middle cerebral artery occlusion.
CLOTBUST-Hands Free: pilot safety study of a novel operator-independent ultrasound device in patients with acute ischemic stroke.
Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial.
Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice.
Combined therapy with PJ34, a poly(ADP-ribose)polymerase inhibitor, reduces tissue plasminogen activator-induced hemorrhagic transformations in cerebral ischemia in mice.
Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models.
Complement depletion does not reduce brain injury in a rabbit model of thromboembolic stroke.
Cystatin C is a potential predictor of unfavorable outcomes for cerebral ischemia with intravenous tissue plasminogen activator treatment: A multicenter prospective nested case-control study.
Decreased neural damage after spinal cord injury in tPA-deficient mice.
Deficiency in Neuroserpin Exacerbates CoCl2 Induced Hypoxic Injury in the Zebrafish Model by Increased Oxidative Stress.
Deficiency in serine protease inhibitor neuroserpin exacerbates ischemic brain injury by increased postischemic inflammation.
Design of a PROspective multi-national CLOTBUST collaboration on reperfusion therapies for stroke (CLOTBUST-PRO).
Dl-NBP (Dl-3-N-Butylphthalide) Treatment Promotes Neurological Functional Recovery Accompanied by the Upregulation of White Matter Integrity and HIF-1?/VEGF/Notch/Dll4 Expression.
Does current oral antiplatelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen-activator-mediated recanalization rate in patients with acute ischemic stroke?
Early Abrogation of Gelatinase Activity Extends the Time Window for tPA Thrombolysis after Embolic Focal Cerebral Ischemia in Mice.
Early Ischemic Blood Brain Barrier Damage: A Potential Indicator for Hemorrhagic Transformation Following Tissue Plasminogen Activator (tPA) Thrombolysis?
Edaravone, a Synthetic Free Radical Scavenger, Enhances Alteplase-Mediated Thrombolysis.
Effect of isoflurane post-treatment on tPA-exaggerated brain injury in a rat ischemic stroke model.
Effectiveness of alteplase in the very elderly after acute ischemic stroke.
Effects of angiopoietin-1 on hemorrhagic transformation and cerebral edema after tissue plasminogen activator treatment for ischemic stroke in rats.
Effects of erythropoietin combined with tissue plasminogen activator on the rats following cerebral ischemia and reperfusion.
Effects of tissue plasminogen activator on cerebral microvessels of rats during focal cerebral ischemia and reperfusion.
Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats.
Emergency superficial temporal artery to middle cerebral artery bypass after intravenous recombinant tissue plasminogen activator administration for acute cerebral ischemia in a patient with moyamoya disease.
Endogenous plasminogen activator expression after embolic focal cerebral ischemia in mice.
Endovascular Thrombectomy for Acute Ischemic Stroke in Failed Intravenous Tissue Plasminogen Activator Versus Non-Intravenous Tissue Plasminogen Activator Patients. Revascularization and Outcomes Stratified by the Site of Arterial Occlusions.
Enhanced poly(ADP-ribose) polymerase-1 activation contributes to recombinant tissue plasminogen activator-induced aggravation of ischemic brain injury in vivo.
Epigallocatechin Gallate Extends the Therapeutic Window of Recombinant Tissue Plasminogen Activator Treatment in Ischemic Rats.
Epigallocatechin Gallate Extends Therapeutic Window of Recombinant Tissue Plasminogen Activator Treatment for Brain Ischemic Stroke: A Randomized Double-Blind and Placebo-Controlled Trial.
Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice.
Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke.
Factors delaying intravenous thrombolytic therapy in acute ischaemic stroke: a systematic review of the literature.
FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
Free Radical Scavenger Edaravone Administration Protects against Tissue Plasminogen Activator Induced Oxidative Stress and Blood Brain Barrier Damage.
Glycoprotein IIb/IIIa antagonist, murine 7E3 F(ab') 2, and tissue plasminogen activator in focal ischemia: evaluation of efficacy and risk of hemorrhage with combination therapy.
Hemorrhagic transformation following tissue plasminogen activator in experimental cerebral infarction.
Hemorrhagic transformation in focal cerebral ischemia: influence of time to artery reopening and tissue plasminogen activator.
Hemostasis and alterations of the central nervous system.
Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA.
IMM-H004 prevents toxicity induced by delayed treatment of tPA in a rat model of focal cerebral ischemia involving PKA-and PI3K-dependent Akt activation.
Immunohistochemical localization of tissue plasminogen activator in vascular endothelium of stroke-prone regions of the rat brain.
Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice.
Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection.
Infarct reduction in rats following intraventricular administration of either tissue plasminogen activator (tPA) or its non-protease mutant S478A-tPA.
Influence of Differences in Case Mix on the Better Outcome of Smokers after Intravenous Thrombolysis for Acute Cerebral Ischemia.
Influence of on-going treatment with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker on the outcome of patients treated with intravenous rt-PA for ischemic stroke.
Influence of tissue plasminogen activator and heparin on cerebral ischemia in a rabbit model.
Inhibition of VEGF signaling pathway attenuates hemorrhage after tPA treatment.
Intra-Arterial Tissue Plasminogen Activator Is a Safe Rescue Therapy with Mechanical Thrombectomy.
Intravenous rtPA thrombolysis in acute ischemic stroke.
Intravenous Thrombolysis in German Stroke Units before and after Regulatory Approval of Recombinant Tissue Plasminogen Activator.
Intravenous tPA therapy does not worsen acute intracerebral hemorrhage in mice.
Intravenous versus combined (intravenous and intra-arterial) thrombolysis in acute ischemic stroke: a transcranial color-coded duplex sonography--guided pilot study.
Intravenously administered recombinant tissue-plasminogen activator attenuates neuronal injury after mild focal cerebral ischemia in mice.
Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats.
Is the benefit of early recanalization sustained at 3 months? A prospective cohort study.
Ischemic stroke therapy.
Isoflurane Postconditioning Inhibits tPA-Induced Matrix Metalloproteinases Activation After Hypoxic Injury via Low-Density Lipoprotein Receptor-Related Protein and Extracellular Signal-Regulated Kinase Pathway.
Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator.
Long-lasting neuronal loss following experimental focal cerebral ischemia is not affected by combined administration of tissue plasminogen activator and hyperbaric oxygen.
Low Levels of Caveolin-1 Predict Symptomatic Bleeding After Thrombolytic Therapy in Patients With Acute Ischemic Stroke.
Matrix metalloproteinase (MMP) induction and inhibition at different doses of recombinant tissue plasminogen activator following experimental stroke.
Matrix metalloproteinase activation and blood-brain barrier breakdown following thrombolysis.
Microglial low-density lipoprotein receptor-related protein 1 mediates the effect of tissue-type plasminogen activator on matrix metalloproteinase-9 activity in the ischemic brain.
Mild stroke: safety and outcome in patients receiving thrombolysis.
Mouse model of in situ thromboembolic stroke and reperfusion.
Multiparametric ISODATA analysis of embolic stroke and rt-PA intervention in rat.
Neuroprotective effect of masitinib in rats with postischemic stroke.
Neuroserpin: a selective inhibitor of tissue-type plasminogen activator in the central nervous system.
Neutrophil and Platelet Activity and Quantification Following Delayed tPA Therapy in a Rabbit Model of Thromboembolic Stroke.
New functions for an old enzyme: nonhemostatic roles for tissue-type plasminogen activator in the central nervous system.
New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator.
Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.
Normobaric hyperoxia slows blood-brain barrier damage and expands the therapeutic time window for tissue-type plasminogen activator treatment in cerebral ischemia.
Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials.
Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window: joint outcome table analysis of the ECASS 3 trial.
Onset of Orolingual Angioedema After Treatment of Acute Brain Ischemia with Alteplase Depends on the Site of Brain Ischemia: A Meta-analysis.
Oxygen glucose deprivation switches the transport of tPA across the blood-brain barrier from an LRP-dependent to an increased LRP-independent process.
PAI-1 but Not PAI-2 Gene Deficiency Attenuates Ischemic Brain Injury After Experimental Stroke.
Partial rescue of the perfusion deficit area by thrombolysis.
Pericyte protection by edaravone after tissue plasminogen activator treatment in rat cerebral ischemia.
Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA.
Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group.
Plasminogen activator inhibitor-1 4G allele in the 4G/5G promoter polymorphism increases the occurrence of cerebral ischemia after aneurysmal subarachnoid hemorrhage.
Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia.
Prevention of rt-PA induced blood-brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice.
Prophylactic thrombosis to prevent new bleeding and to delay aneurysm surgery.
Proportion of single-chain recombinant tissue plasminogen activator and outcome after stroke.
Protease-independent action of tissue plasminogen activator in brain plasticity and neurological recovery after ischemic stroke.
Protective effects of cilostazol against hemorrhagic stroke: Current and future perspectives.
Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia.
Quality of Acute Stroke Care at Primary Stroke Centers Before and After Certification in Comparison to Never-Certified Hospitals.
Receptors, channel proteins, and enzymes involved in microglia-mediated neuroinflammation and treatments by targeting microglia in ischemic stroke.
Recombinant human tissue plasminogen activator protects the basal lamina in experimental focal cerebral ischemia.
Recombinant tissue plasminogen activator attenuates basal lamina antigen loss after experimental focal cerebral ischemia.
Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke.
Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischemia in mouse.
Recombinant tissue-type plasminogen activator transiently enhances blood-brain barrier permeability during cerebral ischemia through vascular endothelial growth factor-mediated endothelial endocytosis in mice.
Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CP101,606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats.
Reduction of hippocampal cell death and proteolytic responses in tissue plasminogen activator knockout mice after transient global cerebral ischemia.
Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats.
Residual flow at the site of intracranial occlusion on transcranial Doppler predicts response to intravenous thrombolysis: a multi-center study.
Role of Carbonic Anhydrase in Cerebral Ischemia and Carbonic Anhydrase Inhibitors as Putative Protective Agents.
Role of Transcranial Doppler Ultrasonography in Cerebrovascular Disease.
rt-PA causes a dose-dependent increase in the extravasation of cellular and non-cellular blood elements after focal cerebral ischemia.
Rt-PA causes a significant increase in endogenous u-PA during experimental focal cerebral ischemia.
Safety and predictors of stroke mimics in The Norwegian Tenecteplase Stroke Trial (NOR-TEST).
Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I.
Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia.
Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia: swift or sure? The acceptable rate of neurovascular mimics among IV tPA-treated patients.
Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene.
Salidroside improves brain ischemic injury by activating PI3K/Akt pathway and reduces complications induced by delayed tPA treatment.
Simulation of Intracranial Acoustic Fields in Clinical Trials of Sonothrombolysis.
Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke.
Small molecule inhibitors in the treatment of cerebral ischemia.
Sonothrombolysis with transcranial color-coded sonography and recombinant tissue-type plasminogen activator in acute middle cerebral artery main stem occlusion: results from a randomized study.
Spinal epidural hematoma: an important stroke mimic.
Stressed neurons protect themselves by a tissue-type plasminogen activator-mediated EGFR-dependent mechanism.
Temporal profile of tissue plasminogen activator (tPA) and inhibitor expression after transient focal cerebral ischemia.
The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity.
The effect of intravenous tissue-type plasminogen activator in a rat model of embolic cerebral ischemia.
The Kringle-2 domain of tissue plasminogen activator significantly reduces mortality and brain infarction in middle cerebral artery occlusion rats.
The Plasminogen Activation System Promotes Neurorepair in the Ischemic Brain.
The Totaled Health Risks in Vascular Events (THRIVE) Score Predicts Ischemic Stroke Outcomes Independent of Thrombolytic Therapy in the NINDS tPA Trial.
Therapeutic Results of Intra-Arterial Thrombolysis after Full-Dose Intravenous Tissue Plasminogen Activator Administration.
Thrombolysis in brain ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator.
Thrombolysis of cerebral clot embolism in rat: effect of treatment delay.
Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke.
Tirofiban combined with rt-PA intraarterial thrombolysis improves the recanalization rate of acute middle cerebral artery occlusion in rabbits.
Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice.
Tissue Plasminogen Activator Causes Brain Microvascular Endothelial Cell Injury After Oxygen Glucose Deprivation by Inhibiting Sonic Hedgehog Signaling.
Tissue plasminogen activator disrupts the blood-brain barrier through increasing the inflammatory response mediated by pericytes after cerebral ischemia.
Tissue plasminogen activator is required for striatal post-ischemic synaptic potentiation.
Tissue plasminogen activator mediated blood-brain barrier damage in transient focal cerebral ischemia in rats: relevance of interactions between thrombotic material and thrombolytic agent.
Tissue plasminogen activator mediates deleterious complement cascade activation in stroke.
Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia.
Tissue plasminogen activator protects hippocampal neurons from oxygen-glucose deprivation injury.
Tissue-plasminogen activator-induced ischemic brain injury is reversed by melatonin: role of iNOS and Akt.
Tissue-type Plasminogen Activator (tPA) Modulates the Postsynaptic Response of Cerebral Cortical Neurons to the Presynaptic Release of Glutamate.
Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system?
Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain.
Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein mediate cerebral ischemia-induced nuclear factor-kappaB pathway activation.
Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein.
Tissue-type plasminogen activator is a neuroprotectant in the central nervous system.
Tissue-type plasminogen activator protects the postsynaptic density in the ischemic brain.
Tissue-type plasminogen activator regulates the neuronal uptake of glucose in the ischemic brain.
Tissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit.
Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial.
Transient ischemic attack after tissue plasminogen activator: aborted stroke or unnecessary stroke therapy?
Ultrasound identification and lysis of clots.
Ultrasound-enhanced thrombolysis for stroke: clinical significance.
Unsuccessful tissue plasminogen activator treatment of acute stroke caused by a calcific embolus.
Uric acid enhances alteplase-mediated thrombolysis as an antioxidant.
Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke.
Visualizing the Distribution of Matrix Metalloproteinases in Ischemic Brain Using In Vivo 19F-Magnetic Resonance Spectroscopic Imaging.
Worse Outcome in Stroke Patients Treated with rt-PA Without Early Reperfusion: Associated Factors.
[Intravenous thrombolytic treatment in acute ischemic stroke: initial results in the Complejo Hospitalario Universitario de Albacete]
[Intravenous tissue-type plasminogen activator for the treatment of acute cerebral ischemia]
[New treatments in cerebrovascular diseases]
[Progranulin].
[Prothymosin?, as a neuroprotective DAMPs/Alarmins molecule].
[Therapeutic aspects of cerebral ischemia]
[Treatment of arterial and venous brain ischemia. Experts' recommendations: stroke management in the intensive care unit].
Brain Neoplasms
An increase in plasminogen activator mRNA occurs at an early stage in ethylnitrosourea-induced transformation of rat brain cells.
Biological significance of tissue plasminogen activator content in brain tumors.
Dexamethasone reduces vascular density and plasminogen activator activity in 9L rat brain tumors.
Different types of plasminogen activator activity in human brain tumours: relation with peritumoral oedema?
Differentiating the Influences of Aging and Adiposity on Brain Weights, Levels of Serum and Brain Cytokines, Gastrointestinal Hormones, and Amyloid Precursor Protein.
Elevated fibroblast growth factor-inducible 14 expression transforms proneural-like gliomas into more aggressive and lethal brain cancer.
Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors.
Immunohistochemical localisation of tissue plasminogen activator in human brain tumours.
Immunohistochemical localization of plasminogen activator inhibitor type 1 in human brain tumors.
In vitro inhibition of human malignant brain tumour cell line proliferation by anti-urokinase-type plasminogen activator monoclonal antibodies.
In vitro plasminogen activator activity in human brain tumors.
Increased levels of plasminogen activator inhibitor-1 (PAI-1) in human brain tumors.
Intravenous Thrombolysis for Ischemic Stroke in Recurrent Oligodendroglioma: A Case Report.
Intravenous thrombolysis in ischemic stroke patients with intracranial neoplasms: two cases and a literature review.
Off-label use of IV t-PA in patients with intracranial neoplasm and cavernoma.
Plasma fibrinolytic profile in patients with brain tumors.
Plasminogen activator activity and molecular weight patterns in human brain tumors.
Plasminogen activator and hemorrhage in brain tumors.
Plasminogen activator inhibitor-1 in brain tumors: relation to malignancy and necrosis.
Postoperative venous thromboembolism and brain tumors: Part III. Biochemical profile.
Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours.
Prognostic significance of proteolytic enzymes in human brain tumors.
Purification and characterization of the plasminogen activator secreted by a rat brain tumor cell line in culture.
Reduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors.
Risk of Thrombolytic Therapy for Acute Ischemic Stroke in Patients With Current Malignancy.
Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: evidence for elevated expression of protease nexin I-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin.
Successful Intra-arterial Thrombolysis in a Patient with an Intracranial Meningioma.
Tissue plasminogen activator as a key effector in neurobiology and neuropathology.
Tissue plasminogen activator expression in meningiomas and glioblastomas.
Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain.
[A plasminogen regulation system in brain tumors].
Brain Stem Infarctions
Brainstem infarction secondary to persistent trigeminal artery occlusion: successful treatment with intravenous rt-PA.
Breast Cyst
[Tumour markers in human breast cyst fluid in gross cystic breast disease (GCBD)]
Breast Diseases
Human tissue polypeptide antigen in breast cancer.
Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Proliferative responses of epithelial cells to 8-bromo-cyclic AMP and to a phorbol ester change during breast pathogenesis.
[MSA--a new sensitive tumor marker in breast carcinoma]
Breast Neoplasms
(-)-Epigallocatechin gallate derivatives reduce the expression of both urokinase plasminogen activator and plasminogen activator inhibitor-1 to inhibit migration, adhesion, and invasion of MDA-MB-231 cells.
12-O-Tetradecanoylphorbol-13-acetate Promotes Breast Cancer Cell Motility by Increasing S100A14 Level in a Kruppel-like Transcription Factor 4 (KLF4)-dependent Manner.
1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells.
A common response element mediates differential effects of phorbol esters and forskolin on type-1 plasminogen activator inhibitor gene expression in human breast carcinoma cells.
A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA.
A personalized approach to cancer treatment: how biomarkers can help.
A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy.
A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols.
Absence of specific cell-surface binding of tissue plasminogen activator in uterine cells.
Accumulation of uPA-PAI-1 complexes inside the tumour cells is associated with axillary nodal invasion in progesterone-receptor-positive early breast cancer.
Activation of human breast carcinoma collagenase through plasminogen activator.
Adipocyte-Derived Leptin Promotes PAI-1 -Mediated Breast Cancer Metastasis in a STAT3/miR-34a Dependent Manner.
Agonist activity of antiestrogen-receptor complexes to regulate urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells.
An individual reference limit for 'early' diagnosis of metastatic breast cancer during postoperative follow-up.
An individual reference limit of the serum CEA-TPA-CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer.
An ultra-sensitive immunoassay for quantifying biomarkers in breast tumor tissue.
Anti-TNF-? treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells.
Anti-urokinase-type plasminogen activator monoclonal antibodies inhibit the proliferation of human breast cancer cell lines in vitro.
Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model.
Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites.
Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer.
Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients.
Association of in vitro invasiveness and gene expression of estrogen receptor, progesterone receptor, pS2 and plasminogen activator inhibitor-1 in human breast cancer cell lines.
Association of plasminogen activator activity and steroid receptors in human breast cancer.
Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
Association of uPA, PAT-1, and uPAR in nipple aspirate fluid (NAF) with breast cancer.
Augmented release of matrix metalloproteinase-9 by PKC activation in organotypic cultures of human breast cancer and adjacent normal breast tissue and fibroadenoma.
Berberine Suppresses the TPA-Induced MMP-1 and MMP-9 Expressions Through the Inhibition of PKC-? in Breast Cancer Cells.
Binding of urokinase to specific receptor sites on human breast cancer membranes.
Biochemical parameters for prognostic evaluation in patients with breast cancer.
Biological activities of tamoxifen aziridine, an antiestrogen-based affinity label for the estrogen receptor, in vivo and in vitro.
Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer.
Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.
Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation.
Breast cancer prognosis is poor when total plasminogen activator activity is low.
Breast cancer statistics and markers.
BreastDefend™ prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer.
CA 15-3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse.
CA 549 and SP2 in postoperative breast cancer patients. Comparison with CA 15.3, CEA and TPA.
CA-15.3, TPA and MCA as markers for breast cancer.
Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment.
Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
CEA, TPA and CA 15.3 in tissue and serum of breast cancer patients.
Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator.
Changes in uPA, PAI-1, and TGF-? Production during Breast Cancer Cell Interaction with Human Mesenchymal Stroma/Stem-Like Cells (MSC).
Characterization of a novel amphiregulin-related molecule in 12-O-tetradecanoylphorbol-13-acetate-treated breast cancer cells.
Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk.
Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.
Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis.
Collagenases in human breast carcinoma cell lines.
Combined diagnosis of breast cancer in the early stage by MRI and detection of gene expression.
Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Comparative study of four extraction procedures for urokinase type plasminogen activator and plasminogen activator inhibitor-1 in breast cancer tissues.
Comparison between CEA, TPA, CA 15/3 and hydroxyproline, alkaline phosphatase, whole body retention of 99mTc MDP in the follow-up of bone metastases in breast cancer.
Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue.
Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients.
Comparison of prolactin, CA 15-3 and TPA in breast carcinomas.
Comparison of serum CEA, PHI, and TPA as tumor markers in breast cancer patients.
Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer.
Counteraction of estradiol-induced activation of tissue-type plasminogen activator in a human breast cancer cell line by an anti-estrogen, LY117018.
Cyclooxygenase-2 uses the protein kinase C/ interleukin-8/urokinase-type plasminogen activator pathway to increase the invasiveness of breast cancer cells.
Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation.
Cytosolic tissue-type plasminogen activator (t-PA) levels in breast tumors and hormone dependence. Role of pS2.
Dehydroepiandrosterone and 16 alpha-Br-epiandrosterone inhibit 12-O-tetradecanoylphorbol-13-acetate stimulation of superoxide radical production by human polymorphonuclear leukocytes.
Design and testing of a packaged microfluidic cell for the multiplexed electrochemical detection of cancer markers.
Determination of TPA levels in breast cancer and controls.
Diagnostic and prognostic value of TPA in breast cancer.
Diagnostic value of measuring serum CA 15-3, TPA, and TPS in women with breast cancer.
Differential effect of retinoic acid on growth regulation by phorbol ester in human cancer cell lines.
Differential immunocytochemical localization of tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) in breast cancer.
Dissemination risk index based on plasminogen activator system components in primary breast cancer.
Divergent Impact of Breast Cancer Laterality on Clinicopathological, Angiogenic, and Hemostatic Profiles: A Potential Role of Tumor Localization in Future Outcomes.
Down-regulation of osteopontin attenuates breast tumour progression in vivo.
Early diagnosis of breast cancer dissemination by tumor markers follow-up and method of prediction.
Effect of berberine on p53 expression by TPA in breast cancer cells.
Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines.
Effect of progesterone on the invasive properties and tumor growth of progesterone receptor-transfected breast cancer cells MDA-MB-231.
Effects of Weight Loss and Weight Regain on Circulating Biomarkers in Overweight/Obese Breast Cancer Survivors Enrolled in a Weight Loss Trial in the Rural Midwest.
EndoPredict versus uPA/PAI-1 in breast cancer: Comparison of markers and association with clinicopathological parameters.
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Enhanced cell-associated plasminogen activator pathway but not coagulation pathway activity contributes to motility in metastatic breast cancer cells.
Enhanced production of tissue-type plasminogen activator by estradiol in a novel type variant of human breast cancer MCF-7 cell line.
Epsilon-aminocaproic acid prevents high glucose and insulin induced-invasiveness in MDA-MB-231 breast cancer cells, modulating the plasminogen activator system.
Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas: correlation with clinical outcome of anti-estrogen therapy.
Estradiol preferentially enhances extracellular tissue plasminogen activators of MCF-7 breast cancer cells.
Estrogen receptor alpha attenuates transforming growth factor-beta signaling in breast cancer cells independent from agonistic and antagonistic ligands.
Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells.
Estrogen regulation of human breast cancer cell line MCF-7 tissue plasminogen activator.
Evaluation of CEA, TPA, CA 15-3, CA 549 and TPS in the monitoring of metastatic breast cancer.
Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
Evaluation of serum CA549, CA M26 and CA M29 levels in the post-operative follow-up of breast cancer patients.
Evaluation of the prognostic value of fibrinolytic elements in invasive breast carcinoma patients.
Exposure of mcf-7 breast cancer cells to electromagnetic fields up-regulates the plasminogen activator system.
Expression and regulation of Cyr61 in human breast cancer cell lines.
Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Expression of the human MTA1 gene in breast cell lines and in breast cancer tissues.
Expression of tumour markers CA50, CEA and TPA in female breast carcinoma as related to histopathological findings and survival.
External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
Extracellular vesicles from MDA-MB-231 breast cancer cells stimulated with linoleic acid promote an EMT-like process in MCF10A cells.
Fabrication of an immunosensor for early and ultrasensitive determination of human tissue plasminogen activator (tPA) in myocardial infraction and breast cancer patients.
Free fatty acids enhance breast cancer cell migration through plasminogen activator inhibitor-1 and SMAD4.
Frondoside A has an anti-invasive effect by inhibiting TPA-induced MMP-9 activation via NF-?B and AP-1 signaling in human breast cancer cells.
Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival.
Glycoprotein isolated from Solanum nigrum L. inhibits the DNA-binding activities of NF-kappaB and AP-1, and increases the production of nitric oxide in TPA-stimulated MCF-7 cells.
Gold-conjugated resveratrol nanoparticles attenuate the invasion and MMP-9 and COX-2 expression in breast cancer cells.
High Expression of Urokinase-Type Plasminogen Activator Is Associated with Lymph Node Metastasis of Invasive Ductal Carcinoma of the Breast.
High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Hormonal control of plasminogen activator secretion in ZR-75-1 human breast cancer cells in culture.
Hormonal modulation of plasminogen activator: an approach to prediction of human breast tumor responsiveness.
Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity.
Human cytomegalovirus interleukin-10 enhances matrigel invasion of MDA-MB-231 breast cancer cells.
Human tissue polypeptide antigen in breast cancer.
Identification of a pituitary factor responsible for enhancement of plasminogen activator activity in breast tumor cells.
IL-6sR: release from MCF-7 breast cancer cells and role in regulating peripheral oestrogen synthesis.
Immuno-histochemical localization of tissue polypeptide antigen (TPA) and carcino-embryonic antigen (CEA) in breast cancer. A comparative study.
Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology.
Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer.
Impact of preoperative CA 15-3 levels in operable breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
In vivo measurements of fibrin formation and fibrinolysis in operable breast cancer.
Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis.
Increased soluble P-selectin in patients with haematological and breast cancer: a comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor.
Increased surface expression and shedding of tumor associated antigens by human breast carcinoma cells treated with recombinant human interferons or phorbol ester tumor promoters.
Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients.
Induction of apoptosis in breast cancer cells by TPA.
Induction of plasminogen activator by estrogen in a human breast cancer cell line (MCF-7).
Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease.
Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissues.
Inhibition of AP-1 and NF-kappaB by manganese-containing superoxide dismutase in human breast cancer cells.
Inhibition of estrogen receptor activity by the tumor promoter 12-O-tetradeconylphorbol-13-acetate: a molecular analysis.
Inhibition of stimulus-dependent epidermal growth factor receptor and transforming growth factor-alpha mRNA accumulation by the protein kinase C inhibitor staurosporine.
Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Interaction of 2,3,7,8-tetrachlorodibenzo-p-dioxin, 12-O-tetradecanoylphorbol-13-acetate (TPA) and 17 beta-estradiol in MCF-7 human breast cancer cells.
Interleukin-6 enhances motility of breast carcinoma cells.
Interleukin-like epithelial-to-mesenchymal transition inducer activity is controlled by proteolytic processing and plasminogen-urokinase plasminogen activator receptor system-regulated secretion during breast cancer progression.
Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.
Inverse correlation between mRNA expression of plasminogen activator inhibitor-2 and lymph node metastasis in human breast cancer.
Is tissue polypeptide antigen still a useful tumor marker in breast carcinoma? Comparison with CA15.3 and MCA.
Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer.
Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells.
Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence.
Luminoimmunometric assay of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA-125) in breast cancer patients.
Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.
Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Mechanism of Telapristone Acetate (CDB4124) on Progesterone Receptor Action in Breast Cancer Cells.
Mendelian randomisation analysis of circulating adipokines and C-reactive protein on breast cancer risk.
Messenger RNA determination of estrogen receptor, progesterone receptor, pS2, and plasminogen activator inhibitor-1 by competitive reverse transcription-polymerase chain reaction in human breast cancer.
Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Migration and invasion induced by linoleic acid are mediated through fascin in MDA-MB-231 breast cancer cells.
Mitochondrial targeting of TR3 is involved in TPA induced apoptosis in breast cancer cells.
Mitogen-induced expression of the fibroblast growth factor-binding protein is transcriptionally repressed through a non-canonical E-box element.
Mitogenic activity and plasminogen activator in harvest fluid concentrates from mammary cells in culture.
Modulation of plasminogen activator systems by matrix components in two breast cancer cell lines: MCF-7 and MDA-MB-231.
Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA.
Morphine and breast tumor metastasis: the role of matrix-degrading enzymes.
Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer.
Multiple forms of plasminogen activator in human breast tumors.
Natural killer cells inhibit breast cancer cell invasion through downregulation of urokinase?type plasminogen activator.
New data on chemotherapy in the adjuvant setting.
Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease.
Novel methods for the determination of the angiogenic activity of human tumors.
Obesity and Breast Cancer: The Roles of Peroxisome Proliferator-Activated Receptor-gamma and Plasminogen Activator Inhibitor-1.
Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting.
Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor.
Optimized immunohistochemistry in combination with image analysis: A reliable alternative to quantitative ELISA determination of uPA and PAI-1 for routine risk group discrimination in breast cancer.
Overexpression of PSMC2 promotes the tumorigenesis and development of human breast cancer via regulating plasminogen activator urokinase (PLAU).
Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis.
PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients.
PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.
Peroxisome Proliferator-Activated Receptor-? Ligands Alter Breast Cancer Cell Motility through Modulation of the Plasminogen Activator System.
Phorbol ester or epidermal growth factor (EGF) stimulates the concurrent accumulation of mRNA for the EGF receptor and its ligand transforming growth factor-alpha in a breast cancer cell line.
Phorbol Ester TPA Modulates Chemoresistance in the Drug Sensitive Breast Cancer Cell Line MCF-7 by Inducing Expression of Drug Efflux Transporter ABCG2.
Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients.
PKC activation sensitizes basal-like breast cancer cell lines to Smac mimetics.
Plasma and tissue CEA and TPA markers in operable breast cancer. Preliminary results.
Plasma Plasminogen Activator Inhibitor-1 (PAI-1) Levels in Breast Cancer - Relationship with Clinical Outcome.
Plasmatic plasminogen activator inhibitor activity in patients with primary breast cancer.
Plasmin induces the formation of multicellular spheroids of breast cancer cells.
Plasminogen activator activity and composition in human breast cancer.
Plasminogen activator activity in human breast cancer cytosols.
Plasminogen activator activity in human prostate and breast tumors: relationship to steroid receptors.
Plasminogen activator and cancer.
Plasminogen activator as a functional marker for estrogen dependence in human breast cancer cells.
Plasminogen activator expression and steroid hormone receptors in female breast cancer: a multifactorial study.
Plasminogen activator in human breast cancer cytosols: revisited after five years.
Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.
Plasminogen activator inhibitor 1 (PAI1) promotes actin cytoskeleton reorganization and glycolytic metabolism in triple negative breast cancer.
Plasminogen activator inhibitor type 1 and 2 in human breast cancer.
Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Plasminogen activator inhibitor type 2 in breast cancer.
Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.
Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer.
Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells.
Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Plasminogen activator inhibitor-1 in cancer research.
Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.
Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine.
Plasminogen activator system in human breast cancer.
Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer.
Plasminogen activators in breast-cancer cells.
Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma.
Prediction of biological behaviour of human breast cancer using multiple parameters. A preliminary study.
Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer.
Preservation of steroid hormone receptors in organ cultures of human breast carcinomas.
Progesterone receptor blockade in human breast cancer cells decreases cell cycle progression through G2/M by repressing G2/M genes.
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.
Prognostic significance of plasminogen activator inhibitor-1 in breast cancer, with special emphasis on locoregional recurrence-free survival.
Prognostic significance of the combined expression of matrix metalloproteinase-9, urokinase type plasminogen activator and its receptor in breast cancer as measured by Northern blot analysis.
Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer.
Prognostic significance of tumor-related proteases as a function of the estrogen receptor status.
Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.
Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.
Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer.
Prognostic value of plasminogen activator inhibitors in breast cancer.
Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer.
Prognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer.
Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations.
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer.
Proteases associated with gynecological tumors.
Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue.
Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts.
Proteinases As Biomarkers In Breast Cancer Prognosis And Diagnosis.
Quantitative measurement of soluble cytokeratin fragments in tissue cytosol of 599 node negative breast cancer patients: a prognostic marker possibly associated with apoptosis.
Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.
Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Regulation of arachidonic acid metabolism, aromatase activity and growth in human breast cancer cells by interleukin-1beta and phorbol ester: dissociation of a mediatory role for prostaglandin E2 in the autocrine control of cell function.
Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
Regulation of thrombin-induced plasminogen activator inhibitor-1 in 4T1 murine breast cancer cells.
Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.
Relationship Between Circulating Tumor Cells and Tissue Plasminogen Activator in Patients with Early Breast Cancer.
Relationship between cytosol TPS, TPA and cell proliferation.
Relationship between multiple forms of plasminogen activator in human breast tumors and plasma and the presence of metastases in lymph nodes.
Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
Restoration of transforming growth factor Beta signaling by functional expression of smad4 induces anoikis.
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.
Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer.
S-phase fraction and urokinase plasminogen activator are better markers for distant recurrences than Nottingham Prognostic Index and histologic grade in a prospective study of premenopausal lymph node-negative breast cancer.
Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancer.
Significance of carcinoembryonic and tissue polypeptide antigen determination in the diagnosis of metastases in breast cancer.
Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells.
Steroid stimulation of plasminogen activator production in a human breast cancer cell line (MCF-7).
Studies on plasminogen activator inhibitor 1 levels in human breast cancer.
Study of lncRNA TPA in Promoting Invasion and Metastasis of Breast Cancer Mediated by TGF-? Signaling Pathway.
Suppression of estrogen-regulated extracellular tissue plasminogen activator activity of MCF-7 cells by 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Synergistic effect of tamoxifen and phorbol ester TPA on retrovirus synthesis in a human mammary carcinoma cell line.
Tamoxifen suppresses tumor promoter-induced hydrogen peroxide formation by human neutrophils.
The clinical significance of tissue polypeptide antigen in breast cancer patients.
The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.
The Effect of Anthracycline-Based (Epirubicin) Adjuvant Chemotherapy on Plasma TAFI and PAI-1 Levels in Operable Breast Cancer.
The estrogen-regulated 52 K protein adn plasminogen activators released by MCF7 cells are different.
The induction of senescence-like growth arrest by protein kinase C-activating diterpene esters in solid tumor cells.
The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells.
The influence of phorbol ester on the effect of tamoxifen in breast cancer cells.
The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas.
The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer.
The status of nuclear medicine techniques in the diagnosis of bone metastases in breast cancer.
Thrombin generation as a predictor of radiotherapy induced skin erythema.
Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells.
Thrombospondin in malignant and non-malignant breast tissue.
Tissue Plasminogen Activator Levels and Risk of Breast Cancer in a Case-Cohort Study on Italian Women: Results from the Moli-sani Study.
Tissue plasminogen activators in breast cancer.
Tissue polypeptide antigen & interleukin-6: Are their serum levels a predictor for response to chemotherapy in breast cancer?
Tissue polypeptide antigen in breast cancer cytosol: a new effective prognostic indicator.
Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
Tissue-type plasminogen activator (tPA) in breast cancer: relationship with clinicopathological parameters and prognostic significance.
Tissue-type plasminogen activator as marker of functional steroid receptors in human breast cancer.
Tissue-type plasminogen activator in breast cancer: relationship with estradiol and progesterone receptors.
Tissue-type plasminogen activator in plasma from breast cancer patients determined by enzyme-linked immunosorbent assay.
Tissue-type plasminogen activator is involved in skeletal metastasis from human breast cancer.
Tissue-type plasminogen activator is upregulated in metastatic breast cancer cells exposed to insulin-like growth factor-I.
Tissue-type plasminogen activator, a new prognostic marker in breast cancer.
TPA and CA 15.3 measurements for breast cancer monitoring in a routine setting.
TPA and CK-BB: new tumor markers in leptomeningeal carcinomatosis secondary to breast cancer.
TPA-induced p21 expression augments G2/M arrest through a p53-independent mechanism in human breast cancer cells.
Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo.
Treatment of superior vena cava thrombosis with recombinant tissue type plasminogen activator.
Tumor markers in breast cancer- European Group on Tumor Markers recommendations.
Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer.
Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.
Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms.
Tumor-associated urokinase-type plasminogen activator: significance in breast cancer.
Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: the EPICOR study.
Type-1 plasminogen activator inhibitor in human breast carcinomas.
Urokinase and macrophages in tumour angiogenesis.
Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors.
Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies.
Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
Urokinase-like plasminogen activator receptor expression on disseminated breast cancer cells.
Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression.
Urokinase-type Plasminogen Activator and Plasminogen-activator-inhibitor Type 1 Predict Metastases in Good Prognosis Breast Cancer Patients.
Urokinase-type plasminogen activator in ascites obtained from the patient with mammary cancer.
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis.
Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer.
Vitamin D Receptor Genetic Variation and Cancer Biomarkers among Breast Cancer Patients Supplemented with Vitamin D3: A Single-Arm Non-Randomized Before and After Trial.
Vitamin D3 modulation of plasminogen activator inhibitor type-1 in human breast carcinomas under organ culture.
Wild-type p53 controls the level of fibronectin expression in breast cancer cells.
Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1.
[A plasminogen regulation system in brain tumors].
[Advanced breast cancer with remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesteron acetate (MPA) after failure of anthracycline therapy: a case report]
[Association of single nucleotide polymorphisms in PAI-1 with breast cancer susceptibility and prognosis].
[Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system]
[CA 15-3 associated with CEA and TPA in the follow-up of breast carcinoma]
[CEA and TPA in cancer of the breast. Findings and criteria of use]
[Changes in carcinoembryonic antigen and tissue polypeptide antigen in monitoring the post-operative course of some tumor types]
[Circulating proteinic biomarkers and breast cancer]
[Clinical and prognostic significance of tumor-associated proteases in gynecologic oncology]
[Clinical evaluation of tumor markers in breast cancer patients]
[Clinical relevance of tumor markers]
[Clinical significance of a tumor marker NCC-ST-439 in breast cancer--a comparative study with CA 15-3, CEA and TPA]
[D-dimer and plasminogen activator of the urokinase type: personal experiences with breast cancer]
[Estrogen dependent plasminogen activator in breast cancer cells; experimental and clinical studies]
[Ferritin, CEA and TPA as tumor markers in breast neoplasms]
[Measurement of plasminogen activator and plasminogen activator inhibitor in breast cancer tissue: preliminary report]
[MSA--a new sensitive tumor marker in breast carcinoma]
[Plasminogen activator inhibitor 1 and prognosis in breast carcinoma]
[Prognostic significance of plasminogen activator inhibitor-1 (PAI-1) in primary breast carcinoma]
[Proliferation and liberation kinetics of the tissue polypeptide antigen of MCF-7 cells. Hormonal influence]
[Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer]
[Study on carbohydrate antigen NCC-ST-439 in breast cancer]
[The concentration of tissue--type plasminogen activator (t-PA) in extracts of breast cancer tissue]
[The tumor markers CEA, TPA and CA 19-9 and ferritin and osteocalcin in follow-up studies in breast cancer]
[The tumor markers TPA and CEA in the after care of breast cancer]
[Tissue polypeptide and carcinoembryonic antigens in patients with breast cancer]
[Tissue polypeptide antigen (TPA) and plasma TPA levels during the postoperative course in female primary breast carcinoma patients. 1st results of a long-term study]
[TPA and TPS in the follow-up of cancer of the breast: preliminary evaluations]
[Tumor markers CEA, CA 15-3, MCA, TPA, ferritin and PTH in the diagnosis and monitoring of primary breast cancer]
Breast Neoplasms, Male
Overexpression of plasminogen activator in male breast cancer.
Bronchial Hyperreactivity
Plasminogen activator inhibitor-1 plasma concentration in allergic asthma patients during allergen challenge.
Bronchiolitis Obliterans
Alteplase treatment for massive lung atelectasis in a child with severe bronchiolitis obliterans complicating Stevens-Johnson syndrome.
Bronchitis
A Role for Low Density Lipoprotein Receptor-Related Protein 1 in the Cellular Uptake of Tissue Plasminogen Activator in the Lungs.
Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.
Fontan patient with plastic bronchitis treated successfully using aerosolized tissue plasminogen activator: a case report and review of the literature.
Long-term treatment of plastic bronchitis with aerosolized tissue plasminogen activator in a Fontan patient.
Management of plastic bronchitis with nebulized tissue plasminogen activator: another brick in the wall.
Management of Plastic Bronchitis With Topical Tissue-type Plasminogen Activator.
Plastic Bronchitis Treated With Topical Tissue-Type Plasminogen Activator and Cryotherapy.
Prospective, Longitudinal Study of Plastic Bronchitis Cast Pathology and Responsiveness to Tissue Plasminogen Activator.
Safety of prolonged, repeated administration of a pulmonary formulation of tissue plasminogen activator in mice.
Tissue Plasminogen Activator Prevents Mortality from Sulfur Mustard Analog-Induced Airway Obstruction.
Treatment of plastic bronchitis in a Fontan patient with tissue plasminogen activator: a case report and review of the literature.
Use of aerosolized tissue plasminogen activator in the treatment of plastic bronchitis.
[Plasminogen activators in assessing the reaction of patients with chronic obstructive bronchitis to physical loading]
Bronchitis, Chronic
An evaluation of tissue polypeptide antigen (TPA) in the two bronchoalveolar lavage fractions of lung cancer patients.
Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer.
Latent alpha1-antichymotrypsin. A molecular explanation for the inactivation of alpha1-antichymotrypsin in chronic bronchitis and emphysema.
Bronchopulmonary Dysplasia
Plasminogen activator activity in preterm infants with respiratory distress syndrome: relationship to the development of bronchopulmonary dysplasia.
The role of plasminogen activator inhibitor-1 and angiotensin-converting enzyme gene polymorphisms in bronchopulmonary dysplasia.
[Expression of TGF-?1 and PAI-1 in premature infants with bronchopulmonary dysplasia].
Budd-Chiari Syndrome
Budd-Chiari syndrome in a child due to a membranous web of the inferior vena cava resolved by systemic and local recombinant tissue plasminogen activator treatment.
Comments to: Budd-Chiari syndrome: Current options in the interventional radiology treatment exemplified by three selected cases.
Fibrinolytic therapy with rt-PA in a patient with paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome.
Recombinant tissue-plasminogen activator for acute Budd-Chiari syndrome secondary to paroxysmal nocturnal hemoglobinuria.
Tissue plasminogen activator and plasminogen activator inhibitor status in Budd-Chiari syndrome.
Tissue plasminogen activator for hepatic vein thrombosis in paroxysmal nocturnal haemoglobinuria.
[Subacute Budd-Chiari syndrome treated with rTPA. Considerations on a case]
[Thrombolytic therapy using r-TPA in Budd-Chiari syndrome in the course of myeloproliferative diseases]
Bundle-Branch Block
A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators.
Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators.
Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial.
[Fatal central pulmonary embolism under heparin therapy: white-clot syndrome]
Burkitt Lymphoma
Autoregulation of Epstein-Barr virus putative lytic switch gene BZLF1.
Differential effect of TPA on cell growth and Epstein-Barr virus reactivation in epithelial cell lines derived from gastric tissues and B cell line Raji.
Epidural hematoma following tissue plasminogen activator (tPA) therapy for pulmonary embolism in a pediatric patient with stage IV Burkitt's lymphoma: a case report.
Tumour-promoting phorbol esters inhibit DNA synthesis and enhance virus-induced interferon production in a human lymphoma cell line.
ZEB1 regulates the latent-lytic switch in infection by Epstein-Barr virus.
Bursitis
Hemorrhagic bursitis complicating treatment with recombinant tissue plasminogen activator.
CADASIL
Successful Use of Intravenous Tissue Plasminogen Activator as Treatment for a Patient with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy: A Case Report and Review of Literature.
Calciphylaxis
Low-dose tissue plasminogen activator for calciphylaxis.
Retrospective analysis of tissue plasminogen activator as an adjuvant treatment for calciphylaxis.
Carcinogenesis
1 alpha,25-Dihydroxyvitamin D3 enhances 12-O-tetradecanoylphorbol-13-acetate- induced tumorigenic transformation and osteopontin expression in mouse JB6 epidermal cells.
12-0-Tetradecanoylphorbol-13-acetate-induced amplification of mesenchymal tumorigenesis in the mouse skin.
12-O-Tetradecanoylphorbol-13-acetate (TPA) is anti-tumorigenic in liver cancer cells via inhibiting YAP through AMOT.
12-O-tetradecanoylphorbol-13-acetate promotion of transgenic mice expressing epidermal-targeted v-fos induces rasHA-activated papillomas and carcinomas without p53 mutation: association of v-fos expression with promotion and tumor autonomy.
12-O-tetradecanoylphorbol-13-acetate-mediated systemic co-promotion in the murine skin multistage carcinogenesis protocol.
A course of very small doses of DMBA, each of them allegedly with no promoting potency, acts with clear synergistic effect as a strong promoter of DMBA-initiated mouse skin carcinogenesis. A comparison of the tumorigenic and carcinogenic effects of DMBA (7,12-dimethylbenz-alpha-anthracene) and TPA (12-O-tetradecanoyl-phorbol-13-acetate) used as initiators and promoters in classical two-stage experimental protocols.
A derivative of chrysin suppresses two-stage skin carcinogenesis by inhibiting mitogen- and stress-activated kinase 1.
A diacetylenic spiroketal enol ether epoxide, AL-1, from Artemisia lactiflora inhibits 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion possibly by suppression of oxidative stress.
A genetic variant of Aurora kinase A promotes genomic instability leading to highly malignant skin tumors.
A protective effect of chromosome 11 against DNA damage by TPA-activated neutrophils but not TPA acting alone.
A strain of hairless mouse susceptible to tumorigenesis by TPA alone: studies with 8-methoxypsoralen and solar simulated radiation.
All-trans beta-carotene enhances mitogenic responses and ornithine decarboxylase activity of BALB/c 3T3 fibroblast cells induced by tumor promoter and fetal bovine serum but suppresses mutagen-dependent umu C gene expression in Salmonella typhimurium (TA 1535/pSK 1002).
Alpha 2-HS glycoprotein (fetuin-A) modulates murine skin tumorigenesis.
alpha-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin.
An antitumor promoter from Moringa oleifera Lam.
Anti-carcinogenic activity of Taraxacum plant. I.
Anti-carcinogenic activity of Taraxacum plant. II.
Anti-carcinogenic activity of the roots of Panax notoginseng. II.
Anti-inflammatory and anti-tumor-promoting effects of 5-deprenyllupulonol C and other compounds from Hop (Humulus lupulus L.).
Anti-inflammatory and anti-tumor-promoting effects of triterpene acids and sterols from the fungus Ganoderma lucidum.
Anti-inflammatory and antitumor-promoting effects of the triterpene acids from the leaves of Eriobotrya japonica.
Anti-inflammatory and chemopreventive effects of triterpene cinnamates and acetates from shea fat.
Anti-tumor promoting activities of isoflavonoids from Wistaria brachybotrys.
Anti-tumor promoting activity of polyphenols from Cowania mexicana and Coleogyne ramosissima.
Anti-tumor promoting diterpenes from the stem bark of Thuja standishii (Cupressaceae).
Anti-tumor-promoting activities of triterpenoids from ferns. I.
Anti-tumor-promoting activity of diterpenes from Excoecaria agallocha.
Anti-tumor-promoting activity of majonoside-R2 from Vietnamese ginseng, Panax vietnamensis Ha et Grushv. (I).
Anti-tumor-Promoting activity of tibolone and its metabolites.
Anti-Tumor-Promoting Effects of 25-Methoxyporicoic Acid A and Other Triterpene Acids from Poria cocos.
Anti-tumor-promoting effects of glycoglycerolipid analogues on two-stage mouse skin carcinogenesis.
Anti-tumor-promotion by principles obtained from Angelica keiskei.
Anticarcinogenic activity of natural sweeteners, cucurbitane glycosides, from Momordica grosvenori.
Antioxidants--carcinogenic and chemopreventive properties.
Antitumor activity of combination therapy with traditional Chinese medicine and OK432 or MMC.
Antitumor activity of compounds isolated from leaves of Eriobotrya japonica.
Antitumor-promoting activities of hydrolyzable tannins in mouse skin.
Antitumor-promoting activities of tannic acid, ellagic acid, and several gallic acid derivatives in mouse skin.
Antitumor-promoting effects and cytotoxic activities of dammar resin triterpenoids and their derivatives.
Antitumour activity of protein A in a mouse skin model of two-stage carcinogenesis.
Auraptene, a citrus coumarin, inhibits 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion in ICR mouse skin, possibly through suppression of superoxide generation in leukocytes.
Biological activities and cellular uptake studies of fluorescent derivatives of indole alkaloid tumor promoter teleocidin.
Biological Activities of Phenolic Compounds and Triterpenoids from the Galls of Terminalia chebula.
Biomarker assessments in asbestos-exposed workers as indicators for selective prevention of mesothelioma or bronchogenic carcinoma: rationale and practical implementations.
Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis.
Building Bridges toward Invasion: Tumor Promoter Treatment Induces a Novel Protein Kinase C-Dependent Phenotype in MCF10A Mammary Cell Acini.
Cancer chemopreventive activity of "rosin" constituents of Pinus spez. and their derivatives in two-stage mouse skin carcinogenesis test.
Cancer chemopreventive activity of 3beta-methoxyserrat-14-en-21beta-ol and several serratane analogs on two-stage mouse skin carcinogenesis.
Cancer chemopreventive activity of carotenoids in the fruits of red paprika Capsicum annuum L.
Cancer chemopreventive activity of diversin from Ferula diversivittata in vitro and in vivo.
Cancer chemopreventive activity of lupane- and oleanane-type triterpenoids from the cones of Liquidamber styraciflua.
Cancer chemopreventive activity of odorine and odorinol from Aglaia odorata.
Cancer chemopreventive activity of oleanane-type triterpenoids from the stem bark of Betula ermanii.
Cancer chemopreventive activity of phenylpropanoid esters of sucrose, vanicoside B and lapathoside A, from Polygonum lapathifolium.
Cancer chemopreventive activity of serratane-type triterpenoids on two-stage mouse skin carcinogenesis.
Cancer chemopreventive activity of the prenylated coumarin, umbelliprenin, in vivo.
Cancer chemopreventive agents (antitumor-promoters) from Ajuga decumbens.
Cancer chemopreventive agents, labdane diterpenoids from the stem bark of Thuja standishii (Gord.) Carr.
Cancer chemopreventive agents, serratane-type triterpenoids from Picea jezoensis.
Cancer chemopreventive effect of bergenin from Peltophorum pterocarpum wood.
Cancer chemopreventive effects of cycloartane-type and related triterpenoids in in vitro and in vivo models.
Cancer chemopreventive effects of polyunsaturated fatty acids.
Cancer chemoprotective effects of Curcuma xanthorrhiza.
Cancer preventive agents. Part 1: chemopreventive potential of cimigenol, cimigenol-3,15-dione, and related compounds.
Cancer preventive agents. Part 8: Chemopreventive effects of stevioside and related compounds.
Cell culture systems for studying multifactor interactions in carcinogenesis.
Cell-mediated immune response in mice during the two-step carcinogenesis experiment by 7,12-dimethylbenz(a)anthracene and 12-O-tetradecanoylphorbol-13-acetate.
Cellular dichotomy between anchorage-independent growth responses to bFGF and TPA reflects molecular switch in commitment to carcinogenesis.
Cellular Senescence Promotes Skin Carcinogenesis through p38MAPK and p44/42MAPK Signaling.
Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
Chemical carcinogenesis by the two-stage protocol in the skin Mastomys natalensis (Muridae) using topical initiation with 7,12-dimethylbenz(a)anthracene and topical promotion with 12-0-tetradecanoylphorbol-13-acetate.
Chemoprevention of DMBA-induced UV-B promoted, NOR-1-induced TPA promoted skin carcinogenesis, and DEN-induced phenobarbital promoted liver tumors in mice by extract of beetroot.
Chemoprevention of Skin Cancer: Effect of Lawsonia Inermis L. (Henna) Leaf Powder and its Pigment Artifact, Lawsone in the Epstein- Barr Virus Early Antigen Activation Assay and in Two-Stage Mouse Skin Carcinogenesis Models.
Chemopreventive effect of Vitis vinifera extract on 12-O-tetradecanoyl-13-phorbol acetate-induced cutaneous oxidative stress and tumor promotion in murine skin.
Chemopreventive effects of alpha-santalol on ultraviolet B radiation-induced skin tumor development in SKH-1 hairless mice.
Chemopreventive effects of emodin and cassiamin B in mouse skin carcinogenesis.
Chemopreventive potential of cyclic diarylheptanoids.
Chronic exposure to 12-O-tetradecanoylphorbol-13-acetate represses sod2 induction in vivo: the negative role of p50.
Collagenase induction promotes mouse tumorigenesis by two independent pathways.
Comparison of gene expression profiles in HepG2 cells exposed to arsenic, cadmium, nickel, and three model carcinogens for investigating the mechanisms of metal carcinogenesis.
Comparison of the effect of sn-1,2-didecanoylglycerol and 12-O-tetradecanoylphorbol-13-acetate on cutaneous morphology, inflammation and tumor promotion in CD-1 mice.
Comparison of the effects of bilobol and 12-O-tetradecanoylphorbol-13-acetate on skin, and test of tumor promoting potential of bilobol in CD-1 mice.
Conjugates of 3?-methoxyserrat-14-en-21?-ol (PJ-1) and 3?-methoxyserrat-14-en-21?-ol (PJ-2) as cancer chemopreventive agents.
Conversion of herpetic lesions to malignancy by ultraviolet exposure and promoter application.
Crucial role of phospholipase Cepsilon in chemical carcinogen-induced skin tumor development.
Cucurbitane Triterpenoids from the Leaves of Momordica charantia, and Their Cancer Chemopreventive Effects and Cytotoxicities.
Cypellocarpins A-C, phenol glycosides esterified with oleuropeic acid, from Eucalyptus cypellocarpa.
Cytogenetic effects caused by phorbol ester tumor promoters in primary mouse keratinocyte cultures: correlation with the convertogenic activity of TPA in multistage skin carcinogenesis.
Cytogenetic effects of phorbol ester tumor promoters: possible role in multistep tumorigenesis.
Cytotoxic Activities and Anti-Tumor-Promoting Effects of Microbial Transformation Products of Prenylated Chalcones from Angelica keiskei.
Defective TPA signalling compromises HaCat cells as a human in vitro skin carcinogenesis model.
Deregulated activity of Akt in epithelial basal cells induces spontaneous tumors and heightened sensitivity to skin carcinogenesis.
Development of phorbol ester responsiveness in neonatal mouse epidermis: correlation between hyperplastic response and sensitivity to first-stage tumor promotion.
Diaplacental carcinogenesis: initiation with the carcinogens dimethylbenzanthracene (DMBA) and urethane during fetal life and postnatal promotion with the phorbol ester TPA in a modified 2-stage Berenblum/Mottram experiment.
Diaplacental carcinogenesis: tumor localization and tumor incidence in NMRI mice after diaplacental initiation with DMBA and urethane and postnatal promotion and the phorbol ester TPA in a modified 2-stage Berenblum/Mottram experiment.
Dietary Supplementation with Methylseleninic Acid Inhibits Mammary Tumorigenesis and Metastasis in Male MMTV-PyMT Mice.
Differential effects of dietary beta-carotene on papilloma and carcinoma formation induced by an initiation-promotion protocol in SENCAR mouse skin.
Distinct inhibitory effects of dihydroteleocidin B and the phorbol ester tumor promoters on the adipocyte differentiation of 3T3-L1 cells.
DMBA/TPA-induced tumor formation is aggravated in human papillomavirus type 16 E6/E7 transgenic mouse skin.
DNA repair, cancer and gene therapy.
Effect of capsaicin on croton oil and TPA induced tumorigenesis and inflammation.
Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis.
Effect of radiofrequency radiation exposure on mouse skin tumorigenesis initiated by 7,12-dimethybenz[alpha]anthracene.
Effects of 12-O-tetradecanoylphorbol-13-acetate on fibroblasts from individuals genetically predisposed to cancer.
Effects of C-Phycocyanin on the representative genes of tumor development in mouse skin exposed to 12-O-tetradecanoyl-phorbol-13-acetate.
Effects of combined treatments with selenium, glutathione, and vitamin E on glutathione peroxidase activity, ornithine decarboxylase induction, and complete and multistage carcinogenesis in mouse skin.
Effects of the tumour promoter 12-O-tetradecanoylphorbol-13-acetate on junctional communication in intact mouse skin: persistence of homologous communication and increase of epidermal-dermal coupling.
Effects of TPA dose variation and mezerein on skin tumorigenesis by initiation promotion protocol in S/RV Cri mice.
Emerging Role of LY6E in Virus-Host Interactions.
Enhanced incorporation of radioactive inorganic phosphate into phospholipids of HeLa cells by tumor promoters.
Enhancement by adriamycin of the effects of 12-O-tetradecanoylphorbol-13-acetate on mouse epidermal glutathione peroxidase activity, ornithine decarboxylase induction and skin tumor promotion.
Enhancement of carcinogenesis in cultured respiratory tract epithelium by 12-0-tetradecanoylphorbol-13-acetate.
Enhancement of clonal proliferation of mouse mast cells by a tumor-promoting phorbol ester.
Enhancement of esophageal carcinogenesis induced in rats by N-amyl-N-methylnitrosamine in the presence of 12-O-tetradecanoylphorbol-13-acetate.
Enhancement of recovery of chemical carcinogen-induced ouabain-resistant mutants in Chinese hamster cells by the tumor-promoting agent, 12-o-tetradecanoyl-phorbol-13-acetate.
Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis.
Epidermal proliferation of nude mouse skin, pig skin, and pig skin grafts. Failure of nude mouse skin to respond to the tumor promoter 12-O-tetradecanoyl phorbol 13-acetate.
ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development.
Evaluation of epidermal cell kinetics following freezing or wounding of mouse skin and their potential as initiators of carcinogenesis.
Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis.
Gene Deletion of Microsomal Prostaglandin E Synthase-1 Suppresses Chemically Induced Skin Carcinogenesis.
Genetic deletion of p21WAF1 enhances papilloma formation but not malignant conversion in experimental mouse skin carcinogenesis.
Glucocorticoid mediation of dietary energy restriction inhibition of mouse skin carcinogenesis.
Heterogeneity of ornithine decarboxylase expression in 12-O-tetradecanoylphorbol-13-acetate-treated mouse skin and in epidermal tumors.
High dietary retinoic acid prevents malignant conversion of skin papillomas induced by a two-stage carcinogenesis protocol in female SENCAR mice.
How the association between obesity and inflammation may lead to insulin resistance and cancer.
Hybrids of 3alpha-methoxyserrat-14-en-21beta-ol (PJ-1) and 3beta-methoxyserrat-14-en-21beta-ol (PJ-2) and various anti-oxidants as cancer chemopreventive agents.
Hyperthermia and phorbol ester tumor promotion in mouse skin.
Ichthyotoxic and anticarcinogenic effects of triterpenoids from Sandoricum koetjape bark.
Immunohistochemical analysis for cell regulatory proteins in bladder carcinogenesis induced by N-methyl-N-nitrosourea-terephthalic acid.
Improvement of carcinogen identification in BALB/3T3 cell transformation by application of a 2-stage method.
In vivo long-term effects of retinoic acid exposure in utero on induced hyperplastic epidermal foci in murine skin.
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Inducible nitric oxide synthase mRNA is upregulated in skin tumors of v-ha-ras transgenic TG-AC mice treated with 12-o-tetradecanoylphorbol-13-acetate.
Induction of mouse brain ornithine decarboxylase by 12-O-tetradecanoylphorbol-13-acetate is independent of TPA receptor concentration.
Induction of mouse epidermal ornithine decarboxylase activity and skin tumors by 7,12-dimethylben.
Induction of murine fibrosarcomas by low dose treatment with 3-methylcholanthrene followed by promotion with 12-O-tetradecanoyl-phorbol-13-acetate.
Induction of putative tumor-suppressing genes in Rat-1 fibroblasts by oncogenic Raf-1 as evidenced by robot-assisted complex hybridization.
Induction of suppressor T cells and inhibition of contact hypersensitivity in mice by 12-O-tetradecanoylphorbol-13-acetate and its analogs.
Influences of sphingosine on two-stage skin tumorigenesis in Sencar mice.
Inhibition by squalene of the tumor-promoting activity of 12-O-tetradecanoylphorbol-13-acetate in mouse-skin carcinogenesis.
Inhibition of both skin and lung tumorigenesis by Car-R mouse-derived cancer modifier loci.
Inhibition of mouse skin tumor promotion by adriamycin and daunomycin in combination with verapamil or palmitoylcarnitine.
Inhibition of multistage tumor promotion in mouse skin by diethyldithiocarbamate.
Inhibition of phorbol ester-caused induction of ornithine decarboxylase and tumor promotion in mouse skin by staurosporine, a potent inhibitor of protein kinase C.
Inhibition of skin carcinomas but not papillomas by sphingosine, N-methylsphingosine, and N-acetylsphingosine.
Inhibition of terminal differentiation of hamster epidermal cells in culture by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate.
Inhibition of the tumor promoting action of 12-O-tetradecanoylphorbol-13-acetate by tubeimoside III isolated from Bolbostemma paniculatum.
Inhibitors of skin-tumor promotion. XIII. Inhibitory effects of euglobals and their related compounds on Epstein-Barr virus activation and on two-stage carcinogenesis of mouse skin tumors. (2).
Inhibitory effect of Actinidia arguta on mutagenesis, inflammation and two-stage mouse skin tumorigenesis.
Inhibitory effects of chlorophyllin on 7,12-dimethylbenz[a]anthracene-induced bacterial mutagenesis and mouse skin carcinogenesis.
Inhibitory effects of glutathione level-raising agents and D-alpha-tocopherol on ornithine decarboxylase induction and mouse skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Inhibitory effects of Momordica grosvenori Swingle extracts on 12-O-tetradecanoylphorbol 13-acetate-induced skin inflammation and tumor promotion in mouse skin.
INK4 Family -A promising target for 'gene-regulating chemoprevention' and 'molecular-targeting prevention' of cancer.
Ionizing radiation as an initiator in the mouse two-stage model of skin tumor formation.
Knockdown of Inwardly Rectifying Potassium Channel Kir2.2 Suppresses Tumorigenesis by Inducing Reactive Oxygen Species-Mediated Cellular Senescence.
Lack of tumor promoting effects of KCB-1, a recombinant human basic fibroblast growth factor, on two-stage skin carcinogenesis in female CD-1 (ICR) mice.
Lanostane-type triterpenoids from the sclerotia of Inonotus obliquus possessing anti-tumor promoting activity.
Melanogenesis inhibitory, anti-inflammatory, and chemopreventive effects of limonoids from the seeds of Azadirachta indicia A. Juss. (neem).
Melanogenesis-inhibitory activity and cancer chemopreventive effect of glucosylcucurbic acid from shea (Vitellaria paradoxa) kernels.
Metabolism of terephthalic acid and its effects on CYP4B1 induction.
Metallothionein deficiency enhances skin carcinogenesis induced by 7,12-dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol-13-acetate in metallothionein-null mice.
Metastatic potential of mouse skin carcinomas produced by different protocols of chemical carcinogenesis.
Mitochondrial targeting of TR3 is involved in TPA induced apoptosis in breast cancer cells.
Moderate enhancement of the promotion phase of skin tumorigenesis in hairless mice by topical pretreatment with a mitosis-inhibiting epidermal pentapeptide.
Modification of N-Methyl-N-Nitrosourea initiated bladder carcinogenesis in Wistar rats by terephthalic acid.
Modulation by adriamycin, daunomycin, verapamil, and trifluoperazine of the biochemical processes linked to mouse skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Modulation of natural killer activity by 12-O-tetradecanoylphorbol-13-acetate and benzoyl peroxide in phorbol ester-sensitive (SENCAR) and resistant (B6C3F1) mice.
Modulation of phorbol ester-elicited events in mouse epidermis by dietary n-3 and n-6 fatty acids.
Morphometric evaluation of dark and clear epidermal basal cells during early 2-stage chemical skin carcinogenesis in the hairless mouse using two different fixation methods.
Multistage chemical carcinogenesis protocols produce spindle cell carcinomas of the mouse skin.
Mutation of p53 in skin papilloma and tubular breast adenoma of albino mice.
Nexrutine(R) inhibits tumorigenesis in mouse skin and induces apoptotic cell death in human squamous carcinoma A431 and human melanoma A375 cells.
Nitroglycerin: a NO donor inhibits TPA-mediated tumor promotion in murine skin.
Non-invasive imaging of carcinogen-induced early neoplasia using ultrahigh-resolution optical coherence tomography.
NTP Toxicology and Carcinogenesis Studies of Diethylphthalate (CAS No. 84-66-2) in F344/N Rats and B6C3F1 Mice (Dermal Studies) with Dermal Initiation/ Promotion Study of Diethylphthalate and Dimethylphthalate (CAS No. 131-11-3) in Male Swiss (CD-1(R)) Mice.
Obesity and cancer: the role of dysfunctional adipose tissue.
On the biochemical mechanism of tumorigenesis in mouse skin. II. Early effects on the biosynthesis of nucleic acids induced by initiating doses of DMBA and by promoting doses of phorbol-12.13-diester TPA.
On the biochemical mechanism of tumorigenesis in mouse skin. IV. Methods for determination of fate and distribution of phorbolester TPA.
Overexpression of PSMC2 promotes the tumorigenesis and development of human breast cancer via regulating plasminogen activator urokinase (PLAU).
PAI-1 Polymorphisms Have Significant Associations With Cancer Risk, Especially Feminine Cancer.
Part I: Synthesis, cancer chemopreventive activity and molecular docking study of novel quinoxaline derivatives.
Persistence of carcinogenic effect in intact progeny of mice treated transplacentally with 7,12-dimethylbenz[a]anthracene.
Phytol is a novel tumor promoter on ICR mouse skin.
Placental glutathione S-transferase isoenzyme expression during promotion of two-stage hamster cheek-pouch carcinogenesis.
Plasminogen activator and cancer.
Plasminogen activator inhibitor type-1: its structure, biological activity and role in tumorigenesis (Review).
Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer.
Plasminogen activator inhibitor-2 (PAI-2) overexpression supports bladder cancer development in PAI-1 knockout mice in N-butyl-N- (4-hydroxybutyl)-nitrosamine- induced bladder cancer mouse model.
Plasminogen activator synthesis accompanying chemical carcinogen-induced in vitro transformation of Syrian hamster and guinea-pig fetal cells.
Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.
Potent suppressive activity of nonpolyphenolic fraction of green tea (Camellia sinensis) against genotoxin-induced umu C gene expression in Salmonella typhimurium (TA 1535/pSK 1002), tumor promotor-dependent ornithine decarboxylase induction of BALB/c 3T3 fibroblast cells, and chemically induced mouse skin tumorigenesis.
Predicting high risk disease using serum and DNA biomarkers.
Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer.
Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer.
Prognostic value of tissue plasminogen activator (tPA) in patients with epithelial ovarian cancer undergoing chemotherapy.
Promoting effect of 12-O-tetradecanoylphorbol-13-acetate on the in vitro malignant transformation of fetal rat brain cells exposed in utero to ethylnitrosourea.
Promotion of BALB/3T3 cell transformation by the okadaic acid class of tumor promoters, okadaic acid and dinophysistoxin-1.
Prophylaxis of Diallyl Disulfide on Skin Carcinogenic Model via p21-dependent Nrf2 stabilization.
Protein Z (PZ) and plasminogen activator inhibitor-1 (PAI-1) plasma levels in patients with previously untreated Hodgkin lymphoma (HL).
Pulse treatment with the tumor promoter TPA delays the onset of desensitization response and prolongs the inhibitory effect on gap junctional intercellular communication of a rat liver epithelial cell line WB F-344.
Rapamycin is a potent inhibitor of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Rapid induction of skin tumors in human but not mouse c-Ha-ras proto-oncogene transgenic mice by chemical carcinogenesis.
RASGRP1 is essential for ras activation by the tumor promoter 12-o-tetradecanoylphorbol-13-acetate in epidermal keratinocytes.
Reciprocal effects of NNK and SLURP-1 on oncogene expression in target epithelial cells.
Resveratrol and black tea polyphenol combination synergistically suppress mouse skin tumors growth by inhibition of activated MAPKs and p53.
Resveratrol synergistically augments anti-tumor effect of 5-FU in vitro and in vivo by increasing S-phase arrest and tumor apoptosis.
Reversal of food restriction-induced inhibition of mouse skin tumor promotion by adrenalectomy.
Role of the Slug Transcription Factor in Chemically-Induced Skin Cancer.
Screening and identification of hub genes in pancreatic cancer by integrated bioinformatics analysis.
SENCAR mouse skin tumors produced by promotion alone have A to G mutations in codon 61 of the c-rasHa gene.
SERPINE1 intron polymorphisms affecting gene expression are associated with diffuse-type gastric cancer susceptibility.
Skin transplantation in the study of chemical carcinogenesis. II. Iso- and autografting of skin from mice intragastrically initiated with 9,10-dimethyl-1,2 benzanthracene with and without subsequent application of the promoting agent TPA.
Skin tumorigenesis by initiators and promoters of different chemical structures in lines of mice selectively bred for resistance (Car-r) or susceptibility (Car-s) to two-stage skin carcinogenesis.
Specific binding, stimulation of rodent urinary bladder epithelial ornithine decarboxylase, and induction of transitional cell hyperplasia by the skin tumor promoter 12-O-tetradecanoylphorbol-13-acetate.
Stimulation of macrophage prostaglandin and neutral protease production by phorbol esters as a model for the induction of vascular changes associated with tumor promotion.
Strain differences in mouse skin tumorigenesis by the promotion of 12-o-tetradecanoylphorbol-13-acetate or benzoyl peroxide.
Structure determination of inonotsuoxides A and B and in vivo anti-tumor promoting activity of inotodiol from the sclerotia of Inonotus obliquus.
Studies on glyphosate-induced carcinogenicity in mouse skin: a proteomic approach.
Suppressive activity of 12-O-tetradecanoyl phorbol-13-acetate on the induction of cytotoxic T cells in vitro.
Susceptibility of 129/SvEv mice in two-stage carcinogenesis protocols to 12-O-tetradecanoylphorbol-13-acetate promotion.
SV40-transfected human melanocyte sensitivity to growth inhibition by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate.
Teleocidin from Streptomyces is a potent promoter of mouse skin carcinogenesis.
The differential effects of retinoic acid and 7,8-benzoflavone on the induction of mouse skin tumors by the initiation-promotion protocol and by the complete carcinogenesis process.
The in vivo effect of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate on N-methyl-N-nitrosourea-induced apoptosis in mouse hair follicles.
The inhibition of DMBA-induced carcinogenesis by neoxanthin in hamster buccal pouch.
The plasminogen activator inhibitor "paradox" in cancer.
The reverse experiment in two-stage skin carcinogenesis. It cannot be genuinely performed, but when approximated, it is not innocuous.
Three-stage tumorigenesis in mouse skin: DNA synthesis as a prerequisite for the conversion stage induced by TPA prior to initiation.
Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo.
Triterpene acids from Poria cocos and their anti-tumor-promoting effects.
Triterpene acids from the leaves of Perilla frutescens and their anti-inflammatory and antitumor-promoting effects.
Tumor promoter TPA activates Wnt/?-catenin signaling in a casein kinase 1-dependent manner.
Two new anti-tumor promoting serratane-type triterpenoids from the stem bark of Picea jezoensis var. jezoensis.
Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor.
XB130 deficiency enhances carcinogen-induced skin tumorigenesis.
[A study of ornithine decarboxylase activity in tumor tissue and rectal mucosa in patients with colorectal cancer or adenoma]
[Anti-tumor promoting activities of kampo prescriptions. II. Inhibitory effects of souseiryu-to on two-stage carcinogenesis of mouse skin tumors and mouse pulmonary tumors]
[Effect of applications of TPA for GGT-positive foci during DMBA-induced cheek pouch carcinogenesis of the hamster]
[Effect of tumor promoting agents on the in vitro malignant transformation of the fetal rat brain cells exposed in utero to ethylnitrosourea]
[Malignant transformation of monkey kidney epithelial cell induced by EBV BARF1 gene and TPA]
[New tumour markers useful in diagnostics and monitoring of cervical cancer]
[Skin transplantation in the study of chemical carcinogenesis. III. Reduced papilloma-formation after initiation during epidermal hyperplasia induced by skin grafting or by a single application of the cocarcinogen TPA.]
[Study on the plasma plasminogen activators in patients with malignant gynecologic tumors]
[The actions of TPA-type as well as non-TPA type tumor promoters and their mechanism(s) in tumor promotion]
[Type I and IV collagenases and their endogenous regulators in immortalized and transformed fibroblasts]
Carcinoid Tumor
Downregulation of prohormone convertase-1 by a phorbol ester.
Effects of transforming growth factor-beta 1 and phorbol ester on PAI-1 and PA genes in human lung cells.
Carcinoma
12-O-tetradecanoylphorbol-13-acetate and UV radiation-induced nucleoside diphosphate protein kinase B mediates neoplastic transformation of epidermal cells.
2-year carcinogenicity study in the male NMRI mouse with 2-ethylhexyl acrylate by epicutaneous administration.
A course of very small doses of DMBA, each of them allegedly with no promoting potency, acts with clear synergistic effect as a strong promoter of DMBA-initiated mouse skin carcinogenesis. A comparison of the tumorigenic and carcinogenic effects of DMBA (7,12-dimethylbenz-alpha-anthracene) and TPA (12-O-tetradecanoyl-phorbol-13-acetate) used as initiators and promoters in classical two-stage experimental protocols.
A model for human colon carcinoma evolution based on the differential response of cultured preneoplastic, premalignant, and malignant cells to 12-O-tetradecanoylphorbol-13-acetate.
A novel 3-dimensional culture system as an in vitro model for studying oral cancer cell invasion.
Absence of specific cell-surface binding of tissue plasminogen activator in uterine cells.
Activation of the rasHa gene in urethane-initiated papillomas induced by protocols with high and low frequencies of malignant conversion.
Activation of the {beta}-catenin/T-cell-specific transcription factor/lymphoid enhancer factor-1 pathway by plasminogen activators in ECV304 carcinoma cells.
Albinism in Nigeria with delineation of new recessive oculocutaneous type.
Alterations in mRNA levels for growth-related genes after transplantation into castrated hosts in oncogene-induced clonal mouse prostate carcinoma.
An evaluation of tissue polypeptide antigen (TPA) in the two bronchoalveolar lavage fractions of lung cancer patients.
An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture.
Analysis of expressions of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells.
Androgen sensitivity and gene expression in ras + myc-induced mouse prostate carcinomas.
Annexin 2 and hemorrhagic disorder in vascular intimal carcinomatosis.
Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
Arsenic exposure in utero exacerbates skin cancer response in adulthood with contemporaneous distortion of tumor stem cell dynamics.
Autocrine regulation of growth stimulation in human epithelial ovarian carcinoma by serine-proteinase-catalysed release of the urinary-type-plasminogen-activator N-terminal fragment.
Azadirachta indica exerts chemopreventive action against murine skin cancer: studies on histopathological, ultrastructural changes and modulation of NF-kappaB, AP-1, and STAT1.
Both TPA and SCC-Ag levels are prognostic even in high-risk stage Ib-IIa cervical carcinoma as determined by a stratification analysis.
C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP.
CA 125 and TPA as markers in ovarian carcinoma.
Carcinoembryonic antigen, ferritin, tissue polypeptide antigen, and CA15/3 in breast cancer: relationship between carcinoma and normal breast tissue.
Cell cycle-specific variation of intracellular plasminogen activator activity in cultured human alveolar epithelial carcinoma and rat hepatoma cells.
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Characterization of skin tumor promotion and progression by chrysarobin in SENCAR mice.
Chemopreventive effect of 4'-demethyl epipodophyllotoxin on DMBA/TPA-induced mouse skin carcinogenesis.
Chromogenic substrate assay for plasminogen activator activity of human oesophageal carcinoma cell lines.
Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian randomization study.
Circulating interleukin-8 and plasminogen activator inhibitor-1 are increased in women with ovarian carcinoma.
Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?
Clinical significance of the number of positive tumor markers in assisting the diagnosis of lung cancer with multiple tumor marker assay.
Clinical-evaluation of serum basic fetoprotein as a marker in urogenital malignant-tumors.
Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma.
Combined immunohistochemical study of tissue polypeptide antigen and cancer antigen 125 in human ovarian tumours.
Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon.
Comparative studies on urokinase and plasminogen activator from cultured pancreatic carcinoma.
Comparative study of plasminogen activator antigens in colonic carcinomas and adenomas.
Comparison between tissue antigen analysis and plasma determinations for TPA and CEA in transitional cell carcinomas and in tumorfree urothelium of the urinary bladder.
Comparison of Cyfra 21-1, TPA and SCC tumor markers in esophageal squamous cell carcinoma.
Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases.
Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer.
Comparison of proteinase activities in squamous cell carcinoma, basal cell epithelioma, and seborrheic keratosis.
Comparison of the effects of 3-isobutyl-1-methylxanthine and adenosine cyclic 3':5'-monophosphate on the induction of skin tumors by the initiation-promotion protocol and by the complete carcinogenesis process.
Comparison of the effects of auranofin and retinoic acid on plasminogen activator activity of peritoneal macrophages and Lewis lung carcinoma cells.
Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues.
Comprehensive analysis of marker gene detection and computed tomography for the diagnosis of human lung cancer.
Constitutive expression and secretion of proteases in non-metastatic SP1 mammary carcinoma cells and its metastatic sublines.
Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium.
Coordinate inhibition of plasminogen activator and tumor growth by hydrocortisone in mouse mammary carcinoma.
Correction: Effects of a high-fat diet on spontaneous metastasis of Lewis lung carcinoma in plasminogen activator inhibitor-1 deficient and wild-type mice.
Cryosurgical treatment of dysplasia and carcinoma in situ of the cervix uteri.
Cryptic and active plasminogen activators secreted by line 10 tumor cells in culture.
Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer.
Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS.
Cytosolic tissue-type plasminogen activator (t-PA) levels in ductal infiltrating carcinomas of the breast classified according to different clinical and biological parameters.
Decrease of epidermal histidase activity by tumor-promoting phorbol esters.
Demonstration of a possible link between high grade malignancy in dimethylbenz[a]anthracene-induced rat mammary carcinoma and increased urokinase plasminogen activator content.
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Detection of the plasmin system in human mammary pathology using immunofluorescence.
Determination of serum levels of different cytokeratins in patients with uterine malignancies.
Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines.
Dietary fat effects on the initiation and promotion of two-stage skin tumorigenesis in the SENCAR mouse.
Different biological effects of the two protein kinase C activators bryostatin-1 and TPA on human carcinoma cell lines.
Differential co-promoting activities of alpha, beta and gamma interferons in the murine skin two-stage carcinogenesis model.
Differential effects of 12-O-tetradecanoylphorbol-13-acetate on cultured normal and neoplastic human bronchial epithelial cells.
Differential effects of dietary beta-carotene on papilloma and carcinoma formation induced by an initiation-promotion protocol in SENCAR mouse skin.
Differential effects of phorbol ester tumor promoters on 3-methylcholanthrene-induced epithelial and mesenchymal skin tumorigenesis.
Differential effects of tumour promoters on the growth of normal human bronchial epithelial cells and human lung tumour cell lines.
Differential expression of prostaglandin H synthase isozymes during multistage carcinogenesis in mouse epidermis.
Differential protease expression by cutaneous squamous and basal cell carcinomas.
Differential regulation of matrix metalloproteinases in human cancer cells by exogenous factors.
Differential response of premalignant epithelial cell classes to phorbol ester tumor promoters and to deoxycholic acid.
Disappearance curves of tumor markers after radical surgery.
Distribution of TPA and cytokeratins in gastrointestinal carcinomas as revealed by immunohistochemistry.
Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines.
Diversity and modulation of plasminogen activator activity in human transitional carcinoma cell lines.
Drug resistant tumor cells have increased levels of tumor markers for invasion and metastasis.
Drug-resistant human laryngeal carcinoma cells have increased levels of cathepsin B.
E2F1 messenger RNA is destabilized in response to a growth inhibitor in normal human keratinocytes but not in a squamous carcinoma cell line.
Early diagnosis of colonic carcinoma: a haemorrhagic complication after the use of tissue plasminogen activator.
Effect of dimethyl sulfoxide on human carcinoma cells, inhibition of plasminogen activator synthesis, change in cell morphology, and alteration of response to cholera toxin.
Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion.
Effect of the active tumor promoter, 12-O-tetradecanoylphorbol-13-acetate on hair follicular growth and development of hair anlage tumors in the mouse skin: a comparison with human adnexal lesions.
Effect of urokinase on the proliferation of primary cultures of human prostatic cells.
Effects of a high-fat diet on spontaneous metastasis of Lewis lung carcinoma in plasminogen activator inhibitor-1 deficient and wild-type mice.
Effects of dose and duration of treatment with the tumor-promoting agent, 12-O-tetradecanoylphorbol-13-acetate on mouse skin carcinogenesis.
Effects of N-acyl dehydroalanines on phorbol ester-elicited tumor development and other events in mouse skin.
Effects of oral versus topical administration of cyclosporine on phorbol ester promotion of murine epidermal carcinogenesis.
Effects of short-term exposure to the tumor promoter, 12-O-tetradecanoylphorbol-13-acetate on skin carcinogenesis in SENCAR mice.
Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Endocrine therapy in pancreatic carcinoma.
Enhancement of carcinogenesis in cultured respiratory tract epithelium by 12-0-tetradecanoylphorbol-13-acetate.
Enhancement of primate retrovirus synthesis by tumour promoters.
Epigenetic alterations of the SERPINE1 gene in oral squamous cell carcinomas and normal oral mucosa.
Eps8 controls Src- and FAK-dependent phenotypes in squamous carcinoma cells.
Epstein-Barr virus in synergy with tumor-promoter-induced malignant transformation of immortalized human epithelial cells.
Erratum to: Smad4 mediates malignant behaviors of human ovarian carcinoma cell through the effect on expressions of E-cadherin, plasminogen activator inhibitor-1 and VEGF.
Ets-1 proto-oncogene as a potential predictor for poor prognosis of lung adenocarcinoma.
Evaluation of 12-lipoxygenase (12-LOX) and plasminogen activator inhibitor 1 (PAI-1) as prognostic markers in prostate cancer.
Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.
Evaluation of seven different tumour markers for the establishment of tumour marker panels in gynecologic malignancies.
Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC).
Evidence for cells possessing t-PA like activity in smears obtained from patients with oral squamous cell carcinoma.
Evidence that weak promotion of carcinogen-initiated cells prevents their progression to malignancy.
Expression and activation of proteases in co-cultures.
Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines.
Expression of Bmi-1 and PAI-1 in esophageal squamous cell carcinoma.
Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance.
Expression of plasminogen activator inhibitor type 1 (PAI-1) by HT-29di human large bowel carcinoma cells is modulated as a function of epithelial differentiation.
Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.
Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma.
Expression of plasminogen activators in basal cell carcinoma.
Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation.
Fluorescent location of tumour cells in fine needle aspirates.
Free radical generating agents lead to the rapid progression of benign skin tumors to carcinoma in iron-overloaded mice.
Functional relevance of urinary-type plasminogen activator receptor-alpha3beta1 integrin association in proteinase regulatory pathways.
Further characterization of skin tumor promotion and progression by mezerein in SENCAR mice.
Gastric mucosal plasminogen activators in Helicobacter pylori infection.
Gene structure, chromosomal localization, and expression of the murine homologue of human proteinase inhibitor 6 (PI-6) suggests divergence of PI-6 from the ovalbumin serpins.
Genetics of chemical carcinogenesis--II. Papilloma induction and malignant conversion in susceptible (Car-s) and resistant (Car-R) lines of mice produced by bidirectional selective breeding and in their (Car-S X Car-R) F1 hybrids.
Glucocorticoid sensitivity of OVCA 433 human ovarian carcinoma cells: inhibition of plasminogen activators, cell growth, and morphological alterations.
Glutathione and glutathione S-transferases as early markers for ovarian carcinomas: case series.
Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice.
Heterologous desensitization in neoplastic thyroid cells: influence of the phospholipase C signal transduction system on the thyrotropin-adenylate cyclase signal transduction system.
High dietary retinoic acid prevents malignant conversion of skin papillomas induced by a two-stage carcinogenesis protocol in female SENCAR mice.
High-fat Diet Enhances and Plasminogen Activator Inhibitor-1 Deficiency Attenuates Bone Loss in Mice with Lewis Lung Carcinoma.
Hmga2 translocation induced in skin tumorigenesis.
Hormone control of total plasminogen activator activity is specific to malignant DMBA-induced rat mammary tumours.
Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner.
Human Co115 colon carcinoma cells potentiate the degradation of laminin mediated by tissue-type plasminogen activator.
Human papillomavirus 16 E5 oncogene contributes to two stages of skin carcinogenesis.
Human primary colon carcinomas xenografted into nude mice. I. Characterization of plasminogen activators expressed by primary tumors and their xenografts.
Human primary colon carcinomas xenografted into nude mice. II. Modulation of tumor plasminogen activator activity by the host tissue environment.
Hydrolyzable tannins: potent inhibitors of hydroperoxide production and tumor promotion in mouse skin treated with 12-O-tetradecanoylphorbol-13-acetate in vivo.
Hyperthermia and phorbol ester tumor promotion in mouse skin.
Identification and characterization of human PEIG-1/GPRC5A as a 12-O-tetradecanoyl phorbol-13-acetate (TPA) and PKC-induced gene.
Identification by differential display of a mRNA specifically induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) in T84 human colon carcinoma cells.
Immunohistochemical and ultrastructural localization of tissue polypeptide antigen in human ovarian tumours.
Immunohistochemical study of lysozyme, alpha 1-anti-chymotrypsin, tissue polypeptide antigen, keratin and carcinoembryonic antigen in effusion sediments.
Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture.
In vitro plasminogen activator activity in human brain tumors.
In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck.
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer.
Inducible cutaneous inflammation reveals a protumorigenic role for keratinocyte CXCR2 in skin carcinogenesis.
Induction of PA2.26, a cell-surface antigen expressed by active fibroblasts, in mouse epidermal keratinocytes during carcinogenesis.
Induction of papillomas with a high probability of conversion to malignancy.
Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell lines.
Induction of urokinase activity and malignant phenotype in bladder carcinoma cells after transfection of the activated Ha-ras oncogene.
Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
Inhibitory effect on the establishment of hepatic metastasis by transduction of the tissue plasminogen activator gene to murine colon cancer.
Inhibitory effects of oligonol on phorbol ester-induced tumor promotion and COX-2 expression in mouse skin: NF-kappaB and C/EBP as potential targets.
Integrin A6 Cleavage in Mouse Skin Tumors.
Intercellular adhesion molecule-1 is upregulated via the protein kinase C pathway in human thyroid carcinoma cell lines.
Invasiveness and MMP expression in pancreatic carcinoma.
Involvement of protein kinase C in translocation of desmoplakins from cytosol to plasma membrane during desmosome formation in human squamous cell carcinoma cells grown in low to normal calcium concentration.
Ionizing radiation as an initiator in the mouse two-stage model of skin tumor formation.
Ionizing radiation as an initiator: effects of proliferation and promotion time on tumor incidence in mice.
Ionizing radiation enhances malignant progression of mouse skin tumors.
Irradiation-induced regulation of plasminogen activator inhibitor type-1 and vascular endothelial growth factor in six human squamous cell carcinoma lines of the head and neck.
Keratinocytes and head and neck squamous cell carcinoma cells regulate urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in fibroblasts.
Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Liver tumor promotion: effect of phenobarbital on EGF and protein kinase C signal transduction and transforming growth factor-beta 1 expression.
Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.
Lupeol suppresses plasminogen activator inhibitor-1-mediated macrophage recruitment and attenuates M2 macrophage polarization.
Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
Malignant conversion and metastasis of mouse skin tumors: a comparison of SENCAR and CD-1 mice.
Malignant conversion, the first stage in progression, is distinct from phorbol ester promotion in mouse skin.
Mathematical modeling of skin papilloma data in SENCAR mice.
Mechanism of mouse skin tumor promotion by chrysarobin.
Metastatic potential of mouse skin carcinomas produced by different protocols of chemical carcinogenesis.
Mitochondria, calcium and nitric oxide in the apoptotic pathway of esophageal carcinoma cells induced by As2O3.
Mitogenic activity and plasminogen activator in harvest fluid concentrates from mammary cells in culture.
Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells.
Modulation of the co-promoting activity of gamma interferon in SENCAR and C57BL/6 mouse skin by difluoromethylornithine and the scheduling and duration of interferon treatment.
Multistage chemical carcinogenesis protocols produce spindle cell carcinomas of the mouse skin.
Neutrophil gelatinase-associated lipocalin in gastric carcinoma cells and its induction by TPA are controlled by C/EBP?.
NF-kappaB, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer.
Non-melanoma skin cancer in mouse and man.
Novel Inhibitors of Urokinase-type Plasminogen Activators: 4-(3H-imidazo[4,5-b]pyridin-2-yl)-N-Substituted Benzamide and Benzamidine Compounds.
NTP Toxicology and Carcinogenesis Studies of 1,2-Dihydro-2,2,4-Trimethylquinoline (CAS No. 147-47-7) in F344/N Rats and B6C3F1 Mice (Dermal Studies) and the Dermal Initiation/Promotion Study in Female Sencar Mice.
NTP Toxicology and Carcinogenesis Studies of Diethylphthalate (CAS No. 84-66-2) in F344/N Rats and B6C3F1 Mice (Dermal Studies) with Dermal Initiation/ Promotion Study of Diethylphthalate and Dimethylphthalate (CAS No. 131-11-3) in Male Swiss (CD-1(R)) Mice.
On the nature of serological tissue polypeptide antigen (TPA); monoclonal keratin 8, 18, and 19 antibodies react differently with TPA prepared from human cultured carcinoma cells and TPA in human serum.
Oncostatin M induces tissue-type plasminogen activator and plasminogen activator inhibitor-1 in Calu-1 lung carcinoma cells.
Overexpression of EGR-1 modulates the activity of NF-?B and AP-1 in prostate carcinoma PC-3 and LNCaP cell lines.
Oxidative properties of 12-O-tetradecanoylphorbol-13-acetate-stimulated human blood monomorphonuclear leukocytes and their toxicity against a human lung carcinoma cell line.
PAI-1 expression and its regulation by promoter 4G/5G polymorphism in clear cell renal cell carcinoma.
PAI-1 expression in intratumoral inflammatory infiltrate contributes to lymph node metastasis in oral cancer: A cross-sectional study.
PAI-1, CAIX, and VEGFA expressions as prognosis markers in oral squamous cell carcinoma.
Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas.
Peaks in plasma plasminogen activator inhibitor-1 concentration may explain thrombotic events in cases of pancreatic carcinoma.
Pharmacologic evidence for involvement of phospholipase C in pemphigus IgG-induced inositol 1,4,5-trisphosphate generation, intracellular calcium increase, and plasminogen activator secretion in DJM-1 cells, a squamous cell carcinoma line.
Phenotypic modification of human glioma and non-small cell lung carcinoma by glucocorticoids and other agents.
Phosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility.
Plasma carcinoembryonic antigen and tissue polypeptide antigen levels in lung cancer: correlation with cell types and stage.
Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard.
Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study.
Plasminogen activator (PA) in Guerin epithelioma. Additional PA inhibitor in plasma of rats bearing the epithelioma.
Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma.
Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Plasminogen activator in cultured Lewis lung carcinoma cells measured by chromogenic substrate assay.
Plasminogen activator in normal and tumor-bearing mice.
Plasminogen activator inhibitor 1 in human carcinoma tissues.
Plasminogen activator inhibitor-1 as a potential marker for the malignancy of esophageal squamous cell carcinoma.
Plasminogen activator inhibitor-1 is a downstream mediator of the PGP9.5-related oncogenic pathway in esophageal squamous cell carcinoma.
Plasminogen activator inhibitor-1 is increased in colonic epithelial cells from patients with colitis-associated cancer.
Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma.
Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro.
Plasminogen activator system in oral squamous cell carcinoma.
Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer.
Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens.
Plasminogen activators in human colorectal neoplasia.
Plasminogen activators in human gastric cancers: correlation with DNA ploidy and immunohistochemical staining.
Plasminogen activators in normal and malignant oral epithelium in vivo and in vitro.
Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.
Plasminogen activators in oesophageal carcinoma.
Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells.
Posttranscriptional regulation of plasminogen activator inhibitor-1 in human lung carcinoma cells in vitro.
Potentiation of tumor formation by topical administration of 15-deoxy-delta12,14-prostaglandin J2 in a model of skin carcinogenesis.
Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma.
Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells.
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Prognostic significance of serum tumour markers in carcinoma of the cervix.
Prognostic significance of tissue-type plasminogen activator (tPA) content in gastric cancer and surrounding mucosa.
Prognostic significance of TPA versus SCC-Ag, CEA and neopterin in carcinoma of the uterine cervix.
Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer.
Prognostic value of plasminogen activator inhibitor-1 in biomarker exploration using multiplex immunoassay in patients with metastatic renal cell carcinoma treated with axitinib.
Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma.
Prognostic value of the plasminogen activation system in patients with gastric carcinoma.
Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer.
Protease and plasminogen activator activity in human bladder carcinoma.
Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer.
Protein kinase C desensitization by phorbol esters and its impact on growth of human breast cancer cells.
Proteinase activity in invasive cancer of the breast. Correlation with tumor progression.
Proteinase suppression by E-cadherin-mediated cell-cell attachment in premalignant oral keratinocytes.
Proteolytic activation of tissue-type plasminogen activator by the culture media of mouse cancer cells.
Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma.
Proteomics-based identification of proteins with altered expression induced by 12-O-tetradecanoylphorbol 13-acetate in nasopharyngeal carcinoma CNE2 cells.
Purification and characterization of a plasminogen activator secreted by cultured human pancreatic carcinoma cells.
Raised expression of the antiapoptotic protein ped/pea-15 increases susceptibility to chemically induced skin tumor development.
Rapid induction of skin and mammary tumors in human c-Ha-ras proto-oncogene transgenic rats by treatment with 7,12-dimethylbenz[a]anthracene followed by 12-O-tetradecanoylphorbol 13-acetate.
Rat mammary carcinoma cells secrete active collagenase and activate latent enzyme in the stroma via plasminogen activator.
Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix.
Regulation of apoptosis through arachidonate cascade in mammalian cells.
Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type I procollagen by transforming growth factor-beta. Divergent responses in lung fibroblasts and carcinoma cells.
Regulation of ornithine decarboxylase gene expression in mouse epidermis and epidermal tumors during two-stage tumorigenesis.
Regulation of p21WAF1/CIP1 expression by p53-independent pathways.
Regulation of plasminogen activator activity in transitional carcinoma cell lines by wound site growth factors.
Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53.
Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Relationship between plasma levels of components of the fibrinolytic system and acute-phase reactants in patients with uterine malignancies.
Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells.
Role of urokinase in colorectal neoplasia.
Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma.
Selective decrease in serum immunoglobulin G1. A tissue nonspecific tumor marker detecting early stages of gynecologic malignant disease with high efficiency.
Selectivity of the plasminogen activator inhibitor (PAI-1) for the iso enzyme of guanidinobenzoatase on the surface of colonic carcinoma cells.
Sequential studies of skin tumorigenesis in phosphoglycerate kinase mosaic mice: effect of resumption of promotion on regressed papillomas.
Serum and tissue levels of CEA, TPA, CA 125 and CA 15.3 in patients with lung cancer.
Serum induction of the fibroblast growth factor-binding protein (FGF-BP) is mediated through ERK and p38 MAP kinase activation and C/EBP-regulated transcription.
Serum tissue polypeptide antigen (S-TPA) in bladder cancer as a tumor marker. A prospective study.
Serum tissue polypeptide antigen in bladder cancer as a tumor marker: a prospective study.
Serum TPS versus TPA in Egyptian bladder cancer patients.
Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy.
Significance of sarcopenia as a prognostic factor for metastatic urothelial carcinoma patients treated with systemic chemotherapy.
Significance of tumour markers in nasopharyngeal carcinoma.
Simultaneous determination of six tumor markers in patients with prostatic carcinoma and bladder tumors.
Skin carcinomas and micronucleus induction in epidermal keratinocytes following 12-O-tetradecanoylphorbol-13-acetate and mezerein treatment.
Skin tumorigenesis by initiators and promoters of different chemical structures in lines of mice selectively bred for resistance (Car-r) or susceptibility (Car-s) to two-stage skin carcinogenesis.
Smad4 mediates malignant behaviors of human ovarian carcinoma cell through the effect on expressions of E-cadherin, plasminogen activator inhibitor-1 and VEGF.
Smad7 is inactivated through a direct physical interaction with the LIM protein Hic-5/ARA55.
Sodium butyrate differentially modulates plasminogen activator inhibitor type-1, urokinase plasminogen activator, and its receptor in a human colon carcinoma cell.
Specific stimulation by estradiol of tissue-type plasminogen activator production in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells.
Specificity and basis of the tissue polypeptide antigen.
Studies on the action of tumour promoters and antipromoters on respiratory-tract epithelium.
Studies on the pathogenesis of coagulopathy in patients with arterial thromboembolism and malignancy.
Successful development of squamous cell carcinoma and hyperplasia in RGEN-mediated p27 KO mice after the treatment of DMBA and TPA.
Suppression of apoptosis in COLO 205 cells by the phorbol ester TPA may be mediated by the PKC isoenzyme alpha.
Synergistic effect of Epstein-Barr virus and tumor promoters on induction of lymphoma and carcinoma in nude mice.
Synergistic effect of tamoxifen and phorbol ester TPA on retrovirus synthesis in a human mammary carcinoma cell line.
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
T1 breast cancer: identification of patients at low risk of axillary lymph node metastases.
Targeting transcription factor NFB: comparative analysis of proteasome and IKK inhibitors.
The effect of promoters on 1,2-dimethylhydrazine-induced colon carcinogenesis.
The effect of the level of dietary corn oil on mouse skin carcinogenesis.
The plasminogen activator inhibitor system in colon cancer cell lines is influenced by the CO(2) pneumoperitoneum.
The prognostic value of TPA and SCC in squamous cell carcinoma of the cervix.
The role of tumour markers (CEA, TPA, CA 19-9) in colon and rectum carcinomas.
The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue-type plasminogen activator.
The state of differentiation of HT-29 colon carcinoma cells alters the secretion of cathepsin D and of plasminogen activator.
The stimulation of prostaglandin production by transforming growth factor-alpha and 12-O-tetradecanoyl-phorbol-13-acetate or 1-oleoyl-2-acetyl-glycerol is synergistic.
The urokinase/PAI-2 complex: a new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein.
The use of the CELLection kit in the isolation of carcinoma cells from mononuclear cell suspensions.
Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro.
Thrombospondin and transforming growth factor-beta 1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells.
Tissue concentrations of tissue polypeptide antigen (TPA) and prostatic specific antigen (PSA) in 42 patients with prostatic carcinoma.
Tissue plasminogen activator activity in prostatic cancer.
Tissue plasminogen activator and urokinase in normal, dysplastic and cancerous squamous epithelium of the uterine cervix.
Tissue polypeptide antigen (TPA) and prostatic acid phosphatase in serum of prostatic cancer patients.
Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: re-evaluation of a human tumor marker.
Tissue polypeptide antigen (TPA), some cytokeratins and epithelial membrane antigen (EMA) in normal, inflamed and malignant urothelium.
Tissue polypeptide antigen and keratins in cervical neoplasia.
Tissue polypeptide antigen expression in human prostate tumors.
Tissue polypeptide antigen immunoreactivity in human semen.
Tissue polypeptide antigen immunostaining in fine needle aspirates from solid breast nodules.
Tissue polypeptide antigen in normal and neoplastic urinary bladder. Preliminary reports.
Tissue polypeptide antigen in the follow-up of patients with urinary bladder cancer compared with conventional urine cytology.
Tissue polypeptide antigen in thyroid tumours of follicular cell origin: an immunohistochemical re-evaluation for diagnostic purposes.
Tissue polypeptide antigen production in a uterine carcinosarcoma cell line in a serum-free culture.
Tissue polypeptide antigen, carcinoembryonic antigen, carbohydrate antigen, and CA125 levels as tumor markers in squamous cell carcinoma of the head and neck.
Tissue polypeptide antigen--a marker antigen differentiating cholangiolar tumors from other hepatic tumors.
Tissue-type plasminogen activator activity in morphologically normal tissues adjacent to gastrointestinal carcinomas is associated with the degree of tumor progression.
Tissue-type plasminogen activator predicts endocrine responsiveness of human pancreatic carcinoma cells.
Topological regulation of cell-membrane phosphoinositidase C.
Total proteolytic activity and content of the main proteinase inhibitors in blood plasma of rats bearing doxorubicin-sensitive and doxorubicin-resistant Guerin carcinoma.
TPA induces transglutaminase C and inhibits cell growth in the colon carcinoma cell line SW620.
TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Transcriptional induction of urokinase in cultured human kidney carcinoma cells by tetradecanoyl-phorbol-acetate.
Transforming growth factor beta1 stimulates urokinase plasminogen activator system on prostate cancer cells.
Transforming growth factor-alpha promotes tumor markers secretion from human ovarian cancers in vitro.
Transforming growth factor-beta 1 is a potent inducer of plasminogen activator inhibitor type-1 in human glioblastoma and carcinoma cell lines.
Transgenic mice overexpressing protein kinase C epsilon in their epidermis exhibit reduced papilloma burden but enhanced carcinoma formation after tumor promotion.
Transmaternal variation of the Berenblum experiment with NMRI-mice: tumour initiation with DMBA via mothers milk followed by promotion with the phorbol ester TPA.
Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo.
Tumor markers and lung cancer: correlation between serum and bronchial secretion levels of CEA, TPA, CanAg CA-50, NSE and ferritin.
Tumor markers in squamous cell carcinoma of esophagus: immunometric assay in cytosol and membrane fraction.
Tumor necrosis factor-alpha regulates mRNA for urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in human neoplastic cell lines.
Tumor progression in Sencar mouse skin as a function of initiator dose and promoter dose, duration, and type.
Tumor progression of murine epidermal cells after treatment in vitro with 12-O-tetradecanoylphorbol-13-acetate or retinoic acid.
Tumor suppression by p27Kip1 and p21Cip1 during chemically induced skin carcinogenesis.
Tumor-promoter-enhanced destruction of noninvasive human benign colon tumor cells by cocultivated carcinoma cells.
Tumorigenesis and carcinogenesis in mouse skin treated with hyperthermia during stage I or stage II of tumor promotion.
Turnover of glutathione S-transferase alpha mRNAs is accelerated by 12-O-tetradecanoyl phorbol-13-acetate in human hepatoma and colon carcinoma cell lines.
Two-stage carcinogenesis in NMRI mice: intravaginal application of 7,12-dimethylbenz[a]anthracene as initiator followed by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate as promoter.
Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy.
Type-1 plasminogen activator inhibitor in human renal cell carcinoma.
Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma.
uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
uPAR-targeted optical near-infrared (NIR) fluorescence imaging and PET for image-guided surgery in head and neck cancer: proof-of-concept in orthotopic xenograft model.
Urinary levels of tumour associated antigens (CA 19-9, TPA and CEA) in patients with neoplastic and non-neoplastic urothelial abnormalities.
Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity.
Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.
Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC).
Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.
Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions.
Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
Usefulness of tissue polypeptide antigen in staging, monitoring, and prognosis of lung cancer.
[A clinical evaluation of the versatility of various tumor markers in diagnosing the primary carcinoma of the lung]
[A clinical study on multiple tumor markers following therapy in patients with uterine cervical carcinoma]
[Analysis of tumor markers in lung biopsies and in bronchial lavage]
[Application of serum tumor markers and support vector machine in the diagnosis of oral squamous cell carcinoma]
[Blood and urine determinations of tissue polypeptide antigen in patients with bladder carcinoma]
[CEA and TPA in bladder carcinoma]
[Clinical evaluation of CA 19-9, TPA, IAP and 5'-NPD-V as tumor markers of hepatocellular, bile duct and pancreas carcinoma]
[Clinical evaluation of combination assay of tumor markers in primary lung cancer patients]
[Clinical relevance of tumor markers]
[Clinical study on tissue polypeptide antigen (TPA) in gastric cancer]
[Clinical, histological, and immunohistochemical studies of squamous cell carcinomas of the oral mucosa and the prolabium]
[Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma]
[Detection of carcinoma in situ of the bladder using TPA antibodies]
[Development and clinical research of computer aided multivariate pattern analysis system (CAMPAS) OV-1 for diagnosis of ovarian carcinoma]
[Diagnostic value of tissue polypeptide antigen in serum of larynx cancer patients]
[Differences in assay sensitivity of selected tumor markers in head and neck neoplasms]
[Effect of cholecystokinin and secretin on insulin binding to rat pancreatic acini and pancreatic cancer cell line AR42J cells]
[Effect of lower androgen levels on arteriosclerosis]
[Establishment and characterization of human esophageal carcinoma cell lines--especially the role of the serum-free culture]
[Evaluation of serum levels of TPA and CEA in different stages of carcinoma of the bladder]
[Expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 in gastric carcinoma]
[Growth suppression of squamous cell carcinoma cell lines by PKCs--possible application to gene therapy]
[Immunohistochemical determination of antigen 19-9 (CA 19-9) in transitional carcinoma of the bladder]
[Immunohistochemical studies in the differential diagnosis of malignant fibrous histiocytoma]
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
[Immunosuppressive acidic protein (IAP) and immunosuppressive substance (ISS) in patients with renal cell carcinoma]
[Importance of serum TPA determination in bronchopulmonary cancer. A comparative study of CEA, CA 19.9 and NSE]
[Induction of human oral carcinoma by human papillomavirus 16 E6/E7 and TPA]
[Matrix metalloproteinases (MMP)--MMP-1,-2,-9 and its endogenous activity regulators in transformed by E7 oncogene HPV16 and HPV18 cervical carcinoma cell lines].
[New developments in the area of markers in diagnosis and monitoring of ovarian cancer]
[Pretreatment evaluation of CA 72.4 in patients with carcinoma of the stomach (0-IV stage) versus CEA, TPA, CA 19-9, FER]
[Prognostic value of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx]
[Role of tissue polypeptide antigen as a marker in bladder cancer]
[Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer]
[Studies on marker substances in cell lines derived from various human gynecologic tumors (author's transl)]
[Studies on the gap junctional intercellular communication (GJIC) of human stomach carcinoma cells in comparison with normal cells and the effect of the tumor promoter, TPA]
[The clinical value of tissue polypeptide antigen in ovarian carcinoma]
[The expressions and diagnostic values of miR-18a and miR-21 in esophageal cancer].
[The prognostic importance of urinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma]
[The study of plasminogen activator in renal cell carcinoma with special remarks on urokinase type plasminogen activator]
[The transfection and morphological changes of human embryonic nasopharyngeal epithelia infected by Epstein-Barr virus cooperated with promoter in vitro and in vivo]
[Therapy and follow-up using TPA in radio-oncologic after-care in bladder cancer]
[Tissue and urokinase plasminogen activators (t-PA, u-PA) and their inhibitor PAI-1 in blood of patients with laryngeal neoplasms]
[Tissue plasminogen activator activity in early prostatic cancer and in bone metastases of prostatic cancer]
[Tissue plasminogen activator in urine of patients with prostatic carcinoma and benign prostatic hyperplasia]
[Tissue polypeptide antigen in serum and tissue in patients with lung cancer]
[Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma]
[Tissue type plasminogen activator antigen in urine of patients with bladder cancer]
[Tumor markers in colorectal cancer]
[Tumor markers useful in the diagnostics and monitoring of endometrial and cervical cancer]
[Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer]
[u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast]
[[Gender Differences in Tissue Cascade of Activation of Plasminogen and PAI-1 in Esophageal Squamous Cell Carcinoma].]
Carcinoma in Situ
Cryosurgical treatment of dysplasia and carcinoma in situ of the cervix uteri.
T1 breast cancer: identification of patients at low risk of axillary lymph node metastases.
Tissue polypeptide antigen and keratins in cervical neoplasia.
[Detection of carcinoma in situ of the bladder using TPA antibodies]
Carcinoma, Adenoid Cystic
Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation.
Carcinoma, Basal Cell
Comparison of proteinase activities in squamous cell carcinoma, basal cell epithelioma, and seborrheic keratosis.
Differential protease expression by cutaneous squamous and basal cell carcinomas.
Expression of plasminogen activators in basal cell carcinoma.
Ionizing radiation as an initiator: effects of proliferation and promotion time on tumor incidence in mice.
Carcinoma, Bronchogenic
Biomarkers and IL-2R in lung cancer.
Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
Prognostic value of the tissue polypeptide antigen in lung cancer.
Tissue polypeptide antigen in bronchogenic carcinoma.
Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9.
Tumor markers kinetic in malignant lung neoplasms.
[Bronchoalveolar lavage. The humoral parameter spectrum in bronchial carcinoma and chronic bronchitis]
[CYFRA 21-1: initial experiences in bronchus carcinoma and other tumors]
Carcinoma, Ductal
Histological grade in breast cancer: association with clinical and biological features in a series of 229 patients.
Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
Proliferative responses of epithelial cells to 8-bromo-cyclic AMP and to a phorbol ester change during breast pathogenesis.
Carcinoma, Ehrlich Tumor
Induction of vimentin synthesis in mouse myeloma cells MPC-11 by 12-0-tetradecanoylphorbol-13-acetate.
Na+/H+ exchange in Ehrlich ascites tumor cells. Regulation by extracellular ATP and 12-O-tetradecanoylphorbol 13-acetate.
Studies on the fibrinolysis in tumor bearing mice. 3. Demonstration of the plasminogen activator in Ehrlich ascites tumor cells.
Carcinoma, Embryonal
Biological activity of retinoids correlates with affinity for nuclear receptors but not for cytosolic binding protein.
Differential expression of fetomodulin and tissue plasminogen activator to characterize parietal endoderm differentiation of F9 embryonal carcinoma cells.
Differentiation of early mouse embryonic and teratocarcinoma cells in vitro: plasminogen activator production.
Differentiation of F9 embryonal carcinoma cells by synthetic retinoids: amplitude of plasminogen activator production does not depend on retinoid potency or affinity for F9 nuclear retinoic acid receptors.
Induction of differentiation of embryonal carcinoma F9 cells by iron chelators.
Stimulation of the clonal growth and differentiation of feeder layer dependent mouse embryonal carcinoma cells by beta-mercaptoethanol.
Teratocarcinoma differentiation: plasminogen activator activity associated with embryoid body formation.
The SV40 TC-II(kappa B) and the related H-2Kb enhansons exhibit different cell type specific and inducible proto-enhancer activities, but the SV40 core sequence and the AP-2 binding site have no enhanson properties.
Carcinoma, Hepatocellular
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces plasminogen activator inhibitor-1 through an aryl hydrocarbon receptor-mediated pathway in mouse hepatoma cell lines.
A Fos-Jun element in the first intron of an alpha 2u-globulin gene.
Activation of cyclic adenosine 3':5'-monophosphate-dependent protein kinase in H35 hepatoma and Chinese hamster ovary cells by a phorbol ester tumor promoter.
Activation of transcription of the human presenilin 1 gene by 12-O-tetradecanoylphorbol 13-acetate.
Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase. Demonstration of the binding, stabilization, and activation of PAI-1 by vitronectin.
AFP, CEA, CA 19-9 and TPA in hepatocellular carcinoma.
Binding and degradation of tissue-type plasminogen activator by the human hepatoma cell line Hep G2.
Cancer?associated fibroblast?induced M2?polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor?1 pathway.
Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.
cDNA cloning and expression in E. coli of a plasminogen activator inhibitor (PAI) related to a PAI produced by Hep G2 hepatoma cell.
Cell cycle-specific variation of intracellular plasminogen activator activity in cultured human alveolar epithelial carcinoma and rat hepatoma cells.
Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells.
Clinical evaluation of tissue plasminogen activator (t-PA) levels in patients with liver diseases.
Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma.
Compound Astragalus and Salvia miltiorrhiza extract inhibits cell invasion by modulating transforming growth factor-beta/Smad in HepG2 cell.
Constitutive plasminogen activator inhibitor 1 (PAI-1) biosynthesis in human Hep G2 hepatoma cells is maintained by an autocrine factor.
Current experimental perspectives on the clinical progression of alcoholic liver disease.
Cyclic nucleotide regulation of plasminogen activator and plasminogen activator-inhibitor messenger RNAs in rat hepatoma cells.
Cyclic nucleotide regulation of type-1 plasminogen activator-inhibitor mRNA stability in rat hepatoma cells. Identification of cis-acting sequences.
Demonstration of a specific clearance receptor for tissue-type plasminogen activator on rat Novikoff hepatoma cells.
Dexamethasone induction of an inhibitor of plasminogen activator in HTC hepatoma cells.
Dexamethasone inhibition of tissue-type plasminogen activator (tPA) activity: paradoxical induction of both tPA antigen and plasminogen activator inhibitor.
Dexamethasone-induced adhesion in hepatoma cells: the role of plasminogen activator.
Diagnostic efficacy of plasma urokinase-type plasminogen activator and plasminogen activator inhibitor-2 in differentiation of hepatocellular carcinoma from cirrhosis.
Dietary administration of tannic acid lowers plasminogen activator activity in the liver of C3H hepatoma bearing male mice.
Different induction of two plasminogen activator inhibitor 1 mRNA species by phorbol ester in human hepatoma cells.
Differential effects of 12-O-tetradecanoylphorbol 13-acetate on cytochrome P-450-dependent monooxygenase activities in rat hepatoma cells: induction of P-450I and suppression of P-450II.
Enhancement of vitronectin expression in human HepG2 hepatoma cells by transforming growth factor-beta 1.
Expression of Plasminogen Activator Inhibitor-2 is Negatively Associated with Invasive Potential in Hepatocellular Carcinoma Cells.
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma.
Expression, clinicopathologic and prognostic significance of plasminogen activator inhibitor 1 in hepatocellular carcinoma.
Glucocorticoid induction of plasminogen activator and plasminogen activator-inhibitor messenger RNA in rat hepatoma cells.
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Hepatocyte growth factor stimulates expression of plasminogen activator inhibitor type 1 and tissue factor in HepG2 cells.
Hormonal regulation of plasminogen activator in rat hepatoma cells.
Human hepatoma cell line plasminogen activator.
Human HuH-7 hepatoma cells express urokinase and plasminogen activator inhibitor-1: identification, characterization and regulation by inflammatory mediators.
Identification and cDNA cloning of a novel RNA-binding protein that interacts with the cyclic nucleotide-responsive sequence in the Type-1 plasminogen activator inhibitor mRNA.
Identification and partial characterization by chemical cross-linking of a binding protein for tissue-type plasminogen activator (t-PA) on rat hepatoma cells. A plasminogen activator inhibitor type 1-independent t-PA receptor.
IL-1 and IL-6 induce hepatocyte plasminogen activator inhibitor-1 expression through independent signaling pathways converging on C/EBPdelta.
Immunoaffinity purification of HTC rat hepatoma cell plasminogen activator-inhibitor-1.
Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro.
Induction of endothelial cell expression of the plasminogen activator inhibitor type 1 gene by thrombosis in vivo.
Induction of lysophosphatidic acid receptor-3 by 12-O-tetradecanoylphorbol-13-acetate stimulates cell migration of rat liver cells.
Induction of plasminogen activator inhibitor-1 in HepG2 human hepatoma cells by mediators of the acute phase response.
Induction of tumors of the liver, lung, ovary and adrenal in adult mice after brief maternal gestational exposure to inorganic arsenic: promotional effects of postnatal phorbol ester exposure on hepatic and pulmonary, but not dermal cancers.
Influence of plasminogen activator inhibitor-1 (SERPINE1) 4G/5G polymorphism on circulating SERPINE-1 antigen expression in HCC associated with viral infection.
Inhibitors of Ca2+ channels, calmodulin and protein kinases prevent A23187 and other inductions of metallothionein mRNA in EC3 rat hepatoma cells.
Inhibitory effect of AP-1 complex on 5-aminolevulinate synthase gene expression through sequestration of cAMP-response element protein (CRE)-binding protein (CBP) coactivator.
Inhibitory role of plasminogen activator inhibitor-1 in invasion and proliferation of HLE hepatocellular carcinoma cells.
Initiation and regulation of fibrinolysis in human plasma at the plasminogen activator level.
Interaction of a 39 kDa protein with the low-density-lipoprotein-receptor-related protein (LRP) on rat hepatoma cells.
Interactions between tissue-type plasminogen activator and extracellular matrix-associated plasminogen activator inhibitor type 1 in the human hepatoma cell line HepG2.
Interleukin-1beta and tetradecanoylphorbol acetate-induced biosynthesis of tumor necrosis factor alpha in human hepatoma cells involves the transcription factors ATF2 and c-Jun and stress-activated protein kinases.
Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
Isolation and characterization of the rat plasminogen activator inhibitor-1 gene.
Isolation of rat hepatoma cell variants selectively resistant to dexamethasone inhibition of plasminogen activator.
Liver tumor promotion: effect of phenobarbital on EGF and protein kinase C signal transduction and transforming growth factor-beta 1 expression.
Loss of glucocorticoid regulation of plasminogen activator activity in anucleate rat hepatoma cells.
Low density lipoprotein receptor-related protein (LRP) expression varies among Hep G2 cell lines.
Low expression of PAI-2 as a novel marker of portal vein tumor thrombosis and poor prognosis in hepatocellular carcinoma.
Mechanism of dexamethasone inhibition of plasminogen activator in rat hepatoma cells.
Mechanism of glucocorticoid induction of the rat plasminogen activator inhibitor-1 gene in HTC rat hepatoma cells: identification of cis-acting regulatory elements.
Mechanisms of PKC-Mediated Enhancement of HIF-1? Activity and its Inhibition by Vitamin K2 in Hepatocellular Carcinoma Cells.
Monoclonal antibodies to tissue-type plasminogen activator which prolong its clearance in vivo.
On the role of c-Jun in the induction of PAI-1 gene expression by phorbol ester, serum, and IL-1alpha in HepG2 cells.
PAI-1, t-PA and circulating hTERT DNA as related to virus infection in liver carcinogenesis.
Paradoxical effects of glucocorticoids on regulation of plasminogen activator activity of rat hepatoma cells.
Paradoxical effects of glucocorticoids on regulation of plasminogen activator activity. Mediation by glucocorticoid receptors.
Phorbol ester induces the transcriptional stimulatory activity of the SV40 enhancer.
Phorbol ester induction of rat hepatic metallothionein in vivo and in vitro.
Phosphatidylinositol 3-kinase is required for the regulation of hepatitis B surface antigen production and mitogen-activated protein kinase activation by insulin but not by TPA.
PKCalpha mediated induction of miR-101 in human hepatoma HepG2 cells.
Plasminogen activator inhibitor 2 (PAI2) inhibits invasive potential of hepatocellular carcinoma cells in vitro via uPA- and RB/E2F1-related mechanisms.
Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin.
Production of latent collagenase by human umbilical vein endothelial cells in response to angiogenic preparations.
Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration.
Reactive oxygen species-mediated PKC and integrin signaling promotes tumor progression of human hepatoma HepG2.
Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells.
Receptor-mediated endocytosis of tissue-type plasminogen activator by the human hepatoma cell line Hep G2.
Regulation of epidermal growth factor receptor gene expression.
Regulation of Ki-ras expression in Reuber H35 cells.
Regulation of tumor suppressor PDCD4 by novel protein kinase C isoforms.
Role of plasminogen activator in the morphological alterations induced by derivatives of adenosine cyclic 3':5'-monophosphate in hepatoma tissue culture cells.
Sarcopenia and chronic liver diseases.
Serum PAI-1 and PAI-1 4G/5G Polymorphism in Hepatitis C Virus-Induced Cirrhosis and Hepatitis C Virus-Induced Hepatocellular Carcinoma patients.
Stimulation of motility in cultured bovine capillary endothelial cells by angiogenic preparations.
Synergistic induction of tissue-type plasminogen activator gene expression by glucocorticoids and cyclic nucleotides in rat HTC hepatoma cells.
The 39-kDa protein regulates LRP activity in cultured endothelial and smooth muscle cells.
The dexamethasone-induced inhibitor of plasminogen activator in hepatoma cells is antigenically-related to an inhibitor produced by bovine aortic endothelial cells.
The effect of trans-palmitoleic acid on cell viability and sirtuin 1 gene expression in hepatocytes and the activity of peroxisome-proliferator-activated receptor-alpha.
The level of substrate ornithine can alter polyamine-dependent DNA synthesis following phorbolester stimulation of cultured hepatoma cells.
The production of heparin cofactor II is not regulated by inflammatory cytokines in human hepatoma cells: comparison with plasminogen activator inhibitor type-1.
The role of plasminogen activator inhibitor type 1 in the clearance of tissue-type plasminogen activator by rat hepatoma cells.
Tissue polypeptide antigen--a marker antigen differentiating cholangiolar tumors from other hepatic tumors.
Trans Fatty Acids Suppress TNF-?-Induced Inflammatory Gene Expression in Endothelial (HUVEC) and Hepatocellular Carcinoma (HepG2) Cells.
Transcriptional activation of the Egr-1 gene mediated by tetradecanoylphorbol acetate and extracellular signal-regulated protein kinase.
Transcriptional and posttranscriptional regulation of type 1 plasminogen activator inhibitor and tissue-type plasminogen activator gene expression in HTC rat hepatoma cells by glucocorticoids and cyclic nucleotides.
Turnover of glutathione S-transferase alpha mRNAs is accelerated by 12-O-tetradecanoyl phorbol-13-acetate in human hepatoma and colon carcinoma cell lines.
Type 1 plasminogen activator inhibitor induces multimerization of plasma vitronectin. A suggested mechanism for the generation of the tissue form of vitronectin in vivo.
[Changes of PAI-1 and biological behaviour of human hepatocellular carcinoma in metastatic model of nude mice]
[Clinical study on tissue polypeptide antigen (TPA) as a tumor marker]
[Immunoreactivities and messenger RNA expression of aldolase A and B in human hepatoma cell lines]
[Inhibitor of plasminogen activator 1 (PAI-1) in hepatocellular carcinoma]
[Qualitative analysis of tissue plasminogen activator in plasma obtained from various liver diseases by gel filtration and affinity chromatography]
[Serum concentrations of tissue polypeptide antigen and alpha 1-fetoprotein in patients with primary liver cancer, liver metastasis and liver cirrhosis]
Carcinoma, Intraductal, Noninfiltrating
Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ.
Plasminogen activator system localization in 60 cases of ductal carcinoma in situ.
Protein and mRNA expression of uPAR and PAI-1 in myoepithelial cells of early breast cancer lesions and normal breast tissue.
Carcinoma, Large Cell
Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases.
Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer.
Comprehensive analysis of marker gene detection and computed tomography for the diagnosis of human lung cancer.
Carcinoma, Lewis Lung
Comparison of the effects of auranofin and retinoic acid on plasminogen activator activity of peritoneal macrophages and Lewis lung carcinoma cells.
Correction: Effects of a high-fat diet on spontaneous metastasis of Lewis lung carcinoma in plasminogen activator inhibitor-1 deficient and wild-type mice.
Effects of a high-fat diet on spontaneous metastasis of Lewis lung carcinoma in plasminogen activator inhibitor-1 deficient and wild-type mice.
Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice.
High-fat Diet Enhances and Plasminogen Activator Inhibitor-1 Deficiency Attenuates Bone Loss in Mice with Lewis Lung Carcinoma.
Plasminogen activator in cultured Lewis lung carcinoma cells measured by chromogenic substrate assay.
Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma.
Proteolytic activation of tissue-type plasminogen activator by the culture media of mouse cancer cells.
Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma.
Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma.
Carcinoma, Medullary
Tissue polypeptide antigen in thyroid tumours of follicular cell origin: an immunohistochemical re-evaluation for diagnostic purposes.
Carcinoma, Non-Small-Cell Lung
Activation of tissue plasminogen activator gene transcription by Neovastat, a multifunctional antiangiogenic agent.
Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
Differential expression profiling of transcripts of IDH1, CEA, Cyfra21-1, and TPA in stage IIIa non-small cell lung cancer (NSCLC) of smokers and non-smokers cases with air quality index.
Differential regulation of protease and extracellular matrix protein expression by transforming growth factor-beta 1 in non-small cell lung cancer cells and normal human bronchial epithelial cells.
Disease monitoring by the tumour markers cyfra 21.1 and TPA in patients with non-small cell lung cancer.
HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells.
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Phenotypic modification of human glioma and non-small cell lung carcinoma by glucocorticoids and other agents.
Plasma carcinoembryonic antigen and tissue polypeptide antigen levels in lung cancer: correlation with cell types and stage.
Plasminogen Activator Inhibitor Type 1 (PAI-1) A15T Gene Polymorphism Is Associated with Prognosis in Patients with EGFR Mutation Positive Pulmonary Adenocarcinoma.
Plasminogen activator inhibitor-1 enhances radioresistance and aggressiveness of non-small cell lung cancer cells.
Plasminogen Activator Inhibitor-2 Plays a Leading Prognostic Role among Protease Families in Non-Small Cell Lung Cancer.
Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer.
Regulation of the plasminogen activator system in non-small cell lung cancer cell lines by growth factors EGF, TGF-alpha and TGF-beta.
Serum markers casa, cea, cyfra-21-1, msa, nse, tpa and tps in lung-cancer.
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer. Diagnostic yield and comparison with conventional staging methods.
Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
[Plasminogen activator inhibitor type 1 (PAI-1) in blood and tissue extracts of patients with non-small cell lung cancer]
[Tumor markers in bronchus cancer]
[Tumor markers TPA and Cyfra 21.1 in patients with non-small cell lung cancer after surgery and chemotherapy]
Carcinoma, Ovarian Epithelial
Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium.
Expression of plasminogen activator inhibitor-2 in epithelial ovarian cancer: a favorable prognostic factor related to the actions of CSF-1.
Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer.
Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients.
Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells.
Prognostic value of tissue plasminogen activator (tPA) in patients with epithelial ovarian cancer undergoing chemotherapy.
The application value of the detection of the level of tissue polypeptide antigen, ovarian cancer antigen X1, cathepsin L and CA125 on the diagnosis of epithelial ovarian cancer.
The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
Variation and prognostic value of serum plasminogen activator inhibitor-1 before and after chemotherapy in patients with epithelial ovarian cancer.
[Development and clinical research of computer aided multivariate pattern analysis system (CAMPAS) OV-1 for diagnosis of ovarian carcinoma]
[The clinical value of tissue polypeptide antigen in ovarian carcinoma]
[Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer]
Carcinoma, Pancreatic Ductal
Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2.
Carcinoma, Papillary
Heterologous desensitization in neoplastic thyroid cells: influence of the phospholipase C signal transduction system on the thyrotropin-adenylate cyclase signal transduction system.
Carcinoma, Renal Cell
Characterization of plasminogen activator from two human renal carcinoma cell lines.
Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian randomization study.
Clinical-evaluation of serum basic fetoprotein as a marker in urogenital malignant-tumors.
Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues.
Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Inhibitory effects of tetradecanoylphorbol acetate and diacylglycerol on erythropoietin production in human renal carcinoma cell cultures.
Mitogenic effect of urokinase on malignant and unaffected adjacent human renal cells.
Modulation of secreted plasminogen activator activity of human renal carcinoma cells by dimethylsulfoxide, butyrate and retinoate.
PAI-1 expression and its regulation by promoter 4G/5G polymorphism in clear cell renal cell carcinoma.
Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer.
Prognostic value of plasminogen activator inhibitor-1 in biomarker exploration using multiplex immunoassay in patients with metastatic renal cell carcinoma treated with axitinib.
Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer.
Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy.
Type-1 plasminogen activator inhibitor in human renal cell carcinoma.
[Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer]
[Immunosuppressive acidic protein (IAP) and immunosuppressive substance (ISS) in patients with renal cell carcinoma]
[The study of plasminogen activator in renal cell carcinoma with special remarks on urokinase type plasminogen activator]
Carcinoma, Signet Ring Cell
[Clinical study on tissue polypeptide antigen (TPA) in gastric cancer]
Carcinoma, Small Cell
Clinical significance of the number of positive tumor markers in assisting the diagnosis of lung cancer with multiple tumor marker assay.
Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases.
Plasma carcinoembryonic antigen and tissue polypeptide antigen levels in lung cancer: correlation with cell types and stage.
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Usefulness of tissue polypeptide antigen in staging, monitoring, and prognosis of lung cancer.
Carcinoma, Squamous Cell
12-O-tetradecanoylphorbol-13-acetate and UV radiation-induced nucleoside diphosphate protein kinase B mediates neoplastic transformation of epidermal cells.
2-year carcinogenicity study in the male NMRI mouse with 2-ethylhexyl acrylate by epicutaneous administration.
A proenzyme form of human urokinase.
Albinism in Nigeria with delineation of new recessive oculocutaneous type.
Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
Arsenic exposure in utero exacerbates skin cancer response in adulthood with contemporaneous distortion of tumor stem cell dynamics.
Azadirachta indica exerts chemopreventive action against murine skin cancer: studies on histopathological, ultrastructural changes and modulation of NF-kappaB, AP-1, and STAT1.
Both TPA and SCC-Ag levels are prognostic even in high-risk stage Ib-IIa cervical carcinoma as determined by a stratification analysis.
Characterization of tissue plasminogen activator binding proteins isolated from endothelial cells and other cell types.
Chemopreventive effect of 4'-demethyl epipodophyllotoxin on DMBA/TPA-induced mouse skin carcinogenesis.
Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?
Clinical significance of the number of positive tumor markers in assisting the diagnosis of lung cancer with multiple tumor marker assay.
Comparison of Cyfra 21-1, TPA and SCC tumor markers in esophageal squamous cell carcinoma.
Comparison of proteinase activities in squamous cell carcinoma, basal cell epithelioma, and seborrheic keratosis.
Concomitant secretion by A431 cells of tissue plasminogen activator and a specific inhibitor masks EGF modulation of tPA activity.
Decrease of epidermal histidase activity by tumor-promoting phorbol esters.
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Determination of serum levels of different cytokeratins in patients with uterine malignancies.
Differential protease expression by cutaneous squamous and basal cell carcinomas.
Down-regulation of epidermal growth factor receptor correlates with plasminogen activator activity in human A431 epidermoid carcinoma cells.
E2F as a regulator of keratinocyte proliferation: implications for skin tumor development.
Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion.
Effects of oral versus topical administration of cyclosporine on phorbol ester promotion of murine epidermal carcinogenesis.
Enhanced production of plasminogen activator activity in human and murine keratinocytes by transforming growth factor-beta 1.
Epidermal growth factor and 12-tetradecanoyl phorbol 13-acetate induction of urokinase in A431 cells.
Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.
Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC).
Evidence for cells possessing t-PA like activity in smears obtained from patients with oral squamous cell carcinoma.
Functional relevance of urinary-type plasminogen activator receptor-alpha3beta1 integrin association in proteinase regulatory pathways.
Gene structure, chromosomal localization, and expression of the murine homologue of human proteinase inhibitor 6 (PI-6) suggests divergence of PI-6 from the ovalbumin serpins.
In vitro urokinase type plasminogen activator levels and total plasminogen activator activity in squamous cell carcinomas of the head and neck.
Integrin A6 Cleavage in Mouse Skin Tumors.
Involvement of protein kinase C in translocation of desmoplakins from cytosol to plasma membrane during desmosome formation in human squamous cell carcinoma cells grown in low to normal calcium concentration.
Ionizing radiation as an initiator in the mouse two-stage model of skin tumor formation.
Ionizing radiation enhances malignant progression of mouse skin tumors.
Irradiation-induced regulation of plasminogen activator inhibitor type-1 and vascular endothelial growth factor in six human squamous cell carcinoma lines of the head and neck.
Keratinocytes and head and neck squamous cell carcinoma cells regulate urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in fibroblasts.
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
Metastatic potential of mouse skin carcinomas produced by different protocols of chemical carcinogenesis.
Modulation of tPA, PAI-1 and PAI-2 antigen and mRNA levels by EGF in the A431 cell line.
Non-melanoma skin cancer in mouse and man.
Normal and transformed human prokeratinocytes express divergent effects of a tumor promoter on cell cycle-mediated control of proliferation and differentiation.
NTP Toxicology and Carcinogenesis Studies of 1,2-Dihydro-2,2,4-Trimethylquinoline (CAS No. 147-47-7) in F344/N Rats and B6C3F1 Mice (Dermal Studies) and the Dermal Initiation/Promotion Study in Female Sencar Mice.
NTP Toxicology and Carcinogenesis Studies of Diethylphthalate (CAS No. 84-66-2) in F344/N Rats and B6C3F1 Mice (Dermal Studies) with Dermal Initiation/ Promotion Study of Diethylphthalate and Dimethylphthalate (CAS No. 131-11-3) in Male Swiss (CD-1(R)) Mice.
Pharmacologic evidence for involvement of phospholipase C in pemphigus IgG-induced inositol 1,4,5-trisphosphate generation, intracellular calcium increase, and plasminogen activator secretion in DJM-1 cells, a squamous cell carcinoma line.
Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.
Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines.
Plasminogen activator production by human tumor cells: effect on tumor cell-extracellular matrix interactions.
Plasminogen activators in normal and malignant oral epithelium in vivo and in vitro.
Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.
Plasminogen activators in oesophageal carcinoma.
Prognostic significance of serum tumour markers in carcinoma of the cervix.
Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma.
Proteome analysis of antiproliferative mechanism of 12-O-tetradecanoylphorbol 13-acetate on cultured nasopharyngeal carcinoma CNE2 cells.
Proteomics-based identification of proteins with altered expression induced by 12-O-tetradecanoylphorbol 13-acetate in nasopharyngeal carcinoma CNE2 cells.
Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix.
Serum and tissue levels of CEA, TPA, CA 125 and CA 15.3 in patients with lung cancer.
Serum induction of the fibroblast growth factor-binding protein (FGF-BP) is mediated through ERK and p38 MAP kinase activation and C/EBP-regulated transcription.
Successful development of squamous cell carcinoma and hyperplasia in RGEN-mediated p27 KO mice after the treatment of DMBA and TPA.
The Mr 17500 region of the A chain of urokinase is required for interaction with a specific receptor in A431 cells.
The prognostic value of TPA and SCC in squamous cell carcinoma of the cervix.
Tissue polypeptide antigen, carcinoembryonic antigen, carbohydrate antigen, and CA125 levels as tumor markers in squamous cell carcinoma of the head and neck.
Transforming growth factor beta1, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in head and neck squamous carcinoma and normal adjacent mucosa.
Tumor progression of murine epidermal cells after treatment in vitro with 12-O-tetradecanoylphorbol-13-acetate or retinoic acid.
uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity.
Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.
Urokinase-type plasminogen activator and its inhibitor plasminogen activator inhibitor-1.
Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck.
[Clinical evaluation of combination assay of tumor markers in primary lung cancer patients]
[Clinical relevance of tumor markers]
[Differences in assay sensitivity of selected tumor markers in head and neck neoplasms]
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
[Prognostic value of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx]
[Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer]
[Studies on marker substances in cell lines derived from various human gynecologic tumors (author's transl)]
[The expressions and diagnostic values of miR-18a and miR-21 in esophageal cancer].
[Tissue polypeptide antigen in serum and tissue in patients with lung cancer]
Carcinoma, Transitional Cell
Comparison between tissue antigen analysis and plasma determinations for TPA and CEA in transitional cell carcinomas and in tumorfree urothelium of the urinary bladder.
Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS.
Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer.
Serum TPS versus TPA in Egyptian bladder cancer patients.
TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Cardiac Tamponade
Alteplase Causing Cardiac Tamponade after Recent Cardiac Pacemaker Placement.
Alteplase for Massive Pulmonary Embolism after Complicated Pericardiocentesis.
Cardiac tamponade following treatment with tissue plasminogen activator: an atypical hemodynamic response to pericardiocentesis.
Hemopericardium and cardiac tamponade after thrombolysis for acute ischemic stroke.
Pericardial Tamponade After Systemic Alteplase in Stroke and Emergent Reversal With Tranexamic Acid.
[A rare case of coronary artery perforation by a PTCA guide wire complicating with postinfarction cardiac rupture after thrombolytic therapy]
[Cardiac tamponade following thrombolysis with low dose rt-PA.]
Cardio-Renal Syndrome
Crosstalk of Various Biomarkers That Might Provide Prompt Identification of Acute or Chronic Cardiorenal Syndromes.
Microinflammation factors in the common diseases of the heart and kidneys.
Cardiomegaly
Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
Caveolin-1 ablation reduces the adverse cardiovascular effects of N-omega-nitro-L-arginine methyl ester and angiotensin II.
Dominant-negative c-Jun inhibits rat cardiac hypertrophy induced by angiotensin II and hypertension.
Kallikrein gene delivery attenuates cardiac remodeling and promotes neovascularization in spontaneously hypertensive rats.
Plasminogen Activator Inhibitor-1: A Novel Therapeutic Target for Hypertension?
Ventricular function and cardiac hypertrophy after coronary thrombolysis with tissue-type plasminogen activator (t-PA) in dogs with coronary artery thrombi.
Cardiomyopathies
In peripartum cardiomyopathy Plasminogen Activator Inhibitor-1 is a potential new biomarker with controversial roles.
Left ventricular thrombus in a 2-year-old boy with cardiomyopathy: lysis with recombinant tissue-type plasminogen activator.
Lysis of a left ventricular thrombus with recombinant tissue plasminogen activator.
Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals.
Persistent plasminogen activator inhibitor 1 gene expression in cardiac transplant recipients with idiopathic dilated cardiomyopathy.
Plasminogen activator inhibitor type 1 in ischemic cardiomyopathy.
Plasminogen activator inhibitor-1 reduces cardiac fibrosis and promotes M2 macrophage polarization in inflammatory cardiomyopathy.
Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy.
Cardiomyopathy, Dilated
Bayesian hierarchical modeling and the integration of heterogeneous information on the effectiveness of cardiovascular therapies.
ERK1/2 mediates the lipopolysaccharide-induced upregulation of FGF-2, uPA, MMP-2, MMP-9 and cellular migration in cardiac fibroblasts.
Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in H9c2 cardiomyoblast cells.
Persistent plasminogen activator inhibitor 1 gene expression in cardiac transplant recipients with idiopathic dilated cardiomyopathy.
[Heparin-induced thrombocythopenia in a patient with massive pulmonary embolism and dilated cardiomyopathy, successfuly treated with fondaparinux - a case report]
Cardiomyopathy, Hypertrophic
Role of double knockdown of tPA and MMP-9 on regulating the left ventricular function and remodeling followed by transverse aortic constriction-induced hypertrophic cardiomyopathy in mice.
Cardiovascular Diseases
4G/4G genotype of PAI-1 gene is associated with reduced risk of stroke in elderly.
A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state.
A small molecule PAI-1 functional inhibitor attenuates neointimal hyperplasia and vascular smooth muscle cell survival by promoting PAI-1 cleavage.
Absence of association between polymorphisms in the hemostatic factor pathway genes and carotid intimal medial thickness: the Framingham Heart Study.
Activation of guanine nucleotide-binding proteins and induction of endothelial tissue-type plasminogen activator gene transcription by alcohol.
Acute ingestion of long-chain (n-3) polyunsaturated fatty acids decreases fibrinolysis in men with metabolic syndrome.
Adipokines: linking obesity and cardiovascular disease.
Adipokines: New Potential Therapeutic Target for Obesity and Metabolic, Rheumatic, and Cardiovascular Diseases.
Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals.
Age relations of cardiovascular risk factors in a traditional Melanesian society: the Kitava Study.
Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients.
Alcohol consumption and hemostatic factors: analysis of the Framingham Offspring cohort.
Alcohol, heart disease, and mortality: a review.
Aldosterone perturbs adiponectin and PAI-1 expression and secretion in 3T3-L1 adipocytes.
Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men.
Androgens are associated with hemostatic and inflammatory factors among women at the mid-life.
Angiotensin I-converting enzyme and plasminogen activator inhibitor-1 gene variants: risk of mortality and fatal cardiovascular disease in an elderly population-based cohort.
Association of adipokines with cardiovascular risk factors in low birth weight children: a case-control study.
Association of blood pressure with fibrinolytic potential in the Framingham offspring population.
Association of markers of hemostasis with death in HIV-infected women.
Association of plasminogen activator inhibitor-1 and low-density lipoprotein heterogeneity as a risk factor of atherosclerotic cardiovascular disease with triglyceride metabolic disorder: a pilot cross-sectional study.
Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis.
Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1.
C-reactive protein (CRP)-lowering agents.
Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies.
Cardiovascular Risk Indices and Their Impact on Outcome in Patients with Hyperglycaemic Emergencies in a Nigerian Hospital.
Carotid artery wall morphology, haemostatic factors and cardiovascular disease. An ultrasound study in men at high and low risk for atherosclerotic disease.
Chronic circadian clock disruption induces expression of the cardiovascular risk factor plasminogen activator inhibitor-1 in mice.
Circadian variability of fibrinolytic markers and endothelial function in patients with obstructive sleep apnea.
Clinical Relevance of Plasma Endogenous Tissue-Plasminogen Activator and Aortic Valve Sclerosis: Performance as a Diagnostic Biomarker.
Clinical utility of biomarkers of endothelial activation and coagulation for prognosis in HIV infection: A systematic review.
CLOCK is involved in obesity-induced disordered fibrinolysis in ob/ob mice by regulating PAI-1 gene expression.
Cloning of a single-chain variable fragment (scFv) switching active plasminogen activator inhibitor-1 to substrate.
Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome.
Combined presence of coagulation factor XIII V34L and plasminogen activator inhibitor 1 4G/5G gene polymorphisms significantly contribute to recurrent pregnancy loss in Serbian population.
Contribution of genetic and metabolic syndrome to omental adipose tissue PAI-1 gene mRNA and plasma levels in obesity.
Data in support of a central role of plasminogen activator inhibitor-2 polymorphism in recurrent cardiovascular disease risk in the setting of high HDL cholesterol and C-reactive protein using Bayesian network modeling.
Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus.
Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene.
Diabetes and cardiovascular disease. The "common soil" hypothesis.
Dietary fatty acids, hemostasis, and cardiovascular disease risk.
Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
Effect of dipeptidyl peptidase-4 inhibitor, vildagliptin on plasminogen activator inhibitor-1 in patients with diabetes mellitus.
Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease.
Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture.
Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: a prospective cohort study in primary care.
Effects of Altered Plasminogen Activator Inhibitor-1 Expression on Cardiovascular Disease.
Effects of High Glucose and Ketosis (Acetoacetate, {beta}-Hydroxybutyrate) on PAI-1 Secretion in Human Umbilical Vascular Endothelial Cells.
Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.
Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.
Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation.
Effects of specific chemical suppressors of plasminogen activator inhibitor-1 in cardiovascular diseases.
Effects of walnut consumption as part of a low-fat, low-cholesterol diet on serum cardiovascular risk factors.
Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease.
Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease.
Elucidation of the binding regions of PAI-1 neutralizing antibodies using chimeric variants of human and rat PAI-1.
Elucidation of the paratope of scFv-8H9D4, a PAI-1 neutralizing antibody derivative.
Endogenous tissue-type plasminogen activator and risk of myocardial infarction.
Etiopathogenesis of cardiovascular disease: hemostasis, thrombosis, and vascular medicine.
Experimental thrombosis I: relation with fibrinogen and other haemostatic parameters.
Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha?
Fabrication of an immunosensor for early and ultrasensitive determination of human tissue plasminogen activator (tPA) in myocardial infraction and breast cancer patients.
Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women.
Fiber intake and plasminogen activator inhibitor-1 in type 2 diabetes: Look AHEAD (Action for Health in Diabetes) trial findings at baseline and year 1.
Fibrinogen, plasminogen activator inhibitor-1, and carotid intima-media wall thickness in the NHLBI Family Heart Study.
Fibrinolytic activity in peripheral atherosclerosis in the elderly.
Fibrinolytic factors and atherothrombotic events: epidemiological evidence.
Functionally stable plasminogen activator inhibitor-1 in a family with cardiovascular disease and vitiligo.
Generation and in vitro characterisation of inhibitory nanobodies towards plasminogen activator inhibitor 1.
Genetic Effects on the Correlation Structure of CVD Risk Factors: Exome-Wide Data From a Ghanaian Population.
Genetic variation at the human tissue-type plasminogen activator (tPA) locus: haplotypes and analysis of association to plasma levels of tPA.
Genetic variation in hyaluronan metabolism loci is associated with plasma plasminogen activator inhibitor-1 concentration.
Genetics of Plasminogen Activator Inhibitor-1 (PAI-1) in a Ghanaian Population.
Genome-Wide Association Study for Circulating Tissue Plasminogen Activator Levels and Functional Follow-Up Implicates Endothelial STXBP5 and STX2.
Green tea polyphenols inhibit plasminogen activator inhibitor-1 expression and secretion in endothelial cells.
Haemostatic parameters and vascular risk.
Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study.
Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines.
Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes.
Identification of signaling pathways involved in aberrant production of adipokines in adipocytes undergoing oxidative stress.
Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women.
Impact of biomarkers for endothelial dysfunction and procoagulant state on 10-year cardiovascular risk in Type?2 diabetes(1).
Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. A systematic review and meta-analysis of randomised controlled trials.
Impact of vitamin C on the cardiometabolic and inflammatory profiles of mice lacking a functional Werner syndrome protein helicase.
Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes.
Importance of N-terminal residues in plasminogen activator inhibitor 1 on its antibody induced latency transition.
In vivo stimulation of vascular plasminogen activator inhibitor-1 production by very low-density lipoprotein involves transcription factor binding to a VLDL-responsive element.
Incidence of Major Bleeding in Patients with Pulmonary Thromboembolism Treated with Fixed Dose Alteplase 100 mg.
Influence of long-term intervention with dietary counseling, long-chain n-3 fatty acid supplements, or both on circulating markers of endothelial activation in men with long-standing hyperlipidemia.
Influences on plasminogen activator inhibitor-2 polymorphism-associated recurrent cardiovascular disease risk in patients with high HDL cholesterol and inflammation.
Inhibition of plasminogen activator inhibitor-1: antibody fragments and their unique sequences as a tool for the development of profibrinolytic drugs.
Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris.
Inverse relationship between adiponectin and plasminogen activator inhibitor-1 in metabolic syndrome patients.
Ketogenic diet disrupts the circadian clock and increases hypofibrinolytic risk by inducing expression of plasminogen activator inhibitor-1.
Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly.
Lipid-independent effects of an estrogen-statin combination: inhibition of expression of adhesion molecules and plasminogen activator inhibitor--I in human endothelial cell cultures.
Low Molecular Weight Antagonists of Plasminogen Activator Inhibitor-1: Therapeutic Potential in Cardiovascular Disease.
Markers of endothelial cell activation in elderly men at high risk for coronary heart disease.
Markers of endothelial dysfunction and cerebral blood flow in older adults.
Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity.
Migraine and biomarkers of endothelial activation in young women.
Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction.
Molecular variation at functional genes and the history of human populations--data on candidate genes for cardiovascular risk in the Mediterranean.
Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms.
Overfatness, stunting and physical inactivity are determinants of plasminogen activator inhibitor-1activity, fibrinogen and thrombin-antithrombin complex in African adolescents.
Overview of hemostatic factors involved in atherosclerotic cardiovascular disease.
PERIOD2 is a circadian negative regulator of PAI-1 gene expression in mice.
Plaque area at carotid and common femoral bifurcations and prevalence of clinical cardiovascular disease.
Plasma cytokines as predictors of coronary heart disease.
Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G/5G genotype.
Plasminogen activator inhibitor 1 and visceral obesity during pronounced weight loss after bariatric surgery.
Plasminogen activator inhibitor and the risk of cardiovascular disease: The Framingham Heart Study.
Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke.
Plasminogen activator inhibitor type-1 (PAI-1) and its role in cardiovascular disease.
Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001.
Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with metabolic syndrome parameters in Malaysian subjects.
Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis.
Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus.
Plasminogen activator inhibitor-1 and relations to fatty acid composition in the diet and in serum cholesterol esters.
Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity.
Plasminogen activator inhibitor-1 in aging.
Plasminogen activator inhibitor-1 is a transcriptional target of the canonical pathway of Wnt/beta-catenin signaling.
Plasminogen activator inhibitor-1: a common denominator in cardiovascular disease.
Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease.
Plasminogen activator inhitor-1 associates with cardiovascular risk factors in healthy young adults in the Cardiovascular Risk in Young Finns Study.
Potential of free-form TFPI and PAI-1 to be useful markers of early atherosclerosis in a Japanese general population (the Suita Study): association with the intimal-medial thickness of carotid arteries.
PPAR? deficiency augments a ketogenic diet-induced circadian PAI-1 expression possibly through PPAR? activation in the liver.
Predictors of Carotid Atherosclerosis in Systemic Lupus Erythematosus.
Predictors of carotid atherosclerosis in systemic lupus erythematosus.
Predictors of neutrophil extracellular traps markers in type 2 diabetes mellitus: associations with a prothrombotic state and hypofibrinolysis.
Principal component analysis of adipocytokines and insulin associate with risk factors of cardiovascular diseases.
Procyanidins exhibits neuroprotective activities against cerebral ischemia reperfusion injury by inhibiting TLR4-NLRP3 inflammasome signal pathway.
Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study.
Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome.
Prospective study of endogenous tissue plasminogen activator and risk of stroke.
Regulation of PAI-1 expression by genetic polymorphisms. Impact on atherogenesis.
Regulation of plasminogen activator inhibitor-1 expression in endothelial cells with exposure to metal nanoparticles.
Relation between dietary fiber consumption and fibrinogen and plasminogen activator inhibitor type 1: The National Heart, Lung, and Blood Institute Family Heart Study.
Relationship between plasma essential fatty acids and smoking, serum lipids, blood pressure and haemostatic and rheological factors.
Relationships of plasminogen activator inhibitor-1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men.
Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study.
Retinoids and fibrinolysis.
Risk factors of ischemic cardiac disease in patients on continuous ambulatory peritoneal dialysis.
Role of c-Jun NH2-terminal kinase in G-protein-coupled receptor agonist-induced cardiac plasminogen activator inhibitor-1 expression.
Role of inherited thrombophilic profile on survival of patients with sepsis.
Role of plasminogen activator inhibitor-1 in senescence and aging.
Role of plasminogen activator inhibitor-1 in the diagnosis and prognosis of patients with Parkinson's disease.
Sedentary subjects have higher PAI-1 and lipoproteins levels than highly trained athletes.
Single fluorescence probes along the reactive center loop reveal site-specific changes during the latency transition of PAI-1.
Stability and activity of alteplase with injectable drugs commonly used in cardiac therapy.
Streptokinase: An Efficient Enzyme in Cardiac Medicine.
Study of recombinant antibody fragments and PAI-1 complexes combining protein-protein docking and results from site-directed mutagenesis.
Successful silencing of plasminogen activator inhibitor-1 in human vascular endothelial cells using small interfering RNA.
Supplementation with ?-Lipoic Acid Alone or in Combination with Eicosapentaenoic Acid Modulates the Inflammatory Status of Healthy Overweight or Obese Women Consuming an Energy-Restricted Diet.
Switching ?-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients.
Systemic and vascular markers of inflammation in relation to metabolic syndrome and insulin resistance in adults with elevated atherosclerosis risk.
The contribution of different adipose tissue depots to plasma plasminogen activator inhibitor-1 (PAI-1) levels.
The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women.
The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial.
The effect of thyroid hormones on the white adipose tissue gene expression of PAI-1 and its serum concentration.
The fat mouse: a powerful genetic model to study elevated plasminogen activator inhibitor 1 in obesity/NIDDM.
The moderating effect of personal mastery and the relations between stress and Plasminogen Activator Inhibitor-1 (PAI-1) antigen.
The plasma levels of plasminogen activator inhibitor-1 in subjects with white coat hypertension.
The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study.
The plasminogen activator inhibitor-1 (PAI-1) promoter haplotype is related to PAI-1 plasma concentrations in lean individuals.
The relationship between cardiometabolic and hemostatic variables: influence of race.
The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases.
The Type and Amount of Dietary Fat Affect Plasma Factor VIIc, Fibrinogen, and PAI-1 in Healthy Individuals and Individuals at High Cardiovascular Disease Risk: 2 Randomized Controlled Trials.
Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice.
Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study.
Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women.
Tissue Plasminogen Activator Levels and Risk of Breast Cancer in a Case-Cohort Study on Italian Women: Results from the Moli-sani Study.
Type 2 diabetes significantly modulates the cardiovascular risk conferred by the PAI-1 -675 4G/5G polymorphism in angiographied coronary patients.
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Ultrasound carotid plaque features, cardiovascular disease risk factors and events: The Multi-Ethnic Study of Atherosclerosis.
Upstream stimulatory factor-2 mediates quercetin-induced suppression of PAI-1 gene expression in human endothelial cells.
V-10153 (Vernalis).
Very low density lipoprotein-mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells.
Whole grain wheat sourdough bread does not affect plasminogen activator inhibitor-1 in adults with normal or impaired carbohydrate metabolism.
[Development of research into the physiology and pathophysiology of the fibrinolysis system]
[Estrogen replacement in postmenopause, blood coagulation and fibrinolysis: comparison of a new kind of transdermal estradiol treatment with oral therapy with conjugated estrogens]
[Inflammatory biomarkers: the link between obesity and associated pathologies]
[Markers of endothelial dysfunction in patients with arterial hypertension exposed to occupational irradiation of ?low intensity].
[Thrombotic tendency and laboratory medicine in metabolic syndrome]
Caroli Disease
Matrix proteins of basement membrane of intrahepatic bile ducts are degraded in congenital hepatic fibrosis and Caroli's disease.
Carotid Artery Diseases
Deep Learning-Based Carotid Plaque Segmentation from B-Mode Ultrasound Images.
The metabolic syndrome and progression of carotid atherosclerosis over 13 years. The Tromso study.
Carotid Artery Thrombosis
Angioedema and Hemorrhage After 4.5-Hour tPA (Tissue-Type Plasminogen Activator) Thrombolysis Ameliorated by T541 via Restoring Brain Microvascular Integrity.
Anticoagulant and Antithrombotic Properties in Vitro and in Vivo of a Novel Sulfated Polysaccharide from Marine Green Alga Monostroma nitidum.
Antithrombotic effects and related mechanisms of Salvia deserta Schang root EtOAc extracts.
Deterioration following improvement with tPA therapy: carotid thrombosis and reocclusion.
Effect of a synthetic factor Xa inhibitor, YM-60828, on blood vessel patency in combination with a thrombolytic agent and on blood loss from the operation site in a rat model of arterial thrombosis.
Experimental model of carotid artery thrombosis in rats and the thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator.
Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis.
PEGylation of Lumbrokinase improves pharmacokinetic profile and enhances anti?thrombotic effect in a rat carotid artery thrombosis model.
Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes.
Repetitive progressive thermal preconditioning hinders thrombosis by reinforcing phosphatidylinositol 3-kinase/Akt-dependent heat-shock protein/endothelial nitric oxide synthase signaling.
Time-Dependent Thrombus Resolution After Tissue-Type Plasminogen Activator in Patients With Stroke and Mice.
[Intravenous thrombolysis with rt-PA in stroke: Experience of the French military hospital of Toulon from September 2003 to June 2009.]
Carotid Artery, Internal, Dissection
Intravenous tPA in acute ischemic stroke related to internal carotid artery dissection.
Stent-assisted endovascular thrombolysis versus intravenous thrombolysis in internal carotid artery dissection with tandem internal carotid and middle cerebral artery occlusion.
Carotid Stenosis
Cerebral hemorrhage after systemic fibrinolysis in a patient with severe carotid artery stenosis.
Co-morbid conditions in use of recombinant tissue plasminogen activator (rt-PA) for the treatment of acute ischaemic stroke.
Consent issues in neurology.
Early carotid endarterectomy for critical carotid artery stenosis after thrombolysis therapy in acute ischemic stroke in the middle cerebral artery.
Effect of renal impairment on atherosclerosis: only partially mediated by homocysteine.
Endothelial dysfunction and systemic inflammation in persons with echolucent carotid plaques.
Hemostatic function and carotid artery disease.
Intravenous tissue-type plasminogen activator therapy is an independent risk factor for symptomatic intracerebral hemorrhage after carotid endarterectomy.
Ischemic stroke. Clinical strategies based on mechanisms and risk factors.
Carotid-Cavernous Sinus Fistula
[The diagnosis and treatment of traumatic optic nerve neuropathy combined with carotid artery injury].
Carpal Tunnel Syndrome
Soluble interleukin 2 receptor and tissue polypeptide antigen serum concentrations in end-stage renal failure.
Cataract
Cytokine and Chemokine Concentration in the Tear of Patients with Age-Related Cataract.
Developmental Factors of Fibrous Opacification in the Atopic Cataract Lens Capsule.
Fibrin membrane pupillary-block glaucoma after uneventful cataract surgery treated with intracameral tissue plasminogen activator: a case report.
Hemorrhagic ocular complications associated with the use of systemic thrombolytic agents.
Immunocytochemical features of lens after cataract tissue--signalling molecules (growth factors, cytokines, other signalling molecules), cytoskeleton proteins, cellular and extracellular matrix proteins.
Intracameral r-tPA for the management of severe fibrinous reactions in TASS after cataract surgery.
Intracameral recombinant tissue plasminogen activator (r-tPA) for refractory toxic anterior segment syndrome.
Intracameral tissue plasminogen activator after glaucoma surgery. Indications, effectiveness, and complications.
Intracameral tissue plasminogen activator to prevent severe fibrinous effusion after congenital cataract surgery.
Intracameral tissue plasminogen activator to treat severe fibrinous effusion after cataract surgery.
Intraocular Lens Opacification following Intracameral Injection of Recombinant Tissue Plasminogen Activator to Treat Inflammatory Membranes after Cataract Surgery.
Intraocular recombinant tissue-plasminogen activator fibrinolysis of fibrin formation after cataract surgery in children.
Involvement of Plasminogen Activator Inhibitor-1 in the Pathogenesis of Atopic Cataract.
Low-dose tissue plasminogen activator in the management of anterior chamber fibrin formation.
Plasminogen activator in human tears.
Postoperative fluctuations of tissue plasminogen activator (t-PA) in aqueous humor of pseudophakes.
Recombinant tissue plasminogen activator (r-TPA) in fibrin dissolution due to postoperative endophthalmitis.
Recombinant tissue plasminogen activator following paediatric cataract surgery.
Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study.
Suprachoroidal haemorrhage (SCH) drainage using suprachoroidal tissue plasminogen activator (t-PA) after complicated cataract extraction (two-staged procedure): early intervention could mean better vision.
SURGICAL OUTCOMES AFTER MASSIVE SUBRETINAL HEMORRHAGE SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
The use of recombinant tissue plasminogen activator for intracameral fibrinolysis following cataract surgery.
Therapeutic application of tissue plasminogen activator for fibrin reaction after cataract surgery.
Tissue plasminogen activator for the treatment of postoperative intraocular fibrinous membranes following cataract surgery.
Treatment of anterior chamber fibrin following cataract surgery with tissue plasminogen activator.
Treatment of intracameral fibrinous membranes with tissue plasminogen activator.
Treatment of postcataract fibrinous membranes with tissue plasminogen activator.
Use of mitomycin C and r-tPA for the management of conjunctival membrane and cataracts in a child with conjunctivitis lignosa.
[Anticoagulant and fibrinolytic therapies for anterior chamber fibrin following cataract surgery in the rabbit eye]
[Cost recovery for the treatment of retinal and vitreal diseases by pars plana vitrectomy under the German DRG system]
[Intraocular rt-PA injection in fibrin formation after combined glaucoma and cataract operation]
[Plasminogen activator inhibitor-1 mRNA expression by the iris and lens epithelial cells of rabbit eye with intraocular lens implantation]
[r-tPA in keratoplasty à chaud. Report of 50 patients]
[Therapeutic and prophylactic application of TPA (recombinant tissue plasminogen activator) into the anterior chamber of the eye]
[Tissue plasminogen activator (t-PA) in aqueous humor of patients with cataract]
[Tissue plasminogen activator in treatment of fibrinous membranes after cataract surgery]
[Treatment of intraocular fibrin formation with tissue plasminogen activator after vitrectomy]
[Treatment with tissue plasminogen activator (tPA) in risk patients with fibrin reactions after cataract operations]
Cell Transformation, Neoplastic
Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
The nicotinic acetylcholine receptor-mediated reciprocal effects of the tobacco nitrosamine NNK and SLURP-1 on human mammary epithelial cells.
Central Nervous System Vascular Malformations
[Cerebrovascular malformation revealed during the prethrombolysis workup in acute ischemic stroke. Impact on therapeutic decision making.]
Central Serous Chorioretinopathy
Plasminogen activator inhibitor 1 in central serous chorioretinopathy.
Pneumatic displacement with perfluoropropane gas and intravitreal tissue plasminogen activator for subretinal subfoveal hemorrhage after focal laser photocoagulation in central serous chorioretinopathy.
Role of the tissue-type plasminogen activator -7351C > T and plasminogen activator inhibitor 1 4G/5G gene polymorphisms in central serous chorioretinopathy.
The prevalence of 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in central serous chorioretinopathy and its association with plasma PAI-1 levels.
[Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-1 in blood obtained from patients of idiopathic central serous chorioretinopathy]
Cerebellar Diseases
Tissue-type plasminogen activator is an extracellular mediator of Purkinje cell damage and altered gait.
Cerebral Amyloid Angiopathy
Cerebral beta-amyloid detected by pittsburgh compound B positron emission topography predisposes to recombinant tissue plasminogen activator-related hemorrhage.
Remote Intracerebral Hemorrhage After Intravenous Thrombolysis: Results From a Multicenter Study.
Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy.
tPA deficiency underlies neurovascular coupling dysfunction by amyloid-?.
Upregulation of tPA/plasminogen proteolytic system in the periphery of amyloid deposits in the Tg2576 mouse model of Alzheimer's disease.
Cerebral Hemorrhage
2016-2017 clinical trials in cerebrovascular neurosurgery.
A novel finding of a low-molecular-weight compound, SMTP-7, having thrombolytic and anti-inflammatory effects in cerebral infarction of mice.
A novel method to promote behavioral improvement and enhance mitochondrial function following an embolic stroke.
A novel protocol to reduce bleeding associated with alteplase treatment of HVAD pump thrombosis.
A Pooled Analysis of Diffusion-Weighted Imaging Lesions in Patients With Acute Intracerebral Hemorrhage.
A randomized 500-subject open-label phase 3 clinical trial of minimally invasive surgery plus alteplase in intracerebral hemorrhage evacuation (MISTIE III).
A review of stereotaxy and lysis for intracranial hemorrhage.
Accuracy of First Recorded "Last Known Normal" Times of Stroke Code Patients.
Accuracy of the ABC/2 Score for Intracerebral Hemorrhage: Systematic Review and Analysis of MISTIE, CLEAR-IVH, and CLEAR III.
ACR Appropriateness Criteria(®) on Cerebrovascular Disease.
Acute Ischemic Stroke Treated with Intravenous Tissue Plasminogen Activator in a Patient Taking Dabigatran with Radiographic Evidence of Recanalization.
Acute stroke: therapeutic transcranial color duplex sonography.
Acute Treatment of Stroke (Except Thrombectomy).
Addition of intravenous N-methyl-D-aspartate receptor antagonists to local fibrinolytic therapy for the optimal treatment of experimental intracerebral hemorrhages.
Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis.
Advances in intravenous thrombolytic therapy for treatment of acute stroke.
Age-Dependent Neonatal Intracerebral Hemorrhage in Plasminogen Activator Inhibitor 1 Knockout Mice.
An ischemic stroke during intravenous recombinant tissue plasminogen activator infusion for evolving myocardial infarction.
And why not thrombolysis in the ambulance (at least for some)?
Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection.
Antiactin-targeted immunoliposomes ameliorate tissue plasminogen activator-induced hemorrhage after focal embolic stroke.
Antithrombotic and thrombolytic therapy for ischemic stroke.
Antithrombotic treatments in acute ischemic stroke.
Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke.
Are patients with acutely recovered cerebral ischemia more unstable?
Artificial neural network based prediction of postthrombolysis intracerebral hemorrhage and death.
ASPECT scoring to estimate >1/3 middle cerebral artery territory infarction.
Assessment of suitability of thrombolysis in middle cerebral artery infarction: a proof of concept study of a stereologically-based technique.
Atherosclerotic intracranial internal carotid artery calcification and intravenous thrombolytic therapy for acute ischemic stroke.
Bed rest or mobilization after rt-PA? A case-crossover study of factors influencing clinical decision making in stroke services.
Beneficial actions of prothymosin alpha-mimetic hexapeptide on central post-stroke pain, reduced social activity, learning-deficit and depression following cerebral ischemia in mice.
Bleeding complications after basilar artery fibrinolysis with tissue plasminogen activator.
Blood Occludin Level as a Potential Biomarker for Early Blood Brain Barrier Damage Following Ischemic Stroke.
Blood Pressure Management and Evolution of Thrombolysis-associated Intracerebral Hemorrhage in Acute Ischemic Stroke.
Blood Pressure Management for Acute Ischemic and Hemorrhagic Stroke: The Evidence.
Brain hemorrhages after rt-PA treatment of embolic stroke in spontaneously hypertensive rats.
Can comprehensive stroke centers erase the 'weekend effect'?
Catastrophic Intracranial Hemorrhages after IV tPA in a Patient with Insidious Onset of Fever and Back Pain.
Caveolin-1 mediates tissue plasminogen activator-induced MMP-9 up-regulation in cultured brain microvascular endothelial cells.
Cerebral Amyloid Angiopathy: A Hidden Risk for IV Thrombolysis?
Cerebral hemorrhage, warfarin, and intravenous tPA: the real risk is not treating.
Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits.
Cerebral microbleeds shouldn't dictate treatment of acute stroke: a retrospective cohort study evaluating risk of intracerebral hemorrhage.
Chronic kidney disease and intravenous thrombolysis in acute stroke: A systematic review and meta-analysis.
Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience.
Clomethiazole (Astra Arcus AB).
Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke.
Combination of ultrasound and rtPA enhances fibrinolysis in an In Vitro clot system.
Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke.
Combination treatment of r-tPA and an optimized human apyrase reduces mortality rate and hemorrhagic transformation 6h after ischemic stroke in aged female rats.
Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial.
Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study.
Combined tissue plasminogen activator and an NK1 tachykinin receptor antagonist: An effective treatment for reperfusion injury following acute ischemic stroke in rats.
Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice.
Comparative safety of thrombolytic agents.
Comparison of 8 scores for predicting symptomatic intracerebral hemorrhage after IV thrombolysis.
Comparison of Partial (.6 mg/kg) versus Full-Dose (.9 mg/kg) Intravenous Recombinant Tissue Plasminogen Activator Followed by Endovascular Treatment for Acute Ischemic Stroke: A Meta-Analysis.
Comparison of quantitative estimation of intracerebral hemorrhage and infarct volumes after thromboembolism in an embolic stroke model.
Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits.
Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model.
Considering hyperglycemia and thrombolysis in the Stroke Hyperglycemia Insulin Network Effort (SHINE) trial.
Controversies in acute stroke treatment.
Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke.
Cysteinyl-leukotriene levels in intracerebral hemorrhage: an edema-promoting factor?
Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials.
Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication.
Derivation and Validation of a Scoring System for Intravenous Tissue Plasminogen Activator Use in Asian Patients.
Development of the nitrone-based spin trap agent NXY-059 to treat acute ischemic stroke.
Diagnostic impact of baseline cerebral blood flow in patients with acute ischemic stroke prior to intravenous recombinant tissue plasminogen activator therapy.
Diffusion-Weighted Imaging Lesions After Intracerebral Hemorrhage and Risk of Stroke: A MISTIE III and ATACH-2 Analysis.
Distinct Effects of Tissue-Type Plasminogen Activator and SMTP-7 on Cerebrovascular Inflammation Following Thrombolytic Reperfusion.
Does High Cerebral Microbleed Burden Increase the Risk of Intracerebral Hemorrhage After Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke?
Does ICA Occlusion Frequently Have Intracerebral Hemorrhage after IV Tissue Plasminogen Activator Therapy for Ischemic Stroke?
Does smoking influence outcome after intravenous thrombolysis for acute ischaemic stroke?
Dosing errors may impact the risk of rt-PA for stroke: the Multicenter rt-PA Acute Stroke Survey.
Early Abrogation of Gelatinase Activity Extends the Time Window for tPA Thrombolysis after Embolic Focal Cerebral Ischemia in Mice.
Early Ischemic Blood Brain Barrier Damage: A Potential Indicator for Hemorrhagic Transformation Following Tissue Plasminogen Activator (tPA) Thrombolysis?
Early recurrent ischemic stroke complicating intravenous thrombolysis for stroke: incidence and association with atrial fibrillation.
Early Use of Statin in Patients Treated with Alteplase for Acute Ischemic Stroke.
Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.
Effect of Clot Stiffness on Recombinant Tissue Plasminogen Activator Lytic Susceptibility in Vitro.
Effect of intrathecal fibrinolytic therapy on clot lysis and vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction.
Effect of intraventricularly administered low-dose recombinant tissue plasminogen activator on interleukin 1-beta and transforming growth factor beta concentrations in cerebrospinal fluid of patients with primary intracerebral hemorrhage associated with intraventricular hemorrhage: A retrospective study.
Effect of Serum Lipid Levels on Stroke Outcome after rt-PA Therapy: SAMURAI rt-PA Registry.
Effect of serum total cholesterol on hemorrhagic complications following thrombolytic therapy for acute myocardial infarction.
Effectiveness of alteplase in the very elderly after acute ischemic stroke.
Effects of hyperacute blood pressure and heart rate on stroke outcomes after intravenous tissue plasminogen activator.
Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats.
Effects of the spin trap agent disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator.
Efficacy and safety of desmoteplase in acute ischemic stroke patients: A systematic review and meta-analysis.
Efficacy and safety of intravenous thrombolysis with alteplase for treating acute ischemic stroke at different time windows: A protocol for systematic review and meta-analysis.
Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: a combination therapy study with tissue plasminogen activator.
Efficacy of Sanqi (Radix Notoginseng) in treating cerebral hemorrhage in rats with traumatic brain injury.
Elevated Homocysteine Level Related to Poor Outcome After Thrombolysis in Acute Ischemic Stroke.
End-of-Treatment Intracerebral and Ventricular Hemorrhage Volume Predicts Outcome: A Secondary Analysis of MISTIE III.
Endogenous tissue plasminogen activator increases hemorrhagic transformation induced by heparin after ischemia reperfusion in rat brains.
Erythrocyte-bound Tissue Plasminogen Activator (tPA) is Neuroprotective in Experimental Traumatic Brain Injury.
Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice.
Evaluating the safety and efficacy of intravenous thrombolysis for acute ischemic stroke patients with a history of intracerebral hemorrhage: a systematic review and meta-analysis.
Evolution of intracerebral hemorrhage after intravenous tPA: reversal of harmful effects with mast cell stabilization.
Exacerbation of perihematomal edema and sterile meningitis with intraventricular administration of tissue plasminogen activator in patients with intracerebral hemorrhage.
Factors Affecting Clot Lysis Rates in Patients With Spontaneous Intraventricular Hemorrhage.
Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials.
Factors preventing African Americans from seeking early intervention in the treatment of ischemic strokes.
Failure of peripheral arterial thrombolysis due to elevated plasminogen activator inhibitor type 1.
Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran.
Fatal intracerebral hemorrhage following thrombolytic therapy of embolic myocardial infarction in unsuspected infective endocarditis.
Feasibility and outcomes of intravenous thrombolysis 3-4.5hours after stroke in Chinese patients.
Fibrinolysis therapy achieved with tissue plasminogen activator and aspiration of the liquefied clot after experimental intracerebral hemorrhage: rapid reduction in hematoma volume but intensification of delayed edema formation.
FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
Frame-based and frameless stereotactic hematoma puncture and subsequent fibrinolytic therapy for the treatment of spontaneous intracerebral hemorrhage.
Frequency and predictors of symptomatic intracerebral hemorrhage in patients with ischemic stroke treated with recombinant tissue plasminogen activator outside clinical trials.
Functional outcome after thrombolytic therapy.
Ginsenoside Represses Symptomatic Intracerebral Hemorrhage after Recombinant Tissue Plasminogen Activator Therapy by Promoting Transforming Growth Factor-?1.
Hematoma expansion in experimental intracerebral hemorrhage is not altered by peracute treatment with recombinant tissue plasminogen activator.
Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm.
Hemorrhagic risk after intravenous thrombolysis for ischemic stroke in patients with cerebral microbleeds and white matter disease.
Hemorrhagic Transformation (HT) and Symptomatic Intracerebral Hemorrhage (sICH) Risk Prediction Models for Postthrombolytic Hemorrhage in the Stroke Belt.
Hemostatic factors as risk markers for intracerebral hemorrhage: a prospective incident case-referent study.
Hesperidin reduces adverse symptomatic intracerebral hemorrhage by promoting TGF-?1 for treating ischemic stroke using tissue plasminogen activator.
Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomes.
How to make better use of thrombolytic therapy in acute ischemic stroke.
Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke.
Hyperglycemia promotes tissue plasminogen activator-induced hemorrhage by Increasing superoxide production.
Immunotherapy blocking the tissue plasminogen activator-dependent activation of N-methyl-d-aspartate glutamate receptors improves hemorrhagic stroke outcome.
Impact of Intracranial Pressure Monitor-Guided Therapy on Neurologic Outcome After Spontaneous Nontraumatic Intracranial Hemorrhage.
Impact of Systems of Care and Blood Pressure Management on Stroke Outcomes.
Implementation of Telemedicine and Stroke Network in Thrombolytic Administration: Comparison Between Walk-in and Referred Patients.
Improved perfusion with rt-PA and hirulog in a rabbit model of embolic stroke.
In Reply: Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure.
In vitro evaluation of dual mode ultrasonic thrombolysis method for transcranial application with an occlusive thrombosis model.
Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected]
Increased microvascular permeability and low level of low-density lipoprotein cholesterol predict symptomatic intracerebral hemorrhage in acute ischemic stroke.
Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection.
Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke: ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) Post Hoc Analysis.
Inhibition of HIF-1? Reduced Blood Brain Barrier Damage by Regulating MMP-2 and VEGF During Acute Cerebral Ischemia.
Intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator (rt-PA) therapy for acute cerebral infarction in a patient with ANCA-associated vasculitis.
Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.
Intracerebral hemorrhage after IV tPA for stroke as early symptom of ANCA-associated vasculitis.
Intracerebral hemorrhage complicating intravenous tissue plasminogen activator treatment.
Intracerebral hemorrhage following intravenous thrombolysis in Thai patients with acute ischemic stroke.
Intracerebral hemorrhage related to cerebral amyloid angiopathy and t-PA treatment.
Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial.
Intraclot recombinant tissue-type plasminogen activator reduces perihematomal edema and mortality in patients with spontaneous intracerebral hemorrhage.
Intracranial Pressure and Cerebral Perfusion Pressure in Large Spontaneous Intracranial Hemorrhage and Impact of Minimally Invasive Surgery.
Intrahematomal Ultrasound Enhances RtPA-Fibrinolysis in a Porcine Model of Intracerebral Hemorrhage.
Intravenous alteplase for stroke in those older than 80 years old.
Intravenous Fibrinolysis for Central Retinal Artery Occlusion: A Cohort Study and Updated Patient-Level Meta-Analysis.
Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan.
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)
Intravenous thrombolytic therapy for acute ischemic stroke. Weighing the risks and benefits of tissue plasminogen activator.
Intravenous tissue plasminogen activator for acute ischemic stroke in patients with renal dysfunction.
Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.
Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus.
Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.
Intravenous tissue-type plasminogen activator therapy is an independent risk factor for symptomatic intracerebral hemorrhage after carotid endarterectomy.
Intravenous tPA in acute ischemic stroke related to internal carotid artery dissection.
Intravenous tPA therapy does not worsen acute intracerebral hemorrhage in mice.
Intraventricular thrombolysis with rt-PA in patients with intraventricular hemorrhage.
Is There a Decreased Risk of Intracerebral Hemorrhage and Mortality in Obese Patients Treated with Intravenous Thrombolysis in Acute Ischemic Stroke?
Isoflurane Postconditioning Inhibits tPA-Induced Matrix Metalloproteinases Activation After Hypoxic Injury via Low-Density Lipoprotein Receptor-Related Protein and Extracellular Signal-Regulated Kinase Pathway.
IV thrombolysis in very severe and severe ischemic stroke: Results from the SITS-ISTR Registry.
IV tPA is associated with increase in rates of intracerebral hemorrhage and length of stay in patients with acute stroke treated with endovascular treatment within 4.5 hours: should we bypass IV tPA in large vessel occlusion?
Late Night Activity Regarding Stroke Codes: LuNAR strokes.
Letter by turc et Al regarding article, "defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the national institute of neurological disorders and stroke tissue-type plasminogen activator trials".
Letter: Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure.
Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke.
Lipid Profile, Lipid-lowering Medications, and Intracerebral Hemorrhage After tPA in Get With The Guidelines-Stroke.
Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator.
Long-term outcomes of post-thrombolytic intracerebral hemorrhage in ischemic stroke patients.
Low-dose versus standard-dose alteplase in acute ischemic stroke in Asian stroke registries: an individual patient data pooling study.
Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.
Low-Dose vs Standard-Dose Alteplase for Patients With Acute Ischemic Stroke: Secondary Analysis of the ENCHANTED Randomized Clinical Trial.
Low-Dose vs Standard-Dose Alteplase in Acute Lacunar Ischemic Stroke: The ENCHANTED Trial.
Low-Dose vs. Standard-Dose Intravenous Alteplase in Bridging Therapy Among Patients With Acute Ischemic Stroke: Experience From a Stroke Center in Vietnam.
Management of delayed edema formation after fibrinolytic therapy for intracerebral hematomas: preliminary experimental data.
Management of non-traumatic intraventricular hemorrhage.
Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey.
Medical University of South Carolina Telestroke: A Telemedicine Facilitated Network for Stroke Treatment in South Carolina-A Progress Report.
Medico-Legal Aspects of Using Tissue Plasminogen Activator in Acute Ischemic Stroke.
Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke.
Microbubbles improve sonothrombolysis in vitro and decrease hemorrhage in vivo in a rabbit stroke model.
Microplasmin and tissue plasminogen activator: comparison of therapeutic effects in rat stroke model at multiparametric MR imaging.
Minimally invasive evacuation of spontaneous intracerebral hemorrhage using sonothrombolysis.
Minimally Invasive Surgery Plus Recombinant Tissue-type Plasminogen Activator for Intracerebral Hemorrhage Evacuation Decreases Perihematomal Edema.
Mismatch-based delayed thrombolysis: a meta-analysis.
Modified diffusion-weighted imaging-Alberta Stroke Program Early Computed Tomography Score including deep white matter lesions predicts symptomatic intracerebral hemorrhage following intravenous thrombolysis.
N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Augments Thrombolysis of tPA (Tissue-Type Plasminogen Activator) in Aged Rats After Stroke.
Neurological Emergencies During Pregnancy.
Neurovascular protection by peroxisome proliferator-activated receptor ? in ischemic stroke.
Neutrophil extracellular traps promote tPA-induced brain hemorrhage via cGAS in mice with stroke.
Neutrophils in tPA-induced hemorrhagic transformations: Main culprit, accomplice or innocent bystander?
New insights on thrombolytic treatment of acute ischemic stroke.
Nicotine increases plasminogen activator inhibitor-1 production by human brain endothelial cells via protein kinase C-associated pathway.
Non-contrast head CT-based thrombolysis for wake-up/unknown onset stroke is safe: A single-center study and meta-analysis.
Noninvasive ventilatory correction as an adjunct to an experimental systemic reperfusion therapy in acute ischemic stroke.
Normobaric Hyperoxia Reduces Blood Occludin Fragments in Rats and Patients With Acute Ischemic Stroke.
Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.
Occludin degradation makes brain microvascular endothelial cells more vulnerable to reperfusion injury in vitro.
Optimal Delay Time of CT Perfusion for Predicting Cerebral Parenchymal Hematoma After Intra-Arterial tPA Treatment.
Optimization of Catheter Based rtPA Thrombolysis in a Novel In Vitro Clot Model for Intracerebral Hemorrhage.
Optimized tPA: A non-neurotoxic fibrinolytic agent for the drainage of intracerebral hemorrhages.
Outcome and Symptomatic Bleeding Complications of Intravenous Thrombolysis Within 6 Hours in MRI-Selected Stroke Patients: Comparison of a German Multicenter Study With the Pooled Data of ATLANTIS, ECASS, and NINDS tPA Trials.
Outcomes of thrombolysis for acute ischemic stroke in octogenarians versus nonagenarians.
Partial Intra-Aortic Occlusion Improves Perfusion Deficits and Infarct Size Following Focal Cerebral Ischemia.
Perfusion Imaging in the 3-hour Time Window Predicts a tPA-associated Hemorrhage in Acute Ischemic Stroke.
Plasmin cleavage of the amyloid beta-protein: alteration of secondary structure and stimulation of tissue plasminogen activator activity.
Plasminogen activator inhibitor-1 induction after experimental intracerebral hemorrhage.
Pooled RCTs: In patients with acute ischemic stroke, alteplase increases intracerebral hemorrhage.
Predicting risk of symptomatic intracerebral hemorrhage and mortality after treatment with recombinant tissue-plasminogen activator using SEDAN score.
Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score.
Predictive value of coagulation factor XIII on bleeding risk in ischemic stroke patients treated with intravenous thrombolysis.
Predictors of Hemorrhage Volume after Intravenous Thrombolysis.
Predictors of In-Hospital Mortality and the Risk of Symptomatic Intracerebral Hemorrhage after Thrombolytic Therapy with Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke.
Predictors of Intracerebral Hemorrhage in Acute Stroke Patients Receiving Intravenous Recombinant Tissue Plasminogen Activator.
Pretissue Plasminogen Activator Blood Pressure Levels and Risk of Symptomatic Intracerebral Hemorrhage.
Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator.
Prior antiplatelet therapy and haematoma expansion after primary intracerebral haemorrhage: an individual patient-level analysis of CLEAR III, MISTIE III and VISTA-ICH.
Protective role of tuftsin fragment 1-3 in an animal model of intracerebral hemorrhage.
Prothymosin alpha and its mimetic hexapeptide improve delayed tPA-induced brain damage following cerebral ischemia.
Quantifying the Benefit of Prehospital Rapid Treatment in Acute Stroke: Benchmark for Future Innovative Clinical Trials.
Quantitatively monitoring acute ischemic stroke patients post recombinant tissue plasminogen activator treatment.
Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy.
Randomized comparison of intra-arterial and intravenous thrombolysis in a canine model of acute basilar artery thrombosis.
Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke).
Rate of Symptomatic Intracerebral Hemorrhage Related to Intravenous tPA Administered Over Telestroke Within 4.5-Hour Window.
Readministration of intravenous alteplase in acute ischemic stroke patients: case series and systematic review.
Recent Updates in Neurosurgical Interventions for Spontaneous Intracerebral Hemorrhage: Minimally Invasive Surgery to Improve Surgical Performance.
Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice.
Recombinant Tissue Plasminogen Activator Induces Neurological Side Effects Independent on Thrombolysis in Mechanical Animal Models of Focal Cerebral Infarction: A Systematic Review and Meta-Analysis.
Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat.
Reduction of intracerebral hemorrhage by rivaroxaban after tPA thrombolysis is associated with downregulation of PAR-1 and PAR-2.
Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats.
Relevance of focal cerebral ischemia models. Experience with fibrinolytic agents.
Remote cerebral hematomas in patients treated with intravenous rt-PA.
Remote or extraischemic intracerebral hemorrhage--an uncommon complication of stroke thrombolysis: results from the safe implementation of treatments in stroke-international stroke thrombolysis register.
Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: minocycline.
Response to letter regarding article, "defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the national institute of neurological disorders and stroke tissue-type plasminogen activator trials".
Retinoic acid ameliorates blood-brain barrier disruption following ischemic stroke in rats.
Retrosternal mass: An interesting allergic reaction to intravenous thrombolytic therapy for acute ischemic stroke.
Risk Factors for Early Intracerebral Hemorrhage after Intravenous Thrombolysis with Alteplase.
Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke.
Risk of intracerebral hemorrhage after thrombolysis in patients with asymptomatic hemorrhage on T2*.
Risk of Symptomatic Intracerebral Hemorrhage after Thrombolysis with rt-PA: The SEDAN Score.
Role of tissue-type plasminogen activator in ischemic stroke.
Routine medical management of acute myocardial infarction. Lessons from overviews of recent randomized controlled trials.
Ruptured arteriovenous malformation complicating thrombolytic therapy with tissue plasminogen activator.
Safety and Efficacy of Intravenous Low-Dose Alteplase in Relative Contraindication Patients with Acute Ischemic Stroke.
Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE-TPA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study.
Safety and efficacy of thrombolysis in telestroke: A systematic review and meta-analysis.
Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies.
Safety and feasibility of a lower dose intravenous TPA therapy for ischemic stroke beyond the first three hours.
Safety of Endovascular Intervention for Stroke on Therapeutic Anticoagulation: Multicenter Cohort Study and Meta-Analysis.
Safety Outcomes After Thrombolysis for Acute Ischemic Stroke in Patients With Recent Stroke.
Severe Cerebral Small Vessel Disease Burden Is Associated With Poor Outcomes After Endovascular Thrombectomy in Acute Ischemic Stroke With Large Vessel Occlusion.
Severe Renal Impairment Is Associated With Symptomatic Intracerebral Hemorrhage After Thrombolysis for Ischemic Stroke.
Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?
Statistical analysis plan for evaluating different intensities of blood pressure control in the ENhanced Control of Hypertension And Thrombolysis strokE stuDy.
Statistical analysis plan for evaluating low- vs. standard-dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED).
Stereotactic puncture and lysis of spontaneous intracerebral hemorrhage using recombinant tissue-plasminogen activator.
Sub-acute systemic erythropoietin administration reduces ischemic brain injury in an age-dependent manner.
Subdural Catheter Injection of Tissue Plasminogen Activator for Residual Hematoma Post Drainage of Acute-on-Chronic Subdural Hematoma: Novel Case Report of 2 Patients.
Subtherapeutic Warfarin Is Not Associated With Increased Hemorrhage Rates in Ischemic Strokes Treated With Tissue Plasminogen Activator.
Successful intravenous thrombolysis for acute ischemic stroke caused by aortic dissection with severe hypofibrinogenemia: a case report and literature review.
Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure.
Surgical Performance in Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation Phase III Clinical Trial.
Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke.
Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis: Predictive Factors and Validation of Prediction Models.
Symptomatic Intracerebral Hemorrhage Among Eligible Warfarin-Treated Patients Receiving Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke.
Symptomatic intracerebral hemorrhage and recanalization after IV rt-PA: a multicenter study.
Symptomatic intracerebral hemorrhage in acute ischemic stroke after thrombolysis with intravenous recombinant tissue plasminogen activator: a review of natural history and treatment.
Targeting neutrophil extracellular traps enhanced tPA fibrinolysis for experimental intracerebral hemorrhage.
Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat.
Tenecteplase versus alteplase in stroke thrombolysis: An individual patient data meta-analysis of randomized controlled trials.
The ASPECTS template is weighted in favor of the striatocapsular region.
The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis.
The Impact of Intracranial Carotid Artery Calcification on the Development of Thrombolysis-Induced Intracerebral Hemorrhage.
The Interventional Management of Stroke (IMS) II Study.
The iScore Predicts Efficacy and Risk of Bleeding in the National Institute of Neurological Disorders and Stroke Tissue Plasminogen Activator Stroke Trial.
The neurovascular unit and combination treatment strategies for stroke.
The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke.
The Relationship of the Type of Intracerebral Hemorrhage to Early Disease Evolution and Long-Term Prognosis After r-tPA Thrombolysis.
The role of endogenous versus exogenous tPA on edema formation in murine ICH.
The safety and efficacy of tPA intravenous thrombolysis for treating acute ischemic stroke patients with a history of cerebral hemorrhage.
The Safety and Feasibility of Image-Guided BrainPath-Mediated Transsulcul Hematoma Evacuation: A Multicenter Study.
The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
The use of abciximab in the treatment of acute cerebral thromboembolic events during neuroendovascular procedures.
Therapeutic Potential of Platelet Glycoprotein IIb/IIIa Receptor Antagonists in the Management of Ischemic Stroke.
Third Ventricle Obstruction by Thalamic Intracerebral Hemorrhage Predicts Poor Functional Outcome Among Patients Treated with Alteplase in the CLEAR III Trial.
Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire.
Thrombolysis for Evacuation of Intracerebral and Intraventricular Hemorrhage: A Guide to Surgical Protocols With Practical Lessons Learned From the MISTIE and CLEAR Trials.
Thrombolysis for stroke caused by infective endocarditis: an illustrative case and review of the literature.
Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke.
Thrombolysis in dementia patients with acute stroke: is it justified?
Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy.
Thrombolysis with reteplase, an unglycosylated plasminogen activator variant, in experimental embolic stroke.
Thrombolytic therapy for acute ischemic stroke.
Thrombolytic therapy in acute myocardial infarction.
Thrombolytic Therapy in Cocaine Users with Ischemic Stroke: A Review of Current Practice.
Thrombus localization with emergency cerebral CT.
Timing of symptomatic intracerebral hemorrhage after rt-PA treatment in ischemic stroke.
Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
Tissue Plasminogen Activator Induced Delayed Edema in Experimental Porcine Intracranial Hemorrhage: Reduction with Plasminogen Activator Inhibitor-1 Administration.
Tissue plasminogen activator mediated blood-brain barrier damage in transient focal cerebral ischemia in rats: relevance of interactions between thrombotic material and thrombolytic agent.
Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia.
Tissue Plasminogen Activator Promotes TXNIP-NLRP3 Inflammasome Activation after Hyperglycemic Stroke in Mice.
Tissue plasminogen activator promotes white matter integrity and functional recovery in a murine model of traumatic brain injury.
Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits.
Tissue-type plasminogen activator improves neurological functions in a rat model of thromboembolic stroke.
Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial.
Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial.
Translational Stroke Research Using a Rabbit Embolic Stroke Model: A Correlative Analysis Hypothesis for Novel Therapy Development.
Treatment of Intracerebral Hemorrhage with Tranexamic Acid After Thrombolysis with Tissue Plasminogen Activator.
Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Trimming the fat in acute ischemic stroke: an assessment of 24-h CT scans in tPA patients.
Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours.
Ultra-early clot aspiration after lysis with tissue plasminogen activator in a porcine model of intracerebral hemorrhage: edema reduction and blood-brain barrier protection.
Urgent carotid intervention is safe after thrombolysis for minor to moderate acute ischemic stroke.
Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset.
Urokinase vs Tissue-Type Plasminogen Activator for Thrombolytic Evacuation of Spontaneous Intracerebral Hemorrhage in Basal Ganglia.
Use and in-hospital outcomes of recombinant tissue plasminogen activator in pediatric arterial ischemic stroke patients.
Use of intralesional tPA in spontaneous intracerebral hemorrhage: retrospective analysis.
Use of intravenous recombinant tissue plasminogen activator in patients with borderline elevation of international normalized ratio.
Use of Noncontrast Computed Tomography and Computed Tomographic Perfusion in Predicting Intracerebral Hemorrhage After Intravenous Alteplase Therapy.
Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience.
When is thrombolysis justified in patients with acute ischemic stroke? A bioethical perspective.
Will symptomatic intracerebral hemorrhages decrease among eligible dabigatran-treated patients who receive intravenous tissue plasminogen activator for acute ischemic stroke?
YAMATO Study (Tissue-Type Plasminogen Activator and Edaravone Combination Therapy).
[Acute ischemic stroke. Diagnostic imaging and interventional options]
[Acute stroke therapy : Current developments.]
[ApoE genotype influences on efficacy and safety of thrombolytic treatment for ischemic stroke]
[Comparison of clinical efficacy of thrombolytic drugs in patients with acute myocardial infarction]
[Development of Biomembrane-mimetic Nanoparticles for the Treatment of Ischemic Stroke].
[Efficacy and safety comparison between pro-urokinase and reteplase in the treatment of patients with acute ST elevation myocardial infarction].
[Intracerebral hemorrhage caused by oral anticoagulant, oral antiplatelet and intravenous tissue plasminogen activator therapy]
[Local thrombolytic treatment of spontaneous intracerebral hemorrhage with plasminogen activator (rt-PA). Indications and limits]
[Lysophosphatidic Acid Receptor Signaling Underlying Chronic Pain and Neuroprotective Mechanisms through Prothymosin ?].
[Neurological complication due to the drug and the maneuver for the treatment and prevention of cerebrovascular diseases: iatrogenic neurology]
[Prothymosin?, as a neuroprotective DAMPs/Alarmins molecule].
[Retrospective analysis of 15 cases with severe pulmonary embolism]
[Role of endogenous tPA in stroke]
[Specific treatment of the acute cerebral infarct. Present and future]
[TCD monitoring during intravenous administration of recombinant tissue plasminogen activator]
[Thrombolysis by intravenous tissue plasminogen activator (t-PA)--current status and future direction]
[Thrombolysis in cerebral ischemia]
Cerebral Infarction
A case of acute cerebral infarction with a favorable prognosis after rt-PA administration by a general physician with telestroke support.
A case of cerebral infarction during a hemodialysis procedure successfully treated with recombinant tissue plasminogen activator.
A Rare Case of Symptomatic Carotid Stenosis Caused by Mechanical Stimulation by Thyroid Cartilage and Frequent Swimming.
A Smartphone Application as a Telemedicine Tool for Stroke Care Management.
A Spontaneous Cervical Epidural Hematoma Mimicking a Stroke: A Challenging Case.
A thromboembolic model for the efficacy and safety evaluation of combined mechanical and pharmacologic revascularization strategies.
Administration of recombinant tissue plasminogen activator to a case of cerebral infarction in the setting of painless aortic dissection.
An Observational Study Investigating the Need for Decompressive Hemicraniectomy after Thrombectomy in Acute Ischemic Stroke of the Middle Cerebral Artery Territory.
Analysis of plasma fibrinolysis in the patients with acute cerebral infarction.
Angiotensin-Converting Enzyme Gene Polymorphism and Plasminogen Activator Inhibitor 1 Levels in Subjects with Cerebral Infarction.
Aortic dissection diagnosed on stroke computed tomography protocol: a case report.
Aspirin ameliorates cerebral infarction through regulation of TLR4/NF??B?mediated endoplasmic reticulum stress in mouse model.
Assessing the Clinical Efficacy of Recombinant Tissue Plasminogen Activator on Acute Cerebral Infarction.
Association of survival and hyperthermia after rt-PA for ischemic stroke.
Body temperature and response to thrombolytic therapy in acute ischaemic stroke.
Catastrophic Secondary Infarctions with Onset Seizure Following Tissue Plasminogen Activator Therapy.
Challenges in the Anesthetic and Intensive Care Management of Acute Ischemic Stroke.
Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase.
Characteristics of blood tests in patients with acute cerebral infarction who developed symptomatic intracranial hemorrhage after intravenous administration of recombinant tissue plasminogen activator.
Clinical effect of mechanical fragmentation combined with recombinant tissue plasminogen activator artery thrombolysis on acute cerebral infarction.
Clinical observation of thrombolytic effect of alteplase combined with butylphthalide in patients with acute anterior circulation cerebral infarction.
Clinical Outcomes of Endovascular Thrombectomy in Tissue Plasminogen Activator versus Non-Tissue Plasminogen Activator Patients at Primary Stroke Care Centers.
Clinical Study of Intravenous, Low-Dose Recombinant Tissue Plasminogen Activator for Acute Cerebral Infarction: Comparison of Treatment within 3?Hours versus 3-4.5?Hours.
Coagulation and fibrinolytic activity in patients with acute cerebral infarction.
Comparative study of intravenous thrombolysis with rt-PA and urokinase for patients with acute cerebral infarction.
Comparative study on the efficacy and safety of alteplase and urokinase in the treatment of acute cerebral infarction.
Comparing outcome and recanalization results in patients with anterior circulation stroke following endovascular treatment with and without a treatment with rt-PA: A single-center study.
Critical Care Needs in Patients with Diffusion-Weighted Imaging Negative MRI after tPA--Does One Size Fit All?
Diabetes and previous stroke: hazards for intravenous thrombolysis?
Dramatic thrombolysis after rapid injection of tissue plasminogen activator: A case report.
Early fibrinogen degradation coagulopathy: a predictive factor of parenchymal hematomas in cerebral rt-PA thrombolysis.
Effect of a modern stroke unit combined with recombinant human tissue-type plasminogen activator intravenous thrombolysis on ischemic cerebral infarction and its influence on limb motor function and activity of daily living.
Effect of combination of a tissue-type plasminogen activator and an endothelin receptor antagonist, FR139317, in the rat cerebral infarction model.
Effect of intravenous thrombolysis with alteplase on clinical efficacy, inflammatory factors, and neurological function in patients with acute cerebral infarction.
Effect of isoflurane post-treatment on tPA-exaggerated brain injury in a rat ischemic stroke model.
Effect of the duration of middle cerebral artery occlusion on the risk of hemorrhagic transformation after tissue plasminogen activator injection in rats.
Effective and safe conditions of low-frequency transcranial ultrasonic thrombolysis for acute ischemic stroke: neurologic and histologic evaluation in a rat middle cerebral artery stroke model.
Effects of edaravone, the free radical scavenger, on outcomes in acute cerebral infarction patients treated with ultra-early thrombolysis of recombinant tissue plasminogen activator.
Effects of intravenous thrombolysis with alteplase combined with edaravone on cerebral hemodynamics and T lymphocyte level in patients with acute cerebral infarction.
Effects of thrombolysis within 6 hours on acute cerebral infarction in an improved rat embolic middle cerebral artery occlusion model for ischaemic stroke.
Efficacy and Safety Evaluation on Arterial Thrombolysis in Treating Acute Cerebral Infarction.
Efficacy of different doses of alteplase thrombolysis on acute ischemic stroke in patients.
Endovascular management for tandem occlusions of anterior cerebral circulation.
Endovascular Thrombectomy, Platelet Count, and Intracranial Hemorrhage.
Endovascular treatment in patients with acute ischemic stroke: Technical aspects and results.
Evaluation of efficacy and safety of Reteplase and Alteplase in the treatment of hyper-acute cerebral infarction.
Expression of neural plasticity related gene in the pontine tegmental area of rats with overactive bladder after cerebral infarction.
Fast multimode MRI based emergency assessment of hyperacute stroke thrombolysis.
Fatal ischaemic brain oedema after early thrombolysis with tissue plasminogen activator in acute stroke.
FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
Frequency of Blood-Brain Barrier Disruption Post-Endovascular Therapy and Multiple Thrombectomy Passes in Acute Ischemic Stroke Patients.
Fucoidan-functionalized polysaccharide submicroparticles loaded with alteplase for efficient targeted thrombolytic therapy.
Hemorrhagic complications of thrombolytic therapy in experimental stroke.
Hemorrhagic transformation following tissue plasminogen activator in experimental cerebral infarction.
High Prestroke Physical Activity Is Associated with Reduced Infarct Growth in Acute Ischemic Stroke Patients Treated with Intravenous tPA and Randomized to Remote Ischemic Perconditioning.
Identifying stroke therapeutics from preclinical models: A protocol for a novel application of network meta-analysis.
Immunohematologic characteristics of infection-associated cerebral infarction.
Impact of complete recanalization on clinical recovery in cardioembolic stroke patients with M2 occlusion.
Implementation of a telestroke system for general physicians without a nearby stroke center to shorten the time to intravenous thrombolysis for acute cerebral infarction.
Intraarterial reteplase and intravenous abciximab for treatment of acute ischemic stroke. A preliminary feasibility and safety study in a non-human primate model.
Intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator (rt-PA) therapy for acute cerebral infarction in a patient with ANCA-associated vasculitis.
Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial.
Intravenous Thrombolysis for Acute Ischemic Stroke Due to Cardiac Myxoma.
Intravenous thrombolysis in combination with mild hypothermia therapy in the treatment of acute cerebral infarction.
Inverse relationship of baseline body temperature and outcome between ischemic stroke patients treated and not treated with thrombolysis: the Bergen stroke study.
Ischemic cerebral infarction after rt-PA and heparin therapy for acute myocardial infarction. The TIMI-II pilot and randomized clinical trial combined experience.
Ischemic stroke, aortic dissection, and thrombolytic therapy--the importance of basic clinical skills.
Left M2 Occlusion With Thrombolysis in Cerebral Infarction (TICI) 2b Recanalization Using "Solumbra" Technique: Video Case.
Microcatheter contrast injections during intra-arterial thrombolysis may increase intracranial hemorrhage risk.
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset.
Neuroserpin extends the time window of tPA thrombolysis in a rat model of middle cerebral artery occlusion.
Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets.
Panax notoginsenoside Rb1 Restores the Neurotrophic Imbalance Following Photothrombotic Stroke in Rats.
Plasminogen activator and cerebral infarction.
Plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish children with cerebral infarct and effect on factor V 1691 A mutation.
Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome.
Potential for treatment with thrombolysis in an Irish stroke unit.
Prevalence of metabolic syndrome and serum marker levels in patients with four subtypes of cerebral infarction in Japan.
Prognostic Value of Diffusion-Weighted Imaging (DWI) Apparent Diffusion Coefficient (ADC) in Patients with Hyperacute Cerebral Infarction Receiving rt-PA Intravenous Thrombolytic Therapy.
Protective effects of non-anticoagulant activated protein C variant (D36A/L38D/A39V) in a murine model of ischaemic stroke.
Randomization of endovascular treatment with stent-retriever and/or thromboaspiration versus best medical therapy in acute ischemic stroke due to large vessel occlusion trial: Rationale and design.
Randomized comparison of intra-arterial and intravenous thrombolysis in a canine model of acute basilar artery thrombosis.
Recombinant Tissue Plasminogen Activator Induces Neurological Side Effects Independent on Thrombolysis in Mechanical Animal Models of Focal Cerebral Infarction: A Systematic Review and Meta-Analysis.
Rectus Sheath Hematoma Following Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Cerebral Infarction: A Case Report.
Relationship of Obesity to Recanalization After Hyperacute Recombinant Tissue-Plasminogen Activator Infusion Therapy in Patients With Middle Cerebral Artery Occlusion.
Renal Subcapsular Hematoma after Intravenous Thrombolysis in a Patient with Acute Cerebral Infarction.
Risk factors for hemorrhagic transformation following intravenous thrombolysis in acute cerebral infarction: a retrospective single center study.
Risk factors of diffuse alveolar hemorrhage after acute ischemic stroke treated with tissue-type plasminogen activator. The effectiveness of activated recombinant factor VII treatment.
Risk factors of hemorrhagic transformation after intravenous thrombolysis with rt-PA in acute cerebral infarction.
Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment.
Safety and outcomes of decompressive craniectomy after intravenous tissue plasminogen activator administration for malignant cerebral infarction.
Safety of Intravenous Thrombolysis within 4.5 h of Symptom Onset in Patients with Negative Post-Treatment Stroke Imaging for Cerebral Infarction.
Significance of clinical-diffusion mismatch in hyperacute cerebral infarction.
Significance of Magnetic Resonance Angiography-Diffusion Weighted Imaging Mismatch in Hyperacute Cerebral Infarction.
Simulation training for emergency teams to manage acute ischemic stroke by telemedicine.
Simultaneous administration of recombinant tissue plasminogen activator and edaravone in acute cerebral ischemic stroke patients.
Stanford type a aortic dissection with cerebral infarction: a rare case report.
Stroke.
Strong neuroprotection with a novel platinum nanoparticle against ischemic stroke- and tissue plasminogen activator-related brain damages in mice.
Study on the effect of urinary kallidinogenase after thrombolytic treatment for acute cerebral infarction.
Successful treatment of cerebral emboli with tissue plasminogen activator in a patient with takotsubo cardiomyopathy: A case report.
Tenecteplase in ischemic stroke offers improved recanalization: Analysis of 2 trials.
The application of fast multiparametric protocol MRI-based thrombolysis with rt-PA hyperacute cerebral infarction.
The ASPECTS template is weighted in favor of the striatocapsular region.
The investigational use of tPA for stroke.
The Kringle-2 domain of tissue plasminogen activator significantly reduces mortality and brain infarction in middle cerebral artery occlusion rats.
The rationale for new therapies in acute ischaemic stroke.
Therapeutic effect of recombinant tissue plasminogen activator on acute cerebral infarction at different times.
Therapeutic effects of alteplase intravenous thrombolysis on different types of acute cerebral infarction: a controlled randomized analysis.
Thrombolysis candidates for the treatment of stroke at an emergency department in Japan.
Thrombolysis Outcomes in Patients with Diabetes and Previous Stroke: A Meta-Analysis.
Tirofiban combined with rt-PA intraarterial thrombolysis improves the recanalization rate of acute middle cerebral artery occlusion in rabbits.
Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background.
Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice.
Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
Tissue plasminogen activator reduces brain injury in a rabbit model of thromboembolic stroke.
Tissue plasminogen activator; identifying major barriers related to intravenous injection in ischemic acute cerebral infraction.
Types of intraparenchymal hematoma as a predictor after revascularization in patients with anterior circulation acute ischemic stroke.
Vasospasm prevention with postoperative intrathecal thrombolytic therapy: a retrospective comparison of urokinase, tissue plasminogen activator, and cisternal drainage alone.
[A case of brain infarction and thoracic aortic dissection without chest nor back pain diagnosed by carotid duplex ultrasonography]
[A case of cerebral infarction treated with tissue-plasminogen activator exhibiting prolonged cerebral edema for more than 1 month].
[A novel photochemical model of the middle cerebral artery for thrombosis research and evaluation of anti-thrombotic agents]
[An analysis on the activity status of fibrinolytic system in Chinese patients with acute cerebral infarction]
[Antithrombotic therapy in cerebral infarction]
[Brain attack in Japan, now and future]
[Cerebral infarction and tPA venous injections]
[Changes of the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cerebral infarction induced by the venous occlusion]
[Clinical study on active factors of vascular endothelial cells in acute cerebral infarction patients and therapeutical effect of activating blood stasis]
[Delayed Diagnosis of Aortic Dissection Following Thrombolytic Therapy in a Patient with Acute Ischemic Stroke;Report of a Case].
[Diagnosis and treatment of cerebral infarction]
[Early detection of ischemic lesions in the super-acute phase of ischemic cerebrovascular diseases by imaging]
[Early intravenous thrombolysis with recombinant tissue plasminogen activator for acute cerebral infarction]
[Effect of intravenous thrombolysis with recombinant tissue type plasminogen activator (rt-PA) in different time windows on acute cerebral infarction patients with atrial fibrillation].
[Effect of recombinant microplasmin on acute cerebral infarction in rats]
[Efficacy of intravenous thrombolysis in acute ischemic stroke with hyperdense middle cerebral artery sign].
[Efficacy of tissue plasminogen activator in older patients]
[Exploration on parameters of TCM syndrome in acute cerebral infarction through investigating active factors of vascular endothelium cells]
[Feasibility of stroke thrombolysis at Pau Hospital, France]
[Fibrinolytic treatment with tissue plasminogen activator. Outcomes in clinical practice with a multidisciplinary model of intervention]
[Intracerebral and subarachnoid hemorrhages after administration of recombinant tissue plasminogen activator in a patient with acute ischemicstroke due to anterior cerebral artery dissection: a case report].
[Intravenous tissue-type plasminogen activator for the treatment of acute cerebral ischemia]
[Neurological complication due to the drug and the maneuver for the treatment and prevention of cerebrovascular diseases: iatrogenic neurology]
[Persistent changes in tissue-type plasminogen activator and plasminogen activator inhibitor fibrinolytic parameters in patients following juvenile ischemic cerebral infarct]
[Prevention of cerebral infarct caused by atherosclerosis]
[Recent advances in pathophysiology and treatment of acute ischemic stroke]
[Recombinant tissue plasminogen activator therapy for acute ischemic stroke in older patients].
[Role of endogenous tPA in stroke]
[Study of hemostatic molecular marker]
[Takotsubo Cardiomyopathy and Neurogenic Pulmonary Edema Following Fibrinolytic Therapy for Embolic Stroke:A Case Report].
[Technical standards for the interventional treatment of acute ischemic stroke].
[The treatment of acute cerebral infarction with urokinase and tissue plasminogen activator]
[Thrombolytic agents in cerebral infarctions]
[Thrombolytic recombinant tissue plasminogen activator (rt-PA) treatment in the acute ischemic stroke with limb arterial embolism; three case reports].
Cerebral Palsy
Genetic polymorphisms and spontaneous preterm birth.
Cerebral Small Vessel Diseases
The global burden of cerebral small vessel disease related to neurological deficit severity and clinical outcomes of acute ischemic stroke after IV rt-PA treatment.
Thrombolytic Therapy in Cocaine Users with Ischemic Stroke: A Review of Current Practice.
Tissue Plasminogen Activator and MRI Signs of Cerebral Small Vessel Disease.
Cerebrospinal Fluid Leak
Experimental study of intracisternal administration of tissue-type plasminogen activator followed by cerebrospinal fluid drainage in the ultra-early stage of subarachnoid haemorrhage.
Cerebrovascular Disorders
Blood coagulation studies in 45 patients with ischemic cerebrovascular disease and 44 patients with venous thromboembolic disease.
Controversies in cerebrovascular disease: High or low doses of recombinant tissue plasminogen activator to treat acute stroke? A literature review.
Corrigendum to "Comparative Analysis of Fibrinolytic Properties of Alteplase, Tenecteplase and Urokinase in an in Vitro Clot Model of Intracerebral Haemorrhage. [Journal of Stroke and Cerebrovascular Diseases, Vol. 29, No. 9 (September), 2020: 105073]".
Determinants of tPA antigen and associations with coronary artery disease and acute cerebrovascular disease.
Effect of dietary ? carotene on cerebral aneurysm and subarachnoid haemorrhage in the brain apo E(-/-) mice.
Equivocal roles of tissue-type plasminogen activator in stroke-induced injury.
Factor VIII related antigen, antithrombin III, spontaneous platelet aggregation and plasminogen activator in ischemic cerebrovascular disease: a study of stroke before 55.
Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: the NINDS Suburban Hospital Stroke Center experience.
Insulin resistance and elevated levels of tissue plasminogen activator in first-degree relatives of South Asian patients with ischemic cerebrovascular disease.
Intrathrombus administration of tissue plasminogen activator in acute cerebrovascular occlusion.
Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke.
Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease.
Plasminogen Activator Inhibitor-1 and Thrombotic Cerebrovascular Diseases.
Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries.
The yield of expanding the therapeutic time window for tPA.
Thrombolytic therapy of cerebral arterial occlusion with recombinant tissue plasminogen activator.
Ultrasound carotid plaque features, cardiovascular disease risk factors and events: The Multi-Ethnic Study of Atherosclerosis.
[Guidelines in diagnosis and therapy for acute-phase ischemic cerebrovascular disorders: Intravenous rt-PA therapy]
[The study of PAI-1 promotor region gene polymorphism in cerebrovascular disease]
Chagas Disease
Safety of IV thrombolysis in acute ischemic stroke related to Chagas disease.
Chancre
Analysis of Treponema pallidum strains from China using improved methods for whole-genome sequencing from primary syphilis chancres.
Chediak-Higashi Syndrome
The thiol proteinase inhibitors improve the abnormal rapid down-regulation of protein kinase C and the impaired natural killer cell activity in (Chediak-Higashi syndrome) beige mouse.
Cholangiocarcinoma
Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Cholangitis
Tissue plasminogen activator and plasminogen activator inhibitor-1 in human choledochal bile.
Choledocholithiasis
Tissue plasminogen activator and plasminogen activator inhibitor-1 in human choledochal bile.
Cholelithiasis
[Hemostatic indices of oncological patients with different forms of jaundice]
Cholera
2,3,7,8-Tetrachlorodibenzo-p-dioxin: examination of biochemical effects involved in the proliferation and differentiation of XB cells.
A cloned, immortal line of murine melanoblasts inducible to differentiate to melanocytes.
A novel mechanism of action of corticotropin releasing factor in rat Leydig cells.
Activation of protein kinase C sensitizes the cyclic AMP signalling system of T51B rat liver cells.
Activation of protein kinase-C stimulates human granulosa-luteal cell prostacyclin production.
Adenosine 3':5'-cyclic monophosphate induces regulated secretion of tissue-type plasminogen activator and von Willebrand factor from cultured human endothelial cells.
An inhibitory role for the protein kinase C pathway in ovarian steroidogenesis. Studies with cultured swine granulosa cells.
Augmentation of phorbol ester-induced T cell proliferation by agents which raise intracellular cyclic adenosine monophosphate.
Calcitonin stimulates plasminogen activator in porcine renal tubular cells: LLC-PK1.
Cholera toxin potentiates TPA-induced mitogenesis and c-fos expression in BALB/c-3T3-derived proadipocytes.
Contribution of known mitogenic signaling pathways to induction of DNA synthesis in quiescent Chinese hamster fibroblasts.
Cyclic nucleotides, possible intracellular mediators of macrophage activation and secretory processes.
Development of melanocyte progenitors in murine Steel mutant neural crest explants cultured with stem cell factor, endothelin-3, or TPA.
Differential effects of luteinizing hormone-releasing hormone on follicle-stimulating hormone-dependent responses in rat granulosa cells and Sertoli cells in vitro.
Effect of cell shape on proteinase secretion by epithelial cells.
Effect of dimethyl sulfoxide on human carcinoma cells, inhibition of plasminogen activator synthesis, change in cell morphology, and alteration of response to cholera toxin.
Effects of phorbol esters on normal and tumorous mouse mammary epithelial cells embedded in collagen gels.
Epidermal growth factor but not insulin-like growth factor-I potentiates adenosine 3',5'-monophosphate-mediated chorionic gonadotropin secretion by cultured human choriocarcinoma cells.
Establishment and characterization of a normal melanocyte cell line derived from pig skin.
Establishment of proliferative, pure cultures of pigmented chicken melanocytes from neural tubes.
Facilitative actions of the protein kinase-C effector system on hormonally stimulated adenosine 3',5'-monophosphate production by swine luteal cells.
Genetic evidence that a phorbol ester tumor promoter stimulates ornithine decarboxylase activity by a pathway that is independent of cyclic AMP-dependent protein kinases in CHO cells.
Growth and differentiation of normal human melanocytes in a TPA-free, cholera toxin-free, low-serum medium and influence of keratinocytes.
Human melanocytes cultured from nevi and melanomas.
Induction of meiotic maturation in Xenopus oocytes by 12-O-tetradecanoylphorbol 13-acetate.
Inhibition by phorbol esters and other tumor promoters of the response of the Sertoli cell to FSH: evidence for dual site of action.
Inhibition of plasminogen activator secretion by cyclic AMP in a macrophage-like cell line.
Inhibition of protein kinase C-dependent cellular proliferation by interaction of endogenous ganglioside GM1 with the B subunit of cholera toxin.
Inhibition of the proliferation of Nb2 cells by femtomolar concentrations of cholera toxin and partial reversal of the effect by 12-O-tetradecanoyl-phorbol-13-acetate.
Insulin-like growth factor-II in human fetal adrenals: regulation by ACTH, protein kinase C and growth factors.
Interaction of phorbol ester and adrenocorticotropin in the regulation of steroidogenic P450 genes in human fetal and adult adrenal cell cultures.
Isolation and culture of melanoma and naevus cells and cell lines.
Modulation of adenylate cyclase in human keratinocytes by protein kinase C.
Modulation of proteolytic activity during neuritogenesis in the PC12 nerve cell: differential control of plasminogen activator and plasminogen activator inhibitor activities by nerve growth factor and dibutyryl-cyclic AMP.
Multiple effects of phorbol ester on secretory activity in rabbit gastric glands and parietal cells.
Multiple effects of phorbol esters on hormone-sensitive adenylate cyclase activity in S49 lymphoma cells.
Phorbol ester inhibition of ovarian and testicular steroidogenesis in vitro.
Phorbol ester modulation of cyclic AMP accumulation in a primary culture of rat aortic smooth muscle cells.
Phorbol esters and thyroliberin have distinct actions regarding stimulation of prolactin secretion and activation of adenylate cyclase in rat pituitary tumour cells (GH4C1 cells).
Potentiation of prostaglandin E1-stimulated cAMP formation by 12-O-tetradecanoylphorbol-13-acetate in BALB/c mouse 3T3 cells.
Properties of protein kinase and adenylate cyclase-deficient variants of a macrophage-like cell line.
Protein kinase C activation mimics but does not mediate thyrotropin-induced desensitization of adenylyl cyclase in cultured dog thyroid cells.
Protein kinase C and Gi-protein mediated modulation of cAMP production in different stages of the rat seminiferous epithelium.
Protein kinase C inhibits cyclic adenosine monophosphate generation by histamine and truncated glucagon like peptide 1 in the human gastric cancer cell line HGT-1.
Regulation of insulin gene expression by dexamethasone, Ca2+ and a phorbol ester.
Regulation of insulin-like growth factor-binding protein-1 production in human granulosa-luteal cells.
Regulation of tissue-type plasminogen activator (tPA) and type-1 plasminogen activator inhibitor (PAI-1) gene expression in rat hepatocytes in primary culture.
Serum response element and flanking sequences mediate the synergistic transcriptional activation of c-fos by 12-O-tetradecanoylphorbol-13-acetate and cholera toxin in AKR-2B cells.
Signal transduction pathway in gastric mucous cells.
Similarities and differences in phorbol ester- and luteinizing-hormone-induced desensitization of rat tumour Leydig-cell adenylate cyclase.
Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vivo: evidence for a dynamic storage pool.
Teratocarcinoma differentiation: plasminogen activator activity associated with embryoid body formation.
The inhibitory GTP-binding protein (Gi) occurs in rat Leydig cells and is differentially modified by lutropin and 12-O-tetradecanoylphorbol 13-acetate.
The mechanisms by which phorbol ester inhibits LH stimulation of progesterone production in rat granulosa cells.
The phorbol ester TPA potentiates cholera toxin- and isoproterenol-stimulated cyclic AMP-synthesis in primary astrocyte cultures.
The phorbol ester TPA prevents the expression of both glucagon desensitisation and the glucagon-mediated block of insulin stimulation of the peripheral plasma membrane cyclic AMP phosphodiesterase in rat hepatocytes.
The phorbol ester, TPA inhibits glucagon-stimulated adenylate cyclase activity.
The stimulation of human synovial fibroblast plasminogen activator activity. Involvement of cyclic AMP and cyclooxygenase products.
Cholestasis
Extra-hepatic cholestasis determines a reversible increase of glycoproteic tumour markers in benign and malignant diseases.
PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA.
Tissue plasminogen activator and plasminogen activator inhibitor-1 in human choledochal bile.
Cholestasis, Intrahepatic
[Qualitative analysis of tissue plasminogen activator in plasma obtained from various liver diseases by gel filtration and affinity chromatography]
Cholesteatoma
Expression pattern of the plasminogen activator-plasmin system in human cholesteatoma.
[Thromboplastic activity and plasminogen activator activity in cholesteatoma and granulation tissue of the middle ear]
Cholesteatoma, Middle Ear
Plasminogen activators in tissue extract of aural cholesteatoma.
Chondrosarcoma
Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes.
Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
Chordoma
Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Tissue polypeptide antigen staining of the chordoma and notochordal remnants.
[Immunohistochemical studies of chordomas and choroid tumors]
Choriocarcinoma
12-O-tetradecanoyl phorbol-13-acetate potentiates adenosine 3',5'-monophosphate-mediated chorionic gonadotropin secretion by cultured human choriocarcinoma cells.
Angiotensin II augmented migration and invasion of choriocarcinoma cells involves PI3K activation through the AT1 receptor.
Inhibition of cytotrophoblastic (JEG-3) cell invasion by interleukin 12 involves an interferon gamma-mediated pathway.
Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells.
Protein C and its inhibitor in malignancy.
Restoration of TGF-beta regulation of plasminogen activator inhibitor-1 in Smad3-restituted human choriocarcinoma cells.
[Studies on marker substances in cell lines derived from various human gynecologic tumors (author's transl)]
Choroid Hemorrhage
Choroidal hemorrhage associated with systemic tissue plasminogen activator.
Postoperative choroidal hemorrhage shows elevated concentration of tissue plasminogen activator.
Choroidal Effusions
Choroidal hemorrhage associated with systemic tissue plasminogen activator.
Management of iatrogenic globe perforation during peribulbar anesthesia with submacular hemorrhage.
Recombinant tissue plasminogen activator in the treatment of suprachoroidal hemorrhage.
Choroidal Neovascularization
Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for subfoveal type 2 choroidal neovascularization.
Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials.
Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization.
Intravitreal Recombinant Tissue Plasminogen Activator and Sulphur Hexafluoride gas for Submacular Hemorrhage Displacement in Age-Related Macular Degeneration: Looking Behind the Blood.
INTRAVITREOUS INJECTION OF BEVACIZUMAB, TISSUE PLASMINOGEN ACTIVATOR, AND GAS IN THE TREATMENT OF SUBMACULAR HEMORRHAGE IN AGE-RELATED MACULAR DEGENERATION.
Mice without uPA, tPA, or plasminogen genes are resistant to experimental choroidal neovascularization.
Tissue Plasminogen Activator as an Antiangiogenic Agent in Experimental Laser-Induced Choroidal Neovascularization in Mice.
Tissue plasminogen activator-assisted surgical excision of subfoveal choroidal neovascularization in age-related macular degeneration: a randomized, double-masked trial.
Chronic Limb-Threatening Ischemia
Approach to Tibiopedal Retrograde Revascularization of Below-The-Knee Peripheral Arterial Diseases With or Without Transradial Guidance Peripheral Angiography.
Retention of endothelial progenitor cells in bone marrow in a murine model of endogenous tissue plasminogen activator (tPA) deficiency in response to critical limb ischemia.
Tissue plasminogen activator enhances mobilization of endothelial progenitor cells and angiogenesis in murine limb ischemia.
Chronic Periodontitis
Adjunctive low-dose doxycycline therapy effect on clinical parameters and gingival crevicular fluid tissue plasminogen activator levels in chronic periodontitis.
Evaluation of gingival crevicular fluid levels of tissue plasminogen activator, plasminogen activator inhibitor 2, matrix metalloproteinase-3 and interleukin 1-? in patients with different periodontal diseases.
Gingival crevicular fluid IL-6, tPA, PAI-2, albumin levels following initial periodontal treatment in chronic periodontitis patients with or without type 2 diabetes.
Plasminogen activator inhibitor-1 polymorphisms as a risk factor for chronic periodontitis in North Indian population.
Plasminogen activator system in smokers and non-smokers with and without periodontal disease.
Short term effects of non-surgical periodontal treatment on gingival crevicular fluid levels of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 2 (PAI-2) in patients with chronic and aggressive periodontitis.
The effect of low-level laser therapy as an adjunct to non-surgical periodontal treatment on gingival crevicular fluid levels of transforming growth factor-beta 1, tissue plasminogen activator and plasminogen activator inhibitor 1 in smoking and non-smoking chronic periodontitis patients: A split-mouth, randomized control study.
Tissue plasminogen activator and plasminogen activator inhibitor-1 gene polymorphisms in patients with chronic periodontitis.
Chronic Urticaria
Blood urokinase plasminogen activator system in chronic urticaria.
Chylothorax
Efficacy and safety of recombinant tissue plasminogen activator for venous thrombosis after paediatric heart surgery.
Use of recombinant tissue-plasminogen activator in a dog with chylothorax secondary to catheter-associated thrombosis of the cranial vena cava.
Ciliary Motility Disorders
Management of plastic bronchitis with nebulized tissue plasminogen activator: another brick in the wall.
Cleft Palate
Effects of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate on phenytoin-induced embryopathy in mice.
coagulation factor xiia deficiency
Acquired and congenital clotting syndromes.
Coinfection
bcl-2 expression in Spodoptera Frugiperda Sf-9 and Trichoplusia Ni BTI-Tn-5B1-4 insect cells: Effect on recombinant protein expression and cell viability.
Cavitary Pulmonary Infarction in a Case of Pulmonary Embolism After Successful Vascular Recanalization.
Isolation and analysis of a baculovirus vector that supports recombinant glycoprotein sialylation by SfSWT-1 cells cultured in serum-free medium.
Colic
Intraoperative catheter directed thrombolytic therapy for the treatment of superior mesenteric and portal Vein thrombosis.
Intravascular and peritoneal coagulation and fibrinolysis in horses with acute gastrointestinal tract diseases.
Menstruation distress is strongly associated with hormone-immune-metabolic biomarkers.
Colitis, Ulcerative
Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease.
Coagulation and fibrinolysis in inflammatory bowel disease and in giant cell arteritis.
Plasminogen activator inhibitor-1 is increased in colonic epithelial cells from patients with colitis-associated cancer.
Tissue-type plasminogen activator of colonic mucosa in ulcerative colitis. Evidence of endothelium-derived fibrinolytic activation.
Treatment of ulcerative colitis by the direct administration of an antifibrinolytic agent as an enema.
[Reduced plasminogen activator activity in patients with inactive ulcerative colitis]
[Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) in children with ulcerative colitis]
Colitis-Associated Neoplasms
Plasminogen activator inhibitor-1 is increased in colonic epithelial cells from patients with colitis-associated cancer.
Collagen Diseases
Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator.
t-PA, PAI, and protein C before and after vascular occlusion of the upper limb in patients with Raynaud's phenomenon.
Colonic Neoplasms
Antipeptide antibodies directed against the C-terminus of protein kinase C zeta (PKC zeta) react with a Ca(2+)- and TPA-sensitive PKC in HT-29 human intestinal epithelial cells.
Chemotherapy induced stroke mimic: 5-Fluorouracil encephalopathy fulfilling criteria for tissue plasminogen activator therapy.
Cytokines may influence tumor growth and spread. An in vitro study in two human cancer cell lines.
Decreased urokinase receptor expression by overexpression of the plasminogen activator in a colon cancer cell line.
Downregulation of a human colonic sialyltransferase by a secondary bile acid and a phorbol ester.
Effects of cotreatment of 12-O-tetradecanoylphorbol-13-acetate and H2O2 on apoptotic regulation via AMP-activated protein kinase-cyclooxygenase-2 signals.
Examination of the effects of epidermal growth factor on the production of urokinase and the expression of the plasminogen activator receptor in a human colon cancer cell line.
Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation.
Examination of urokinase protein/transcript levels and their relationship with laminin degradation in cultured colon carcinoma.
Expression of tissue-type plasminogen activator, plasminogen activator inhibitor and von Willebrand factor in the supernatant of endothelial cell cultures in response to the seeding of adenocarcinoma cell line HRT-18.
Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.
Inhibitory effect on the establishment of hepatic metastasis by transduction of the tissue plasminogen activator gene to murine colon cancer.
Insensitivity of laminin degradation directed by receptor bound urokinase to PAI-1 in cultured colon cancer.
Intraperitoneal infusion of recombinant plasminogen activator inhibitor type 2 induced apoptosis in implanted human colon cancer and inhibited its growth and liver metastasis.
Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1.
Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.
Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.
Low-dose tissue plasminogen activator in the treatment of a massive pulmonary thromboembolism in a colon cancer patient treated with bevacizumab: A case report.
p38? MAPK Mediates 17?-Estradiol Inhibition of MMP-2 and -9 Expression and Cell Migration in Human LoVo Colon Cancer Cells.
Phorbol esters activate proteoglycan metabolism in human colon cancer cells en route to terminal differentiation.
Phorbol myristate acetate selectively stimulates apical endocytosis via protein kinase C in polarized MDCK cells.
Preferential requirement for protein tyrosine phosphatase activity in the 12-O-tetradecanoylphorbol-13-acetate-induced differentiation of human colon cancer cells.
Proenzyme to urokinase-type plasminogen activator in human colon cancer: in vitro inhibition by monocyte minactivin after proteolytic activation.
Protein kinase C activation selectively increases mRNA levels for one of the regulatory subunits (RI alpha) of cAMP-dependent protein kinases in HT-29 cells.
Specificity of tumor markers (CEA, GICA, TPA, alpha-FP, FpA, gamma-GT) for the diagnosis of hepatic metastases from large bowel cancers.
The induction of senescence-like growth arrest by protein kinase C-activating diterpene esters in solid tumor cells.
The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma.
The plasminogen activator inhibitor system in colon cancer cell lines is influenced by the CO(2) pneumoperitoneum.
Tissue-type plasminogen activator-induced fibrinolysis is enhanced in patients with breast, lung, pancreas and colon cancer.
TPA induces transglutaminase C and inhibits cell growth in the colon carcinoma cell line SW620.
Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
[A study of ornithine decarboxylase activity in tumor tissue and rectal mucosa in patients with colorectal cancer or adenoma]
[Clinical evaluation of tissue polypeptide antigen in patients with esophageal, stomach and colon cancer]
[Clinical utility of tumor markers in gastric and colon cancer]
[Protease activities in gastric and colon cancer tissues]
Colorectal Neoplasms
Adipokines linking obesity with colorectal cancer risk in postmenopausal women.
Anti-cancer effect of Aquaporin 5 silencing in colorectal cancer cells in association with inhibition of Wnt/?-catenin pathway.
Association between Five Common Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms and Colorectal Cancer Susceptibility.
Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer.
Association between Plasma Levels of Plasminogen Activator Inhibitor-1 and Colorectal Neoplasms.
Association between plasma plasminogen activator inhibitor-1 and survival in colorectal cancer. Measuring C reactive protein concentrations may be more useful.
Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer.
Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma.
Caveolin-1 mediates the expression and localization of cathepsin B, pro-urokinase plasminogen activator and their cell-surface receptors in human colorectal carcinoma cells.
Chromosomal localization of the human urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 genes: implications in colorectal cancer.
Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer.
Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients.
Combination of tissue polypeptide antigen (TPA) and carcino embryonic antigen (CEA) in different types of cancer.
Comparative analysis of certain metals and tumor markers in bronchopulmonary cancer and colorectal cancers. Metals and tumor markers in the neoplastic process.
Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon.
Comparison of the tumor markers CEA, TPA, and CA 19-9 in colorectal carcinoma.
Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.
Correlation between metastatic potential and variants from colorectal tumor cell line HT-29.
D-dimer, plasminogen activator inhibitor-1, prothrombin fragments and protein C - role in prothrombotic state of colorectal cancer.
Follow-up of colorectal cancer resected for cure. An experience with CEA, TPA, Ca 19-9 analysis and second-look surgery.
Histopathological and prognostic evaluation of immunohistochemical findings in colorectal cancer.
Immunohistochemical analysis of plasminogen activator expression in human colorectal carcinomas: correlation with CEA distribution and tumor cell kinetics.
In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers.
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival.
Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers.
Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Limited clinical significance of the serum tumour marker Ca 72-4 in colorectal cancer.
Multivariate analysis of a tissue CEA, TPA, and CA 19.9 quantitative study in colorectal cancer patients. A preliminary finding.
Perioperative PAI-1 values in surgically treated colorectal carcinoma patients under low molecular weight heparin thromboprophylaxis.
Plasminogen activator inhibitor 1 (PAI-1) 1334G/A genetic polymorphism in colorectal cancer.
Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer.
Plasminogen activator inhibitor in stomach and colorectal carcinomas.
Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer.
Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis.
Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
Plasminogen activators and plasminogen activator inhibitor in malignant and non-malignant ascitic fluid.
Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumour cells.
Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.
Plasminogen activators in endoscopic biopsies as indicators of gastrointestinal cancer: comparison with resection specimens.
Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?
Plasminogen activators in human colorectal neoplasia.
Predictive performance of TPA testing for recurrent disease during follow-up after curative intent surgery for colorectal carcinoma.
Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group.
Prognostic role of tumor-associated proteases in colorectal cancer.
Protein-kinase-C iso-enzymes support DNA synthesis and cell survival in colorectal-tumor cells.
Role of urokinase in colorectal neoplasia.
Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas.
Silencing of plasminogen activator inhibitor-1 suppresses colorectal cancer progression and liver metastasis.
Specificity of tumor markers (CEA, GICA, TPA, alpha-FP, FpA, gamma-GT) for the diagnosis of hepatic metastases from large bowel cancers.
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.
The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology.
The prognostic and predictive significance of plasma type 1 plasminogen activator inhibitor and endoglin in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy.
The role of CEA, TPA and CA 19-9 in the early detection of recurrent colorectal cancer.
The role of cysteine and serine proteases in colorectal carcinoma.
Tissue-type plasminogen activator (tPA) content in colorectal cancer and in surrounding mucosa: relationship with clinicopathologic parameters and prognostic significance.
Tumor associated proteases -- prognostic markers of colorectal cancer.
Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.
Tumor markers carcinoembryonic antigen, tissue polypeptide antigen, and carbohydrate antigen 19/9 in liver diseases.
Tumor markers in staging and prognosis of colorectal carcinoma.
Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: the EPICOR study.
Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer.
Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse.
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.
[Advantages and limitations of combined assays of 4 serum markers in various types of malignant neoplasms]
[Clinical evaluation of a combination assay of CEA, CA-19-9 and TPA in patients with colorectal cancer]
[Clinical evaluation of four tumor markers (CEA, TPA, CA50 and CA72-4) in colorectal cancer]
[Clinical evaluation of tumor markers in patients with colorectal cancer]
[Clinical relevance of tumor markers]
[Comparative analysis of metastatic variants from the colorectal tumor cell line HT-29]
[Correlation of microangiographic findings of colorectal carcinoma with the level of various tumor markers in portal blood]
[Effect of jianpi-jiedu formula on tumor angiogenesis-relevant genes expression in colorectal cancer].
[Effectiveness of quarterly assessment of CEA, TPA and GICA serum levels in gastric and colorectal carcinomas: Prospective study of 174 patients undergoing radical surgery]
[Experience in the use of the tumor markers CEA, GICA and TPA in the postoperative monitoring of colorectal neoplasms]
[Follow-up of colorectal neoplasms: use of TPA]
[Measurement of serum tissue polypeptide antigen (TPA) in patients with malignant tumor using prolifigen TPA-M "Daiichi" kit]
[Measurement of serum tissue-polypeptide antigen (TPA) levels by EIA employing monoclonal antibody]
[New prognostic and predictive factors in advanced colorectal cancer]
[Preoperative determination of TPA in colorectal neoplasms. Evaluation of a group consisting of 75 patients]
[The optimal combination of serum tumor markers with bioinformatics in diagnosis of colorectal carcinoma.]
Coma
Bilateral internal carotid artery occlusions resulting in near total acute brain infraction.
Catastrophic Secondary Infarctions with Onset Seizure Following Tissue Plasminogen Activator Therapy.
Intraventricular hemorrhage after aneurysmal subarachnoid hemorrhage: pilot study of treatment with intraventricular tissue plasminogen activator.
Intraventricular thrombolysis with rt-PA in patients with intraventricular hemorrhage.
Safety and Efficacy of Transcatheter Administration of Tissue Plasminogen Activating Factor as Adjuvant Therapy for Intraventricular Hemorrhage.
Successful Endovascular Management of Massive Pansinus Thrombosis: Case Report and Review of Literature.
The Safety and Feasibility of Image-Guided BrainPath-Mediated Transsulcul Hematoma Evacuation: A Multicenter Study.
Common Cold
Plasminogen activator inhibitor-1 in sputum and nasal lavage fluids increases in asthmatic patients during common colds.
Common Variable Immunodeficiency
Failure of c-myc gene expression in B cells of some patients with common variable immunodeficiencies.
Communicable Diseases
Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states.
Fibrinolysis and coagulation in patients with infectious disease and sepsis.
Communication Disorders
Early dramatic recovery during intravenous tissue plasminogen activator infusion: clinical pattern and outcome in acute middle cerebral artery stroke.
Compartment Syndromes
Compartment syndrome following use of tissue plasminogen activator for frostbite in the setting of concomitant diaphyseal tibia fracture.
Forearm compartment syndrome following intravenous thrombolytic therapy for acute ischemic stroke.
Forearm compartment syndrome following thrombolytic therapy for acute myocardial infarction.
Hemorrhagic upper extremity complications from tissue plasminogen activator.
Reversal of acute ischemic stroke after THA using tissue plasminogen activator.
Thigh Compartment Syndrome After Thrombolytic Therapy of an Occluded Lower Extremity Bypass Graft.
Tissue Plasminogen Activator (t-PA) Induced Compartment Syndrome and Dopamine Infiltration Ñ Is There a Connection?
Upper extremity acute compartment syndrome during tissue plasminogen activator therapy for pulmonary embolism in a morbidly obese patient.
Confusion
Alteplase and Tenecteplase Confusion; Lack of E-Prescribing Interoperability Leads to Double Dosing; Accidental Overdoses Involving Fluorouracil Infusions.
Bed rest or mobilization after rt-PA? A case-crossover study of factors influencing clinical decision making in stroke services.
Chemotherapy induced stroke mimic: 5-Fluorouracil encephalopathy fulfilling criteria for tissue plasminogen activator therapy.
Perception and measurement of food texture: Solid foods.
Takayasu arteritis presenting as embolic stroke.
Vasospasm prevention with postoperative intrathecal thrombolytic therapy: a retrospective comparison of urokinase, tissue plasminogen activator, and cisternal drainage alone.
Congenital Abnormalities
12-O-Tetradecanoyl-phorbol-13-acetate (TPA) induced congenital kidney defects and embryomortality in the CD-1 mouse.
Cervical sagittal deformity develops after PJK in adult thoracolumbar deformity correction: radiographic analysis utilizing a novel global sagittal angular parameter, the CTPA.
Clinical disorders of fibrinolysis: a critical review.
Correction of Excessive Tibial Plateau Angle and Limb Shortening in a Juvenile Dog Using a Hinged Circular Fixator Construct and Distraction Osteogenesis.
Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients.
MRI findings of temporomandibular joints with disk perforation.
Sagittal Vertical Axias, Spinosacral Angle, Spinopelvic Angle, and T1 Pelvic Angle: Which Parameters May Effectively Predict the Quality of Life in Ankylosing Spondylitis Patients With Thoracolumbar Kyphosis?
Surgical treatment of a proximal diaphyseal tibial deformity associated with partial caudal and cranial cruciate ligament deficiency and patella baja.
T1 pelvic angle (TPA) effectively evaluates sagittal deformity and assesses radiographical surgical outcomes longitudinally.
T1 Pelvic Angle Is a Useful Parameter for Postoperative Evaluation in Adult Spinal Deformity Patients.
The aging spine: the effect of vertebral fragility fracture on sagittal alignment.
The Impact of Global Spinal Alignment on Standing Spinopelvic Alignment Change After Total Hip Arthroplasty.
Usefulness of cone beam computed tomography in temporomandibular joints with soft tissue pathology.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Clinical disorders of fibrinolysis: a critical review.
Venous thrombosis and procoagulant factors in high-risk neuroblastoma.
Conjunctival Diseases
Determination of plasminogen activator activities in normal and pathological human tears. The significance of tear plasminogen activators in the inflammatory and traumatic lesions of the cornea and the conjunctiva.
Plasminogen activator inhibitors in human tears.
Conjunctivitis
Use of mitomycin C and r-tPA for the management of conjunctival membrane and cataracts in a child with conjunctivitis lignosa.
Connective Tissue Diseases
Tissue plasminogen activator treatment of digital thrombosis in severe Raynaud's phenomenon--a case report.
Consciousness Disorders
Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy.
Contracture
Keloid scarring, but not Dupuytren's contracture, is associated with unexplained carotid atherosclerosis.
Corneal Dystrophies, Hereditary
Successful pediatric DMEK facilitated by intracameral tissue plasminogen activator to mitigate anterior chamber fibrin reaction.
Corneal Edema
Intracameral r-tPA for the management of severe fibrinous reactions in TASS after cataract surgery.
Treatment of total hyphema with relatively low-dose tissue plasminogen activator.
Corneal Injuries
Cytotoxicity of viscoelastics on cultured corneal epithelial cells measured by plasminogen activator release.
Corneal Neovascularization
A Novel Peptide Derived from Tissue-Type Plasminogen Activator Potently Inhibits Angiogenesis and Corneal Neovascularization.
The role of the fibrinolytic system in corneal angiogenesis.
Tissue Plasminogen Activator as an Antiangiogenic Agent in Experimental Corneal Neovascularization in Rabbits.
Corneal Opacity
[Band-like keratopathy after treatment of postoperative fibrin reaction with tissue plasminogen activator]
Coronary Aneurysm
Combination thrombolytic and anti-platelet therapies in an infant with incomplete kawasaki disease and coronary aneurysms.
Decreased plasminogen activator inhibitor-1 levels in coronary artery aneurysmatic patients.
Successful thrombolytic therapy using tissue-type plasminogen activator in Kawasaki disease.
Tissue plasminogen activator in pediatric myocardial infarction.
Coronary Artery Disease
Adipokines, linking adipocytes and vascular function in hemodialyzed patients, may also be possibly related to CD146, a novel adhesion molecule.
Adiponectin is inversely related to plasminogen activator inhibitor type 1 in patients with stable exertional angina.
Age-Biomarkers-Clinical Risk Factors for Prediction of Cardiovascular Events in Patients With Coronary Artery Disease.
Altered Daytime Fluctuation Pattern of Plasminogen Activator Inhibitor 1 in Type 2 Diabetes Patients with Coronary Artery Disease: A Strong Association with Persistently Elevated Plasma Insulin, Increased Insulin Resistance, and Abdominal Obesity.
Association of Plasminogen Activator Inhibitor 1 (SERPINE1) Polymorphisms and Aneurysmal Subarachnoid Hemorrhage.
Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain.
Atherosclerosis, cigarette smoking, and endogenous fibrinolysis: is there a direct link?
Brain Natriuretic Peptide Is a Powerful Predictor of Outcome in Stroke Patients with Atrial Fibrillation?.
Changes in plasminogen activator inhibitor 1 and tissue-type plasminogen activator during exercise in patients with coronary artery disease.
Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction.
Circulating acute phase proteins in relation to extent and composition of coronary atherosclerosis and cardiovascular outcome: results from the ATHEROREMO-IVUS study.
Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patients with stable and unstable angina.
Clinical and biochemical factors associated with prognosis after myocardial infarction at a young age.
Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial).
Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease.
Coronary artery disease in cardiac allografts: association with depleted arteriolar tissue plasminogen activator.
D-dimer increase after percutaneous transluminal angioplasty and clinical recurrence after primary revascularization in acute myocardial infarction? A pilot study.
Decreased plasminogen activator inhibitor-1 activity in newly diagnosed type 2 diabetic patients following dietary modification.
Detection of impaired fibrinolytic activity in coronary artery disease--electrophoretic and immuno-blotting analysis of tissue plasminogen activator.
Determinants of tPA antigen and associations with coronary artery disease and acute cerebrovascular disease.
Effect of niceritrol on fibrinolysis and lipoprotein (a) levels in patients with coronary artery disease.
Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT Study)--a rebuttal.
Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
Effects of metabolic risk factors on production of plasminogen activator inhibitor-1 and adiponectin by adipocytes.
Effects of nicorandil on endogenous fibrinolytic capacity in patients with coronary artery disease.
Effects of simvastatin or hormone replacement therapy, or both, on fibrinogen, factor VII, and plasminogen activator inhibitor levels in postmenopausal women with proven coronary artery disease.
Effects of vitamin D analogs on the expression of plasminogen activator inhibitor-1 in human vascular cells.
Efficacy and safety of intracoronary prourokinase during percutaneous coronary intervention in treating ST-segment elevation myocardial infarction patients: a randomized, controlled study.
Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators.
Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis.
Ethanol downregulates transcription of the PAI-1 gene in cultured human endothelial cells.
Evaluation of fibronectin, vitronectin, and leptin levels in coronary artery disease: impacts on thrombosis and thrombolysis.
Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease.
Fibrinolysis and atherogenesis in the JCR:LA-cp rat in relation to insulin and triglyceride concentrations in blood.
Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy.
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Fibrinolytic variables in postmenopausal women with unstable coronary artery disease.
Gene Polymorphisms for PAI-1 Are Associated with the Angiographic Extent of Coronary Artery Disease.
Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease.
Genetic contribution to circulating levels of hemostatic factors in healthy families with effects of known genetic polymorphisms on heritability.
Genetic variations of Renin-angiontensin and Fibrinolytic systems and susceptibility to coronary artery disease: a population genetics perspective.
Genotype-specific transcriptional regulation of PAI-1 gene by insulin, hypertriglyceridemic VLDL, and Lp(a) in transfected, cultured human endothelial cells.
Hemostatic risk factors of coronary artery disease in the Chinese.
Heparin induced increase of t-PA antigen plasma levels in patients with unstable angina: no evidence for clinical benefit of heparinization during the initial phase of treatment.
How cost-effective are new preventive strategies for cardiovascular disease?
Human epicardial adipokine messenger RNAs: comparisons of their expression in substernal, subcutaneous, and omental fat.
Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis.
Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina.
Increased plasminogen activator inhibitor-1 and apolipoprotein (a) in coronary atherectomy specimens in acute coronary syndromes.
Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.
Interaction among 5,10 methylenetetrahydrofolate reductase, plasminogen activator inhibitor and endothelial nitric oxide synthase gene polymorphisms predicts the severity of coronary artery disease in Turkish patients.
Interrelation between angiographic severity of coronary artery disease and plasma levels of insulin, C-peptide and plasminogen activator inhibitor-1.
Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis.
Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction.
Low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty.
Low-density lipoproteins induce the polar secretion of PAI-1 by endothelial cells in culture.
Mechanisms Linking Nonalcoholic Fatty Liver Disease with Coronary Artery Disease.
Modulators of induction of plasminogen activator inhibitor type-1 in HepG2 cells by transforming growth factor-?.
No association of the plasminogen activator inhibitor-1 promoter 4G/5G polymorphism with inhibitor level during basal transcription in vitro.
PAI-1 4G/5G polymorphism and coronary artery disease risk: a meta-analysis.
PAI-I 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease.
Patient preferences for thrombolytic therapy in acute myocardial infarction.
Plasma Adiponectin, T94G Gene Polymorphism and PAI-1 in Patients with and without Hypertension.
Plasma and platelet plasminogen activator inhibitor-1 in patients with acute myocardial infarction.
Plasma concentrations of fibrinolytic factors in the subacute phase of myocardial infarction predict recurrent myocardial infarction or sudden cardiac death.
Plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 are correlated with the presence of transplant coronary artery disease in cardiac transplant recipients.
Plasma protein C inhibitor is elevated in survivors of myocardial infarction.
Plasma t-PA/PAI-1 complex and blood coagulability in patients with coronary artery disease.
Plasma tissue factor pathway inhibitor levels in angiographically defined coronary artery disease among saudis.
Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations.
Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease.
Plasminogen activator inhibitor (PAI-1) and non-insulin-dependent diabetes in Pima Indians, south Asians and Europeans. Populations at varying risk of NIDDM and coronary artery disease.
Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.
Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.
Plasminogen activator inhibitor in the blood of patients with coronary artery disease.
Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease.
Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes.
Plasminogen activator inhibitor-1 4G/5G gene polymorphism and coronary artery disease in the Chinese Han population: a meta-analysis.
Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with coronary artery disease risk: a meta-analysis.
Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and coagulation factor VII Arg353-->Gln polymorphism in Korean patients with coronary artery disease.
Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease.
Plasminogen activator inhibitor-1 is associated with coronary artery calcium in Type 1 diabetes.
Plasminogen activator inhibitor-1 levels in patients with chronic angina pectoris with or without angiographic evidence of coronary sclerosis.
Plasminogen activator system in human coronary atherosclerosis.
Platelet function and fibrinolytic agents: two sides of a coin?
Polymorphism and synergism of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) genes in coronary artery disease.
Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up.
Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function.
Randomized, double-blind, placebo-controlled trial of tissue plasminogen activator in unstable angina.
Reduction in plasminogen activator inhibitor-1 (PAI-1) with omega-3 polyunsaturated fatty acid (PUFA) intake.
Relationship of tissue plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen with coronary artery disease in South Indian male subjects.
Role of Genetic Polymorphism of Angiotensin-Converting Enzyme, Plasminogen Activator Inhibitor-1 and Endothelial Nitric Oxide Synthase in the Prognosis of Coronary Artery Disease.
Role of IgG-seropositivity to Chlamydia pneumoniae in early thrombotic events after coronary stent placement.
Role of plasminogen activator inhibitor type 1 in the pathogenesis of coronary artery diseases.
Serum level of plasminogen activator inhibitor type-1 in addicted patients with coronary artery disease.
Single effects of apolipoprotein B, (a), and E polymorphisms and interaction between plasminogen activator inhibitor-1 and apolipoprotein(a) genotypes and the risk of coronary artery disease in Czech male caucasians.
Stroke severity and outcomes for octogenarians receiving statins.
TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
Testosterone and atherosclerosis.
The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease.
The influence of metabolic syndrome components on plasma PAI-1 concentrations is modified by the PAI-1 4G/5G genotype and ethnicity.
The molecular markers of hemostatic activation on coronary artery disease.
The plasminogen activator inhibitor 1 4G/5G polymorphism is not associated with longevity: a study in octogenarians.
The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study.
The Synergistic Effect of Plasminogen Activator Inhibitor-1 (PAI-1) Polymorphisms and Metabolic Syndrome on Coronary Artery Disease in the Korean Population.
The use of tissue-type plasminogen activator for acute myocardial infarction in the elderly: results from thrombolysis in myocardial infarction Phase I, open label studies and the Thrombolysis in Myocardial Infarction Phase II pilot study. The TIMI Investigators.
Thrombolysis with recombinant human tissue-type plasminogen activator during instability in coronary artery disease: effect on myocardial ischemia and need for coronary revascularization. TRIC Study Group.
Thrombotic/Thrombolytic Balance as a Cardiac Treatment Determinant in Patients With Diabetes Mellitus and Coronary Artery Disease.
Timing of Symptomatic Infarct Swelling Following Intravenous Thrombolysis in Acute Middle Cerebral Artery Infarction: A Case-Control Study.
Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries.
Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris.
Tissue plasminogen activator release and plasminogen activator inhibitor levels in coronary artery disease.
Tissue plasminogen activator, fibrin D-dimer, and insulin resistance in the relatives of patients with premature coronary artery disease.
Variant of PAI-2 gene is associated with coronary artery disease and recurrent coronary event risk in Chinese Han population.
Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplant recipients.
[Association of PAI-1 gene polymorphism with prognosis of coronary artery disease]
[Effects of exercise on markers of hemostatic activation in young survivors of myocardial infarction]
[Plasminogen activator inhibitor and protein C: their relation to plasma lipids and lipo- and apoproteins in ischemic heart disease of different duration]
[Role of the hemostatic system in pathogenesis of atherosclerosis as the main etiology of coronary ischemia] [corrected]
[Tissue plasminogen activator, its inhibitor and other factors of the blood fibrinolytic system in stable coronary heart disease]
Coronary Disease
A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency.
A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome.
Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study.
Angiotensin-converting enzyme inhibition attenuates hypofibrinolysis and reduces cardiac perivascular fibrosis in genetically obese diabetic mice.
Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease.
Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women.
Associations of von Willebrand factor, fibrin D-dimer and tissue plasminogen activator with incident coronary heart disease: British Women's Heart and Health cohort study.
Basal plasma concentration of tissue plasminogen activator (t-PA) and the adaption to strenuous exercise in familial hypercholesterolaemia (FH).
Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease.
Circulating miR-30c as a predictive biomarker of type 2 diabetes mellitus with coronary heart disease by regulating PAI-1/VN interactions.
Comparative analysis of plasminogen activator inhibitor-1 expression in different types of atherosclerotic lesions in coronary arteries from human heart explants.
Comparison of Cardiovascular Risk Factors for Coronary Heart Disease and Stroke Type in Women.
Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population.
Dual-reporter high-throughput screen for small-molecule in vivo inhibitors of plasminogen activator inhibitor type-1 yields a clinical lead candidate.
Dynamic variability of hemostatic and fibrinolytic factors in young women.
Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
Elevation of plasma fibrinogen in silent myocardial ischaemia.
Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction.
Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men.
Endogenous tissue-type plasminogen activator and risk of myocardial infarction.
Endothelial fibrinolytic capacity predicts future adverse cardiovascular events in patients with coronary heart disease.
Endothelial release of tissue-type plasminogen activator and ischemia-induced vasodilatation are linked in patients with coronary heart disease.
Endothelial tissue-type plasminogen activator release in coronary heart disease: Transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction.
Fibrinogen and plasminogen activator inhibitor-1 levels in hypertension and coronary heart disease. Potential effects of beta-blockade.
Fibrinolytic activity in coronary heart disease.
Genotype combinations of plasminogen activator inhibitor-1 and angiotensin-converting enzyme genes and risk for early onset of coronary heart disease.
Hematological risk factors for coronary heart disease.
Hemostatic and rheological variables and risk of cardiovascular disease.
Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses.
Hemostatic variables in Japanese and Caucasian men. Tissue plasminogen activator, antithrombin III, and protein C and their relations to coronary risk factors.
High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.
Histone deacetylase inhibition enhances tissue plasminogen activator release capacity in atherosclerotic man.
Impact and mechanism for oxidized and glycated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells.
Impact of biomarkers for endothelial dysfunction and procoagulant state on 10-year cardiovascular risk in Type?2 diabetes(1).
Impaired fibrinolysis in hypertension and obesity due to high plasminogen activator inhibitor-1 level in plasma.
Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis.
Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity.
Interaction of physical activity and diet: implications for haemostatic factors.
Lack of evidence for secretion of plasminogen activator inhibitor-1 by human subcutaneous adipose tissue in vivo.
Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort.
Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.
Monounsaturated fatty acid-enriched diet decreases plasma plasminogen activator inhibitor type 1.
Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
Plasma tissue plasminogen activator levels in patients with coronary heart disease.
Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease.
Plasminogen activator inhibitor 1 activity and other coronary risk factors.
Plasminogen activator inhibitor type 1 (PAI-1) and platelet glycoprotein IIIa (PGIIIa) polymorphisms in young Asian Indians with acute myocardial infarction.
Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy.
Plasminogen activator inhibitor-1 gene: selection of tagging single nucleotide polymorphisms and association with coronary heart disease.
Plasminogen activator inhibitor-1, free fatty acids, and insulin resistance in patients with myocardial infarction.
Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy1.
Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction.
Reduced fibrinolytic activity in coronary heart disease in basal conditions and after exercise.
Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
Relation of hemostatic risk factors to other risk factors for coronary heart disease and to sex hormones in men.
Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men.
Segregation analysis of plasminogen activator inhibitor-1 and fibrinogen levels in the NHLBI family heart study.
Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls.
Sex differences in the relationship between inflammatory and hemostatic biomarkers and metabolic syndrome: British 1958 Birth Cohort.
Specific elevation in plasma tissue plasminogen activator antigen concentrations in South Asians relative to Europeans.
Stimulated release of endothelin-converting enzyme is simultaneous with tissue-type plasminogen activator and decrease in coronary heart disease.
Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells.
Tea drinking and haemostasis: a randomized, placebo-controlled, crossover study in free-living subjects.
The Deidesheimer meeting: significance of classical and new risk factors in non-insulin-dependent diabetes mellitus.
The effect of supplementation with omega-3 fatty acids on soluble markers of endothelial function in patients with coronary heart disease.
The platelet-related effects of tenecteplase versus alteplase versus reteplase.
The relationships between insulin and plasminogen activator inhibitor 1 levels: assessment in groups of subjects with dyslipidaemia and hypertension.
The role of tissue plasminogen activator on the progression of the coronary disease.
Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis.
Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women.
Tissue plasminogen activator genetic polymorphisms do not influence tissue plasminogen activator release in patients with coronary heart disease.
Tissue plasminogen activator on admission is an important predictor of 30-day mortality in patients with acute myocardial infarction undergoing primary angioplasty.
Tissue-type plasminogen activator and C-reactive protein in acute coronary heart disease. A nested case-control study.
Ultrasound carotid plaque features, cardiovascular disease risk factors and events: The Multi-Ethnic Study of Atherosclerosis.
[A study on the circadian variation of tissue-type plasminogen activator and its rapid inhibitor in patients with coronary heart disease]
[Association of plasminogen activator inhibitor-1 gene 4G/5G polymorphism and coronary heart disease in Chinese patients]
[Blood coagulation and fibrinolysis in arteriosclerosis]
[Changes in plasma tissue-type plasminogen activator and its inhibitor in coronary heart disease and diabetic patients and their clinical significance]
[Clinical and experimental study on codonopsis pilosula oral liquor in treating coronary heart disease with blood stasis]
[Clinical significance of fibrinolytic system defectiveness in exercise induced myocardial ischemia and its mechanism]
[Coronary risk factors in chronic hemodialysis patients]
[Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations.]
[Does extracorporeal circulation during coronary artery bypass grafting damage vascular endothelium?]
[Effect of puerarin on fibrinolytic activity and lipid peroxide in patients with coronary heart disease]
[Effects of guan-mai-shu on tissue-type plasminogen activator and plasminogen activator inhibitor in the plasma of patients with coronary heart disease]
[New cardiovascular drugs: expanded therapeutic possibilities in coronary heart disease and in heart failure]
[Plasminogen activator inhibitor and protein C: their relation to plasma lipids and lipo- and apoproteins in ischemic heart disease of different duration]
[Plasminogen activator inhibitor-1 (PAI-1) - pathogenetic role in coronary disease.]
[Tissue plasminogen activator, its inhibitor and other factors of the blood fibrinolytic system in stable coronary heart disease]
[Urokinase-type plasminogen activator and its inhibitor type 1 in the diagnosis of evolving complications in coronary heart disease]
Coronary Occlusion
Activation of the complement system by recombinant tissue plasminogen activator.
Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion.
Cocaine-associated myocardial infarction. A word of caution about thrombolytic therapy.
Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.
Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model.
Determinants of recurrent ischaemia and revascularisation procedures after thrombolysis with recombinant tissue plasminogen activator in primary coronary occlusion.
ECG evidence of limited myocardial infarction following coronary occlusion treated by early intravenous rt-PA infusion.
Endogenous tissue plasminogen activator and platelet reactivity as risk factors for reocclusion after recanalization of chronic total coronary occlusions.
Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial.
Late (one month) reversible ischaemia after primary coronary occlusion treated with recombinant tissue plasminogen activator (rTPA).
Recombinant tissue-type plasminogen activator ameliorates ischemic derangements induced by thrombotic occlusion in closed chest anesthetized dogs.
Reteplase in the treatment of peripheral arterial and venous occlusions: a pilot study.
Reteplase infusion in the treatment of acute lower extremity occlusions.
Retrograde coronary venous administration of recombinant tissue-type plasminogen activator: a unique and effective approach to coronary artery thrombolysis.
Temporal expression of extracellular matrix metalloproteinases and tissue plasminogen activator in the development of collateral vessels in the canine model of coronary occlusion.
Thrombin generation in myocardial infarction and hypercholesterolemia: effects of aspirin.
[Intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction]
[Platelet activation in the early phases of acute myocardial infarction]
Coronary Restenosis
A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis.
Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis.
Plasminogen activator inhibitor-1 plasma levels and coronary restenosis.
Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: dependence on stent implantation and antithrombotic medication.
Coronary Stenosis
Angiographic assessment of the infarct-related residual coronary stenosis after spontaneous or therapeutic thrombolysis.
Characteristics of vasospastic angina with exercised-induced ischemia--analysis of parameters of hemostasis and fibrinolysis.
Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis.
Clinical and biochemical factors associated with prognosis after myocardial infarction at a young age.
Correlation between coronary morphology and molecular markers of fibrinolysis in unstable angina pectoris.
Effects of thrombolytic therapy in unstable angina: clinical and angiographic results.
Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease.
Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled, randomized trial.
Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
Plasminogen activator inhibitor activity as a possible indicator of disease activity in rest angina with angiographically insignificant coronary artery stenosis.
Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
Progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function.
Residual coronary stenoses and calculated transstenotic gradients after intravenous streptokinase versus tissue plasminogen activator.
Residual coronary stenosis after thrombolysis with rt-PA or streptokinase: acute results and 3 weeks follow-up.
The relationship between hemostatic tests and cardiovascular risk factors in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities (ECAT) Angina Pectoris Group.
[Prediction of coronary artery stenosis by measurement of total plaque area and thickness versus intima media thickness of the carotid artery].
Coronary Thrombosis
A novel modified tissue-type plasminogen activator (t-PA), E6010, gradually increases coronary blood flow after thrombolysis compared with native t-PA, urokinase and balloon catheter occlusion-reperfusion.
Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis.
Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model.
Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men.
Angiographic demonstration of coronary dethrombosis with eptifibatide.
Antiplatelet effects of urokinase and their clinical implications.
Association between the ACE genotype and coronary artery disease. Insights from studies on restenosis, vasomotion and thrombosis.
Attenuation of the synthesis of plasminogen activator inhibitor type 1 by niacin. A potential link between lipid lowering and fibrinolysis.
Captopril reduced plasminogen activator inhibitor activity in patients with acute myocardial infarction.
Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
Comparative effects of anti-platelet agents as adjuncts to tissue plasminogen activator in a dog model of occlusive coronary thrombosis.
Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates.
Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration.
Coronary thrombolysis with recombinant human tissue-type plasminogen activator.
Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.
Coronary thrombolysis with recombinant tissue plasminogen activator. Intracoronary vs intravenous administration.
Coronary thrombolysis with recombinant tissue-type plasminogen activator. A hematologic and pharmacologic study.
Coronary thrombolysis. Comparative effects of intracoronary administration of recombinant tissue plasminogen activator and urokinase.
Dietary fish oil accelerates the response to coronary thrombolysis with tissue-type plasminogen activator. Evidence for a modest platelet inhibitory effect in vivo.
Differential effect of recombinant tissue plasminogen activator-induced thrombolysis in the central nervous system and systemic arteries.
Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis.
Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis.
Effect of rate of administration of recombinant tissue plasminogen activator on efficacy of coronary thrombolysis.
Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, in a rhesus monkey model of coronary thrombosis.
Fish oils in cardiovascular disease.
Improved coronary thrombolysis by tissue-type plasminogen activator in the presence of BAY U 3405.
Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo.
Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator.
Intracoronary recombinant tissue plasminogen activator in an infant with hypoplastic left heart syndrome and complete left main coronary artery thrombosis.
Laboratory monitoring of hemostasis during thrombolytic therapy with recombinant human tissue-type plasminogen activator.
Leukotriene-receptor antagonist FPL-55712 and t-PA-induced thrombolysis in canine coronary thrombosis.
Locoregional fibrinolysis using tissue plasminogen activator in 2 cases of acute thrombosis of the renal artery.
Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets.
Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
Myocardial release of endothelin (ET) and enhanced ET(A) receptor-mediated coronary vasoconstriction after coronary thrombosis and thrombolysis in pigs.
Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly.
Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography.
Plasminogen activator inhibitor-1, which is released from blood product transfusions, might be associated with (sub)acute thrombosis after coronary dilatation and stenting: a case report.
Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator.
Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis.
Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
Role of heparin in coronary thrombolysis.
Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.
Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model.
Short-term intravenous eptifibatide infusion combined with reduced dose recombinant tissue plasminogen activator inhibits platelet recruitment at sites of coronary artery injury.
Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
Successful Treatment of Myocardial Infarction in an Infant With Kawasaki Disease.
Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs.
Superoxide dismutase decreases reperfusion arrhythmias and preserves myocardial function during thrombolysis with tissue plasminogen activator.
Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator.
Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.
The thrombolytic effects of native tissue-type plasminogen activator (AK-124) on experimental canine coronary thrombosis.
Thrombolytic effects of a novel modified tissue plasminogen activator, E6010, on coronary thrombosis in the pig.
Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries.
Tissue plasminogen activator for coronary thrombosis.
Tissue plasminogen activator for neonatal coronary thrombosis presenting with mitral valve regurgitation and impaired ventricular function.
Tissue-type plasminogen activator for acute coronary thrombosis.
Tissue-type plasminogen activator for acute coronary thrombosis. The Medical Letter.
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site.
Coronary Vasospasm
The dynamic changes of plasma tissue-type plasminogen activator level and the activity of its inhibitor during coronary vasospasm.
COVID-19
Abdominal pain in a patient with COVID-19 infection: A case of multiple thromboemboli.
Acute Ischemic Stroke and COVID-19: Experience From a Comprehensive Stroke Center in Midwest US.
An aberrant STAT pathway is central to COVID-19.
Biomarkers of endothelial dysfunction and outcomes in coronavirus disease 2019 (COVID-19) patients: A systematic review and meta-analysis.
Circulating Levels of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Are Independent Predictors of Coronavirus Disease 2019 Severity: A Prospective, Observational Study.
Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York.
Coagulation disorders and thromboembolic disease in COVID-19: review of current evidence in search of a better approach.
Combination of thrombolytic and immunosuppressive therapy for coronavirus disease 2019: A case report.
Comparison of the coagulopathies associated with COVID-19 and sepsis.
Consideration Needed for early Anticoagulation Following Intravenous tPA in Patients with COVID-19.
COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis.
COVID-19 Critical Illness Pathophysiology Driven by Diffuse Pulmonary Thrombi and Pulmonary Endothelial Dysfunction Responsive to Thrombolysis.
Covid-19-Associated Coagulopathy: Biomarkers of Thrombin Generation and Fibrinolysis Leading the Outcome.
Current Perspectives of Anticoagulation in Patients With COVID-19.
Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19.
Dysregulation of Pulmonary Responses in Severe COVID-19.
Emergent Carotid Artery Stenting Following Intravenous Alteplase Infusion After Rapid Negative Diagnosis for COVID-19 by Loop-Mediated Isothermal Amplification Assay.
Extracorporeal Membrane Oxygenation Induces Early Alterations in Coagulation and Fibrinolysis Profiles in COVID-19 Patients with Acute Respiratory Distress Syndrome.
Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID-19.
Hematological Phenotype of COVID-19-Induced Coagulopathy: Far from Typical Sepsis-Induced Coagulopathy.
Impact of a Stay-at-Home Order on Stroke Admission, Subtype, and Metrics during the COVID-19 Pandemic.
Impaired fibrinolysis in critically ill COVID-19 patients.
Implementing the SNIS recommendations for neurointerventional emergent care in the setting of COVID-19: impact on stroke metrics and patient outcomes.
In-Hospital Delays for Acute Stroke Treatment Delivery During the COVID-19 Pandemic.
Intravenous tPA for Acute Ischemic Stroke in Patients with COVID-19.
Is there a role for tissue plasminogen activator as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome?
Mechanisms of immunothrombosis in COVID-19.
Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space.
Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients.
Platelet Reactivity and Coagulation Markers in Patients with COVID-19.
Pulmonary Embolism in COVID-19 Treated with VA-ECLS and Catheter tPA.
Recombinant tissue plasminogen activator treatment for COVID-19 associated ARDS and acute cor pulmonale.
Response to the Letter to the Editor: Consideration Needed for Early Anticoagulation Following Intravenous tPA in Patients with COVID-19.
Role of Tissue Plasminogen Activator for Diffuse Pulmonary Microemboli in Coronavirus Disease 2019 Patient.
Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis.
Severe Epistaxis after Tissue Plasminogen Activator administration for Acute Ischemic Stroke in SARS-COV-2 Infection.
Severe SARS-CoV-2 infection inhibits fibrinolysis leading to changes in viscoelastic properties of blood clot: A descriptive study of fibrinolysis.
Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers.
Stroke Systems of Care During the COVID-19 Epidemic in Kobe City.
Stroke Thrombolysis With Tenecteplase to Reduce Emergency Department Spread of Coronavirus Disease 2019 and Shortages of Alteplase.
Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitations.
Successful use of tPA for thrombolysis in COVID related ARDS: a case series.
The characteristics and outcomes of critically Ill patients with COVID-19 who received systemic thrombolysis for presumed pulmonary embolism: an observational study.
The multifaceted role of plasminogen in inflammation.
The Pandemic's impacts on patients without Covid-19 on multidisciplinary aspects in emergency medicine care.
Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19.
Thrombolysis and use of argatroban for the treatment of massive pulmonary embolism following anticoagulation failure in a patient with COVID-19.
Thrombosis and Haemostasis challenges in COVID-19 - Therapeutic perspectives of heparin and tissue-type plasminogen activator and potential toxicological reactions-a mini review.
Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad.
Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series.
Tissue Plasminogen Activator in Critically Ill Adults with COVID-19.
Treatment and Outcomes of Patients With Ischemic Stroke During COVID-19: An Analysis From Get With The Guidelines-Stroke.
Cowpox
Identification of proteins cleaved downstream of caspase activation in monocytes undergoing macrophage differentiation.
Craniocerebral Trauma
Posttrauma coagulation and fibrinolysis.
Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial).
[The role of tissue plasminogen activator in chronic subdural hematomas]
[Tissue plasminogen activator (T-PA) and tissue plasminogen activator inhibitor (PAI-1) in patients after head injury]
Crohn Disease
Abnormalities of the urokinase system in colonic crypt cells from patients with ulcerative colitis.
Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease.
Coagulation and fibrinolysis in inflammatory bowel disease and in giant cell arteritis.
Combined type-1 plasminogen activator inhibitor and NOD2/CARD15 genotyping predicts complicated Crohn's disease behaviour.
The 4G/4G genotype of the 4G/5G polymorphism of the type-1 plasminogen activator inhibitor (PAI-1) gene is a determinant of penetrating behaviour in patients with Crohn's disease.
[Biological manifestations of a prethrombotic state in developmental Crohn's disease]
Cryptorchidism
Plasminogen activator in cultured cells of human undescended testis.
Cushing Syndrome
Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma.
Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers.
Cystadenocarcinoma
Expression of urokinase-type plasminogen-activator (upa) and its receptor (upar) in human ovarian-cancer cells and in-vitro invasion capacity.
Cystadenocarcinoma, Mucinous
Characterization of matrix-degrading proteinases and their inhibitors secreted by human gynecological carcinoma cells.
Proliferation tissue polypeptide antigen distinguishes malignant mucinous cystadenocarcinomas from benign cystic tumors and pseudocysts.
Relation between serum levels of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125) and their immunohistochemical identification in benign and malignant gynecological disease.
Serum levels of six tumor markers in patients with benign and malignant gynecological disease.
Cystadenocarcinoma, Serous
Relation between serum levels of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125) and their immunohistochemical identification in benign and malignant gynecological disease.
Serum levels of six tumor markers in patients with benign and malignant gynecological disease.
Cystadenoma
A plasminogen activator from benign ovarian cystadenoma: partial purification and characterization.
Cystadenoma, Mucinous
Proliferation tissue polypeptide antigen distinguishes malignant mucinous cystadenocarcinomas from benign cystic tumors and pseudocysts.
Cystadenoma, Serous
A plasminogen activator from benign ovarian cystadenoma: partial purification and characterization.
Proliferation tissue polypeptide antigen distinguishes malignant mucinous cystadenocarcinomas from benign cystic tumors and pseudocysts.
Cystic Fibrosis
Enzymes approved for human therapy: indications, mechanisms and adverse effects.
Plasminogen activator inhibitor type 1 gene is located at region q21.3-q22 of chromosome 7 and genetically linked with cystic fibrosis.
Role of pirfenidone in TGF-? pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective.
Cystitis
A case of veno-occlusive disease complicated by severe hemorrhagic cystitis successfully treated with recombinant plasminogen activator.
Cysts
Cause of hematic cysts of the orbit: increased fibrinolysis and immunohistologic expression of tissue plasminogen activator.
Concentrations of tissue-type plasminogen activator and relaxin in normal and induced-cystic follicles of gilts.
Diaphragmatic cyst with elevated level of serum tissue polypeptide antigen.
Fibrinolytic activity in aneurysmal bone cysts.
Herpes encephalitis : a stroke mimicker.
Intracystic evaluation of tumor markers in benign and malignant ovarian pathology.
Perturbations in the fibrinolytic pathway abolish cyst formation but not capillary-like organization of cultured murine endothelial cells.
Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids.
Proliferation tissue polypeptide antigen distinguishes malignant mucinous cystadenocarcinomas from benign cystic tumors and pseudocysts.
Role of tissue-plasminogen activator (t-PA) in a mouse model of neonatal white matter lesions: interaction with plasmin inhibitors and anti-inflammatory drugs.
Death, Sudden, Cardiac
[Effects of thrombolytic therapy in patients with cardiac arrest from suspected pulmonary thromboembolism].
Decompression Sickness
DNA A-tract bending in three dimensions: solving the dA4T4 vs. dT4A4 conundrum.
Optimization of unilateral molar rotation correction by a trans-palatal bar: a three-dimensional analysis using the finite element method.
Deglutition Disorders
Benchmarks and determinants of adherence to stroke performance measures.
Clinical Characteristics, Management, and In-Hospital Outcomes in Patients With Stroke or Transient Ischemic Attack in China.
Closing gaps between evidence-based stroke care guidelines and practices with a collaborative quality improvement project.
Dysphagia as a predictor of outcome and transition to palliative care among middle cerebral artery ischemic stroke patients.
Dysphagia in the setting of left ventricular assist device hemolysis.
Network Mapping of Time to Antithrombotic Therapy Among Patients With Ischemic Stroke and Transient Ischemic Attack (TIA).
Opalski Syndrome Treated with Intravenous Recombinant Tissue Type Plasminogen Activator-Case Report and Review of Literature.
Patient-Level and Hospital-Level Determinants of the Quality of Acute Stroke Care. A Multilevel Modeling Approach.
Paul Coverdell National Acute Stroke Registry Surveillance - four states, 2005-2007.
Small Rural Hospitals Have a Harder Time Achieving Success in Continuous Quality Improvement: An Example From a Stroke Care Network.
The Stroke Practice Improvement Network: a quasiexperimental trial of a multifaceted intervention to improve quality.
Dehydration
Effects of phorbol ester and teleocidin on Ca2+-induced fusion of liposomes.
Synthesis and verification of biobased terephthalic Acid from furfural.
The influence of dehydration on the prognosis of acute ischemic stroke for patients treated with tissue plasminogen activator.
Delirium
Associations of markers of inflammation and coagulation with delirium during critical illness.
Endothelial Activation and Blood-Brain Barrier Injury as Risk Factors for Delirium in Critically Ill Patients.
Dementia
Coagulation and fibrinolysis markers and risk of dementia. The Dutch Vascular Factors in Dementia Study.
Factors that influence clinicians' decisions to offer intravenous alteplase in acute ischemic stroke patients with uncertain treatment indication: Results of a discrete choice experiment.
Hot topics in risk management in neurologic practice.
Prestroke Dementia is Associated with Poor Outcomes after Reperfusion Therapy among Elderly Stroke Patients.
Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial).
Thrombolysis in dementia patients with acute stroke: is it justified?
Thrombolysis safety and effectiveness in acute ischemic stroke patients with pre-morbid disability.
Dementia, Vascular
Association between circulating hemostatic measures and dementia or cognitive impairment: systematic review and meta-analyzes.
Hemostasis abnormalities in patients with vascular dementia and Alzheimer's disease.
Is sticky blood bad for the brain?: Hemostatic and inflammatory systems and dementia in the Caerphilly Prospective Study.
Sequence variants of ACE, AGT, AT1R, and PAI-1 as genetic risk factors for vascular dementia.
tPA in the central nervous system: relations between tPA and cell surface LRPs.
Demyelinating Diseases
A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis.
Basic FGF and FGF receptor 1 are expressed in microglia during experimental autoimmune encephalomyelitis: temporally distinct expression of midkine and pleiotrophin.
Complement potentiates the degradation of myelin proteins by plasmin: implications for a mechanism of inflammatory demyelination.
Decreased neural damage after spinal cord injury in tPA-deficient mice.
Degradation of the P0, P1, and Pr proteins in peripheral nervous system myelin by plasmin: implications regarding the role of macrophages in demyelinating diseases.
Plasminogen activator activity and plasmin inhibition in nerves.
Plasminogen Activator Inhibitor-1 Antagonist TM5484 Attenuates Demyelination and Axonal Degeneration in a Mice Model of Multiple Sclerosis.
The modification of experimental allergic encephalomyelitis with epsilon aminocaproic acid.
Tissue plasminogen activator as a key effector in neurobiology and neuropathology.
Tissue plasminogen activator gene expression in multiple sclerosis brain tissue.
Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury.
Dengue
Cooperation between CD4+ T Cells and Humoral Immunity Is Critical for Protection against Dengue Using a DNA Vaccine Based on the NS1 Antigen.
Dengue virus regulates the expression of hemostasis-related molecules in human vein endothelial cells.
Impaired fibrinolysis in the pathogenesis of dengue hemorrhagic fever.
Increase of Plasminogen Activator Inhibitor-1 and Decrease of Transforming Growth Factor-B1 in Children with Dengue Haemorrhagic Fever in Indonesia.
Increased PAI-1 plasma levels and risk of death from dengue: no association with the 4G/5G promoter polymorphism.
Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence.
Stimulation of plasminogen activator inhibitor activity in human monocytes infected with dengue virus.
Tissue plasminogen activator induced by dengue virus infection of human endothelial cells.
Dermatitis
Enhancing effect of ultraviolet A on ornithine decarboxylase induction and dermatitis evoked by 12-o-tetradecanoylphorbol-13-acetate and its inhibition by curcumin in mouse skin.
Involvement of tumor necrosis factor (TNF)-alpha in phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin edema in mice.
Oleanonic acid, a 3-oxotriterpene from Pistacia, inhibits leukotriene synthesis and has anti-inflammatory activity.
Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity.
Topical anti-inflammatory potential of Physalin E from Physalis angulata on experimental dermatitis in mice.
Dermatitis, Contact
Epidermal protein kinase C-beta 2 is highly sensitive to downregulation and is exclusively expressed in Langerhans cells: downregulation is associated with attenuated contact hypersensitivity.
Eugenol as a Promising Molecule for the Treatment of Dermatitis: Antioxidant and Anti-inflammatory Activities and Its Nanoformulation.
Langerhans cell migration patterns from sheep skin following topical application of carcinogens.
Retinoic acid protects Langerhans' cells from the effects of the tumour promotor 12-O-tetradecanoylphorbol 13-acetate.
Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model.
Dermatitis, Irritant
Cumulative irritant dermatitis and abnormal epidermal plasminogen activator activity: what connection?
Diabetes Complications
A significant relationship between plasminogen activator inhibitor type-1 and lipoprotein(a) in non-insulin-dependent diabetes mellitus without complications.
Do plasminogen activator inhibitor (PAI-1) or tissue plasminogen activator PAI-1 complexes predict complications in Type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study.
Normalisation of tissue factor pathway inhibitor activity after glycaemic control optimisation in type 1 diabetic patients.
Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
Diabetes Insipidus, Nephrogenic
A variant of nephrogenic diabetes insipidus: V2 receptor abnormality restricted to the kidney.
Normal homeostasis of fibrinolysis in nephrogenic diabetes insipidus in spite of defective V2- receptor-mediated responses of tissue plasminogen activator release.
Diabetes Mellitus
A significant relationship between plasminogen activator inhibitor type-1 and lipoprotein(a) in non-insulin-dependent diabetes mellitus without complications.
A strong inverse relationship between PAI-1 and Lp(a) in hypertensive Type 2 diabetic patients.
Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1.
Alu DNA Polymorphism of Human Tissue Plasminogen Activator (tPA) Gene in Diabetic Jordanian Patients
Analysis of the correlation between plasma coagulation factor VII, PAI-1, and uric acid with insulin resistance and macrovascular complications in elderly patients with type 2 diabetes.
Antiplatelet aggregation and endothelial protection of I4, a new synthetic anti-diabetes sulfonylurea compound.
Association between Plasma Levels of PAI-1, tPA/PAI-1 Molar Ratio, and Mild Cognitive Impairment in Chinese Patients with Type 2 Diabetes Mellitus.
Association of PAI-1 4G/5G Polymorphism with Ischemic Stroke in Chinese Patients with Type 2 Diabetes Mellitus.
Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D.E.S.I.R. prospective cohort.
Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states.
Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis.
Brain Natriuretic Peptide Is a Powerful Predictor of Outcome in Stroke Patients with Atrial Fibrillation?.
Circulating miR-30c as a predictive biomarker of type 2 diabetes mellitus with coronary heart disease by regulating PAI-1/VN interactions.
Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator.
Comparative effects of low-dose versus standard-dose alteplase in ischemic patients with prior stroke and/or diabetes mellitus: The ENCHANTED trial.
Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial).
Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus.
Desmopressin stimulates parallel norepinephrine and tissue plasminogen activator release in normal subjects and patients with diabetes mellitus.
Development of a plasminogen activator inhibitor (PAI-1) assay and comparison of plasma PAI-1 activity in hyperlipidemic/dyslipidemic dogs with either hyperadrenocorticism or diabetes mellitus, and healthy dogs.
Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells.
Does chronic smoking influence fibrinolytic potential in type 1 diabetes mellitus?
Early changes of serum N-acetyl-beta-glucosaminidase, tissue plasminogen activator and erythrocyte superoxide dismutase in relation to retinopathy in type 1 diabetes mellitus.
Effect of 4G/5G PAI-1 polymorphism on the response of PAI-1 activity to vitamin E supplementation in Type 2 diabetic patients.
Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus.
Effect of dipeptidyl peptidase-4 inhibitor, vildagliptin on plasminogen activator inhibitor-1 in patients with diabetes mellitus.
Effect of plasminogen activator inhibitor-1 and tissue plasminogen activator polymorphisms on susceptibility to type 2 diabetes in Malaysian subjects.
Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease.
Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome.
Efficacy of a pedometer-based physical activity program on parameters of diabetes control in type 2 diabetes mellitus.
Endothelial haemostatic factors may be associated with mortality in patients on long-term anticoagulant treatment.
Fibrinolytic activity, autonomic neuropathy, and circulation in diabetes mellitus.
Fibronectin and lipoprotein(a) are inversely related to plasminogen activator inhibitor type-1 levels in Type 2 diabetic patients without complications.
Gingival crevicular fluid PGE2, IL-1beta, t-PA, PAI-2 levels in type 2 diabetes and relationship with periodontal disease.
Hyperbaric Oxygen Reduces Infarction Volume and Hemorrhagic Transformation Through ATP/NAD(+)/Sirt1 Pathway in Hyperglycemic Middle Cerebral Artery Occlusion Rats.
Identification and modulation of a caveolae-dependent signal pathway that regulates plasminogen activator inhibitor-1 in insulin-resistant adipocytes.
Immunolocalization of tissue plasminogen activator in the diabetic and nondiabetic retina and choroid.
Impact and mechanism for oxidized and glycated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells.
Impaired endogenous fibrinolysis in diabetes mellitus: mechanisms and therapeutic approaches.
Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina.
Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.
Induction of plasminogen activator inhibitor I by the PPARalpha ligand, Wy-14,643, is dependent on ERK1/2 signaling pathway.
Inflammation, insulin resistance, and atherosclerosis.
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Intraocular bacterial contamination during cataract surgery in dogs.
Intravenous thrombolysis in Chinese patients with mild acute ischemic stroke.
Intravenous Tissue Plasminogen Activator Thrombolysis in Patients With Diabetes Mellitus and Previous Stroke.
Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus.
Low Carotid Artery Wall Shear Stress is Associated with Significant Coronary Artery Disease in Patients with Chest Pain.
Morphological Carotid Plaque Area Is Associated With Glomerular Filtration Rate: A Study of South Asian Indian Patients With Diabetes and Chronic Kidney Disease.
Multiple roles of tissue plasminogen activator in schizophrenia pathophysiology.
Normal tissue plasminogen activator and plasminogen activator inhibitor activity in plasma from patients with type 1 diabetes mellitus.
Not only the Sugar, Early infarct sign, hyperDense middle cerebral artery, Age, Neurologic deficit score but also atrial fibrillation is predictive for symptomatic intracranial hemorrhage after intravenous recombinant tissue plasminogen activator.
Physical inactivity is correlated with levels of quantitative C-reactive protein in serum, independent of obesity: results of the national surveillance of risk factors of non-communicable diseases in Iran.
Physical training decreases plasma thrombomodulin in type I and type II diabetic patients.
Pioglitazone suppresses advanced glycation end product-induced expression of plasminogen activator inhibitor-1 in vascular smooth muscle cells.
Plasminogen activation in diabetes mellitus. Kinetics of plasmin formation with tissue plasminogen activator and plasminogen from individual diabetic donors and with in vitro glucosylated plasminogen.
Plasminogen activation in diabetes mellitus: kinetics of plasmin formation with plasminogen and tissue plasminogen activator from diabetic donors.
Plasminogen Activator Inhibitor -1 (PAI-1) Predicts Negative Alterations in Whole Body Insulin Sensitivity in Chronic HIV Infection.
Plasminogen activator inhibitor is elevated in plasma and diminished in platelets in patients with diabetes mellitus.
Plasminogen Activator Inhibitor Type-1 Tag Single-Nucleotide Polymorphisms in Patients with Diabetes Mellitus Type 2 and Diabetic Retinopathy.
Plasminogen activator inhibitor-1 (PAI-1) in children and adolescents With Type 1 Diabetes Mellitus: relation to diabetic micro-vascular complications and carotid intima media thickness.
Plasminogen activator inhibitor-1 5G/5G genotype is a protecting factor preventing posttransplant diabetes mellitus.
Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus.
Plasminogen activator inhibitor-1 and the risk of Type 2 diabetes mellitus in American Indians: the Strong Heart Study.
Plasminogen activator inhibitor-1 concentrations and bone mineral density in postmenopausal women with type 2 diabetes mellitus.
Plasminogen Activator Inhibitor-1 in poorly controlled vs well controlled Type-2 Diabetes Mellitus patients: A case-control study in a district hospital in Ghana.
Predictors of functional outcome in patients with stroke thrombolysis in a tertiary hospital in Malaysia.
Predictors of good outcome after intravenous tPA for acute ischemic stroke.
Predisposing factors to post-operative adhesion development.
Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome.
Regulation of PAI-1 gene expression during adipogenesis.
Relationship of oxidative stress and fibrinolysis in diabetes mellitus.
Risk factors for intracranial hemorrhage after mechanical thrombectomy: a systematic review and meta-analysis.
Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. The Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators.
Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.
Short- and long-term treatments with iloprost in diabetic patients with peripheral vascular disease: effects on the cardiovascular risk factor plasminogen activator inhibitor type-1.
Short-term effects of air temperature on blood markers of coagulation and inflammation in potentially susceptible individuals.
Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a population-based study.
Specific inhibition of plasminogen activator inhibitor 1 reduces blood glucose level by lowering TNF-a.
Stimulation in vivo of expression of intra-abdominal adipose tissue plasminogen activator inhibitor Type I by proinsulin.
Suboptimal glycaemic control enhances the risk of impaired prothrombotic state in youths with type 1 diabetes mellitus.
The association between PAI-1 -675 4G/5G polymorphism and type 2 diabetes mellitus.
The association of fibrinolysis and hyperlipidaemia with quantitative sensory tests in an epidemiological study of Swedish type 1 diabetic patients.
The Burden of Diabetes and the Chance of a Previous Stroke: Thrombolysis for Recurrent Stroke in Diabetics.
The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy.
The pattern and risk factors associated with adverse drug reactions induced by Reteplase in patients with acute ST-elevation myocardial infarction: The first report from Iranian population.
The plasminogen activator activity of arteries and veins in diabetes mellitus.
The potential influence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes.
The Prognostic Value of Homocysteine in Acute Ischemic Stroke Patients: A Systematic Review and Meta-Analysis.
The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus.
The use of tissue-type plasminogen activator for acute myocardial infarction in the elderly: results from thrombolysis in myocardial infarction Phase I, open label studies and the Thrombolysis in Myocardial Infarction Phase II pilot study. The TIMI Investigators.
Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus.
Thrombolysis Outcomes in Patients with Diabetes and Previous Stroke: A Meta-Analysis.
Thrombotic/Thrombolytic Balance as a Cardiac Treatment Determinant in Patients With Diabetes Mellitus and Coronary Artery Disease.
Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in diabetic foot syndrome.
Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
Tissue plasminogen activator inhibition in diabetes mellitus.
Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus.
Vitamin E intake reduces plasminogen activator inhibitor type 1 in T2DM patients.
Who will benefit more from low-dose alteplase in acute ischemic stroke?
[Biochemical characteristics associated with diabetes mellitus one year after myocardial infarction].
[Clinical characteristics and management of patients with ST segment elevation myocardial infarction in China: survey of 7510 cases]
[Development and optimization of the methods for determining activity of plasminogen activator inhibitor-1 in plasma].
[Effects of Danshen injection on the reserve of tissue plasminogen activator and nitric oxide in endothelium and vasodilatation in diabetic patients]
[Effects of zhenqing recipe and earthworm on the expressions of transforming growth factor-beta1 and plasminogen activator inhibitor 1 in renal tissues of type 2 diabetic rats].
[Levels of tissue-type plasminogen activator (T-PA), its inhibitor (PAI-1) and fibrinogen in the blood of patients with type 1 and 2 diabetes mellitus]
[Monoclonal antibody therapy for disorders of hemostasis and coagulation]
[Plasminogen activator inhibitor (PAI-1) and diabetes mellitus. I. Regulation of PAI-1 levels]
[Plasminogen activator inhibitor (PAI-1) and diabetes mellitus. II. PAI-1 in insulin resistant conditions]
[Plasminogen activator inhibitor (PAI-1) and markers of endothelial dysfunction in patients with diabetes mellitus]
[Plasminogen activator inhibitor-1 (PAI-1), ischemic heart disease and diabetes mellitus]
[Tissue plasminogen activator and diabetes mellitus]
Diabetes Mellitus, Type 1
Coagulation and fibrinolysis variables in pregnant women with type 1 diabetes mellitus.
Do plasminogen activator inhibitor (PAI-1) or tissue plasminogen activator PAI-1 complexes predict complications in Type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study.
Does chronic smoking influence fibrinolytic potential in type 1 diabetes mellitus?
Early changes of serum N-acetyl-beta-glucosaminidase, tissue plasminogen activator and erythrocyte superoxide dismutase in relation to retinopathy in type 1 diabetes mellitus.
Endothelial perturbation in children and adolescents with type 1 diabetes: association with markers of the inflammatory reaction.
Hypofibrinolysis in type 2 diabetes: the role of the inflammatory pathway and complement C3.
Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy.
Intraperitoneal insulin administration does not modify plasminogen activator inhibitor 1 levels in IDDM patients.
Normal tissue plasminogen activator and plasminogen activator inhibitor activity in plasma from patients with type 1 diabetes mellitus.
PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria.
Plasminogen activator inhibitor-1 (PAI-1) in children and adolescents With Type 1 Diabetes Mellitus: relation to diabetic micro-vascular complications and carotid intima media thickness.
Plasminogen activator inhibitor-1 is associated with coronary artery calcium in Type 1 diabetes.
Suboptimal glycaemic control enhances the risk of impaired prothrombotic state in youths with type 1 diabetes mellitus.
Diabetes Mellitus, Type 2
A nutritional nonalcoholic steatohepatitis minipig model.
A significant relationship between plasminogen activator inhibitor type-1 and lipoprotein(a) in non-insulin-dependent diabetes mellitus without complications.
A strong inverse relationship between PAI-1 and Lp(a) in hypertensive Type 2 diabetic patients.
Abdominal adiposity and cardiometabolic risk: do we have all the answers?
Activity of tissue plasminogen activator and plasminogen activator inhibitor in noninsulin-dependent diabetes mellitus.
Altered Daytime Fluctuation Pattern of Plasminogen Activator Inhibitor 1 in Type 2 Diabetes Patients with Coronary Artery Disease: A Strong Association with Persistently Elevated Plasma Insulin, Increased Insulin Resistance, and Abdominal Obesity.
Analysis of the correlation between plasma coagulation factor VII, PAI-1, and uric acid with insulin resistance and macrovascular complications in elderly patients with type 2 diabetes.
Antiplatelet aggregation and endothelial protection of I4, a new synthetic anti-diabetes sulfonylurea compound.
Association analysis of ADPRT1, AKR1B1, RAGE, GFPT2 and PAI-1 gene polymorphisms with chronic renal insufficiency among Asian Indians with type-2 diabetes.
Association between Plasma Levels of PAI-1, tPA/PAI-1 Molar Ratio, and Mild Cognitive Impairment in Chinese Patients with Type 2 Diabetes Mellitus.
Association of PAI-1 4G/5G Polymorphism with Ischemic Stroke in Chinese Patients with Type 2 Diabetes Mellitus.
Association of pigment epithelium derived factor with von Willebrand factor and plasminogen activator inhibitor 1 in patients with type 2 diabetes.
Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects.
Association of SERPINE1 rs6092 with type 2 diabetes and related metabolic traits in a Chinese population.
Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D.E.S.I.R. prospective cohort.
Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type 1 induced by insulin and its precursors.
Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease.
Beneficial effects of metformin on haemostasis and vascular function in man.
Blood glucose lowering by means of lifestyle intervention has different effects on adipokines as compared with insulin treatment in subjects with type 2 diabetes.
Cardiovascular disease in type 2 diabetics: epidemiology, risk factors and therapeutic modalities.
Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study.
Cellular and molecular mechanisms of vascular injury in diabetes - Part I: Pathways of vascular disease in diabetes.
Cellular carbonyl stress enhances the expression of plasminogen activator inhibitor-1 in rat white adipocytes via reactive oxygen species-dependent pathway.
Circulating miR-30c as a predictive biomarker of type 2 diabetes mellitus with coronary heart disease by regulating PAI-1/VN interactions.
Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial).
Comparison of skin microvascular reactivity with hemostatic markers of endothelial dysfunction and damage in type 2 diabetes.
Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-malignant diseases.
Cross talk of tumor necrosis factor-alpha and the renin-angiotensin system in tumor necrosis factor-alpha-induced plasminogen activator inhibitor-1 production from hepatocytes.
Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications.
Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus.
Decreased Insulin Sensitivity and Impaired Fibrinolytic Activity in Type 2 Diabetes Patients and Nondiabetics with Ischemic Stroke.
Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene.
Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients.
Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes.
Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells.
Differential response of plasma plasminogen activator inhibitor 1 after weight loss surgery in patients with or without type 2 diabetes.
Dyslipidaemia and coagulation defects of insulin resistance.
Effect of 4G/5G PAI-1 polymorphism on the response of PAI-1 activity to vitamin E supplementation in Type 2 diabetic patients.
Effect of bezafibrate on hypercoagulability assessed by fluorogenic prothrombin time in hyperlipidemic patients with non-insulin-dependent diabetes mellitus.
Effect of chlorpropamide and gliclazide on plasminogen activator activity in vascular walls in patients with maturity onset diabetes.
Effect of plasminogen activator inhibitor-1 and tissue plasminogen activator polymorphisms on susceptibility to type 2 diabetes in Malaysian subjects.
Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.
Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome.
Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Efficacy of a pedometer-based physical activity program on parameters of diabetes control in type 2 diabetes mellitus.
Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study.
Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis.
Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus.
Fiber intake and plasminogen activator inhibitor-1 in type 2 diabetes: Look AHEAD (Action for Health in Diabetes) trial findings at baseline and year 1.
Fibrinogen and plasminogen activator inhibitor-1 level in peripheral arterial disease of type 2 diabetes patients.
Fibrinolysis and atherogenesis in the JCR:LA-cp rat in relation to insulin and triglyceride concentrations in blood.
Fibrinolysis and diabetic retinopathy in NIDDM.
Fibrinolytic measurements in type 2 diabetic patients with acute cerebral infarction.
Fibronectin and lipoprotein(a) are inversely related to plasminogen activator inhibitor type-1 levels in Type 2 diabetic patients without complications.
Food intake patterns associated with incident type 2 diabetes: the Insulin Resistance Atherosclerosis Study.
Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria.
Free radical activity and hemostatic factors in NIDDM patients with and without microalbuminuria.
Genetic variation in promoter (4G/5G) of plasminogen activator inhibitor 1 gene in type 2 diabetes. Absence of relationship with microangiopathy.
Gingival crevicular fluid IL-6, tPA, PAI-2, albumin levels following initial periodontal treatment in chronic periodontitis patients with or without type 2 diabetes.
Gingival crevicular fluid PGE2, IL-1beta, t-PA, PAI-2 levels in type 2 diabetes and relationship with periodontal disease.
Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture.
High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA study.
Hormone-specific defect in insulin regulation of (Ca2+ + Mg2+)-adenosine triphosphatase activity in kidney membranes from streptozocin non-insulin-dependent diabetic rats.
Identification and modulation of a caveolae-dependent signal pathway that regulates plasminogen activator inhibitor-1 in insulin-resistant adipocytes.
Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.
Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.
Increased soluble fibrin monomer and soluble thrombomodulin levels in non-insulin-dependent diabetes mellitus.
Increased tissue-type plasminogen activator: a facade in the fibrinolytic system in type 2 diabetes.
Increased urinary orosomucoid excretion: a proposed marker for inflammation and endothelial dysfunction in patients with type 2 diabetes.
Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects.
Inflammation, insulin resistance, and atherosclerosis.
Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen activator inhibitor type-1 in non-insulin-dependent diabetes mellitus.
Insertion/deletion plasminogen activator inhibitor 1 and insertion/deletion angiotensin-converting enzyme gene polymorphisms in diabetic retinopathy in type 2 diabetes.
Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes.
Insulin resistance and risk factors for coronary heart disease.
Insulinoma, type 2 diabetes and plasminogen activator inhibitor type-I.
Lipoprotein(a), tissue plasminogen activator and plasminogen activator inhibitor 1 levels in hyperlipidaemic patients in Kuwait.
Loss of insulin receptor substrate-1 signaling induces the cardiovascular and proteo(fibrino)lytic system derangements typical of insulin resistance.
Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity.
Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study.
Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
Modulators of induction of plasminogen activator inhibitor type-1 in HepG2 cells by transforming growth factor-?.
Morphological Carotid Plaque Area Is Associated With Glomerular Filtration Rate: A Study of South Asian Indian Patients With Diabetes and Chronic Kidney Disease.
Multiple roles of tissue plasminogen activator in schizophrenia pathophysiology.
Obesity, microalbuminuria, hyperinsulinemia, and increased plasminogen activator inhibitor 1 activity associated with parasympathetic neuropathy in type 2 diabetes.
PAI-1 Gene 4G/5G polymorphism and risk of type 2 diabetes in a population-based sample.
Paraoxonase 1 Gln/Arg polymorphism is associated with the risk of microangiopathy in Type 2 diabetes mellitus.
Pathogenetic implications of hyaluronan-induced modification of vascular smooth muscle cell fibrinolysis in diabetes.
Performance of plasminogen activator inhibitor-1 as a biomarker in patients undergoing coronary angiography: Analytical and biological considerations.
Plasma Adiponectin, T94G Gene Polymorphism and PAI-1 in Patients with and without Hypertension.
Plasma levels of thrombomodulin, plasminogen activator inhibitor-1 and fibrinogen in elderly, diabetic patients with depressive symptoms.
Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
Plasminogen activator inhibitor (PAI-1) and non-insulin-dependent diabetes in Pima Indians, south Asians and Europeans. Populations at varying risk of NIDDM and coronary artery disease.
Plasminogen activator inhibitor 1 activity and lipoprotein(a) in nephropathic patients with non-insulin-dependent diabetes mellitus versus patients with nondiabetic nephropathy.
Plasminogen activator inhibitor-1 (PAI-1) activity and retinal vascular calibre in type 2 diabetes.
Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis.
Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with metabolic syndrome parameters in Malaysian subjects.
Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with type 2 diabetes risk.
Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy.
Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus.
Plasminogen activator inhibitor-1 and the risk of Type 2 diabetes mellitus in American Indians: the Strong Heart Study.
Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity.
Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies.
Plasminogen activator inhibitor-1 concentrations and bone mineral density in postmenopausal women with type 2 diabetes mellitus.
Plasminogen activator inhibitor-1 in nonobese subjects with non-insulin-dependent diabetes mellitus.
Plasminogen Activator Inhibitor-1 in poorly controlled vs well controlled Type-2 Diabetes Mellitus patients: A case-control study in a district hospital in Ghana.
Plasminogen activator inhibitor-1 is associated with renal dysfunction independent of BMI and serum lipid levels in patients with type 2 diabetes.
Plasminogen Activator Inhibitor-1 Level Correlates with Lipoprotein Subfractions in Obese Nondiabetic Subjects.
Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy.
Preserved tissue-type plasminogen activator release and endothelium-dependent vasodilation in postmenopausal women with NIDDM.
Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes.
Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome.
Regulation of PAI-1 gene expression during adipogenesis.
Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus.
Relationship of hepatic and peripheral insulin resistance with plasminogen activator inhibitor-1 in Pima Indians.
Relationship of oxidative stress and fibrinolysis in diabetes mellitus.
Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS).
Role of plasminogen activator inhibitor-1 in senescence and aging.
Sex differences in coagulation and fibrinolysis in white subjects with non-insulin-dependent diabetes mellitus.
Short-term effects of air temperature on blood markers of coagulation and inflammation in potentially susceptible individuals.
Should patients with polycystic ovarian syndrome be treated with metformin?
Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a population-based study.
Specific inhibition of plasminogen activator inhibitor 1 reduces blood glucose level by lowering TNF-a.
Stimulation of PAI-1 and adipokines by glucose in human adipose tissue in vitro.
The association between PAI-1 -675 4G/5G polymorphism and type 2 diabetes mellitus.
The Deidesheimer meeting: significance of classical and new risk factors in non-insulin-dependent diabetes mellitus.
The effect of PGI2 analogue on vascular endothelial function and platelet aggregation in patients with NIDDM.
The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy.
The lost correlation between heat shock protein 70 (HSPA1A) and plasminogen activator inhibitor-1 in patients with type 2 diabetes and albuminuria.
The potential influence of insulin and plasminogen activator inhibitor type 1 on the formation of vulnerable atherosclerotic plaques associated with type 2 diabetes.
The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus.
Thrombotic/Thrombolytic Balance as a Cardiac Treatment Determinant in Patients With Diabetes Mellitus and Coronary Artery Disease.
Time course of endothelial dysfunction and atherothrombosis markers in patients with acute myocardial infarction with st segment elevation and type 2 diabetes mellitus depending on reperfusion therapy approach.
Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes.
Tissue plasminogen activator (tPA) activity is a novel and early marker of asymptomatic LEAD in type 2 diabetes.
Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men.
TISSUE-SPECIFIC PAI-1 GENE EXPRESSION AND GLYCOSYLATION PATTERN IN INSULIN-RESISTANT OLD RATS.
Type 2 diabetes significantly modulates the cardiovascular risk conferred by the PAI-1 -675 4G/5G polymorphism in angiographied coronary patients.
Type 2 diabetes: assessment of endothelial lesion and fibrinolytic system markers.
Vascular effects of TZDs: new implications.
Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women.
Vitamin C affects thrombosis/ fibrinolysis system and reactive hyperemia in patients with type 2 diabetes and coronary artery disease.
Vitamin E intake reduces plasminogen activator inhibitor type 1 in T2DM patients.
[Effects of zhenqing recipe and earthworm on the expressions of transforming growth factor-beta1 and plasminogen activator inhibitor 1 in renal tissues of type 2 diabetic rats].
[Expression of plasminogen activator inhibitor-1 and tissue plasminogen activator in the kidney of KKAy mice with type 2 diabetes]
[Monoclonal antibody therapy for disorders of hemostasis and coagulation]
[Tissue plasminogen activator and diabetes mellitus]
[Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)]
Diabetes, Gestational
Adiponectin, C-reactive protein, fibrinogen and tissue plasminogen activator antigen levels among glucose-intolerant women with and without histories of gestational diabetes.
Coagulation and fibrinolysis parameters in normal pregnancy and in gestational diabetes.
Elevated Expression of Vascular Adhesion Molecule-1, Plasminogen Activator Inhibitor-1, Cyclooxygenase-2, and Thrombomodulin in Human Umbilical Vein Endothelial Cells from Hospitalized Gestational Diabetes Mellitus Patients.
Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy.
Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy.
Plasminogen activator inhibitor 1 gene polymorphism and gestational diabetes mellitus.
Rising plasminogen activator inhibitor-1 and hypoadiponectinemia characterize the cardiometabolic biomarker profile of women with recent gestational diabetes.
Diabetic Angiopathies
A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.
Coagulation and fibrinolysis variables in pregnant women with type 1 diabetes mellitus.
Plasminogen activator inhibitor-1 and apolipoprotein E gene polymorphisms and diabetic angiopathy.
Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice.
Diabetic Cardiomyopathies
Treadmill exercise alleviates diabetic cardiomyopathy by suppressing plasminogen activator inhibitor expression and enhancing eNOS in streptozotocin-induced male diabetic rats.
Diabetic Foot
Observation of clinical efficacy of rt-PA intravenous thrombolytic treatment for patients combined with grade 0-1 diabetic foot by Wagner classification and acute ischemic stroke.
Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in diabetic foot syndrome.
Diabetic Nephropathies
4?G/4?G polymorphism of plasminogen activator inhibitor-1 gene increases the risk of diabetic nephropathy.
A high concentration of glucose alters the production of tPA, uPA and PAI-1 antigens from human mesangial cells.
ACE, PAI-1, decorin and Werner helicase genes are not associated with the development of renal disease in European patients with type 1 diabetes.
Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients.
Association between PAI-1 4G/5G polymorphism and diabetic nephropathy: a meta-analysis in the Chinese population.
Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients.
Association of plasminogen activator inhibitor-1 4G5G Polymorphism with risk of diabetic nephropathy and retinopathy: a systematic review and meta-analysis.
Association of plasminogen activator inhibitor-1 gene polymorphism and type 2 diabetic nephropathy.
Challenging delivery of VLHL NS plasminogen activator inhibitor-1 by osmotic pumps in diabetic mouse: A case report.
Close relationship of plasminogen activator inhibitor-1 4G/5G polymorphism and progression of IgA nephropathy.
Effects of Bone Marrow Mesenchymal Stem Cells on Plasminogen Activator Inhibitor-1 and Renal Fibrosis in Rats with Diabetic Nephropathy.
Expression of transforming growth factor-beta isoforms in human glomerular diseases.
Extracellular matrix degradation by cultured mesangial cells: mediators and modulators.
Inhibition of PAI-1 attenuates perirenal fat inflammation and the associated nephropathy in high-fat diet-induced obese mice.
Involvement of p300/CBP and epigenetic histone acetylation in TGF-?1-mediated gene transcription in mesangial cells.
Novel curcumin analog C66 prevents diabetic nephropathy via JNK pathway with the involvement of p300/CBP-mediated histone acetylation.
Novel Plasminogen Activator Inhibitor-1 Inhibitors Prevent Diabetic Kidney Injury in a Mouse Model.
O-linked {beta}-N-acetylglucosamine (O-GlcNAc) supports p38 MAPK activation by high glucose in glomerular mesangial cells.
Plasminogen activator inhibitor-1 and diabetic nephropathy.
Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy.
Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1.
Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes.
Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
Solitary pancreas transplantation: preliminary findings about early reduction of proteinuria in incipient or evident diabetic type I nephropathy.
Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells.
Targeted therapies in diabetic nephropathy: an update.
The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy.
[ASSOCIATION OF FIBROBLAST GROWTH FACTOR 23 WITH MARKERS OF INFLAMMATION AND FIBROSIS IN DIABETIC NEPHROPATHY].
[Diabetic nephropathy and plasminogen activator inhibitor 1 in urine samples]
[Relationship between plasminogen activator inhibitor-1 gene 4G/5G polymorphism and type 2 diabetic nephropathy in Chinese Han patients in Guangdong Province]
Diabetic Neuropathies
Microvascular tissue plasminogen activator is reduced in diabetic neuropathy.
Diabetic Retinopathy
Absent elevations in growth hormone, factor VIII related antigen, and plasminogen activator activity during exercise in diabetic patients resistant to retinopathy.
Attenuation of diabetic retinopathy by enhanced inhibition of MMP-2 and MMP-9 using aspirin and minocycline in streptozotocin-diabetic rats.
Blockade by phosphorothioate aptamers of advanced glycation end products-induced damage in cultured pericytes and endothelial cells.
Changes of plasma tPA and PAI activities in patients with diabetic retinopathy.
Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study.
Comment on roles of tissue plasminogen activator and its inhibitor in proliferative diabetic retinopathy.
Diabetic retinopathy in Euro-Brazilian type 2 diabetic patients: relationship with polymorphisms in the aldose reductase, the plasminogen activator inhibitor-1 and the methylenetetrahydrofolate reductase genes.
Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients.
Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes.
Fibrinolytic activity of the retinae in streptozotocin-diabetic rats.
Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization.
Insertion/deletion plasminogen activator inhibitor 1 and insertion/deletion angiotensin-converting enzyme gene polymorphisms in diabetic retinopathy in type 2 diabetes.
Plasma plasminogen activator inhibitor-1 is associated with end-stage proliferative diabetic retinopathy in the Northern Chinese Han population.
Plasminogen Activator Inhibitor Type-1 Tag Single-Nucleotide Polymorphisms in Patients with Diabetes Mellitus Type 2 and Diabetic Retinopathy.
Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis.
Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy.
Plasminogen activator inhibitor-1 overexpression in nonproliferative diabetic retinopathy.
Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy.
Role of ACE and PAI-1 Polymorphisms in the Development and Progression of Diabetic Retinopathy.
Roles of tissue plasminogen activator and its inhibitor in proliferative diabetic retinopathy.
TPA-assisted vitrectomy for proliferative diabetic retinopathy: results of a double-masked, multicenter trial.
[Intravitreal tissue plasminogen activator for treatment of central retinal vein occlusion associated with diabetic retinopathy]
[Vitreous hemorrhage after vitrectomy in diabetic retinopathy and tissue plasminogen activator]
Diphtheria
CD 1-8 antigens on human diphtheria toxoid T lymphocyte clones: expression and modulation by TPA, sodium butyrate, and 5-azacytidine.
Contribution of plasminogen activator urokinase to in vitro cytotoxicity of diphtheria toxin.
Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Entry of diphtheria toxin linked to concanavalin A into primate and murine cells.
Interactions between diphtheria toxin entry and anion transport in vero cells. III. Effect on toxin binding and anion transport of tumor-promoting phorbol esters, vanadate, fluoride, and salicylate.
Disseminated Intravascular Coagulation
4G4G genotype of the plasminogen activator inhibitor-1 promoter polymorphism associates with disseminated intravascular coagulation in children with systemic meningococcemia.
Antithrombin III (AT) and recombinant tissue plasminogen activator (R-TPA) used singly and in combination versus supportive care for treatment of endotoxin-induced disseminated intravascular coagulation (DIC) in the neonatal pig.
Asphyxia by Drowning Induces Massive Bleeding Due To Hyperfibrinolytic Disseminated Intravascular Coagulation.
Changes in plasma levels of tissue-plasminogen activator/inhibitor complex and active plasminogen activator inhibitor in patients with disseminated intravascular coagulation.
Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator.
Close relationship of tissue plasminogen activator-plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreas.
Cytokines and plasminogen activator inhibitor-1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome.
Disseminated intravascular coagulation at an early phase of trauma is associated with consumption coagulopathy and excessive fibrinolysis both by plasmin and neutrophil elastase.
Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome.
Effect of the administration of recombinant hirudin and/or tissue-plasminogen activator (t-PA) on endotoxin-induced disseminated intravascular coagulation model in rabbits.
Hematologic Emergencies in the Postoperative Neurointensive Care Unit Setting: Illustrative Case Series and Differential Diagnosis.
Hemostasis associated with abnormalities of fibrinolysis.
Increased neutrophil elastase, persistent intravascular coagulation, and decreased fibrinolytic activity in patients with posttraumatic acute respiratory distress syndrome.
Increased vascular endothelial cell markers in patients with disseminated intravascular coagulation.
Localization of tissue plasminogen activator on experimental microthrombi in rats. Microautoradiographic observations.
Localization of tissue plasminogen activator on experimental thrombi in rats.
Microvascular thrombosis in pediatric multiple organ failure: Is it a therapeutic target?
Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans.
Plasma Levels of Plasminogen Activator Inhibitor-1 (PAI-1) and Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Patients with Disseminated Intravascular Coagulation (DIC).
Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura.
Plasminogen activator inhibitor 1 promotes a poor prognosis in sepsis-induced disseminated intravascular coagulation.
Plasminogen activator inhibitor-1 levels determine the profibrinolytic response in disseminated intravascular coagulation.
Potential of continuous tPA infusion for multiple-organ failure from lipopolysaccharide-induced disseminated intravascular coagulation in rats.
Recent advances in disseminated intravascular coagulation: endothelial cells and fibrinolysis in sepsis-induced DIC.
Redirection of the reaction between activated protein C and a serpin to the substrate pathway.
Role of Vascular Endothelial Cells in Disseminated Intravascular Coagulation Induced by Seawater Immersion in a Rat Trauma Model.
Severe heat stroke associated with high plasma levels of plasminogen activator inhibitor 1.
Study of the balance between coagulation and fibrinolysis in disseminated intravascular coagulation using molecular markers.
The association between plasminogen activator inhibitor type-1 and clinical outcome in paediatric sepsis.
The endotoxin-induced plasminogen activator inhibitor-1 increase in rabbits is not tumor necrosis factor-alpha dependent and can occur in the absence of interleukin-1beta.
The predictive value of the hemostasis parameters in the development of preeclampsia.
The seamless web revisited: tissue plasminogen activator in disseminated intravascular coagulation.
The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia.
Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation: clinicopathologic correlations.
Tissue-type plasminogen activator, type 1 plasminogen activator inhibitor and their complex in plasma with disseminated intravascular coagulation.
Two fetal deaths associated with maternal sepsis and with thrombosis of the intervillous space of the placenta.
Validating plasminogen activator inhibitor-1 as a poor prognostic factor in sepsis.
[Activity of procoagulant and fibrinolysis in homogenate of leukemic cells]
[Disseminated intravascular coagulation induced by endotoxin in rabbits: effect of treatment with t-PA and urokinase]
[Fluctuations of tissue-type plasminogen activator.plasminogen activator inhibitor-1 complex in patients with DIC]
[Levels of tissue-type plasminogen activator and plasminogen activator inhibitor 1 in disseminated intravascular coagulation syndrome]
[Qualitative analysis of tissue plasminogen activator in plasma obtained from various liver diseases by gel filtration and affinity chromatography]
Down Syndrome
A giant thrombus in the right ventricle of a newborn with Down syndrome: successful treatment with rt-PA.
Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?
Down's syndrome lymphoid cell lines exhibit increased adhesion due to the over-expression of lymphocyte function-associated antigen (LFA-1).
Enhancement of plasminogen activator activity stimulated by LPS in gingival fibroblasts of individuals with Down syndrome.
Gene expression in periodontal tissues following treatment.
Nerve growth factor metabolic dysfunction in Down's syndrome brains.
Plasminogen activator inhibitor type 1 in adults with Down syndrome and protection against macrovascular disease.
Successful Treatment of Severe Mechanical Mitral Valve Thrombosis With Tissue Plasminogen Activator in a 7-Month-Old Infant.
Treatment of infective endocarditis with recombinant tissue plasminogen activator.
Drug-Related Side Effects and Adverse Reactions
The pattern and risk factors associated with adverse drug reactions induced by Reteplase in patients with acute ST-elevation myocardial infarction: The first report from Iranian population.
Urticaria, angioedema, and type I hypersensitivity reactions associated with fibrinolytic agents.
Ductus Arteriosus, Patent
Use of tissue plasminogen activator for femoral artery thrombosis following transcatheter coil occlusion of patent ductus arteriosus.
Duodenal Ulcer
Impaired fibrinolysis and increased protease levels in gastric and duodenal mucosa of patients with active duodenal ulcer.
Reduced tissue type plasminogen activator activity of the gastroduodenal mucosa in peptic ulcer disease.
Dupuytren Contracture
Enzymes approved for human therapy: indications, mechanisms and adverse effects.
Possible role of plasminogen activator content of the palmar nodules in recurrence of Dupuytren's contracture.
Dysarthria
Opalski Syndrome Treated with Intravenous Recombinant Tissue Type Plasminogen Activator-Case Report and Review of Literature.
Recovery after ischemic stroke: criteria for good outcome by level of disability at day 7.
Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report.
Telemedicine physician providers: augmented acute stroke care delivery in rural Texas: an initial experience.
Use of Intra-Arterial Tissue Plasminogen Activator in Acute Stroke: Video Case.
Validation of minor stroke definitions for thrombolysis decision making.
Dyskinesias
Cortical myoclonus during IV thrombolysis for ischemic stroke.
Successful treatment with intravenous recombinant tissue plasminogen activator in an acute stroke patient presenting with hemiballism.
Dyslipidemias
'True' fasting serum insulin level, insulin resistance syndrome and coronary artery disease.
4B.06: EFFECT OF CHRONIC KIDNEY DISEASE, DYSLIPIDEMIA AND HYPERTENSION ON CAROTID ATHEROSCLEROSIS IN ELDERLY PATIENTS WITH TYPE 2 DIABETES.
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
Biomarkers of cardiometabolic complications in survivors of childhood acute lymphoblastic leukemia.
Brain Natriuretic Peptide Is a Powerful Predictor of Outcome in Stroke Patients with Atrial Fibrillation?.
Cardiovascular disease in the diabetic woman.
Closing gaps between evidence-based stroke care guidelines and practices with a collaborative quality improvement project.
Contribution of genetic and metabolic syndrome to omental adipose tissue PAI-1 gene mRNA and plasma levels in obesity.
Coronary artery disease in South asians: an emerging risk group.
Epidemiology of diabetes and obesity in the United States.
Gender and thrombolysis therapy in stroke patients with incidence of dyslipidemia.
Impaired fibrinolytic activity is present in children with dyslipidemias.
Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?
Insulin resistance and vascular dysfunction in nondiabetic Asian Indians.
Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias.
Nicotine exposure suppresses hyperinsulinemia and improves endothelial dysfunction mediators independent of corticosteroids in insulin-resistant oral contraceptive-treated female rats.
Not only the Sugar, Early infarct sign, hyperDense middle cerebral artery, Age, Neurologic deficit score but also atrial fibrillation is predictive for symptomatic intracranial hemorrhage after intravenous recombinant tissue plasminogen activator.
Plasminogen activator inhibitor-1 4G/5G polymorphism and dyslipidemia with branch retinal artery occlusion in a young lady.
Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function.
Prothrombotic markers in asymptomatic dyslipidemic subjects.
Psychosocial stress and the insulin resistance syndrome.
The Deidesheimer meeting: significance of classical and new risk factors in non-insulin-dependent diabetes mellitus.
The impact of metabolic syndrome and CRP on vascular phenotype in type 2 diabetes mellitus.
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
[Insulin-like growth factor-binding protein-1: a new biochemical marker of nonalcoholic fatty liver disease?]
[Markers of endothelial dysfunction in patients with arterial hypertension exposed to occupational irradiation of ?low intensity].
[Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia]
[Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia]
[The influence of I/D polymorphism of the angiotensin I converting enzyme (ACE) gene and 4G/5G polymorphism of plasminogen activator inhibitor (PAI-1) gene promoter on the haemostatic system in patients with essential hypertension and dyslipidemia]
Dysphonia
Efficacy of Water Resistance Therapy in Subjects Diagnosed With Behavioral Dysphonia: A Randomized Controlled Trial.
Dyspnea
A Case Report of Pulmonary Thromboendarterectomy for Chronic Thromboembolism in a Patient with Protein C Deficiency.
Cardiometabolic biomarkers are predictors of readmission and death in patients hospitalized for acute dyspnea.
Emergency Department Focused Bedside Echocardiography in Massive Pulmonary Embolism.
Recurrent Pulmonary Embolism Caused by Superficial Femoral Vein Aneurysm.
Sudden cardiac death caused by migration of a TrapEase inferior vena cava filter: case report and review of the literature.
[A case of advanced gastric cancer with carcinomatous pericarditis effectively treated by S-1/CDDP combined therapy].
Ebstein Anomaly
Case study and review: Treatment of tricuspid prosthetic valve thrombosis.
Ecchymosis
Massive subfascial hematoma after alteplase therapy for acute myocardial infarction.
Reversal of acute ischemic stroke after THA using tissue plasminogen activator.
Eclampsia
Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia.
Ectodermal Dysplasia
A nutritional nonalcoholic steatohepatitis minipig model.
Eczema
Assessment of the anti-inflammatory activity and free radical scavenger activity of tiliroside.
Isolation of two triterpenoids and a biflavanone with anti-Inflammatory activity from Schinus molle fruits.
Eisenmenger Complex
Markers of endothelial dysfunction and severity of hypoxaemia in the Eisenmenger syndrome.
Embolic Stroke
A comparison of intra-arterial and intravenous tissue-type plasminogen activator on autologous arterial emboli in the cerebral circulation of rabbits.
A laser-induced liquid jet catheter system: a novel endovascular device for rapid and reliable fibrinolysis in acute cerebral embolism.
A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding.
A novel method to promote behavioral improvement and enhance mitochondrial function following an embolic stroke.
Acute enoxaparin treatment widens the therapeutic window for tPA in a mouse model of embolic stroke.
Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke.
Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.
Altered gene expression in an embolic stroke model after thrombolysis with tissue plasminogen activator and Stachybotrys microspora triprenyl phenol-7.
Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIb/IIIa inhibitor.
Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke.
Annexin A2 Plus Low-Dose Tissue Plasminogen Activator Combination Attenuates Cerebrovascular Dysfunction After Focal Embolic Stroke of Rats.
Anticoagulation after cardioembolic stroke: to bridge or not to bridge?
Atorvastatin downregulates tissue plasminogen activator-aggravated genes mediating coagulation and vascular permeability in single cerebral endothelial cells captured by laser microdissection.
Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats.
Atrial fibrillation and cardiembolic stroke. Treatment and issue in acute phase.
Brain hemorrhages after rt-PA treatment of embolic stroke in spontaneously hypertensive rats.
Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke.
Cardioembolic stroke in a young male with cor triatriatum sinister: a case report.
CDP-choline at high doses is as effective as i.v. thrombolysis in experimental animal stroke.
Cerebral endothelial cell-derived small extracellular vesicles enhance neurovascular function and neurological recovery in rat acute ischemic stroke models of mechanical thrombectomy and embolic stroke treatment with tPA.
Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits.
Combination treatment with low-dose Niaspan and tissue plasminogen activator provides neuroprotection after embolic stroke in rats.
Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia.
Combined systemic thrombolysis with alteplase and early hyperbaric oxygen therapy in experimental embolic stroke in rats: relationship to functional outcome and reduction of structural damage.
Combined treatment with recombinant tissue plasminogen activator and dexamethasone phosphate-containing liposomes improves neurological outcome and restricts lesion progression after embolic stroke in rats.
Combined X-ray angiography and diffusion-perfusion MRI for studying stroke evolution after rt-PA treatment in rats.
Comparative Analysis of Different Methods of Ischemia/Reperfusion in Hyperglycemic Stroke Outcomes: Interaction with tPA.
Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits.
Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model.
Complement-Dependent Synaptic Uptake and Cognitive Decline after Stroke and Reperfusion Therapy.
Danhong Injection Combined With t-PA Improves Thrombolytic Therapy in Focal Embolic Stroke.
Delayed rt-PA treatment in a rat embolic stroke model: diagnosis and prognosis of ischemic injury and hemorrhagic transformation with magnetic resonance imaging.
Delayed treatment with a t-PA analogue and streptokinase in a rabbit embolic stroke model.
Diabetes Worsens Functional Outcomes in Young Female Rats: Comparison of Stroke Models, Tissue Plasminogen Activator Effects, and Sexes.
Diffusion-, T2-, and perfusion-weighted nuclear magnetic resonance imaging of middle cerebral artery embolic stroke and recombinant tissue plasminogen activator intervention in the rat.
Digital angiographic quantification of blood flow dynamics in embolic stroke treated with tissue-type plasminogen activator.
Dose-response of rt-PA and its combination with aspirin in a rat embolic stroke model.
Dynamic Detection of Thrombolysis in Embolic Stroke Rats by Synchrotron Radiation Angiography.
Early administration of pyrrolidine dithiocarbamate extends the therapeutic time window of tissue plasminogen activator in a male rat model of embolic stroke.
Early computed tomographic findings for thrombolytic therapy in patients with acute brain embolism.
Early insulin glycemic control combined with tPA thrombolysis reduces acute brain tissue damages in a focal embolic stroke model of diabetic rats.
Early prediction of gross hemorrhagic transformation by noncontrast agent MRI cluster analysis after embolic stroke in rat.
Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator.
Effect of Alteplase Use on Outcomes in Patients With Atrial Fibrillation: Analysis of the Initiation of Anticoagulation After Cardioembolic Stroke Study.
Effect of Cardioembolic Etiology on Intravenous Thrombolysis Efficacy for Acute Ischemic Stroke.
Effect of delayed thrombolysis with rt-PA in a rat embolic stroke model.
Effect of intra-arterial tissue plasminogen activator and urokinase on autologous arterial emboli in the cerebral circulation of rabbits [corrected]
Effect of recombinant plasminogen activator timing on thrombolysis in a novel rat embolic stroke model.
Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats.
Effects of ML351 and tissue plasminogen activator combination therapy in a rat model of focal embolic stroke.
Effects of the spin trap agent disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator.
Effects of tissue plasminogen activator and annexin A2 combination therapy on long-term neurological outcomes of rat focal embolic stroke.
Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats.
Enhancing the efficacy of thrombolysis by AMPA receptor blockade with NBQX in a rat embolic stroke model.
Erythropoietin in combination of tissue plasminogen activator exacerbates brain hemorrhage when treatment is initiated 6 hours after stroke.
Evaluation of recombinant tissue plasminogen activator in embolic stroke.
Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke.
Fibrinolytic gene polymorphism and ischemic stroke.
FK-506 extended the therapeutic time window for thrombolysis without increasing the risk of hemorrhagic transformation in an embolic rat stroke model.
Functional recovery after embolic stroke in rodents by activated protein C.
Hemostatic disturbances in acute ischemic stroke: a study of 86 patients.
Herpes encephalitis : a stroke mimicker.
Hyperglycemia Worsens Outcome After rt-PA Primarily in the Large-Vessel Occlusive Stroke Subtype.
Improved model of thromboembolic stroke and rt-PA induced reperfusion in the rat.
Improved perfusion with rt-PA and hirulog in a rabbit model of embolic stroke.
Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected]
Increases in circulating matrix metalloproteinase-9 levels following fibrinolysis for acute pulmonary embolism.
Infarct in new territory after endovascular stroke treatment: A diffusion-weighted imaging study.
Infarct prediction and treatment assessment with MRI-based algorithms in experimental stroke models.
Influence of a 'brain protector' drug 21-amino steroid on the effects of experimental embolic stroke treated by thrombolysis.
Influence of tissue plasminogen activator and heparin on cerebral ischemia in a rabbit model.
Inhibition of PI3K? by AS605240 plus low-dose tissue plasminogen activator (tPA) combination improves thrombolytic therapy in a rat model of embolic stroke.
Interrelations between blood-brain barrier permeability and matrix metalloproteinases are differently affected by tissue plasminogen activator and hyperoxia in a rat model of embolic stroke.
Intra-arterial thrombolysis in a 2-year-old with cardioembolic stroke.
Intravenous aspirin causes a paradoxical attenuation of cerebrovascular thrombolysis.
Intravenous recombinant tissue plasminogen activator in a pregnant woman with cardioembolic stroke.
Intravenous recombinant tissue plasminogen activator therapy in a 14-week pregnant woman with embolic stroke due to protein S deficiency.
Intravenous Thrombolysis for Acute Ischemic Stroke: Review of 97 Patients.
Intravenous thrombolysis on early recurrent cardioembolic stroke: 'Dr Jekyll' or 'Mr Hyde'?
Intravenous thrombolysis with recombinant staphylokinase versus tissue-type plasminogen activator in a rabbit embolic stroke model.
Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator.
Long-term functional and neurological outcome after simultaneous treatment with tissue-plasminogen activator and hyperbaric oxygen in early phase of embolic stroke in rats.
Magnetic resonance imaging characterization of hemorrhagic transformation of embolic stroke in the rat.
Magnetic resonance imaging indexes of therapeutic efficacy of recombinant tissue plasminogen activator treatment of rat at 1 and 4 hours after embolic stroke.
Map-ISODATA demarcates regional response to combination rt-PA and 7E3 F(ab')2 treatment of embolic stroke in the rat.
Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke.
Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits.
MRI evaluation of BBB disruption after adjuvant AcSDKP treatment of stroke with tPA in rat.
MRI evaluation of treatment of embolic stroke in rat with intra-arterial and intravenous rt-PA.
Multiparametric ISODATA analysis of embolic stroke and rt-PA intervention in rat.
N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Augments Thrombolysis of tPA (Tissue-Type Plasminogen Activator) in Aged Rats After Stroke.
Neuroprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke model.
Neuroprotection by excitatory amino acid antagonist augments the benefit of thrombolysis in embolic stroke in rats.
Neuroprotection with NBQX and thrombolysis with rt-PA in rat embolic stroke.
Neuroprotective effect of asiatic acid in rat model of focal embolic stroke.
Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator.
Normobaric hyperoxia and delayed tPA treatment in a rat embolic stroke model.
Opening the window: Ischemic postconditioning reduces the hyperemic response of delayed tissue plasminogen activator and extends its therapeutic time window in an embolic stroke model.
Optimized thrombolysis of cerebral clots with tissue-type plasminogen activator in a rabbit model of embolic stroke.
Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke.
Potential advantages of Chinese medicine Taohong Siwu Decoction () combined with tissue-plasminogen activator for alleviating middle cerebral artery occlusion-induced embolic stroke in rats.
Prediction of hemorrhagic transformation after experimental ischemic stroke using MRI-based algorithms.
Protective effects of 2-(2-benzonfuranyl)-2-imidazoline combined with tissue plasminogen activator after embolic stroke in rats.
Protective effects of pamiteplase, a modified t-PA, in a rat model of embolic stroke.
Quantitative evaluation of BBB permeability after embolic stroke in rat using MRI.
Rapid breakdown of microvascular barriers and subsequent hemorrhagic transformation after delayed recombinant tissue plasminogen activator treatment in a rat embolic stroke model.
Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke.
Recurrent embolization during intravenous administration of tissue plasminogen activator in acute cardioembolic stroke. A case report.
Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CP101,606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats.
Reduction of infarct volume and mortality by thrombolysis in a rat embolic stroke model.
Reduction of infarct volume by thrombolysis with rt-PA in an embolic rat stroke model.
Remote Ischemic Perconditioning is Effective After Embolic Stroke in Ovariectomized Female Mice.
Remote Ischemic Perconditioning Is Effective Alone and in Combination With Intravenous Tissue-Type Plasminogen Activator in Murine Model of Embolic Stroke.
Safe use of alteplase in a 10 months old infant with cardio-embolic stroke.
Serum S100B indicates successful combination treatment with recombinant tissue plasminogen activator and MK-801 in a rat model of embolic stroke.
Sigma receptor activation reduces infarct size at 24 hours after permanent middle cerebral artery occlusion in rats.
Spatio-temporal course of macrophage-like cell accumulation after experimental embolic stroke depending on treatment with tissue plasminogen activator and its combination with hyperbaric oxygenation.
Stachybotrys microspora triprenyl phenol-7, a novel fibrinolytic agent, suppresses superoxide production, matrix metalloproteinase-9 expression, and thereby attenuates ischemia/reperfusion injury in rat brain.
Successful intra-arterial thrombolytic therapy for a right middle cerebral artery stroke in a 2-year-old supported by a ventricular assist device.
Successful intravenous rt-PA thrombolysis for a childhood cardioembolic stroke with Emery-Dreifuss muscular dystrophy.
Synergistic Effect of AJW200, a von Willebrand Factor Neutralizing Antibody with Low Dose (0.9 mg/mg) Thrombolytic Therapy Following Embolic Stroke in Rabbits.
Synergistic effect of an endothelin type A receptor antagonist, S-0139, with rtPA on the neuroprotection after embolic stroke.
Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat.
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits.
The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity.
The effects of a new tissue plasminogen activator analogue, Fb-Fb-CF, on cerebral reperfusion in a rabbit embolic stroke model.
The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator.
Thrombolysis for Ischemic Stroke during Pregnancy: A Case Report and Review of the Literature.
Thrombolysis in acute stroke: ongoing challenges based on a tertiary hospital audit and comparisons with other Australian studies.
Thrombolysis with reteplase, an unglycosylated plasminogen activator variant, in experimental embolic stroke.
Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain.
Thrombolytic and anticoagulation treatment in a rat embolic stroke model.
Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab: Case Report and Literature Review.
Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study.
Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke.
Tissue plasminogen activator reduces neurological damage after cerebral embolism.
Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke.
tPA Mobilizes Immune Cells That Exacerbate Hemorrhagic Transformation in Stroke.
Transient brain hypothermia reduces the reperfusion injury of delayed tissue plasminogen activator and extends its therapeutic time window in a focal embolic stroke model.
Translational Stroke Research Using a Rabbit Embolic Stroke Model: A Correlative Analysis Hypothesis for Novel Therapy Development.
Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator.
Variations in the anatomy of the rabbit cervical carotid artery.
Vepoloxamer Enhances Fibrinolysis of tPA (Tissue-Type Plasminogen Activator) on Acute Ischemic Stroke.
Visualization of clot lysis in a rat embolic stroke model: application to comparative lytic efficacy.
Whole body hypothermia extends tissue plasminogen activator treatment window in the rat model of embolic stroke.
Worsened outcome from middle cerebral artery occlusion in aged rats receiving 17?-estradiol.
[Acute embolic stroke treated with rt-PA during elective coronary angiography]
[Changes of haemostatic parameters in patients with acute cardioembolic stroke].
[Intravenous recombinant tissue plasminogen activator in an 18-week pregnant woman with embolic stroke]
[Subtypes of acute ischemic stroke and neurological prognosis].
Embolism
A case of renal artery embolism treated by selective intra-arterial infusion of tissue plasminogen activator.
A Case Report of Unilateral Orolingual Angioedema Secondary to Alteplase Administration.
A novel model for evaluating thrombolytic therapy in dogs with ST-elevation myocardial infarction.
A Successful Treatment Strategy for Paradoxical Cerebral Embolism Accompanied by Entrapped Thrombus in Patent Foramen Ovale: A Case Report.
Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats.
Biochemical and functional characterization of human tissue-type plasminogen activator variants with mutagenized kringle domains.
Blood-brain barrier disturbances after rt-PA treatment of thromboembolic stroke in the rat.
Brain hemorrhages after rt-PA treatment of embolic stroke in spontaneously hypertensive rats.
Can catheter-directed thrombolysis be applied to acute lower extremity artery embolism after recent cerebral embolism from atrial fibrillation?
Catheter-directed thrombolysis following vena cava filtration for severe deep venous thrombosis.
Combining Normobaric Oxygen with Ethanol or Hypothermia Prevents Brain Damage from Thromboembolic Stroke via PKC-Akt-NOX Modulation.
Coronary embolism in a patient with mitral valve prosthesis: successful management with tirofiban and half-dose tissue-type plasminogen activator.
Coronary saddle embolism causing myocardial infarction in a patient with mechanical mitral valve prosthesis: Treatment with thrombolytic therapy.
Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke.
Diffusion-, T2-, and perfusion-weighted nuclear magnetic resonance imaging of middle cerebral artery embolic stroke and recombinant tissue plasminogen activator intervention in the rat.
Early thrombolysis inhibits peri-infarct depolarizations in embolic MCA occlusion.
Effect of thrombolysis on the dynamics of infarct evolution after clot embolism of middle cerebral artery in mice.
Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke model.
Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism.
EMBOLIC MIDDLE CEREBRAL ARTERY OCCLUSION MODEL USING THROMBIN AND FIBRINOGEN COMPOSED CLOTS IN RAT.
Embolization of calcific thrombi after tissue plasminogen activator treatment.
Endovascular Thrombectomy for Acute Ischemic Stroke in Failed Intravenous Tissue Plasminogen Activator Versus Non-Intravenous Tissue Plasminogen Activator Patients. Revascularization and Outcomes Stratified by the Site of Arterial Occlusions.
Experimental pulmonary embolus in the rat: a new in vivo model to test thrombolytic drugs.
Fatal intracerebral hemorrhage following thrombolytic therapy of embolic myocardial infarction in unsuspected infective endocarditis.
Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group.
Fibrinolytic therapy for acute embolic stroke: intravenous, intracarotid, and intra-arterial local approaches.
Fragmentation of an intracerebral embolus after IV tissue plasminogen activator treatment.
Gene expressions after thrombolytic treatment of middle cerebral artery clot embolism in mice.
Homonymous hemianopia caused by occipital lobe infarction in heparin-induced thrombocytopenia and thrombosis syndrome.
Hybrid approach in patients with recurrent brachial artery embolism: adjunctive tissue plasminogen activator infusion following embolectomy.
Hybrid treatment of acute massive pulmonary thromboembolism: mechanical fragmentation with a modified rotating pigtail catheter, local fibrinolytic therapy, and clot aspiration followed by systemic fibrinolytic therapy.
Imaging of experimental stroke models.
Infections causing stroke or stroke-like syndromes.
Influence of a 'brain protector' drug 21-amino steroid on the effects of experimental embolic stroke treated by thrombolysis.
Inhibition of PI3K? by AS605240 plus low-dose tissue plasminogen activator (tPA) combination improves thrombolytic therapy in a rat model of embolic stroke.
Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism.
Intravenous aspirin causes a paradoxical attenuation of cerebrovascular thrombolysis.
Intravenous low-dose native tissue plasminogen activator for distal embolism in the middle cerebral artery divisions or branches: a pilot study.
Magnetic resonance prediction of outcome after thrombolytic treatment.
Mechanisms of fibrinolysis resistance and potential targets for thrombolysis in acute ischaemic stroke: lessons from retrieved stroke emboli.
Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model.
Nitrous oxide inhalant abuse and massive pulmonary embolism in COVID-19.
Paradoxical embolus illustrating speed of action of recombinant tissue plasminogen activator in massive pulmonary embolism.
Pathophysiology and mechanisms of acute ischemic stroke. The NINDS rt-PA Stroke Study Group.
Probability of metabolic tissue recovery after thrombolytic treatment of experimental stroke: a magnetic resonance spectroscopic imaging study in rat brain.
Prospects of Therapeutic Target and Directions for Ischemic Stroke.
Pulmonary embolism after lung resection: diagnosis and treatment.
Pulmonary perfusion after rt-PA therapy for acute embolism: early improvement assessed with segmental perfusion scanning.
Recanalization of Middle Cerebral Artery and Intracranial Aneurysm in the Same Ischemic Territory With Intravenous Administration of Recombinant Tissue Plasminogen Activator: Case Report.
Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group.
Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents.
Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and ?2-Antiplasmin Inactivation.
Renal artery embolism: thrombolysis with recombinant tissue-type plasminogen activator.
Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I.
Space-occupying lesions in the right ventricle of a patient with antiphospholipid syndrome.
Successful treatment of renal artery embolism even forty-eight hours after event.
Successful treatment of renal artery thromboembolism with low-dose prolonged infusion of tissue-typed plasminogen activator in a patient with mitral mechanical heart valve thrombosis under the guidance of multimodality imaging.
Systemic thrombolysis using tissue plasminogen activator for a patient with paradoxic embolism: a case report.
The Totaled Health Risks in Vascular Events (THRIVE) Score Predicts Ischemic Stroke Outcomes Independent of Thrombolytic Therapy in the NINDS tPA Trial.
The transpedicular surgical approach for the development of intervertebral disc targeting regenerative strategies in an ovine model.
Therapeutic application of 20-kHz transcranial ultrasound in an embolic middle cerebral artery occlusion model in rats: safety concerns.
Therapeutic effect of tPA in ischemic stroke is enhanced by its combination with normobaric oxygen and hypothermia or ethanol.
Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus.
Thrombolysis of cerebral clot embolism in rat: effect of treatment delay.
Thrombolysis of Pulmonary Emboli via Endobronchial Ultrasound-Guided Transbronchial Needle Injection.
Thrombolytic therapy by pro-Urokinase combined with tissue plasminogen activator in an acute internal carotid occlusion.
Thrombolytic therapy in acute ischemic stroke patients with cardiac thrombus.
Thrombolytic treatment of clot embolism in rat: comparison of intra-arterial and intravenous application of recombinant tissue plasminogen activator.
Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model.
Tissue plasminogen activator and cardiopulmonary bypass for massive pulmonary embolus.
Tissue Plasminogen Activator for Cortical Embolism Stroke with Magnetic Resonance Perfusion Imaging: A Report of Two Cases.
Tissue plasminogen activator thrombolysis of a middle cerebral artery embolus in a patient with an arteriovenous malformation. Case report.
Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke.
To Treat or Not to Treat M2 Occlusions? The Question (and Answer) From a Single Institution.
Treatment of Mobile Right Heart Thrombi.
Unsuccessful tissue plasminogen activator treatment of acute stroke caused by a calcific embolus.
Vascular Risk Factors in Patients with Different Subtypes of Ischemic Stroke May Affect Their Outcome after Intravenous tPA.
[A case of successful application of tissue plasminogen activator actilyse in complex intensive therapy for massive pulmonary artery embolism]
[A survival case of amniotic fluid embolism treated by percutaneous cardiopulmonary support and thrombolysis with tissue-plasminogen activator]
[Bilateral renal embolism during thrombolytic therapy with tissue-type plasminogen activator in a patient with thrombosis of the left ventricle]
[Diagnostic and therapeutic progress. Venous thromboembolism, cardiac insufficiency and radio contrast agents]
[Examinations to detect left atrial thrombus and blood coagulation test analyses in aged patients with atrial fibrillation]
[Intravenous thrombolysis in pediatric arterial ischemic stroke: A case report and a review of the literature.]
[Massive pulmonary embolism mimicking ST-elevation acute coronary syndrome successfully treated with hybrid therapy in a trauma patient receiving nadroparin: diagnostic and therapeutic dilemmas]
[Renal artery embolism treated by selective intra-arterial infusion of tissue plasminogen activator: report of 2 cases]
[Short-term thrombolytic therapy in pulmonary artery embolism with rt-PA]
[Study of the function of coagulation, fibrinolysis and pulmonary vascular endothelium before and after experimental pulmonary thromboembolism in rabbits]
[Systemic lysotherapy using recombinant tissue plasminogen activator for fulminant pulmonary embolism]
[Systemic venous thrombolysis with rt-PA in arterial embolism of the legs in the elderly]
[t-PA activity, antigen and PAI-1 antigen levels in blood obtained from the patients with cerebral infarction]
[Thrombolytic recombinant tissue plasminogen activator (rt-PA) treatment in the acute ischemic stroke with limb arterial embolism; three case reports].
[Thrombolytic therapy of pulmonary artery embolism in early pregnancy with recombinant tissue-type plasminogen activator]
[Tumor cell embolism to pulmonary arteries]
[Undesirable side effects in thrombolytic therapy]
Embolism and Thrombosis
Thrombolytic therapy in pregnancy.
Embolism, Amniotic Fluid
[A survival case of amniotic fluid embolism treated by percutaneous cardiopulmonary support and thrombolysis with tissue-plasminogen activator]
Embolism, Paradoxical
eComment: Systemic thrombolysis with alteplase in impending paradoxical embolism.
Paradoxical Brain Embolism Caused by Isolated Pulmonary Arteriovenous Fistula Successfully Treated with Recombinant Tissue Plasminogen Activator.
Paradoxical embolus illustrating speed of action of recombinant tissue plasminogen activator in massive pulmonary embolism.
Thrombolysis for Ischemic Stroke during Pregnancy: A Case Report and Review of the Literature.
Tissue Plasminogen Activator to Treat a Stroke after Foam Sclerotherapy in a Woman with a Patent Foramen Ovale.
Transcranial duplex monitoring discloses hemorrhagic complication following rt-PA thrombolysis.
Embryo Loss
Effect of blockage of costimulatory signal on murine abortion-prone model.
Empyema
A combined intrapleural administration of dornase alfa and tissue plasminogen activator is safe in children with empyema - A pilot study.
A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions.
Alteplase and DNase for the treatment of pleural empyema in rats.
Alteplase: pleural effusion (parapneumonic) and empyema in children.
Asymptomatic man with an incidental finding of a massive empyema.
Cost-Effectiveness Analysis of Fibrinolysis vs Thoracoscopic Decortication for Early Empyema.
Efficacy and safety of intrapleural instillation of alteplase in the management of complicated pleural effusion or empyema.
Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema.
Intrapleural alteplase in a patient with complicated pleural effusion.
Intrapleural Dornase and Tissue Plasminogen Activator in pediatric empyema (DTPA): a study protocol for a randomized controlled trial.
Intrapleural tissue plasminogen activator and deoxyribonuclease therapy for pleural infection.
Intrapleural Tissue Plasminogen Activator for Traumatic Retained Hemothorax.
Is observation for traumatic hemothorax safe?
Lung Resection in Children with Necrotizing Pneumonia: Outcome and Follow-up.
Mixing It Up: Coadministration of tPA/DNase in Complicated Parapneumonic Pleural Effusions and Empyema.
Organizing empyema induced in mice by Streptococcus pneumoniae: effects of plasminogen activator inhibitor-1 deficiency.
Precision targeting of the plasminogen activator inhibitor-1 mechanism increases efficacy of fibrinolytic therapy in empyema.
Rethinking the Doses of Tissue Plasminogen Activator and Deoxyribonuclease Administrated Concurrently for Intrapleural Therapy for Complicated Pleural Effusion and Empyema.
Retrospective analysis of large-dose intrapleural alteplase for complicated pediatric parapneumonic effusion and empyema.
The use of thrombolytics in the management of complex pleural fluid collections.
Tissue plasminogen activator and DNase in empyema.
Tissue plasminogen activator as an adjuvant therapy for pleural empyema in pediatric patients.
Tissue plasminogen activator combined with human recombinant deoxyribonuclease is effective therapy for empyema in a rabbit model.
Tissue Plasminogen Activator for the Treatment of Parapneumonic Effusions in Pediatric Patients.
Two sequential tPA/DNase courses for noncommunicating loculated collections in pleural infection.
Empyema, Pleural
Alteplase and DNase for the treatment of pleural empyema in rats.
Effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema: A Randomized Clinical Trial.
Recombinant tissue plasminogen activator in the treatment of pleural infections in adults.
Tissue plasminogen activator as an adjuvant therapy for pleural empyema in pediatric patients.
Empyema, Tuberculous
Analysis of Cytokine Levers in Pleural Effusions of Tuberculous Pleurisy and Tuberculous Empyema.
Encephalitis
Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases.
Cerebrospinal fluid plasminogen activator inhibitor-1 in patients with neurological disease.
Effect of intrathecal thrombolytic therapy on subarachnoid clot and chronic vasospasm in a primate model of SAH.
Herpes encephalitis : a stroke mimicker.
Rationale and design of combination of an immune modulator Fingolimod with Alteplase bridging with Mechanical Thrombectomy in Acute Ischemic Stroke (FAMTAIS) trial.
The fibrinolytic system: A new target for treatment of depression with psychedelics.
Tissue plasminogen activator as a key effector in neurobiology and neuropathology.
Encephalitis, Japanese
Protective efficacy of a plasmid DNA encoding Japanese encephalitis virus envelope protein fused to tissue plasminogen activator signal sequences: studies in a murine intracerebral virus challenge model.
Encephalomyelitis
Involvement of cytokines in N-methyl-N'-nitro-N-nitrosoguanidine-induced plasminogen activator activity in acute disseminated encephalomyelitis and multiple sclerosis lymphocytes.
Role of tissue plasminogen activator in clinical aggravation of experimental autoimmune encephalomyelitis and its therapeutic potential.
The Influence of Differentially Expressed Tissue-Type Plasminogen Activator in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis.
Tissue plasminogen activator as a key effector in neurobiology and neuropathology.
Tissue plasminogen activator worsens experimental autoimmune encephalomyelitis by complementary actions on lymphoid and myeloid cell responses.
Encephalomyelitis, Acute Disseminated
Involvement of cytokines in N-methyl-N'-nitro-N-nitrosoguanidine-induced plasminogen activator activity in acute disseminated encephalomyelitis and multiple sclerosis lymphocytes.
Encephalomyelitis, Autoimmune, Experimental
A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis.
Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis during neuroinflammation.
Fibrinolytic activity of plaques and white matter in multiple sclerosis.
Involvement of tissue plasminogen activator in onset and effector phases of experimental allergic encephalomyelitis.
Neurovascular fibrinolytic activity in normal Lewis rats and rats with cell-transferred experimental allergic encephalomyelitis.
Role of tissue plasminogen activator in clinical aggravation of experimental autoimmune encephalomyelitis and its therapeutic potential.
Suppression of clinical signs of cell-transferred experimental allergic encephalomyelitis and altered cerebrovascular permeability in Lewis rats treated with a plasminogen activator inhibitor.
The Influence of Differentially Expressed Tissue-Type Plasminogen Activator in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis.
Tissue plasminogen activator as a key effector in neurobiology and neuropathology.
Tissue plasminogen activator worsens experimental autoimmune encephalomyelitis by complementary actions on lymphoid and myeloid cell responses.
Tissue-type plasminogen activator is a regulator of monocyte diapedesis through the brain endothelial barrier.
Endocarditis
Acute stroke thrombolysis in infective endocarditis.
Catastrophic Intracranial Hemorrhages after IV tPA in a Patient with Insidious Onset of Fever and Back Pain.
Effect of tissue-type plasminogen activator (t-PA) on the treatment with benzylpenicillin of rabbits with experimental Streptococcus sanguis endocarditis.
Effects of tissue-type plasminogen activator (t-PA) on Streptococcus sanguis-infected endocardial vegetations in vitro.
Fatal intracerebral hemorrhage following thrombolytic therapy of embolic myocardial infarction in unsuspected infective endocarditis.
Infections causing stroke or stroke-like syndromes.
Infective endocarditis successfully treated in extremely low birth weight infants with recombinant tissue plasminogen activator.
Intracranial Hemorrhage Following Thrombolytic Use for Stroke Caused by Infective Endocarditis.
Intravenous Thrombolysis in Acute Ischemic Stroke Patients with Unsuspected Infective Endocarditis.
Recombinant tissue plasminogen activator as a novel treatment option for infective endocarditis: a retrospective clinical study in 32 children.
Successful management of multiple permanent pacemaker complications--infection, 13 year old silent lead perforation and exteriorisation following failed percutaneous extraction, superior vena cava obstruction, tricuspid valve endocarditis, pulmonary embolism and prosthetic tricuspid valve thrombosis.
Successful treatment of a staphylococcal endocarditis vegetation with tissue plasminogen activator.
Successful treatment of Candida albicans endocarditis vegetations with recombinant tissue plasminogen activator in an extremely low birth weight preterm infant.
Successful treatment of infective endocarditis with recombinant tissue plasminogen activator.
Therapeutic advantage of recombinant human plasminogen activator in endocarditis: evidence from experiments in rabbits.
Thrombolysis for stroke caused by infective endocarditis: an illustrative case and review of the literature.
Treatment of infective endocarditis with recombinant tissue plasminogen activator.
Treatment of neonatal fungal infective endocarditis with recombinant tissue plasminogen: activator in a low birth weight infant case report and review of the literature.
Endocarditis, Bacterial
Effects of tissue-type plasminogen activator on Staphylococcus epidermidis--infected plasma clots as a model of infected endocardial vegetations.
Endoleak
Recanalization of previously thrombosed type II endoleak with aneurysm sac expansion after systemic thrombolysis.
Endometrial Hyperplasia
Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
[Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia]
Endometrial Neoplasms
A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study.
Absence of specific cell-surface binding of tissue plasminogen activator in uterine cells.
Characterization of a 54 kDa, alpha 1-antitrypsin-like protein isolated from ascitic fluid of an endometrial cancer patient.
Clinical significance of different serum tumor markers in gynecological malignancies.
Comparative study on expression of plasminogen activator inhibitor 1 and its mRNA in endometrial cancers and normal endometria.
Determination of serum levels of different cytokeratins in patients with uterine malignancies.
Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
Evaluation of seven different tumour markers for the establishment of tumour marker panels in gynecologic malignancies.
Genetic polymorphism of the plasminogen activator inhibitor-1 is associated with an increased risk of endometrial cancer.
High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer.
Immunohistochemical localization of placental proteins and tumor-associated antigens in endometrial cancer and endometrial hyperplasia.
Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer.
Modulation of plasminogen activator activity in human endometrial adenocarcinoma cells by basic fibroblast growth factor and transforming growth factor beta.
Plasminogen activator activity in human endometrial carcinoma.
Plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas.
Plasminogen activator inhibitor-1 (PAI-1) 4 G/5 G polymorphism and endometrial cancer. Influence of PAI-1 polymorphism on tissue PAI-1 antigen and mRNA expression and tumor severity.
Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer.
Relationship between plasma levels of components of the fibrinolytic system and acute-phase reactants in patients with uterine malignancies.
Release of plasminogen activator from normal and neoplastic endometrium.
Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Serum levels of six tumor markers in patients with benign and malignant gynecological disease.
Sex steroids in uterine endometrial cancers.
Sex steroids regulate the expression of plasminogen activator inhibitor-1 (PAI-1) and its mRNA in uterine endometrial cancer cell line Ishikawa.
The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer.
The clinical value of tissue polypeptide antigen in patients with gynecologic tumors.
The plasminogen activator urokinase and its inhibitor PAI-2 in endometrial cancer.
The value of serum CA 125 and association CA 125/CA 19-9 in endometrial carcinoma.
Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma.
Two-port access for laparoscopic surgery for endometrial cancer using conventional laparoscopic instruments.
Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer.
[Clinical significances of tissue polypeptide antigen in patients with gynecological malignancies]
[Effect of phorbol ester on tissue-type plasminogen activator (t-PA) secretion in endometrial carcinoma cell line in vitro]
[In vitro study on the effect of sex steroid and growth factor on growth and laminin, collagen IV, and tissue plasminogen activator production of normal endometrial cells and endometrial cancer cells in culture]
[Possibility of the combined use of tumor markers in endometrial carcinoma]
[Serum CA125 and CA19-9 levels in adenocarcinoma of the uterine cervix and endometrial carcinoma]
[The clinical significance of tissue polypeptide antigen (TPA) in the patients with gynecologic tumor]
[Tissue polypeptide antigen as a tumor marker for gynecologic malignancies]
Endometriosis
A role for the fibrinolytic system in postsurgical adhesion formation.
Expression of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis.
Expression of the fibrinolytic components in endometriosis.
Fibrin clot properties among women with endometriosis and the impact of ovarian stimulation.
Fibrinolytic properties of peritoneal fluid in endometriosis.
Genetic polymorphisms and endometriosis: contribution of genes that regulate vascular function and tissue remodeling.
Genetic polymorphisms in the fibrinolytic system of placentas with massive perivillous fibrin deposition.
Immunoreactivity of Plasminogen Activator Inhibitor 1 and Its Correlation with Dysmenorrhea and Lesional Fibrosis in Adenomyosis.
In situ localization of mRNA for the fibrinolytic factors uPA, PAI-1 and uPAR in endometriotic and endometrial tissue.
Ion Channels in The Pathogenesis of Endometriosis: A Cutting-Edge Point of View.
miR-30c may serve a role in endometriosis by targeting plasminogen activator inhibitor-1.
mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay.
Peritoneal fluid plasminogen activator activity in endometriosis and pelvic adhesive disease.
Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and endometriosis. Influence of PAI-1 polymorphism on PAI-1 antigen and mRNA expression.
Plasminogen activator inhibitor-1 (PAI-1) expression in endometriosis.
Plasminogen activator inhibitor-1 4G/5G polymorphism and susceptibility to endometriosis in the Italian population.
Plasminogen activator inhibitor-1 4G/5G polymorphism in infertile women with and without endometriosis.
Plasminogen activators and plasminogen activator inhibitors in endometriosis.
Plasminogen activators in ectopic and uterine endometrium.
Soluble urokinase-type plasminogen activator receptor is over-expressed in uterine endometrium from women with endometriosis.
[Serodiagnostic tests by factor analysis and stepwise discriminating analysis with tumor markers for the detection of ovarian cancer]
Endophthalmitis
Endophthalmitis after intravitreal injection of frozen preprepared tissue plasminogen activator (tPA) for pneumatic displacement of submacular hemorrhage.
Intracameral recombinant tissue plasminogen activator for the treatment of severe fibrin reaction in endophthalmitis.
Intravitreal recombinant tissue plasminogen activator in the treatment of experimentally induced bacterial endophthalmitis.
Recombinant tissue plasminogen activator (r-TPA) in fibrin dissolution due to postoperative endophthalmitis.
Tissue plasminogen activator and Staphylococcus epidermidis endophthalmitis.
Tissue plasminogen activator for postvitrectomy fibrin formation.
Tissue plasminogen activator for treatment of fibrin in endophthalmitis.
Tissue plasminogen activator in the treatment of vitreoretinal diseases.
Treatment of intracameral fibrinous membranes with tissue plasminogen activator.
[Experience with Dohlman-Doane keratoprosthesis: case reports]
[Treatment of intraocular fibrin formation with tissue plasminogen activator after vitrectomy]
Endotoxemia
Abrogation of plasminogen activator inhibitor-1-vitronectin interaction ameliorates acute kidney injury in murine endotoxemia.
Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue.
Chronic plasminogen activator inhibitor-1 (PAI-1) overexpression dampens CD25+ lymphocyte recruitment after lipopolysaccharide endotoxemia in mouse lung.
Expression of type 1 plasminogen activator inhibitor in renal tissue in murine lupus nephritis.
In vivo anticoagulant effect of ethyl pyruvate in endotoxemic rats.
Nafamostat Attenuated the Impairment of Fibrinolysis in Animal Sepsis Model by Suppressing the Increase of Plasminogen Activator Inhibitor Type 1.
Prevention of renal fibrin deposition in endotoxin-induced DIC through inhibition of PAI-1.
Protease-Activated Receptors 1 and 3 are Differentially Expressed on Human Monocyte Subsets and are Upregulated by Lipopolysaccharide Ex Vivo and In Vivo.
Recent advances in disseminated intravascular coagulation: endothelial cells and fibrinolysis in sepsis-induced DIC.
Regionally differentiated fibrinolytic responses during volume-resuscitated acute endotoxemia in pigs.
Regulation by nitric oxide of endotoxin-induced tissue factor and plasminogen activator inhibitor-1 in endothelial cells.
Short-Term Dietary Restriction Rescues Mice From Lethal Abdominal Sepsis and Endotoxemia and Reduces the Inflammatory/Coagulant Potential of Adipose Tissue.
The endotoxin-induced plasminogen activator inhibitor-1 increase in rabbits is not tumor necrosis factor-alpha dependent and can occur in the absence of interleukin-1beta.
Time- and dose-related regional fluxes of tissue-type plasminogen activator in anesthetized endotoxemic pigs.
Enteritis
Cholelithiasis in infants, children, and adolescents.
Global gene expression profiles reveal an increase in mRNA levels of collagens, MMPs, and TIMPs in late radiation enteritis.
Eosinophilia
Association of plasminogen activators and matrix metalloproteinase-9 proteolytic cascade with blood-CNS barrier damage of angiostrongyliasis.
Eosinophilic Esophagitis
Plasminogen Activator Inhibitor-1 as a Marker of Esophageal Functional Changes in Pediatric Eosinophilic Esophagitis.
Epidermolysis Bullosa
Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes.
Epidermolysis Bullosa Dystrophica
Studies on two siblings with recessive dystrophic epidermolysis bullosa (Hallopeau-Siemens) and the plasminogen activator and its inhibitor in the lesion.
Epilepsy
Does treatment with t-PA increase the risk of developing epilepsy after stroke?
Extracellular proteases in epilepsy.
Hot topics in risk management in neurologic practice.
Hypercoagulability and Migraine.
Increased risk and worse prognosis of myocardial infarction in patients with prior hospitalization for epilepsy--the Stockholm Heart Epidemiology Program.
Neuroserpin: a serpin to think about.
Role of t-PA and PAI-1 variants in temporal lobe epilepsy in Chinese Han population.
Temporal pole signal abnormality on MR imaging in temporal lobe epilepsy with hippocampal sclerosis: a fluid-attenuated inversion-recovery study.
Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies.
Tissue plasminogen activator does not alter development of acquired epilepsy.
Tissue Plasminogen Activator Expression Is Restricted to Subsets of Excitatory Pyramidal Glutamatergic Neurons.
[Clinico-biochemical study in epilepsy]
Epilepsy, Temporal Lobe
Role of t-PA and PAI-1 variants in temporal lobe epilepsy in Chinese Han population.
Epiretinal Membrane
Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders.
Epistaxis
Acute subdural hematoma after intra-arterial thrombolysis for acute ischemic stroke--case report.
Severe Epistaxis after Tissue Plasminogen Activator administration for Acute Ischemic Stroke in SARS-COV-2 Infection.
[Intravenous thrombolysis by recombinant plasminogen activator (rt-PA) in unstable angina. A randomized multicenter study versus placebo]
[Massive pulmonary embolism treated with a reduced dose of alteplase in a patient with acute renal failure.]
Epstein-Barr Virus Infections
Differentially Expressed Gene Profiles of hCR2-transfected Mouse Cells before and after EBV Infection and TPA Treatment.
Erectile Dysfunction
Circulating monocyte oxidative activity is increased in patients with type 2 diabetes and erectile dysfunction.
Erythema
Tachyphylaxis in 12-0-tetradecanoylphorbol acetate- and arachidonic acid-induced ear edema.
[Simple and effective rt-PA thrombolysis design]
Esophageal Neoplasms
Enhancement of esophageal carcinogenesis induced in rats by N-amyl-N-methylnitrosamine in the presence of 12-O-tetradecanoylphorbol-13-acetate.
Impact of sarcopenia on outcomes of locally advanced esophageal cancer patients treated with neoadjuvant chemoradiation followed by surgery.
Relationship Between Early Postoperative Change in Total Psoas Muscle Area and Long-term Prognosis in Esophagectomy for Patients with Esophageal Cancer.
Tumor markers in serum of patients with primary squamous cell carcinoma of the esophagus.
[Clinical effects of PSK on esophageal and gastric cancer patients and usefulness of serum levels of glycoproteins and HLA antigens as prognostic indicators]
[Clinical evaluation of tissue polypeptide antigen in patients with esophageal, stomach and colon cancer]
[Gastrointestinal cancer]
[The expressions and diagnostic values of miR-18a and miR-21 in esophageal cancer].
Esophageal Squamous Cell Carcinoma
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Comparison of Cyfra 21-1, TPA and SCC tumor markers in esophageal squamous cell carcinoma.
Expression of Bmi-1 and PAI-1 in esophageal squamous cell carcinoma.
Plasminogen activator inhibitor-1 as a potential marker for the malignancy of esophageal squamous cell carcinoma.
Plasminogen activator inhibitor-1 is a downstream mediator of the PGP9.5-related oncogenic pathway in esophageal squamous cell carcinoma.
[[Gender Differences in Tissue Cascade of Activation of Plasminogen and PAI-1 in Esophageal Squamous Cell Carcinoma].]
Essential Hypertension
Abnormalities of fibrinolysis in essential hypertension.
Age-related increase of pulse pressure and plasminogen activator inhibitor-1 I/D gene polymorphism in essential hypertension.
Association of insulin resistance with polymorphic variants of Clock and Bmal1 genes: A case-control study.
Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension.
Effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients.
Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms.
Elevated intraluminal pressure inhibits vascular tissue plasminogen activator secretion and downregulates its gene expression.
Fibrinolytic system in normotensive subjects and hypertensive patients.
Fingertips ischemia, nephroangiosclerosis, and focal segmental glomerulosclerosis: is genetic thrombophilia the unique explanation?
Gender differences in the relationships between plasma plasminogen activator inhibitor-1 activity and factors linked to the insulin resistance syndrome in essential hypertension.
Haemostatic variables in arterial hypertension.
Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden.
Low order correlations of lipoprotein(a) with other blood lipids and with coagulation and fibrinolysis parameters in hypertensive and diabetic patients.
Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels in patients with essential hypertension.
Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy.
Relationships between fibrinogen, plasminogen activator inhibitor-1, and their gene polymorphisms in current smokers with essential hypertension.
Tissue plasminogen activator in essential hypertension.
[Changes in the fibrinolytic activity in hypertension and acute cerebral infarction]
[Effect of yimai jiangya extract on platelet activation and fibrinolytic activity and angiotensin II in aged patients with essential hypertension]
[Effects of Naoxinduotai capsule on markers of prothrombotic state in patients with essential hypertension].
[Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia]
[The effect of doxazosin on blood pressure, lipids, fibrinogen and plasminogen activator inhibitor. A comparative study among smokers and non-smokers with essential hypertension]
[The hemostasis parameters and ACE gene polymorphism in patients with essential hypertension treated with perindopril]
[The influence of I/D polymorphism of the angiotensin I converting enzyme (ACE) gene and 4G/5G polymorphism of plasminogen activator inhibitor (PAI-1) gene promoter on the haemostatic system in patients with essential hypertension and dyslipidemia]
[The influences of genetic and environmental factors on plasma plasminogen activator inhibitor-1 levels in patients with essential hypertension]
Exanthema
Anaphylactoid reaction to recombinant tissue plasminogen activator.
[Cholesterol crystal embolisms due to systemic thrombolysis of an acute myocardial infarct]
Exostoses
Effect of C-reactive protein on gene expression in vascular endothelial cells.
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Fabry Disease
Intravenous Thrombolysis For Acute Ischemic Stroke in Fabry Disease.
Facial Paralysis
Recovery after ischemic stroke: criteria for good outcome by level of disability at day 7.
Telemedicine physician providers: augmented acute stroke care delivery in rural Texas: an initial experience.
Validation of minor stroke definitions for thrombolysis decision making.
Factor XII Deficiency
Acquired and congenital clotting syndromes.
Factor XIII Deficiency
Laboratory testing for bleeding disorders: strategic uses of high and low-yield tests.
Familial Mediterranean Fever
The Effect of Plasminogen Activator Inhibitor-1 -675 4G/5G Polymorphism on Familial Mediterranean Fever (FMF) Disease.
Familial Primary Pulmonary Hypertension
Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension.
Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7.
t-plasminogen activator inhibitor-1 polymorphism in idiopathic pulmonary arterial hypertension.
Fanconi Anemia
Enhanced induction of tissue-type plasminogen activator in normal human cells compared to cancer-prone cells following ionizing radiation.
Fatty Liver
Association between plasminogen activator inhibitor-1 and severity of liver injury and cardiovascular risk in children with non-alcoholic fatty liver disease.
Central role of ceramide biosynthesis in body weight regulation, energy metabolism and the metabolic syndrome.
Emerging risk factors for cardiovascular diseases: Indian context.
Ethanol and liver: recent advances in the mechanisms of ethanol-induced hepatosteatosis.
Ethanol and liver: recent insights into the mechanisms of ethanol-induced fatty liver.
Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease.
Female mice are more susceptible to non-alcoholic fatty liver disease: sex-specific regulation of the hepatic AMP-activated protein kinase - plasminogen activator inhibitor 1-cascade but not the hepatic endotoxin response.
Hemostatic alterations in fatty liver disease.
Liver steatosis and its relation to plasma haemostatic factors in apparently healthy men--role of the metabolic syndrome.
Overexpression of hepatic plasminogen activator inhibitor type 1 mRNA in rabbits with fatty liver.
Plasma PAI-1 levels are independently related to fatty liver and hypertriglyceridemia in familial combined hyperlipidemia, involvement of apolipoprotein E.
Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation.
Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of metabolic syndrome.
Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis.
Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease.
Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
Plasminogen activator inhibitor-1 is independently associated with non-alcoholic fatty liver disease whereas leptin and adiponectin vary between genders.
Sarcopenia and chronic liver diseases.
TM5441, a plasminogen activator inhibitor-1 inhibitor, protects against high fat diet-induced non-alcoholic fatty liver disease.
[Effects of pravastatin on hepatic plasminogen activator inhibitor 1 mRNA expression in rabbits with fatty liver]
[Proinflammatory cytokine levels depending on the stage of hepatic fibrosis in patients with metabolic syndrome and non-alcoholic fatty liver disease].
Fetal Alcohol Spectrum Disorders
Plasminogen activator system homeostasis and its dysregulation by ethanol in astrocyte cultures and the developing brain.
Tissue plasminogen activator is required for the development of fetal alcohol syndrome in mice.
Fetal Diseases
Effects of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate on phenytoin-induced embryopathy in mice.
[Myocardial infarction and thromboembolism during pregnancy]
Fetal Growth Retardation
Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation.
Coagulation and fibrinolytic parameters in normal pregnancy and in pregnancy complicated by intrauterine growth retardation.
Evaluation of plasminogen activators and plasminogen activator inhibitors in plasma and amniotic fluid in pregnancies complicated with intrauterine fetal growth retardation.
Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia.
Fibrinolytic system and reproductive process with special reference to fibrinolytic failure in pre-eclampsia.
Genetic hypofibrinolysis in complicated pregnancies.
Plasminogen activator of urokinase type and its inhibitor of placental type in hypertensive pregnancies and in intrauterine growth retardation: possible markers of placental function.
The 4G/4G polymorphism of the plasminogen activator inhibitor-1 (PAI-1) gene as an independent risk factor for placental insufficiency, which triggers fetal hemodynamic centralization.
The fast inhibitor of tissue plasminogen activator in plasma during pregnancy.
Fetal Resorption
Effects of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate on phenytoin-induced embryopathy in mice.
Fibroadenoma
Augmented release of matrix metalloproteinase-9 by PKC activation in organotypic cultures of human breast cancer and adjacent normal breast tissue and fibroadenoma.
Fibromatosis, Aggressive
An association between the 4G polymorphism in the PAI-1 promoter and the development of aggressive fibromatosis (desmoid tumor) in familial adenomatous polyposis patients.
Plasminogen activator inhibitor-1 (PAI-1) modifies the formation of aggressive fibromatosis (desmoid tumor).
Fibrosarcoma
12-0-Tetradecanoylphorbol-13-acetate-induced amplification of mesenchymal tumorigenesis in the mouse skin.
Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.
Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase. Demonstration of the binding, stabilization, and activation of PAI-1 by vitronectin.
Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis.
Cell- and gene-specific interactions between signal transduction pathways revealed by okadaic acid. Studies on the plasminogen activating system.
Collagenase expression in ovarian cancer cell lines.
Differential effects of phorbol ester on the in vitro invasiveness of malignant and non-malignant human fibroblast cells.
Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
Fibrinolytic activity in a human fibrosarcoma cell line and evidence for the induction of plasminogen activator secretion during tumor formation.
Forskolin down-regulates type-1 plasminogen activator inhibitor and tissue-type plasminogen activator and their mRNAs in human fibrosarcoma cells.
Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2.
Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies.
Inactivation of human anaphylatoxin C5a and C5a des-Arg through cleavage by the plasminogen activator activity of a human fibrosarcoma cell line.
Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells.
Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis.
Influence of short-term topical exposure to phorbol ester tumor promoters on subcutaneously induced skin tumorigenesis in S/RVCri mice.
Initiation and regulation of fibrinolysis in human plasma at the plasminogen activator level.
Measurement of plasminogen activator activity from human fibrosarcoma cells by a new microassay.
Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.
Modulation of extracellular proteolytic activity and anchorage-independent growth of cultured cells by sarcoma cell-derived factors: relationships to transforming growth factor-beta.
Modulation of type IV collagenase and plasminogen activator in a hamster fibrosarcoma by basement membrane components and lung fibroblasts.
Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification.
Nuclear c-Myc plays an important role in the cytotoxicity of tumor necrosis factor alpha in tumor cells.
Overexpression of a dominant negative CREB protein in HT-1080 cells selectively disrupts plasminogen activator inhibitor type 2 but not tissue-type plasminogen activator gene expression.
Phorbol ester-inducible T-cell-specific expression of variant mouse mammary tumor virus long terminal repeats.
Plasminogen activator activity in clonogenic cell populations separated from a murine fibrosarcoma.
Plasminogen activator activity of metastatic variants from a murine fibrosarcoma; effect of thrombin in vitro.
Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor/cachectin-responsive genes.
Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway.
Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.
Plasminogen activator inhibitor type 1 biosynthesis and mRNA level are increased by dexamethasone in human fibrosarcoma cells.
Plasminogen activator inhibitor type 1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin via alpha(v)beta(5) integrin.
Plasminogen activator inhibitor type 2 gene induction by tumor necrosis factor and phorbol ester involves transcriptional and post-transcriptional events. Identification of a functional nonameric AU-rich motif in the 3'-untranslated region.
Plasminogen activator inhibitor-1 accelerates lung metastasis formation of human fibrosarcoma cells.
Plasminogen activator inhibitors from placenta and fibrosarcoma cells are antigenically different as evaluated with monoclonal and polyclonal antibodies.
Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass.
Plasminogen activators in nude mice xenotransplanted with human tumorigenic cells.
Production of plasminogen activator by a primary HSV-2-induced hamster fibrosarcoma and its in vivo derived sublines.
Proteolytic and metastatic activities of clones derived from a methylcholanthrene-induced murine fibrosarcoma.
Purification of high and low molecular weight plasminogen activator inhibitor 1 from fibrosarcoma cell-line HT 1080 conditioned medium.
Rat testicular peritubular cells in culture secrete an inhibitor of plasminogen activator activity.
Regulation of plasminogen activator activity in human fibroblastic cells by fibrosarcoma cell-derived factors.
Regulatory elements involved in constitutive and phorbol ester-inducible expression of the plasminogen activator inhibitor type 2 gene promoter.
Retinoic acid enhances plasminogen activation on the cell surface.
Role of tissue inhibitor of metalloproteinases-2 (TIMP-2) in regulation of pro-gelatinase A activation catalyzed by membrane-type matrix metalloproteinase-1 (MT1-MMP) in human cancer cells.
Solvent effects on activity and conformation of plasminogen activator inhibitor-1.
Subcellular distribution of plasminogen activator in cultured human fibrosarcoma cells.
The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice.
The pharmacokinetics of plasminogen activator inhibitor-1 in the rabbit.
The transcription factor EGR-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-beta1, fibronectin, and plasminogen activator inhibitor-1.
Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
Tumor necrosis factor-alpha regulates mRNA for urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in human neoplastic cell lines.
Foramen Ovale, Patent
Multiplane transesophageal echocardiography to detect effectiveness of selective pulmonary recombinant tissue-type plasminogen activator thrombolysis in pulmonary embolism and patent foramen ovale.
Paradoxical embolus illustrating speed of action of recombinant tissue plasminogen activator in massive pulmonary embolism.
Successful administration of alteplase in a venous thromboembolism crossing through a patent foramen ovale.
Thrombolysis for Ischemic Stroke during Pregnancy: A Case Report and Review of the Literature.
Tissue Plasminogen Activator to Treat a Stroke after Foam Sclerotherapy in a Woman with a Patent Foramen Ovale.
Frontotemporal Lobar Degeneration
Serum C-Peptide, Visfatin, Resistin, and Ghrelin are Altered in Sporadic and GRN-Associated Frontotemporal Lobar Degeneration.
Gallbladder Neoplasms
Plasminogen activators and plasminogen activator inhibitor in malignant and non-malignant ascitic fluid.
Gallstones
Fibrinolysis and the biliary tree.
The role of fibrinolytic system proteins in cholesterol gallstone formation.
Ganglioglioma
Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies.
Gardner Syndrome
Oncogenic potential in fibroblasts from individuals genetically predisposed to cancer.
The use of a tumor promoter for the detection of individuals with the Gardner syndrome.
Gastritis
Gastric mucosal plasminogen activators in Helicobacter pylori infection.
Gastritis, Hypertrophic
Anti-fibrinolytic therapy of giant hypertrophic gastritis (Menetrier's disease).
Gastrointestinal Hemorrhage
Aberrant celio-mesenteric supply of the splenic flexure: provoking a bleed.
Considerations affecting selection of thrombolytic agents.
Subtherapeutic Warfarin Is Not Associated With Increased Hemorrhage Rates in Ischemic Strokes Treated With Tissue Plasminogen Activator.
Gastrointestinal Neoplasms
Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients.
Gastrointestinal cancer follow-up: the effectiveness of sequential CEA, TPA and Ca 19-9 evaluation in the early diagnosis of recurrences.
Tumor marker determinations.
Genetic Diseases, Inborn
The utility of thromboelastography and tranexamic acid in plasminogen activator inhibitor deficiency during pregnancy: a rare case report.
Genital Diseases, Female
Evaluation of seven different tumour markers for the establishment of tumour marker panels in gynecologic malignancies.
Relation between serum levels of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125) and their immunohistochemical identification in benign and malignant gynecological disease.
Serum levels of six tumor markers in patients with benign and malignant gynecological disease.
Gestational Trophoblastic Disease
Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease.
Giant Cell Arteritis
Coagulation and fibrinolysis in inflammatory bowel disease and in giant cell arteritis.
von Willebrand factor antigen and plasminogen activator inhibitor in giant cell arteritis.
Gingival Overgrowth
Regulation of type I plasminogen activator inhibitor in human gingival fibroblasts with cyclosporine A.
Gingivitis
A clinical study of plasminogen activator activity in gingival tissue in dogs with gingivitis and periodontitis.
Aggravation of gingival inflammatory symptoms during pregnancy associated with the concentration of plasminogen activator inhibitor type 2 (PAI-2) in gingival fluid.
Detection of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 2(PAI-2) in gingival crevicular fluid from healthy, gingivitis and periodontitis patients.
Physicochemical characterization and preliminary in vivo efficacy of bioadhesive, semisolid formulations containing flurbiprofen for the treatment of gingivitis.
Plasminogen activator system in smokers and non-smokers with and without periodontal disease.
Glaucoma
Comparative evaluation of TonoPen AVIA, Goldmann applanation tonometry and non-contact tonometry.
Corneal endothelial permeability in protection glaucoma filter bleb with tissue plasminogen activator.
Effect of immediate postoperative intracameral tissue plasminogen activator (tPA) on anterior chamber fibrin formation in dogs undergoing phacoemulsification.
Effects of tissue plasminogen activator on glaucoma filter blebs in rabbits.
Fibrin membrane pupillary-block glaucoma after uneventful cataract surgery treated with intracameral tissue plasminogen activator: a case report.
Hemorrhagic ocular complications associated with the use of systemic thrombolytic agents.
Intracameral recombinant tissue plasminogen activator for refractory glaucoma secondary to a fungal corneal abscess.
Intracameral tissue plasminogen activator after glaucoma surgery. Indications, effectiveness, and complications.
Intracameral tissue plasminogen activator for resolution of fibrin clots after glaucoma filtering procedures.
Intracameral tissue plasminogen activator to treat blocked glaucoma implants.
Intracameral tissue plasminogen activator to treat severe fibrinous effusion after cataract surgery.
Intracameral tissue plasminogen activator use in a large series of eyes with valved glaucoma drainage implants.
Intracameral urokinase for dissolution of fibrin or blood clots after glaucoma surgery.
Intravitreal injection of tissue plasminogen activator as treatment for an occluded pars plana glaucoma tube.
Mechanisms regulating plasminogen activators in transformed retinal ganglion cells.
Plasminogen activator inhibitor-1 in the aqueous humor of patients with and without glaucoma.
Promotion of glaucoma filter bleb with tissue plasminogen activator after sclerectomy under a clot.
Receptor-Associated Prorenin System in the Trabecular Meshwork of Patients with Primary Open-Angle Glaucoma and Neovascular Glaucoma.
Reduced fibrinolytic activity in aqueous humor of chronic simple glaucoma.
Risk of Visual Field Progression in Glaucoma Patients with Progressive Retinal Nerve Fiber Layer Thinning: A 5-Year Prospective Study.
Tissue plasminogen activator and glaucoma drainage implants.
Tissue plasminogen activator attenuates outflow facility reduction in mouse model of juvenile open angle glaucoma.
Tissue plasminogen activator modifies healing of glaucoma filtering surgery in rabbits.
Tissue plasminogen activator reduces the elevated intraocular pressure induced by prednisolone in sheep.
Tissue plasminogen activator to treat impending pupillary block glaucoma in patients with acute fibrinous HLA-B27 positive iridocyclitis.
Treatment of failing glaucoma filtering cystic blebs with tissue plasminogen activator (tPA).
Treatment of intracameral fibrinous membranes with tissue plasminogen activator.
Treatment of post-traumatic trabecular mashwork thrombosis and secondary glaucoma with intracameral tissue plasminogen activator in previously unrecognized sickle cell anemia.
Trend-Based Progression Analysis for Examination of the Topography of Rates of Retinal Nerve Fiber Layer Thinning in Glaucoma.
[Experience with Dohlman-Doane keratoprosthesis: case reports]
[Intraocular rt-PA injection in fibrin formation after combined glaucoma and cataract operation]
[Therapeutic and prophylactic application of TPA (recombinant tissue plasminogen activator) into the anterior chamber of the eye]
Glaucoma, Angle-Closure
Hemorrhagic ocular complications associated with the use of systemic thrombolytic agents.
Glaucoma, Neovascular
Comparison of surgical treatments for central retinal vein occlusion; RON vs. cannulation of tissue plasminogen activator into the retinal vein.
Histopathological findings after retinal endovascular lysis in central retinal vein occlusion.
Intracameral tissue plasminogen activator in neovascular glaucoma.
Tissue plasminogen activator and glaucoma drainage implants.
Glaucoma, Open-Angle
Intracameral tissue plasminogen activator in trabeculectomy: a 1-year prospective, randomized, controlled study.
Open-angle glaucoma secondary to blood clot in the Schlemm's canal following scleral buckle surgery and its treatment with tPA.
Plasminogen activator inhibitor-1 4G/5G gene polymorphism and primary open-angle glaucoma.
Promotion of glaucoma filter bleb with tissue plasminogen activator after sclerectomy under a clot.
Tissue plasminogen activator attenuates outflow facility reduction in mouse model of juvenile open angle glaucoma.
Glioblastoma
12-O-tetradecanoylphorbol-13-acetate-induced invasion/migration of glioblastoma cells through activating PKCalpha/ERK/NF-kappaB-dependent MMP-9 expression.
4G/5G and A-844G Polymorphisms of Plasminogen Activator Inhibitor-1 Associated with Glioblastoma in Iran--a Case-Control Study.
Amplification of the epidermal growth factor receptor gene in human gliomas.
Bacterial O6-methylguanine-DNA methyltransferase reduces N-methyl-N'-nitro-N-nitrosoguanidine induction of plasminogen activator in Mer- human glioblastoma A1235 cell line.
Cisplatin resistant glioblastoma cells may have increased concentration of urokinase plasminogen activator and plasminogen activator inhibitor type 1.
Drug-resistant human laryngeal carcinoma cells have increased levels of cathepsin B.
EGF regulates plasminogen activator inhibitor-1 (PAI-1) by a pathway involving c-Src, PKCdelta, and sphingosine kinase 1 in glioblastoma cells.
Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors.
Functional role of the cis-acting elements in human monocyte chemotactic protein-1 gene in the regulation of its expression by phorbol ester in human glioblastoma cells.
Hematologic Emergencies in the Postoperative Neurointensive Care Unit Setting: Illustrative Case Series and Differential Diagnosis.
High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas.
Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies.
Induction of plasminogen activator by alkylating agents in a repair defective human glioblastoma cell strain.
Plasminogen activator inhibitor-1 in brain tumors: relation to malignancy and necrosis.
Plasminogen activators and inhibitors in gliomas: an immunohistochemical study.
Prognostic significance of proteolytic enzymes in human brain tumors.
Purification and characterization of the plasminogen activator inhibitors PAI-1, PAI-2, and PN-1 from the human glioblastoma U138.
Purification and partial characterization of a plasminogen activator inhibitor from the human glioblastoma, U138.
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody.
Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation of their expression.
Regulation of epidermal growth factor receptor gene expression.
Role of plasminogen activator and of 92-KDa type IV collagenase in glioblastoma invasion using an in vitro matrigel model.
Secretion of alpha 2-macroglobulin, alpha 2-antiplasmin, and plasminogen activator inhibitor-1 by glioblastoma multiforme in primary organ culture.
Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness.
The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251.
Thrombolytic therapy for massive pulmonary embolism in a patient with a known intracranial tumor.
Tissue plasminogen activator expression in meningiomas and glioblastomas.
Transforming growth factor-? pathway activity in glioblastoma.
Transforming growth factor-beta 1 is a potent inducer of plasminogen activator inhibitor type-1 in human glioblastoma and carcinoma cell lines.
Type beta transforming growth factor and epidermal growth factor suppress the plasminogen activator activity in a human glioblastoma cell line.
[A plasminogen regulation system in brain tumors].
Glioma
A Chimeric Signal Peptide-Galectin-3 Conjugate Induces Glycosylation-Dependent Cancer Cell-Specific Apoptosis.
A comparison of the effect of several factors on the plasminogen activator activity of cloned lines from an ethylnitrosourea-induced glioma and from normal tissue.
Amplification of the epidermal growth factor receptor gene in human gliomas.
Biological significance of tissue plasminogen activator content in brain tumors.
Changes in Ca2+ concentration in phorbol ester and thapsigargin treated glioma C6 cells. The role of protein kinase C in regulation of Ca2+ entry.
CXCL12-mediated induction of plasminogen activator inhibitor-1 expression in human CXCR4 positive astroglioma cells.
Differences in pattern and level of plasminogen activator production between a cloned cell line from an ethylnitrosourea-induced glioma and one from normal adult rat brain.
Different regulation of phospholipase D activity in glioma C6 cells by sphingosine, propranolol, imipramine and phorbol ester.
Down-modulation of Bis reduces the invasive ability of glioma cells induced by TPA through NF-?B mediated activation of MMP-9.
EGF regulates plasminogen activator inhibitor-1 (PAI-1) by a pathway involving c-Src, PKCdelta, and sphingosine kinase 1 in glioblastoma cells.
Elevated fibroblast growth factor-inducible 14 expression transforms proneural-like gliomas into more aggressive and lethal brain cancer.
Expression of calmodulin-dependent phosphodiesterase, calmodulin-dependent protein phosphatase, and other calmodulin-binding proteins in human SMS-KCNR neuroblastoma cells.
Expression of heterogeneous profiles of plasminogen activators and plasminogen activator inhibitors by human glioma lines.
Expression of Progesterone Receptor Membrane Component 1 (PGRMC1), Progestin and AdipoQ Receptor 7 (PAQPR7), and Plasminogen Activator Inhibitor 1 RNA-Binding Protein (PAIRBP1) in Glioma Spheroids In Vitro.
Expression of the proteolytic factors, tPA and uPA, PAI-1 and VEGF during malignant glioma progression.
Functional effect of contortrostatin, a snake venom disintegrin, on human glioma cell invasion in vitro.
Genetic and plasma markers of venous thromboembolism in patients with high grade glioma.
High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas.
Human glioma U-251 cells contain type 1 plasminogen activator inhibitor in a rapidly releasable form.
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis.
Influence of microwave irradiation on cultured glioma cells I. An enzymatic and scanning electron microscopy study.
Interrelationship between differentiation and malignancy-associated properties in glioma.
Lipopolysaccharide enhancement of 12-o-tetradecanoylphorbol 13-acetate-mediated transformation in rat glioma C6, accompanied by induction of inducible nitric oxide synthase.
Mis-trafficking of endosomal urokinase proteins triggers drug-induced glioma nonapoptotic cell death.
Modulation of tissue-type plasminogen activator expression by platelet activating factor in human glioma cells.
Plasminogen activator and inhibitor activity in human glioma cells and modulation by sodium butyrate.
Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells.
Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.
Plasminogen activators and inhibitors in gliomas: an immunohistochemical study.
Production and Post-Surgical Modification of VEGF, tPA and PAI-1 in Patients with Glioma.
Prognostic significance of proteolytic enzymes in human brain tumors.
Protein kinase C alpha, delta, epsilon and zeta in C6 glioma cells. TPA induces translocation and down-regulation of conventional and new PKC isoforms but not atypical PKC zeta.
Regulation of alternative splicing of Bcl-x by IL-6, GM-CSF and TPA.
Response of malignant glioma cell lines to activation and inhibition of protein kinase C-mediated pathways.
Simultaneous up-regulation of urokinase-type plasminogen activator (uPA) and uPA receptor by hepatocyte growth factor/scatter factor in human glioma cells.
The effect of phorbol ester treatment on migration of C3H 10T1/2 and BT5C glioma cells: possible application to carcinogenesis.
The mechanical and pharmacological regulation of glioblastoma cell migration in 3D matrices.
The pleiotropic effect of TPA on in vitro invasion/migration of glioma and melanoma cell lines.
The role of protein kinase C in migration of rat glioma cells from spheroid cultures.
Tissue-type plasminogen activator has antiangiogenic properties without effect on tumor growth in a rat C6 glioma model.
Tristetraprolin Inhibits the Growth of Human Glioma Cells through Downregulation of Urokinase Plasminogen Activator/Urokinase Plasminogen Activator Receptor mRNAs.
VEGF and tPA co-expressed in malignant glioma.
Glomerulonephritis
A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis.
A streptococcal plasminogen activator in the focus of infection and in the kidneys during the initial phase of experimental streptococcal glomerulonephritis.
Dysfunction of glomerular fibrinolysis in experimental antiglomerular basement membrane antibody glomerulonephritis.
Expression and clinical significance of thrombospondin-1 and plasminogen activator inhibitor-1 in patients with mesangial proliferative glomerulonephritis.
Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis.
Expression of transforming growth factor-beta isoforms in human glomerular diseases.
Induction of plasminogen activator inhibitor type 1 in murine lupus-like glomerulonephritis.
Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrome.
Loquat leaf polysaccharides improve glomerular injury in rats with anti-Thy 1 nephritis via peroxisome proliferator-activated receptor alpha pathway.
Loss of heparin-binding protein prevents necrotizing glomerulonephritis: first clues hint at plasminogen activator inhibitor-1.
Midkine in nephrogenesis, hypertension and kidney diseases.
mRNA expression of urokinase and plasminogen activator inhibitor-1 in human crescentic glomerulonephritis.
Plasminogen activator in nephrotic syndrome.
Plasminogen activator inhibitor type 1: the two faces of the same coin.
Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis.
Role of plasminogen activator inhibitor on nephrotoxic nephritis and its modulation by tumor necrosis factor.
Tissue factor, plasminogen activator inhibitor-1, and thrombin receptor expression in human crescentic glomerulonephritis.
Tissue plasminogen activator therapy of rabbit nephrotoxic nephritis.
Tissue-type plasminogen activator and its inhibitor in human glomerulonephritis.
Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta.
Urinary UK, t-PA and urinary trypsin inhibitor in health and glomerular diseases.
Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis.
Vitronectin dictates intraglomerular fibrinolysis in immune-mediated glomerulonephritis.
[Fibrinolytic activity of the urine during chronic glomerulonephritis and amyloidosis]
[Fibrinolytic and peripheral serotonergic system in patients with glomerulonephritis]
[Studies on cortical tissue plasminogen activator in renal disease. Part I: Studies in the glomerulonephritis (author's transl)]
[Urokinase as a blood and urine plasminogen activator in chronic glomerulonephritis and amyloidosis]
Glomerulonephritis, IGA
Association between plasminogen activator inhibitor-1 4G/5G gene polymorphism and immunoglobulin A nephropathy susceptibility.
Close relationship of plasminogen activator inhibitor-1 4G/5G polymorphism and progression of IgA nephropathy.
Determination of tissue type plasminogen activator in the glomeruli of patients with IgA nephropathy.
Impact of the -675 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene on childhood IgA nephropathy.
Glomerulonephritis, Membranoproliferative
Protease nexin-1, tPA, and PAI-1 are upregulated in cryoglobulinemic membranoproliferative glomerulonephritis.
Glomerulonephritis, Membranous
Acute inferior vena cava thrombosis in a patient with membranous nephropathy treated by rt-PA lysis.
Alternative therapies and future intervention for treatment of membranous nephropathy.
Impact of plasminogen activator inhibitor-1 gene polymorphisms on primary membranous nephropathy.
The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy.
Glomerulosclerosis, Focal Segmental
Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis.
[Effects of Shensu II Recipe on the expressions of transforming growth factor-beta1, and plasminogen activator inhibitor-1 in the focal segmental glomerulosclerosis rats].
Glucose Intolerance
Brief review: hypertension in pregnancy : a manifestation of the insulin resistance syndrome?
Cardiovascular risk factors and the prediabetic syndrome.
Differences in risk factors, atherosclerosis and cardiovascular disease between ethnic groups in Canada: the study of health assessment and risk in ethnic groups (SHARE).
Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE)
Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease.
Effects of dietary fat modification on fibrinogen, factor VII, and plasminogen activator inhibitor-1 activity in subjects with impaired glucose tolerance.
Effects of gemfibrozil therapy on glucose tolerance, insulin sensitivity and plasma plasminogen activator inhibitor activity in hypertriglyceridaemia.
Glucagon as a determinant of fibrinolytic activity in men with different stages of glucose tolerance: impact of glucagon on fibrinolysis.
Hormone replacement therapy: prothrombotic vs. protective effects.
Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study.
Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study.
Interrelations between carbohydrates, lipids, and the hemostatic system in relation to the risk of thrombotic and cardiovascular disease.
Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease.
Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome.
Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS).
Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP).
Short-term effects of air temperature on blood markers of coagulation and inflammation in potentially susceptible individuals.
The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance.
The effect of plasminogen activator inhibitor-1 -675 4G/5G polymorphism on PAI-1 gene expression and adipocyte differentiation.
The metabolic syndrome and progression of carotid atherosclerosis over 13 years. The Tromso study.
[Evolution of fibrinolysis status with D-dimer level and the rate of plasminogen activator inhibitor type-1/D-dimer in acute coronary syndrome patients complicated with impaired glucose tolerance]
Goiter
Clinical evaluation of serum tissue polypeptide specific antigen in patients with thyroid carcinoma.
Management of airway compromise following thyroid cyst hemorrhage after thrombolytic therapy.
Thyroid peroxidase, thyroglobulin, cAMP and DNA in human thyroid.
Gout
Enzymes approved for human therapy: indications, mechanisms and adverse effects.
Increased frequency of metabolic syndrome and its individual metabolic abnormalities in Japanese patients with primary gout.
Not only the Sugar, Early infarct sign, hyperDense middle cerebral artery, Age, Neurologic deficit score but also atrial fibrillation is predictive for symptomatic intracranial hemorrhage after intravenous recombinant tissue plasminogen activator.
Graft vs Host Disease
Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications.
[Activation of endothelium-dependent hemostatic factors following bone marrow transplantation]
Granuloma
Anti-inflammatory activity of Lippia dulcis.
Detection of granuloma-associated plasminogen activator in experimental murine schistosomiasis.
Inactivity of fecapentaene-12 as a rodent carcinogen or tumor initiator.
Plasminogen activator and plasminogen activator inhibitor associated with granulomatous inflammation: a study with murine leprosy.
Plasminogen activator of the blood vessels in tumours and in carrageenin-induced granulomas.
Granulomatosis with Polyangiitis
Hemorrhagic conversion after alteplase administration in a patient with vasculitis and acute ischemic stroke.
New target antigens for anti-endothelial cell antibodies.
Granulomatous Disease, Chronic
Cytoplasmic pH regulation in normal and abnormal neutrophils. Role of superoxide generation and Na+/H+ exchange.
Graves Disease
Impaired release of tissue plasminogen activator from the endothelium in Graves' disease - indicator of endothelial dysfunction and reduced fibrinolytic capacity.
Graves Ophthalmopathy
The 4G/5G Polymorphism of Plasminogen Activator Inhibitor Type 1 is a Predictor of Moderate-to-Severe Thyroid Eye Disease.
Gray Platelet Syndrome
Grey platelet syndrome: evidence for alpha-granule localization of the platelet plasminogen activator inhibitor-1 pool.
Growth Hormone-Secreting Pituitary Adenoma
Phorbol ester and phospholipase C-induced growth hormone secretion from pituitary somatotroph adenoma cells in culture: effects of somatostatin, bromocriptine, and pertussis toxin.
Hamartoma
[Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients]
Hamartoma Syndrome, Multiple
Transcatheter embolization of arteriovenous malformations in Cowden disease.
Head and Neck Neoplasms
Plasminogen activator inhibitor-1 as regulator of tumor-initiating cell properties in head and neck cancers.
Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression.
Use of serum markers in the diagnosis and management of laryngeal cancer.
Use of tumor markers in the management of head and neck cancer.
[Measurement of serum tissue polypeptide antigen (TPA) in patients with malignant tumor using prolifigen TPA-M "Daiichi" kit]
Hearing Loss
Intravenous infusion of recombinant tissue plasminogen activator for the treatment of patients with sudden and/or chronic hearing loss.
Restoration of hearing loss with tissue plasminogen activator. Case report.
The use of recombinant tissue-type plasminogen activator for the treatment of sudden and chronic hearing loss.
Hearing Loss, Sensorineural
Association between the 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene and sudden sensorineural hearing loss in Caucasian population: a meta-analysis.
Association of the 4?g/5?g polymorphism of plasminogen activator inhibitor-1 gene with sudden sensorineural hearing loss. A case control study.
Hearing Loss, Sudden
Intravenous infusion of recombinant tissue plasminogen activator for the treatment of patients with sudden and/or chronic hearing loss.
The use of recombinant tissue-type plasminogen activator for the treatment of sudden and chronic hearing loss.
[Fibrinolytic therapy in sudden deafness with recombinant tissue-type plasminogen activator. Hemorheologic and therapeutic effects]
Heart Arrest
"Real-World" Application of Thrombolysis in Cardiac Arrest.
Benefits of thrombolytics in prolonged cardiac arrest and hypothermia over its bleeding risk.
Cardiac arrest following massive pulmonary embolism during mechanical declotting of thrombosed hemodialysis fistula: successful resuscitation with tPA.
Central Venous Catheter-directed Tissue Plasminogen Activator in Massive Pulmonary Embolism.
Changes of fibrinolytic system in thrombolytic resuscitation of pulmonary thromboembolism-induced cardiac arrest model.
Characterization of alteplase therapy for presumed or confirmed pulmonary embolism during cardiac arrest.
Complete Cognitive Recovery and Survival From Massive Pulmonary Embolism During General Anesthesia after Administration of Alteplase: A Case Report.
Disseminated intravascular coagulation in cardiac arrest and resuscitation.
Double Bolus Alteplase Therapy during Cardiopulmonary Resuscitation for Cardiac Arrest due to Massive Pulmonary Embolism Guided by Focused Bedside Echocardiography.
Double Bolus Thrombolysis for Suspected Massive Pulmonary Embolism during Cardiac Arrest.
Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial.
Erythropoietin: Powerful protection of ischemic and post-ischemic brain.
Evaluation of Rescue Thrombolysis in Cardiac Arrest Secondary to Suspected or Confirmed Pulmonary Embolism.
Heparin but not tissue plasminogen activator improves outcomes in DCD liver transplantation in a porcine model.
Improving patient outcomes from acute cardiovascular events through regionalized systems of care.
Massive fibrin formation with consecutive impairment of fibrinolysis in patients with out-of-hospital cardiac arrest.
Massive pulmonary embolism with cardiac arrest in pregnancy: A case report.
Mechanical cardiopulmonary resuscitation for venoarterial ECMO implantation in pulmonary embolism complicated by type B aortic dissection and retroperitoneal hemorrhage.
Multiple boluses of alteplase followed by extracorporeal membrane oxygenation for massive pulmonary embolism.
Neurologically normal survival after fibrinolysis during prolonged cardiac arrest: case report and discussion.
Neuron-specific enolase and S-100B are associated with neurologic outcome after pediatric cardiac arrest.
Outcome of out-of-hospital cardiac arrest after fibrinolysis with reteplase in comparison to the return of spontaneous circulation after cardiac arrest score in a geographic region without emergency coronary intervention.
Pulmonary embolism with cardiac arrest: a STEMI patient's unexpected course.
Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics.
Rapid induction of cerebral hypothermia by aortic flush during normovolemic cardiac arrest in pigs.
Successful alteplase bolus administration for a presumed massive pulmonary embolism during cardiopulmonary resuscitation.
Successful treatment of pulmonary embolism-induced cardiac arrest by thrombolysis and targeted temperature management during pregnancy.
Tenecteplase and return of spontaneous circulation after refractory cardiopulmonary arrest.
Therapeutic hypothermia for stroke: Where to go?
Thrombolysis and use of argatroban for the treatment of massive pulmonary embolism following anticoagulation failure in a patient with COVID-19.
Thrombolysis using plasminogen activator and heparin reduces cerebral no-reflow after resuscitation from cardiac arrest: an experimental study in the cat.
Thrombolytic therapy of massive pulmonary embolism during prolonged cardiac arrest using recombinant tissue-type plasminogen activator.
Tissue plasminogen activator in cardiac arrest with pulseless electrical activity.
Tissue Plasminogen Activator Use in Cardiac Arrest Secondary to Fulminant Pulmonary Embolism.
Translational research in acute central nervous system injury: lessons learned and the future.
Usefulness of thrombolysis in cardiac arrest secondary to suspected or confirmed pulmonary embolism.
[A successful lytic treatment of a perioperative pulmonary embolism necessitating resuscitation using recombinant tissue-type plasminogen activator]
[Acute heart arrest during urologic routine interventions in 2 cases. Interdisciplinary crisis management assures tumor-free survival despite fulminant lung embolism with acute heart arrest during thoraco-abdominal tumor nephrectomy and radical cystoprostatovesiculectomy]
[Bolus injection of recombinant tissue-type plasminogen activator during cardiopulmonary resuscitation in massive pulmonary embolism complicated with heart arrest. Report of 2 cases and review of the literature]
[Cardiac arrest caused by massive pulmonary embolism during treatment with tranexamic acid].
[Effects of thrombolytic therapy in patients with cardiac arrest from suspected pulmonary thromboembolism].
[Successful cardiopulmonary resuscitation with a high-dosage bolus injection of rt-PA after fulminant pulmonary embolism]
Heart Block
Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI II.
Heart Defects, Congenital
Effective tranexamic acid concentration for 95% inhibition of tissue-type plasminogen activator induced hyperfibrinolysis in children with congenital heart disease: A prospective, controlled, in-vitro study.
Intra-atrial tissue plasminogen activator infusion for prosthetic valve thrombosis.
Long-term treatment of plastic bronchitis with aerosolized tissue plasminogen activator in a Fontan patient.
Pulmonary blood flow regulates plasma tissue plasminogen activator concentrations in patients with congenital heart defects.
Heart Diseases
Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating factor in men with ischaemic heart disease.
Clot lysis: role of plasminogen activator inhibitors in haemostasis and therapy.
Effect of early intravenous rt-PA on infarct size estimated from serum enzyme activity: results from the TEAHAT Study.
Effects of gemfibrozil therapy on glucose tolerance, insulin sensitivity and plasma plasminogen activator inhibitor activity in hypertriglyceridaemia.
Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN).
Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study.
Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Haemostatic variables in Pacific Islanders apparently free from stroke and ischaemic heart disease--the Kitava Study.
Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study.
Increased plasminogen activator inhibitor and tissue plasminogen activator levels in subjects with electrocardiographic abnormality indicative of ischaemic heart disease: a cross-sectional study in Norsjö, Sweden.
Interaction of fibrinolysis and prothrombotic risk factors in neonates, infants and children with and without thromboembolism and underlying cardiac disease. a prospective study.
Interrelationship between coagulant activity and tissue-type plasminogen activator (t-PA) system in acute ischaemic heart disease. Possible role of the endothelium.
Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice.
Plasma resistance to activated protein C regulates the activation of coagulation induced by thrombolysis in patients with ischaemic heart disease.
Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
Plasminogen activator inhibitor-1, the acute phase response and vitamin C.
Possible role of vascular intima for generation of coagulant activity in patients undergoing coronary thrombolysis with recombinant tissue-type plasminogen activator. A randomized, placebo-controlled study.
Regulation of tissue-type plasminogen activator-mediated fibrinolysis by plasminogen activator inhibitor type-1 in patients with ischaemic heart disease: possible unfavourable effect of diuretics.
Role of plasminogen activator inhibitor type 1 in the pathogenesis of coronary artery diseases.
Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease.
The long-term effects of metoprolol and epanolol on tissue-type plasminogen activator and plasminogen activator inhibitor 1 in patients with ischaemic heart disease.
von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis.
[Plasmin-mediated activation of the coagulation system. A study of patients with acute ischemic heart disease treated with recombinant tissue-plasminogen activator]
Heart Failure
A comparative study of captopril and enalapril on endothelial cell function in congestive heart failure patients.
A Prothrombotic State in Patients With a History of Left Ventricular Thrombus.
Abnormalities of pathways of fibrin turnover in the human pleural space.
Admission levels of C-reactive protein and plasminogen activator inhibitor-1 in patients with acute myocardial infarction with and without cardiogenic shock or heart failure on admission.
Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction.
Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3 Investigators.
Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction.
B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure.
Biomarkers of Inflammation, Fibrosis, and Acute Kidney Injury in Patients with Heart Failure with and without Left Ventricular Assist Device Implantation.
CA 125 and its relation to cardiac function.
Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study. Anglo-Scandinavian Study of Early Thrombolysis.
Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure.
Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure - a COMET substudy.
ERK1/2 mediates the lipopolysaccharide-induced upregulation of FGF-2, uPA, MMP-2, MMP-9 and cellular migration in cardiac fibroblasts.
Experience with the use of tPA in the treatment of acute myocardial infarction.
Fibrinolytic activity in coronary heart disease.
Global secretome analysis of resident cardiac progenitor cells from wild-type and transgenic heart failure mice: Why ambience matters.
How cost-effective are new preventive strategies for cardiovascular disease?
Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial.
Inflammatory and metalloproteinases profiles predict three-month poor outcomes in ischemic stroke treated with thrombolysis.
Intracardiac thrombus formation with rapidly progressive heart failure in the neonate: treatment with tissue type plasminogen activator.
Intraoperative Thrombolysis of Massive Pulmonary Embolus During Spine Surgery: Case Report of Survival Complicated by Massive Bleeding and Review of the Literature.
Irreversible Inhibition of Serine Proteases - Design and In Vivo Activity of Diaryl alpha-Aminophosphonate Derivatives.
Lanoteplase.
Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in H9c2 cardiomyoblast cells.
Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice.
Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy.
Pathogenesis of venous thromboembolism: when the cup runneth over.
PATHOPHYSIOLOGICAL AND ATHOMORPHOLOGICAL ASPECTS OF RELAPSE OF VARICOSE VEINS AFTER ENDOVASCULAR LASER VEIN COAGULATION.
Peripheral vascular smooth muscle responsiveness to tumour-promoting phorbol esters in pacing-induced heart failure.
Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients.
Prediction of event-free survival after hospital discharge in acute myocardial infarction treated with tissue-plasminogen activator.
Procoagulant state in heart failure with preserved left ventricular ejection fraction.
Prognostic impact of haemostatic derangements in chronic heart failure.
Proteomic exploration of common pathophysiological pathways in diabetes and cardiovascular disease.
Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics.
ST-elevation myocardial infarction associated with acute ischemic stroke.
Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors.
The Prevalence and Impact of Mortality of the Acute Respiratory Distress Syndrome on Admissions of Patients With Ischemic Stroke in the United States.
The renin angiotensin system and endothelial dysfunction in chronic heart failure: role of endogenous fibrinolysis.
The use of tissue-type plasminogen activator for acute myocardial infarction in the elderly: results from thrombolysis in myocardial infarction Phase I, open label studies and the Thrombolysis in Myocardial Infarction Phase II pilot study. The TIMI Investigators.
Tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty: one-year TIMI phase II pilot results. TIMI Investigators.
Tissue plasminogen activator on admission is an important predictor of 30-day mortality in patients with acute myocardial infarction undergoing primary angioplasty.
Tissue plasminogen activator release in chronic venous hypertension due to heart failure.
[Comparative assessment of efficacy of tissue plasminogen activator and streptokinase in the treatment of patients with acute myocardial infarction]
[Late thrombolysis in acute myocardial infarct: short and long term effects on left ventricular function]
[Tumor cell embolism to pulmonary arteries]
Heart Failure, Diastolic
Loss of insulin receptor substrate-1 signaling induces the cardiovascular and proteo(fibrino)lytic system derangements typical of insulin resistance.
Heart Neoplasms
Neurological Complications of Cardiac Tumors.
Heart Rupture
Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy (LATE) study.
Enhanced expression of plasminogen activator inhibitor may prevent cardiac rupture in female and castrated mice after myocardial infarction.
Postinfarction cardiac rupture despite immediate reperfusion therapy in a patient with severe aortic valve stenosis.
Successful Low-Dose tPA for Mechanical Mitral Valve Thrombosis in a Patient with Postinfarction Contained Left Ventricular Free Wall Rupture.
[A rare case of coronary artery perforation by a PTCA guide wire complicating with postinfarction cardiac rupture after thrombolytic therapy]
Heart Septal Defects, Atrial
Chronic Thromboembolic Pulmonary Hypertension Secondary to Thrombophilia and Incidentally Diagnosed Atrial Septal Defect.
Heart Septal Defects, Ventricular
Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators.
Thrombolysis of a modified Blalock-Taussig shunt with recombinant tissue plasminogen activator in a newborn infant with pulmonary atresia and ventricular septal defect.
Heart Valve Diseases
Not only the Sugar, Early infarct sign, hyperDense middle cerebral artery, Age, Neurologic deficit score but also atrial fibrillation is predictive for symptomatic intracranial hemorrhage after intravenous recombinant tissue plasminogen activator.
HELLP Syndrome
Clinical and haemostatic parameters in the HELLP syndrome: relevance of plasminogen activator inhibitors.
Proteases and their inhibitors are indicative in gestational disease.
The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with HELLP syndrome.
The Role of Fibrinolytic and Antifibrinolytic Activities in the Pathophysiology of HELLP Syndrome.
Tumor markers in hypertensive disorders of pregnancy.
[Changes in fibrinolysis-associated parameters in HELLP syndrome]
Hemangioblastoma
Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Hemangioma
Vascular complications in Chuvash polycythemia.
Hemangioma, Cavernous
Immunohistochemically identifiable tissue plasminogen activator in cavernous angioma: mechanism for re-hemorrhage and lesion growth.
Hemangioma, Cavernous, Central Nervous System
Safety of thrombolysis in patients with acute ischemic stroke and cerebral cavernous malformations.
Hemangiosarcoma
Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice.
Hematologic Neoplasms
Abundant urokinase activity on the surface of mononuclear cells from blood and bone marrow of acute leukemia patients.
Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate.
Can biomarkers of coagulation, platelet activation, and inflammation predict mortality in patients with hematological malignancies?
CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review.
Changes in levels of t-PA and alpha 2PI-plasmin complex in plasma in patients with DIC.
Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator.
Plasminogen activator as a prognostic factor in hematological malignancies.
Recombinant human tissue plasminogen activator for the treatment of established severe venocclusive disease of the liver after bone marrow transplantation.
Thrombin Generation among Sudanese Patients with Hematological Malignancies.
[Plasma concentrations of plasminogen activator inhibitor 2 in patients with hematological malignancies and their clinical significance]
[The significance of plasminogen activator inhibitor 2 in patients with hematologic malignancies]
Hematoma, Subdural
In Reply to the Letter to the Editor Regarding "Subdural Catheter Injection of Tissue Plasminogen Activator for Residual Hematoma Post Drainage of Acute-on-Chronic Subdural Hematoma: Novel Case Report of 2 Patients".
Intracatheter Tissue Plasminogen Activator for Chronic Subdural Hematomas after Failed Bedside Twist Drill Craniostomy: A Retrospective Review.
Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial.
Letter to the Editor Regarding "Subdural Catheter Injection of Tissue Plasminogen Activator for Residual Hematoma Post Drainage of Acute-on-Chronic Subdural Hematoma: Novel Case Report of 2 Patients".
Spinal subdural hematoma following tissue plasminogen activator treatment for acute ischemic stroke.
Subdural Catheter Injection of Tissue Plasminogen Activator for Residual Hematoma Post Drainage of Acute-on-Chronic Subdural Hematoma: Novel Case Report of 2 Patients.
Subdural Instillation of a Thrombolytic Agent for Treatment of Recurrent Subdural Hematoma.
Hematoma, Subdural, Acute
Delayed recurrence of acute subdural hematoma in a patient with plasminogen activator inhibitor mutation.
Subdural Catheter Injection of Tissue Plasminogen Activator for Residual Hematoma Post Drainage of Acute-on-Chronic Subdural Hematoma: Novel Case Report of 2 Patients.
Hematoma, Subdural, Chronic
Immunohistochemical localization of tissue-type plasminogen activator in the lining wall of chronic subdural hematoma.
Intracatheter Tissue Plasminogen Activator for Chronic Subdural Hematomas after Failed Bedside Twist Drill Craniostomy: A Retrospective Review.
Minimally Invasive Subacute to Chronic Subdural Hematoma Evacuation with Angled Matchstick Drill and Repurposed Antibiotic Ventriculostomy Catheter Augmented with Alteplase: A Technical Case Report.
Recurrence-Free Chronic Subdural Hematomas: A Retrospective Analysis of the Instillation of Tissue Plasminogen Activator in Addition to Twist Drill or Burr Hole Drainage in the Treatment of Chronic Subdural Hematomas.
Relationship between tissue plasminogen activator, plasminogen activator inhibitor and CT image in chronic subdural hematoma.
Safe Use of Tissue Plasminogen Activator in Conjunction with the Integra Camino Bolt for the Drainage of Chronic Subdural Hematoma.
Subdural Catheter Injection of Tissue Plasminogen Activator for Residual Hematoma Post Drainage of Acute-on-Chronic Subdural Hematoma: Novel Case Report of 2 Patients.
Tissue plasminogen activator in chronic subdural hematomas as a predictor of recurrence.
Tissue-type plasminogen activator in the chronic subdural hematoma.
[The role of tissue plasminogen activator in chronic subdural hematomas]
Hematuria
Focus on urinary bladder cancer markers: a review.
Successful treatment of acute inferior vena cava and unilateral renal vein thrombosis by local infusion of recombinant tissue plasminogen activator.
[Massive pulmonary embolism treated with a reduced dose of alteplase in a patient with acute renal failure.]
Hemianopsia
Acute posterior ischemic optic neuropathy mimicking posterior cerebral artery stroke visualized by 3-tesla MRI.
Late resolution of diffusion-weighted MRI changes in a patient with prolonged reversible ischemic neurological deficit after thrombolytic therapy.
Hemiplegia
Dissolution of emboli in rats with experimental cerebral thromboembolism by recombinant human tissue plasminogen activator (TD-2061).
Emergency superficial temporal artery to middle cerebral artery bypass after intravenous recombinant tissue plasminogen activator administration for acute cerebral ischemia in a patient with moyamoya disease.
Emergent Carotid Artery Stenting Following Intravenous Alteplase Infusion After Rapid Negative Diagnosis for COVID-19 by Loop-Mediated Isothermal Amplification Assay.
Endovascular treatment of an acute left middle cerebral artery >6 h post stroke in a patient presenting with dysphasia and dense right hemiplegia.
Hemiplegia and thrombolysis.
Not All Patients with Hemiplegia Need Alteplase: A Case of Hemiplegic Migraine.
Opalski Syndrome Treated with Intravenous Recombinant Tissue Type Plasminogen Activator-Case Report and Review of Literature.
Telemedicine physician providers: augmented acute stroke care delivery in rural Texas: an initial experience.
The dilemma of treating vertebrobasilar dolichoectasia.
[Diagnostic image (162) A woman with temporary hemiplegia. Temporary embolic occlusion of the left middle cerebral artery by a thrombus]
[Patient with innominate artery steal accompanied with cerebral infarction]
Hemochromatosis
Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction.
Hemoglobinopathies
The role of hypercoagulability in the development of osteonecrosis of the femoral head.
Hemoglobinuria
Fibrinolytic therapy with rt-PA in a patient with paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome.
Recombinant tissue-plasminogen activator for acute Budd-Chiari syndrome secondary to paroxysmal nocturnal hemoglobinuria.
Hemoglobinuria, Paroxysmal
Fibrinolytic therapy with rt-PA in a patient with paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome.
Recombinant tissue-plasminogen activator for acute Budd-Chiari syndrome secondary to paroxysmal nocturnal hemoglobinuria.
Hemolytic-Uremic Syndrome
Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome.
Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome following allogeneic bone marrow transplantation.
Tissue plasminogen activator therapy of glomerular thrombi in the Shwartzman reaction.
[Human immunodeficiency virus and acute renal insufficiency]
Hemophilia A
Development and application of global assays of hyper- and hypofibrinolysis.
Emerging applications of aptamers for anticoagulation and hemostasis.
Factor VII and fibrinolytic response to deamino-8-D-argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease.
Inhibitory effects of lysine analogues on t-PA induced whole blood clot lysis.
Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia.
Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven) therapy in haemophilia A patients.
Proceedings: Hemophilia: modified by a post-exercise plasminogen activator.
Recombinant tissue plasminogen activator may reduce frequency of central venous access device infection in hemophilia patients undergoing immune tolerance therapy.
Solulin increases clot stability in whole blood from individuals and dogs with hemophilia.
The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration.
Updated analysis: central venous access device infection rates in an expanded cohort of paediatric patients with severe haemophilia receiving prophylactic recombinant tissue plasminogen activator.
Hemoptysis
A Case Report of Pulmonary Thromboendarterectomy for Chronic Thromboembolism in a Patient with Protein C Deficiency.
Fatal Hemoptysis during Coronary Thrombolysis.
Hemoptysis and unilateral intra-alveolar hemorrhage complicating intravenous thrombolysis for myocardial infarction.
Hemorrhagic Disorders
A new life-long hemorrhagic disorder due to excess plasminogen activator.
Hemorrhagic Fever with Renal Syndrome
Differential Regulation of PAI-1 in Hantavirus Cardiopulmonary Syndrome and Hemorrhagic Fever With Renal Syndrome.
Hemorrhagic Fever, Crimean
Evaluation of Prognostic Values of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Crimean-Congo Hemorrhagic Fever Patients.
Hemorrhagic Stroke
A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators.
Acute stroke therapy: beyond i.v. tPA.
An overview of the patency and stroke rates following thrombolysis with streptokinase, alteplase, and anistreplase used to treat an acute myocardial infarction.
ASPECTS-Region-Dependent Functional Outcomes after Endovascular Therapy in Patients with Cardioembolic Stroke.
Biomarkers for acute diagnosis and management of stroke in neurointensive care units.
Brain Drug Delivery Systems for the Stroke Intervention and Recovery.
CE: Acute Ischemic Stroke.
Clot-selective coronary thrombolysis with pro-urokinase.
Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators.
Immunotherapy blocking the tissue plasminogen activator-dependent activation of N-methyl-d-aspartate glutamate receptors improves hemorrhagic stroke outcome.
Intravenous Thrombolysis for Stroke and Presumed Stroke in Human Immunodeficiency Virus-Infected Adults: A Retrospective, Multicenter US Study.
Involvement of SSAO/VAP-1 in oxygen-glucose deprivation-mediated damage using the endothelial hSSAO/VAP-1-expressing cells as experimental model of cerebral ischemia.
Methodologic challenges in the design and conduct of hyperacute stroke research.
Modern medical management of acute ischemic stroke.
National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate.
Neuroendovascular treatments/procedures: are they efficacious and have they improved patient outcomes poststroke?
Patency trials with reteplase (r-PA): what do they tell us?
Polymorphisms of coagulation factor XIII subunit A and risk of nonfatal hemorrhagic stroke in young white women.
Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators.
Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I Investigators.
Reteplase: a review of its use in the management of thrombotic occlusive disorders.
Systemic Thrombolysis, Catheter-Directed Thrombolysis, and Anticoagulation for Intermediate-risk Pulmonary Embolism: A Simulation Modeling Analysis.
Thrombolytic therapy for stroke.
Thrombolytics in VAD management - A single-center experience.
[How did the results of ECASS II influence clinical practice of treatment of acute stroke]
[Intravenous rt-PA for acute ischemic stroke: 69 consecutive patients managed in an emergency stroke centre]
[The endothelial dysfunction in patients with arterial hypertension after old hemorrhagic stroke.]
Hemothorax
Agitation Techniques to Enhance Drainage of Retained Hemothorax.
Effectiveness of Delayed Intrapleural Alteplase Instillation for Infected Residual Traumatic Hemothorax. Case Report.
Evaluation of chest tube administration of tissue plasminogen activator to treat retained hemothorax.
Hemothorax after the intravenous administration of tissue plasminogen activator in a patient with acute ischemic stroke and rib fractures.
Hemothorax following administration of intrapleural alteplase.
Hemothorax under thrombolytic therapy with recombinant tissue: plasminogen activator (rt-PA) in a 16-year-old girl.
Intrapleural fibrinolysis during pediatric extracorporeal life support.
Intrapleural r-tPA in Association with Low-Molecular Heparin May Cause Massive Hemothorax Resulting in Hypovolemia.
Intrapleural tissue plasminogen activator for complicated pleural effusions.
Intrapleural Tissue Plasminogen Activator for Traumatic Retained Hemothorax.
Spontaneous Hemothorax Resulting from Tissue Plasminogen Activator in a Patient with Ischemic Stroke and Unrecognized Recent Myocardial Infarction.
The use of thrombolytics in the management of complex pleural fluid collections.
Tissue plasminogen activator and pulmozyme for postoperative-retained hemothorax: A safe alternative to postoperative re-exploration.
[Endovenous thrombolysis in acute myocardial infarct. The experience in a community hospital. An analysis of 120 patients]
Hepatic Encephalopathy
Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA).
Hepatic Veno-Occlusive Disease
Alteplase for hepatic veno-occlusive disease after bone marrow transplantation.
Alteplase for hepatic veno-occlusive disease after bone-marrow transplantation.
Alteplase for hepatic veno-occlusive disease complicating bone-marrow transplantation.
Diagnosis of hepatic veno-occlusive disease by plasminogen activator inhibitor-1 plasma antigen levels: a prospective analysis in 350 allogeneic hematopoietic stem cell recipients.
Double treatment of severe hepatic veno-occlusive disease after allogeneic peripheral blood progenitor cell transplantation with recombinant tissue plasminogen activator.
Fatal hemorrhage after recombinant tissue plasminogen activator therapy for hepatic veno-occlusive disease complicating autologous BMT.
Hepatic veno-occlusive disease with severe capillary leakage after peripheral stem cell transplantation: treatment with recombinant plasminogen activator and C1-esterase inhibitor concentrate.
Hepatic Veno-Occlusive Disease: A Role for Tissue Plasminogen Activator?
Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation.
No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation.
Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation.
Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide.
Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients.
Recombinant human tissue plasminogen activator without heparin is effective in the treatment of hepatic veno-occlusive disease.
Recombinant tissue plasminogen activator (rTPA) for hepatic veno-occlusive disease after allogeneic BMT in a pediatric patient.
Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD).
Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment.
Reversal of severe hepatic veno-occlusive disease by combined plasma exchange and rt-PA treatment.
Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF).
The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation.
Treatment of hepatic veno-occlusive disease with low-dose tissue plasminogen activator: impact on coagulation profile.
[Treatment of hepatic veno-occlusive disease after bone marrow transplantation with recombinant human tissue plasminogen activator (rh-tPA)]
[Usefulness of serum plasminogen activator inhibitor-1 for diagnosis and monitoring of late-onset sinusoidal obstruction syndrome after allogeneic stem cell transplantation]
Hepatitis
Applications of cell culture for the improvement of human health.
Clinical evaluation of tissue plasminogen activator (t-PA) levels in patients with liver diseases.
Fibrogenesis in acute liver injuries.
Inflammatory markers and platelet aggregation tests as predictors of hemoglobin and endogenous erythropoietin levels in hemodialysis patients.
Observations on optimal conditions for lysis of whole blood clots and use of this assay as a screening assay in clinical investigation.
Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
The immune response to mouse hepatitis virus: expression of monocyte procoagulant activity and plasminogen activator during infection in vivo.
The value of serum concentrations of tissue polypeptide antigen in the diagnosis of hepatocellular carcinoma.
Thrombin and plasmin generation in patients with liver disease.
Tissue polypeptide antigen (TPA) in chronic active hepatitis and mild liver diseases.
Tissue polypeptide antigen (TPA) modifications in hepatic cirrhosis, aggressive chronic hepatitis, persistent chronic hepatitis, and in minimal pathology.
Use of TPA in hepatology of infectious nature. Initial observations.
[Clinical study on tissue polypeptide antigen (TPA) as a tumor marker]
[Course of the serum determination of 4 tumor markers in viral hepatitis]
[Qualitative analysis of tissue plasminogen activator in plasma obtained from various liver diseases by gel filtration and affinity chromatography]
[The clinical significance of plasma tissue plasminogen activator (t-PA) levels in severe acute or fulminant hepatitis]
Hepatitis A
Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
Hepatitis B
Clinical trials of gene/biotechnology products.
Continuous cell substrate considerations.
Drug products of recombinant DNA technology.
Enhancement of antibody responses to an HIV-2 DNA envelope vaccine using an expression vector containing a constitutive transport element.
Phosphatidylinositol 3-kinase is required for the regulation of hepatitis B surface antigen production and mitogen-activated protein kinase activation by insulin but not by TPA.
Safety issues related to the use of recombinant DNA-derived cell culture products. I. Cellular components.
Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients.
Hepatitis B, Chronic
[The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B]
Hepatitis C
Elevation of Plasminogen Activator Inhibitor-1 promotes differentiation of Cancer Stem-like Cell state by Hepatitis C Virus infection.
Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha.
Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model: role of the innate antiviral immune response.
Hepatitis C, Chronic
Link between plasminogen activator inhibitor-1 and cardiovascular risk in chronic hepatitis C after viral clearance.
[Changes in plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) by the interferon treatment for chronic hepatitis C]
Hepatitis E
Sexual Dimorphism in Hepatocyte Xenograft Models.
Hepatitis, Chronic
Alpha-fetoprotein and tissue polypeptide antigen in non neoplastic hepatic disorders.
Clinical evaluation of tissue plasminogen activator (t-PA) levels in patients with liver diseases.
Quantitation of tissue polypeptide antigen (TPA) in hepatic and systemic circulation in patients with chronic liver diseases.
The value of serum concentrations of tissue polypeptide antigen in the diagnosis of hepatocellular carcinoma.
Thrombin activation and increased fibrinolysis in patients with chronic liver disease.
Thrombin and plasmin generation in patients with liver disease.
Tissue polypeptide antigen (TPA) in chronic active hepatitis and mild liver diseases.
[Clinical study on tissue polypeptide antigen (TPA) as a tumor marker]
[Qualitative analysis of tissue plasminogen activator in plasma obtained from various liver diseases by gel filtration and affinity chromatography]
Hepatoblastoma
Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.
The activation of plasminogen activator inhibitor-1 expression by IL-1beta is attenuated by estrogen in hepatoblastoma HepG2 cells expressing estrogen receptor alpha.
Hepatopulmonary Syndrome
Mcp-1, eNOS, tPA and PAI-1 gene polymorphism and correlation of genotypes and phenotypes in hepatopulmonary syndrome.
Hereditary Complement Deficiency Diseases
Angioedema: A Life-threatening Complication of Tissue Plasminogen Activator.
Hernias, Diaphragmatic, Congenital
The use of alteplase in a newborn with an aortic arch thrombus during extracorporeal membrane oxygenation.
Herpes Simplex
Characterization of rat embryo cells transformed by ts mutants and sheared DNA of herpes simplex virus types 1 and 2 and a derived tumor cell line.
Herpes simplex virus decreases endothelial cell plasminogen activator inhibitor.
Herpesviruses enhance fibrin clot lysis.
Identification of the 12-O-tetradecanoylphorbol-13-acetate-responsive enhancer of the MS gene of the Epstein-Barr virus.
Phenotypic properties of herpesvirus-transformed cells with high tumorigenic and metastatic ability.
Production of plasminogen activator by cells transformed by herpesviruses.
Quantification of plasminogen activator activity associated with herpesvirus-transformed cells.
Herpes Zoster
A broad-spectrum matrix metalloproteinase inhibitor prevents hemorrhagic complications induced by tissue plasminogen activator in mice.
Antibodies generated in response to plasmid DNA encoding zona pellucida glycoprotein-B inhibit in vitro human sperm-egg binding.
Changes in the bovine zona pellucida induced by plasmin or embryonic plasminogen activator.
Characterization of immune response in mice to plasmid DNA encoding dog zona pellucida glycoprotein-3.
Effects of blastocoelic expansion and plasminogen activator activity on hatching and zona pellucida solubility in bovine embryos in vitro.
Effects of culture conditions on the developmental programme of mouse blastocysts.
Effects of Kaixinjieyu, a Chinese herbal medicine preparation, on neurovascular unit dysfunction in rats with vascular depression.
Identification and regulation of tissue plasminogen activator activity in rat cumulus-oocyte complexes.
Phosphorylation of atrial natriuretic factor R1 receptor by serine/threonine protein kinases: evidences for receptor regulation.
Protein kinase C enhances tight junction barrier function of human nasal epithelial cells in primary culture by transcriptional regulation.
Protein kinase C signal transduction pathway in ACTH-induced growth effect of rat adrenocortical cells in primary culture.
Receptor-Associated Prorenin System in the Trabecular Meshwork of Patients with Primary Open-Angle Glaucoma and Neovascular Glaucoma.
Relationship between plasminogen activator production and bovine embryo development in vitro.
Release of tissue-type plasminogen activator by activated rat eggs and its possible role in the zona reaction.
Stimulation of cortisol production in isolated bovine zona fasciculata cells by phorbol ester: role of ion fluxes.
Studies on the temporal correlation between secretion of plasminogen activator and stages of early mouse embryogenesis.
The effects of plasminogen on in vitro ovine embryo development.
The involvement of extracellular proteinases and proteinase inhibitors in mammalian fertilization.
Tissue plasminogen activator and neuropathy open the blood-nerve barrier with upregulation of microRNA-155-5p in male rats.
Histiocytic Sarcoma
Regulation of TNF-alpha and IL-1 gene expression during TPA-induced differentiation of "Malignant histiocytosis" DEL cell line t(5;6) (q35:p21).
[Plasma concentrations of plasminogen activator inhibitor 2 in patients with hematological malignancies and their clinical significance]
Histiocytoma, Malignant Fibrous
Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas.
Histiocytosis
[Peculiar increase of plasma plasminogen activator inhibitor 1 levels in patients with hemophagocytic histiocytosis]
[Plasma concentrations of plasminogen activator inhibitor 2 in patients with hematological malignancies and their clinical significance]
Histiocytosis, Langerhans-Cell
Production of plasminogen activator by alveolar macrophages in normal subjects and patients with interstitial lung disease.
HIV Infections
Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance.
Plasminogen Activator Inhibitor -1 (PAI-1) Predicts Negative Alterations in Whole Body Insulin Sensitivity in Chronic HIV Infection.
HIV-Associated Lipodystrophy Syndrome
Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines.
Hodgkin Disease
Protein Z (PZ) and plasminogen activator inhibitor-1 (PAI-1) plasma levels in patients with previously untreated Hodgkin lymphoma (HL).
Homocystinuria
Homocystinuria with Cerebral Venous Sinus Thrombosis: Excellent Recovery with Intravenous Recombinant Tissue Plasminogen Activator.
Huntington Disease
Tissue-type plasminogen activator is an extracellular mediator of Purkinje cell damage and altered gait.
[Transcriptional regulation of Huntington disease gene]
Hyaline Membrane Disease
Localization of plasminogen activator in neonatal lung in the presence of hyaline membrane disease.
Hydatidiform Mole
Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease.
Coagulation and fibrinolysis in intact hydatidiform molar pregnancy.
Does plasminogen activator inhibitor-1 (PAI-1) control trophoblast invasion? A study of fetal and maternal tissue in intrauterine, tubal and molar pregnancies.
Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, pre-eclampsia and hydatidiform mole.
Hydrocephalus
Cerebrospinal fluid plasminogen activator inhibitor-1: a prognostic factor in posthaemorrhagic hydrocephalus.
Intraventricular administration of human recombinant plasminogen activator for posthemorrhagic hydrocephalus of the newborn.
Intraventricular administration of recombinant tissue plasminogen activator for intraventricular hemorrhage in the newborn.
Intraventricular tissue plasminogen activator for the prevention of vasospasm and hydrocephalus after aneurysmal subarachnoid hemorrhage.
Morphological changes following experimental intraventricular haemorrhage and intraventricular fibrinolytic treatment with recombinant tissue plasminogen activator.
Phase I study of intraventricular recombinant tissue plasminogen activator for treatment of posthaemorrhagic hydrocephalus.
Plasminogen activator inhibitor-1: defining characteristics in the cerebrospinal fluid of newborns.
Recombinant tissue plasminogen activator in the treatment of intraventricular hemorrhage secondary to periventricular arteriovenous malformation before surgery: case report.
Ruptured saccular aneurysm of distal vertebral artery fenestration managed with Guglielmi detachable coils and intraventricular tissue plasminogen activator.
Safety and outcomes of decompressive craniectomy after intravenous tissue plasminogen activator administration for malignant cerebral infarction.
Stereotactic evacuation of hypertensive cerebellar hemorrhage using plasminogen activator.
Subacute hydrocephalus after experimental subarachnoid hemorrhage: its prevention by intrathecal fibrinolysis with recombinant tissue plasminogen activator.
Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Traumatic intraventricular hemorrhage treated with intraventricular recombinant-tissue plasminogen activator: technical case report.
Use of intraventricular tissue plasminogen activator and Guglielmi detachable coiling for the acute treatment of casted ventricles from cerebral aneurysm hemorrhage: two technical case reports.
[Treatment of intraventricular hemorrhage and hydrocephalus.]
[Treatment of posthemorrhagic hydrocephalus with intraventricular administration of recombinant plasminogen activator (rt-PA) and dexamethasone--possible prevention of permanent shunt implantation?]
Hyperalgesia
Annexin A2 in primary afferents contributes to neuropathic pain associated with tissue type plasminogen activator.
Antinociceptive properties of mixture of alpha-amyrin and beta-amyrin triterpenes: evidence for participation of protein kinase C and protein kinase A pathways.
Lysophosphatidic acid LPA1 and LPA3 receptors play roles in the maintenance of late tissue plasminogen activator-induced central poststroke pain in mice.
Tissue plasminogen activator and neuropathy open the blood-nerve barrier with upregulation of microRNA-155-5p in male rats.
Tissue plasminogen activator contributes to morphine tolerance and induces mechanical allodynia via astrocytic IL-1? and ERK signaling in the spinal cord of mice.
Tissue plasminogen activator in primary afferents induces dorsal horn excitability and pain response after peripheral nerve injury.
Tissue type plasminogen activator induced in rat dorsal horn astrocytes contributes to mechanical hypersensitivity following dorsal root injury.
Hyperandrogenism
Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system.
Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome.
Hypercholesterolemia
Activated factor XII levels are dependent on factor XII 46C/T genotypes and factor XII zymogen levels, and are associated with vascular risk factors in patients and healthy subjects.
Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease.
Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia.
Hemostatic effects of simvastatin in subjects with impaired glucose tolerance.
Icariin attenuates the enhanced prothrombotic state in atherosclerotic rabbits independently of its lipid-lowering effects.
Laboratory markers of hypercoagulability.
Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia.
Local intraarterial fibrinolysis administered in aliquots for the treatment of central retinal artery occlusion: the Johns Hopkins Hospital experience.
Low-density lipoproteins induce the polar secretion of PAI-1 by endothelial cells in culture.
Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
Potentiation by hypercholesterolemia of the induction of aortic intramural synthesis of plasminogen activator inhibitor type 1 by endothelial injury.
Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 expression of glomerular mesangial cells in hypercholesterolemic rabbits.
The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients.
[Effect of hypercholesteremia on vascular endothelial function and albumin excretion rate in patients with diabetes mellitus]
Hyperemia
Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis.
Gastric cytoprotection by tetraprenylacetone in human subjects.
Opening the window: Ischemic postconditioning reduces the hyperemic response of delayed tissue plasminogen activator and extends its therapeutic time window in an embolic stroke model.
Oral glucose tolerance response curve predicts disposition index but not other cardiometabolic risk factors in healthy adolescents.
Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients.
Post-challenge hyperglycemia in older adults is associated with increased cardiovascular risk profile.
Reactive hyperemia and tissue-type plasminogen activator release in hypertensive men.
Salvage of a congested DIEAP flap with subcutaneous recombinant tissue plasminogen activator treatment.
The ADP receptor P2Y(1) mediates t-PA release in pigs during cardiac ischemia.
tPA deficiency underlies neurovascular coupling dysfunction by amyloid-?.
Transient brain hypothermia reduces the reperfusion injury of delayed tissue plasminogen activator and extends its therapeutic time window in a focal embolic stroke model.
Vitamin C affects thrombosis/ fibrinolysis system and reactive hyperemia in patients with type 2 diabetes and coronary artery disease.
[The protective effects of Radix Astragali and Rhizoma Ligustici chuanxiong on endothelial dysfunction in type 2 diabetic patients with microalbuminuria]
Hyperferritinemia
Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases.
Hyperglycemia
Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat.
Admission hyperglycemia and outcome after intravenous thrombolysis: is there a difference among the stroke-subtypes?
Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis.
Association of Acute and Chronic Hyperglycemia With Acute Ischemic Stroke Outcomes Post-Thrombolysis: Findings From Get With The Guidelines-Stroke.
Baseline diabetic status and admission blood glucose were poor prognostic factors in the EPITHET trial.
Brain capillary tissue plasminogen activator in a diabetes stroke model.
Cerebrovascular Complications of Diabetes: Focus on Stroke.
Clinical Outcome of Patients With Large Vessel Occlusion and Low National Institutes of Health Stroke Scale Scores: Subanalysis of the RESCUE-Japan Registry 2.
Coagulation markers and functional outcome in acute ischemic stroke: Impact of intensive versus standard hyperglycemia control.
Comparative Analysis of Different Methods of Ischemia/Reperfusion in Hyperglycemic Stroke Outcomes: Interaction with tPA.
Diabetes Mellitus/Poststroke Hyperglycemia: a Detrimental Factor for tPA Thrombolytic Stroke Therapy.
Early insulin glycemic control combined with tPA thrombolysis reduces acute brain tissue damages in a focal embolic stroke model of diabetic rats.
Early Neurological Deterioration within 24 Hours after Intravenous rt-PA Therapy for Stroke Patients: The Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
Effect of hyperglycemia on stroke outcome is not homogeneous to all patients treated with mechanical thrombectomy.
Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients.
Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats.
Endothelial dysfunction in metabolic syndrome.
Endothelium-specific SIRT1 overexpression inhibits hyperglycemia-induced upregulation of vascular cell senescence.
Factors predicting hemorrhagic complications after multimodal reperfusion therapy for acute ischemic stroke.
Hemostasis and glycemic control in the cardiac surgical patient.
Hyperglycemia during ischemia rapidly accelerates brain damage in stroke patients treated with tPA.
Hyperglycemia modulates plasminogen activator inhibitor-1 expression and aortic diameter in experimental aortic aneurysm disease.
Hyperglycemia promotes tissue plasminogen activator-induced hemorrhage by Increasing superoxide production.
Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans.
Hyperglycemia Worsens Outcome After rt-PA Primarily in the Large-Vessel Occlusive Stroke Subtype.
Hyperglycemia, Acute Ischemic Stroke, and Thrombolytic Therapy.
Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation.
Impact of admission hyperglycemia on stroke outcome after thrombolysis: risk stratification in relation to time to reperfusion.
Impaired fasting glucose is associated with unfavorable outcome in ischemic stroke patients treated with intravenous alteplase.
Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects.
Nurse-Initiated Acute Stroke Care in Emergency Departments.
Phosphorylated recombinant HSP27 protects the brain and attenuates blood-brain barrier disruption following stroke in mice receiving intravenous tissue-plasminogen activator.
Postprandial hyperglycemia alters inflammatory and hemostatic parameters.
Predisposing factors to post-operative adhesion development.
Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises.
Psychosocial stress and the insulin resistance syndrome.
Reactive oxygen species, reactive nitrogen species and antioxidants in etiopathogenesis of diabetes mellitus type-2.
Role of altered coagulation-fibrinolytic system in the pathophysiology of diabetic retinopathy.
Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.
Sp1 sites mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in vascular smooth muscle cells.
The correlation between admission blood glucose and intravenous rt-PA-induced arterial recanalization in acute ischemic stroke: a multi-centre TCD study.
The silver effect of admission glucose level on excellent outcome in thrombolysed stroke patients.
Tissue Plasminogen Activator Promotes TXNIP-NLRP3 Inflammasome Activation after Hyperglycemic Stroke in Mice.
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Verapamil as an Adjunct Therapy to Reduce tPA Toxicity in Hyperglycemic Stroke: Implication of TXNIP/NLRP3 Inflammasome.
[Hyperglycemia: a predictor of poor prognosis in acute stroke]
Hyperhomocysteinemia
Assessment of hemostatic risk factors in predicting arterial thrombotic events.
Bilateral Acute Renal Infarction Secondary to Methylene Tetrahydrofolate Reductase A1298C and PAI-1 Mutation.
Cardiovascular and thrombophilic risk factors for central retinal vein occlusion.
Dysfunction in the coagulation system and schizophrenia.
Homocysteine and hemostatic disorder as a risk factor for myocardial infarction at a young age.
Inherited thrombophilias in pregnant patients: detection and treatment paradigm.
Interaction of smoking, hyperhomocysteinemia, and metabolic syndrome with carotid atherosclerosis: A cross-sectional study in 972 non-diabetic patients.
Methionine-induced hyperhomocysteinemia reverts fibrinolytic pathway activation in a murine model of acute promyelocytic leukemia.
Multifactorial Painful Leg Ulcers Due to Hyperhomocysteinemia, Plasminogen Activator Inhibitor-1 4G/5G Heterozygote Gene Mutation, and Beta Thalassemia Minor: A Case Report.
Multiple roles of tissue plasminogen activator in schizophrenia pathophysiology.
Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach.
Risk-factor profile in severe, generalized, obliterating vascular disease.
Thrombophilic risk factors for retinal vein occlusion.
Thrombosis and occlusion of vascular access in hemodialyzed patients.
[Femoral and humeral head osteonecrosis in a patient with hypofibrinolysis and hyperhomocysteinemia. A case report and a review of the literature]
Hyperinsulinism
Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system.
Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat.
Anxiety-Related Bleeding and Thrombosis.
Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states.
Brief review: hypertension in pregnancy : a manifestation of the insulin resistance syndrome?
Cellular and molecular mechanisms of vascular injury in diabetes - Part I: Pathways of vascular disease in diabetes.
Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults.
Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy.
Dysfunction in the coagulation system and schizophrenia.
Effect of angiotensin II receptor blockade on fibrinolysis during acute hyperinsulinemia in patients with essential hypertension.
Effect of hyperinsulinemia and very-low-calorie diet on interstitial cytokine levels in subcutaneous adipose tissue of obese women.
Effects of metformin and metoprolol CR on hormones and fibrinolytic variables during a hyperinsulinemic, euglycemic clamp in man.
Endothelial dysfunction in metabolic syndrome.
Estrogen-progestin oral contraceptive and nicotine exposure synergistically confers cardio-renoprotection in female Wistar rats.
Forkhead transcription factor FoxO1 inhibits insulin- and transforming growth factor-beta-stimulated plasminogen activator inhibitor-1 expression.
Hemostasis and glycemic control in the cardiac surgical patient.
Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans.
Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population: the Northern Sweden MONICA Study.
Hypofibrinolysis and the insulin resistance syndrome.
Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance.
Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.
Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects.
Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.
Insulin and PAI-1 levels during oral glucose tolerance test in patients with coronary heart disease.
Insulin resistance and elevated levels of tissue plasminogen activator in first-degree relatives of South Asian patients with ischemic cerebrovascular disease.
Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
Insulin sensitivity, insulin action, and fibrinolysis activity in nondiabetic and diabetic obese subjects.
Interrelations between carbohydrates, lipids, and the hemostatic system in relation to the risk of thrombotic and cardiovascular disease.
Local insulin infusion stimulates expression of plasminogen activator inhibitor-1 and tissue-type plasminogen activator in normal subjects.
Metabolic interrelationships, cardiovascular disease, and sex steroids.
Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.
Obesity, microalbuminuria, hyperinsulinemia, and increased plasminogen activator inhibitor 1 activity associated with parasympathetic neuropathy in type 2 diabetes.
Plasma plasminogen activator inhibitor-1 activity in normoglycemic hypertriglyceridemic north Asian Indian subjects: a preliminary case-control study.
Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin.
Psychosocial stress and the insulin resistance syndrome.
Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients.
The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance.
The Deidesheimer meeting: significance of classical and new risk factors in non-insulin-dependent diabetes mellitus.
The MAPK pathway and HIF-1 are involved in the induction of the human PAI-1 gene expression by insulin in the human hepatoma cell line HepG2.
Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1.
[Theoretical aspects of the relationship between diabetic macroangiopathy and hyperinsulinism]
Hyperkalemia
Prospective evaluation of tissue plasminogen activator in 11 cats with arterial thromboembolism.
Hyperlipidemia, Familial Combined
Endothelial haemostatic markers in members of families with familial combined hyperlipidemia.
Hyperlipidemias
A new life-long hemorrhagic disorder due to excess plasminogen activator.
Brief review: hypertension in pregnancy : a manifestation of the insulin resistance syndrome?
Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease.
Dietary fat and postprandial lipids.
Effect of bezafibrate on hypercoagulability assessed by fluorogenic prothrombin time in hyperlipidemic patients with non-insulin-dependent diabetes mellitus.
Effects and mechanism of tissue-type plasminogen activator and plasminogen activator inhibitor on vascular smooth muscle cell proliferation.
Endothelial haemostatic markers in members of families with familial combined hyperlipidemia.
Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients.
Fibrinolytic activity in Chinese patients with diabetes or hyperlipidemia in comparison with healthy controls.
Icariin attenuates the enhanced prothrombotic state in atherosclerotic rabbits independently of its lipid-lowering effects.
Impaired fibrinolytic system in ApoE gene-deleted mice with hyperlipidemia augments deep vein thrombosis.
Intravenous Thrombolysis Is Safe and Effective for the Cryptogenic Stroke in China: Data From the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China).
Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias.
Lipoprotein (a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes.
Osteonecrosis induced by a single administration of low-dose lipopolysaccharide in rabbits.
Perilla oil and exercise decrease expressions of tumor necrosis factor-alpha, plasminogen activator inhibitor-1 and highly sensitive C-reactive protein in patients with hyperlipidemia.
Plasminogen Activator Inhibitor-1 Deficiency Ameliorates Insulin Resistance and Hyperlipidemia but not Bone Loss in Obese Female Mice.
Platelet activation supports the development of venous thrombosis in hyperlipidemic rats.
Postprandial lipoprotein(a) is affected differently by specific individual dietary fatty acids in healthy young men.
Proxisome proliferator-activated receptor-? mediates high-fat, diet-enhanced daily oscillation of plasminogen activator inhibitor-1 activity in mice.
Relationship between thyroid hormones and plasma D-dimer levels.
Retinoids and fibrinolysis.
Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients.
Stroke severity and outcomes for octogenarians receiving statins.
The impact of postprandial lipemia in accelerating atherothrombosis.
The Prognostic Value of Homocysteine in Acute Ischemic Stroke Patients: A Systematic Review and Meta-Analysis.
The tissue plasminogen activator and plasma fibrinolysis in diet induced lipemia in rats.
[Monoclonal antibody therapy for disorders of hemostasis and coagulation]
Hyperlipoproteinemia Type II
Hemostatic variables in homozygous familial hypercholesterolemia. Effect of regular plasma cholesterol removal by low density lipoprotein apheresis.
Hyperlipoproteinemias
Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein.
[Evaluation of platelet function and tissue plasminogen activator activity in ischemic heart disease depending on concurrence with hyperlipoproteinemia and aspirin therapy]
Hyperparathyroidism, Primary
Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
Hyperphosphatemia
Alteplase as hemodialysis catheter locking solution and spurious hyperphosphatemia.
Hyperprolactinemia
Induction of specific gelatinolytic proteinases in the lateral prostate of rats by ectopic pituitary grafts.
Hypersensitivity
Analysis of related factors of orolingual angioedema after rt-PA intravenous thrombolytic therapy.
Anti-inflammatory and antioxidant properties of Helichrysum italicum.
Cell-mediated immune response in mice during the two-step carcinogenesis experiment by 7,12-dimethylbenz(a)anthracene and 12-O-tetradecanoylphorbol-13-acetate.
Clot activators do not expedite the time to predict massive transfusion in trauma patients analyzed with tissue plasminogen activator thrombelastography.
Comparative safety of thrombolytic agents.
Comparing Pathways of Bradykinin Formation in Whole Blood From Healthy Volunteers and Patients With Hereditary Angioedema Due to C1 Inhibitor Deficiency.
Drug eruptions and isotypic antibody responses to streptokinase after infusions of anisoylated plasminogen-streptokinase complex (APSAC, anistreplase).
Evidence of anaphylaxy after alteplase infusion.
Evolving concepts in the treatment of acute myocardial infarction.
Fibrinolysis shutdown is associated with a fivefold increase in mortality in trauma patients lacking hypersensitivity to tissue plasminogen activator.
Hemobiological activity of gliclazide in diabetes mellitus.
Hypersensitivity reactions associated with recombinant tissue-type plasminogen activator and urokinase.
Hypersensitivity reactions to recombinant tissue plasminogen activator.
Incidence of urticaria, angioedema, and type I hypersensitivity reactions associated with fibrinolytic agents in Thailand using the database of the health product vigilance center.
Lysophosphatidic acid LPA1 and LPA3 receptors play roles in the maintenance of late tissue plasminogen activator-induced central poststroke pain in mice.
Mechanisms of graft acceptance: evidence that plasminogen activator controls donor-reactive delayed-type hypersensitivity responses in cardiac allograft acceptor mice.
Mega-trials and equivalence trials: experience from the INJECT study.
Oropharyngeal angioneurotic edema due to recombinant tissue plasminogen activator following massive pulmonary thromboembolism.
Plasminogen activator and plasminogen activator inhibitor associated with granulomatous inflammation: a study with murine leprosy.
Properties of a novel plasminogen activator (BM 06.022) produced in Escherichia coli.
Protection of plasminogen activator inhibitor-1-deficient mice from nasal allergy.
Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism.
Resistance to skin tumorigenesis in DNAPK-deficient SCID mice is not due to immunodeficiency but results from hypersensitivity to TPA-induced apoptosis.
The molecular basis of thrombolysis and its clinical application in stroke.
The urokinase system in patients with intermittent and persistent allergic rhinitis.
Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Thrombolytic treatment (alteplase; rt-Pa) in acute massive pulmonary embolism and cardiopulmonary arrest.
Tissue plasminogen activator contributes to morphine tolerance and induces mechanical allodynia via astrocytic IL-1? and ERK signaling in the spinal cord of mice.
Tissue type plasminogen activator induced in rat dorsal horn astrocytes contributes to mechanical hypersensitivity following dorsal root injury.
[A randomized study of streptokinase and recombinant tissue plasminogen activator, with and without heparin, in patients with acute myocardial infarction. The results of GISSI-2/International tPA/SK Mortality Trial]
[Cardiovascular pharmacology (XIII). The efficacy of different thrombolytic drugs in the treatment of acute myocardial infarct]
[Comparison of clinical efficacy of thrombolytic drugs in patients with acute myocardial infarction]
Hypersensitivity, Delayed
Effect of the basidiomycete Poria cocos on experimental dermatitis and other inflammatory conditions.
Hypersensitivity, Immediate
Incidence of urticaria, angioedema, and type I hypersensitivity reactions associated with fibrinolytic agents in Thailand using the database of the health product vigilance center.
Hypertension
4B.06: EFFECT OF CHRONIC KIDNEY DISEASE, DYSLIPIDEMIA AND HYPERTENSION ON CAROTID ATHEROSCLEROSIS IN ELDERLY PATIENTS WITH TYPE 2 DIABETES.
4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke.
A left MCA territory infarction during intravenous recombinant tissue plasminogen activator therapy for right MCA territory ischaemic stroke.
A pilot protocol and review of triple neuroprotection with targeted hypothermia, controlled induced hypertension, and barbiturate infusion during emergency carotid endarterectomy for acute stroke after failed tPA or beyond 24-hour window of opportunity.
A role for tissue plasminogen activator in thrombotic thrombocytopenic purpura.
Abnormalities of fibrinolysis in essential hypertension.
ACE/DD genotype is associated with hemostasis balance disturbances reflecting hypercoagulability and endothelial dysfunction in patients with untreated hypertension.
Activated factor XII levels are dependent on factor XII 46C/T genotypes and factor XII zymogen levels, and are associated with vascular risk factors in patients and healthy subjects.
Acute haemorrhagic stroke.
Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1.
Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator and the risk of hypertension in a Chinese Han population.
Analysis of tissue plasminogen activator eligibility by sex in the greater cincinnati/northern kentucky stroke study.
Angioedema After tPA: What Neurointensivists Should Know.
Angioedema Secondary to tPA Use in Acute Ischemic Stroke Patient with Hypertension: A Case Report.
Antihypertensive drugs and fibrinolytic function.
Apelin elevates blood pressure in ICR mice with L?NAME?induced endothelial dysfunction.
Association of cardiovascular risk factors and endothelial dysfunction in japanese hypertensive patients: implications for early atherosclerosis.
Association of interleukin-6 gene G-174C polymorphism and plasma plasminogen activator inhibitor-1 level in Chinese patients with and without hypertension.
Association of parental hypertension with concentrations of select biomarkers in nonhypertensive offspring.
Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states.
Beneficial effects of metformin on haemostasis and vascular function in man.
Beta blockers, Lp(a), hypertension, and reduced basal fibrinolytic activity.
Biological risk factors for sudden death in patients with coronary artery disease and without heart failure.
Birth weight and the insulin resistance syndrome: association of low birth weight with truncal obesity and raised plasminogen activator inhibitor-1 but not with abdominal obesity or plasma lipid disturbances.
Bleeding risks, risk factors and management of bleeding complications after treatment with anticoagulants, specific antithrombins, thrombolytics IIb-IIIa receptor blockers.
Brain imaging abnormalities and outcome after acute ischaemic stroke: the ENCHANTED trial.
Brain Imaging Signs and Health-Related Quality of Life after Acute Ischemic Stroke: Analysis of ENCHANTED Alteplase Dose Arm.
Brain Natriuretic Peptide Is a Powerful Predictor of Outcome in Stroke Patients with Atrial Fibrillation?.
Cardiovascular disease and risk factors: the role of growth hormone.
Cardiovascular disease risk factors predict the development of type 2 diabetes: the insulin resistance atherosclerosis study.
Cardiovascular risk continuum: implications of insulin resistance and diabetes.
Cardiovascular risk factors in non-insulin-dependent diabetics compared to non-diabetic controls: a population-based survey among Asians in Singapore.
Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults.
Characteristics, management and response to alteplase in China versus non-China participants of the ENCHANTED trial.
Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience.
Clinical Utility of Electronic Alberta Stroke Program Early Computed Tomography Score Software in the ENCHANTED Trial Database.
Co-morbid conditions in use of recombinant tissue plasminogen activator (rt-PA) for the treatment of acute ischaemic stroke.
Collagen receptor- and metalloproteinase-dependent hypertensive stress response in mesangial and glomerular endothelial cells.
Comparative effects of low-dose versus standard-dose alteplase in ischemic patients with prior stroke and/or diabetes mellitus: The ENCHANTED trial.
Controversies in Thrombolysis.
Correlation between family history of hypertension and haemostatic disorders.
Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator.
Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression.
Differences between carotid wall morphological phenotypes measured by ultrasound in one, two and three dimensions.
Dominant-negative c-Jun inhibits rat cardiac hypertrophy induced by angiotensin II and hypertension.
Early computed tomography hypodensity predicts hemorrhage after intravenous tissue plasminogen activator in acute ischemic stroke.
Effects of Lisinopril, Irbesartan, and Amlodipine on the Thrombogenic Variables in the Early and Late Stages of the Treatment in Hypertensive Patients.
Effects of losartan and delapril on the fibrinolytic system in patients with mild to moderate hypertension.
Effects of the total physical activity and its changes on incidence, progression, and remission of hypertension.
Efficacy of olmesartan therapy on fibrinolytic capacity in patients with hypertension.
Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease.
Elevated plasma plasminogen activator inhibitor type-1 is an independent predictor of coronary microvascular dysfunction in hypertension.
Elevated tissue plasminogen activator antigen and stroke risk: The Stroke Prevention In Young Women Study.
Elevated tissue plasminogen activator in patients with screening-detected abdominal aortic aneurysm.
Elevation of plasminogen activator inhibitor 1 in borderline hypertension is linked to concomitant metabolic disturbances.
Endothelial haemostatic factors may be associated with mortality in patients on long-term anticoagulant treatment.
Endothelium-dependent vasodilation and tissue-type plasminogen activator release in borderline hypertension.
Enhanced levels of tissue-type plasminogen activator in borderline hypertension.
Epidemiology of diabetes and obesity in the United States.
Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease.
Exploring biomarkers associated with deteriorating vascular health using a targeted proteomics chip: The SABPA study.
Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke.
Feasibility of prehospital r-TPA therapy in chest pain patients.
Fenofibrate ameliorates insulin resistance, hypertension and novel oxidative stress markers in patients with metabolic syndrome.
Fibrinogen and plasminogen activator inhibitor-1 levels in hypertension and coronary heart disease. Potential effects of beta-blockade.
Fibrinolytic function after dietary supplementation with omega3 polyunsaturated fatty acids.
Frequency, determinants, and effects of early seizures after thrombolysis for acute ischemic stroke: The ENCHANTED trial.
Gender-specific association of the plasminogen activator inhibitor-1 4G/5G polymorphism with central arterial blood pressure.
Green tea polyphenols inhibit plasminogen activator inhibitor-1 expression and secretion in endothelial cells.
Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model.
Hemorrhagic Transformation during Thrombolytic Therapy and Reperfusion: Effects of Age, Blood Pressure, and Matrix Metalloproteinases.
Hemostasis and fibrinolysis factors in first-degree relatives of patients with Type 2 diabetes without hypertension.
High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.
High Prevalence of Diabetes and Prediabetes and Their Coexistence with Cardiovascular Risk Factors in a Hispanic Community.
History of hypertension and enhanced thrombogenic activity in postinfarction patients.
Hospital mortality from atrial fibrillation associated with ischemic stroke: a national data report.
Hourly blood pressure monitoring after intravenous tissue plasminogen activator for ischemic stroke: does everyone need it?
Hypertension and hemostatic/fibrinolytic balance disorders.
Hypertension and its treatment in the NINDS rt-PA Stroke Trial.
Hypertension as a metabolic disorder--an overview.
Impaired capacity for stimulated fibrinolysis in primary hypertension is restored by antihypertensive therapy.
Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertension.
Impaired fibrinolysis and insulin resistance in patients with hypertension.
Impaired fibrinolysis in hypertension and obesity due to high plasminogen activator inhibitor-1 level in plasma.
Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower enough?
In a stroke cohort with incident hypertension; are more women than men likely to be excluded from recombinant tissue-type Plasminogen Activator (rtPA)?
Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina.
Individual risk assessment for intracranial haemorrhage during thrombolytic therapy.
Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke: ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) Post Hoc Analysis.
Interaction of Blood Pressure Lowering and Alteplase Dose in Acute Ischemic Stroke: Results of the Enhanced Control of Hypertension and Thrombolysis Stroke Study.
Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction.
Intravenous Thrombolysis Is Safe and Effective for the Cryptogenic Stroke in China: Data From the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China).
Investigation of thrombomodulin and plasminogen activator inhibitor type-I in pregnancy induced hypertension and its clinical significance.
Is the effect of antihypertensive drugs on platelet aggregability and fibrinolysis clinically relevant?
Is the plasminogen activator inhibitor-1 gene a candidate gene predisposing to hypertension? Results from a population-based study in Spain.
Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin.
Lipid-Lowering Pretreatment and Outcome Following Intravenous Thrombolysis for Acute Ischaemic Stroke: A Post Hoc Analysis of the Enhanced Control of Hypertension and Thrombolysis Stroke Study Trial.
Local insulin infusion stimulates expression of plasminogen activator inhibitor-1 and tissue-type plasminogen activator in normal subjects.
Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study).
Low- versus Standard-Dose Intravenous Alteplase in the Context of Bridging Therapy for Acute Ischemic Stroke: A Korean ENCHANTED Study.
Low-Dose vs Standard-Dose Alteplase for Patients With Acute Ischemic Stroke: Secondary Analysis of the ENCHANTED Randomized Clinical Trial.
Low-Dose vs Standard-Dose Alteplase in Acute Lacunar Ischemic Stroke: The ENCHANTED Trial.
Maladaptive arterial remodeling with systemic hypertension associated with increased concentrations in blood of plasminogen activator inhibitor type-1 (PAI-1).
Management of dyslipidemia in adults with diabetes.
Markers of fibrinolysis may predict development of lower extremity arterial disease in patients with diabetes: A longitudinal prospective cohort study with 10?years of follow-up.
Microalbuminuria and endothelial dysfunction in essential hypertension.
Morphological Carotid Plaque Area Is Associated With Glomerular Filtration Rate: A Study of South Asian Indian Patients With Diabetes and Chronic Kidney Disease.
Multiple biomarkers and the risk of incident hypertension.
Multiple Heritable and Acquired Risk Factors in a Case of Recurrent Retinal Vein Occlusion.
Myocardial infarction following recombinant tissue plasminogen activator treatment for acute ischemic stroke: a dangerous complication.
New atherosclerosis risk factors in obese, hypertensive and diabetic children and adolescents.
P38 MAPK inhibitors suppress biomarkers of hypertension end-organ damage, osteopontin and plasminogen activator inhibitor-1.
Pathogenesis of vascular disease.
Performance of plasminogen activator inhibitor-1 as a biomarker in patients undergoing coronary angiography: Analytical and biological considerations.
Plasma plasminogen activator inhibitor 1 (PAI-1) and P-selectin levels in urgent hypertension: effect of single dose captopril and nifedipine on fibrinolytic activity.
Plasminogen activator inhibitor type 1 inhibits smooth muscle cell proliferation in pulmonary arterial hypertension.
Plasminogen Activator Inhibitor Type-1 Gene 4G/5G Polymorphism Is Associated with Hypertensive Patients in Turkish Population.
Plasminogen activator inhibitor-1 activity and the 4G/5G polymorphism are prospectively associated with blood pressure and hypertension status.
Plasminogen activator inhibitor-1 and angiotensin I converting enzyme gene polymorphism in patients with hypertension.
Plasminogen activator inhibitor-1 and carotid intima-media thickening in patients with newly detected primary hypertension.
Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice.
Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition.
Plasminogen activator inhibitor-1 in obstructive sleep apnea patients with and without hypertension.
Plasminogen Activator Inhibitor-1: A Novel Therapeutic Target for Hypertension?
Plasminogen activator Inhibitor-2 inhibits pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension via PI3K/Akt and ERK signaling.
Plasminogen activator of urokinase type and its inhibitor of placental type in hypertensive pregnancies and in intrauterine growth retardation: possible markers of placental function.
Plasminogen activators, venous leg ulcers and reepithelialization.
Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition.
Prevalence of the fibrinogen beta-chain, angiotensin-converting enzyme and plasminogen activator inhibitor-1 polymorphisms in Costa Rican young adults with thrombotic disease.
Prolonged cyclic strain impairs the fibrinolytic system in cultured vascular endothelial cells.
Psychosocial stress and the insulin resistance syndrome.
Pulmonary artery thromboembolism in a critically ill neonate successfully treated using thrombolytic therapy.
Quantitative measurement of carotid atherosclerosis in relation to levels of von Willebrand factor and fibrinolytic variables in plasma--a 2-year follow-up study.
Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2?×?2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment.
Re-canalization in acute ischemic stroke: the strategies.
Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease.
Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy.
Relationship between endothelial function and fibrinolysis in early hypertension.
Relationship between plasma plasminogen activator inhibitor-1 and hypertension in American Indians: findings from the Strong Heart Study.
Relationship of plasminogen activator inhibitor 1 gene 4G/5G polymorphisms to hypertension in Korean women.
Relationship of tissue plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen with coronary artery disease in South Indian male subjects.
Renoprotective Effects of Direct Renin Inhibition in Glomerulonephritis.
Review of the ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study): How Low Can We Go With Intravenous Tissue-Type Plasminogen Activator Dose and Blood Pressure Level?
Rosiglitazone: potential beneficial impact on cardiovascular disease.
S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood.
Serial measurements of circulating tissue plasminogen activator and fibrin(ogen) degradation products predict outcome in gestational proteinuric hypertension.
Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension.
Statistical analysis plan for evaluating different intensities of blood pressure control in the ENhanced Control of Hypertension And Thrombolysis strokE stuDy.
Statistical analysis plan for evaluating low- vs. standard-dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED).
Strategies to prevent hemorrhagic transformation after reperfusion therapies for acute ischemic stroke: A literature review.
Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries.
Stroke severity and outcomes for octogenarians receiving statins.
Stroke warning syndromes.
Suppression of endothelial t-PA expression by prolonged high laminar shear stress.
Surfer's Myelopathy : Case Series and Literature Review.
Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure.
Systolic blood pressure contributes to intracerebral haemorrhage after thrombolysis for ischemic stroke.
t-plasminogen activator inhibitor-1 polymorphism in idiopathic pulmonary arterial hypertension.
The Association of Periprocedural Hypertension and Adverse Outcomes in Patients Undergoing Catheter-directed Thrombolysis.
The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance.
The effect of experimental chronic hypertension on tissue plasminogen activator activity, plasminogen activator inhibition and plasmin inhibition.
The effects of the overexpression of recombinant uncoupling protein 2 on proliferation, migration and plasminogen activator inhibitor 1 expression in human vascular smooth muscle cells.
The metabolic syndrome - an ongoing story.
The metabolic syndrome and progression of carotid atherosclerosis over 13 years. The Tromso study.
The plasma levels of plasminogen activator inhibitor-1 in subjects with white coat hypertension.
The Prevalence and Impact of Mortality of the Acute Respiratory Distress Syndrome on Admissions of Patients With Ischemic Stroke in the United States.
The problem of strict image-based inclusion criteria for mechanical thrombectomy - an analysis of stroke patients with an initial low CBV-ASPECTS score.
The Prognostic Value of Homocysteine in Acute Ischemic Stroke Patients: A Systematic Review and Meta-Analysis.
The relationship among TAFI, t-PA, PAI-1 and F1?+?2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
The relationships between insulin and plasminogen activator inhibitor 1 levels: assessment in groups of subjects with dyslipidaemia and hypertension.
Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire.
Thrombolysis outcomes according to arterial characteristics of acute ischemic stroke by alteplase dose and blood pressure target.
Thrombosis and occlusion of vascular access in hemodialyzed patients.
Tissue plasminogen activator (tPA) activity is a novel and early marker of asymptomatic LEAD in type 2 diabetes.
Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris.
Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
Tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty: one-year TIMI phase II pilot results. TIMI Investigators.
Tissue plasminogen activator release in chronic venous hypertension due to heart failure.
Tumor markers in hypertensive disorders of pregnancy.
Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1.
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Type 2 diabetes: assessment of endothelial lesion and fibrinolytic system markers.
Utilization of intravenous thrombolysis is increasing in the United States.
Venous hypertension of the hand caused by hemodialysis shunt: immunofluorescence studies of pericapillary cuffs.
Who will benefit more from low-dose alteplase in acute ischemic stroke?
[ A rare complication of thrombolytic therapy: spinal epidural hematoma. A case report ]
[Cardiovascular risk factors in type 2 diabetes]
[Changes of relative variables about prethrombosis state and its clinical significance in patients with pregnancy induced hypertension]
[Clinical characteristics and management of patients with ST segment elevation myocardial infarction in China: survey of 7510 cases]
[Detection of kidney dysfunction potential biomarkers with hypertension in the persons of 25-45 years].
[Effect of electroacupuncture on renal fibrosis in spontaneously hypertension rats and its related mechanisms].
[Effects of Danshen injection on the reserve of tissue plasminogen activator and nitric oxide in endothelium and vasodilatation in diabetic patients]
[Hypertension and hyperuricemia]
[Metabolic syndrome and hyperlipidemia in HIV-positive patients]
[Study on thrombomodulin and plasminogen activator inhibitor type-1 in patients of pregnancy induced hypertension]
[The effect of doxazosin on blood pressure, lipids, fibrinogen and plasminogen activator inhibitor. A comparative study among smokers and non-smokers with essential hypertension]
[The endothelial dysfunction in patients with arterial hypertension after old hemorrhagic stroke.]
[The influence of I/D polymorphism of the angiotensin I converting enzyme (ACE) gene and 4G/5G polymorphism of plasminogen activator inhibitor (PAI-1) gene promoter on the haemostatic system in patients with essential hypertension and dyslipidemia]
[Thrombus in transit - two cases of patients with massive pulmonary embolism treated with thrombolysis]
Hypertension, Malignant
P38 MAPK inhibitors suppress biomarkers of hypertension end-organ damage, osteopontin and plasminogen activator inhibitor-1.
Hypertension, Portal
Effects of lysine vasopressin and glypressin on the fibrinolytic system in cirrhosis.
Ischemia reperfusion-facilitated sinusoidal endothelial cell injury in liver transplantation and the resulting impact of extravasated platelet aggregation.
Lack of relationship between plasma thrombomodulin and portal hypertension in alcoholic liver disease.
Quantitation of tissue polypeptide antigen (TPA) in hepatic and systemic circulation in patients with chronic liver diseases.
[Expression of plasminogen activator system components in the gastric mucosa in portal hypertensive gastropathy].
[Importance of portal hypertension in the release of tissue plasminogen activator (t-PA): experimental study in the rat]
Hypertension, Pregnancy-Induced
4G/5G Variant of Plasminogen Activator Inhibitor-1 Gene and Severe Pregnancy-Induced Hypertension: Subgroup Analyses of Variants of Angiotensinogen and Endothelial Nitric Oxide Synthase.
Effect of nitric oxide deficiency on tissue-type plasminogen activator expression in the umbilical cord in a pregnancy-induced hypertension rat model.
Investigation of thrombomodulin and plasminogen activator inhibitor type-I in pregnancy induced hypertension and its clinical significance.
Predictive value of increased plasma levels of fibronectin in gestational hypertension.
The search for thrombophilic gene mutations in women with gestational hypertension does not help in predicting poor pregnancy outcome.
Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.
[Changes of relative variables about prethrombosis state and its clinical significance in patients with pregnancy induced hypertension]
[Relationship between the 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and the pathogenesis of pregnancy-induced hypertension syndrome]
[Study on thrombomodulin and plasminogen activator inhibitor type-1 in patients of pregnancy induced hypertension]
Hypertension, Pulmonary
Altered hemostasis in pulmonary hypertension.
Coagulation and fibrinolytic parameters in patients with pulmonary hypertension.
Comparison of long-term outcomes of 50 and 100 mg rt-PA in the management of acute pulmonary thromboembolism.
Fibrinolytic system related to pulmonary arterial pressure and lung function of patients with idiopathic pulmonary fibrosis.
Low-Dose Alteplase for the Treatment of Submassive Pulmonary Embolism: A Case Series.
Peroxisome proliferator-activated receptor-?-mediated transcription of miR-301a and miR-454 and their host gene SKA2 regulates endothelin-1 and PAI-1 expression in sickle cell disease.
Rapid reversal of canine thromboembolic pulmonary hypertension by bolus injection of the novel recombinant plasminogen activator BM 06.022.
Recombinant tissue-type plasminogen activator in canine embolic pulmonary hypertension. Effects of bolus versus short-term administration on dynamics of thrombolysis and on pulmonary vascular pressure-flow characteristics.
Successful Treatment of Severe Mechanical Mitral Valve Thrombosis With Tissue Plasminogen Activator in a 7-Month-Old Infant.
Treatment of canine embolic pulmonary hypertension with recombinant tissue plasminogen activator. Efficacy of dosing regimes.
Use of thrombolytic drugs in non-coronary disorders.
[Chronic effects of 100 mg/2 hours recombinant tissue-type plasminogen activator therapy regimen for patients with acute pulmonary thromboembolism].
[Clinical study on qingning oral liquid in treating senile chronic obstructive pulmonary disease with pulmonary hypertension]
[Expression of PAI-2 mRNA in peripheral blood leucocytes and regulation by sGC activator in pulmonary hypertension].
[Thrombolytic therapy in the treatment of thromboembolism of the right cardiac cavity during pulmonary embolism: our experience with rt-PA and review of the literature]
Hyperthyroidism
Effects of Thyroid Function on Hemostasis, Coagulation, and Fibrinolysis: A Mendelian Randomization Study.
Impaired release of tissue plasminogen activator from the endothelium in Graves' disease - indicator of endothelial dysfunction and reduced fibrinolytic capacity.
Increased adipose tissue secretion of interleukin-6, but not of leptin, plasminogen activator inhibitor-1 or tumour necrosis factor alpha, in Graves' hyperthyroidism.
Is thyroid hormone suppression therapy prothrombotic?
Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders.
Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
Thyroid peroxidase, thyroglobulin, cAMP and DNA in human thyroid.
Tissue plasminogen activator (PA) and urokinase inhibitor in the tissue of neutral and hyperthyroid goitre.
Hypertriglyceridemia
Cardiovascular risk continuum: implications of insulin resistance and diabetes.
Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults.
Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease.
Effect of individual dietary fatty acids on postprandial activation of blood coagulation factor VII and fibrinolysis in healthy young men.
Endothelial dysfunction in metabolic syndrome.
Gemfibrozil predictably lowers triglycerides but does not significantly change plasminogen activator inhibitor activity in hypertriglyceridemic patients with a history of thrombosis.
Hypertriglyceridemic VLDL downregulates tissue plasminogen activator gene transcription through cis-repressive region(s) in the tissue plasminogen activator promoter in cultured human endothelial cells.
Hypofibrinolysis and the insulin resistance syndrome.
Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects.
Interrelations between carbohydrates, lipids, and the hemostatic system in relation to the risk of thrombotic and cardiovascular disease.
Levels of three hemostatic factors in relation to serum lipids. Monocyte procoagulant activity, tissue plasminogen activator, and type-1 plasminogen activator inhibitor.
No Influence of acute hypertriglyceridemia on plasma t-PA in healthy male volunteers.
Plasma plasminogen activator inhibitor-1 activity in normoglycemic hypertriglyceridemic north Asian Indian subjects: a preliminary case-control study.
Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease.
Role of insulin and proinsulin in diabetic vascular disease.
The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance.
Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia.
Hypertrophy, Left Ventricular
Coagulative and fibrinolytic changes in patients with essential hypertension and the effect of sustained-release nifedipine.
Impact of ?-thalassemia trait carrier state on cardiovascular risk factors and metabolic profile in patients with newly diagnosed hypertension.
Increased gene expression of plasminogen activators and inhibitors in left ventricular hypertrophy.
Review of the molecular pharmacology of Losartan and its possible relevance to stroke prevention in patients with hypertension.
Hypertrophy, Right Ventricular
Secretion of cardiac plasminogen activator during hypoxia-induced right ventricular hypertrophy.
Serum copper concentration as an index of cardiopulmonary injury in monocrotaline-treated rats.
Hyperventilation
Increased plasma plasminogen activator inhibitor activity after coronary spasm.
Hypervitaminosis A
Modulation of tissue-type plasminogen activator by retinoids in rat plasma and tissues.
Hypesthesia
Spinal Epidural Hematoma as a Complication of Intravenous Thrombolysis in an Acute Ischemic Stroke Patient.
Hyphema
Intracameral tissue plasminogen activator use in a large series of eyes with valved glaucoma drainage implants.
Intraocular tissue plasminogen activator in a rabbit model of traumatic hyphema.
Intravitreal tissue plasminogen activator treatment of experimental vitreous hemorrhage.
Low-dose intraocular tissue plasminogen activator treatment for traumatic total hyphema, postcataract, and penetrating keratoplasty fibrinous membranes.
Rebleeding in experimental traumatic hyphema treated with intraocular tissue plasminogen activator.
Tissue plasminogen activator for postvitrectomy fibrin formation.
Tissue plasminogen activator for preserving inferior peripheral iridectomy patency in eyes with silicone oil.
Tissue plasminogen activator in the trabecular endothelium.
Topical treatment of postvitrectomy fibrin formation with tissue plasminogen activator.
Treatment of failing glaucoma filtering cystic blebs with tissue plasminogen activator (tPA).
Treatment of post-traumatic trabecular mashwork thrombosis and secondary glaucoma with intracameral tissue plasminogen activator in previously unrecognized sickle cell anemia.
Treatment of total hyphema with relatively low-dose tissue plasminogen activator.
Use of tissue plasminogen activator in experimental hyphema.
[Treatment of anterior segment fibrinous reactions and hemorrhage with intracameral low dose rt-PA: clinical study and review of the literature]
[Treatment with tissue plasminogen activator (tPA) in risk patients with fibrin reactions after cataract operations]
Hypobetalipoproteinemias
Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham offspring population.
Hypocalcemia
Regulation of parathyroid hormone gene expression and peptide secretion in human parathyroid cells.
Hypoglycemia
Effects of acute hypoglycemia on inflammatory and pro-atherothrombotic biomarkers in individuals with type 1 diabetes and healthy individuals.
Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study.
Periprocedural Risk of Stroke Is Elevated in Patients with End-Stage Renal Disease on Hemodialysis.
Tissue-type plasminogen activator is a neuroprotectant in the central nervous system.
Hypogonadism
Effects of androgens on haemostasis.
Hypokinesia
Intrathoracic pulmonary artery catheter allocation in the background of left atrial dilatation.
Hyponatremia
Periprocedural Risk of Stroke Is Elevated in Patients with End-Stage Renal Disease on Hemodialysis.
Hypoplastic Left Heart Syndrome
Fontan patient with plastic bronchitis treated successfully using aerosolized tissue plasminogen activator: a case report and review of the literature.
Intracoronary recombinant tissue plasminogen activator in an infant with hypoplastic left heart syndrome and complete left main coronary artery thrombosis.
Hypotension
A Case of Oropharyngeal Angioedema Following Intravenous Recombinant Tissue Plasminogen Activator (rt-PA) and Mechanical Thrombectomy.
Age relations of cardiovascular risk factors in a traditional Melanesian society: the Kitava Study.
Analysis of related factors of orolingual angioedema after rt-PA intravenous thrombolytic therapy.
Anaphylactoid reaction to recombinant tissue plasminogen activator.
Cardiovascular Instability Preceded by Orolingual Angioedema after Alteplase Treatment.
Combination therapy with glucagon and a novel plasminogen activator inhibitor-1-derived peptide enhances protection against impaired cerebrovasodilation during hypotension after traumatic brain injury through inhibition of ERK and JNK MAPK.
Comparative safety of thrombolytic agents.
Comparative tolerability profiles of thrombolytic agents. A review.
Early tPA treatment and aeromedical transport of patients with acute myocardial infarction.
Evaluation and comparison of the adverse effects of streptokinase and alteplase.
Evidence of anaphylaxy after alteplase infusion.
Glucagon Protects Against Impaired NMDA-Mediated Cerebrovasodilation and Cerebral Autoregulation during Hypotension after Brain Injury by Activating cAMP Protein Kinase A and Inhibiting Upregulation of tPA.
Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial.
Intraaortic balloon counterpulsation enhances coronary thrombolysis induced by intravenous administration of a thrombolytic agent.
Intraoperative Thrombolysis of Massive Pulmonary Embolus During Spine Surgery: Case Report of Survival Complicated by Massive Bleeding and Review of the Literature.
Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator.
Nitrous oxide inhalant abuse and massive pulmonary embolism in COVID-19.
PAI-1 derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia.
PAI-1-derived peptide EEIIMD prevents hypoxia/ischemia-induced aggravation of endothelin- and thromboxane-induced cerebrovasoconstriction.
Periprocedural Risk of Stroke Is Elevated in Patients with End-Stage Renal Disease on Hemodialysis.
Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics.
RBC-coupled tPA Prevents Whereas tPA Aggravates JNK MAPK-Mediated Impairment of ATP- and Ca-Sensitive K Channel-Mediated Cerebrovasodilation After Cerebral Photothrombosis.
Red blood cell-coupled tissue plasminogen activator prevents impairment of cerebral vasodilatory responses through inhibition of c-Jun-N-terminal kinase and potentiation of p38 mitogen-activated protein kinase after cerebral photothrombosis in the newborn pig.
Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation.
Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. The Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators.
Role of platelet-activating factor in hypotension and platelet activation induced by infusion of thrombolytic agents in rabbits.
Should thrombolysis be contraindicated in patients with cerebral arteriovenous malformations?
Thrombolytic Therapy by Tissue Plasminogen Activator for Pulmonary Embolism.
Thrombolytic therapy in cardiogenic shock: effect of increased aortic pressure and rapid tPA administration.
tPA contributes to impairment of ATP and Ca sensitive K channel mediated cerebrovasodilation after hypoxia/ischemia through upregulation of ERK MAPK.
[Comparative assessment of efficacy of tissue plasminogen activator and streptokinase in the treatment of patients with acute myocardial infarction]
[Comparison of clinical efficacy of thrombolytic drugs in patients with acute myocardial infarction]
[Delayed Diagnosis of Aortic Dissection Following Thrombolytic Therapy in a Patient with Acute Ischemic Stroke;Report of a Case].
[Fatal central pulmonary embolism under heparin therapy: white-clot syndrome]
Hypothyroidism
Acquired von Willebrand's syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism.
Case Report: Placental Maternal Vascular Malperfusion Affecting Late Fetal Development and Multiorgan Infection Caused by SARS-CoV-2 in Patient With PAI-1 4G/5G Polymorphism.
Effect of levothyroxine replacement therapy on coagulation and fibrinolysis in severe hypothyroidism.
Effects of Thyroid Function on Hemostasis, Coagulation, and Fibrinolysis: A Mendelian Randomization Study.
Experimental hypothyroidism increases plasminogen activator inhibitor activity in rat plasma.
Hemostasis in Hypothyroidism and Autoimmune Thyroid Disorders.
Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
Neonatal hypothyroidism alters the pattern of prostatic growth and differentiation, as well as plasminogen activator and metalloprotease expression, in the rat.
Hypoxia-Ischemia, Brain
Neonatal cerebral hypoxia-ischemia in mice triggers age-dependent vascular effects and disabilities in adults; implication of tissue plasminogen activator (tPA).
Therapeutic hypothermia for stroke: Where to go?
Ichthyosis
Plasminogen activator inhibitor-2 is expressed in different types of congenital ichthyosis: in vivo evidence for its cross-linking into the cornified cell envelope by transglutaminase-1.
Idiopathic Interstitial Pneumonias
A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia.
Idiopathic Pulmonary Fibrosis
Fibrinolytic system related to pulmonary arterial pressure and lung function of patients with idiopathic pulmonary fibrosis.
Idiopathic pulmonary fibrosis in relation to gene polymorphisms of transforming growth factor-?1 and plasminogen activator inhibitor 1.
Increased alveolar plasminogen activator in early asbestosis.
Inhibition of Myocardin-Related Transcription Factor/Serum Response Factor Signaling Decreases Lung Fibrosis and Promotes Mesenchymal Cell Apoptosis.
PLASMA BIOMARKER PROFILES IN ACUTE EXACERBATION OF IDIOPATHIC PULMONARY FIBROSIS.
Production of plasminogen activator by alveolar macrophages in normal subjects and patients with interstitial lung disease.
tPA promotes the proliferation of lung fibroblasts and activates the Wnt/?-catenin signaling pathway in idiopathic pulmonary fibrosis.
Ileus
Role of Pararectal Retroperitoneal Approach in Abdominal Aortic Aneurysm Repair.
Immunoglobulin G4-Related Disease
[IgG4-related disease: about 3 cases].
Impetigo
Roles of the plasminogen activator streptokinase and the plasminogen-associated M protein in an experimental model for streptococcal impetigo.
Infarction, Middle Cerebral Artery
12/15-Lipoxygenase Inhibition or Knockout Reduces Warfarin-Associated Hemorrhagic Transformation After Experimental Stroke.
A broad-spectrum matrix metalloproteinase inhibitor prevents hemorrhagic complications induced by tissue plasminogen activator in mice.
A novel mouse model of thromboembolic stroke.
A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator.
Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia.
Acute Ischemic Stroke Treated with Intravenous Tissue Plasminogen Activator in a Patient Taking Dabigatran with Radiographic Evidence of Recanalization.
Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase.
Albumin ameliorates tissue plasminogen activator-mediated blood-brain barrier permeability and ischemic brain injury in rats.
Alteplase Reduces Downstream Microvascular Thrombosis and Improves the Benefit of Large Artery Recanalization in Stroke.
Alteplase treatment does not increase brain injury after mechanical middle cerebral artery occlusion in the rat.
Ascorbic Acid Reduces the Adverse Effects of Delayed Administration of Tissue Plasminogen Activator in a Rat Stroke Model.
Assessment of the Therapeutic Potential of Metallothionein-II Application in Focal Cerebral Ischemia In Vitro and In Vivo.
Beneficial Role of Rosuvastatin in Blood-Brain Barrier Damage Following Experimental Ischemic Stroke.
Bilateral internal carotid artery occlusions resulting in near total acute brain infraction.
Bryostatin extends tPA time window to 6 h following middle cerebral artery occlusion in aged female rats.
Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke.
Cell permeable HMGB1-binding heptamer peptide ameliorates neurovascular complications associated with thrombolytic therapy in rats with transient ischemic stroke.
Cerebral endothelial cell-derived small extracellular vesicles enhance neurovascular function and neurological recovery in rat acute ischemic stroke models of mechanical thrombectomy and embolic stroke treatment with tPA.
Cerebroprotective effects of TAK-937, a novel cannabinoid receptor agonist, in permanent and thrombotic focal cerebral ischemia in rats: therapeutic time window, combination with t-PA and efficacy in aged rats.
Chronic nicotine treatment enhances focal ischemic brain injury and depletes free pool of brain microvascular tissue plasminogen activator in rats.
Circadian rhythms in the efficacy of intravenous alteplase in patients with acute ischemic stroke and middle cerebral artery occlusion.
CLOTBUST: design of a randomized trial of ultrasound-enhanced thrombolysis for acute ischemic stroke.
Combination treatment with low-dose Niaspan and tissue plasminogen activator provides neuroprotection after embolic stroke in rats.
Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia.
Combined contrast-enhanced ultrasound and rt-PA treatment is safe and improves impaired microcirculation after reperfusion of middle cerebral artery occlusion.
Combined intravenous recombinant-tissular plasminogen activator and endovascular treatment of spontaneous occlusive internal carotid dissection with tandem intracranial artery occlusion.
Combined Treatment With 2-(2-Benzofu-Ranyl)-2-Imidazoline and Recombinant Tissue Plasminogen Activator Protects Blood-Brain Barrier Integrity in a Rat Model of Embolic Middle Cerebral Artery Occlusion.
Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice.
Continuous Glibenclamide Prevents Hemorrhagic Transformation in a Rodent Model of Severe Ischemia-Reperfusion.
Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication.
Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain.
Dual Antiplatelet Therapy Increases Hemorrhagic Transformation Following Thrombolytic Treatment in Experimental Stroke.
DWI-ASPECTS as a predictor of dramatic recovery after intravenous recombinant tissue plasminogen activator administration in patients with middle cerebral artery occlusion.
Dysphagia as a predictor of outcome and transition to palliative care among middle cerebral artery ischemic stroke patients.
Early disruptions of the blood-brain barrier may contribute to exacerbated neuronal damage and prolonged functional recovery following stroke in aged rats.
Early dramatic recovery during intravenous tissue plasminogen activator infusion: clinical pattern and outcome in acute middle cerebral artery stroke.
Early recurrent ischemic stroke complicating intravenous thrombolysis for stroke: incidence and association with atrial fibrillation.
Effect of helicopter transport on neurological outcomes in a mouse model of embolic stroke with reperfusion: AIR-MICE pilot study.
Effect of hyperglycemia on stroke outcome is not homogeneous to all patients treated with mechanical thrombectomy.
Effect of the duration of middle cerebral artery occlusion on the risk of hemorrhagic transformation after tissue plasminogen activator injection in rats.
Effective and safe conditions of low-frequency transcranial ultrasonic thrombolysis for acute ischemic stroke: neurologic and histologic evaluation in a rat middle cerebral artery stroke model.
Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II).
Effects of alteplase, a thrombolytic agent, in a rat photothrombotic middle cerebral artery occlusion model.
Effects of angiopoietin-1 on hemorrhagic transformation and cerebral edema after tissue plasminogen activator treatment for ischemic stroke in rats.
Effects of erythropoietin combined with tissue plasminogen activator on the rats following cerebral ischemia and reperfusion.
Effects of ML351 and tissue plasminogen activator combination therapy in a rat model of focal embolic stroke.
Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice.
Effects of Pretreatment with Warfarin or Rivaroxaban on Neurovascular Unit Dissociation after Tissue Plasminogen Activator Thrombolysis in Ischemic Rat Brain.
Elevation of mRNA levels of tissue-type plasminogen activator and urokinase-type plasminogen activator in hippocampus and cerebral cortex following middle cerebral artery occlusion in rats.
Epigallocatechin Gallate Extends the Therapeutic Window of Recombinant Tissue Plasminogen Activator Treatment in Ischemic Rats.
Erythropoietin in combination of tissue plasminogen activator exacerbates brain hemorrhage when treatment is initiated 6 hours after stroke.
Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice.
Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model.
Fatal ischaemic brain oedema after early thrombolysis with tissue plasminogen activator in acute stroke.
Full-Dose Thrombolysis for a Right Middle Cerebral Artery Stroke after an Acute Aortic Dissection.
Granulocyte colony-stimulating factor attenuates delayed tPA-induced hemorrhagic transformation in ischemic stroke rats by enhancing angiogenesis and vasculogenesis.
Hemorrhagic transformation in focal cerebral ischemia: influence of time to artery reopening and tissue plasminogen activator.
High-permeability region size on perfusion CT predicts hemorrhagic transformation after intravenous thrombolysis in stroke.
Highly glycosylated CD147 promotes hemorrhagic transformation after rt-PA treatment in diabetes: a novel therapeutic target?
Human neural stem cells improve early stage stroke outcome in delayed tissue plasminogen activator-treated aged stroke brains.
Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke.
IMM-H004 prevents toxicity induced by delayed treatment of tPA in a rat model of focal cerebral ischemia involving PKA-and PI3K-dependent Akt activation.
Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat.
Increasing tPA activity in astrocytes induced by multipotent mesenchymal stromal cells facilitate neurite outgrowth after stroke in the mouse.
Inhibition of tPA-induced hemorrhagic transformation involves adenosine A2b receptor activation after cerebral ischemia.
Innovative thrombolytic strategy using a heterodimer diabody against TAFI and PAI-1 in mouse models of thrombosis and stroke.
Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model.
Intravenous alteplase versus rescue endovascular procedure in patients with proximal middle cerebral artery occlusion.
Intravenous infusion of mesenchymal stem cells inhibits intracranial hemorrhage after recombinant tissue plasminogen activator therapy for transient middle cerebral artery occlusion in rats.
Intravenous recombinant tissue plasminogen activator thrombolysis in a patient with acute ischemic stroke secondary to aortic dissection.
Intravenous thrombolysis of basilar artery occlusion: thrombus length versus recanalization success.
Is the benefit of early recanalization sustained at 3 months? A prospective cohort study.
Ischemic middle cerebral artery stroke missing the tissue plasminogen activator time window: transcranial Doppler evaluation.
Large vessel stroke as initial presentation of thrombotic thrombocytopenic purpura.
LDL receptor blockade reduces mortality in a mouse model of ischaemic stroke without improving tissue-type plasminogen activator-induced brain haemorrhage: towards pre-clinical simulation of symptomatic ICH.
Long-lasting neuronal loss following experimental focal cerebral ischemia is not affected by combined administration of tissue plasminogen activator and hyperbaric oxygen.
Matrix metalloproteinase (MMP) induction and inhibition at different doses of recombinant tissue plasminogen activator following experimental stroke.
Metabolic Syndrome Predicts Refractoriness to Intravenous Thrombolysis in Acute Ischemic Stroke.
Microglial low-density lipoprotein receptor-related protein 1 mediates the effect of tissue-type plasminogen activator on matrix metalloproteinase-9 activity in the ischemic brain.
Modifying neurorepair and neuroregenerative factors with tPA and edaravone after transient middle cerebral artery occlusion in rat brain.
Monoacylglycerol Lipase Inhibitor is Safe when Combined with Delayed r-tPA Administration in Treatment of Stroke.
N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Augments Thrombolysis of tPA (Tissue-Type Plasminogen Activator) in Aged Rats After Stroke.
Neuroproteome changes after ischemia/reperfusion injury and tissue plasminogen activator administration in rats: a quantitative iTRAQ proteomics study.
Neuroserpin extends the time window of tPA thrombolysis in a rat model of middle cerebral artery occlusion.
Neuroserpin protects neurons from ischemia-induced plasmin-mediated cell death independently of tissue-type plasminogen activator inhibition.
Neutrophil extracellular traps promote tPA-induced brain hemorrhage via cGAS in mice with stroke.
Nitrite does not provide additional protection to thrombolysis in a rat model of stroke with delayed reperfusion.
NOX2 inhibition with apocynin worsens stroke outcome in aged rats.
Outcome and Symptomatic Bleeding Complications of Intravenous Thrombolysis Within 6 Hours in MRI-Selected Stroke Patients: Comparison of a German Multicenter Study With the Pooled Data of ATLANTIS, ECASS, and NINDS tPA Trials.
Phosphodiesterase-III inhibitor prevents hemorrhagic transformation induced by focal cerebral ischemia in mice treated with tPA.
Phthalide derivative CD21 attenuates tissue plasminogen activator-induced hemorrhagic transformation in ischemic stroke by enhancing macrophage scavenger receptor 1-mediated DAMP (peroxiredoxin 1) clearance.
Plasmin-resistant PSD-95 inhibitors resolve effect-modifying drug-drug interactions between alteplase and nerinetide in acute stroke.
Plasminogen activator inhibitor type 1 derived peptide, EEIIMD, diminishes cortical infarct but fails to improve neurological function in aged rats following middle cerebral artery occlusion.
Posterior cerebral artery laterality on magnetic resonance angiography predicts long-term functional outcome in middle cerebral artery occlusion.
Potential advantages of Chinese medicine Taohong Siwu Decoction () combined with tissue-plasminogen activator for alleviating middle cerebral artery occlusion-induced embolic stroke in rats.
PPAR-Alpha Agonist Used at the Acute Phase of Experimental Ischemic Stroke Reduces Occurrence of Thrombolysis-Induced Hemorrhage in Rats.
Pro: Intravenous Tissue Plasminogen Activator in Stroke Patients With Rapid, Complete Recovery During Evaluation (Transient Ischemic Attack) and Evidence of Middle Cerebral Artery Occlusion.
Progesterone attenuates hemorrhagic transformation after delayed tPA treatment in an experimental model of stroke in rats: involvement of the VEGF-MMP pathway.
Prognostic significance of blood pressure variability after thrombolysis in acute stroke.
Protective Effect of ApoA1 (Apolipoprotein A1)-Milano in a Rat Model of Large Vessel Occlusion Stroke.
Protective effects of 2-(2-benzonfuranyl)-2-imidazoline combined with tissue plasminogen activator after embolic stroke in rats.
Protective effects of non-anticoagulant activated protein C variant (D36A/L38D/A39V) in a murine model of ischaemic stroke.
Quantitative MRI reveals the elderly ischemic brain is susceptible to increased early blood-brain barrier permeability following tissue plasminogen activator related to claudin 5 and occludin disassembly.
Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion.
Recent progress in drug treatment for acute ischemic stroke.
Recombinant human microplasmin: production and potential therapeutic properties.
Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischemia in mouse.
Recombinant tissue-type plasminogen activator transiently enhances blood-brain barrier permeability during cerebral ischemia through vascular endothelial growth factor-mediated endothelial endocytosis in mice.
Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat.
Reduction of intracerebral hemorrhage by rivaroxaban after tPA thrombolysis is associated with downregulation of PAR-1 and PAR-2.
Relationship of Obesity to Recanalization After Hyperacute Recombinant Tissue-Plasminogen Activator Infusion Therapy in Patients With Middle Cerebral Artery Occlusion.
Remote Ischemic Perconditioning Is Effective Alone and in Combination With Intravenous Tissue-Type Plasminogen Activator in Murine Model of Embolic Stroke.
Residual Vessel Length on Magnetic Resonance Angiography Identifies Poor Responders to Alteplase in Acute Middle Cerebral Artery Occlusion Patients. Exploratory Analysis of the Japan Alteplase Clinical Trial II.
REVASCAT: a randomized trial of revascularization with SOLITAIRE FR® device vs. best medical therapy in the treatment of acute stroke due to anterior circulation large vessel occlusion presenting within eight-hours of symptom onset.
Right internal carotid artery occlusion during intravenous thrombolysis for left middle cerebral artery occlusion.
Rivaroxaban does not increase hemorrhage after thrombolysis in experimental ischemic stroke.
Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke.
Rosuvastatin Reduces Neuroinflammation in the Hemorrhagic Transformation After rt-PA Treatment in a Mouse Model of Experimental Stroke.
Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke.
Selective inhibition of carboxypeptidase U may reduce microvascular thrombosis in rat experimental stroke.
Simulation of Intracranial Acoustic Fields in Clinical Trials of Sonothrombolysis.
Simultaneous treatment of ischaemic bowel and ischaemic stroke with intravenous thrombolysis therapy.
Spatio-temporal course of macrophage-like cell accumulation after experimental embolic stroke depending on treatment with tissue plasminogen activator and its combination with hyperbaric oxygenation.
Speed of tPA-induced clot lysis predicts DWI lesion evolution in acute stroke.
Stent-assisted endovascular thrombolysis versus intravenous thrombolysis in internal carotid artery dissection with tandem internal carotid and middle cerebral artery occlusion.
Stent-based thrombectomy versus intravenous tissue plasminogen activator in patients with acute middle cerebral artery occlusion.
Stroke in ovarian hyperstimulation syndrome in early pregnancy treated with intra-arterial rt-PA.
Strong neuroprotection with a novel platinum nanoparticle against ischemic stroke- and tissue plasminogen activator-related brain damages in mice.
Subacute intranasal administration of tissue plasminogen activator improves stroke recovery by inducing axonal remodeling in mice.
Successful intravenous thrombolysis in a 14-year-old boy with ischemic stroke.
Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion.
Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat.
TGF-?1 prevents blood-brain barrier damage and hemorrhagic transformation after thrombolysis in rats.
The Effect of Clot Volume and Permeability on Response to Intravenous Tissue Plasminogen Activator in Acute Ischemic Stroke.
The Kringle-2 domain of tissue plasminogen activator significantly reduces mortality and brain infarction in middle cerebral artery occlusion rats.
The PI3K/Akt pathway mediates the neuroprotective effect of atorvastatin in extending thrombolytic therapy after embolic stroke in the rat.
The transient intraluminal filament middle cerebral artery occlusion model as a model of endovascular thrombectomy in stroke.
Three Cases of Middle Cerebral Artery Occlusion Emergently Revascularized with A Balloon-expandable Coronary Bare Stent After Intravenous Tissue Plasminogen Activator.
Thrombolysis with rt-PA under Rivaroxaban Anticoagulation in a Hypertensive Rat Model of Intraluminal Middle Cerebral Artery Occlusion.
Thrombolytic efficacy of a modified tissue-type plasminogen activator, SUN9216, in the rat middle cerebral artery thrombosis model.
Thrombus Migration and Fragmentation After Intravenous Alteplase Treatment: The INTERRSeCT Study.
Tirofiban combined with rt-PA intraarterial thrombolysis improves the recanalization rate of acute middle cerebral artery occlusion in rabbits.
Tissue Plasminogen Activator Promotes TXNIP-NLRP3 Inflammasome Activation after Hyperglycemic Stroke in Mice.
Tissue plasminogen activator thrombolysis of a middle cerebral artery embolus in a patient with an arteriovenous malformation. Case report.
Tissue plasminogen activator treatment of stroke in type-1 diabetes rats.
Tissue plasminogen activator via cross-collateralization for tandem internal carotid and middle cerebral artery occlusion.
Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke.
Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein mediate cerebral ischemia-induced nuclear factor-kappaB pathway activation.
Tissue-type plasminogen activator has paradoxical roles in focal cerebral ischemic injury by thrombotic middle cerebral artery occlusion with mild or severe photochemical damage in mice.
Tissue-type plasminogen activator mediates neuronal detection and adaptation to metabolic stress.
Toll-Like Receptor 4 Mediates Hemorrhagic Transformation After Delayed Tissue Plasminogen Activator Administration in In Situ Thromboembolic Stroke.
Treatment with tPA predicts better outcome even if MCA occlusion persists.
Tumor Cells Detected in Retrieved Thrombus: Cancer-associated Stroke.
Use of a spectrophotometric hemoglobin assay to objectively quantify intracerebral hemorrhage in mice.
Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke.
Vepoloxamer Enhances Fibrinolysis of tPA (Tissue-Type Plasminogen Activator) on Acute Ischemic Stroke.
Very Mild Hypothermia (35°C) Postischemia Reduces Infarct Volume and Blood/Brain Barrier Breakdown Following tPA Treatment in the Mouse.
Worsened outcome from middle cerebral artery occlusion in aged rats receiving 17?-estradiol.
[Acute stroke therapy : Current developments.]
Infections
4G/5G plasminogen activator inhibitor-1 polymorphisms and haplotypes are associated with pneumonia.
A review of the management of complex para-pneumonic effusion in adults.
A streptococcal plasminogen activator in the focus of infection and in the kidneys during the initial phase of experimental streptococcal glomerulonephritis.
Abdominal pain in a patient with COVID-19 infection: A case of multiple thromboemboli.
Activation of plasminogen activator inhibitor implicates protease InhA in the acute-phase response to Bacillus anthracis infection.
Active human tissue plasminogen activator secreted from insect cells using a baculovirus vector.
Acute-phase response of human hepatocytes after infection with Chlamydia pneumoniae and cytomegalovirus.
Adaptive upregulation of Clumping Factor A (ClfA) by S. aureus in the obese, type 2 diabetic host mediates increased virulence.
Adenovirus E1A-mediated negative control of genes activated during F9 differentiation.
Adenovirus-mediated expression of heparin cofactor II inhibits thrombin-induced cellular responses in fibroblasts and vascular smooth muscle cells.
Advances in parenteral nutrition.
Altered patterns of cellular gene expression in dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus.
Analysis of Hepatitis C Virus Particle Heterogeneity in Immunodeficient Human Liver Chimeric fah-/- Mice.
Antibodies to Chlamydia pneumoniae and haemostatic factors in acute coronary syndrome without ST segment elevation.
Association between hepatitis B virus and MHC class I polypeptide-related chain A in human hepatocytes derived from human-mouse chimeric mouse liver.
Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation.
Azithromycin therapy in patients with chronic Chlamydia pneumoniae infection and coronary heart disease: immediate and long-term effects on inflammation, coagulation, and lipid status in a double-blind, placebo-controlled study.
Bacille Calmette-Guérin infection in the mouse. Regulation of macrophage plasminogen activator by T lymphocytes and specific antigen.
bcl-2 expression in Spodoptera Frugiperda Sf-9 and Trichoplusia Ni BTI-Tn-5B1-4 insect cells: Effect on recombinant protein expression and cell viability.
Bed rest or mobilization after rt-PA? A case-crossover study of factors influencing clinical decision making in stroke services.
Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice.
Biological activity of manganese(i) tricarbonyl complexes on multidrug-resistant Gram-negative bacteria: From functional studies to in vivo activity in Galleria mellonella.
Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients.
Bronchopleural communication following intrapleural doses of tPA/DNase for empyema.
Characterization of Yersinia Using MALDI-TOF Mass Spectrometry and Chemometrics.
Characterizing the role of tissue-type plasminogen activator in a mouse model of Group A streptococcal infection.
Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis.
Citrate versus heparin for apheresis catheter locks: an efficacy analysis.
Clinical efficacy and bleeding outcomes of tissue plasminogen activator and dornase alfa in pleural space infection with once daily concurrent administration: a retrospective cohort study.
Coagulation and fibrinolytic systems in the ill preterm newborn.
Coagulopathy in malaria.
Complementary approaches to understanding the role of proteases and their natural inhibitors in neoplastic development: retrospect and prospect.
Concurrent Intrapleural Instillation of Tissue Plasminogen Activator and DNase for Pleural Infection. A Single-Center Experience.
Concurrent Versus Sequential Intrapleural Instillation of Tissue Plasminogen Activator and Deoxyribonuclease for Pleural Infection.
Correlation of the L-Arginine Pathway with Thrombo-Inflammation May Contribute to the Outcome of Acute Ischemic Stroke.
Cost-effectiveness of intrapleural use of tissue plasminogen activator and DNase in pleural infection: evidence from the MIST2 randomised controlled trial.
Critical role of type 1 plasminogen activator inhibitor (PAI-1) in early host defense against nontypeable Haemophilus influenzae (NTHi) infection.
CVAD Homecare Management: Investigating the Use of a Digital Education Tool During Nurse-Delivered Instruction to Parents for New Central Lines in Children With Cancer.
Cylindromatosis (CYLD) inhibits Streptococcus pneumonia-induced plasminogen activator inhibitor-1 expression via interacting with TRAF-6.
De novo infection and serial transmission of Kaposi's sarcoma-associated herpesvirus in cultured endothelial cells.
Delayed administration of tissue plasminogen activator reduces intra-abdominal abscess formation.
Detection of granuloma-associated plasminogen activator in experimental murine schistosomiasis.
Detection of Yersinia pestis in sputum by real-time PCR.
Differential cytotoxicity of tumour promoter TPA for EBV-negative human lymphoma cell lines and their EBV-converted sublines.
Diverse effects: augmentation, inhibition, and non-efficacy of 12-O-tetradecanoylphorbol-13-acetate (TPA) on retrovirus genome expression in vivo and in vitro.
Dose De-Escalation of Intrapleural Tissue Plasminogen Activator Therapy for Pleural Infection: The ADAPT Project.
Early epileptic seizures in ischaemic stroke treated by mechanical thrombectomy: influence of rt-PA.
Effect of Puumala hantavirus infection on human umbilical vein endothelial cell hemostatic function: platelet interactions, increased tissue factor expression and fibrinolysis regulator release.
Effects of a diet containing Brazilian propolis on lipopolysaccharide-induced increases in plasma plasminogen activator inhibitor-1 levels in mice.
Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters.
Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis.
Empyema thoracis.
Endogenous tissue-type plasminogen activator is protective during ascending urinary tract infection.
Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice.
Evidence-based criteria for the choice and the clinical use of the most appropriate lock solutions for central venous catheters (excluding dialysis catheters): a GAVeCeLT consensus.
Exploration of Efficacy and Safety of Interventions for Intraventricular Hemorrhage: A Network Meta-Analysis.
Factors affecting human cytomegalovirus gene expression in human monocyte cell lines.
Forty Years Later and the Role of Plasminogen Activator Inhibitor Type 2/SERPINB2 Is Still an Enigma.
Gender differences in stroke examined in a 10-year cohort of patients admitted to a Canadian teaching hospital.
Genetics of otitis media.
Helicobacter pylori induces plasminogen activator inhibitor 2 in gastric epithelial cells through nuclear factor-kappaB and RhoA: implications for invasion and apoptosis.
Helicobacter pylori infection stimulates plasminogen activator inhibitor 1 production by gastric epithelial cells.
Helicobacter pylori interactions with plasminogen.
Hemostatic/fibrinolytic protein changes in C3H/HeN mice infected with Rickettsia conorii--a model for Rocky Mountain spotted fever.
Herpes simplex virus decreases endothelial cell plasminogen activator inhibitor.
Herpesvirus saimiri-induced proteins in lytically infected cells. I. Time-ordered synthesis.
Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model: role of the innate antiviral immune response.
Human cytomegalovirus circumvents NF-kappa B dependence in retinal pigment epithelial cells.
Human cytomegalovirus induces apoptosis in promonocyte THP-1 cells but not in promyeloid HL-60 cells.
Human cytomegalovirus infection induces mRNA expression and secretion of plasminogen inhibitor type-1 in endothelial cells.
Human cytomegalovirus replication correlates with differentiation in a hematopoietic progenitor cell line and can be modulated by HIV-1.
Identifying cellular genes crucial for the reactivation of Kaposi's sarcoma-associated herpesvirus latency.
Immunogenetic factors affecting susceptibility of humans and rodents to hantaviruses and the clinical course of hantaviral disease in humans.
Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection.
Increased ventriculostomy infection rate with use of intraventricular tissue plasminogen activator: A single-center observation.
Induction of integrated adenovirus E1A and E1B genes in transformed human cells by phorbol ester tumor promoters.
Induction of SerpinB2 and Th1/Th2 Modulation by SerpinB2 during Lentiviral Infections In Vivo.
Infection with a periodontal pathogen induces procoagulant effects in human aortic endothelial cells.
Infections Increase the Risk of 30-Day Readmissions Among Stroke Survivors.
Inflammatory and metalloproteinases profiles predict three-month poor outcomes in ischemic stroke treated with thrombolysis.
Influence of Plasminogen Activator Inhibitor -1 Gene Polymorphism on Renal Scarring After First Febrile Urinary Tract Infection in Infants.
Interactions between adenovirus, a tumor promoter, and chemical carcinogens in transformation of rat embryo cell cultures.
Intracellular infections enhance interleukin-6 and plasminogen activator inhibitor 1 production by cocultivated human adipocytes and THP-1 monocytes.
Intrapleural Fibrinolytic Therapy versus Early Medical Thoracoscopy for Treatment of Pleural Infection. Randomized Controlled Clinical Trial.
Intrapleural Fibrinolytics and Deoxyribonuclease for Treatment of Indwelling Pleural Catheter-Related Pleural Infection: A Multi-Center Observational Study.
Intrapleural fibrinolytics combined with image-guided chest tube drainage for pleural infection.
Intrapleural r-tPA in Association with Low-Molecular Heparin May Cause Massive Hemothorax Resulting in Hypovolemia.
Intrapleural therapy in management of complicated parapneumonic effusions and empyema.
Intrapleural tissue plasminogen activator and deoxyribonuclease for pleural infection. An effective and safe alternative to surgery.
Intrapleural tissue plasminogen activator and deoxyribonuclease therapy for pleural infection.
Intrapleural use of tissue plasminogen activator and DNase in pleural infection.
Intravenous Thrombolysis for Stroke and Presumed Stroke in Human Immunodeficiency Virus-Infected Adults: A Retrospective, Multicenter US Study.
Intraventricular fibrinolytic for the treatment of intraventricular hemorrhage: a network meta-analysis.
Link between plasminogen activator inhibitor-1 and cardiovascular risk in chronic hepatitis C after viral clearance.
Low dose intrapleural alteplase and pulmozyme (DNase) in two post-surgical patients with pleural sepsis.
Macrophage activation in murine African trypanosomiasis.
Management of community-acquired pneumonia in immunocompetent adults: updated Swedish guidelines 2017.
Management of parapneumonic effusions and empyema.
Metabolic Dysregulation in Hepacivirus Infection of Common Marmosets (Callithrix jacchus).
Meticillin-resistant Staphylococcus aureus infection in diabetic mice enhanced inflammation and coagulation.
Monocytic differentiation inhibits infection and granulocytic differentiation potentiates infection by the agent of human granulocytic ehrlichiosis.
Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia.
Myeloid-derived tissue-type plasminogen activator promotes macrophage motility through FAK, Rac1, and NF-?B pathways.
New strategies to manage complicated pleural effusions.
NF-kappaB translocation prevents host cell death after low-dose challenge by Legionella pneumophila.
NF1 regulatory element functions as a repressor of tissue plasminogen activator expression.
PAI-1 and IFN-? in the regulation of innate immune homeostasis during sublethal yersiniosis.
Phorbol ester-induced differentiation permits productive human cytomegalovirus infection in a monocytic cell line.
Picornavirus receptor down-regulation by plasminogen activator inhibitor type 2.
Plasminogen Activator Inhibitor-1 Mitigates Brain Injury in a Rat Model of Infection-Sensitized Neonatal Hypoxia-Ischemia.
Post-transcriptional regulation of endothelial cell plasminogen activator inhibitor-1 expression during R. rickettsii infection.
Presence of thrombin-activatable fibrinolysis inhibitor in Helicobacter pylori-associated gastroduodenal disease.
Previous cytomegalovirus infection and risk of coronary thrombotic events after stent placement.
Production of plasminogen activator and plasminogen activator inhibitors by alveolar macrophages in control subjects and AIDS patients.
Prognostic Significance of Stroke-Associated Infection and other Readily Available Parameters in Acute Ischemic Stroke Treated by Intravenous Thrombolysis.
Proinflammatory cytokines, fibrinolytic system enzymes, and biochemical indices in children with infectious para-pneumonic effusions.
Prothrombotic activation of pulmonary arterial endothelial cells in a patient with tuberculosis.
Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome.
Recent developments in the management of pleural infection: A comprehensive review.
Recombinant tissue plasminogen activator in the treatment of pleural infections in adults.
Recombinant tissue plasminogen activator may reduce frequency of central venous access device infection in hemophilia patients undergoing immune tolerance therapy.
Reversal of acute ischemic stroke after THA using tissue plasminogen activator.
Risk factors of diffuse alveolar hemorrhage after acute ischemic stroke treated with tissue-type plasminogen activator. The effectiveness of activated recombinant factor VII treatment.
Role of IgG-seropositivity to Chlamydia pneumoniae in early thrombotic events after coronary stent placement.
Role of Tissue Plasminogen Activator for Diffuse Pulmonary Microemboli in Coronavirus Disease 2019 Patient.
Safety and Efficacy of Intrapleural Tissue Plasminogen Activator and DNase during Extended Use in Complicated Pleural Space Infections.
Safety and efficacy of taurolidine/urokinase versus taurolidine/heparin as a tunneled catheter lock solution in hemodialysis patients: a prospective, randomized, controlled study.
Safety of Intraventricular Hemorrhage (IVH) Thrombolysis Based on CT Localization of External Ventricular Drain (EVD) Fenestrations and Analysis of EVD Tract Hemorrhage.
Sarcopenia Does Not Affect Survival or Outcomes in Soft-Tissue Sarcoma.
Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by Rickettsia conorii- and Rickettsia rickettsii-infected cultured endothelial cells.
SerpinB2 deficiency modulates Th1?Th2 responses after schistosome infection.
Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection.
Sexual Dimorphism in Hepatocyte Xenograft Models.
Short-course modified regimen intrapleural alteplase and pulmozyme (DNase) in pleural infection.
Stable expression of mammalian beta 1,4-galactosyltransferase extends the N-glycosylation pathway in insect cells.
Studies on the role of plasminogen activator in systemic infection by virulent Yersinia pestis strain C092.
Substitution of citrate with tissue plasminogen activator (rt-PA) for catheter lock does not improve patency of tunnelled haemodialysis catheters in a randomised trial.
Successful conduct of an acute stroke clinical trial during COVID.
Successful management of pleural infection with very low dose intrapleural tissue plasminogen activator/deoxyribonuclease regime.
Successful use of recombinant tissue plasminogen activator in a patient with relapsing peritonitis.
Synergistic enhancement of immunogenicity and protection in mice against Schistosoma japonicum with codon optimization and electroporation delivery of SjTPI DNA vaccines.
The cyclic AMP receptor protein, CRP, is required for both virulence and expression of the minimal CRP regulon in Yersinia pestis biovar microtus.
The effects of treatment with chemical agents or infection with feline viruses on protein-binding properties of the feline immunodeficiency virus long terminal repeat.
The fibrinolytic system in dissemination and matrix protein deposition during a mycobacterium infection.
The immune response to mouse hepatitis virus: expression of monocyte procoagulant activity and plasminogen activator during infection in vivo.
The phorbol ester TPA strongly inhibits HIV-1-induced syncytia formation but enhances virus production: possible involvement of protein kinase C pathway.
The priming effect of human interferon-alpha is mediated by protein kinase C.
The role of topical treatment as a determinant of infection in outpatient burns.
Thrombogenic alleles, Escherichia coli O157:H7 infections, and hemolytic uremic syndrome.
Time course of peritoneal tissue plasminogen activator after experimental colonic surgery: effect of hyaluronan-based antiadhesive agents and bacterial peritonitis.
Tissue Plasminogen Activator Coating on Implant Surfaces Reduces Staphylococcus aureus Biofilm Formation.
Tissue plasminogen activator for stroke and concomitant influenza infection: is this a dangerous combination?
Tissue plasminogen activator induced by dengue virus infection of human endothelial cells.
Tissue Plasminogen Activator Potently Stimulates Pleural Effusion via an MCP-1 Dependent Mechanism.
Tissue plasminogen activator reverses the deleterious effect of infection on colonic wound healing.
Tissue plasminogen activator to prevent central venous access device infections: a systematic review of central venous access catheter thrombosis, infection and thromboprophylaxis.
Transformation phenotype of polyoma virus-transformed rat fibroblasts: plasminogen activator production is modulated by the growth state of the cells and regulated by the expression of an early viral gene function.
Transgenic tissue-type plasminogen activator expression improves host defense during Klebsiella pneumonia.
Treatment of hemodialysis catheter-associated fibrin sheaths by rt-PA infusion: critical analysis of 124 procedures.
Tumor promoters alter the temporal program of adenovirus replication in human cells.
Unintentional intramuscular administration of tPA/DNase for pleural infection.
Updated analysis: central venous access device infection rates in an expanded cohort of paediatric patients with severe haemophilia receiving prophylactic recombinant tissue plasminogen activator.
Use of intrapleural tissue plasminogen activator and deoxyribonuclease in pleural space infections: an update on alternative regimens.
Vaccination with the plasminogen activator from Streptococcus uberis induces an inhibitory response and protects against experimental infection in the dairy cow.
[Disseminated intravascular coagulation--pathophysiology]
[r-tPA in keratoplasty à chaud. Report of 50 patients]
[Serum and urinary tissue polypeptide antigen (TPA) in patients with urological cancer]
[Serum tissue polypeptide antigen (TPA) in patients with urogenital cancer]
[Use of fibrinolytics and deoxyribonuclease in patients with pleural infection].
Inferior Wall Myocardial Infarction
Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression: immediate and long-term results of a randomized study.
Early thrombolytic therapy does not enhance the recovery of the right ventricle in patients with acute inferior myocardial infarction and predominant right ventricular involvement.
Early tPA treatment and aeromedical transport of patients with acute myocardial infarction.
Impact of early accelerated dose tissue plasminogen activator on in-hospital patency of the infarcted vessel in patients with acute right ventricular infarction.
Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI II.
Spontaneous coronary artery dissection in an elderly woman with acute inferior myocardial infarction. A case report.
Successful treatment of acute myocardial infarction during pregnancy with tissue plasminogen activator.
[ A rare complication of thrombolytic therapy: spinal epidural hematoma. A case report ]
[Cholesterol crystal embolisms due to systemic thrombolysis of an acute myocardial infarct]
Infertility
Activity and dosage of alteplase dilution for clearing occlusions of venous-access devices.
Association of plasminogen activator inhibitor-type 1 (PAI-1) -675 4G/5G polymorphism with unexplained female infertility.
Functionally inactive protein C inhibitor in seminal plasma may be associated with infertility.
Human seminal plasma fibrinolytic activity.
New approaches to insulin resistance in polycystic ovarian syndrome.
Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).
Recurrent pregnancy loss and its relation to FV Leiden, FII G20210A and polymorphisms of plasminogen activator and plasminogen activator inhibitor.
Review of the role of the plasminogen activator system and vascular endothelial growth factor in subfertility.
Stability and sterility of recombinant tissue plasminogen activator at -30 degrees C.
Tissue polypeptide antigen immunoreactivity in human semen.
[Consequences for labile blood products of leukocyte depletion by whole blood filtration using the Leucoflex LST1 in-line filter. Evaluation of the Leucoflex LST1 filter]
Infertility, Female
Association between plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and risk of Alzheimer's disease, metabolic syndrome, and female infertility: A meta-analysis.
Association of plasminogen activator inhibitor-type 1 (PAI-1) -675 4G/5G polymorphism with unexplained female infertility.
Infertility, Male
[How chronic prostatitis affects plasminogen activator system]
Inflammatory Bowel Diseases
Antibodies to tissue-type plasminogen activator (t-PA) in patients with inflammatory bowel disease: high prevalence, interactions with functional domains of t-PA and possible implications in thrombosis.
Association of plasminogen activator inhibitor-1 gene polymorphism with inflammatory bowel disease in Iranian Azeri Turkish patients.
Chronic inflammatory bowel disease--increased plasminogen activator secretion by mononuclear phagocytes.
Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease.
Enzymatically Inactive Tissue-Type Plasminogen Activator Reverses Disease Progression in the Dextran Sulfate Sodium Mouse Model of Inflammatory Bowel Disease.
Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Plasminogen activators in the intestine of patients with inflammatory bowel disease.
[Impaired fibrinolytic response to the venous occlusion test in patients with cryptogenic colitis]
Influenza, Human
Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1.
Glycosylation: heterogeneity and the 3D structure of proteins.
Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
Immunological effects of tumor vaccines: III. Influenza virus oncolysates inhibit the TPA induced activation of peripheral blood mononuclear cells.
Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection.
Plasminogen activator inhibitor-1 in cigarette smoke exposure and influenza A virus infection-induced lung injury.
Tissue plasminogen activator for stroke and concomitant influenza infection: is this a dangerous combination?
[ Influenza virus proteins modulate hemostasis in vitro and in vivo ]
[Modulation of endothelial factors activity in human endothelial cells in influenza A(H1N1)pdm09 virus infection].
[The role of influenza virus hemagglutinin in blood anticoagulation processes]
Infratentorial Neoplasms
Treatment of intraventricular hemorrhage with tissue plasminogen activator.
Insulin Resistance
'True' fasting serum insulin level, insulin resistance syndrome and coronary artery disease.
A 12-week aerobic exercise program without energy restriction improves intrahepatic fat, liver function and atherosclerosis-related factors.
A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome.
A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
A novel plasminogen activator inhibitor-1 inhibitor, TM5441, protects against high-fat diet-induced obesity and adipocyte injury in mice.
A randomized trial of exercise for blood pressure reduction in type 2 diabetes: Effect on flow-mediated dilation and circulating biomarkers of endothelial function.
A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol.
Abdominal adiposity and cardiometabolic risk: do we have all the answers?
Abdominal obesity, impaired nonesterified fatty acid suppression, and insulin-mediated glucose disposal are early metabolic abnormalities in families with premature myocardial infarction.
Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent?
Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity: the biguanides and the prevention of the risk of obesity (BIGPRO) 1 study.
Adipocyte-derived factors potentiate nutrient-induced production of plasminogen activator inhibitor-1 by macrophages.
Adipocyte-derived hormones, cytokines, and mediators.
Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis.
Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer.
Adipokines: New Potential Therapeutic Target for Obesity and Metabolic, Rheumatic, and Cardiovascular Diseases.
Adiponectin and its role in cardiovascular diseases.
Adipose tissue activity in relation to overweight or obesity.
Aldosterone perturbs adiponectin and PAI-1 expression and secretion in 3T3-L1 adipocytes.
Altered Daytime Fluctuation Pattern of Plasminogen Activator Inhibitor 1 in Type 2 Diabetes Patients with Coronary Artery Disease: A Strong Association with Persistently Elevated Plasma Insulin, Increased Insulin Resistance, and Abdominal Obesity.
Amelioration of the inhibition of fibrinolysis in elderly, obese subjects by moderate energy intake restriction.
Ameliorative effect of nicotine exposure on insulin resistance is accompanied by decreased cardiac glycogen synthase kinase-3 and plasminogen activator inhibitor-1 during oral oestrogen-progestin therapy.
Analysis of the correlation between plasma coagulation factor VII, PAI-1, and uric acid with insulin resistance and macrovascular complications in elderly patients with type 2 diabetes.
Androgens and coronary artery disease.
Angiotensin-converting enzyme inhibition attenuates hypofibrinolysis and reduces cardiac perivascular fibrosis in genetically obese diabetic mice.
Anti-inflammatory effects of troglitazone in nondiabetic obese subjects independent of changes in insulin sensitivity.
Antihypertensive drugs and fibrinolytic function.
Association analyses of porcine SERPINE1 reveal sex-specific effects on muscling, growth, fat accretion and meat quality.
Association analysis of the plasminogen activator inhibitor-1 4G/5G polymorphism in Hispanics and African Americans: the IRAS family study.
Association between plasminogen activator inhibitor-1 and severity of liver injury and cardiovascular risk in children with non-alcoholic fatty liver disease.
Association of ambulatory heart rate and atherosclerosis risk factors with blood pressure in young non-hypertensive adults.
Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease.
Association of endogenous tissue plasminogen activator (t-PA) with clinical characteristics of the insulin resistance syndrome.
Association of inflammation markers with impaired insulin sensitivity and coagulative activation in obese healthy women.
Association of Peripheral Insulin Resistance and Other Markers of Type 2 Diabetes Mellitus with Brain Amyloid Deposition in Healthy Individuals at Risk of Dementia.
Association of plasminogen activator inhibitor-1 with insulin resistance in Japan where obesity is rare.
Association of pulse pressure with serum TNF-? and neutrophil count in the elderly.
Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters.
Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women.
Associations of Cardiac Structure with Obesity, Blood Pressure, Inflammation, and Insulin Resistance in African-American Adolescents.
Associations of hyperglycemia and insulin resistance with biomarkers of endothelial dysfunction in Hispanic/Latino youths: Results from the Hispanic Community Children's Health Study/Study of Latino Youth (SOL Youth).
Associations of sedentary time patterns and TV viewing time with inflammatory and endothelial function biomarkers in children.
Beneficial effects of metformin on haemostasis and vascular function in man.
Biomarkers and insulin sensitivity in women with Polycystic Ovary Syndrome: Characteristics and predictive capacity.
Biomarkers of cardiometabolic complications in survivors of childhood acute lymphoblastic leukemia.
Birth weight and the insulin resistance syndrome: association of low birth weight with truncal obesity and raised plasminogen activator inhibitor-1 but not with abdominal obesity or plasma lipid disturbances.
Body adiposity but not insulin resistance is associated with -675 4G/5G polymorphism in the PAI-1 gene in a sample of Mexican children.
Body composition and metabolic effects of a diet and exercise weight loss regimen on obese, HIV-infected women.
Brief review: hypertension in pregnancy : a manifestation of the insulin resistance syndrome?
C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?
Cardiorespiratory capacity is associated with favourable cardiovascular risk profile in patients with Type 2 diabetes.
Cellular and molecular mechanisms of vascular injury in diabetes - Part I: Pathways of vascular disease in diabetes.
Central role of ceramide biosynthesis in body weight regulation, energy metabolism and the metabolic syndrome.
Changes in biomarkers and 24 hours blood pressure in hypertensive African Americans with the metabolic syndrome: Comparison of amlodipine/olmesartan versus hydrochlorothiazide/losartan.
Changes in Soluble TWEAK Concentrations, but Not Those in Amyloid-?(1-40), Are Associated with a Decrease in Carotid Intima-Media Thickness after Bariatric Surgery in Obese Women.
Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy.
Childhood obesity: evidence of an association between plasminogen activator inhibitor-1 levels and visceral adiposity.
Circulating adhesion molecules, matrix metalloproteinase-9, plasminogen activator inhibitor-1, and myeloperoxidase in coronary artery disease patients with stable and unstable angina.
Circulating Levels of TNF-? Are Associated with Impaired Glucose Tolerance, Increased Insulin Resistance, and Ethnicity: The Insulin Resistance Atherosclerosis Study.
Circulating Osteocalcin Level Is Not Associated With Incident Type 2 Diabetes in Middle-Aged Male Subjects: Mean 8.4-year retrospective follow-up study.
Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes.
Coagulation factor XIII and atherothrombosis. A mini-review.
Coagulation Signalling and Metabolic Disorders: Lessons Learned from Animal Models.
Cognitive Patterns in Relation to Biomarkers of Cerebrovascular Disease and Vascular Risk Factors.
Cognitive-behavioural stress management does not improve biological cardiovascular risk indicators in women with ischaemic heart disease: a randomized-controlled trial.
Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS).
Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study.
Contribution of genetic and metabolic syndrome to omental adipose tissue PAI-1 gene mRNA and plasma levels in obesity.
Copeptin, Insulin Resistance, and Risk of Incident Diabetes in Older Men.
Coronary artery disease in South asians: an emerging risk group.
Cortisol/cortisone ratio and matrix metalloproteinase-9 activity are associated with pediatric primary hypertension.
Decreased Insulin Sensitivity and Impaired Fibrinolytic Activity in Type 2 Diabetes Patients and Nondiabetics with Ischemic Stroke.
Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men.
Determinants of plasminogen activator inhibitor-1 in South Asians with ischaemic stroke.
Dietary Blueberry and Soluble Fiber Improve Serum Antioxidant and Adipokine Biomarkers and Lipid Peroxidation in Pregnant Women with Obesity and at Risk for Gestational Diabetes.
Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women.
Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome.
Diminished fibrinolysis and thrombosis: clinical implications for accelerated atherosclerosis.
Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.
Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women's Heart Health Study.
Dose-Responses Relationship in Glucose Lowering and Gut Dysbiosis to Saskatoon Berry Powder Supplementation in High Fat-High Sucrose Diet-Induced Insulin Resistant Mice.
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
Effect of dietary anthocyanins on biomarkers of glycemic control and glucose metabolism: A systematic review and meta-analysis of randomized clinical trials.
Effect of estrogen therapy on insulin resistance and plasminogen activator inhibitor type 1 concentrations in postmenopausal women.
Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects.
Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes.
Effects of gemfibrozil therapy on glucose tolerance, insulin sensitivity and plasma plasminogen activator inhibitor activity in hypertriglyceridaemia.
Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus.
Effects of iron supplementation in mice with hypoferremia induced by obesity.
Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.
Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Elevated expression of transforming growth factor-beta in adipose tissue from obese mice.
Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study.
Elevated plasma activator inhibitor 1 is not related to insulin resistance and to gene polymorphism in healthy centenarians.
Endothelial dysfunction of coronary arteries in subjects without diabetes: An association with both insulin resistance and impaired insulin secretion response.
Endothelial Function in Youth: A Biomarker Modulated by Adiposity-Related Insulin Resistance.
Estrogen replacement therapy and cardiovascular protection: lipid mechanisms are the tip of an iceberg.
Evening chronotype is associated with elevated biomarkers of cardiometabolic risk in the EpiHealth cohort: a cross-sectional study.
Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease.
Female mice are more susceptible to non-alcoholic fatty liver disease: sex-specific regulation of the hepatic AMP-activated protein kinase - plasminogen activator inhibitor 1-cascade but not the hepatic endotoxin response.
Fenofibrate ameliorates insulin resistance, hypertension and novel oxidative stress markers in patients with metabolic syndrome.
Fibrinolysis and atherogenesis in the JCR:LA-cp rat in relation to insulin and triglyceride concentrations in blood.
Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities.
Fibrinolytic risk factor clustering and insulin resistance in healthy male relatives of men with intermittent claudication.
Foxc2 is a common mediator of insulin and transforming growth factor beta signaling to regulate plasminogen activator inhibitor type I gene expression.
Gender differences in the relation between fibrinogen, tissue-type plasminogen activator antigen and markers of insulin resistance: effects of smoking. D.E.S.I.R. Study Group. Data from an Epidemiological Study on Insulin Resistance Syndrome.
Gender differences in the relationships between plasma plasminogen activator inhibitor-1 activity and factors linked to the insulin resistance syndrome in essential hypertension.
Haemostatic parameters and vascular risk.
Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome.
High-Calorie-Expenditure Exercise. A New Approach to Cardiac Rehabilitation for Overweight Coronary Patients.
High-fat diet decreases energy expenditure and expression of genes controlling lipid metabolism, mitochondrial function and skeletal system development in the adipose tissue, along with increased expression of extracellular matrix remodelling- and inflammation-related genes.
Higher Insulin Resistance Level is Associated with Worse Clinical Response in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis.
Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications.
How the association between obesity and inflammation may lead to insulin resistance and cancer.
Hyperbaric oxygen therapy affects insulin sensitivity/resistance by increasing adiponectin, resistin, and plasminogen activator inhibitor-I in rats
Hypofibrinolysis and the insulin resistance syndrome.
Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes.
Identification of signaling pathways involved in aberrant production of adipokines in adipocytes undergoing oxidative stress.
Immunohistochemical detection of plasminogen activator inhibitor-1 in polycystic ovaries.
Impaired fibrinolysis and insulin resistance in patients with hypertension.
Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes.
Implication of low level inflammation in the insulin resistance of adipose tissue at late pregnancy.
Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower enough?
Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
Improvement in HOMA-IR is an independent predictor of reduced carotid intima-media thickness in obese adolescents participating in an interdisciplinary weight-loss program.
In Vivo Magnetic Resonance Imaging-Based Detection of Heterogeneous Endothelial Response in Thoracic and Abdominal Aorta to Short-Term High-Fat Diet Ascribed to Differences in Perivascular Adipose Tissue in Mice.
In young post-myocardial infarction male patients elevated plasminogen activator inhibitor-1 correlates with insulin resistance and endothelial dysfunction.
Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome.
Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance.
Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis.
Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.
Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?
Induction of insulin resistance by the adipokines resistin, leptin, plasminogen activator inhibitor-1 and retinol binding protein 4 in human megakaryocytes.
Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion.
Inflammation, insulin resistance, and atherosclerosis.
Influence of body fatness on the coronary risk profile of physically active postmenopausal women.
Infusion of angiotensin II increases fibrinolysis in healthy individuals but not in patients with familial combined hyperlipidemia.
Insertion/Deletion Polymorphism on ACE Gene is Associated with Endothelial Dysfunction in Young Patients with Hypertension.
Insulin resistance and elevated levels of tissue plasminogen activator in first-degree relatives of South Asian patients with ischemic cerebrovascular disease.
Insulin resistance and endothelial dysfunction in atherosclerosis: implications and interventions.
Insulin resistance and risk factors for coronary heart disease.
Insulin resistance and vascular dysfunction in nondiabetic Asian Indians.
Insulin resistance but not visceral adipose tissue is associated with plasminogen activator inhibitor type 1 levels in overweight and obese premenopausal African-American women.
Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome.
Insulin resistance increases PAI-1 in the heart.
Insulin resistance syndrome in postmenopausal women with cardiological syndrome X.
Insulin resistance syndrome: interaction with coagulation and fibrinolysis.
Insulin resistance, hemostatic factors, and hormone interactions in pre- and perimenopausal women: SWAN.
Insulin resistance, inflammation, and the prediabetic state.
Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
Insulin resistance/hyperinsulinemia and reproductive disorders in infertile women.
Insulin sensitivity and hemostatic factors in clinically healthy 58-year-old men.
Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity.
Insulin sensitivity, insulin action, and fibrinolysis activity in nondiabetic and diabetic obese subjects.
Interaction of physical activity and diet: implications for haemostatic factors.
Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation.
Is There a Tendency for Thrombosis in Gestational Diabetes Mellitus?
Is visceral adipose tissue a determinant of von Willebrand factor in overweight and obese premenopausal women?
Lewis phenotypes and the insulin resistance syndrome in young healthy white men and women.
Lifestyle changes may reverse development of the insulin resistance syndrome. The Oslo Diet and Exercise Study: a randomized trial.
Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program.
Liver fat content measured by magnetic resonance spectroscopy at 3.0 tesla independently correlates with plasminogen activator inhibitor-1 and body mass index in type 2 diabetic subjects.
Loss of insulin receptor substrate-1 signaling induces the cardiovascular and proteo(fibrino)lytic system derangements typical of insulin resistance.
Low PAI-1 activity in relation to inflammatory parameters, insulin profile and body mass index.
Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study.
Low-dose spironolactone ameliorates insulin resistance and suppresses elevated plasminogen activator inhibitor-1 during gestational testosterone exposure.
Luteolin-Enriched Artichoke Leaf Extract Alleviates the Metabolic Syndrome in Mice with High-Fat Diet-Induced Obesity.
Markers of intestinal permeability are already altered in early stages of non-alcoholic fatty liver disease: Studies in children.
Markers of remodeling in subcutaneous adipose tissue are strongly associated with overweight and insulin sensitivity in healthy non-obese men.
Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity.
Metabolic Effects of Gastrectomy and Duodenal Bypass in Early Gastric Cancer Patients with T2DM: A Prospective Single-Center Cohort Study.
Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status.
Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy.
Metformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial.
Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial.
Multiple roles of tissue plasminogen activator in schizophrenia pathophysiology.
Nicotine exposure suppresses hyperinsulinemia and improves endothelial dysfunction mediators independent of corticosteroids in insulin-resistant oral contraceptive-treated female rats.
Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue.
North American Wild Rice-Attenuated Hyperglycemia in High-Fat-Induced Obese Mice: Involvement of AMP-Activated Protein Kinase.
Obesity and cancer: the role of dysfunctional adipose tissue.
Obesity without established comorbidities of the metabolic syndrome is associated with a proinflammatory and prothrombotic state, even before the onset of puberty in children.
Obesity, haemostasis and the fibrinolytic system.
Obesity-related derangements of coagulation and fibrinolysis: a study of obesity-discordant monozygotic twin pairs.
Objectively measured sedentary behavior, physical activity, and cardiometabolic risk in Hispanic youth: HCHS/SOL Youth.
On the role of plasminogen activator inhibitor-1 in adipose tissue development and insulin resistance in mice.
Oral glucose tolerance response curve predicts disposition index but not other cardiometabolic risk factors in healthy adolescents.
Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression through reactive oxygen species generation and ERK1/2 activation in 3T3-L1 adipocytes.
PAI-1 in human hypertension: relation to hypertensive groups.
Pathogenesis of vascular disease.
Physical Activity Associations with Bone Mineral Density and Modification by Metabolic Traits.
Plasma adiponectin and insulin resistance in Korean type 2 diabetes mellitus.
Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects.
Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus.
Plasma leptin: associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease.
Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation.
Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity.
Plasma plasminogen activator inhibitor activity in rats with nutritionally induced insulin resistance.
Plasma plasminogen activator inhibitor-1 activity in normoglycemic hypertriglyceridemic north Asian Indian subjects: a preliminary case-control study.
Plasminogen Activator Inhibitor -1 (PAI-1) Predicts Negative Alterations in Whole Body Insulin Sensitivity in Chronic HIV Infection.
Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance states.
Plasminogen activator inhibitor 1 gene polymorphism and gestational diabetes mellitus.
Plasminogen activator inhibitor-1 5G/5G genotype is a protecting factor preventing posttransplant diabetes mellitus.
Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis.
Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men.
Plasminogen Activator Inhibitor-1 Deficiency Ameliorates Insulin Resistance and Hyperlipidemia but not Bone Loss in Obese Female Mice.
Plasminogen activator inhibitor-1 expression and secretion are stimulated by growth hormone and interleukin-6 in 3T3-L1 adipocytes.
Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function.
Plasminogen activator inhibitor-1 modulates adipocyte differentiation.
Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin.
Plasminogen activator inhibitor-1, adipose tissue and insulin resistance.
Plasminogen Activator Inhibitor-1, Body Fat and Insulin Action in Aging Women.
Plasminogen activator inhibitor-1, free fatty acids, and insulin resistance in patients with myocardial infarction.
Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk.
Plasminogen activator inhitor-1 associates with cardiovascular risk factors in healthy young adults in the Cardiovascular Risk in Young Finns Study.
Positive association of adiponectin with soluble thrombomodulin, von Willebrand factor and soluble VCAM-1 in dyslipidemic subjects.
Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.
Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes.
Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction.
Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study.
Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome.
Quinoa Extract Enriched in 20-Hydroxyecdysone Protects Mice From Diet-Induced Obesity and Modulates Adipokines Expression.
Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).
Relationship between circulating leptin and peripheral fat distribution in obese subjects.
Relationship between dietary quality, determined by DASH score, and cardiometabolic health biomarkers: A cross-sectional analysis in adults.
Relationship between endothelial function and fibrinolysis in early hypertension.
Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance.
Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men.
Relationship between resistin and aPAI-1 levels with insulin resistance in Saudi children.
Relationship of hepatic and peripheral insulin resistance with plasminogen activator inhibitor-1 in Pima Indians.
Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women.
Replacing dairy fat with rapeseed oil causes rapid improvement of hyperlipidaemia: a randomised controlled study.
Risk of type 2 diabetes among individuals with high and low glomerular filtration rates.
Role of insulin and proinsulin in diabetic vascular disease.
Role of plasminogen activator inhibitor-1 in the diagnosis and prognosis of patients with Parkinson's disease.
Rosiglitazone: potential beneficial impact on cardiovascular disease.
Saskatoon berry powder reduces hepatic steatosis and insulin resistance in high fat-high sucrose diet-induced obese mice.
Selective insulin resistance affecting nitric oxide release but not plasminogen activator inhibitor-1 synthesis in fibroblasts from insulin-resistant individuals.
Sepsis-Induced Adipokine Change with regard to Insulin Resistance.
Sex-related differences in the associations between hyperleptinemia, insulin resistance and dysfibrinolysis.
Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.
Skin microvascular vasodilatory capacity in offspring of two parents with Type 2 diabetes.
Stimulation in vivo of expression of intra-abdominal adipose tissue plasminogen activator inhibitor Type I by proinsulin.
Stimulation of PAI-1 and adipokines by glucose in human adipose tissue in vitro.
Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits.
Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss.
Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic and Type 2 diabetic subjects.
Swimming, but not vitamin E, ameliorates prothrombotic state and hypofibrinolysis in a rat model of nonalcoholic fatty liver disease.
Testosterone and atherosclerosis in aging men: purported association and clinical implications.
Testosterone and atherosclerosis.
The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance.
The Deidesheimer meeting: significance of classical and new risk factors in non-insulin-dependent diabetes mellitus.
The effect of plasminogen activator inhibitor-1 -675 4G/5G polymorphism on PAI-1 gene expression and adipocyte differentiation.
The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
The genetics of atherothrombotic disorders: a clinician's view.
The influence of obesity and consequent insulin resistance on coronary risk factors in medically treated patients with coronary disease.
The insulin resistance syndrome in smokers is related to smoking habits.
The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men.
The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus.
The role of norepinephrine and insulin resistance in an early stage of hypertension.
The therapeutic potential of bradykinin B2 receptor agonists in the treatment of cardiovascular disease.
Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
Tissue plasminogen activator, fibrin D-dimer, and insulin resistance in the relatives of patients with premature coronary artery disease.
Tissue plasminogen activator, von Willebrand factor, and risk of type 2 diabetes in older men.
TISSUE-SPECIFIC PAI-1 GENE EXPRESSION AND GLYCOSYLATION PATTERN IN INSULIN-RESISTANT OLD RATS.
Tissue-type plasminogen activator antigen and consumption of dairy products. The DESIR study. Data from an Epidemiological Study on Insulin Resistance Syndrome.
Transition of pathophysiological significance of plasminogen activator inhibitor-From a chief player in antiinflammation, antifibrinolysis to that in the development of insulin resistance.
Treatment of polycystic ovary syndrome with insulin-lowering agents.
Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes.
Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1.
Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line.
Unexpected inverse relationship between insulin resistance and serum homocysteine in healthy subjects.
Up-regulated expression of plasminogen activator inhibitor-1 in Hep G2 cells: interrelationship between insulin and insulin-like growth factor 1.
Use of confirmatory factor analysis for the identification of new components of the metabolic syndrome: The role of plasminogen activator inhibitor-1 and Haemoglobin A1c.
Variables of the insulin resistance syndrome are associated with reduced arterial distensibility in healthy non-diabetic middle-aged women.
Xanthine oxidase inhibition by febuxostat attenuates stress-induced hyperuricemia, glucose dysmetabolism, and prothrombotic state in mice.
[A multicompartmental and multifactorial model of production of plasminogen activator inhibitor (PAI-1). II. Clinical study in patients with insulin resistance]
[Clinical research of Yiqi Sanju Formula in treating central obese men at high risk of metabolic syndrome]
[Effects of resolving phlegm method on fibrinolytic status in non-alcoholic steatohepatitis patients of phlegm and blood-stasis syndrome]
[Hypertension and hyperuricemia]
[Inflammatory biomarkers: the link between obesity and associated pathologies]
[Insulin resistance in preeclampsia].
[Insulin resistance: an etiological factor in essential arterial hypertension and coronary cardiopathy]
[Molecular mechanisms of insulin resistance in obesity and type 2 diabetes mellitus.]
[Study on interventing effect of puerarin on insulin resistance in patients with coronary heart disease]
[Theoretical aspects of the relationship between diabetic macroangiopathy and hyperinsulinism]
Insulinoma
Dexamethasone inhibition of tissue-type plasminogen activator (tPA) activity: paradoxical induction of both tPA antigen and plasminogen activator inhibitor.
Effect of estradiol on insulin secreting INS-1 cells overexpressing estrogen receptors.
Glucose- and phorbol ester-induced insulin secretion in human insulinoma cells--association with protein kinase C activation.
Insulinoma, type 2 diabetes and plasminogen activator inhibitor type-I.
Rat oocyte tissue plasminogen activator is a catalytically efficient enzyme in the absence of fibrin. Endogenous potentiation of enzyme activity.
Intermittent Claudication
Association between physical activity and endogenous fibrinolysis in peripheral arterial disease: a cross-sectional study.
Fibrinolytic risk factor clustering and insulin resistance in healthy male relatives of men with intermittent claudication.
Intestinal Perforation
Tissue plasminogen activator for the treatment of intraabdominal abscesses in a neonate.
Intestinal Volvulus
Therapeutic targeting of extracellular DNA improves the outcome of intestinal ischemic reperfusion injury in neonatal rats.
Intraabdominal Infections
Prevention of intra-abdominal abscesses by fibrinolysis using recombinant tissue plasminogen activator.
Intracranial Aneurysm
Cerebral aneurysm rupture after r-TPA thrombolysis for acute myocardial infarction.
Coagulative and fibrinolytic activation in cerebrospinal fluid and plasma after subarachnoid hemorrhage.
Effect of dietary ? carotene on cerebral aneurysm and subarachnoid haemorrhage in the brain apo E(-/-) mice.
Efficacy and Safety of Intravenous Thrombolysis for the Treatment of Acute Ischemic Stroke Patients with Saccular Intracranial Aneurysms of ?3 mm.
Influence of intraoperative using of recombinant tissue plasminogen activator on the development of cerebral angiospasm after subarachnoid haemorrhage in patients with ruptured intracranial aneurysms.
Intrathecal Tissue-type Plasminogen Activator Therapy after Coil Embolization or Surgical Clipping for Ruptured Intracranial Aneurysms: A Prospective Study: ISC 128.
Intravenous rt-PA is not Associated with Increased Risk of Hemorrhage in Patients with Intracranial Aneurysms.
Intraventricular fibrinolysis with tissue plasminogen activator is associated with transient cerebrospinal fluid inflammation: a randomized controlled trial.
Neuroendovascular treatments/procedures: are they efficacious and have they improved patient outcomes poststroke?
Post-thrombolysis rupture of small lenticulostriate aneurysms: A report of 2 consecutive cases.
Recanalization of Middle Cerebral Artery and Intracranial Aneurysm in the Same Ischemic Territory With Intravenous Administration of Recombinant Tissue Plasminogen Activator: Case Report.
Rupture of an Occult Intracranial Mycotic Aneurysm after Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke.
Safety of tissue plasminogen activator factor in an acute stroke patient with two unruptured cerebral aneurysms.
Successful Thrombolysis despite Having an Incidental Unruptured Cerebral Aneurysm.
The risk of intravenous thrombolysis-induced intracranial hemorrhage in Taiwanese patients with unruptured intracranial aneurysm.
The safety of intravenous thrombolysis for ischemic stroke in patients with pre-existing cerebral aneurysms: a case series and review of the literature.
Thrombolysis for intraventricular hemorrhage after endovascular aneurysmal coiling.
Tissue plasminogen activator for acute ischemic stroke in patients with unruptured cerebral aneurysms.
Unruptured Cerebral Aneurysm Detected after Intravenous Tissue Plasminogen Activator for Stroke.
Use of intraventricular tissue plasminogen activator and Guglielmi detachable coiling for the acute treatment of casted ventricles from cerebral aneurysm hemorrhage: two technical case reports.
Vascular Tissue-Type Plasminogen Activator Promotes Intracranial Aneurysm Formation.
[A case of acute ischemic stroke due to cardiac myxoma treated by intravenous thrombolysis and endovascular therapy].
[Application of alteplase in prevention of cerebral vasospasm and its sequelae in patients after aneurysmal subarachnoid hemorrhage from ruptured cerebral aneurysm]
[Postoperative intrathecal irrigation with plasminogen activator (Urokinase) after early stage operation on ruptured cerebral aneurysm]
Intracranial Arteriovenous Malformations
Ruptured arteriovenous malformation complicating thrombolytic therapy with tissue plasminogen activator.
Intracranial Embolism
A Successful Treatment Strategy for Paradoxical Cerebral Embolism Accompanied by Entrapped Thrombus in Patent Foramen Ovale: A Case Report.
Can catheter-directed thrombolysis be applied to acute lower extremity artery embolism after recent cerebral embolism from atrial fibrillation?
Cerebral embolism complicating Libman-Sacks endocarditis--full recovery using recombinant tissue plasminogen activator.
Cerebral embolism during elective carotid endarterectomy treated with tissue plasminogen activator: Utility of intraoperative EEG monitoring.
Correlative Magnetic Resonance Imaging and Autopsy Findings in A Patient with Coagulation Necrosis Treated with Tissue Plasminogen Activator.
Early computed tomographic findings for thrombolytic therapy in patients with acute brain embolism.
Fibrinolytic effect of tissue plasminogen activator on cerebral embolism in stroke-prone spontaneously hypertensive rats.
Mouse model of microembolic stroke and reperfusion.
Paradoxical Brain Embolism Caused by Isolated Pulmonary Arteriovenous Fistula Successfully Treated with Recombinant Tissue Plasminogen Activator.
Recombinant tissue plasminogen activator for both pulmonary and cerebral embolism.
Successful treatment of cerebral emboli with tissue plasminogen activator in a patient with takotsubo cardiomyopathy: A case report.
Tissue plasminogen activator reduces neurological damage after cerebral embolism.
Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits.
[Intravenous recombinant tissue plasminogen activator in an 18-week pregnant woman with embolic stroke]
[Myocardial infarction, late fibrinolysis and resolving cerebral embolism]
Intracranial Hemorrhages
A Four-Year Experience of Symptomatic Intracranial Hemorrhage Following Intravenous Tissue Plasminogen Activator at a Comprehensive Stroke Center.
A Matched Comparison of Eptifibatide Plus RT-PA Versus RT-PA Alone in Acute Ischemic Stroke.
A polymeric micelle magnetic resonance imaging (MRI) contrast agent reveals blood-brain barrier (BBB) permeability for macromolecules in cerebral ischemia-reperfusion injury.
A Prehospital Acute Stroke Trial has Only Modest Impact on Enrollment in Concurrent, Post-arrival-Recruiting Stroke Trials.
A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm.
A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism: The OPTALYSE PE Trial.
A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke.
A Score for Risk of Thrombolysis-Associated Hemorrhage Including Pretreatment with Statins.
Accuracy of Stroke Diagnosis in Telestroke-Guided Tissue Plasminogen Activator Patients.
Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage.
Acute endovascular treatment delivery to ischemic stroke patients transferred within a telestroke network: a retrospective observational study.
Acute stroke: usefulness of early CT findings before thrombolytic therapy.
Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator.
Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy.
Alteplase for acute ischemic stroke.
Alteplase for Acute Ischemic Stroke: Outcomes by Clinically Important Subgroups in the Third International Stroke Trial.
Alteplase for the treatment of central venous catheter occlusion in children: results of a prospective, open-label, single-arm study (The Cathflo Activase Pediatric Study).
An autopsy case of intracranial hemorrhage during tissue plasminogen activator infusion.
An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.
Anterior Communicating Artery Aneurysm Rupture After Intravenous Thrombolysis for Acute Middle Cerebral Artery Thromboembolism.
Antiplatelet therapy and the risk of intracranial hemorrhage after intravenous tissue plasminogen activator therapy for acute ischemic stroke.
Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset?
Assessing the Clinical Efficacy of Recombinant Tissue Plasminogen Activator on Acute Cerebral Infarction.
Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion.
Biomarkers for acute diagnosis and management of stroke in neurointensive care units.
Blood pressure excursions in acute ischemic stroke patients treated with intravenous thrombolysis.
Bolus fibrinolytic therapy in acute myocardial infarction.
Brain hemorrhages after rt-PA treatment of embolic stroke in spontaneously hypertensive rats.
Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke.
Catastrophic Intracranial Hemorrhages after IV tPA in a Patient with Insidious Onset of Fever and Back Pain.
Catastrophic Secondary Infarctions with Onset Seizure Following Tissue Plasminogen Activator Therapy.
Causes, Predictors, and Timing of Early Neurological Deterioration and Symptomatic Intracranial Hemorrhage After Administration of IV tPA.
Cell permeable HMGB1-binding heptamer peptide ameliorates neurovascular complications associated with thrombolytic therapy in rats with transient ischemic stroke.
Characteristics of blood tests in patients with acute cerebral infarction who developed symptomatic intracranial hemorrhage after intravenous administration of recombinant tissue plasminogen activator.
Chronic kidney disease and bleeding complications after intravenous thrombolytic therapy for acute ischemic stroke.
Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis.
Clinical importance of microbleeds in patients receiving IV thrombolysis.
Clot Burden Score and Early Ischemia Predict Intracranial Hemorrhage following Endovascular Therapy.
Clotting Factors to Treat Thrombolysis-related Symptomatic Intracranial Hemorrhage in Acute Ischemic Stroke.
Cluster-Randomized Trial of Thrombolysis Implementation Support in Metropolitan and Regional Australian Stroke Centers: Lessons for Individual and Systems Behavior Change.
Cohort-Based Identification of Predictors of Symptomatic Intracerebral Hemorrhage After IV Thrombolysis.
Combination of reactive oxygen species and tissue-type plasminogen activator enhances the induction of gelatinase B in brain endothelial cells.
Combination therapy with normobaric oxygen (NBO) plus thrombolysis in experimental ischemic stroke.
Community hospital experience with recombinant tissue plasminogen activator in acute myocardial infarction.
Community use of intravenous tissue plasminogen activator for acute stroke: results of the brain matters stroke management survey.
Comparative effects of APSAC and rt-PA on infarct size and left ventricular function in acute myocardial infarction. A multicenter randomized study.
Comparison of different types of endovascular mechanical embolectomy in acute ischemic stroke.
Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. The TIMI Study Group.
Comparison of Stroke Outcomes of Hub and Spoke Hospital Treated Patients in Mayo Clinic Telestroke Program.
Conjugate eye deviation as predictor of acute cortical and subcortical ischemic brain lesions.
Considerations affecting selection of thrombolytic agents.
Correction to: Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
Correction: The impact of general anesthesia, baseline ASPECTS, time to treatment, and IV tPA on intracranial hemorrhage after neurothrombectomy: pooled analysis of the SWIFT PRIME, SWIFT, and STAR trials.
Current progress in searching for clinically useful biomarkers of blood-brain barrier damage following cerebral ischemia.
Disparities between Asian and Non-Asian Thrombolyzed Acute Ischemic Stroke Patients in the Enhanced Control of Hypertension and Thrombolysis Stroke Trial.
Does Prestroke Antiplatelet Therapy Increase the Risk of Symptomatic Intracranial Hemorrhage in Patients Receiving Tissue Plasminogen Activator for Acute Ischemic Stroke?
Drop of PT Quick percent value is associated with both symptomatic and asymptomatic intracranial hemorrhage in patients treated with rt-PA for acute ischemic stroke.
Dual Antiplatelet Therapy after Intravenous Thrombolysis for Acute Minor Ischemic Stroke.
Early recurrent ischemic stroke in stroke patients undergoing intravenous thrombolysis.
Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study.
Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.
Effect of erroneous body-weight estimation on outcome of thrombolyzed stroke patients.
Effect of glycated hemoglobin index and mean arterial pressure on acute ischemic stroke prognosis after intravenous thrombolysis with recombinant tissue plasminogen activator.
Effect of isoflurane post-treatment on tPA-exaggerated brain injury in a rat ischemic stroke model.
Effect of the duration of middle cerebral artery occlusion on the risk of hemorrhagic transformation after tissue plasminogen activator injection in rats.
Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism.
Effectiveness of alteplase in the very elderly after acute ischemic stroke.
Efficacy of Telemedicine for Stroke: Pooled Analysis of the Stroke Team Remote Evaluation Using a Digital Observation Camera (STRokE DOC) and STRokE DOC Arizona Telestroke Trials.
Endovascular administration after intravenous infusion of thrombolytic agents for the treatment of patients with acute ischemic strokes.
Endovascular Mechanical Thrombectomy in Large-Vessel Occlusion Ischemic Stroke Presenting with Low National Institutes of Health Stroke Scale: Systematic Review and Meta-Analysis.
Endovascular Thrombectomy Alone versus Combined with Intravenous Thrombolysis.
Endovascular Thrombectomy for Acute Ischemic Stroke: A Meta-analysis.
Erythropoietin in combination of tissue plasminogen activator exacerbates brain hemorrhage when treatment is initiated 6 hours after stroke.
Extending the time window for intravenous thrombolysis in acute ischemic stroke using magnetic resonance imaging-based patient selection.
Extension of the thrombolytic time window with minocycline in experimental stroke.
External validation of the SEDAN score: The real world practice of a single center.
Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis.
Factors Predicting Outcome in Stroke Patients Treated With 0.6 mg/kg Alteplase: Evidence From the Japan Alteplase Clinical Trial (J-ACT).
Fatal intracranial hemorrhage after intravenous thrombolytic therapy for acute ischemic stroke associated with cancer-related nonbacterial thrombotic endocarditis.
Full-Dose Thrombolysis for a Right Middle Cerebral Artery Stroke after an Acute Aortic Dissection.
Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial.
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Hemorrhagic transformation of ischemic brain tissue after t-PA thrombolysis as detected by MRI may be asymptomatic, but impair neurological recovery.
Imaging strategy for acute stroke therapy.
Impact of Telemedicine Implementation in Thrombolytic Use for Acute Ischemic Stroke: The University of Pittsburgh Medical Center Telestroke Network Experience.
In acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous?
Incidence and Clinical Correlation of Intracranial Hemorrhages Observed by 3-Tesla Gradient Echo T(2)*-Weighted Images following Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator.
Inhibition of PI3K? by AS605240 plus low-dose tissue plasminogen activator (tPA) combination improves thrombolytic therapy in a rat model of embolic stroke.
Intraarterial thrombolytic therapy within 3 hours of the onset of stroke.
Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator.
Intracranial Hemorrhage After Reperfusion Therapies in Acute Ischemic Stroke Patients.
Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis.
Intracranial Hemorrhage Following Thrombolytic Use for Stroke Caused by Infective Endocarditis.
Intracranial hemorrhage rates and effect of immediate beta-blocker use in patients with acute myocardial infarction treated with tissue plasminogen activator. Participants in the National Registry of Myocardial Infarction-2.
Intracranial hemorrhage, outcome, and mortality after intra-arterial therapy for acute ischemic stroke in patients under oral anticoagulants.
Intravenous Alteplase for Acute Ischemic Stroke in Taiwan: Can We Expand the National Health Insurance's Reimbursement Criteria?
Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial.
Intravenous infusion of mesenchymal stem cells inhibits intracranial hemorrhage after recombinant tissue plasminogen activator therapy for transient middle cerebral artery occlusion in rats.
Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS).
Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.
Intravenous Thrombolysis for Stroke Patients with G6PD Deficiency.
Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): final results.
Intravenous Thrombolysis With Tenecteplase in Patients With Large Vessel Occlusions: Systematic Review and Meta-Analysis.
Intravenous thrombolysis with tissue-plasminogen activator in small vessel occlusion.
Intravenous tissue plasminogen activator and stroke in the elderly.
Intravenous tissue plasminogen activator before endovascular treatment increases symptomatic intracranial hemorrhage in patients with occlusion of the middle cerebral artery second division: subanalysis of the RESCUE-Japan Registry.
Intravenous Tissue Plasminogen Activator Improves the Outcome in Very Elderly Korean Patients with Acute Ischemic Stroke.
Intravenous Tissue Plasminogen Activator in Combination With Mechanical Thrombectomy: Clot Migration, Intracranial Bleeding, and the Impact of "Drip and Ship" on Effectiveness and Outcomes.
Ischemic and Bleeding Risk After Percutaneous Coronary Intervention in Patients With Prior Ischemic and Hemorrhagic Stroke.
Isoflurane Postconditioning Inhibits tPA-Induced Matrix Metalloproteinases Activation After Hypoxic Injury via Low-Density Lipoprotein Receptor-Related Protein and Extracellular Signal-Regulated Kinase Pathway.
Isoflurane preconditioning inhibits the effects of tissue-type plasminogen activator on brain endothelial cell in an in vitro model of ischemic stroke.
Lessons from the European Cooperative recombinant tissue-type plasminogen activator (rt-PA) versus placebo trial.
Letter by Dai et al regarding article, "Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the Third International Stroke Trial".
Local intraarterial tirofiban after formation of anterograde flow in patients with acute ischemic stroke: Preliminary experience and short term follow-up results.
Low Alberta Stroke Program Early Computed Tomography Score Within 3 Hours of Onset Predicts Subsequent Symptomatic Intracranial Hemorrhage in Patients Treated with 0.6 mg/kg Alteplase.
Low free triiodothyronine levels predict symptomatic intracranial hemorrhage and worse short-term outcome of thrombolysis in patients with acute ischemia stroke.
Low-Dose Recombinant Tissue-Type Plasminogen Activator Enhances Clot Resolution in Brain Hemorrhage: The Intraventricular Hemorrhage Thrombolysis Trial.
Low-dose versus standard-dose intravenous alteplase for octogenerian acute ischemic stroke patients: A multicenter prospective cohort study.
Management of spinal epidural hematoma after tissue plasminogen activator. A case report.
Matrix Metalloproteinase-9 Expression is Enhanced by Ischemia and Tissue Plasminogen Activator and Induces Hemorrhage, Disability and Mortality in Experimental Stroke.
Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator.
Microbubble-Augmented Ultrasound Sonothrombolysis Decreases Intracranial Hemorrhage in a Rabbit Model of Acute Ischemic Stroke.
Microcatheter contrast injections during intra-arterial thrombolysis may increase intracranial hemorrhage risk.
Mild Hypothermia Reduces Tissue Plasminogen Activator-Related Hemorrhage and Blood Brain Barrier Disruption After Experimental Stroke.
Mild stroke: safety and outcome in patients receiving thrombolysis.
Modified ASPECTS for DWI including deep white matter lesions predicts subsequent intracranial hemorrhage.
MRI-Based Ultrafast Protocol Thrombolysis with rt-PA for Acute Ischemia Stroke in 12-Hour Time Window.
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset.
Multimodal Nanoprobes Evaluating Physiological Pore Size of Brain Vasculatures in Ischemic Stroke Models.
Multimode Computed-Tomography-Guided Thrombolysis under a Prolonged Time Window in Acute Ischemic Stroke Patients with Atrial Fibrillation.
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries.
Not only the Sugar, Early infarct sign, hyperDense middle cerebral artery, Age, Neurologic deficit score but also atrial fibrillation is predictive for symptomatic intracranial hemorrhage after intravenous recombinant tissue plasminogen activator.
Novel Telestroke Program Improves Thrombolysis for Acute Stroke Across 21 Hospitals of an Integrated Healthcare System.
Nursing management of acute complications following rt-PA in acute ischemic stroke. The NINDS rt-PA Stroke Study Group.
NXY-059 for acute ischemic stroke.
Outcome of mechanical thrombectomy in the very elderly for the treatment of acute ischemic stroke: the real world experience.
Outcomes and Treatment Complications of Intravenous Urokinase Thrombolysis in Acute Ischemic Stroke in China.
Outcomes in acute ischemic strokes presenting with disabling neurologic deficits without intracranial vascular occlusion.
Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.
Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke.
Posterior vs. anterior circulation infarction: demography, outcomes, and frequency of hemorrhage after thrombolysis.
Prediction of Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis in Acute Ischemic Stroke: The Symptomatic Intracranial Hemorrhage Score.
Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke.
Predictors of post-thrombolysis symptomatic intracranial hemorrhage in Chinese patients with acute ischemic stroke.
Prestroke Antiplatelet Effect on Symptomatic Intracranial Hemorrhage and Functional Outcome in Intravenous Thrombolysis.
Pretissue Plasminogen Activator Blood Pressure Levels and Risk of Symptomatic Intracerebral Hemorrhage.
Pretreatment blood-brain barrier damage and post-treatment intracranial hemorrhage in patients receiving intravenous tissue-type plasminogen activator.
Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients.
Prognostic Parameters for Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis in Acute Ischemic Stroke in an Asian Population.
Properties of a novel plasminogen activator (BM 06.022) produced in Escherichia coli.
Protective role of tuftsin fragment 1-3 in an animal model of intracerebral hemorrhage.
Proteomic Protease Substrate Profiling of tPA Treatment in Acute Ischemic Stroke Patients: A Step Toward Individualizing Thrombolytic Therapy at the Bedside.
Prothymosin alpha and its mimetic hexapeptide improve delayed tPA-induced brain damage following cerebral ischemia.
Protocol for the perfusion and angiography imaging sub-study of the Third International Stroke Trial (IST-3) of alteplase treatment within six-hours of acute ischemic stroke.
Pulmonary Embolism in a Stroke Patient after Systemic Thrombolysis: Clinical Decisions and Literature Review.
Pyruvate and cilostazol protect cultured rat cortical pericytes against tissue plasminogen activator (tPA)-induced cell death.
Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update.
Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis.
Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial.
Reduction of intracerebral hemorrhage by rivaroxaban after tPA thrombolysis is associated with downregulation of PAR-1 and PAR-2.
Release of Matrix Metalloproteinases-2 and 9 by S-Nitrosylated Caveolin-1 Contributes to Degradation of Extracellular Matrix in tPA-Treated Hypoxic Endothelial Cells.
Relevance of the Updated Food and Drug Administration Alteplase Label for Acute Ischemic Stroke: The Estimated Impact and Current Guidelines.
Remote evaluation of acute ischemic stroke in rural community hospitals in Georgia.
Renal Dysfunction Associated with Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis.
Reperfusion therapy for minor stroke: A systematic review and meta-analysis.
Response to letter regarding article, "Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the Third International Stroke Trial".
Rheolytic catheter thrombectomy, balloon angioplasty, and direct recombinant tissue plasminogen activator thrombolysis of dural sinus thrombosis with preexisting hemorrhagic infarctions.
Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial).
Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies.
Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2.
Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator.
Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator.
Role of Bedside Preparation in Reducing "Door-to-Needle" Tissue-Type Plasminogen Activator (Alteplase) Administration Times and Association with Patient Outcomes.
Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic Stroke.
Rupture of an Occult Intracranial Mycotic Aneurysm after Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke.
Safety and feasibility of intraarterial eptifibatide as a revascularization tool in acute ischemic stroke.
Safety and Tolerability of Desmoteplase Within 3 to 9 Hours After Symptoms Onset in Japanese Patients With Ischemic Stroke.
Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)
Safety of Early Repeated Thrombolysis: A Case Report.
Safety of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Taking Warfarin with Subtherapeutic INR.
Safety of Intravenous Thrombolysis in Chronic Intracranial Hemorrhage: A Five-Year Multicenter Study.
Safety of IV thrombolysis in acute ischemic stroke related to Chagas disease.
Safety of thrombolysis in acute ischemic stroke: a review of complications, risk factors, and newer technologies.
Serum creatinine may indicate risk of symptomatic intracranial hemorrhage after intravenous tissue plasminogen activator (IV tPA).
Shorter Intensive Care Unit Stays? The Majority of Post-Intravenous tPA (Tissue-Type Plasminogen Activator) Symptomatic Hemorrhages Occur Within 12 Hours of Treatment.
Should Age Limit the Use of Catheter-Directed Thrombolysis: Results of National Survey.
Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders.
Simultaneous administration of recombinant tissue plasminogen activator and edaravone in acute cerebral ischemic stroke patients.
Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction.
Statin use and lipid profile in relation to safety and functional outcome after thrombolysis in ischemic stroke.
Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries.
Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic Transformation.
Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure.
Symptomatic intracranial hemorrhage in the ALIAS Multicenter Trial: relationship to endovascular thrombolytic therapy.
Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial.
Tenecteplase versus alteplase after acute ischemic stroke at high age.
Tenecteplase Versus Alteplase Between 3 and 4.5 Hours in Low National Institutes of Health Stroke Scale.
Tenecteplase vs Alteplase Before Endovascular Therapy in Basilar Artery Occlusion.
Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion.
Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction.
Tenecteplase: a review.
The biotechnological potential of fibrinolytic enzymes in the dissolution of endogenous blood thrombi.
The clinical value of antiplatelet therapy for patients with hemorrhage after thrombolysis based on susceptibility-weighted imaging: A prospective pilot study.
The impact of general anesthesia, baseline ASPECTS, time to treatment, and IV tPA on intracranial hemorrhage after neurothrombectomy: pooled analysis of the SWIFT PRIME, SWIFT, and STAR trials.
The risk of intravenous thrombolysis-induced intracranial hemorrhage in Taiwanese patients with unruptured intracranial aneurysm.
The Risk of Symptomatic Intracranial Hemorrhage after Thrombolysis for Acute Stroke: Current Concepts and Perspectives.
The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty.
The use of intraventricular thrombolytics in intraventricular hemorrhage.
The use of recombinant tissue-type plasminogen activator in a newborn with an intracardiac thrombus developed during extracorporeal membrane oxygenation.
Thromboembolic Complications Following Tissue Plasminogen Activator Therapy in Patients of Acute Ischemic Stroke - Case Report and Possibility for Detection of Cardiac Thrombi.
Thrombolysis in young adults with stroke: Findings from Get With The Guidelines-Stroke.
Thrombolysis related symptomatic intracranial hemorrhage in estimated versus measured body weight.
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Thrombolytic Therapy for Acute Ischemic Stroke beyond Three Hours.
Thrombolytic therapy for acute ischemic stroke.
Thrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardial infarction: A decision analysis.
Thrombolytic treatment of acute ischemic stroke.
Timing of symptomatic intracerebral hemorrhage after rt-PA treatment in ischemic stroke.
Tissue plasminogen activator and intracranial hemorrhage.
Tissue Plasminogen Activator Induced Delayed Edema in Experimental Porcine Intracranial Hemorrhage: Reduction with Plasminogen Activator Inhibitor-1 Administration.
Tissue Plasminogen Activator Overdose in Acute Ischemic Stroke Patients Linked to Poorer Functional Outcomes.
Tissue plasminogen activator treatment of stroke in type-1 diabetes rats.
TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.
Towards safer thrombolytic therapy.
tPA Helpers in the Treatment of Acute Ischemic Stroke: Are They Ready for Clinical Use?
tPA Mobilizes Immune Cells That Exacerbate Hemorrhagic Transformation in Stroke.
tPA-S(481)A Prevents Impairment of Cerebrovascular Autoregulation by Endogenous tPA after Traumatic Brain Injury by Upregulating p38 MAPK and Inhibiting ET-1.
Transfusion of Resting Platelets Reduces Brain Hemorrhage After Intracerebral Hemorrhage and tPA-Induced Hemorrhage After Cerebral Ischemia.
Treatment for ischemic stroke: From thrombolysis to thrombectomy and remaining challenges.
Treatment of acute ischemic stroke: systemic or local?
Treatment of acute stroke with recombinant tissue plasminogen activator and abciximab.
Treatment patterns and short-term outcomes in ischemic stroke in pregnancy or postpartum period.
Treatment with tissue plasminogen activator is not associated with increased use of neurosurgery.
Ultrasound Acceleration of rt-PA Thrombolysis Depends on Acoustic Intensity.
Unexplained early neurological deterioration after intravenous thrombolysis: incidence, predictors, and associated factors.
Update on intravenous recombinant tissue plasminogen activator for acute ischemic stroke.
Update on the effects of treatment with recombinant tissue-type plasminogen activator (rt-PA) in acute ischemic stroke.
Use of fibrinolytics for the management of massive pulmonary embolism in a patient with a history of subdural hemorrhage.
Using tPA for acute stroke in a rural setting.
Utilization of intravenous thrombolysis is increasing in the United States.
Validated automatic brain extraction of head CT images.
Validity of HAT score for predicting symptomatic intracranial hemorrhage in acute stroke patients with proximal occlusions: data from randomized trials of sonothrombolysis.
Very mild stroke patients benefit from intravenous tissue plasminogen activator without increase of intracranial hemorrhage.
Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in a rat model of thromboembolic stroke.
[Bilateral intracranial hemorrhage following thrombolytic therapy with alteplase (rTPA) in acute myocardial infarction]
[Effects of statin use on intracranial hemorrhage and clinical outcome after intravenous rt-PA for acute ischemic stroke: SAMURAI rt-PA registry]
[Endovenous thrombolysis in acute myocardial infarct. The experience in a community hospital. An analysis of 120 patients]
[Intravenous thrombolysis in ischemic stroke: Therapeutic perspectives].
[New strategies in the treatment of acute myocardial infarction]
[Non-contrast brain ct based systemic thrombolysis of two wake up ischemic stroke patients in rural settings].
[Systemic thrombolysis with plasminogen activator in chronic stroke patients]
[The Bleeding Safety of Ticagrelor in Patients With ST-Elevation Acute Coronary Syndrome Treated With Fibrinolytic Therapy].
Intracranial Hypertension
Dural sinus mechanical thrombectomy and continuous local rt-PA infusion in a child with refractory intracranial hypertension and progressive visual loss: A case report.
[Treatment of posthemorrhagic hydrocephalus with intraventricular administration of recombinant plasminogen activator (rt-PA) and dexamethasone--possible prevention of permanent shunt implantation?]
Intracranial Thrombosis
Association of Clinical, Imaging, and Thrombus Characteristics With Recanalization of Visible Intracranial Occlusion in Patients With Acute Ischemic Stroke.
Comparison of different methods of thrombus permeability measurement and impact on recanalization in the INTERRSeCT multinational multicenter prospective cohort study.
Differential effect of recombinant tissue plasminogen activator-induced thrombolysis in the central nervous system and systemic arteries.
Intra-arterial tissue plasminogen activator for thrombosis complicating cerebral angiography in a 17-year-old girl.
Intraarterial reteplase and intravenous abciximab for treatment of acute ischemic stroke. A preliminary feasibility and safety study in a non-human primate model.
Neutrophil to lymphocyte ratio predicts intracranial hemorrhage after endovascular thrombectomy in acute ischemic stroke.
Pathologic validation of clot length determined using thin section non-contrast CT.
Radiomics-Based Intracranial Thrombus Features on CT and CTA Predict Recanalization with Intravenous Alteplase in Patients with Acute Ischemic Stroke.
Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial.
Significance of factor V, prothrombin, MTHFR, and PAI-1 genotypes in childhood cerebral thrombosis.
Thrombolytic effects of a combined therapy with targeted microbubbles and ultrasound in a 6 h cerebral thrombosis rabbit model.
Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background.
Invasive Fungal Infections
Macrophage-related fibrinolysis in experimental disseminated histoplasmosis.
Iridocorneal Endothelial Syndrome
Intracameral injection of tissue plasminogen activator to treat severe postoperative fibrinous reaction in iridocorneal endothelial syndrome.
Iridocyclitis
Tissue plasminogen activator to treat impending pupillary block glaucoma in patients with acute fibrinous HLA-B27 positive iridocyclitis.
Iron Overload
Iron Overload Exacerbates the Risk of Hemorrhagic Transformation After tPA (Tissue-Type Plasminogen Activator) Administration in Thromboembolic Stroke Mice.
Ischemic Attack, Transient
Aneurysmal subarachnoid hemorrhage models: do they need a fix?
Can comprehensive stroke centers erase the 'weekend effect'?
Comparison of thrombolysis versus surgery as a first line therapy for prosthetic heart valve thrombosis.
Cost Burden of Stroke Mimics and Transient Ischemic Attack after Intravenous Tissue Plasminogen Activator Treatment.
Dl-NBP (Dl-3-N-Butylphthalide) Treatment Promotes Neurological Functional Recovery Accompanied by the Upregulation of White Matter Integrity and HIF-1?/VEGF/Notch/Dll4 Expression.
Effect of isoflurane post-treatment on tPA-exaggerated brain injury in a rat ischemic stroke model.
In acute ischemic stroke patients with smoking incidence, are more women than men more likely to be included or excluded from thrombolysis therapy?
Intravenous Thrombolysis Is Safe and Effective for the Cryptogenic Stroke in China: Data From the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China).
Intravenous thrombolysis with rt-PA for acute ischemic stroke within 24h of a transient ischemic attack.
Intravenous thrombolytic treatment in a patient with transient ischemic attack associated with mural carotid thrombi.
Intravenous Tissue Plasminogen Activator in Stroke Mimics.
Late Night Activity Regarding Stroke Codes: LuNAR strokes.
Modifying neurorepair and neuroregenerative factors with tPA and edaravone after transient middle cerebral artery occlusion in rat brain.
No-Go to Tissue Plasminogen Activator for Transient Ischemic Attack.
Plasminogen activator inhibitor in acute stroke.
Progression of symptomatic intracranial large artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis.
Safety and efficacy of non-vitamin K oral anticoagulant treatment compared with warfarin in patients with non-valvular atrial fibrillation who develop acute ischemic stroke or transient ischemic attack: a multicenter prospective cohort study (daVinci study).
Stent Retriever-Assisted Mechanical Thrombectomy for Acute Basilar Artery Occlusion: Single US Institution Experience.
Strategies to prevent hemorrhagic transformation after reperfusion therapies for acute ischemic stroke: A literature review.
Tissue plasminogen activator for transient ischemic attack: the case for "off-label" use of thrombolytics.
Transient ischemic attack after tissue plasminogen activator: aborted stroke or unnecessary stroke therapy?
Ischemic Stroke
"Time is Brain:" A concept anaiysis.
'Where are we now with intravenous thrombolysis for acute ischaemic stroke'?
17?-estradiol attenuates breakdown of blood-brain barrier and hemorrhagic transformation induced by tissue plasminogen activator in cerebral ischemia.
2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C.
24-hour blood pressure variability and treatment effect of intravenous alteplase in acute ischaemic stroke.
24/7 Neurocritical Care Nurse Practitioner Coverage Reduced Door-to-Needle Time in Stroke Patients Treated with Tissue Plasminogen Activator.
3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase.
4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke.
5-Fluorouracil associated neurovascular toxicities.
?2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke.
A 2-point difference of NIHSS as a predictor of acute ischemic stroke outcome at 3 months after thrombolytic therapy.
A blinded, randomized study of l-arginine in small clot embolized rabbits.
A call for formal telemedicine training during stroke fellowship.
A Canine Model of Hemorrhagic Transformation Using Recombinant Tissue Plasminogen Activator Administration After Acute Ischemic Stroke.
A Case of Late Diagnosis of Acute Aortic Dissection Involving the Carotid Arteries in a Patient Presenting with Signs of Acute Ischemic Stroke.
A case report of thrombolysis resistance: thrombus ultrastructure in an ischemic stroke patient.
A case-control study of the effectiveness of tissue plasminogen activator on 6 month patients--reported outcomes and health care utilization.
A case-control study of tissue plasminogen activator for acute ischemic stroke.
A Citywide Prehospital Protocol Increases Access to Stroke Thrombolysis in Toronto.
A Clinical Observation of Intravenous Thrombolysis in Acute Ischemic Stroke with Minor Trauma.
A collaborative sequential meta-analysis of individual patient data from randomized trials of endovascular therapy and tPA vs. tPA alone for acute ischemic stroke: ThRombEctomy And tPA (TREAT) analysis: statistical analysis plan for a sequential meta-analysis performed within the VISTA-Endovascular collaboration.
A cost-utility analysis of mechanical thrombectomy as an adjunct to intravenous tissue-type plasminogen activator for acute large-vessel ischemic stroke.
A Critical Analysis of Intra-arterial Thrombolytic Doses in Acute Ischemic Stroke Treatment.
A CT perfusion based model predicts outcome in wake-up stroke patients treated with recombinant tissue plasminogen activator.
A Decade of Improvement in Door-to-Needle Time Among Acute Ischemic Stroke Patients, 2008 to 2017.
A Diagnostic Approach to Stroke in Young Adults.
A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects.
A graphic reanalysis of the NINDS Trial.
A higher body temperature is associated with hemorrhagic transformation in patients with accute stroke non-treated with recombinant tissue-type plasminogen activator (rtPA).
A left MCA territory infarction during intravenous recombinant tissue plasminogen activator therapy for right MCA territory ischaemic stroke.
A literature review of cost-effectiveness of intravenous recombinant tissue plasminogen activator for treating acute ischemic stroke.
A Matched Comparison of Eptifibatide Plus RT-PA Versus RT-PA Alone in Acute Ischemic Stroke.
A Model of Cost-effectiveness of Tissue Plasminogen Activator in Patient Subgroups 3 to 4.5 Hours After Onset of Acute Ischemic Stroke.
A Model to Prevent Fibrinolysis in Patients with Stroke Mimics.
A modified in vitro clot lysis assay predicts outcomes and safety in acute ischemic stroke patients undergoing intravenous thrombolysis.
A multicenter, randomized, controlled study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits with Intra-Arterial therapy (EXTEND-IA).
A multicenter, randomized, double-blind, placebo-controlled trial to test efficacy and safety of magnetic resonance imaging-based thrombolysis in wake-up stroke (WAKE-UP).
A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND).
A Myocardial Infarction During Intravenous Recombinant Tissue Plasminogen Activator Infusion for Evolving Ischemic Stroke.
A Narrative Study of Women's Early Symptom Experience of Ischemic Stroke.
A National Evaluation of Door-to-Imaging Times among Acute Ischemic Stroke Patients within the Veterans Health Administration.
A nationwide study on topography and efficacy of the stroke treatment network in the Czech republic.
A new nomogram for individualized prediction of the probability of hemorrhagic transformation after intravenous thrombolysis for ischemic stroke patients.
A nonfibrin macromolecular cofactor for tPA-mediated plasmin generation following cellular injury.
A novel approach to screening for new neuroprotective compounds for the treatment of stroke.
A Novel Approach to the Treatment of Orolingual Angioedema After Tissue Plasminogen Activator Administration.
A novel effect of Noscapine on patients with massive ischemic stroke: A pseudo-randomized clinical trial.
A patient with anaphylaxis after alteplase infusion.
A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China.
A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke.
A pilot protocol and review of triple neuroprotection with targeted hypothermia, controlled induced hypertension, and barbiturate infusion during emergency carotid endarterectomy for acute stroke after failed tPA or beyond 24-hour window of opportunity.
A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke.
A pilot study of the ticagrelor role in ischemic stroke secondary prevention.
A pragmatic approach to sonothrombolysis in acute ischaemic stroke: the Norwegian randomised controlled sonothrombolysis in acute stroke study (NOR-SASS).
A predictive clinical-genetic model of tissue plasminogen activator response in acute ischemic stroke.
A Prospective Study to Assess the Safety and Effectiveness of Intra-Arterial Reteplase and Intravenous Abciximab in Patients with Acute Ischemic Stroke: Paper 60.
A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke.
A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial.
A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.
A rat model of studying tissue-type plasminogen activator thrombolysis in ischemic stroke with diabetes.
A Regional System of Stroke Care Provides Thrombolytic Outcomes Comparable With the NINDS Stroke Trial.
A resident boot camp for reducing door-to-needle times at academic medical centers.
A Retrospective Study of thrombolysis with 0.6?mg/kg Recombinant Tissue Plasminogen Activator (rt-PA) in Mild Stroke.
A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage.
A Review of the Mechanisms of Blood-Brain Barrier Permeability by Tissue-Type Plasminogen Activator Treatment for Cerebral Ischemia.
A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator.
A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke.
A Score for Risk of Thrombolysis-Associated Hemorrhage Including Pretreatment with Statins.
A spontaneous cervical epidural hematoma mimicking a stroke - A case report.
A Step-up Approach for Cell Therapy in Stroke: Translational Hurdles of Bone Marrow-Derived Stem Cells.
A stroke preparedness RCT in a multi-ethnic cohort: design and methods.
A Stroke Registry Data on the Use of Intravenous Recombinant Tissue Plasminogen Activator in Stroke of Unknown Time of Onset.
A systematic review and meta-analysis of interventions to increase stroke thrombolysis.
A systematic review of economic evaluations on stent-retriever thrombectomy for acute ischemic stroke.
A systemized stroke code significantly reduced time intervals for using intravenous tissue plasminogen activator under magnetic resonance imaging screening.
A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group.
A visit to the stroke belt of the United States.
Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke.
About 30% of wake-up stroke patients may be candidate for the tPA therapy using Negative-FLAIR as a "tissue clock".
Absolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke.
Access of Stroke Patients' to Optimal Healthcare Technology in Greece: Messages to Policy Makers.
Access to Expert Stroke Care with Telemedicine: REACH MUSC.
Accuracy of stroke diagnosis by registered nurses using the ROSIER tool compared to doctors using neurological assessment on a stroke unit: A prospective audit.
Accuracy of the New ICD-9-CM Code for "Drip-and-Ship" Thrombolytic Treatment in Patients with Ischemic Stroke.
ACP Journal Club. In ischemic stroke, early intraarterial treatment plus alteplase improved reperfusion and functional outcome.
ACP Journal Club. rt-PA within 6 hours of acute ischemic stroke did not improve clinical outcomes at 6 months.
ACP Journal Club: adding neurovascular thrombectomy to IV t-PA reduced disability in acute ischemic stroke.
ACR Appropriateness Criteria(®) on Cerebrovascular Disease.
Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats.
Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage.
Activated protein C, protease activated receptor 1, and neuroprotection.
Activation of blood coagulation and thrombin generation in acute ischemic stroke treated with rtPA.
Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke.
Actylise treatment does not influence nitric oxide metabolites serum level.
Acute 'strokenomics': efficacy and economic analyses of alteplase for acute ischemic stroke.
Acute antithrombotic treatment of ischemic stroke.
Acute Blood Pressure Management in Acute Ischemic Stroke and Spontaneous Cerebral Hemorrhage.
Acute changes of coagulation and fibrinolysis parameters after experimental thromboembolic stroke and thrombolytic therapy.
Acute endovascular stroke therapy.
Acute hemorrhagic cholecystitis with gallbladder rupture and massive intra-abdominal hemorrhage.
Acute intravenous--intra-arterial revascularization therapy for severe ischemic stroke.
Acute ischemic stroke after cardiac catheterization: the protamine low-dose recombinant tissue plasminogen activator pathway.
Acute ischemic stroke and long-term outcome after thrombolysis: nationwide propensity score-matched follow-up study.
Acute ischemic stroke as a complication of Stanford type A acute aortic dissection: a review and proposed clinical recommendations for urgent diagnosis.
Acute Ischemic Stroke in Term Pregnancy Treated with Recombinant Tissue Plasminogen Activator.
Acute ischemic stroke therapy.
Acute Ischemic Stroke Treated with Intravenous Tissue Plasminogen Activator in a Patient Taking Dabigatran with Radiographic Evidence of Recanalization.
Acute ischemic stroke treatment and the occurrence of seizures.
Acute ischemic stroke update.
Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis.
Acute Ischemic Stroke: Acute Management and Selection for Endovascular Therapy.
Acute ischemic stroke: comparison of low-dose and standard-dose regimes of tissue plasminogen activator.
Acute Ischemic Stroke: Current Status and Future Directions.
Acute ischemic stroke: emergency department management after the 3-hour window.
Acute ischemic stroke: improving access to intravenous tissue plasminogen activator.
Acute ischemic stroke: new strategies for management and prevention. Interview by Wayne Kuznar.
Acute M2 bifurcation stenting for cerebral infarction: lessons learned from the heart: technical case report.
Acute management and research of stroke in Taiwan: an update.
Acute Management in Very Old Patients: Is Thrombolysis Safe?
Acute Management of Hemostasis in Patients With Neurological Injury.
Acute middle cerebral artery occlusion: reappraisal of the role of endovascular revascularization.
Acute myocardial infarction following intravenous tissue plasminogen activator for acute ischemic stroke: An unknown danger.
Acute pancreatitis is a very rare comorbidity of acute ischemic stroke.
Acute revascularization therapy in pregnant patients.
Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment.
Acute spinal cord ischemia during aortography treated with intravenous thrombolytic therapy.
Acute stroke care in non-urban emergency departments.
Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry.
Acute stroke management in the elderly.
Acute stroke management.
Acute stroke reperfusion therapy trends in the expanded treatment window era.
Acute stroke therapy with tissue plasminogen activator (tPA) since it was approved by the U.S. Food and Drug Administration (FDA).
Acute stroke therapy: beyond i.v. tPA.
Acute stroke thrombolysis in infective endocarditis.
Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital.
Acute stroke with hyperdense middle cerebral artery sign benefits from IV rtPA.
Acute stroke: postprocedural care and management of complications.
Acute stroke: usefulness of early CT findings before thrombolytic therapy.
Acute therapy and prevention of stroke in spontaneous carotid dissection.
Acute treatment for ischemic stroke in 2004.
Acute Treatment of Stroke (Except Thrombectomy).
ADAMTS13-mediated thrombolysis of t-PA resistant occlusions in ischemic stroke in mice.
ADAMTS13: An Emerging Target in Stroke Therapy.
Added Benefit of Stent Retriever Technology for Acute Ischemic Stroke: A Pooled Analysis of the NINDS tPA, SWIFT, and STAR Trials.
Additional Endovascular Therapy in Patients with Acute Ischemic Stroke Who Are Nonresponsive to Intravenous Tissue Plasminogen Activator: Usefulness of Magnetic Resonance Angiography-Diffusion Mismatch.
Adequate Knowledge of Stroke Symptoms, Risk Factors, and Necessary Actions in the General Population of Southern Poland.
Adherence to Guidelines by Emergency Medical Services During Transport of Stroke Patients Receiving Intravenous Thrombolytic Infusion.
Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-hour exclusions and association with outcome: data from Get with the Guidelines-Stroke.
Adjunctive Therapy Approaches for Ischemic Stroke: Innovations to Expand Time Window of Treatment.
Adjuvant intra-arterial rt-PA injection at the initially deployed solitaire stent enhances the efficacy of mechanical thrombectomy in acute ischemic stroke.
Administration of free radical scavenger edaravone associated with higher frequency of hemorrhagic transformation in patients with cardiogenic embolism.
Administration of intravenous tissue plasminogen activator in a pediatric patient with acute ischemic stroke.
Administration of tissue plasminogen activator for acute ischemic stroke in a rural Wisconsin hospital.
Administration of Uric Acid in the Emergency Treatment of Acute Ischemic Stroke.
Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial.
Admission hyperglycemia and outcome after intravenous thrombolysis: is there a difference among the stroke-subtypes?
Advanced Age and Higher National Institutes of Health Stroke Scale Score as Predictors of Poor Outcome in Ischemic Stroke Patients Treated with Alteplase: A Study from a Tertiary Care Centre in Rural North-west India.
Advanced imaging application for acute ischemic stroke.
Advances and challenges in treatment and prevention of ischemic stroke.
Advances in intravenous thrombolytic therapy for treatment of acute stroke.
Advances in ischemic stroke treatment: neuroprotective and combination therapies.
Advances in revascularization for acute ischemic stroke treatment.
Advances in revascularization for acute ischemic stroke treatment: an update.
Advances in treatment of acute ischemic stroke.
Adverse outcome of early recurrent ischemic stroke secondary to atrial fibrillation after repeated systemic thrombolysis.
Age accounts for racial differences in ischemic stroke volume in a population-based study.
Age differences in utilization and outcomes of tissue-plasminogen activator and mechanical thrombectomy in acute ischemic stroke.
Age-specific Cost Effectiveness of Using Intravenous Recombinant Tissue Plasminogen Activator for Treating Acute Ischemic Stroke.
Aggressive blood pressure-lowering treatment before intravenous tissue plasminogen activator therapy in acute ischemic stroke.
Aggressive mechanical clot disruption and low-dose intra-arterial third-generation thrombolytic agent for ischemic stroke: a prospective study.
Agreement Among Stroke Faculty and Fellows in Treating Ischemic Stroke Patients With Tissue-Type Plasminogen Activator and Thrombectomy.
Airway compromise secondary to lingual hematoma complicating administration of tissue plasminogen activator for acute ischemic stroke.
Alberta Stroke Program early computed tomography score to select patients for endovascular treatment: Interventional Management of Stroke (IMS)-III Trial.
Albumin ameliorates tissue plasminogen activator-mediated blood-brain barrier permeability and ischemic brain injury in rats.
Albumin therapy augments the effect of thrombolysis on local vascular dynamics in a rat model of arteriolar thrombosis: a two-photon laser-scanning microscopy study.
Alfimeprase.
Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke: Clinical Outcomes from a Phase 1 Safety Study.
Alteplase and Adjuvant Therapies for Acute Ischemic Stroke.
Alteplase and ischaemic stroke: have new reviews of old data helped?
Alteplase and tenecteplase: applications in the peripheral circulation.
Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT).
Alteplase beyond three hours in ischemic stroke: do we know enough?
Alteplase Causing Cardiac Tamponade after Recent Cardiac Pacemaker Placement.
Alteplase for Acute Ischemic Stroke after Heparin Reversal with Protamine: A Case Report and Review.
Alteplase for Acute Ischemic Stroke Beyond 3 hours: Enthusiasm Outpaces Evidence.
Alteplase for Acute Ischemic Stroke in Patients Aged >80 Years: Pooled Analyses of Individual Patient Data.
Alteplase for acute ischemic stroke.
Alteplase for Acute Ischemic Stroke: Outcomes by Clinically Important Subgroups in the Third International Stroke Trial.
Alteplase for ischaemic stroke.
Alteplase for the Treatment of Acute Ischaemic Stroke: A NICE Single Technology Appraisal; an Evidence Review Group Perspective.
Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal.
Alteplase for the treatment of acute ischaemic stroke: NICE technology appraisal guidance.
Alteplase for the treatment of acute ischemic stroke in patients with low National Institutes of Health Stroke Scale and not clearly disabling deficits (Potential of rtPA for Ischemic Strokes with Mild Symptoms PRISMS): Rationale and design.
Alteplase for thrombolysis in acute ischemic stroke.
Alteplase in acute ischaemic stroke: no time to slow down.
Alteplase in acute ischaemic stroke: the need for speed.
Alteplase in acute ischemic stroke: putting the guidelines into practice.
Alteplase not yet proven for acute ischaemic stroke.
Alteplase Therapy for Acute Ischemic Stroke in Pregnancy: Two Case Reports and a Systematic Review of the Literature.
Alteplase therapy in acute ischemic stroke: a Danish pilot study.OFF.
Alteplase treatment does not increase brain injury after mechanical middle cerebral artery occlusion in the rat.
Alteplase Treatment in Acute Stroke: Incorporating Food and Drug Administration Prescribing Information into Existing Acute Stroke Management Guide.
Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.
Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.
Alteplase: a review of its use in the management of acute ischaemic stroke.
Alteplase: new indication. Inadequately assessed in ischaemic stroke.
Ambulance use affects timely emergency treatment of acute ischaemic stroke.
Amelioration of Cerebral Ischemic Injury by a Synthetic Seco-nucleoside LMT497.
An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.
An alternative facility for a stroke unit in a community hospital.
An assessment of point-of-care measurement of INR using the Coaguchek(®) XS Plus system in the setting of acute ischaemic stroke.
An early successful surgical treatment of fibrinolysis-related symptomatic intracerebral hemorrhage without procoagulant therapy.
An in vitro Model System for Evaluating Remote Magnetic Nanoparticle Movement and Fibrinolysis.
An ischemic stroke during intravenous recombinant tissue plasminogen activator infusion for evolving myocardial infarction.
An Outcome Model for Intravenous rt-PA in Acute Ischemic Stroke.
An uncommon complication of acute stroke thrombolysis.
An uncovered risk factor of sonothrombolysis: Substantial fluctuation of ultrasound transmittance through the human skull.
Analyses of the Turkish National Intravenous Thrombolysis Registry.
Analysis of 16,922 patients with acute ischemic stroke and transient ischemic attack in Japan. A hospital-based prospective registration study.
Analysis of Canadian population with potential geographic access to intravenous thrombolysis for acute ischemic stroke.
Analysis of Metabolite and Lipid Association Networks Reveals Molecular Mechanisms Associated with 3-Month Mortality and Poor Functional Outcomes in Patients with Acute Ischemic Stroke after Thrombolytic Treatment with Recombinant Tissue Plasminogen Activator.
Analysis of plasma fibrinolysis in the patients with acute cerebral infarction.
Analysis of related factors of orolingual angioedema after rt-PA intravenous thrombolytic therapy.
Analysis of Risk Factors Increased Hemorrhagic Transformation after Acute Ischemic Stroke.
Analysis of the Association Between Polymorphisms within PAI-1 and ACE genes and Ischemic Stroke Outcome After rt-PA Therapy.
Analysis of the Efficacy and Safety of Recombinant Tissue Plasminogen Activator for Chinese Patients over 80 Years of Age with Acute Ischemic Stroke: A Pilot Study.
Analysis of Thrombolysis Process for Acute Ischemic Stroke in Urban and Rural Hospitals in Nova Scotia Canada.
Analysis of Workflow and Time to Treatment and the Effects on Outcome in Endovascular Treatment of Acute Ischemic Stroke: Results from the SWIFT PRIME Randomized Controlled Trial.
Anaphylactoid reaction to recombinant tissue plasminogen activator.
Anaphylactoid reactions and angioedema during alteplase treatment of acute ischemic stroke.
Angioedema after administration of tPA for ischemic stroke: case report.
Angioedema after rt-PA treatment in acute ischemic stroke may be attended by shock and worsening of stroke outcome.
Angioedema after thrombolysis with tissue plasminogen activator: an airway emergency.
Angioedema After tPA: What Neurointensivists Should Know.
Angioedema and Hemorrhage After 4.5-Hour tPA (Tissue-Type Plasminogen Activator) Thrombolysis Ameliorated by T541 via Restoring Brain Microvascular Integrity.
Angioedema from recombinant TPA administration: case report and pathophysiology review.
Angioedema in Stroke Patients With Thrombolysis.
Angioedema in the neurointerventional suite.
Angioedema Secondary to IV Tissue Plasminogen Activator Administration for Treatment of Acute Ischemic Stroke.
Angioedema Secondary to tPA Use in Acute Ischemic Stroke Patient with Hypertension: A Case Report.
Angioedema: A Life-threatening Complication of Tissue Plasminogen Activator.
Angiogenesis in Ischemic Stroke and Angiogenic Effects of Chinese Herbal Medicine.
Angioneurotic orolingual oedema following thrombolysis in acute ischaemic stroke.
Angioplasty and stenting for mechanical thrombectomy in acute ischemic stroke.
Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke.
Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection.
Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-Updated series of 120 cases.
Anterior Communicating Artery Aneurysm Rupture After Intravenous Thrombolysis for Acute Middle Cerebral Artery Thromboembolism.
Anti-inflammatory treatments for stroke: from bench to bedside.
Antibodies preventing the interaction of tissue-type plasminogen activator with N-methyl-d-aspartate receptors reduce stroke damages and extend the therapeutic window of thrombolysis.
Anticoagulation Protocol for Secondary Prevention of Acute Ischemic Stroke Associated with Nonvalvular Atrial Fibrillation.
Antihypertensive therapy in acute ischemic stroke: where do we stand?
Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke.
Antiphospholipid-protein antibodies and acute ischemic stroke in the NINDS rt-PA Stroke Trial.
Antiplatelet pretreatment and outcomes in intravenous thrombolysis for stroke: a systematic review and meta-analysis.
Antiplatelet therapy and the risk of intracranial hemorrhage after intravenous tissue plasminogen activator therapy for acute ischemic stroke.
Antiplatelet therapy in combination with rt-PA thrombolysis in ischemic stroke (ARTIS): rationale and design of a randomized controlled trial.
Antiplatelet therapy within 24 hours of tPA: lessons learned from patients requiring combined thrombectomy and stenting for acute ischemic stroke.
Antiplatelet vs. R-tPA for acute mild ischemic stroke: A prospective, random, and open label multi-center study.
Antithrombotic Agents for tPA-Induced Cerebral Hemorrhage: A Systematic Review and Meta-Analysis of Preclinical Studies.
Antithrombotic and thrombolytic therapy for ischemic stroke.
Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Antithrombotic treatments in acute ischemic stroke.
Antithrombotic trials in acute ischaemic stroke: a selective review.
Anton-Babinski syndrome in an old patient: a case report and literature review.
Aortic transgraft hemorrhage after intravenous tissue plasminogen activator therapy in patients with acute ischemic stroke.
Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke.
Application of beta regression to analyze ischemic stroke volume in NINDS rt-PA clinical trials.
Applications and development of permeability imaging in ischemic stroke.
Applications of Liposomal Drug Delivery Systems to Develop Neuroprotective Agents for the Treatment of Ischemic Stroke.
Appropriate Treatment of Ischemic Stroke That Is Essential for the Reduction of Mortality and Morbidity: Should We Use Hyperbaric Oxygen Therapy Together With Recombinant Tissue Plasminogen Activator for Improving Brain Oxygenation and Before Recombinant Tissue Plasminogen Activator to Minimize the Risk of Massive Bleeding?
Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial.
Are patients with acutely recovered cerebral ischemia more unstable?
Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset?
Are there time-dependent differences in diffusion and perfusion within the first 6 hours after stroke onset?
Are Underlying Assumptions of Current Animal Models of Human Stroke Correct: from STAIRs to High Hurdles?
Argatroban tPA stroke study: study design and results in the first treated cohort.
Arrhenius temperature dependence of in vitro tissue plasminogen activator thrombolysis.
Arterial occlusion sites on magnetic resonance angiography influence the efficacy of intravenous low-dose (0.6 mg/kg) alteplase therapy for ischaemic stroke.
Arterial occlusive lesions recanalize more frequently in women than in men after intravenous tissue plasminogen activator administration for acute stroke.
Arterial status after intravenous TPA therapy for ischaemic stroke. A need for further interventions.
Artificial neural network based prediction of postthrombolysis intracerebral hemorrhage and death.
Aspiration Thrombectomy After Intravenous Alteplase Versus Intravenous Alteplase Alone.
Assessing the efficacy of endovascular therapy in stroke treatments: updates from the new generation of trials.
Assessing the impact of thrombolysis on progress through inpatient rehabilitation after stroke: a multivariable approach.
Assessment of Arterial Collateralization and Its Relevance to Intra-arterial Therapy for Acute Ischemic Stroke.
Assessment of eligibility for thrombolysis in acute ischaemic stroke patients in Morocco.
Assessment of Intracranial Collaterals on CT Angiography in Anterior Circulation Acute Ischemic Stroke.
Assessment of recombinant tissue plasminogen activator (rtPA) toxicity in cultured neural cells and subsequent treatment with poly-arginine peptide R18D.
Assessment of the Therapeutic Potential of Metallothionein-II Application in Focal Cerebral Ischemia In Vitro and In Vivo.
Assessment scales for the evaluation of stroke patients.
Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial.
Association between platelet distribution width and poor outcome of acute ischemic stroke after intravenous thrombolysis.
Association Between the Change of Coagulation Parameters and Clinical Prognosis in Acute Ischemic Stroke Patients After Intravenous Thrombolysis With rt-PA.
Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke.
Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke.
Association of Acute and Chronic Hyperglycemia With Acute Ischemic Stroke Outcomes Post-Thrombolysis: Findings From Get With The Guidelines-Stroke.
Association of Admission Leukocyte Count with Clinical Outcomes in Acute Ischemic Stroke Patients Undergoing Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator.
Association of Clinical, Imaging, and Thrombus Characteristics With Recanalization of Visible Intracranial Occlusion in Patients With Acute Ischemic Stroke.
Association of genetic variants of fibrinolytic system with stroke and stroke subtypes.
Association of geographical factors with administration of tissue plasminogen activator for acute ischemic stroke.
Association of growth factors with arterial recanalization and clinical outcome in patients with ischemic stroke treated with tPA.
Association of lower leukocyte count before thrombolysis with early neurological improvement in acute ischemic stroke patients.
Association of PAI-1 4G/5G and -844G/A gene polymorphism and changes in PAI-1/tPA levels in stroke: a case-control study.
Association of PAI-1 4G/5G Polymorphism with Ischemic Stroke in Chinese Patients with Type 2 Diabetes Mellitus.
Association of pretreatment blood pressure with tissue plasminogen activator-induced arterial recanalization in acute ischemic stroke.
Association of Reperfusion After Thrombolysis With Clinical Outcome Across the 4.5- to 9-Hours and Wake-up Stroke Time Window: A Meta-Analysis of the EXTEND and EPITHET Randomized Clinical Trials.
Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study.
Association of survival and hyperthermia after rt-PA for ischemic stroke.
Association of time from last known well to alteplase administration and outcomes in acute stroke.
Associations of inflammatory and hemostatic variables with the risk of recurrent stroke.
Associations of thrombus perviousness derived from entire thrombus segmentation with functional outcome in patients with acute ischemic stroke.
Asymmetric angioneurotic edema associated with thrombolysis for acute stroke.
Asymmetric oro-facial angioedema following alteplase for acute ischaemic stroke.
Asymmetrical cortical vessel sign predicts prognosis after acute ischemic stroke.
Asymptomatic hemorrhagic transformation of cerebral infarction does not worsen long-term outcome.
ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
Atrial fibrillation as an independent predictor for no early recanalization after IV-t-PA in acute ischemic stroke.
Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model.
Audit report and systematic review of orolingual angioedema in post-acute stroke thrombolysis.
Awareness of stroke warning symptoms--13 States and the District of Columbia, 2005.
Azygous Anterior Cerebral Artery Acute Occlusion Managed With Endovascular Mechanical Thrombectomy: 2-Dimensional Operative Video.
Baicalin Attenuates Blood-Brain Barrier Disruption and Hemorrhagic Transformation and Improves Neurological Outcome in Ischemic Stroke Rats with Delayed t-PA Treatment: Involvement of ONOO
Barriers to administering intravenous tissue plasminogen activator (tPA) for acute ischemic stroke in the emergency department: A cross-sectional survey of stroke centers.
Barriers to the Use of Intravenous Tissue Plasminogen Activator for In-hospital Strokes.
Baseline computed tomography changes and clinical outcome after thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke.
Baseline national institutes of health stroke scale-adjusted time window for intravenous tissue-type plasminogen activator in acute ischemic stroke.
Baseline serum glucose concentration and symptomatic haemorrhagic transformation in non-diabetic stroke patients treated by intravenous thrombolysis.
Basilar artery occlusion in a teenaged boy treated with intra-arterial thrombolysis.
Beating the clock: time delays to thrombolytic therapy with advanced imaging and impact of optimized workflow.
Bedside ultrasound diagnosis of a spontaneous splenic hemorrhage after tissue plasminogen activator administration.
Benchmarking Telestroke Proficiency: Page-to-Needle Time Among Neurovascular Fellows and Attendings.
Beneficial effects of the 30-minute door-to-needle time standard for alteplase administration.
Benefits of stroke treatment delivered using a mobile stroke unit trial.
Benign angioedema after thrombolysis for acute stroke.
Beyond intravenous thrombolysis.
Beyond the time window of intravenous thrombolysis: standing by or by stenting?
Beyond tissue plasminogen activator: mechanical intervention in acute stroke.
Bigger, Faster?: Associations Between Hospital Thrombolysis Volume and Speed of Thrombolysis Administration in Acute Ischemic Stroke.
Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: an in vitro experimental approach.
Biological signatures of brain damage associated with high serum ferritin levels in patients with acute ischemic stroke and thrombolytic treatment.
Biomarkers for acute diagnosis and management of stroke in neurointensive care units.
Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients.
Bleeding risk in patients with cardiac disease from ischaemic stroke reperfusion therapy: an update.
Blood Occludin Level as a Potential Biomarker for Early Blood Brain Barrier Damage Following Ischemic Stroke.
Blood pressure during the first minutes of focal cerebral ischemia.
Blood pressure excursions in acute ischemic stroke patients treated with intravenous thrombolysis.
Blood Pressure Management and Evolution of Thrombolysis-associated Intracerebral Hemorrhage in Acute Ischemic Stroke.
Blood Pressure Management Following Acute Ischemic Stroke: A Review of Primary Literature.
Blood Pressure Management Following Large Vessel Occlusion Strokes: A Narrative Review
Blood-Brain Barrier Damage in Ischemic Stroke and Its Regulation by Endothelial Mechanotransduction.
Blood-brain barrier permeability assessed by perfusion computed tomography predicts hemorrhagic transformation in acute reperfusion therapy.
Bolus-Infusion Delays of Alteplase during Thrombolysis in Acute Ischaemic Stroke and Functional Outcome at 3 Months.
Bone marrow-derived NCS-01 cells for ischemic stroke.
Brain Drug Delivery Systems for the Stroke Intervention and Recovery.
Brain imaging abnormalities and outcome after acute ischaemic stroke: the ENCHANTED trial.
Brain imaging modality before systemic thrombolysis for ischemic stroke within three hours.
Brain Imaging Signs and Health-Related Quality of Life after Acute Ischemic Stroke: Analysis of ENCHANTED Alteplase Dose Arm.
Bridge mechanical thrombectomy may be a better choice for acute large vessel occlusions.
Bridging versus direct endovascular therapy in basilar artery occlusion.
Bringing Emergency Neurology to Ambulances: Mobile Stroke Unit.
Bryostatin extends tPA time window to 6 h following middle cerebral artery occlusion in aged female rats.
Budget Impact Analysis of The Use of Alteplase In The Treatment of Acute Ischaemic Stroke In Mexico.
Building a "brain attack" team to administer thrombolytic therapy for acute ischemic stroke.
Can Children Reduce Delayed Hospital Arrival for Ischemic Stroke?: A Systematic Review of School-Based Stroke Education.
Can comprehensive stroke centers erase the 'weekend effect'?
Can Pay-for Performance Incentive Levels be Determined Using a Cost-Effectiveness Framework?
Canadian guidelines for intravenous thrombolytic treatment in acute stroke. A consensus statement of the Canadian Stroke Consortium.
Candesartan and glycyrrhizin ameliorate ischemic brain damage through downregulation of the TLR signaling cascade.
Candidates for thrombolytic treatment in acute ischaemic stroke--where are our patients in Hong Kong?
Canonical Wnt Pathway Maintains Blood-Brain Barrier Integrity upon Ischemic Stroke and Its Activation Ameliorates Tissue Plasminogen Activator Therapy.
Cardiac Tamponade after Thrombolysis for Acute Ischemic Stroke A Case with an Excellent Outcome.
Cardioembolic stroke on unaffected side during thrombolysis for acute ischemic stroke.
Carotid Artery Dissection and Ischemic Stroke Originating from Localized Aortic Arch Dissection.
Carotid Artery Stenting for Acute Ischemic Stroke Patients after Intravenous Recombinant Tissue Plasminogen Activator Treatment.
Carotid Ultrasonography Can Identify Stroke Patients Ineligible for Intravenous Thrombolysis Therapy due to Acute Aortic Dissection.
Catastrophic Intracranial Hemorrhages after IV tPA in a Patient with Insidious Onset of Fever and Back Pain.
Cathepsin K Knockout Exacerbates Haemorrhagic Transformation Induced by Recombinant Tissue Plasminogen Activator After Focal Cerebral Ischaemia in Mice.
Causes and Treatment of Acute Ischemic Stroke During Pregnancy.
CE: Acute Ischemic Stroke.
Cell permeable HMGB1-binding heptamer peptide ameliorates neurovascular complications associated with thrombolytic therapy in rats with transient ischemic stroke.
Cell-Based Therapies for Stroke: Are We There Yet?
Centenarian middle cerebral artery occlusion treated with intra-arterial mechanical embolectomy.
Central Nervous System Agents for Ischemic Stroke: Neuroprotection Mechanisms.
Cerebral Amyloid Angiopathy: A Hidden Risk for IV Thrombolysis?
Cerebral aneurysm as an exacerbating factor in stroke pathology and a therapeutic target for neuroprotection.
Cerebral autoregulation and response to intravenous thrombolysis for acute ischemic stroke.
Cerebral autoregulation dynamics in acute ischemic stroke after rtPA thrombolysis.
Cerebral beta-amyloid detected by pittsburgh compound B positron emission topography predisposes to recombinant tissue plasminogen activator-related hemorrhage.
Cerebral endothelial cell-derived small extracellular vesicles enhance neurovascular function and neurological recovery in rat acute ischemic stroke models of mechanical thrombectomy and embolic stroke treatment with tPA.
Cerebral glucose transporter: The possible therapeutic target for ischemic stroke.
Cerebral hemorrhage after systemic fibrinolysis in a patient with severe carotid artery stenosis.
Cerebral Microbleeds are an Independent Predictor of Hemorrhagic Transformation Following Intravenous Alteplase Administration in Acute Ischemic Stroke.
Cerebral microbleeds development after stroke thrombolysis: A secondary analysis of the THAWS randomized clinical trial.
Cerebral microbleeds shouldn't dictate treatment of acute stroke: a retrospective cohort study evaluating risk of intracerebral hemorrhage.
Cerebrovascular Complications of Diabetes: Focus on Stroke.
Cerebrovascular disease--advances in management.
Cervene (Nalmefene) in acute ischemic stroke : final results of a phase III efficacy study. The Cervene Stroke Study Investigators.
Cervical spinal epidural hematoma mimics acute ischemic stroke.
Challenges of Decision Making Regarding Futility in a Randomized Trial: The Interventional Management of Stroke III Experience.
Challenges of Thrombolysis in a Developing Country: Characteristics and Outcomes in Peru.
Change in hemostatic markers after recombinant tissue-type plasminogen activator is not associated with the chance of recanalization.
Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator.
Changes in Informed Consent Policy and Treatment Delays in Stroke Thrombolysis.
Changes in neutrophil, lymphocyte, platelet ratios and their relationship with NIHSS after rtPA and/or thrombectomy in ischemic stroke.
Changing contraindications for t-PA in acute stroke: review of 20 years since NINDS.
Characteristics and outcome of patients with early complete neurological recovery after thrombolysis for acute ischemic stroke.
Characteristics and Outcomes Among Patients Transferred to a Regional Comprehensive Stroke Center for Tertiary Care.
Characteristics and Outcomes of Patients who Refuse Intravenous Thrombolysis for Acute Ischemic Stroke - The San Diego Experience.
Characteristics of academic medical centers and ischemic stroke outcomes.
Characteristics of blood tests in patients with acute cerebral infarction who developed symptomatic intracranial hemorrhage after intravenous administration of recombinant tissue plasminogen activator.
Chemotherapy induced stroke mimic: 5-Fluorouracil encephalopathy fulfilling criteria for tissue plasminogen activator therapy.
Chinese herbal injections combined with rt-PA intravenous thrombolysis for acute ischemic stroke: A systematic review and meta-analysis protocol.
Cholesterol reducer and thrombolytic therapy in acute ischemic stroke patients.
Choosing the Correct "-ase" in Acute Ischemic Stroke: Alteplase, Tenecteplase, and Reteplase.
Chronic nicotine treatment enhances focal ischemic brain injury and depletes free pool of brain microvascular tissue plasminogen activator in rats.
Circadian rhythms in the efficacy of intravenous alteplase in patients with acute ischemic stroke and middle cerebral artery occlusion.
Circadian rhythms may not influence the outcomes of thrombolysis in patients with ischemic stroke: A study from China.
Citation bias favoring positive clinical trials of thrombolytics for acute ischemic stroke: a cross-sectional analysis.
Cleavage of the NR2B subunit amino terminus of N-methyl-D-aspartate (NMDA) receptor by tissue plasminogen activator: identification of the cleavage site and characterization of ifenprodil and glycine affinities on truncated NMDA receptor.
Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours.
Clinical and radiological factors associated with unfavorable outcome after intravenous thrombolysis in patients with mild ischemic stroke.
Clinical and sonographic patterns of tandem internal carotid artery/middle cerebral artery occlusion in tissue plasminogen activator-treated patients.
Clinical and tissue response to intravenous thrombolysis in tandem internal carotid artery/middle cerebral artery occlusion: an MRI study.
Clinical characteristics and risk score for poor clinical outcome of acute ischemic stroke patients treated with intravenous thrombolysis therapy.
Clinical Course of Acute Ischemic Stroke Due to Medium Vessel Occlusion With and Without Intravenous Alteplase Treatment.
Clinical Deterioration and Early Imaging Changes after Intravenous Tissue Plasminogen Activator Administration in Acute Ischemic Stroke Patients.
Clinical efficacy and imaging evaluation of recombinant tissue plasminogen activator thrombolytic therapy in patients with wake up stroke: A randomized controlled trial.
Clinical efficacy and safety of hypernormal shortened door to needle time (DNT) plus individualized low-dose alteplase therapy in treating acute ischemic stroke.
Clinical features and efficacy of reperfusion therapy in minor ischemic stroke patients with atrial fibrillation.
Clinical implication of hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator.
Clinical importance of microbleeds in patients receiving IV thrombolysis.
Clinical Outcomes among Stroke Patients Receiving Tissue Plasminogen Activator Therapy Beyond the 3-hour Time Window.
Clinical outcomes of acute stroke thrombolysis in neurologist and non-neurologist centres - A comparative study in Malaysia.
Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department.
Clinical Policy: Use of intravenous tPA for the management of acute ischemic stroke in the emergency department.
Clinical Utility of Electronic Alberta Stroke Program Early Computed Tomography Score Software in the ENCHANTED Trial Database.
Clinical, Biochemical and Neuroimaging Parameters after Thrombolytic Therapy Predict Long-Term Stroke Outcome.
Cloning and expression of functional full-length human tissue plasminogen activator in Pichia pastoris.
Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion.
CLOTBUST-Hands Free: pilot safety study of a novel operator-independent ultrasound device in patients with acute ischemic stroke.
CLOTBUST: design of a randomized trial of ultrasound-enhanced thrombolysis for acute ischemic stroke.
Clotting Factors to Treat Thrombolysis-related Symptomatic Intracranial Hemorrhage in Acute Ischemic Stroke.
Cluster-Randomized Trial of Thrombolysis Implementation Support in Metropolitan and Regional Australian Stroke Centers: Lessons for Individual and Systems Behavior Change.
Co-administration of tissue plasminogen activator and hyperbaric oxygen in ischemic stroke: a continued promise for neuroprotection.
Co-morbid conditions in use of recombinant tissue plasminogen activator (rt-PA) for the treatment of acute ischaemic stroke.
Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores.
Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke.
Cocktail treatment, a promising strategy to treat acute cerebral ischemic stroke?
Code stroke in Asturias.
Code Stroke: rapid transport, triage and treatment using rt-PA therapy. The NINDS rt-PA Stroke Study Group.
Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke: Findings From Get With The Guidelines-Stroke.
Cognitive and functional outcome after intravenous recombinant tissue plasminogen activator treatment in patients with a first symptomatic brain infarct.
Cognitive deficits in acute mild ischemic stroke and TIA and effects of rt-PA.
Cohort-Based Identification of Predictors of Symptomatic Intracerebral Hemorrhage After IV Thrombolysis.
Collaterals: an important determinant of prolonged ischemic penumbra versus rapid cerebral infarction?
Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial.
Combination of thrombolytic therapy and neuroprotective therapy in acute ischemic stroke: is it important?
Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice.
Combination therapy for ischemic stroke: Novel approaches to lengthen therapeutic window of tissue plasminogen activator.
Combination therapy of 17beta-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke.
Combination therapy of intravenous glycoprotein IIB/IIIA inhibitors and tissue plasminogen activator for acute ischemic stroke.
Combination Therapy Using tPA and Edaravone Improves the Neurotoxic Effect of tPA.
Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke.
Combination treatment of r-tPA and an optimized human apyrase reduces mortality rate and hemorrhagic transformation 6h after ischemic stroke in aged female rats.
Combination treatment with rt-PA is more effective than rt-PA alone in an in vitro human clot model.
Combination treatment with U0126 and rt-PA prevents adverse effects of the delayed rt-PA treatment after acute ischemic stroke.
Combined administration of the GPVI-Fc fusion protein Revacept with low-dose thrombolysis in the treatment of stroke.
Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke?
Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial.
Combined intraarterial/intravenous thrombolysis for acute ischemic stroke.
Combined intravenous and intra-arterial approach in acute stroke treatment.
Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial.
Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke.
Combined intravenous and intraarterial revascularization therapy using MRI perfusion/diffusion mismatch selection for acute ischemic stroke at 3-6 h after symptom onset.
Combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator for emergent revascularization in acute ischemic stroke (CLOTBUST-ER): design and methodology of a multinational phase 3 trial.
Combined systemic thrombolysis with alteplase and early hyperbaric oxygen therapy in experimental embolic stroke in rats: relationship to functional outcome and reduction of structural damage.
Combined therapy of intensive statin plus intravenous rt-PA in acute ischemic stroke: the INSPIRE randomized clinical trial.
Combined therapy with PJ34, a poly(ADP-ribose)polymerase inhibitor, reduces tissue plasminogen activator-induced hemorrhagic transformations in cerebral ischemia in mice.
Combined tissue plasminogen activator and an NK1 tachykinin receptor antagonist: An effective treatment for reperfusion injury following acute ischemic stroke in rats.
Combined Treatment With 2-(2-Benzofu-Ranyl)-2-Imidazoline and Recombinant Tissue Plasminogen Activator Protects Blood-Brain Barrier Integrity in a Rat Model of Embolic Middle Cerebral Artery Occlusion.
Comment on US geographic distribution of recombinant tissue plasminogen activator use by hospitals for acute ischemic stroke.
Comment on: A Cost-Utility Analysis of Mechanical Thrombectomy as an Adjunct of Intravenous Tissue-Type Plasminogen Activator for Acute Large-Vessel Ischemic Stroke : Kim AS, Nguyen-Huynh M, Johnston SC. Stroke 2011;42:2013-2018.
Commentary on NICE guidelines for alteplase for the treatment of acute ischaemic stroke.
Communication-type smartphone application can contribute to reducing elapsed time to reperfusion therapy.
Community implementation of intravenous thrombolysis for acute ischemic stroke in the 3- to 4.5-hour window.
Community-based thrombolytic therapy of acute ischemic stroke in Helsinki.
Comparative Analysis on Low- and Standard-Dose Regimes of Alteplase Thrombolytic Therapy for Acute Ischemic Stroke: Efficacy and Safety.
Comparative Assessment of the Proteolytic Stability and Impact of Poly-Arginine Peptides R18 and R18D on Infarct Growth and Penumbral Tissue Preservation Following Middle Cerebral Artery Occlusion in the Sprague Dawley Rat.
Comparative effects of low-dose versus standard-dose alteplase in ischemic patients with prior stroke and/or diabetes mellitus: The ENCHANTED trial.
Comparative effects of microplasmin and tissue-type plasminogen activator (tPA) on cerebral hemorrhage in a middle cerebral artery occlusion model in mice.
Comparing outcome and recanalization results in patients with anterior circulation stroke following endovascular treatment with and without a treatment with rt-PA: A single-center study.
Comparison of acute nonthrombolytic and thrombolytic treatments in ischemic stroke patients 80 years or older.
Comparison of Cardiovascular Risk Factors for Coronary Heart Disease and Stroke Type in Women.
Comparison of Clinical Care and In-Hospital Outcomes of Asian American and White Patients With Acute Ischemic Stroke.
Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.
Comparison of intravenous and intra-arterial urokinase thrombolysis for acute ischaemic stroke.
Comparison of MRI-based thrombolysis for patients with middle cerebral artery occlusion
Comparison of multistate Markov modeling with contemporary outcomes in a reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
Comparison of Partial (.6 mg/kg) versus Full-Dose (.9 mg/kg) Intravenous Recombinant Tissue Plasminogen Activator Followed by Endovascular Treatment for Acute Ischemic Stroke: A Meta-Analysis.
Comparison of plasmin with recombinant tissue-type plasminogen activator in lysis of cerebral thromboemboli retrieved from patients with acute ischemic stroke.
Comparison of the post-embolization effects of tissue-plasminogen activator and simvastatin on neurological outcome in a clinically relevant rat model of acute ischemic stroke.
Comparison of the Time Course of Return to Work After Stroke Between Two Cohort Studies in Japan.
Comparison of Therapeutic Effect of Recombinant Tissue Plasminogen Activator by Treatment Time after Onset of Acute Ischemic Stroke.
Comparison of thrombolytic agents in treatment of patients with acute ischemic stroke; findings from a single centre follow up study in real-life settings.
Comparison of time to treatment between intravenous and endovascular thrombolytic treatments for acute ischemic stroke.
Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke.
Complications of Microvascular Upper Lip and Free Grafted Nasal and Eyebrow Replantation After Assault via Human Bite.
Complications of the endovascular management of acute ischemic stroke.
Computational simulations of thrombolysis in acute stroke: Effect of clot size and location on recanalisation.
Computational Simulations of Thrombolytic Therapy in Acute Ischaemic Stroke.
Computed tomography perfusion-based selection of patients for endovascular recanalization.
Computer-Aided Diagnosis of Hyperacute Stroke with Thrombolysis Decision Support Using a Contralateral Comparative Method of CT Image Analysis.
Conjugate Eye Deviation on CT Associated With Worse Outcomes Despite IV Thrombolysis.
Consensus statement on the use of intravenous recombinant tissue plasminogen activator to treat acute ischemic stroke by the Chinese Stroke Therapy Expert Panel.
Consent for intravenous thrombolysis in acute stroke: review and future directions.
Consent issues in neurology.
Consent to thrombolysis in acute ischaemic stroke: from trial to practice.
Considering hyperglycemia and thrombolysis in the Stroke Hyperglycemia Insulin Network Effort (SHINE) trial.
Contemporary acute ischemic stroke therapy with intravenous recombinant tissue plasminogen activator.
Continuous monitoring of middle cerebral artery recanalization with transcranial color-coded sonography and Levovist.
Contraindications to intravenous rtPA for acute stroke: A critical reappraisal.
Controversies about tissue plasminogen activator: extending the window of therapy.
Coronary aspiration thrombectomy after using intravenous recombinant tissue plasminogen activator in a patient with acute ischemic stroke: a case report.
Correction: Correction to 'Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department' [Annals of Emergency Medicine 66 (2015) 322-333.e31].
Correlation of cavitation with ultrasound enhancement of thrombolysis.
Cortical myoclonus during IV thrombolysis for ischemic stroke.
Cost analysis review of stroke centers, telestroke, and rt-PA.
Cost Effectiveness of Drive and Retrieve System in Hokkaido for Acute Ischemic Stroke Patient Treatment Using Geographic Information System.
Cost-effectiveness analysis of mechanical thrombectomy in acute ischemic stroke.
Cost-effectiveness analysis of mechanical thrombectomy plus tissue-type plasminogen activator compared with tissue-type plasminogen activator alone for acute ischemic stroke in France.
Cost-effectiveness analysis of mechanical thrombectomy with stent retriever in the treatment of acute ischemic stroke in Italy.
Cost-effectiveness analysis of tissue plasminogen activator for acute ischemic stroke: a comparative review.
Cost-effectiveness analysis of tissue plasminogen activator in acute ischemic stroke in Iran.
Cost-effectiveness of CT perfusion for selecting patients for intravenous thrombolysis: a US hospital perspective.
Cost-Effectiveness of Intra-Arterial Treatment as an Adjunct to Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke.
Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke.
Cost-effectiveness of mechanical thrombectomy using stent retriever after intravenous tissue plasminogen activator compared with intravenous tissue plasminogen activator alone in the treatment of acute ischaemic stroke due to large vessel occlusion in Spain.
Cost-effectiveness of patient selection using penumbral-based MRI for intravenous thrombolysis.
Cost-effectiveness of recombinant tissue plasminogen activator in the management of acute ischemic stroke: a systematic review.
Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence.
Cost-Effectiveness of Solitaire Stent Retriever Thrombectomy for Acute Ischemic Stroke: Results From the SWIFT-PRIME Trial (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke).
Cost-effectiveness of Stent-retriever Thrombectomy in combination with IV t-PA Compared with IV t-PA Alone for Acute Ischemic Stroke in the UK.
Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs.
Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China.
Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke.
Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group.
Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke.
Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective.
Criteria for Emergency Brain MRI During Stroke-Alert.
Critical Care Needs in Patients with Diffusion-Weighted Imaging Negative MRI after tPA--Does One Size Fit All?
Cryptogenic stroke in relation to genetic variation in clotting factors and other genetic polymorphisms among young men and women.
Cryptogenic stroke: clinical consideration of a heterogeneous ischemic subtype.
CT Angiography in an Acute Stroke Protocol: Correlation between Occlusion Site and Outcome of Intravenous Thrombolysis.
CT for Treatment Selection in Acute Ischemic Stroke: A Code Stroke Primer.
Current and future use of intravenous thrombolysis for acute ischemic stroke.
Current concepts in neurocritical care.
Current controversies: thrombolysis for patients with acute ischaemic stroke aged over 80.
Current Drug Treatment of Acute Ischemic Stroke: Challenges and Opportunities.
Current Endovascular Treatment of Acute Ischemic Stroke.
Current endovascular treatment of acute stroke and future aspects.
Current indications and results of thrombolysis by intravenous recombinant tissue plasminogen activator.
Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke.
Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke.
Current practice versus willingness to enroll in clinical trials: paradox among vascular neurologists about treatment for acute ischemic stroke.
Current progress in searching for clinically useful biomarkers of blood-brain barrier damage following cerebral ischemia.
Current Smoking Does Not Modify the Treatment Effect of Intravenous Thrombolysis in Acute Ischemic Stroke Patients-A Post-hoc Analysis of the WAKE-UP Trial.
Current status of intravenous tissue plasminogen activator dosage for acute ischaemic stroke: an updated systematic review.
Current understanding of TRPM7 pharmacology and drug development for stroke.
Cystatin C is a potential predictor of unfavorable outcomes for cerebral ischemia with intravenous tissue plasminogen activator treatment: A multicenter prospective nested case-control study.
Cytoprotective Drug-Tissue Plasminogen Activator Protease Interaction Assays: Screening of Two Novel Cytoprotective Chromones.
D1 receptor-mediated endogenous tPA upregulation contributes to blood-brain barrier injury after acute ischaemic stroke.
Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke.
Decade-Long Nationwide Trends and Disparities in Use of Comfort Care Interventions for Patients With Ischemic Stroke.
Decompressive craniectomy after intravenous tissue plasminogen activator administration for stroke.
Decompressive craniectomy after unsuccessful intravenous thrombolysis of malignant cerebral infarction.
Decrease in blood pressure after intravenous administration of urapidil during recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke.
Decreased clot burden is associated with factor XIII Val34Leu polymorphism and better functional outcomes in acute ischemic stroke patients treated with intravenous thrombolysis.
Decreased Insulin Sensitivity and Impaired Fibrinolytic Activity in Type 2 Diabetes Patients and Nondiabetics with Ischemic Stroke.
Defibrinogen Therapy for Acute Ischemic Stroke: 1332 Consecutive Cases.
Deficiency in serine protease inhibitor neuroserpin exacerbates ischemic brain injury by increased postischemic inflammation.
Defining mild stroke: outcomes analysis of treated and untreated mild stroke patients.
Delay in presentation after acute ischemic stroke: the Careggi Hospital Stroke Registry.
Delayed matrix metalloproteinase inhibition reduces intracerebral hemorrhage after embolic stroke in rats.
Delayed postconditioning protects against focal ischemic brain injury in rats.
Delayed treatment with a novel neurotrophic compound reduces behavioral deficits in rabbit ischemic stroke.
Delayed treatment with ADAMTS13 ameliorates cerebral ischemic injury without hemorrhagic complication.
Delays in Door-to-Needle Times and Their Impact on Treatment Time and Outcomes in Get With The Guidelines-Stroke.
Derivation and Validation of a Scoring System for Intravenous Tissue Plasminogen Activator Use in Asian Patients.
Description of a novel telemedicine-enabled comprehensive system of care: drip and ship plus drip and keep within a system of stroke care delivery.
Design of a PROspective multi-national CLOTBUST collaboration on reperfusion therapies for stroke (CLOTBUST-PRO).
Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke: The DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke).
Desmoteplase After Ischemic Stroke in Patients With Occlusion or High-Grade Stenosis in Major Cerebral Arteries.
Desmoteplase as a potential treatment for cerebral ischaemia.
Desmoteplase for Acute Ischemic Stroke within 3 to 9?Hours after Symptom Onset: Evidence from Randomized Controlled Trials.
Desmoteplase for Acute Ischemic Stroke: A Systematic Review and Metaanalysis of Randomized Controlled Trials.
Desmoteplase in the treatment of acute ischemic stroke.
Desmoteplase.
Desmoteplase: discovery, insights and opportunities for ischaemic stroke.
Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis.
Detection of early CT signs of >1/3 middle cerebral artery infarctions : interrater reliability and sensitivity of CT interpretation by physicians involved in acute stroke care.
Determinants of early outcomes in patients with acute ischemic stroke and proximal artery occlusion.
Determinants of outcome in patients eligible for thrombolysis for ischemic stroke.
Determinants of plasminogen activator inhibitor-1 in South Asians with ischaemic stroke.
Determinants of tPA antigen and associations with coronary artery disease and acute cerebrovascular disease.
Determining intravenous rt-PA eligibility in the Emergency Department.
Detriments of tPA for acute stroke in routine clinical practice.
Developing a multivariable prediction model for functional outcome after reperfusion therapy for acute ischaemic stroke: study protocol for the Targeting Optimal Thrombolysis Outcomes (TOTO) multicentre cohort study.
Developing therapy for acute ischemic stroke.
Development and initial testing of the stroke rapid-treatment readiness tool.
Development of a metropolitan matrix of primary stroke centers: the Phoenix experience.
Development of the nitrone-based spin trap agent NXY-059 to treat acute ischemic stroke.
Diabetes and previous stroke: hazards for intravenous thrombolysis?
Diabetes Mellitus/Poststroke Hyperglycemia: a Detrimental Factor for tPA Thrombolytic Stroke Therapy.
Diabetes Worsens Functional Outcomes in Young Female Rats: Comparison of Stroke Models, Tissue Plasminogen Activator Effects, and Sexes.
Diagnostic impact of baseline cerebral blood flow in patients with acute ischemic stroke prior to intravenous recombinant tissue plasminogen activator therapy.
Dietary Supplementations as Neuroprotective Therapies: Focus on NT-020 Diet Benefits in a Rat Model of Stroke.
Differences between predictive factors for early neurological deterioration due to hemorrhagic and ischemic insults following intravenous recombinant tissue plasminogen activator.
Different doses of recombinant tissue-type plasminogen activator for acute stroke in Chinese patients.
Different doses of tenecteplase vs alteplase in thrombolysis therapy of acute ischemic stroke: evidence from randomized controlled trials.
Differential Effect of Baseline Computed Tomographic Angiography Collaterals on Clinical Outcome in Patients Enrolled in the Interventional Management of Stroke III Trial.
Dilemma of Indication for Thrombolysis in a Patient with Acute Ischemic Stroke Treated with a Novel Oral Anticoagulant.
Direct arterial damage and neurovascular unit disruption by mechanical thrombectomy in a rat stroke model.
Direct thrombectomy versus bridging thrombolysis with mechanical thrombectomy in middle cerebral artery stroke: a real-world analysis through National Inpatient Sample data.
Disparities and Trends in Door-to-Needle Time: The FL-PR CReSD Study (Florida-Puerto Rico Collaboration to Reduce Stroke Disparities).
Distance Neurological Supervision Using Telestroke Does Not Increase Door-to-Needle Time in Acute Ischemic Stroke Management: The Experience of Two Regional Stroke Units.
Diverse roles of mitochondria in ischemic stroke.
Dl-3-n-Butylphthalide (NBP): A Promising Therapeutic Agent for Ischemic Stroke.
Do centres with well-developed protocols, training and infrastructure have higher rates of thrombolysis for acute ischaemic stroke?
Does a "Code Stroke" Rapid Access Protocol Decrease Door-to-Needle Time for Thrombolysis?
Does body weight influence the response to intravenous tissue plasminogen activator in stroke patients?
Does High Cerebral Microbleed Burden Increase the Risk of Intracerebral Hemorrhage After Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke?
Does Intravenous Administration of Recombinant Tissue Plasminogen Activator for Ischemic Stroke can Cause Inferior Myocardial Infarction?
Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator?
Does smoking influence outcome after intravenous thrombolysis for acute ischaemic stroke?
Does the Addition of Non-Approved Inclusion and Exclusion Criteria for rtPA Impact Treatment Rates? Findings in Australia, the UK, and the USA.
Does the administration of sonothrombolysis along with tissue plasminogen activator improve outcomes in acute ischemic stroke? A systematic review and meta-analysis.
Does the admission blood pressure associate with short- and long term outcome in stroke patients treated with thrombolysis? A single centre study.
Does the application of X-ray contrast agents impair the clinical effect of intravenous recombinant tissue-type plasminogen activator in acute ischemic stroke patients?
Door to Intravenous Tissue Plasminogen Activator Time and Hospital Length of Stay in Acute Ischemic Stroke Patients, Georgia, 2007-2013.
Door to needle time and functional outcome for mild ischemic stroke over telestroke.
Door to Needle Time over Telestroke-A Comprehensive Stroke Center Experience.
Door-to-needle times for patients with ischaemic stroke treated with alteplase by on-site and off-site on-duty neurologists. PRISA study.
Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.
Door-to-needle times in patients treated by on-site and off-site on-call neurologists. PRISA study.
Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset.
Dosing errors may impact the risk of rt-PA for stroke: the Multicenter rt-PA Acute Stroke Survey.
Dosing of Tissue Plasminogen Activator Often Differs from 0.9 mg/kg, but Does Not Affect the Outcome.
Doubts, fears and misconceptions. What is the future of thrombolysis in acute stroke?
DRAGON score predicts functional outcomes in acute ischemic stroke patients receiving both intravenous tissue plasminogen activator and endovascular therapy.
Dramatic Changes of a DWI Lesion in a Patient with Acute Ischemic Stroke Treated with IV t-PA.
Drill down analysis of door-to-needle time of acute ischemic stroke patients treated with intravenous tissue plasminogen activator.
Drip-and-Ship Thrombolytic Therapy for Acute Ischemic Stroke.
Drip-and-Ship Thrombolytic Therapy Supported by the Telestroke System for Acute Ischemic Stroke Patients Living in Medically Under-served Areas.
Drop of PT Quick percent value is associated with both symptomatic and asymptomatic intracranial hemorrhage in patients treated with rt-PA for acute ischemic stroke.
Drug delivery to the ischemic brain.
Duty cycle dependence of ultrasound enhanced thrombolysis in a human clot model.
Dynamic changes in plasma tissue plasminogen activator, plasminogen activator inhibitor-1 and beta-thromboglobulin content in ischemic stroke.
Dynamic increase in neutrophil levels predicts parenchymal hemorrhage and function outcome of ischemic stroke with r-tPA thrombolysis.
E-Mail Is an Effective Tool for Rapid Feedback in Acute Stroke.
Early Abrogation of Gelatinase Activity Extends the Time Window for tPA Thrombolysis after Embolic Focal Cerebral Ischemia in Mice.
Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial.
Early administration of pyrrolidine dithiocarbamate extends the therapeutic time window of tissue plasminogen activator in a male rat model of embolic stroke.
Early and Continuous Neurologic Improvements after Intravenous Thrombolysis Are Strong Predictors of Favorable Long-term Outcomes in Acute Ischemic Stroke.
Early and intermediate prognosis of intravenous thrombolytic therapy in acute ischemic stroke subtypes according to the causative classification of stroke system.
Early carotid endarterectomy following thrombolysis in the hyperacute treatment of stroke.
Early carotid endarterectomy for critical carotid artery stenosis after thrombolysis therapy in acute ischemic stroke in the middle cerebral artery.
Early changes in fibrinogen after administration of alteplase are associated with the short-term efficacy of thrombolysis.
Early changes in tissue perfusion after tissue plasminogen activator administration in hyperacute ischemic stroke: initial experiences with arterial spin labeling perfusion magnetic resonance imaging.
Early changes of tissue perfusion after tissue plasminogen activator in hyperacute ischemic stroke.
Early computed tomography hypodensity predicts hemorrhage after intravenous tissue plasminogen activator in acute ischemic stroke.
Early epileptic seizures in ischaemic stroke treated by mechanical thrombectomy: influence of rt-PA.
Early intravenous thrombolysis for acute ischemic stroke in a community-based approach.
Early intravenous thrombolysis with recombinant tissue-type plasminogen activator in vertebrobasilar ischemic stroke.
Early ischemic stroke presentation in Pakistan.
Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: Insights into the pathophysiology of acute stroke in the thrombolysis era.
Early neurologic decline in acute ischemic stroke patients receiving thrombolysis with large vessel occlusion and mild deficits.
Early Neurologic Improvement Based on the National Institutes of Health Stroke Scale Score Predicts Favorable Outcome within 30 Minutes after Undergoing Intravenous Recombinant Tissue Plasminogen Activator Therapy.
Early Neurological Deterioration after Recanalization Treatment in Patients with Acute Ischemic Stroke: A Retrospective Study.
Early Neurological Deterioration During Alteplase Infusion for Acute Ischemic Stroke: An Uncommon Complication of Intravenous Thrombolysis.
Early neurological improvement after intravenous tissue plasminogen activator infusion in patients with ischemic stroke aged 80 years or older.
Early neutrophil-to-lymphocyte ratio is a prognostic marker in acute minor stroke or transient ischemic attack.
Early NT-ProBNP (N-Terminal Probrain Natriuretic Peptide) Elevation Predicts Malignant Edema and Death After Reperfusion Therapy in Acute Ischemic Stroke Patients.
Early outcomes of thrombolysis for acute ischaemic stroke in a South African tertiary care centre.
Early Profiles of Clinical Evolution after Intravenous Thrombolysis in an Unselected Stroke Population.
Early recanalization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre- and post-thrombolytic angiography in acute ischemic stroke patients.
Early Recanalization Postintravenous Thrombolysis in Ischemic Stroke with Large Vessel Occlusion: A Digital Subtraction Angiography Study.
Early recurrent ischemic stroke complicating intravenous thrombolysis for stroke: incidence and association with atrial fibrillation.
Early recurrent ischemic stroke in stroke patients undergoing intravenous thrombolysis.
Early reperfusion rates with IV tPA are determined by CTA clot characteristics.
Early treatment of ischemic stroke with intravenous tPA reduces disability risk.
Early Use of Statin in Patients Treated with Alteplase for Acute Ischemic Stroke.
Early [(11)C]Flumazenil/H(2)O positron emission tomography predicts irreversible ischemic cortical damage in stroke patients receiving acute thrombolytic therapy.
ECASS II: intravenous alteplase in acute ischaemic stroke. European Co-operative Acute Stroke Study-II.
ECASS-II: intravenous alteplase in acute ischaemic stroke. European Co-operative Acute Stroke Study-II.
Echoplanar magnetic resonance imaging in acute stroke.
Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States.
Economic Benefit of Increasing Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke in the United States.
Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States.
Economic Evaluation of a Pre-Hospital Protocol for Patients with Suspected Acute Stroke.
Edaravone with and without .6?Mg/Kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study (PROTECT4.5).
Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator.
Edaravone, a Synthetic Free Radical Scavenger, Enhances Alteplase-Mediated Thrombolysis.
Editorial comment--Remote evaluation of acute ischemic stroke: a reliable tool to extend tissue plasminogen activator use to community and rural stroke patients?
Educating North America: lessons learned.
Effect of Acute Stroke Care Regionalization on Intravenous Alteplase Use in Two Urban Counties.
Effect of Age on Arterial Recanalization and Clinical Outcome in Thrombolyzed Acute Ischemic Stroke in CLOTBUST Cohort.
Effect of Alteplase Administration on International Normalized Ratio in Patients With Acute Ischemic Stroke.
Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke.
Effect of Alteplase Use on Outcomes in Patients With Atrial Fibrillation: Analysis of the Initiation of Anticoagulation After Cardioembolic Stroke Study.
Effect of alteplase versus aspirin plus clopidogrel in acute minor stroke.
Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
Effect of alteplase within 6 hours of acute ischemic stroke on all-cause mortality (third International Stroke Trial).
Effect of antiplatelet pretreatment on platelet aggregation and clinical outcomes in acute ischemic stroke patients treated with recombinant tissue-type plasminogen activator.
Effect of blood pressure on early neurological deterioration of acute ischemic stroke patients with intravenous rt-PA thrombolysis may be mediated through oxidative stress induced blood-brain barrier disruption and AQP4 upregulation.
Effect of Clot Aging and Cholesterol Content on Ultrasound-Assisted Thrombolysis.
Effect of Clot Stiffness on Recombinant Tissue Plasminogen Activator Lytic Susceptibility in Vitro.
Effect of educational television commercial on pre-hospital delay in patients with ischemic stroke.
Effect of Endovascular Treatment Alone vs Intravenous Alteplase Plus Endovascular Treatment on Functional Independence in Patients With Acute Ischemic Stroke: The DEVT Randomized Clinical Trial.
Effect of erroneous body-weight estimation on outcome of thrombolyzed stroke patients.
Effect of glycated hemoglobin index and mean arterial pressure on acute ischemic stroke prognosis after intravenous thrombolysis with recombinant tissue plasminogen activator.
Effect of glycated hemoglobin index and mean arterial pressure on acute ischemic stroke prognosis after intravenous thrombolysis with recombinant tissue plasminogen activator: Erratum.
Effect of hyperglycemia on stroke outcome is not homogeneous to all patients treated with mechanical thrombectomy.
Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. NINDS; The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group.
Effect of Intravenous Recombinant Tissue-Type Plasminogen Activator in Patients With Mild Stroke in the Third International Stroke Trial-3: Post Hoc Analysis.
Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial.
Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours.
Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial.
Effect of intraventricularly administered low-dose recombinant tissue plasminogen activator on interleukin 1-beta and transforming growth factor beta concentrations in cerebrospinal fluid of patients with primary intracerebral hemorrhage associated with intraventricular hemorrhage: A retrospective study.
Effect of isoflurane post-treatment on tPA-exaggerated brain injury in a rat ischemic stroke model.
Effect of IV alteplase on the ischemic brain lesion at 24-48 hours after ischemic stroke.
Effect of low frequency ultrasound on combined rt-PA and eptifibatide thrombolysis in human clots.
Effect of Pretreatment Blood Pressure on Outcomes in Thrombolysed Acute Ischemic Stroke Patients: A Systematic Review and Meta-analysis.
Effect of recombinant plasminogen activator timing on thrombolysis in a novel rat embolic stroke model.
Effect of rt-PA intravenous thrombolysis on the prognosis of patients with minor ischemic stroke.
Effect of selective serotonin re-uptake inhibitors (SSRIs) on functional outcome in patients with acute ischemic stroke treated with tPA.
Effect of Serum Lipid Levels on Stroke Outcome after rt-PA Therapy: SAMURAI rt-PA Registry.
Effect of the 2013 AHA/ASA guidelines on TPA use in acute ischemic stroke at Assaf Harofeh Medical Center in Israel.
Effect of the Pleiotropic Drug CNB-001 on Tissue Plasminogen Activator (tPA) Protease Activity in vitro: Support for Combination Therapy to Treat Acute Ischemic Stroke.
Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial.
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.
Effective management of patients with acute ischemic stroke based on lean production on thrombolytic flow optimization.
Effectiveness and safety of different doses of tenecteplase in the treatment of acute ischemic stroke: A protocol for systematic review and meta-analysis.
Effectiveness of alteplase in the very elderly after acute ischemic stroke.
Effectiveness of intravenous r-tPA versus UK for acute ischaemic stroke: a nationwide prospective Chinese registry study.
Effectiveness of t-PA in acute ischemic stroke: outcome relates to appropriateness.
Effectiveness of thrombolysis with intravenous alteplase for acute ischemic stroke in older adults.
Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion: Japan Alteplase Clinical Trial II (J-ACT II).
Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial.
Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials.
Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials.
Effects of alteplase in the treatment of acute ischemic stroke.
Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trial.
Effects of angiopoietin-1 on hemorrhagic transformation and cerebral edema after tissue plasminogen activator treatment for ischemic stroke in rats.
Effects of Blood Pressure and Blood Pressure-Lowering Treatment During the First 24 Hours Among Patients in the Third International Stroke Trial of Thrombolytic Treatment for Acute Ischemic Stroke.
Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator.
Effects of erythropoietin combined with tissue plasminogen activator on the rats following cerebral ischemia and reperfusion.
Effects of increasing IV tPA-treated stroke mimic rates at CT-based centers on clinical outcomes.
Effects of Meteorological Conditions on the Risk of Ischemic Stroke Events in Patients Treated with Alteplase--HEWS-tPA.
Effects of ML351 and tissue plasminogen activator combination therapy in a rat model of focal embolic stroke.
Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice.
Effects of SSRI exposure on hemorrhagic complications and outcome following thrombolysis in ischemic stroke.
Effects of Therapeutic Hypothermia Combined with Other Neuroprotective Strategies on Ischemic Stroke: Review of Evidence.
Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
Effects of tissue plasminogen activator on cerebral microvessels of rats during focal cerebral ischemia and reperfusion.
Effects of tissue plasminogen activator timing on blood-brain barrier permeability and hemorrhagic transformation in rats with transient ischemic stroke.
Effects of uric Acid levels on outcome in severe ischemic stroke patients treated with intravenous recombinant tissue plasminogen activator.
Efficacy and Safety of a Modified Intravenous Recombinant Tissue Plasminogen Activator Regimen in Chinese Patients with Acute Ischemic Stroke.
Efficacy and safety of desmoteplase in acute ischemic stroke patients: A systematic review and meta-analysis.
Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke.
Efficacy and safety of i.v. alteplase therapy up to 4.5 hours after acute ischemic stroke onset.
Efficacy and safety of intravenous recombinant tissue plasminogen activator in mild ischaemic stroke: a meta-analysis.
Efficacy and Safety of Intravenous rtPA in Ischemic Strokes Due to Small-Vessel Occlusion: Systematic Review and Meta-Analysis.
Efficacy and Safety of Intravenous Thrombolysis for the Treatment of Acute Ischemic Stroke Patients with Saccular Intracranial Aneurysms of ?3 mm.
Efficacy and safety of intravenous thrombolysis with alteplase for treating acute ischemic stroke at different time windows: A protocol for systematic review and meta-analysis.
Efficacy and Safety of Low-Dose Versus Standard-Dose Alteplase Regimens in Patients with Acute Ischaemic Stroke.
Efficacy and Safety of REVIVE SE Thrombectomy Device for Acute Ischemic Stroke: River JAPAN (Reperfuse Ischemic Vessels with Endovascular Recanalization Device in Japan).
Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis.
Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: a combination therapy study with tissue plasminogen activator.
Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke: A Retrospective Pooled Analysis.
Efficacy of cerebral thrombolysis in an extended 'time window'.
Efficacy of different doses of alteplase thrombolysis on acute ischemic stroke in patients.
Efficacy of fingolimod combined with alteplase in acute ischemic stroke and rehabilitation nursing.
Efficacy of intra-arterial and intravenous prourokinase in an embolic stroke model evaluated by diffusion-perfusion magnetic resonance imaging.
Efficacy of Telemedicine for Stroke: Pooled Analysis of the Stroke Team Remote Evaluation Using a Digital Observation Camera (STRokE DOC) and STRokE DOC Arizona Telestroke Trials.
Efficacy of Tirofiban Administered at Different Time Points after Intravenous Thrombolytic Therapy with Alteplase in Patients with Acute Ischemic Stroke.
Efforts to reduce the door-to-needle time of thrombolysis in acute ischemic stroke: Video-assisted therapeutic risk communication.
Elements of cerebral microvascular ischaemia.
Elevated Homocysteine Level Related to Poor Outcome After Thrombolysis in Acute Ischemic Stroke.
Elevated international normalized ratio as a manifestation of post-thrombolytic coagulopathy in acute ischemic stroke.
Elevated plasma fibrinogen indicates short-term poor outcome in patients with acute ischemic stroke after intravenous thrombolysis.
Elevated tissue plasminogen activator antigen and stroke risk: The Stroke Prevention In Young Women Study.
Eligibility and rate of treatment for recombinant tissue plasminogen activator in acute ischemic stroke using different criteria.
Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke. Way to Endeavor.
Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study.
Embolic middle cerebral artery occlusion (MCAO) for ischemic stroke with homologous blood clots in rats.
Embolization of calcific thrombi after tissue plasminogen activator treatment.
Emergency Care of Patients with Acute Ischemic Stroke in the Kaiser Permanente Southern California Integrated Health System.
Emergency department arrival times after acute ischemic stroke during the 1990s.
Emergency management of acute ischemic stroke.
Emergency medical service hospital prenotification is associated with improved evaluation and treatment of acute ischemic stroke.
Emergency Medical Services Providers' Knowledge, Practices, And Barriers To Stroke Management.
Emergency medicine in the Veterans Health Administration-results from a nationwide survey.
Emergency Medicine Pharmacist Impact on Door-to-Needle Time in Patients With Acute Ischemic Stroke.
Emergency Medicine Physicians Accurately Select Acute Stroke Patients for Tissue-Type Plasminogen Activator Treatment Using a Checklist.
Emergency physician attitudes toward thrombolytic therapy in acute stroke.
Emergency physician treatment of acute stroke with recombinant tissue plasminogen activator: a retrospective analysis.
Emergency transfer of acute stroke patients within the East Saxony telemedicine stroke network: a descriptive analysis.
Emergent Double-barrel Bypass Shortly after Intravenous Administration of Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke.
Emergent Loading Dose of Antiplatelets for Stenting after IV rt-PA in Acute Ischemic Stroke: A Feasibility Study.
Emerging temporal trends in tissue plasminogen activator use: Results from the BASIC project.
Empirical characteristics of litigation involving tissue plasminogen activator and ischemic stroke.
Encapsulation of tissue plasminogen activator in pH-sensitive self-assembled antioxidant nanoparticles for ischemic stroke treatment - Synergistic effect of thrombolysis and antioxidant.
Endogenous activated protein C predicts hemorrhagic transformation and mortality after tissue plasminogen activator treatment in stroke patients.
Endogenous regeneration: Engineering growth factors for stroke.
Endogenous tissue plasminogen activator increases hemorrhagic transformation induced by heparin after ischemia reperfusion in rat brains.
Endothelial markers are associated with thrombolysis resistance in acute stroke patients.
Endothelial progenitor cells: Potential novel therapeutics for ischaemic stroke.
Endovascular (intraarterial) treatment of acute ischemic stroke: efficacy not supported by clinical trials.
Endovascular clot retrieval for acute ischaemic stroke: the Auckland City Hospital experience.
Endovascular interventions following intravenous thrombolysis may improve survival and recovery in patients with acute ischemic stroke: a case-control study.
Endovascular mechanical clot retrieval in a broad ischemic stroke cohort.
Endovascular Mechanical Thrombectomy for Acute Ischemic Stroke: A New Standard of Care.
Endovascular Stroke Therapy Focused on Stent Retriever Thrombectomy and Direct Clot Aspiration: Historical Review and Modern Application.
Endovascular stroke therapy: a single-center retrospective review.
Endovascular stroke treatment does not preclude high thrombolysis rates.
Endovascular therapy after intravenous t-PA versus t-PA alone for stroke.
Endovascular therapy for acute ischaemic stroke: a systematic review and meta-analysis of randomized trials.
Endovascular therapy for hemodialysis patients with atrial fibrillation and cerebral thromboembolism: A case series.
Endovascular therapy for ischemic stroke.
Endovascular therapy including thrombectomy for acute ischemic stroke: A systematic review and meta-analysis with trial sequential analysis.
Endovascular Therapy Is Effective and Safe for Patients With Severe Ischemic Stroke: Pooled Analysis of Interventional Management of Stroke III and Multicenter Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke in the Netherlands Data.
Endovascular Thrombectomy Alone versus Combined with Intravenous Thrombolysis.
Endovascular Thrombectomy for Acute Ischemic Stroke in Failed Intravenous Tissue Plasminogen Activator Versus Non-Intravenous Tissue Plasminogen Activator Patients. Revascularization and Outcomes Stratified by the Site of Arterial Occlusions.
Endovascular Thrombectomy for Acute Ischemic Stroke: A Meta-analysis.
Endovascular Thrombectomy for Ischemic Stroke Increases Disability-Free Survival, Quality of Life, and Life Expectancy and Reduces Cost.
Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke.
Endovascular Treatment in Patients with Persistent Internal Carotid Artery Occlusion after Intravenous Tissue Plasminogen Activator: A Clinical Effectiveness Study.
Endovascular treatment of acute ischaemic stroke.
Endovascular Treatment of Acute Ischemic Stroke.
Endovascular treatment versus medical care alone for ischaemic stroke: systematic review and meta-analysis.
Endovascular Treatment With or Without Prior Intravenous Alteplase for Acute Ischemic Stroke.
Endovascular vs medical management of acute ischemic stroke.
Engineered Nanoplatelets for Targeted Delivery of Plasminogen Activators to Reverse Thrombus in Multiple Mouse Thrombosis Models.
Enhanced dispatch and rendezvous doubles the catchment area and number of patients treated on a mobile stroke unit.
Enhanced poly(ADP-ribose) polymerase-1 activation contributes to recombinant tissue plasminogen activator-induced aggravation of ischemic brain injury in vivo.
Enhancement of enzymatic fibrinolysis with 2-MHz ultrasound and microbubbles.
Ephrin-Eph Signaling as a Novel Neuroprotection Path in Ischemic Stroke.
Epidemiology of a large telestroke cohort in the Delaware valley.
Epigallocatechin Gallate Extends Therapeutic Window of Recombinant Tissue Plasminogen Activator Treatment for Brain Ischemic Stroke: A Randomized Double-Blind and Placebo-Controlled Trial.
Epigenetic Regulation of Tissue-Type Plasminogen Activator in Human Brain Tissue and Brain-Derived Cells.
Equipoise among recanalization strategies.
Erythrocyte-Derived Nanoparticles as a Theranostic Agent for Near-Infrared Fluorescence Imaging and Thrombolysis of Blood Clots.
Erythrocyte-Inspired Discoidal Polymeric Nanoconstructs Carrying Tissue Plasminogen Activator for the Enhanced Lysis of Blood Clots.
Established treatments for acute ischaemic stroke.
Estimated cost savings of increased use of intravenous tissue plasminogen activator for acute ischemic stroke in Canada.
Estimated versus actual weight when dosing rt-PA in acute ischemic stroke: is there a difference?
Estimated weight is not a reliable measure for dosing tissue plasminogen activator for thrombolysis in acute ischaemic stroke.
Estimating Weight of Patients With Acute Stroke When Dosing for Thrombolysis.
Estimation of seizures prevalence in ischemic strokes after thrombolytic therapy.
Ethical Challenges in Acute Evaluation of Suspected Psychogenic Stroke Mimics.
Ethnicity and Other Determinants of Quality of Functional Outcome in Acute Ischemic Stroke: The ENCHANTED Trial.
European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits ECASS-4: ExTEND.
European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke.
Evaluating Target: Stroke guideline implementation on assessment and treatment times for patients with suspected stroke.
Evaluating the safety and efficacy of intravenous thrombolysis for acute ischemic stroke patients with a history of intracerebral hemorrhage: a systematic review and meta-analysis.
Evaluation of applied cases of thrombolytic therapy against ultra-acute ischemic stroke. Using the Japanese Standard Stroke Registry Database.
Evaluation of Cerebral Perfusion in Patients Undergoing Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis.
Evaluation of common housekeeping proteins under ischemic conditions and/or rt-PA treatment in bEnd.3 cells.
Evaluation of functional outcome measured by modified Rankin scale in rtPA treated patients with acute ischemic stroke.
Evaluation of initial diffusion-weighted image findings in acute stroke patients using a semiquantitative score.
Evaluation of long-term rt-PA effects on bEnd.3 endothelial cells under ischemic conditions; changes in ZO-1 expression and glycosylation of the bradykinin B2 receptor.
Evaluation of the implementation of a 24-hour stroke thrombolysis emergency treatment for patients with acute ischemic stroke.
Evidence of anaphylaxy after alteplase infusion.
Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke.
Evidence-based surgical treatment of carotid stenosis. Literature review.
Evolution of a US County System for Acute Comprehensive Stroke Care.
Evolution of intracerebral hemorrhage after intravenous tPA: reversal of harmful effects with mast cell stabilization.
Evolution of thrombectomy approaches and devices for acute stroke: a technical review.
Evolving therapeutic approaches to treating acute ischemic stroke.
Existence of the diffusion-perfusion mismatch within 24 hours after onset of acute stroke: dependence on proximal arterial occlusion.
Exogenous neural stem cell transplantation for cerebral ischemia.
Exogenous stem cells pioneer a biobridge to the advantage of host brain cells following stroke: New insights for clinical applications.
Expanded Indication for Recombinant Tissue Plasminogen Activator from 3 to 4.5 h after Onset of Stroke in Japan.
Expanded modes of tissue plasminogen activator delivery in a comprehensive stroke center increases regional acute stroke interventions.
Expanding the range of therapies for acute ischemic stroke: the early experience of the Regional Stroke Center at Hartford Hospital.
Expansion of Intravenous Tissue Plasminogen Activator Eligibility Beyond National Institute of Neurological Disorders and Stroke and European Cooperative Acute Stroke Study III Criteria.
Expansion Of Telestroke Services Improves Quality Of Care Provided In Super Rural Areas.
Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association.
Expedited Computed Tomography Perfusion and Angiography in Acute Ischemic Stroke: A Feasibility Study.
Expediting MRI-based proof-of-concept stroke trials using an earlier imaging end point.
Experience of a neurology service during the 2016 Olympic and Paralympic Games.
Experience with t-PA treatment in a large south American City.
Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke.
Experimental models of focal and multifocal cerebral ischemia: a review.
Expression of plasminogen activator inhibitor-1 and protease nexin-1 in human astrocytes: Response to injury-related factors.
Extending the time window for intravenous thrombolysis in acute ischemic stroke using magnetic resonance imaging-based patient selection.
Extending the time window for thrombolysis: evidence from acute stroke trials.
Extending the window for thrombolysis for treatment of acute ischaemic stroke during pregnancy: a review.
Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data.
Extension of the thrombolytic time window with minocycline in experimental stroke.
Extremely early computed tomography signs in hyperacute ischemic stroke as a predictor of parenchymal hematoma.
Facilities available in French hospitals treating acute stroke patients: comparison with 24 other European countries.
Factors affecting in-hospital delay of intravenous thrombolysis for acute ischemic stroke: A retrospective cohort study.
Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis.
Factors associated with early recanalization failure following intravenous rt-PA therapy for ischemic stroke.
Factors Associated with Early Recovery after Intravenous Thrombolytic Therapy in Acute Ischemic Stroke.
Factors associated with hospital arrival time for stroke patients.
Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials.
Factors associated with late arrival of acute stroke patients to emergency department in Saudi Arabia.
Factors Associated with the Administration of Tissue Plasminogen Activator for Acute Ischemic Stroke.
Factors Associated With the Hospital Arrival Time in Patients With Ischemic Stroke in Korea.
Factors associated with the presence of cerebral microbleeds and its influence on outcomes of stroke not treated with alteplase.
Factors Associated with Thrombolysis Outcome in Ischemic Stroke Patients with Atrial Fibrillation.
Factors Influencing Acute Stroke Thrombolytic Treatments in Hispanics In the San Diego Region.
Factors influencing clinical outcomes of acute ischemic stroke treated with intravenous recombinant tissue plasminogen activator.
Factors influencing early admission in a French stroke unit.
Factors Predicting Outcome in Stroke Patients Treated With 0.6 mg/kg Alteplase: Evidence From the Japan Alteplase Clinical Trial (J-ACT).
Factors predicting the outcome of intravenous thrombolysis in stroke patients before rt-PA administration.
Factors preventing African Americans from seeking early intervention in the treatment of ischemic strokes.
Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke.
Factors that influence clinicians' decisions to offer intravenous alteplase in acute ischemic stroke patients with uncertain treatment indication: Results of a discrete choice experiment.
Factors that influence health-seeking behaviors of patients experiencing acute stroke.
Fast multimode MRI based emergency assessment of hyperacute stroke thrombolysis.
Fast Protocol for Treating Acute Ischemic Stroke by Emergency Physicians.
FASTER (Face, Arm, Speech, Time, Emergency Response): experience of Central Coast Stroke Services implementation of a pre-hospital notification system for expedient management of acute stroke.
Fatal Intraperitoneal Bleeding after Intravenous Administration of Tissue Plasminogen Activator.
Fatal ischaemic brain oedema after early thrombolysis with tissue plasminogen activator in acute stroke.
Favorable Renal Outcomes after Intravenous Thrombolytic Therapy for Acute Ischemic Stroke: Clinical Implication of Kidney-Brain axis.
Feasibility and outcomes of intravenous thrombolysis 3-4.5hours after stroke in Chinese patients.
Feasibility and Safety of Intravenous Thrombolysis in Multiethnic Asian Stroke Patients in Singapore.
Feasibility of IA thrombolysis for acute ischemic stroke among anticoagulated patients.
Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: a review.
Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis.
Fibrinogen Concentrate for the Treatment of Thrombolysis-Associated Hemorrhage in Adult Ischemic Stroke Patients.
Fibrinogen concentrate replacement in ischemic stroke patients after recombinant tissue plasminogen activator treatment.
Fibrinolysis: strategies to enhance the treatment of acute ischemic stroke.
Fibrinolytic gene polymorphism and ischemic stroke.
Fibrinolytic measurements in type 2 diabetic patients with acute cerebral infarction.
Fibrinolytic treatment for acute ischaemic stroke.
Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke.
Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
Fingolimod Enhances the Efficacy of Delayed Alteplase Administration in Acute Ischemic Stroke by Promoting Anterograde Reperfusion and Retrograde Collateral Flow.
First case of ischemic stroke which happened during continuous intravenous infusion of rt-PA.
Fisetin Prolongs Therapy Window of Brain Ischemic Stroke Using Tissue Plasminogen Activator: A Double-Blind Randomized Placebo-Controlled Clinical Trial.
Fixed Dose IV rt-PA and Clinical Outcome in Ischemic Stroke Patients With Body Weight >100 kg: Pooled Data From 3 Randomized Clinical Trials.
Focusing on claudin-5: A promising candidate in the regulation of BBB to treat ischemic stroke.
For how long is brain tissue salvageable? Thrombolysis-based evidence.
Former antiplatelet drug administration and consequences of intravenous thrombolysis in acute ischemic stroke.
Fortifying the BBB: Border control by increasing regulators.
Four Decades of Ischemic Penumbra and Its Implication for Ischemic Stroke.
Four evolving strategies in the emergent treatment of acute ischemic stroke.
Free Radical Damage in Ischemia-Reperfusion Injury: An Obstacle in Acute Ischemic Stroke after Revascularization Therapy.
Frequency and predictors of symptomatic intracerebral hemorrhage in patients with ischemic stroke treated with recombinant tissue plasminogen activator outside clinical trials.
Frequency of Blood-Brain Barrier Disruption Post-Endovascular Therapy and Multiple Thrombectomy Passes in Acute Ischemic Stroke Patients.
Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group.
Frequency, determinants, and effects of early seizures after thrombolysis for acute ischemic stroke: The ENCHANTED trial.
Frequency, Risk Factors, and Clinical Significance of Incorrect Dose of Alteplase Due to Weight Estimation in Acute Ischemic Stroke Patients: A Single-Center Retrospective Study.
Frequent Hub-Spoke Contact Is Associated with Improved Spoke Hospital Performance: Results from the Massachusetts General Hospital Telestroke Network.
Fucoidan-functionalized polysaccharide submicroparticles loaded with alteplase for efficient targeted thrombolytic therapy.
Full-Dose Thrombolysis for a Right Middle Cerebral Artery Stroke after an Acute Aortic Dissection.
Functional outcome after thrombolytic therapy.
Functional role of the fibrinolytic system in development of adipose tissue.
FUNDC1-dependent mitophagy induced by tPA protects neurons against cerebral ischemia-reperfusion injury.
Further evolution toward effective therapy for acute ischemic stroke.
Future demographic trends decrease the proportion of ischemic stroke patients receiving thrombolytic therapy: a call to set-up therapeutic studies in the very old.
Future directions of acute ischaemic stroke therapy.
G-Protein-Coupled Receptors and Ischemic Stroke: a Focus on Molecular Function and Therapeutic Potential.
Gender and thrombolysis therapy in stroke patients with incidence of dyslipidemia.
Gender differences in acute ischemic stroke: etiology, stroke patterns and response to thrombolysis.
Gender differences in acute stroke treatment: the University of California San Diego experience.
Gender Differences in Exclusion Criteria for Recombinant Tissue-Type Plasminogen Activator.
Gender-Linked Stem Cell Alterations in Stroke and Postpartum Depression.
Genome response to tissue plasminogen activator in experimental ischemic stroke.
Geographic access to acute stroke care in the United States.
Ginkgo biloba extract and its diterpene ginkgolide constituents ameliorate the metabolic disturbances caused by recombinant tissue plasminogen activator in rat prefrontal cortex.
Ginsenoside Represses Symptomatic Intracerebral Hemorrhage after Recombinant Tissue Plasminogen Activator Therapy by Promoting Transforming Growth Factor-?1.
Global fibrinolytic activity, PAI-1 level, and 4G/5G polymorphism in Thai children with arterial ischemic stroke.
GLP-1 secretion in acute ischemic stroke: association with functional outcome and comparison with healthy individuals.
Go ahead for 'clot busting' drug for patients with stroke.
Good clinical outcome after ischemic stroke with successful revascularization is time-dependent.
Good Intracranial Collaterals Trump Poor ASPECTS (Alberta Stroke Program Early CT Score) for Intravenous Thrombolysis in Anterior Circulation Acute Ischemic Stroke.
Good Outcome Rate of 35% in IV-tPA-Treated Patients With Computed Tomography Angiography Confirmed Severe Anterior Circulation Occlusive Stroke.
Graduating US Neurology Residents' Experience With Tissue-Type Plasminogen Activator for Acute Stroke: A 10-Year Comparison.
Granulocyte colony-stimulating factor attenuates delayed tPA-induced hemorrhagic transformation in ischemic stroke rats by enhancing angiogenesis and vasculogenesis.
GSK-3? inhibitor TWS119 attenuates rtPA-induced hemorrhagic transformation and activates the Wnt/?-catenin signaling pathway after acute ischemic stroke in rats.
Guidelines For Extending the Tissue Plasminogen Activator Treatment Window for Ischemic Stroke.
Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society.
HandiStroke: a handheld tool for the emergent evaluation of acute stroke patients.
Haplotypes of the plasminogen activator gene associated with ischemic stroke.
Hemi Orolingual Angioedema after tPA Administration for Acute Ischemic Stroke.
Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke.
Hemiplegia and thrombolysis.
Hemopericardium and cardiac tamponade after thrombolysis for acute ischemic stroke.
Hemorrhagic complications of thrombolytic therapy.
Hemorrhagic conversion after alteplase administration in a patient with vasculitis and acute ischemic stroke.
Hemorrhagic Transformation after Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke: Mechanisms, Models, and Biomarkers.
Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment in Acute Ischemic Stroke.
Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study.
Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort.
Hemostasis and alterations of the central nervous system.
Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke.
Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA.
Hemothorax after the intravenous administration of tissue plasminogen activator in a patient with acute ischemic stroke and rib fractures.
Hepatitis C and recurrent treatment-resistant acute ischemic stroke.
Hesperidin reduces adverse symptomatic intracerebral hemorrhage by promoting TGF-?1 for treating ischemic stroke using tissue plasminogen activator.
Hi1a as a Novel Neuroprotective Agent for Ischemic Stroke by Inhibition of Acid-Sensing Ion Channel 1a.
High Prestroke Physical Activity Is Associated with Reduced Infarct Growth in Acute Ischemic Stroke Patients Treated with Intravenous tPA and Randomized to Remote Ischemic Perconditioning.
High-resolution CT with arch/neck/head CT angiography on a mobile stroke unit.
Higher Insulin Resistance Level is Associated with Worse Clinical Response in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis.
Higher Left Ventricle Mass Indices Predict Favorable Outcome in Stroke Patients with Thrombolysis.
Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomes.
HMGB-1 promotes fibrinolysis and reduces neurotoxicity mediated by tissue plasminogen activator.
Hospital Arrival Time and Intravenous t-PA Use in US Academic Medical Centers, 2001-2004.
Hospital mortality from atrial fibrillation associated with ischemic stroke: a national data report.
Hospital Variation in Thrombolysis Times Among Patients With Acute Ischemic Stroke: The Contributions of Door-to-Imaging Time and Imaging-to-Needle Time.
Hospitalized stroke surveillance in the community of Durango, Mexico: the brain attack surveillance in Durango study.
Hourly blood pressure monitoring after intravenous tissue plasminogen activator for ischemic stroke: does everyone need it?
How a CT-Direct Protocol at an American Comprehensive Stroke Center Led to Door-to-Needle Times Less Than 30 Minutes.
How baseline severity affects efficacy and safety outcomes in acute ischemic stroke intervention trials.
How can we improve stroke thrombolysis rates? A review of health system factors and approaches associated with thrombolysis administration rates in acute stroke care.
How Do Physicians Approach Intravenous Alteplase Treatment in Patients with Acute Ischemic Stroke Who Are Eligible for Intravenous Alteplase and Endovascular Therapy? Insights from UNMASK-EVT.
How important is surrogate consent for stroke research?
How temporal evolution of intracranial collaterals in acute stroke affects clinical outcomes.
How to Establish the Outer Limits of Reperfusion Therapy.
Human neural stem cells improve early stage stroke outcome in delayed tissue plasminogen activator-treated aged stroke brains.
Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke.
Hyperacute Management of Ischemic Strokes: JACC Focus Seminar.
Hyperacute stroke therapy with tissue plasminogen activator.
Hyperacute therapy of ischemic stroke: intravenous thrombolysis.
Hyperacute thrombolysis with recombinant tissue plasminogen activator of acute ischemic stroke: Feasibility and effectivity from an Indian perspective.
Hyperbaric Oxygen Reduces Infarction Volume and Hemorrhagic Transformation Through ATP/NAD(+)/Sirt1 Pathway in Hyperglycemic Middle Cerebral Artery Occlusion Rats.
Hyperdense artery sign, symptomatic infarct swelling and effect of alteplase in acute ischaemic stroke.
Hyperglycemia and hemorrhagic transformation of cerebral infarction: a macroscopic hemorrhagic transformation rat model.
Hypersensitivity reactions to recombinant tissue plasminogen activator.
Hypointense transcerebral veins at T2*-weighted MRI: a marker of hemorrhagic transformation risk in patients treated with intravenous tissue plasminogen activator.
Hypothermia and Ischemic Stroke.
Hypothermia for acute ischaemic stroke.
Icatibant as a Potential Treatment of Life-Threatening Alteplase-Induced Angioedema.
ICU Interventions in Ischemic Stroke Patients Treated Using Liberalized IV-tPA Criteria.
Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence.
Identification of Rate-Limiting Steps in the Provision of Thrombolytics for Acute Ischemic Stroke.
Identification of the penumbra and infarct core on hyperacute noncontrast and perfusion CT.
Identifying and Addressing Barriers to Systemic Thrombolysis for Acute Ischemic Stroke in the Inpatient Setting: A Quality Improvement Initiative.
Identifying errors and safety considerations in patients undergoing thrombolysis for acute ischemic stroke.
Identifying implications of thrombolysis for stroke rehabilitation: Knowledge gaps in current research.
Identifying stroke therapeutics from preclinical models: A protocol for a novel application of network meta-analysis.
IL-38 as an early predictor of the ischemic stroke prognosis.
IL1B and VWF Variants Are Associated With Fibrinolytic Early Recanalization in Patients With Ischemic Stroke.
IM-12 activates the Wnt-?-catenin signaling pathway and attenuates rtPA-induced hemorrhagic transformation in rats after acute ischemic stroke.
Imaging Evidence for Cerebral Hyperperfusion Syndrome after Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke.
Imaging in acute stroke.
Imaging Negative Stroke: Diagnoses and Outcomes in Intravenous Tissue Plasminogen Activator-Treated Patients.
Imaging predictors of outcome following intravenous thrombolysis in acute stroke.
Imaging-based thrombolysis trial in acute ischemic stroke-II (ITAIS-II).
IMM-H004 prevents toxicity induced by delayed treatment of tPA in a rat model of focal cerebral ischemia involving PKA-and PI3K-dependent Akt activation.
Immunoinflammatory activation during the acute phase of lacunar and non-lacunar ischemic stroke: association with time of onset and diabetic state.
Impact of alcohol consumption on the outcome of ischemic stroke and thrombolysis: role of the hepatic clearance of tissue-type plasminogen activator.
Impact of Baseline Thrombocytopenia on Bleeding and Mortality After Percutaneous Coronary Intervention.
Impact of Computed Tomography Perfusion Imaging on the Response to Tenecteplase in Ischemic Stroke: Analysis of 2 Randomized Controlled Trials.
Impact of emergency room meetings on improvement of door-to-needle times in acute ischemic stroke patients: A single center's experience.
Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: the NINDS Suburban Hospital Stroke Center experience.
Impact of estimated-weight-base dose of alteplase in acute stroke treatment on clinical outcome.
Impact of homocysteine levels on clinical outcome in patients with acute ischemic stroke receiving intravenous thrombolysis therapy.
Impact of Hospital Level on Stroke Outcomes in the Thrombolytic Therapy Era in Northeast Thailand: A Retrospective Study.
Impact of hyperglycaemia on complications in patients who had a stroke after thrombolysis.
Impact of Mechanical Thrombectomy on the Organization of the Management of Acute Ischemic Stroke.
Impact of Participation in a Telestroke Network on Clinical Outcomes.
Impact of Protocol Deviations in Acute Ischemic Stroke Treated With Intravenous rt-PA Within 4.5 Hours After Symptom Onset.
Impact of stroke center certification on rt-PA thrombolysis after acute ischemic stroke in South China from 2015 to 2020.
Impact of Systems of Care and Blood Pressure Management on Stroke Outcomes.
Impact of the approval of intravenous recombinant tissue plasminogen activator therapy on the processes of acute stroke management in Japan: the Stroke Unit Multicenter Observational (SUMO) Study.
Impact of the neutrophil response to granulocyte colony-stimulating factor on the risk of hemorrhage when used in combination with tissue plasminogen activator during the acute phase of experimental stroke.
Impact of thrombolysis in acute ischaemic stroke without occlusion: an observational comparative study.
Impact of Thrombus Length on Outcomes After Intra-Arterial Aspiration Thrombectomy in the THERAPY Trial.
Impact of Tissue Plasminogen Activator Dosing on Patients Weighing More Than 100?kg on 3-Month Outcomes in Acute Ischemic Stroke.
Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence.
Impaired fasting glucose is associated with unfavorable outcome in ischemic stroke patients treated with intravenous alteplase.
Implementation and outcome of thrombolysis with alteplase 3 to 4.5 h after acute stroke in Chinese patients.
Implementation Challenges of Regionalized Acute Stroke Care.
Implementation of a stroke thrombolysis service within a tertiary neurosciences centre in the United Kingdom.
Implementation of Computerized Physician Order Entry Is Associated With Increased Thrombolytic Administration for Emergency Department Patients With Acute Ischemic Stroke.
Implementation of Telemedicine and Stroke Network in Thrombolytic Administration: Comparison Between Walk-in and Referred Patients.
Implementing a mobile stroke unit program in the United States: why, how, and how much?
Implications of immune system in stroke for novel therapeutic approaches.
Implications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic Stroke.
Improved door-to-needle times and neurologic outcomes when IV tissue plasminogen activator is administered by emergency physicians with advanced neuroscience training.
Improved outcomes in stroke thrombolysis with pre-specified imaging criteria.
Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice.
Improvement in Door-to-Needle Time in Patients with Acute Ischemic Stroke via a Simple Stroke Activation Protocol.
Improvement in thrombolytic therapy administration in acute stroke with feedback.
Improving access to acute stroke therapies: a controlled trial of organised pre-hospital and emergency care.
Improving Door to Needle time in Patients for Thrombolysis.
Improving Door-to-Needle Times for Acute Ischemic Stroke: Effect of Rapid Patient Registration, Moving Directly to Computed Tomography, and Giving Alteplase at the Computed Tomography Scanner.
Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: Stroke initiative.
Improving Door-to-needle Times in the Treatment of Acute Ischemic Stroke Across a Canadian Province: Methodology.
Improving the efficiency of delivery of thrombolysis for acute stroke: a systematic review.
Improving the translation of animal ischemic stroke studies to humans.
Improving timely treatment with a stroke emergency map: The case of northern China.
In acute ischemic stroke patients with smoking incidence, are more women than men more likely to be included or excluded from thrombolysis therapy?
In acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous?
In imaging-selected ischemic stroke with unknown onset, alteplase increases favorable outcomes and death at 90 d.
In ischemic stroke with viable hypoperfused tissue, alteplase > 4.5 h after last seen well improves function.
In ischemic stroke, thrombectomy alone was noninferior to thrombectomy plus alteplase for functional outcome at 90 days.
In vitro thrombolytic efficacy of echogenic liposomes loaded with tissue plasminogen activator and octafluoropropane gas.
In vivo ultrasound-activated delivery of recombinant tissue plasminogen activator from the cavity of sub-micrometric capsules.
In-Hospital Delays for Acute Stroke Treatment Delivery During the COVID-19 Pandemic.
In-hospital delays to stroke thrombolysis: Out of hours versus regular hours and reduction in treatment times through the creation of a 24/7 mobile thrombolysis team.
Incidence and Risk Factors of Postcontrast Acute Kidney Injury in Patients with Acute Ischemic Stroke.
Incidence, predictors and clinical characteristics of orolingual angio-oedema complicating thrombolysis with tissue plasminogen activator for ischaemic stroke.
Incidental Thrombotic Thrombocytopenic Purpura during Acute Ischemic Stroke and Thrombolytic Treatment.
Increase in neutrophils after recombinant tissue plasminogen activator thrombolysis predicts poor functional outcome of ischaemic stroke: a longitudinal study.
Increased benefit of alteplase in patients with ischemic stroke and a high body temperature.
Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke.
Increased brain plasmin levels following experimental ischemic stroke in male mice.
Increased fibrinogen levels and acquired hypofibrinolysis in young adults with ischemic stroke.
Increased fibrinogen, von Willebrand factor and tissue plasminogen activator levels in insulin resistant South Asian patients with ischaemic stroke.
Increased microvascular permeability and low level of low-density lipoprotein cholesterol predict symptomatic intracerebral hemorrhage in acute ischemic stroke.
Increasing use of intravenous rt-PA does not affect safety in acute stroke.
Individual lytic efficacy of recombinant tissue plasminogen activator in an in vitro human clot model: rate of "nonresponse".
Indole-3-carbinol improves neurobehavioral symptoms in a cerebral ischemic stroke model.
Infarct volume predicts critical care needs in stroke patients treated with intravenous thrombolysis.
Infections Increase the Risk of 30-Day Readmissions Among Stroke Survivors.
Inflammation and hemostasis biomarkers for predicting stroke in postmenopausal women: the Women's Health Initiative Observational Study.
Inflammatory and hemostatic biomarkers associated with early recurrent ischemic lesions in acute ischemic stroke.
Influence of antiplatelet pre-treatment on the risk of intracranial haemorrhage in acute ischaemic stroke after intravenous thrombolysis.
Influence of antiplatelet pre-treatment on the risk of symptomatic intracranial haemorrhage after intravenous thrombolysis.
Influence of intravenous alteplase on endovascular treatment decision-making in acute ischemic stroke due to primary medium-vessel occlusion: a case-based survey study.
Influence of on-going treatment with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker on the outcome of patients treated with intravenous rt-PA for ischemic stroke.
Influence of pretreatment MRI parameters on clinical outcome, recanalization and infarct size in 49 stroke patients treated by intravenous tissue plasminogen activator.
Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke: ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) Post Hoc Analysis.
Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of tPA and of tPA on the variant's anticoagulant activity.
Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients.
Influence of Thrombolysis on the Safety and Efficacy of Blocking Platelet Adhesion or Secretory Activity in Acute Ischemic Stroke in Mice.
Inherited and Uncommon Causes of Stroke.
Inhibiting endogenous tissue plasminogen activator enhanced neuronal apoptosis and axonal injury after traumatic brain injury.
Inhibition of hypoxia inducible factor 1 by YC-1 attenuates tissue plasminogen activator induced hemorrhagic transformation by suppressing HMGB1/TLR4/NF-?B mediated neutrophil infiltration in thromboembolic stroke rats.
Inhibition of PI3K? by AS605240 plus low-dose tissue plasminogen activator (tPA) combination improves thrombolytic therapy in a rat model of embolic stroke.
Inhibition of Thrombin-Activatable Fibrinolysis Inhibitor and Plasminogen Activator Inhibitor-1 Reduces Ischemic Brain Damage in Mice.
Inhibition of tPA-induced hemorrhagic transformation involves adenosine A2b receptor activation after cerebral ischemia.
Initial 'TTP Map-Defect' of Computed Tomography Perfusion as a Predictor of Hemorrhagic Transformation of Acute Ischemic Stroke.
Initial body temperature in ischemic stroke: nonpotentiation of tissue-type plasminogen activator benefit and inverse association with severity.
Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group.
Inside the Thrombus: Association of Hemostatic Parameters With Outcomes in Large Vessel Stroke Patients.
Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial.
Interaction of Blood Pressure Lowering and Alteplase Dose in Acute Ischemic Stroke: Results of the Enhanced Control of Hypertension and Thrombolysis Stroke Study.
Interactions between nitrous oxide and tissue plasminogen activator in a rat model of thromboembolic stroke.
Interferon-? alleviates delayed tPA-induced adverse effects via modulation of MMP3/9 production in ischemic stroke.
Interferon-? Modulates Inflammatory Response in Cerebral Ischemia.
Interhospital transfer on intravenous thrombolysis in patients with acute ischemic stroke in three chinese municipal stroke centers.
Interleukin 1 alpha administration is neuroprotective and neuro-restorative following experimental ischemic stroke.
Interventional Ischemic Stroke Treatment - A (R)evolution.
Intra-Arterial Adjunctive Medications for Acute Ischemic Stroke During Mechanical Thrombectomy: A Meta-Analysis.
Intra-arterial adjuvant tirofiban after unsuccessful intra-arterial thrombolysis of acute ischemic stroke: preliminary experience in 16 patients.
Intra-Arterial Alteplase Thrombolysis during Mechanical Thrombectomy for Acute Ischemic Stroke.
Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke: an open-label, dose-ranging, phase I study.
Intra-arterial reteplase compared to urokinase for thrombolytic recanalization in acute ischemic stroke.
Intra-arterial third-generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke.
Intra-arterial thrombolysis after full-dose intravenous recombinant tissue plasminogen activator for patients older than 80 years with acute ischemic stroke: what is the safety limit?
Intra-Arterial Thrombolysis after Full-Dose Intravenous tPA via the "Drip and Ship" Approach in Patients with Acute Ischemic Stroke: Preliminary Report.
Intra-arterial thrombolysis and thrombectomy for acute ischemic stroke: technique and results.
Intra-arterial thrombolysis for acute ischemic stroke: preliminary experience with platelet glycoprotein IIb/IIIa inhibitors as adjunctive therapy.
Intra-arterial thrombolysis for the treatment of perioperative childhood cardioembolic stroke.
Intra-arterial thrombolysis in a 2-year-old with cardioembolic stroke.
Intra-arterial thrombolysis in acute ischaemic stroke.
Intra-arterial thrombolysis using rt-PA in patients with acute stroke due to vessel occlusion of anterior and/or posterior cerebral circulation.
Intra-arterial thrombolysis: tissue plasminogen activator and other thrombolytic agents.
Intra-arterial tissue plasminogen activator for an ischemic stroke in a 21-year-old Hispanic woman with elevated beta human chorionic gonadotropin and complex clinical history.
Intraarterial recombinant tissue plasminogen activator for ischemic stroke: an accelerated dosing regimen.
Intraarterial recombinant tissue plasminogen activator for ischemic stroke: an accelerating dosing regimen.
Intraarterial reteplase and intravenous abciximab for treatment of acute ischemic stroke. A preliminary feasibility and safety study in a non-human primate model.
Intraarterial thrombolysis for treatment of acute stroke: experience in 26 patients with long-term follow-up.
Intraarterial Thrombolysis with r-tPA for Treatment of Anterior Circulation Acute Ischemic Stroke. Technical and Clinical Results.
Intraarterial thrombolysis with reteplase in acute ischaemic stroke in a Pakistani center.
Intraarterial thrombolytic therapy within 3 hours of the onset of stroke.
Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.
Intracerebral hemorrhage after IV tPA for stroke as early symptom of ANCA-associated vasculitis.
Intracerebral overexpression of miR-669c is protective in mouse ischemic stroke model by targeting MyD88 and inducing alternative microglial/macrophage activation.
Intracranial Hemorrhage Following Thrombolytic Use for Stroke Caused by Infective Endocarditis.
Intracranial hemorrhage, outcome, and mortality after intra-arterial therapy for acute ischemic stroke in patients under oral anticoagulants.
Intracranial Internal Carotid Artery Wall Calcification in Ischemic Strokes Treated with Thrombolysis.
Intravenous alteplase for acute ischaemic stroke.
Intravenous Alteplase for acute ischemic stroke in patients with current malignant neoplasm.
Intravenous Alteplase for Acute Ischemic Stroke in Taiwan: Can We Expand the National Health Insurance's Reimbursement Criteria?
Intravenous Alteplase for Acute Stroke and Pulmonary Embolism in a Patient With Recent Abdominoplasty.
Intravenous alteplase for Chinese patients with stroke and borderline eligibility.
Intravenous alteplase for ischaemic stroke.
Intravenous Alteplase for Mild Nondisabling Acute Ischemic Stroke: A Bridge Too Far?
Intravenous alteplase for stroke in those older than 80 years old.
Intravenous alteplase in ischemic stroke patients not fully adhering to the current drug license in Central and Eastern Europe.
Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial.
Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial.
Intravenous and Arterial Treatments for Acute Ischemic Stroke: Indications and the Role of Imaging.
Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study.
Intravenous fibrinolysis eligibility: a survey of stroke clinicians' practice patterns and review of the literature.
Intravenous Fibrinolysis in Ischemic Stroke of Large Vessel after Reversing Effect of Dabigatran with Idarucizumab.
Intravenous infusion of mesenchymal stem cells inhibits intracranial hemorrhage after recombinant tissue plasminogen activator therapy for transient middle cerebral artery occlusion in rats.
Intravenous r-tPA Dose Influence on Outcome after Middle Cerebral Artery Ischemic Stroke Treatment by Mechanical Thrombectomy.
Intravenous recombinant tissue plasminogen activator administered after 3 h following onset of ischaemic stroke: a metaanalysis.
Intravenous Recombinant Tissue Plasminogen Activator and Ischemic Stroke: Focused Update of 2010 Clinical Practice Advisory From the American Academy of Emergency Medicine.
Intravenous Recombinant Tissue Plasminogen Activator Does Not Impact Mortality in Acute Ischemic Stroke at Any Time Point up to 6 Months: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study.
Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke.
Intravenous Recombinant Tissue Plasminogen Activator Therapy for Acute Basilar Artery Ischemic Stroke Following Transfemoral Transcatheter Aortic Valve Implantation.
Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.
Intravenous recombinant tissue plasminogen activator thrombolysis in a patient with acute ischemic stroke secondary to aortic dissection.
Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis in Acute Ischemic Stroke due to Middle Cerebral Artery Dissection.
Intravenous Recombinant Tissue-Type Plasminogen Activator: Influence on Outcome in Anterior Circulation Ischemic Stroke Treated by Mechanical Thrombectomy.
Intravenous rt-PA in patients with ischaemic stroke and renal dysfunction.
Intravenous rt-PA versus Endovascular Therapy for Acute Ischemic Stroke.
Intravenous Thrombolysis Administration 3-4.5 h After Acute Ischemic Stroke: A Retrospective, Multicenter Study.
Intravenous Thrombolysis and Risk Factors for Ischemic Stroke.
Intravenous thrombolysis and thrombectomy decisions in acute ischemic stroke: An interrater and intrarater agreement study.
Intravenous thrombolysis for acute ischaemic stroke in a hospital without a specialised neuro-intensive care unit.
Intravenous thrombolysis for acute ischaemic stroke: preliminary experience with recombinant tissue plasminogen activator in the UK.
Intravenous Thrombolysis for Acute Ischemic Stroke After Recent Myocardial Infarction: Case Series and Systematic Review.
Intravenous Thrombolysis for Acute Ischemic Stroke Due to Cardiac Myxoma.
Intravenous Thrombolysis for Acute Ischemic Stroke due to Cervical Internal Carotid Artery Occlusion.
Intravenous thrombolysis for acute ischemic stroke in centenarians.
Intravenous Thrombolysis For Acute Ischemic Stroke in Fabry Disease.
Intravenous Thrombolysis for Acute Ischemic Stroke in Patients with Thrombocytopenia.
Intravenous thrombolysis for acute ischemic stroke in the 3- to 4·5-hour window - the Malabar experience.
Intravenous Thrombolysis for Acute Ischemic Stroke Within 3 Hours Versus Between 3 and 4.5 Hours of Symptom Onset.
Intravenous thrombolysis for acute ischemic stroke--our experiences.
Intravenous thrombolysis for acute ischemic stroke.
Intravenous thrombolysis for acute ischemic stroke: a bridge between two centuries.
Intravenous thrombolysis for acute ischemic stroke: the Malabar experience 2003 to 2008.
Intravenous thrombolysis for acute stroke: current standards and future directions.
Intravenous Thrombolysis for Ischemic Stroke in Recurrent Oligodendroglioma: A Case Report.
Intravenous Thrombolysis for Stroke and Presumed Stroke in Human Immunodeficiency Virus-Infected Adults: A Retrospective, Multicenter US Study.
Intravenous thrombolysis for stroke in pregnancy should be administered if the benefit outweighs the risk: A case report and recommended diagnostic workup.
Intravenous thrombolysis for stroke increases over time at primary stroke centers.
Intravenous Thrombolysis for Stroke Patients with G6PD Deficiency.
Intravenous thrombolysis for the management of acute ischemic stroke in patients therapeutically anticoagulated with heparin: A review.
Intravenous thrombolysis in a patient using factor Xa inhibitor.
Intravenous thrombolysis in acute ischaemic stroke: optimising its use in routine clinical practice.
Intravenous thrombolysis in acute ischemic stroke after dabigatran reversal with idarucizumab - a case report.
Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan.
Intravenous Thrombolysis in Acute Ischemic Stroke Patients with Unsuspected Infective Endocarditis.
Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer.
Intravenous thrombolysis in acute ischemic stroke: standard and potential future applications.
Intravenous Thrombolysis in an Elderly Patient With Acute Ischemic Stroke Masking Aortic Dissection.
Intravenous Thrombolysis in Chinese Patients with Different Subtype of Mild Stroke: Thrombolysis in Patients with Mild Stroke.
Intravenous thrombolysis in Chinese patients with mild acute ischemic stroke.
Intravenous Thrombolysis in Expanded Time Window (3-4.5 hours) in General Practice with Concurrent Availability of Endovascular Treatment.
Intravenous Thrombolysis in German Stroke Units before and after Regulatory Approval of Recombinant Tissue Plasminogen Activator.
Intravenous thrombolysis in ischemic stroke patients with intracranial neoplasms: two cases and a literature review.
Intravenous thrombolysis in Sneddon's syndrome.
Intravenous thrombolysis in the elderly is facilitated by a tele-stroke network: A cross-sectional study.
Intravenous thrombolysis in the emergency department for the treatment of acute ischaemic stroke.
Intravenous Thrombolysis in Unknown-Onset Stroke: Results From the Safe Implementation of Treatment in Stroke-International Stroke Thrombolysis Registry.
Intravenous thrombolysis in young stroke patients: Results from the SITS-ISTR.
Intravenous Thrombolysis Is Safe and Effective for the Cryptogenic Stroke in China: Data From the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China).
Intravenous thrombolysis on early recurrent cardioembolic stroke: 'Dr Jekyll' or 'Mr Hyde'?
Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): final results.
Intravenous thrombolysis with 0.9 mg/kg alteplase for acute ischaemic stroke: a network meta-analysis of treatment delay.
Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in acute ischemic stroke.
Intravenous Thrombolysis with Neuroprotective Therapy by Edaravone for Ischemic Stroke Patients Older than 80 Years of Age.
Intravenous thrombolysis with recombinant staphylokinase versus tissue-type plasminogen activator in a rabbit embolic stroke model.
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke in a patient treated with rivaroxaban.
Intravenous thrombolysis with recombinant tissue plasminogen activator for ischemic stroke patients over 80 years old: the Fukuoka Stroke Registry.
Intravenous Thrombolysis with Recombinant Tissue-type Plasminogen Activator for Acute Ischemic Stroke in Patients with Metabolic Syndrome.
Intravenous thrombolysis with rt-PA for acute ischemic stroke within 24h of a transient ischemic attack.
Intravenous thrombolysis with rt-PA in acute ischemic stroke patients aged older than 80 years in Italy.
Intravenous Thrombolysis With Tenecteplase in Patients With Large Vessel Occlusions: Systematic Review and Meta-Analysis.
Intravenous thrombolysis with tissue-plasminogen activator in small vessel occlusion.
Intravenous thrombolytic therapy for acute anterior ischemic stroke: Experience at the French Military Teaching Hospital in Toulon from 2003 to 2014.
Intravenous thrombolytic therapy for acute ischemic stroke. Weighing the risks and benefits of tissue plasminogen activator.
Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital.
Intravenous thrombolytic therapy for stroke: a review of recent studies and controversies.
Intravenous thrombolytic treatment in a patient with transient ischemic attack associated with mural carotid thrombi.
Intravenous thrombolytic treatment of acute ischemic stroke associated with left atrial myxoma: A case report.
Intravenous Tissue Plasminogen Activator Administration for Ischemic Stroke 1 Hour After Epidural Catheter Removal: A Case Report.
Intravenous tissue plasminogen activator and flow improvement in acute ischemic stroke patients with internal carotid artery occlusion.
Intravenous tissue plasminogen activator and stroke in the elderly.
Intravenous Tissue Plasminogen Activator Can Be Safely Given without Complete Blood Count Results Back.
Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older : the tPA stroke survey experience.
Intravenous tissue plasminogen activator for acute ischemic stroke in patients with renal dysfunction.
Intravenous tissue plasminogen activator for acute ischemic stroke: A Canadian hospital's experience.
Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice.
Intravenous tissue plasminogen activator for an ischemic stroke with occult double primary cancer.
Intravenous tissue plasminogen activator for ischemic stroke in early pregnancy dosed by actual body weight.
Intravenous Tissue Plasminogen Activator for Large Vessel Ischemic Stroke - Is There Still a Role?
Intravenous Tissue Plasminogen Activator for Patients with Minor Ischemic Stroke.
Intravenous Tissue Plasminogen Activator for Stroke: A Review of the ECASS III Results in Relation to Prior Clinical Trials.
Intravenous Tissue Plasminogen Activator for Wake-Up Stroke: A Propensity Score-Matched Analysis.
Intravenous Tissue Plasminogen Activator Improves the Outcome in Very Elderly Korean Patients with Acute Ischemic Stroke.
Intravenous Tissue Plasminogen Activator in Patients With Cocaine-Associated Acute Ischemic Stroke.
Intravenous tissue plasminogen activator in patients with stroke increases the bioavailability of insulin-like growth factor-1.
Intravenous Tissue Plasminogen Activator in Stroke Mimics.
Intravenous Tissue Plasminogen Activator Therapy for an Acute Ischemic Stroke Patient with Later Diagnosed Unilateral Moyamoya Syndrome.
Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients.
Intravenous tissue plasminogen activator, ischemic stroke, and the risk of Kounis Syndrome.
Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.
Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus.
Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.
Intravenous tissue-type plasminogen activator therapy is an independent risk factor for symptomatic intracerebral hemorrhage after carotid endarterectomy.
Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke.
Intravenous tPA Delays Door-To-Puncture Time in Acute Ischemic Stroke with Large Vessel Occlusion.
Intravenous tPA for Acute Ischemic Stroke in Patients with COVID-19.
Intravenous tPA for ischemic stroke team performance over time, safety, and efficacy in a single-center, 2-year experience.
Intravenous tPA in acute ischemic stroke related to internal carotid artery dissection.
Intravenous tPA therapy does not worsen acute intracerebral hemorrhage in mice.
Introduction of an acute stroke team: an effective approach to hasten assessment and management of stroke in the emergency department.
Investigation of Gender Differences and Exclusive Criteria in a Diabetic Acute Ischemic Stroke Population Treated with Recombinant Tissue-Type Plasminogen Activator (rtPA).
Investigational therapies for ischemic stroke: neuroprotection and neurorecovery.
Involvement of emergency medicine pharmacists in stroke thrombolysis: A cohort study.
Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats.
Involvement of SSAO/VAP-1 in oxygen-glucose deprivation-mediated damage using the endothelial hSSAO/VAP-1-expressing cells as experimental model of cerebral ischemia.
Iodinated Contrast Agents Reduce the Efficacy of Intravenous Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients: a Multicenter Cohort Study.
Iron Overload Exacerbates the Risk of Hemorrhagic Transformation After tPA (Tissue-Type Plasminogen Activator) Administration in Thromboembolic Stroke Mice.
Is CT perfusion helpful in the treatment allocation of patients with acute ischemic stroke? An expert-opinion analysis.
Is higher body temperature beneficial in ischemic stroke patients with normal admission CT angiography of the cerebral arteries?
Is intra-arterial thrombolysis safe after full-dose intravenous recombinant tissue plasminogen activator for acute ischemic stroke?
Is intravenous recombinant plasminogen activator effective up to 4.5 h after onset of ischemic stroke?
Is intravenous thrombolysis still necessary in patients who undergo mechanical thrombectomy?
Is IV tissue plasminogen activator beneficial in patients with hyperdense artery sign?
Is the maximum dose of 90 mg alteplase sufficient for patients with ischemic stroke weighing >100 kg?
Is There a Decreased Risk of Intracerebral Hemorrhage and Mortality in Obese Patients Treated with Intravenous Thrombolysis in Acute Ischemic Stroke?
Ischaemic stroke and the recanalization drug tissue plasminogen activator interfere with antibacterial phagocyte function.
Ischaemic stroke following tranexamic acid in young patients carrying heterozygosity of MTHFR C677T.
Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin.
Ischaemic stroke: decide rapidly.
Ischemic and Bleeding Risk After Percutaneous Coronary Intervention in Patients With Prior Ischemic and Hemorrhagic Stroke.
Ischemic diffusion lesion reversal is uncommon and rarely alters perfusion-diffusion mismatch.
Ischemic stroke and excellent recovery after administration of intravenous tissue plasminogen activator.
Ischemic stroke and mitochondria: mechanisms and targets.
Ischemic stroke subtype is associated with outcome in thrombolyzed patients.
Ischemic stroke therapy.
Ischemic stroke. Clinical strategies based on mechanisms and risk factors.
Ischemic strokes arriving too late for tPA are an ideal and ethical control group for continuing studies of tPA efficacy.
Ischemic tolerance in the brain: Endogenous adaptive machinery against ischemic stress.
Isoflurane Postconditioning Inhibits tPA-Induced Matrix Metalloproteinases Activation After Hypoxic Injury via Low-Density Lipoprotein Receptor-Related Protein and Extracellular Signal-Regulated Kinase Pathway.
Isoflurane preconditioning inhibits the effects of tissue-type plasminogen activator on brain endothelial cell in an in vitro model of ischemic stroke.
Isoforms of apolipoprotein E can modulate tPA-induced clot lysis in vitro.
Isolated tongue angioedema after alteplase infusion in acute ischemic stroke.
IV t-PA therapy in acute stroke patients with atrial fibrillation.
IV thrombolysis for treatment of patients with stroke upon awakening: Yes? No?
IV thrombolysis in very severe and severe ischemic stroke: Results from the SITS-ISTR Registry.
IV tPA for acute ischemic stroke: results of the first 101 patients in a community practice.
IV tPA for acute ischemic stroke: Times are changing.
IV vs. IA TPA in Acute Ischemic Stroke with CT Angiographic Evidence of Major Vessel Occlusion: A Feasibility Study.
IV-Thrombolysis in Ischemic Stroke With Unknown Time of Onset-Safety and Outcomes in Posterior vs. Anterior Circulation Stroke.
Joint Commission Primary Stroke Centers Utilize More rt-PA in the Nationwide Inpatient Sample.
Knowledge and Attitudes of Saudi Emergency Physicians toward t-PA Use in Stroke.
Knowledge of Tissue Plasminogen Activator for Acute Stroke Among Michigan Adults.
Knowledge Regarding Basic Facts of Stroke Among Final Year MBBS Students and House Officers: A Cross-Sectional Survey of 708 Respondents from Pakistan.
Lack of Associations Between PAI-1 and FXIII Polymorphisms and Arterial Ischemic Stroke in Children: A Systematic Review and Meta-Analysis.
Lack of collagen XV is protective after ischemic stroke in mice.
Lack of TAFI increases brain damage and microparticle generation after thrombolytic therapy in ischemic stroke.
Language barriers between physicians and patients are not associated with thrombolysis of stroke mimics.
Large ischemic lesions on diffusion-weighted imaging done before intravenous tissue plasminogen activator thrombolysis predicts a poor outcome in patients with acute stroke.
Large Vessel Occlusion Identification Through Prehospital Administration of Stroke Scales: A County-wide Emergency Medical Services Prospective Research Protocol.
Large-Vessel Occlusion Is Associated with Poor Outcome in Stroke Patients Aged 80 Years or Older Who Underwent Intravenous Thrombolysis.
Late Night Activity Regarding Stroke Codes: LuNAR strokes.
LDL receptor blockade reduces mortality in a mouse model of ischaemic stroke without improving tissue-type plasminogen activator-induced brain haemorrhage: towards pre-clinical simulation of symptomatic ICH.
Lean thinking turns 'time is brain' into reality.
Left ventricular apical thrombus after systemic thrombolysis with recombinant tissue plasminogen activator in a patient with acute ischemic stroke.
Lessons learned from 2 years experience in intravenous thrombolysis for acute ischemic stroke in a single tertiary medical center.
Lessons of the month 2: FAST is not always FAST.
Letter by Behrouz et Al regarding article, "Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion".
Letter by Dai et al regarding article, "Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the Third International Stroke Trial".
Letter by Wu et al Regarding Article, "Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus".
Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke.
Leukoaraiosis and risk of intracranial hemorrhage and outcome after stroke thrombolysis.
Leukocytes May Have 2 Opposing Effects in Intravenous rtPA Treatment for Ischemic Stroke.
LEX 032: a novel recombinant human protein for the treatment of ischaemic reperfusion injury.
Life-Threatening Anaphylactoid Reaction in an Acute Ischemic Stroke Patient With Intravenous rt-PA Thrombolysis, Followed by Successful Intra-Arterial Thrombolysis.
Lingual angioedema after alteplase treatment in a patient with acute ischemic stroke.
Lingual angioedema with macroglossia during the treatment of acute ischemic stroke with alteplase.
Lipid Profile, Lipid-lowering Medications, and Intracerebral Hemorrhage After tPA in Get With The Guidelines-Stroke.
Liposomes for drug delivery in stroke.
Liquid biopsy markers for stroke diagnosis.
Local intra-arterial thrombolysis with urokinase for acute ischemic stroke before and after the approval of intravenous tissue plasminogen activator treatment in Taiwan.
Local intraarterial tirofiban after formation of anterograde flow in patients with acute ischemic stroke: Preliminary experience and short term follow-up results.
Local tissue-type plasminogen activator release in patients with ischemic stroke.
Logistics in acute stroke management.
Long-term functional and neurological outcome after simultaneous treatment with tissue-plasminogen activator and hyperbaric oxygen in early phase of embolic stroke in rats.
Long-term stability of recombinant tissue plasminogen activator at -80 C.
Long-Term Survival After Intravenous Thrombolysis for Ischemic Stroke: A Propensity Score-Matched Cohort With up to 10-Year Follow-Up.
Low Body Temperature Does Not Compromise the Treatment Effect of Alteplase.
Low dosis of alteplase, for ischemic stroke after Enchanted and its determinants, a single center experience.
Low factor XIII levels after intravenous thrombolysis predict short-term mortality in ischemic stroke patients.
Low free triiodothyronine levels predict symptomatic intracranial hemorrhage and worse short-term outcome of thrombolysis in patients with acute ischemia stroke.
Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action.
Low thrombin generation predicts poor prognosis in ischemic stroke patients after thrombolysis.
Low versus standard dose intravenous alteplase in the treatment of acute ischemic stroke in Egyptian patients.
Low vs standard dose of recombinant tissue plasminogen activator in treating East Asian patients with acute ischemic stroke.
Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study).
Low- versus Standard-Dose Intravenous Alteplase in the Context of Bridging Therapy for Acute Ischemic Stroke: A Korean ENCHANTED Study.
Low- versus Standard-Dose Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: An Updated Meta-Analysis.
Low-density lipoprotein level on admission is not associated with postintravenous thrombolysis intracranial hemorrhage in patients with acute ischemic stroke.
Low-Dose Intra-Arterial Urokinase and Aggressive Mechanical Clot Disruption for Acute Ischemic Stroke after Failure of Intravenous Thrombolysis.
Low-dose intravenous tissue plasminogen activator for acute ischaemic stroke: an alternative or a new standard?
Low-dose rt-PA may not decrease the incidence of symptomatic intracranial haemorrhage in patients with high risk of symptomatic intracranial haemorrhage.
Low-dose tissue plasminogen activator and standard-dose tissue plasminogen activator in acute ischemic stroke in Asian populations: a review.
Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
Low-dose tissue plasminogen activator is as effective as standard tissue plasminogen activator administration for the treatment of acute ischemic stroke.
Low-dose versus standard-dose alteplase in acute ischemic stroke in Asian stroke registries: an individual patient data pooling study.
Low-dose versus standard-dose intravenous alteplase for octogenerian acute ischemic stroke patients: A multicenter prospective cohort study.
Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.
Low-dose versus standard-dose tissue plasminogen activator for intravenous thrombolysis in Asian acute ischemic stroke patients.
Low-Dose Versus Standard-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke in Asian Populations: A Meta-Analysis.
Low-Dose vs Standard-Dose Alteplase for Patients With Acute Ischemic Stroke: Secondary Analysis of the ENCHANTED Randomized Clinical Trial.
Low-Dose vs Standard-Dose Alteplase in Acute Lacunar Ischemic Stroke: The ENCHANTED Trial.
Low-Dose vs. Standard-Dose Intravenous Alteplase in Bridging Therapy Among Patients With Acute Ischemic Stroke: Experience From a Stroke Center in Vietnam.
Low-frequency, low-intensity ultrasound accelerates thrombolysis through the skull.
Low-Versus Standard-Dose Alteplase for Ischemic Strokes Within 4.5 Hours: A Comparative Effectiveness and Safety Study.
Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA.
Magnetic resonance imaging in acute ischemic stroke treatment.
Magnetic Resonance Imaging or Computed Tomography Before Treatment in Acute Ischemic Stroke.
Magnetic resonance imaging-based versus computed tomography-based thrombolysis in acute ischemic stroke: comparison of safety and efficacy within a cohort study.
Magnetic Resonance Imaging-DRAGON Score: Three-Month Outcome Prediction After Intravenous Thrombolysis for Anterior Circulation Stroke.
Making a case for the right "-ase" in acute ischemic stroke: alteplase, tenecteplase, and reteplase.
Making the call: is telestroke cost effective?
Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study.
Management of acute ischaemic stroke in the elderly: tolerability of thrombolytics.
Management of acute ischemic stroke.
Management of acute ischemic stroke. An update for primary care physicians.
Management of acute ischemic stroke. What is the role of tPA and antithrombotic agents?
Management of acute stroke.
Management of airway compromise following thyroid cyst hemorrhage after thrombolytic therapy.
Management of blood pressure after acute ischemic stroke: An evidence-based guide for the hospitalist.
Management of ischaemic stroke in the acute setting: review of the current status.
Management of patients with atherosclerotic carotid occlusion.
Management of Postthrombolysis Hemorrhagic and Orolingual Angioedema Complications.
Management of thrombolysis-associated symptomatic intracerebral hemorrhage.
Marked Regional Variation in Acute Stroke Treatment Among Medicare Beneficiaries.
Markers of Coagulation and Fibrinolysis Predicting the Outcome of Acute Ischemic Stroke Thrombolysis Treatment: A Review of the Literature.
Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey.
Massive cerebral edema after recanalization post-thrombolysis.
Mathematical Modelling of Intravenous Thrombolysis in Acute Ischaemic stroke: Effects of Dose Regimens on Levels of Fibrinolytic Proteins and Clot Lysis Time.
Matrix Metalloproteinase-9 Expression is Enhanced by Ischemia and Tissue Plasminogen Activator and Induces Hemorrhage, Disability and Mortality in Experimental Stroke.
Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke.
Maximum intravenous alteplase dose for obese stroke patients is not associated with greater likelihood of worse outcomes.
Measurement of Length of Hyperdense MCA Sign in Acute Ischemic Stroke Predicts Disappearance after IV tPA.
Measuring Quality Improvement in Acute Ischemic Stroke Care: Interrupted Time Series Analysis of Door-to-Needle Time.
Mechanical disruption of thrombus following intravenous tissue plasminogen activator for ischemic stroke.
Mechanical endovascular therapy for acute ischemic stroke: An indirect treatment comparison between Solitaire and Penumbra thrombectomy devices.
Mechanical endovascular treatment of acute stroke due to cardiac myxoma.
Mechanical thrombectomy for acute ischemic stroke in pregnancy using the penumbra system.
Mechanical thrombectomy for acute ischemic stroke using the MERCI Retriever and Penumbra Aspiration Systems.
Mechanical thrombectomy with the solitaire stent at Lyon, France.
Mechanisms and markers for hemorrhagic transformation after stroke.
Mechanisms in blood-brain barrier opening and metabolism-challenged cerebrovascular ischemia with emphasis on ischemic stroke.
Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke.
Mechanistic insight into Neurotoxicity of Tissue Plasminogen Activator-Induced Thrombolysis Products in a Rat Intraluminal Middle Cerebral Artery Occlusion Model.
Medical Decision Making: Hyposphagma Prior to Intravenous Tissue Plasminogen Activator in Acute Ischemic Stroke.
Medical management of patients with an acute stroke: treatment and prevention.
Medical Treatment for Spontaneous Anticoagulation-Related Intracerebral Hemorrhage in the Netherlands.
Medical University of South Carolina Telestroke: A Telemedicine Facilitated Network for Stroke Treatment in South Carolina-A Progress Report.
Medico-Legal Aspects of Using Tissue Plasminogen Activator in Acute Ischemic Stroke.
Medicolegal Considerations with Intravenous Tissue Plasminogen Activator in Stroke: A Systematic Review.
Meet Me in Computed Tomography Suite: Decreasing Tissue Plasminogen Activator Door-to-Needle Time for Acute Ischemic Stroke Patients.
Melatonin attenuates the postischemic increase in blood-brain barrier permeability and decreases hemorrhagic transformation of tissue-plasminogen activator therapy following ischemic stroke in mice.
Memantine Improves Safety of Thrombolysis for Stroke.
Meningovascular syphilis with fatal vertebrobasilar occlusion.
Mesenchymal Stem Cells: The Potential Therapeutic Cell Therapy to Reduce Brain Stroke Side Effects.
Meta-analysis of clinical outcomes of intravenous recombinant tissue plasminogen activator for acute ischemic stroke: within 3 hours versus 3-4.5 hours.
Meta-analysis of genetic studies from journals published in China of ischemic stroke in the Han Chinese population.
Meta-analysis of Vascular Imaging Features to Predict Outcome Following Intravenous rtPA for Acute Ischemic Stroke.
Metabolic Syndrome and its Profound Effect on Prevalence of Ischemic Stroke.
Metabolic syndrome and resistance to IV thrombolysis in middle cerebral artery ischemic stroke.
Metabolic Syndrome Predicts Refractoriness to Intravenous Thrombolysis in Acute Ischemic Stroke.
Methodologic challenges in the design and conduct of hyperacute stroke research.
Methodology for the Canadian Activase for Stroke Effectiveness Study (CASES). CASES Investigators.
Methodology of the Interventional Management of Stroke III Trial.
Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
Metronidazole Induced Encephalopathy Mimicking an Acute Ischemic Stroke Event.
Microbleeds, Cerebral Hemorrhage, and Functional Outcome After Stroke Thrombolysis: Individual Patient Data Meta-Analysis.
Microbubble-Augmented Ultrasound Sonothrombolysis Decreases Intracranial Hemorrhage in a Rabbit Model of Acute Ischemic Stroke.
Microbubbles improve sonothrombolysis in vitro and decrease hemorrhage in vivo in a rabbit stroke model.
Microglial-mediated PDGF-CC activation increases cerebrovascular permeability during ischemic stroke.
Microsurgical embolectomy with superficial temporal artery-middle cerebral artery bypass for acute internal carotid artery dissection: A technical case report.
Middle Cerebral Artery Occlusion Allowing Reperfusion via Common Carotid Artery Repair in Mice.
Might life-threatening acute pulmonary edema occur after using recombinant tissue plasminogen activator? A case report.
Mild Hypothermia Reduces Tissue Plasminogen Activator-Related Hemorrhage and Blood Brain Barrier Disruption After Experimental Stroke.
Minimum intravenous thrombolysis utilization rates in acute ischemic stroke to achieve population effects on disability: A discrete-event simulation model.
Minocycline and Magnesium As Neuroprotective Agents for Ischemic Stroke: A Systematic Review.
Minocycline Development for Acute Ischemic Stroke.
Minor Non-Disabling Stroke Patients with Large Vessel Severe Stenosis or Occlusion Might Benefit from Thrombolysis.
Misdiagnosis of stroke in tissue plasminogen activator-treated patients: characteristics and outcomes.
Mitral Valve Papillary Fibroelastoma as the Cause of Ischemic Stroke in a Young Patient: A Case Report.
MMP-9 Inhibition: a Therapeutic Strategy in Ischemic Stroke.
Mobile Stroke Units: Bringing Treatment to the Patient.
Mobile stroke units: taking stroke care to the patient.
Model-based assessment of the benefits and risks of recombinant tissue plasminogen activator treatment in acute ischaemic stroke.
Modeling Stroke Patient Transport for All Patients With Suspected Large-Vessel Occlusion.
Modeling the Cost Effectiveness of Neuroimaging-Based Treatment of Acute Wake-Up Stroke.
Modified diffusion-weighted imaging-Alberta Stroke Program Early Computed Tomography Score including deep white matter lesions predicts symptomatic intracerebral hemorrhage following intravenous thrombolysis.
Modulation by the noble gas argon of the catalytic and thrombolytic efficiency of tissue plasminogen activator.
Modulation by the Noble Gas Helium of Tissue Plasminogen Activator: Effects in a Rat Model of Thromboembolic Stroke.
Modulation of ?7nAchR by Melatonin Alleviates Ischemia and Reperfusion-Compromised Integrity of Blood-Brain Barrier Through Inhibiting HMGB1-Mediated Microglia Activation and CRTC1-Mediated Neuronal Loss.
Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator.
Molecular mechanisms in the pathogenesis and treatment of acute ischemic stroke.
Molecular requirements for safer generation of thrombolytics by bioengineering the tissue-type plasminogen activator A chain.
Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI.
Monoacylglycerol Lipase Inhibitor is Safe when Combined with Delayed r-tPA Administration in Treatment of Stroke.
Monte Carlo Simulation Modeling of a Regional Stroke Team's Use of Telemedicine.
More on Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.
More Time Is Taken to Administer Tissue Plasminogen Activator in Ischemic Stroke Patients with Earlier Presentations.
Mouse model of intraluminal MCAO: cerebral infarct evaluation by cresyl violet staining.
MRI evaluation of BBB disruption after adjuvant AcSDKP treatment of stroke with tPA in rat.
MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS.
MRI-Based Ultrafast Protocol Thrombolysis with rt-PA for Acute Ischemia Stroke in 12-Hour Time Window.
MT-DRAGON score for outcome prediction in acute ischemic stroke treated by mechanical thrombectomy within 8 hours.
Multicenter Study of Adverse Events After Intravenous Tissue-Type Plasminogen Activator Treatment of Acute Ischemic Stroke.
Multicenter Study of Intravenous Recombinant Tissue Plasminogen Activator Infusion around Hiroshima, Japan: The Hiroshima Acute Stroke Retrospective and Prospective Registry Study.
Multimodal computed tomography-guided intravenous rtPA for aborted stroke in a HIV-infected young man: a case report.
Multimodal Imaging Does Not Delay Intravenous Thrombolytic Therapy in Acute Stroke.
Multiparametric ISODATA analysis of embolic stroke and rt-PA intervention in rat.
Multiple ischemic strokes associated with use of recombinant activated factor VII.
Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST).
Myocardial Infarction Following Intravenous Thrombolysis for Acute Ischemic Stroke: Case Report and Literature Review.
Myocardial infarction following recombinant tissue plasminogen activator treatment for acute ischemic stroke: a dangerous complication.
N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Augments Thrombolysis of tPA (Tissue-Type Plasminogen Activator) in Aged Rats After Stroke.
N-acetylaspartate: Serum marker of reperfusion in ischemic stroke.
National trends in outcomes of ischemic stroke and prognostic influence of stroke center capability in Japan, 2010-2016.
National Trends in Telestroke Utilization in a US Commercial Platform Prior to the COVID-19 Pandemic.
National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate.
National use of thrombolysis with alteplase for acute ischaemic stroke via telemedicine in Denmark: a model of budgetary impact and cost effectiveness.
Nationwide "Hospital Emergent Capability Accreditation by Level-Stroke" Improves Stroke Treatment in Taiwan.
Nationwide Estimates of 30-Day Readmission in Patients With Ischemic Stroke.
Neuroendocrinal, Neurodevelopmental, and Embryotoxic Effects of Recombinant Tissue Plasminogen Activator Treatment for Pregnant Women with Acute Ischemic Stroke.
Neuroendovascular Rescue: Interventional Treatment of Acute Ischemic Stroke.
Neuroendovascular treatments/procedures: are they efficacious and have they improved patient outcomes poststroke?
Neurohospitalists Improve Door-to-Needle Times for Patients With Ischemic Stroke Receiving Intravenous tPA.
Neuroimaging Paradigms to Identify Patients for Reperfusion Therapy in Stroke of Unknown Onset.
Neuroimaging, biochemical and cellular evidence of protection by mycophenolate mofetil on middle cerebral artery occlusion induced injury in rats.
Neuroimmunomodulatory effects of transcranial laser therapy combined with intravenous tPA administration for acute cerebral ischemic injury.
Neuroinflammation and neuroprotective strategies in acute ischaemic stroke - from bench to bedside.
Neuroinflammation in hemorrhagic transformation after tissue plasminogen activator thrombolysis: Potential mechanisms, targets, therapeutic drugs and biomarkers.
Neurological Complications of Cardiac Tumors.
Neurological complications of coronary angiographic procedures.
Neurological Emergencies During Pregnancy.
Neurologists' attitudes regarding rt-PA for acute ischemic stroke.
Neurology residency program as factor associated with thrombolysis utilization in acute stroke.
Neuroprotection and stroke: time for a compromise.
Neuroprotection and thrombolysis: combination therapy in acute ischaemic stroke.
Neuroprotection by urokinase plasminogen activator in the hippocampus.
Neuroprotection for ischemic stroke: moving past shortcomings and identifying promising directions.
Neuroprotection via AT2 receptor agonists in ischemic stroke.
Neuroprotective effect of masitinib in rats with postischemic stroke.
Neuroprotective effects of adjunctive treatments for acute stroke thrombolysis: a review of clinical evidence.
Neuroprotective Effects of Curcumin in Cerebral Ischemia: Cellular and Molecular Mechanisms.
Neuroprotective effects of Yiqihuoxue calm wind capsule on ischemic stroke in rats.
Neuroprotective mechanisms and translational potential of therapeutic hypothermia in the treatment of ischemic stroke.
Neuroproteome changes after ischemia/reperfusion injury and tissue plasminogen activator administration in rats: a quantitative iTRAQ proteomics study.
Neuroserpin polymorphisms and stroke risk in a biracial population: the stroke prevention in young women study.
Neuroserpin, a neuroprotective factor in focal ischemic stroke.
Neuroserpin: a selective inhibitor of tissue-type plasminogen activator in the central nervous system.
Neurotoxic effects of exogenous recombinant tissue-type plasminogen activator on the normal rat brain.
Neurovascular function recovery after focal ischemic stroke by enhancing cerebral collateral circulation via peripheral stimulation-mediated interarterial anastomosis.
Neurovascular protection by peroxisome proliferator-activated receptor ? in ischemic stroke.
Neutrophil extracellular traps contribute to tissue plasminogen activator resistance in acute ischemic stroke.
Neutrophil extracellular traps promote tPA-induced brain hemorrhage via cGAS in mice with stroke.
Neutrophil-to-lymphocyte ratio in predicting neurologic outcome of patients with acute ischemic stroke treated with intravenous thrombolytics.
New and investigational treatment options for ischemic stroke.
New insights on thrombolytic treatment of acute ischemic stroke.
New pathways for evaluating potential acute stroke therapies.
New perspectives on the pharmacotherapy of ischemic stroke.
New strategies for endovascular recanalization of acute ischemic stroke.
New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator.
New treatments for stroke.
New treatments in acute ischemic stroke.
New windows, same old house: an update on acute stroke management.
New-generation oral anticoagulants for the prevention of stroke: Implications for neurosurgery.
No Relation between Body Temperature and Arterial Recanalization at Three Days in Patients with Acute Ischaemic Stroke.
Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial.
Nonatrial Fibrillation was Associated With Early Neurological Improvement After Intravenous Thrombolysis With rt-PA in Patients With Acute Ischemic Stroke.
Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator.
Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.
Normobaric hyperoxia slows blood-brain barrier damage and expands the therapeutic time window for tissue-type plasminogen activator treatment in cerebral ischemia.
North Carolina stroke prevention and treatment facilities survey: rtPA therapy for acute stroke.
Not All Clots Are Created Equal: A Review of Deficient Thrombolysis with Tissue Plasminogen Activator (tPA) in Patients with Metabolic Syndrome.
Not only the Sugar, Early infarct sign, hyperDense middle cerebral artery, Age, Neurologic deficit score but also atrial fibrillation is predictive for symptomatic intracranial hemorrhage after intravenous recombinant tissue plasminogen activator.
Novel lytics, novel imaging: a new treatment strategy in stroke?
Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: Intracranial bleeding associated with the treatment of ischemic stroke: thrombolytic treatment of ischemia-affected endothelial cells with tissue-type plasminogen activator.
Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: Protective effects of antiplatelet agents against stroke.
Novel Telestroke Program Improves Thrombolysis for Acute Stroke Across 21 Hospitals of an Integrated Healthcare System.
Novel thrombolytic drugs: will they make a difference in the treatment of ischaemic stroke?
Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities.
Novel Use of a Nurse-Led Telemedicine Team in Acute Stroke: A Retrospective Review of the Impact on a Regional Health Care System.
Nuclear neuroimaging in acute and subacute ischemic stroke.
NURR1 Involvement in Recombinant Tissue-Type Plasminogen Activator Treatment Complications After Ischemic Stroke.
Nursing management of acute complications following rt-PA in acute ischemic stroke. The NINDS rt-PA Stroke Study Group.
Obesity in acute ischaemic stroke patients treated with intravenous thrombolysis therapy.
Observation of clinical efficacy of rt-PA intravenous thrombolytic treatment for patients combined with grade 0-1 diabetic foot by Wagner classification and acute ischemic stroke.
Observational Multicenter Study of a Direct-to-CT Protocol for EMS-transported Patients with Suspected Stroke.
Observational Study of Telephone Consults by Stroke Experts Supporting Community Tissue Plasminogen Activator Delivery.
Obstacles to the use of intravenous tissue plasminogen activator for acute ischemic stroke. Is time the only barrier?
Occludin degradation makes brain microvascular endothelial cells more vulnerable to reperfusion injury in vitro.
Odds of favourable 3-month outcome following ischaemic stroke are greatest when treatment with intravenous alteplase is initiated up to 90 min following event, with no benefit seen if alteplase is given after 270 min.
Off-label thrombolysis is not associated with poor outcome in patients with stroke.
Off-label thrombolysis versus full adherence to the current European Alteplase license: impact on early clinical outcomes after acute ischemic stroke.
Older Stroke Patients with High Stroke Scores Have Delayed Door-To-Needle Times.
One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke.
One-year follow-Up in acute stroke patients treated with rtPA in clinical routine.
One-Year Home-Time and Mortality After Thrombolysis Compared With Nontreated Patients in a Propensity-Matched Analysis.
Onset of Orolingual Angioedema After Treatment of Acute Brain Ischemia with Alteplase Depends on the Site of Brain Ischemia: A Meta-analysis.
Opalski Syndrome Treated with Intravenous Recombinant Tissue Type Plasminogen Activator-Case Report and Review of Literature.
Opinion of New Zealand physicians on management of acute ischaemic stroke: results of a national survey.
Optimal Delay Time of CT Perfusion for Predicting Cerebral Parenchymal Hematoma After Intra-Arterial tPA Treatment.
Optimal dose for stroke thrombolysis in Asians: low dose may have similar safety and efficacy as standard dose.
Optimising Clinical Trial Design for Proof of Neuroprotection in Acute Ischaemic Stroke: The SAINT Clinical Trial Programme.
Optimizing blood pressure in neurological emergencies.
Optimizing the Concentration and Bolus of a Drug Delivered by Continuous Infusion.
Optimizing the Economic Impact of rtPA Use in a Stroke Belt State: The Case of South Carolina.
Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).
Organisational barriers to thrombolysis treatment of acute ischaemic stroke.
Organizing Healthcare for Optimal Acute Ischemic Stroke Treatment.
Orolingual angioedema after alteplase therapy of acute ischaemic stroke: incidence and risk of prior angiotensin-converting enzyme inhibitor use.
Orolingual angioedema after thrombolysis is not associated with insular cortex ischemia on pre-thrombolysis CT.
Orolingual Angioedema After Tissue Plasminogen Activator Administration in Patients Taking Angiotensin-Converting Enzyme Inhibitors.
Orolingual angioedema to alteplase. Identify, counsel and monitor at risk patients.
Orolingual angioedema with alteplase administration for treatment of acute ischemic stroke.
Orolingual angioneurotic edema following therapy of acute ischemic stroke with alteplase.
Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or =80 years) stroke patients.
Outcome of acute ischemic stroke after intra-arterial thrombolysis: A study from India.
Outcome of Acute Ischemic Stroke after the Treatment with Edaravone and 0.6 Mg/Kg Alteplase in Japanese Patients with Diabetes.
Outcome of intravenous recombinant tissue plasminogen activator for acute ischemic stroke in patients aged over 80 years.
Outcome of Intravenous Thrombolysis in Stroke Patients Weighing over 100 kg.
Outcome of multimodal MRI-guided intravenous thrombolysis in patients with stroke with unknown time of onset.
Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Outcome of patients with atrial fibrillation after intravenous thrombolysis for cerebral ischaemia.
Outcome of Repeated Thrombolysis in Debrecen Thrombolysis Database.
Outcome of stroke patients without angiographically revealed arterial occlusion within four hours of symptom onset.
Outcome of the 'Drip-and-Ship' Paradigm among Patients with Acute Ischemic Stroke: Results of a Statewide Study.
Outcomes Among Patients With Ischemic Stroke Treated With Intravenous tPA (Tissue-Type Plasminogen Activator) via Telemedicine.
Outcomes and Treatment Complications of Intravenous Urokinase Thrombolysis in Acute Ischemic Stroke in China.
Outcomes of Endovascular Thrombectomy with and without Thrombolysis for Acute Large Artery Ischaemic Stroke at a Tertiary Stroke Centre.
Outcomes of endovascular versus intravenous thrombolytic treatment for acute ischemic stroke in dialysis patients.
Outcomes of intravenous tissue plasminogen activator for acute ischaemic stroke in HIV-infected adults.
Outcomes of intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 90 years or older.
Outcomes of Patients Requiring Blood Pressure Control Before Thrombolysis with tPA for Acute Ischemic Stroke.
Outcomes of systemic anticoagulation with bivalirudin for Impella 5.0.
Outcomes of thrombolysis for acute ischemic stroke in octogenarians versus nonagenarians.
Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study.
Overview of Cochrane thrombolysis meta-analysis.
Oxfordshire community stroke project clinical stroke syndrome and appearances of tissue and vascular lesions on pretreatment ct in hyperacute ischemic stroke among the first 510 patients in the Third International Stroke Trial (IST-3).
Oxidative Stress and the Use of Antioxidants in Stroke.
Paediatric acute basilar thrombosis successfully treated with intravenous alteplase.
PAI-1 5G/5G genotype is an independent risk of intracranial hemorrhage in post-lysis stroke patients.
Panax notoginsenoside Rb1 Restores the Neurotrophic Imbalance Following Photothrombotic Stroke in Rats.
Paradoxical Brain Embolism Caused by Isolated Pulmonary Arteriovenous Fistula Successfully Treated with Recombinant Tissue Plasminogen Activator.
Paradoxical Myocardial Infarction After Thrombolytic Therapy for Acute Ischemic Stroke.
Partial Intra-Aortic Occlusion Improves Perfusion Deficits and Infarct Size Following Focal Cerebral Ischemia.
Partial Recanalization of a Large Vessel Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator, Followed by Systemic Anticoagulation, in the Setting of COVID-19-Induced Hypercoagulability: A Case Report.
Participation in Get With the Guidelines-Stroke and Its Association With Quality of Care for Stroke.
Past, present and future of alteplase for acute ischemic stroke.
Pathologic validation of clot length determined using thin section non-contrast CT.
Pathophysiologic mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic significance beyond thrombolysis.
Pathophysiology and mechanisms of acute ischemic stroke. The NINDS rt-PA Stroke Study Group.
Pathophysiology of ischemic stroke: role of oxidative stress.
Patient refusal of thrombolytic therapy for suspected acute ischemic stroke.
Patient-Centered Decision Support in Acute Ischemic Stroke: Qualitative Study of Patients' and Providers' Perspectives.
Patients with Low National Institutes of Health Stroke Scale Scores Have Longer Door-to-Needle Times: Analysis of a Telestroke Network.
Pennsylvania comprehensive stroke center collaborative: Statement on the recently updated IV rt-PA prescriber information for acute ischemic stroke.
Penumbra Stroke System as an "add-on" for the treatment of large vessel occlusive disease following thrombolysis: first results.
Penumbral selection of patients for trials of acute stroke therapy.
Peptide5 attenuates rtPA related brain microvascular endothelial cells reperfusion injury via the Wnt/?-catenin signalling pathway.
Percutaneous clot removal devices in acute ischemic stroke: a systematic review and meta-analysis.
Perfusion Angiography in Acute Ischemic Stroke.
Perfusion computed tomography in patients with stroke thrombolysis.
Perfusion Computed Tomography-Guided Intravenous Thrombolysis for Acute Ischemic Stroke beyond 4.5 Hours: A Case-Control Study.
Peripheral Monocyte Count Predicts Outcomes in Patients with Acute Ischemic Stroke Treated with rtPA Thrombolysis.
Permeability Measures Predict Hemorrhagic Transformation after Ischemic Stroke.
Permeable Thrombi Are Associated With Higher Intravenous Recombinant Tissue-Type Plasminogen Activator Treatment Success in Patients With Acute Ischemic Stroke.
Peroxynitrite Decomposition Catalyst Reduces Delayed Thrombolysis-induced Hemorrhagic Transformation in Ischemia-reperfused Rat Brains.
Persistence of hyperdense middle cerebral artery sign on follow-up CT scan after intravenous thrombolysis is associated with poor outcome.
Pharmacist Participation in Acute Ischemic Stroke Decreases Door-to-Needle Time to Recombinant Tissue Plasminogen Activator.
Pharmacoeconomic impact of an alternative workflow process for stroke.
Pharmacogenetics of neural injury recovery.
Pharmacokinetics of alteplase in the treatment of ischaemic stroke.
Pharmacological and non-pharmacological recanalization strategies in acute ischemic stroke.
Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly.
Pharmacological Management Options to Prevent and Reduce Ischemic Hemorrhagic Transformation.
Pharmacological Modulation of Neutrophil Extracellular Traps Reverses Thrombotic Stroke tPA (Tissue-Type Plasminogen Activator) Resistance.
Pharmacological recanalization therapy in acute ischemic stroke - Evolution, current state and perspectives of intravenous and intra-arterial thrombolysis.
Pharmacological revascularization of acute ischaemic stroke: focus on challenges and novel strategies.
Pharmacotherapy of cerebral ischemia.
Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial.
Phased changes in strategies can reduce delay of intravenous thrombolysis administration to 15?min.
Phosphorylated recombinant HSP27 protects the brain and attenuates blood-brain barrier disruption following stroke in mice receiving intravenous tissue-plasminogen activator.
Physician knowledge of the benefits, risks, and contraindications of tissue plasminogen activator for acute ischemic stroke.
Physiopathology of ischemic stroke and its modulation using memantine: evidence from preclinical stroke.
Physiotherapists' experiences of early mobilization after stroke thrombolysis in England and Wales: A qualitative study.
Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group.
Pinocembrin Protects Blood-Brain Barrier Function and Expands the Therapeutic Time Window for Tissue-Type Plasminogen Activator Treatment in a Rat Thromboembolic Stroke Model.
Place of drug therapy in the treatment of carotid stenosis.
Plasma let-7i and miR-15a expression are associated with the effect of recombinant tissue plasminogen activator treatment in acute ischemic stroke patients.
Plasma levels of coagulation and fibrinolysis markers in acute ischemic stroke patients with lone atrial fibrillation.
Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke.
Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?
Plasmin-loaded echogenic liposomes for ultrasound-mediated thrombolysis.
Plasminogen activation and thrombolysis for ischemic stroke.
Plasminogen Activation-Based Thrombolysis for Ischaemic Stroke: The Diversity of Targets may Demand New Approaches.
Plasminogen activator inhibitor in acute stroke.
Plasminogen activator inhibitor-1 4G/5G polymorphism and ischemic stroke risk: a meta-analysis in Chinese population.
Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of ischemic stroke: a meta-analysis.
Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts.
Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and PAI-1 plasma levels in young patients with ischemic stroke.
Plasminogen activator inhibitor-1 contributes to the deleterious effect of obesity on the outcome of thrombotic ischemic stroke in mice.
Plasminogen activator inhibitor-1 in patients with ischemic stroke.
Platelet derived growth factor-CC isoform is associated with hemorrhagic transformation in ischemic stroke patients treated with tissue plasminogen activator.
Platelet microparticles: a biomarker for recanalization in rtPA-treated ischemic stroke patients.
Point-of-care quantification of serum cellular fibronectin levels for stratification of ischemic stroke patients.
Polyacrylic acid-coated nanoparticles loaded with recombinant tissue plasminogen activator for the treatment of mice with ischemic stroke.
Polypharmacy, functional outcome and treatment effect of intravenous alteplase for acute ischaemic stroke.
Pooled RCTs: alteplase within 4.5 hours of ischemic stroke improves the likelihood of good outcome.
Pooled RCTs: In acute ischemic stroke with salvageable brain tissue, alteplase at 4.5 to 9 hours improved function.
Pooled RCTs: In patients with acute ischemic stroke, alteplase increases intracerebral hemorrhage.
Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke.
Poor Recognition of Prompted Treatment Seeking Even with Good Knowledge of Stroke Warning Signs Contribute to Delayed Arrival of Acute Ischemic Stroke Patients in Thailand.
Post t-PA transfer to hub improves outcome of moderate to severe ischemic stroke patients.
Post-licensed 1-year experience of systemic thrombolysis with tissue plasminogen activator for ischemic stroke in a Japanese neuro-unit.
Post-stroke inflammation and the potential efficacy of novel stem cell therapies: focus on amnion epithelial cells.
Post-Stroke Seizures Is Associated with Low Alberta Stroke Program Early CT Score.
Post-stroke treatment with 17?-estradiol exerts neuroprotective effects in both normotensive and hypertensive rats.
Post-thrombolysis hemorrhage in a patient with hypothyroidism and acute ischemic stroke: Case report.
Post-thrombolysis rupture of small lenticulostriate aneurysms: A report of 2 consecutive cases.
Posterior circulation stroke is associated with prolonged door-to-needle time.
Posterior vs. anterior circulation infarction: demography, outcomes, and frequency of hemorrhage after thrombolysis.
Postprocedure intravenous eptifibatide following intra-arterial reteplase in patients with acute ischemic stroke.
Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis.
Postthrombolysis blood pressure elevation is associated with hemorrhagic transformation.
Potential advantages of Chinese medicine Taohong Siwu Decoction () combined with tissue-plasminogen activator for alleviating middle cerebral artery occlusion-induced embolic stroke in rats.
Potential eligibility for recombinant tissue plasminogen activator therapy in children: a population-based study.
Potential gains and costs from increasing access to thrombolysis for acute ischemic stroke patients in New Zealand hospitals.
Potential molecular targets of peroxynitrite in mediating blood-brain barrier damage and haemorrhagic transformation in acute ischaemic stroke with delayed tissue plasminogen activator treatment.
Potential of immunosuppressive agents in cerebral ischaemia.
Potential of Stem Cell-Based Therapy for Ischemic Stroke.
Potential Role of Neuroprotective Agents in the Treatment of Patients with Acute Ischemic Stroke.
Potentiating intra-arterial sonothrombolysis for acute ischemic stroke by the addition of the ultrasound contrast agents (Optison & SonoVue((R))).
Practical considerations in the early treatment of ischemic stroke.
Practical model-based dose finding in early-phase clinical trials: optimizing tissue plasminogen activator dose for treatment of ischemic stroke in children.
Pre-hospital Assessment of Large Vessel Occlusion Strokes: Implications for Modeling and Planning Stroke Systems of Care.
Pre-Hospital Delay in Patients with Acute Ischemic Stroke in a Multicenter Stroke Registry: K-PLUS.
Pre-hospital delay in the use of intravenous rt-PA for acute ischemic stroke in Japan.
Pre-hospital notification reduced the door-to-needle time for iv t-PA in acute ischaemic stroke.
Preclinical Evidence Toward the Use of Ketamine for Recombinant Tissue-Type Plasminogen Activator-Mediated Thrombolysis Under Anesthesia or Sedation.
Preclusion of Ischemic Stroke Patients from Intravenous Tissue Plasminogen Activator Treatment for Mild Symptoms Should Not be Based on Low National Institutes of Health Stroke Scale Scores.
Predicting abnormal coagulation in ischemic stroke: reducing delay in rt-PA use.
Predicting neuroimaging eligibility for extended-window endovascular thrombectomy.
Predicting outcome in hyper-acute stroke: validation of a prognostic model in the Third International Stroke Trial (IST3).
Predicting outcome in ischemic stroke: external validation of predictive risk models.
Predicting outcome of IV thrombolysis-treated ischemic stroke patients: the DRAGON score.
Predicting prognosis in patients with stroke treated with intravenous alteplase through the 24-h trajectory of blood pressure changes.
Predicting risk of symptomatic intracerebral hemorrhage and mortality after treatment with recombinant tissue-plasminogen activator using SEDAN score.
Predicting Stroke Outcome Using Clinical- versus Imaging-based Scoring System.
Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score.
Prediction of clinical outcome with baseline and 24-hour perfusion CT in acute middle cerebral artery territory ischemic stroke treated with intravenous recanalization therapy.
Prediction of Early Arterial Recanalization and Tissue Fate in the Selection of Patients With the Greatest Potential to Benefit From Intravenous Tissue-Type Plasminogen Activator.
Prediction of hospital disposition after thrombolysis for acute ischemic stroke using the National Institutes of Health Stroke Scale.
Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores.
Predictive Factors of Hemorrhage After Thrombolysis in Patients With Acute Ischemic Stroke.
Predictive value of coagulation factor XIII on bleeding risk in ischemic stroke patients treated with intravenous thrombolysis.
Predictors and early outcome of hemorrhagic transformation after acute ischemic stroke.
Predictors for hemorrhagic transformation with intravenous tissue plasminogen activator in acute ischemic stroke.
Predictors of critical care needs after IV thrombolysis for acute ischemic stroke.
Predictors of functional outcome and hemorrhagic complications in acute ischemic stroke patients treated with intravenous thrombolysis - A retrospective analysis?.
Predictors of functional outcome in patients with stroke thrombolysis in a tertiary hospital in Malaysia.
Predictors of good outcome after intravenous tPA for acute ischemic stroke.
Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume.
Predictors of In-Hospital Mortality and the Risk of Symptomatic Intracerebral Hemorrhage after Thrombolytic Therapy with Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke.
Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy.
Predictors of increased intravenous tissue plasminogen activator use among hospitals participating in the Massachusetts Primary Stroke Service Program.
Predictors of Intracerebral Hemorrhage in Acute Stroke Patients Receiving Intravenous Recombinant Tissue Plasminogen Activator.
Predictors of major neurological improvement after intravenous thrombolysis in acute ischemic stroke: a hospital-based study from south India.
Predictors of poor hospital discharge outcome in acute stroke due to atrial fibrillation.
Predictors of post-thrombolysis symptomatic intracranial hemorrhage in Chinese patients with acute ischemic stroke.
Predictors of Postthrombolysis Outcome and Symptomatic Postthrombolysis Hemorrhage following Intravenous Thrombolysis with Alteplase for Acute Ischemic Stroke.
Predictors of symptomatic intracranial haemorrhage in patients with an ischaemic stroke with neurological deterioration after intravenous thrombolysis.
Predictors of systemic inflammatory response syndrome in ischemic stroke undergoing systemic thrombolysis with intravenous tissue plasminogen activator.
Prehospital and hospital delays after stroke onset--United States, 2005-2006.
Prehospital diagnosis and management of patients with acute stroke.
Prehospital Notification Procedure Improves Stroke Outcome by Shortening Onset to Needle Time in Chinese Urban Area.
Prehospital stroke care: limitations of current interventions and focus on new developments.
Prehospital stroke care: potential, pitfalls, and future.
Prehospital thrombolysis in acute stroke: results of the PHANTOM-S pilot study.
Prehospital triage to primary stroke centers and rate of stroke thrombolysis.
Preliminary Efficacy Report of a Novel Thrombolytic Agent for Acute Ischaemic Stroke within a 5-Hour Window.
Preliminary Experience with Air Transfer of Patients for Rescue Endovascular Therapy after Failure of Intravenous Tissue Plasminogen Activator.
Preliminary experience with intra-arterial nicardipine in patients with acute ischemic stroke.
PREMISE: Posterior Circulation Results Comparing Embolectomy to Medical Intervention in Stroke Emergencies.
Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy.
Preprocedure Intravenous Recombinant Tissue Plasminogen Activator and Risk of Distal Embolization with Thrombectomy in Acute Ischemic Stroke.
Presenting Symptoms and Dysphagia Screen Predict Outcome in Mild and Rapidly Improving Acute Ischemic Stroke Patients.
Preserved structural connectivity mediates the clinical effect of thrombolysis in patients with anterior-circulation stroke.
Pretissue Plasminogen Activator Blood Pressure Levels and Risk of Symptomatic Intracerebral Hemorrhage.
Pretreatment blood-brain barrier damage and post-treatment intracranial hemorrhage in patients receiving intravenous tissue-type plasminogen activator.
Pretreatment Diffusion-Weighted Imaging Lesion Volume Predicts Favorable Outcome After Intravenous Thrombolysis With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke.
Prevalence and Outcomes of Medium Vessel Occlusions With Discrepant Infarct Patterns.
Prevalence of Imaging Targets in Patients With Minor Stroke Selected for IV tPA Treatment Using MRI: The Treatment of Minor Stroke With MRI Evaluation Study (TIMES).
Prevalence of prothrombotic polymorphisms in a selected cohort of cryptogenic and noncryptogenic ischemic stroke patients.
Prevention of rt-PA induced blood-brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice.
Primary and Comprehensive Stroke Centers: History, Value and Certification Criteria.
Prior antiplatelet agent use and outcomes after intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: a meta-analysis of cohort studies and randomized controlled trials.
Prior Asymptomatic Parenchymal Hemorrhage Does Not Increase the Risk for Intracranial Hemorrhage after Intravenous Thrombolysis.
Priority Nursing Interventions Caring for the Stroke Patient.
Probing the Effective Treatment Thresholds for Alteplase in Acute Ischemic Stroke With Regression Discontinuity Designs.
Procalcitonin related to stroke-associated pneumonia and clinical outcomes of acute ischemic stroke after IV rt-PA treatment.
Procyanidins exhibits neuroprotective activities against cerebral ischemia reperfusion injury by inhibiting TLR4-NLRP3 inflammasome signal pathway.
Production of Desmodus rotundus salivary plasminogen activator alpha1 (DSPAalpha1) in tobacco is hampered by proteolysis.
Progesterone attenuates hemorrhagic transformation after delayed tPA treatment in an experimental model of stroke in rats: involvement of the VEGF-MMP pathway.
Progesterone in experimental permanent stroke: a dose-response and therapeutic time-window study.
Prognostic factors in patients with acute ischemic stroke treated with intravenous tissue plasminogen activator: The first study among Iranian patients.
Prognostic Parameters for Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis in Acute Ischemic Stroke in an Asian Population.
Prognostic Significance of Stroke-Associated Infection and other Readily Available Parameters in Acute Ischemic Stroke Treated by Intravenous Thrombolysis.
Prognostic Value of the 24-Hour Neurological Examination in Anterior Circulation Ischemic Stroke: A post hoc Analysis of Two Randomized Controlled Stroke Trials.
Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy.
Progress in Intravenous Thrombolytic Therapy for Acute Stroke.
Progressive rural-urban disparity in acute stroke care.
Promoting Neurovascular Recovery in Aged Mice after Ischemic Stroke - Prophylactic Effect of Omega-3 Polyunsaturated Fatty Acids.
Promoting Thrombolysis in Acute Ischemic Stroke.
Prompt treatment with alteplase is essential for patients with severe ischaemic stroke.
Propagating Relationship of Cerebral Oximetric Volume and the Clinical Outcome of Recombinant Tissue Plasminogen Activator (r-TPA) Therapy on Acute Cerebral Ischemic Stroke Patients.
Prospective, open-label safety study of intravenous recombinant tissue plasminogen activator in wake-up stroke.
Protease-independent action of tissue plasminogen activator in brain plasticity and neurological recovery after ischemic stroke.
Protective Effects and Target Network Analysis of Ginsenoside Rg1 in Cerebral Ischemia and Reperfusion Injury: A Comprehensive Overview of Experimental Studies.
Protective effects of 2-(2-benzonfuranyl)-2-imidazoline combined with tissue plasminogen activator after embolic stroke in rats.
Protective Effects of Autologous Bone Marrow Mononuclear Cells After Administering t-PA in an Embolic Stroke Model.
Proteomic Protease Substrate Profiling of tPA Treatment in Acute Ischemic Stroke Patients: A Step Toward Individualizing Thrombolytic Therapy at the Bedside.
Protocol adherence and safety of intravenous thrombolysis after telephone consultation with a stroke center.
Protocol Deviations before and after Treatment with Intravenous Tissue Plasminogen Activator in Community Hospitals.
Protocol for the perfusion and angiography imaging sub-study of the Third International Stroke Trial (IST-3) of alteplase treatment within six-hours of acute ischemic stroke.
Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage.
Proton-sensitive cation channels and ion exchangers in ischemic brain injury: New therapeutic targets for stroke?
Provider perceptions of barriers to the emergency use of tPA for acute ischemic stroke: a qualitative study.
Providing full recovery with single-dose intravenous reteplase in a patient presented to emergency department with acute ischemic stroke.
Psoriasis does not worsen outcomes in patients admitted for ischemic stroke: an analysis of the National Inpatient Sample.
Puerperium Stroke and Subsequent Tissue-Type Plasminogen Activator-Induced Hemorrhage: A Case Report.
Pulmonary Embolism in a Stroke Patient after Systemic Thrombolysis: Clinical Decisions and Literature Review.
Qualitative data collection and analysis methods: the INSTINCT trial.
Quality adjusted life year gains associated with administration of recombinant tissue-type plasminogen activator for treatment of acute ischemic stroke: 1998-2011.
Quality and safety of Telemedicine in acute ischemic stroke: Early experience in Taiwan.
Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update.
Quality of Life After Off-Label Thrombolysis for Ischemic Stroke in Elderly Patients.
Quantifying the Benefit of Prehospital Rapid Treatment in Acute Stroke: Benchmark for Future Innovative Clinical Trials.
Quantitative MRI reveals the elderly ischemic brain is susceptible to increased early blood-brain barrier permeability following tissue plasminogen activator related to claudin 5 and occludin disassembly.
Quantitative Signal Intensity in Fluid-Attenuated Inversion Recovery and Treatment Effect in the WAKE-UP Trial.
Quantitatively monitoring acute ischemic stroke patients post recombinant tissue plasminogen activator treatment.
Questions about authorisation of alteplase for ischaemic stroke.
R1--systemic thrombolysis in German stroke units--the experience from the German Stroke data bank.
Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy.
Racial and Ethnic Disparities in the Use of Intravenous Recombinant Tissue Plasminogen Activator and Outcomes for Acute Ischemic Stroke.
Racial disparities in refusal of stroke thrombolysis in Chicago.
Racial disparities in tissue plasminogen activator treatment rate for stroke: a population-based study.
Radiation Monitoring Results from the First Year of Operation of a Unique Ambulance-based Computed Tomography Unit for the Improved Diagnosis and Treatment of Stroke Patients.
Radiomics-Based Intracranial Thrombus Features on CT and CTA Predict Recanalization with Intravenous Alteplase in Patients with Acute Ischemic Stroke.
Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.
Randomized trial of argatroban plus recombinant tissue-type plasminogen activator for acute ischemic stroke (ARAIS): Rationale and design.
Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke).
Rapamycin treatment improves neuron viability in an in vitro model of stroke.
Rapid Alteplase Administration Improves Functional Outcomes in Patients With Stroke due to Large Vessel Occlusions.
Rapid Apparent Diffusion Coefficient Evolution After Early Revascularization.
Rapid clot removal for acute stroke therapy: technical case report.
Rapid EEG changes indicate reperfusion after tissue plasminogen activator injection in acute ischaemic stroke.
Rapid neurological recovery after intravenous tissue plasminogen activator in stroke: prognostic factors and outcome.
Rapid Systematic Review: Intra-Arterial Thrombectomy ("Clot Retrieval") for Selected Patients with Acute Ischemic Stroke.
Rapidly improving stroke symptoms: a pilot, prospective study.
Rate of intravenous thrombolysis for acute ischaemic stroke in the North-of-France region and evolution over time.
Rate of Symptomatic Intracerebral Hemorrhage Related to Intravenous tPA Administered Over Telestroke Within 4.5-Hour Window.
Rationale and design of combination of an immune modulator Fingolimod with Alteplase bridging with Mechanical Thrombectomy in Acute Ischemic Stroke (FAMTAIS) trial.
Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2?×?2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment.
Re-canalization in acute ischemic stroke: the strategies.
Re-examining the exclusion criterion of early recurrent ischemic stroke in intravenous thrombolysis: A meta-analysis.
Re: utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers.
Readministration of intravenous alteplase in acute ischemic stroke patients: case series and systematic review.
Real-life costs and effects of an implementation program to increase thrombolysis in stroke.
Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
Real-world comparative safety and efficacy of tenecteplase versus alteplase in acute ischemic stroke patients with large vessel occlusion.
Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator.
Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Thrombolysis: A Systematic Review and Meta-Analysis.
Reappraisal of microsurgical revascularization for anterior circulation ischemia in patients with progressive stroke.
Reasons why few patients with acute stroke receive tissue plasminogen activator.
Recanalisation of the internal carotid artery following treatment of an acute ischemic stroke with intravenous rT-PA.
Recanalization and Reperfusion Therapies of Acute Ischemic Stroke: What have We Learned, What are the Major Research Questions, and Where are We Headed?
Recanalization between 1 and 24 hours after t-PA therapy is a strong predictor of cerebral hemorrhage in acute ischemic stroke patients.
Recanalization of Chronic Occlusion of the Middle Cerebral Artery With Tissue Plasminogen Activator Treatment: A Case Report.
Recanalization of Middle Cerebral Artery and Intracranial Aneurysm in the Same Ischemic Territory With Intravenous Administration of Recombinant Tissue Plasminogen Activator: Case Report.
Recanalization of previously thrombosed type II endoleak with aneurysm sac expansion after systemic thrombolysis.
Recanalization therapies in acute ischemic stroke: pharmacological agents, devices, and combinations.
Recent advances in stroke management.
Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke.
Recent Myocardial Infarction is Associated With Increased Risk in Older Adults With Acute Ischemic Stroke Receiving Thrombolytic Therapy.
Recent progress in drug treatment for acute ischemic stroke.
Recent progress in translational research on neurovascular and neurodegenerative disorders.
Recent Trends in Clot Retrieval Devices: A Review.
Receptors, channel proteins, and enzymes involved in microglia-mediated neuroinflammation and treatments by targeting microglia in ischemic stroke.
Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice.
Recombinant Desmodus rotundus salivary plasminogen activator crosses the blood-brain barrier through a low-density lipoprotein receptor-related protein-dependent mechanism without exerting neurotoxic effects.
Recombinant human tissue plasminogen activator protects the basal lamina in experimental focal cerebral ischemia.
Recombinant T cell receptor ligand treatment improves neurological outcome in the presence of tissue plasminogen activator in experimental ischemic stroke.
Recombinant tissue plasminogen activator (rt-PA) utilisation by rural clinicians in acute ischaemic stroke: a survey of barriers and enablers.
Recombinant tissue plasminogen activator (rt-PA) utilisation by rural clinicians in acute ischaemic stroke: An audit of current practice and clinical outcomes.
Recombinant tissue plasminogen activator (rtPA) and stroke unit for acute ischaemic stroke in developing countries, are they cost-effective?
Recombinant tissue plasminogen activator enhances microparticle release from mouse brain-derived endothelial cells through plasmin.
Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis.
Recombinant tissue plasminogen activator for acute ischemic stroke.
Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
Recombinant tissue plasminogen activator for the treatment of acute ischemic stroke.
Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Patients receiving Thrombectomy: Standard or Low Dose Therapy?
Recombinant Tissue Plasminogen Activator Increases Blood-Brain Barrier Disruption in Acute Ischemic Stroke: An MR Imaging Permeability Study.
Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischemia in mouse.
Recombinant Tissue Plasminogen Activator Induces Neurological Side Effects Independent on Thrombolysis in Mechanical Animal Models of Focal Cerebral Infarction: A Systematic Review and Meta-Analysis.
Recombinant tissue plasminogen activator: in my community hospital ED, will early administration of rt-PA to patients with the initial diagnosis of acute ischemic stroke reduce mortality and disability?
Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis.
Recombinant Tissue-Type Plasminogen Activator Study of Wake-Up Ischemic Strokes Guided by Rapid MRI.
Recombinant tissue-type plasminogen activator transiently enhances blood-brain barrier permeability during cerebral ischemia through vascular endothelial growth factor-mediated endothelial endocytosis in mice.
Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years.
Recommendations and treatment strategies for the management of acute ischemic stroke.
Red cell index: A novel biomarker for 3-month mortality in acute ischemic stroke patients treated with intravenous thrombolysis.
Redefining Early Neurological Improvement After Reperfusion Therapy in Stroke.
Reduced risk of poststroke pneumonia in thrombolyzed stroke patients with continued statin treatment.
Reducing Door-to-Needle Time for Tissue Plasminogen Activator Administration in a Community Hospital: An Operations Study.
Reducing Door-to-Needle Times for Ischaemic Stroke to a Median of 30 Minutes at a Community Hospital.
Reducing door-to-needle times using Toyota's lean manufacturing principles and value stream analysis.
Reducing haemorrhagic transformation after thrombolysis for stroke: a strategy utilising minocycline.
Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat.
Reduction of Ischemia Reperfusion-Related Brain Hemorrhage by Stachybotrys Microspora Triprenyl Phenol-7 in Mice With Antioxidant Effects.
Regarding "Meet Me in Computed Tomography Suite: Decreasing Tissue Plasminogen Activator Door-to-Needle Time for Acute Ischemic Stroke Patients".
Regeneration after stroke: Stem cell transplantation and trophic factors.
Regional access to acute ischemic stroke intervention.
Regional attenuation without delta (RAWOD): a distinctive EEG pattern that can aid in the diagnosis and management of severe acute ischemic stroke.
Regional Learning Collaboratives Produce Rapid and Sustainable Improvements in Stroke Thrombolysis Times.
Regional Pediatric Acute Stroke Protocol: Initial Experience During 3 Years and 13 Recanalization Treatments in Children.
Regulatory T cells ameliorate tissue plasminogen activator-induced brain haemorrhage after stroke.
Related factors with orolingual angioedema after intravenous alteplase in acute ischemic stroke: results from a single-center cohort and meta-analysis.
Relation between reperfusion and hemorrhagic transformation in acute ischemic stroke.
Relationship between homocysteine level and prognosis of elderly patients with acute ischemic stroke treated by thrombolysis with recombinant tissue plasminogen activator.
Relationship between hospital volume and early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator.
Relationships Between Imaging Assessments and Outcomes in Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke.
Relative CBV ratio on perfusion-weighted MRI indicates the probability of early recanalization after IV t-PA administration for acute ischemic stroke.
Releasable tissue plasminogen activators in ischemic stroke.
Release of IL-6 After Stroke Contributes to Impaired Cerebral Autoregulation and Hippocampal Neuronal Necrosis Through NMDA Receptor Activation and Upregulation of ET-1 and JNK.
Release of Matrix Metalloproteinases-2 and 9 by S-Nitrosylated Caveolin-1 Contributes to Degradation of Extracellular Matrix in tPA-Treated Hypoxic Endothelial Cells.
Relevance of Post-Stroke Circulating BDNF Levels as a Prognostic Biomarker of Stroke Outcome. Impact of rt-PA Treatment.
Relevance of the Updated Food and Drug Administration Alteplase Label for Acute Ischemic Stroke: The Estimated Impact and Current Guidelines.
Reliability and Utility of the Alberta Stroke Program Early Computed Tomography Score in Hyperacute Stroke.
Reliability of the Acutely Estimated Premorbid Modified Rankin Scale for Stroke Treatment Decision Making.
Reliability, Reproducibility and Prognostic Accuracy of the Alberta Stroke Program Early CT Score on CT Perfusion and Non-Contrast CT in Hyperacute Stroke.
Remote Assessment of Stroke Using the iPhone 4.
Remote Intracerebral Hemorrhage After Intravenous Thrombolysis: Results From a Multicenter Study.
Remote Intracerebral Hemorrhage Following Intravenous Thrombolysis in Pregnancy at 31 Weeks Gestation: A Case Report and Review of the Literature.
Remote ischemic conditioning for acute ischemic stroke: dawn in the darkness.
Remote ischemic perconditioning as an adjunct therapy to thrombolysis in patients with acute ischemic stroke: a randomized trial.
Remote ischemic perconditioning in thrombolysed stroke patients: Randomized study of activating endogenous neuroprotection - design and MRI measurements.
Remote or extraischemic intracerebral hemorrhage--an uncommon complication of stroke thrombolysis: results from the safe implementation of treatments in stroke-international stroke thrombolysis register.
Renal Dysfunction and In-Hospital Outcomes in Patients With Acute Ischemic Stroke After Intravenous Thrombolytic Therapy.
Renal dysfunction and thrombolytic therapy in patients with acute ischemic stroke: a systematic review and meta-analysis.
Renal Dysfunction Associated with Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis.
Reocclusion of recanalized arteries during intra-arterial thrombolysis for acute ischemic stroke.
Repeat measurement of case-control data: corrections for measurement error in a study of ischaemic stroke and haemostatic factors.
Repeated Intra-Arterial Thrombectomy within 72 Hours in a Patient with a Clear Contraindication for Intravenous Thrombolysis.
Repeated intravenous thrombolysis in early recurrent stroke secondary to carotid web: Case report.
Repeated Intravenous Treatment with Recombinant Tissue-Type Plasminogen Activator in Patients with Acute Ischemic Stroke.
Repeated thrombolysis for chronologically separated ischemic strokes: a case series.
Reperfusion Rates Following Intra-Arterial Thrombolysis for Acute Ischemic Stroke: The Influence of the Method for Alteplase Delivery.
Reperfusion seizures: a manifestation of cerebral reperfusion injury after administration of recombinant tissue plasminogen activator for acute ischemic stroke.
Reperfusion Therapies For Acute Ischemic Stroke: An Update.
Reperfusion therapies of acute ischemic stroke: potentials and failures.
Reperfusion therapy for acute stroke improves outcome by decreasing neuroinflammation.
Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: minocycline.
Repurposing of Approved Cardiovascular Drugs against Ischemic Cerebrovascular Disease by Disease-Disease Associated Network-Assisted Prediction.
Rescue localized intra-arterial thrombolysis for hyperacute MCA ischemic stroke patients after early non-responsive intravenous tissue plasminogen activator therapy.
Rescue therapy with local intra-arterial urokinase after poor clinical response with intravenous recombinant tissue plasminogen activator in acute ischaemic stroke.
Resident-based acute stroke protocol is expeditious and safe.
Resource Allocation: Stable Patients Remain Stable 12-24 h Post-tPA.
Response of blood pressure and blood glucose to treatment with recombinant tissue-type plasminogen activator in acute ischemic stroke: evidence from the virtual international stroke trials archive.
Response to letter regarding article, "Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the Third International Stroke Trial".
Response to letter regarding article, "Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion".
Results of a 1-year quality-improvement process to reduce door-to-needle time in acute ischemic stroke with MRI screening.
Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect.
Resveratrol improves delayed r-tPA treatment outcome by reducing MMPs.
Reteplase: a review of its use in the management of thrombotic occlusive disorders.
Retinoic acid ameliorates blood-brain barrier disruption following ischemic stroke in rats.
Retrospective study of Heparin Administration for Ischemic Stroke when there is an IV-tPA Contraindication.
Retrosternal mass: An interesting allergic reaction to intravenous thrombolytic therapy for acute ischemic stroke.
Revascularization and functional outcomes after mechanical thrombectomy: an update to key metrics.
Revascularization for acute ischemic stroke is safe for rivaroxaban users.
Revascularization results in the Interventional Management of Stroke II trial.
Reversal of acute ischemic stroke after THA using tissue plasminogen activator.
Reversal of locked-in syndrome with anticoagulation, induced hypertension, and intravenous t-PA.
Reversing the deleterious effects of ?2-antiplasmin on tissue plasminogen activator therapy improves outcomes in experimental ischemic stroke.
Review Cerebral Ischemic Tolerance and Preconditioning: Methods, Mechanisms, Clinical Applications, and Challenges.
Review of acute ischaemic stroke in Pakistan: progress in management and future perspectives.
Review of tissue plasminogen activator, ischemic stroke, and potential legal issues.
Review, Historical Context, and Clarifications of the NINDS rt-PA Stroke Trials Exclusion Criteria: Part 1: Rapidly Improving Stroke Symptoms.
Right internal carotid artery occlusion during intravenous thrombolysis for left middle cerebral artery occlusion.
Risk Factors and Consequences of Atrial Fibrillation with Rapid Ventricular Response in Patients with Ischemic Stroke Treated with Intravenous Thrombolysis.
Risk factors and outcomes of intravenous tissue plasminogen activator and endovascular thrombectomy utilization amongst pediatrics acute ischemic stroke.
Risk Factors Associated with Outcomes of Recombinant Tissue Plasminogen Activator Therapy in Patients with Acute Ischemic Stroke.
Risk Factors for Early Intracerebral Hemorrhage after Intravenous Thrombolysis with Alteplase.
Risk Factors for Epilepsy After Thrombolysis for Ischemic Stroke: A Cohort Study.
Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies.
Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).
Risk factors of diffuse alveolar hemorrhage after acute ischemic stroke treated with tissue-type plasminogen activator. The effectiveness of activated recombinant factor VII treatment.
Risk factors of haemorrhagic transformation for acute ischaemic stroke in Chinese patients receiving intravenous recombinant tissue plasminogen activator: a systematic review and meta-analysis.
RISK FACTORS OF rt-PA THERAPY IN PATIENTS WITH ISCHEMIC STROKE.
Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis.
Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
Risk of pneumonia associated with zero-degree head positioning in acute ischemic stroke patients treated with intravenous tissue plasminogen activator.
Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator.
Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator.
Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator.
ROCK as a therapeutic target for ischemic stroke.
Rodent models of ischemic stroke: a useful tool for stroke drug development.
Role of acute-phase protein ORM in a mice model of ischemic stroke.
Role of diffusion and perfusion MRI in selecting patients for reperfusion therapies.
Role of Intravenous Tissue Plasminogen Activator in Acute Ischemic Stroke with Large Vessel Occlusion.
Role of tissue plasminogen activator in acute ischemic stroke.
Role of tissue-type plasminogen activator in ischemic stroke.
Role of Transporters in Central Nervous System Drug Delivery and Blood-Brain Barrier Protection: Relevance to Treatment of Stroke.
Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke.
Routine thrombolysis with intravenous tissue plasminogen activator in acute ischaemic stroke patients aged 80 years or older: a single centre experience.
Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic Stroke.
rt-PA for ischaemic stroke: what will the next question be?
rt-PA with remote ischemic postconditioning for acute ischemic stroke.
Rupture of a thoracic aortic aneurysm: a rare adverse reaction following systemic tissue plasminogen activator infusion.
Rupture of an Occult Intracranial Mycotic Aneurysm after Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke.
Safe implementation of thrombolysis in stroke-monitoring study in Italy.
Safe Intravenous Thrombolysis after Traumatic Cardiopulmonary Resuscitation with Rib Fractures: A Case Report.
Safety and Angiographic Efficacy of Intra-Arterial Fibrinolytics as Adjunct to Mechanical Thrombectomy: Results from the INFINITY Registry.
Safety and dose-escalation study design of Transcranial Ultrasound in Clinical SONolysis for acute ischemic stroke: the TUCSON Trial.
Safety and Effectiveness of Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in 80 Years and Older Acute Ischemic Stroke Patients.
Safety and effectiveness of intravenous thrombolysis with recombinant tissue plasminogen activator in eighty years and older acute ischemic stroke patients.
Safety and efficacy of alteplase in the treatment of acute ischemic stroke.
Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.
Safety and efficacy of edaravone combined with alteplase for patients with acute ischemic stroke: A systematic review and meta-analysis.
Safety and efficacy of glibenclamide combined with rtPA in acute cerebral ischemia with occlusion/stenosis of anterior circulation (SE-GRACE): study protocol for a randomized controlled trial.
Safety and Efficacy of Intravenous Low-Dose Alteplase in Relative Contraindication Patients with Acute Ischemic Stroke.
Safety and efficacy of intravenous thrombolytic treatment in wake-up stroke: Experiences from a single center.
Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke.
Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial.
Safety and efficacy of mechanical thrombectomy in acute ischemic stroke of anticoagulated patients.
Safety and Efficacy of Mechanical Thrombectomy Using Stent Retrievers in the Endovascular Treatment of Acute Ischaemic Stroke: A Systematic Review.
Safety and efficacy of non-vitamin K oral anticoagulant treatment compared with warfarin in patients with non-valvular atrial fibrillation who develop acute ischemic stroke or transient ischemic attack: a multicenter prospective cohort study (daVinci study).
Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE-TPA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study.
Safety and Efficacy of Repeated Thrombolysis with Alteplase in Early Recurrent Ischemic Stroke: A Systematic Review.
Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase 3, randomised controlled trial.
Safety and efficacy of stroke thrombolysis at a secondary provincial hospital in New Zealand.
Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study.
Safety and efficacy of thrombectomy in acute ischaemic stroke (REVASCAT): 1-year follow-up of a randomised open-label trial.
Safety and efficacy of thrombolysis in telestroke: A systematic review and meta-analysis.
Safety and efficacy of thrombolysis with intravenous alteplase in older stroke patients.
Safety and Efficacy of Thrombolytic Therapy Using rt-PA (Alteplase) in Acute Ischemic Stroke.
Safety and feasibility of a lower dose intravenous TPA therapy for ischemic stroke beyond the first three hours.
Safety and Outcome of Decompressive Hemicraniectomy After Recombinant Tissue Plasminogen Activator Thrombolysis for Acute Ischemic Stroke: A Systematic Review.
Safety and outcome of rtPA in acute ischemic stroke in patients with active cancer: case-control study.
Safety and outcomes of intravenous thrombolysis in stroke mimics: a 6-year, single-care center study and a pooled analysis of reported series.
Safety and Outcomes of Intravenous tPA in Acute Ischemic Stroke Patients With Prior Stroke Within 3 Months: Findings From Get With The Guidelines-Stroke.
Safety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke.
Safety and predictors of stroke mimics in The Norwegian Tenecteplase Stroke Trial (NOR-TEST).
Safety and Preliminary Efficacy of Early Tirofiban Treatment After Alteplase in Acute Ischemic Stroke Patients.
Safety and Time Course of Drip-and-Ship in Treatment of Acute Ischemic Stroke.
Safety and Tolerability of Desmoteplase Within 3 to 9 Hours After Symptoms Onset in Japanese Patients With Ischemic Stroke.
Safety evaluation of a recombinant plasmin derivative lacking kringles 2-5 and rt-PA in a rat model of transient ischemic stroke.
Safety of air medical transportation after tissue plasminogen activator administration in acute ischemic stroke.
Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke.
Safety of early initiation of rivaroxaban or dabigatran after thrombolysis in acute ischemic stroke.
Safety of full-dose intravenous recombinant tissue plasminogen activator followed by multimodal endovascular therapy for acute ischemic stroke.
Safety of Glycoprotein IIb-IIIa Inhibitors Used in Stroke-Related Treatment: A Systematic Review and Meta-Analysis.
Safety of High Doses of Urokinase and Reteplase for Acute Ischemic Stroke.
Safety of Intravenous Thrombolysis among Stroke Patients Taking New Oral Anticoagulants-Case Series and Systematic Review of Reported Cases.
Safety of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Taking Warfarin with Subtherapeutic INR.
Safety of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients with Thrombocytopenia.
Safety of intravenous thrombolysis for acute ischemic stroke in specific conditions.
Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin.
Safety of Intravenous Thrombolysis in Acute Ischemic Stroke Patients with Saccular Intracranial Aneurysms.
Safety of Intravenous Thrombolysis in Chronic Intracranial Hemorrhage: A Five-Year Multicenter Study.
Safety of intravenous thrombolysis in ischemic stroke caused by left atrial myxoma.
Safety of Intravenous Thrombolysis within 4.5 h of Symptom Onset in Patients with Negative Post-Treatment Stroke Imaging for Cerebral Infarction.
Safety of IV thrombolysis in acute ischemic stroke related to Chagas disease.
Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, part I.
Safety of Protocol Violations in Acute Stroke tPA Administration.
Safety of routine IV thrombolysis between 3 and 4.5 h after ischemic stroke.
Safety of standard-dose (.9-mg/kg) alteplase intravenous thrombolysis for acute ischemic stroke in Afro-Caribbeans, French West Indies.
Safety of thrombolysis in acute ischemic stroke: a review of complications, risk factors, and newer technologies.
Safety of thrombolysis in patients with acute ischemic stroke and cerebral cavernous malformations.
Safety of tissue plasminogen activator factor in an acute stroke patient with two unruptured cerebral aneurysms.
Safety of tissue plasminogen activator for acute stroke in menstruating women.
Safety of urgent carotid endarterectomy following thrombolysis.
Safety of urgent STA-MCA anastomosis after intravenous rt-PA treatment: a report of five cases and literature review.
Safety Outcomes After Thrombolysis for Acute Ischemic Stroke in Patients With Recent Stroke.
Safety outcomes of Alteplase among acute ischemic stroke patients with special characteristics.
Saving the ischemic penumbra: potential role for statins and phosphodiesterase inhibitors.
Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.
Screening with MRI for Accurate and Rapid Stroke Treatment: SMART.
Select hyperacute complications of ischemic stroke: cerebral edema, hemorrhagic transformation, and orolingual angioedema secondary to intravenous Alteplase.
Selection for delayed intravenous alteplase treatment based on a prognostic score.
Sequential combination of intravenous recombinant tissue plasminogen activator and intra-arterial urokinase in acute ischemic stroke.
Sequential MR Assessment of the Susceptibility Vessel Sign and Arterial Occlusion in Acute Stroke.
Sequentially Site-Specific Delivery of Thrombolytics and Neuroprotectant for Enhanced Treatment of Ischemic Stroke.
Serial changes in fibrinolysis and coagulation activation markers in acute and convalescent phase of ischemic stroke.
Serious Adverse Events and Their Impact on Functional Outcome in Acute Ischemic Stroke in the WAKE-UP Trial.
Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study.
Serum creatinine may indicate risk of symptomatic intracranial hemorrhage after intravenous tissue plasminogen activator (IV tPA).
Serum lipid level is not associated with symptomatic intracerebral hemorrhage after intravenous thrombolysis for acute ischemic stroke.
Serum S100B indicates successful combination treatment with recombinant tissue plasminogen activator and MK-801 in a rat model of embolic stroke.
Serum uric acid is neuroprotective in Chinese patients with acute ischemic stroke treated with intravenous recombinant tissue plasminogen activator.
Severe Epistaxis after Tissue Plasminogen Activator administration for Acute Ischemic Stroke in SARS-COV-2 Infection.
Sex Differences in Prehospital Delay in Patients With Acute Stroke: A Systematic Review.
Sex Differences in Revascularization Interventions after Acute Ischemic Stroke.
Sex differences in the impact of acute stroke treatment in a population-based study: a sex-specific propensity score approach.
Sex differences in the use of intravenous rt-PA thrombolysis treatment for acute ischemic stroke: a meta-analysis.
Sex-Based Differences in Response to Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke.
Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke.
Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials.
Sex-related differences among ischaemic stroke patients treated with intravenous thrombolysis in Poland.
Shenzhen stroke emergency map improves access to rt-PA for patients with acute ischaemic stroke.
Shifting of global aphasia to Wernicke's aphasia in a patient with intact motor function: a case report.
Short- and Long-Term Reduction of Door-to-Needle Time in Thrombolysis for Acute Stroke.
Short-term High-Dose Effect of Lovastatin on Thrombolysis by rt-PA in a Human Whole-Blood in vitro Clot Model.
Shortening time to stroke treatment using ambulance telemedicine: TeleBAT.
Should more patients with ischemic stroke be eligible for tPA treatment?
Should the Window for Intravenous Administration of Tissue Plasminogen Activator in the Treatment of Acute Ischemic Stroke be Extended to 4.5 Hours?
Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?
Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders.
Similar thrombolysis outcomes in acute stroke patients with and without atrial fibrillation if pre-stroke CHA2DS2-VASc score is low: A retrospective study.
Simple In-Hospital Interventions to Reduce Door-to-CT Time in Acute Stroke.
Simple text-messaging intervention is associated with improved door-to-needle times for acute ischemic stroke.
Simulation of Intracranial Acoustic Fields in Clinical Trials of Sonothrombolysis.
Simultaneous Acute Anterior ST-Elevation Myocardial Infarction and Acute Ischemic Stroke of Left Middle Cerebral Artery: A Case Report.
Simultaneous administration of recombinant tissue plasminogen activator and edaravone in acute cerebral ischemic stroke patients.
Simultaneous cardio-cerebral embolization associated with atrial fibrillation: a case report.
Simultaneous treatment with intravenous recombinant tissue plasminogen activator and endovascular therapy for acute ischemic stroke within 3 hours of onset.
Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator.
Simvastatin pretreatment ameliorates t-PA-induced hemorrhage transformation and MMP-9/TIMP-1 imbalance in thromboembolic cerebral ischemic rats.
Single- and two- chain tissue type plasminogen activator treatments differentially influence cerebral recovery after stroke.
Smoking-thrombolysis paradox: recanalization and reperfusion rates after intravenous tissue plasminogen activator in smokers with ischemic stroke.
Social History Matters-The Impact of Illicit Drug Use on tPA Use and In-Hospital Mortality in Acute Ischemic Stroke.
Sodium Tanshinone IIA Sulfonate Enhances Effectiveness Rt-PA Treatment in Acute Ischemic Stroke Patients Associated with Ameliorating Blood-Brain Barrier Damage.
SOLITAIRE™ with the intention for thrombectomy (SWIFT) trial: design of a randomized, controlled, multicenter study comparing the SOLITAIRE™ Flow Restoration device and the MERCI Retriever in acute ischaemic stroke.
Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke.
Sonothrombolysis for acute ischemic stroke - Break on through to the other side.
Sonothrombolysis for acute ischemic stroke: a systematic review of randomized controlled trials.
Sonothrombolysis in acute ischemic stroke for patients ineligible for rt-PA.
Sonothrombolysis: An effective adjunct to intravenous tissue plasminogen activator therapy in acute ischemic stroke.
Sonothrombolysis: is the story (t)old or just the beginning.
South African guideline for management of ischaemic stroke and transient ischaemic attack 2010: a guideline from the South African Stroke Society (SASS) and the SASS Writing Committee.
Spinal subdural hematoma following tissue plasminogen activator treatment for acute ischemic stroke.
Spontaneous Hemothorax Resulting from Tissue Plasminogen Activator in a Patient with Ischemic Stroke and Unrecognized Recent Myocardial Infarction.
Spontaneous hyperacute postischemic hemorrhage leading to death.
Spotlight on reteplase in thrombotic occlusive disorders.
ST-elevation myocardial infarction associated with acute ischemic stroke.
Stability of alteplase in presence of cavitation.
Statin pretreatment may increase the risk of symptomatic intracranial haemorrhage in thrombolysis for ischemic stroke: results from a case-control study and a meta-analysis.
Statin use and functional outcome after tissue plasminogen activator treatment in acute ischaemic stroke.
Statin use and lipid profile in relation to safety and functional outcome after thrombolysis in ischemic stroke.
Statistical analysis plan for evaluating different intensities of blood pressure control in the ENhanced Control of Hypertension And Thrombolysis strokE stuDy.
Statistical analysis plan for evaluating low- vs. standard-dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED).
Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
Status of endovascular interventions to treat acute ischemic stroke.
Stent-based thrombectomy versus intravenous tissue plasminogen activator in acute ischaemic stroke: A systematic review and meta-analysis.
Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke.
Strategies to Extend Thrombolytic Time Window for Ischemic Stroke Treatment: An Unmet Clinical Need.
Strategies to prevent hemorrhagic transformation after reperfusion therapies for acute ischemic stroke: A literature review.
Strategies Used by Hospitals to Improve Speed of Tissue-Type Plasminogen Activator Treatment in Acute Ischemic Stroke.
Streamlining of prehospital stroke management: the golden hour.
Streamlining the Process for Intravenous Tissue Plasminogen Activator.
Stroke and Drug Delivery-In Vitro Models of the Ischemic Blood-Brain Barrier.
Stroke and Helicopter Emergency Medical Service Transports: An Analysis of 25,332 Patients.
Stroke and immunotherapy: Potential mechanisms and its implications as immune-therapeutics.
Stroke and TIA. Prevention and management of cerebrovascular events in primary care.
Stroke center characteristics which influence the administration of thrombolytic therapy for acute ischemic stroke: a national survey of stroke centers in Taiwan.
Stroke Fast Track Reduces Time Delay to Neuroimaging and Increases Use of Thrombolysis in an Academic Medical Center in Thailand.
Stroke following internal carotid artery occlusion - a contra-indication for intravenous thrombolysis?
Stroke in a Child Safely Treated with Intravenous Tissue Plasminogen Activator and Edaravone, a Free Radical Scavenger.
Stroke Mimics in a Stroke Care Pathway Based on MRI Screening.
Stroke Mimics: An Important Source of Bias in Acute Ischemic Stroke Research.
Stroke networks and telemedicine: An Italian national survey.
Stroke Neurologist's Perspective on the New Endovascular Trials.
Stroke neuroprotection: targeting mitochondria.
Stroke onset to needle delay: Where these golden hours are lost? An Egyptian center experience.
Stroke Outcomes in Thai Elderly Patients Treated with and without Intravenous Thrombolysis.
Stroke Outcomes of Japanese Patients with Major Cerebral Artery Occlusion in the Post-Alteplase, Pre-MERCI Era.
Stroke patients, what to do and what to avoid.
Stroke Scale Items Associated with Neurologic Deterioration within 24 Hours after Recombinant Tissue Plasminogen Activator Therapy.
Stroke secondary to aortic dissection treated with a thrombolytic: a successful case.
Stroke thrombolysis given by emergency physicians cuts in-hospital delays significantly immediately after implementing a new treatment protocol.
Stroke Thrombolysis in a Centralized and a Decentralized System (Helsinki and Telemedical Project for Integrative Stroke Care Network).
Stroke Thrombolysis in Patients Taking Ticagrelor -Two Successful Cases and a Review of the Literature.
Stroke thrombolysis in the emergency department as an alternative service for community hospitals lacking a stroke unit.
Stroke Treatment Using Intravenous and Intra-Arterial Tissue Plasminogen Activator.
Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.
Stroke warning syndrome: 18 new cases.
Stroke-induced microRNAs: The potential therapeutic role for stroke.
Stroke.
Stroke: Basic and Clinical.
Stroke: morbidity, risk factors, and care in taiwan.
Stroke: part II. Management of acute ischemic stroke.
Stroke: Support for IV tPA in ischaemic stroke in elderly people.
Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials.
Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice.
Strong neuroprotection with a novel platinum nanoparticle against ischemic stroke- and tissue plasminogen activator-related brain damages in mice.
Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1.
Structural requirements for activation of latent platelet-derived growth factor CC by tissue plasminogen activator.
Stuttering Lacunes: An Acute Role for Clopidogrel?
Sub-acute systemic erythropoietin administration reduces ischemic brain injury in an age-dependent manner.
Subacute intranasal administration of tissue plasminogen activator increases functional recovery and axonal remodeling after stroke in rats.
Subacute intranasal administration of tissue plasminogen activator promotes neuroplasticity and improves functional recovery following traumatic brain injury in rats.
Subtherapeutic Warfarin Is Not Associated With Increased Hemorrhage Rates in Ischemic Strokes Treated With Tissue Plasminogen Activator.
Successful Delayed Aortic Surgery for a Patient with Ischemic Stroke Secondary to Aortic Dissection.
Successful Intravenous Alteplase for a Centenarian Woman with Acute Ischaemic Stroke.
Successful intravenous thrombolysis for acute stroke in a child.
Successful intravenous thrombolysis in a patient with antiphospholipid syndrome, acute ischemic stroke and severe thrombocytopenia.
Successful microbubble sonothrombolysis without tissue-type plasminogen activator in a rabbit model of acute ischemic stroke.
Successful recanalization with multimodality endovascular interventional therapy in acute ischemic stroke.
Successful Thrombolysis despite Having an Incidental Unruptured Cerebral Aneurysm.
Successful thrombolysis for acute ischaemic stroke in haemodialysis.
Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report.
Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report.
Successful Tissue Plasminogen Activator for a Patient with Stroke After Stanford Type A Aortic Dissection Treatment.
Successful treatment of ischemic stroke associated with brachiocephalic artery stenosis using alteplase.
Successful treatment of pediatric stroke with recombinant tissue plasminogen activator (rt-PA): a case report and review of the literature.
Successful use of Alteplase during cardiopulmonary resuscitation following massive PE in a patient presenting with ischaemic stroke and haemorrhagic transformation.
SUR1-TRPM4 channel activation and phasic secretion of MMP-9 induced by tPA in brain endothelial cells.
Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke.
Sustained benefit of a community and professional intervention to increase acute stroke therapy.
Symptomatic intracerebral hemorrhage after intravenous thrombolysis in Chinese patients: comparison of prediction models.
Symptomatic Intracerebral Hemorrhage Among Eligible Warfarin-Treated Patients Receiving Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke.
Symptomatic intracerebral hemorrhage in acute ischemic stroke after thrombolysis with intravenous recombinant tissue plasminogen activator: a review of natural history and treatment.
Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke.
SYNTHESIS expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast-track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke.
Systematic Review and Pooled Analyses of Recent Neurointerventional Randomized Controlled Trials: Setting a New Standard of Care for Acute Ischemic Stroke Treatment after 20 Years.
Systematic review and stratified meta-analysis of the efficacy of RhoA and Rho kinase inhibitors in animal models of ischaemic stroke.
Systematic Review of Malpractice Litigation in the Diagnosis and Treatment of Acute Stroke.
Systematic review of stroke thrombolysis service configuration.
Systematic review of survival time in experimental mouse stroke with impact on reliability of infarct estimation.
Systemic Inflammation Indices in Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator: Clinical Yield and Utility.
Systemic Reperfusion Therapy in Acute Ischemic Stroke.
Systemic Sclerosis Is Not Associated With Worse Outcomes of Patients Admitted for Ischemic Stroke: Analysis of the National Inpatient Sample.
SYSTEMIC THROMBOLYSIS AND ENDOVASCULAR INTERVENTION IN POSTPARTUM STROKE.
Systemic thrombolysis in ischaemic stroke patients with COVID-19.
Systemic Thrombolysis in Ischemic Stroke After Recent Oral Surgery and Management of Oral Cavity Bleeding.
Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion.
Systemic thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: first Croatian experiences.
Systemic thrombolytic therapy of acute ischemic stroke with rtPA.
t-PA, but not desmoteplase, induces a plasmin-dependent opening of a blood-brain barrier model under normoxic and ischaemic conditions which can be reversed within a limited time frame.
t-PA-specific modulation of a human BBB model involves plasmin-mediated activation of the Rho-kinase pathway in astrocytes.
Taboos and opportunities in sonothrombolysis for stroke.
Takayasu arteritis presenting as embolic stroke.
Target Door-to-Needle Time for Tissue Plasminogen Activator Treatment with Magnetic Resonance Imaging Screening Can Be Reduced to 45 min.
Target Stroke: Best Practice Strategies Cut Door to Thrombolysis Time to <30 Minutes in a Large Urban Academic Comprehensive Stroke Center.
Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial.
Targets of vascular protection in acute ischemic stroke differ in type 2 diabetes.
Technology evaluation: desmoteplase, PAION/Forest.
Telemedicine physician providers: augmented acute stroke care delivery in rural Texas: an initial experience.
Teleradiology Assessment of Computerized Tomographs Online Reliability Study (TRACTORS) for acute stroke evaluation.
Telestroke in resource-poor developing country model.
Telestroke Program Participation and Improvement in Door-To-Needle Times.
Temperature Affects Thrombolytic Efficacy Using rt-PA and Eptifibatide, an In Vitro Study.
Temporal Trends in Clinical Characteristics and Door-to-Needle Time in Patients Receiving Intravenous Tissue Plasminogen Activator: A Retrospective Study of 4 Hospitals in Japan.
Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at get with the guidelines-stroke hospitals.
Ten-Year Evaluation of the TOYOTA Prehospital Stroke Scale for Tissue Plasminogen Activator Intravenous Therapy in the Real World.
Tenecteplase before thrombectomy for ischemic stroke improved reperfusion compared with alteplase.
Tenecteplase for Acute Ischemic Stroke Treatment.
Tenecteplase for Acute Ischemic Stroke: Current Evidence and Practical Considerations.
Tenecteplase for the treatment of acute ischemic stroke: A review of completed and ongoing randomized controlled trials.
Tenecteplase for thrombolysis in stroke patients: Systematic review with meta-analysis.
Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-II (TRACE II): rationale and design.
Tenecteplase Thrombolysis for Acute Ischemic Stroke.
Tenecteplase Thrombolysis in Posterior Circulation Stroke.
Tenecteplase utility in acute ischemic stroke patients: A clinical review of current evidence.
Tenecteplase versus alteplase after acute ischemic stroke at high age.
Tenecteplase versus alteplase before endovascular thrombectomy (EXTEND-IA TNK): A multicenter, randomized, controlled study.
Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke.
Tenecteplase Versus Alteplase Between 3 and 4.5 Hours in Low National Institutes of Health Stroke Scale.
Tenecteplase versus alteplase for acute ischemic stroke.
Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.
Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials.
Tenecteplase versus Alteplase for the Management of Acute Ischemic Stroke in a Low-income Country-Nepal: Cost, Efficacy, and Safety.
Tenecteplase versus alteplase in acute ischemic stroke: systematic review and meta-analysis.
Tenecteplase versus alteplase in stroke thrombolysis: An individual patient data meta-analysis of randomized controlled trials.
Tenecteplase vs Alteplase Before Endovascular Therapy in Basilar Artery Occlusion.
Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion.
TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after stroke onset.
The "drip-and-ship" approach: starting IV t-PA for acute ischemic stroke at outside hospitals prior to transfer to a regional stroke center.
The -7351C/T polymorphism in the TPA Gene and ischemic stroke risk: a meta-analysis.
The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I: Physiological responses and safety results.
The application of fast multiparametric protocol MRI-based thrombolysis with rt-PA hyperacute cerebral infarction.
The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study.
The Association between t-PA Administration and In-Hospital Mortality following Acute Ischemic Stroke in Puerto Rican Patients.
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.
The chain of care enabling tPA treatment in acute ischemic stroke: a comprehensive review of organisational models.
The Clinical Conundrum of Managing Ischemic Stroke in Patients with Immune Thrombocytopenia.
The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results.
The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.
The contribution of L-arginine to the neurotoxicity of recombinant tissue plasminogen activator following cerebral ischemia: a review of rtPA neurotoxicity.
The correlation between admission blood glucose and intravenous rt-PA-induced arterial recanalization in acute ischemic stroke: a multi-centre TCD study.
The Desmoteplase in Acute Ischemic Stroke (DIAS) clinical trial program.
The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.
The diagnostic utility of S-100B protein and TPA in patients with ischemic stroke.
The Door to Needle Time Metric Can Be Achieved via Telestroke.
The Early Outcomes of Nurse Case Management in Patients with Acute Ischemic Stroke Treated with Intravenous Recombinant Tissue Plasminogen Activator: A Prospective Randomized Controlled Trial.
The economic case for new stroke thrombolytics.
The economics of treating stroke as an acute brain attack.
The effect of 220?kHz insonation scheme on rt-PA thrombolytic efficacy in vitro.
The Effect of Age and Sex on Clinical Outcome after Intravenous Recombinant Tissue Plasminogen Activator Treatment in Patients with Acute Ischemic Stroke.
The Effect of Clot Volume and Permeability on Response to Intravenous Tissue Plasminogen Activator in Acute Ischemic Stroke.
The effect of race and gender on patterns of rt-PA use within a population.
The effectiveness of thrombolysis with intravenous alteplase for acute ischemic stroke in daily practice.
The effects of alcohol on coagulation and fibrinolytic factors: a controlled trial.
The effects of alteplase 3 to 6 hours after stroke in the EPITHET-DEFUSE combined dataset: post hoc case-control study.
The efficacy and safety of endovascular recanalization of occluded large cerebral arteries during the subacute phase of cerebral infarction: a case series report.
The Efficacy and Safety of Intravenous Thrombolysis in Older Chinese Patients with Acute Ischemic Stroke.
The efficacy and safety of intravenous thrombolysis with alteplase in the treatment of ischaemic stroke in a rural hospital.
The efficacy and safety of tissue plasminogen activator in acute ischemic strokes.
The Efficacy of IV Tissue Plasminogen Activator for Restoring Cerebral Blood Flow in the Hours Immediately after Administration in Patients with Acute Stroke.
The efficacy of thrombolysis in lacunar stroke - evidence from the Austrian Stroke Unit Registry.
The evolution of transcranial laser therapy for acute ischemic stroke, including a pooled analysis of NEST-1 and NEST-2.
The Extended Treatment Window's Impact on Emergency Systems of Care for Acute Stroke.
The FAST-ED App: A Smartphone Platform for the Field Triage of Patients With Stroke.
The First 10 Thrombolysis for Acute Ischemic Stroke in Lao People's Democratic Republic under Teleconsultation from Thailand.
The free-radical scavenger edaravone accelerates thrombolysis with alteplase in an experimental thrombosis model.
The global burden of cerebral small vessel disease related to neurological deficit severity and clinical outcomes of acute ischemic stroke after IV rt-PA treatment.
The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis.
The hemodynamic status within 24 h after intravenous thrombolysis predicts infarct growth in acute ischemic stroke.
The immune system and stroke: from current targets to future therapy.
The impact of antihypertensive use in the treatment of acute ischemic stroke in patients receiving alteplase.
The impact of intravenous alteplase on long-term patient survival: The Georgia Coverdell acute stroke registry's experience.
The Impact of Loading Dose on Outcome in Stroke Patients Receiving Low-Dose Tissue Plasminogen Activator Thrombolytic Therapy.
The impact of the DWI-FLAIR-mismatch in the ECASS-4 trial - A post hoc analysis.
The implementation of intravenous tissue plasminogen activator in acute ischaemic stroke--a scientific position statement from the National Stroke Foundation and the Stroke Society of Australasia.
The influence of dehydration on the prognosis of acute ischemic stroke for patients treated with tissue plasminogen activator.
The iScore Predicts Effectiveness of Thrombolytic Therapy for Acute Ischemic Stroke.
The management of hypertension for an acute stroke: what is the blood pressure goal?
The Massachusetts General Hospital acute stroke imaging algorithm: an experience and evidence based approach.
The mean platelet volume on admission predicts unfavorable stroke outcomes in patients treated with IV thrombolysis.
The medicolegal issue of tissue plasminogen activator in ischemic stroke: a review of judiciary decrees in Taiwan.
The metabolic syndrome is associated with a higher resistance to intravenous thrombolysis for acute ischemic stroke in women than in men.
The molecular basis of thrombolysis and its clinical application in stroke.
The multiarm optimization of stroke thrombolysis phase 3 acute stroke randomized clinical trial: Rationale and methods.
The natural tissue plasminogen activator inhibitor neuroserpin and acute ischaemic stroke outcome.
The need for a population-based, dose optimization study for recombinant tissue plasminogen activator in acute ischemic stroke: A study from a tertiary care teaching hospital from South India.
The need for new therapies for acute ischaemic stroke.
The Neuroprotective Role of Neuroserpin in Ischemic and Hemorrhagic Stroke.
The neuroprotective role of the brain opioid system in stroke injury.
The next challenges for optimal reperfusion in the era of mechanical thrombectomy.
The NIH Stroke Scale Has Limited Utility in Accurate Daily Monitoring of Neurologic Status.
The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke.
The PAI-1 4G/5G gene polymorphism and ischemic stroke: an association study and meta-analysis.
The Paul Coverdell National Acute Stroke Registry: initial results from four prototypes.
The phenylpropanoid micronutrient chlorogenic acid improves clinical rating scores in rabbits following multiple infarct ischemic strokes: synergism with tissue plasminogen activator.
The plasminogen activator inhibitor (PAI)-1 promoter 4G/4G genotype is not associated with ischemic stroke in a population of German children. Childhood Stroke Study Group.
The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study.
The potential use of transdermal drug delivery for the prophylaxis and management of stroke and coronary artery disease.
The prospects and predicaments of intravenous rt-PA in childhood ischemic stroke.
The Protective Role of Immunomodulators on Tissue-Type Plasminogen Activator-Induced Hemorrhagic Transformation in Experimental Stroke: A Systematic Review and Meta-Analysis.
The receptor-receptor interaction between mGluR1 receptor and NMDA receptor: a potential therapeutic target for protection against ischemic stroke.
The Relationship of the Type of Intracerebral Hemorrhage to Early Disease Evolution and Long-Term Prognosis After r-tPA Thrombolysis.
The Risk Factors for Death within 6 Months After Ischemic Stroke in Patients with Cancer.
The Risk of Hemorrhagic Transformation After Thrombolysis for Acute Ischemic Stroke in Chinese Versus North Americans: A Comparative Study.
The risk of intravenous thrombolysis-induced intracranial hemorrhage in Taiwanese patients with unruptured intracranial aneurysm.
The role of Akt (protein kinase B) and protein kinase C in ischemia-reperfusion injury.
The Role of Angioplasty Alone in Intracranial Atherosclerosis: 2-Dimensional Operative Video.
The role of connexin43 in hemorrhagic transformation after thrombolysis in vivo and in vitro.
The role of endogenous tissue-type plasminogen activator in neuronal survival after ischemic stroke: friend or foe?
The Role of Informed Consent for Thrombolysis in Acute Ischemic Stroke.
The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia.
The role of stroke nurses in thrombolysis administration in Australia and the United Kingdom: A cross-sectional survey of current practice.
The role of uric acid as a potential neuroprotectant in acute ischemic stroke: a review of literature.
The safety and effectiveness of early anti-platelet therapy after alteplase for acute ischemic stroke: A meta-analysis.
The Safety and Effectiveness of Low-Dose Recombinant Tissue Plasminogen Activator (0.6 mg/kg) Therapy for Elderly Acute Ischemic Stroke Patients (? 80 Years Old) in the Pre-endovascular Era.
The safety and efficacy of thrombolysis for strokes after cardiac catheterization.
The safety and efficacy of tPA intravenous thrombolysis for treating acute ischemic stroke patients with a history of cerebral hemorrhage.
The safety of intravenous thrombolysis for ischemic stroke in patients with pre-existing cerebral aneurysms: a case series and review of the literature.
The SITS-MOST registry.
The SITS-UTMOST: A registry-based prospective study in Europe investigating the impact of regulatory approval of intravenous Actilyse in the extended time window (3-4.5?h) in acute ischaemic stroke.
The start of a new era for stroke treatment: mechanical thrombectomy devices.
The story of an exceptional serine protease, tissue-type plasminogen activator (tPA).
The stroke pharmacopeia: current medical therapies.
The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke.
The telestroke and thrombolysis therapy in diabetic stroke patients.
The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke.
The Third International Stroke Trial: Thrombolysis (IST-3) in Poland: are we recruiting the right patients?
The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
The THRIVE score strongly predicts outcomes in patients treated with the Solitaire device in the SWIFT and STAR trials.
The ThRombolysis in UnconTrolled Hypertension (TRUTH) protocol: an observational study on treatment strategy of elevated blood pressure in stroke patients eligible for IVT.
The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans.
The Totaled Health Risks in Vascular Events (THRIVE) Score Predicts Ischemic Stroke Outcomes Independent of Thrombolytic Therapy in the NINDS tPA Trial.
The use and misuse of thrombolytic therapy within the Veterans Health Administration.
The use of desmoteplase (bat saliva) in the treatment of ischaemia.
The use of intravenous recombinant tissue plasminogen activator in acute ischemic stroke.
The use of recombinant tissue plasminogen activator in in acute ischemic stroke is associated with increased level of BDNF.
The use of the Chandler loop to examine the interaction potential of NXY-059 on the thrombolytic properties of rtPA on human thrombi in vitro.
The Value of ADAMTS13 in Predicting Clinical Outcomes in Patients With Acute Ischemic Stroke Receiving Thrombolysis.
The very acute stroke treatment: fibrinolysis and after.
The yield of expanding the therapeutic time window for tPA.
Therapeutic applications of bone marrow-derived stem cells in ischemic stroke.
Therapeutic benefits of combined treatment with tissue plasminogen activator and 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxy-?-d-pyranoside in an animal model of ischemic stroke.
Therapeutic benefits of nanoparticles in stroke.
Therapeutic effect of tPA in ischemic stroke is enhanced by its combination with normobaric oxygen and hypothermia or ethanol.
Therapeutic hypothermia for acute ischemic stroke.
Therapeutic hypothermia for stroke: Where to go?
Therapeutic hypothermia: Applications in adults with acute ischemic stroke.
Therapeutic Potential of Platelet Glycoprotein IIb/IIIa Receptor Antagonists in the Management of Ischemic Stroke.
Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke.
Therapeutic strategies for the treatment of stroke.
Therapeutic Strategies to Attenuate Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment for Acute Ischemic Stroke.
Therapeutic treatment with vitamin C reduces focal cerebral ischemia-induced brain infarction in rats by attenuating disruptions of blood brain barrier and cerebral neuronal apoptosis.
Therapeutic yield and outcomes of a community teaching hospital code stroke protocol.
Therapy for acute ischemic stroke: the door opens. Interpreting the NINDS rt-PA stroke study.
Therapy for early reperfusion after stroke.
Third generation thrombolytics for the treatment of ischemic stroke.
Third International Stroke Trial 3: an update.
Three Cases of Middle Cerebral Artery Occlusion Emergently Revascularized with A Balloon-expandable Coronary Bare Stent After Intravenous Tissue Plasminogen Activator.
Thrombectomy in patients ineligible for iv tPA (THRILL).
Thrombectomy within 8 hours after symptom onset in ischemic stroke.
Thrombelastography does not predict clinical response to rtPA for acute ischemic stroke.
Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke.
Thromboelastographic Changes in Patients Experiencing an Acute Ischemic Stroke and Receiving Alteplase.
Thromboelastography in patients with acute ischemic stroke.
Thromboembolic Complications Following Tissue Plasminogen Activator Therapy in Patients of Acute Ischemic Stroke - Case Report and Possibility for Detection of Cardiac Thrombi.
Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke.
Thrombolysis 2004: the good, the bad, and the ugly.
Thrombolysis After Protamine Reversal of Heparin for Acute Ischemic Stroke After Cardiac Catheterization: Case Report and Literature Review.
Thrombolysis and hyperacute reperfusion therapy for stroke in renal patients.
Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion.
Thrombolysis at 3-4.5 hours after acute ischemic stroke onset--evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry.
Thrombolysis beyond 3 hours for acute ischaemic stroke.
Thrombolysis Following Central Venous Catheter Placement.
Thrombolysis Following Heparin Reversal With Protamine Sulfate in Acute Ischemic Stroke: Case Series and Literature Review.
Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW).
Thrombolysis for acute ischaemic stroke: core nursing requirements.
Thrombolysis for Acute Ischemic Stroke Following Transcatheter Aortic Valve Replacement: Case Report and Literature Review.
Thrombolysis for acute ischemic stroke in South Africa.
Thrombolysis for acute ischemic stroke--our experiences as part of SITS-MOST.
Thrombolysis for acute ischemic stroke.
Thrombolysis for Acute Ischemic Stroke: Do Patients Treated Out of Hours Have a Worse Outcome?
Thrombolysis for acute ischemic stroke: future directions.
Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study.
Thrombolysis for Acute Minor Stroke: Outcome and Barriers to Management. Results from the RESUVAL Stroke Network.
Thrombolysis for Acute Stroke in Hemodialysis: International Survey of Expert Opinion.
Thrombolysis for acute stroke in the United Kingdom.
Thrombolysis for acute stroke under antiplatelet therapy: safe enough to be beneficial?
THrombolysis for Acute Wake-up and unclear-onset Strokes with alteplase at 0·6?mg/kg (THAWS) Trial.
Thrombolysis for cerebral ischemia.
Thrombolysis for Ischemic Stroke during Pregnancy: A Case Report and Review of the Literature.
Thrombolysis for stroke caused by infective endocarditis: an illustrative case and review of the literature.
Thrombolysis for stroke in the elderly.
Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke.
Thrombolysis in acute childhood stroke: design and challenges of the thrombolysis in pediatric stroke clinical trial.
Thrombolysis in acute ischaemic stroke within 3 hours of symptom onset: a report of the first 100 cases.
Thrombolysis in acute ischaemic stroke: a guide to patient selection.
Thrombolysis in acute ischemic stroke is associated with lower long-term hospital bed day use: A nationwide propensity score-matched follow-up study.
Thrombolysis in acute ischemic stroke.
Thrombolysis in acute ischemic stroke: controlled trials and clinical experience.
Thrombolysis in acute ischemic stroke: successes, failures, and new hopes.
Thrombolysis in acute stroke: ongoing challenges based on a tertiary hospital audit and comparisons with other Australian studies.
Thrombolysis in an acute ischemic stroke patient with rivaroxaban anticoagulation: A case report.
Thrombolysis in dementia patients with acute stroke: is it justified?
Thrombolysis in elderly stroke patients in Italy (TESPI) trial and updated meta-analysis of randomized controlled trials.
Thrombolysis in ischaemic stroke -- present and future: role of combined therapy.
Thrombolysis in ischemic strokes with no arterial occlusion.
Thrombolysis in Mild Stroke: A Comparative Analysis of the PRISMS and MaRISS Studies.
Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study.
Thrombolysis in patients with acute ischemic stroke due to arterial extracranial dissection.
Thrombolysis in patients with mild stroke: results from the Austrian Stroke Unit Registry.
Thrombolysis in Real Time: Demonstration of Revascularization with Intravenous Thrombolysis Therapy in the CT Scanner.
Thrombolysis in stroke despite contraindications or warnings?
Thrombolysis in stroke.
Thrombolysis in the developing world: is there a role for streptokinase?
Thrombolysis in the Treatment of Acute Ischemic Stroke.
Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive.
Thrombolysis in Young Adults With Ischemic Stroke.
Thrombolysis in young adults with stroke: Findings from Get With The Guidelines-Stroke.
Thrombolysis outcomes according to arterial characteristics of acute ischemic stroke by alteplase dose and blood pressure target.
Thrombolysis Outcomes in Patients with Diabetes and Previous Stroke: A Meta-Analysis.
Thrombolysis rate and impact of a stroke code: a French hospital experience and a systematic review.
Thrombolysis related symptomatic intracranial hemorrhage in estimated versus measured body weight.
Thrombolysis risk prediction: applying the SITS-SICH and SEDAN scores in South African patients.
Thrombolysis safety and effectiveness in acute ischemic stroke patients with pre-morbid disability.
Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS).
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study.
Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: the first multicentre, phase III trial in China.
Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances.
Thrombolysis with alteplase 4.5-6 hours after acute ischemic stroke.
Thrombolysis With Alteplase at 0.6 mg/kg for Stroke With Unknown Time of Onset: A Randomized Controlled Trial.
Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.
Thrombolysis with alteplase for acute ischemic stroke patients with atrial fibrillation.
Thrombolysis with alteplase for acute ischemic stroke: review of SITS-MOST and other Phase IV studies.
Thrombolysis with alteplase for acute ischemic stroke: safe and effective outside the 3-hour time window?
Thrombolysis with intravenous tissue plasminogen activator predicts a favorable discharge disposition in patients with acute ischemic stroke.
Thrombolysis with Low-Dose Tissue Plasminogen Activator 3-4.5 h After Acute Ischemic Stroke in Five Hospital Groups in Japan.
Thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: evaluation with rCBF-SPECT.
Thrombolysis with tissue plasminogen activator (tPA) is temperature dependent.
Thrombolysis' benefits on early post-stroke language recovery in aphasia patients.
Thrombolysis, stroke units and other strategies for reducing acute stroke costs.
Thrombolytic Agents for Acute Ischaemic Stroke Treatment: the Past, Present and Future.
Thrombolytic DNT and fatality and disability rates in acute ischemic stroke: a study from Bigdata Observatory Platform for Stroke of China.
Thrombolytic dosing in acute ischaemic stroke.
Thrombolytic Refusal Over Telestroke.
Thrombolytic Therapy following Rhytidectomy and Blepharoplasty.
Thrombolytic therapy for acute ischaemic stroke.
Thrombolytic therapy for acute ischaemic stroke: successful implementation in an Australian tertiary hospital.
Thrombolytic therapy for acute ischaemic stroke: what can we do to improve outcomes?
Thrombolytic therapy for acute ischemic stroke - Tissue plasminogen activator for acute ischemic stroke: Is the CAEP Position Statement too negative?
Thrombolytic therapy for acute ischemic stroke : issues and answers.
Thrombolytic Therapy for Acute Ischemic Stroke beyond Three Hours.
Thrombolytic therapy for acute ischemic stroke.
Thrombolytic therapy for acute ischemic stroke: 3 h and beyond.
Thrombolytic Therapy for Acute Stroke in the Elderly: An Emergent Condition in Developing Countries.
Thrombolytic therapy for ischemic stroke--a review. Part I--Intravenous thrombolysis.
Thrombolytic therapy for stroke.
Thrombolytic therapy for wake-up stroke: A systematic review and meta-analysis.
Thrombolytic therapy in acute ischaemic stroke.
Thrombolytic therapy in acute ischemic stroke - basic concepts.
Thrombolytic Therapy in Acute Ischemic Stroke in Patients Not Fulfilling Conventional Criteria.
Thrombolytic Therapy in Acute Ischemic Stroke.
Thrombolytic therapy in acute ischemic stroke. A Danish pilot study.
Thrombolytic therapy in cerebrovascular disorders.
Thrombolytic Therapy in Cocaine Users with Ischemic Stroke: A Review of Current Practice.
Thrombolytic therapy in older acute ischemic stroke patients with gastrointestinal malignancy or recent bleeding.
Thrombolytic therapy in pregnancy.
Thrombolytic therapy in the treatment of stroke.
Thrombolytic Therapy of Acute Ischemic Stroke during Early Pregnancy.
Thrombolytic therapy of acute ischemic stroke: correlation of angiographic recanalization with clinical outcome.
Thrombolytic therapy with alteplase for ischaemic stroke.
Thrombolytic therapy with intravenous recombinant tissue plasminogen activator in Japanese older patients with acute ischemic stroke: Fukuoka Stroke Registry.
Thrombolytic therapy with recombinant tissue plasminogen activator for acute ischemic stroke: where do we go from here? A cumulative meta-analysis.
Thrombolytic therapy within 3 to 6 hours after onset of ischemic stroke: useful or harmful?
Thrombolytic treatment decreases glutamate/GABA ratio in serum during acute ischaemic stroke: a pilot study.
Thrombolytic treatment of acute ischemic stroke.
Thrombolytic Treatment of Cardiac Myxoma-Induced Ischemic Stroke: a Review.
Thrombolytics in acute ischaemic stroke: a guide to patient selection and optimum use.
Thrombotic occlusion of the common carotid artery (CCA) in acute ischemic stroke treated with intravenous tissue plasminogen activator (TPA).
Thrombus localization with emergency cerebral CT.
Thromobolysis for acute ischemic stroke: is intra-arterial better than intravenous? A treatment effects model.
Thyroid Hemorrhage Causing Airway Obstruction After Intravenous Thrombolysis for Acute Ischemic Stroke.
Time for a neurorestorative therapy in stroke.
Time is Penumbra: imaging, selection and outcome. The Johann jacob wepfer award 2014.
Time of day, outcome, and response to thrombolytic therapy: the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trial experience.
Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial.
Time to Blood Pressure Control Before Thrombolytic Therapy in Patients With Acute Ischemic Stroke: Comparison of Labetalol, Nicardipine, and Hydralazine.
Time to brain imaging in acute stroke is improving: secondary analysis of the INSTINCT trial.
Time to recanalization and risk of symptomatic intracerebral haemorrhage in patients treated with intravenous thrombolysis.
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.
Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke.
TIME TO WAKE-UP: EXTENDING THE WINDOW FOR MANAGEMENT OF UNKNOWN-ONSET STROKES.
Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes.
Timing of arrival to a tertiary hospital after acute ischaemic stroke - A follow-up survey 5 years later.
Timing of Recanalization After Intravenous Thrombolysis and Functional Outcomes After Acute Ischemic Stroke.
Timing of recanalization after intravenous thrombolysis and functional outcomes after acute ischemic stroke.
Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke.
Timing of Recanalization and Functional Recovery in Acute Ischemic Stroke.
Timing of recanalization and outcome in ischemic-stroke patients treated with recombinant tissue plasminogen activator.
Timing of symptomatic intracerebral hemorrhage after rt-PA treatment in ischemic stroke.
Timing of tissue plasminogen activator for acute ischemic stroke: outcomes-based recommendations for practice.
Tissue at risk of infarction rescued by early reperfusion: a positron emission tomography study in systemic recombinant tissue plasminogen activator thrombolysis of acute stroke.
Tissue plasminogen activator (rt-PA) in acute ischemic stroke: Outcomes associated with ambulation.
Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies.
Tissue plasminogen activator (tPA) for acute ischaemic stroke: why so much has been made of so little.
Tissue plasminogen activator (tPA) for ischemic stroke in patients aged ?80 years.
Tissue plasminogen activator (tPA) in acute ischaemic stroke: time for collegiate communication and consensus.
Tissue plasminogen activator -7351C/T enhancer polymorphism is a risk factor for lacunar stroke.
Tissue plasminogen activator administration does not result in clinically relevant neuropsychological dysfunction in patients with myocardial ischemia.
Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: relation to stroke etiology.
Tissue Plasminogen Activator and Stroke: Review of the Literature for the Clinician.
Tissue plasminogen activator as a key effector in neurobiology and neuropathology.
Tissue plasminogen activator deficiency preserves neurological function and protects against murine acute ischemic stroke.
Tissue plasminogen activator does not alter development of acquired epilepsy.
Tissue plasminogen activator does not increase neuronal damage in rat models of global and focal ischemia.
Tissue plasminogen activator enhances the hypoxia/reoxygenation-induced impairment of the blood-brain barrier in a primary culture of rat brain endothelial cells.
Tissue plasminogen activator expression and barrier properties of human brain microvascular endothelial cells.
Tissue plasminogen activator for acute ischaemic stroke.
Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data.
Tissue plasminogen activator for acute ischemic stroke in patients with unruptured cerebral aneurysms.
Tissue plasminogen activator for acute ischemic stroke.
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
Tissue plasminogen activator for acute ischemic stroke: a New York city emergency medicine perspective.
Tissue plasminogen activator for acute ischemic stroke: calculation of dose based on estimated patient weight can increase the risk of cerebral bleeding.
Tissue Plasminogen Activator for Cortical Embolism Stroke with Magnetic Resonance Perfusion Imaging: A Report of Two Cases.
Tissue plasminogen activator for ischaemic stroke: highly effective, reasonably safe and grossly underused.
Tissue plasminogen activator for ischemic stroke: unintended consequences.
Tissue Plasminogen Activator for preclinical stroke research: Neither "rat" nor "human" dose mimics clinical recanalization in a carotid occlusion model.
Tissue plasminogen activator is elevated in women with ischemic stroke.
Tissue plasminogen activator mediated blood-brain barrier damage in transient focal cerebral ischemia in rats: relevance of interactions between thrombotic material and thrombolytic agent.
Tissue plasminogen activator mediates deleterious complement cascade activation in stroke.
Tissue Plasminogen Activator Neurotoxicity is Neutralized by Recombinant ADAMTS 13.
Tissue Plasminogen Activator Overdose in Acute Ischemic Stroke Patients Linked to Poorer Functional Outcomes.
Tissue Plasminogen Activator Prescription and Administration Errors within a Regional Stroke System.
Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia.
Tissue Plasminogen Activator Promotes TXNIP-NLRP3 Inflammasome Activation after Hyperglycemic Stroke in Mice.
Tissue Plasminogen Activator Thrombolytic Therapy for Acute Ischemic Stroke in 4 Hospital Groups in Japan.
Tissue plasminogen activator use in a patient with acute ischemic stroke coexisting with meningioma.
Tissue plasminogen activator use: evaluation and initial management of ischemic stroke from an iowa hospital perspective.
Tissue plasminogen activator-based nanothrombolysis for ischemic stroke.
Tissue Plasminogen Activator-Induced Angioedema Involving a Posterior Cerebral Artery Infarct: A Case Presentation.
Tissue plasminogen activator-mediated PDGF signaling and neurovascular coupling in stroke.
Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke.
Tissue type plasminogen activator amplifies hemoglobin-induced neurotoxicity in rat neuronal cultures.
Tissue-plasminogen activator for acute ischaemic stroke.
Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein.
Tissue-Type Plasminogen Activator and Tenecteplase-Mediated Increase in Blood Brain Barrier Permeability Involves Cell Intrinsic Complement.
Tissue-type plasminogen activator as a therapeutic target in stroke.
Tissue-type plasminogen activator for acute ischemic stroke.
Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic.
Tissue-type plasminogen activator regulates the neuronal uptake of glucose in the ischemic brain.
Tissue-type plasminogen activator should not be used in acute ischemic stroke.
Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalisation.
Too good to treat? ischemic stroke patients with small computed tomography perfusion lesions may not benefit from thrombolysis.
Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
Toward safer thrombolytic agents in stroke: molecular requirements for NMDA receptor-mediated neurotoxicity.
Towards best practice in acute stroke care in Ghana: a survey of hospital services.
tPA Deficiency in Mice Leads to Rearrangement in the Cerebrovascular Tree and Cerebroventricular Malformations.
tPA for Acute Ischemic Stroke and Its Controversies: A Review.
TPA for acute ischemic stroke.
TPA for ischemic stroke in patients ?80 years.
tPA Helpers in the Treatment of Acute Ischemic Stroke: Are They Ready for Clinical Use?
TPA in acute ischemic stroke. A Calgary experience.
tPA in acute ischemic stroke: United States experience and issues for the future.
tPA in the central nervous system: relations between tPA and cell surface LRPs.
tPA in the injured central nervous system: different scenarios starring the same actor?
tPA Mobilizes Immune Cells That Exacerbate Hemorrhagic Transformation in Stroke.
tPA promotes cortical neuron survival via mTOR-dependent mechanisms.
tPA treatment for acute ischaemic stroke in patients with leukoaraiosis.
TPA use for stroke in the Registry of the Canadian Stroke Network.
tPA variant tPA-A(296-299) Prevents impairment of cerebral autoregulation and necrosis of hippocampal neurons after stroke by inhibiting upregulation of ET-1.
Traditional Chinese medicine, Xue-Fu-Zhu-Yu decoction, potentiates tissue plasminogen activator against thromboembolic stroke in rats.
Transcranial diffuse optical assessment of the microvascular reperfusion after thrombolysis for acute ischemic stroke.
Transcranial Doppler sonography for detecting stenosis or occlusion of intracranial arteries in people with acute ischaemic stroke.
Transcranial doppler ultrasound criteria for recanalization after thrombolysis for middle cerebral artery stroke.
Transcranial Pulsed Ultrasound with Alteplase Intravenous Thrombolysis for Vascular Recanalisation in Acute Ischemic Stroke.
Transfusion of Resting Platelets Reduces Brain Hemorrhage After Intracerebral Hemorrhage and tPA-Induced Hemorrhage After Cerebral Ischemia.
Transient brain hypothermia reduces the reperfusion injury of delayed tissue plasminogen activator and extends its therapeutic time window in a focal embolic stroke model.
Transient ischemic attack after tissue plasminogen activator: aborted stroke or unnecessary stroke therapy?
Transition of European Cooperative Acute Stroke Study III Results to Clinical Practice: Ninety-Day Outcomes in a US Cohort.
Translation of the 'time is brain' concept into clinical practice: focus on prehospital stroke management.
Translational Stroke Research Using a Rabbit Embolic Stroke Model: A Correlative Analysis Hypothesis for Novel Therapy Development.
Trapped cerebral thrombectomy device: A case report of a rare complication.
Treating acute ischemic stroke with intravenous alteplase.
Treating acute ischemic stroke.
Treating acute stroke patients with intravenous tPA. The OSF stroke network experience.
Treating ischaemic stroke with intravenous tPA beyond 4.5 hours under the guidance of a MRI DWI/T2WI mismatch was safe and effective.
Treating patients with ischemic stroke with tissue plasminogen activator in the 3.5- to 4-hour window: numbers support benefit but the message is to still go fast.
Treating stroke as a medical emergency: a survey of resident physicians' attitudes toward "brain attack" and carotid endarterectomy.
Treatment and Outcome of Hemorrhagic Transformation After Intravenous Alteplase in Acute Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.
Treatment and Outcome of Thrombolysis-Related Hemorrhage: A Multicenter Retrospective Study.
Treatment Delays for Patients With Acute Ischemic Stroke in an Iranian Emergency Department: A Retrospective Chart Review.
Treatment evaluation of acute stroke for using in regenerative cell elements (TREASURE) trial: Rationale and design.
Treatment of acute cerebral artery occlusion using the penumbra system: our early experience.
Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment.
Treatment of acute ischemic stroke.
Treatment of acute ischemic stroke: from fibrinolysis to neurointervention.
Treatment of acute ischemic stroke: intravenous and endovascular therapies.
Treatment of acute ischemic stroke: recent progress.
Treatment of acute ischemic stroke: systemic or local?
Treatment of Acute Stroke in Patients on Dabigatran: A Survey of US Stroke Specialists.
Treatment of acute stroke with recombinant tissue plasminogen activator and abciximab.
Treatment of Intracerebral Hemorrhage with Tranexamic Acid After Thrombolysis with Tissue Plasminogen Activator.
Treatment of ischemic stroke with r-tPA: implementation challenges in a tertiary hospital in Brazil.
Treatment of stroke with liposomal neuroprotective agents under cerebral ischemia conditions.
Treatment patterns and short-term outcomes in ischemic stroke in pregnancy or postpartum period.
Treatment With Intravenous Alteplase for Acute Ischemic Stroke After Reversal of Dabigatran With Idarucizumab: A Case Study.
Treatment with recombinant tissue plasminogen activator alters the microRNA expression profiles in mouse brain after acute ischemic stroke.
Treatment with statins in the acute phase of ischemic stroke.
Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals.
Treatment With Tissue Plasminogen Activator in the Golden Hour and the Shape of the 4.5-Hour Time-Benefit Curve in the National United States Get With The Guidelines-Stroke Population.
Trends in mechanical thrombectomy and decompressive hemicraniectomy for stroke: A multicenter study.
Trends in New Zealand stroke thrombolysis treatment rates.
Trends in thrombolytic use for ischemic stroke in the United States.
Trends of Acute Ischemic Stroke Reperfusion Therapies from 2012 to 2016 in the United States.
Trends of r-tPA (Recombinant Tissue-Type Plasminogen Activator) Treatment and Treatment-Influencing Factors in Acute Ischemic Stroke.
Trimming the fat in acute ischemic stroke: an assessment of 24-h CT scans in tPA patients.
Trombolysis in acute stroke.
TT genotype of the MMP-9-1562C/T polymorphism may be a risk factor for thrombolytic therapy-induced hemorrhagic complications after acute ischemic stroke.
Tumor Cells Detected in Retrieved Thrombus: Cancer-associated Stroke.
TURN: A Simple Predictor of Symptomatic Intracerebral Hemorrhage After IV Thrombolysis.
Turning a stroke into a TIA: curative thrombolysis with combined intravenous and intra-arterial tPA.
Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours.
Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: the EPICOR study.
Ultrasound Acceleration of rt-PA Thrombolysis Depends on Acoustic Intensity.
Ultrasound assisted thrombolysis in acute ischaemic stroke: preliminary experience in Singapore.
Ultrasound enhancement of fibrinolysis.
Ultrasound- and microspheres-enhanced thrombolysis for stroke treatment: state of the art.
Ultrasound-enhanced thrombolysis for stroke: clinical significance.
Ultrasound-enhanced thrombolysis with tPA-loaded echogenic liposomes.
Ultrasound-enhanced tissue plasminogen activator thrombolysis in an in vitro porcine clot model.
Ultrasound-induced thermal elevation in clotted blood and cranial bone.
Unanswered questions in thrombolytic therapy for acute ischemic stroke.
Unequal access to treatment with intravenous alteplase for women with acute ischemic stroke.
Uneventful Pregnancy and Delivery after Thrombolysis Plus Thrombectomy for Acute Ischemic Stroke: Case Study and Literature Review.
Unfavorable Outcome of Thrombolysis in Chinese Patients with Cardioembolic Stroke: a Prospective Cohort Study.
Unruptured Cerebral Aneurysm Detected after Intravenous Tissue Plasminogen Activator for Stroke.
Unsuspected coagulopathy rarely prevents IV thrombolysis in acute ischemic stroke.
Update on intravenous recombinant tissue plasminogen activator for acute ischemic stroke.
Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice.
Update on the effects of treatment with recombinant tissue-type plasminogen activator (rt-PA) in acute ischemic stroke.
Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited.
Update on therapies for acute ischemic stroke.
Update on Treatment of Acute Ischemic Stroke.
Upper limb compartment syndrome: An unusual complication of stroke thrombolysis.
Urgent carotid intervention is safe after thrombolysis for minor to moderate acute ischemic stroke.
Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes.
Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset.
Uric acid administration in patients with acute stroke: a novel approach to neuroprotection.
Uric Acid Therapy Improves Clinical Outcome in Women With Acute Ischemic Stroke.
Uric Acid Therapy Prevents Early Ischemic Stroke Progression: A Tertiary Analysis of the URICO-ICTUS Trial (Efficacy Study of Combined Treatment With Uric Acid and r-tPA in Acute Ischemic Stroke).
US Geographic Distribution of rt-PA Utilization by Hospital for Acute Ischemic Stroke.
Use and in-hospital outcomes of recombinant tissue plasminogen activator in pediatric arterial ischemic stroke patients.
Use and Outcomes of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients ?90 Years of Age.
Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial.
Use of alteplase beyond 3 hours of ischemic stroke onset.
Use of alteplase in childhood arterial ischaemic stroke: a multicentre, observational, cohort study.
Use of Emergency department transcranial doppler assessment of reperfusion after intravenous tPA for ischemic stroke.
Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke.
Use of intravenous recombinant tissue plasminogen activator in patients with borderline elevation of international normalized ratio.
Use of intravenous tissue plasminogen activator and hospital costs for patients with acute ischaemic stroke aged 18-64?years in the USA.
Use of intravenous tissue plasminogen activator in a 16-year-old patient with basilar occlusion.
Use of l-3-n-Butylphthalide within 24 h after intravenous thrombolysis for acute cerebral infarction.
Use of Noncontrast Computed Tomography and Computed Tomographic Perfusion in Predicting Intracerebral Hemorrhage After Intravenous Alteplase Therapy.
Use of self-expanding intracranial stents in the treatment of acute ischemic stroke.
Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke.
Use of telemedicine to increase thrombolysis and advance care in acute ischemic stroke.
Use of telemedicine to manage severe ischaemic strokes in a rural area with an elderly population.
Use of tissue plasminogen activator to treat acute ischemic stroke.
Use of tissue-type plasminogen activator before and after publication of the European Cooperative Acute Stroke Study III in Get With The Guidelines-Stroke.
Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience.
Usefulness of cervical magnetic resonance imaging for detecting type A acute aortic dissection with acute stroke symptoms.
Usefulness of Fibrinogen/Fibrin Degradation Products Value in Differential Diagnosis Between Acute Ischemic Stroke and Acute Aortic Dissection.
Usefulness of Thromboelastography in the Detection and Management of Tissue Plasminogen Activator-Associated Hyperfibrinolysis.
Usefulness of triphasic perfusion computed tomography for intravenous thrombolysis with tissue-type plasminogen activator in acute ischemic stroke.
Using a quality improvement process to create measurable improvement in care delivery for acute stroke.
Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR).
Using Tenecteplase for Acute Ischemic Stroke: What Is the Hold Up?
Utility of Minimum Apparent Diffusion Coefficient Ratios in Alberta Stroke Program Early CT Score Regions for Deciding on Stroke Therapy.
Utility of the stroke-thrombolytic predictive instrument.
Utilization and outcomes with low dose tissue plasminogen activator as intravenous thrombolytic therapy for ischaemic stroke at Aga Khan University Hospital, Karachi: a retrospective analysis.
Utilization of a Parental Approach to Informed Consent in Intravenous Tissue Plasminogen Activator Administration Decision-Making: Patient Preference and Ethical Considerations.
Utilization of intravenous thrombolysis is increasing in the United States.
Utilization of Intravenous Tissue Plasminogen Activator and Reasons for Nonuse in Acute Ischemic Stroke in Saudi Arabia.
Utilization of intravenous tissue plasminogen activator for acute ischemic stroke.
Utilization of intravenous tissue plasminogen activator for ischemic stroke: are there sex differences?
Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity.
Validation and iteration of CT perfusion defined malignant profile thresholds for acute ischemic stroke.
Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
Validation of TURN, a simple predictor of symptomatic intracerebral hemorrhage after IV thrombolysis.
Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score.
Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration.
Vampire bats yield potent clot buster for ischemic stroke.
Variability in the Perception of Informed Consent for IV-tPA during Telestroke Consultation.
Variability of the Modified Rankin Scale Score Between Day 90 and 1 Year After Ischemic Stroke.
Vascular Aphasia Outcome after Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis for Ischemic Stroke.
Vascular occlusion enables selecting acute ischemic stroke patients for treatment with desmoteplase.
Vascular protection and restorative therapy in ischemic stroke.
Vascular Protection Following Cerebral Ischemia and Reperfusion.
Vascular protection to increase the safety of tissue plasminogen activator for stroke.
Vascular Risk Factors in Patients with Different Subtypes of Ischemic Stroke May Affect Their Outcome after Intravenous tPA.
Vepoloxamer Enhances Fibrinolysis of tPA (Tissue-Type Plasminogen Activator) on Acute Ischemic Stroke.
Very early neurologic improvement after intravenous thrombolysis.
Very Early versus Delayed Rehabilitation for Acute Ischemic Stroke Patients with Intravenous Recombinant Tissue Plasminogen Activator: A Nationwide Retrospective Cohort Study.
Very mild stroke patients benefit from intravenous tissue plasminogen activator without increase of intracranial hemorrhage.
Views on the use of tissue plasminogen activator in acute ischemic stroke: A state-wide survey among neurologists and emergency medicine physicians in Indiana.
Virtual TeleStroke support for the emergency department evaluation of acute stroke.
Vitreo-retinal hemorrhage after thrombolysis in a patient with acute ischemic stroke: a case report.
Von Willebrand factor and risk of ischemic stroke.
Wake-up Stroke Within 3 Hours of Symptom Awareness: Imaging and Clinical Features Compared to Standard Recombinant Tissue Plasminogen Activator Treated Stroke.
What causes intracerebral bleeding after thrombolysis for acute ischaemic stroke? Recent insights into mechanisms and potential biomarkers.
What is the Role for Intra-Arterial Therapy in Acute Stroke Intervention?
What is the value of conducting a trial of r-tPA for the treatment of mild stroke patients?
What's new in stroke? The top 10 studies of 2006-2008. Part II.
Who may benefit from lower dosages of intravenous tissue plasminogen activator? Results from a cluster data analysis.
Who will benefit more from low-dose alteplase in acute ischemic stroke?
Whole body hypothermia extends tissue plasminogen activator treatment window in the rat model of embolic stroke.
Why are acute ischemic stroke patients not receiving IV tPA? Results from a national registry.
Why are acute ischemic stroke patients not receiving thrombolysis in a telestroke network?
Why are eligible thrombolysis candidates left untreated?
Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility.
Why don't more patients receive intravenous rt-PA for acute stroke?
Why emergency XeCT-CBF should become routine in acute ischemic stroke before thrombolytic therapy.
Why not Intravenous Thrombolysis in Patients with Recurrent Stroke within 3 Months?
Widespread subcutaneous haematoma after thrombolytic therapy in stroke patients. Mild falls at stroke onset may be dangerous.
Will delays in treatment jeopardize the population benefit from extending the time window for stroke thrombolysis?
Window of opportunity: Estrogen as a treatment for ischemic stroke.
Women's interpretation of and cognitive and behavioral responses to the symptoms of acute ischemic stroke.
Workflow Optimization for Ischemic Stroke in a Community-Based Stroke Center.
Worldwide reported use of IV tissue plasminogen activator for acute ischemic stroke.
Worse prognosis in women, compared with men, after thrombolysis: An individual patient data pooling study of Asian acute stroke registries.
Worse stroke outcome in atrial fibrillation is explained by more severe hypoperfusion, infarct growth, and hemorrhagic transformation.
Would a Large tPA Trial for Those 4.5 to 6.0 Hours from Stroke Onset Be Good Value for Information?
Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in a rat model of thromboembolic stroke.
YiQiFuMai Lyophilized Injection ameliorates tPA-induced hemorrhagic transformation by inhibiting cytoskeletal rearrangement associated with ROCK1 and NF-?B signaling pathways.
["Time is brain". Optimizing prehospital stroke management].
[Acute ischemic stroke: time is brain!]
[Acute management and secondary prevention of ischemic stroke]
[Acute stroke management in elderly patients].
[Acute stroke therapy : Current developments.]
[An update on limitations of intravenous thrombolysis to treat acute ischemic stroke.]
[ApoE genotype influences on efficacy and safety of thrombolytic treatment for ischemic stroke]
[ASPECTS-DWI, arterial occlusion sites and subtype of acute ischemic stroke have a relation with outcome following intravenous rt-PA therapy].
[Causes of a prolonged prehospital phase in patients admitted to a stroke unit. Can it be influenced by campaigns to educate the public?]
[Cell therapy for stroke: From myth to reality.]
[Cerebral CT perfusion in the diagnosis of acute brain infarction]
[Cerebral ischemia--challenges and perspectives]
[Cerebrovascular malformation revealed during the prethrombolysis workup in acute ischemic stroke. Impact on therapeutic decision making.]
[Clinical Manifestations of Spinal Epidural Hematoma-Stroke Mimic and Pitfalls in Diagnosis].
[Computer tomographic and laboratory predictors of clinical outcomes of acute ischemic stroke patients after the systemic thrombolytic therapy]
[Current and future aspects of intravenous thrombolysis for acute stroke].
[Current and future prospects of endovascular treatment for acute ischemic stroke].
[Current state of recanalization therapy in acute ischemic stroke].
[Current status and future of recombinant tissue plasminogen activator for acute ischemic stroke]
[Current status and perspectives in the development of therapeutic agents targeting post-ischemic inflammation in the acute stage of stroke].
[Current status of endovascular therapy for acute ischemic stroke].
[Definition and treatment of stroke over the centuries].
[Determination of plasma tissue type plasminogen activator and plasminogen activator inhibitor activity in patients with ischemic stroke]
[Development of Biomembrane-mimetic Nanoparticles for the Treatment of Ischemic Stroke].
[Diagnosis and treatment of acute ischemic stroke].
[Early thrombolysis indicated in threatened cerebral infarction. A study of 60 patients treated at Akademiska sjukhuset in Uppsala]
[Effect of prehospital intervention based on emergency medical services on door-to-needle time of thrombolysis in acute ischemic stroke].
[Effective acute stroke treatment beyond approval limitations: intravenous thrombolysis within an extended time window (3-6 h) and in old patients (aged 80 or older)]
[Effects of statin use on intracranial hemorrhage and clinical outcome after intravenous rt-PA for acute ischemic stroke: SAMURAI rt-PA registry]
[Efficacy of intravenous thrombolysis in acute ischemic stroke with hyperdense middle cerebral artery sign].
[Endovascular treatment of ischemic strokes : outcomes and practical issues].
[Estimating weight accurately for safe treatment: body weight estimation in patients with acute ischaemic stroke is frequently inaccurate].
[Evaluation for antithrombotic agents by a thrombotic model in animals].
[Experimental therapy approaches for ischemic stroke].
[Fibrinolysis in acute CVA: the current status]
[Fibrinolytic treatment with tissue plasminogen activator. Outcomes in clinical practice with a multidisciplinary model of intervention]
[Future neuroprotective strategies in the post-thrombolysis era--neurovascular unit protection and vascular endothelial protection].
[Guideline for intravenous rt-PA therapy of patients with ischemic stroke]
[Guidelines for the general management of patients with acute ischemic stroke]
[HaNDL is transient headache, neurological deficits and lymphocytic pleocytosis in the cerebrospinal fluid].
[Implementation of thrombolysis in acute stroke--10-year results of the Innsbruck stroke registry]
[Indications for thrombolytics]
[Influence of the experience and of out-of-hospital stroke code in thrombolytic treatment of acute stroke]
[Intraarterial thrombolysis in the treatment of acute ischemic stroke: Technical and clinical results]
[Intravenous administration of a tissue plasminogen activator beyond 3 hours of the onset of acute ischemic stroke--MRI-based decision making]
[Intravenous rt-PA for acute ischemic stroke: 69 consecutive patients managed in an emergency stroke centre]
[Intravenous rt-PA therapy for acute ischemic stroke: efficacy and limitations]
[Intravenous rt-PA therapy: current status and extending therapeutic time window in Japan].
[Intravenous thrombolysis for acute ischemic stroke. A four years? experience in a Chilean public hospital].
[Intravenous thrombolysis for acute ischemic stroke: past, present and future].
[Intravenous thrombolysis for ischemic stroke: Experience in 54 patients].
[Intravenous thrombolytic therapy and its unresolved problems in Japan]
[Intravenous thrombolytic therapy with Revelisa of ischemic stroke in real-world clinical practice: interim results of an open-label, prospective, multicenter, non-interventional study IVT-AIS-R].
[Intravenous thrombolytic therapy: ideal treatment for acute ischemic stroke]
[Intravenous thrombolytic treatment in acute ischemic stroke: initial results in the Complejo Hospitalario Universitario de Albacete]
[Intravenous tissue plasminogen activator (t-PA) for acute ischemic stroke in a local university hospital]
[Intravenous tissue plasminogen activator in the treatment of acute ischemic stroke: feasibility, safety, and efficiency in the 2 first years of the clinical practice]
[Is endovenous thrombolysis safety and efficacy in ischemic stroke comparable between patients aged over and above 80 years? Experience from an Argentinean cohort].
[IV t-pA thrombolysis in acute stroke patients]
[Major stroke clinical trials in 2006]
[Management of ischemic strokes derived from intraventricular thrombi: report of two cases].
[Mobile CT: technical aspects of prehospital stroke imaging before intravenous thrombolysis].
[Multi-mode MRI-based intravenous thrombolysis with recombinant tissue plasminogen activator (rtPA) reduces hemorrhagic transformation in ischemic stroke patients].
[Neuroprotective therapy for ischemic stroke with free radical scavenger and gene-stem cell therapy]
[New aspects of stroke medicine].
[Non-contrast brain ct based systemic thrombolysis of two wake up ischemic stroke patients in rural settings].
[Not Available].
[Pharmacotherapy of stroke]
[Plasma tissue-type plasminogen activator and plasminogen activator inhibitor activities and their ratio in patients with ischemic stroke associated with stagnation of blood during various stages]
[Position of the German Society of Neurology on limited approval of rt-PA for treatment of acute ischemic stroke]
[Preliminary study on rt-PA intravenous thrombolysis for elderly Chinese patients with acute stroke].
[Prerequisites, indications and contraindications of IV-lysis of ischemic stroke with rt-PA]
[Primary emergencies: management of acute ischemic stroke].
[Prognostic impact of time-point and degree of arterial recanalization of acute middle cerebral artery occlusions after intravenous tPA administration.]
[Pulseless arrest in an elderly patient treated with intravenous tissue plasminogen activator for cardioembolic ischemic stroke]
[Recent advances in therapeutic strategies of hyperacute and acute ischemic stroke in Japan].
[Recent progress in developing of thrombolytic agents for ischemic stroke].
[Recombinant tissue plasminogen activator therapy for acute ischemic stroke in older patients].
[Reperfusion therapies in acute ischemic stroke].
[Role of neurologists on the management of stroke care unit and/or stroke unit]
[Safety of intra-arterial autologous bone marrow mononuclear cell transplantation for acute ischemic stroke]
[Signifiance of brush sign on susceptibility-weighted imaging predicts hemorrhagic transformation after intravenous thrombolysis in patients with acute ischemic stroke].
[Stroke Thrombectomy: Anaesthesiologic Aspects].
[Systemic thrombolysis in ischemic stroke]
[Systemic thrombolytic therapy with rt-PA in acute medial territory infarct. Experiences in routine clinical practice]
[TCD monitoring during intravenous administration of recombinant tissue plasminogen activator]
[The development of new drugs for acute stroke]
[The future perspective of acute thrombolytic therapy for acute ischemic stroke].
[The prospects of thrombolytic therapy for acute ischemic stroke]
[Thrombolysis accelerated by ultrasound and microbubbles]
[Thrombolysis and acute cerebral infarction]
[Thrombolysis by intravenous tissue plasminogen activator (t-PA)--current status and future direction]
[Thrombolysis changes the care of stroke]
[Thrombolysis for acute ischemic stroke with recombinant tissue plasminogen activator in a Chilean public hospital].
[Thrombolysis in acute ischemic stroke with intravenous recombinant tissue-type plasminogen activator]
[Thrombolysis in stroke: inappropriate consideration of the 'window period' as the time available]
[Thrombolytic recombinant tissue plasminogen activator (rt-PA) treatment in the acute ischemic stroke with limb arterial embolism; three case reports].
[Thrombolytic therapy for acute ischemic stroke. Experience of SITS (Safe Implementation of Thrombolysis in Stroke) register.]
[Thrombolytic therapy of ischemic stroke].
[Thrombolytic treatment in acute ischemic stroke in a center without previous experience. Development of internal organization and first results]
[Thrombolytic treatment in stroke in patients with intracardiac thrombus: presentation of one case]
[Treatment of acute ischaemic stroke via the venous and arterial routes].
[Treatment of arterial and venous brain ischemia. Experts' recommendations: stroke management in the intensive care unit].
[Treatment with intravenous rt-PA in a general hospital context: A review of the Saint-Jean Hospital experience from Perpignan, France]
[Update on interventional treatment of acute ischemic stroke.]
[Use and results of intravenous fibrinolysis in a stroke unit].
[Use of alteplase in the treatment of acute ischemic stroke: what nurses know?].
[Use of tissue plasminogen activator factor for acute ischemic stroke]
[VEGF-A therapeutic target against hemorrhagic transformation after t-PA treatment].
Joint Diseases
Observer variability of tibial plateau slope measurement in 40 dogs with cranial cruciate ligament-deficient stifle joints.
Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis.
Significance of serine proteinase and matrix metalloproteinase systems in the destruction of human articular cartilage.
[Plasminogen activator activity of the synovial fluid as an indicator of activation phenomena in degenerative joint diseases]
Keloid
Adenoviral overexpression and small interfering RNA suppression demonstrate that plasminogen activator inhibitor-1 produces elevated collagen accumulation in normal and keloid fibroblasts.
Association of plasminogen activator inhibitor-1 and vitamin D receptor expression with the risk of keloid disease in a Chinese population.
Association of the plasminogen activator inhibitor-1 (PAI-1) Gene -675 4G/5G and -844 A/G promoter polymorphism with risk of keloid in a Chinese Han population.
Crosstalk of hypoxia-mediated signaling pathways in upregulating plasminogen activator inhibitor-1 expression in keloid fibroblasts.
Culture medium and cell density impact gene expression in normal skin and abnormal scar-derived fibroblasts.
Effect of Human Wharton's Jelly Mesenchymal Stem Cell Paracrine Signaling on Keloid Fibroblasts.
Elevated levels of plasminogen activator inhibitor-1 may account for the altered fibrinolysis by keloid fibroblasts.
Ex vivo evaluation of antifibrotic compounds in skin scarring: EGCG and silencing of PAI-1 independently inhibit growth and induce keloid shrinkage.
Increased plasminogen activator inhibitor-1 in keloid fibroblasts may account for their elevated collagen accumulation in fibrin gel cultures.
Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts.
Keloid scarring, but not Dupuytren's contracture, is associated with unexplained carotid atherosclerosis.
Mechanisms of hypoxic regulation of plasminogen activator inhibitor-1 gene expression in keloid fibroblasts.
Nintedanib inhibits keloid fibroblast functions by blocking the phosphorylation of multiple kinases and enhancing receptor internalization.
Transdermal delivery of 10,11-methylenedioxycamptothecin by hyaluronic acid based nanoemulsion for inhibition of keloid fibroblast.
TSG-6 Inhibits the Growth of Keloid Fibroblasts Via Mediating the TGF-?1/Smad Signaling Pathway.
Keratitis
Determination of plasminogen activator activities in normal and pathological human tears. The significance of tear plasminogen activators in the inflammatory and traumatic lesions of the cornea and the conjunctiva.
Keratoacanthoma
N-nitrosocimetidine as a modifier of chemically-initiated tumors in mice.
Keratoconus
Determination of plasminogen activator activities in normal and pathological human tears. The significance of tear plasminogen activators in the inflammatory and traumatic lesions of the cornea and the conjunctiva.
Keratoderma, Palmoplantar
Abnormal keratinization and cutaneous inflammation in Mal de Meleda.
Biological effects of SLURP-1 on human keratinocytes.
Mal de Meleda: A Focused Review.
Novel mutations in the gene encoding secreted lymphocyte antigen-6/urokinase-type plasminogen activator receptor-related protein-1 (SLURP-1) and description of five ancestral haplotypes in patients with Mal de Meleda.
SLURP-1 modulates corneal homeostasis by serving as a soluble scavenger of urokinase-type plasminogen activator.
SLURP-1 Mutation Impaired T-Cell Activation in a Mal de Meleda Family.
Keratosis
Albinism in Nigeria with delineation of new recessive oculocutaneous type.
Keratosis, Seborrheic
Comparison of proteinase activities in squamous cell carcinoma, basal cell epithelioma, and seborrheic keratosis.
[Seborrheic keratoses. Intact epidermal differentiation despite disordered morphogenesis]
Ketosis
Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises.
Kidney Diseases
Analysis of the plasminogen activator activity of the human glomerulus.
Corrigendum to "Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy".
Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats.
In healthy normotensive subjects age and blood pressure better predict subclinical vascular and cardiac organ damage than atherosclerosis biomarkers.
NF-?B and tPA Signaling in Kidney and Other Diseases.
Novel actions of tissue-type plasminogen activator in chronic kidney disease.
PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA.
Physiological consequences of over- or under-expression of fibrinolytic system components in transgenic mice.
Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-beta1-induced kidney disease.
The role of hypoxia-inducible factor-1? in zinc oxide nanoparticle-induced nephrotoxicity in vitro and in vivo.
Kidney Failure, Chronic
Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients.
Coagulation and fibrinolysis in chronic renal failure. Change in tissue-type plasminogen activator activity.
Coagulation, fibrinolysis and fibrinolysis inhibitors in haemodialysis patients: contribution of arteriovenous fistula.
Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure.
Fibrinolytic activity in end-stage renal disease.
Intrapleural hemorrhage after administration of tPA: a case report and review of the literature.
Molecular biology-based assessment of vitamin e-coated dialyzer effects on oxidative stress, inflammation, and vascular remodeling.
Polymorphism in methylenetetrahydrofolate reductase, plasminogen activator inhibitor-1, and apolipoprotein E in hemodialysis patients.
Studies of fibrinolytic activity of uremic and longterm hemodialytic patients with special reference to fibrinolytic inhibitor.
[Assessment of plasminogen activator inhibitor-1 and von Willebrand factor as a markers of endothelial function in patients with end-stage kidney disease after allotransplantation during a one-year follow-up]
[Plasma Lp (a) levels and correlation of Lp (a) with fibrinolysis activation in chronic renal failure]
[Tissue plasminogen activator antigen (t-PA Ag) and tissue plasminogen activator inhibitor (PAI-1) in the course of hemodialysis in patients with chronic renal failure]
Kidney Neoplasms
Absolute quantitative proteomics using the total protein approach to identify novel clinical immunohistochemical markers in renal neoplasms.
Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
Interferon-beta can induce the production of plasminogen activator by cultured human cancer cells.
Klinefelter Syndrome
Association between venous leg ulcers and sex chromosome anomalies in men.
Increased plasma activity of plasminogen activator inhibitor 1 (PAI-1) in two patients with Klinefelter's syndrome complicated by leg ulcers.
Leg ulcers in Klinefelter's syndrome--further evidence for an involvement of plasminogen activator inhibitor-1.
Venous leg ulcers in a patient with Klinefelter's syndrome and increased activity of plasminogen activator inhibitor-1.
Kounis Syndrome
Intravenous tissue plasminogen activator, ischemic stroke, and the risk of Kounis Syndrome.
Kyphosis
Effect of mono- or bisegmental lordosizing fusion on short term global and index sagittal balance: a radiographic study.
Measurement of Spinopelvic Angles on Prone Intraoperative Long-Cassette Lateral Radiographs Predicts Postoperative Standing Global Alignment in Adult Spinal Deformity Surgery.
Multilevel Schwab grade II osteotomies for sagittal plane correction in the management of adult spinal deformity.
Postoperative lower limb compensation in patient with adult spinal deformity.
Sagittal Vertical Axias, Spinosacral Angle, Spinopelvic Angle, and T1 Pelvic Angle: Which Parameters May Effectively Predict the Quality of Life in Ankylosing Spondylitis Patients With Thoracolumbar Kyphosis?
T1 pelvic angle: a new predictor for postoperative sagittal balance and clinical outcomes in adult scoliosis.
Thoracolumbar Realignment Surgery Results in Simultaneous Reciprocal Changes in Lower Extremities and Cervical Spine.
Virtual Modeling of Postoperative Alignment Following Adult Spinal Deformity (ASD) Surgery Helps Predict associations between Compensatory Spinopelvic Alignment Changes, Overcorrection and Proximal Junctional Kyphosis (PJK).
Language Disorders
Ten-Year Evaluation of the TOYOTA Prehospital Stroke Scale for Tissue Plasminogen Activator Intravenous Therapy in the Real World.
Laryngeal Neoplasms
Tissue polypeptide antigen, carcinoembryonic antigen, carbohydrate antigen, and CA125 levels as tumor markers in squamous cell carcinoma of the head and neck.
[Diagnostic value of tissue polypeptide antigen in serum of larynx cancer patients]
Latent Infection
A myeloid progenitor cell line capable of supporting human cytomegalovirus latency and reactivation, resulting in infectious progeny.
Epstein-Barr-virus-associated lymphoproliferative syndrome in severe combined immunodeficiency: establishment of a lymphoblastoid cell line as an in vitro model for biological and therapeutic studies.
Regulation of viral and cellular gene expression by Kaposi's sarcoma associated herpesvirus (KSHV) PAN RNA.
Lateral Medullary Syndrome
The Use of Tissue Plasminogen Activator in the Treatment of Wallenberg Syndrome Caused by Vertebral Artery Dissection.
Lateral Sinus Thrombosis
Transverse sinus thrombosis with hemorrhagic venous infarction treated with thrombectomy, endovascular tissue plasminogen activator, and systemic anticoagulation.
Learning Disabilities
Rapid, specific and active site-catalyzed effect of tissue-plasminogen activator on hippocampus-dependent learning in mice.
Leg Ulcer
Association between venous leg ulcers and sex chromosome anomalies in men.
Differential effects of acute and chronic wound fluids on urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and tissue-type plasminogen activator in cultured human keratinocytes and fibroblasts.
Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Expression of tissue-type and urokinase-type plasminogen activator activities in chronic venous leg ulcers.
Increased plasma activity of plasminogen activator inhibitor 1 (PAI-1) in two patients with Klinefelter's syndrome complicated by leg ulcers.
Leg ulcers in Klinefelter's syndrome--further evidence for an involvement of plasminogen activator inhibitor-1.
Leg ulcers revealing familial thrombophilia: prothrombin G20210A gene mutation and plasminogen activator inhibitor type 1 (PAI-1) polymorphism.
Local treatment of venous ulcers with tissue type plasminogen activator containing ointment.
Modulation of urokinase-type and tissue-type plasminogen activator occurs at an early stage of progressing stages of chronic venous insufficiency.
Multifactorial Painful Leg Ulcers Due to Hyperhomocysteinemia, Plasminogen Activator Inhibitor-1 4G/5G Heterozygote Gene Mutation, and Beta Thalassemia Minor: A Case Report.
Plasminogen activators, venous leg ulcers and reepithelialization.
Severity of venous insufficiency is related to the density of microvascular deposition of PAI-1, uPA and von Willebrand factor.
Temporal expression of urokinase plasminogen activator, plasminogen activator inhibitor and gelatinase-B in chronic wound fluid switches from a chronic to acute wound profile with progression to healing.
Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers.
Venous leg ulcers in a patient with Klinefelter's syndrome and increased activity of plasminogen activator inhibitor-1.
[Post-phlebitic leg ulcers and XYY karyotype: fibrinolysis and androgenic function tests. Apropos of 3 cases]
Legg-Calve-Perthes Disease
Protein C and S deficiency, thrombophilia, and hypofibrinolysis: pathophysiologic causes of Legg-Perthes disease.
Leiomyoma
Comparative assays of tissue plasminogen activator in myometrium, cervix, and fibromyomas of the human uterus.
Gonadotropin releasing hormone and transforming growth factor beta activate mitogen-activated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells.
Plasminogen activator inhibitor 1 messenger RNA expression and molecular evidence for del(7)(q22) in uterine leiomyomas.
The role of TWIST, SERPINB5, and SERPIN1 genes in uterine leiomyomas.
Leiomyosarcoma
Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas.
Lemierre Syndrome
A case of Lemierre's syndrome with septic shock and complicated parapneumonic effusions requiring intrapleural fibrinolysis.
Leprosy
Comparative study with two polar types of murine leprosy: an involvement of plasminogen activator and its possible regulating factor in the granulomatous tissue reaction.
New target antigens for anti-endothelial cell antibodies.
Plasminogen activator and plasminogen activator inhibitor associated with granulomatous inflammation: a study with murine leprosy.
Leukemia
1alpha,25-dihydroxyvitamin D3 stimulates phosphorylation of IkappaBalpha and synergizes with TPA to induce nuclear translocation of NFkappaB during monocytic differentiation of NB4 leukemia cells.
A plasminogen activator inhibitor-2 from a promyelocytic leukemia cell line, PL-21, binds to the carboxy-terminal chain of plasminogen activators.
Activation of human leukemia protein kinase C by tumor promoters and its inhibition by N-trifluoroacetyladriamycin-14-valerate (AD 32).
Activation of MAP kinase family members triggered by TPA or ionomycin occurs via the protein phosphatase 4 pathway in Jurkat leukemia T cells.
Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists.
Acute leukemia with mediastinal mass, lymphadenopathy, and monocytic precursor cells.
Alteration of cell cycle progression in human leukemia cell line (KOPM-28) induced by 12-o-tetradecanoylphorbol-13-acetate.
Alteration of nm23 gene expression during the induced differentiation of human leukemia cell lines.
Alteration of p60c-src expression in human leukemia-lymphoma cells correlated with induced differentiation.
Analysis of signal transduction in B chronic lymphocytic leukemia cells.
Analysis of the TPA regulatory element in the genomic poly(ADP-ribose) synthetase gene in human leukemia U937 cells.
Antileukemic agent alkyllysophospholipid regulates phosphorylation of distinct proteins in HL60 and K562 cells and differentiation of HL60 cells promoted by phorbol ester.
Antioxidative and melanogenesis-inhibitory activities of caffeoylquinic acids and other compounds from moxa.
Aphidicolin, an inhibitor of DNA replication, blocks the TPA-induced differentiation of a human megakaryoblastic cell line, MEG-O1.
Arachidonic acid enhances TPA-induced differentiation in human leukemia HL-60 cells via reactive oxygen species-dependent ERK activation.
Arsenic trioxide downregulates the expression of annexin II in bone marrow cells from patients with acute myelogenous leukemia.
Augmentation of mixed lymphocyte response. Stimulatory activity by phorbol ester.
Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40).
Bisphenol compounds regulate decidualized stromal cells in modulating trophoblastic spheroid outgrowth and invasion in vitro†.
CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review.
Cellular dichotomy between anchorage-independent growth responses to bFGF and TPA reflects molecular switch in commitment to carcinogenesis.
Changes in levels of t-PA and alpha 2PI-plasmin complex in plasma in patients with DIC.
Chromosomal locations of human tissue plasminogen activator and urokinase genes.
Circadian locomotor output cycles kaput accelerates atherosclerotic plaque formation by upregulating plasminogen activator inhibitor-1 expression.
Clinical application of phorbol diester-induced leukemic cell differentiation for the definite diagnosis of acute leukemias.
Cloning and functional characterization of GMPR2, a novel human guanosine monophosphate reductase, which promotes the monocytic differentiation of HL-60 leukemia cells.
Coagulant and fibrinolytic activities in the leukemic cell lysates.
Complete nucleotide sequence of the chromosomal gene for human IL-4 and its expression.
Constitutive overexpression of the c-fos gene in radiation-induced granulocytic leukemia in mice.
Cremophor EL inhibits 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced protein phosphorylation in human myeloblastic leukemia ML-1 cells.
Declined asparagine synthetase mRNA expression and enhanced sensitivity to asparaginase in HL-60 cells committed to monocytic differentiation.
Decrease in CuZn-superoxide dismutase mRNA level during differentiation of human monocytic and promyelotic leukemia cells.
Decreased tissue factor and tissue-plasminogen activator antigen in relapsed acute promyelocytic leukemia.
Design and testing of a packaged microfluidic cell for the multiplexed electrochemical detection of cancer markers.
Detection of a countertranscript in promyelocytic leukemia cells HL60 during early differentiation by TPA.
Dexamethasone and phorbol ester, but not cytokines, increase the production of plasminogen activator inhibitor type-2 in the PL-21 human promyelocytic leukemia cell line.
Different effects of the two protein kinase C activators bryostatin-1 and TPA on growth and differentiation of human monocytic leukemia cell lines.
Differential effects of phorbol esters on normal myeloid precursors and leukemic cells: basis for autologous bone marrow reconstitution in acute nonlymphocytic leukemia using phorbol ester-treated bone marrow from patients in remission.
Differential expression of TRAP Isoenzyme in B-CLL Cells Treated with Different Inducers.
Differentiation in vitro of human myelogenous leukemia cells from patients in relapse.
Differentiation of human leukemias in response to 12-0-tetradecanoylphorbol-13-acetate in vitro.
Differentiation-associated miR-22 represses Max expression and inhibits cell cycle progression.
Distinctive phorbol ester-induced morphological and surface antigen changes in mycosis fungoides, the Sézary syndrome, and adult T-cell leukemia.
Diverse effects: augmentation, inhibition, and non-efficacy of 12-O-tetradecanoylphorbol-13-acetate (TPA) on retrovirus genome expression in vivo and in vitro.
Down-regulation of proteolytic activity in 12-O-tetradecanoyl-phorbol-13-acetate-induced K562 leukemia cell cultures: depletion of active urokinase by excess type 1 plasminogen activator inhibitor.
Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in myeloid leukemia and other malignant cells.
Effects of phorbol ester on translocation and down-regulation of protein kinase C and phosphorylation of endogenous proteins in human acute myeloid leukemia cell line KG-1 and its phorbol ester-resistant subline KG-1a.
Effects of retinoic acid and phorbol ester on lymphocytes and monocytes in B-lymphocytic leukemia.
Enzymes approved for human therapy: indications, mechanisms and adverse effects.
Exposure to phorbol diester (TPA) in vitro as an aid in the classification of blasts in human myelogenous and lymphoid leukemias: in vitro differentiation, growth patterns, and ultrastructural observations.
Expression of a novel immediate early gene during 12-O-tetradecanoylphorbol-13-acetate-induced macrophagic differentiation of HL-60 cells.
Expression of Bmi-1 and PAI-1 in esophageal squamous cell carcinoma.
Expression of selected genes and oncogenes in differentiated HL-60 cells and primary cells from human leukemias.
Expression of selected genes in differentiated HL-60 cells and primary cells from human leukemias.
Expression of the Ku protein during cell proliferation.
FDP D-dimer induces the secretion of interleukin-1, urokinase-type plasminogen activator, and plasminogen activator inhibitor-2 in a human promonocytic leukemia cell line.
Flow cytometric analysis of the phenotypic changes in tumour cell lines following TPA induction.
Flow cytometry of TPA-induced changes in cells of chronic B-cell leukemias.
Gene expression of TPA induced differentiation in HL-60 cells by DNA microarray analysis.
Growth stimulation of microenvironment-dependent mouse leukemias by tumor-promoting phorbol esters.
Heterogenous response of primary cultured bone marrow cells of patients with different varieties of leukemia to differentiation inducers.
HIV-1 gp120 up-regulation of the mu opioid receptor in TPA-differentiated HL-60 cells.
Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester.
Immune phenotype and some enzyme patterns in phorbol ester-induced chronic lymphocytic leukemia cells.
In vitro differentiation of a null-acute leukemia: T-lymphoid surface antigen expression associated with rearrangement in T-cell receptor beta chain variable genes.
In vivo and in vitro expression of myeloid antigens on B-lineage acute lymphoblastic leukemia cells.
Increase in the D-dimer levels during treatment in patients with acute myelogenous leukemia.
Increment of the cyclin D1 mRNA level in TPA-treated three human myeloid leukemia cell lines: HEL, CMK and HL-60 cells.
Induction of differentiation-specific miRNAs in TPA-induced myeloid leukemia cells through MEK/ERK activation.
Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester.
Induction of plasminogen activator by 12-O-tetradecanoylphorbol-13-acetate and calcium ionophore. Suppression by inhibitors of fatty acid lipoxygenase.
Induction of smg p21/rap1A p21/krev-1 p21 gene expression during phorbol ester-induced differentiation of a human megakaryocytic leukemia cell line.
Inhibitory effects of curcumin and capsaicin on phorbol ester-induced activation of eukaryotic transcription factors, NF-kappaB and AP-1.
Internucleosomal DNA fragmentation during phorbol ester-induced monocytic differentiation and G0/G1 arrest.
Involvement of diverse protein kinase C isoforms in the differentiation of ML-1 human myeloblastic leukemia cells induced by the vitamin D3 analogue KH1060 and the phorbol ester TPA.
K562 erythroid and HL60 macrophage differentiation downregulates polycystin, a large membrane-associated protein.
Lack of correlation between effects of tumor promoter TPA on plasminogen activator production, phosphatidyl choline synthesis, and hexose transport in mammalian cell culture systems.
Lineage relationship of chronic lymphocytic leukemia and hairy cell leukemia: studies with TPA.
M-CSF and 1,25 dihydroxy vitamin D3 synergize with 12-O-tetradecanoylphorbol-13-acetate to induce macrophage differentiation in acute promyelocytic leukemia NB4 cells.
Modulation of protectin (CD59 antigen) cell surface expression on human neoplastic cell lines.
Myeloid leukemia differentiation by phorbol ester and retinoic acid: a practical approach.
Neutral and sialosyl glycosphingolipid composition and metabolism of human T-lymphoblastic cell line MOLT-3 cells: distinctive changes as markers specific for their differentiation.
Neutrophil defect associated with hairy cell leukemia.
Occurrence of particular isoenzymes in fresh and cultured leukemia-lymphoma cells. I. Tartrate-resistant acid phosphatase isoenzyme.
Occurrence of particular isoenzymes in fresh and cultured leukemia-lymphoma cells. III. Esterase isoenzyme in monocytes.
Phenotypic modulation of chronic lymphocytic, prolymphocytic, and lymphoplasmacytic leukemia cells by TPA: induction of TRAP isoenzyme 5 and HD6 (CD22) antigen and enhancement of IgM messenger RNA.
Phorbol ester induction of plasmacytoid and hairy cell leukemia features in B-type lymphocytic leukemias: the relation to B-cell differentiation and maturation.
Phorbol ester responsiveness of the glutathione S-transferase P1 gene promoter involves an inducible c-jun binding in human K562 leukemia cells.
Phorbol esters and hairy cell leukemia: effects on cell morphology and surface membrane features and comparison with other B cell leukemias.
Phospholipase C-induced monocytic differentiation in a human monocytic leukemia cell line THP-1.
PKC pathway and ERK/MAPK pathway are required for induction of cyclin D1 and p21Waf1 during 12-o-tetradecanoylphorbol 13-acetate-induced differentiation of myeloleukemia cells.
Plasminogen activator activity in differentiating leukemia cells.
Plasminogen activator in normal and tumor-bearing mice.
Plasminogen activator inhibitor-2 in patients with monocytic leukemia.
Plasminogen activators and their inhibitors in leukemic cell homogenates.
Polyadenylic acid polymerase activity in chronic myelogenous leukemia.
Proteome analysis of antiproliferative mechanism of 12-O-tetradecanoylphorbol 13-acetate on cultured nasopharyngeal carcinoma CNE2 cells.
Regulation and secretion of plasminogen activators and their inhibitors in a human leukemic cell line (K562).
Regulation of p21WAF1/CIP1 expression by p53-independent pathways.
Requirement for caspase activation in monocytic differentiation of myeloid leukemia cells.
Retroviral vector-mediated transfer and expression of human tissue plasminogen activator cDNA in bovine brain endothelial cells.
Retroviral vector-mediated transfer and expression of human tissue plasminogen activator gene in human endothelial and vascular smooth muscle cells.
Reversal of multidrug resistance by tyrosine-kinase inhibitors in a non-P-glycoprotein-mediated multidrug-resistant cell line.
Role of beta-defensin 2 and interleukin-4 receptor as stroke outcome biomarkers.
STAT3 and PKC differentially regulate telomerase activity during megakaryocytic differentiation of K562 cells.
Stimulated production of urokinase and plasminogen activator inhibitor-2 by the human promyelocytic leukemia cell line HL-60.
Synergistic effects of clinically achievable concentrations of 12-O-tetradecanoylphorbol-13-acetate in combination with all-trans retinoic acid, 1alpha,25-dihydroxyvitamin D3, and sodium butyrate on differentiation in HL-60 cells.
Synergistic induction of gene expression during the differentiation into mature macrophage in human myeloblastic leukemia cells treated with TPA and KH1060.
Synergistic stimulating effect between cyclic AMP and phorbol ester on plasminogen activator inhibitor type 2 production in human promyelocytic leukemia cell line PL-21.
Terminal differentiation of human leukemic blasts in response to 12-0-tetradecanoyl-13-phorbol acetate (TPA).
Tetradecanoyl phorbol acetate induces expression of Toll-like receptor 2 in U937 cells: involvement of PKC, ERK, and NF-kappaB.
The analysis of the variation of the surface proteins of leukemic lymphocytes of B-chronic lymphocytic leukemia patients by high performance liquid chromatography.
The bcr-c-abl tyrosine kinase activity is extinguished by TPA in K562 leukemia cells.
The in-vitro response of CD2-positive acute myelogenous leukemia to proliferation and differentiation inducing agents.
The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia.
The THP-1 cell line is a urokinase-secreting mononuclear phagocyte with a novel defect in the production of plasminogen activator inhibitor-2.
The tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate inhibits or enhances induction of differentiation of mouse myeloid leukemia cells depending on the type of serum in the medium.
Tpa-induced maturation in secretory human B-leukemic cells in vitro: DNA synthesis, antigenic changes, and immunoglobulin secretion.
Transcriptional and post-transcriptional regulation of c-jun expression during monocytic differentiation of human myeloid leukemic cells.
Transient posttranslational up-regulation of telomerase activity during megakaryocytic differentiation of K562 cells.
Treatment of infective endocarditis with recombinant tissue plasminogen activator.
Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma.
Tumor necrosis factor alpha up-regulates in an autocrine manner the synthesis of plasminogen activator inhibitor type-1 during induction of monocytic differentiation of human HL-60 leukemia cells.
Tumor promoter-mediated effects on Friend leukemia cells induced by actinomycin D: flow microfluorometry analysis and erythroid differentiation.
Two-stage carcinogenesis in NMRI mice: intravaginal application of 7,12-dimethylbenz[a]anthracene as initiator followed by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate as promoter.
Ubash3b promotes TPA-mediated suppression of leukemogenesis through accelerated downregulation of PKC? protein.
Vitamin D3 analogue KH1060 combined with TPA synergistically induces mature macrophages in human myeloblastic leukemia ML-1 cells.
[Active factors released by endothelial cells in acute leukemia]
[Effect of cyclic AMP and phorbol ester on PAI-2 synthesis in a leukemic cell line PL-21 and on u-PA secretion in a pre-B cell lymphoma cell line RC-K8]
[Plasma concentrations of plasminogen activator inhibitor 2 in patients with hematological malignancies and their clinical significance]
[Plasminogen activator level in the vein walls in a patient with promyelocytic leukemia]
[Production and secretion of the plasminogen activator inhibitor type-2 in a leukemia cell line]
[Retinoic acid and 12-0-tetradecanoylphorbol-13-acetate (TPA) inducing bipotent differentiation of cultured primary bone marrow cells from leukemia patients]
[Study of fibrinolysis inhibitors in 117 acute leukemia patients]
Leukemia, B-Cell
Decrease in CuZn-superoxide dismutase mRNA level during differentiation of human monocytic and promyelotic leukemia cells.
Phenotypic modulation of chronic lymphocytic leukemia cells by phorbol ester: induction of IgM secretion and changes in the expression of B cell-associated surface antigens.
Leukemia, Erythroblastic, Acute
12-O-tetradecanoylphorbol-13-acetate (TPA) downregulates expression of CD30 in erythroleukemia cell line K562.
Aphidicolin, an inhibitor of DNA replication, blocks the TPA-induced differentiation of a human megakaryoblastic cell line, MEG-O1.
Cellular-oncogene expression in Friend erythroleukemia cells: relationship to differentiation, commitment and TPA effects.
Comparative effects of a complete tumor promoter, TPA, and a second-stage tumor promoter, RPA, on intercellular communication, cell differentiation and cell transformation.
Exposure of JB-6 mouse epidermal cells to 12-O-tetradecanoyl-phorbol-13-acetate is not accompanied by a significant change in total DNA-cytosine methylation.
Human erythroleukemia cell line (HEL) undergoes a drastic macrophage-like shift with TPA.
Increased glucocorticoid receptor concentration in macrophage differentiation of myeloid leukemia cells with 12-O-tetradecanoylphorbol-13-acetate.
Induction of polyploidization in the human erythroleukemia cell line (HEL) by protein kinase inhibitor (K252a) and the phorbol-ester TPA.
Phorbol ester 12-O-tetradecanoylphorbol-13-acetate down-regulates expression of the c-kit proto-oncogene product.
Plasminogen activator and its enhancement in differentiating mouse Friend erythroleukemia cells.
Leukemia, Feline
FeLV-induced immunosuppression through alterations in signal transduction: down regulation of protein kinase C.
Leukemia, Hairy Cell
Differential expression of TRAP Isoenzyme in B-CLL Cells Treated with Different Inducers.
Immune phenotype and some enzyme patterns in phorbol ester-induced chronic lymphocytic leukemia cells.
Lineage relationship of chronic lymphocytic leukemia and hairy cell leukemia: studies with TPA.
Neutrophil defect associated with hairy cell leukemia.
Phorbol ester induction of plasmacytoid and hairy cell leukemia features in B-type lymphocytic leukemias: the relation to B-cell differentiation and maturation.
Phorbol esters and hairy cell leukemia: effects on cell morphology and surface membrane features and comparison with other B cell leukemias.
Leukemia, Lymphocytic, Chronic, B-Cell
B cell maturation in chronic lymphocytic leukemia. II. Clonal heterogeneity in the response to various B cell activators and recombinant cytokines (rIFN-gamma, rIFN-alpha, rIL2).
Chromosome abnormalities in chronic lymphocytic leukemia revealed by TPA as a mitogen.
Chromosome studies in stimulated lymphocytes of 50 patients with B-cell chronic lymphocytic leukemia.
Clonal chromosome abnormalities in chronic lymphocytic leukemia patients revealed by TPA stimulation of whole blood cultures.
Lineage relationship of chronic lymphocytic leukemia and hairy cell leukemia: studies with TPA.
Modulation of chronic lymphocytic leukemia cells by phorbol ester: increase in Ia expression, IgM secretion and MLR stimulatory capacity.
Monoclonal antibodies detecting plasminogen activators on the membrane of leukemic lymphoid cells of T-cell origin.
Occurrence of particular isoenzymes in fresh and cultured leukemia-lymphoma cells. I. Tartrate-resistant acid phosphatase isoenzyme.
Occurrence of particular isoenzymes in fresh and cultured leukemia-lymphoma cells. II. Hexosaminidase I isoenzyme.
Optimized mitogen stimulation induces proliferation of neoplastic B cells in chronic lymphocytic leukemia: significance for cytogenetic analysis.The Tampere Chronic Lympocytic Leukemia group.
Phorbol ester and B cell-stimulatory factor synergize to induce B-chronic lymphocytic leukemia cells to simultaneous immunoglobulin secretion and DNA synthesis.
Phorbol ester induction of plasmacytoid and hairy cell leukemia features in B-type lymphocytic leukemias: the relation to B-cell differentiation and maturation.
Phorbol esters and hairy cell leukemia: effects on cell morphology and surface membrane features and comparison with other B cell leukemias.
Plasminogen-dependent fibrinolytic activity in normal human lymphocytes: diminished lymphocyte plasminogen activator in chronic lymphocytic leukemia.
Regulation of IgM biosynthesis in human chronic lymphocytic leukemia. Normal and neoplastic B cells respond differently to TPA.
Sister chromatid exchange frequency in B-cells stimulated by TPA in chronic lymphocytic leukemia.
Leukemia, Lymphoid
Cell cycle progression of B-chronic lymphocytic leukemia cells induced to differentiate by TPA.
Coagulant and fibrinolytic activities in the leukemic cell lysates.
Differential expression of TRAP Isoenzyme in B-CLL Cells Treated with Different Inducers.
Effect of TPA on fructose 2,6-bisphosphate levels and protein kinase C activity in B-chronic lymphocytic leukemia (B-CLL).
Exposure to phorbol diester (TPA) in vitro as an aid in the classification of blasts in human myelogenous and lymphoid leukemias: in vitro differentiation, growth patterns, and ultrastructural observations.
Lineage relationship of chronic lymphocytic leukemia and hairy cell leukemia: studies with TPA.
Myeloid leukemia differentiation by phorbol ester and retinoic acid: a practical approach.
Phenotypic modulation of chronic lymphocytic leukemia cells by phorbol ester: induction of IgM secretion and changes in the expression of B cell-associated surface antigens.
Phorbol diester-induced macrophage differentiation of leukemic blasts from patients with human myelogenous leukemia.
Rapid expression of protooncogenes c-fos and c-myc in B-chronic lymphocytic leukemia cells during differentiation induced by phorbol ester and calcium ionophore.
Synergistic action of calcium ionophore A23187 and phorbol ester TPA on B-chronic lymphocytic leukemia cells.
[Proteolytic enzymes in human lymphocytic leukemia cells. I. Activity of dipeptidylaminopeptidase IV, plasminogen activator and cathepsins B and L in cells with different immunologic phenotype]
[T-PA and PAI-1 in lymphocytes of patients with chronic lymphoid leukemia]
Leukemia, Monocytic, Acute
Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Coagulant and fibrinolytic activities in the leukemic cell lysates.
Effect of phorbol ester on differentiation of human myeloid colony forming cells (CFU-C).
Heterogenous response of primary cultured bone marrow cells of patients with different varieties of leukemia to differentiation inducers.
Macrophage-like cell transformation and CFU(c) fluctuations in normal and leukemic human marrow cultures treated by phorbol diester.
Occurrence of particular isoenzymes in fresh and cultured leukemia-lymphoma cells. I. Tartrate-resistant acid phosphatase isoenzyme.
Phorbol ester tumor promoters specifically stimulate choline phospholipid metabolism in human leukemic cells.
STAT3 and PKC differentially regulate telomerase activity during megakaryocytic differentiation of K562 cells.
Study of differentiation of fresh human leukemic cells by low dose cytosine arabinoside (LD Ara-C) and 12-O-tetradecanoylphorbol-13-acetate (TPA).
Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells.
TPA induces differentiation of purified human myeloblasts in the absence of proliferation.
[Retinoic acid and 12-0-tetradecanoylphorbol-13-acetate (TPA) inducing bipotent differentiation of cultured primary bone marrow cells from leukemia patients]
Leukemia, Myeloid
A gene coding for a zinc finger protein is induced during 12-O-tetradecanoylphorbol-13-acetate-stimulated HL-60 cell differentiation.
Characterization of human TUR leukemia cells: continued cell cycle progression in the presence of phorbol ester is associated with resistance to apoptosis.
Constitutive overexpression of the c-fos gene in radiation-induced granulocytic leukemia in mice.
Different regulation of plasminogen activator inhibitor 2 gene expression by phorbol ester and cAMP in human myeloid leukemia cell line PL-21.
Differential responsiveness to phorbol esters correlates with differential expression of protein kinase C in KG-1 and KG-1a human myeloid leukemia cells.
Differentiation and retrodifferentiation of human myeloid leukemia cells is associated with reversible induction of cell cycle-regulatory genes.
Differentiation of human leukemia cells and its usefulness for clinical diagnosis.
Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity.
Enhancement of TPA-induced growth inhibition and apoptosis in myeloid leukemia cells by BAY 11-7082, an NF-kappaB inhibitor.
Exposure to phorbol diester (TPA) in vitro as an aid in the classification of blasts in human myelogenous and lymphoid leukemias: in vitro differentiation, growth patterns, and ultrastructural observations.
Expression of SOCS genes in normal and leukemic human leukocytes stimulated by prolactin, growth hormone and cytokines.
Functional role for protein kinase Cbeta as a regulator of stress-activated protein kinase activation and monocytic differentiation of myeloid leukemia cells.
Gene expression of TPA induced differentiation in HL-60 cells by DNA microarray analysis.
Increased glucocorticoid receptor concentration in macrophage differentiation of myeloid leukemia cells with 12-O-tetradecanoylphorbol-13-acetate.
Mitochondrial targeting of JNK/SAPK in the phorbol ester response of myeloid leukemia cells.
Modification by serum of differentiation of cultured human myeloid leukemia cells in response to 12-O-tetradecanoylphorbol-13-acetate.
Modification of growth and differentiation of myeloid leukemia cells by tumor promoters.
Modulation of transglutaminase activity in mononuclear phagocytes and macrophage-like tumor cell lines by differentiation agents.
Myeloid leukemia differentiation by phorbol ester and retinoic acid: a practical approach.
Phorbol diester-induced macrophage differentiation of leukemic blasts from patients with human myelogenous leukemia.
Phorbol ester effect on differentiation of human myeloid leukemia cell lines blocked at different stages of maturation.
Phorbol ester-induced monocytic differentiation is associated with G2 delay and down-regulation of cdc25 expression.
Protein kinase C activation modulates pro- and anti-apoptotic signaling pathways.
Somatic cell hybrids between human lymphoma and human myeloid leukemia cells. I. Induction of resident viral genome transcription and viral antigen formation by IUDR and TPA.
Synergistic stimulatory effect of 12-O-tetradecanoylphorbol-13-acetate and capsaicin on macrophage differentiation in HL-60 and HL-525 human myeloid leukemia cells.
Transcriptional regulation of a hematopoietic proteoglycan core protein gene during hematopoiesis.
Leukemia, Myeloid, Acute
Clinical significance of tissue polypeptide antigen in serum of acute nonlymphocytic leukemia.
Coagulant and fibrinolytic activities in the leukemic cell lysates.
Combination of diethyldithiocarbamate with 12-O-tetradecanoyl phorbol-13-acetate inhibits the growth of human myeloid leukemia HL-60 cells in vitro and in xenograft model.
Differential effects of phorbol esters on normal myeloid precursors and leukemic cells: basis for autologous bone marrow reconstitution in acute nonlymphocytic leukemia using phorbol ester-treated bone marrow from patients in remission.
Differentiation-linked secretion of urokinase and tissue plasminogen activator by normal human hemopoietic cells.
Expression of selected genes and oncogenes in differentiated HL-60 cells and primary cells from human leukemias.
Expression of selected genes in differentiated HL-60 cells and primary cells from human leukemias.
High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphoblastic leukemia.
Increase in the D-dimer levels during treatment in patients with acute myelogenous leukemia.
Near-tetraploid poorly differentiated acute myeloid leukemia M0 diagnosed by short-term cultures with a phorbol ester TPA.
STAT3 and PKC differentially regulate telomerase activity during megakaryocytic differentiation of K562 cells.
Study of differentiation of fresh human leukemic cells by low dose cytosine arabinoside (LD Ara-C) and 12-O-tetradecanoylphorbol-13-acetate (TPA).
Terminal differentiation of human leukemic blasts in response to 12-0-tetradecanoyl-13-phorbol acetate (TPA).
The effects of dexamethasone and tetradecanoyl phorbol acetate on plasminogen activator release by human acute myeloid leukemia cells.
The secretion of plasminogen activators by human myeloid leukemic cells in vitro.
Transient posttranslational up-regulation of telomerase activity during megakaryocytic differentiation of K562 cells.
Treatment of infective endocarditis with recombinant tissue plasminogen activator.
Leukemia, Myelomonocytic, Acute
Coagulant and fibrinolytic activities in the leukemic cell lysates.
Differential effects of phorbol esters on normal myeloid precursors and leukemic cells: basis for autologous bone marrow reconstitution in acute nonlymphocytic leukemia using phorbol ester-treated bone marrow from patients in remission.
Leukemia, Plasma Cell
Phorbol ester induction of plasmacytoid and hairy cell leukemia features in B-type lymphocytic leukemias: the relation to B-cell differentiation and maturation.
Leukemia, Prolymphocytic
Cytogenetic studies on prolymphocytic leukemia. 1. B-cell prolymphocytic leukemia.
Phorbol ester induction of plasmacytoid and hairy cell leukemia features in B-type lymphocytic leukemias: the relation to B-cell differentiation and maturation.
Phorbol esters and hairy cell leukemia: effects on cell morphology and surface membrane features and comparison with other B cell leukemias.
Leukemia, Promyelocytic, Acute
1alpha,25-dihydroxyvitamin D3 stimulates phosphorylation of IkappaBalpha and synergizes with TPA to induce nuclear translocation of NFkappaB during monocytic differentiation of NB4 leukemia cells.
Arsenic trioxide downregulates the expression of annexin II in bone marrow cells from patients with acute myelogenous leukemia.
Changes in levels of t-PA and alpha 2PI-plasmin complex in plasma in patients with DIC.
Coagulant and fibrinolytic activities in the leukemic cell lysates.
Decreased tissue factor and tissue-plasminogen activator antigen in relapsed acute promyelocytic leukemia.
Differential effects of phorbol esters on normal myeloid precursors and leukemic cells: basis for autologous bone marrow reconstitution in acute nonlymphocytic leukemia using phorbol ester-treated bone marrow from patients in remission.
Synergistic effects of clinically achievable concentrations of 12-O-tetradecanoylphorbol-13-acetate in combination with all-trans retinoic acid, 1alpha,25-dihydroxyvitamin D3, and sodium butyrate on differentiation in HL-60 cells.
The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia.
[Retinoic acid and 12-0-tetradecanoylphorbol-13-acetate (TPA) inducing bipotent differentiation of cultured primary bone marrow cells from leukemia patients]
Leukemia, T-Cell
Complete nucleotide sequence of the chromosomal gene for human IL-4 and its expression.
Heterologous protein expression affects the death kinetics of baculovirus-infected insect cell cultures: a quantitative study by use of n-target theory.
Leukemia-Lymphoma, Adult T-Cell
Distinctive phorbol ester-induced morphological and surface antigen changes in mycosis fungoides, the Sézary syndrome, and adult T-cell leukemia.
The effects of tumor promoters on HTLV-1 expression in a low-virus producer and a non-virus producer cell line.
Leukocytosis
Effects of iron supplementation in mice with hypoferremia induced by obesity.
Haemostatic and fibrinolytic parameters in septic patients with leukopenia or leukocytosis.
Interleukin-12 induces sustained activation of multiple host inflammatory mediator systems in chimpanzees.
Tissue plasminogen activator for the treatment of intraventricular hematoma: the dose-effect relationship.
Leukoencephalopathies
5-Fluorouracil-induced Leukoencephalopathy with Acute Stroke-like Presentation Fulfilling Criteria for Recombinant Tissue Plasminogen Activator Therapy.
Hemorrhagic risk after intravenous thrombolysis for ischemic stroke in patients with cerebral microbleeds and white matter disease.
Successful Use of Intravenous Tissue Plasminogen Activator as Treatment for a Patient with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy: A Case Report and Review of Literature.
Leukopenia
A triazolodiazepine platelet activating factor receptor antagonist (WEB 2086) reduces pulmonary dysfunction during endotoxin shock in swine.
Activation of plasma systems and blood cells by endotoxin in rabbits.
Haemostatic and fibrinolytic parameters in septic patients with leukopenia or leukocytosis.
Methylprednisolone prophylaxis protects against endotoxin-induced death in rabbits.
Protective effects of leukopenia and tissue plasminogen activator in microvascular ischemia-reperfusion injury.
Lichen Sclerosus et Atrophicus
Do plasminogen activators play a role in lichen sclerosus?
Lipodystrophy
Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy.
Endothelial function is impaired in HIV-infected patients with lipodystrophy.
Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy.
Lipoma
12-0-Tetradecanoylphorbol-13-acetate-induced amplification of mesenchymal tumorigenesis in the mouse skin.
Cellular and molecular features of lipoma tissue: comparison with normal adipose tissue.
Influence of short-term topical exposure to phorbol ester tumor promoters on subcutaneously induced skin tumorigenesis in S/RVCri mice.
Liposarcoma
12-0-Tetradecanoylphorbol-13-acetate-induced amplification of mesenchymal tumorigenesis in the mouse skin.
Livedo Reticularis
Mesenteric vein thrombosis and vascular plasminogen activator.
[Cholesterol crystal embolisms due to systemic thrombolysis of an acute myocardial infarct]
Livedoid Vasculopathy
Dramatic response of livedoid vasculitis to tissue plasminogen activator (tPA)
Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy.
Enhanced mRNA expression of plasminogen activator inhibitor-1 in livedoid vasculopathy lesions.
Failure of livedoid vasculitis to respond to tissue plasminogen activator.
Livedoid vasculopathy (LV) associated with sticky platelets syndrome type 3 (SPS type 3) and enhanced activity of plasminogen activator inhibitor (PAI-1) anomalies.
Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) and prothrombin G20210A heterozygosity: response to t-PA therapy.
Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator.
Plasminogen activator inhibitor-1: a potential etiological role in livedoid vasculopathy.
Successful long-term use of intravenous immunoglobulin to treat livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity.
Tissue plasminogen activator for treatment of livedoid vasculitis.
[Vasculitis and vasculopathy].
Liver Abscess
The value of serum concentrations of tissue polypeptide antigen in the diagnosis of hepatocellular carcinoma.
Liver Abscess, Pyogenic
Successful Use of Tissue Plasminogen Activator in an Adolescent Male with Pyogenic Liver Abscess.
Liver Cirrhosis
Alpha-fetoprotein and tissue polypeptide antigen in non neoplastic hepatic disorders.
Alpha-fetoprotein, tissue polypeptide antigen and ferritin in diagnosing primary hepatocellular carcinoma in patients with liver cirrhosis.
Clinical evaluation of tissue plasminogen activator (t-PA) levels in patients with liver diseases.
Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-malignant diseases.
Diagnostic efficacy of plasma urokinase-type plasminogen activator and plasminogen activator inhibitor-2 in differentiation of hepatocellular carcinoma from cirrhosis.
Disruption of tissue-type plasminogen activator gene in mice aggravated liver fibrosis.
Effects of shikonin from Zicao on high-fat diet-induced nonalcoholic fatty liver disease in rats.
Endothelium releases more von Willebrand factor and tissue-type plasminogen activator upon venous occlusion in patients with liver cirrhosis than in normals.
Enhanced plasminogen activator inhibitor-1 expression in transgenic mice with hepatocyte-specific overexpression of superoxide dismutase or glutathione peroxidase.
Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids.
Fibrogenic Polymorphisms (TGF-beta, PAI-1, AT) in Mexican Patients With Established Liver Fibrosis. Potential Correlation With Pirfenidone Treatment.
Fraxinus rhynchophylla ethanol extract attenuates carbon tetrachloride-induced liver fibrosis in rats via down-regulating the expressions of uPA, MMP-2, MMP-9 and TIMP-1.
Hemostasis associated with abnormalities of fibrinolysis.
Hepatic clearance of tissue-type plasminogen activator and plasma kallikrein in experimental liver fibrosis.
Hepatic synthesis and clearance of components of the fibrinolytic system in healthy volunteers and in patients with different stages of liver cirrhosis.
Hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein (HIP/PAP) confers protection against hepatic fibrosis through downregulation of transforming growth factor ? receptor II.
Inhibition of inducible nitric oxide synthase activity prevents liver recovery in rat thioacetamide-induced fibrosis reversal.
PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA.
Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
Properties of urokinase type-plasminogen activator found in chest fluid.
Sarcopenia and chronic liver diseases.
The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor.
Thrombin and plasmin generation in patients with liver disease.
Tissue-type plasminogen activator is not necessary for platelet-derived growth factor-c activation.
Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line.
[Effects of Qinggan Huoxue Recipe and its separated recipes on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 fibrinolytic system in rats with alcoholic liver fibrosis]
[Qualitative analysis of tissue plasminogen activator in plasma obtained from various liver diseases by gel filtration and affinity chromatography]
[Studies on the mechanism of hyperfibrinolysis in liver cirrhosis--changes of plasma t-PA, PAI-1 and active PAI-1 levels in liver cirrhosis]
[The plasma levels of urokinase plasminogen activator and plasminogen activator inhibitor-1 and the protein expressions of alpha-SMA and MMP-1 and TIMP-1 in patients with different grades of liver fibrosis]
[The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B]
Liver Cirrhosis, Alcoholic
Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Liver Diseases
A clinical and biochemical study on tissue polypeptide antigen (TPA) in non-malignant hepatic disorders.
A kinetic model of the circulatory regulation of tissue plasminogen activator during orthotopic liver transplantation.
A review of tissue plasminogen activator in the treatment of veno-occlusive liver disease after bone marrow transplantation.
Association between plasminogen activator inhibitor-1 and severity of liver injury and cardiovascular risk in children with non-alcoholic fatty liver disease.
Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA.
Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states.
Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator.
Clinical evaluation of tissue plasminogen activator (t-PA) levels in patients with liver diseases.
Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer.
Comments to: Budd-Chiari syndrome: Current options in the interventional radiology treatment exemplified by three selected cases.
Different role of liver dysfunction and damage in increasing serum CA 19-9, TPA, and CEA in patients with pancreatic cancer.
Emerging risk factors for cardiovascular diseases: Indian context.
Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease.
Female mice are more susceptible to non-alcoholic fatty liver disease: sex-specific regulation of the hepatic AMP-activated protein kinase - plasminogen activator inhibitor 1-cascade but not the hepatic endotoxin response.
Forkhead transcription factor FoxO1 inhibits insulin- and transforming growth factor-beta-stimulated plasminogen activator inhibitor-1 expression.
Hepatic microenvironment affects oval cell localization in albumin-urokinase-type plasminogen activator transgenic mice.
Inhibition of Plasminogen Activator Inhibitor 1 Attenuates Hepatic Steatosis but Does Not Prevent Progressive Nonalcoholic Steatohepatitis in Mice.
Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model.
Modulation of the macrophage hepatocytotoxicity and plasminogen activator activity of activated macrophages from guinea pigs by serum components from normal human and patients with liver diseases.
Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake.
Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis.
Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease.
Plasminogen activator inhibitor-1 is independently associated with non-alcoholic fatty liver disease whereas leptin and adiponectin vary between genders.
Plasminogen activator inhibitor-2 and alpha-fetoprotein in various liver disease states.
Recombinant tissue plasminogen activator (rt-PA) for veno-occlusive liver disease in pediatric autologous bone marrow transplant patients.
Sarcopenia and chronic liver diseases.
The Prevalence and Impact of Mortality of the Acute Respiratory Distress Syndrome on Admissions of Patients With Ischemic Stroke in the United States.
The significance of colocalization of plasminogen activator inhibitor-1 and vitronectin in hepatic fibrosis.
Thrombin activation and increased fibrinolysis in patients with chronic liver disease.
Thrombin and plasmin generation in patients with liver disease.
Tissue plasminogen activator, plasminogen activator inhibitors, and activator-inhibitor complex in liver disease.
Tissue polypeptide antigen (TPA) in chronic active hepatitis and mild liver diseases.
Tissue-type plasminogen activator deficiency exacerbates cholestatic liver injury in mice.
TM5441, a plasminogen activator inhibitor-1 inhibitor, protects against high fat diet-induced non-alcoholic fatty liver disease.
Tumor markers carcinoembryonic antigen, tissue polypeptide antigen, and carbohydrate antigen 19/9 in liver diseases.
Use of tissue type plasminogen activator in neonates: case reports and review of the literature.
[A retrospective study of the serum CEA, AFP, TPA and ferritin values in 500 patients with chronic liver diseases]
[Effects of serum components of patients with liver diseases on hepatocyte cytotoxicity and plasminogen activator production of activated macrophages]
[Evaluation of plasma tissue plasminogen activator (I-PA) levels in patients with liver diseases]
[Insulin-like growth factor-binding protein-1: a new biochemical marker of nonalcoholic fatty liver disease?]
[Proinflammatory cytokine levels depending on the stage of hepatic fibrosis in patients with metabolic syndrome and non-alcoholic fatty liver disease].
[Qualitative analysis of tissue plasminogen activator in plasma obtained from various liver diseases by gel filtration and affinity chromatography]
[Serum concentrations of tissue polypeptide antigen and alpha 1-fetoprotein in patients with primary liver cancer, liver metastasis and liver cirrhosis]
Liver Diseases, Alcoholic
Alcoholic liver disease and the potential role of plasminogen activator inhibitor-1 and fibrin metabolism.
Fructose-induced steatosis in mice: role of plasminogen activator inhibitor-1, microsomal triglyceride transfer protein and NKT cells.
Liver Failure
Enhancing Hepatic Microcirculation in Postoperative Hepatic Failure With Intra-arterial Recombinant Tissue Plasminogen Activator Treatment.
Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC Group. Coagulation Abnormalities in Liver Cirrhosis.
Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats.
Prothrombinex-induced thrombosis and its management with regional plasminogen activator in hepatic failure.
Therapeutic efficacy of human hepatocyte transplantation in a SCID/uPA mouse model with inducible liver disease.
Liver Neoplasms
12-O-Tetradecanoylphorbol-13-acetate (TPA) is anti-tumorigenic in liver cancer cells via inhibiting YAP through AMOT.
Analysis of the correlation between alterations in N?glycans and invasiveness in liver cancer cell lines.
Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance.
Plumbagin inhibits invasion and migration of liver cancer HepG2 cells by decreasing productions of matrix metalloproteinase-2 and urokinase- plasminogen activator.
Synergy of urokinase?type plasminogen activator receptor isomer (D1D2) and integrin ?5?1 causes malignant transformation of hepatic cells and the occurrence of liver cancer.
Transcriptome analysis of PPAR? target genes reveals the involvement of lysyl oxidase in human placental cytotrophoblast invasion.
[Clinical relevance of tumor markers]
[Diagnostic value of 5'nucleotidase in primary and secondary neoplasms of the liver]
[Measurement of serum tissue polypeptide antigen (TPA) in patients with malignant tumor using prolifigen TPA-M "Daiichi" kit]
[Serum concentrations of tissue polypeptide antigen and alpha 1-fetoprotein in patients with primary liver cancer, liver metastasis and liver cirrhosis]
Liver Neoplasms, Experimental
Demonstration of a specific clearance receptor for tissue-type plasminogen activator on rat Novikoff hepatoma cells.
Locked-In Syndrome
Locked in and out: a case of emerging basilar artery obstruction secondary to vertebral artery dissection thrombolysed with intravenous rt-PA.
Smog Sign: Hazy Diffusion-weighted Imaging Restriction in Dense Axonal Tracts in the Pons on Hyperacute MRI with Remarkable Clinical Improvement After Intra-arterial Thrombectomy.
[Intra-arterial thrombolysis in basilar artery thrombosis. Recovery of two patients with locked-in syndrome]
Lordosis
Activation of protein kinase C in the hypothalamic ventromedial nucleus or the midbrain central gray facilitates lordosis.
Compensation for standing posture by whole-body sagittal alignment in relation to health-related quality of life.
Effect of mono- or bisegmental lordosizing fusion on short term global and index sagittal balance: a radiographic study.
Postoperative lower limb compensation in patient with adult spinal deformity.
Surgical Planning for Adult Spinal Deformity: Anticipated Sagittal Alignment Corrections According to the Surgical Level.
T1 pelvic angle (TPA) effectively evaluates sagittal deformity and assesses radiographical surgical outcomes longitudinally.
T1 Pelvic Angle Is a Useful Parameter for Postoperative Evaluation in Adult Spinal Deformity Patients.
T1 pelvic angle: a new predictor for postoperative sagittal balance and clinical outcomes in adult scoliosis.
Thoracolumbar Realignment Surgery Results in Simultaneous Reciprocal Changes in Lower Extremities and Cervical Spine.
Lung Abscess
Efficacy and safety of intrapleural instillation of alteplase in the management of complicated pleural effusion or empyema.
Lung Diseases
A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia.
An evaluation of tissue polypeptide antigen (TPA) in the two bronchoalveolar lavage fractions of lung cancer patients.
Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squamous cell lung cancer.
Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?
Disordered pathways of fibrin turnover in lung lavage of premature infants with respiratory distress syndrome.
Fatal Hemoptysis during Coronary Thrombolysis.
Hydrolytic enzymes of alveolar macrophages.
Phagocyte enzymes in bronchoalveolar lavage from patients with pulmonary sarcoidosis and collagen vascular disorders.
Serum and tissue levels of CEA, TPA, CA 125 and CA 15.3 in patients with lung cancer.
Serum markers casa, cea, cyfra-21-1, msa, nse, tpa and tps in lung-cancer.
Tissue polypeptide antigen in bronchogenic carcinoma.
Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes.
[An immunoradiometric assay of the serum TPA from patients with primary lung cancer and a comparison with the conventional double antibody method]
[Clinical evaluation of combination assay of tumor markers in primary lung cancer patients]
[Clinical significance of tumor markers in the diagnosis of lung cancer.]
[Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer]
[The sensitivity and specificity of tumor markers (CEA, ferritin, beta 2-MG, TPA, IAP, sialic acid) in malignant and non-malignant pulmonary diseases and their relation to smoking and sex]
Lung Diseases, Interstitial
Increased alveolar plasminogen activator in early asbestosis.
Production of plasminogen activator by alveolar macrophages in normal subjects and patients with interstitial lung disease.
Lung Injury
Alveolar epithelial cells express both plasminogen activator and tissue factor. Potential role in repair of lung injury.
Developmental expression of plasminogen activator inhibitor type 1 by human alveolar macrophages. Possible role in lung injury.
Disordered pathways of fibrin turnover in lung lavage of premature infants with respiratory distress syndrome.
Fibrinolytic system related to pulmonary arterial pressure and lung function of patients with idiopathic pulmonary fibrosis.
Genetic variants in the plasminogen activator inhibitor-1 gene are associated with an increased risk of radiation pneumonitis in lung cancer patients.
Hemoptysis and unilateral intra-alveolar hemorrhage complicating intravenous thrombolysis for myocardial infarction.
Irreversible Inhibition of Serine Proteases - Design and In Vivo Activity of Diaryl alpha-Aminophosphonate Derivatives.
Localization of plasminogen activator activity within normal and injured lungs by in situ zymography.
Mechanical ventilation affects alveolar fibrinolysis in LPS-induced lung injury.
Monocrotaline-induced pulmonary endothelial dysfunction in rats.
p53- and PAI-1-mediated induction of C-X-C chemokines and CXCR2: Importance in Pulmonary Inflammation due to Cigarette Smoke exposure.
Plasminogen activator inhibitor type-1 deficiency exaggerates LPS-induced acute lung injury through enhancing Toll-like receptor 4 signaling pathway.
Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin.
Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury.
Plasminogen activator inhibitor-1 in cigarette smoke exposure and influenza A virus infection-induced lung injury.
Plasminogen Activator Inhibitor-1 Regulates LPS-Induced TLR4/MD-2 Pathway Activation and Inflammation in Alveolar Macrophages.
Potentiation of endogenous fibrinolysis and rescue from lung ischemia/reperfusion injury in interleukin (IL)-10-reconstituted IL-10 null mice.
Procoagulant and plasminogen activator activities of bronchoalveolar fluid in patients with pulmonary sarcoidosis.
Procollagen-III in serum, plasminogen activation and fibronectin in bronchoalveolar lavage fluid during and following irradiation of human lung.
Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk.
Regulation of lung injury and fibrosis by p53-mediated changes in urokinase and plasminogen activator inhibitor-1.
Role of plasminogen activator inhibitor-1 in methotrexate-induced epithelial-mesenchymal transition in alveolar epithelial A549 cells.
Role of the urokinase-fibrinolytic system in epithelial-mesenchymal transition during lung injury.
Systemic coagulation and fibrinolysis in patients with or at risk for the adult respiratory distress syndrome.
The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system.
The effect of composition, size, and solubility on acute pulmonary injury in rats following exposure to Mexico city ambient particulate matter samples.
The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome.
The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice.
Tissue plasminogen activator attenuates ventilator-induced lung injury in rats.
Treatment of sepsis-induced acquired protein C deficiency reverses Angiotensin-converting enzyme-2 inhibition and decreases pulmonary inflammatory response.
Truncated Plasminogen Activator Inhibitor-1 Protein Protects From Pulmonary Fibrosis Mediated by Irradiation in a Murine Model.
[Role of alveolar macrophage plasminogen activator in the development of endotoxin-induced lung injury]
Lung Neoplasms
A Chimeric Signal Peptide-Galectin-3 Conjugate Induces Glycosylation-Dependent Cancer Cell-Specific Apoptosis.
Activation of tissue plasminogen activator gene transcription by Neovastat, a multifunctional antiangiogenic agent.
An evaluation of tissue polypeptide antigen (TPA) in the two bronchoalveolar lavage fractions of lung cancer patients.
Analysis of expressions of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells.
Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
Characterization of a family of high-molecular-weight plasminogen activators secreted by a lung tumor cell line.
Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?
Clinical usefulness of serum TPA (tissue polypeptide antigen) in postsurgical diagnosis, prognosis and follow-up of lung cancer.
Combined Effect of MTHFR C677T and PAI-1 4G/5G Polymorphisms on the Risk of Venous Thromboembolism in Chinese Lung Cancer Patients.
Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases.
Content and characterization of plasminogen activators in human lung tumors and normal lung tissue.
Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-malignant diseases.
Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-small cell lung cancer.
Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer.
Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells.
Deficiency of antiproliferative family protein Ana correlates with development of lung adenocarcinoma.
Detection of cathepsin B, plasminogen activators and plasminogen activator inhibitor in human non-small lung cancer cell lines.
Diagnostic usefulness of 5 tumor-markers in patients with primary lung-cancer.
Differential effect of retinoic acid on growth regulation by phorbol ester in human cancer cell lines.
Differential expression of TIS21 and TIS1 genes in the various organs of Balb/c mice, thymic carcinoma tissues and human cancer cell lines.
Differential expression profiling of transcripts of IDH1, CEA, Cyfra21-1, and TPA in stage IIIa non-small cell lung cancer (NSCLC) of smokers and non-smokers cases with air quality index.
Differential regulation of protease and extracellular matrix protein expression by transforming growth factor-beta 1 in non-small cell lung cancer cells and normal human bronchial epithelial cells.
Disease monitoring by the tumour markers cyfra 21.1 and TPA in patients with non-small cell lung cancer.
Early diagnosis of lung cancer by detection of tumor liberated protein.
Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC).
Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
Genetic variants in the plasminogen activator inhibitor-1 gene are associated with an increased risk of radiation pneumonitis in lung cancer patients.
Genetic variations in TGF?1, tPA, and ACE and radiation-induced thoracic toxicities in patients with non-small-cell lung cancer.
HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells.
Hybrid approach in patients with recurrent brachial artery embolism: adjunctive tissue plasminogen activator infusion following embolectomy.
Hypoxia enhances the expression of plasminogen activator inhibitor-1 in human lung cancer cells, EBC-1.
Immunological analysis of plasminogen activators from cultured human cancer cells.
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Lung cancer cells often express high levels of protein kinase C activity.
Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
Monitoring lung cancer with tissue polypeptide antigen: an ancillary, profitable serum test to evaluate treatment response and posttreatment disease status.
Multiple tumour markers for diagnosis, management and follow-up of potentially resectable lung cancer.
Neuron-specific enolase in the diagnosis and therapy monitoring of lung cancer: a comparison with CEA, TPA, ferritin and calcitonin.
Plasma carcinoembryonic antigen and tissue polypeptide antigen levels in lung cancer: correlation with cell types and stage.
Plasminogen Activator Inhibitor 1 Promotes Immunosuppression in Human Non-Small Cell Lung Cancers by Enhancing TGF-?1 Expression in Macrophage.
Plasminogen Activator Inhibitor Type 1 (PAI-1) A15T Gene Polymorphism Is Associated with Prognosis in Patients with EGFR Mutation Positive Pulmonary Adenocarcinoma.
Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis.
Plasminogen activator inhibitor-1 and susceptibility to lung cancer: a population genetics perspective.
Plasminogen activator inhibitor-1 enhances radioresistance and aggressiveness of non-small cell lung cancer cells.
Plasminogen activator inhibitor-1 gene promoter 4G/5G polymorphism and risks of peripherally inserted central catheter-related venous thrombosis in patients with lung cancer: a prospective cohort study.
Plasminogen Activator Inhibitor-2 Plays a Leading Prognostic Role among Protease Families in Non-Small Cell Lung Cancer.
Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Posttranscriptional regulation of plasminogen activator inhibitor-1 in human lung carcinoma cells in vitro.
Preliminary study on auxiliary value of serum basic fetoprotein in diagnosing lung cancer.
Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer.
Progesterone receptor membrane component 1 (Pgrmc1): a heme-1 domain protein that promotes tumorigenesis and is inhibited by a small molecule.
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Prognostic value of the tissue polypeptide antigen in lung cancer.
Regulation of the plasminogen activator system in non-small cell lung cancer cell lines by growth factors EGF, TGF-alpha and TGF-beta.
Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer.
Serum and tissue levels of CEA, TPA, CA 125 and CA 15.3 in patients with lung cancer.
Serum markers casa, cea, cyfra-21-1, msa, nse, tpa and tps in lung-cancer.
Short-term and long-term monitoring of the serum level of TPA after radical resection of gastrointestinal or lung cancer.
Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis.
Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells.
The clinical significance of serum adipocytokines level in patients with lung cancer.
The concentrations of five tumor markers in both BAL fractions in lung cancer patients in relation to cigarette smoking.
The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer. Diagnostic yield and comparison with conventional staging methods.
The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma.
Tumor markers and lung cancer: correlation between serum and bronchial secretion levels of CEA, TPA, CanAg CA-50, NSE and ferritin.
Tumor markers in detection of lung cancer.
Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
Usefulness of tissue polypeptide antigen in staging, monitoring, and prognosis of lung cancer.
Values and limits of combined use of 4 tumor markers (CEA, TPA, NSE and SCC) in un-treated patients with lung cancer.
[Advantages and limitations of combined assays of 4 serum markers in various types of malignant neoplasms]
[An immunoradiometric assay of the serum TPA from patients with primary lung cancer and a comparison with the conventional double antibody method]
[Auxiliary value of TPA in diagnosing neoplastic diseases]
[CEA and TPA in serum and pleural exudates in patients with pulmonary neoplasms: preliminary results]
[Clinical evaluation of combination assay of tumor markers in primary lung cancer patients]
[Clinical relevance of tumor markers]
[Clinical significance of CEA levels in lung cancer]
[Clinical significance of tumor markers in the diagnosis of lung cancer.]
[Diagnositic values of combined determination of carbohydrate antigen and tissue polypeptide antigen and neuron-specific enolase and carcinoembryonic antigen in the malignant pleural effusion.]
[Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma]
[Distribution and prognostic value of CEA and TPA in cancer of the lung]
[Measurement of serum tissue polypeptide antigen (TPA) in patients with malignant tumor using prolifigen TPA-M "Daiichi" kit]
[Plasminogen activator inhibitor type 1 (PAI-1) in blood and tissue extracts of patients with non-small cell lung cancer]
[Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer]
[The application of spiral CT angiography in cancerous invasion of central pulmonary artery in lung cancer.]
[The diagnostic value of serum TPA and CEA in lung cancer]
[The diagnostic values of CA242 combining other tumor markers for lung cancer]
[The evaluation of the newly produced assay kit for the cytokeratin fragment, "ball ELSA CYFRA21-1"]
[Tissue polypeptide antigen in serum and tissue in patients with lung cancer]
[Trials of the diagnostic potentials of TPA in tumorous and nontumorous lung pathologies in 303 cases]
[Tumor markers in bronchus cancer]
[Tumor markers TPA and Cyfra 21.1 in patients with non-small cell lung cancer after surgery and chemotherapy]
[Update regarding the role of biomarkers in early diagnosis of non-small cell bronchopulmonary cancer].
Lupus Erythematosus, Systemic
4G/5G plasminogen activator inhibitor-1 and -308 A/G tumor necrosis factor-? promoter gene polymorphisms in Argentinean lupus patients: focus on lupus nephritis.
Antibodies to fibrin-bound tissue-type plasminogen activator in systemic lupus erythematosus are associated with Raynaud's phenomenon and thrombosis.
Association between plasminogen activator inhibitor?1 (PAI-1) 4G/5G polymorphism and circulating PAI-1 level in systemic lupus erythematosus and rheumatoid arthritis : A meta-analysis.
Association between the PAI-1 4G/5G Gene Polymorphism and the Risk of Systemic Lupus Erythematosus/Lupus Nephritis.
Clinical significance of the venous occlusion test on systemic lupus erythematosus patients with a focus on changes in blood levels of tissue plasminogen activator, von Willebrand factor antigen, and thrombomodulin.
Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome.
Plasminogen activator inhibitor-1 is associated with impaired endothelial function in women with systemic lupus erythematosus.
Plasminogen activator inhibitor-1 polymorphisms (-844 G>A and HindIII C>G) in systemic lupus erythematosus: association with clinical variables.
Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7.
Serum antibodies to distinct epitopes of the tissue-type plasminogen activator (t-PA) in patients with systemic lupus erythematosus.
Successful intravenous thrombolysis in a patient with antiphospholipid syndrome, acute ischemic stroke and severe thrombocytopenia.
The prevalence and clinical significance of autoantibodies to plasminogen activator inhibitor 1 in systemic lupus erythematosus.
The role of hypercoagulability in the development of osteonecrosis of the femoral head.
The secretion of the third component of complement (C3) by human polymorphonuclear leucocytes from both normal and systemic lupus erythematosus cases.
Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis.
[Prognostic value of allelic variants affecting the hemostatic system in the development of antiphospholipid syndrome and kidney lesion in patients with systemic lupus erythematosus].
Lupus Nephritis
4G/5G plasminogen activator inhibitor-1 and -308 A/G tumor necrosis factor-? promoter gene polymorphisms in Argentinean lupus patients: focus on lupus nephritis.
Close relationship of plasminogen activator inhibitor-1 4G/5G polymorphism and progression of IgA nephropathy.
Epistatic effect of plasminogen activator inhibitor 1 and beta-fibrinogen genes on risk of glomerular microthrombosis in lupus nephritis: interaction with environmental/clinical factors.
Expression of type 1 plasminogen activator inhibitor in renal tissue in murine lupus nephritis.
Plasminogen activator inhibitor-1 gene polymorphism 4G/4G genotype and lupus nephritis in Chinese patients.
[Genetic variations in plasminogen activator inhibitor-1 gene and beta fibrinogen gene associated with glomerular microthrombosis in lupus nephritis and the gene dosage effect]
[Tissue-type plasminogen activator in patients with lupus nephritis]
Lupus Vasculitis, Central Nervous System
Relationship between elevated cerebrospinal fluid levels of plasminogen activator inhibitor 1 and neuronal destruction in patients with neuropsychiatric systemic lupus erythematosus.
Lymphatic Metastasis
Both TPA and SCC-Ag levels are prognostic even in high-risk stage Ib-IIa cervical carcinoma as determined by a stratification analysis.
Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.
Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer.
Functional evaluation of plasmin formation in primary breast cancer.
Inverse correlation between mRNA expression of plasminogen activator inhibitor-2 and lymph node metastasis in human breast cancer.
Levels of tissue polypeptide antigen in serum and the progression of gastric cancer.
Overexpression of Plasminogen Activator Inhibitor-1 in Advanced Gastric Cancer with Aggressive Lymph Node Metastasis.
Plasminogen Activation System in Rectal Adenocarcinoma.
Pre-operative serum levels of tissue polypeptide antigen in patients with gastric cancer.
Proteolytic enzymes and plasminogen activator in melanoma.
Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer.
Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis.
Urinary-type plasminogen activator receptor (uPAR) modulates oral cancer cell behavior with alteration in p130cas.
[Diagnostic value of tissue polypeptide antigen in serum of larynx cancer patients]
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
Lymphoma
Chromosomal locations of human tissue plasminogen activator and urokinase genes.
Conversion of high grade lymphoma tumor cell line to intermediate grade with TPA and bryostatin 1 as determined by polypeptide analysis on 2D gel electrophoresis.
De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
Different responses elicited in vitro by antibodies to IgM and IgD in cells from a surface IgM + D-positive human follicular lymphoma.
Differential cytotoxicity of tumour promoter TPA for EBV-negative human lymphoma cell lines and their EBV-converted sublines.
Down-regulation of urokinase secretion from a human lymphoma cell line RC-K8 by dexamethasone without inducing plasminogen activator inhibitors.
Establishment of a new human lymphoma line that secretes plasminogen activator.
Evaluation of carcinoembryonic antigen, tissue polypeptide antigen, placental alkaline phosphatase, and modified nucleosides as biological markers in malignant lymphomas.
Flow cytometric analysis of the phenotypic changes in tumour cell lines following TPA induction.
Fumagillin, a potent angiogenesis inhibitor, induces Kaposi sarcoma-associated herpesvirus replication in primary effusion lymphoma cells.
Functional studies on B-cell hybridomas with B-cell surface antigens. III. Differentiative response to phorbol esters.
Increased mononuclear cell tissue factor and type-2 plasminogen activator inhibitor and reduced plasma fibrinolytic capacity in children with lymphoma.
Induction of surface marker changes and monoclonal idiotypic immunoglobulin secretion in lymphoma/leukemia cells: comparative study with interleukin-1, interleukin-2, interleukin-4, 8-bromo-guanosine, pokeweed mitogen, and tetradecanoyl phorbol-13-acetate.
Induction of the lytic viral cycle in Epstein Barr virus carrying Burkitt lymphoma lines is accompanied by increased expression of major histocompatibility complex molecules.
Intracellular Epstein-Barr virus DNA is methylated in and around the EcoRI-J fragment in both producer and nonproducer cell lines.
Involvement of both heparanase and plasminogen activator in lymphoma cell-mediated degradation of heparan sulfate in the subendothelial extracellular matrix.
Lymphoma protein kinase C is associated with the transmembrane glycoprotein, GP85, and may function in GP85-ankyrin binding.
Monoclonal human B lymphoma cells respond to DNA synthesis to anti-immunoglobulins in the presence of the tumour promotor TPA.
Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells.
Plasminogen activator inhibitor-2 in patients with monocytic leukemia.
Prolactin stimulation of ornithine decarboxylase and mitogenesis in Nb2 node lymphoma cells: the role of protein kinase C and calcium mobilization.
Right atrial thrombosis associated with central venous catheters in children with cancer.
Somatic cell hybrids between human lymphoma and human myeloid leukemia cells. I. Induction of resident viral genome transcription and viral antigen formation by IUDR and TPA.
Synergistic effect of Epstein-Barr virus and tumor promoters on induction of lymphoma and carcinoma in nude mice.
The tumour promoter TPA does not affect mutation to ouabain resistance in L5178Y mouse lymphoma cells.
TPA stimulation culture for improved detection of t(11;14)(q13;q32) in mantle cell lymphoma.
Transplacental carcinogenicity of cisplatin: initiation of skin tumors and induction of other preneoplastic and neoplastic lesions in SENCAR mice.
Triggering of neoplastic B cells via surface IgM and the cell surface antigens CD20 and CDw40. Responses differ from normal blood B cells and are restricted to certain morphologic subsets.
Tumour-promoting phorbol esters inhibit DNA synthesis and enhance virus-induced interferon production in a human lymphoma cell line.
Use of E mu-PIM-1 transgenic mice short-term in vivo carcinogenicity testing: lymphoma induction by benzo[a]pyrene, but not by TPA.
[Effect of cyclic AMP and phorbol ester on PAI-2 synthesis in a leukemic cell line PL-21 and on u-PA secretion in a pre-B cell lymphoma cell line RC-K8]
Lymphoma, B-Cell
Ecto-5'-nucleotidase. II. Effect of 12-O-tetradecanoylphorbol 13-acetate on the expression of enzyme in normal and neoplastic B-cell lines.
Induction of maturation in different types of B-cell lymphomas in vitro with TPA and antibodies to surface immunoglobulin.
Lymphoma, Large B-Cell, Diffuse
A plasminogen activator inhibitor (PAI-2) circulates in two molecular forms during pregnancy.
Characterization of a new human lymphoma cell line (RC-K8) with t(11;14) chromosome abnormality.
Differential expression of TIS21 and TIS1 genes in the various organs of Balb/c mice, thymic carcinoma tissues and human cancer cell lines.
Expression of major histocompatibility class I genes in differentiating leukemic cells is temporally related to activation of c-fos proto-oncogene.
Phorbol ester-induced differentiation of chronic lymphocytic leukaemia cells.
Plasminogen activator inhibitor 2: regulation of gene transcription during phorbol ester-mediated differentiation of U-937 human histiocytic lymphoma cells.
Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937.
Lymphoma, Mantle-Cell
TPA stimulation culture for improved detection of t(11;14)(q13;q32) in mantle cell lymphoma.
Lymphoma, Non-Hodgkin
Induction of plasmacytoid and hairy cell features by phorbol esters (TPA) in B-lymphoma cells: attempted correlation with disease activity.
Phorbol ester induction of plasmacytoid and hairy cell leukemia features in B-type lymphocytic leukemias: the relation to B-cell differentiation and maturation.
Phorbol esters and hairy cell leukemia: effects on cell morphology and surface membrane features and comparison with other B cell leukemias.
Serum tissue polypeptide antigen (TPA) in thyroid cancer.
Tpa-induced maturation in secretory human B-leukemic cells in vitro: DNA synthesis, antigenic changes, and immunoglobulin secretion.
Lymphoma, Primary Effusion
De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
Fumagillin, a potent angiogenesis inhibitor, induces Kaposi sarcoma-associated herpesvirus replication in primary effusion lymphoma cells.
Lymphoma, T-Cell
Synergistic effect of Epstein-Barr virus and tumor promoters on induction of lymphoma and carcinoma in nude mice.
Lymphoproliferative Disorders
[Protein kinase activity in lymphoid cells in various forms of lymphoproliferative disorders]
Macroglossia
Lingual angioedema with macroglossia during the treatment of acute ischemic stroke with alteplase.
Macrophage Activation Syndrome
The multifaceted role of plasminogen in inflammation.
Macular Degeneration
Can intravitreal tissue plasminogen activator and SF6 gas facilitate management of macular degeneration with photodynamic therapy?
Combined Administration of Preoperative Intravitreal and Intraoperative Subretinal Recombinant Tissue Plasminogen Activator in Acute Hemorrhagic Age-related Macular Degeneration.
Comparison between different techniques for treatment of submacular haemorrhage due to Age-Related Macular Degeneration.
Comparison of subretinal versus intravitreal injection of recombinant tissue plasminogen activator with gas for submacular hemorrhage secondary to wet age-related macular degeneration: treatment outcomes and brief literature review.
Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
Compatibility of Recombinant Tissue Plasminogen Activator and Bevacizumab Co-Applied for Neovascular Age-Related Macular Degeneration With Submacular Hemorrhage.
Cytokine and Chemokine Concentration in the Tear of Patients with Age-Related Cataract.
Displacement of submacular hemorrhage associated with age-related macular degeneration using vitrectomy and submacular tPA injection followed by intravitreal ranibizumab.
Displacement of submacular hemorrhages in age-related macular degeneration with subretinal tissue plasminogen activator and air.
Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials.
Effects of intravitreal gas with or without tissue plasminogen activator on submacular haemorrhage in age-related macular degeneration.
Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage.
Flattening of retinal pigment epithelial detachments after pneumatic displacement of submacular hemorrhages secondary to age-related macular degeneration.
Hemorrhagic age-related macular degeneration managed with vitrectomy, subretinal injection of tissue plasminogen activator, gas tamponade, and upright positioning.
In-patient management and treatment satisfaction after intravitreous plasminogen activator injection.
Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization.
Intraocular hemorrhage after systemic thrombolytic therapy in a patient with exudative macular degeneration.
Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage.
Intravitreal Expansile Gas and Bevacizumab Injection for Submacular Hemorrhage Due to Neovascular Age-related Macular Degeneration.
Intravitreal injection of tissue plasminogen activator and gas bubble for treatment of subretinal hemorrhage in ARMD.
Intravitreal injection of tissue plasminogen activator and gas in subretinal hemorrhage caused by age-related macular degeneration.
Intravitreal Recombinant Tissue Plasminogen Activator and Sulphur Hexafluoride gas for Submacular Hemorrhage Displacement in Age-Related Macular Degeneration: Looking Behind the Blood.
Intravitreal recombinant tissue plasminogen activator without and with additional gas injection in patients with submacular haemorrhage associated with age-related macular degeneration.
Intravitreal tissue plasminogen activator, perfluoropropane (c3f8), and ranibizumab or photodynamic therapy for submacular hemorrhage secondary to wet age-related macular degeneration.
Intravitreal tPA Injection and Pneumatic Displacement for Submacular Hemorrhage in a 10-Year-Old Child.
INTRAVITREAL VERSUS SUBRETINAL ADMINISTRATION OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR COMBINED WITH GAS FOR ACUTE SUBMACULAR HEMORRHAGES DUE TO AGE-RELATED MACULAR DEGENERATION: An Exploratory Prospective Study.
INTRAVITREOUS INJECTION OF BEVACIZUMAB, TISSUE PLASMINOGEN ACTIVATOR, AND GAS IN THE TREATMENT OF SUBMACULAR HEMORRHAGE IN AGE-RELATED MACULAR DEGENERATION.
Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions.
Intravitreous recombinant tissue plasminogen activator and gas to treat submacular hemorrhage in age-related macular degeneration.
Literature review of recombinant tissue plasminogen activator used for recent-onset submacular hemorrhage displacement in age-related macular degeneration.
Little effect of tissue plasminogen activator in subretinal surgery for acute hemorrhage in age-related macular degeneration.
Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
Long-term visual outcome and its predictive factors following treatment of acute submacular hemorrhage with intravitreous injection of tissue plasminogen factor and gas.
Management of acute submacular hemorrhage using intravitreal injection of tissue plasminogen activator and gas: A case series.
Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas.
Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration.
Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration.
Modified Approach in Management of Submacular Hemorrhage Secondary to Wet Age-Related Macular Degeneration.
Paracentral Acute Middle Maculopathy as a Presenting Sign of CRAO in Sickle Cell Disease Treated with Tissue Plasminogen Activator.
Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration.
Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator.
Preoperative use of tissue plasminogen activator for large submacular hemorrhage.
Quantitative effect of intravitreally injected tissue plasminogen activator and gas on subretinal hemorrhage.
Recombinant tissue plasminogen activator, vitrectomy, and gas for recent submacular hemorrhage displacement due to retinal macroaneurysm.
Risk factors for breakthrough vitreous hemorrhage after intravitreal tissue plasminogen activator and gas injection for submacular hemorrhage associated with age related macular degeneration.
Sequential tissue plasminogen activator, pneumatic displacement, and anti-VEGF treatment for submacular hemorrhage.
Silicone oil-induced displacement of subretinal hemorrhage in age-related macular degeneration.
Submacular combination treatment for management of acute, massive submacular hemorrhage in age-related macular degeneration.
Submacular hemorrhage secondary to age-related macular degeneration managed with vitrectomy, subretinal injection of tissue plasminogen activator, hemorrhage displacement with liquid perfluorocarbon, gas tamponade, and face-down positioning.
Subretinal alteplase injections in massive subretinal hemorrhage due to age-related macular degeneration: A case report series.
Subretinal coapplication of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular haemorrhage.
Subretinal Coapplication of Tissue Plasminogen Activator and Bevacizumab with Concurrent Pneumatic Displacement for Submacular Hemorrhages Secondary to Neovascular Age-Related Macular Degeneration.
Subretinal Injection of Recombinant Tissue Plasminogen Activator and Gas Tamponade to Displace Acute Submacular Haemorrhages Secondary to Age-Related Macular Degeneration.
Subretinal recombinant tissue plasminogen activator and pneumatic displacement for the management of subretinal hemorrhage occurring after anti-VEGF injections for wet AMD.
Subretinal recombinant tissue plasminogen activator injection and pneumatic displacement of thick submacular hemorrhage in Age-Related macular degeneration.
Subretinal tissue plasminogen activator injection to treat submacular haemorrhage during age-related macular degeneration.
Successful treatment of acute subretinal hemorrhage in age-related macular degeneration by combined intravitreal injection of recombinant tissue plasminogen activator and gas.
The effect of initial intravitreal tissue plasminogen activator and gas injection on vision improvement in patients with submacular haemorrhage associated with age-related macular degeneration.
The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator.
The role of pigment epithelial detachment in AMD with submacular hemorrhage treated with vitrectomy and subretinal co-application of rtPA and anti-VEGF.
Tissue plasminogen activator (tPA) in the management of predominantly hemorrhagic age-related macular degeneration, milligram/milliliter or microgram/milliliter?
TISSUE PLASMINOGEN ACTIVATOR FOR SUBFOVEAL HEMORRHAGE DUE TO AGE-RELATED MACULAR DEGENERATION: Comparison of 3 Treatment Modalities.
Tissue plasminogen activator irrigation to facilitate removal of subretinal hemorrhage during vitrectomy.
Tissue plasminogen activator plus gas injection in patients with subretinal hemorrhage caused by age-related macular degeneration: predictive variables for visual outcome.
Tissue plasminogen activator-assisted surgical excision of subfoveal choroidal neovascularization in age-related macular degeneration: a randomized, double-masked trial.
Tissue plasminogen activator-assisted vitrectomy for submacular hemorrhage due to age-related macular degeneration.
Transconjunctival sutureless vitrectomy with tissue plasminogen activator, gas and intravitreal bevacizumab in the management of predominantly hemorrhagic age-related macular degeneration.
Treatment of hematomas in age related macular degeneration by vitrectomy and subretinal injection of r-tPA: Preliminary results.
Treatment of submacular haemorrhage in patients with neovascular age related macular degeneration.
Treatment of submacular hemorrhage with low-dose intravitreal tissue plasminogen activator injection and pneumatic displacement.
Treatment of submacular hemorrhage with tissue plasminogen activator and pneumatic displacement in age-related macular degeneration.
Vitrectomy and subretinal injection of tissue plasminogen activator for large submacular hemorrhage secondary to AMD.
VITRECTOMY WITH SUBRETINAL TISSUE PLASMINOGEN ACTIVATOR AND GAS TAMPONADE FOR SUBFOVEAL HEMORRHAGE: Prognostic Factors and Clinical Outcomes.
Vitrectomy with subretinal tissue plasminogen activator and ranibizumab for submacular haemorrhages secondary to age-related macular degeneration: retrospective case series of 45 consecutive cases.
[Clinical results of intravitreal administration of tissue-type plasminogen activator (tPA) and gas for removal of subretinal hemorrhage in senile macular degeneration]
[Combination of Intravitreal rTPA, gas and ranibizumab for extensive subfoveal haemorrhages secondary to neovascular age-related macular degeneration]
[Intravitreal injection of rt-PA and gas in the management of minor submacular haemorrhages secondary to age-related macular degeneration]
[Pars plana vitrectomy, subretinal injection of recombinant tissue plasminogen activator and fluid-gas exchange in the management of massive submacular hemorrhages secondary to age-related macular degeneration]
[Stability of postoperative visual acuity after rt-PA -SF6-treatment of submacular hemorrhage in age-related macular degeneration]
[Subretinal hematoma in age-related macular degeneration: treatment with intravitreal injection of tPA and gas]
[Traumatic submacular hemorrhage treated with rt-PA and SF6]
[Treatment of hematomas in age related macular degeneration by vitrectomy and subretinal injection of r-tPA: Preliminary results (French translation of the article)].
Macular Edema
Intravitreal tissue plasminogen activator to treat macular edema associated with branch retinal vein occlusion.
Intravitreal tissue plasminogen activator to treat refractory diabetic macular edema by induction of posterior vitreous detachment.
Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion.
Management of macular edema in branch retinal vein occlusion with sheathotomy and recombinant tissue plasminogen activator.
Photoreceptor status after resolved macular edema in branch retinal vein occlusion treated with tissue plasminogen activator.
Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal vein occlusion.
Surgical treatments of central retinal vein occlusion.
THREE TREATMENTS FOR MACULAR EDEMA BECAUSE OF BRANCH RETINAL VEIN OCCLUSION: Intravitreous Bevacizumab or Tissue Plasminogen Activator, and Vitrectomy.
Treatment of central retinal vein occlusion by vitrectomy with lysis of vitreopapillary and epipapillary adhesions, subretinal peripapillary tissue plasminogen activator injection, and photocoagulation.
[Intravitreal tissue plasminogen activator for treatment of central retinal vein occlusion associated with diabetic retinopathy]
Malaria
Gateways to clinical trials.
The use of particle concentration fluorescence immunoassay technology for the analysis of rDNA products.
Malformations of Cortical Development
Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies.
Malnutrition
Impact of nutritional recovery with linear growth on the concentrations of adipokines in undernourished children living in Brazilian slums.
Thrombosis and occlusion of vascular access in hemodialyzed patients.
Malocclusion
Effects of Palatal Expansion with Torque Activation using a Transpalatal Arch: A Preliminary Single-Blind Randomized Clinical Trial.
[A study on the combination of Nance arch and TPA in the use of straight-wire arch orthodontic treatment].
[The effects of combined reverse Nance and TPA on reinforcement of anchorage]
Mania
Combined serum levels of multiple proteins in tPA-BDNF pathway may aid the diagnosis of five mental disorders.
Peripheral blood mRNA expressions of stress biomarkers in manic episode and subsequent remission.
Massive Hepatic Necrosis
Clinical evaluation of tissue plasminogen activator (t-PA) levels in patients with liver diseases.
[Qualitative analysis of tissue plasminogen activator in plasma obtained from various liver diseases by gel filtration and affinity chromatography]
[The clinical significance of plasma tissue plasminogen activator (t-PA) levels in severe acute or fulminant hepatitis]
Mastitis
Effect of mastitis on plasminogen activator activity of milk somatic cells.
Genetic analysis of Streptococcus uberis plasminogen activators.
Staphylococcus aureus stimulates urokinase-type plasminogen activator expression by bovine mammary cells.
Vaccines and diagnostic methods for bovine mastitis: fact and fiction.
Mastocytoma
De Novo synthesis and posttranslational processing of L-histidine decarboxylase in mice.
Enhanced expression of the mouse L-histidine decarboxylase gene with a combination of dexamethasone and 12-O-tetradecanoylphorbol-13-acetate.
Plasminogen activator production from murine mastocytoma cells. Dissociation of plasminogen activator and histamine production by sodium butyrate.
Plasminogen activator release from cultured murine mast cells.
Synergistic effects of cyclic AMP and Ca2+ ionophore A23187 on de novo synthesis of histidine decarboxylase in mastocytoma P-815 cells.
The effect of tranexamic acid on growth and spread of an experimental tumor model.
Measles
Applications of cell culture for the improvement of human health.
Early signal transduction in measles virus-infected lymphocytes is unaltered, but second messengers activate virus replication.
Melanoma
12-O-tetradecanoylphorbol-13-acetate induces transient cell cycle arrest in G1 and G2 in metastatic melanoma cells: inhibition of phosphorylation of p34cdc2.
A collaborative study to establish the 3rd International Standard for tissue plasminogen activator.
A comparison of the plasminogen activator activity units of urinary-type plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA).
A family of novel, acidic N-glycans in Bowes melanoma tissue plasminogen activator have L2/HNK-1-bearing antennae, many with sulfation of the fucosylated chitobiose core.
A new culture system for the cultivation of mammalian cells for the production of several biologically active substances.
A novel regulatory sequence affecting the constitutive expression of tissue plasminogen activator (tPA) gene in human melanoma (Bowes) cells.
A novel sialylated N-acetylgalactosamine-containing oligosaccharide is the major complex-type structure present in Bowes melanoma tissue plasminogen activator.
A role for platelets and thrombin in the juvenile stroke of two siblings with defective thrombin-adsorbing capacity of fibrin(ogen).
A sensitive assay for tissue plasminogen activator activity in plasma, using adsorption on lysine-sepharose.
Active human tissue plasminogen activator secreted from insect cells using a baculovirus vector.
Active transforming growth factor-beta in human melanoma cell lines: no evidence for plasmin-related activation of latent TGF-beta.
Alteplase.
Alterations in endothelial cell proteinase and inhibitor polarized secretion following treatment with interleukin-1, phorbol ester, and human melanoma cell conditioned medium.
Angiogenic capacity and lung-colonizing potential in vivo is increased in weakly metastatic B16F1 cells and decreased in highly metastatic BL6 cells by phorbol esters.
Angiostatin generating capacity and anti-tumour effects of D-penicillamine and plasminogen activators.
Angiostatin generation by human tumor cell lines: involvement of plasminogen activators.
Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation.
Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model.
Beneficial effects of tissue-type plasminogen activator in acute myocardial ischemia in cats.
Bimodal relationship between invasion of the amniotic membrane and plasminogen activator activity.
Binding of tissue plasminogen activator to human aortic endothelial cells.
Binding of tissue-type plasminogen activator to human melanoma cells.
Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.
Characterisation of epitopes on human tissue plasminogen activator recognised by a group of monoclonal antibodies.
Characterization of urokinase-type plasminogen activator of rat decidual tissue.
Clearance of a novel recombinant tissue plasminogen activator in rabbits.
Clinical results of immunoscintigraphy in a variety of malignant tumors with special reference to immunohistochemistry.
Co-cultivation of tumorigenic mouse melanoma cells with cells of a non-tumorigenic subclone inhibits plasminogen activator expression by the melanoma cells.
Comparison of calmodulin gene expression in human neonatal melanocytes and metastatic melanoma cell lines.
Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue.
Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro.
Construction of a tissue plasminogen activator gene having unique restriction sites to facilitate domain manipulation: a model for the analysis of multi-domain proteins.
Correlated suppression by 5-bromodeoxyuridine of tumorigenicity and plasminogen activator in mouse melanoma cells.
Correlation of the production of plasminogen activator with tumor metastasis in B16 mouse melanoma cell lines.
Cultivation of Bowes melanoma cells in the Opticell system: influence of the addition of protein supplements to the serum-free medium on the production of plasminogen activator.
De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation.
Decreased tissue plasminogen activator and increased plasminogen activator inhibitors and increased activator protein-1 and specific promoter 1 are associated with inhibition of invasion in human A375 melanoma deprived of tyrosine and phenylalanine.
Deletion of specific protein kinase C subspecies in human melanoma cells.
Determination of plasminogen activator activities in normal and pathological human tears. The significance of tear plasminogen activators in the inflammatory and traumatic lesions of the cornea and the conjunctiva.
Determination of tissue plasminogen activator by an enzyme-immunoassay method.
Determination of tissue plasminogen activator in plasma samples by means of a radioimmunoassay.
Differences between uterine and melanoma forms of tissue plasminogen activator.
Different effects of GPR120 and GPR40 on cellular functions stimulated by 12-O-tetradecanoylphorbol-13-acetate in melanoma cells.
Different inhibition of one and two chain tissue plasminogen activator by a placental inhibitor studied with two tripeptide-p-nitroanilide substrates.
Differential fibrinolytic properties of the recombinant plasminogen activator BM 06.022 in human plasma and blood clot systems in vitro.
Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor.
Differential proteolysis and evidence for a residue exchange in tissue plasminogen activator suggest possible association between two types of protein microheterogeneity.
Differential regulation of gelatinase B and tissue-type plasminogen activator expression in human Bowes melanoma cells.
Dissociation of plasminogen activator from the transformed phenotype in a 5-bromodeoxyuridine dependent mutant of Syrian hamster melanoma cells.
Diversity of melanoma plasma membrane proteinases: inhibition of collagenolytic and cytolytic activities by minocycline.
Dose-ranging study with a new two-chain rt-PA in patients with acute myocardial infarction: a multicenter trial.
Down-regulation of tyrosinase mRNA levels in melanoma cells by tumor promoters and by insulin.
Dual regulation of phospholipase D1 by protein kinase C alpha in vivo.
Effect of monensin on secretion of t-PA from melanoma (Bowes).
Effect of Na+, K+ ion concentration on the production of plasminogen activator from a melanoma cell line.
Effect of phorbol ester tumor promoters on the expression of melanogenesis in B-16 melanoma cells.
Effect of retinoic acid on plasminogen activator expression in human melanoma cells.
Effect of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate and its nonpromoting analogue 4-O-methyl-TPA on dorsal dermal melanocytes of the Syrian golden hamster (Mesocricetus auratus).
Effect of transforming growth factor-beta on plasminogen activator production of cultured human uveal melanoma cells.
Effect of viscous macromolecules on peritoneal plasminogen activator activity: a potential mechanism for their ability to reduce postoperative adhesion formation.
Effects of 12-O-tetradecanoylphorbol 13-acetate on the production of mRNAs for human tissue-type plasminogen activator.
Effects of 12-O-tetradecanoylphorbol-13-acetate on the differentiation of avian melanocytes.
Effects of 5-bromodeoxyuridine on tumorigenicity, immunogenicity, virus production, plasminogen activator, and melanogenesis of mouse melanoma cells.
Effects of N-glycosylation on in vitro activity of Bowes melanoma and human colon fibroblast derived tissue plasminogen activator.
Effects of serum-free medium on the cell growth of melanoma and the secretion of plasminogen activator.
Effects of teleocidin and the phorbol ester tumor promoters on cell transformation, differentiation, and phospholipid metabolism.
Endogenous gene and amplifiable cDNA construct both produce unstable t-PA mRNA in Bowes melanoma cells.
Enhanced synthesis of tumor necrosis factor-inducible proteins, plasminogen activator inhibitor-2, manganese superoxide dismutase, and protein 28/5.6, is selectively triggered by the 55-kDa tumor necrosis factor receptor in human melanoma cells.
Estradiol preferentially enhances extracellular tissue plasminogen activators of MCF-7 breast cancer cells.
Estrogen regulation of tissue plasminogen activator in a human melanoma cell line.
Ethinylestradiol and d-norgestrel regulation of plasminogen activator in a human melanoma cell line.
Evaluation of epithelial tissue plasminogen activator as a thrombolytic agent in a rabbit model of venous thrombosis.
Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines.
Expression of active human uterine tissue plasminogen activator in yeast.
Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
Functional properties of carbohydrate-depleted tissue plasminogen activator.
Functional role of MIA in melanocytes and early development of melanoma.
Gangliosides of normal and neoplastic human melanocytes.
Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro.
Glycosylation at Asn-184 inhibits the conversion of single-chain to two-chain tissue-type plasminogen activator by plasmin.
Growth inhibition of human melanoma-derived cells by 12-O-tetradecanoyl phorbol 13-acetate.
Growth inhibition of vascular smooth muscle cells derived from urokinase receptor (u-PAR)-deficient mice in the presence of carcinoma cells.
Growth regulation of human melanocytes: mitogenic factors in extracts of melanoma, astrocytoma, and fibroblast cell lines.
Heterogeneity of human tissue-type plasminogen activator.
Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies.
Human extrinsic plasminogen activator fibrinolytic properties and neutralization in vivo.
Immunohistochemical localisation of tissue plasminogen activator and urokinase in the vessel wall.
Immunological characterization of plasminogen activators in human mixed saliva.
Immunological comparison between human and rat plasminogen activators in blood and the vessel wall.
Immunoradiometric quantification of tissue plasminogen activator secreted by fetal organs. Comparison with urokinase.
Importance of intramolecular interactions in the control of the fibrin affinity and activation of human plasminogen.
In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers.
In vitro differentiation and antigenic changes in human melanoma cell lines.
In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody.
Increased yield of human tissue-type plasminogen activator obtained by means of recombinant DNA technology.
Induction of melanoma in TPras transgenic mice.
Induction of tissue-type plasminogen activator by ionizing radiation in human malignant melanoma cells.
Influence of carbohydrate side chains on activity of tissue-type plasminogen activator.
Inhibition of B16BL6 melanoma invasion by tyrosine and phenylalanine deprivation is associated with decreased secretion of plasminogen activators and increased plasminogen activator inhibitors.
Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model.
Inhibition of the human tissue plasminogen activator in plasma from different species.
Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
Interleukin 1 preferentially stimulates the production of tissue-type plasminogen activator by human articular chondrocytes.
Isolation and characterization of three different carbohydrate chains from melanoma tissue plasminogen activator.
Isolation of an X-ray-responsive element in the promoter region of tissue-type plasminogen activator: potential uses of X-ray-responsive elements for gene therapy.
Isolation, identification and pharmacokinetic properties of human tissue-type plasminogen activator species: possible localisation of a clearance recognition site.
Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator.
Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma.
Large scale, rapid purification of recombinant tissue-type plasminogen activator.
Large-scale purification of human tissue-type plasminogen activator using monoclonal antibodies.
Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex.
Lectin affinity bioassay: an assay method for glycoprotein enzyme.
Malignant mouse melanoma cells do not form tumors when mixed with cells of a non-malignant subclone: relationships between plasminogen activator expression by the tumor cells and the host's immune response.
Matrix plasminogen activator inhibitor. Modulation of the extracellular proteolytic environment.
Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay.
Mechanism of the stimulatory effect of phorbol 12-myristate 13-acetate on cellular production of plasminogen activator.
Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system.
Messenger RNA for human tissue plasminogen activator.
Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
Modification of invasion and differentiation in human melanoma cell clones.
Modulation of growth of melanoma.
Modulation of murine B16F10 melanoma plasminogen activator production by a synthetic peptide derived from the laminin A chain.
Monoclonal antibodies detecting plasminogen activators on the membrane of leukemic lymphoid cells of T-cell origin.
Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification.
Monoclonal antibody to human tissue plasminogen activator.
Neutralization by plasminogen activator inhibitor-1 of mutants of tissue plasminogen activator.
Neutralization of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for a specific inhibitor.
New approaches to thrombolytic therapy.
On the composition and function of the carbohydrate moiety of tissue-type plasminogen activator from human melanoma cells.
Opposite effects of TPA on G1/S transition and on cell size in the low metastatic B16F1 with respect to high metastatic BL6 murine melanoma cells.
Overexpression of Hsp27 in a human melanoma cell line: regulation of E-cadherin, MUC18/MCAM, and plasminogen activator (PA) system.
Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice.
Phorbol ester stimulates the synthesis and phosphorylation of a 48 kDa-intracellular protein in plasminogen activator secreting melanoma cells.
Phorbol ester-induced neutrophilic inflammatory responses selectively promote metastatic spread of melanoma in a TLR4-dependent manner.
PKC-dependent modulation of IkB alpha-NFkB pathway in low metastatic B16F1 murine melanoma cells and in highly metastatic BL6 cells.
Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion.
Plasminogen activation in melanocytic neoplasia.
Plasminogen activator inhibitor type-2 is a major protein induced in human fibroblasts and SK-MEL-109 melanoma cells by tumor necrosis factor.
Plasminogen activator inhibitor-1 regulates infiltration of macrophages into melanoma via phosphorylation of FAK-Tyr?²?.
Plasminogen Activator Inhibitor-1 Secretion by Autophagy Contributes to Melanoma Resistance to Chemotherapy through Tumor Microenvironment Modulation.
Plasminogen activator production by human tumor cells: effect on tumor cell-extracellular matrix interactions.
Plasminogen activators in human malignant melanoma.
Plasminogen activators in nude mice xenotransplanted with human tumorigenic cells.
Plasminogen detection in oocytes and plasminogen activator activities in the porcine oviduct during the estrous cycle.
Polyoma middle T abrogates TPA requirement of murine melanocytes and induces malignant melanoma.
Positive and negative regulation of a tumor necrosis factor response in melanoma cells.
Prevention of microvascular thrombosis with low-dose tissue plasminogen activator.
Production of plasminogen activator in a melanoma cell line.
Production of tissue plasminogen activator (tPA) in two and three dimensionally growing cultures of Bowes melanoma cells.
Production, purification and characterization of the plasminogen activator in teratocarcinoma stem cells induced with sodium butyrate.
Progestogen regulation of tissue plasminogen activator in a human melanoma cell line.
Prognostic significance of proteolytic enzymes in human brain tumors.
Properties of metastasizing and nonmetastasizing human melanoma cells.
Protein kinase C beta expression in melanoma cells and melanocytes: differential expression correlates with biological responses to 12-O-tetradecanoylphorbol 13-acetate.
Proteolytic activation of tissue-type plasminogen activator by the culture media of mouse cancer cells.
Proteolytic enzymes and plasminogen activator in melanoma.
Purification and characterization of a melanoma cell plasminogen activator.
Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.
Purification of an active plasminogen activator inhibitor immunologically related to the endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line.
Purification of human tissue plasminogen activator with Erythrina trypsin inhibitor.
Purification of human tissue-type plasminogen activator in centigram quantities from human melanoma cell culture fluid and its conditioning for use in vivo.
Regulation of expression of MSG1 melanocyte-specific nuclear protein in human melanocytes and melanoma cells.
Regulation of the cell cycle at the G2/M boundary in metastatic melanoma cells by 12-O-tetradecanoyl phorbol-13-acetate (TPA) by blocking p34cdc2 kinase activity.
Release of cell cycle constraints in mouse melanocytes by overexpressed mutant E2F1E132, but not by deletion of p16INK4A or p21WAF1/CIP1.
Retinoic acid-induced inhibition of metastatic melanoma cell lung colonization and adhesion to endothelium and subendothelial extracellular matrix.
Simultaneous microanalysis of N-linked oligosaccharides in a glycoprotein using microbore graphitized carbon column liquid chromatography-mass spectrometry.
Spatial orientation of tissue-type plasminogen activator bound at the melanoma cell surface.
Specificity of antigen assays of plasminogen activator inhibitor in plasma: Innotest PAI-1 immunoassay evaluated.
Spitz naevi may express components of the plasminogen activation system.
Structural determinants of the noncatalytic chain of tissue-type plasminogen activator that modulate its association rate with plasminogen activator inhibitor-1.
Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro.
Suppression of properties associated with malignancy in murine melanoma-melanocyte hybrid cells.
Survival mechanisms induced by 12-O-tetradecanoylphorbol-13-acetate in normal human melanocytes include inhibition of apoptosis and increased Bcl-2 expression.
Synthesis and refolding of human tissue-type plasminogen activator in Bacillus subtilis.
TGF-beta inhibits human cutaneous melanoma cell migration and invasion through regulation of the plasminogen activator system.
The active fraction of plasmatic plasminogen activator inhibitor type 1 as a possible indicator of increased risk for metastatic melanoma.
The expression of integrin alpha 2 beta 1 and attachment to type I collagen of melanoma cells are preferentially induced by tumour promoter, TPA (12-O-tetradecanoyl phorbol-13-acetate).
The fibrinolytic factor tPA drives LRP1-mediated melanoma growth and metastasis.
The glycosylation of Bowes melanoma tissue plasminogen activator: lectin mapping, reaction with anti-L2/HNK-1 antibodies and the presence of sulphated/glucuronic acid containing glycans.
The induction of senescence-like growth arrest by protein kinase C-activating diterpene esters in solid tumor cells.
The plasminogen activation system in melanoma cell lines and in melanocytic lesions.
The pleiotropic effect of TPA on in vitro invasion/migration of glioma and melanoma cell lines.
The production and properties of a tissue plasminogen activator from normal epithelial cells grown in microcarrier culture.
The stimulation of normal human melanocyte proliferation in vitro by melanocyte growth factor from bovine brain.
The tissue-type plasminogen activator story.
Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.
Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor--and kringle one-domains.
Tissue plasminogen activator and inhibitors of fibrinolysis in malignant melanoma.
Tissue plasminogen activator in human plasma measured by radioimmunoassay.
Tissue plasminogen activator inhibitor in the epidermis.
Tissue plasminogen activator is released into cultured medium by cultured human uveal melanocytes.
Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms.
Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas.
TPA inhibits melanoma growth by inactivation of STAT3 through PKC-activated tyrosine phosphatase(s).
Transformation of Bowes melanoma cells with SV40 T antigen.
Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling.
Tumor growth and metastases in malignant disease. A review.
Tumor marker determinations.
Turnover of human tissue plasminogen activator (tPA) in rabbits.
Ultraviolet radiation-induced melanogenesis in human melanocytes. Effects of modulating protein kinase C.
Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells.
Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
[Attempts at analyzing the initiation of the initial processes of carcinogenesis based on the Xiphophorus melanoma model]
[Expression and characterization of t-PA in insect cells]
[Immunohistochemical studies in the differential diagnosis of malignant fibrous histiocytoma]
[Scintigraphic detection of malignancies with radioactively labelled tumor antibodies. Clinical results based on immunohistochemical research]
[Untreatable ventricular hemorrhage revealing cerebral metastasis of malignant melanoma]
Melanoma, Experimental
Differences between the F10, BL6 and F1 sublines of the B16 melanoma in the enhancement of plasminogen activator and plasminogen activator inhibitor secretion by phorbol myristate acetate.
Differences in expression of metalloproteinases and plasminogen activators in murine melanocytes and B16 melanoma variants: lack of association with in vitro invasion.
In B16 melanoma cells, the inhibition of melanogenesis by TPA results from PKC activation and diminution of microphthalmia binding to the M-box of the tyrosinase promoter.
Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard.
Proteolytic activation of tissue-type plasminogen activator by the culture media of mouse cancer cells.
Regulatory effect of phorbol esters on sphingosine kinase in BALB/C 3T3 fibroblasts (variant A31): demonstration of cell type-specific response--a preliminary note.
The effect of 5-bromodeoxyuridine on messenger RNA production in cultured cells.
Melanosis
Effect of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate and its nonpromoting analogue 4-O-methyl-TPA on dorsal dermal melanocytes of the Syrian golden hamster (Mesocricetus auratus).
Melena
Clinical experience with recombinant tissue plasminogen activator in the management of intracardiac and arterial thrombosis in children.
Thrombolysis Using Tissue Plasminogen Activator: Experience from a Critical Care Setting.
Melioidosis
Endogenous tissue-type plasminogen activator impairs host defense during severe experimental Gram-negative sepsis (melioidosis)*.
Plasminogen Activator Inhibitor Type I Contributes to Protective Immunity During Experimental Gram-Negative Sepsis (Melioidosis).
Meningeal Carcinomatosis
TPA and CK-BB: new tumor markers in leptomeningeal carcinomatosis secondary to breast cancer.
Meningioma
Biological significance of tissue plasminogen activator content in brain tumors.
Correlation of tumor plasminogen activator with peritumoral cerebral edema. A CT and biochemical study.
Detection and quantification of farnesol-induced apoptosis in difficult primary cell cultures by TaqMan protein assay.
Immunohistochemical characterization of brain-invasive meningiomas.
Involvement of protein kinase C in growth regulation of human meningioma cells.
Postoperative venous thromboembolism and brain tumors: Part III. Biochemical profile.
Progesterone receptor synthesis in human meningiomas: relation to the estrogen-induced proteins pS2 and cathepsin-D and influence of epidermal growth factor, Forskolin and phorbol ester in vitro.
Prognostic significance of proteolytic enzymes in human brain tumors.
Tissue plasminogen activator expression in meningiomas and glioblastomas.
Tissue plasminogen activator use in a patient with acute ischemic stroke coexisting with meningioma.
Tissue-type plasminogen activator in patients with intracranial meningiomas.
Transpalpebral Approach for Microsurgical Removal of Tuberculum Sellae Meningiomas.
[A plasminogen regulation system in brain tumors].
Meningitis
Angiostrongylus cantonensis: efficacy of albendazole-dexamethasone co-therapy against infection-induced plasminogen activators and eosinophilic meningitis.
Biochemical and pathological evaluation of albendazole/thalidomide co-therapy against eosinophilic meningitis or meningoencephalitis induced by Angiostrongylus cantonensis.
Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases.
Comparative efficacies of albendazole and the Chinese herbal medicine long-dan-xie-gan-tan, used alone or in combination, in the treatment of experimental eosinophilic meningitis induced by Angiostrongylus cantonensis.
Differences of proteolytic enzymes and pathological changes in permissive and nonpermissive animal hosts for Angiostrongylus cantonensis infection.
Elevation of plasminogen activators in cerebrospinal fluid of mice with eosinophilic meningitis caused by Angiostrongylus cantonensis.
Exacerbation of perihematomal edema and sterile meningitis with intraventricular administration of tissue plasminogen activator in patients with intracerebral hemorrhage.
Rheumatoid meningitis presenting with a stroke-like attack treated with recombinant tissue plasminogen activator: a case presentation.
Meningitis, Bacterial
Increased serum concentrations of tissue plasminogen activator correlate with an adverse clinical outcome in patients with bacterial meningitis.
Procoagulant and fibrinolytic activity in cerebrospinal fluid from adults with bacterial meningitis.
Urokinase-type plasminogen activator receptor regulates leukocyte recruitment during experimental pneumococcal meningitis.
Meningitis, Pneumococcal
Plasminogen activator inhibitor-1 influences cerebrovascular complications and death in pneumococcal meningitis.
Urokinase-type plasminogen activator receptor regulates leukocyte recruitment during experimental pneumococcal meningitis.
Meningococcal Infections
4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia.
Extreme plasminogen activator inhibitor and endotoxin values in patients with meningococcal disease.
Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis.
Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease.
The 4G/4G Genotype of PAI-1 Polymorphism Is Associated with Higher Plasma PAI-1 Concentrations and Mortality in Patients with Severe Sepsis.
Thrombolytic therapy in adult meningococcal purpura fulminans with acute renal failure and severe perfusion deficits to the extremities.
[Recombinant tissue plasminogen activator in treatment of fulminant meningococcal infection]
Meningoencephalitis
Differences of proteolytic enzymes and pathological changes in permissive and nonpermissive animal hosts for Angiostrongylus cantonensis infection.
Severe acute myocardial infarction during a staphylococcal septicemia with meningoencephalitis. A possible contraindication to thrombolytic treatment.
Menorrhagia
Antifibrinolytics for heavy menstrual bleeding.
Cyclic changes in endometrial tissue plasminogen activator and plasminogen activator inhibitor type 1 in women with normal menstruation and essential menorrhagia.
Menorrhagia due to a qualitative deficiency of plasminogen activator inhibitor-1: case report and literature review.
The fibrinolytic enzyme system in normal menstruation and excessive uterine bleeding and the effect of tranexamic acid.
Mesenteric Ischemia
Infusion of recombinant human tissue plasminogen activator through the superior mesenteric artery in the treatment of acute mesenteric venous thrombosis.
Treatment of portal venous thrombosis with selective superior mesenteric artery infusion of recombinant tissue plasminogen activator.
Mesothelioma
Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?
Expression of plasminogen activator and plasminogen activator inhibitor by rat mesothelioma induced by asbestos.
Immunohistochemical study of lysozyme, alpha 1-anti-chymotrypsin, tissue polypeptide antigen, keratin and carcinoembryonic antigen in effusion sediments.
L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray.
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Tissue polypeptide antigen (TPA) in pleural effusions.
[Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma]
[Tissue polypeptide antigen as a biological marker of malignant pleural mesothelioma]
Mesothelioma, Malignant
Cyfra 21-1 and TPA as markers in malignant mesothelioma.
L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray.
[Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma]
[Tissue polypeptide antigen as a biological marker of malignant pleural mesothelioma]
Metabolic Syndrome
A novel plasminogen activator inhibitor-1 inhibitor, TM5441, protects against high-fat diet-induced obesity and adipocyte injury in mice.
A state of the art review on the novel mediator asprosin in the metabolic syndrome.
Acute ingestion of long-chain (n-3) polyunsaturated fatty acids decreases fibrinolysis in men with metabolic syndrome.
Adipokines (adiponectin and plasminogen activator inhhibitor-1) in metabolic syndrome.
Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome.
Assessing risk across the spectrum of patients with the metabolic syndrome.
Association among Fibrinolytic Proteins, Metabolic Syndrome Components, Insulin Secretion, and Resistance in Schoolchildren.
Association between plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and risk of Alzheimer's disease, metabolic syndrome, and female infertility: A meta-analysis.
Association of pigment epithelium derived factor with von Willebrand factor and plasminogen activator inhibitor 1 in patients with type 2 diabetes.
Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study.
Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects.
Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D.E.S.I.R. prospective cohort.
Biochemical markers of psoriasis as a metabolic disease.
Body Fat Distribution and Inflammation Among Obese Older Adults With and Without Metabolic Syndrome.
Body Size Phenotypes and Inflammation in the Women's Health Initiative Observational Study.
Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.
C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis.
Cardiometabolic risk among African American women: a pilot study.
Cell adhesion molecules and plasminogen activator inhibitor type-1 (PAI-1) in patients with rheumatoid arthritis: influence of metabolic syndrome.
Cell adhesion molecules, plasminogen activator inhibitor type 1, and metabolic syndrome in patients with psoriasis.
Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults.
Circulating levels of plasminogen activator inhibitor-1 are associated with metabolic syndrome rather than with menopause.
Cognitive Patterns in Relation to Biomarkers of Cerebrovascular Disease and Vascular Risk Factors.
Comparable Enhanced Prothrombogenesis in Simple Central Obesity and Metabolic Syndrome.
Coronary artery disease in South asians: an emerging risk group.
Correction to: Cell adhesion molecules, plasminogen activator inhibitor type 1, and metabolic syndrome in patients with psoriasis.
Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome.
Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome.
Effect of abdominal obesity on prothrombotic tendency in type 2 diabetes. Behavior of clotting factors VII and VIII, fibrinogen and von Willebrand Factor.
Effect of plasminogen activator inhibitor-1 and tissue plasminogen activator polymorphisms on susceptibility to type 2 diabetes in Malaysian subjects.
Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease.
Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome.
Elevated plasminogen activator inhibitor 1 in sleep apnea and its relation to the metabolic syndrome: an investigation in 2 different study samples.
Endothelial dysfunction in metabolic syndrome.
Fenofibrate ameliorates insulin resistance, hypertension and novel oxidative stress markers in patients with metabolic syndrome.
Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner.
Fibrinolytic dysfunction after gestation is associated to components of insulin resistance and early type 2 diabetes in latino women with previous gestational diabetes.
Hemostasis at Extremes of Body Weight.
High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA study.
Identification of palmitate-regulated genes in HepG2 cells by applying microarray analysis.
Impaired spontaneous thrombolytic activity measured by global thrombosis test in males with metabolic syndrome.
Increased concentration of plasminogen activator inhibitor-1 and fibrinogen in individuals with metabolic syndrome.
Insulin resistance after precocious pubarche: relation to PAI-1-675 4G/5G polymorphism, and opposing influences of prenatal and postnatal weight gain.
Insulin resistance but not visceral adipose tissue is associated with plasminogen activator inhibitor type 1 levels in overweight and obese premenopausal African-American women.
Insulin sensitivity and hemostatic factors in clinically healthy 58-year-old men.
Intravenous Thrombolysis with Recombinant Tissue-type Plasminogen Activator for Acute Ischemic Stroke in Patients with Metabolic Syndrome.
Inverse relationship between adiponectin and plasminogen activator inhibitor-1 in metabolic syndrome patients.
Low-grade systemic inflammation, hypoadiponectinemia and a high concentration of leptin are present in very young obese children, and correlate with metabolic syndrome.
Metabolic syndrome accompanied by hypercholesterolemia is strongly associated with proinflammatory state and impairment of fibrinolysis in patients with type 2 diabetes: synergistic effects of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor.
Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1.
Metabolic Syndrome Predicts Refractoriness to Intravenous Thrombolysis in Acute Ischemic Stroke.
Metabolic syndrome X: a review.
Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome.
Not All Clots Are Created Equal: A Review of Deficient Thrombolysis with Tissue Plasminogen Activator (tPA) in Patients with Metabolic Syndrome.
Novel oral plasminogen activator inhibitor?1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats.
Nox4 mediates the expression of plasminogen activator inhibitor-1 via p38 MAPK pathway in cultured human endothelial cells.
Obesity, haemostasis and the fibrinolytic system.
PAI-1 and the metabolic syndrome: links, causes, and consequences.
PAI-1 Exacerbates White Adipose Tissue Dysfunction and Metabolic Dysregulation in High Fat Diet-Induced Obesity.
Plasma Adiponectin, T94G Gene Polymorphism and PAI-1 in Patients with and without Hypertension.
Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of metabolic syndrome.
Plasminogen activator inhibitor type 1 (PAI-1) is a valuable biomarker for predicting the metabolic syndrome (MS) in institutionalized elderly residents in Taiwan.
Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with metabolic syndrome parameters in Malaysian subjects.
Plasminogen Activator Inhibitor-1 and Diagnosis of the Metabolic Syndrome in a West African Population.
Plasminogen activator inhibitor-1 is independently associated with non-alcoholic fatty liver disease whereas leptin and adiponectin vary between genders.
Plasminogen Activator Inhibitor-1 Level Correlates with Lipoprotein Subfractions in Obese Nondiabetic Subjects.
Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: Effect of dieting with or without exercise in overweight postmenopausal women.
Plasminogen activator inhibitor-1and Adiponectin are associated with metabolic syndrome components.
Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes.
Predisposing factors to post-operative adhesion development.
Reduced cardiac expression of plasminogen activator inhibitor 1 and transforming growth factor beta1 in obese Zucker rats by perindopril.
Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins.
Relationship between Insulin Resistance and Some Coagulation and Fibrinolytic Parameters in Patients with Metabolic Syndrome.
Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease.
Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
Role of PAI-1 in hepatic steatosis and dyslipidemia.
Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome.
Study of Prothrombotic Changes in Metabolic Syndrome.
The Association of the Metabolic Syndrome with PAI-1 and t-PA Levels.
The effect of plasminogen activator inhibitor-1 -675 4G/5G polymorphism on PAI-1 gene expression and adipocyte differentiation.
The effect of thyroid hormones on the white adipose tissue gene expression of PAI-1 and its serum concentration.
The effects of physical activity and sedentary time on the prevalence rate of metabolic syndrome and perceived stress in Korean adults.
The relation of adipose tissue to cardiometabolic risk.
The relationships between insulin and plasminogen activator inhibitor 1 levels: assessment in groups of subjects with dyslipidaemia and hypertension.
The Synergistic Effect of Plasminogen Activator Inhibitor-1 (PAI-1) Polymorphisms and Metabolic Syndrome on Coronary Artery Disease in the Korean Population.
Thrombolysis Outcomes among Obese and Overweight Stroke Patients: An Age-and National Institutes of Health Stroke Scale-matched Comparison.
TNF-alpha, but not IL-6, stimulates plasminogen activator inhibitor-1 expression in human subcutaneous adipose tissue.
Use of confirmatory factor analysis for the identification of new components of the metabolic syndrome: The role of plasminogen activator inhibitor-1 and Haemoglobin A1c.
[Blood coagulation and fibrinolysis in arteriosclerosis]
[Genetic predisposition in multiple metabolic syndrome. Part 2. Candidate genes in type II diabetes mellitus]
[Inflammatory biomarkers: the link between obesity and associated pathologies]
[Insulin-like growth factor-binding protein-1: a new biochemical marker of nonalcoholic fatty liver disease?]
[Proinflammatory cytokine levels depending on the stage of hepatic fibrosis in patients with metabolic syndrome and non-alcoholic fatty liver disease].
Metrorrhagia
Safety of tissue plasminogen activator for acute stroke in menstruating women.
Microaneurysm
Successful Use of tPA for Saddle Pulmonary Embolism in Perimesencephalic Non-aneurysmal Subarachnoid Hemorrhage: Case Report.
Microcephaly
Associations of DNA Methylation Mortality Risk Markers with Congenital Microcephaly from Zika Virus: A Study of Brazilian Children Less than 4 Years of Age.
Microphthalmos
In B16 melanoma cells, the inhibition of melanogenesis by TPA results from PKC activation and diminution of microphthalmia binding to the M-box of the tyrosinase promoter.
Stimulation of melanogenesis by tetradecanoylphorbol 13-acetate (TPA) in mouse melanocytes and neural crest cells.
Migraine Disorders
Hypercoagulability and Migraine.
Migraine and biomarkers of endothelial activation in young women.
Not All Patients with Hemiplegia Need Alteplase: A Case of Hemiplegic Migraine.
Transtentorial herniation after unilateral infarction of the anterior cerebral artery.
MINOCA
Increased Inflammatory Activity in Patients 3 Months after Myocardial Infarction with Nonobstructive Coronary Arteries.
Mitochondrial Diseases
Use and in-hospital outcomes of recombinant tissue plasminogen activator in pediatric arterial ischemic stroke patients.
Mitral Valve Insufficiency
Tissue plasminogen activator for neonatal coronary thrombosis presenting with mitral valve regurgitation and impaired ventricular function.
Mitral Valve Stenosis
An abnormal systemic and regional hypercoagulable state in patients with mitral stenosis.
Hypercoagulability existing in the local left atrium of patient with mitral stenosis.
Intrathoracic pulmonary artery catheter allocation in the background of left atrial dilatation.
Prothrombotic state and elevated levels of plasminogen activator inhibitor-1 in mitral stenosis with and without atrial fibrillation.
Mouth Neoplasms
Effect of Olmesartan on the Level of Oral Cancer Risk Factor PAI1.
Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer.
Prognostic value of tissue polypeptide antigen in oral squamous cell carcinoma.
Tissue polypeptide antigen, carcinoembryonic antigen, carbohydrate antigen, and CA125 levels as tumor markers in squamous cell carcinoma of the head and neck.
Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity.
Urinary-type plasminogen activator receptor (uPAR) modulates oral cancer cell behavior with alteration in p130cas.
[Circulating biomarkers association in the follow-up of patients with oral cancer]
Moyamoya Disease
Emergency superficial temporal artery to middle cerebral artery bypass after intravenous recombinant tissue plasminogen activator administration for acute cerebral ischemia in a patient with moyamoya disease.
Intravenous Tissue Plasminogen Activator Therapy for an Acute Ischemic Stroke Patient with Later Diagnosed Unilateral Moyamoya Syndrome.
Mucocutaneous Lymph Node Syndrome
Effects of intracoronary tissue-type plasminogen activator treatment in kawasaki disease and acute myocardial infarction.
Low tissue plasminogen activator relative to plasminogen activator inhibitor-1 as a marker of cardiac complication in children with Kawasaki disease.
Management of myocardial infarction in children with Kawasaki disease.
Plasminogen activator inhibitor-1 in patients with Kawasaki disease: diagnostic value for the prediction of coronary artery lesion and implication for a new mode of therapy.
Successful thrombolysis with intracoronary administration of tissue plasminogen activator in an infant with Kawasaki disease.
Successful thrombolytic therapy using tissue-type plasminogen activator in Kawasaki disease.
Successful Treatment of Myocardial Infarction in an Infant With Kawasaki Disease.
Multiple Endocrine Neoplasia Type 2a
Catheter-Directed Intraarterial Thrombolysis as Part of a Multidisciplinary Management Protocol of Frostbite Injury.
Pharmacomechanical thrombectomy for treatment of symptomatic lower extremity deep venous thrombosis: safety and feasibility study.
Multiple Myeloma
CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review.
Hepatocyte growth factor measurement in AL amyloidosis.
Morphological and isoenzymatic differentiation of B-chronic lymphocytic leukaemia cells induced by phorbolester.
Occurrence of particular isoenzymes in fresh and cultured leukemia-lymphoma cells. II. Hexosaminidase I isoenzyme.
Multiple Sclerosis
A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis.
Can Aspirin Minimize Stroke Risk and New Lesion Formation in Multiple Sclerosis?
Can fibrinolytic system components explain cognitive impairment in multiple sclerosis?
Cerebrospinal fluid activity of tissue plasminogen activator in patients with neurological diseases.
Cerebrospinal fluid plasminogen activator inhibitor-1 in patients with neurological disease.
Co-localization of human herpes virus 6 and tissue plasminogen activator in multiple sclerosis brain tissue.
Fibrinolytic activity of plaques and white matter in multiple sclerosis.
Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors.
Involvement of cytokines in N-methyl-N'-nitro-N-nitrosoguanidine-induced plasminogen activator activity in acute disseminated encephalomyelitis and multiple sclerosis lymphocytes.
PAI and TPA gene polymorphisms in multiple sclerosis.
Plasminogen Activator Inhibitor-1 Antagonist TM5484 Attenuates Demyelination and Axonal Degeneration in a Mice Model of Multiple Sclerosis.
Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system.
Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage.
The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution.
The Influence of Differentially Expressed Tissue-Type Plasminogen Activator in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis.
The role of TPA I/D and PAI-1 4G/5G polymorphisms in multiple sclerosis.
Tissue plasminogen activator as a key effector in neurobiology and neuropathology.
Tissue plasminogen activator gene expression in multiple sclerosis brain tissue.
Tissue plasminogen activator worsens experimental autoimmune encephalomyelitis by complementary actions on lymphoid and myeloid cell responses.
Tissue-type plasminogen activator is a regulator of monocyte diapedesis through the brain endothelial barrier.
tPA in the injured central nervous system: different scenarios starring the same actor?
tPA receptors and the fibrinolytic response in multiple sclerosis lesions.
Multiple Sclerosis, Relapsing-Remitting
Elevated plasma level of plasminogen activator inhibitor-1 (PAI-1) in patients with relapsing-remitting multiple sclerosis.
Mumps
Applications of cell culture for the improvement of human health.
Augmentation of interferon production after cell-differentiation of U937 cells by TPA.
Muscle Spasticity
Plasma plasminogen activator inhibitor activity and tissue plasminogen activator levels in patients with unstable angina and those with coronary spastic angina.
Muscle Weakness
Relationships between muscle size, strength, and physical activity in adults with muscular dystrophy.
Muscular Atrophy
Plasminogen activator inhibitor type 1 up-regulation is associated with skeletal muscle atrophy and associated fibrosis.
Muscular Dystrophy, Emery-Dreifuss
Successful intravenous rt-PA thrombolysis for a childhood cardioembolic stroke with Emery-Dreifuss muscular dystrophy.
Myasthenia Gravis
Tissue plasminogen activator involvement in experimental autoimmune myasthenia gravis: Aggravation and therapeutic potential.
Mycoplasma Infections
Modulation of plasminogen activator activity in human skin fibroblasts infected with mycoplasmas.
Myeloproliferative Disorders
Human tissue-type plasminogen activator gene located near chromosomal breakpoint in myeloproliferative disorder.
[Thrombolytic therapy using r-TPA in Budd-Chiari syndrome in the course of myeloproliferative diseases]
Myocardial Infarction
"Rescue" thrombolysis with intracoronary tissue plasminogen activator for failed intravenous thrombolysis with streptokinase for acute myocardial infarction.
1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial.
39-kD protein inhibits tissue-type plasminogen activator clearance in vivo.
A case of neonatal myocardial infarction: left coronary artery thrombus resolution and normalisation of ventricular function by intracoronary low-dose tissue plasminogen activator.
A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators.
A comparative study on the effects of low dose of tPA and different regimens of intravenous urokinase in acute myocardial infarction.
A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.
A comparison between intravenous streptokinase and tissue plasminogen activator with early intravenous heparin in acute myocardial infarction.
A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators.
A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction.
A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group.
A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators.
A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.
A critical review of the relationship between impaired fibrinolysis and myocardial infarction.
A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction.
A difference between front-loaded streptokinase and standard-dose recombinant tissue-type plasminogen activator in preserving left ventricular function after acute myocardial infarction (the Central Illinois Thrombolytic Therapy Study).
A double blind placebo controlled study of early and late administration of recombinant tissue plasminogen activator in acute myocardial infarction.
A fresh look at the molecular pharmacology of plasminogen activators: from theory to test tube to clinical outcomes.
A history of streptokinase use in acute myocardial infarction.
A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study.
A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction.
A mutant streptokinase lacking the C-terminal 42 amino acids is less immunogenic.
A Myocardial Infarction During Intravenous Recombinant Tissue Plasminogen Activator Infusion for Evolving Ischemic Stroke.
A new thrombolytic agent, monteplase, is independent of the plasminogen activator inhibitor in patients with acute myocardial infarction: initial results of the COmbining Monteplase with Angioplasty (COMA) trial.
A new thrombolytic regimen for acute myocardial infarction using combination half dose tissue-type plasminogen activator with full dose streptokinase: a pilot study. KAMIT Study Group.
A novel model for evaluating thrombolytic therapy in dogs with ST-elevation myocardial infarction.
A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction.
A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
A proposed reference method for plasminogen activators that enables calculation of enzyme activities in SI units.
A prospective randomized comparison of the accuracy of computer-assisted versus GUSTO nomogram--directed heparin therapy.
A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Kentucky Acute Myocardial Infarction Trial (KAMIT) Group.
A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: comparison with native t-PA. E6010 Study Group.
A randomised dose ranging study of recombinant tissue plasminogen activator in acute myocardial infarction.
A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.
A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction.
A randomized dose-ranging study of rt-PA in acute myocardial infarction. Effects on coronary patency and fibrinolytic parameters.
A randomized placebo-controlled trial of combined early intravenous captopril and recombinant tissue-type plasminogen activator therapy in acute myocardial infarction.
A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial.
A randomized trial comparing the effect of ramipril and losartan in survivors of ST-elevation myocardial infarction.
A randomized trial confirming the efficacy of reduced dose recombinant tissue plasminogen activator in a Chinese myocardial infarction population and demonstrating superiority to usual dose urokinase: the TUCC trial.
A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction.
A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty.
A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. The STAR Trial Group.
A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the Myocardial Infarction using Novastan(R) and T-PA (MINT) Study.
A randomized, placebo-controlled trial of intravenous recombinant tissue-type plasminogen activator and emergency coronary angioplasty in patients with acute myocardial infarction.
A selective depression of tissue plasminogen activator (t-PA) activity in euglobulins characterises a risk group among survivors of acute myocardial infarction.
A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study.
Abciximab combined with half-dose reteplase has beneficial effects on inflammatory myocardial response in patients with myocardial infarction.
Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.
Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group.
Accelerated plasminogen activator inhibitor may prevent late restenosis after coronary stenting in acute myocardial infarction.
Accelerated ST-segment reduction after thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) compared to urokinase.
Accelerated tPA versus streptokinase for suspected myocardial infarction: waiting for our Mountain Dew.
ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time.
Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator.
Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator.
Activation of the complement system by recombinant tissue plasminogen activator.
Acute allergic reaction due to the administration of fibrinolytic therapy for ST-segment elevation myocardial infarction: case report and discussion.
Acute and sustained release of atrial natriuretic factor with acute myocardial infarction.
Acute and sustained release of the atrial natriuretic factor prohormone N-terminus with acute myocardial infarction.
Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion.
Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate.
Acute intraprocedural thrombus formation during wingspan intracranial stent placement for intracranial atherosclerotic disease.
Acute Myocardial Infarction During Thrombolysis of Mechanical Aortic Valve Thrombosis Associated With Heparin-Induced Thrombocytopenia.
Acute myocardial infarction following intravenous tissue plasminogen activator for acute ischemic stroke: An unknown danger.
Acute phase reaction, infarct size and in-hospital morbidity in myocardial infarction patients treated with streptokinase or recombinant tissue type plasminogen activator.
Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality.
Addendum: a standardized nursing care plan for the acute myocardial infarction patient receiving tissue-type plasminogen activator.
Adhesion molecules in different treatments of acute myocardial infarction.
Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
Adjunctive therapies in the cath lab. Combination of tirofiban and alteplase in acute myocardial infarction.
Adjunctive therapies in the cath lab. Successful thrombolysis using the combination of tissue plasminogen activator and abciximab in an adult with Kawasaki's disease.
Admission levels of C-reactive protein and plasminogen activator inhibitor-1 in patients with acute myocardial infarction with and without cardiogenic shock or heart failure on admission.
Alteplase (r-TPA) vs streptokinase.
Alteplase and anistreplase in acute myocardial infarction.
Alteplase and tenecteplase: applications in the peripheral circulation.
Alteplase for acute myocardial infarction.
Alteplase treatment affects circulating matrix metalloproteinase concentrations in patients with ST segment elevation acute myocardial infarction.
Alteplase versus placebo in myocardial infarction.
Alteplase.
Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.
Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.
Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction.
Alteplase: a tissue plasminogen activator for acute myocardial infarction.
Alteplase: descendancy in myocardial infarction, ascendancy in stroke.
Alteplase: double bolus versus accelerated regimen.
Alterations in the fibrinolytic system components during acute myocardial infarction.
Altered rheological properties of blood following administrations of tissue plasminogen activator and streptokinase in patients with acute myocardial infarction.
Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men.
An analysis of time delays preceding thrombolysis for acute myocardial infarction.
An angiographic assessment of alteplase: double-bolus and front-loaded infusion regimens in myocardial infarction. DouBLE Study Investigators. Double Bolus Lysis Efficacy.
An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validation.
An autopsy case of intracranial hemorrhage during tissue plasminogen activator infusion.
An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase.
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators.
An ischemic stroke during intravenous recombinant tissue plasminogen activator infusion for evolving myocardial infarction.
An overview of the patency and stroke rates following thrombolysis with streptokinase, alteplase, and anistreplase used to treat an acute myocardial infarction.
Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.
Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators.
Anaphylactoid reaction during an infusion of recombinant tissue-type plasminogen activator for acute myocardial infarction.
Angiographic assessment of the infarct-related residual coronary stenosis after spontaneous or therapeutic thrombolysis.
Angiographic predictors of reocclusion after thrombolysis: results from the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
Angiographic study of mutant tissue-type plasminogen activator versus urokinase for acute myocardial infarction.
Angiographic validation of bedside markers of reperfusion.
Angiography and revascularization in patients with heart failure following fibrinolytic therapy for ST-elevation acute myocardial infarction.
Angioplasty in acute myocardial infarction after low-dose alteplase and abciximab in transferred patients. A comparison with primary angioplasty on site.
Angiotensin converting enzyme DD genotype affects the changes of plasma plasminogen activator inhibitor-1 activity after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction patients.
Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3 Investigators.
Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Anti-t-PA antibodies in acute myocardial infarction after thrombolysis with rt-PA.
Antibody-targeted thrombolytic agents.
Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model.
Antithrombotic agents from salivary glands of hematophagous animals.
Applicability of percutaneous transluminal coronary angioplasty to patients with recombinant tissue plasminogen activator mediated thrombolysis.
Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset?
Are the various thrombolytic agents equally effective in the treatment of acute transmural myocardial infarction?
Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study.
Asn and asn: critical residues for in vitro biological activity of reteplase.
Association of angiotensin converting enzyme and plasminogen activator inhibitor-1 promoter gene polymorphisms with features of the insulin resistance syndrome in patients with premature coronary heart disease.
Association of PAI-1 4G/5G and -844G/A gene polymorphisms and changes in PAI-1/tissue plasminogen activator levels in myocardial infarction: a case-control study.
Association of patency of the infarct-related coronary artery with plasma levels of plasminogen activator inhibitor activity in acute myocardial infarction.
Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI-1, and metabolic parameters: the HIFMECH study.
Association of the plasminogen activator inhibitor-1 gene 4G/5G polymorphism with ST elevation acute myocardial infarction in young patients.
Association of the Plasminogen Activator Inhibitor-1 Gene 4G/5G Polymorphism With ST Elevation Acute Myocardial Infarction in Young Patients.
Association of tissue plasminogen activator and plasminogen activator inhibitor polymorphism with myocardial infarction: A meta-analysis.
Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries.
Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Augmentation of plasminogen activator inhibitor type 1 activity in plasma by thrombosis and by thrombolysis.
Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction.
B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy.
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
Bayesian cost-effectiveness analysis. An example using the GUSTO trial.
Benefical effects of reteplase in combination with abciximab: platelet/leukocyte interactions and coagulation system.
Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptokinase and TPA for occluded arteries.
Benefit-risk ratios in the assessment of the clinical evidence of a new therapy.
Biological risk factors for sudden death in patients with coronary artery disease and without heart failure.
Biotechnological production of recombinant tissue plasminogen activator protein (reteplase) from transplastomic tobacco cell cultures.
Bleeding after thrombolysis in acute myocardial infarction.
Bolus application of a novel recombinant plasminogen activator in acute myocardial infarction patients: pharmacokinetics and effects on the hemostatic system.
Bolus fibrinolytic therapy in acute myocardial infarction.
Bolus, front-loaded, and accelerated thrombolytic infusions for myocardial infarction and pulmonary embolism.
C-reactive protein in offspring is associated with the occurrence of myocardial infarction in first-degree relatives.
Cangrelor for patients undergoing percutaneous coronary intervention: evidence from a meta-analysis of randomized trials.
Captopril reduced plasminogen activator inhibitor activity in patients with acute myocardial infarction.
Carbohydrate structures of human tissue plasminogen activator expressed in Chinese hamster ovary cells.
Cardiac morphologic findings in patients with acute myocardial infarction treated with recombinant tissue plasminogen activator.
Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy (LATE) study.
Cardiac tamponade early after thrombolysis for acute myocardial infarction: a rare but not reported hemorrhagic complication.
Cardiogenic shock complicating acute myocardial infarction: predictors of death. GUSTO Investigators. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries.
Care of the patient receiving recombinant tissue plasminogen activator.
Cellular response of the evolving myocardial infarction after therapeutic coronary artery reperfusion.
Cerebral aneurysm rupture after r-TPA thrombolysis for acute myocardial infarction.
Cerebral hemorrhage from amyloid angiopathy and coronary thrombolysis.
Changes in interstitial collagen metabolism during acute myocardial infarction treated with streptokinase or tissue plasminogen activator.
Changes in plasma C-reactive protein and hemostatic factors prior to and after a first myocardial infarction with a median follow-up time of 8 years.
Changes in plasma levels of tissue plasminogen activator and its inhibitor in aged myocardial infarction patients.
Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial.
Characterization of a modified human tissue plasminogen activator comprising a kringle-2 and a protease domain.
Characterization of plasmin-induced platelet aggregation.
Cholesterol embolization syndrome after intravenous tissue plasminogen activator for acute myocardial infarction.
Choosing the Correct "-ase" in Acute Ischemic Stroke: Alteplase, Tenecteplase, and Reteplase.
Choroidal hemorrhage associated with systemic tissue plasminogen activator.
Circadian clock genes cause activation of the human PAI-1 gene promoter with 4G/5G allelic preference.
Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction.
Circadian variation in the efficacy of tissue-type plasminogen activator.
Circulating thrombotic and haemostatic components in patients with coronary artery disease.
CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression.
Clinical and biochemical predictors affect the choice and the short-term outcomes of different thrombolytic agents in acute myocardial infarction.
Clinical application of tissue plasminogen activator therapy in acute myocardial infarction.
Clinical benefit of angiotensin converting enzyme inhibition after acute myocardial infarction: myocardial reperfusion revisited.
Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York.
Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2).
Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience.
Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology.
Clinical trials in thrombolytic therapy, Part 1: Outcome markers that go beyond mortality reduction.
Clinical trials in thrombolytic therapy, Part 2: The open-artery hypothesis and RAPID-1 and RAPID-2.
Clinical trials with alteplase (rt-PA) in acute myocardial infarction.
Cloning and expression of functional full-length human tissue plasminogen activator in Pichia pastoris.
Cloning and purification of an anti-thrombotic, chimeric Staphylokinase in Pichia pastoris.
Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction.
Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group.
Clot-selective coronary thrombolysis with tissue-type plasminogen activator.
Co-administration of tissue plasminogen activator and hyperbaric oxygen in ischemic stroke: a continued promise for neuroprotection.
Coagulation abnormalities and cardiovascular disease.
Coagulation factor XIII and atherothrombosis. A mini-review.
Coffee consumption and risk of acute myocardial infarction in Italian males. GISSI-EFRIM. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto, Epidemiologia dei Fattori di Rischio del'Infarto Miocardico.
Collaborative Angiographic Patency Trial Of Recombinant Staphylokinase (CAPTORS II).
Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators.
Combination thrombolytic therapy: a comparison of simultaneous and sequential regimens of tissue plasminogen activator and urokinase.
Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI).
Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators.
Combined fibrinolysis using reduced-dose alteplase plus abciximab with immediate rescue angioplasty versus primary angioplasty with adjunct use of abciximab for the treatment of acute myocardial infarction: Asia-Pacific Acute Myocardial Infarction Trial (APAMIT) pilot study.
Combined stent placement and thrombolysis in acute vertebrobasilar ischemic stroke.
Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group.
Community hospital administration of intravenous tissue plasminogen activator in acute myocardial infarction: improved timing, thrombolytic efficacy and ventricular function.
Community hospital experience with recombinant tissue plasminogen activator in acute myocardial infarction.
Comparative effects of APSAC and rt-PA on infarct size and left ventricular function in acute myocardial infarction. A multicenter randomized study.
Comparative fibrinolytic activity of front-loaded alteplase and the single-bolus mutants tenecteplase and lanoteplase during treatment of acute myocardial infarction.
Comparative properties of two clinical preparations of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.
Comparative safety of thrombolytic agents.
Comparative Significance of Invasive Measures of Microvascular Injury in Acute Myocardial Infarction.
Comparative study of a mutant tissue-type plasminogen activator, YM866, with a tissue-type plasminogen activator in a canine model of femoral arterial thrombosis.
Comparative tolerability profiles of thrombolytic agents. A review.
Comparison of "accelerated" tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction.
Comparison of Cardiovascular Risk Factors for Coronary Heart Disease and Stroke Type in Women.
Comparison of clot lysis activity and biochemical properties of originator tenecteplase (Metalyse(®)) with those of an alleged biosimilar.
Comparison of coronary and myocardial morphologic findings in patients with and without thrombolytic therapy during fatal first acute myocardial infarction. The TIMI Investigators.
Comparison of double bolus urokinase versus front-loaded alteplase regimen for acute myocardial infarction. Thrombolysis in Myocardial Infarction in Korea (TIMIKO) study group.
Comparison of Efficacy and Safety of Recombinant Human Prourokinase and Alteplase in the Treatment of STEMI and Analysis of Influencing Factors of Efficacy.
Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
Comparison of heparin and aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction.
Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial.
Comparison of in-hospital outcome in men versus women treated by either thrombolytic therapy or primary coronary angioplasty for acute myocardial infarction.
Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. The TIMI Study Group.
Comparison of peak serum C-reactive protein and hydroxybutyrate dehydrogenase levels in patients with acute myocardial infarction treated with alteplase and streptokinase.
Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction.
Comparison of plasma tissue factor levels in unstable and stable angina pectoris.
Comparison of rapidity of coronary recanalization in men with tenecteplase versus alteplase in acute myocardial infarction.
Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction.
Comparison of the effects of streptokinase and tissue plasminogen activator on regional wall motion after first myocardial infarction: analysis by the centerline method with correction for area at risk.
Comparison of thrombolytic agents: selected hematologic, vascular and clinical events.
Comparison of thrombolytic therapies with mutant tPA (lanoteplase/SUN9216) and recombinant tPA (alteplase) for acute myocardial infarction.
Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior myocardial infarction with precordial ST-segment depression: immediate and long-term results of a randomized study.
Comparison of tissue plasminogen activator and streptokinase in the management of acute myocardial infarction.
Comparison of two dose regimens of intravenous tissue plasminogen activator for acute myocardial infarction.
Comparison of very early treatment with either fibrinolysis or percutaneous coronary intervention facilitated with abciximab with respect to ST recovery and infarct-related artery epicardial flow in patients with acute ST-segment elevation myocardial infarction: the Swedish Early Decision (SWEDES) reperfusion trial.
Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
Complement components and fibrinogen: correlations and association with previous myocardial infarction.
Complete dysphagia after thrombolytic treatment for myocardial infarction.
Complications of Microvascular Upper Lip and Free Grafted Nasal and Eyebrow Replantation After Assault via Human Bite.
Concurrent nitroglycerin administration reduces the efficacy of recombinant tissue-type plasminogen activator in patients with acute anterior wall myocardial infarction.
Concurrent use of reteplase and lepirudin in the treatment of acute anterior wall myocardial infarction.
Contribution of genetic and metabolic syndrome to omental adipose tissue PAI-1 gene mRNA and plasma levels in obesity.
Controlled trials comparing reteplase with alteplase and streptokinase in patients with acute myocardial infarction.
Coronary angioplasty after recombinant tissue-type plasminogen activator in acute myocardial infarction: a report from the Thrombolysis in Myocardial Infarction (TIMI) Trial.
Coronary angioplasty performed within the thrombolysis in Myocardial Infarction II study.
Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction.
Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
Coronary patency after intravenous infusion of recombinant tissue-type plasminogen activator in acute myocardial infarction.
Coronary patency, infarct size and left ventricular function after thrombolytic therapy for acute myocardial infarction: results from the tissue plasminogen activator: Toronto (TPAT) placebo-controlled trial. TPAT Study Group.
Coronary recanalization rate after intravenous bolus of alteplase in acute myocardial infarction.
Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Coronary saddle embolism causing myocardial infarction in a patient with mechanical mitral valve prosthesis: Treatment with thrombolytic therapy.
Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators.
Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 hours after onset of myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.
Coronary thrombolysis with clot-selective plasminogen activators.
Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology.
Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.
Coronary thrombolysis with recombinant tissue-type plasminogen activator: patency rate and regional wall motion after 3 months.
Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction.
Coronary thrombolysis--clinical guidelines and public policy: results of an Ontario practitioner survey.
Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?
Correction to: Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction).
Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction.
Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator.
Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction.
Correlations between fibrinolytic function and acute myocardial infarction.
Cost and health outcome of primary percutaneous coronary intervention versus thrombolysis in acute ST-segment elevation myocardial infarction-Results of the Swedish Early Decision reperfusion Study (SWEDES) trial.
Cost and procedure implications of thrombolytic therapy for acute myocardial infarction.
Cost comparison of immediate angioplasty versus thrombolysis followed by conservative therapy for acute myocardial infarction: a randomized prospective trial. Mayo Coronary Care Unit and Catheterization Laboratory Groups.
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction.
Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
Cost effectiveness of thrombolytic treatment for myocardial infarction: comparison of anistreplase, alteplase and streptokinase in 270 patients treated within 4 hours.
Cost, uncertainty, and doctors' decisions. The case of thrombolytic therapy.
Cost-effectiveness of thrombolysis--a randomized study of intravenous rt-PA in suspected myocardial infarction.
Creatine kinase is associated with bleeding after myocardial infarction.
Creation of the recombinant tissue plasminogen activator (rt-PA) image and its influence on practice habits.
Critical role for white blood cell NAD(P)H oxidase-mediated plasminogen activator inhibitor-1 oxidation and ventricular rupture following acute myocardial infarction.
Current approaches to glycoprotein analysis.
Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective.
Current developments in thrombolytic therapy using novel plasminogen activators.
Current issues concerning thrombolytic therapy for acute myocardial infarction.
D-dimer in local thrombolytic therapy with low doses of recombinant human tissue-type plasminogen activator (rt-PA) in patients with peripheral arterial occlusive disease.
D-dimer increase after percutaneous transluminal angioplasty and clinical recurrence after primary revascularization in acute myocardial infarction? A pilot study.
DANAMI-2: is primary angioplasty superior to thrombolysis in acute MI when the patient has to be transferred to an invasive centre?
De Winter's pattern: an uncommon but very important electrocardiographic sign in the prompt recognition of spontaneous occlusive coronary artery dissection in young patients with chest pain (a case report).
Death or nonfatal stroke in patients with acute myocardial infarction treated with tissue plasminogen activator. Participants in the National Registry of Myocardial Infarction 2.
Decreased protein C inhibitor after percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction.
Deleterious effects of lack of cardiac PAI-1 after coronary occlusion in mice and their pathophysiologic determinants.
Delivery of tissue plasminogen activator and streptokinase magnetic nanoparticles to target vascular diseases.
Demonstration of the formation of hydroxyl radicals in acute myocardial infarction in man using salicylate as probe.
Depression of factor XII-dependent fibrinolytic activity characterizes patients with early myocardial reinfarction after recombinant tissue-type plasminogen activator therapy.
Depression of tissue plasminogen activator (t-PA) activity and rise of t-PA inhibition and acute phase reactants in blood of patients with acute myocardial infarction (AMI).
Detection of coronary artery reperfusion with creatine kinase-MB determinations during thrombolytic therapy: correlation with acute angiography.
Determinants of plasminogen activator inhibitor-1 activity in survivors of myocardial infarction.
Determinants of transmitral inflow pattern 10-14 days after acute myocardial infarction.
Determination of a weight-adjusted dose of TNK-tissue plasminogen activator.
Determination of Biological Activity of Recombinant Reteplase Using Clot Lysis Time and Activated Partial Thromboplastin Time (APTT) Lysis Methods: A Comparative Study.
Differences in the treatment of myocardial infarction between the United States and Canada. A survey of physicians in the GUSTO trial.
Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy.
Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial.
Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis.
Disappearance of a syndrome: Dressler's syndrome in the era of thrombolysis.
Distal hyperintense vessels on FLAIR: an MRI marker for collateral circulation in acute stroke?
Distribution of tissue plasminogen activator insertion/deletion polymorphism in myocardial infarction and control subjects.
Distribution patterns of Gd-DTPA-enhanced magnetic resonance imaging after intravenous tissue plasminogen activator therapy for acute myocardial infarction.
Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1).
Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)? An evaluation of the risks and benefits of TPA from the patient's perspective.
Do the investigative sites that take part in a positive clinical trial translate that evidence into practice?
Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction.
Does tissue-type plasminogen activator have direct beneficial effects on the myocardium independent of its ability to lyse intracoronary thrombi?
Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German Recombinant Plasminogen Activator Study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK).
Dose ranging study of tissue plasminogen activator in acute myocardial infarction.
Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis.
Dose-ranging study with a new two-chain rt-PA in patients with acute myocardial infarction: a multicenter trial.
Dose-related efficacy and bleeding complications of double-chain tissue plasminogen activator in acute myocardial infarction. The Wellcome Tissue Plasminogen Activator Study Group.
Double bolus of 0.75 MU streptokinase plus enoxaparin versus front-loaded alteplase plus unfractionated heparin in ST-segment elevation myocardial infarction.
Double-blind randomised trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction.
Double-blind randomized trial of alteplase versus placebo in patients with chest pain at rest.
Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study.
Downregulated expression of plasminogen activator inhibitor-1 augments myocardial neovascularization and reduces cardiomyocyte apoptosis after acute myocardial infarction.
Dynamic expression of the main related indicators of thrombosis, inflammatory reaction and tissue damage in a rat model of myocardial infarction.
Dynamic QRS-complex and ST-segment monitoring in acute myocardial infarction during recombinant tissue-type plasminogen activator therapy. The TEAHAT Study Group.
Dyslipidaemia and coagulation defects of insulin resistance.
Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial.
Early and late effects of rt-PA vs placebo on left ventricular function measured by nuclear ventriculography.
Early and late exercise capacity after acute myocardial infarction treated with recombinant tissue-plasminogen activator.
Early coronary reperfusion blunts the procoagulant response of plasminogen activator inhibitor-1 and von Willebrand factor in acute myocardial infarction.
Early diagnosis of colonic carcinoma: a haemorrhagic complication after the use of tissue plasminogen activator.
Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial.
Early electrocardiographic changes in acute myocardial infarction treated by streptokinase or alteplase: a randomized study with dynamic, multi-lead, electrocardiographic monitoring.
Early monitoring of serum cardiac troponin I for assessment of coronary reperfusion following thrombolytic therapy.
Early patency of the infarct-related artery after myocardial infarction preserves diastolic filling.
Early reactivation of ischaemia after abrupt discontinuation of heparin in acute myocardial infarction.
Early routine angioplasty versus selective angioplasty after successful thrombolysis in acute ST-segment elevation myocardial infarction.
Early spontaneous intermittent myocardial reperfusion during acute myocardial infarction is associated with augmented thrombogenic activity and less myocardial damage.
Early T wave inversion after thrombolytic therapy predicts better coronary perfusion: clinical and angiographic study.
Early thrombolytic therapy in suspected acute myocardial infarction--role of the electrocardiogram: results from the TEAHAT Study.
Early thrombolytic treatment reduces analgesic requirement in patients with myocardial infarction.
Early tPA treatment and aeromedical transport of patients with acute myocardial infarction.
ECG evidence of limited myocardial infarction following coronary occlusion treated by early intravenous rt-PA infusion.
Echocardiographic evaluation of segmental wall motion early and late after thrombolytic therapy in acute myocardial infarction: the Western Washington Tissue Plasminogen Activator Emergency Room Trial.
Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
Effect of abciximab on prothrombin activation and thrombin generation in patients with acute myocardial infarction also receiving reteplase.
Effect of activated protein C on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction treated with alteplase: comparison with unfractionated heparin.
Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction.
Effect of combined administration of saruplase and single-chain alteplase on coronary recanalization in acute myocardial infarction.
Effect of continued rt-PA administration on the residual stenosis after initially successful recanalization in acute myocardial infarction--a quantitative coronary angiography study of a randomized trial.
Effect of coronary flow on intracoronary alteplase: a prespecified analysis from a randomised trial.
Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial.
Effect of early intravenous rt-PA on infarct size estimated from serum enzyme activity: results from the TEAHAT Study.
Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction.
Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction.
Effect of low frequency ultrasound on combined rt-PA and eptifibatide thrombolysis in human clots.
Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial.
Effect of post-solubilization conditions on the yield and efficiency of recombinant streptokinase purification at large-scale.
Effect of recombinant plasminogen activator timing on thrombolysis in a novel rat embolic stroke model.
Effect of reperfusion modality on outcome in nonsmokers and smokers with acute myocardial infarction (a Primary Angioplasty in Myocardial Infarction [PAMI] substudy). PAMI Investigators.
Effect of reteplase on hemostasis variables: analysis of fibrin specificity, relation to bleeding complications and coronary patency.
Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy.
Effect of the initial bolus volume of recombinant tissue-type plasminogen activator on coronary recanalization and infarct size in Japanese acute myocardial infarction patients. Kumamoto University Myocardial Infarction Study (KUMIS) Group.
Effect of thrombolysis on acute mitral regurgitation during evolving myocardial infarction. Experience from the Thrombolysis in Myocardial Infarction (TIMI) Trial.
Effect of thrombolysis on myocardial injury: recombinant tissue plasminogen activator vs. alfimeprase.
Effect on collagen metabolism of thrombolytic therapy with tissue-plasminogen activator. A randomized, placebo-controlled study.
Effect on outcome of the presence or absence of chest pain at initiation of recombinant tissue plasminogen activator therapy in acute myocardial infarction. The Thrombolysis in Myocardial Infarction Investigators.
Effectiveness and safety of a single intravenous bolus injection of tissue-type plasminogen activator in acute myocardial infarction. Bolus Dose-Escalation Study of Tissue-Type Plasminogen Activator (BEST) Investigators.
Effectiveness of double bolus alteplase in the treatment of acute myocardial infarction.
Effectiveness of multiple bolus administration of tissue-type plasminogen activator in acute myocardial infarction.
Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study. Anglo-Scandinavian Study of Early Thrombolysis.
Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction.
Effects of Intracoronary Alteplase on Microvascular Function in Acute Myocardial Infarction.
Effects of intracoronary tissue-type plasminogen activator treatment in kawasaki disease and acute myocardial infarction.
Effects of intravenous administration of tissue plasminogen activator before thrombectomy in patients with acute myocardial infarction.
Effects of intravenous recombinant tissue-type plasminogen activator therapy on the incidence and associations of left ventricular thrombus in patients with a first acute Q wave anterior myocardial infarction.
Effects of late administration of tissue-type plasminogen activator on left ventricular remodeling and function after myocardial infarction.
Effects of lipoprotein (a) on success rate of thrombolytic therapy in acute myocardial infarction.
Effects of lipoprotein(a) on thrombolysis.
Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries.
Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study.
Effects of time required for reperfusion (thrombolysis or angioplasty, or both) and location of acute myocardial infarction on left ventricular functional reserve capacity several months later.
Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia.
Effects of tissue plasminogen activator therapy on the frequency of acute right ventricular myocardial infarction associated with acute left ventricular infarction.
Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex on mortality in acute myocardial infarction.
Effects on chest pain of early thrombolytic treatment in suspected acute myocardial infarction: results from the TEAHAT Study.
Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction).
Efficacy and Safety of Low-Dose Streptokinase plus Desmopressin in Acute Myocardial Infarction: A Pilot Study.
Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction.
Efficacy of a two-hour infusion of 150-mg tissue plasminogen activator in acute myocardial infarction.
Efficacy of recombinant tissue-type plasminogen activator thrombolysis and primary coronary stenting after acute myocardial infarction.
Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers.
Efficient renaturation and fibrinolytic properties of prourokinase and a deletion mutant expressed in Escherichia coli as inclusion bodies.
Electrically induced ventricular arrhythmias in acute myocardial infarction treated with thrombolytic agents.
Electrocardiographic assessment of infarct size: comparison between QRS scoring of 12-lead electrocardiography and dynamic vectorcardiography.
Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators.
Elevated fibrinogen levels decrease following treatment of acromegaly.
Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction.
Elevated serum Lp(a) concentration and the rare apo(a) phenotype in a patient with myocardial infarction.
Elevation of thrombin-antithrombin complexes during thrombolytic therapy in patients with myocardial infarction.
Emergency coronary artery bypass surgery preserves global and regional left ventricular function after intravenous tissue plasminogen activator therapy for acute myocardial infarction.
Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction.
Endogenous tissue-type plasminogen activator and risk of myocardial infarction.
Endothelial tissue-type plasminogen activator release in coronary heart disease: Transient reduction in endothelial fibrinolytic reserve in patients with unstable angina pectoris or acute myocardial infarction.
Enhanced expression of plasminogen activator inhibitor may prevent cardiac rupture in female and castrated mice after myocardial infarction.
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events).
Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: a role for plasminogen activator inhibitor?
Enzymes approved for human therapy: indications, mechanisms and adverse effects.
Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial.
Equivocal roles of tissue-type plasminogen activator in stroke-induced injury.
ERK1/2 mediates the lipopolysaccharide-induced upregulation of FGF-2, uPA, MMP-2, MMP-9 and cellular migration in cardiac fibroblasts.
ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction.
Ethanol downregulates transcription of the PAI-1 gene in cultured human endothelial cells.
Evaluation and comparison of the adverse effects of streptokinase and alteplase.
Evaluation of a prolonged infusion of recombinant tissue-type plasminogen activator (Duteplase) in preventing reocclusion following successful thrombolysis in acute myocardial infarction.
Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus alteplase.
Evaluation of paradoxic beneficial effects of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: mechanism of the "smoker's paradox" from the GUSTO-I trial, with angiographic insights. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries.
Evaluation of the effect of thrombolytic treatment on infarct size and left ventricular function by enzymatic, scintigraphic, and angiographic methods. The European Cooperative Study Group for Recombinant Tissue Type Plasminogen Activator.
Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial.
Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-I levels in acute myocardial infarction.
Evolving concepts in the treatment of acute myocardial infarction.
Experience with low-dose intracoronary recombinant tissue-type plasminogen activator for nonacute total occlusions before percutaneous transluminal coronary angioplasty.
Experience with the use of tPA in the treatment of acute myocardial infarction.
Exploration of rapid bedside monitoring of coagulation and fibrinolysis parameters during thrombolytic therapy.
Expression of the recombinant plasminogen activator (reteplase) by a non-lytic insect cell expression system.
Extent of ST-segment deviation in a single electrocardiogram lead 90 min after thrombolysis as a predictor of medium-term mortality in acute myocardial infarction.
Extent of ST-segment deviation in the single ECG lead of maximum deviation present 90 or 180 minutes after start of thrombolytic therapy best predicts outcome in acute myocardial infarction.
Facilitated PCI by combination fibrinolysis or upstream tirofiban in acute ST-segment elevation myocardial infarction: results of the Alteplase and Tirofiban in Acute Myocardial Infarction (ATAMI) trial.
Facilitated PCI in patients with ST-elevation myocardial infarction.
Facilitated PCI in younger Chinese patients with AMI.
Facilitated percutaneous intervention following combination therapy with reteplase and abciximab for acute myocardial infarction.
Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial.
Factors influencing myocardial preservation after recombinant tissue plasminogen activator (rt-PA) in acute myocardial infarction.
Factors influencing the time to administration of thrombolytic therapy with recombinant tissue plasminogen activator (data from the National Registry of Myocardial Infarction). Participants in the National Registry of Myocardial Infarction.
Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis.
Fatal Hemoptysis during Coronary Thrombolysis.
Fatal intracerebral hemorrhage following thrombolytic therapy of embolic myocardial infarction in unsuspected infective endocarditis.
Favorable early and long-term prognosis following coronary bypass surgery therapy for myocardial infarction: results of a multicenter trial. TAMI Study Group.
Feasibility and timing of prehospital administration of reteplase in patients with acute myocardial infarction.
Feasibility of prehospital r-TPA therapy in chest pain patients.
Feasibility of tomographic 99mTc-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging for the assessment of myocardial area at risk and the effect of treatment in acute myocardial infarction.
Fibrin formation and platelet activation in patients with myocardial infarction and normal coronary arteries.
Fibrin fragment D-dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction.
Fibrin metabolism in patients with acute myocardial infarction during and after treatment with tissue-type plasminogen activator.
Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction.
Fibrinogen and plasminogen activator inhibitor-1 levels in hypertension and coronary heart disease. Potential effects of beta-blockade.
Fibrinogen breakdown, long-lasting systemic fibrinolysis, and procoagulant activation during alteplase double-bolus regimen in acute myocardial infarction.
Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis.
Fibrinolysis: a Misunderstood Natural Defense Whose Therapeutic Potential Is Unknown.
Fibrinolytic activity in coronary heart disease.
Fibrinolytic PLGA nanoparticles for slow clot lysis within abdominal aortic aneurysms attenuate proteolytic loss of vascular elastic matrix.
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.
Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries.
Frequency of "optimal anticoagulation" for acute myocardial infarction after thrombolysis with front-loaded recombinant tissue-type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW 023). ALKK Study Group.
Front-loaded infusion therapy of rT-PA during active menstruation. A case report.
Future role of thrombolytic therapy in emergency medicine.
Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model.
Genetic polymorphism of 5,10-MTHFR reductase gene in offspring of patients with myocardial infarction.
Genetic polymorphisms in preoperative myocardial infarction.
Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity.
Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review.
Genetics of coagulation factors in acute lung injury.
Genome-Wide Association Study for Circulating Tissue Plasminogen Activator Levels and Functional Follow-Up Implicates Endothelial STXBP5 and STX2.
Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II.
GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.
Glycocalicin: a new assay--the normal plasma levels and its potential usefulness in selected diseases.
Glycosylation of therapeutic proteins in different production systems.
Graded exercise testing following thrombolytic therapy for acute myocardial infarction: the importance of timing and infarct location. TPAT Study Group.
Guidelines for the use of intravenous thrombolytic agents in acute myocardial infarction. Ontario Medical Association Consensus Group on Thrombolytic Therapy.
GUSTO V: combination drug treatment of acute myocardial infarction. Global Use of Strategies to Open Occluded Coronary Arteries.
Haemostatic function in myocardial infarction.
HBW 023 (recombinant hirudin) for the acceleration of thrombolysis and prevention of coronary reocclusion in acute myocardial infarction: results of a dose-finding study (HIT-II) by the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte.
Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokinase and TPA for Occluded Arteries.
Hemoptysis and unilateral intra-alveolar hemorrhage complicating intravenous thrombolysis for myocardial infarction.
Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction.
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Hemorrhagic upper extremity complications from tissue plasminogen activator.
Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study.
Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.
Heparin-induced thrombocytopenia: a critical risk/benefit analysis of patients in intensive care treated with R-hirudin.
Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis.
Hierarchy of risk based on history and location of prior myocardial infarction in the thrombolytic era. GUSTO-I Investigators.
High glucose induces plasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-kappaB activation in bovine aortic endothelial cells.
High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.
High-dose intra-arterial urokinase for the treatment of hepatic artery thrombosis in liver transplantation.
Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries.
Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial.
Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Homocysteine and hemostatic disorder as a risk factor for myocardial infarction at a young age.
Hospitalization costs of primary stenting versus thrombolysis in acute myocardial infarction: cost analysis of the Canadian STAT Study.
How cost-effective are new preventive strategies for cardiovascular disease?
How do smokers differ from nonsmokers in their response to thrombolysis? (the TIMI-4 trial)
How late is too late and how early is early: the clinician's view of the first 100 minutes.
How to search for the role and prevalence of defective fibrinolytic states as triggers of myocardial infarction? The haemostasis epidemiologist's view.
HTUPA as a new thrombolytic agent for acute myocardial infarction: A multicenter, randomized study.
Human alpha -defensins neutralize fibrinolytic activity exerted by staphylokinase.
Hyperbaric oxygen and thrombolysis in myocardial infarction: the "HOT MI" pilot study.
Hypercoagulability and reduced fibrinolysis in hyperlipidemia: relationship to the metabolic cardiovascular syndrome.
Identification of a plasminogen binding region in streptokinase that is necessary for the creation of a functional streptokinase-plasminogen activator complex.
Imbalance of plasminogen activator inhibitor-I/ tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction.
Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial.
Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study.
Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. The TIMI Research Group.
Immunohistochemical localization of plasminogen activator inhibitor-1 in human coronary atherosclerotic lesions involved in acute myocardial infarction.
Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study.
Impact of Baseline Thrombocytopenia on Bleeding and Mortality After Percutaneous Coronary Intervention.
Impact of different reperfusion modalities on ventricular function after acute myocardial infarction.
Impact of early thrombolysis on chest pain score reflecting myocardial ischemia in relation to various markers of ischemic damage. TEAHAT Study Group.
Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V.
Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study.
Impact of thrombus aspiration on the activity of plasminogen activator inhibitor?1 during acute ST-segment elevation myocardial infarction.
Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction (The second National Registry of Myocardial Infarction).
Impact of tissue plasminogen activator and heparin versus heparin alone on quantitative coronary angiographic findings in myocardial infarction. The Toronto Tissue Plasminogen Activator Trial Study Group.
Impairment of the blood-brain barrier: a potential surrogate delineating the determinants of cerebral bleeding caused by fibrinolytic drugs.
Implications of recurrent ischemia after reperfusion therapy in acute myocardial infarction: a comparison of thrombolytic therapy and primary angioplasty.
Importance of myocardial infarct artery patency on the prevalence of ventricular arrhythmia and late potentials after thrombolysis in acute myocardial infarction.
Importance of ST-segment depression as a determinant of ventricular premature complex frequency after thrombolysis for acute myocardial infarction. Tissue Plasminogen Activator: Toronto (TPAT) Study Group.
Importance of the pharmacological profile of thrombolytic agents in clinical practice.
Importance of thrombosis and thrombolysis in silent ischaemia: comparison of patients with acute myocardial infarction and unstable angina.
Improved fibrinolysis after one year of treatment with enalapril in men and women with uncomplicated myocardial infarction.
Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: results of a multicenter randomized trial of two dosage regimens.
Improved left ventricular function in myocardial infarction following intravenous thrombolytic therapy with acylated plasminogen activator.
Improved survival but not left ventricular function with early and prehospital treatment with tissue plasminogen activator in acute myocardial infarction.
Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS)
Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator.
Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase.
Improving natural principles with genetic engineering: TNK-tissue plasminogen activator.
In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group.
Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators.
Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA.
Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: results from TIMI II.
Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial.
Incidence of left ventricular thrombi formation after thrombolytic therapy with recombinant tissue plasminogen activator, heparin, and aspirin in patients with acute myocardial infarction.
Incomplete recanalization as an important determinant of Thrombolysis in Myocardial Infarction (TIMI) grade 2 flow after thrombolytic therapy for acute myocardial infarction. TEAM Investigators. Thrombolytic Trial of Eminase in Acute Myocardial Infarction.
Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction.
Increased fibrin specificity and reduced paradoxical thrombin activation of the combined thrombolytic regimen with reteplase and abciximab versus standard reteplase thrombolysis.
Increased left ventricular dysfunction in elderly patients despite successful thrombolysis: the GUSTO-I angiographic experience.
Increased level of von Willebrand factor is significantly and independently associated with diabetes in postinfarction patients. THROMBO Investigators.
Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.
Increased plasminogen activator inhibitor activity and diabetes predict subsequent coronary events in patients with angina pectoris.
Increased plasminogen activator inhibitor activity in survivors of myocardial infarction is associated with metabolic risk factors of atherosclerosis.
Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA.
Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy.
Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation.
Incremental cost-effectiveness ratio of alteplase in patients with acute myocardial infarction in the French setting.
Individual lytic efficacy of recombinant tissue plasminogen activator in an in vitro human clot model: rate of "nonresponse".
Induction of plasminogen activator inhibitor by products released from platelets.
Influence of a rehabilitation sports programme on the fibrinolytic activity of patients after myocardial infarction.
Influence of acute myocardial infarction and rt-PA therapy on circulating fibrinogen.
Influence of acute myocardial infarction location on in-hospital and late outcome after primary percutaneous transluminal coronary angioplasty versus tissue plasminogen activator therapy.
Influence of cardiac output on peak t-PA plasma levels in patients receiving thrombolytic therapy with recombinant tissue-type plasminogen activator--correlation with patency rate.
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity.
Influence of the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-1) trial on the use of thrombolytics in Germany. ALKK Study Group. Arbeitsgemeinschaft der Leitenden Kardiologischen Krankenhausärtze.
Influence of the plasminogen activator system on necrosis in acute myocardial infarction: analysis of urokinase- and urokinase receptor-knockout mouse models.
Influence of the rt-PA dose (1 mg/kg versus 1.5 mg/kg) and duration of administration on the patency of infarct-related coronary arteries in 81 patients.
Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group.
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure.
Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction.
Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy.
Innovative approaches to plasminogen activator therapy.
Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen activator, improves thrombolysis.
Insights derived from the thrombolysis and angioplasty in myocardial infarction (TAMI) trials.
Insulin resistance increases PAI-1 in the heart.
Interaction between air pollution exposure and genes in relation to levels of inflammatory markers and risk of myocardial infarction.
Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction.
Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.
Intermittent, dose-related fluctuations of pain and ST elevation during infusion of recombinant tissue plasminogen activator during acute myocardial infarction.
Intraarterial recombinant tissue plasminogen activator for ischemic stroke: an accelerating dosing regimen.
Intracerebral hemorrhage after fibrinolytic therapy for acute myocardial infarction.
Intracerebral hemorrhage after thrombolytic therapy managed with ventricular drainage.
Intracerebral hemorrhage complicating intravenous tissue plasminogen activator treatment.
Intracerebral hemorrhage related to cerebral amyloid angiopathy and t-PA treatment.
Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial.
Intracoronary recombinant tissue-type plasminogen activator (rt-PA).
Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator.
Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis.
Intracranial hemorrhage rates and effect of immediate beta-blocker use in patients with acute myocardial infarction treated with tissue plasminogen activator. Participants in the National Registry of Myocardial Infarction-2.
Intraocular hemorrhage after systemic thrombolytic therapy in a patient with exudative macular degeneration.
Intravenous diltiazem in acute myocardial infarction. Diltiazem as adjunctive therapy to activase (DATA) trial.
Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction.
Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS).
Intravenous recombinant tissue-type plasminogen activator (rt-PA) and urokinase (UK) in patients with evolving myocardial infarction--a multicenter double-blind, randomized trial in Japan.
Intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction.
Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction--a report from the multicenter thrombolysis trial.
Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial.
Intravenous tenecteplase in acute ischemic stroke: an updated review.
Intravenous Thrombolysis for Acute Ischemic Stroke After Recent Myocardial Infarction: Case Series and Systematic Review.
Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.
Intravenous Tissue Plasminogen Activator as Provocateur of Myocardial Infarction.
Is smoking associated with favourable outcome in tPA-treated stroke patients?
Ischemic cerebral infarction after rt-PA and heparin therapy for acute myocardial infarction. The TIMI-II pilot and randomized clinical trial combined experience.
ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group.
Laboratory assessment of thrombolytic therapy in acute myocardial infarction.
Laboratory evaluation of fibrinolysis in patients with a history of myocardial infarction.
Laboratory monitoring of hemostasis during thrombolytic therapy with recombinant human tissue-type plasminogen activator.
Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction.
Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction.
Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. The TAMI Study Group.
Lanoteplase.
Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction.
LATE assessment of thrombolytic efficacy with alteplase (rt-PA) six-24 hours after onset of acute myocardial infarction.
Late ventricular potentials in risk assessment of the occurrence of complex ventricular arrhythmia in patients with myocardial infarction and heart failure.
Left ventricular function after late thrombolysis with alteplase in myocardial infarction.
Left ventricular thrombus in anterior acute myocardial infarction after thrombolysis. A GISSI-2 connected study.
Levels of haemostatic factors, arteriosclerosis and cardiovascular disease.
Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator.
Lingual haematoma after treatment with alteplase (recombinant tissue plasminogen activator) for acute myocardial infarction.
Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators.
Lipid peroxidation and antioxidant status following thrombolytic therapy for acute myocardial infarction.
Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in H9c2 cardiomyoblast cells.
Lipoprotein (a) levels do not influence the outcome of rt-PA therapy in acute myocardial infarction.
Lipoprotein(a) and apolipoproteins B and A-I after acute myocardial infarction.
Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator.
Long-lasting depression of the factor XII-dependent fibrinolytic system in patients with myocardial infarction undergoing thrombolytic therapy with recombinant tissue-type plasminogen activator: a randomized placebo-controlled study.
Long-term effect of thrombolytic therapy on left ventricular ejection fraction after acute myocardial infarction.
Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Long-term outcome after primary angioplasty: report from the primary angioplasty in myocardial infarction (PAMI-I) trial.
Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial.
Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction.
Long-term stability of recombinant tissue plasminogen activator at -80 C.
Low density lipoprotein receptor-related protein is necessary for the internalization of both tissue-type plasminogen activator-inhibitor complexes and free tissue-type plasminogen activator.
Low level of tissue plasminogen activator activity in non-diabetic patients with a first myocardial infarction.
Low-Dose Alteplase During Primary Percutaneous Coronary Intervention According to Ischemic Time.
Low-dose tissue plasminogen activator followed by planned rescue angioplasty reduces time to reperfusion for acute myocardial infarction treated at community hospitals.
Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA.
Magnesium therapy, fibrinolytic parameters and von Willebrand factor in acute myocardial infarction.
Making a case for the right "-ase" in acute ischemic stroke: alteplase, tenecteplase, and reteplase.
Management of myocardial infarction in children with Kawasaki disease.
Management of spinal epidural hematoma after tissue plasminogen activator. A case report.
Manual ELISA assays on tPA and PAI-1 automated on Novapath I.S. preliminary report.
Massive subfascial hematoma after alteplase therapy for acute myocardial infarction.
Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study.
Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
Medico-Legal Issues in Cardiology.
Methodologic and clinical validation of the TIMI myocardial perfusion grade in acute myocardial infarction.
Microvascular obstruction after successful fibrinolytic therapy in acute myocardial infarction. Comparison of reteplase vs reteplase+abciximab: A cardiovascular magnetic resonance study.
Mild hyperhomocysteinemia is associated with a decreased fibrinolytic activity in patients after ST-elevation myocardial infarction.
Molecular cloning of Reteplase and its expression in E. coli using tac promoter.
Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator.
Monitoring of Functional Plasminogen in Blood of Patients Receiving Fibrinolytics.
Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator.
Monitoring of plasmin and plasminogen activator activity in blood of patients under fibrinolytic treatment by reteplase.
More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
Mortality and morbidity 1 year after early thrombolysis in suspected AMI: results from the TEAHAT Study.
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
MRI-Guided High-Intensity Focused Ultrasound as an Emerging Therapy for Stroke: A Review.
Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase.
Multiple spontaneous coronary artery dissections in a middle aged woman: support for an underlying eosinophilic arteritis predisposing to intimal disruption.
Multivariate associates of QT dispersion in patients with acute myocardial infarction: primacy of patency status of the infarct-related artery. TEAM-3 Investigators. Third trial of Thrombolysis with Eminase in Acute Myocardial Infarction.
Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction.
Myocardial infarct artery patency and reocclusion rates after treatment with duteplase at the dose used in the International Study of Infarct Survival-3. Burroughs Wellcome Study Group.
Myocardial infarct size reduction by the synergistic effect of hyperbaric oxygen and recombinant tissue plasminogen activator.
Myocardial infarction as a complication of dobutamine stress echocardiography.
Myocardial Infarction Following Intravenous Thrombolysis for Acute Ischemic Stroke: Case Report and Literature Review.
Myocardial infarction following recombinant tissue plasminogen activator treatment for acute ischemic stroke: a dangerous complication.
Myocardial infarction in a 35-year-old man with homocysteinemia, high plasminogen activator inhibitor activity, and resistance to activated protein C.
Myocardial Infarction Occurs with a Similar 24 h Pattern in the 4G/5G Versions of Plasminogen Activator Inhibitor-1.
Myocardial Infarction: Symptoms and Treatments.
Myocardial Production of Plasminogen Activator Inhibitor-1 is Associated with Coronary Endothelial and Ventricular Dysfunction after Acute Myocardial Infarction.
Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial.
Myocardial salvage after reduced-dose thrombolysis combined with glycoprotein IIb/IIIa blockade versus thrombolysis alone in patients with acute myocardial infarction.
Myocardium at risk and infarct size after thrombolytic therapy for acute myocardial infarction: implications for the design of randomized trials of acute intervention.
Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B.
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries.
Neutrophil adhesion and activation during systemic thrombolysis in acute myocardial infarction.
New Accelerated rt-PA Strategy Has Sufficient Advantage over Older Streptokinase Strategies that It should Be the Trhombolytic Strategy of Choice in Anterior and Large Infarctions.
New approaches to treatment of myocardial infarction.
New developments in thrombolytic therapy.
New heparin dosing recommendations for patients with acute coronary syndromes.
New process results in dramatic improvement for heart attack patients, lower hospital costs.
Newer thrombolytic agents.
Newer thrombolytic drugs for acute myocardial infarction.
Niacin affects cell adhesion molecules and plasminogen activator inhibitor-1 in HepG2 cells.
No association of the plasminogen activator inhibitor-1 promoter 4G/5G polymorphism with inhibitor level during basal transcription in vitro.
No evidence of association between prothrombotic gene polymorphisms and the development of acute myocardial infarction at a young age.
Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein.
Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators.
Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Noninvasive transcutaneous low frequency ultrasound enhances thrombolysis in peripheral and coronary arteries.
Noninvasive transcutaneous ultrasound augments thrombolysis in the left circumflex coronary artery--an in vivo canine study.
Noninvasive transthoracic low frequency ultrasound augments thrombolysis in a canine model of acute myocardial infarction--evaluation of the extent of ST-segment resolution.
Nox4 mediates the expression of plasminogen activator inhibitor-1 via p38 MAPK pathway in cultured human endothelial cells.
Nuclear magnetic resonance solution structure of the plasminogen-activator protein staphylokinase.
Nursing care of acute stroke patients after receiving rt-PA therapy. The NINDS rt-PA Stroke Study Group.
On-demand cleavable linkers for radioimmunotherapy.
One-year follow-up after recombinant tissue plasminogen activator administered to patients with acute myocardial infarction.
One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction.
One-year outcome after therapy with tissue plasminogen activator: report from the Thrombolysis and Angioplasty in Myocardial Infarction trial.
One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction.
One-year results of the Thrombolysis in Myocardial Infarction investigation (TIMI) Phase II Trial.
One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: results from the GUSTO-I trial.
Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction.
Optimal thrombolytic strategies for acute myocardial infarction--bolus administration.
Outcome of different reperfusion strategies in patients with former contraindications to thrombolytic therapy: a comparison of primary angioplasty and tissue plasminogen activator. Primary Angioplasty in Myocardial Infarction (PAMI) Investigators.
Outcome of Hispanic patients treated with thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I and III trials. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Outcome of recombinant tissue plasminogen activator in ST-segment elevation myocardial infarction in Buriram Hospital.
Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries.
Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice.
Overview: rationale of thrombolysis in treating acute myocardial infarction.
PAI-1 level and the PAI-1 4G/5G polymorphism in relation to risk of non-fatal myocardial infarction: results from the Stockholm Heart Epidemiology Program (SHEEP).
Panax quinquefolius saponins combined with dual antiplatelet drug therapy alleviate gastric mucosal injury and thrombogenesis through the COX/PG pathway in a rat model of acute myocardial infarction.
Paraplegia subsequent to administration of tissue plasminogen activator and intravenous heparin following myocardial infarction--a case report.
Patency trials with reteplase (r-PA): what do they tell us?
Pathophysiology and prognostic significance of Holter-detected ST segment depression after myocardial infarction. The Tissue Plasminogen Activator: Toronto (TPAT) Study Group.
PEGylation of Truncated Streptokinase Leads to Formulation of a Useful Drug with Ameliorated Attributes.
Pentoxifylline Lowers Plasminogen Activator Inhibitor 1 Levels in Obese Individuals: A Pilot Study.
Percutaneous coronary intervention in st-elevation myocardial infarction.
Percutaneous coronary intervention-related time delay, patient's risk profile, and survival benefits of primary angioplasty vs lytic therapy in ST-segment elevation myocardial infarction.
Pericardial effusion after intravenous recombinant tissue-type plasminogen activator for acute myocardial infarction.
Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group.
Pharmacoepidemiology of bleeding events after use of r-alteplase or streptokinase in acute myocardial infarction.
Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction.
Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction.
Pharmacokinetics and hepatic catabolism of tissue-type plasminogen activator.
Pharmacokinetics and pharmacodynamics of recombinant tissue-type plasminogen activator following intravenous administration in rabbits: a comparison of three dosing regimens.
Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.
Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction.
Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction.
Pharmacokinetics of alteplase in the treatment of ischaemic stroke.
Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue.
Pharmacology and clinical trial results of lanoteplase in acute myocardial infarction.
Physical activity and the risk of acute myocardial infarction. GISSI-EFRIM Investigators. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-Epidemiologia dei Fattori di Rischio dell'Infarto Miocardico.
Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups.
PlA polymorphism of the glycoprotein IIIa and efficacy of reperfusion therapy in patients with acute myocardial infarction.
Plasma and platelet plasminogen activator inhibitor-1 in patients with acute myocardial infarction.
Plasma Concentration of Endogenous Tissue Plasminogen Activator and the Occurrence of Future Cardiovascular Events.
Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study Group.
Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men.
Plasma levels of plasminogen activator inhibitor type 1, beta-thromboglobulin, and fibrinopeptide A before, during, and after treatment of acute myocardial infarction with alteplase.
Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.
Plasma lipoprotein (a) levels and fibrinolytic activity in acute myocardial infarction.
Plasma plasminogen activator inhibitor-1 predicts myocardial infarction in HIV-1-infected individuals.
Plasma plasminogen activator inhibitor-1, tissue plasminogen activator and serum lipoprotein(a) after reperfusion therapy in acute myocardial infarction: comparison between sequential and direct percutaneous transluminal coronary angioplasty.
Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
Plasma thrombomodulin activity, tissue factor activity and high levels of circulating procoagulant phospholipid as prognostic factors for acute myocardial infarction.
Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 levels in acute myocardial infarction.
Plasmin inhibitors in the prevention of systemic effects during thrombolytic therapy: specific role of the plasminogen-binding form of alpha 2-antiplasmin.
Plasminogen activator activity in venous walls of patients who died of myocardial infarction.
Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease.
Plasminogen activator inhibitor 1 (PAI-1) in plasma: its role in thrombotic disease.
Plasminogen activator inhibitor 1 activity and other coronary risk factors.
Plasminogen activator inhibitor 1 in thrombotic disease.
Plasminogen activator inhibitor 1 is elevated in the children of men with premature myocardial infarction.
Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.
Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction.
Plasminogen activator inhibitor contributes to the coronary wall thickening in patients with angiographically normal coronary.
Plasminogen activator inhibitor in patients with acute myocardial infarction and re-infarction in syndrome X.
Plasminogen activator inhibitor in plasma is related to testosterone in men.
Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.
Plasminogen activator inhibitor type 1 (PAI-1) and platelet glycoprotein IIIa (PGIIIa) polymorphisms in young Asian Indians with acute myocardial infarction.
Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke.
Plasminogen activator inhibitor type 1 in adults with Down syndrome and protection against macrovascular disease.
Plasminogen activator inhibitor type 1 increases neointima formation in balloon-injured rat carotid arteries.
Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly.
Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease.
Plasminogen activator inhibitor-1 (PAI-1) activity post myocardial infarction: the role of acute phase reactants, insulin-like molecules and promoter (4G/5G) polymorphism in the PAI-1 gene.
Plasminogen activator inhibitor-1 (PAI-1), toll-like receptor 4 (TLR4), factor II (FII), FXIII and fibrinogen polymorphisms are not associated with the prevalence of sudden death due to ventricular fibrillation during myocardial infarction.
Plasminogen activator inhibitor-1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction.
Plasminogen activator inhibitor-1 4G/5G-polymorphism and factor V Q506 mutation are not associated with myocardial infarction in young men.
Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease.
Plasminogen activator inhibitor-1 5G/5G genotype is associated with early spontaneous recanalization of the infarct-related artery in patients presenting with acute ST-elevation myocardial infarction.
Plasminogen activator inhibitor-1 activity and long-term outcome in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: a prospective cohort study.
Plasminogen activator inhibitor-1 and the calculus of mortality after myocardial infarction.
Plasminogen activator inhibitor-1 gene and myocardial infarction.
Plasminogen activator inhibitor-1 in patients with atrial arrhythmias during acute myocardial infarction, treated with streptokinase.
Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography.
Plasminogen activator inhibitor-1 promoter 4G/5G genotype is not a risk factor for myocardial infarction in a Japanese population.
Plasminogen activator inhibitor-1, free fatty acids, and insulin resistance in patients with myocardial infarction.
Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients.
Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction.
Plasminogen activator/plasmin system: a major player in wound healing?
Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
Platelet activity during acute myocardial infarction treated with tissue plasminogen activator.
Platelet Activity in the Early Stage of Acute Myocardial Infarction: Relation to Time of Presentation, Treatment with Either Tissue Plasminogen Activator or Streptokinase and Cyclooxygenase Inhibition.
Platelet function after in vivo and in vitro treatment with thrombolytic agents.
Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase.
Platelet glycoprotein IIIA PIA2 polymorphism is associated with ST elevation acute myocardial infarction in young Mexican population.
Platelet inhibition with cangrelor in patients undergoing PCI.
Platelet-dependent thrombin generation after in vitro fibrinolytic treatment.
Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation.
Post-Reteplase Evaluation of Clinical Safety & Efficacy in Indian Patients (Precise-In Study).
Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction.
PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease.
Practice guidelines and professional autonomy in a universal health insurance system: the case of tissue plasminogen activator in Ontario.
Pre-hospital thrombolytic therapy with either alteplase or streptokinase. Practical applications, complications and long-term results in 529 patients.
Predicting pharmacodynamic response to tissue plasminogen activator: a preliminary report.
Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial.
Prediction of early recurrent myocardial ischemia and coronary reocclusion after successful thrombolysis: a qualitative and quantitative angiographic study.
Prediction of event-free survival after hospital discharge in acute myocardial infarction treated with tissue-plasminogen activator.
Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores.
Predictive value for thrombotic disease of plasminogen activator inhibitor-1 plasma levels.
Predictive value of fibrinolytic factors in coronary heart disease.
Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) trail.
Prehospital diagnosis and treatment of acute myocardial infarction: a north-south perspective. The Cincinnati Heart Project and the Nashville Prehospital TPA Trial.
Prehospital thrombolysis in suspected acute myocardial infarction: results from the TEAHAT Study.
Prehospital thrombolysis with alteplase (rt-PA) in acute myocardial infarction.
Prehospital thrombolysis with reteplase: the Nijmegen/Rotterdam study.
Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial.
Premature compared with late onset of coronary artery disease: young patients show a severe defect in fibrinolytic response to venous occlusion.
Pretreatment plasminogen activator inhibitor-1 (PAI-1) levels and the outcome of thrombolysis with streptokinase in patients with acute myocardial infarction.
Prevention of an early re-occlusion after thrombolytic therapy of acute myocardial infarction by ketanserin.
Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
Primary intracoronary stenting in comparison with intravenous rt-PA thrombolysis plus rescue intracoronary intervention in patients with acute myocardial infarction.
Primary percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: does the choice of fibrinolytic agent impact on the importance of time-to-treatment?
Primary PTCA versus thrombolysis with tPA in acute myocardial infarction: a formal cost-effectiveness analysis.
Procoagulant effects of thrombolytic therapy in acute myocardial infarction.
Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator.
Prodromal angina limits infarct size. A role for ischemic preconditioning.
Prodromal unstable angina in acute myocardial infarction: prognostic value of short- and long-term outcome and predictor of infarct size.
Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study.
Prognosis following interventional therapy for acute myocardial infarction: utility of dipyridamole thallium scintigraphy.
Prognostic implications and predictors of enhanced regional wall motion of the noninfarct zone after thrombolysis and angioplasty therapy of acute myocardial infarction. The TAMI Study Groups.
Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Proinsulin-like molecules and plasminogen activator inhibitor type 1 (PAI-1) activity in diabetic and non-diabetic subjects with and without myocardial infarction.
Prolonged activation of fibrinolytic system induced by fibrin nonselective thrombolytic agent can contribute to preventing early reocclusion after coronary thrombolytic therapy.
Prolonged coagulation instability is associated with a higher-dose regimen of tissue-type plasminogen activator in patients with acute myocardial infarction.
Prolonged improvement of Raynaud's phenomenon and scleroderma after recombinant tissue plasminogen activator therapy.
Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study.
Prostaglandin E1 does not accelerate rTPA-induced thrombolysis in acute myocardial infarction.
Protection by alpha2-macroglobulin of tissue plasminogen activator against inhibition by plasminogen activator inhibitor-1.
Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase.
Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction.
Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men.
Quality of life six months after myocardial infarction treated with thrombolytic therapy. AUS-TASK Group. Australian arm of International tPA/SK Mortality Trial.
Quantitative immunocytochemical staining for recombinant tissue-type plasminogen activator in transfected Chinese hamster ovary cells.
Quantitative measurement of carotid atherosclerosis in relation to levels of von Willebrand factor and fibrinolytic variables in plasma--a 2-year follow-up study.
Quantitative radionuclide assessment of regional ventricular function after thrombolytic therapy for acute myocardial infarction: results of phase I Thrombolysis in Myocardial Infarction (TIMI) trial.
Race and prognosis after myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
Racial differences in responses to thrombolytic therapy with recombinant tissue-type plasminogen activator. Increased fibrin(ogen)olysis in blacks. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator.
Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics.
Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction. RAAMI Study Investigators.
Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarction.
Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction.
Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction.
Rapid resolution of ST elevation and prediction of clinical outcome in patients undergoing thrombolysis with alteplase (recombinant tissue-type plasminogen activator): results of the Israeli Study of Early Intervention in Myocardial Infarction.
Rapid, homogeneous genotyping of the 4G/5G polymorphism in the promoter region of the PAII gene by fluorescence resonance energy transfer and probe melting curves.
Rate of fibrinogen breakdown related to coronary patency and bleeding complications in patients with thrombolysis in acute myocardial infarction--results from the PRIMI trial.
Reactive coagulation induced by plasmin in patients treated with recombinant tissue-type plasminogen activator.
Reasons for the lack of benefit of immediate angioplasty during recombinant tissue plasminogen activator therapy for acute myocardial infarction: a regional wall motion analysis. European Cooperative Study Group.
Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used.
Recanalization characteristics of intracoronary streptokinase compared to intravenous tissue plasminogen activator following acute myocardial infarction: a community hospital experience.
Recent Myocardial Infarction is Associated With Increased Risk in Older Adults With Acute Ischemic Stroke Receiving Thrombolytic Therapy.
Recombinant expression of rt-PA gene (encoding Reteplase) in gametophytes of the seaweed Laminaria japonica (Laminariales, Phaeophyta).
Recombinant Expression of Thrombolytic Agent Reteplase in Marine Microalga Tetraselmis subcordiformis (Chlorodendrales, Chlorophyta).
Recombinant hirudin (HBW 023) produces stable anticoagulation unaffected by circadian variation in patients with thrombolysis for acute myocardial infarction.
Recombinant hirudin and front-loaded alteplase in acute myocardial infarction: final results of a pilot study. HIT-I (hirudin for the improvement of thrombolysis).
Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) versus alteplase (rt-PA) as fibrinolytic therapy for acute ST-segment elevation myocardial infarction (China TNK STEMI): protocol for a randomised, controlled, non-inferiority trial.
Recombinant plasminogen activators: a comparative review of the clinical pharmacology and therapeutic use of alteplase and reteplase.
Recombinant t-PA in myocardial ischemia after switch operation.
Recombinant tissue plasminogen activator in acute myocardial infarction in the Chinese in Hong Kong.
Recombinant tissue-plasminogen activator (rt-PA) in acute myocardial infarction in the Chinese in Hong Kong.
Recombinant tissue-type plasminogen activator and immediate angioplasty in acute myocardial infarction. One-year follow-up. The European Cooperative Study Group.
Recombinant tissue-type plasminogen activator as a thrombolytic agent in acute myocardial infarction.
Recombinant tissue-type plasminogen activator in acute myocardial infarction: role of the critical care nurse.
Recombinant tissue-type plasminogen activator: current concepts and guidelines for clinical use in acute myocardial infarction. Part I.
Recombinant tissue-type plasminogen activator: current concepts and guidelines for clinical use in acute myocardial infarction. Part II.
Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the fibronectin finger-like domain and the kringle 1 domain.
Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the finger domain.
Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator.
Reduced carriership of 4G allele of plasminogen activator inhibitor-1 4G/5G polymorphism in very young survivors of myocardial infarction.
Reduced synthesis of tissue plasminogen activator by vascular endothelium during acute myocardial infarction.
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Regional wall motion improvement after coronary thrombolysis with recombinant tissue plasminogen activator: importance of coronary angioplasty.
Regulation of the PAI-1 promoter by circadian clock components: differential activation by BMAL1 and BMAL2.
Regulation of the procoagulant response to arterial injury.
Reimbursement and pharmacoeconomic perspectives in biotechnology.
Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial.
Relation of PAI-1 and TPA genes polymorphisms to acute myocardial infarction and its outcomes in Egyptian patients.
Relation of reperfusion success with anistreplase or alteplase in acute myocardial infarction to body weight. The TEAM-3 investigators.
Relation of von Willebrand factor to occurrence of Q waves and thrombolytic treatment in acute myocardial infarction.
Relationship between gene polymorphism of the PAI-1 promoter and myocardial infarction.
Relationship between serum angiotensin-converting enzyme activity and plasma plasminogen activator inhibitor activity in patients with recent myocardial infarction.
Relationship between smoking and fibrinolytic system with special reference to t-PA and PA inhibitor.
Relationship between triglycerides and factor VIIc and plasminogen activator inhibitor type-1: lack of threshold value.
Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes.
Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease.
Relationships of plasminogen activator inhibitor activity and lipoprotein(a) with insulin, testosterone, 17 beta-estradiol, and testosterone binding globulin in myocardial infarction patients and healthy controls.
Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation.
Repeat infusion of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction and early recurrent myocardial ischemia.
Repeated doses of tissue plasminogen activator for failed thrombolysis: case report and review of the literature.
Repeated thrombolysis for chronologically separated ischemic strokes: a case series.
Reperfusion strategy for acute myocardial infarction in elderly patients aged 75 to 80 years.
Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.
Reperfusion therapy in patients with acute myocardial infarction and prior coronary artery bypass graft surgery (National Registry of Myocardial Infarction-2).
Rescue angioplasty in the thrombolysis in myocardial infarction (TIMI) 4 trial.
Rescue thrombolysis: alteplase as adjuvant treatment after streptokinase in acute myocardial infarction.
Residual coronary stenoses and calculated transstenotic gradients after intravenous streptokinase versus tissue plasminogen activator.
Residual coronary stenosis after thrombolysis with rt-PA or streptokinase: acute results and 3 weeks follow-up.
Restoration of hearing loss with tissue plasminogen activator. Case report.
Results of percutaneous transluminal coronary angioplasty in unstable angina and non-Q-wave myocardial infarction. Observations from the TIMI IIIB Trial.
Results of the RAPID 1 and RAPID 2 thrombolytic trials in acute myocardial infarction.
Reteplase (r-PA): a new plasminogen activator.
Reteplase but not alteplase affects early soluble PECAM-1 and P-selectin release in patients with acute myocardial infarction.
Reteplase in acute myocardial infarction.
Reteplase in ST elevation myocardial infarction.
Reteplase versus Streptokinase in Management of ST-segment Elevation Myocardial Infarction; a Letter to the Editor.
Reteplase: a new thrombolytic for the treatment of acute myocardial infarction.
Reteplase: a review of its use in the management of thrombotic occlusive disorders.
Reteplase: new preparation. Minimal value: bolus versus infusion.
Reteplase: Structure, Function, and Production.
Retreatment with alteplase for early signs of reocclusion after thrombolysis. The European Cooperative Study Group.
Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells.
Ridogrel as an adjunct to thrombolysis in acute myocardial infarction.
Ridogrel does not increase the speed and rate of coronary recanalization in patients with myocardial infarction treated with alteplase and heparin.
Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators.
Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2.
Risk reduction for cardiac events after primary coronary intervention compared with thrombolysis for acute ST-elevation myocardial infarction (five-year results of the Swedish early decision reperfusion strategy [SWEDES] trial).
Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. The Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators.
Risks versus benefits: the alteplase experience.
Role of tissue plasminogen activator and plasminogen activator inhibitor polymorphism in myocardial infarction.
Ruptured arteriovenous malformation complicating thrombolytic therapy with tissue plasminogen activator.
Safety and efficacy of a new regimen of intravenous recombinant tissue-type plasminogen activator potentially suitable for either prehospital or in-hospital administration.
Safety and efficacy of tenecteplase versus alteplase in acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings.
Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators.
Safety of coronary stenting early after thrombolysis in patients with acute myocardial infarction: one- and six-month clinical and angiographic evolution.
Safety of helicopter transport and out-of-hospital intravenous fibrinolytic therapy in patients with evolving myocardial infarction.
Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial.
Saruplase in Myocardial Infarction.
Scintigraphic visualization of pulmonary thrombi with 123I-YPACK-TNK-tPA.
Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators.
Selective versus routine predischarge coronary arteriography after therapy with recombinant tissue-type plasminogen activator, heparin and aspirin for acute myocardial infarction. TIMI II Investigators.
Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial.
Serial changes in plasma concentration of plasminogen activator inhibitor-1 before and serially after thrombolytic therapy for acute myocardial infarction.
Serial changes of plasma plasminogen activator inhibitor activity in acute myocardial infarction: difference between thrombolytic therapy and direct coronary angioplasty.
Serial thrombolysis-related changes after thrombolytic therapy with TPA in patients with acute myocardial infarction.
Serum lipoprotein(a) level is related to thrombin generation and spontaneous intermittent coronary occlusion in patients with acute myocardial infarction.
Severe acute myocardial infarction during a staphylococcal septicemia with meningoencephalitis. A possible contraindication to thrombolytic treatment.
Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension.
Significance of arrhythmias during the first 24 hours of acute myocardial infarction treated with alteplase and effect of early administration of a beta-blocker or a bradycardiac agent on their incidence.
Significance of initial ST segment changes for thrombolytic treatment in first inferior myocardial infarction.
Significance of initial ST segment elevation and depression for the management of thrombolytic therapy in acute myocardial infarction. European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator.
Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction.
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators.
Six- and twelve-month follow-up of the phase I Thrombolysis in Myocardial Infarction (TIMI) trial.
Six-month survival in 20,891 patients with acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. GISSI-2 and International Study Group. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto.
Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction.
Soluble expression of active recombinant human tissue plasminogen activator derivative (K2S) in Escherichia coli.
Specific determination and identification of cross-linked fibrin degradation products in patients under thrombolytic therapy for myocardial infarction.
Spinal epidural hematoma associated with tissue plasminogen activator treatment of acute myocardial infarction.
Spinal epidural hematoma following tissue plasminogen activator and heparinization for acute myocardial infarction.
Splenic hemorrhage after tissue plasminogen activator for acute myocardial infarction.
Splenic hemorrhage: a complication of tissue plasminogen activator treatment.
Spontaneous arterial embolization after thrombolytic therapy for acute myocardial infarction: the role of transesophageal echocardiography.
Spontaneous hemarthrosis following fibrinolytic therapy for acute myocardial infarction: a case report and literature review.
Spontaneous Hemothorax Resulting from Tissue Plasminogen Activator in a Patient with Ischemic Stroke and Unrecognized Recent Myocardial Infarction.
Spontaneous suprachoroidal hemorrhage secondary to thrombolysis for the treatment of myocardial infarction.
Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
Spotlight on reteplase in thrombotic occlusive disorders.
ST variability during the first 4 hours of acute myocardial infarction predicts 1-year mortality.
ST-elevation myocardial infarction associated with acute ischemic stroke.
ST-segment resolution 60 minutes after combination treatment of abciximab with reteplase or reteplase alone for acute myocardial infarction (30-day mortality results from the resolution of ST-segment after reperfusion therapy substudy).
Staphylokinase as a plasminogen activator component in recombinant fusion proteins.
Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis.
Stenting plus abciximab vs tPA in acute myocardial infarction.
Stenting versus thrombolysis in acute myocardial infarction trial (STAT).
Strategies for administration of tissue plasminogen activator.
Streptokinase and recombinant tissue plasminogen activator (rt-PA) are equally effective in treating acute myocardial infarction.
Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction.
Streptokinase and tissue plasminogen activator in acute myocardial infarction.
Streptokinase or tissue plasminogen activator and left ventricular function after myocardial infarction.
Streptokinase versus alteplase in acute myocardial infarction.
Streptokinase, but not tissue plasminogen activator, attenuates platelet aggregation in patients with acute myocardial infarction.
Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long-term prognosis.
Stroke secondary to calcific bicuspid aortic valve: Case report and literature review.
Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1.
Studies on the functionality of fibrinogen during rt-PA therapy: results of three different methods of fibrinogen determination.
Studies on the pathogenesis of coagulopathy in patients with arterial thromboembolism and malignancy.
Study of recombinant antibody fragments and PAI-1 complexes combining protein-protein docking and results from site-directed mutagenesis.
Subarachnoid hemorrhage after thrombolytic therapy for acute myocardial infarction: A case report.
Subcapsular hepatic and intraperitoneal bleed after administration of tissue plasminogen activator in a patient with acute myocardial infarction.
Successful Management of Neonatal Myocardial Infarction with ECMO and Intracoronary r-tPA lysis.
Successful thrombolysis on a mechanical tricuspid prosthesis.
Successful thrombolytic therapy using tissue-type plasminogen activator in Kawasaki disease.
Successful treatment of acute myocardial infarction during pregnancy with tissue plasminogen activator.
Successful Treatment of Massive Pulmonary Thromboembolism with Reteplase: Case Series.
Successful Treatment of Myocardial Infarction in an Infant With Kawasaki Disease.
Superiority of warfarin over aspirin long term after thrombolytic therapy for acute myocardial infarction.
Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.
Suspension culture of gametophytes of transgenic kelp in a photobioreactor
Suspension culture of gametophytes of transgenic kelp in a photobioreactor.
Sustained fibrinolysis after administration of t-PA despite its short half-life in the circulation.
Systolic left ventricular function after reperfusion therapy for acute myocardial infarction. Analysis of determinants of improvement. The TAMI Study Group.
Targeted introduction of tissue plasminogen activator (TPA) at the AAVS1 locus in mesenchymal stem cells (MSCs) and its stable and effective expression.
Temporal evolution and functional outcome of no reflow: sustained and spontaneously reversible patterns following successful coronary recanalisation.
Tenecteplase (TNK tissue plasminogen activator): A new fibrinolytic for the acute treatment of myocardial infarction.
Tenecteplase and alteplase in acute myocardial infarction.
Tenecteplase for the treatment of acute ischemic stroke: A review of completed and ongoing randomized controlled trials.
Tenecteplase utility in acute ischemic stroke patients: A clinical review of current evidence.
Tenecteplase Versus Reteplase in Acute Myocardial Infarction: A Network Meta-Analysis of Randomized Clinical Trials.
Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction.
Tenecteplase: a review.
Tenecteplase: new preparation. Another thrombolytic agent for myocardial infarction: a slightly simpler treatment.
Tenecteplase: stability and bioactivity of thawed or diluted solutions used in peripheral thrombolysis.
The 4G/4G genotype at nucleotide position -675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls.
The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Etude CasTemoins de I'nfarctus du Mycocarde.
The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction.
The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease.
The acute myocardial infarction patient receiving tissue-type plasminogen activator.
The association between plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G polymorphism, and myocardial infarction: a Mendelian randomization meta-analysis.
The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women.
The complex between tPA and PAI-1: risk factor for myocardial infarction as studied in the SHEEP project.
The effect of high plasma levels of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor (PAI-1) on the reperfusion after thrombolytic therapy in patients presented with acute myocardial infarction.
The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial.
The effects of the angiotensin-converting enzyme inhibitor imidapril on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction.
The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators.
The efficacy and safety of recombinant tissue plasminogen activator infusion in acute myocardial infarction.
The efficacy and safety of tissue plasminogen activator in acute ischemic strokes.
The European Cooperative Study Group trial of intravenous recombinant tissue-type plasminogen activator (rt-PA) and conservative therapy versus rt-PA and immediate coronary angioplasty.
The FDA Advisory Panel's decision on rt-PA.
The impact of economic considerations on clinical decisionmaking: the case of thrombolytic therapy.
The impact of thrombolytic therapy on hospital mortality from acute myocardial infarction in the Chinese in Hong Kong.
The international standard for plasminogen activator inhibitor-1 (PAI-1) activity.
The late open artery hypothesis--a decade later.
The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study.
The pattern and risk factors associated with adverse drug reactions induced by Reteplase in patients with acute ST-elevation myocardial infarction: The first report from Iranian population.
The pharmacokinetics of recombinant double-chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction.
The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study.
The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma.
The prevalence of myocardial ischemia six months after thrombolytic treatment of acute coronary episodes. A subset of a placebo controlled, randomised trial, the ASSET Study.
The prognostic value of Bleeding Academic Research Consortium (BARC) defined bleeding complications in ST-segment elevation myocardial infarction: A Comparison with the Thrombolysis In Myocardial Infarction (TIMI), Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) and International Society of Thrombosis and Haemostasis (ISTH) bleeding classifications.
The Relationship of Plasminogen Activator Inhibitor-1 Levels to the ST Deviation Pattern of Acute Myocardial Infarction.
The role of the fibrinolytic system in acute myocardial infarction after a normal exercise test.
The role of thrombolytic drugs in the management of myocardial infarction. Comparative clinical trials.
The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator.
The safety and angiographic efficacy of tissue plasminogen activator in a cerebral embolization model.
The search for the ideal thrombolytic agent: maximize the benefit and minimize the risk.
The state of lipid peroxidation and antioxidants following thrombolytic therapy with rt-PA and streptokinase in acute myocardial infarction.
The thrombolysis and angioplasty in myocardial infarction (TAMI) trial: review and nursing implications.
The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty.
The tissue-type plasminogen activator story.
The use of recombinant tissue-type plasminogen activator for the treatment of sudden and chronic hearing loss.
The use of tissue-type plasminogen activator for acute myocardial infarction in the elderly: results from thrombolysis in myocardial infarction Phase I, open label studies and the Thrombolysis in Myocardial Infarction Phase II pilot study. The TIMI Investigators.
The Western Washington Myocardial Infarction Registry and Emergency Department Tissue Plasminogen Activator Treatment Trial.
Therapeutic Fibrinolysis: How Efficacy and Safety Can Be Improved.
Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke.
Third-generation thrombolytic drugs.
Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction.
Thrombin generation and myocardial infarction during infusion of tissue-plasminogen activator.
Thrombin Generation in Patients with Acute Myocardial Infarction Treated with Front-Loaded rt-PA and Recombinant Hirudin (HBW 023).
Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Thrombolysis after acute myocardial infarction.
Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality.
Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators.
Thrombolysis in acute myocardial infarction: analysis of studies comparing accelerated t-PA and streptokinase.
Thrombolysis in Myocardial Infarction (TIMI) phase II trial: outcome comparison of a "conservative strategy" in community versus tertiary hospitals. The TIMI Research Group.
Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.
Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.
Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator.
Thrombolysis in the management of acute myocardial infarction and unstable angina pectoris.
Thrombolysis in unstable angina: results of clinical studies.
Thrombolysis with intravenous human recombinant tissue-type plasminogen activator in acute myocardial infarction: the European experience.
Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty.
Thrombolysis with tissue plasminogen activator in suspected acute myocardial infarction. The ASSET Study.
Thrombolysis with tissue-type plasminogen activator in acute myocardial infarction. Potentials and pitfalls.
Thrombolysis, anticoagulation, and reocclusion.
Thrombolysis, streptokinase, and TPA in the treatment of acute myocardial infarction.
Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Thrombolysis: A Critical First-Line Therapy with an Unfulfilled Potential.
Thrombolysis: state of the art.
Thrombolysis: the need for a critical review.
Thrombolytic therapy and proteolysis of factor V.
Thrombolytic Therapy for Acute Myocardial Infarction : A Review.
Thrombolytic Therapy for Acute Myocardial Infarction in Patients with Prior Coronary Bypass Surgery: Results from the Thrombolysis in Myocardial Infarction (TIMI) 4 Trial.
Thrombolytic therapy for acute myocardial infarction: a brief review.
Thrombolytic therapy for stroke.
Thrombolytic therapy in acute myocardial infarction.
Thrombolytic therapy in acute myocardial infarction: comparison of procoagulant effects of streptokinase and alteplase regimens with focus on the kallikrein system and plasmin.
Thrombolytic therapy in cardiogenic shock: effect of increased aortic pressure and rapid tPA administration.
Thrombolytic therapy in pregnancy.
Thrombolytic therapy in selected patients with impending myocardial reinfarction.
Thrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardial infarction: A decision analysis.
Thrombolytic therapy with tissue-type plasminogen activator: new modes and novel variant plasminogen activators.
Thrombolytic therapy within one hour of the onset of acute myocardial infarction.
Thrombolytic therapy: overview of results in major vascular occlusions.
Thrombolytic therapy: then and now.
Thrombolytic treatment of an acute anterior myocardial infarction based upon echocardiography and in the absence of electrocardiographic criteria.
Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA.
Thrombolytic versus fibrinogenolytic activity of rt-PA and streptokinase in patients with acute myocardial infarction.
Thrombotic markers during myocardial infarction.
Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model.
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trial.
Time to treatment and cost of thrombolysis: a multicenter comparison of tPA and rPA.
TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study.
Timing, causes, and predictors of death after three years' follow-up in the Danish Multicenter Randomized Study of Fibrinolysis versus Primary Angioplasty in Acute Myocardial Infarction (DANAMI-2) trial.
Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes.
Tissue plasminogen activator (tPA) inhibits human neutrophil superoxide anion production in vitro.
Tissue plasminogen activator activity and inhibition in acute myocardial infarction and angiographically normal coronary arteries.
Tissue plasminogen activator administration does not result in clinically relevant neuropsychological dysfunction in patients with myocardial ischemia.
Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris.
Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: relation to stroke etiology.
Tissue plasminogen activator and plasminogen activator inhibitor-1 levels in patients with acute myocardial infarction and unstable angina.
Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study.
Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women.
Tissue plasminogen activator antigen predicts medium-term left ventricular end-systolic volume after acute myocardial infarction.
Tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty: one-year TIMI phase II pilot results. TIMI Investigators.
Tissue plasminogen activator in pediatric myocardial infarction.
Tissue plasminogen activator induced fibrinolysis: standardization of method using thromboelastography.
Tissue plasminogen activator on admission is an important predictor of 30-day mortality in patients with acute myocardial infarction undergoing primary angioplasty.
Tissue plasminogen activator using a rapid-infusion low-dose regimen for unstable angina.
Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
Tissue plasminogen activator: a new thrombolytic agent.
Tissue plasminogen activator: an evaluation of clinical efficacy in acute myocardial infarction.
Tissue plasminogen activator: from molecular biology to myocardial infarction.
Tissue plasminogen activator: hospital experience.
Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction.
Tissue-type plasminogen activator -7,351C/T enhancer polymorphism is associated with a first myocardial infarction.
Tissue-type plasminogen activator and risk of myocardial infarction.
Tissue-type plasminogen activator therapy versus primary coronary angioplasty: impact on myocardial tissue perfusion and regional function 1 month after uncomplicated myocardial infarction.
Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.
Tissue-type plasminogen activator: intracoronary applications.
TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.
TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial.
tPA Alu (I/D) polymorphism associates with bacterial osteomyelitis.
tPA in the injured central nervous system: different scenarios starring the same actor?
Transmyocardial fibrinolytic activity in patients with unstable angina pectoris.
Treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator.
Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies.
Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group.
Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).
Trials of the European Working Party on streptokinase and of the European Cooperative Study Group on alteplase in patients with acute myocardial infarction. European Investigators.
Two- and three-year results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II clinical trial.
Ultrasound accelerates thrombolysis of acutely induced platelet-rich thrombi similar to those in acute myocardial infarction.
Ultrasound-enhanced tissue plasminogen activator thrombolysis in an in vitro porcine clot model.
Unsuspected vasculitis and intracranial hemorrhage following thrombolysis.
Urgent carotid intervention is safe after thrombolysis for minor to moderate acute ischemic stroke.
Use of alteplase for myocardial infarction in two community hospitals.
Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial).
Use of reteplase for thrombolysis in patients with massive pulmonary embolism diagnosed by bedside transthoracic echocardiography: A retrospective study of safety and efficacy.
Use of thrombolytic drugs in non-coronary disorders.
Use of tissue plasminogen activator in the emergency department for acute myocardial infarction.
Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction.
Usefulness of late coronary thrombolysis (recombinant tissue-type plasminogen activator) in preserving left ventricular function in acute myocardial infarction.
Using HIS data for health care research.
Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
Value of electrocardiographic scoring systems for the assessment of thrombolytic therapy in acute myocardial infarction. The European Cooperative Study Group for Recombinant Tissue Type Plasminogen Activator.
Variables predictive of good functional outcome following thrombolytic therapy in the Thrombolysis in Myocardial Infarction phase II (TIMI II) pilot study.
Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
Vascular and haemostatic gene polymorphisms associated with non-fatal myocardial infarction: a critical review.
Vascular rhexis: loss of integrity of coronary vasculature in mice subjected to myocardial infarction.
Ventricular arrhythmias during treatment with alteplase (recombinant tissue plasminogen activator) in suspected acute myocardial infarction.
Very early thrombolytic therapy in suspected acute myocardial infarction. The Thrombolysis Early in Acute Heart Attack Trial Study Group.
Von Willebrand factor, plasminogen activator inhibitor-1 and C-reactive protein are markers of thrombolytic efficacy in acute myocardial infarction.
von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction.
Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. TIMI 10B Investigators.
YM866, a novel modified tissue-type plasminogen activator, affects left ventricular function and myocardial infarct development in dogs with coronary artery thrombi.
[A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs]
[A comparative evaluation between streptokinase and r-TPA in limiting the myocardial damage during an acute myocardial infarct. An echocardiographic study]
[A randomized clinical trial on comparison of weight-adjusted dose with low dose recombinant tissue-type plasminogen activator on Chinese patients with acute myocardial infarction]
[A randomized multicenter trial comparing recombinant staphylokinase with recombinant tissue-type plasminogen activator in patients with acute myocardial infarction]
[A randomized study of streptokinase and recombinant tissue plasminogen activator, with and without heparin, in patients with acute myocardial infarction. The results of GISSI-2/International tPA/SK Mortality Trial]
[A rare case of coronary artery perforation by a PTCA guide wire complicating with postinfarction cardiac rupture after thrombolytic therapy]
[A successful repair of concomitant rupture of the interventricular septum and left ventricular free wall after acute myocardial infarction]
[Acute myocardial infarction: immediate coronary angioplasty for failure or contra-indications of thrombolytic therapy. Apropos of a series of 100 cases]
[Advantages of immediate coronary dilatation after thrombolysis using tissue-type plasminogen activator in acute myocardial infarction. A European Cooperative Group trial]
[Alteplase administration in patients with ST-segment elevation acute myocardial infarction in typical clinical practice]
[Alteplase in acute coronary syndromes]
[An angiographic trial to evaluate the efficacy and safety of tenecteplase in Chinese patients with acute myocardial infarction]
[Anaphylactoid reaction during administration of tissue plasminogen activator (t-PA)]
[Angioneurotic orolingual edema associated with the use of rt-PA following a stroke.]
[Antithrombin therapy in acute coronary syndromes]
[Application of chronotherapy to cardiovascular diseases]
[Arrhythmia as an indicator for reperfusion following acute myocardial infarct?]
[Assessment of myocardial reperfusion in patients with acute myocardial infarction treated with combination of fibrinolysis and IIb/IIIa platelet inhibitor]
[Bilateral intracranial hemorrhage following thrombolytic therapy with alteplase (rTPA) in acute myocardial infarction]
[Biochemical characteristics associated with diabetes mellitus one year after myocardial infarction].
[Changes in plasma tissue plasminogen activator and plasminogen activator inhibitor in acute myocardial infarction and its clinical significance]
[Changes in tissue plasminogen activator and plasminogen activator inhibitor during administration of nitroglycerine into internal thoracic artery in dogs with acute myocardial ischemia]
[Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis]
[Commentary to the article: Di Mario C, Dudek D, Piscione F, et al.; CARESS-in-AMI (Combined Abciximab RE-teplase Stent Study in Acute Myocardial Infarction) Investigators. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet 2008; 371: 559-68]
[Comparative assessment of efficacy of tissue plasminogen activator and streptokinase in the treatment of patients with acute myocardial infarction]
[Comparative effect of streptokinase and alteplase on electrocardiogram and angiogram signs of myocardial reperfusion in ST segment elevation acute myocardial infarction]
[Comparative randomized study of the effectiveness of intravenous recombinant tissue-type plasminogen activator and intravenous streptokinase in patients with acute myocardial infarct. Report of the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator]
[Comparison of effects of thrombolytic therapy followed by elective coronary intervention and direct coronary intervention in acute myocardial infarction: usefulness of dobutamine stress echocardiography]
[Comparison of the clinical efficacy of recombinant tissue-type plasminogen activator thrombolysis with primary coronary stenting in acute myocardial infarction]
[Content of fibrinogen degradation products, soluble fibrin and the fibrinolytic activity of blood in myocardial infarct]
[Contributory changes in variables of coagulation and fibrinolysis to the patency of coronary arteries in patients with acute myocardial infarction]
[Coronary flow and hemorrhagic complications after alteplase and streptokinase administration in patients with acute myocardial infarction]
[Coronary microembolization in acute coronary syndrome: indicative hypothesis or still unknown phenomenon? Description of a clinical case]
[Dynamic changes in fibrinolytic system in patients with acute myocardial infarction]
[Earlier treatment of acute myocardial infarction with administration of alteplase (rt-PA) before hospitalization]
[Early evaluation of results from systemic thrombolysis in acute myocardial infarct: the value of troponin I]
[Effects of Erigeron breviscapus injection on TNF-alpha, PAI-1 and tPA in rats with acute myocardial infarction].
[Efficacy and safety comparison between pro-urokinase and reteplase in the treatment of patients with acute ST elevation myocardial infarction].
[Efficacy of low-dose mutant tissue-type plasminogen activator followed by planned rescue percutaneous transluminal coronary angioplasty as reperfusion therapy for acute myocardial infarction]
[Efficacy of thrombolytic therapy using reteplase in cases with acute ST-segment elevation myocardial infarction: results from a multicenter clinical trial].
[Elements of choice of thrombolytic agents in myocardial infarction]
[Epidural spinal hematoma following thrombolytic therapy for an acute myocardial infarct]
[Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective]
[Evaluation of the kinetics of MB creatine kinase in patients undergoing systemic thrombolytic therapy]
[Faster treatment of acute myocardial infarct by administration of alteplase (rt-PA) prior to hospitalization]
[Fatal central pulmonary embolism under heparin therapy: white-clot syndrome]
[Haematoma of the floor of the mouth associated to acute myocardial infarction.]
[Heparin induced thrombocytopenia, left ventricular thrombus and cerebral embolism during an acute myocardial infarction]
[Immediate and long-term results of thrombolytic therapy in patients with myocardial infarct: the necessity of differential treatment]
[Immediate delayed coronary angioplasty after intravenous thrombolysis in myocardial infarction. Prospective study]
[Impact of intravenous thrombolysis prior to percutaneous coronary intervention in reperfusion therapy for acute myocardial infarction]
[Indications for thrombolytics]
[Insulin resistance: an etiological factor in essential arterial hypertension and coronary cardiopathy]
[Intracoronary administration of the combined fibrinolytic therapy a in patient with acute myocardial infarction and end-stage coronary heart disease - a case report]
[Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)]
[Intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction]
[Intravenous thrombolysis by recombinant plasminogen activator (rt-PA) in unstable angina. A randomized multicenter study versus placebo]
[Intravenous thrombolysis with tissue plasminogen activator (rt-PA) at the prehospital phase of acute myocardial infarction. Apropos of 49 cases]
[Ischemic cardiopathy (VIII). Thrombolysis with plasminogen activator in myocardial infarct]
[Levels of vascular plasminogen activator and its ability to be released into the blood in recent myocardial infarct]
[Massive endocardial thrombosis in a patient with a peritoneo-jugular shunt for refractory ascites: the therapeutic success of tissue plasminogen activator and defibrotide]
[Monoclonal antibody therapy for disorders of hemostasis and coagulation]
[Multiple spontaneous coronary dissection. Case report and review of the literature]
[Myocardial infarction treated within 4 hrs: comparison of the cost-benefit ratio of 3 thrombolytic treatments: APSAC, rt-PA and streptokinase in 270 patients]
[Myocardial infarction, late fibrinolysis and resolving cerebral embolism]
[New substances and dosages for thrombolysis in acute myocardial infarct]
[Pathophysiology of acute coronary syndromes]
[Pilot study of the effectiveness of combination therapy with reduced dose alteplase and the glycoprotein IIb/IIIa antagonist tirofiban in acute myocardial infarct]
[Platelet activation in the early phases of acute myocardial infarction]
[Prehospital fibrinolysis with rt-PA in acute myocardial infarction]
[Primary coronary angioplasty in acute anterior myocardial infarction: immediate results]
[Pulmonary hemorrhage and acute respiratory failure secondary to thrombolytic treatment with tissue plasminogen activator (rt-PA) in patients with acute myocardial infarction]
[Randomized double-blind study comparing tissue-type plasminogen activator with placebo in acute myocardial infarct]
[Refibrinolysis with r-tPA for thrombosis of the mitral prosthesis after an acute myocardial infarct]
[Repeat thrombolysis in acute myocardial infarction]
[Role of the infection and inflammation in atherosclerosis development (literature review)].
[Role of thrombolysis in the treatment of cardiogenic shock following myocardial infarct]
[rt-PA in acute myocardial infarct, randomized studies in Europe and the USA]
[Study of hemostatic molecular marker]
[Study of new thrombolytic agents in myocardial infarction: a multicenter randomized trial (APSAC versus rt-PA)]
[Success and complications of rTPA treatment of the anterior eye segment]
[Suprachoroidal haemorrhage and acute glaucoma associated with systemic fibrinolysis]
[Surgical repair of left ventricular free wall rupture using layered fibrin glue sheet and fibrin glue; report of a case]
[Systemic lytic state as marker of therapeutic success after rt-PA in bolus in myocardial infarction]
[Systemic venous thrombolysis with rt-PA in arterial embolism of the legs in the elderly]
[The absence of a procoagulant effect after TNK-t-PA: a comparison with streptokinase and rt-PA]
[The fibrinolysis system in recurrent myocardial infarction]
[The influence of lipoprotein (a) in thrombolysis with r-TPA for myocardial infarction]
[The kinetics of plasma coagulation fibrinolysis levels in acute myocardial infarction before and after treatment with intravenous urokinase]
[The prevention of reocclusion after thrombolysis in acute myocardial infarct: is tissue-type plasminogen activator really superior to streptokinase?]
[The relationship between tissue type plasminogen activator therapy and ventricular late potentials in acute myocardial infarction]
[Thrombolysis by tissue plasminogen activator in acute myocardial infarct]
[Thrombolysis in acute myocardial infarction. Streptokinase or r-TPA?]
[Thrombolysis with tissue plasminogen activator in patients with acute myocardial infarction. Preliminary report]
[Thrombolysis with tissue-type plasminogen activator in acute myocardial infarct]
[Thrombolytic therapy in acute myocardial infarct]
[Thrombolytic therapy of ischemic stroke].
[Thrombolytic treatment in acute myocardial infarction. Choice of preparations in Norwegian hospitals]
[Tissue plasminogen activator (t-PA) in myocardial infarction. Biological aspects]
[Tissue plasminogen activator as a prognostic factor in myocardial infarct patients]
[Tissue-type plasminogen activator and pro-urokinase--new fibrinolytic agents in the treatment of myocardial infarction]
[Treatment of acute myocardial infarction with rt-PA in 60 minutes. Cooperative study]
[Type of Thrombolytic Agent and Rate of Acute Kidney Injury in Patients With Myocardial Infarction].
[Usefulness and safety of intravenous thrombolytic therapy for elderly patients with acute myocardial infarction: relationship with cardiac rupture]
[Variations in hemostasis and fibrinolysis during the treatment of acute myocardial infarct (AMI) with tissue-type plasminogen activator (TTPA). A study of 17 cases]
[Venous thrombolysis with the recombinant human tissue-type plasminogen activator (rt-PA) during the first 3 hours following acute myocardial infarction. Controlled pilot study with placebo]
Myocardial Ischemia
4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study.
An uncommon case of variant angina.
Beneficial effects of tissue-type plasminogen activator in acute myocardial ischemia in cats.
Cardiac ischemia and endothelial function in the isolated rabbit heart.
Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology.
Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA Trial).
Creatine kinase during non-ST-segment elevation acute coronary syndromes is associated with major bleeding.
Different cardiac tissue plasminogen activator release patterns by local stimulation of the endothelium and sympathetic nerves in pigs.
Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial.
Effect of maximum dose of atorvastatin on inflammation, thrombogenesis, and fibrinolysis in high-risk patients with ischemic heart disease.
Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction.
Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia.
Elevated tissue plasminogen activator antigen and stroke risk: The Stroke Prevention In Young Women Study.
Experimental study on establishing eukaryotic expression vector pcDNA3.1(+) TPA and its expressing activity in human skin fibroblists.
Foxc2 is a common mediator of insulin and transforming growth factor beta signaling to regulate plasminogen activator inhibitor type I gene expression.
Genetic factors determining thrombosis and fibrinolysis.
Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, phase IIIB trial).
High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.
Increased levels of factor VII, fibrinogen and activity of plasminogen activator inhibitor during postprandial triglyceridemia in patients with ischemic heart disease confirmed by angiography.
Influence of acute myocardial infarction location on in-hospital and late outcome after primary percutaneous transluminal coronary angioplasty versus tissue plasminogen activator therapy.
Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice.
Lifestyle and hemostatic risk factors for ischemic heart disease : the Caerphilly Study.
Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy.
MicroRNA-30b protects myocardial cell function in patients with acute myocardial ischemia by targeting plasminogen activator inhibitor-1.
Neutrophil extracellular traps in ischemia-reperfusion injury-induced myocardial no-reflow: therapeutic potential of DNase-based reperfusion strategy.
New antiplatelet agents prescribed to patients with ischemic heart disease: implications for treatment of stroke.
Not only the Sugar, Early infarct sign, hyperDense middle cerebral artery, Age, Neurologic deficit score but also atrial fibrillation is predictive for symptomatic intracranial hemorrhage after intravenous recombinant tissue plasminogen activator.
Overweight/obesity, smoking, and heavy alcohol consumption are important determinants of plasma PAI-1 levels in healthy men.
Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations.
Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction.
Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q wave myocardiaL infarction. Thrombolysis in Myocardial Ischemia III B Investigators.
Repeat infusion of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction and early recurrent myocardial ischemia.
S-nitrosylated tissue-type plasminogen activator protects against myocardial ischemia/reperfusion injury in cats: role of the endothelium.
The impact of cardiac ischemia and reperfusion on markers of activated haemostasis and fibrinolysis during cardiopulmonary bypass: comparison of plasma levels in arterial and coronary venous blood.
The prevalence of myocardial ischemia six months after thrombolytic treatment of acute coronary episodes. A subset of a placebo controlled, randomised trial, the ASSET Study.
Thrombolysis with recombinant human tissue-type plasminogen activator during instability in coronary artery disease: effect on myocardial ischemia and need for coronary revascularization. TRIC Study Group.
Tissue plasminogen activator administration does not result in clinically relevant neuropsychological dysfunction in patients with myocardial ischemia.
Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
[Blood coagulation and fibrinolysis in ischemic heart disease]
[Changes in tissue plasminogen activator and plasminogen activator inhibitor during administration of nitroglycerine into internal thoracic artery in dogs with acute myocardial ischemia]
[Effect of maximum dose of atorvastatin on inflammation, thrombogenesis and fibrinolysis in high-risk patients with ischemic heart disease]
[Evaluation of platelet function and tissue plasminogen activator activity in ischemic heart disease depending on concurrence with hyperlipoproteinemia and aspirin therapy]
[Gender differences in the state of the system of hemostasis in patients with ischemic heart disease]
[Plasmin-mediated activation of the coagulation system. A study of patients with acute ischemic heart disease treated with recombinant tissue-plasminogen activator]
[Plasminogen activator inhibitor and protein C: their relation to plasma lipids and lipo- and apoproteins in ischemic heart disease of different duration]
[Plasminogen activator inhibitor-1 (PAI-1), ischemic heart disease and diabetes mellitus]
[Seasonal changes in the blood coagulating and anticoagulating system indices in men at the preclinical stage of ischemic heart disease]
[Should hemostatic factors be considered in the prevention of cardiovascular disease?]
[Tissue plasminogen activator and plasminogen activator inhibitor gene polymorphisms: possible relation to atherosclerosis and its complications]
Myocarditis
A specific inhibitor of plasminogen activator inhibitor-1 suppresses rat autoimmune myocarditis.
Myoma
The clinical value of tissue polypeptide antigen in patients with gynecologic tumors.
[The clinical significance of tissue polypeptide antigen (TPA) in the patients with gynecologic tumor]
[Tissue polypeptide antigen as a tumor marker for gynecologic malignancies]
Myopia
Displacement of Submacular Hemorrhage With Subretinal Injection of Recombinant Tissue Plasminogen Activator and Gas Tamponade in the Setting of Myopic Degeneration.
Myotonic Dystrophy
Increased levels of tPA antigen and tPA/PAI-1 complex in myotonic dystrophy.
Myxoma
Cerebral embolism associated with left atrial myxoma that was treated with thrombolytic therapy.
Inhibition of plasmin, urokinase, tissue plasminogen activator, and C1S by a myxoma virus serine proteinase inhibitor.
Intravenous Thrombolysis for Acute Ischemic Stroke Due to Cardiac Myxoma.
Intravenous thrombolysis of occlusion in the middle cerebral and retinal arteries from presumed ventricular myxoma.
Neuroserpin, a thrombolytic serine protease inhibitor (serpin), blocks transplant vasculopathy with associated modification of T-helper cell subsets.
Prevention of cerebral embolism progression by emergency surgery of the left atrial myxoma.
Safe and effective intravenous thrombolysis for acute ischemic stroke caused by left atrial myxoma.
Safety of intravenous thrombolysis in ischemic stroke caused by left atrial myxoma.
Thrombolytic Treatment of Cardiac Myxoma-Induced Ischemic Stroke: a Review.
[A case of acute ischemic stroke due to cardiac myxoma treated by intravenous thrombolysis and endovascular therapy].
Nasal Polyps
Chronic Rhinosinusitis and the Coagulation System.
Common fibrin deposition and tissue plasminogen activator downregulation in nasal polyps with distinct inflammatory endotypes.
Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression.
Partial purification and characterization of the tissue plasminogen activator in nasal mucosa and nasal polyp.
Plasminogen activators in human nasal polyps and mucosa.
Nasopharyngeal Carcinoma
Identification of a plasminogen activator derived from nasopharyngeal carcinoma.
Proteome analysis of antiproliferative mechanism of 12-O-tetradecanoylphorbol 13-acetate on cultured nasopharyngeal carcinoma CNE2 cells.
Proteomics-based identification of proteins with altered expression induced by 12-O-tetradecanoylphorbol 13-acetate in nasopharyngeal carcinoma CNE2 cells.
The concentration of u-PA and PAI-1 antigen in tissue extracts of nasopharyngeal carcinoma.
Neoplasm Metastasis
(-)-Epigallocatechin gallate derivatives reduce the expression of both urokinase plasminogen activator and plasminogen activator inhibitor-1 to inhibit migration, adhesion, and invasion of MDA-MB-231 cells.
A direct link between expression of urokinase plasminogen activator receptor, growth rate and oncogenic transformation in mouse embryonic fibroblasts.
A functional role for hemostasis in early cancer development.
A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis.
A model to account for the effects of oncogenes, TPA, and retinoic acid on the regulation of genes involved in metastasis.
A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA.
A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development.
A prospective, blinded trial of touch prep analysis versus frozen section for intraoperative evaluation of sentinel lymph nodes in breast cancer.
Active Expression of Human Tissue Plasminogen Activator (t-PA) c-DNA from Pulmonary Metastases in the Methylotrophic Yeast Pichia Pastoris KM71H Strain
Activity Regulation by Fibrinogen and Fibrin of Streptokinase from Streptococcus Pyogenes.
ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway.
An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo.
An individual reference limit of the serum CEA-TPA-CA 15-3 tumor marker panel in the surveillance of asymptomatic women following surgery for primary breast cancer.
Analysis of expressions of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells.
Antibodies to plasminogen activator inhibit human tumor metastasis.
Antimetastatic Potentials of Phyllanthusurinaria L on A549 and Lewis Lung Carcinoma Cells via Repression of Matrix-Degrading Proteases.
Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients.
Association between Plasma Levels of Plasminogen Activator Inhibitor-1 and Colorectal Neoplasms.
Body Composition Parameters May Be Prognostic Factors in Upper Urinary Tract Urothelial Carcinoma Treated by Radical Nephroureterectomy.
Both TPA and SCC-Ag levels are prognostic even in high-risk stage Ib-IIa cervical carcinoma as determined by a stratification analysis.
Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis.
Breast-conserving therapy: proteases as risk factors in relation to survival after local relapse.
Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squamous cell lung cancer.
Cellular and secreted tumor plasminogen activator: the effects of NaCl.
Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer.
Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma.
Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer.
Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.
Clotting activation and impairment of fibrinolysis in malignancy.
Comparative study on expression of plasminogen activator inhibitor 1 and its mRNA in endometrial cancers and normal endometria.
Comparison between CEA, TPA, CA 15/3 and hydroxyproline, alkaline phosphatase, whole body retention of 99mTc MDP in the follow-up of bone metastases in breast cancer.
Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.
Correction: Effects of a high-fat diet on spontaneous metastasis of Lewis lung carcinoma in plasminogen activator inhibitor-1 deficient and wild-type mice.
Correlation of the production of plasminogen activator with tumor metastasis in B16 mouse melanoma cell lines.
CSF levels of growth factors and plasminogen activators in leptomeningeal metastases.
Cysteine and serine proteases in gastric cancer.
Detection of cathepsin B, plasminogen activators and plasminogen activator inhibitor in human non-small lung cancer cell lines.
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Diagnosis of bone and liver metastases in breast cancer comparing tumor markers and imaging techniques.
Diagnostic and prognostic value of TPA in breast cancer.
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer.
Diagnostic value of cerebrospinal fluid cytology in comparison with tumor marker activity in central nervous system metastases secondary to breast cancer.
Diagnostic value of serum tumor markers in skeletal metastasis of carcinomas.
Differential tumor markers and hepatitis markers profile in liver tumors.
Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
Distribution of plasminogen activator inhibitor in normal liver, cirrhotic liver, and liver with metastases.
Drug-resistant human laryngeal carcinoma cells have increased levels of cathepsin B.
Early and late endothelial response in breast cancer metastasis in mice: simultaneous quantification of endothelial biomarkers using mass spectrometry-based method.
Early diagnosis for bone metastasis of breast cancer based on bone metabolism.
Effect of transforming growth factor-beta on plasminogen activator production of cultured human uveal melanoma cells.
Effects of a high-fat diet on spontaneous metastasis of Lewis lung carcinoma in plasminogen activator inhibitor-1 deficient and wild-type mice.
Endothelial cells promote triple-negative breast cancer cell metastasis via PAI-1 and CCL5 signaling.
Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer.
Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
Evaluation of tissue polypeptide antigen serum levels for monitoring disease activity during chemotherapy in patients with transitional carcinoma of the urinary tract.
Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: Association with tumor progression.
Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance.
Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.
Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer.
Fibrinolytic System and Cancer: Diagnostic and Therapeutic Applications.
Fibrinolytic system in plasma and pleural fluid in malignant pleural mesothelioma.
Flavokawain B inhibits growth of human squamous carcinoma cells: Involvement of apoptosis and cell cycle dysregulation in vitro and in vivo.
Functional evaluation of plasmin formation in primary breast cancer.
Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival.
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes.
Helicobacter pylori infection stimulates plasminogen activator inhibitor 1 production by gastric epithelial cells.
Human plasma fibronectin as a substrate for human urokinase.
Human tissue polypeptide antigen in breast cancer.
Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitor properties concomitant with an allosteric up-regulation of its antiadhesive properties.
Immunoreactivity of Plasminogen Activator Inhibitor 1 and Its Correlation with Dysmenorrhea and Lesional Fibrosis in Adenomyosis.
Importance of viability and attachment to an ascites tumor in the release of plasminogen activator.
In vitro and in vivo antimetastatic effects of Terminalia catappa L. leaves on lung cancer cells.
Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis.
Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis.
Induction of membrane ruffling by growth factors in morphologically TPA-resistant Balb/c3T3 TR4 cells.
Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue.
Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model.
Inhibitory effect on the establishment of hepatic metastasis by transduction of the tissue plasminogen activator gene to murine colon cancer.
Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.
Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.
Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.
Intraperitoneal infusion of recombinant plasminogen activator inhibitor type 2 induced apoptosis in implanted human colon cancer and inhibited its growth and liver metastasis.
Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor.
Inverse correlation between mRNA expression of plasminogen activator inhibitor-2 and lymph node metastasis in human breast cancer.
Involvement of plasminogen activator production with tumor metastasis in a rat model.
Irreversible Inhibition of Serine Proteases - Design and In Vivo Activity of Diaryl alpha-Aminophosphonate Derivatives.
Is tissue polypeptide antigen still a useful tumor marker in breast carcinoma? Comparison with CA15.3 and MCA.
JNK Suppression is Essential for 17beta-Estradiol Inhibits Prostaglandin E2-Induced uPA and MMP-9 Expressions and Cell Migration in Human LoVo Colon Cancer Cells.
Kondrat'eva ligation: Diels-Alder-based irreversible reaction for bioconjugation.
Levels of tissue polypeptide antigen in serum and the progression of gastric cancer.
Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array.
Limited proteolysis of angiogenin by elastase is regulated by plasminogen.
Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells.
Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin.
Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
Malignant conversion and metastasis of mouse skin tumors: a comparison of SENCAR and CD-1 mice.
Matrix metalloproteinases and their inhibitors in correlation to proliferative and classical tumour markers during surgical therapy of colorectal liver metastases.
Measurement of plasminogen activator activity from human fibrosarcoma cells by a new microassay.
Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Metastatic suppressor CD44 is related with oxidative stress in breast cancer cell lines.
Modulation of cell-associated plasminogen activator activity by cocultivation of a stem cell and its tumorigenic descendant.
Modulatory effects of 5-azacytidine, phorbol ester, and retinoic acid on the malignant phenotype of human lung cancer cells.
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
Multiple forms of plasminogen activator in human breast tumors.
Multivariate analysis of serum tumor markers for diagnosis of skeletal metastases.
Non-muscle alpha-actinin-4 interacts with plasminogen activator inhibitor type-1 (PAI-1).
Old dogs and new tricks: proteases, inhibitors, and cell migration.
Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines.
Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice.
Overexpression of Plasminogen Activator Inhibitor-1 in Advanced Gastric Cancer with Aggressive Lymph Node Metastasis.
p38? MAPK Mediates 17?-Estradiol Inhibition of MMP-2 and -9 Expression and Cell Migration in Human LoVo Colon Cancer Cells.
p53 regulates the expression of the tumor suppressor gene maspin.
PAI-1 and functional blockade of SNAI1 in breast cancer cell migration.
PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells.
PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination.
Pattern of fibrinolytic parameters in patients with gastrointestinal carcinomas.
Plasminogen Activation System in Rectal Adenocarcinoma.
Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Plasminogen activator activity of metastatic variants from a murine fibrosarcoma; effect of thrombin in vitro.
Plasminogen activator and cancer.
Plasminogen activator content of gynecological tumors and their metastases.
Plasminogen activator inhibitor (PAI) trap3, an exocellular peptide inhibitor of PAI-1, attenuates the rearrangement of F-actin and migration of cancer cells.
Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.
Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo.
Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells.
Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis.
Plasminogen activator inhibitor-1 accelerates lung metastasis formation of human fibrosarcoma cells.
Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis.
Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis.
Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines.
Plasminogen activator system in oral squamous cell carcinoma.
Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer.
Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues.
Pre-operative serum levels of tissue polypeptide antigen in patients with gastric cancer.
Prediction of biological behaviour of human breast cancer using multiple parameters. A preliminary study.
Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells.
Production of plasminogen activator by a primary HSV-2-induced hamster fibrosarcoma and its in vivo derived sublines.
Prognostic significance of proteolytic enzymes in human brain tumors.
Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer.
Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.
Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer.
Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma.
Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer.
Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Proteases and protease inhibitors in tumor progression.
Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma.
Reactive oxygen species-mediated PKC and integrin signaling promotes tumor progression of human hepatoma HepG2.
Reduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors.
Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors.
Reduction of tumor-associated fibrinolytic-activity by antimetastatic dosages of 2 ru(ii)-dmso complexes in mice bearing lewis lung-carcinoma.
Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Relationship between multiple forms of plasminogen activator in human breast tumors and plasma and the presence of metastases in lymph nodes.
Rodent-specific hypoxia response elements enhance PAI-1 expression through HIF-1 or HIF-2 in mouse hepatoma cells.
Role of CEA, TPA, and Ca 19-9 in the early detection of localized and diffuse recurrent rectal cancer.
Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer.
Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells--role in metastasis.
Sensitivity of monoclonal antibodies to carcinoembryonic antigen, tissue polypeptide antigen, alpha-fetoprotein, carbohydrate antigen 50, and carbohydrate antigen 19-9 in the diagnosis of colorectal adenocarcinoma.
Serum tissue polypeptide antigen (TPA) in thyroid cancer.
Sex steroids regulate the expression of plasminogen activator inhibitor-1 (PAI-1) and its mRNA in uterine endometrial cancer cell line Ishikawa.
Significance of carcinoembryonic and tissue polypeptide antigen determination in the diagnosis of metastases in breast cancer.
Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis.
Significance of tissue polypeptide antigen (TPA) levels in nasopharyngeal cancer.
Significance of tumour markers in nasopharyngeal carcinoma.
Silencing of plasminogen activator inhibitor-1 suppresses colorectal cancer progression and liver metastasis.
SK-216, a Novel Inhibitor of Plasminogen Activator Inhibitor-1, Suppresses Lung Metastasis of Human Osteosarcoma.
Specificity of tumor markers (CEA, GICA, TPA, alpha-FP, FpA, gamma-GT) for the diagnosis of hepatic metastases from large bowel cancers.
Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer.
Studies on the pathogenesis of coagulopathy in patients with arterial thromboembolism and malignancy.
Study of lncRNA TPA in Promoting Invasion and Metastasis of Breast Cancer Mediated by TGF-? Signaling Pathway.
Targeting invasion induction as a therapeutic strategy for the treatment of cancer.
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Targeting urokinase-type plasminogen activator and its receptor for cancer therapy.
The active fraction of plasmatic plasminogen activator inhibitor type 1 as a possible indicator of increased risk for metastatic melanoma.
The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice.
The effect of TNP-470 on cell proliferation and urokinase-type plasminogen activator and its inhibitor in human lung cancer cell lines.
The fibrinolytic factor tPA drives LRP1-mediated melanoma growth and metastasis.
The fibrinolytic system in experimental prostate tumor.
The plasminogen activator inhibitor "paradox" in cancer.
The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.
The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer.
The role of cysteine and serine proteases in colorectal carcinoma.
The role of proteolytic enzymes in cancer invasion and metastasis.
The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma.
The role of thrombospondin-1 in tumor progression and angiogenesis.
The Role of TPS and TPA in the Diagnostics of Distant Metastases.
The urokinase plasminogen activator system in breast cancer invasion and metastasis.
The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis.
The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group.
Tissue plasminogen activator is released into cultured medium by cultured human uveal melanocytes.
Tissue polypeptide antigen (TPA) and beta 2-microglobulin (beta 2-MG) as tumour markers in nasopharyngeal cancer.
Tissue polypeptide antigen (TPA) as a predictor for genitourinary cancers and their metastases.
Tissue polypeptide antigen in tumor cytosol: a new prognostic indicator in primary breast cancer.
Tissue polypeptide antigen--a marker antigen differentiating cholangiolar tumors from other hepatic tumors.
Tissue-type plasminogen activator is involved in skeletal metastasis from human breast cancer.
Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas.
Total proteolytic activity and levels of the main proteinase inhibitors in blood plasma of mice bearing Lewis lung carcinoma upon development of resistance to cisplatin.
Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling.
Transforming growth factor-beta1-dependent activation of Smad2/3 and up-regulation of PAI-1 expression is negatively regulated by Src in SKOV-3 human ovarian cancer cells.
Tumor cell dissemination in colon cancer does not predict extrahepatic recurrence in patients undergoing surgery for hepatic metastases.
Tumor markers in colorectal carcinoma. An evaluation of carcinoembryonic antigen, tissue polypeptide antigen, placental alkaline phosphatase and pseudouridine.
Tumor progression of murine epidermal cells after treatment in vitro with 12-O-tetradecanoylphorbol-13-acetate or retinoic acid.
Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases.
Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma.
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial.
Urinary-type plasminogen activator receptor (uPAR) modulates oral cancer cell behavior with alteration in p130cas.
Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.
Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors.
Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.
Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.
Value of CA 15.3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis.
[A case of acute ischemic stroke due to cardiac myxoma treated by intravenous thrombolysis and endovascular therapy].
[A plasminogen regulation system in brain tumors].
[CA 15-3 associated with CEA and TPA in the follow-up of breast carcinoma]
[Clinical study of the measurement of tissue polypeptide antigen in patients with breast cancer]
[Comparison of the value of LDH isoenzyme and tissue polypeptide antigen levels in tumor patients during radiotherapy and as a control of tumor growth]
[Diagnosis of skeletal metastases by serum tumor markers]
[Diagnostic value of tissue polypeptide antigen in serum of larynx cancer patients]
[Effect of phorbol ester on tissue-type plasminogen activator (t-PA) secretion in endometrial carcinoma cell line in vitro]
[Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer]
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
[Mechanism of the activation of extracellular signal-regulated kinase (ERK) in prostate cancer cell lines with different metastatic potential]
[Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer]
[Proteolysis in the cells of malignant human and animal tumors]
[Serum levels of tissue polypeptide antigen in patients with the head and neck cancer according to presence of metastases in lymph nodes]
[Study of the cytosolic concentrations of the tissue poly-peptide specific (TPS) antigen in infiltrating ductal carcinomas of the breast. Positive relationship with hormone dependency and negative with cellular proliferation]
[Study on the plasma plasminogen activators in patients with malignant gynecologic tumors]
[The effects of tumor antigen gene OVA66 on biological characteristics of tumor cells.]
[The selection of taxol resistance associated genes in ovarian cancer cell line by mRNA DD]
[The tumor markers TPA and CEA in the after care of breast cancer]
[Therapy and follow-up using TPA in radio-oncologic after-care in bladder cancer]
[Tissue plasminogen activator activity in early prostatic cancer and in bone metastases of prostatic cancer]
[Tumoral markers and acute-phase reactants in the diagnosis of pancreatic cancer]
[Untreatable ventricular hemorrhage revealing cerebral metastasis of malignant melanoma]
Neoplasm Micrometastasis
T1 breast cancer: identification of patients at low risk of axillary lymph node metastases.
Tissue polypeptide antigen expression in human prostate tumors.
Neoplasm, Residual
Discrete roles of cytokines, TNF-alpha, IL-1, IL-6 in tumor promotion and cell transformation.
Serum levels of scc, cea, ca-125 and tpa in the management of cervical-carcinoma.
Neoplasms
'Early' mammalian myoblasts are resistant to phorbol ester-induced block of differentiation.
(S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
1 alpha, 25-Dihydroxyvitamin D3 inhibits phorbol ester-dependent chemical carcinogenesis in mouse skin.
1'-Acetoxychavicol acetate, a superoxide anion generation inhibitor, potently inhibits tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in ICR mouse skin.
12-0-Tetradecanoyl Phorbol-13-Acetate (TPA) and Its Effect on Leukaemic Cells, In-vitro-A Review.
12-0-Tetradecanoylphorbol-13-acetate-induced amplification of mesenchymal tumorigenesis in the mouse skin.
12-O-tetradecanoyl phorbol-13-acetate (TPA) stimulates somatostatin release from isolated perfused rat stomach.
12-O-tetradecanoyl-phorbol-13-acetate enhancement of the tumorigenic potential of herpes simplex virus type 2 transformed cells.
12-O-Tetradecanoylphorbol-13-acetate (TPA) is anti-tumorigenic in liver cancer cells via inhibiting YAP through AMOT.
12-O-tetradecanoylphorbol-13-acetate and staurosporine induce increased retinoblastoma tumor suppressor gene expression with megakaryocytic differentiation of leukemic cells.
12-O-tetradecanoylphorbol-13-acetate and UV radiation-induced nucleoside diphosphate protein kinase B mediates neoplastic transformation of epidermal cells.
12-O-tetradecanoylphorbol-13-acetate not only modulates proliferation rates, but also alters antigen expression and LAK-cell susceptibility of normal human melanocytes in vitro.
12-O-tetradecanoylphorbol-13-acetate promotes tumors prior to initiation in two-stage promotion.
12-O-tetradecanoylphorbol-13-acetate promotion of transgenic mice expressing epidermal-targeted v-fos induces rasHA-activated papillomas and carcinomas without p53 mutation: association of v-fos expression with promotion and tumor autonomy.
12-O-tetradecanoylphorbol-13-acetate promotion of transgenic mouse epidermis coexpressing transforming growth factor-alpha and v-fos: acceleration of autonomous papilloma formation and malignant conversion via c-Ha-ras activation.
12-O-tetradecanoylphorbol-13-acetate-induced apoptosis is mediated by tumor necrosis factor alpha in human monocytic U937 cells.
12-O-tetradecanoylphorbol-13-acetate-induced differentiation of a human rhabdomyosarcoma cell line.
12-O-tetradecanoylphorbol-13-acetate-mediated systemic co-promotion in the murine skin multistage carcinogenesis protocol.
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) does not inhibit intercellular communication in Chinese hamster V79 cells.
2,3-epoxy-4-hydroxynonanal as a potential tumor-initiating agent of lipid peroxidation.
2-Methoxyestradiol confers neuroprotection and inhibits a maladaptive HIF-1? response after traumatic brain injury in mice.
26-Week dermal oncogenicity study evaluating pure trans-capsaicin in Tg.AC hemizygous mice (FBV/N).
28-deacetylbelamcandal, a tumor-promoting triterpenoid from Iris tectorum.
3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
4 Beta- and 4 alpha-12-O-tetradecanoylphorbol-13-acetate elicit arachidonate release from epidermal cells through different mechanisms.
4G/5G plasminogen activator inhibitor-1 and -308 A/G tumor necrosis factor-? promoter gene polymorphisms in Argentinean lupus patients: focus on lupus nephritis.
7,12-Dimethylbenz[a]anthracene/12-O-tetradecanoyl-phorbol-13-acetate-mediated skin tumor initiation and promotion in male Sprague-Dawley rats.
A cell culture assay for tumor-promoter-dependent progression toward neoplastic phenotype: detection of tumor promoters and promotion inhibitors.
A Chimeric Signal Peptide-Galectin-3 Conjugate Induces Glycosylation-Dependent Cancer Cell-Specific Apoptosis.
A clinical and biochemical study on tissue polypeptide antigen (TPA) in non-malignant hepatic disorders.
A clinical and laboratory evaluation of the behavior of tissue polypeptide antigen in liver cirrhosis.
A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer.
A Comparative Study of Clinical Intervention and Interventional Photothermal Therapy for Pancreatic Cancer.
A comparison between the epidermal regenerative responses provoked by a skin irritant and a tumor promoter using anti-BrdUrd/DNA flow cytometry.
A comparison of the effects of tumor promoters 12-O-tetradecanoylphorbol-13-acetate and teleocidin on gene expression in human skin cell fibroblasts.
A comparison of the expression of the malignant phenotype in two androgen-independent human prostate cancer cell lines after orthotopic implantation in nude mice.
A comparison regarding antiproliferative action between soy total extract and genistein.
A Comprehensive Gene Expression Analysis of Resistance Formation upon Metronomic Cyclophosphamide Therapy.
A course of very small doses of DMBA, each of them allegedly with no promoting potency, acts with clear synergistic effect as a strong promoter of DMBA-initiated mouse skin carcinogenesis. A comparison of the tumorigenic and carcinogenic effects of DMBA (7,12-dimethylbenz-alpha-anthracene) and TPA (12-O-tetradecanoyl-phorbol-13-acetate) used as initiators and promoters in classical two-stage experimental protocols.
A curcumin-based TPA four-branched copper(II) complex probe for in vivo early tumor detection.
A diacetylenic spiroketal enol ether epoxide, AL-1, from Artemisia lactiflora inhibits 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion possibly by suppression of oxidative stress.
A direct link between expression of urokinase plasminogen activator receptor, growth rate and oncogenic transformation in mouse embryonic fibroblasts.
A farnesyl transferase inhibitor suppresses TPA-mediated skin tumor development without altering hyperplasia in the ras transgenic Tg.AC mouse.
A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model.
A functional role for hemostasis in early cancer development.
A gene involved in action of tumor promoters is identified and mapped in Caenorhabditis elegans.
A Harvey-ras responsive transcription element is also responsive to a tumour-promoter and to serum.
A hybrid protein of the amino-terminal fragment of urokinase and mutant plasminogen activator inhibitor-2 efficiently inhibits tumor cell invasion and metastasis.
A keratin of fetal skin is reexpressed in human keratinocytes transformed by SV40 virus or treated with the tumor promoter TPA.
A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules.
A macrophage tumor cell line and plasminogen activator. A potential model system for macrophage regulation of enzyme production.
A malignant transformation of human cells by 2,3,7,8-tetrachlorodibenzo-p-dioxin exhibits altered expressions of growth regulatory factors.
A mechanism for assembly of complexes of vitronectin and plasminogen activator inhibitor-1 from sedimentation velocity analysis.
A mechanism-based antioxidant approach for the reduction of skin carcinogenesis.
A mediator of cell surface-specific plasmin generation.
A model for human colon carcinoma evolution based on the differential response of cultured preneoplastic, premalignant, and malignant cells to 12-O-tetradecanoylphorbol-13-acetate.
A multiprotein complex consisting of the cellular coactivator p300, AP-1/ATF, as well as NF-kappaB is responsible for the activation of the mouse major histocompatibility class I (H-2K(b)) enhancer A.
A murine model of squamous intraepithelial neoplasia.
A mutagenesis-enhancing activity of 12-O-tetradecanoylphorbol 13-acetate detected in Chinese hamster ovary cells.
A new CA125-like antigen (CA602) recognized by two monoclonal antibodies against a newly established ovarian clear cell carcinoma cell line (RMG-II).
A new concept of tumor promotion by tumor necrosis factor-alpha, and cancer preventive agents (-)-epigallocatechin gallate and green tea--a review.
A new human breast cancer cell line, KPL-1 secretes tumour-associated antigens and grows rapidly in female athymic nude mice.
A new human cholangiocellular carcinoma cell line (KMC-1).
A new translocation t(11;13)(q13;q14) in a mature B-cell neoplasm.
A nomogram to predict individual prognosis in node-negative breast carcinoma.
A novel aspartic protease gene, ALP56, is up-regulated in human breast cancer independently from the cathepsin D gene.
A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
A novel mechanism of skin tumor promotion involving interferon-gamma (IFN?)/signal transducer and activator of transcription-1 (Stat1) signaling.
A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA.
A Novel Peptide Derived from Tissue-Type Plasminogen Activator Potently Inhibits Angiogenesis and Corneal Neovascularization.
A novel protein (p10) induced by 12-O-tetradecanoyl-phorbol-13-acetate (TPA) and other hyperplasiogenic tumor-promoting and non-promoting agents in murine epidermis.
A partial catalog of proteins secreted by epidermal keratinocytes in culture.
A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state.
A personalized approach to cancer treatment: how biomarkers can help.
A phase I clinical trial of 12- O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies.
A Pilot Trial to Examine the Changes in Carotid Arterial Inflammation in Renal Transplant Recipients as Assessed by 18F-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography Computed Tomography (PET/CT).
A polypeptide secreted by transformed cells that modulates human plasminogen activator production.
A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development.
A proenzyme from chicken plasma similar to human plasma prekallikrein.
A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol.
A simple fluorescent technique for the location of tumour cells in frozen sections of the head and neck region.
A simple phenolic antioxidant protocatechuic acid enhances tumor promotion and oxidative stress in female ICR mouse skin: dose-and timing-dependent enhancement and involvement of bioactivation by tyrosinase.
A state of the art review on the novel mediator asprosin in the metabolic syndrome.
A subpopulation of 12-O-tetradecanoylphorbol-13-acetate-induced papillomas is not inhibited by retinoic acid.
A tumor promoting phorbol ester, TPA, enhances polyomavirus DNA replication by activating the function of the viral enhancer.
A tumour promoter induces alterations in vinculin and actin distribution in human renal epithelium.
Aberrant expression of aromatase in breast cancer tissues.
Ability of the non-phorbol ester-type tumor-promoter thapsigargin to mimic the stimulatory effects of 12-0-tetradecanoylphorbol-13-acetate on ornithine decarboxylase activity, hydroperoxide production, and macromolecule synthesis in mouse epidermis in vivo.
Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung.
Abrogation of the suppressive effect of 12-O-tetradecanoylphorbol 13-acetate and 7,12-dimethylbenz[a]anthracene on footpad reaction of mice by indomethacin and some inhibitors of tumor promotion.
Absence of enhanced systemic inflammatory response at 18 weeks of gestation in women with subsequent pre-eclampsia.
Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization.
Absolute quantitative proteomics using the total protein approach to identify novel clinical immunohistochemical markers in renal neoplasms.
Accelerated urokinase-receptor protein turnover triggered by interference with the addition of the glycolipid anchor.
Acceleration of papilloma growth in mice fed high-fat diets during promotion of two-stage skin carcinogenesis.
Acetaldehyde activates Jun/AP-1 expression and DNA binding activity in human oral keratinocytes.
Acquisition of a growth-inhibitory response to phorbol ester involves DNA damage.
ACSL3-PAI-1 signaling axis mediates tumor-stroma cross-talk promoting pancreatic cancer progression.
Actin cytoskeletal organization loss in the benign-to-malignant tumor transition in cultured human colonic epithelial cells.
Action of 12-O-tetradecanoylphorbol-13-acetate on Y1 adrenal cells apparently requires the regulatory subunit of type 1 cyclic AMP dependent protein kinase.
Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase C agonists.
Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study.
Activation of protein kinase C by tumor promoting phorbol esters, teleocidin and aplysiatoxin in the absence of added calcium.
Activation of the c-Raf protein kinase by protein kinase C phosphorylation.
Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met.
Activation of the {beta}-catenin/T-cell-specific transcription factor/lymphoid enhancer factor-1 pathway by plasminogen activators in ECV304 carcinoma cells.
Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of Escherichia coli.
Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Acute effects of different alcoholic beverages on vascular endothelium, inflammatory markers and thrombosis fibrinolysis system.
Acute renal failure in African children with Burkitt's lymphoma: A comparison of two treatment regimens.
ADAM9 promotes lung cancer progression through vascular remodeling by VEGFA, ANGPT2, and PLAT.
Adding Multiple Adipokines into the Model do not Improve Weight Gain Prediction by Leptin Levels in Newborns.
Additional prognostic factors in right colon cancer staging.
Adherence to the Mediterranean Diet and Inflammatory Markers.
Adipocyte-derived hormones, cytokines, and mediators.
Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1.
Adipocytokines and metabolic syndrome.
Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis.
Adipocytokines attenuate the association between visceral adiposity and diabetes in older adults.
Adipokine and insulin profiles distinguish diabetogenic and non-diabetogenic obesities in mice.
Adipokine Profiling in Adult Women With Central Obesity and Hypertension.
Adipokines demonstrate the interacting influence of central obesity with other cardiometabolic risk factors of metabolic syndrome in Hong Kong Chinese adults.
Adipokines in diabetes and cardiovascular diseases.
Adipokines, inflammation, and the endothelium in diabetes.
Adiponectin and its role in cardiovascular diseases.
Adiponectin Inhibits TNF-?-Activated PAI-1 Expression Via the cAMP-PKA-AMPK-NF-?B Axis in Human Umbilical Vein Endothelial Cells.
Adiponectin: A Key Player in Obesity Related Disorders.
Adipose tissue dysfunction in obesity, diabetes, and vascular diseases.
Adipose Tissue: The New Endocrine Organ? A Review Article.
Adjuvant Chemotherapy in Node-negative Breast Cancer: UPA/PAI-1 Determinations for 163 Cases.
Administration of Steamed and Freeze-Dried Mature Silkworm Larval Powder Prevents Hepatic Fibrosis and Hepatocellular Carcinogenesis by Blocking TGF-?/STAT3 Signaling Cascades in Rats.
AFP, CEA, CA 19-9 and TPA in hepatocellular carcinoma.
Akkermansia muciniphila can reduce the damage of gluco/lipotoxicity, oxidative stress and inflammation, and normalize intestine microbiota in streptozotocin-induced diabetic rats.
Albinism in Nigeria with delineation of new recessive oculocutaneous type.
Alda-1, an aldehyde dehydrogenase-2 agonist, causes deterioration in renal functions following ischemia-reperfusion injury due to crystalline nephropathy.
All-trans beta-carotene enhances mitogenic responses and ornithine decarboxylase activity of BALB/c 3T3 fibroblast cells induced by tumor promoter and fetal bovine serum but suppresses mutagen-dependent umu C gene expression in Salmonella typhimurium (TA 1535/pSK 1002).
Alpha 2-HS glycoprotein (fetuin-A) modulates murine skin tumorigenesis.
Alteration of Egr-1 mRNA during multistage carcinogenesis in mouse skin.
Alterations in epidermal sulfated proteoglycan production following topical application of the tumor promoter 12-O-tetradecanoyl phorbol-13-acetate to mouse skin.
Alterations in insulin signalling pathway induced by prolonged insulin treatment of 3T3-L1 adipocytes.
Alterations of intercellular communication associated with the transformation of C3H/10T1/2 cells.
Alterations to the fibrinolytic enzyme system in patients with non-small cell lung carcinoma.
Altered expression of insulin-like growth factor I and its receptor during multistage carcinogenesis in mouse skin.
Altered expression of metabolic proteins and adipokines in patients with amyotrophic lateral sclerosis.
Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor beta 1.
Altered skin development and impaired proliferative and inflammatory responses in transgenic mice overexpressing the glucocorticoid receptor.
Alveolar fibrinolytic capacity suppressed by injurious mechanical ventilation.
Alveolar macrophage plasminogen activator.
Amphetamines induce tissue factor and impair tissue factor pathway inhibitor: role of dopamine receptor type 4.
Amplification of bovine papillomavirus DNA by N-methyl-N'-nitro-N-nitrosoguanidine, ultraviolet irradiation, or infection with herpes simplex virus.
An antitumor promoter from Moringa oleifera Lam.
An assay method for the prediction of tumor promoting potential of chemicals by the use of Bhas 42 cells.
An association between the 4G polymorphism in the PAI-1 promoter and the development of aggressive fibromatosis (desmoid tumor) in familial adenomatous polyposis patients.
An ELISA avoiding interference by heterophilic antibodies in the measurement of components of the plasminogen activation system in blood.
An evaluation of tissue polypeptide antigen (TPA) in the two bronchoalveolar lavage fractions of lung cancer patients.
An increase in plasminogen activator mRNA occurs at an early stage in ethylnitrosourea-induced transformation of rat brain cells.
An inhibitor of plasminogen activator produced by tumour cell fusion hybrids.
An inhibitor of urokinase and tissue plasminogen activators in Dunning R3327H prostate tumors of rats treated with D-Trp6-LH-RH.
An upward shift of intracellular pH rather than the final absolute pH value is critical for controlling gap junction permeability in tumor promoter-treated cells.
Anabolic steroids and fibrinolysis.
Analysis of c-Ha-ras gene mutations in skin tumors induced in carcinogenesis-susceptible and carcinogenesis-resistant mice by different two-stage protocols or tumor promoter alone.
Analysis of Cytokine Levers in Pleural Effusions of Tuberculous Pleurisy and Tuberculous Empyema.
Analysis of expressions of components in the plasminogen activator system in high- and low-metastatic human lung cancer cells.
Analysis of human promyelocytic leukemia cell (HL60) variants insensitive to phorbol ester tumor promoters.
Analysis of NM23 protein and components of plasminogen activation system in tumors of patients with stomach cancer with consideration for disease clinical picture and morphology.
Analysis of the ability of 12-O-tetradecanoylphorbol-13-acetate to induce epidermal hyperplasia, transforming growth factor-alpha, and skin tumor promotion in wa-1 mice.
Analysis of tumor-promoter-induced inflammation in rats: participation of histamine and prostaglandin E2.
Analyzing skin tumor development in mice by the DMBA/TPA model.
Antagonistic effect of selenite on tumor promoter induced cell proliferation in cultures of rat tongue epithelium.
Anthocyanin- and hydrolyzable tannin-rich pomegranate fruit extract modulates MAPK and NF-kappaB pathways and inhibits skin tumorigenesis in CD-1 mice.
Anti-angiogenic and anti-cancer evaluation of betulin nanoemulsion in chicken chorioallantoic membrane and skin carcinoma in Balb/c mice.
Anti-angiogenic effects of mangiferin and mechanism of action in metastatic melanoma.
Anti-carcinogenic activity of Taraxacum plant. I.
Anti-carcinogenic activity of Taraxacum plant. II.
Anti-carcinogenic activity of the roots of Panax notoginseng. II.
Anti-histaminic Effects of Resveratrol and Silymarin on Human Gingival Fibroblasts.
Anti-infective efficacy of the lactoferrin-derived antimicrobial peptide HLR1r.
Anti-inflammatory and antitumor-promoting effects of the triterpene acids from the leaves of Eriobotrya japonica.
Anti-inflammatory and chemopreventive effects of triterpene cinnamates and acetates from shea fat.
Anti-inflammatory Effects of KOTMIN13: A Mixed Herbal Medicine in LPS-stimulated RAW 264.7 Cells and Mouse Edema Models.
Anti-inflammatory effects of troglitazone in nondiabetic obese subjects independent of changes in insulin sensitivity.
Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model.
Anti-tumor promoting action of phthalic acid mono-n-butyl ester cupric salt, a biomimetic superoxide dismutase.
Anti-tumor-promoting action of FK506, a potent immunosuppressive agent.
Anti-tumor-promoting activities of triterpenoids from ferns. I.
Anti-tumor-promoting activity of a polyphenolic fraction isolated from grape seeds in the mouse skin two-stage initiation-promotion protocol and identification of procyanidin B5-3'-gallate as the most effective antioxidant constituent.
Anti-tumor-promoting activity of derivatives of abieslactone, a natural triterpenoid isolated from several Abies genus.
Anti-tumor-promoting activity of diterpenes from Excoecaria agallocha.
Anti-Tumor-Promoting Effects of 25-Methoxyporicoic Acid A and Other Triterpene Acids from Poria cocos.
Anti-tumorigenic chalcones.
Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro.
Antibodies to plasminogen activator inhibit human tumor metastasis.
Anticarcinogenic activity of natural sweeteners, cucurbitane glycosides, from Momordica grosvenori.
Anticoagulant activities of persicarin and isorhamnetin.
Anticoagulant activities of piperlonguminine in vitro and in vivo.
Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
Antimetastatic agents. II. Summary of the interactions of tumor cells with blood coagulation factors, platelets, fibrinolytic factors, and inflammatory cells and their soluble mediators: potential for therapeutic interventions.
Antimetastatic Potential of PAI-1-Specific RNA Aptamers.
Antimetastatic Potentials of Phyllanthusurinaria L on A549 and Lewis Lung Carcinoma Cells via Repression of Matrix-Degrading Proteases.
Antimigratory effect of TK1-2 is mediated in part by interfering with integrin alpha2beta1.
Antimutagenic and antitumorigenic activities of nordihydroguaiaretic acid.
Antiobesity Effects of yerba maté Extract (Ilex paraguariensis) in High-fat Diet-induced Obese Mice.
Antioxidant and anti-inflammatory activities of alpha lipoic acid protect against indomethacin-induced gastric ulcer in rats.
Antiplatelet and antithrombotic activities of purpurogallin in vitro and in vivo.
Antiplatelet, anticoagulant, and profibrinolytic activities of baicalin.
Antiplatelet, anticoagulant, and profibrinolytic activities of cudratricusxanthone A.
Antiplatelet, anticoagulant, and profibrinolytic activities of withaferin A.
Antipromotional activity of dietary N-(4-hydroxyphenyl)retinamide in two-stage skin tumorigenesis in CD-1 and SENCAR mice.
Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first-episode psychosis patients: A 7-month follow-up study.
Antitcoagulant and antiplatelet activities of scolymoside.
Antithrombotic activities of aspalathin and nothofagin via inhibiting platelet aggregation and FIIa/FXa.
Antithrombotic activities of epi-sesamin in vitro and in vivo.
Antithrombotic activities of oroxylin A in vitro and in vivo.
Antithrombotic activities of pellitorine in vitro and in vivo.
Antithrombotic activities of sulforaphane via inhibiting platelet aggregation and FIIa/FXa.
Antithrombotic activities of wogonin and wogonoside via inhibiting platelet aggregation.
Antithrombotic and antiplatelet activities of vicenin-2.
Antithrombotic and profibrinolytic activities of eckol and dieckol.
Antithrombotic and profibrinolytic activities of isorhamnetin-3-O-galactoside and hyperoside.
Antithrombotic and profibrinolytic activities of phloroglucinol.
Antitumor promotion by phenolic antioxidants: inhibition of AP-1 activity through induction of Fra expression.
Antitumor-promoting activities of hydrolyzable tannins in mouse skin.
Antitumor-promoting activities of tannic acid, ellagic acid, and several gallic acid derivatives in mouse skin.
Antitumor-promoting activity of garlic extracts.
Antitumor-promoting activity of oligomeric proanthocyanidins in mouse epidermis in-vivo.
Antitumor-promoting activity of scopadulcic acid B, isolated from the medicinal plant Scoparia dulcis L.
Antitumor-promoting effects and cytotoxic activities of dammar resin triterpenoids and their derivatives.
Antitumor-promoting effects of gallotannins extracted from various sources in mouse skin in vivo.
Antitumorigenic effect of atmospheric-pressure dielectric barrier discharge on human colorectal cancer cells via regulation of Sp1 transcription factor.
AP-1, NF-kappa-B, and ERK activation thresholds for promotion of neoplastic transformation in the mouse epidermal JB6 model.
AP1, a composite transcription factor implicated in abnormal growth control.
Apelin: A Peptide Involved in Cardiovascular Risk in Hemodialysis Patients?
ApoA-I Mimetic Peptide Reduces Vascular and White Matter Damage After Stroke in Type-2 Diabetic Mice.
Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
Application of tumor markers SCC-Ag, CEA, and TPA in patients with cervical precancerous lesions.
Apposition-dependent induction of plasminogen activator inhibitor type 1 expression: a mechanism for balancing pericellular proteolysis during angiogenesis.
Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors.
Arsenic exposure in utero and nonepidermal proliferative response in adulthood in Tg.AC mice.
Arsenic exposure in utero exacerbates skin cancer response in adulthood with contemporaneous distortion of tumor stem cell dynamics.
Arterial stiffness, inflammatory and pro-atherogenic markers in gestational diabetes mellitus.
Asafoetida inhibits early events of carcinogenesis: a chemopreventive study.
Aspirin Modifies Inflammatory Mediators and Metabolomic Profiles and Contributes to the Suppression of Obesity-Associated Breast Cancer Cell Growth.
Aspirin-triggered proresolving mediators stimulate resolution in cancer.
Assessment of the antioxidant/prooxidant status of murine skin following topical treatment with 12-O-tetradecanoylphorbol-13-acetate and throughout the ontogeny of skin cancer. Part I: Quantitation of superoxide dismutase, catalase, glutathione peroxidase and xanthine oxidase.
Assessment of the antioxidant/prooxidant status of murine skin following topical treatment with 12-O-tetradecanoylphorbol-13-acetate and throughout the ontogeny of skin cancer. Part II: Quantitation of glutathione and glutathione disulfide.
Assessment of the effects of breast cancer on bone and the response to therapy.
Association Between Circulating Electronegative Low-Density Lipoproteins and Serum Ferritin in Hemodialysis Patients: A Pilot Study.
Association between circulatory levels of adipokines and bone mineral density in postmenopausal women.
Association between Five Common Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms and Colorectal Cancer Susceptibility.
Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes.
Association between obesity and adipokines levels in saliva and gingival crevicular fluid: A systematic review and meta-analysis.
Association between obesity and periodontal risk indicators in adolescents.
Association between Plasma Levels of Plasminogen Activator Inhibitor-1 and Colorectal Neoplasms.
Association of a murine chromosome 9 locus (Psl1) with susceptibility to mouse skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Association of advanced glycoxidation end products and inflammation markers with thrombosis of arteriovenous grafts in hemodialysis patients.
Association of cardiovascular risk factors and endothelial dysfunction in japanese hypertensive patients: implications for early atherosclerosis.
Association of dietary fatty acids intake with pro-coagulation and inflammation in Saudi Adults.
Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer.
Association of Metabolic Syndrome with Serum Adipokines in Community-Living Elderly Japanese Women: Independent Association with Plasminogen Activator-Inhibitor-1.
Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer.
Association of Oxytocin with Glucose Intolerance and Inflammation Biomarkers in Metabolic Syndrome Patients with and without Prediabetes.
Association of pulse pressure with serum TNF-? and neutrophil count in the elderly.
Association of the -159 C --> T polymorphism in the CD14 promoter with variations in serum lipoproteins in healthy subjects.
Association of the IGF1/pregnancy-associated plasma protein-A system and adipocytokine levels with the presence and the morphology of carotid plaques in type 2 diabetes mellitus patients with stable glycaemic control.
Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
Association of uPA, PAT-1, and uPAR in nipple aspirate fluid (NAF) with breast cancer.
Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Associations of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-aged and older Chinese.
Associations of sedentary time patterns and TV viewing time with inflammatory and endothelial function biomarkers in children.
Associations of serum anti-ganglioside antibodies and inflammatory markers in diabetic peripheral neuropathy.
Atorvastatin restores the balance between pro-inflammatory and anti-inflammatory mediators in rats with acute myocardial infarction.
Atractylodis Rhizoma extract and its component, atractylon, inhibit tumor promotion in mouse skin two-stage carcinogenesis.
Attenuated adiposopathy in perivascular adipose tissue compared with subcutaneous human adipose tissue.
Attenuation of Diabetes-Induced Cardiac Inflammation and Pathological Remodeling by Low-Dose Radiation.
Attenuation of diabetes-induced cardiac inflammation and pathological remodeling by low-dose radiation.
Attenuation of p53 expression and Bax down-regulation during phorbol ester mediated inhibition of apoptosis.
Attenuation over 24 hours of the efficacy of thrombolysis of pulmonary embolism among patients with cancer.
Augmentation of 12-O-tetradecanoyl 13-phorbol acetate-mediated tumor promoting response by the porphyrin photosensitization of 7,12-dimethyl benz[a]anthracene-initiated murine skin: role of in situ generated reactive oxygen species.
Auraptene, a citrus coumarin, inhibits 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion in ICR mouse skin, possibly through suppression of superoxide generation in leukocytes.
Azaphilones inhibit tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mice.
Baseline Markers of Inflammation Are Associated With Progression to Macroalbuminuria in Type 1 Diabetic Subjects.
bcl-2 enhancement of malignant transformation in mouse epidermal JB6 cells.
Behaviour of tissue plasminogen activator, plasminogen activator inhibitor 1 and their complex in various disease states.
Beneficial effects of statins in patients with non-ischemic heart failure.
Beneficial Fatty Acid Ratio of Salvia hispanica L. (Chia Seed) Potentially Inhibits Adipocyte Hypertrophy, and Decreases Adipokines Expression and Inflammation in Macrophage.
Benzodiazepine-Associated Carcinogenesis: Focus on Lorazepam-Associated Cancer Biomarker Changes in Overweight Individuals.
Berberine protects against esophageal mucosal damage in reflux esophagitis by suppressing proinflammatory cytokines.
Berberine Suppresses the TPA-Induced MMP-1 and MMP-9 Expressions Through the Inhibition of PKC-? in Breast Cancer Cells.
beta-Catenin and NF-kappaB cooperate to regulate the uPA/uPAR system in cancer cells.
Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma.
Bidirectional control of membrane expression and/or activation of the tumor cell IRGpIIb/IIIa receptor and tumor cell adhesion by lipoxygenase products of arachidonic acid and linoleic acid.
Bimodal relationship between invasion of the amniotic membrane and plasminogen activator activity.
Binding of epidermal growth factor to primary and permanent cultures of mouse epidermal cells: inhibition by tumor-promoting phorbol esters.
Biochemical and pathological evaluation of albendazole/thalidomide co-therapy against eosinophilic meningitis or meningoencephalitis induced by Angiostrongylus cantonensis.
Biochemical markers of type 2 diabetes as a late complication of myocardial infarction: a case-control study.
Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1.
Biochemical studies of primate retroviruses.
Biochemically-defined differentiation markers on human early haemopoietic (K562) cells.
Biological activities and cellular uptake studies of fluorescent derivatives of indole alkaloid tumor promoter teleocidin.
Biological activities of tamoxifen aziridine, an antiestrogen-based affinity label for the estrogen receptor, in vivo and in vitro.
Biological and biochemical characterization of cell lines derived from initiation-promotion transformed C3H/10T1/2 cells.
Biological properties of baicalein in cardiovascular system.
Biological significance of tissue plasminogen activator content in brain tumors.
Biomarker assessments in asbestos-exposed workers as indicators for selective prevention of mesothelioma or bronchogenic carcinoma: rationale and practical implementations.
Biomarkers in sepsis at time zero: intensive care unit scores, plasma measurements and polymorphisms in Argentina.
Biomarkers of cardiometabolic complications in survivors of childhood acute lymphoblastic leukemia.
Biomarkers of inflammation and hemostasis associated with left ventricular mass: The Multiethnic Study of Atherosclerosis (MESA).
Biphasic response of Na+-dependent amino acid transport to tumor promoting phorbol esters in cultured renal epithelial cells, LLC-PK1.
Bisphenol compounds regulate decidualized stromal cells in modulating trophoblastic spheroid outgrowth and invasion in vitro†.
Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation.
Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation.
Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma.
Blue light inhibits the growth of skin tumors in the v-Ha-ras transgenic mouse.
Body Fat Distribution and Inflammation Among Obese Older Adults With and Without Metabolic Syndrome.
Body Size Phenotypes and Inflammation in the Women's Health Initiative Observational Study.
Boosting two-photon photodynamic therapy with mitochondria-targeting ruthenium-glucose conjugates.
Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
Both TPA and SCC-Ag levels are prognostic even in high-risk stage Ib-IIa cervical carcinoma as determined by a stratification analysis.
Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis.
Both UFH and NAH alleviate shedding of endothelial glycocalyx and coagulopathy in LPS-induced sepsis.
Bradykinin and nitric oxide in infectious disease and cancer.
Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation.
Brief review: hypertension in pregnancy : a manifestation of the insulin resistance syndrome?
Building Bridges toward Invasion: Tumor Promoter Treatment Induces a Novel Protein Kinase C-Dependent Phenotype in MCF10A Mammary Cell Acini.
c-jun and multistage carcinogenesis: association of overexpression of introduced c-jun with progression toward a neoplastic endpoint in mouse JB6 cells sensitive to tumor promoter-induced transformation.
c-myc gene expression and activation of human thymocytes.
C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?
CA 125 and its relation to cardiac function.
CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse.
Ca(2+)-independent, phospholipid-activated protein kinase in 3Y1 cells.
CA-15.3, TPA and MCA as markers for breast cancer.
Ca-calmodulin mediates the DNA-synthetic response of calcium-deprived liver cells to the tumor promoter TPA.
Caffeic acid attenuates 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced NF-?B and COX-2 expression in mouse skin: abrogation of oxidative stress, inflammatory responses and proinflammatory cytokine production.
Caffeine and other phosphodiesterase inhibitors are potent inhibitors of the promotional effect of TPA on morphological transformation of hamster embryo cells.
Calcium Fructoborate Prevents Skin Cancer Development in Balb-c Mice: Next Part, Reverse Inflammation, and Metabolic Alteration.
Calcium-, phospholipid-dependent protein kinase activity of cultured rat Sertoli cells and its modifications by vitamin A.
Calcium-dependent release of arachidonic acid from a murine epidermal cell line induced by the tumor promoter TPA or ionophore A 23187: dissection of ionophoretic and phospholipase A2-stimulating activity.
Calmodulin involvement in TPA and DDT induced inhibition of intercellular communication.
Calphostin C induces tyrosine dephosphorylation/inactivation of protein kinase FA/GSK-3 alpha in a pathway independent of tumor promoter phorbol ester-mediated down-regulation of protein kinase C.
Camptothecin post-treatments inhibit the biochemical events linked to the tumor-promoting component of carcinogenesis in mouse epidermis in vivo.
Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
Cancer and thrombosis in women - molecular mechanisms.
Cancer chemoprevention: inhibitory effect of soybeans fermented with basidiomycetes on 7,12-dimethylbenz[alpha]anthracene/12-O-tetradecanoylphorbol-13-acetate-induced mouse skin carcinogenesis.
Cancer chemopreventive activity of serratane-type triterpenoids on two-stage mouse skin carcinogenesis.
Cancer chemopreventive activity of synthetic colorants used in foods, pharmaceuticals and cosmetic preparations.
Cancer chemopreventive activity of the prenylated coumarin, umbelliprenin, in vivo.
Cancer chemopreventive effect of bergenin from Peltophorum pterocarpum wood.
Cancer chemopreventive effect of phenothiazines and related tri-heterocyclic analogues in the 12-O-tetradecanoylphorbol-13-acetate promoted Epstein-Barr virus early antigen activation and the mouse skin two-stage carcinogenesis models.
Cancer chemopreventive effects of cycloartane-type and related triterpenoids in in vitro and in vivo models.
Cancer chemopreventive effects of polyunsaturated fatty acids.
Cancer chemoprotective effects of Curcuma xanthorrhiza.
Cancer prevention by antioxidants.
Cancer preventive agents. Part 1: chemopreventive potential of cimigenol, cimigenol-3,15-dione, and related compounds.
Cancer promotion in a mouse-skin model by a 60-Hz magnetic field: II. Tumor development and immune response.
Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Cancer?associated fibroblast?induced M2?polarized macrophages promote hepatocellular carcinoma progression via the plasminogen activator inhibitor?1 pathway.
Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke.
Candidate genetic markers and the risk of restenosis after coronary angioplasty.
Capacitation suppression by mouse seminal vesicle autoantigen involves a decrease in plasma membrane Ca(2+)-ATPase (PMCA)-mediated intracellular calcium.
Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squamous cell lung cancer.
Carcinoembryonic antigen, ferritin, tissue polypeptide antigen, and CA15/3 in breast cancer: relationship between carcinoma and normal breast tissue.
Carcinoembryonic proteins produced by Wilms' tumor cells in vitro and in vivo.
Carcinogen-induced DNA repair in nucleotide-permeable Escherichia coli cells. Analysis of DNA repair induced by carcinogenic K-region epoxides and 1,2,3,4-diepoxybutane.
Carcinogenic potential of metal nanoparticles in BALB/3T3 cell transformation assay.
Carcinoma and stromal enzyme activity profiles associated with breast tumor growth in vivo.
Cardiometabolic biomarkers are predictors of readmission and death in patients hospitalized for acute dyspnea.
Carob pod insoluble fiber exerts anti-atherosclerotic effects in rabbits through sirtuin-1 and peroxisome proliferator-activated receptor-? coactivator-1?.
Caspase I-related protease inhibition retards the execution of okadaic acid- and camptothecin-induced apoptosis and PAI-2 cleavage, but not commitment to cell death in HL-60 cells.
Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat.
Catheter tips are a possible resource for biological study on catheter failure.
CEA, TPA, CA 19-9, SCC and CYFRA at diagnosis and in the follow-up of anal canal tumors.
Cell biologic factors and cancer spread.
Cell culture studies on the mechanism of action of chemical carcinogens and tumor promoters.
Cell culture systems for studying multifactor interactions in carcinogenesis.
Cell population kinetics in hairless mouse epidermis following a single topical application of 12-O-tetradecanoylphorbol-13-acetate I.
Cell surface immunophenotype and gelatinase activity of the human breast carcinoma cell line (MCF-7/6) with functionally defective E-cadherin.
Cell transformation and promoter activity of insulation oils in the Syrian hamster embryo cell and in the C3H/10T1/2 mouse embryo fibroblast test systems.
Cell Type-Specific p38? Targeting Reveals a Context-, Stage-, and Sex-Dependent Regulation of Skin Carcinogenesis.
Cell- and gene-specific interactions between signal transduction pathways revealed by okadaic acid. Studies on the plasminogen activating system.
Cell-specific regulation of oncogene-responsive sequences of the c-fos promoter.
Cellular and extracellular plasminogen activator and inhibitor in an experimental tumour.
Cellular and molecular features of lipoma tissue: comparison with normal adipose tissue.
Cellular and secreted tumor plasminogen activator: the effects of NaCl.
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues.
Central role of ceramide biosynthesis in body weight regulation, energy metabolism and the metabolic syndrome.
Cepharanthine inhibits two-stage tumor promotion by 12-O-tetradecanoylphorbol 13-acetate and mezerein on skin tumor formation in mice initiated with 7,12-dimethylbenz[a]anthracene.
Cerebral embolism associated with left atrial myxoma that was treated with thrombolytic therapy.
Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
Changes in fibrinolysis in patients with localized tumors.
Changes in gap-junction permeability, phosphorylation, and number mediated by phorbol ester and non-phorbol-ester tumor promoters in rat liver epithelial cells.
Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy.
Characteristics of a metastatic variant to the liver of human rectal adenocarcinoma cell line RCM-1.
Characteristics of phorbol ester stimulated growth hormone release: inhibition by insulin-like growth factor I, somatostatin, and low calcium medium and comparison with growth hormone releasing factor.
Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
Characterization of a cell line derived from rhabdoid tumor of kidney.
Characterization of a high-affinity receptor for phorbol esters in rat alveolar macrophages.
Characterization of an 8-lipoxygenase activity induced by the phorbol ester tumor promoter 12-O-tetradecanoylphorbol-13-acetate in mouse skin in vivo.
Characterization of an inbred strain of the SENCAR mouse that is highly sensitive to phorbol esters.
Characterization of rat embryo cells transformed by ts mutants and sheared DNA of herpes simplex virus types 1 and 2 and a derived tumor cell line.
Characterization of the antitumor-promoting activity of camptothecin in SENCAR mouse skin.
Characterization of the binding sites for plasminogen and tissue-type plasminogen activator in cytokeratin 8 and cytokeratin 18.
Characterization of the hydroperoxide response observed in mouse skin treated with tumor promoters in vivo.
Characterization of the morphological, growth, and steroidogenic effect of TPA on mouse Y-1 adrenal cortical tumor cells in culture.
Characterization of the neuropilin-1 promoter; gene expression is mediated by the transcription factor Sp1.
Characterization of the tumor-promoting activity of m-chloroperoxybenzoic acid in SENCAR mouse skin and its inhibition by gallotannin, oligomeric proanthocyanidin, and their monomeric units.
Characterization of the tumor-promoting activity of thapsigargin in cf-1 mouse skin.
Chelerythrine suppresses proliferation and metastasis of human prostate cancer cells via modulating MMP/TIMP/NF-?B system.
Chemical and viral transformation of cultured skin fibroblasts from patients with familial polyposis coli.
Chemical carcinogenesis by the two-stage protocol in the skin Mastomys natalensis (Muridae) using topical initiation with 7,12-dimethylbenz(a)anthracene and topical promotion with 12-0-tetradecanoylphorbol-13-acetate.
Chemical skin carcinogenesis is prevented in mice by the induced expression of a TGF-beta related transgene.
Chemical sympathectomy attenuates inflammation, glycocalyx shedding and coagulation disorders in rats with acute traumatic coagulopathy.
Chemically induced DNA damage in isolated rabbit lung cells.
Chemiluminometric determination of tissue polypeptide antigen (TPA), cancer antigen 15-3 (CA 15-3), carcinoembryonic antigen (CEA) in comparison with vascular endothelial growth factor (VEGF) in follow-up of breast cancer.
Chemomodulatory Effect of Trigonella foenum graecum (L.) Seed Extract on Two Stage Mouse Skin Carcinogenesis.
Chemoprevention of DMBA-induced UV-B promoted, NOR-1-induced TPA promoted skin carcinogenesis, and DEN-induced phenobarbital promoted liver tumors in mice by extract of beetroot.
Chemoprevention of Skin Cancer: Effect of Lawsonia Inermis L. (Henna) Leaf Powder and its Pigment Artifact, Lawsone in the Epstein- Barr Virus Early Antigen Activation Assay and in Two-Stage Mouse Skin Carcinogenesis Models.
Chemopreventive activities of etodolac and oxyphenbutazone against mouse skin carcinogenesis.
Chemopreventive effect of 4'-demethyl epipodophyllotoxin on DMBA/TPA-induced mouse skin carcinogenesis.
Chemopreventive effect of farnesol on DMBA/TPA-induced skin tumorigenesis: involvement of inflammation, Ras-ERK pathway and apoptosis.
Chemopreventive effects of emodin and cassiamin B in mouse skin carcinogenesis.
Chemopreventive potential of cyclic diarylheptanoids.
Chromosomal events in carcinogenic initiation and promotion: implications for carcinogenicity testing and cancer prevention strategies.
Chronic 12-O-tetradecanoylphorbol-13-acetate treatment prevents restoration of collagen loss associated with its inflammatory effect on mouse skin.
Chronic application of a tumor promoter to confluent nontransformed rat cells induces the irreversible expression of transformed phenotype.
Chronic exposure to 12-O-tetradecanoylphorbol-13-acetate represses sod2 induction in vivo: the negative role of p50.
Chronic exposure to ionizing radiation as a tumor promoter in mouse skin.
Chronic inflammation potentiates kidney aging.
Chronological expression of PAR isoforms in acute liver injury and its amelioration by PAR2 blockade in a rat model of sepsis.
Circadian Rhythm of Methylated Septin 9, Cell-Free DNA Amount and Tumor Markers in Colorectal Cancer Patients.
Circadian rhythm of tumor promotion in the two-stage model of mouse tumorigenesis.
Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian randomization study.
Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk.
Circulating interleukin-8 and plasminogen activator inhibitor-1 are increased in women with ovarian carcinoma.
Circulating Levels of Bone and Inflammatory Markers in Gestational Diabetes Mellitus.
Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis.
Circulating matrix metalloproteinase-9 level is associated with cerebral white matter hyperintensities in non-stroke individuals.
Circulating white blood cell count and measures of adipose tissue inflammation predict higher 24-h energy expenditure.
Cisplatin as an initiating agent in two-stage mouse skin carcinogenesis.
Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York.
Clinical evaluation of serum tissue polypeptide specific antigen in patients with thyroid carcinoma.
Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
Clinical features and molecular analysis of a family with multiple colon tumours and reduced plasminogen activator activity.
Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients.
Clinical implications of urokinase and tissue type plasminogen activators and their inhibitor (PAI-1) in breast cancer tissue.
Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen.
Clinical relevance of prognostic factors in axillary node-negative breast cancer.
Clinical relevance of uPA, uPAR, PAI 1 and PAI 2 tissue expression and plasma PAI 1 level in colorectal carcinoma patients.
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Clinical results of immunoscintigraphy in a variety of malignant tumors with special reference to immunohistochemistry.
Clinical significance of different serum tumor markers in gynecological malignancies.
Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients.
Clinical tumour markers in ovarian cancer.
Clinical use of CA 125 and its combination assay with other tumor marker in patients with ovarian carcinoma.
Clinical usefulness of computer-assisted diagnosis using combination assay of tumor markers for pancreatic carcinoma.
Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin.
Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer.
Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma.
Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients.
Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Clonal heterogeneity in plasminogen activator activity produced by two murine tumor cell lines.
Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes.
Coagulant and fibrinolytic activities of a metastasising and non-metastasising tumour line.
Coagulation and fibrinolysis in chronic venous insufficiency.
Coagulation disorders and tumor markers in the diagnosis of pancreatic cancer.
Codon 61 mutations in the c-Harvey-ras gene in mouse skin tumors induced by 7,12-dimethylbenz[a]anthracene plus okadaic acid class tumor promoters.
Coexistence of anti-phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state.
Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissues.
Coinfection with human herpesvirus 8 is associated with persistent inflammation and immune activation in virologically suppressed HIV-infected patients.
Collagenase induction promotes mouse tumorigenesis by two independent pathways.
Collagenases in human breast carcinoma cell lines.
Combination of 12-O-tetradecanoylphorbol-13-acetate with diethyldithiocarbamate markedly inhibits pancreatic cancer cell growth in 3D culture and in immunodeficient mice.
Combination of diethyldithiocarbamate with 12-O-tetradecanoyl phorbol-13-acetate inhibits the growth of human myeloid leukemia HL-60 cells in vitro and in xenograft model.
Combination of tissue polypeptide antigen (TPA) and carcino embryonic antigen (CEA) in different types of cancer.
Combined determination of serum CA 19-9 and tissue polypeptide antigen: why no improvement in pancreatic cancer diagnosis?
Combined diagnosis of breast cancer in the early stage by MRI and detection of gene expression.
Combined immunohistochemical study of tissue polypeptide antigen and cancer antigen 125 in human ovarian tumours.
Combined treatment of ulinastatin and tranexamic Acid provides beneficial effects by inhibiting inflammatory and fibrinolytic response in patients undergoing heart valve replacement surgery.
Combined use of carcinoembryonic antigen and tissue polypeptide antigen in oncologic therapy and surveillance.
Combining Ruthenium(II) Complexes with Metal-Organic Frameworks to Realize Effective Two-Photon Absorption for Singlet Oxygen Generation.
Comparative analysis of certain metals and tumor markers in bronchopulmonary cancer and colorectal cancers. Metals and tumor markers in the neoplastic process.
Comparative effects of a complete tumor promoter, TPA, and a second-stage tumor promoter, RPA, on intercellular communication, cell differentiation and cell transformation.
Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon.
Comparative proteomic analysis of PAI-1 and TNF-alpha-derived endothelial microparticles.
Comparative study between the free radicals and tumor markers in patients with gastrointestinal tumors.
Comparative study on expression of plasminogen activator inhibitor 1 and its mRNA in endometrial cancers and normal endometria.
Comparative two-stage cancer tests of ethylene oxide, N-(2-hydroxyethyl)-N-nitrosourea and X-rays.
Comparison of 12-O-tetradecanoylphorbol-13-acetate and teleocidin for induction of epidermal hyperplasia, activation of epidermal PKC isozymes and skin tumor promotion in SENCAR and C57BL/6 mice.
Comparison of adipose tissue derived genes in endogenous Cushing's syndrome versus diet-induced obesity.
Comparison of Cyfra 21-1, TPA and SCC tumor markers in esophageal squamous cell carcinoma.
Comparison of epidermal protein kinase C activity, ornithine decarboxylase induction and DNA synthesis stimulated by TPA or dioctanoylglycerol in mouse strains with differing susceptibility to TPA-induced tumor promotion.
Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue.
Comparison of messenger RNA distribution for 60 proteins in fat cells vs the nonfat cells of human omental adipose tissue.
Comparison of octahydromezerein and mezerein as protein kinase C activators and as mouse skin tumor promoters.
Comparison of prolactin, CA 15-3 and TPA in breast carcinomas.
Comparison of proteinase activities in squamous cell carcinoma, basal cell epithelioma, and seborrheic keratosis.
Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Comparison of serum CEA, PHI, and TPA as tumor markers in breast cancer patients.
Comparison of the effect of sn-1,2-didecanoylglycerol and 12-O-tetradecanoylphorbol-13-acetate on cutaneous morphology, inflammation and tumor promotion in CD-1 mice.
Comparison of the effects of bilobol and 12-O-tetradecanoylphorbol-13-acetate on skin, and test of tumor promoting potential of bilobol in CD-1 mice.
Comparison of the tumor markers CEA, TPA, and CA 19-9 in colorectal carcinoma.
Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.
Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues.
Components of the plasminogen activator system in astrocytes are modulated by tumor necrosis factor-alpha and interleukin-1 beta through similar signal transduction pathways.
Comprehensive analysis of marker gene detection and computed tomography for the diagnosis of human lung cancer.
Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer.
Conditioned media from (pre)adipocytes stimulate fibrinogen and PAI-1 production by HepG2 hepatoma cells.
Confirmation of the mapping of a 12-O-tetradecanoylphorbol-13-acetate promotion susceptibility locus, Psl1, to distal mouse chromosome 9.
Constituents of the Sea Cucumber Cucumaria okhotensis. Structures of Okhotosides B1-B3 and Cytotoxic Activities of Some Glycosides from this Species.
Constitutive expression and secretion of proteases in non-metastatic SP1 mammary carcinoma cells and its metastatic sublines.
Consumption of a high-fat diet abrogates inhibitory effects of methylseleninic acid on spontaneous metastasis of Lewis lung carcinoma in mice.
Content and characterization of plasminogen activators in human lung tumors and normal lung tissue.
Contrasting responses of normal and transformed rat tracheal epithelial cells to the tumor promoter 12-O-tetradecanoylphorbol-13-acetate.
Control Mechanisms of the Tumor Suppressor PDCD4: Expression and Functions.
Conversion of herpetic lesions to malignancy by ultraviolet exposure and promoter application.
Conversion of high grade lymphoma tumor cell line to intermediate grade with TPA and bryostatin 1 as determined by polypeptide analysis on 2D gel electrophoresis.
Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium.
Coordinate inhibition of plasminogen activator and tumor growth by hydrocortisone in mouse mammary carcinoma.
Correction to: Influence of three BALB/c substrain backgrounds on the skin tumor induction efficacy to DMBA and TPA cotreatment.
Correlation between expression of urokinase-type plasminogen activator receptor and metastasis in gastric carcinoma.
Correlation between hormone dependency and the regulation of epidermal growth factor receptor by tumor promoters in human mammary carcinoma cells.
Correlation between PAI-1, leptin and ferritin with HOMA in HIV/AIDS patients.
Correlation between plasma endotoxin, plasma cytokines, and plasminogen activator inhibitor-1 activities in septic patients.
Correlation between plasminogen activator activity of immunizing tumor cells and complement-mediated cytotoxic antibodies secreted by cloned hybrid cells.
Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-malignant diseases.
Correlation between serum cytokeratin 19 fragment and tissue polypeptide antigen levels in patients with non-small cell lung cancer.
Correlation between urokinase-type plasminogen activator production and the metastasizing ability of two murine mammary adenocarcinomas.
Correlation of collagenase secretion with metastatic-colonization potential in naturally occurring murine mammary tumours.
Correlation of phorbol ester promotion in the resistant C57BL/6J mouse with sustained hyperplasia but not ornithine decarboxylase or protein kinase C.
Correlation of the production of plasminogen activator with tumor metastasis in B16 mouse melanoma cell lines.
Correlation of tissue and blood plasminogen activation system in breast cancer.
Correlation of tumor plasminogen activator with peritumoral cerebral edema. A CT and biochemical study.
CpG methyl-seq and RNA-seq epigenomic and transcriptomic studies on the preventive effects of Moringa isothiocyanate in mouse epidermal JB6 cells induced by the tumor promoter TPA.
Cremophor EL inhibits 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced protein phosphorylation in human myeloblastic leukemia ML-1 cells.
Critical biochemical and regulatory events in malignant transformation in vitro.
Critical comparison of histological and morphometric changes in SENCAR mouse epidermis in response to n-dodecane, 12-O-tetradecanoylphorbol-13-acetate and mezerein.
Cross talk of tumor necrosis factor-alpha and the renin-angiotensin system in tumor necrosis factor-alpha-induced plasminogen activator inhibitor-1 production from hepatocytes.
Crosstalk between PARP-1 and NF-kappaB modulates the promotion of skin neoplasia.
Crucial role of phospholipase C epsilon in skin inflammation induced by tumor-promoting phorbol ester.
Cryosurgical treatment of dysplasia and carcinoma in situ of the cervix uteri.
CSF levels of growth factors and plasminogen activators in leptomeningeal metastases.
Curcumin and obesity.
Current approaches to glycoprotein analysis.
Cyclic nucleotide levels in rat embryo fibroblasts treated with tumor-promoting phorbol diester.
Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer.
Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group.
Cysteine and serine proteases in gastric cancer.
Cytogenetic analysis of malignant skin tumors induced in chemically treated TG-AC transgenic mice.
Cytogenetic effects caused by phorbol ester tumor promoters in HeLa cells: mechanistic aspects.
Cytogenetic effects caused by phorbol ester tumor promoters in primary mouse keratinocyte cultures: correlation with the convertogenic activity of TPA in multistage skin carcinogenesis.
Cytokeratin expression in simple epithelia. II. cDNA cloning and sequence characteristics of bovine cytokeratin A (no. 8).
Cytokeratin fragments in the serum: their utility for the management of oral cancer.
Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer.
Cytokeratins and proliferation in breast cancer patients.
Cytokeratins and tissue polypeptide antigen.
Cytokine and Chemokine Concentration in the Tear of Patients with Age-Related Cataract.
Cytokine modulation of plasminogen activator inhibitor-1 (PAI-1) production by human articular cartilage and chondrocytes. Down-regulation by tumor necrosis factor alpha and up-regulation by transforming growth factor-B basic fibroblast growth factor.
Cytokine-induced release of plasminogen activator inhibitor-1 by human mesothelial cells.
Cytokines and fibrinolytic enzymes in tuberculous and parapneumonic effusions.
Cytokines and plasminogen activator inhibitor-1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome.
Cytolytic activities of activated macrophages versus paraformaldehyde-fixed macrophages; soluble versus membrane-associated TNF.
Cytoskeletal active drugs modulate signal transduction in the protein kinase C pathway.
Cytotoxic Activities and Anti-Tumor-Promoting Effects of Microbial Transformation Products of Prenylated Chalcones from Angelica keiskei.
D-dimer and Body CT to Identify Occult Malignancy in Acute Ischemic Stroke.
D-dimer, plasminogen activator inhibitor-1, prothrombin fragments and protein C - role in prothrombotic state of colorectal cancer.
Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis.
Daunorubicin attenuates tumor necrosis factor-alpha-induced biosynthesis of plasminogen activator inhibitor-1 in human umbilical vein endothelial cells.
DBA/2 mice are as sensitive as SENCAR mice to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Deacylated lipopolysaccharide inhibits plasminogen activator inhibitor-1, prostacyclin, and prostaglandin E2 induction by lipopolysaccharide but not by tumor necrosis factor-alpha.
Decrease of epidermal histidase activity by tumor-promoting phorbol esters.
Decreased accumulation of cyclic adenosine 3',5'-monophosphate in "ischemic" skin after 12-0-tetradecanoyl-phorbol-13-acetate treatment.
Decreased ratio of reduced/oxidized glutathione in mouse epidermal cells treated with tumor promoters.
Deep vein thrombosis and changes in coagulation and fibrinolysis after gynaecological operations in Chinese: the effect of oral contraceptives and malignant disease.
Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.
Defective release of vascular plasminogen activator in patients with gynecologic malignancies.
Defibrotide enhances fibrinolysis in human endotoxemia - a randomized, double blind, crossover trial in healthy volunteers.
Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate.
Deficiency of NRH:quinone oxidoreductase 2 increases susceptibility to 7,12-dimethylbenz(a)anthracene and benzo(a)pyrene-induced skin carcinogenesis.
Deficiency of plasminogen activator inhibitor-2 results in accelerated tumor growth.
Deficiency of protein kinase Calpha in mice results in impairment of epidermal hyperplasia and enhancement of tumor formation in two-stage skin carcinogenesis.
Degradation of the Tumor Suppressor PDCD4 Is Impaired by the Suppression of p62/SQSTM1 and Autophagy.
Dehydroepiandrosterone and 16 alpha-Br-epiandrosterone inhibit 12-O-tetradecanoylphorbol-13-acetate stimulation of superoxide radical production by human polymorphonuclear leukocytes.
Delayed neutrophil apoptosis in granulomatosis with polyangiitis: dysregulation of neutrophil gene signature and circulating apoptosis-related proteins.
Demonstration of a possible link between high grade malignancy in dimethylbenz[a]anthracene-induced rat mammary carcinoma and increased urokinase plasminogen activator content.
Deregulated Expression of Urokinase and its Inhibitor Type 1 in Prostate Cancer Cells: Role of Epigenetic Mechanisms.
Design and testing of a packaged microfluidic cell for the multiplexed electrochemical detection of cancer markers.
Destruction of extracellular matrices containing glycoproteins, elastin, and collagen by metastatic human tumor cells.
Detailed technical analysis of urine RNA-based tumor diagnostics reveals ETS2/urokinase plasminogen activator to be a novel marker for bladder cancer.
Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancer.
Detection of five circulating antigens in patients with head and neck squamous cell carcinoma.
Detection of gastric cancer by a combination of tissue polypeptide antigen (TPA), lipid-bound sialic acid (LBSA) and carcinoembryonic antigen (CEA).
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Detection of the plasmin system in human mammary pathology using immunofluorescence.
Detection of tissue polypeptide antigen in salivary glands and salivary gland tumors. An immunohistochemical study.
Determinants of hypofibrinolysis in patients with digestive tract cancer.
Determination of tissue polypeptide antigen (TPA) levels in different cancer types and controls.
Determination of tissue polypeptide antigens (TPA) and carcinoembryonic antigen (CEA) in serum: its value in the preliminary cancer risk assessment in asbestos exposed workers.
Determination of TPA levels in breast cancer and controls.
Development and initial characterization of several new inbred strains of SENCAR mice for studies of multistage skin carcinogenesis.
Development of Na+-dependent hexose transport in a cultured line of porcine kidney cells.
Development of phorbol ester responsiveness in neonatal mouse epidermis: correlation between hyperplastic response and sensitivity to first-stage tumor promotion.
Dexamethasone effect on the growth rate, the plasminogen activator, and the MMTV RNA dependent DNA polymerase in a mouse mammary tumor cell line.
Dexamethasone increased plasminogen activator inhibitor-1 expression on human umbilical vein endothelial cells: an additive effect to tumor necrosis factor-alpha.
Dexamethasone reduces vascular density and plasminogen activator activity in 9L rat brain tumors.
Diabetes/obesity-related inflammation, cardiac cell death and cardiomyopathy.
Diagnosis of bone and liver metastases in breast cancer comparing tumor markers and imaging techniques.
Diagnostic and prognostic value of TPA in breast cancer.
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer.
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
Diagnostic Power of Circulatory Metabolic Biomarkers as Metabolic Syndrome Risk Predictors in Community-Dwelling Older Adults in Northwest of England (A Feasibility Study).
Diagnostic usefulness of 5 tumor-markers in patients with primary lung-cancer.
Diagnostic value of measuring serum CA 15-3, TPA, and TPS in women with breast cancer.
Diaphragmatic cyst with elevated level of serum tissue polypeptide antigen.
Diaplacental carcinogenesis: initiation with the carcinogens dimethylbenzanthracene (DMBA) and urethane during fetal life and postnatal promotion with the phorbol ester TPA in a modified 2-stage Berenblum/Mottram experiment.
Diaplacental carcinogenesis: tumor localization and tumor incidence in NMRI mice after diaplacental initiation with DMBA and urethane and postnatal promotion and the phorbol ester TPA in a modified 2-stage Berenblum/Mottram experiment.
Dietary conjugated linoleic acid modulation of phorbol ester skin tumor promotion.
Dietary factors associated with subclinical inflammation among girls.
Dietary oleic acid supplementation and blood inflammatory markers: a systematic review and meta-analysis of randomized controlled trials.
Dietary Quality Determined by the Healthy Eating Index-2015 and Biomarkers of Chronic Low-Grade Inflammation: A Cross-Sectional Analysis in Middle-to-Older Aged Adults.
Differences in expression of metalloproteinases and plasminogen activators in murine melanocytes and B16 melanoma variants: lack of association with in vitro invasion.
Different Associations of Trunk and Lower-Body Fat Mass Distribution with Cardiometabolic Risk Factors between Healthy Middle-Aged Men and Women.
Different effects of GPR120 and GPR40 on cellular functions stimulated by 12-O-tetradecanoylphorbol-13-acetate in melanoma cells.
Different responses elicited in vitro by antibodies to IgM and IgD in cells from a surface IgM + D-positive human follicular lymphoma.
Different sensitivities of p42 mitogen-activated protein kinase to phorbol ester and okadaic acid tumor promoters among cell types.
Differential activation and inhibition of lymphocyte proliferation by phorbol esters, mezerein, teleocidin, and okadaic acid.
Differential carcinogenic effects of intraperitoneal initiation with 7,12-dimethylbenz(a)anthracene or urethane and topical promotion with 12-O-tetradecanoylphorbol-13-acetate in skin and internal tissues of female SENCAR and BALB/c mice.
Differential co-promoting activities of alpha, beta and gamma interferons in the murine skin two-stage carcinogenesis model.
Differential cytotoxicity of tumour promoter TPA for EBV-negative human lymphoma cell lines and their EBV-converted sublines.
Differential down-regulation of epidermal protein kinase C by 12-O-tetradecanoylphorbol-13-acetate and diacylglycerol: association with epidermal hyperplasia and tumor promotion.
Differential effects of bryostatin 1 and 12-O-tetradecanoylphorbol-13-acetate on the regulation and activation of RasGRP1 in mouse epidermal keratinocytes.
Differential effects of diacylglycerols and 12-O-tetradecanoylphorbol-13-acetate on protein phosphorylation and cell proliferation of tumor promoter-dependent leukemia cell line A65T.
Differential effects of phorbol ester tumor promoters on 3-methylcholanthrene-induced epithelial and mesenchymal skin tumorigenesis.
Differential effects of sphingomyelinase and cell-permeable ceramide analogs on proliferation of Swiss 3T3 fibroblasts.
Differential effects of tumor promoters on P210bcr-abl expression.
Differential effects of tumour promoters on the growth of normal human bronchial epithelial cells and human lung tumour cell lines.
Differential effects of various skin tumor-promoting agents on prostaglandin E2 release from primary cultures of mouse epidermal cells.
Differential expression of laminin-5/ladsin subunits in human tissues and cancer cell lines and their induction by tumor promoter and growth factors.
Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-alpha, TNF-alpha converting enzyme and ADAMTS family members in murine fat territories.
Differential expression of TRAP Isoenzyme in B-CLL Cells Treated with Different Inducers.
Differential gene expression in epidermis of mice sensitive and resistant to phorbol ester skin tumor promotion.
Differential immunocytochemical localization of tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) in breast cancer.
Differential inducibility of Epstein-Barr virus in cloned, non-producer Raji cells.
Differential inhibition by staurosporine, a potent protein kinase C inhibitor, of 12-O-tetradecanoylphorbol-13-acetate-caused skin tumor promotion, epidermal ornithine decarboxylase induction, hyperplasia and inflammation.
Differential inhibition of Epstein-Barr virus induction by the amino acid analogue, L-canavanine.
Differential mechanisms of plasminogen activator inhibitor-1 gene activation by transforming growth factor-beta and tumor necrosis factor-alpha in endothelial cells.
Differential oxidative stress induced by two different types of skin tumor promoters, benzoyl peroxide and 12-O-tetradecanoylphorbol-13-acetate.
Differential protein phosphorylation in induction of thyroid cell proliferation by thyrotropin, epidermal growth factor, or phorbol ester.
Differential regulation of matrix metalloproteinases in human cancer cells by exogenous factors.
Differential regulation of plasminogen activation in normal keratinocytes and SCC-4 cells by fibroblasts.
Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53.
Differential regulation of plasminogen activators by epidermal growth factor in normal and neoplastic human urothelium.
Differential response of premalignant epithelial cell classes to phorbol ester tumor promoters and to deoxycholic acid.
Differential stimulation of mononuclear phagocyte IL 1 production and oxidative burst by tumor-promoting and non-tumor-promoting agents.
Differential tumor markers and hepatitis markers profile in liver tumors.
Differentiation of chronic lymphocytic leukemia cells after in vitro treatment with Epstein-Barr virus or phorbol ester. I. Immunologic and morphologic studies.
Differentiation-dependent localisation of tissue-type plasminogen activator in human bladder urothelium.
Direct evidence of incorporation of 12-O-[20-2H1]tetradecanoylphorbol-13-acetate into artificial membranes as determined by deuterium magnetic resonance.
Directed migration of murine and human tumor cells to collagenases and other proteases.
Discordant expression of Bcl-x and Bcl-2 by keratinocytes in vitro and psoriatic keratinocytes in vivo.
Discrete roles of cytokines, TNF-alpha, IL-1, IL-6 in tumor promotion and cell transformation.
Disease monitoring by the tumour markers cyfra 21.1 and TPA in patients with non-small cell lung cancer.
Disruption of protein kinase Ceta results in impairment of wound healing and enhancement of tumor formation in mouse skin carcinogenesis.
Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis.
Dissociated glucocorticoids equipotently inhibit cytokine- and cAMP-induced matrix degrading proteases in rat mesangial cells.
Dissociation of tumor promoter-stimulated ornithine decarboxylase activity and DNA synthesis in mouse epidermis in vivo and in vitro by fluocinolone acetonide, a tumor-promotion inhibitor.
Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells.
Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide.
Distribution of actin filaments in human malignant keratinocytes.
Distribution of phorbol ester TPA-induced structural chromosomal aberrations in HeLa cells.
Distribution of TPA and cytokeratins in gastrointestinal carcinomas as revealed by immunohistochemistry.
Distribution of tumor promoters in lipid membranes and changes in membrane structure.
Disturbances of early sea-urchin development by the tumor promoter TPA (phorbol ester).
Divergent roles for p55 and p75 TNF-alpha receptors in the induction of plasminogen activator inhibitor-1.
Diversity of Epithelial-Mesenchymal Phenotypes in Circulating Tumour Cells from Prostate Cancer Patient-Derived Xenograft Models.
Diversity of human pancreatic cancer cell proteinases: role of cell membrane metalloproteinases in collagenolysis and cytolysis.
DNA damage by smoke: protection by turmeric and other inhibitors of ROS.
DNA repair, cancer and gene therapy.
DNA-binding activity of Jun is increased through its interaction with Fos.
DNA-synthesizing enzymes in breast cancer (thymidine kinase, thymidylate synthase and thymidylate kinase): association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients.
DNase I hypersensitive sites in the 5' flanking region of the human plasminogen activator inhibitor type 2 (PAI-2) gene are associated with basal and tumor necrosis factor-alpha-induced transcription in monocytes.
Do novel risk factors differ between men and women aged 18 to 39 years with a high risk of coronary heart disease?
Do plasminogen activators play a role in lichen sclerosus?
Dose and frequency effect in mouse skin tumor promotion.
Dose-dependent mutation profile in the c-Ha-ras proto-oncogene of skin tumors in mice initiated with benzo[a]pyrene.
Dose-Responses Relationship in Glucose Lowering and Gut Dysbiosis to Saskatoon Berry Powder Supplementation in High Fat-High Sucrose Diet-Induced Insulin Resistant Mice.
Down-regulation of protein kinase C alpha and gamma and enhanced TPA-induced neurite formation in DAN-transfected neuroblastoma cells.
Downregulation of G3BPs inhibits the growth, migration and invasion of human lung carcinoma H1299 cells by suppressing the Src/FAK-associated signaling pathway.
Downregulation of vascular endothelial-cadherin expression is associated with an increase in vascular tumor growth and hemorrhagic complications.
Drug-resistant human laryngeal carcinoma cells have increased levels of cathepsin B.
Dynamics of serum levels of tumour markers and prognosis of recurrence and survival after liver surgery for colorectal liver metastases.
Early blood pressure alterations are associated with pro-inflammatory markers in type 1 diabetes mellitus.
Early changes in the cell cycle traverse of HeLa cells induced by tumor promoter TPA resemble irradiation effects.
Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling.
Early diagnosis for bone metastasis of breast cancer based on bone metabolism.
Early diagnosis of breast cancer dissemination by tumor markers follow-up and method of prediction.
Early diagnosis of lung cancer by detection of tumor liberated protein.
Early effects of TPA on protein kinase activity in murine thymocytes. Reduction of protein kinase C activity in the cytosol and increase of Ca2+ and phospholipid-independent kinase activity in the particulate fractions.
Early events of fusion between Epstein Barr virus and human lymphoblastoid cells (Raji) detected by R18 fluorescence dequenching measurements.
Early hemostatic alterations following bone marrow transplantation: a prospective study.
Early inflammatory changes in the skin of SENCAR and C57BL/6 mice following exposure to 12-O-tetradecanoylphorbol-13-acetate.
Early propranolol treatment ameliorates endothelial dysfunction in experimental septic lung.
Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion.
Early release of soluble receptor for advanced glycation endproducts after severe trauma in humans.
Ecotropic C-type retrovirus of B16 melanoma and malignant transformation of normal melanocytes.
Ecto-5'-nucleotidase. II. Effect of 12-O-tetradecanoylphorbol 13-acetate on the expression of enzyme in normal and neoplastic B-cell lines.
Effect of 1,8-dihydroxy-9-anthrone (anthralin) on rat hepatic ornithine decarboxylase activity in vivo.
Effect of 4-[3,5-bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) on the liver metastasis of colon 26-L5 carcinoma cells.
Effect of a Low-Fat Versus a Low-Gycemic-Load Diet on Inflammatory Biomarker and Adipokine Concentrations.
Effect of actinomycin D and cycloheximide on Epstein-Barr virus early antigen induction in lymphoblastoid cells.
Effect of application frequency on epidermal ornithine decarboxylase induction by chrysarobin in SENCAR mice.
Effect of ascorbic acid and its synthetic lipophilic derivative ascorbyl palmitate on phorbol ester-induced skin-tumor promotion in mice.
Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects.
Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells.
Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia.
Effect of berberine on p53 expression by TPA in breast cancer cells.
Effect of body-weight loading onto the articular cartilage on the occurrence of quinolone-induced chondrotoxicity in juvenile rats.
Effect of bone resorbing factors on u-PA and its specific receptor in osteosarcoma cell line.
Effect of Chenodeoxycholic Acid on Fibrosis, Inflammation and Oxidative Stress in Kidney in High-Fructose-Fed Wistar Rats.
Effect of Chinese drugs for activating blood circulation and detoxifying on indices of thrombosis, inflammatory reaction, and tissue damage in a rabbit model of toxin-heat and blood stasis syndrome.
Effect of colchicine injection prior to the initiating phase of two-stage skin carcinogenesis in mice.
Effect of Combined Treatment with Ursolic Acid and Resveratrol on Skin Tumor Promotion by 12-O-Tetradecanoylphorbol-13-Acetate.
Effect of diet-induced weight loss on endothelial dysfunction: early improvement after the first week of dieting.
Effect of dietary linoleic Acid on markers of inflammation in healthy persons: a systematic review of randomized controlled trials.
Effect of diterpene esters on actin cytoskeleton of SV40-transformed keratinocytes is not reproduced by diacylglycerols.
Effect of intra-abdominal administration of ligustrazine nanoparticles nano spray on postoperative peritoneal adhesion in rat model.
Effect of intraperitoneal chemotherapy and fibrinolytic therapy on tumor implantation in wound sites.
Effect of Long Term Vitamin D Supplementation on Biomarkers of Inflammation in Latino and African-American Subjects with Pre-Diabetes and Hypovitaminosis D.
Effect of Olmesartan on the Level of Oral Cancer Risk Factor PAI1.
Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis.
Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumor and normal cell lines.
Effect of phorbol ester TPA on macrophage metabolic activity.
Effect of phorbol ester tumor promoters on the expression of melanogenesis in B-16 melanoma cells.
Effect of protein kinase C activation on mast cell histamine release.
Effect of radiofrequency radiation exposure on mouse skin tumorigenesis initiated by 7,12-dimethybenz[alpha]anthracene.
Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation.
Effect of repeated thoracenteses on fluid characteristics, cytokines, and fibrinolytic activity in malignant pleural effusion.
Effect of retinoic acid pretreatment on 12-O-tetradecanoylphorbol-13-acetate-induced cell population kinetics and polyamine biosynthesis in hairless mouse epidermis.
Effect of silk fibroin peptide derived from silkworm Bombyx mori on the anti-inflammatory effect of Tat-SOD in a mice edema model.
Effect of Tacrolimus on Myocardial Infarction Is Associated with Inflammation, ROS, MAP Kinase and Akt Pathways in Mini-Pigs.
Effect of the active tumor promoter, 12-O-tetradecanoylphorbol-13-acetate on hair follicular growth and development of hair anlage tumors in the mouse skin: a comparison with human adnexal lesions.
Effect of the protein phosphatase inhibitor okadaic acid on FSH-induced granulosa cell steroidogenesis.
Effect of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate and its nonpromoting analogue 4-O-methyl-TPA on dorsal dermal melanocytes of the Syrian golden hamster (Mesocricetus auratus).
Effect of TPA on fructose 2,6-bisphosphate levels and protein kinase C activity in B-chronic lymphocytic leukemia (B-CLL).
Effect of transforming growth factor-beta on plasminogen activator production of cultured human uveal melanoma cells.
Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture.
Effect of tumor promoter TPA on spontaneous and mitomycin C induced mitotic recombination in Drosophila melanogaster.
Effect of tumor promoting phorbol ester TPA on epidermal protein synthesis: stimulation of an elongation factor 2 phosphatase activity by TPA in vivo.
Effect of tumour necrosis factor-alpha on proliferation, activation and protein synthesis of rat hepatic stellate cells.
Effect of various genetic polymorphisms on the incidence and outcome of severe sepsis.
Effect of vitreoscilla hemoglobin expression on growth and specific tissue plasminogen activator productivity in recombinant chinese hamster ovary cells.
Effects of 12-0-tetradecanoyl-phorbol-13-acetate on oral epithelium in vitro.
Effects of 12-0-Tetradecanoylphorbol-13-acetate (TPA) on rat pheochromocytoma (PC12) cells: interactions with epidermal growth factor and nerve growth factor.
Effects of 12-O-tetradecanoyl phorbol-13-acetate and epidermal growth factor on the proliferation of human mutant fibroblasts in vitro.
Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
Effects of 12-O-tetradecanoylphorbol-13-acetate and mezerein on gamma radiation-induced DNA repair in resting bovine lymphocytes.
Effects of 12-O-tetradecanoylphorbol-13-acetate in combination with gemcitabine on Panc-1 pancreatic cancer cells cultured in vitro or Panc-1 tumors grown in immunodeficient mice.
Effects of 12-O-tetradecanoylphorbol-13-acetate on carcinogenesis in the heterotopically transplanted rat urinary bladder.
Effects of 12-O-tetradecanoylphorbol-13-acetate on fibroblasts from individuals genetically predisposed to cancer.
Effects of 12-O-tetradecanoylphorbol-13-acetate on the incorporation of labelled precursors into RNA, DNA and protein in epidermis, dermis and subcutis from precancerous mouse skin with reference to enhanced tumorigenesis.
Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on protein kinase C and inositol phosphate metabolism in primary cultures of rat hepatocytes.
Effects of 2-phenyl-1,4-benzoquinone and 2,5-dihydroxybiphenyl on two-stage mouse skin carcinogenesis.
Effects of 2.45-GHz microwave radiation and phorbol ester 12-O-tetradecanoylphorbol-13-acetate on dimethylhydrazine-induced colon cancer in mice.
Effects of 5-azacytidine, sodium butyrate, and phorbol esters on amino acid transport system A in a kidney epithelial cell line, MDCK: evidence for multiple mechanisms of regulation.
Effects of 8-bromoadenosine 3':5'-cyclic monophosphate on proteolytic enzymes, adhesiveness and lung-colonizing ability of cloned low-metastatic Lewis lung carcinoma cells.
Effects of a biomimetic superoxide dismutase on complete and multistage carcinogenesis in mouse skin.
Effects of a community-based weight loss intervention on adipose tissue circulating factors.
Effects of a High-Fat or High-Sucrose Diet on Ultraviolet B Irradiation-Induced Carcinogenesis and Tumor Growth in Melanin-Possessing Hairless Mice.
Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells.
Effects of acyclovir on herpes simplex virus type 1 infection in mice treated with 12-O-tetradecanoylphorbol 13-acetate.
Effects of amino acid treatments on 12-O-tetradecanoylphorbol-13-acetate-induced ornithine decarboxylase activity in mouse epidermis in vivo and in vitro.
Effects of Angiotensin-Converting Enzyme Inhibition and Alpha 1-Adrenergic Receptor Blockade on Inflammation and Hemostasis in Human Hypertension.
Effects of anti-promoters and strain of mouse on tumor promoter-induced oxidants in murine epidermal cells.
Effects of antihistamines on phorbol ester tumor promotion and vascular permeability changes.
Effects of antiinflammatory agents on mouse skin tumor promotion, epidermal DNA synthesis, phorbol ester-induced cellular proliferation, and production of plasminogen activator.
Effects of asbestos on epithelioid cell lines.
Effects of C-Phycocyanin on the representative genes of tumor development in mouse skin exposed to 12-O-tetradecanoyl-phorbol-13-acetate.
Effects of combined treatments with selenium, glutathione, and vitamin E on glutathione peroxidase activity, ornithine decarboxylase induction, and complete and multistage carcinogenesis in mouse skin.
Effects of complete and incomplete tumor promoters on hair growth, angiogenesis, and tenascin expression in the skin of NMRI mice.
Effects of dietary retinyl palmitate or 13-cis-retinoic acid on the promotion of tumors in mouse skin.
Effects of different hypocaloric diets on protein secretion from adipose tissue of obese women.
Effects of diverse intracellular thiol delivery agents on glutathione peroxidase activity, the ratio of reduced/oxidized glutathione, and ornithine decarboxylase induction in isolated mouse epidermal cells treated with 12-O-tetradecanoylphorbol-13-acetate.
Effects of dose and duration of treatment with the tumor-promoting agent, 12-O-tetradecanoylphorbol-13-acetate on mouse skin carcinogenesis.
Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis.
Effects of gabexate mesilate on coagulopathy and organ dysfunction in rats with endotoxemia: a potential use of thrombelastography in endotoxin-induced sepsis.
Effects of garlic and onion oils on glutathione peroxidase activity, the ratio of reduced/oxidized glutathione and ornithine decarboxylase induction in isolated mouse epidermal cells treated with tumor promoters.
Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
Effects of insulin and a tumour promoter, TPA, on glucose transport and metabolism in retinal pigmented epithelium in vitro.
Effects of Intense Exercise and Moderate Caloric Restriction on Cardiovascular Risk Factors and Inflammation.
Effects of inter-alpha-inhibitor in experimental endotoxic shock and disseminated intravascular coagulation.
Effects of interleukin-1, tumor necrosis factor -beta, and forskolin on tissue plasminogen activator activity in human osteoblastic osteosarcoma cells.
Effects of lifestyle intervention on left ventricular regional myocardial function in metabolic syndrome patients from the RESOLVE randomized trial.
Effects of margarine enriched with plant sterol esters from rapeseed and tall oils on markers of endothelial function, inflammation and hemostasis.
Effects of methoxychlor on skin tumor development.
Effects of nicotinamide on mouse skin tumor development and its mode of action.
Effects of omega-3 fatty acids on endothelial function, arterial wall properties, inflammatory and fibrinolytic status in smokers: A cross over study.
Effects of oral versus topical administration of cyclosporine on phorbol ester promotion of murine epidermal carcinogenesis.
Effects of pentoxifylline infusion on response of horses to in vivo challenge exposure with endotoxin.
Effects of pergolide mesylate on transduction efficiency of PEP-1-catalase protein.
Effects of phorbol ester tumor promoters and hyperplasiogenic agents on cytoplasmic glucocorticoid receptors in epidermis.
Effects of phorbol esters on normal and tumorous mouse mammary epithelial cells embedded in collagen gels.
Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation.
Effects of polymyxin B-immobilized fiber using a rat cecal ligation and perforation model.
Effects of polyurethane membrane on septic colon anastomosis and intra-abdominal adhesions.
Effects of resveratrol on 12-O-tetradecanoylphorbol-13-acetate-induced oxidative events and gene expression in mouse skin.
Effects of Rubus occidentalis extract on blood pressure in patients with prehypertension: Randomized, double-blinded, placebo-controlled clinical trial.
Effects of short-term exposure to the tumor promoter, 12-O-tetradecanoylphorbol-13-acetate on skin carcinogenesis in SENCAR mice.
Effects of Simulated Heat Wave and Ozone on High Fat Diet ApoE Deficient Mice.
Effects of single applications of 12-O-tetradecanoylphorbol-13-acetate, mezerein, or ethylphenylpropiolate on DNA synthesis and polyamine levels in hairless mouse epidermis.
Effects of suramin on metastatic ability, proliferation, and production of urokinase-type plasminogen activator and plasminogen activator inhibitor type 2 in human renal cell carcinoma cell line SN12C-PM6.
Effects of the tumor promoter TPA on the induction of DNA synthesis in normal and RSV-transformed rat fibroblasts.
Effects of TPA on short-circuit current across frog skin.
Effects of tumor necrosis factor alpha and beta on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes.
Effects of tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate on morphology and anchorage-independent growth of normal and established chick embryo cells.
Effects of tumor promoters (mezerein, teleocidin and palytoxin) on growth hormone secretion from rat anterior pituitary cells cultured in monolayer.
Effects of tumor promoters and extracellular calcium on the growth of normal, transformed and temperature sensitive rat liver epithelial cells.
Effects of tumor promoters on sodium ion transport across frog skin.
Effects of tumor promoters, genotoxic carcinogens and hepatocytotoxins on mouse hepatocyte intercellular communication.
Effects of tumour cell culture supernatants on some biochemical activities of macrophages.
Effects of tumour necrosis factor alpha (TNF alpha) on ovulation in the rat ovary.
Effects of tumour promoters on metabolic cooperation between human hepatoma cells.
Effects of two disiloxanes ALIS-409 and ALIS-421 on chemoprevention in model experiments.
Effects of type of dietary fat on phorbol ester-elicited tumor promotion and other events in mouse skin.
Effects of urokinase receptor occupancy on plasmin generation and proteolysis of basement membrane by human tumor cells.
Effects of UV light and tumor promoters on endogenous vitamin E status in mouse skin.
Effects of UV, 4-NQO and TPA on gene expression in cultured human epidermal keratinocytes.
Effects of various tumor promoters on expression of cartilage phenotypes in rabbit costal chondrocytes in culture.
Effects on blood glucose, insulin, lipid and proatherosclerotic parameters in stable type 2 diabetic subjects during an oral fat challenge.
Efficacy and safety of reteplase for central venous catheter occlusion in patients with cancer.
Efficacy of eight serially measured markers for diagnosis of prostatic carcinoma.
EGFR signaling leads to downregulation of PTP-LAR via TACE-mediated proteolytic processing.
Eicosanoids and multistage carcinogenesis in NMRI mouse skin: role of prostaglandins E and F in conversion (first stage of tumor promotion) and promotion (second stage of tumor promotion).
Elevated Activation of ERK1 and ERK2 Accompany Enhanced Liver Injury Following Alcohol Binge in Chronically Ethanol-Fed Rats.
Elevated expression of secondary, but not early, responding genes to phorbol ester tumor promoters in papillomas and carcinomas of mouse skin.
Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation.
Elevated fibroblast growth factor-inducible 14 expression transforms proneural-like gliomas into more aggressive and lethal brain cancer.
Elevated resistin is related to inflammation and residual renal function in haemodialysed patients.
Elevated Serum Levels of Lp-PLA2 and IL-18 are Associated with Progression of Diabetic Foot Ulcers.
Elevated tumour markers in patients with Balkan endemic nephropathy.
Elevation of Plasminogen Activator Inhibitor-1 promotes differentiation of Cancer Stem-like Cell state by Hepatitis C Virus infection.
Elimination of metabolic cooperation by glycyrrhetinic acid, an anti-tumor promoter, in cultured Chinese hamster cells.
ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1).
Emodin improves alveolar hypercoagulation and inhibits pulmonary inflammation in LPS-provoked ARDS in mice via NF-?B inactivation.
Endocrine and signalling role of adipose tissue: new perspectives on fat.
Endocrine therapy in pancreatic carcinoma.
Endogenous modulators for drug dependence.
Endogenous protein kinase-C activation in osteoblast-like cells modulates responsiveness to estrogen and estrogen receptor levels.
Endothelial cells degrade extracellular matrix proteins produced in vitro.
Endothelial Function, Inflammation, Thrombosis, and Basal Ganglia Perivascular Spaces in Patients with Stroke.
Endotoxin and Plasminogen Activator Inhibitor-1 Serum Levels Associated With Nonalcoholic Steatohepatitis in Children.
Endotoxin induced expression of tumour necrosis factor, tissue factor and plasminogen activator inhibitor activity by peritoneal macrophages.
Enhanced cell-associated plasminogen activator pathway but not coagulation pathway activity contributes to motility in metastatic breast cancer cells.
Enhanced expression of urokinase receptor induced through the tissue factor-factor VIIa pathway in human pancreatic cancer.
Enhanced induction of epidermal ornithine decarboxylase activity in C57BL/6 compared to DBA/2 mice by protein kinase C-activating skin tumor promoters: relevance to genetically mediated differences in promotion susceptibility.
Enhanced induction of the anchorage-independent phenotype in initiated rat tracheal epithelial cell cultures by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate.
Enhanced sensitivity to tumor growth and development in multistage skin carcinogenesis by transforming growth factor-alpha-induced epidermal growth factor receptor activation but not p53 inactivation.
Enhanced skin carcinogenesis in transgenic mice with high expression of glutathione peroxidase or both glutathione peroxidase and superoxide dismutase.
Enhanced synthesis of tumor necrosis factor-inducible proteins, plasminogen activator inhibitor-2, manganese superoxide dismutase, and protein 28/5.6, is selectively triggered by the 55-kDa tumor necrosis factor receptor in human melanoma cells.
Enhancement of Epstein-Barr virus membrane protein (LMP) expression by serum, TPA, or n-butyrate in latently infected Raji cells.
Enhancement of esophageal carcinogenesis induced in rats by N-amyl-N-methylnitrosamine in the presence of 12-O-tetradecanoylphorbol-13-acetate.
Enhancement of macrophage-induced cytotoxicity by phorbol ester tumor promoters.
Enhancement of neointima formation with tissue-type plasminogen activator.
Enhancement of outgrowth of EB virus-transformed cells from normal human peripheral blood by a tumor promoter, TPA.
Enhancement of sister-chromatid exchanges by tumour promoters.
Enhancement of two-stage skin carcinogenesis by exposure of distant skin to UV radiation.
Enhancing effect of tumor promoters, phorbol esters and teleocidins on nuclear receptor-mediated transcription.
Enhancing Mitochondrial Respiration Suppresses Tumor Promoter TPA Induced PKM2 Expression and Cell Transformation in Skin Epidermal JB6 Cells.
Enzymes approved for human therapy: indications, mechanisms and adverse effects.
Epidermal changes following application of 7,12-dimethylbenz(a)anthracene and 12-O-tetradecanoylphorbol-13-acetate to human skin transplanted to nude mice studied with histological species markers.
Epidermal expression of transforming growth factor-alpha in transgenic mice: induction of spontaneous and 12-O-tetradecanoylphorbol-13-acetate-induced papillomas via a mechanism independent of Ha-ras activation or overexpression.
Epidermal fatty acid binding protein prevents chemical-induced skin tumorigenesis by regulation of TPA-induced IFN/p53/SOX2 pathway in keratinocytes.
Epidermal growth factor and pro-inflammatory cytokines regulate the expression of components of plasminogen activation system in U373-MG astrocytoma cells.
Epidermal growth factor promotes invasiveness of pancreatic cancer cells through NF-kappaB-mediated proteinase productions.
Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis.
Epidermal proliferation of nude mouse skin, pig skin, and pig skin grafts. Failure of nude mouse skin to respond to the tumor promoter 12-O-tetradecanoyl phorbol 13-acetate.
Epigenetic alterations of the SERPINE1 gene in oral squamous cell carcinomas and normal oral mucosa.
Episomal and nonepisomal herpesvirus DNA in lymphoid tumor cell lines.
Epitopes of components of the plasminogen activation system are re-exposed in formalin-fixed paraffin sections by different retrieval techniques.
Epstein-Barr virus induced proteins V: comparison of EBV-specific polypeptides from different virus strains.
Epstein-Barr virus-induced proteins. IV. Characterization of an EBV-associated phosphopolypeptide.
ERBB3 is required for tumor promotion in a mouse model of skin carcinogenesis.
ERK signaling pathway is involved in p15INK4b/p16INK4a expression and HepG2 growth inhibition triggered by TPA and Saikosaponin a.
Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice.
Establishment and cell cycle kinetics of a human squamous cell carcinoma in nude mice and in vitro.
Establishment and characterization of a human ovarian serous cystadenocarcinoma cell line that produces the tumor markers CA-125 and tissue polypeptide antigen.
Establishment and characterization of ovarian endometrioid adenocarcinoma cell line in nude mice and analyses of the immunohistochemical property among the original, recurred, and heterotransplanted tumor.
Establishment of a human leukemia subline resistant to the growth-inhibitory effect of 12-O-tetradecanoylphorbol 13-acetate (TPA) and showing non-P-glycoprotein-mediated multi-drug resistance.
Establishment of a peritoneal mesothelial cell line from a transgenic rat harbouring the temperature-sensitive simian virus 40 large T-antigen gene.
Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure.
Estimated Association Between Cytokines and the Progression to Diabetes: 10-year Follow-Up From a Community-Based Cohort.
Estimation of usefulness of monitoring tissue polypeptide antigen--TPA-M concentrations in the effectiveness surgical treatment of urinary bladder cancer.
Estrogen-dependent plasminogen activator in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors in vivo and in vitro.
Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice.
ETS family of genes in leukemia and Down syndrome.
Eugenol precludes cutaneous chemical carcinogenesis in mouse by preventing oxidative stress and inflammation and by inducing apoptosis.
Evaluation of 12-lipoxygenase (12-LOX) and plasminogen activator inhibitor 1 (PAI-1) as prognostic markers in prostate cancer.
Evaluation of breviscapine on prevention of experimentally induced abdominal adhesions in rats.
Evaluation of carcinogenic effect of jute batching oil (JBO-P) fractions following topical application to mouse skin.
Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
Evaluation of pentacyclic triterpenes found in Perilla frutescens for inhibition of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
Evaluation of TATI and other markers in solid tumors.
Evaluation of the prognostic value of fibrinolytic elements in invasive breast carcinoma patients.
Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC).
Evaluation of tissue polypeptide antigen serum levels for monitoring disease activity during chemotherapy in patients with transitional carcinoma of the urinary tract.
Evidence against a role of general protein kinase C downregulation in skin tumor promotion.
Evidence for potential involvement of pro-inflammatory adipokines in the pathogenesis of idiopathic intracranial hypertension.
Evidence for the functional similarity between tumour cell surface guanidinobenzoatase and tissue type plasminogen activator.
Evidence for two pathways of protein kinase C induction of 2ar expression: correlation with mitogenesis.
Evidence that beta 1-6 branched Asn-linked oligosaccharides on metastatic tumor cells facilitate invasion of basement membranes.
Evidence that gsta4 modifies susceptibility to skin tumor development in mice and humans.
Evidence that mirex promotes a unique population of epidermal cells that cannot be distinguished by their mutant Ha-ras genotype.
Exercise and caloric restriction improve cardiovascular and erectile function in rats with metabolic syndrome.
Existence of slow-cycling limbal epithelial basal cells that can be preferentially stimulated to proliferate: implications on epithelial stem cells.
Exogenous Cu,Zn-superoxide dismutase suppresses the stimulation of neonatal rat hepatocytes' growth by tumor promoters.
Experimental and Clinical Evidence Supports the Use of Urokinase Plasminogen Activation System Components as Clinically Relevant Biomarkers in Gastroesophageal Adenocarcinoma.
Experimental model for quantitative study of metastasis.
Experiments with tissue cultures from a human ovarian serous cystadenocarcinoma producing cancer antigen 125 (CA125), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA).
Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: Association with tumor progression.
Expression and Clinical Signification of Cytosolic Hyaluronan Levels in Invasive Breast Cancer.
Expression and clinical signification of cytosolic hyaluronan levels in invasive breast cancer.
Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers.
Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance.
Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
Expression of integrins, degradative enzymes and their inhibitors in uveal melanoma: differences between in vitro and in vivo expression.
Expression of leukemia inhibitory factor is regulated in human mesenchymal cells.
Expression of p56lck in B-cell neoplasias.
Expression of plasminogen activator as a marker of stimulation in tumor-associated macrophages.
Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.
Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
Expression of plasminogen activators in basal cell carcinoma.
Expression of the alpha 6, beta 1 and beta 4 integrin subunits, basement membrane organization and proteolytic capacities in low and high metastatic human colon carcinoma xenografts.
Expression of the epidermal growth factor receptor gene in human brain metastases.
Expression of the non-glycosylated kringle domain of tissue type plasminogen activator in Pichia and its anti-endothelial cell activity.
Expression of the proteolytic factors, tPA and uPA, PAI-1 and VEGF during malignant glioma progression.
Expression of tissue-type plasminogen activator, plasminogen activator inhibitor and von Willebrand factor in the supernatant of endothelial cell cultures in response to the seeding of adenocarcinoma cell line HRT-18.
Expression of trophoblast derived prostaglandin E2 receptor 2 (EP2) is reduced in patients with recurrent miscarriage and EP2 regulates cell proliferation and expression of inflammatory cytokines.
Expression of tumour markers CA50, CEA and TPA in female breast carcinoma as related to histopathological findings and survival.
Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Expression of urokinase-type plasminogen activator, its receptor and type-1 plasminogen activator inhibitor is differently regulated by inhibitors of protein synthesis in human cancer cell lines.
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma.
Expression of urokinase-type plasminogen-activator (upa) and its receptor (upar) in human ovarian-cancer cells and in-vitro invasion capacity.
Expression pattern of a gene for a secreted metalloproteinase during late stages of tumor progression.
Expression pattern of the urokinase-plasminogen activator system in rat DS-sarcoma: role of oxygenation status and tumour size.
Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer Network.
Extra-hepatic cholestasis determines a reversible increase of glycoproteic tumour markers in benign and malignant diseases.
Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation.
Extraglycemic effects of glp-1-based therapeutics: Addressing metabolic and cardiovascular risks associated with type 2 diabetes.
Fabrication of an immunosensor for early and ultrasensitive determination of human tissue plasminogen activator (tPA) in myocardial infraction and breast cancer patients.
Factors associated with progression to death in patients with Lassa fever in Nigeria: an observational study.
Factors regulating pS2-reporter gene expression in MCF-7 breast cancer cell line.
Failure of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) to inhibit cell-cell coupling in newborn mouse epidermal cells and Chinese hamster V79 cells under non-standard culture conditions.
Fatty acids and expression of adipokines.
Fibrin and Fibrinolysis in Cancer.
Fibrin degradation by rtPA enhances the delivery of nanotherapeutics to A549 tumors in nude mice.
Fibrinogen-fibrin transformation in situ in renal cell carcinoma.
Fibrinolysis associated with human neoplasia: production of plasminogen activator by human tumours.
Fibrinolysis-inhibitory activity of cultured human cancer cell lines.
Fibrinolytic activity in a human fibrosarcoma cell line and evidence for the induction of plasminogen activator secretion during tumor formation.
Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids.
Fibrinolytic Enzyme Cotherapy Improves Tumor Perfusion and Therapeutic Efficacy of Anticancer Nanomedicine.
Fibrinolytic shutdown after cardiopulmonary bypass surgery is caused by circulating cytokines during operation, accompanied by endothelial injury.
Fibrinolytic System and Cancer: Diagnostic and Therapeutic Applications.
Fibrinolytic system in plasma and pleural fluid in malignant pleural mesothelioma.
Fibrinolytic tissue plasminogen activator installed redox-active nanoparticles (t-PA@iRNP) for cancer therapy.
Fibroblast contractility and actin organization are stimulated by microtubule inhibitors.
Five human tumour cell lines derived from a primary squamous carcinoma of the tongue, two subsequent local recurrences and two nodal metastases.
Flavokawain B inhibits growth of human squamous carcinoma cells: Involvement of apoptosis and cell cycle dysregulation in vitro and in vivo.
Flow cytofluorometry in tumour cell receptor analysis. Survey of the literature and recent developments concerning the urokinase-type plasminogen activator (uPA).
Flow cytometric analysis of the phenotypic changes in tumour cell lines following TPA induction.
Focused PCR screen reveals p53 dependence of nitric oxide-induced apoptosis and up-regulation of maspin and plasminogen activator inhibitor-1 in tumor cells.
Follow-up of colorectal cancer resected for cure. An experience with CEA, TPA, Ca 19-9 analysis and second-look surgery.
Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis.
Forskolin and a tumor promoter are able to induce c-fos and c-myc expression in normal, but not in a v-ras-transformed rat thyroid cell line.
Fractionation of a tumor-initiating UV dose introduces DNA damage-retaining cells in hairless mouse skin and renders subsequent TPA-promoted tumors non-regressing.
Frequent codon 12 Ki-ras mutations in mouse skin tumors initiated by N-methyl-N'-nitro-N-nitrosoguanidine and promoted by mezerein.
From Rous sarcoma virus to plasminogen activator, src oncogene and cancer management.
Functional evaluation of plasmin formation in primary breast cancer.
Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line.
Functional plasminogen activator inhibitor-1 gene variants and breast cancer survival.
Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes.
Functional role of MIA in melanocytes and early development of melanoma.
Functional role of the cis-acting elements in human monocyte chemotactic protein-1 gene in the regulation of its expression by phorbol ester in human glioblastoma cells.
Functions of mononuclear phagocytes in mice exposed to diethylstilbestrol: a model of aberrant macrophage development.
Further characterization of prolymphocytic leukemia cells as a tumor of activated B cells.
Further genetic analyses of skin tumor promoter susceptibility using inbred and recombinant inbred mice.
Further inhibition studies on guanidinobenzoatase, a trypsin-like enzyme associated with tumour cells.
Further studies on the mitogenic and immune-modulating effects of plasminogen activator.
Galectin-1 is a novel functional receptor for tissue plasminogen activator in pancreatic cancer.
Games network and application to PAs system.
Gap junctional intercellular communication and connexin expression in normal and SV 40-transformed human liver cells in vitro.
Gap junctional intercellular communication in mouse lung epithelial cell lines: effects of cell transformation and tumor promoters.
Gap junctional intercellular communication of primary and asbestos-associated malignant human mesothelial cells.
Gastrin stimulates expression of plasminogen activator inhibitor (PAI)-1 in gastric epithelial cells.
Gene activation by induced DNA rearrangements.
Gene expression analysis of a porcine native abdominal aortic aneurysm model.
Gene expression of adipose tissue, endothelial cells and platelets in subjects with metabolic syndrome (Review).
Gene expression of TPA induced differentiation in HL-60 cells by DNA microarray analysis.
Genes regulating glutathione concentrations in X-ray-transformed rat embryo fibroblasts: changes in gamma-glutamylcysteine synthetase and gamma-glutamyltranspeptidase expression.
Genetic and plasma markers of venous thromboembolism in patients with high grade glioma.
Genetic evidence that a phorbol ester tumor promoter stimulates ornithine decarboxylase activity by a pathway that is independent of cyclic AMP-dependent protein kinases in CHO cells.
Genetic factors controlling responsiveness to skin tumor promotion in mice.
Genetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasia.
Genetics of chemical carcinogenesis--II. Papilloma induction and malignant conversion in susceptible (Car-s) and resistant (Car-R) lines of mice produced by bidirectional selective breeding and in their (Car-S X Car-R) F1 hybrids.
Genetics of chemical carcinogenesis--III. Tissue-specificity of the genes controlling susceptibility and resistance to skin carcinogenesis in the mouse.
Genetics of chemical carcinogenesis. 1. Bidirectional selective breeding of susceptible and resistant lines of mice to two-stage skin carcinogenesis.
Genetics of chemical carcinogenesis: analysis of bidirectional selective breeding inducing maximal resistance or maximal susceptibility to 2-stage skin tumorigenesis in the mouse.
Genetics of otitis media.
Genistein reduces tumor necrosis factor alpha-induced plasminogen activator inhibitor-1 transcription but not urokinase expression in human endothelial cells.
Genomic 5-methyldeoxycytidine decreases associated with the induction of squamous differentiation in cultured normal human bronchial epithelial cells.
Germinated Brown Rice Attenuates Atherosclerosis and Vascular Inflammation in Low-Density Lipoprotein Receptor-Knockout Mice.
Ghrelin attenuates plasminogen activator inhibitor-1 production induced by tumor necrosis factor-alpha in HepG2 cells via NF-kappaB pathway.
GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells.
Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomised controlled trials.
Glucocorticoid-regulated adipose tissue secretion of PAI-1, but not IL-6, TNFalpha or leptin in vivo.
Glycoxidation and inflammation in renal failure patients.
Glycyrrhetic acid inhibits tumor-promoting activity of teleocidin and 12-O-tetradecanoylphorbol-13-acetate in two-stage mouse skin carcinogenesis.
Gomisin A inhibits tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin.
Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells.
Graves' Orbitopathy Results in Profound Changes in Tear Composition: A Study of Plasminogen Activator Inhibitor-1 and Seven Cytokines.
Graves' orbitopathy results in profound changes in tear composition; a study of Plasminogen activator inhibitor-1 (PAI-1) and seven cytokines.
Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice.
Growth stimulation of microenvironment-dependent mouse leukemias by tumor-promoting phorbol esters.
Growth-dependent AIB and meAIB uptake in LLC-PK1 cells: effects of differentiation inducers and of TPA.
Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation.
Helicobacter pylori infection stimulates plasminogen activator inhibitor 1 production by gastric epithelial cells.
Hemodynamic forces modulate the effects of cytokines on fibrinolytic activity of endothelial cells.
Hemodynamic stability during adrenalectomy for pheochromocytoma: A case control study of posterior retroperitoneal vs lateral transperitoneal approaches.
Hemostasis in malignancy.
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Hemostatic and fibrinolytic indices in neonatal foals with presumed septicemia.
Hemostatic response to postprandial lipemia before and after exercise training.
Hepadnavirus enhancer and its binding proteins.
Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha.
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Hereditary adenomatosis of the colon and rectum: relevance to cancer promotion and cancer control in humans.
Heterogeneity of murine erythroleukemia cells with respect to tumor promoter-mediated inhibition of cell differentiation.
Heterogeneity of plasminogen activator expression in various Moloney virus-induced tumor cell lines. Lack of correlation with tumor growth and cell phenotype.
Heterogeneous distribution of macrophages, tumour necrosis factor alpha, tissue factor and fibrinolytic regulators in atherosclerotic vessels.
Hexahydro-?-acids potently inhibit 12-O-tetradecanoylphorbol 13-acetate-induced skin inflammation and tumor promotion in mice.
Hexose uptake as an indicator of JB6 mouse epidermal cell resistance to the mitogenic activity of TPA.
HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling.
High expression of plasminogen activator inhibitor-2 (PAI-2) is a predictor of improved survival in patients with pancreatic adenocarcinoma.
High In-Vitro Antitumour Activity of Triphenyltin Coumarin 3-Carboxylate and its Coordination Complexes With Monodentate Oxygen Donor Ligands Against the Epstein Barr Virus (EBV)-DNA Positive Raji and the P-388 Murine Leukaemia Cell Lines, and Evidence for the Suppression by Organotin of the Early Antigen Complex in the EBV Lytic Cycle.
High macrophage migration inhibitory factor levels in disseminated intravascular coagulation patients with systemic inflammation.
High preoperative plasma concentration of tissue plasminogen activator (tPA) is an independent marker for shorter overall survival in patients with ovarian cancer.
High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.
High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas.
High tPA-expression in primary melanoma of the limb correlates with good prognosis.
High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer.
High-dose antithrombin III treatment of severely injured patients: results of a prospective study.
High-fat Diet Enhances Mammary Tumorigenesis and Pulmonary Metastasis and Alters Inflammatory and Angiogenic Profiles in MMTV-PyMT Mice.
Histochemical study of the biphasic cellular pattern of tubular adenoid cystic carcinoma with azophloxine, amidoblack and acid blue.
Histogenesis of the intradermal melanocytic tumor in BDF1 mice induced by topical application of 9,10-dimethyl-1,2-benzanthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA).
Histone Deacetylase Inhibitor Impairs Plasminogen Activator Inhibitor-1 Expression via Inhibiting TNF- ? -Activated MAPK/AP-1 Signaling Cascade.
Histopathological and prognostic evaluation of immunohistochemical findings in colorectal cancer.
HIV--associated lipodystrophy in children.
HMGA1 regulates the Plasminogen activation system in the secretome of breast cancer cells.
Hormonal modulation of plasminogen activator: an approach to prediction of human breast tumor responsiveness.
Hormonal regulation of plasminogen activator and peroxidase activities in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors and the rat uterus.
Hormone control of total plasminogen activator activity is specific to malignant DMBA-induced rat mammary tumours.
Hormone-sensitive cholesterol ester hydrolase in adrenal tumor cells: activation by corticotropin and tetradecanoyl phorbol acetate.
Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner.
Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth.
Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity.
Human epicardial adipokine messenger RNAs: comparisons of their expression in substernal, subcutaneous, and omental fat.
Human monocyte or recombinant interleukin 1's are specific for the secretion of a metalloproteinase from chondrocytes.
Human myelogenous leukemia: enhanced clonal proliferation in the presence of phorbol diesters.
Human papilloma virus transformed CaSki cells constitutively express high levels of functional SerpinB2.
Human plasma fibronectin as a substrate for human urokinase.
Human primary colon carcinomas xenografted into nude mice. II. Modulation of tumor plasminogen activator activity by the host tissue environment.
Human prostate tumor angiogenesis in nude mice: metalloprotease and plasminogen activator activities during tumor growth and neovascularization of subcutaneously injected matrigel impregnated with human prostate tumor cells.
Human tissue polypeptide antigen in breast cancer.
Humulon, a bitter in the hop, inhibits tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin.
Hybrid recombinant human leukocyte interferon inhibits differentiation in murine B-16 melanoma cells.
Hydrogen peroxide inhibits gap junctional intercellular communication in glutathione sufficient but not glutathione deficient cells.
Hydrogenated fat intake during pregnancy and lactation modifies serum lipid profile and adipokine mRNA in 21-day-old rats.
Hydrolyzable tannins: potent inhibitors of hydroperoxide production and tumor promotion in mouse skin treated with 12-O-tetradecanoylphorbol-13-acetate in vivo.
Hydroquinones cause specific mutations and lead to cellular transformation and in vivo tumorigenesis.
Hydroxycinnamic acid derivatives: a potential class of natural compounds for the management of lipid metabolism and obesity.
Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid.
Hypoadiponectinemia as a marker of adipocyte dysfunction--part II: the functional significance of low adiponectin secretion.
Hypothalamic ischemia and metabolic syndrome Comment to: Apelin and visfatin: Unique "beneficial" adipokines upregulated in obesity? Jerzy Bełtowski Med Sci Monit, 2006; 12(6): RA112-19.
Ichthyotoxic and anticarcinogenic effects of triterpenoids from Sandoricum koetjape bark.
Identification and characterization of a radiation-inducible glycosylated human early-response gene.
Identification and quantification of a carcinogen-induced molecular initiation event in cell transformation.
Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue.
Identification of cembratriene-4,6-diol as antitumor-promoting agent from cigarette smoke condensate.
Identification of novel genetic loci contributing to 12-O-tetradecanoylphorbol-13-acetate skin tumor promotion susceptibility in DBA/2 and C57BL/6 mice.
Identification of tumor promotion marker genes for predicting tumor promoting potential of chemicals in BALB/c 3T3 cells.
Imbalance between intraperitoneal coagulation and fibrinolysis during peritonitis of CAPD patients: the role of mesothelial cells.
Immune-inflammatory markers and arterial stiffness indexes in subjects with acute ischemic stroke.
Immuno-histochemical localization of tissue polypeptide antigen (TPA) and carcino-embryonic antigen (CEA) in breast cancer. A comparative study.
Immuno-histological localization of tissue polypeptide antigen (TPA) in gynecological malignancies.
Immunocytochemical features of lens after cataract tissue--signalling molecules (growth factors, cytokines, other signalling molecules), cytoskeleton proteins, cellular and extracellular matrix proteins.
Immunohistochemical analysis of plasminogen activator expression in human colorectal carcinomas: correlation with CEA distribution and tumor cell kinetics.
Immunohistochemical and ultrastructural localization of tissue polypeptide antigen in human ovarian tumours.
Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
Immunohistochemical localisation of tissue plasminogen activator in human brain tumours.
Immunohistochemical localization of plasminogen activator inhibitor type 1 in human brain tumors.
Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas.
Immunological effects of tumor vaccines: III. Influenza virus oncolysates inhibit the TPA induced activation of peripheral blood mononuclear cells.
Immunological study of tissue polypeptide antigen (TPA)--demonstration of keratin-like sites and blood group antigen-like sites on TPA molecules.
Immunophenotypic and immunoelectron microscopic characterization of major constituent cells in malignant fibrous histiocytoma using human cell lines and their transplanted tumors in immunodeficient mice.
Immunoreactivity of Plasminogen Activator Inhibitor 1 and Its Correlation with Dysmenorrhea and Lesional Fibrosis in Adenomyosis.
Immunosuppressive activity and tissue polypeptide antigen content of human ascitic fluids.
Impact of atrial fibrillation on inflammatory and fibrinolytic variables in the elderly.
Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes.
Impact of Saskatoon berry powder on insulin resistance and relationship with intestinal microbiota in high fat-high sucrose diet-induced obese mice.
Importance of viability and attachment to an ascites tumor in the release of plasminogen activator.
Improved insulin sensitivity by the angiotensin II-receptor blocker losartan is not explained by adipokines, inflammatory markers, or whole blood viscosity.
Improved tumour yields by means of a TPA-DMBA-TPA variation of the Berenrlum-Mottram experiment on the back skin of NMRI mice. The effect of stationary hyperplasia without inflammation.
In B16 melanoma cells, the inhibition of melanogenesis by TPA results from PKC activation and diminution of microphthalmia binding to the M-box of the tyrosinase promoter.
In patients with superficial vein thrombosis the inflammatory response is increased and related to the recanalization rate.
In vitro and in vivo antimetastatic effects of Terminalia catappa L. leaves on lung cancer cells.
In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril.
In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers.
In vitro assay for tumor promoters and anti-promoters.
In vitro differentiation of a null-acute leukemia: T-lymphoid surface antigen expression associated with rearrangement in T-cell receptor beta chain variable genes.
In vivo generation of angiostatin isoforms by administration of a plasminogen activator and a free sulfhydryl donor: a phase I study of an angiostatic cocktail of tissue plasminogen activator and mesna.
In vivo induction of rat hepatic ornithine decarboxylase and plasminogen activator by 12-O-tetradecanoylphorbol 13-acetate.
In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase.
In vivo overexpression of tumstatin domains by tumor cells inhibits their invasive properties in a mouse melanoma model.
Inactivation of human anaphylatoxin C5a and C5a des-Arg through cleavage by the plasminogen activator activity of a human fibrosarcoma cell line.
Inactivity of fecapentaene-12 as a rodent carcinogen or tumor initiator.
Increase in cytosolic calcium upregulates the synthesis of type 1 plasminogen activator inhibitor in the human histiocytic cell line U937.
Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis.
Increase in telomere sequence-binding activity in normal human fibroblasts in senescence or in cells treated with phorbol ester or N-methyl-N'-nitro-N-nitrosoguanidine.
Increase in the synthesis of a Mr 32,000 protein in BALB/c 3T3 cells treated with tumor-promoting indole alkaloids or polyacetates.
Increased adipose tissue secretion of interleukin-6, but not of leptin, plasminogen activator inhibitor-1 or tumour necrosis factor alpha, in Graves' hyperthyroidism.
Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Increased expression of ornithine decarboxylase by gamma-ray in mouse epidermal cells: relationship with protein kinase C signaling pathway.
Increased expression of p21Waf1/Cip1 and JNK with costimulation of prostate cancer cell activation by an siRNA Egr-1 inhibitor.
Increased expression of uPA, uPAR, and PAI-1 in psoriatic skin and in basal cell carcinomas.
Increased Food Intake and Energy Expenditure Following Administration of Olanzapine to Healthy Men.
Increased Insulin following an Oral Glucose Load, Genetic Variation near the Melatonin Receptor MTNR1B, but No Biochemical Evidence of Endothelial Dysfunction in Young Asian Men and Women.
Increased levels of specific leukocyte- and platelet-derived substances during normal anti-tetanus antibody synthesis in patients with inactive Crohn disease.
Increased levels of tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor (PAI) correlate with tumor necrosis factor alpha (TNF alpha)-release in patients suffering from microangiopathy following allogeneic bone marrow transplantation (BMT).
Increased levels of tumor markers in the follow-up of 400 patients with breast cancer without recurrence or metastasis: interpretation of false-positive results.
Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome.
Increased plasminogen activator inhibition levels in malignancy.
Increased secretion of urokinase-type plasminogen activator by human lung microvascular endothelial cells.
Increased sensitivity to two-stage skin carcinogenesis of mice heterozygous for the repeated epilation mutation (Er).
Increased sequence-specific p53-DNA binding activity after DNA damage is attenuated by phorbol esters.
Increased surface expression and shedding of tumor associated antigens by human breast carcinoma cells treated with recombinant human interferons or phorbol ester tumor promoters.
Increased urokinase activity to antigen ratio in human renal-cell carcinoma.
Independent mechanisms for tumor promoters phenobarbital and 12-O-tetradecanoylphorbol-13-acetate in reduction of epidermal growth factor binding by rat hepatocytes.
Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients.
Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer.
Independent relation of vital exhaustion and inflammation to fibrinolysis in apparently healthy subjects.
Indication of a role of plasminogen activator inhibitor type I in protecting murine fibrosarcoma cells against apoptosis.
Indirect induction of a clastogenic effect in epidermal cells by a tumor promoter.
Indomethacin enhancement of TPA tumor promotion in mice.
Inducible binding of a factor to the c-fos enhancer.
Inducible cutaneous inflammation reveals a protumorigenic role for keratinocyte CXCR2 in skin carcinogenesis.
Induction and desensitization of plasminogen activator gene expression by tumor promoters.
Induction and secretion of the chemokines interleukin-8 and monocyte chemotactic protein-1 in human immature leukemia cell lines.
Induction of apoptosis in breast cancer cells by TPA.
Induction of apoptosis in human HaCaT keratinocytes.
Induction of cells with acinar cell phenotype including presence of intracellular amylase. Treatment with 12-O-tetradecanoyl-phorbol-13-acetate in a neoplastic human salivary intercalated duct cell line grown in athymic nude mice.
Induction of chemotaxis in mouse peritoneal macrophages by phorbol ester tumor promoters.
Induction of cutaneous mast cell tumors by N-methyl-N'-nitro-N-nitrosoguanidine followed by TPA in female mice of 4 out of 5 strains tested.
Induction of dark keratinocytes by 12-O-tetradecanoylphorbol-13-acetate and mezerein as an indicator of tumor-promoting efficiency.
Induction of EL4 cell resistance to syngeneic macrophage-mediated lysis by protein kinase C ligands; effects of cultured TPA-treated target cell and protein phosphorylation.
Induction of Epstein-Barr virus by an new tumor promoter, teleocidin, compared to induction by TPA.
Induction of Epstein-Barr virus lytic cycle by tumor-promoting and non-tumor-promoting phorbol esters requires active protein kinase C.
Induction of fibrinolytic activity in HeLa cells by phorbol myristate acetate. Tissue-type plasminogen activator antigen and mRNA augmentation require intermediate protein biosynthesis.
Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia.
Induction of incoordinate synthesis of muscle proteins by the tumor promoter TPA and the carcinogen EMS.
Induction of low density lipoprotein receptor and a transcription factor SP-1 by tumor necrosis factor in human microvascular endothelial cells.
Induction of metallothionein mRNA by tumor promoters in mouse skin and its constitutive expression in papillomas.
Induction of monocytic differentiation and modulation of the expression of c-fos, c-fms and c-myc protooncogenes in human monoblasts by cytokines and phorbolester.
Induction of mouse epidermal ornithine decarboxylase activity and skin tumors by 7,12-dimethylben.
Induction of murine fibrosarcomas by low dose treatment with 3-methylcholanthrene followed by promotion with 12-O-tetradecanoyl-phorbol-13-acetate.
Induction of nitroblue tetrazolium reduction in mouse peritoneal macrophages by tumour promoters and inhibition of the induced nitroblue tetrazolium reduction by some inhibitors.
Induction of oral mucosal tumors in hamsters and rats treated with methyl(acetoxymethyl)nitrosamine.
Induction of ornithine decarboxylase and histidine decarboxylase activities in rat colon mucosa after application of 12-o-tetradecanoylphorbol-13-acetate (TPA), sodium deoxycholate and indole.
Induction of ornithine decarboxylase in specific subpopulations of murine epidermal cells following multiple exposures to 12-O-tetradecanoylphorbol-13-acetate, mezerein and ethyl phenylpropriolate.
Induction of plasminogen activator by alkylating agents in a repair defective human glioblastoma cell strain.
Induction of plasminogen activator by N-methyl-N'-nitro-N-nitrosoguanidine in mer+ and mer- human tumour cell strains.
Induction of plasminogen activator in cultured cells by macrocyclic plant diterpene esters and other agents related to tumor promotion.
Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha.
Induction of plasminogen activator inhibitor-2 is associated with suppression of invasive activity in TPA-mediated differentiation of human prostate cancer cells.
Induction of rat hepatic ornithine decarboxylase by the tumor promotors 12-O-tetradecanoylphorbol-13-acetate and phenobarbital in vivo; effect of retinyl-acetate.
Induction of renal fibrotic genes by TGF-?1 requires EGFR activation, p53 and reactive oxygen species.
Induction of suppressor T cells and inhibition of contact hypersensitivity in mice by 12-O-tetradecanoylphorbol-13-acetate and its analogs.
Induction of the fibrinolytic system by cartilage extract mediates its antiangiogenic effect in mouse glioma.
Induction of thioredoxin, thioredoxin reductase and glutaredoxin activity in mouse skin by TPA, a calcium ionophore and other tumor promoters.
Induction of tumors of the liver, lung, ovary and adrenal in adult mice after brief maternal gestational exposure to inorganic arsenic: promotional effects of postnatal phorbol ester exposure on hepatic and pulmonary, but not dermal cancers.
Induction of type 1 plasminogen activator inhibitor in human liver ischemia and reperfusion.
Induction of type-C retrovirus by the tumor promotor TPA.
Induction of vimentin synthesis in mouse myeloma cells MPC-11 by 12-0-tetradecanoylphorbol-13-acetate.
Induction or suppression of SV40 amplification by genotoxic carcinogens, non-genotoxic carcinogens or tumor promoters.
Infection-induced inflammatory response of adipocytes in vitro.
Inflammation and hemostasis biomarkers for predicting stroke in postmenopausal women: the Women's Health Initiative Observational Study.
Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells.
Inflammatory Biomarkers are Correlated with Some Forms of Regressive Autism Spectrum Disorder.
Inflammatory biomarkers predict depressive, but not anxiety symptoms during aging: The prospective Sydney Memory and Aging Study.
Inflammatory markers and metabolic syndrome among adolescents.
Influence of diet restriction and tumor promoter dose on cell proliferation, oxidative DNA damage and rate of papilloma appearance in the mouse skin after initiation with DMBA and promotion with TPA.
Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease.
Influence of preoperative core biopsies on uPA/PAI-1 expression in breast cancer tissue.
Influence of renin-angiotensin-aldosterone system-blocking drugs on peritoneal membrane in peritoneal dialysis patients.
Influence of short-term topical exposure to phorbol ester tumor promoters on subcutaneously induced skin tumorigenesis in S/RVCri mice.
Influence of the duration of topical 13-cis-retinoic acid treatment on inhibition of mouse skin tumor promotion.
Influence of the tumour promoter TPA upon erythroid burst formation in vitro.
Influence of three BALB/c substrain backgrounds on the skin tumor induction efficacy to DMBA and TPA cotreatment.
Inhibiting interleukin-1 and tumor necrosis factor-alpha does not reduce induction of plasminogen activator inhibitor type-1 by endotoxin in rats in vivo.
Inhibition by bovine endothelial cells of degradation by HT-1080 fibrosarcoma cells of extracellular matrix proteins.
Inhibition by dexamethasone of the reperfusion phenomena in cardiopulmonary bypass.
Inhibition by gossypol of tumor promoter-induced arachidonic acid metabolism in rat peritoneal macrophages.
Inhibition by phorbol esters and other tumor promoters of the response of the Sertoli cell to FSH: evidence for dual site of action.
Inhibition of 12-O-tetradecanoylphorbol-13-acetate and other skin tumor-promoter-caused induction of epidermal interleukin-1 alpha mRNA and protein expression in SENCAR mice by green tea polyphenols.
Inhibition of 12-O-tetradecanoylphorbol-13-acetate induction of ornithine decarboxylase activity, DNA synthesis, and tumor promotion in mouse skin by ascorbic acid and ascorbyl palmitate.
Inhibition of 12-O-tetradecanoylphorbol-13-acetate promoted mouse skin papilloma by digalactosyl diacylglycerols from the fresh water cyanobacterium Phormidium tenue.
Inhibition of 12-O-tetradecanoylphorbol-13-acetate-caused tumor promotion in 7,12-dimethylbenz[a]anthracene-initiated SENCAR mouse skin by a polyphenolic fraction isolated from green tea.
Inhibition of 12-O-tetradecanoylphorbol-13-acetate-caused tumor promotion in benzo[a]pyrene-initiated CD-1 mouse skin by geniposide.
Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced epidermal ornithine decarboxylase activity and tumor promotion by N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7) in mouse skin.
Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced induction in Epstein-Barr virus early antigen in Raji cells.
Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion and epidermal ornithine decarboxylase activity in mouse skin by palmitoylcarnitine.
Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion in murine skin by systemic effects of ultraviolet irradiation.
Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion markers in CD-1 mouse skin by oleandrin.
Inhibition of 12-O-tetradecanoylphorbol-13-acetate-mediated epidermal ornithine decarboxylase induction and skin tumor promotion by new lipoxygenase inhibitors lacking protein kinase C inhibitory effects.
Inhibition of 12-O-tetradecanoylphorbol-13-acetate-promoted mouse skin papilloma by saponins.
Inhibition of a cell surface protease after cisplatin chemotherapy.
Inhibition of both stage I and stage II mouse skin tumour promotion by retinoic acid and the dependence of inhibition of tumor promotion on the duration of retinoic acid treatment.
Inhibition of both stage I and stage II skin tumor promotion in SENCAR mice by a polyphenolic fraction isolated from green tea: inhibition depends on the duration of polyphenol treatment.
Inhibition of carcinogen induced c-Ha-ras and c-fos proto-oncogenes expression by dietary curcumin.
Inhibition of development of characteristic indices of myeloid differentiation by a factor released from a tetraploid variant of the human promyelocytic cell line, HL-60.
Inhibition of DNA synthesis and sugar uptake and lack of induction of ornithine decarboxylase in human epidermal cells treated with mouse skin tumor promoters.
Inhibition of initiator-promoter-induced skin tumorigenesis in female SENCAR mice fed a vitamin A-deficient diet and reappearance of tumors in mice fed a diet adequate in retinoid or beta-carotene.
Inhibition of intercellular communication by nickel(II): antagonistic effect of magnesium.
Inhibition of metabolic cooperation between mammalian cells in culture by tumor promoters.
Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model.
Inhibition of mouse skin tumor promotion and of promoter-stimulated epidermal polyamine biosynthesis by alpha-difluoromethylornithine.
Inhibition of mouse skin tumor promotion by adriamycin and daunomycin in combination with verapamil or palmitoylcarnitine.
Inhibition of mouse skin tumor promotion by anti-inflammatory diarylheptanoids derived from Alpinia oxyphylla Miquel (Zingiberaceae).
Inhibition of multistage tumor promotion in mouse skin by diethyldithiocarbamate.
Inhibition of NF-kappaB by (E)3-[(4-methylphenyl)-sulfonyl]-2-propenenitrile (BAY11-7082; BAY) is associated with enhanced 12-O-tetradecanoylphorbol-13-acetate-induced growth suppression and apoptosis in human prostate cancer PC-3 cells.
Inhibition of NF-kappaB signaling interferes with phorbol ester-induced growth arrest of keratinocytes in a TNFR1-independent manner.
Inhibition of p70(S6) kinase during transforming growth factor-beta 1/vitamin D(3)-induced monocyte differentiation of HL-60 cells allows tumor necrosis factor-alpha to stimulate plasminogen activator inhibitor-1 synthesis.
Inhibition of phorbol ester-caused induction of ornithine decarboxylase and tumor promotion in mouse skin by staurosporine, a potent inhibitor of protein kinase C.
Inhibition of phorbol ester-induced ornithine decarboxylase gene transcription by retinoic acid: a possible mechanism of antitumor promoting activity of retinoids.
Inhibition of phorbol ester-induced tumor promotion in mice by vitamin A analog and anti-inflammatory steroid.
Inhibition of phorbol ester-mediated interleukin-2 production by cellular differentiating agents.
Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.
Inhibition of pro-inflammatory cytokine gene expression and papilloma growth during murine multistage carcinogenesis by pentoxifylline.
Inhibition of protein kinase C by the 12-O-tetradecanoylphorbol-13-acetate antagonist glycyrrhetic acid.
Inhibition of proteolytic enzymes in the in vitro amnion model for basement membrane invasion.
Inhibition of pulmonary tumor seeding by antiplatelet and fibrinolytic therapy in an animal experimental model.
Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif.
Inhibition of skin carcinomas but not papillomas by sphingosine, N-methylsphingosine, and N-acetylsphingosine.
Inhibition of skin tumor promotion by retinoic acid and its metabolite 5,6-epoxyretinoic acid.
Inhibition of skin tumor promotion by TPA using a combination of topically applied ursolic acid and curcumin.
Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid.
Inhibition of the effects of 12-O-tetradecanoylphorbol-13-acetate on mouse epidermal glutathione peroxidase and ornithine decarboxylase activities by glutathione level-raising agents and selenium-containing compounds.
Inhibition of the formation of electrical cell coupling of FL cell by tumor promoters.
Inhibition of the induction of cancer by antioxidants.
Inhibition of the induction of ornithine decarboxylase activity by 12-O-tetradecanoylphorbol-13-acetate in mouse skin by sphingosine sulfate.
Inhibition of TPA and 12(S)-HETE-stimulated tumor cell adhesion by prostacyclin and its stable analogs: rationale for their antimetastatic effects.
Inhibition of TPA-induced tumor promotion in CD-1 mouse epidermis by a polyphenolic fraction from grape seeds.
Inhibition of tumor implantation at sites of trauma by plasminogen activators.
Inhibition of tumor promoter-induced ornithine decarboxylase activity by tannic acid and other polyphenols in mouse epidermis in vivo.
Inhibition of tumor promotion in benzo[a]pyrene-initiated CD-1 mouse skin by crocetin.
Inhibition of tumor promotion in mouse skin by 1 alpha,25-dihydroxyvitamin D3.
Inhibition of tumor promotion in SENCAR mouse skin by ethanol extract of Zingiber officinale rhizome.
Inhibiton of phorbol ester-stimulated chemiluminescence in human polymorphonuclear leukocytes by retinoic acid and 5,6-epoxyretinoic acid.
Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice.
Inhibitory effect of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans-retinoic acid on the growth of LNCaP prostate tumors in immunodeficient mice.
Inhibitory effect of 12-O-tetradecanoylphorbol-13-acetate-caused tumor promotion in benzo[a]pyrene-initiated CD-1 mouse skin by baicalein.
Inhibitory effect of a spicamycin derivative, KRN5500, on the growth of hepatic metastasis of human colon cancer-producing tissue polypeptide antigen.
Inhibitory effect of ailanthoidol on 12-O-tetradecanoyl-phorbol-13-acetate-induced tumor promotion in mouse skin.
Inhibitory effect of alkane-6,8-diols, the components of safflower, on tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin.
Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate.
Inhibitory effect of dietary curcumin on skin carcinogenesis in mice.
Inhibitory effect of heliantriol C; a component of edible Chrysanthemum, on tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin.
Inhibitory effect of herbal remedies on 12-O-tetradecanoylphorbol-13-acetate-promoted Epstein-Barr virus early antigen activation.
Inhibitory effect of Hibiscus protocatechuic acid on tumor promotion in mouse skin.
Inhibitory effect of karounidiol on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion.
Inhibitory effect of NH4Cl treatment on renal Tgfß1 signaling following unilateral ureteral obstruction.
Inhibitory effect of Perilla leaf extract and luteolin on mouse skin tumor promotion.
Inhibitory effect of protease inhibitor on endothelial cell activation.
Inhibitory effect of stevioside on tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin.
Inhibitory effect of taraxastane-type triterpenes on tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin.
Inhibitory effects of 1,3-bis-(2-substituted-phenyl)-propane-1,3-dione, ?-diketone structural analogues of curcumin, on chemical-induced tumor promotion and inflammation in mouse skin.
Inhibitory effects of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans retinoic acid on the growth of cultured human pancreas cancer cells and pancreas tumor xenografts in immunodeficient mice.
Inhibitory effects of asiatic acid on 7,12-dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol 13-acetate-induced tumor promotion in mice.
Inhibitory effects of caffeic acid phenethyl ester (CAPE) on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion in mouse skin and the synthesis of DNA, RNA and protein in HeLa cells.
Inhibitory effects of chlorophyllin on 7,12-dimethylbenz[a]anthracene-induced bacterial mutagenesis and mouse skin carcinogenesis.
Inhibitory effects of curcumin on tumor initiation by benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene.
Inhibitory effects of curcumin on tumorigenesis in mice.
Inhibitory effects of glutathione level-raising agents and D-alpha-tocopherol on ornithine decarboxylase induction and mouse skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Inhibitory effects of new types of biflavonoid-related polyphenols; lophirone A and lophiraic acid, on some tumor promoter-induced biological responses in vitro and in vivo.
Inhibitory effects of tetradecanoylphorbol acetate and diacylglycerol on erythropoietin production in human renal carcinoma cell cultures.
Inhibitory effects of topical application of low doses of curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion and oxidized DNA bases in mouse epidermis.
Inhibitory effects of ursolic and oleanolic acid on skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Inhibitory role of plasminogen activator inhibitor-1 in invasion and proliferation of HLE hepatocellular carcinoma cells.
Inhibitory serpins. New insights into their folding, polymerization, regulation and clearance.
Initiating activity in a two-stage mouse skin model of nine mutagenic pyrolysates of amino acids, soybean globulin and proteinaceous food.
Initiating activity of eight pyrolysates of carbohydrates in a two-stage mouse skin tumorigenesis model.
Initiating potential of 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide (AF-2), butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT) and 3,3',4',5,7-pentahydroxyflavone (quercetin) in two-stage mouse skin carcinogenesis.
Initiation and promotion at different ages and doses in 2200 mice. I. Methods, and the apparent persistence of initiated cells.
Initiation and promotion at different ages and doses in 2200 mice. II. Decrease in promotion by TPA with ageing.
Initiation of in vitro cell transformation by formaldehyde and acetaldehyde as measured by attachment-independent survival of cells in aggregates.
Injured tissues favor cancer cell implantation via fibrin deposits on scar zones.
Insulin resistance in polycystic ovarian disease.
Insulin resistance syndrome in children : pathophysiology and potential management strategies.
Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome.
Integrated Haematological Profiles of Redox Status, Lipid, and Inflammatory Protein Biomarkers in Benign Obesity and Unhealthy Obesity with Metabolic Syndrome.
Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells.
Intense Pulsed Light: Friend or Foe? Molecular Evidence to Clarify Doubts.
Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival.
Interaction between air pollution exposure and genes in relation to levels of inflammatory markers and risk of myocardial infarction.
Interaction between latent papovavirus genomes and the tumor promoter TPA.
Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis.
Interaction between quercetin, TPA and DDT in the V79 metabolic cooperation assay.
Interaction of IL 1 and TPA in modulation of eosinophil function.
Interaction of Metabolic Syndrome with Asthma in Postmenopausal Women: Role of Adipokines.
Interaction of phorbol derivatives with replicating cells.
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.
Interaction of tumor and surrounding tissue of mice inoculated B16 melanoma variants in terms of enzyme activity.
Interaction of tumour promoters with epithelial cells in culture. An immunofluorescence study.
Interactions between diphtheria toxin entry and anion transport in vero cells. III. Effect on toxin binding and anion transport of tumor-promoting phorbol esters, vanadate, fluoride, and salicylate.
Interactions between tumor-promoting agents and histones studied by circular dichroism.
Intercellular communication of transformed and non-transformed rat liver epithelial cells. Modulation by TPA.
Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours.
Interferon production potentials of various human lymphoblastoid cell lines.
Interferon-beta can induce the production of plasminogen activator by cultured human cancer cells.
Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures.
Interleukin-1, endotoxin or tumor necrosis factor/cachectin enhance the level of plasminogen activator inhibitor messenger RNA in bovine aortic endothelial cells.
Interleukin-1? inhibits luteinizing hormone-induced plasminogen activator activity in rat preovulatory folliclesin vitro.
Interrelationship between differentiation and malignancy-associated properties in glioma.
Interventions to obstructive long-term central venous catheter in cancer patients: a meta-analysis.
Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans.
Intra-individual variation of plasma adipokine levels and utility of single measurement of these biomarkers in population-based studies.
Intracellular calcium mobilization suppresses the TNF-alpha-stimulated synthesis of PAI-1 in human endothelial cells. Indications that calcium acts at a translational level.
Intracellular Expression of PAI-1 Specific Aptamers Alters Breast Cancer Cell Migration, Invasion and Angiogenesis.
Intracellular infections enhance interleukin-6 and plasminogen activator inhibitor 1 production by cocultivated human adipocytes and THP-1 monocytes.
Intracystic evaluation of tumor markers in benign and malignant ovarian pathology.
Intraperitoneal administration of activated protein C prevents postsurgical adhesion band formation.
Intravenous Alteplase for acute ischemic stroke in patients with current malignant neoplasm.
Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer.
Intravenous tissue plasminogen activator for an ischemic stroke with occult double primary cancer.
Intraventricular fibrinolysis with tissue plasminogen activator is associated with transient cerebrospinal fluid inflammation: a randomized controlled trial.
Intravesical recombinant tissue plasminogen activator for the prevention of implantation-mediated bladder tumor recurrence.
Invasion and metastases in gastric cancer: in vitro and in vivo models with clinical correlations.
Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display.
Inverse correlation between mRNA expression of plasminogen activator inhibitor-2 and lymph node metastasis in human breast cancer.
Inverse regulation of oestrogen receptor and epidermal growth factor receptor gene expression in MCF-7 breast cancer cells treated with phorbol ester.
Inversion of carcinogen-promoter sequence: effects on mouse skin tumorigenesis and cellular growth kinetics.
Involvement of Erks activation in cadmium-induced AP-1 transactivation in vitro and in vivo.
Involvement of p-15(INK4b) and p-16(INK4a) gene expression in saikosaponin a and TPA-induced growth inhibition of HepG2 cells.
Involvement of plasminogen activator production with tumor metastasis in a rat model.
Involvement of Platelets in Cancers.
Involvement of protein kinase C activation in ornithine decarboxylase gene expression in primary culture of newborn mouse epidermal cells and in skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Involvement of Retrotransposition of Long Interspersed Nucleotide Element-1 in DMBA/TPA-induced Skin Tumorigenesis.
Iodoacetic acid and related sulfhydryl reagents fail to inhibit cell-cell communication: mechanisms of immunotoxicity in vitro.
Ionic signal transduction in growth factor action.
Ionizing radiation as an initiator in the mouse two-stage model of skin tumor formation.
Ionizing radiation as an initiator: effects of proliferation and promotion time on tumor incidence in mice.
Iron overload augments 7,12-dimethylbenz(a)anthracene-initiated and 12-O-tetradecanoylphorbol-13-acetate-promoted skin tumorigenesis.
Irreversible Inhibition of Serine Proteases - Design and In Vivo Activity of Diaryl alpha-Aminophosphonate Derivatives.
Irritant and co-carcinogenic diterpene esters from the latex of Euphorbia cauducifolia L.
Is acetylcholine a signaling molecule for human colon cancer progression?
Is tissue polypeptide antigen still a useful tumor marker in breast carcinoma? Comparison with CA15.3 and MCA.
Isocitrate dehydrogenase 1 is downregulated during early skin tumorigenesis which can be inhibited by overexpression of manganese superoxide dismutase.
Isolation and analysis of inducibility of the rat N-methylpurine-DNA glycosylase promoter.
Isolation and characterization of complementary DNA clones corresponding to genes induced in mouse epidermis in vivo by tumor promoters.
Isolation and characterization of the human tissue-type plasminogen activator structural gene including its 5' flanking region.
Isolation of an X-ray-responsive element in the promoter region of tissue-type plasminogen activator: potential uses of X-ray-responsive elements for gene therapy.
Isolation of the oncogene and epidermal growth factor-induced transin gene: complex control in rat fibroblasts.
Isolation of tissue-type plasminogen activator, cathepsin H, and non-specific cross-reacting antigen from SK-PC-1 pancreas cancer cells using subtractive hybridization.
Isolation, characterization, and in vitro cultivation of keratinocyte subfractions from adult NMRI mouse epidermis: epidermal target cells for phorbol esters.
Isolation, structural elucidation, and inhibitory effects of terpenoid and lipid constituents from sunflower pollen on Epstein-Barr virus early antigen induced by tumor promoter, TPA.
Isorhynchophylline exerts anti-inflammatory and anti-oxidative activities in LPS-stimulated murine alveolar macrophages.
JC virus-induced owl monkey glioblastoma cells in culture: biological properties associated with the viral early gene product.
JNK Suppression is Essential for 17beta-Estradiol Inhibits Prostaglandin E2-Induced uPA and MMP-9 Expressions and Cell Migration in Human LoVo Colon Cancer Cells.
Keratinocyte Growth Factor Combined with a Sodium Hyaluronate Gel Inhibits Postoperative Intra-Abdominal Adhesions.
Key contribution of CPEB4-mediated translational control to cancer progression.
Ki-67 and proliferating cell nuclear antigen tumor proliferative indices in DNA diploid colorectal adenocarcinomas. Correlation with histopathologic characteristics and cell cycle analysis with two-color DNA flow cytometry.
Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines.
Kinin-generating cascade in advanced cancer patients and in vitro study.
Knock-down of plasminogen-activator inhibitor-1 enhances expression of E-cadherin and promotes epithelial differentiation of human pancreatic adenocarcinoma cells.
Knockdown of Inwardly Rectifying Potassium Channel Kir2.2 Suppresses Tumorigenesis by Inducing Reactive Oxygen Species-Mediated Cellular Senescence.
Kondrat'eva ligation: Diels-Alder-based irreversible reaction for bioconjugation.
Lack of a co-promoting effect of a 60 Hz magnetic field on skin tumorigenesis in SENCAR mice.
Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer.
Lack of correlation between effects of tumor promoter TPA on plasminogen activator production, phosphatidyl choline synthesis, and hexose transport in mammalian cell culture systems.
Lack of effect of a 60 Hz magnetic field on biomarkers of tumor promotion in the skin of SENCAR mice.
Lack of promotion of mammary, lung and skin tumorigenesis by 20 kHz triangular magnetic fields.
Lack of tumor promoting effects of KCB-1, a recombinant human basic fibroblast growth factor, on two-stage skin carcinogenesis in female CD-1 (ICR) mice.
Laminin degradation by human colon carcinoma cells: a role for urinary and tissue plasminogen activators.
Langerhans cell migration patterns from sheep skin following topical application of carcinogens.
Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1.
Leptin signaling molecular actions and drug target in hepatocellular carcinoma.
Leptin, adiponectin and ghrelin, new potential mediators of ischemic stroke.
Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry.
Levels of tissue polypeptide antigen in serum and the progression of gastric cancer.
Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array.
Limited clinical significance of the serum tumour marker Ca 72-4 in colorectal cancer.
Limiting factors of the V79 cell metabolic cooperation assay for tumor promoters.
Lineage relationship of chronic lymphocytic leukemia and hairy cell leukemia: studies with TPA.
Lineage-associated Underrepresented Permutations (LAUPs) of Mammalian Genomic Sequences Based on a Jellyfish-based LAUPs analysis application (JBLA).
Lipid and apoprotein profile in HIV-1-infected patients after CD4-guided treatment interruption.
Lipoproteins do not modulate the tissue factor activity, plasminogen activator or tumour necrosis factor production induced by lipopolysaccharide stimulation of human monocytes.
Little evidence of systemic and adipose tissue inflammation in overweight individuals(†).
Local perivascular adiponectin associates with lower extremity vascular operative wound complications.
Local tumor regression after intralesional injection of croton oil.
Localization of blood coagulation factors in situ in pancreatic carcinoma.
Localization of human malignant tumors with radioiodinated recombinant tissue plasminogen activator.
Localization of plasminogen activators in human colon cancer by immunoperoxidase staining.
Location of plasminogen activator (PA) and PA inhibitor in human colorectal adenocarcinomas.
Long-term efficacy and downstream mechanism of anti-annexinA2 monoclonal antibody (anti-ANX A2 mAb) in a pre-clinical model of aggressive human breast cancer.
Loosening of cell cycle controls of human lymphocytes under the action of tumour promoter TPA.
Loss of mouse epidermal protein kinase C isozyme activities following treatment with phorbol ester and non-phorbol ester tumor promoters.
Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells.
Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence.
Low iron diet retards 12-O-tetradecanoyl phorbol-13-acetate-mediated tumor promotion in murine skin.
Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells.
Lung tumour markers in oncology practice: a study of TPA and CA125.
Lymphocyte activation by the tumor-promoting agent 12-O-tetradecanoylphorbol-13-acetate (TPA).
Lymphokines produced by herpesvirus-transformed marmoset monkey lymphoid cell lines. I. Characterization of a constitutively produced interferon.
Lysosome labilizers potentiate the antitumor effects of tumor necrosis factor-alpha.
Macrophage oxidative burst and related cytotoxicity. I. Differential activation by tumor-promoting and non-tumor-promoting phorbol esters.
Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents.
Macrophages associated with murine tumours express plasminogen activator activity.
Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
MAGE-A gene expression pattern in primary breast cancer.
Magnolia bioactive constituent 4-O-methylhonokiol prevents the impairment of cardiac insulin signaling and the cardiac pathogenesis in high-fat diet-induced obese mice.
Maintenance of human skin on nude mice for studies of chemical carcinogenesis.
Malignant conversion and metastasis of mouse skin tumors: a comparison of SENCAR and CD-1 mice.
Malignant conversion, the first stage in progression, is distinct from phorbol ester promotion in mouse skin.
Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ.
Malignant mouse melanoma cells do not form tumors when mixed with cells of a non-malignant subclone: relationships between plasminogen activator expression by the tumor cells and the host's immune response.
Malignant transformation of simian virus 40-immortalized human milk epithelial cells by chemical carcinogenesis accompanied by loss of heterozygosity on chromosome 1 but not microsatellite instability.
Malignant transformation of wild-type but not plasminogen activator inhibitor-1 gene-deficient fibroblasts decreases cellular sensitivity to chemotherapy-mediated apoptosis.
Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor.
Marker determination for response monitoring: radiotherapy and disappearance curves.
Markers of angiogenesis and epidermal growth factor receptor signalling in patients with pancreatic and gastroesophageal junction cancer.
Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism.
Markers of the uPA system and common prognostic factors in breast cancer.
Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients.
Maspin inhibits cell migration in the absence of protease inhibitory activity.
Matrilysin (matrix metalloprotease-7) cleaves membrane-bound annexin II and enhances binding of tissue-type plasminogen activator to cancer cell surfaces.
Matrix-Bound PAI-1 Supports Cell Blebbing via RhoA/ROCK1 Signaling.
Measurement of neutrophil activation and epidermal cell toxicity by palytoxin and 12-O-tetradecanoylphorbol-13-acetate.
Measurement of plasminogen activator activity from human fibrosarcoma cells by a new microassay.
Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
Mechanism of mouse skin tumor promotion by chrysarobin.
Mechanism of the stimulatory effect of phorbol 12-myristate 13-acetate on cellular production of plasminogen activator.
Mechanisms of action of okadaic acid class tumor promoters on mouse skin.
Mechanisms of cancer chemoprevention by curcumin.
Mechanisms of cell transformation in the Syrian hamster embryo (SHE) cell transformation system.
Mechanisms of enhancement of Epstein-Barr virus-induced transformation of peripheral blood lymphocytes by a tumor promoter, TPA, with special reference to lowering of cytotoxicity of T cells.
Mechanisms of multistage chemical carcinogenesis and their relevance to respiratory tract cancer.
Mechanisms underlying arsenic carcinogenesis: hypersensitivity of mice exposed to inorganic arsenic during gestation.
Melanogenesis inhibitory, anti-inflammatory, and chemopreventive effects of limonoids from the seeds of Azadirachta indicia A. Juss. (neem).
Melanogenesis-inhibitory activity and cancer chemopreventive effect of glucosylcucurbic acid from shea (Vitellaria paradoxa) kernels.
Membrane proteinases from normal and neoplastic tissues in man and the rat.
Membrane-mediated responses to 12-O-tetradecanoylphorbol-13-acetate in human skin fibroblasts.
Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome.
Metabolic activation of TM5441 in vitro and in vivo: Formation of reactive metabolites and human enzymes involved.
Metabolic alterations and systemic inflammation in overweight/obese children with obstructive sleep apnea.
Metabolic endotoxaemia in childhood obesity.
Metabolic syndrome in youths.
Metabolic syndrome: Clinical concept and molecular basis.
Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke.
Metallothionein deficiency enhances skin carcinogenesis induced by 7,12-dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol-13-acetate in metallothionein-null mice.
Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Metastasis-promoting role of extravasated platelet activation in tumor.
Metformin inhibits skin tumor promotion in overweight and obese mice.
MHC class I expression on human tumour cells and their susceptibility to NK lysis.
Mice defective in the mismatch repair gene Msh2 show increased predisposition to UVB radiation-induced skin cancer.
Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis.
Microassay for the photometric quantitation of cell-associated plasminogen activator using a chromogenic tripeptide substrate.
Microenvironmental control of premalignant disease: the role of intercellular adhesion in the progression of squamous cell carcinoma.
Microglia activation due to obesity programs metabolic failure leading to type two diabetes.
Microinjected Xenopus oocytes synthesize active human plasminogen activator.
MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-?B and TGF-? signaling pathways.
Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines.
Minimal role of enhanced cell proliferation in skin tumor promotion by mirex: a nonphorbol ester-type promoter.
miR-30b, down-regulated in gastric cancer, promotes apoptosis and suppresses tumor growth by targeting plasminogen activator inhibitor-1.
miR-34a exerts as a key regulator in the dedifferentiation of osteosarcoma via PAI-1-Sox2 axis.
Mitochondrial targeting of TR3 is involved in TPA induced apoptosis in breast cancer cells.
Moderate alcohol consumption diminishes the development of non-alcoholic fatty liver disease (NAFLD) in ob/ob mice.
Moderate enhancement of the promotion phase of skin tumorigenesis in hairless mice by topical pretreatment with a mitosis-inhibiting epidermal pentapeptide.
Modification of growth and differentiation of myeloid leukemia cells by tumor promoters.
Modification of N-Methyl-N-Nitrosourea initiated bladder carcinogenesis in Wistar rats by terephthalic acid.
Modulating factors in the expression of radiation-induced oncogenic transformation.
Modulation by adriamycin, daunomycin, verapamil, and trifluoperazine of the biochemical processes linked to mouse skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Modulation by endothelin-1 of tissue plasminogen activator and plasminogen activator inhibitor-1 release from cultured human vascular endothelial cells: interaction of endothelin-1 with cytokines.
Modulation of 12-0-tetradecanoylphorbol-13-acetate-induced epidermal ornithine decarboxylase activity by calcium and verapamil in mouse.
Modulation of antitumour activity of macrophages by regulation of eicosanoids and cytokine production.
Modulation of cell-associated plasminogen activator activity by cocultivation of a stem cell and its tumorigenic descendant.
Modulation of growth of melanoma.
Modulation of inducible nitric oxide synthase in RINm5F cells.
Modulation of interleukin-1 beta RNA in monocytic cells infected with human immunodeficiency virus-1.
Modulation of lipoxidase activity by urokinase-type plasminogen activator.
Modulation of luteinizing hormone-stimulated inositol phosphate accumulation by phorbol esters in bovine luteal cells.
Modulation of mouse fibroblast adipocyte differentiation by X-rays and TPA.
Modulation of mouse skin tumor promotion by dietary 13-cis-retinoic acid and alpha-difluoromethylornithine.
Modulation of natural killer activity by 12-O-tetradecanoylphorbol-13-acetate and benzoyl peroxide in phorbol ester-sensitive (SENCAR) and resistant (B6C3F1) mice.
Modulation of plasminogen activator activity in human endometrial adenocarcinoma cells by basic fibroblast growth factor and transforming growth factor beta.
Modulation of plasminogen activator in rodent mammary tumors by hormones and other effectors.
Modulation of plasminogen activator inhibitor-1 and urokinase in retinal pigmented epithelial cells.
Modulation of plasminogen activator synthesis in chick embryo fibroblasts by cyclic nucleotides and phorobol myristate acetate.
Modulation of protectin (CD59 antigen) cell surface expression on human neoplastic cell lines.
Modulation of the co-promoting activity of gamma interferon in SENCAR and C57BL/6 mouse skin by difluoromethylornithine and the scheduling and duration of interferon treatment.
Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells.
Modulators of the urokinase-type plasminogen activation system for cancer.
Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Molecular cloning of a tumor promoter-inducible mRNA found in JB6 mouse epidermal cells: induction is stable at high, but not at low, cell densities.
Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
Molecular interactions in cancer cell metastasis.
Molecular mechanisms of tumor necrosis factor-alpha-mediated plasminogen activator inhibitor-1 expression in adipocytes.
Molecular targets and abdominal aortic aneurysms.
Molecular targets of curcumin.
Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA.
Monitoring lung cancer with tissue polypeptide antigen: an ancillary, profitable serum test to evaluate treatment response and posttreatment disease status.
Monoclonal antibody M3 used in tissue polypeptide-specific antigen assay for the quantification of tissue polypeptide antigen recognizes keratin 18.
Monoclonal human B lymphoma cells respond to DNA synthesis to anti-immunoglobulins in the presence of the tumour promotor TPA.
Monocyte chemotactic protein-1 deficiency reduces spontaneous metastasis of Lewis lung carcinoma in mice fed a high-fat diet.
Monocyte tissue factor-like activity in post myocardial infarction patients.
Monolayer freeze-fracture and scanning tunneling microscopy.
Morphine and breast tumor metastasis: the role of matrix-degrading enzymes.
Morphological transformation and catalase activity of Syrian hamster embryo cells treated with hepatic peroxisome proliferators, TPA and nickel sulphate.
Mosaic structure of the secreted ECM metalloproteases and interaction of the type IV collagenases with inhibitors.
Mouse skin ornithine decarboxylase induction and tumor promotion by cyclohexane.
mRNA expression of adipocytokines and glucocorticoid-related genes are associated with downregulation of E-cadherin mRNA in colorectal adenocarcinomas.
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
Multistage skin carcinogenesis: a useful model for the study of the chemoprevention of cancer.
Multistage transformation of cultured rat urothelium: the effects of N-methyl-N-nitrosourea, sodium saccharin, sodium cyclamate and 12-O-tetradecanoylphorbol-13-acetate.
Multistage tumor development in the human esophagus - the first identification of cocarcinogens of the tumor promoter type as principal carcinogenic risk factors in a local life style cancer.
Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy.
Must initiators come first? Tumorigenic and carcinogenic effects on skin of 3-methylcholanthrene and TPA in various sequences.
Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression.
Mutation of p53 in skin papilloma and tubular breast adenoma of albino mice.
Myeloperoxidase Is an Early Biomarker of Inflammation and Cardiovascular Risk in Prepubertal Obese Children.
Myocardial (123)I-mIBG scintigraphy in relation to markers of inflammation and long-term clinical outcome in patients with stable chronic heart failure.
N-Nitroso-N-(3-keto-1,2-butanediol)-3'-nitrotyramine. A new genotoxic agent derived from the reaction of tyrosine and glucose in the presence of sodium nitrite.
N-nitrosocimetidine as an initiator of murine skin tumors with associated H-ras oncogene activation.
N-terminal peptide of type III procollagen: a possible predictor of colorectal carcinoma recurrence.
Na+/H+ exchange in Ehrlich ascites tumor cells. Regulation by extracellular ATP and 12-O-tetradecanoylphorbol 13-acetate.
Nafamostat mesilate inhibits the expression of HMGB1 in lipopolysaccharide-induced acute lung injury.
Nanosized TiO2-induced reproductive system dysfunction and its mechanism in female mice.
Need for tissue plasminogen activator for central venous catheter dysfunction is significantly associated with thrombosis in pediatric cancer patients.
Negative regulation of expression of the pituitary-specific transcription factor GHF-1/Pit-1 by thyroid hormones through interference with promoter enhancer elements.
Neoplasms produced from C3H/10T 1/2 cells attached to plastic plates; saturation density, anchorage dependence and serum requirement of in vitro lines correlated with growth aggressiveness in vivo.
Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC).
Neutrophil defect associated with hairy cell leukemia.
New classes of environmental tumor promoters: indole alkaloids and polyacetates.
Nexrutine(R) inhibits tumorigenesis in mouse skin and induces apoptotic cell death in human squamous carcinoma A431 and human melanoma A375 cells.
Nicotinamide and nicotinamide analogues as antitumor promoters in mouse skin.
Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease.
Nitroglycerin: a NO donor inhibits TPA-mediated tumor promotion in murine skin.
Nivalenol, a main Fusarium toxin in dietary foods from high-risk areas of cancer of esophagus and gastric cardia in China, induced benign and malignant tumors in mice.
No Involvement of Lysophosphatidic Acid Receptor-3 in Cell Migration of Mouse Lung Tumor Cells Stimulatedby 12-O-Tetradecanoylphorbol-13-acetate.
Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a step-II diet.
Non-muscle alpha-actinin-4 interacts with plasminogen activator inhibitor type-1 (PAI-1).
Nonionic contrast agents produce thrombotic effect by inducing adhesion of leukocytes on human endothelium.
Nordihydroguaiaretic Acid from Creosote Bush (Larrea tridentata) Mitigates 12-O-Tetradecanoylphorbol-13-Acetate-induced Inflammatory and Oxidative Stress Responses of Tumor Promotion Cascade in Mouse Skin.
Nordihydroguiaretic acid attenuates skin tumorigenesis in Swiss albino mice with the condition of topical co-administration of an immunosuppressant.
Notes to application of the V79 metabolic cooperation assay for detection of potential tumor promoters.
Notoginsenoside R1 from Panax notoginseng inhibits TNF-alpha-induced PAI-1 production in human aortic smooth muscle cells.
Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases.
Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNF alpha.
Novel immunologic tolerance of human cancer cell xenotransplants in zebrafish.
Novel inhibitors of urokinase-type plasminogen activator and matrix metalloproteinase expression in metastatic cancer cell lines.
NTP Comparative Initiation/Promotion Skin Paint Studies of B6C3F1 Mice, Swiss (CD-1(R)) Mice, and SENCAR Mice.
NTP Initiation/Promotion Study of o-Benzyl-p-Chlorophenol (CAS No. 120-32-1) in Swiss (CD-1(R)) Mice (Mouse Skin Study).
Obesity and cancer: the role of dysfunctional adipose tissue.
Obesity and dementia: Adipokines interact with the brain.
Obesity as a cardiovascular risk factor.
Obesity as a disease state: a new paradigm for diagnosis and treatment.
Observations on the mechanism of skin tumor promotion by phorbol esters.
Obstructive Sleep Apnea in Acute Stroke: A Role for Systemic Inflammation.
Occurrence of components of fibrinolytic pathways in situ in laryngeal cancer.
Of mice and men: a critical reappraisal of the two-stage theory of carcinogenesis.
Off-label use of IV t-PA in patients with intracranial neoplasm and cavernoma.
Okadaic acid and phorbol esters: comparative effects of these tumor promoters on cell transformation, intercellular communication and differentiation in vitro.
Okadaic acid induces the expression of both early and secondary response genes in mouse keratinocytes.
Okadaic acid, sphingosine, and phorbol ester reversibly modulate heat induction on protein kinase FA/GSK-3 alpha in A431 cells.
Okadaic acid: a reversible inhibitor of neoplastic transformation of mouse fibroblasts.
Omentectomy added to Roux-en-Y gastric bypass surgery: a randomized, controlled trial.
On the active principles of the spurge family (Euphorbiaceae). V. Extremely skin-irritant and moderately tumor-promoting diterpene esters from Euphorbia resinifera Berg.
On the mechanisms of cell uncoupling induced by a tumor promoter phorbol ester in clone 9 cells, a rat liver epithelial cell line.
On the role of superoxide anion radicals in skin tumour promotion.
Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans.
One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease.
Only a subset of 12-O-tetradecanoylphorbol-13-acetate-promoted mouse skin papillomas are promotable by benzoyl peroxide.
Open adhesiolysis is more effective in reducing adhesion reformation than laparoscopic adhesiolysis in an experimental model.
Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
Optimization of construct design and fermentation strategy for the production of bioactive ATF-SAP, a saporin based anti-tumoral uPAR-targeted chimera.
Optimized mitogen stimulation induces proliferation of neoplastic B cells in chronic lymphocytic leukemia: significance for cytogenetic analysis.The Tampere Chronic Lympocytic Leukemia group.
Oral carcinogenesis is not achieved in different carcinogen-treated PAI-1 transgenic and wild-type mouse models.
Oral eicosapentaenoic acid for complications of bone marrow transplantation.
Oral Glutamine Supplementation Protects Female Mice from Nonalcoholic Steatohepatitis.
Ornithine decarboxylase activity and DNA synthesis in primary and transformed hamster epidermal cells exposed to tumor promoter.
Ornithine decarboxylase activity in foetal rat brain cells and in the mouse embryo fibroblasts C3H/10T1/2 CL8 cells: differences in response to medium change and to the tumor promoter TPA.
Ornithine decarboxylase in rat skin: 2. Differential response to hair plucking and a tumor promoter.
Orthovanadate, an inhibitor of protein tyrosine phosphatases, acts more potently as a promoter than as an initiator in the BALB/3T3 cell transformation.
Overexpression of a dominant-negative ornithine decarboxylase in mouse skin: effect on enzyme activity and papilloma formation.
Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines.
Overexpression of bone morphogenetic protein-6 (BMP-6) in murine epidermis suppresses skin tumor formation by induction of apoptosis and downregulation of fos/jun family members.
Overexpression of CEP72 Promotes Bladder Urothelial Carcinoma Cell Aggressiveness via Epigenetic CREB-Mediated Induction of SERPINE1.
Overexpression of connexin26 in the basal keratinocytes reduces sensitivity to tumor promoter TPA.
Overexpression of endoplasmic reticulum protein 29 regulates mesenchymal-epithelial transition and suppresses xenograft tumor growth of invasive breast cancer cells.
Overexpression of protein kinase C-alpha in the epidermis of transgenic mice results in striking alterations in phorbol ester-induced inflammation and COX-2, MIP-2 and TNF-alpha expression but not tumor promotion.
Overview of the molecular mechanisms contributing to the formation of cancer?associated adipocytes (Review).
Overweight and obesity: the pathogenesis of cardiometabolic risk.
Oxidation of polycyclic hydrocarbons by oxygen radicals.
Oxidative stress mediates tumor promoter-induced proliferin gene-expression in c3h10t1/2 cells.
Oxygen uptake, ATPase activity, and superoxide dismutase activity in isolated rat liver mitochondria are not influenced by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate.
p-HPEA-EDA, a phenolic compound of virgin olive oil, activates AMP-activated protein kinase to inhibit carcinogenesis.
p38? MAPK Mediates 17?-Estradiol Inhibition of MMP-2 and -9 Expression and Cell Migration in Human LoVo Colon Cancer Cells.
p53 expression and tumor proliferative activity in testicular germ-cell tumors.
p53 regulates the expression of the tumor suppressor gene maspin.
P53 tumor suppressor factor, plasminogen activator inhibitor, and vascular endothelial growth factor gene polymorphisms and recurrent implantation failure.
p53- and PAI-1-mediated induction of C-X-C chemokines and CXCR2: Importance in Pulmonary Inflammation due to Cigarette Smoke exposure.
PAI-1 - a potential therapeutic target in cancer.
PAI-1 4G/5G Polymorphism Contributes to Cancer Susceptibility: Evidence from Meta-Analysis.
PAI-1 4G/5G repeat is a target in gastric carcinomas with microsatellite instability.
PAI-1 and EGFR expression in adult glioma tumors: toward a molecular prognostic classification.
PAI-1 and functional blockade of SNAI1 in breast cancer cell migration.
PAI-1 gene 4G/5G polymorphism, cytokine levels and their relations with metabolic parameters in obese children.
PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin.
PAI-1 overexpression promotes invasion and migration of esophageal squamous carcinoma cells.
PAI-1 Polymorphisms Have Significant Associations With Cancer Risk, Especially Feminine Cancer.
PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: Evidence from meta-analysis.
PAI-1-Dependent Inactivation of SMAD4-Modulated Junction and Adhesion Complex in Obese Endometrial Cancer.
Palm oil alleviates 12-O-tetradecanoyl-phorbol-13-acetate-induced tumor promotion response in murine skin.
Parent-offspring transmission of adipocytokine levels and their associations with metabolic traits.
PARP14 inhibits microglial activation via LPAR5 to promote post-stroke functional recovery.
Part I: Synthesis, cancer chemopreventive activity and molecular docking study of novel quinoxaline derivatives.
Pathogenesis of venous thromboembolism: when the cup runneth over.
Pathophysiology of disseminated intravascular coagulation in sepsis.
Pathophysiology of transitional tumor cell adherence to sites of urothelial injury in rats: mechanisms mediating intravesical recurrence due to implantation.
Pathways of fibrin turnover of human pleural mesothelial cells in vitro.
Pattern of expression of inflammatory markers in adipose tissue of untreated hypertensive patients.
Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans.
Pediatric CNS Tumor Patients Have Significantly Lower Requirement of Tissue Plasminogen Activator for Episodes of Central Venous Catheter Dysfunction Compared With Other Pediatric Oncology Patients: Results of a Population-based Cohort Study.
Pentoxifylline prevents upregulation of monocyte tissue factor in renal transplant recipients undergoing post-graft complications.
Peracetylated (-)-epigallocatechin-3-gallate (AcEGCG) potently prevents skin carcinogenesis by suppressing the PKD1-dependent signaling pathway in CD34+ skin stem cells and skin tumors.
Perilla oil and exercise decrease expressions of tumor necrosis factor-alpha, plasminogen activator inhibitor-1 and highly sensitive C-reactive protein in patients with hyperlipidemia.
Perillyl alcohol attenuates Ras-ERK signaling to inhibit murine skin inflammation and tumorigenesis.
Periodontal disease and biomarkers related to cardiovascular disease.
Peripheral blood mRNA expressions of stress biomarkers in manic episode and subsequent remission.
Peritoneal adhesions: Occurrence, prevention and experimental models.
Peritoneal changes in patients on long-term peritoneal dialysis.
Perivascular Adipose Tissue, Vascular Reactivity and Hypertension.
Permeable endothelium and the interstitial space of brain.
Peroxisome proliferator-activated receptor gamma (PPAR?) as a target for concurrent management of diabetes and obesity-related cancer.
Peroxisome proliferators show tumor-promoting but no direct transforming activity in vitro.
Persistence of carcinogenic effect in intact progeny of mice treated transplacentally with 7,12-dimethylbenz[a]anthracene.
Persisting oncogenic herpesvirus induced by the tumour promotor TPA.
PGE1 inhibits the expression of PAI-1 mRNA induced by TNF-alpha in human mesangial cells.
pH effects on the lifespan and transformation frequency of Syrian hamster embryo (SHE) cells.
Phenobarbital decreases hepatocyte EGF receptor expression independent of protein kinase C activation.
Phenolic fraction of tobacco smoke condensate potentiates benzo[a]pyerene diol epoxide-induced cell transformation: Role of protein kinase C.
Phenotypic differences between tumor cells derived from different stages of neoplastic growth.
Phenotypic effects of overexpression of PKC beta 1 in rat liver epithelial cells.
Phenotypic expression of carcinogen-initiated epidermal cells to tumor cells by 12-O-tetradecanoylphorbol-13-acetate in a manner dependent on 3T3 fibroblast-derived humoral factor(s).
Phenotypic markers in human skin fibroblasts as possible diagnostic indices of hereditary adenomatosis of the colon and rectum.
Phorbol diester and epidermal growth factor receptors in 12-O-tetradecanoylphorbol-13-acetate-resistant and -sensitive mouse epidermal cells.
Phorbol ester at concentrations 10(-18)-10(-7) M inhibits lipid peroxidation in rat brain plasma membranes via activation of protein kinase C.
Phorbol ester effects on splenic lymphocyte composition and cytotoxic T cell activities of SSIN mice: a strain deficient in CD8+ T cells.
Phorbol ester induction of 8-lipoxygenase in inbred SENCAR (SSIN) but not C57BL/6J mice correlated with hyperplasia, edema, and oxidant generation but not ornithine decarboxylase induction.
Phorbol ester-induced alteration of protein kinase C catalytic properties occurs at the membrane level and is not reproduced by physiological stimuli.
Phorbol ester-induced morphological changes in transformed chick fibroblasts: evidence for direct catalytic involvement of plasminogen activator.
Phorbol ester-mediated protein phosphorylations in S49 mouse lymphoma cells.
Phorbol esters of different biological activities may preferentially act as mitogens of human suppressor T-cells and are equi-effective mitogens of IL-2 dependent cells.
Phorbol-ester-stimulated human lymphoid cell lines produce a plasminogen activator modulator inducing cell-bound urokinase-type plasminogen activator in malignant tumor cell lines.
Phospholipase C-induced monocytic differentiation in a human monocytic leukemia cell line THP-1.
Phospholipid/calcium-dependent protein kinase (protein kinase C) system: a major site of bioregulation.
Phosphorylation of a 75,000 molecular weight cytosol protein induced by platelet derived growth factor and tumor promoter in BALB/c-3T3 cells.
Photoperiod-induced differential expression of angiogenesis genes in testes of adult Peromyscus leucopus.
Photosensitized reactions and carcinogenesis.
Physical activity increases the resistin concentration in hemodialyzed patients without metabolic syndrome.
Physiological consequences of over- or under-expression of fibrinolytic system components in transgenic mice.
Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ.
Physiological, pathological and potential therapeutic roles of adipokines.
Phytol is a novel tumor promoter on ICR mouse skin.
Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients.
PKC activation sensitizes basal-like breast cancer cell lines to Smac mimetics.
PKCalpha activation downregulates ATM and radio-sensitizes androgen-sensitive human prostate cancer cells in vitro and in vivo.
PKCalpha mediated induction of miR-101 in human hepatoma HepG2 cells.
Placental alkaline phosphatase (PLAP)/PLAP-like alkaline phosphatase as tumour marker in relation to CA 125 and TPA for ovarian epithelial tumours.
Plasma adiponectin and insulin resistance in Korean type 2 diabetes mellitus.
Plasma adiponectin plays an important role in improving insulin resistance with glimepiride in elderly type 2 diabetic subjects.
Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus.
Plasma and tissue CEA and TPA markers in operable breast cancer. Preliminary results.
Plasma levels of cytokines in primary septic shock in humans: correlation with disease severity.
Plasma Levels of Plasminogen Activator Inhibitor Type 1 and Vitronectin in Children With Cancer.
Plasma membrane-dependent activation of gelatinase A in human vascular endothelial cells.
Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Plasma Plasminogen Activator Inhibitor-1 (PAI-1) Levels in Breast Cancer - Relationship with Clinical Outcome.
Plasma von Willebrand factor as a predictor of survival in pulmonary arterial hypertension associated with congenital heart disease.
Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard.
Plasmin-catalyzed proteolysis in colorectal neoplasia.
Plasminogen activation in human leukemia and in normal hematopoietic cells.
Plasminogen Activation System in Rectal Adenocarcinoma.
Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma.
Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.
Plasminogen activator activity in clonogenic cell populations separated from a murine fibrosarcoma.
Plasminogen activator activity in human endometrial carcinoma.
Plasminogen activator activity of metastatic variants from a murine fibrosarcoma; effect of thrombin in vitro.
Plasminogen activator and cancer.
Plasminogen activator and its inhibitor in cancer patients treated with tumor necrosis factor.
Plasminogen activator and metalloprotease activities of Du-145, PC-3, and 1-LN-PC-3-1A human prostate tumors grown in nude mice: correlation with tumor invasive behavior.
Plasminogen activator and nuclear androgen receptor in rat prostate tumors after treatment with D-Trp-6-LH-RH.
Plasminogen activator and plasmin-like activities in experimental rat tumours.
Plasminogen activator and progesterone receptor are correlated in human mammary tumors.
Plasminogen activator as a functional marker for estrogen dependence in human breast cancer cells.
Plasminogen activator content of gynecological tumors and their metastases.
Plasminogen activator content of human colon tumors and normal mucosae: separation of enzymes and partial purification.
Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo.
Plasminogen activator expression and steroid hormone receptors in female breast cancer: a multifactorial study.
Plasminogen activator gene expression is induced by the src oncogene product and tumor promoters.
Plasminogen activator in human breast cancer cytosols: revisited after five years.
Plasminogen activator in normal and tumor-bearing mice.
Plasminogen activator in prostatic tumors of Nb rats.
Plasminogen activator induction and platelet aggregation by phorbol and some of its derivatives: correlation with skin irritancy and tumor-promoting activity.
Plasminogen activator inhibitor (PAI) trap3, an exocellular peptide inhibitor of PAI-1, attenuates the rearrangement of F-actin and migration of cancer cells.
Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.
Plasminogen activator inhibitor 1 (PAI-1) 1334G/A genetic polymorphism in colorectal cancer.
Plasminogen activator inhibitor 1 (PAI1) promotes actin cytoskeleton reorganization and glycolytic metabolism in triple negative breast cancer.
Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor/cachectin-responsive genes.
Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma.
Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes.
Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis.
Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway.
Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo.
Plasminogen Activator Inhibitor Type 1 (PAI-1) A15T Gene Polymorphism Is Associated with Prognosis in Patients with EGFR Mutation Positive Pulmonary Adenocarcinoma.
Plasminogen activator inhibitor type 1 (PAI-1) is a valuable biomarker for predicting the metabolic syndrome (MS) in institutionalized elderly residents in Taiwan.
Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications.
Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
Plasminogen activator inhibitor type 1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin via alpha(v)beta(5) integrin.
Plasminogen activator inhibitor type 2 gene induction by tumor necrosis factor and phorbol ester involves transcriptional and post-transcriptional events. Identification of a functional nonameric AU-rich motif in the 3'-untranslated region.
Plasminogen activator inhibitor type 2 in breast cancer.
Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function.
Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells.
Plasminogen activator inhibitor type-2 (PAI-2) gene transcription requires a novel NF-kappaB-like transcriptional regulatory motif.
Plasminogen activator inhibitor type-2 is a major protein induced in human fibroblasts and SK-MEL-109 melanoma cells by tumor necrosis factor.
Plasminogen activator inhibitor-1 (PAI-1) 4 G/5 G polymorphism and endometrial cancer. Influence of PAI-1 polymorphism on tissue PAI-1 antigen and mRNA expression and tumor severity.
Plasminogen activator inhibitor-1 (PAI-1) expression in relation to hypoxia and oncoproteins in clinical cervical tumors.
Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.
Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis.
Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer.
Plasminogen activator inhibitor-1 as a potential marker for the malignancy of esophageal squamous cell carcinoma.
Plasminogen activator inhibitor-1 as a potential marker for the malignancy of gastric cancer.
Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer patients with and without thrombosis.
Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer patients.
Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis.
Plasminogen activator inhibitor-1 in brain tumors: relation to malignancy and necrosis.
Plasminogen activator inhibitor-1 in cancer research.
Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing.
Plasminogen activator inhibitor-1 in the cerebrospinal fluid as an index of neurological disease.
Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling.
Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells.
Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis.
Plasminogen activator inhibitor-1 is a downstream mediator of the PGP9.5-related oncogenic pathway in esophageal squamous cell carcinoma.
Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment.
Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients.
Plasminogen activator inhibitor-1 is increased in colonic epithelial cells from patients with colitis-associated cancer.
Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin.
Plasminogen activator inhibitor-1 promotes immunosuppression in cancer by modulating immune component of tumor microenvironment.
Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer.
Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis.
Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis.
Plasminogen Activator Inhibitor-1 Secretion by Autophagy Contributes to Melanoma Resistance to Chemotherapy through Tumor Microenvironment Modulation.
Plasminogen activator inhibitor-2 but not cystatin C inhibits the pro-metastatic activity of tissue inhibitor of metalloproteinases-1 in the liver.
Plasminogen activator inhibitor-2 in patients with monocytic leukemia.
Plasminogen Activator Inhibitor-2 Plays a Leading Prognostic Role among Protease Families in Non-Small Cell Lung Cancer.
Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.
Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis.
Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines.
Plasminogen activator of the blood vessels in tumours and in carrageenin-induced granulomas.
Plasminogen activator production by human tumor cells: effect on tumor cell-extracellular matrix interactions.
Plasminogen activator release from cultured murine mast cells.
Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors.
Plasminogen activator system in oral squamous cell carcinoma.
Plasminogen activator system modulates invasive capacity and proliferation in prostatic tumor cells.
Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.
Plasminogen activator uPA is a direct transcriptional target of the JAG1-Notch receptor signaling pathway in breast cancer.
Plasminogen activator urokinase expression reveals TRAIL responsiveness and supports fractional survival of cancer cells.
Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.
Plasminogen activator, fibronectin, lymphotoxin sensitivity, and natural skin reactivity relationships to guinea pig cell tumorigenicity.
Plasminogen activator/plasminogen activator inhibitor-1 and cytokine modulation by the PROACT System.
Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer.
Plasminogen activators and plasminogen activator inhibitor before and after surgery in patients with and without gastric malignancy.
Plasminogen activators and plasminogen activator inhibitor in malignant and non-malignant ascitic fluid.
Plasminogen activators and plasminogen activator inhibitor in portal blood from patients with and without gastric malignancy.
Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.
Plasminogen activators and plasminogen activator inhibitors in human colorectal carcinoma tissues are not expressed by the tumour cells.
Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas.
Plasminogen activators and their inhibitor in bone tumors and tumor-like damages.
Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Plasminogen activators are involved in angiostatin generation in vivo in benign and malignant ovarian tumor cyst fluids.
Plasminogen activators in experimental colorectal neoplasia: a role in the adenoma-carcinoma sequence?
Plasminogen activators in human malignant melanoma.
Plasminogen activators in human xenografted oro-pharyngeal squamous cell carcinomas.
Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines.
Plasminogen activators: regulators of tumor cell adherence to sites of lower urinary tract surgical trauma.
Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages.
Platelet-activating factor stimulates arachidonic acid metabolism in rat liver cells (C-9 cell line) by a receptor-mediated mechanism.
PLAU Promotes Cell Proliferation and Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma.
Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients.
Polymeric prodrug for release of an antitumoral agent by specific enzymes.
Polymorphism of genes related to cardiovascular disease in patients with rheumatoid arthritis.
Polymorphisms in the genes related to angiogenesis are associated with uterine cervical cancer.
Polymorphonuclear leukocytes increase the adhesion of circulating tumor cells to microvascular endothelium.
Pooled Assessment of Computed Tomography Interpretation by Vascular Neurologists in the STRokE DOC Telestroke Network.
Population and single?cell transcriptome analyses reveal diverse transcriptional changes associated with radioresistance in esophageal squamous cell carcinoma.
Porphyrin-mediated photosensitization has a weak tumor promoting activity in mouse skin: possible role of in situ-generated reactive oxygen species.
Positive and negative regulation of specific gene expression by the tumor promoter TPA in human erythroleukemic K562 cells.
Possible dissociation of the phorbol ester-induced oxidant response and tumor promotion in the F1 offspring of SSIN x C57BL/6J mice.
Possible implication of arachidonic acid metabolism in the decrease of chemiluminescence production after exposure of murine peritoneal macrophages to diethylnitrosamine and tumour promoter, 12-O-tetradecanoylphorbol-13-acetate.
Possible involvement of reorganization of actin filaments, induced by tumor-promoting phorbol esters, in changes in colony shape and enhancement of proliferation of cultured epithelial cells.
Post-transcriptional suppression of human ornithine decarboxylase gene expression by phorbol esters in human keratinocytes.
Postnatal programming of glucocorticoid metabolism in rats modulates high-fat diet-induced regulation of visceral adipose tissue glucocorticoid exposure and sensitivity and adiponectin and proinflammatory adipokines gene expression in adulthood.
Postoperative Statin Therapy Attenuates the Intensity of Systemic Inflammation and Increases Fibrinolysis After Coronary Artery Bypass Grafting.
Postprandial hypertriglyceridemia associated with inflammatory response and procoagulant state after a high-fat meal in hypertensive patients.
Postprandial vascular-inflammatory and thrombotic responses to high-fat feeding are augmented by manipulating the lipid droplet size distribution.
Potent inhibitory effects of suicide inhibitors of P450 isozymes on 7,12-dimethylbenz[a]anthracene and benzo[a]pyrene initiated skin tumors.
Potent suppressive activity of nonpolyphenolic fraction of green tea (Camellia sinensis) against genotoxin-induced umu C gene expression in Salmonella typhimurium (TA 1535/pSK 1002), tumor promotor-dependent ornithine decarboxylase induction of BALB/c 3T3 fibroblast cells, and chemically induced mouse skin tumorigenesis.
Potent suppressive activity of pheophytin a and b from the non-polyphenolic fraction of green tea (Camellia sinensis) against tumor promotion in mouse skin.
Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
Potentiation of prostaglandin E1-stimulated cAMP formation by 12-O-tetradecanoylphorbol-13-acetate in BALB/c mouse 3T3 cells.
Pre-operative serum levels of tissue polypeptide antigen in patients with gastric cancer.
Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI Chemoprevention Drug Development Program.
Prediagnostic circulating markers of inflammation and risk of oesophageal adenocarcinoma: a study within the National Cancer Institute Cohort Consortium.
Predicting the sites of metastases from lung cancer using molecular biologic markers.
Prediction of biological behaviour of human breast cancer using multiple parameters. A preliminary study.
Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury*
Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury.
Predisposing factors to post-operative adhesion development.
Prematurity With Extrauterine Growth Restriction Increases the Risk of Higher Levels of Glucose, Low-Grade of Inflammation and Hypertension in Prepubertal Children.
Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer.
Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group.
Preoperative serum markers in carcinoma of the rectum and rectosigmoid. I. Prediction of tumour stage.
Preparation of immunoaffinity mini-columns for the analysis of platelet activating factor (PAF) in biological samples.
Preparation of tissue polypeptide antigen (TPA) from sera pools of cancer patients.
Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease.
Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: relevance for differential diagnosis.
Prevalence of thrombophilic genetic factors among patients with retinitis pigmentosa.
Prevalence of tumor prevention rather than tumor enhancement when repetitive UV radiation treatments precede initiation and promotion.
Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation.
Prevention of intraperitoneal adhesions and abscesses by polysaccharides isolated from Phellinus spp in a rat peritonitis model.
Prevention of metastasis by inhibition of the urokinase receptor.
Primary cultures of neonatal rat liver as an assay system to identify compounds belonging to the tumor promoters class.
Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.
Pristane induced gene activation.
Pro- and antifibrinolytic properties of human pulmonary microvascular versus artery endothelial cells: impact of endotoxin and tumor necrosis factor-alpha.
Pro-addictive and anti-addictive factors for drug dependence.
Procoagulant and fibrinolytic activities of gastric and colorectal cancer.
Production and Post-Surgical Modification of VEGF, tPA and PAI-1 in Patients with Glioma.
Production of angiotensin II receptors type one (AT1) and type two (AT2) during the differentiation of 3T3-L1 preadipocytes.
Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells.
Profibrinolytic properties characterize a stably transformed human endothelial cell line.
Profile of gene expression induced by the tumour promotor TPA in murine epithelial cells.
Progesterone receptor antagonism inhibits progestogen-related carcinogenesis and suppresses tumor cell proliferation.
Prognostic impact of plasminogen activator inhibitor type 1 expression in bladder cancer.
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer.
Prognostic role of tumor-associated proteases in colorectal cancer.
Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.
Prognostic significance of proteolytic enzymes in human brain tumors.
Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer.
Prognostic significance of tissue-type plasminogen activator (tPA) content in gastric cancer and surrounding mucosa.
Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.
Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer.
Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression.
Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma.
Prognostic value of tissue plasminogen activator (tPA) in patients with epithelial ovarian cancer undergoing chemotherapy.
Prognostic value of tissue polypeptide antigen (TPA) plasma levels in patients with malignant salivary gland tumors.
Prognostic value of tissue polypeptide antigen in oral squamous cell carcinoma.
Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer.
Progress in studies on the antimutagenicity and anticarcinogenicity of green tea epicatechins.
Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.
Proinflammatory cytokine and chemokine gene expression profiles in subcutaneous and visceral adipose tissue depots of insulin-resistant and insulin-sensitive light breed horses.
Proinflammatory cytokines and fibrinolytic enzymes in tuberculous and malignant pleural effusions.
Proinflammatory cytokines, transforming growth factor-beta1, and fibrinolytic enzymes in loculated and free-flowing pleural exudates.
Prolactin is a tumor promoter in rat liver.
Proliferation of a human epidermal tumor cell line stimulated by urokinase.
Proliferation tissue polypeptide antigen distinguishes malignant mucinous cystadenocarcinomas from benign cystic tumors and pseudocysts.
Proliferative responses of epithelial cells to 8-bromo-cyclic AMP and to a phorbol ester change during breast pathogenesis.
Promoter function and structure of the growth factor-inducible immediate early gene cyr61.
Promoter independence as a feature of most skin papillomas in SENCAR mice.
Promoting effect of 12-O-tetradecanoylphorbol-13-acetate on the in vitro malignant transformation of fetal rat brain cells exposed in utero to ethylnitrosourea.
Promotion of BALB/3T3 cell transformation by the okadaic acid class of tumor promoters, okadaic acid and dinophysistoxin-1.
Promotion of skin tumors by 12-O-tetradecanoylphorbol-13-acetate in two generations of descendants of male mice exposed to X-ray irradiation.
Promotion of skin tumours by TPA in the progeny of mice exposed pre-natally to DMBA.
Promotion-like enhancement of tracheal carcinogenesis in rats by 12-O-tetradecanoylphorbol-13-acetate.
Promotion: is saccharin a promoter in the urinary bladder?
Properties of cell lots suitable for focus assay in the chemical transformation of Syrian hamster cells in culture.
Properties of urokinase type-plasminogen activator found in chest fluid.
Prospective study of hemostatic alterations in children with acute lymphoblastic leukemia.
Prostaglandin modulation of phorbol ester skin tumor promotion.
Prostaglandins, cyclic nucleotides and the effect of phorbol ester tumor promoters on mouse skin in vivo.
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Protease inhibitor 10 inhibits tumor necrosis factor alpha -induced cell death. Evidence for the formation of intracellular high M(r) protease inhibitor 10-containing complexes.
Protease inhibitor antipain suppresses 12-O-tetradecanoyl-phorbol-13-acetate induction of plasminogen activator in transformable mouse embryo fibroblasts.
Protease nexin-1 expression is altered in human breast cancer.
Protease-activated receptor 2 (PAR2) blocking peptide counteracts endotoxin-induced inflammation and coagulation and ameliorates renal fibrin deposition in a rat model of acute renal failure.
Proteases and metastasis: clinical relevance nowadays?
Proteases and protease inhibitors in tumor progression.
Proteases associated with gynecological tumors.
Proteases during the growth of Ehrlich ascites tumor. I. The fibrinolysin system.
Protection against 12-O-tetradecanoylphorbol-13-acetate induced skin-hyperplasia and tumor promotion, in a two-stage carcinogenesis mouse model, by the 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-[2,3-b]quinoxaline analogue of ellipticine.
Protection against chemically induced skin tumorigenesis in SENCAR mice by tannic acid.
Protection against induction of mouse skin papillomas with low and high risk of conversion to malignancy by green tea polyphenols.
Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2.
Protective effect of all trans retinoic acid against tumor promotion and progression in low- and high-risk protocols of mouse skin chemical carcinogenesis.
Protective role of cathepsin L in mouse skin carcinogenesis.
Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.
Protein kinase C (PKC) isoenzyme expression pattern as an indicator of proliferative activity in uterine tumor cells.
Protein kinase C activation leads to dephosphorylation of occludin and tight junction permeability increase in LLC-PK1 epithelial cell sheets.
Protein kinase C and adenylate cyclase as targets for growth inhibition of human gastric cancer cells.
Protein kinase C delta overexpressing transgenic mice are resistant to chemically but not to UV radiation-induced development of squamous cell carcinomas: a possible link to specific cytokines and cyclooxygenase-2.
Protein kinase C-activating tumor promoters modulate the DNA damage response in UVC-irradiated TK6 cells.
Protein kinase C-alpha is an upstream activator of the IkappaB kinase complex in the TPA signal transduction pathway to NF-kappaB in U2OS cells.
Protein kinase Cdelta-mediated signal to ornithine decarboxylase induction is independent of skin tumor suppression.
Protein kinase Cepsilon is linked to 12-O-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor-alpha ectodomain shedding and the development of metastatic squamous cell carcinoma in protein kinase Cepsilon transgenic mice.
Protein Microarrays for Quantitative Detection of PAI-1 in Serum.
Protein phosphorylation in response to the tumor promoter TPA is dependent on the state of differentiation of muscle cells.
Proteinase activity in invasive cancer of the breast. Correlation with tumor progression.
Proteinase-alpha 2 macroglobulin complexes are not increased in plasma of patients with cancer.
Proteinases and proteinase inhibition by cytotoxic and antimetastatic drugs in transplantable solid metastasizing tumors in mice.
Proteins and carbohydrates in nipple aspirate fluid predict the presence of atypia and cancer in women requiring diagnostic breast biopsy.
Proteolytic activation of tissue-type plasminogen activator by the culture media of mouse cancer cells.
Proteolytic enzymes and plasminogen activator in melanoma.
Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma.
Proteome analysis of antiproliferative mechanism of 12-O-tetradecanoylphorbol 13-acetate on cultured nasopharyngeal carcinoma CNE2 cells.
Proto-oncogene expression during two-stage carcinogenesis in mouse skin.
pS2 and PAI-1 in ovarian cancer: correlation to pathohistological parameters.
Puerarin prevents vascular endothelial injury through suppression of NF-?B activation in LPS-challenged human umbilical vein endothelial cells.
Pulse treatment with the tumor promoter TPA delays the onset of desensitization response and prolongs the inhibitory effect on gap junctional intercellular communication of a rat liver epithelial cell line WB F-344.
Purification and characterization of a platelet-derived growth factor and heavy metal-modulated nuclear protein.
Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines.
Purification of plasminogen activator from Rous sarcoma virus transformed chick embryo fibroblasts treated with the tumor promoter phorbol 12-myristate 13-acetate.
Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements.
Qualitative and quantitative separation of a series of phorbol-ester tumor promoters by high-pressure liquid chromatography.
Quantification of ligand density and stoichiometry on the surface of liposomes using single-molecule fluorescence imaging.
Quantitative high-performance liquid chromatography analysis of DNA oxidized in vitro and in vivo.
Quantitative measurement of soluble cytokeratin fragments in tissue cytosol of 599 node negative breast cancer patients: a prognostic marker possibly associated with apoptosis.
Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Rapamycin is a potent inhibitor of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Rapid acceleration of deoxyglucose transport by phorbol esters in bovine lymphocytes.
Rapid induction of skin and mammary tumors in human c-Ha-ras proto-oncogene transgenic rats by treatment with 7,12-dimethylbenz[a]anthracene followed by 12-O-tetradecanoylphorbol 13-acetate.
Ras-independent activation of Rel-family transcription factors by UVB and TPA in cultured keratinocytes.
RASGRP1 is essential for ras activation by the tumor promoter 12-o-tetradecanoylphorbol-13-acetate in epidermal keratinocytes.
Reaction of the tumor markers CEA and TPA to a surgical trauma.
Reactivation of ribosomal RNA genes in human-mouse hybrid cells by 12-O-tetradecanoylphorbol 13-acetate.
Reactive oxygen species-mediated PKC and integrin signaling promotes tumor progression of human hepatoma HepG2.
Recent insight into potential acute respiratory distress syndrome.
Recent studies on the biofunctions and biotransformations of curcumin.
Receptor downregulation and DNA synthesis are modulated by EGF and TPA in cells expressing an EGFR/neu chimera.
Reciprocal regulation of tissue-type and urokinase-type plasminogen activators in the differentiation of murine preadipocyte line 3T3-L1 and the hormonal regulation of fibrinolytic factors in the mature adipocytes.
Recombinagenic activity of the phorbol ester 12-O-tetradecanoylphorbol-13-acetate in human lymphoblastoid cells.
Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation in children: effectiveness and a scoring system for initiating treatment.
Red algae (Gelidium amansii) reduces adiposity via activation of lipolysis in rats with diabetes induced by streptozotocin-nicotinamide.
Reduced plasma zinc levels, lipid peroxidation, and inflammation biomarkers levels in hemodialysis patients: implications to cardiovascular mortality.
Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents.
Reduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors.
Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors.
Reduction of tumor-associated fibrinolytic-activity by antimetastatic dosages of 2 ru(ii)-dmso complexes in mice bearing lewis lung-carcinoma.
Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study.
Regulation and interactions in the activation of cell-associated plasminogen.
Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix.
Regulation of Airway and Alveolar Epithelial Cell Apoptosis by p53 Induced PAI-1 During Cigarette Smoke Exposure Injury.
Regulation of CD36 expression in human melanoma cells.
Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion.
Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor.
Regulation of expression of MSG1 melanocyte-specific nuclear protein in human melanocytes and melanoma cells.
Regulation of fibrin deposition by malignant mesothelioma.
Regulation of gene expression by tumor promoters. III. Complementation of the developmental program in myeloid leukemic cells by regulating mRNA production and mRNA translation.
Regulation of glutathione transferase P (GST-P) gene expression during chemical hepatocarcinogenesis.
Regulation of hepatocyte epidermal growth factor receptors by n-butyrate and dimethyl sulfoxide: sensitivity to modulation by the tumor promoter TPA.
Regulation of IGFBP6 gene and protein is mediated by the inverse expression and function of c-jun N-terminal kinase (JNK) and NFkappaB in a model of oral tumor cells.
Regulation of leukaemic cells by interleukin 6 and leukaemia inhibitory factor.
Regulation of mammary parenchymal growth by the fat pad in prepubertal dairy heifers: role of inflammation-related proteins.
Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells.
Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta.
Regulation of ornithine decarboxylase gene expression in mouse epidermis and epidermal tumors during two-stage tumorigenesis.
Regulation of plasminogen activator in 3T3 cells: effect of phorbol myristate acetate on subcellular distribution and molecular weight.
Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53.
Regulation of plasminogen-activator in mastocytoma cells by lymphokines.
Regulation of production of a platelet-derived growth factor-like protein by cultured bovine aortic endothelial cells.
Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAI-1).
Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis.
Regulation of the plasminogen activator activity of macrophage tumor cell lines.
Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene.
Regulation of trans-activating capacity of CRE-BPa by phorbol ester tumor promoter TPA.
Regulation of trophoblastic gelatinases by proto-oncogenes.
Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha.
Regulation of urokinase-type plasminogen activator expression in squamous-cell carcinoma of the oral cavity.
Regulatory elements involved in constitutive and phorbol ester-inducible expression of the plasminogen activator inhibitor type 2 gene promoter.
Relation between coagulation/fibrinolysis and lactate in the course of human septic shock.
Relation between fat distributions and several plasma adipocytokines after exercise training in premenopausal and postmenopausal women.
Relation between serum levels of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125) and their immunohistochemical identification in benign and malignant gynecological disease.
Relation between the regulation of DNA synthesis and the production of two secreted glycoproteins by 12-O-tetradecanoylphorbol-13-acetate in 3T3 cells and in phorbol ester nonresponsive 3T3 variants.
Relation of in vitro properties to tumorigenicity for a series of sublines of the human breast cancer cell line MCF-7.
Relation of the induction of epidermal ornithine decarboxylase and hyperplasia to the different skin tumor-promotion susceptibilities of protein kinase C alpha, -delta and -epsilon transgenic mice.
Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.
Relationship Between Circulating Tumor Cells and Tissue Plasminogen Activator in Patients with Early Breast Cancer.
Relationship between dietary quality, determined by DASH score, and cardiometabolic health biomarkers: A cross-sectional analysis in adults.
Relationship between expression of plasminogen activator system and metastatic ability in human cancers.
Relationship between protein kinase C and adenylyl cyclase activity in the regulation of growth hormone secretion by human pituitary somatotrophinomas.
Relationship of alcohol intake with inflammatory markers and plasminogen activator inhibitor-1 in well-functioning older adults: the Health, Aging, and Body Composition study.
Relationship of circulating biomarkers of inflammation and hemostasis with preclinical atherosclerotic burden in nonsmoking hypercholesterolemic men.
Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
Relationship of thoracic fat depots with coronary atherosclerosis and circulating inflammatory biomarkers.
Relationships among tumor burden, tumor size, and the changing concentrations of fibrin degradation products and fibrinolytic factors in the pleural effusions of rabbits with VX2 lung tumors.
Relationships between brachial artery flow mediated dilation and carotid artery intima-media thickness in patients with suspected coronary artery disease.
Relationships of systemic oxidative stress to body fat distribution, adipokines and inflammatory markers in healthy middle-aged women.
Relative inhibitory activity of bile acids against 12-O-tetradecanoylphorbol-13-acetate-induced inflammation, and chenodeoxycholic acid inhibition of tumour promotion in mouse skin two-stage carcinogenesis.
Relevance of the mouse skin initiation-promotion model for the classification of carcinogenic substances encountered at the workplace.
Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure.
Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia.
Renoprotective effects of soy protein hydrolysates in N(omega)-nitro-L-arginine methyl ester hydrochloride-induced hypertensive rats.
Repeated thoracenteses affect proinflammatory cytokines, vascular endothelial growth factor, and fibrinolytic activity in pleural transudates.
Repression of 5-aminolevulinate synthase gene by the potent tumor promoter, TPA, involves multiple signal transduction pathways.
Requirements for protein synthesis and calcium for stimulation of prostaglandin synthesis in cultured rat liver cells by tumor promoters.
Rescue from programmed cell death in leukemic and normal myeloid cells.
Resistance to skin tumorigenesis in DNAPK-deficient SCID mice is not due to immunodeficiency but results from hypersensitivity to TPA-induced apoptosis.
Response of Drosophila embryonic cells to tumor promoters.
Response of Jurkat T cells to phorbol ester and bryostatin. Development of sublines with distinct functional responses and changes in protein kinase C activity.
Response of low-passage human malignant gliomas in vitro to stimulation and selective inhibition of growth factor-mediated pathways.
Response of malignant glioma cell lines to activation and inhibition of protein kinase C-mediated pathways.
Response of neoplasms of B cell lineage to the proliferative effects of B cell growth factor and the phorbol ester TPA.
Response of Walker 256 carcinosarcoma cells to 12-O-tetradecanoylphorbol 13-acetate: possible regulation by endogenous cyclooxygenase metabolites.
Resting state depth and saturation density as modulated by tumor promoters and culture conditions: relationship to chemical transformation in C3H/10T1/2 cells.
Resveratrol induces apoptosis involving mitochondrial pathways in mouse skin tumorigenesis.
Resveratrol reverses tumor-promoter-induced inhibition of gap-junctional intercellular communication.
Resveratrol synergistically augments anti-tumor effect of 5-FU in vitro and in vivo by increasing S-phase arrest and tumor apoptosis.
Retargeted adenoviral cancer gene therapy for tumour cells overexpressing epidermal growth factor receptor or urokinase-type plasminogen activator receptor.
Retinoic acid nuclear receptors and tumor promotion: decreased expression of retinoic acid nuclear receptors by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate.
Retinoids and skin: microarrays shed new light on chemopreventive action of all-trans retinoic acid.
Retinoids block ornithine decarboxylase induction in cells treated with the tumor promotor TPA or the peptide growth hormones, EGF and SGF.
Reversal of food restriction-induced inhibition of mouse skin tumor promotion by adrenalectomy.
Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase.
Reversal of the TPA-induced inhibition of gap junctional intercellular communication by Chaga mushroom (Inonotus obliquus) extracts: effects on MAP kinases.
Reverse tracing anti-thrombotic active ingredients from dried Rehmannia Radix based on multidimensional spectrum-effect relationship analysis of steaming and drying for nine cycles.
Reversible Smad-dependent signaling between tumor suppression and oncogenesis.
RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene.
Ribosomal protein S6 phosphorylation and morphological changes in response to the tumour promoter 12-O-tetradecanoylphorbol 13-acetate in primary human tumour cells, established and transformed cell lines.
Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation.
RIP4 Regulates Epidermal Differentiation and Cutaneous Inflammation.
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.
Rodent-specific hypoxia response elements enhance PAI-1 expression through HIF-1 or HIF-2 in mouse hepatoma cells.
Role for different cell proteinases in cancer invasion and cytolysis.
Role of -675 4G/5G in the Plasminogen Activator Inhibitor-1 Gene and -308G/A Tumor Necrosis Factor-? Gene Polymorphisms in Obese Argentinean Patients.
Role of activated protein C in facilitating basement membrane invasion by tumor cells.
Role of arachidonic acid release in the G2 delay induced by tumor promoter TPA in HeLa cells.
Role of bacterial lipopolysaccharide and lymphokine in the regulation of macrophage activation: correlates between secretion of plasminogen activator and tumor lysis.
Role of beta-defensin 2 and interleukin-4 receptor as stroke outcome biomarkers.
Role of Ca2+ in stimulation of DNA synthesis by epidermal growth factor and tumor promoters in cultured rat hepatocytes.
Role of cutaneous GSH in 12-O-tetradecanoyl-phorbol 13-acetate-induced mouse skin tumor promotion.
Role of cytoskeleton changes and expression of the H-ras oncogene during promotion of neoplastic transformation in mouse epidermal JB6 cells.
Role of mitogen activated protein kinases in skin tumorigenicity of patulin.
Role of parnaparin in atherosclerosis.
Role of plasminogen activator inhibitor on nephrotoxic nephritis and its modulation by tumor necrosis factor.
ROLE OF PLASMINOGEN ACTIVATOR INHIBITOR-1 IN UROKINASE'S PARADOXICAL IN VIVO TUMOR SUPPRESSING OR PROMOTING EFFECTS.
Role of plasminogen in matrix breakdown by neoplastic cells.
Role of protein kinase C in chick embryo skeletal myoblast fusion.
Role of reactive oxygen in tumor promotion: implication of superoxide anion in promotion of neoplastic transformation in JB-6 cells by TPA.
Role of the epidermal growth factor receptor and transforming growth factor alpha in mouse skin carcinogenesis.
Role of the mitogenic property and kinase activity of p60src in tumor formation by Rous sarcoma virus.
Safety issues related to the use of recombinant DNA-derived cell culture products. I. Cellular components.
Safety of Intravenous Thrombolysis for Acute Stroke in Patients with an Active Malignancy: Case Series and Review of the Literature.
Safety, dose, and timing of reteplase in treating occluded central venous catheters in children with cancer.
Salvianolic acid B attenuates plasminogen activator inhibitor type 1 production in TNF-alpha treated human umbilical vein endothelial cells.
SCUBE3 is an endogenous TGF-? receptor ligand and regulates the epithelial-mesenchymal transition in lung cancer.
Secretion of plasminogen activator and its inhibitor by glomerular epithelial cells.
Secretion of plasminogen activator by normal, reactive and neoplastic human tissues cultured in vitro.
Secretion of plasminogen activators by human colorectal and gastric tumor explants.
Selective angiography with the possibility of thrombolysis in patients with central retinal artery occlusion.
Selective decrease in serum immunoglobulin G1. A tissue nonspecific tumor marker detecting early stages of gynecologic malignant disease with high efficiency.
Selective detachment of a tetraploid subline of primary keratinocytes after treatment with the tumor promoter 12-0-tetradecanoylphorbol-13-acetate.
Selective loss of the expression of OKT-4 or Leu-3A defined antigen by 12-0-tetradecanoylphorbol-13-acetate (TPA) in human lymphoid cells.
Selective targeting of 2'-deoxy-5-fluorouridine to urokinase positive malignant cells in vitro.
SENCAR mouse skin tumorigenesis model versus other strains and stocks of mice.
SENCAR mouse skin tumors produced by promotion alone have A to G mutations in codon 61 of the c-rasHa gene.
Sensitivity of monoclonal antibodies to carcinoembryonic antigen, tissue polypeptide antigen, alpha-fetoprotein, carbohydrate antigen 50, and carbohydrate antigen 19-9 in the diagnosis of colorectal adenocarcinoma.
Sensitivity of the skin of different mouse strains to the promoting effect of 12-0-tetradecanoyl-phorbol-13-acetate.
Sequential studies of skin tumorigenesis in phosphoglycerate kinase mosaic mice: effect of resumption of promotion on regressed papillomas.
Serglycin--structure and biology.
Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
SERPINE1 intron polymorphisms affecting gene expression are associated with diffuse-type gastric cancer susceptibility.
Serpins for diagnosis and therapy in cancer.
Serpins promote cancer cell survival and vascular co-option in brain metastasis.
Serum amylase and tissue polypeptide antigen as biochemical indicators of salivary gland injury during iodine-131 therapy.
Serum biomarkers of non-neuron-endocrine origin in small-cell lung cancer: a 16-year study on carcinoembryonic antigen, tissue polypeptide antigen and lactate dehydrogenase.
Serum concentrations of tissue polypeptide antigen in patients with vulvar intraepithelial neoplasia and vulvar cancer.
Serum levels of six tumor markers in patients with benign and malignant gynecological disease.
Serum levels of T.P.A. (tissue polypeptide antigen) in gynecological malignancies.
Serum Plasminogen Activator Inhibitor-1 (PAI-1) and Tumor Necrosis Factor-Alpha (TNF-?) Levels in Obesity and Periodontal Disease.
Serum SCC-Ag in head and neck squamous cell carcinoma.
Serum tissue inhibitor of matrix metalloproteinase-1 levels are associated with mortality in patients with malignant middle cerebral artery infarction.
Serum tissue polypeptide antigen (TPA) and prostatic acid phosphatase (PAP) in patients with prostatic cancer.
Serum tissue polypeptide antigen (TPA) as tumor marker for bladder cancer.
Serum TPS versus TPA in Egyptian bladder cancer patients.
Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Serum tumour markers CA 15-3, TPA, TPS, hCGbeta and TATI in the monitoring of chemotherapy response in metastatic breast cancer.
Seven tumor markers in benign and malignant germ cell tumors of the ovary.
Severe hypertriglyceridemia and hypercholesterolemia accelerating renal injury: a novel model of type 1 diabetic hamsters induced by short-term high-fat / high-cholesterol diet and low-dose streptozotocin.
Short-term and long-term monitoring of the serum level of TPA after radical resection of gastrointestinal or lung cancer.
Should adipokines be considered in the choice of the treatment of obesity-related health problems?
Signalling role of adipose tissue: adipokines and inflammation in obesity.
Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease.
Significance of plasma tissue polypeptide antigen determination for diagnosis and follow-up of urothelial bladder cancer.
Significance of tissue polypeptide antigen (TPA) levels in nasopharyngeal cancer.
Significance of tumour markers in nasopharyngeal carcinoma.
Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
Sildenafil protects against bile duct ligation induced hepatic fibrosis in rats: Potential role for silent information regulator 1 (SIRT1).
Silencing of plasminogen activator inhibitor-1 suppresses colorectal cancer progression and liver metastasis.
Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways.
Similarity of teleocidin B and phorbol ester tumour promoters in effects on membrane receptors.
Simple phorbol esters as inhibitors of tumor promotion by TPA in mouse skin.
Single fluorescence probes along the reactive center loop reveal site-specific changes during the latency transition of PAI-1.
SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis.
SKI knockdown inhibits human melanoma tumor growth in vivo.
Skin tumor promotion is associated with increased type V collagen content in the dermis.
Skin tumorigenesis and Ki-ras and Ha-ras mutations in tumors from adult mice exposed in utero to 3'-azido-2',3'-dideoxythymidine.
Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity.
sn-1,2-Diacylglycerols mimic the effects of 12-O-tetradecanoylphorbol-13-acetate in vivo by inducing biochemical changes associated with tumor promotion in mouse epidermis.
Sodium butyrate differentially modulates plasminogen activator inhibitor type-1, urokinase plasminogen activator, and its receptor in a human colon carcinoma cell.
Sodium dodecyl sulfate induces plasminogen activator inhibitor type 2 expression in epidermal keratinocytes in vivo and in vitro.
Sodium Intake Is associated With Endothelial Damage Biomarkers and Metabolic Dysregulation.
Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers.
Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis.
Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease--preliminary report.
Some effects of the tumor promoter 12-0-tetradecanoylphorbol 13-acetate on cell interactions in vitro.
Specific amino acid dependency regulates the cellular behavior of melanoma.
Specific binding of the tumor promoter TPA in various mouse organs as measured by a "cold acetone-filter assay'.
Specific binding, stimulation of rodent urinary bladder epithelial ornithine decarboxylase, and induction of transitional cell hyperplasia by the skin tumor promoter 12-O-tetradecanoylphorbol-13-acetate.
Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro.
Specific stimulation by estradiol of tissue-type plasminogen activator production in 7,12-dimethylbenz[a]anthracene-induced rat mammary tumor cells.
Specificity and basis of the tissue polypeptide antigen.
Specificity of carcinoembryonic antigen, gastrointestinal cancer-associated antigen, tissue polypeptide antigen, fibrinopeptide A and gamma-glutamyltransferase in the diagnosis and follow-up of gastric cancer.
Specificity of response in hamster cells induced to produce plasminogen activator by the tumor promoter, 12-O-tetradecanoylphorbol-13-acetate.
Specificity of tumor markers (CEA, GICA, TPA, alpha-FP, FpA, gamma-GT) for the diagnosis of hepatic metastases from large bowel cancers.
Spitz naevi may express components of the plasminogen activation system.
Spontaneous channel activity induced by tumor promoter TPA in chick myotubes.
Spontaneous reversal of polarity of the voltage across LLC-PK1 renal epithelial cell sheets.
Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation.
Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.
Status of the gamma-glutamyl transpeptidase enzyme activity in mouse skin exposed to polyaromatic hydrocarbons and tumor promotor TPA.
Steroid stimulation of plasminogen activator production in a human breast cancer cell line (MCF-7).
Sterol and triterpene derivatives from plants inhibit the effects of a tumor promoter, and sitosterol and betulinic acid inhibit tumor formation in mouse skin two-stage carcinogenesis.
Stimulation and desensitization of tissue plasminogen activator release from human endothelial cells.
Stimulation of arachidonic acid release and prostaglandin synthesis by bryostatin 1.
Stimulation of collagenase production by rat osteosarcoma cells can occur in a subpopulation of cells.
Stimulation of DNA synthesis by tumor promoters in primary rat hepatocytes is not mediated by arachidonic acid metabolites.
Stimulation of human amnion prostaglandin E2 production by activators of protein kinase-C.
Stimulation of macrophage activity by 12-O-tetradecanoylphorbol-13-acetate.
Stimulation of macrophage prostaglandin and neutral protease production by phorbol esters as a model for the induction of vascular changes associated with tumor promotion.
Stimulation of PAI-1 and adipokines by glucose in human adipose tissue in vitro.
Stimulation of plasminogen activator activity and matrix metalloproteinases of human dental pulp-derived cells by tumor necrosis factor-alpha.
Stimulation of plasminogen activator inhibitor-1 expression in immortalized human trophoblast cells cultured under low levels of oxygen.
Stimulation of prostaglandin E2 production by 12-O-tetradecanoylphorbol 13-acetate (TPA)-type and non-TPA-type tumor promoters in macrophages and its inhibition by cycloheximide.
Stimulation of the Na/H exchanger of sea urchin eggs by phorbol ester.
Stimulatory effect of thapsigargin, a non-TPA-type tumor promoter, on arachidonic acid metabolism in the murine keratinocyte line HEL30 and on epidermal cell proliferation in vivo as compared to the effects of phorbol ester TPA.
Strain differences in mouse skin tumorigenesis by the promotion of 12-o-tetradecanoylphorbol-13-acetate or benzoyl peroxide.
Stroke in patients with cancer in the era of hyper-acute stroke intervention.
Strong Parent-Child Correlation in Circulating Vitamin B12 levels and Its Association with Inflammatory Markers in Saudi Families.
Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
Structural analysis of isosteviol and related compounds as DNA polymerase and DNA topoisomerase inhibitors.
Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1.
Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancy.
Studies on glyphosate-induced carcinogenicity in mouse skin: a proteomic approach.
Studies on rat mammary adenocarcinomas: a model for metastasis.
Studies on the action of tumour promoters and antipromoters on respiratory-tract epithelium.
Studies on the anti-tumor-promoting activity of naturally occurring substances. IV. Pd-II [(+)anomalin, (+)praeruptorin B], a seselin-type coumarin, inhibits the promotion of skin tumor formation by 12-O-tetradecanoylphorbol-13-acetate in 7,12-dimethylbenz[a]anthracene-initiated mice.
Studies on the fibrinolysis in tumor bearing mice. 3. Demonstration of the plasminogen activator in Ehrlich ascites tumor cells.
Studies on tumor induced angiogenesis.
Study of changes of obesity-related inflammatory cytokines after laparoscopic sleeve gastrectomy.
Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences.
Successful treatment of a catheter-related right atrial thrombosis with recombinant tissue plasminogen activator and heparin.
Sudden limb weakness.
Superinduction of mouse epidermal ornithine decarboxylase activity by repeated 12-o-tetradecanoylphorbol-13-acetate treatments.
Superoxide and hydrogen peroxide production by macrophages of New Zealand black mice.
Suppression of footpad reaction in mice by anthralin.
Suppression of natural tumor resistance by tumor promoters.
Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese.
Suppression of protein kinase C and nuclear oncogene expression as possible action mechanisms of cancer chemoprevention by Curcumin.
Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin.
Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice.
Suppression of the in vitro specific antibody response by 12-O-tetradecanoylphorbol-13-acetate (TPA) in the mouse.
Suppression of tumor growth and invasion in 9,10 dimethyl benz(a) anthracene induced mammary carcinoma by the plant bioflavonoid quercetin.
Suppression of tumor promoter-induced chemiluminescence in mouse epidermal cells by several inhibitors of arachidonic acid metabolism.
Suppressive activity of 12-O-tetradecanoyl phorbol-13-acetate on the induction of cytotoxic T cells in vitro.
Suppressor cell activation and enhanced skin allograft survival after tumor promotor but not initiator induced depletion of cutaneous Langerhans cells.
Susceptibility of 129/SvEv mice in two-stage carcinogenesis protocols to 12-O-tetradecanoylphorbol-13-acetate promotion.
Susceptibility to phorbol ester skin tumor promotion in (C57BL/6 x DBA/2) F1 mice is inherited as an incomplete dominant trait: evidence for multi-locus involvement.
Synergistic effect of tumor virus transformation and tumor promoter treatment on the production of plasminogen activator by chick embryo fibroblasts.
Synergistic interaction between the non-phorbol ester-type promoter mirex and 12-O-tetradecanoylphorbol-13-acetate in mouse skin tumor promotion.
Synergistic stimulation of histamine release from rat peritoneal mast cells by 12-O-tetradecanoylphorbol 13-acetate (TPA)-type and non-TPA-type tumor promoters.
Synthesis and biological activity of N,N-dialkylaminoalkyl-substituted bisindolyl and diphenyl pyrazolone derivatives.
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Synthesis, characterization and biological evaluation of Co(III) complexes with quinolone drugs.
Synthesis, characterization and cytotoxicity studies of Co(III)-flavonolato complexes.
Synthetic lipid second messenger sn-1,2-didecanoylglycerol: a complete tumor promoter in mouse skin.
Synthetic urokinase inhibitors as potential anti-invasive drugs.
Synthetic urokinase inhibitors as potential antitumor drugs.
Systemic administration of autologous adipose-derived mesenchymal stem cells alleviates hepatic ischemia-reperfusion injury in rats.
Systemic inflammatory markers, periodontal diseases, and periodontal infections in an elderly population.
Systemic thrombolysis in anterior spinal artery syndrome: what has to be considered?
Systemic two-stage carcinogenesis in the epithelium of the forestomach of mice using 7,12-dimethylbenz(a)anthracene as initiator and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate as promoter.
T1 breast cancer: identification of patients at low risk of axillary lymph node metastases.
TAF test in primary esophageal carcinoma: comparison with other tumor markers.
Targeted alpha therapy for cancer.
Targeted proteomics driven verification of biomarker candidates associated with breast cancer aggressiveness.
Targeting invasion induction as a therapeutic strategy for the treatment of cancer.
Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin.
Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model.
Targeting urokinase-type plasminogen activator and its receptor for cancer therapy.
Teleocidin and phorbol ester tumor promoters exert similar mitogenic effects on human lymphocytes.
Teleocidin, lyngbyatoxin A and their hydrogenated derivatives, possible tumor promoters, induce terminal differentiation in HL-60 cells.
Telomere length in relation to insulin resistance, inflammation and obesity among Arab youth.
Testosterone and atherosclerosis in aging men: purported association and clinical implications.
TGF-? induces p53/Smads complex formation in the PAI-1 promoter to activate transcription.
TGF-?-mediated regulation of plasminogen activators is human telomerase reverse transcriptase dependent in cancer cells.
Thapsigargin, a histamine secretagogue, is a non-12-O-tetradecanoylphorbol-13-acetate (TPA) type tumor promoter in two-stage mouse skin carcinogenesis.
Thapsigargin, a weak skin tumor promoter, alters the growth and differentiation of mouse keratinocytes in culture.
The action of the tumour promoter, TPA, on mutagenesis induced by different agents (UV light, chemical and viral mutagens).
The active fraction of plasmatic plasminogen activator inhibitor type 1 as a possible indicator of increased risk for metastatic melanoma.
The alpha isoform of protein kinase C mediates phorbol ester-induced growth inhibition and p21cip1 induction in HC11 mammary epithelial cells.
The Apparent uPA/PAI-1 Paradox in Cancer: More than Meets the Eye.
The application value of the detection of the level of tissue polypeptide antigen, ovarian cancer antigen X1, cathepsin L and CA125 on the diagnosis of epithelial ovarian cancer.
The ARE-binding protein Tristetraprolin (TTP) is a novel target and mediator of calcineurin tumor suppressing function in the skin.
The Aryl Hydrocarbon Receptor Nuclear Translocator (Arnt) is required for tumor initiation by benzo(a)pyrene.
The association between Annexin A2 and epithelial cell adhesion molecule in breast cancer cells.
The Association between Body Mass Index and Plasma Cytokine Levels in Patients with Acute Lung Injury.
The association between systemic inflammation and cognitive performance in the elderly: the Sydney Memory and Ageing Study.
The C-D interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF-alpha induced apoptosis.
The c-ets proto-oncogenes encode transcription factors that cooperate with c-Fos and c-Jun for transcriptional activation.
The carcinogenic effect of TPA (12-0-tetradecanoylphorbol-13-acetate) when applied to the skin of hairless mice.
The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease.
The clinical significance of serum adipocytokines level in patients with lung cancer.
The clinical value of tissue polypeptide antigen in patients with gynecologic tumors.
The close relationship between DNA replication and the selection of differentiation lineages of human erythroleukemia cell lines K562, HEL, and TF1 into either erythroid or megakaryocytic lineages.
The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA.
The Concentration of Selected Cancer Markers (TPA, TPS, Cyfra 21-1, CEA) in Workers Occupationally Exposed to Arsenic (As) and Some Heavy Metals (Pb, Cd) During a Two-Year Observation Study.
The concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors.
The differential effects of retinoic acid and 7,8-benzoflavone on the induction of mouse skin tumors by the initiation-promotion protocol and by the complete carcinogenesis process.
The double role of epicardial adipose tissue as pro- and anti-inflammatory organ.
The effect of 12-O-tetradecanoylphorbol-13-acetate and other tumor promoters on the colony formation of rat tracheal epithelial cells in culture.
The effect of a tumor promotor, 12-O-tetradecanoyl-phorbol-13-acetate (TPA), on sister-chromatid exchange formation in cultured Chinese hamster cells.
The effect of cyclooxygenase-2 overexpression on skin carcinogenesis is context dependent.
The effect of dapagliflozin treatment on epicardial adipose tissue volume.
The effect of dietary supplementation with limonene or myo-inositol on the induction of neoplasia and matrix metalloproteinase and plasminogen activator activities in accessory sex organs of male Lobund-Wistar rats.
The effect of disease activity related cytokines on the fibrinolytic potential and cICAM-1 expression in rheumatoid arthritis.
The effect of interleukin-4 on tumour necrosis factor-alpha induced expression of tissue factor and plasminogen activator inhibitor-1 in human umbilical vein endothelial cells.
The effect of phorbol esters on tumor cell sensitivity to macrophage-mediated cytostasis.
The effect of promoters on 1,2-dimethylhydrazine-induced colon carcinogenesis.
The effect of short-term cold exposure on risk factors for cardiovascular disease.
The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy.
The effect of the tumour promoter 12-O-tetradecanoyl-phorbol-13-acetate (TPA) on UV- and MNNG-induced sister chromatid exchanges in mammalian cells.
The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects.
The effect of TNP-470 on cell proliferation and urokinase-type plasminogen activator and its inhibitor in human lung cancer cell lines.
The effect of tranexamic acid on growth and spread of an experimental tumor model.
The effects of angiotensin receptor blockers vs. calcium channel blockers on the acute exercise-induced inflammatory and thrombotic response.
The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
The effects of teleocidin and aplysiatoxin tumor promoters on epithelial tight junctions and transepithelial permeability: comparison to phorbol esters.
The effects of tumor promoters on HTLV-1 expression in a low-virus producer and a non-virus producer cell line.
The endotoxin-induced plasminogen activator inhibitor-1 increase in rabbits is not tumor necrosis factor-alpha dependent and can occur in the absence of interleukin-1beta.
The expression of integrin alpha 2 beta 1 and attachment to type I collagen of melanoma cells are preferentially induced by tumour promoter, TPA (12-O-tetradecanoyl phorbol-13-acetate).
The fibrinolytic factor tPA drives LRP1-mediated melanoma growth and metastasis.
The fibrinolytic system in experimental prostate tumor.
The fibrinolytic system in the hemolytic uremic syndrome: in vivo and in vitro studies.
The genetic control of chemically and radiation-induced skin tumorigenesis: a study with carcinogenesis-susceptible and carcinogenesis-resistant mice.
The genotoxic air pollutant 3-nitrobenzanthrone and its reactive metabolite N-hydroxy-3-aminobenzanthrone lack initiating and complete carcinogenic activity in NMRI mouse skin.
The impact of concomitant administration of vanadium and insulin on endothelial dysfunction markers (PAI-1 and ET-1) in type 1 diabetic rats.
The impact of gene polymorphisms in angiotensin receptor 1 and aldosterone synthase in peritoneal dialysis patients.
The importance of tumor markers in oral pathology. II. Cell membrane and cytoplasmic antigens as tumour markers.
The in vitro effect of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate on Sertoli cell morphology.
The induction of epidermal transglutaminase and terminal differentiation by tumor promoters in cultured epidermal cells.
The induction of ornithine decarboxylase by the tumor promoter TPA is controlled at the post-transcriptional level in murine Swiss 3T3 fibroblasts.
The induction of senescence-like growth arrest by protein kinase C-activating diterpene esters in solid tumor cells.
The influence of a hyperthermia treatment on chemically induced tumor initiation and progression in mouse skin.
The Influence of Lipid and Proinflammatory Status on Maternal Uterine Blood Flow in Women With Late Onset Gestational Diabetes.
The influence of platelet membranes on tumour cell behaviour.
The inhibitor reacting with a tumour cell surface protease can be exchanged with plasminogen activator inhibitor (PAI-1).
The inhibitory effect of PGE2 on T cell activation is not associated with inhibition of PKC translocation.
The interaction of plasminogen activator with a reconstituted basement membrane matrix and extracellular macromolecules produced by cultured epithelial cells.
The involvement of mitogen-activated protein kinases in the 1?,25-dihydroxy-cholecalciferol-induced inhibition of adipocyte differentiation in vitro.
The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1.
The kringle domain of tissue-type plasminogen activator inhibits extracellular matrix-induced adhesion and migration of endothelial cells.
The kringle domain of tissue-type plasminogen activator inhibits in vivo tumor growth.
The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy.
The malignancy index is a robust predictor of prostate cancer.
The mammographic appearance of breast carcinomas of invasive ductal type: relationship with clinicopathological parameters, biological features and prognosis.
The mechanical and pharmacological regulation of glioblastoma cell migration in 3D matrices.
The mechanism and significance of synergistic induction of the expression of plasminogen activator inhibitor-1 by glucocorticoid and transforming growth factor beta in human ovarian cancer cells.
The mechanism of skin tumor promotion caused by phorbol esters: possible involvement of arachidonic acid cascade/lipoxygenase, protein kinase C and calcium/calmodulin systems.
The mechanisms by which polyamines accelerate tumor spread.
The Merkel Cell Polyomavirus T Antigens Function as Tumor Promoters in Murine Skin.
The metabolic syndrome - an ongoing story.
The metabolic syndrome and adipocytokines.
The metabolic syndrome is associated with circulating adipokines in older adults across a wide range of adiposity.
The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer.
The morphological oncogenic signature. Reorganization of epithelial cytoarchitecture and metabolic regulation by tumor promoters and by transformation.
The multiplex bead array approach to identifying serum biomarkers associated with breast cancer.
The murine gene encoding secreted phosphoprotein 1 (osteopontin): promoter structure, activity, and induction in vivo by estrogen and progesterone.
The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas.
The Naïve Murine Cornea as a Model System to Identify Novel Endogenous Regulators of Lymphangiogenesis: TRAIL and rtPA.
The NGFI-B family of transcription factors regulates expression of 3beta-hydroxysteroid dehydrogenase type 2 in the human ovary.
The nucleotide-permeable Escherichia coli cell, a sensitive DNA repair indicator for carcinogens, mutagens, and antitumor agents binding covalently to DNA.
The p38 SAPK pathway regulates the expression of the MMP-9 collagenase via AP-1-dependent promoter activation.
The phorbol ester, TPA, increases transepithelial epidermal growth factor flux.
The plasmin system in human colonic tumors: an immunofluorescence study.
The plasminogen activation system in melanoma cell lines and in melanocytic lesions.
The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology.
The plasminogen activator inhibitor "paradox" in cancer.
The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies.
The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.
The plasminogen activator system and cancer.
The Plasminogen System in Microdissected Colonic Mucosa Distant from an Isolated Adenoma.
The plasminogen-plasmin system in malignancy.
The possible separation of 12-O-tetradecanoylphorbol-13-acetate-induced skin inflammation and hyperplasia by compound A.
The potent anti-tumor-promoting agent isoliquiritigenin.
The presence of p53 transformation-related protein in Ab-MuLV transformed cells is required for their development into lethal tumors in mice.
The preventive role of breadfruit against inflammation-associated epithelial carcinogenesis in mice.
The prognostic value of BCAR1 in patients with primary breast cancer.
The prognostic value of TPA and SCC in squamous cell carcinoma of the cervix.
The prognostic value of vascular endothelial growth factor, urokinase plasminogen activator and plasminogen activator inhibitor-1 in node-negative breast cancer.
The proliferative response of low-density human cell cultures to tumor promoters and its relevance to carcinogenic mechanisms in vitro.
The protein kinase C activator L-alpha-dioctanoylglycerol: a potent stage II mouse skin tumor promoter.
The protein kinase C inhibitor, bisindolylmaleimide, inhibits the TPA-induced but not the TNF-induced increase in LLC-PK1 transepithelial permeability.
The reduction of tumor initiating activity and cell mediated mutagenicity of dimethylbenz[a]anthracene by a copper coordination compound.
The regulation of inflammation-related genes after palmitic acid and DHA treatments is not mediated by DNA methylation.
The relation of adipose tissue to cardiometabolic risk.
The relationship between tumor promoter binding and Epstein-Barr virus induction in human lymphoblastoid cell lines.
The relevance of gap junctions to stage I tumor promotion in mouse epidermis.
The reverse experiment in two-stage skin carcinogenesis. It cannot be genuinely performed, but when approximated, it is not innocuous.
The Risk Factors for Death within 6 Months After Ischemic Stroke in Patients with Cancer.
The role of calcium in macrophage chemotaxis to the phorbol ester tumor promoter TPA.
The role of cAMP and calcium in the stimulation of proliferation of immature erythroblasts by erythropoietin.
The role of cysteine and serine proteases in colorectal carcinoma.
The role of plasminogen activator receptor in cancer invasion and dormancy.
The role of plasminogen-plasmin system in cancer.
The role of prostaglandin E1 in ornithine decarboxylase induction by tumor promoters.
The role of protein kinase C in migration of rat glioma cells from spheroid cultures.
The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma.
The Role of Smoking and Gingival Crevicular Fluid Markers on Coronally Advanced Flap Outcomes.
The role of thrombospondin-1 in tumor progression and angiogenesis.
The role of TNF-? and PAI-1 gene polymorphisms in familial Mediterranean fever.
The role of tumour markers (CEA, TPA, CA 19-9) in colon and rectum carcinomas.
The root bark of Morus alba L. regulates tumor-associated macrophages by blocking recruitment and M2 polarization of macrophages.
The state of differentiation of HT-29 colon carcinoma cells alters the secretion of cathepsin D and of plasminogen activator.
The status of nuclear medicine techniques in the diagnosis of bone metastases in breast cancer.
The synthesis of specific proteins in adult mouse epidermis during phases of proliferation and differentiation induced by the tumor promoter TPA, and in basal and differentiating layers of neonatal mouse epidermis.
The Tg.AC Transgenic Mouse as a Screening Tool for Anticarcinogens: Broccoli Juice Protected Against 12-O-Tetradecanoylphorbol-13-Acetate (TPA) But Not Benzo[a]Pyrene (B[a]P)-Induced Skin Tumors.
The transformed phenotype in culture and tumorigenicity of Fischer rat fibroblast cells (FR3T3) transformed with bovine papilloma virus type 1.
The transient increase of tight junction permeability induced by bryostatin 1 correlates with rapid downregulation of protein kinase C-alpha.
The tumor markers CEA, TPA and CA 19-9 in gastric cancer.
The tumor markers TPA, TPS, TPACYK and CYFRA 21-1 react differently with the keratins 8, 18 and 19.
The tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA) provokes a prolonged morphologic response and ERK activation in Tsc2-null renal tumor cells.
The tumor promoter phorbol-12,13-dibutyrate [P(Bu)2] stimulates cytotoxic activity of human blood lymphocytes.
The tumor promoter TPA enhances benzo[a]pyrene and benzo[a]pyrene diolepoxide mutagenesis in Big Blue mouse skin.
The tumor promoters TPA, phenobarbital, and nafenopin and the prostaglandins of A, E, and F series overcome the G1/S block imposed by extracellular calcium deprivation on neonatal rat hepatocytes.
The tumor-initiating and -promoting effects of ionizing radiations in mouse skin.
The tumour promoter 12-O-tetradecanoylphorbol-13-acetate (TPA) induces the production of lymphocyte-activating factors (LAP) in human lymphocyte cultures.
The tumour promoter 12-O-tetradecanoylphorbol-13-acetate increases the activities of some peroxisome-associated enzymes in in vitro cell culture.
The tumour promoter TPA does not affect mutation to ouabain resistance in L5178Y mouse lymphoma cells.
The tumourigenic and carcinogenic effect of 12-0-tetradecanoylphorbol-13-acetate when applied to the skin of BALB/cA and hairless (hr/hr) mice.
The urokinase plasminogen activator and its receptor: role in cell growth and apoptosis.
The urokinase plasminogen activator system in breast cancer invasion and metastasis.
The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis.
The urokinase type of plasminogen activator in cancer of digestive tracts.
The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group.
The weak immunosuppressant cyclosporine D as well as the immunologically inactive cyclosporine H are potent inhibitors in vivo of phorbol ester TPA-induced biological effects in mouse skin and of Ca2+/calmodulin dependent EF-2 phosphorylation in vitro.
Therapeutic effect of Cerebrolysin on reducing impaired cerebral endothelial cell permeability.
Therapeutical effect of activated human macrophages on a human tumor line growing in nude mice.
Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation.
Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
Three-stage tumorigenesis in mouse skin: DNA synthesis as a prerequisite for the conversion stage induced by TPA prior to initiation.
Thrombin-antithrombin III complex, proinflammatory cytokines, and fibrinolytic indices for assessing the severity of inflammation in pleural effusions.
Thrombolytic therapy in older acute ischemic stroke patients with gastrointestinal malignancy or recent bleeding.
Thromboplastic and fibrinolytic activities of V2 and V7 carcinomas of rabbit, with special reference to fibrin deposition and thrombus formation in the tumors.
Thrombospondin (TSP) and transforming growth factor beta 1 (TGF-beta) promote human A549 lung carcinoma cell plasminogen activator inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro.
Thyroid function, endothelium, and inflammation in hemodialyzed patients: possible relations?
Tissue and serum TPA in subjects at risk for bladder cancer.
Tissue concentrations of tissue polypeptide antigen (TPA) and prostatic specific antigen (PSA) in 42 patients with prostatic carcinoma.
Tissue extraction procedures for investigation of urokinase plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in human breast carcinomas.
Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer.
Tissue plasminogen activator and inhibitors of fibrinolysis in malignant melanoma.
Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women.
Tissue plasminogen activator expression in meningiomas and glioblastomas.
Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumors and contribution to cancer progression.
Tissue plasminogen activator increases canine endothelial cell proliferation rate through a plasmin-independent, receptor-mediated mechanism.
Tissue plasminogen activator induces microglial inflammation via a noncatalytic molecular mechanism involving activation of mitogen-activated protein kinases and Akt signaling pathways and AnnexinA2 and Galectin-1 receptors.
Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2.
Tissue plasminogen activator is a potent activator of PDGF-CC.
Tissue plasminogen activator is released into cultured medium by cultured human uveal melanocytes.
Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells.
Tissue Plasminogen Activator Levels and Risk of Breast Cancer in a Case-Cohort Study on Italian Women: Results from the Moli-sani Study.
Tissue Plasminogen Activator Promotes TXNIP-NLRP3 Inflammasome Activation after Hyperglycemic Stroke in Mice.
Tissue polypeptide antigen & interleukin-6: Are their serum levels a predictor for response to chemotherapy in breast cancer?
Tissue polypeptide antigen (TPA) as a predictor for genitourinary cancers and their metastases.
Tissue polypeptide antigen (TPA) as a prognostic aid in human prostatic carcinoma.
Tissue polypeptide antigen (TPA) in urinary bladder cancer cytology: a follow-up study.
Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: re-evaluation of a human tumor marker.
Tissue polypeptide antigen (TPA) modifications in hepatic cirrhosis, aggressive chronic hepatitis, persistent chronic hepatitis, and in minimal pathology.
Tissue polypeptide antigen (TPA), some cytokeratins and epithelial membrane antigen (EMA) in normal, inflamed and malignant urothelium.
Tissue polypeptide antigen (TPA): usefulness in urological neoplasia.
Tissue polypeptide antigen and carcinoembryonic antigen as tumor markers in lung cancer.
Tissue polypeptide antigen and carcinoembryonic antigen in colon tumors: serum levels and immunohistochemical localization.
Tissue polypeptide antigen and carcinoembryonic antigen lack diagnostic accuracy in urothelial carcinoma.
Tissue polypeptide antigen and keratins in cervical neoplasia.
Tissue polypeptide antigen expression in human prostate tumors.
Tissue polypeptide antigen immunoreactivity in human semen.
Tissue polypeptide antigen in breast cancer cytosol: a new effective prognostic indicator.
Tissue polypeptide antigen in normal and neoplastic urinary bladder. Preliminary reports.
Tissue polypeptide antigen, galactosyltransferase isoenzyme II and pancreatic oncofetal antigen serum determination: role in pancreatic cancer diagnosis.
Tissue- and urokinase-type plasminogen activators and type 1 plasminogen activator inhibitor in melanomas and benign skin pigment neoplasms.
Tissue-type plasminogen activator (tPA) content in colorectal cancer and in surrounding mucosa: relationship with clinicopathologic parameters and prognostic significance.
Tissue-type plasminogen activator (tPA) in breast cancer: relationship with clinicopathological parameters and prognostic significance.
Tissue-type plasminogen activator activity in morphologically normal tissues adjacent to gastrointestinal carcinomas is associated with the degree of tumor progression.
Tissue-type plasminogen activator has a neuroprotective effect in the ischemic brain mediated by neuronal TNF-?
Tissue-type plasminogen activator has antiangiogenic properties without effect on tumor growth in a rat C6 glioma model.
Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin.
Tissue-type plasminogen activator is involved in skeletal metastasis from human breast cancer.
Tissue-type plasminogen activator is upregulated in metastatic breast cancer cells exposed to insulin-like growth factor-I.
Tissue-type plasminogen activator, a new prognostic marker in breast cancer.
Tissue-type plasminogen activator-induced fibrinolysis is enhanced in patients with breast, lung, pancreas and colon cancer.
TNF-alpha mediated suppression of tissue type plasminogen activator expression in vascular endothelial cells is NF-kappaB- and p38 MAPK-dependent.
Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin.
Topically applied vitamin E prevents massive cutaneous inflammatory and oxidative stress responses induced by double application of 12-O-tetradecanoylphorbol-13-acetate (TPA) in mice.
Toxicodendron vernicifluum Stokes extract inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice.
Toxicokinetics of tumour promoters of mouse skin. II. Metabolism of the tumour promoter 12-O-tetradecanoylphorbol-13-acetate in mouse skin and biological activities of metabolites.
Toxicological review and oral risk assessment of terephthalic acid (TPA) and its esters: A category approach.
TPA (12-O-tetradecanoyl-phorbol-13-acetate) as a carcinogen for mouse skin. A positive dose-response relationship.
TPA and CA 15.3 measurements for breast cancer monitoring in a routine setting.
TPA and CK-BB: new tumor markers in leptomeningeal carcinomatosis secondary to breast cancer.
TPA decreases the p53 response to benzo[a]pyrene-DNA adducts in vivo in mouse skin.
TPA induces simultaneous alterations in the synthesis and organization of vimentin.
TPA prognostic value in superficial bladder cancer.
TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
TPA, tumor promoter-induced suppression of immunoglobulin secretion in human blood lymphocytes.
TPA-enhanced invasion of Matrigel associated with augmentation of cell motility but not metalloproteinase activity in a highly metastatic variant (L-10) of human rectal adenocarcinoma cell line RCM-1.
TPA-induced differentiation of human rhabdomyosarcoma cells involves dephosphorylation and nuclear accumulation of mutant P53.
TPA-induced differentiation of human rhabdomyosarcoma cells: expression of the myogenic regulatory factors.
TPA-induced inhibition of the expression of differentiative traits in cultured myotubes: dependence on protein synthesis.
TPA-induction of c-fos mRNA during the cell cycle of WI-38 human fibroblasts.
Traditional Chinese medicine, Xue-Fu-Zhu-Yu decoction, potentiates tissue plasminogen activator against thromboembolic stroke in rats.
Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial.
Transactivation of the epidermal growth factor receptor is involved in 12-O-tetradecanoylphorbol-13-acetate-induced signal transduction.
Transcriptional activation of the urokinase receptor gene in invasive colon cancer.
Transdermal Progesterone: Effects on Menopausal Symptoms and on Thrombotic, Anticoagulant, and Inflammatory Factors in Postmenopausal Women.
Transformation and tumor promoter sensitive phosphoproteins in JB-6 mouse epidermal cells: one is also sensitive to heat stress.
Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition.
Transformation of human keratinocytes by SV40 virus alters their response to the tumor promoter TPA.
Transformation-related cellular protein p53: increased level in untransformed rat cells following treatment with the tumorpromoter, tetradecanoylphorbol-acetate.
Transforming growth factor beta 1 and sodium butyrate differentially modulate urokinase plasminogen activator and plasminogen activator inhibitor-1 in human breast normal and cancer cells.
Transforming growth factor beta1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro.
Transforming growth factor beta1 stimulates urokinase plasminogen activator system on prostate cancer cells.
Transforming growth factor-alpha promotes tumor markers secretion from human ovarian cancers in vitro.
Transforming Growth Factor-Beta Signaling Leads to uPA/PAI-1 Activation and Metastasis: A Study on Human Breast Cancer Tissues.
Transforming growth factor-beta1 induces tumor stroma and reduces tumor infiltrate in cervical cancer.
Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.
Transforming growth factor-beta1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells.
Transforming growth factor-beta1-dependent activation of Smad2/3 and up-regulation of PAI-1 expression is negatively regulated by Src in SKOV-3 human ovarian cancer cells.
Transgenic mice overexpressing protein kinase C epsilon in their epidermis exhibit reduced papilloma burden but enhanced carcinoma formation after tumor promotion.
Transgenic mice overexpressing protein kinase Cdelta in the epidermis are resistant to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Transient elevation of ribonucleotide reductase activity, M2 mRNA and M2 protein in BALB/c 3T3 fibroblasts in the presence of 12-O-tetradecanoylphorbol-13-acetate.
Transmaternal modification of the Berenblum/Mottram experiment in mice.
Transmaternal variation of the Berenblum experiment with NMRI-mice: tumour initiation with DMBA via mothers milk followed by promotion with the phorbol ester TPA.
Transplacental and transgeneration carcinogenic effect of 7,12-dimethylbenz[a]anthracene: relationship with ras oncogene activation.
Transplacental arsenic plus postnatal 12-O-teradecanoyl phorbol-13-acetate exposures associated with hepatocarcinogenesis induce similar aberrant gene expression patterns in male and female mouse liver.
Transplacental carcinogenic potential of the carbamate fungicide mancozeb.
Transplacental carcinogenicity of cisplatin: initiation of skin tumors and induction of other preneoplastic and neoplastic lesions in SENCAR mice.
Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients.
Treatment of intact hepatocytes with either the phorbol ester TPA or glucagon elicits the phosphorylation and functional inactivation of the inhibitory guanine nucleotide regulatory protein Gi.
Treatment of intraventricular hemorrhage with tissue plasminogen activator.
Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
Treatment with dextromethorphan improves endothelial function, inflammation and oxidative stress in male heavy smokers.
Triethylenemelamine: an initiator of two-stage carcinogenesis in mouse skin which lacks the potential of a complete carcinogen.
Triggering of neutrophil cytotoxicity against an antibody-coated tumour target by TPA.
Triterpene acids from Poria cocos and their anti-tumor-promoting effects.
Triterpene acids from the leaves of Perilla frutescens and their anti-inflammatory and antitumor-promoting effects.
Triterpenoid corosolic acid modulates global CpG methylation and transcriptome of tumor promotor TPA induced mouse epidermal JB6 P+ cells.
Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2.
Tumor associated proteases -- prognostic markers of colorectal cancer.
Tumor cell dissemination in colon cancer does not predict extrahepatic recurrence in patients undergoing surgery for hepatic metastases.
Tumor copromoting activity of gamma-interferon in the murine skin multistage carcinogenesis model.
Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
Tumor growth and metastases in malignant disease. A review.
Tumor initiation in mouse skin by cutting oils.
Tumor invasion, proteolysis, and angiogenesis.
Tumor marker determination after orthotopic heart transplantation.
Tumor marker determinations.
Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.
Tumor markers (CEA, TPA and CA 19-9) in urine of bladder cancer patients.
Tumor markers and lung cancer: correlation between serum and bronchial secretion levels of CEA, TPA, CanAg CA-50, NSE and ferritin.
Tumor markers as useful predictors of survival rate after exploratory laparotomy for liver malignancies.
Tumor markers for cancer detection. II.
Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer.
Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9.
Tumor markers in detection of lung cancer.
Tumor markers in hypertensive disorders of pregnancy.
Tumor markers in pleural effusions.
Tumor markers in serum of patients with primary squamous cell carcinoma of the esophagus.
Tumor markers in staging and prognosis of colorectal carcinoma.
Tumor necrosis factor (TNF) stimulates plasminogen activator inhibitor (PAI) production by endothelial cells and decreases blood fibrinolytic activity in the rat.
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site.
Tumor necrosis factor alpha inhibits rat granulosa cell plasminogen activator activity in vitro during follicular development.
Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1.
Tumor necrosis factor alpha is involved in the induction of plasminogen activator inhibitor-1 by endotoxin.
Tumor necrosis factor alpha up-regulates in an autocrine manner the synthesis of plasminogen activator inhibitor type-1 during induction of monocytic differentiation of human HL-60 leukemia cells.
Tumor necrosis factor and epidermal growth factor modulate migration of human microvascular endothelial cells and production of tissue-type plasminogen activator and its inhibitor.
Tumor necrosis factor increases the production of plasminogen activator inhibitor in human endothelial cells in vitro and in rats in vivo.
Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells.
Tumor necrosis factor production during human renal allograft rejection is associated with depression of plasma protein C and free protein S levels and decreased intragraft thrombomodulin expression.
Tumor Necrosis Factor-? Regulates Plasminogen Activator Inhibitor-1 in Rat Testicular Peritubular Cells.
Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells.
Tumor necrosis factor-alpha inhibits trophoblast migration through elevation of plasminogen activator inhibitor-1 in first-trimester villous explant cultures.
Tumor necrosis factor-alpha regulates mRNA for urokinase-type plasminogen activator and type-1 plasminogen activator inhibitor in human neoplastic cell lines.
Tumor necrosis factor-alpha regulates plasminogen activator inhibitor-1 in rat testicular peritubular cells.
Tumor necrosis factor-alpha stimulates the biosynthesis of matrix metalloproteinases and plasminogen activator in cultured human chorionic cells.
Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line.
Tumor necrosis factor-alpha-induced release of plasminogen activator inhibitor-1 from human umbilical vein endothelial cells: involvement of intracellular ceramide signaling event.
Tumor production in the nude mouse, fibrinolytic activity and cross-reactivity with antimelanoma sera of various human tumor cell lines.
Tumor production of angiostatin is enhanced after exposure to TNF-alpha.
Tumor progression in vitro: tumor-promoter-induced reversible decrease in natural immune susceptibility.
Tumor progression of murine epidermal cells after treatment in vitro with 12-O-tetradecanoylphorbol-13-acetate or retinoic acid.
Tumor promoter 12-O-tetradecanoylphorbol 13-acetate alters state, fluidity and hydration of 1,2-diacyl-sn-glycero-3-phosphocholine bilayers.
Tumor promoter 12-O-tetradecanoylphorbol 13-acetate stimulates simian virus 40 induction by DNA-damaging agents and tumor initiators.
Tumor promoter 12-O-tetradecanoylphorbol 13-acetate, like epidermal growth factor, stimulates cell proliferation and inhibits differentiation of mouse mammary epithelial cells in culture.
Tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced chromosome aberrations in mouse keratinocyte cell lines: a possible genetic mechanism of tumor promotion.
Tumor promoter 12-O-tetradecanoylphorbol-13-acetate receptors in normal human transitional epithelial cells.
Tumor promoter PMA stimulates the synthesis and secretion of mouse pro-urokinase in MSV-transformed 3T3 cells: this is mediated by an increase in urokinase mRNA content.
Tumor promoter TPA activates Wnt/?-catenin signaling in a casein kinase 1-dependent manner.
Tumor promoter TPA increases initiation of replication on DNA injected into xenopus eggs.
Tumor promoter TPA mimics irradiation effects on the cell cycle of HeLa cells.
Tumor promoter TPA stimulates MMP-9 secretion from human keratinocytes by activation of superoxide-producing NADPH oxidase.
Tumor promoter, TPA, enhances replication of HTLV-III/LAV.
Tumor promoter-mediated effects on Friend leukemia cells induced by actinomycin D: flow microfluorometry analysis and erythroid differentiation.
Tumor promoter-stimulated synthesis of Mason-:Pfizer monkey virus.
Tumor promoter-stimulated translocation of glucose transport system in mouse embryo fibroblast Swiss 3T3 cell.
Tumor promoters alter the temporal program of adenovirus replication in human cells.
Tumor promoters and epidermal growth factor stimulate anchorage-independent growth of adenovirus-tranformed rat embryo cells.
Tumor promoters cause a rapid and reversible inhibition of the formation and maintenance of electrical cell coupling in culture.
Tumor promoters in conjunction with calcium ionophores mimic antigenic stimulation by reactivation of alloantigen-primed murine T lymphocytes.
Tumor promoters increase the synthesis of a 32,000-dalton protein in BALB/c 3T3 cells.
Tumor promoters induce a specific morphological signature in the nuclear matrix-intermediate filament scaffold of Madin-Darby canine kidney (MDCK) cell colonies.
Tumor promoters induce changes in the chick embryo fibroblast cytoskeleton.
Tumor promotion resistant cells are deficient in AP-1 DNA binding, JunD DNA binding and JunD expression and form different AP-1-DNA complexes than promotion sensitive cells.
Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer.
Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.
Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.
Tumor-associated urokinase-type plasminogen activator: significance in breast cancer.
Tumor-initiating activity of the (+)-(S,S)- and (-)-(R,R)- enantiomers of trans-11,12-dihydroxy-11,12-dihydrodibenzo[a,l]pyrene in mouse skin.
Tumor-initiating and promoting activities of di(2-ethylhexyl) phthalate in vivo and in vitro.
Tumor-promoter-enhanced destruction of noninvasive human benign colon tumor cells by cocultivated carcinoma cells.
Tumor-promoting diterpene esters prevent macrophage activation and suppress macrophage tumoricidal capacity.
Tumor-promoting phorbol esters and cell proliferation stimulate secretion of basement membrane (type IV) collagen-degrading metalloproteinase by human fibroblasts.
Tumor-promoting phorbol esters cause a stable reduction of dermal collagen in mouse skin.
Tumor-promoting phorbol esters induce angiogenesis in vitro.
Tumour initiatory activity of a herbicide diuron on mouse skin.
Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway.
Tumour necrosis factor-mediated release of plasminogen activator inhibitor 1 by human peritoneal mesothelial cells.
Tumour promoter TPA enhances transformation of human leukocytes by Epstein-Barr virus.
Tumour promoter-induced release and metabolism of arachidonic acid: Comparison between mouse and human epidermal cells.
Tumour promotor induces plasminogen activator.
Tumour vascularity and proliferation: clear evidence of a close relationship.
Tumour-promoting activity of ninhydrin on mouse skin.
Tumour-promoting effect of chilli extract in BALB/c mice.
Tumour-promoting phorbol esters inhibit DNA synthesis and enhance virus-induced interferon production in a human lymphoma cell line.
Two diallyl sulphides derived from garlic inhibit meticillin-resistant Staphylococcus aureus infection in diabetic mice.
Two new anti-tumor promoting serratane-type triterpenoids from the stem bark of Picea jezoensis var. jezoensis.
Two tumor promoters, 12-O-tetradecanoylphorbol-13-acetate and thapsigargin, act synergistically via distinct signaling pathways to stimulate gene expression.
Two waves of transcriptomic changes in periovulatory human granulosa cells.
Two-Port Access Staging Laparoscopy for Gynecologic Cancers: A Pilot Study.
Two-port access versus conventional staging laparoscopy for endometrial cancer.
Two-stage carcinogenesis in NMRI mice: intravaginal application of 7,12-dimethylbenz[a]anthracene as initiator followed by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate as promoter.
Two-stage carcinogenesis with rat embryo cells in tissue culture.
Two-stage skin carcinogenesis by systemic initiation of pregnant mice with 7,12-dimethylbenz(a)anthracene during gestation days 6-20 and postnatal promotion of the F 1-generation with the phorbol ester 12-tetradecanoylphorbol-13-acetate.
Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: the EPICOR study.
Type-1 plasminogen activator inhibitor in human renal cell carcinoma.
Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis.
Ultrastructural analysis of epidermal hyperplasia induced by multiple 12-0-tetradecanoyl-phorbol-13-acetate (TPA) treatment of mouse skin.
Ultrastructural pathology of nitrosamine induced hamster cheek pouch tumours exposed to TPA.
Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor.
Unique features of the okadaic acid activity class of tumor promoters.
Unlinked control of multiple glucocorticoid-induced processes in HTC cells.
Untypical autoimmune pancreatitis and pancreatic cancer: differential diagnosis experiences extracted from misdiagnose of two cases.
Up-regulation of p21(WAF1/CIP1) levels leads to growth suppression of prostate cancer cell lines.
Up-Regulation of PAI-1 and Down-Regulation of uPA Are Involved in Suppression of Invasiveness and Motility of Hepatocellular Carcinoma Cells by a Natural Compound Berberine.
Up-to-date information on polymyxin B-immobilized fiber column direct hemoperfusion for septic shock.
uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.
uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial.
Upregulated MiR-9-5p Protects Against Inflammatory Response in Rats with Deep Vein Thrombosis via Inhibition of NF-?B p50.
Upregulation of Plasminogen Activator Inhibitor-1 in Irradiated Recipient Arteries and Veins from Free Tissue Transfer Reconstruction in Cancer Patients.
Urethan (ethyl carbamate) is an effective promoter of 7,12-dimethylbenz[a]anthracene-induced carcinogenesis in mouse skin two-stage experiments.
Urinary levels of tumour associated antigens (CA 19-9, TPA and CEA) in patients with neoplastic and non-neoplastic urothelial abnormalities.
Urinary-type plasminogen activator receptor (uPAR) modulates oral cancer cell behavior with alteration in p130cas.
Urinary-type plasminogen activator receptor/alpha 3 beta 1 integrin signaling, altered gene expression, and oral tumor progression.
Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma.
Urokinase and plasminogen activator-inhibitor (PAI-1) status in primary ovarian carcinomas and ovarian metastases compared to benign ovarian tumors as a function of histopathological parameters.
Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Urokinase and type I plasminogen activator inhibitor production by normal human hepatocytes: modulation by inflammatory agents.
Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix.
Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors.
Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain.
Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas.
Urokinase Plasminogen Activator Receptor-Mediated Targeting of a Stable Nanocomplex Coupled with Specific Peptides for Imaging of Cancer.
Urokinase plasminogen activator: a prognostic marker in multiple types of cancer.
Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer.
Urokinase type plasminogen activator receptor (uPAR) and human epidermal growth factor receptor 2 (HER2) expression in metastasis of breast cancer.
Urokinase-like plasminogen activator as a marker of endometrial neoplasia.
Urokinase-like plasminogen activator receptor expression on disseminated breast cancer cells.
Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.
Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression.
Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.
Use of E mu-PIM-1 transgenic mice short-term in vivo carcinogenicity testing: lymphoma induction by benzo[a]pyrene, but not by TPA.
Use of primary keratinocyte cultures from plucked human hairs for analysis of gap junctional intercellular communication.
Use of recombinant tissue plasminogen activator in cancer patients with acute stroke.
Use of tissue plasminogen activator (rt-PA) in young children with cancer and dysfunctional central venous catheters.
Use of Tissue Plasminogen Activator as a Surrogate Measure for Central Venous Catheter Dysfunction and Survival Outcome in Children with Cancer: A Population-Based Retrospective Cohort Study.
Use of TPA in hepatology of infectious nature. Initial observations.
Use of tumor markers in the management of head and neck cancer.
Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes.
Usefulness of tissue polypeptide antigen in the follow-up of bladder cancer.
Utilization rates of tissue plasminogen activator and mechanical thrombectomy in patients with acute stroke and underlying malignancy.
UV-induced extracellular factor from human fibroblasts communicates the UV response to nonirradiated cells.
Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer.
Values and limits of combined use of 4 tumor markers (CEA, TPA, NSE and SCC) in un-treated patients with lung cancer.
Variant generation and selection: an in vitro model of tumor progression.
Vascular endothelial growth factor expression in the basal subtype of breast carcinoma.
Vascular plasminogen activator levels and thromboembolic disease in patients with gynecologic malignancies.
Vectorettes for long chromosome walking in genomic DNA of the human p53 gene.
VEGF and tPA co-expressed in malignant glioma.
VEGF mRNA is reversibly stabilized by hypoxia and persistently stabilized in VEGF-overexpressing human tumor cell lines.
Vesicular transport of histamine in stimulated human basophils.
Visfatin and endothelial function in dialyzed patients.
Vitamin D Receptor Genetic Variation and Cancer Biomarkers among Breast Cancer Patients Supplemented with Vitamin D3: A Single-Arm Non-Randomized Before and After Trial.
Vitamin E is a complete tumor promoter in mouse skin.
Waist circumference is related to low-grade inflammation in youth.
Weighing in on fistula failure.
Weight loss improves biomarkers endothelial function and systemic inflammation in obese postmenopausal Saudi women.
Weight reduction ameliorates inflammatory cytokines, adipocytokines and endothelial dysfunction biomarkers among Saudi patients with type 2 diabetes.
What structure and function of avian plasminogen activator and matrix metalloproteinase-2 reveal about their counterpart mammalian enzymes, their regulation and their role in tumor invasion.
White adipose tissue and cardiovascular disease.
Whole genome expression analysis for biologic rational pathway modeling: application in cancer prognosis and therapy prediction.
Wild-type p53 controls the level of fibronectin expression in breast cancer cells.
Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Xenogeneic Transplantation of Human Placenta-Derived Mesenchymal Stem Cells Alleviates Renal Injury and Reduces Inflammation in a Mouse Model of Lupus Nephritis.
Xiang-Qi-Tang and its active components exhibit anti-inflammatory and anticoagulant properties by inhibiting MAPK and NF-?B signaling pathways in LPS-treated rat cardiac microvascular endothelial cells.
XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro.
[A cancer marker study in patients with neoplastic pathology of the neck and head area]
[A case report of ovarian squamous cell carcinoma developing into a dermoid cyst with malignant transformation--immunohistochemical study]
[A clinical study of the significance of the gradient between feeding arterial tissue polypeptide antigen (TPA) and draining venous TPA in assessing the risk for recurrent breast cancers]
[A comparative evaluation of tumor markers (TPA and CEA) in various malignant neoplasms at an advanced stage]
[A retrospective study of the serum CEA, AFP, TPA and ferritin values in 500 patients with chronic liver diseases]
[A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers]
[A study of urological tumor associated antigens. I. Serum and urinary TPA in urological tumor patients]
[A study of urological tumor-associated antigens. IV. Immunocytochemical study of TPA, ABH antigen using urothelial exfoliated cells in bladder tumors]
[A study on tumor marker of tissue-polypeptide-antigen (TPA) in gynecologic malignancies]
[Acute-phase serum proteins and adipocytokines in women with type 2 diabetes mellitus: Relationships with body composition and blood glucose fluctuations].
[Adipocytokines and metabolic syndrome--molecular mechanism and clinical implication]
[Adipocytokines as mediators of metabolic role of adipose tissue].
[Adipocytokines: implications in the prognosis and drug treatment of cardiovascular diseases]
[Adiponectin: a new adipocytokine]
[Adipose tissue as an endocrine organ]
[Adipose tissue: a new endocrine organ]
[Advantages and limitations of combined assays of 4 serum markers in various types of malignant neoplasms]
[Algal toxins, inhibitors of serine/threonine phosphatases]
[Ambulatory venous thromboembolitic disease. Clinical, etiological and evolutive data]
[Anti-tumor promoting activities of kampo prescriptions. II. Inhibitory effects of souseiryu-to on two-stage carcinogenesis of mouse skin tumors and mouse pulmonary tumors]
[Application of serum tumor markers and support vector machine in the diagnosis of oral squamous cell carcinoma]
[Assessment of the activity of plasminogen activators in the differential diagnosis of pleural effusion]
[Assessment of variables relative to prethrombotic state after operation in patients with gynecological malignancies]
[Attempts at analyzing the initiation of the initial processes of carcinogenesis based on the Xiphophorus melanoma model]
[Auxiliary value of TPA in diagnosing neoplastic diseases]
[Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system]
[CEA and TPA in cancer of the breast. Findings and criteria of use]
[Changes in carcinoembryonic antigen and tissue polypeptide antigen in monitoring the post-operative course of some tumor types]
[Changes in serum levels of gynecological tumor markers throughout the period from early gestation to puerperium]
[Changes in the plasma levels of plasminogen activator in various tumors]
[Clinical evaluation of CA 19-9, TPA, IAP and 5'-NPD-V as tumor markers of hepatocellular, bile duct and pancreas carcinoma]
[Clinical evaluation of combination assay of tumor markers in primary lung cancer patients]
[Clinical evaluation of four tumor markers (CEA, TPA, CA50 and CA72-4) in colorectal cancer]
[Clinical evaluation of serum tissue polypeptide antigen (TPA) concentrations in patients with malignancy of the digestive system using TPA RIA kit Prolifigen]
[Clinical evaluation of six tumor markers (ferritin, CEA, TPA, AFP, PAP, gamma-Sm) in serum in patients with urogenital malignancies]
[Clinical evaluation of tissue polypeptide antigen in patients with esophageal, stomach and colon cancer]
[Clinical evaluation of TPA-assay kit using monoclonal antibodies]
[Clinical evaluation of tumor markers in breast cancer patients]
[Clinical evaluation of various tumor markers in pleural effusion and in the serum]
[Clinical experiences with the tumor marker TPA in the maxillofacial region]
[Clinical importance of determination of tumor markers during follow-up in breast carcinoma]
[Clinical relevance of tumor markers]
[Clinical significance of a tumor marker NCC-ST-439 in breast cancer--a comparative study with CA 15-3, CEA and TPA]
[Clinical significance of serum tumor markers (CEA, TPA, IAP and ferritin) in pulmonary tuberculosis]
[Clinical significance of tumor markers in the diagnosis of lung cancer.]
[Clinical significances of tissue polypeptide antigen in patients with gynecological malignancies]
[Clinical studies on nine cases with miliary tuberculosis: serum level of tumor markers and bronchoscopy in differential diagnosis]
[Clinical studies on the measurement of urinary tissue polypeptide antigen (TPA) levels using Prolifigen TPA kit "Daiichi"-II in urothelial cancers]
[Clinical study on tissue polypeptide antigen (TPA) as a tumor marker]
[Clinical usefulness of serum sialyl Le(x)-i measurement in patients with ovarian cancer]
[Clinical usefulness of serum TPA, IAP and CEA levels in gynecological cancer]
[Clinical, histological, and immunohistochemical studies of squamous cell carcinomas of the oral mucosa and the prolabium]
[Comparative morphologic and biochemical determinations of CEA and TPA in invasive breast cancers with special reference to lectin histochemistry and hormone receptor status]
[Comparison of the value of LDH isoenzyme and tissue polypeptide antigen levels in tumor patients during radiotherapy and as a control of tumor growth]
[Correlation of microangiographic findings of colorectal carcinoma with the level of various tumor markers in portal blood]
[Course of the serum determination of 4 tumor markers in viral hepatitis]
[Cytokines, endothelial dysfunction, and insulin resistance]
[Detection of tumor markers in uterine cancer (plasminogen activators, plasminogen activator inhibitors) using fibrin autography]
[Determination of plasminogen activator of the head and neck tumor tissue]
[Development and clinical research of computer aided multivariate pattern analysis system (CAMPAS) OV-1 for diagnosis of ovarian carcinoma]
[Development and optimization of the methods for determining activity of plasminogen activator inhibitor-1 in plasma].
[Diagnosis of ovarian tumor by measuring tumor markers]
[Diagnosis of skeletal metastases by serum tumor markers]
[Diagnostic predictability of CEA and TPA tumor markers in bronchoalveolar lavage fluid]
[Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms]
[Diagnostic value of 5'nucleotidase in primary and secondary neoplasms of the liver]
[Diagnostic value of serological tumor marker tests in patients with ovarian cancer]
[Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma]
[Differences in assay sensitivity of selected tumor markers in head and neck neoplasms]
[Distribution and prognostic value of CEA and TPA in cancer of the lung]
[Dynamic CT under angiotensin II-induced hypertension--application for the differential diagnosis between benign and malignant solid ovarian tumors]
[Effect of AP-1 on expression of plasminogen activator inhibitor-1 in human vascular endothelial cells]
[Effect of high-dose medroxyprogesterone acetate on coagulative and fibrinolytic factors in patients with gynecological cancers]
[Effect of inhalation of aerosolized unfractioned heparin on peri alveolar coagulability and inflammatory response in endotoxin induced acute lung injury rat model.]
[Effect of phorbol ester on tissue-type plasminogen activator (t-PA) secretion in endometrial carcinoma cell line in vitro]
[Effect of the tumor promoter TPA on the distribution of PHA-stimulated human lymphocytes by cell cycle phases]
[Effect of the tumor promotor 12-o-tetradecanoyl phorbol-13--acetate on cyclic adenosine monophosphate levels in cell cultures. Relation to cell proliferation]
[Effect of tumor promoting agents on the in vitro malignant transformation of the fetal rat brain cells exposed in utero to ethylnitrosourea]
[Effects of hypoxia and tumor necrosis factor-alpha on production of plasminogen activator inhibitor-1 in human proximal renal tubular cells]
[Enhancement of the transforming activity of simian adenovirus S5 and of the DNA from human adenovirus type I by benzo(a)pyrene and TPA]
[Establishment and characterization of a human rectal cancer cell line, SRM from primary diffuse infiltrating type cancer]
[Establishment and characterization of a human small cell lung carcinoma cell line (MT-428) derived from the patient who showed neurological paraneoplastic syndrome]
[Establishment and characterization of a tumor marker producing cell line (JR-1) derived from a gastric scirrhous cancer]
[Establishment and characterization of endometrial clear cell carcinoma cell line (TMCC-2)]
[Establishment and characterization of human esophageal carcinoma cell lines--especially the role of the serum-free culture]
[Establishment and characterization of the new cell line (EI) from a human endometrial adenocarcinoma]
[Estrogen dependent plasminogen activator in breast cancer cells; experimental and clinical studies]
[Evaluation of BEKI TPS radioassay kit as a one-step immunoradiometric assay utilizes monoclonal and polyclonal antibodies specific for serum tissue polypeptide antigen]
[Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer]
[Experience in the use of the tumor markers CEA, GICA and TPA in the postoperative monitoring of colorectal neoplasms]
[Experimental chemotherapy of xenotransplanted oral squamous epithelial carcinoma: effectiveness of docetaxel (taxotere) in the nude mouse model]
[Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer]
[Factors controlling tumor promotion induced by TPA]
[Ferritin, CEA and TPA as tumor markers in breast neoplasms]
[Field trial of the early detection in patients with ovarian cancer]
[Hemostasis and tumor invasion. Therapeutic implications]
[Hemostatic indices of oncological patients with different forms of jaundice]
[Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients]
[Immunohistochemical studies on factors involved in after cataract]
[Immunohistochemical study of tissue polypeptide antigen (TPA) in human urinary bladder tumors]
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
[Importance of serum TPA determination in bronchopulmonary cancer. A comparative study of CEA, CA 19.9 and NSE]
[Importance of the tissue polypeptide antigen level in neoplastic patients. Its correlation with other tumor markers]
[In vitro transformation of human embryonic nasopharyngeal epithelial cells with Epstein-Barr virus]
[Inflammatory biomarkers: the link between obesity and associated pathologies]
[Inhibition of ornithine decarboxylase activity and epidermal papilloma in mice by beta-carotene]
[Inhibitory effect of a third generation retinoid R8923 and all-trans retinoic acid on two-stage chemical carcinogenesis of BALB/3T3-A31 cells in vitro]
[Intra-arterial infusion chemotherapy for advanced cancer--40 years of experience]
[Intraglomerular coagulation and fibrinolysis in human primary glomerular diseases]
[Lower grade chronic inflammation is associated with obstructive sleep apnea syndrome in type 2 diabetes mellitus].
[Malignant transformation of monkey kidney epithelial cell induced by EBV BARF1 gene and TPA]
[Markers of endothelial dysfunction in patients with arterial hypertension exposed to occupational irradiation of ?low intensity].
[Matured mediastinal teratoma with high levels of tumor markers in cystic fluid]
[Measurement of serum tissue polypeptide antigen (TPA) in patients with malignant tumor using prolifigen TPA-M "Daiichi" kit]
[Measurement of serum tissue-polypeptide antigen (TPA) levels by EIA employing monoclonal antibody]
[Microanalysis of tryptophan metabolites and suppressor factor of delayed-type hypersensitivity in mice]
[Modifications of gene expression by tumor promoters]
[Molecular mechanisms of insulin resistance in obesity and type 2 diabetes mellitus.]
[New tumour markers useful in diagnostics and monitoring of cervical cancer]
[On the mechanisms of actions of tumor promoters]
[Ovarian cancer--a comparison between CT diagnosis and serum tumor markers]
[Pancreatic secretory trypsin inhibitor in urothelial cancer]
[Pathogenesis of hemostasis disorders in malignant neoplasms]
[Percutaneous transcatheter thermotherapy (PTCT): use of hotwire for local tumor control]
[Plasma PAI-1 levels in patients with various tumors with or without metastasis]
[Plasminogen activator inhibitor 1 and prognosis in breast carcinoma]
[Plasminogen activator inhibitor activity of cultured cancer bearing and non-bearing xeroderma pigmentosum fibroblasts]
[Plasminogen activator inhibitor type 1 (PAI-1) in blood and tissue extracts of patients with non-small cell lung cancer]
[Plasminogen activator system and its clinical significance in patients with a malignant disease].
[Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases]
[Preclinical features of anti-angiogenesis therapy]
[Primary culture of human bladder carcinomas and establishment of human bladder carcinoma cell line by serum-free culture]
[Production and secretion of the plasminogen activator inhibitor type-2 in a leukemia cell line]
[Prognostic implications of biologic markers in intracranial meningiomas: 120 cases]
[Prognostic significance of plasminogen activator inhibitor-1 (PAI-1) in primary breast carcinoma]
[Prognostic value of tumor markers in the follow up of malignant neoplasms of the head and neck]
[Progress on evaluation criterion of wound healing]
[Protease activities in gastric and colon cancer tissues]
[Protein synthesis inhibitor--antitumor activity and mode of action of KRN 5500]
[Proteolysis in the cells of malignant human and animal tumors]
[Proteolytic changes in plasma fibrinogen from ovarian venous blood in patients with cervix cancer]
[Regulation of EGF receptor by tumor promoters]
[Relationship between tumor markers and clinical symptoms in ovarian cancer]
[Relationship of single nucleotide polymorphisms and genetic susceptibility to sepsis].
[Research on the gap junctional intercellular communication of CHL cells and human cancer cells induced by c9, t11-conjugated linoleic acid]
[Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis]
[Role of plasminogen activator inhibitor type 1 in tumor angiogenesis]
[Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis]
[Scintigraphic detection of malignancies with radioactively labelled tumor antibodies. Clinical results based on immunohistochemical research]
[Screening of human and animal tissue cell cultures as potential producers of plasminogen activator]
[Second look operations in ovarian cancer--a clinical study on the detection of recurrent tumors and the judgment on termination of treatment in 84 cases]
[Serum and urinary tissue polypeptide antigen (TPA) in patients with urological cancer]
[Serum CA 125 and TPA determination in malignant neoplasms of the uterus]
[Serum CA125 and CA19-9 levels in adenocarcinoma of the uterine cervix and endometrial carcinoma]
[Serum CA125 in malignant ovarian tumor--periodical monitoring and correlation with other tumor markers]
[Serum concentrations of tissue polypeptide antigen and alpha 1-fetoprotein in patients with primary liver cancer, liver metastasis and liver cirrhosis]
[Serum levels of tissue polypeptide antigen in patients with the head and neck cancer according to presence of metastases in lymph nodes]
[Serum tissue polypeptide antigen (TPA) in patients with urogenital cancer]
[Serum tissue polypeptide antigen in the differential diagnosis of chronic pancreatitis and exocrine pancreatic tumors. Preliminary results]
[Signals and transcription factors]
[Significance of tumor markers in the treatment of patients with ovarian malignancies]
[Significance of urokinase and its inhibitors in the invasiveness and metastasing of malignant tumors].
[Skin carcinogenesis induced be neonatal administration of 5-bromo-2'-deoxyuridine and subsequent treatment with 12-O-tetradecanoylphorbol-13-acetate in mice]
[Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer]
[Studies on fibrinolysis and ascites accumulation associated with peritonitis carcinomatosa--inducer of plasminogen activator (IPA) in malignant ascites tumor]
[Studies on gap junction formation and junctional communication between cultured endothelial cells and smooth muscle cells]
[Studies on the clinical significance of type III procollagen peptide in sera as a tumor marker in patients with ovarian tumors]
[Studies on the gap junctional intercellular communication (GJIC) of human stomach carcinoma cells in comparison with normal cells and the effect of the tumor promoter, TPA]
[Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer]
[Study of plasminogen activator and trypsin inhibitor in gastric cancer, ulcer and experimental tumor.]
[Study of the cytosolic concentrations of the tissue poly-peptide specific (TPS) antigen in infiltrating ductal carcinomas of the breast. Positive relationship with hormone dependency and negative with cellular proliferation]
[Study on carbohydrate antigen NCC-ST-439 in breast cancer]
[Study on the plasma plasminogen activators in patients with malignant gynecologic tumors]
[The accuracy of CT and tumor markers in the detection of a recurrent ovarian carcinoma]
[The actions of TPA-type as well as non-TPA type tumor promoters and their mechanism(s) in tumor promotion]
[The antioxidative mechanisms of tea polyphenols in inhibiting tumor promotion by TPA]
[The auto- and endocrine function of the adipose tissue. Significance for metabolic complications in obesity]
[The changes in tumor markers such as serum CEA, CA 19-9, TPA and CA 125 in the chemotherapy of patients with advanced gastric cancer]
[The clinical investigation of tumor markers for renal cell carcinoma--a comparison among TPA, ferritin and immunosuppressive substance]
[The clinical significance of tissue polypeptide antigen (TPA) in the patients with gynecologic tumor]
[The clinical value of tissue polypeptide antigen in ovarian carcinoma]
[The diagnostic values of CA242 combining other tumor markers for lung cancer]
[The effect of phorbol ester in a wide range of concentrations on the lipid structure of microsome membranes of tumor cells in vitro]
[The effects of tumor antigen gene OVA66 on biological characteristics of tumor cells.]
[The evaluation of the newly produced assay kit for the cytokeratin fragment, "ball ELSA CYFRA21-1"]
[The investigation on early diagnosis of the bladder tumor. II: A study on urinary cytology, urinary fibrin/fibrinogen degradation products, tissue fibrin deposition and tissue plasminogen activator activity in patients with bladder tumors (author's transl)]
[The location of components of fibrinolytic system in laryngeal cancer]
[The present status of tumor markers in malignant ovarian tumor]
[The role of CEA, CA 19-9 and TPA in the diagnosis of pancreatic cancer. Evaluation by discriminant analysis]
[The role of intermediate filaments in forming cellular processes induced in fibroblasts by the tumor promoter TPA]
[The role of proteases in the growth, invasion and spread of cancer cells]
[The sensitivity and specificity of tumor markers (CEA, ferritin, beta 2-MG, TPA, IAP, sialic acid) in malignant and non-malignant pulmonary diseases and their relation to smoking and sex]
[The significance of plasminogen activator inhibitor 2 in patients with hematologic malignancies]
[The tumor markers CEA, TPA and CA 19-9 and ferritin and osteocalcin in follow-up studies in breast cancer]
[The tumor markers TPA and CEA in the after care of breast cancer]
[The use of recombinant interferon alfa-2b in the follow-up of patients laryngectomized for advanced stage carcinoma]
[Therapy and follow-up using TPA in radio-oncologic after-care in bladder cancer]
[THROMBOGENIC RISK FACTORS IN PATIENTS WITH EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE].
[Tissue plasminogen activator activity in early prostatic cancer and in bone metastases of prostatic cancer]
[Tissue polypeptide and carcinoembryonic antigens in patients with breast cancer]
[Tissue polypeptide antigen (TPA) and plasma TPA levels during the postoperative course in female primary breast carcinoma patients. 1st results of a long-term study]
[Tissue polypeptide antigen (TPA) as a tumor marker in disorders of the digestive tract: comparison with CEA]
[Tissue polypeptide antigen (TPA) in non-neoplastic diseases]
[Tissue polypeptide antigen and carcinoembryonic antigen in bladder neoplasms]
[Tissue polypeptide antigen as a biological marker of malignant pleural mesothelioma]
[Tissue polypeptide antigen as a tumor marker for gynecologic malignancies]
[Tissue polypeptide antigen in gynecological cancer]
[Tissue polypeptide antigen in serum and tissue in patients with lung cancer]
[TPA and TPS in the follow-up of cancer of the breast: preliminary evaluations]
[tPA, uPA, PAI-1 as prognostic factors of breast cancers]
[Transformation of Chinese hamster cells by plasmid pBR325::tk::HS3 and the effect on transformant stability of tumor promotor TPA]
[Treatment of acromegaly. Results in 56 patients]
[Trials of the diagnostic potentials of TPA in tumorous and nontumorous lung pathologies in 303 cases]
[Tumor marker--present and future]
[Tumor marker--screening for gynecological cancer; personal experience. Utility of tumor markers in screening of ovarian cancer]
[Tumor markers CEA, CA 15-3, MCA, TPA, ferritin and PTH in the diagnosis and monitoring of primary breast cancer]
[Tumor markers in bronchus cancer]
[Tumor markers in cervical carcinoma]
[Tumor markers in gynecology]
[Tumor markers in monitoring of neoplasms]
[Tumor markers in some chronic inflammatory diseases in rheumatology: a statistical evaluation]
[Tumor markers of pancreatic cancer]
[Tumor markers TPA and Cyfra 21.1 in patients with non-small cell lung cancer after surgery and chemotherapy]
[Tumor markers useful in the diagnostics and monitoring of endometrial and cervical cancer]
[Tumor markers. II. Their significance in the follow-up of patients after radical resection of lung neoplasms]
[Tumor metastasis and the fibrinolytic system]
[Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer]
[Tumor-associated markers in malignant lung neoplasms]
[Urine determination of CEA, CA50 and TPA as tumor markers in bladder neoplasms]
[Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer]
[Use of color Doppler technique and estimation of CA 125 amd TPA levels in blood serum for the diagnosis of adnexal masses]
[Utility of measurement of tumor markers for preoperative staging of gastric cancer]
[Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia]
[Xinfeng capsule improves hypercoagulative state by inhibiting miR-155/NF-?B signaling pathway in patients with active ankylosing spondylitis].
[[Gender Differences in Tissue Cascade of Activation of Plasminogen and PAI-1 in Esophageal Squamous Cell Carcinoma].]
Neoplasms, Germ Cell and Embryonal
A personalized approach to cancer treatment: how biomarkers can help.
Seven tumor markers in benign and malignant germ cell tumors of the ovary.
[Clinical relevance of tumor markers]
Neoplasms, Squamous Cell
Use of tumor markers in the management of head and neck cancer.
Neoplastic Cells, Circulating
Molecular interactions in cancer cell metastasis.
Relationship Between Circulating Tumor Cells and Tissue Plasminogen Activator in Patients with Early Breast Cancer.
Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Nephritis
A streptococcal plasminogen activator in the focus of infection and in the kidneys during the initial phase of experimental streptococcal glomerulonephritis.
Association between plasminogen activator inhibitor?1 (PAI-1) 4G/5G polymorphism and circulating PAI-1 level in systemic lupus erythematosus and rheumatoid arthritis : A meta-analysis.
Effects of ancrod and rtPA on fibrin accumulation, glomerular inflammation and renal function in nephrotoxic nephritis.
Role of plasminogen activator inhibitor on nephrotoxic nephritis and its modulation by tumor necrosis factor.
Tissue plasminogen activator therapy of rabbit nephrotoxic nephritis.
[Effects of tissue-type plasminogen activator from a culture of calf kidney cells on hemostasis and fibrinolysis in experimental nephritis]
[Prognostic value of allelic variants affecting the hemostatic system in the development of antiphospholipid syndrome and kidney lesion in patients with systemic lupus erythematosus].
Nephrotic Syndrome
Coagulopathy of childhood nephrotic syndrome--a reappraisal of the role of natural anticoagulants and fibrinolysis.
Comprehensive study on platelet function, hemostasis, fibrinolysis, peripheral serotonergic system and serum lipids in nephrotic syndrome.
Enhanced expression of plasminogen activator inhibitor 1 in patients with nephrotic syndrome.
Impact of the 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene on primary nephrotic syndrome.
Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrome.
Markers of Endothelial Dysfunction in Children with Idiopathic Nephrotic Syndrome.
Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
Plasminogen activator in nephrotic syndrome.
Pulmonary thrombo-embolism in nephrotic syndrome treated with tissue plasminogen activator.
Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome.
Successful systemic low-dose lysis of a caval thrombus by rt-PA in a neonate with congenital nephrotic syndrome.
Successful thrombolysis by prolonged low-dose alteplase in catheter-directed infusion.
Successful treatment of neonatal pulmonary thrombosis in congenital nephrotic syndrome.
[Concentration of tissue plasminogen activator and its inhibitor 1 in cyclosporine A-treated children with idiopathic nephrotic syndrome]
[Fibrinolytic and lipid disturbances in patients with nephrotic syndrome]
[Tissue-type plasminogen activator in patients with lupus nephritis]
Nervous System Diseases
A Matched Comparison of Eptifibatide Plus RT-PA Versus RT-PA Alone in Acute Ischemic Stroke.
A Regional System of Stroke Care Provides Thrombolytic Outcomes Comparable With the NINDS Stroke Trial.
A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group.
Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis.
Acute myocardial infarction following intravenous tissue plasminogen activator for acute ischemic stroke: An unknown danger.
Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial.
Advances in revascularization for acute ischemic stroke treatment: an update.
Alteplase and ischaemic stroke: have new reviews of old data helped?
Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT).
Analysis of the National Institute of Neurological Disorders and Stroke tissue plasminogen activator studies following European Cooperative Acute Stroke Study III patient selection criteria.
Are patients with acutely recovered cerebral ischemia more unstable?
Aspirin Treatment Failure and the Risk of Recurrent Stroke and Death Among Patients with Ischemic Stroke.
Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study.
Asymmetric angioneurotic edema associated with thrombolysis for acute stroke.
Asymptomatic hemorrhagic transformation of cerebral infarction does not worsen long-term outcome.
Baseline computed tomography changes and clinical outcome after thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke.
Bayesian hierarchical modeling and the integration of heterogeneous information on the effectiveness of cardiovascular therapies.
Beyond intravenous thrombolysis.
Can emergency department physicians safely and effectively initiate thrombolysis for acute ischemic stroke?
Candidates for thrombolytic treatment in acute ischaemic stroke--where are our patients in Hong Kong?
Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial.
Complications of endovascular therapy for acute ischemic stroke and proposed management approach.
Confirmation of tPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-tPA stroke trials.
Critical early thrombolytic and endovascular reperfusion therapy for acute ischemic stroke victims: a call for adjunct neuroprotection.
Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke.
Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials.
Design and validation of a prehospital scale to predict stroke severity: Cincinnati Prehospital Stroke Severity Scale.
Determinants of outcome in patients eligible for thrombolysis for ischemic stroke.
Developments in endovascular therapy for acute ischemic stroke.
Dietary supplement with fermented soybeans, natto, improved the neurobehavioral deficits after sciatic nerve injury in rats.
Early intravenous thrombolysis with recombinant tissue-type plasminogen activator in vertebrobasilar ischemic stroke.
Early recurrent ischemic stroke in stroke patients undergoing intravenous thrombolysis.
Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study.
Early [(11)C]Flumazenil/H(2)O positron emission tomography predicts irreversible ischemic cortical damage in stroke patients receiving acute thrombolytic therapy.
Education to improve stroke awareness and emergent response. The NINDS rt-PA Stroke Study Group.
Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. NINDS; The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group.
Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
Enhancing Recovery after Acute Ischemic Stroke with Donepezil as an Adjuvant Therapy to Standard Medical Care: Results of A Phase IIa Clinical Trial.
Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline.
Expansion of Intravenous Tissue Plasminogen Activator Eligibility Beyond National Institute of Neurological Disorders and Stroke and European Cooperative Acute Stroke Study III Criteria.
Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial.
Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
For how long is brain tissue salvageable? Thrombolysis-based evidence.
Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm.
Hemorrhage in the interventional management of stroke study.
How baseline severity affects efficacy and safety outcomes in acute ischemic stroke intervention trials.
How important is surrogate consent for stroke research?
Impact of Tissue Plasminogen Activator Dosing on Patients Weighing More Than 100?kg on 3-Month Outcomes in Acute Ischemic Stroke.
Implementation Challenges of Regionalized Acute Stroke Care.
Improved outcomes in stroke thrombolysis with pre-specified imaging criteria.
Improving Door to Needle time in Patients for Thrombolysis.
Intraarterial thrombolytic therapy within 3 hours of the onset of stroke.
Intravenous recombinant tissue plasminogen activator improves arterial recanalization rates and reduces infarct volumes in patients with hyperdense artery sign on baseline computed tomography.
Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.
Intravenous Thrombolysis and Risk Factors for Ischemic Stroke.
Intravenous thrombolysis for acute ischemic stroke: the phase IV data.
Intravenous tissue plasminogen activator and stroke in the elderly.
Intravenous tissue plasminogen activator for acute ischemic stroke: A Canadian hospital's experience.
Intravenous Tissue Plasminogen Activator for Stroke: A Review of the ECASS III Results in Relation to Prior Clinical Trials.
Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.
Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.
Letter by turc et Al regarding article, "defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the national institute of neurological disorders and stroke tissue-type plasminogen activator trials".
Leukoaraiosis, Cerebral Hemorrhage, and Outcome After Intravenous Thrombolysis for Acute Ischemic Stroke: A Meta-Analysis (v1).
Logistics in acute stroke management.
Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
Magnitude of Benefit of Combined Endovascular Thrombectomy and Intravenous Fibrinolysis in Large Vessel Occlusion Ischemic Stroke.
Management of acute ischemic stroke.
Management of patients with atherosclerotic carotid occlusion.
Minimal sufficient balance--a new strategy to balance baseline covariates and preserve randomness of treatment allocation.
Neuroprotection for acute stroke: making clinical trials work.
Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke.
Nursing management of acute complications following rt-PA in acute ischemic stroke. The NINDS rt-PA Stroke Study Group.
Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).
Outcome and Symptomatic Bleeding Complications of Intravenous Thrombolysis Within 6 Hours in MRI-Selected Stroke Patients: Comparison of a German Multicenter Study With the Pooled Data of ATLANTIS, ECASS, and NINDS tPA Trials.
Outcomes of intravenous thrombolytic therapy for acute ischemic stroke with an integrated acute stroke referral network: initial experience of a community-based hospital in a developing country.
Patients with Thrombolysed Stroke in Vietnam have an Excellent Outcome: Results from the Vietnam Thrombolysis Registry.
Percent change on the National Institutes of Health Stroke Scale: a useful acute stroke outcome measure.
Pharmacological and non-pharmacological recanalization strategies in acute ischemic stroke.
Plasminogen activator inhibitor-1 induction after experimental intracerebral hemorrhage.
Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke.
Predicting outcome in ischemic stroke: external validation of predictive risk models.
Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial.
Predictors of good outcome after intravenous tPA for acute ischemic stroke.
Predictors of major neurological improvement after intravenous thrombolysis in acute ischemic stroke: a hospital-based study from south India.
Prehospital diagnosis and management of patients with acute stroke.
Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update.
Recent progress in drug treatment for acute ischemic stroke.
Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
Redefined Measure of Early Neurological Improvement Shows Treatment Benefit of Alteplase Over Placebo.
Referral and care for acute ischemic stroke in a Japanese tertiary emergency hospital.
Repeated-Measures Analysis of the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial.
Reperfusion therapy for acute stroke improves outcome by decreasing neuroinflammation.
Response to letter regarding article, "defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the national institute of neurological disorders and stroke tissue-type plasminogen activator trials".
Review, Historical Context, and Clarifications of the NINDS rt-PA Stroke Trials Exclusion Criteria: Part 1: Rapidly Improving Stroke Symptoms.
Risk adjustment effect on stroke clinical trials.
Role of tissue plasminogen activator in clinical aggravation of experimental autoimmune encephalomyelitis and its therapeutic potential.
Safety of Endovascular Intervention for Stroke on Therapeutic Anticoagulation: Multicenter Cohort Study and Meta-Analysis.
Safety of Intravenous Thrombolytic Use in Four Emergency Departments Without Acute Stroke Teams.
Serum creatinine may indicate risk of symptomatic intracranial hemorrhage after intravenous tissue plasminogen activator (IV tPA).
Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials.
Stroke following internal carotid artery occlusion - a contra-indication for intravenous thrombolysis?
Stroke Prognostication using Age and NIH Stroke Scale: SPAN-100.
Stroke treatment: beyond the three-hour window and in the pregnant patient.
Stroke: call 911. Nursing recognition & response.
Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials.
Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke.
T-patterns in the study of movement and behavioral disorders.
Targeting neuroprotection clinical trials to ischemic stroke patients with potential to benefit from therapy.
Tenecteplase for the treatment of acute ischemic stroke: A review of completed and ongoing randomized controlled trials.
The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study.
The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis.
The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study.
The iScore Predicts Efficacy and Risk of Bleeding in the National Institute of Neurological Disorders and Stroke Tissue Plasminogen Activator Stroke Trial.
The Risk of Hemorrhagic Transformation After Thrombolysis for Acute Ischemic Stroke in Chinese Versus North Americans: A Comparative Study.
The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
The Totaled Health Risks in Vascular Events (THRIVE) Score Predicts Ischemic Stroke Outcomes Independent of Thrombolytic Therapy in the NINDS tPA Trial.
Therapeutic yield and outcomes of a community teaching hospital code stroke protocol.
Thirty Years After the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Trial: A New Era for Stroke Therapy.
Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire.
Thrombolysis 2004: the good, the bad, and the ugly.
Thrombolysis and Thrombectomy for Acute Ischemic Stroke: Strengths and Synergies.
Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW).
Thrombolysis for acute stroke in routine clinical practice.
Thrombolysis for acute stroke in the United Kingdom.
Thrombolysis in patients with transient neurologic deficits.
Thrombolytic therapy for acute ischemic stroke : issues and answers.
Thrombolytic therapy for acute ischemic stroke.
Thrombolytic therapy for ischemic stroke--a review. Part I--Intravenous thrombolysis.
Thrombolytic therapy in the treatment of stroke.
Thrombolytic treatment for acute ischemic stroke: a 2 year-experience at King Chulalongkorn Memorial Hospital.
Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities.
Time of day, outcome, and response to thrombolytic therapy: the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trial experience.
Time of hospital presentation in patients with acute stroke.
Tissue at risk of infarction rescued by early reperfusion: a positron emission tomography study in systemic recombinant tissue plasminogen activator thrombolysis of acute stroke.
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
Tissue plasminogen activator induces microglial inflammation via a noncatalytic molecular mechanism involving activation of mitogen-activated protein kinases and Akt signaling pathways and AnnexinA2 and Galectin-1 receptors.
Tissue plasminogen activator involvement in experimental autoimmune myasthenia gravis: Aggravation and therapeutic potential.
Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
tPA-associated reperfusion after acute stroke demonstrated by SPECT.
Trimming the fat in acute ischemic stroke: an assessment of 24-h CT scans in tPA patients.
Two-Hour Improvement of Patients in the National Institute of Neurological Disorders and Stroke Trials and Prediction of Final Outcome.
Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators.
Unsuccessful tissue plasminogen activator treatment of acute stroke caused by a calcific embolus.
Using the baseline CT scan to select acute stroke patients for IV-IA therapy.
Validation of minor stroke definitions for thrombolysis decision making.
Variability of the Modified Rankin Scale Score Between Day 90 and 1 Year After Ischemic Stroke.
Variables associated with hospital arrival time after stroke: effect of delay on the clinical efficiency of early treatment.
Very mild stroke patients benefit from intravenous tissue plasminogen activator without increase of intracranial hemorrhage.
When is thrombolysis justified in patients with acute ischemic stroke? A bioethical perspective.
Years of disability-adjusted life gained as a result of thrombolytic therapy for acute ischemic stroke.
[Alteplase treatment for acute stroke 2007: an effective therapeutic option at our disposal]
[Intravenous rt-PA therapy for acute ischemic stroke: efficacy and limitations]
[Intravenous tissue plasminogen activator in the treatment of acute ischemic stroke: feasibility, safety, and efficiency in the 2 first years of the clinical practice]
[New era has begun since the approval of thrombolytic therapy for acute ischemic stroke in Japan]
[The prospects of thrombolytic therapy for acute ischemic stroke]
[Thrombolysis for stroke in 93 years old female: report of one case]
[Thrombolysis in acute ischemic stroke in basic hospitals. Four cases reports.]
[Thrombolytic therapy in ischemic infarct]
Neuralgia
Amygdaloid administration of tetrapentylammonium attenuates development of pain and anxiety-like behavior following peripheral nerve injury.
Annexin A2 in primary afferents contributes to neuropathic pain associated with tissue type plasminogen activator.
Identification of the key genes associated with neuropathic pain.
Induction of plasminogen activator inhibitor-1 and -2 in dorsal root ganglion neurons after peripheral nerve injury.
Tissue plasminogen activator in primary afferents induces dorsal horn excitability and pain response after peripheral nerve injury.
Neurilemmoma
Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas.
Neuroblastoma
A multimolecular signaling complex including PrPC and LRP1 is strictly dependent on lipid rafts and is essential for the function of tissue plasminogen activator.
Alterations in plasminogen activator and inhibitor activity during the differentiation of a human neuroblastoma cell line, SMS-KAN.
Binding of tissue-type plasminogen activator to the glucose-regulated protein 78 (GRP78) modulates plasminogen activation and promotes human neuroblastoma cell proliferation in vitro.
Changes in gene expression of kringle domain-containing proteins in murine brains and neuroblastoma cells infected by prions.
Characterization and partial purification of the plasminogen activator from human neuroblastoma cell line, SK-N-SH. A comparison with human urokinase.
Complete nucleotide sequence of human vasoactive intestinal peptide/PHM-27 gene and its inducible promoter.
Continuous phosphorylation of GAP-43 and MARCKS by long-term TPA treatment in SK-N-SH human neuroblastoma cells.
Decline in c-myc mRNA expression but not the induction of c-fos mRNA expression is associated with differentiation of SH-SY5Y human neuroblastoma cells.
Different regulation of N- and c-myc expression during phorbol ester-induced maturation of human SH-SY5Y neuroblastoma cells.
Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo.
Down-regulation of protein kinase C alpha and gamma and enhanced TPA-induced neurite formation in DAN-transfected neuroblastoma cells.
Effect of retinoic acid on human neuroblastoma: correlation between morphological differentiation and changes in plasminogen activator and inhibitor activity.
Exploration of human miRNA target genes in neuronal differentiation.
Fos and Jun form cell specific protein complexes at the neuropeptide tyrosine promoter.
Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas.
Increased neurite development and plasminogen activator expression by exposure of human neuroblastoma cells to plasminogen-deficient growth medium.
Induction of morphological differentiation of human neuroblastoma cells is accompanied by induction of tissue-type plasminogen activator.
Induction of tissue plasminogen activator in differentiated NG108-15 cells.
Involvement of activator protein-1 in transcriptional regulation of the human mu-opioid receptor gene.
LRP6 mediated signal transduction pathway triggered by tissue plasminogen activator acts through lipid rafts in neuroblastoma cells.
Malignant rhabdoid tumor shows incomplete neural characteristics as revealed by expression of SNARE complex.
Modulation in the levels and localization of plasminogen activator in differentiating neuroblastoma cells.
Muscarinic receptors in human SH-SY5Y neuroblastoma cell line: regulation by phorbol ester and retinoic acid-induced differentiation.
Opposing regulation of ciliary neurotrophic factor receptors on neuroblastoma cells by distinct differentiating agents.
Phosphatidic acid activation of protein kinase C in LA-N-1 neuroblastoma cells.
Plasminogen activator release at the neuronal growth cone.
Protein kinase C remains functionally active during TPA induced neuronal differentiation of SH-SY5Y human neuroblastoma cells.
Reduction of muscarinic receptor density and of guanine nucleotide-stimulated phosphoinositide hydrolysis in human SH-SY5Y neuroblastoma cells following long-term treatment with 12-O-tetradecanoylphorbol 13-acetate or mezerein.
Regulation of neuroblastoma differentiation by forkhead transcription factors FOXO1/3/4 through the receptor tyrosine kinase PDGFRA.
Retinoic acid induction of human tissue-type plasminogen activator gene expression via a direct repeat element (DR5) located at -7 kilobases.
Retinoic acid-enhanced invasion through reconstituted basement membrane by human SK-N-SH neuroblastoma cells involves membrane-associated tissue-type plasminogen activator.
Reverse T3 and modulators of the calcium messenger system rapidly decrease T4-5'-deiodinase II activity in cultured mouse neuroblastoma cells.
Testosterone and progesterone metabolism in the human neuroblastoma cell line SH-SY5Y.
The voltage-dependent anion channel (VDAC) binds tissue-type plasminogen activator and promotes activation of plasminogen on the cell surface.
TPA induced expression and function of human connexin 26 by post-translational mechanisms in stably transfected neuroblastoma cells.
TPA-induced neurite formation in a neuroblastoma cell line (SH-SY5Y) is associated with increased IGF-I receptor mRNA and binding.
Transcriptional regulation of the rat tissue type plasminogen activator gene: localization of DNA elements and nuclear factors mediating constitutive and cyclic AMP-induced expression.
Translocation of the PKC isoforms present in the human neuroblastoma, SH-SY5Y, following short-term treatment with the phorbol ester, TPA.
Tumor promoter modulation of epidermal growth factor- and nerve growth factor-induced adhesion and growth factor binding of PC-12 pheochromocytoma cells.
Neurodegenerative Diseases
Detection of Protein Uptake in In Vitro Cultured Astrocytes Exemplified by the Uptake of the Serine Protease, Tissue Plasminogen Activator.
Lithium inhibits Smad3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling.
Tissue plasminogen activator as a key effector in neurobiology and neuropathology.
Tissue-type plasminogen activator is an extracellular mediator of Purkinje cell damage and altered gait.
Neurofibroma
Expression of selected growth factors and oncogenes in neurofibrosarcomas complicating von Recklinghausen disease.
Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas.
Neurofibrosarcoma
Differential immunocytochemical localization of tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) in breast cancer.
Expression of selected growth factors and oncogenes in neurofibrosarcomas complicating von Recklinghausen disease.
Immuno-histochemical localization of tissue polypeptide antigen (TPA) and carcino-embryonic antigen (CEA) in breast cancer. A comparative study.
Neuroinflammatory Diseases
Calcitriol protects the Blood-Brain Barrier integrity against ischemic stroke and reduces vasogenic brain edema via antioxidant and antiapoptotic actions in rats.
Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis during neuroinflammation.
Deficiency of tPA Exacerbates White Matter Damage, Neuroinflammation, Glymphatic Dysfunction and Cognitive Dysfunction in Aging Mice.
Glutamate controls tPA recycling by astrocytes, which in turn influences glutamatergic signals.
Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment in Acute Ischemic Stroke.
Neuroinflammation in hemorrhagic transformation after tissue plasminogen activator thrombolysis: Potential mechanisms, targets, therapeutic drugs and biomarkers.
Recombinant tissue plasminogen activator enhances microglial cell recruitment after stroke in mice.
Regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by alpha-synuclein in rat primary glial cells.
Rosuvastatin Reduces Neuroinflammation in the Hemorrhagic Transformation After rt-PA Treatment in a Mouse Model of Experimental Stroke.
Suppression of neuroinflammation in forebrain-specific Cdk5 conditional knockout mice by PPAR? agonist improves neuronal loss and early lethality.
Synergy between plasminogen activator inhibitor-1, ?-synuclein, and neuroinflammation in Parkinson's disease.
The fibrinolytic system: A new target for treatment of depression with psychedelics.
Tissue plasminogen activator induces microglial inflammation via a noncatalytic molecular mechanism involving activation of mitogen-activated protein kinases and Akt signaling pathways and AnnexinA2 and Galectin-1 receptors.
Tissue-type plasminogen activator is a regulator of monocyte diapedesis through the brain endothelial barrier.
Neurologic Manifestations
Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience.
Cost-Effectiveness of Emergent MRI during Stroke Alert to Diagnose Stroke Mimics: Single-Center Experience.
COVID-19 and Stroke: Casual or Causal Role?
Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
Effectiveness of Thrombolytic Therapy in Acute Embolic Stroke due to Infective Endocarditis.
Efficacy of SMTP-7, a small-molecule anti-inflammatory thrombolytic, in embolic stroke in monkeys.
Emergent Double-barrel Bypass Shortly after Intravenous Administration of Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke.
Evolution of intracerebral hemorrhage after intravenous tPA: reversal of harmful effects with mast cell stabilization.
FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat.
Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator.
Intravenous Fibrinolysis in Ischemic Stroke of Large Vessel after Reversing Effect of Dabigatran with Idarucizumab.
Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with rivaroxaban.
Isolated Anisocoria as a Presenting Stroke Code Symptom is Unlikely to Result in Alteplase Administration.
Not only the Sugar, Early infarct sign, hyperDense middle cerebral artery, Age, Neurologic deficit score but also atrial fibrillation is predictive for symptomatic intracranial hemorrhage after intravenous recombinant tissue plasminogen activator.
Periprocedural Risk of Stroke Is Elevated in Patients with End-Stage Renal Disease on Hemodialysis.
Preclusion of Ischemic Stroke Patients from Intravenous Tissue Plasminogen Activator Treatment for Mild Symptoms Should Not be Based on Low National Institutes of Health Stroke Scale Scores.
Recombinant plasminogen activator therapy for cerebral vein thrombosis in a child carrier of prothrombin gene mutation.
Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
Recurrent embolization during intravenous administration of tissue plasminogen activator in acute cardioembolic stroke. A case report.
Relationship between Cardiac Troponin and Thrombo-Inflammatory Molecules in Prediction of Outcome after Acute Ischemic Stroke.
Reversal of acute ischemic stroke after THA using tissue plasminogen activator.
Safety of urgent carotid endarterectomy following thrombolysis.
Stroke Scale Items Associated with Neurologic Deterioration within 24 Hours after Recombinant Tissue Plasminogen Activator Therapy.
Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke.
Use of tissue plasminogen activator in a stroke after radiofrequency ablation of a left-sided accessory pathway.
What is the value of conducting a trial of r-tPA for the treatment of mild stroke patients?
[Thrombolytic therapy in arterial disorders other than myocardial infarction]
Neuroma, Acoustic
Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors.
Nevus
Growth-regulatory factors for normal, premalignant, and malignant human cells in vitro.
In vitro growth patterns of normal human melanocytes and melanocytes from different stages of melanoma progression.
Induction of melanoma in TPras transgenic mice.
Nerve growth factor chromatin receptor and cell surface receptor-regulated growth of melanocytes and nevus cells.
Oncogenic potential in fibroblasts from individuals genetically predisposed to cancer.
Newcastle Disease
Characterization of thermostable Newcastle disease virus recombinants expressing the hemagglutinin of H5N1 avian influenza virus as bivalent vaccine candidates.
Non-alcoholic Fatty Liver Disease
A randomized, controlled, crossover pilot study of losartan for pediatric nonalcoholic fatty liver disease.
Analysis of adipokine concentrations in paediatric non-alcoholic fatty liver disease.
Association between plasminogen activator inhibitor-1 and severity of liver injury and cardiovascular risk in children with non-alcoholic fatty liver disease.
Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA.
Changes in the levels of endothelium-derived coagulation parameters in nonalcoholic fatty liver disease.
Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease.
Emerging risk factors for cardiovascular diseases: Indian context.
Endoplasmic reticulum stress induces hepatic plasminogen activator inhibitor 1 in murine nonalcoholic steatohepatitis.
Endotoxin and Plasminogen Activator Inhibitor-1 Serum Levels Associated With Nonalcoholic Steatohepatitis in Children.
Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease.
Female mice are more susceptible to non-alcoholic fatty liver disease: sex-specific regulation of the hepatic AMP-activated protein kinase - plasminogen activator inhibitor 1-cascade but not the hepatic endotoxin response.
Hemostatic alterations in fatty liver disease.
Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?
Inhibition of Plasminogen Activator Inhibitor 1 Attenuates Hepatic Steatosis but Does Not Prevent Progressive Nonalcoholic Steatohepatitis in Mice.
Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model.
Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake.
Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of metabolic syndrome.
Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis.
Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease.
Plasminogen activator inhibitor-1 is independently associated with non-alcoholic fatty liver disease whereas leptin and adiponectin vary between genders.
Sarcopenia and chronic liver diseases.
Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.
TM5441, a plasminogen activator inhibitor-1 inhibitor, protects against high fat diet-induced non-alcoholic fatty liver disease.
Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease.
Vascular Disease in Patients with Nonalcoholic Fatty Liver Disease.
[Insulin-like growth factor-binding protein-1: a new biochemical marker of nonalcoholic fatty liver disease?]
[Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease; Relation of non-alcoholic fatty liver disease to carotid atherosclerosis.]
[Proinflammatory cytokine levels depending on the stage of hepatic fibrosis in patients with metabolic syndrome and non-alcoholic fatty liver disease].
Noonan Syndrome
Imbalance of plasminogen activator inhibitor type-1 (PAI-1) and tissue plasminogen activator (t-PA) activity in patients with Noonan syndrome.
Obesity
'True' fasting serum insulin level, insulin resistance syndrome and coronary artery disease.
A hypofibrinolytic state in overweight patients with cerebral venous thrombosis and isolated intracranial hypertension.
A low-glycemic-index diet reduces plasma plasminogen activator inhibitor-1 activity, but not tissue inhibitor of proteinases-1 or plasminogen activator inhibitor-1 protein, in overweight women.
A Noncanonical Role for Plasminogen Activator Inhibitor Type 1 in Obesity-Induced Diabetes.
A novel plasminogen activator inhibitor-1 inhibitor, TM5441, protects against high-fat diet-induced obesity and adipocyte injury in mice.
A nutritional nonalcoholic steatohepatitis minipig model.
A role for plasminogen activator inhibitor-1 in obesity: from pie to PAI?
Adipokine and insulin profiles distinguish diabetogenic and non-diabetogenic obesities in mice.
Adipokines and Thrombosis.
Adipokines in diabetes and cardiovascular diseases.
Adipose tissue activity in relation to overweight or obesity.
Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals.
Aging and thrombosis.
Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patients with type 2 diabetes mellitus and lack of association with PAI-1 plasma levels.
Angiotensin-converting enzyme inhibition attenuates hypofibrinolysis and reduces cardiac perivascular fibrosis in genetically obese diabetic mice.
Ashitaba (Angelica Keiskei) Exudate Prevents Increases in Plasminogen Activator Inhibitor-1 Induced by Obesity in Tsumura Suzuki Obese Diabetic Mice.
Association analyses of porcine SERPINE1 reveal sex-specific effects on muscling, growth, fat accretion and meat quality.
Association between adiposity indices and cardiometabolic risk factors among adults living in Puerto Rico.
Association between obesity and adipokines levels in saliva and gingival crevicular fluid: A systematic review and meta-analysis.
Association between plasminogen activator inhibitor-1 and severity of liver injury and cardiovascular risk in children with non-alcoholic fatty liver disease.
Association of parental obesity with concentrations of select systemic biomarkers in nonobese offspring: the Framingham Heart Study.
Association of plasminogen activator inhibitor-1 with insulin resistance in Japan where obesity is rare.
Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states.
Beneficial Fatty Acid Ratio of Salvia hispanica L. (Chia Seed) Potentially Inhibits Adipocyte Hypertrophy, and Decreases Adipokines Expression and Inflammation in Macrophage.
Biomarkers of cardiometabolic complications in survivors of childhood acute lymphoblastic leukemia.
Birth weight and the insulin resistance syndrome: association of low birth weight with truncal obesity and raised plasminogen activator inhibitor-1 but not with abdominal obesity or plasma lipid disturbances.
Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation.
Body adiposity but not insulin resistance is associated with -675 4G/5G polymorphism in the PAI-1 gene in a sample of Mexican children.
Bone marrow plasminogen activator inhibitor-1 influences the development of obesity.
Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? (Review).
Changes in leptin, plasminogen activator factor and oxidative stress in morbidly obese patients following open and laparoscopic Swedish adjustable gastric banding.
Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes.
Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome.
Coagulation and fibrinolysis abnormalities in obesity.
Coagulation Signalling and Metabolic Disorders: Lessons Learned from Animal Models.
Connecting the dots: obesity, fatty acids and cancer.
Contribution of genetic and metabolic syndrome to omental adipose tissue PAI-1 gene mRNA and plasma levels in obesity.
Cross talk of tumor necrosis factor-alpha and the renin-angiotensin system in tumor necrosis factor-alpha-induced plasminogen activator inhibitor-1 production from hepatocytes.
Deficiency of plasminogen activator inhibitor-2 impairs nutritionally induced murine adipose tissue development.
Degree of obesity influences the relationship of PAI-1 with body fat distribution and metabolic variables in African women.
Diabetes/obesity-related inflammation, cardiac cell death and cardiomyopathy.
Differential response of plasma plasminogen activator inhibitor 1 after weight loss surgery in patients with or without type 2 diabetes.
Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.
Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide.
Divergent roles for p55 and p75 TNF-alpha receptors in the induction of plasminogen activator inhibitor-1.
Does Inflammation Determine Metabolic Health Status in Obese and Nonobese Adults?
Effect of obesity on endogenous fibrinolytic activity in diabetes mellitus.
Effect of plasminogen activator inhibitor-1 deficiency on nutritionally-induced obesity in mice.
Effect of plasminogen activator inhibitor-1 on adipogenesis in vivo.
Effect of tumor necrosis factor alpha and transforming growth factor beta 1 on plasminogen activator inhibitor-1 secretion from subcutaneous and omental human fat cells in suspension culture.
Effects of a diet containing Brazilian propolis on lipopolysaccharide-induced increases in plasma plasminogen activator inhibitor-1 levels in mice.
Effects of Obesity Surgery on Blood Coagulation and Fibrinolysis: A Literature Review.
Effects of the Magenstrasse and Mill operation for obesity on plasma plasminogen activator inhibitor type 1, tissue plasminogen activator, fibrinogen and insulin.
Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease.
Elevated expression of transforming growth factor-beta in adipose tissue from obese mice.
Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease.
Elevated leptin and decreased adiponectin independently predict the post-thrombotic syndrome in obese and non-obese patients.
Epidemiology of diabetes and obesity in the United States.
Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha?
Feeble awake effects of plasminogen activator inhibitor type-1 in mice.
Fenofibrate inhibits thrombogenic and fibrinolytic factors expression in adipose tissue of atherosclerotic rabbits.
Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA Study.
Fibrinolysis and atherogenesis in the JCR:LA-cp rat in relation to insulin and triglyceride concentrations in blood.
Functional role of the fibrinolytic system in development of adipose tissue.
Gastric expression of plasminogen activator inhibitor (PAI)-1 is associated with hyperphagia and obesity in mice.
Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects.
Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue.
Hemostasis at Extremes of Body Weight.
High-fat diet decreases energy expenditure and expression of genes controlling lipid metabolism, mitochondrial function and skeletal system development in the adipose tissue, along with increased expression of extracellular matrix remodelling- and inflammation-related genes.
Identification of signaling pathways involved in aberrant production of adipokines in adipocytes undergoing oxidative stress.
Impact of bariatric surgery on subclinical atherosclerosis in patients with morbid obesity.
Impact of Tissue Plasminogen Activator Dosing on Patients Weighing More Than 100?kg on 3-Month Outcomes in Acute Ischemic Stroke.
Impaired fibrinolysis in hypertension and obesity due to high plasminogen activator inhibitor-1 level in plasma.
Improvement in HOMA-IR is an independent predictor of reduced carotid intima-media thickness in obese adolescents participating in an interdisciplinary weight-loss program.
Increased low-grade inflammation and plasminogen-activator inhibitor-1 level in nondippers with sleep apnea syndrome.
Increased plasminogen activator inhibitor results in a hypofibrinolytic state in adolescents with obesity: in vivo and ex vivo evidence.
Increased plasminogen activator inhibitor-1 levels in android obesity: correlation with oxidative stress.
Inflammation, obesity, and thrombosis.
Inflammatory and prothrombotic parameters in normotensive non-diabetic obese women: effect of weight loss obtained by gastric banding.
Influence of t-pA and u-PA on adipose tissue development in a murine model of diet-induced obesity.
Inhibition of PAI-1 Promotes Lipolysis and Enhances Weight Loss in Obese Mice.
Inhibition of Plasminogen Activator Inhibitor 1 Attenuates Hepatic Steatosis but Does Not Prevent Progressive Nonalcoholic Steatohepatitis in Mice.
Inhibition of Plasminogen Activator Inhibitor-1 Activation Suppresses High Fat Diet-Induced Weight Gain via Alleviation of Hypothalamic Leptin Resistance.
Inhibitory effects of harpagoside on TNF-?-induced pro-inflammatory adipokine expression through PPAR-? activation in 3T3-L1 adipocytes.
Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes.
Interacting hepatic PAI-1/tPA gene regulatory pathways influence impaired fibrinolysis severity in obesity.
Interrelations between carbohydrates, lipids, and the hemostatic system in relation to the risk of thrombotic and cardiovascular disease.
Inverse relationship between adiponectin and plasminogen activator inhibitor-1 in metabolic syndrome patients.
Investigating the association of vitamin D seasonality on inflammatory and hemostatic markers.
Is the neck circumference an emergent predictor for inflammatory status in obese adults?
Is There a Decreased Risk of Intracerebral Hemorrhage and Mortality in Obese Patients Treated with Intravenous Thrombolysis in Acute Ischemic Stroke?
Ketogenic diet disrupts the circadian clock and increases hypofibrinolytic risk by inducing expression of plasminogen activator inhibitor-1.
Leptin levels are not affected by enalapril treatment after an uncomplicated myocardial infarction, but associate strongly with changes in fibrinolytic variables in men.
Leptin links with plasminogen activator inhibitor-1 in human obesity: the SABPA study.
Leptin upregulates the expression of plasminogen activator inhibitor-1 in human vascular endothelial cells.
Liver fat content measured by magnetic resonance spectroscopy at 3.0 tesla independently correlates with plasminogen activator inhibitor-1 and body mass index in type 2 diabetic subjects.
Local insulin infusion stimulates expression of plasminogen activator inhibitor-1 and tissue-type plasminogen activator in normal subjects.
Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men.
Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study.
Metabolic syndrome and endothelial fibrinolytic capacity in obese adults.
Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.
Microglia activation due to obesity programs metabolic failure leading to type two diabetes.
Molecular mechanisms of tumor necrosis factor-alpha-mediated plasminogen activator inhibitor-1 expression in adipocytes.
No Impact of Body Mass Index on Outcome in Stroke Patients Treated with IV Thrombolysis BMI and IV Thrombolysis Outcome.
Novel bis-arylsulfonamides and aryl sulfonimides as inactivators of plasminogen activator inhibitor-1 (PAI-1).
Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1.
Obesity and Breast Cancer: The Roles of Peroxisome Proliferator-Activated Receptor-gamma and Plasminogen Activator Inhibitor-1.
Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1.
Obesity and thrombin-generation profiles in women with venous thromboembolism.
Obesity and thromboembolic disease.
Obesity enhances the induction of plasminogen activator inhibitor-1 by restraint stress: a possible mechanism of stress-induced renal fibrin deposition in obese mice.
Obesity, haemostasis and the fibrinolytic system.
Obesity, microalbuminuria, hyperinsulinemia, and increased plasminogen activator inhibitor 1 activity associated with parasympathetic neuropathy in type 2 diabetes.
PAI-1 and the metabolic syndrome: links, causes, and consequences.
PAI-1 Exacerbates White Adipose Tissue Dysfunction and Metabolic Dysregulation in High Fat Diet-Induced Obesity.
PAI-1 gene 4G/5G polymorphism, cytokine levels and their relations with metabolic parameters in obese children.
Pathogenesis of venous thromboembolism: when the cup runneth over.
Performance of plasminogen activator inhibitor-1 as a biomarker in patients undergoing coronary angiography: Analytical and biological considerations.
Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation.
Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G/5G genotype.
Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity.
Plasminogen activator inhibitor 1 and visceral obesity during pronounced weight loss after bariatric surgery.
Plasminogen activator inhibitor 1 gene polymorphism and gestational diabetes mellitus.
Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke.
Plasminogen activator inhibitor-1 (PAI-1) gene polymorphism (-675 4G/5G) associated with obesity and vascular risk in children.
Plasminogen activator inhibitor-1 5G/5G genotype is a protecting factor preventing posttransplant diabetes mellitus.
Plasminogen activator inhibitor-1 and haemostasis in obesity.
Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity.
Plasminogen activator inhibitor-1 contributes to the deleterious effect of obesity on the outcome of thrombotic ischemic stroke in mice.
Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice.
Plasminogen activator inhibitor-1 expression and secretion are stimulated by growth hormone and interleukin-6 in 3T3-L1 adipocytes.
Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function.
Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism.
Plasminogen activator inhibitor-1 modulates adipocyte differentiation.
Plasminogen activator inhibitor-1 promoter activity in adipocytes is not influenced by the 4 G/5 G promoter polymorphism and is regulated by a USF-1/2 binding site immediately preceding the polymorphic region.
Plasminogen Activator Inhibitor-1, Body Fat and Insulin Action in Aging Women.
Plasminogen activator inhibitor-1, fibrinogen, and lung function in adolescents with asthma and obesity.
Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk.
Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease.
Plasminogen activator inhitor-1 associates with cardiovascular risk factors in healthy young adults in the Cardiovascular Risk in Young Finns Study.
Predisposing factors to post-operative adhesion development.
Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.
Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1.
Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).
Reciprocal regulation of tissue-type and urokinase-type plasminogen activators in the differentiation of murine preadipocyte line 3T3-L1 and the hormonal regulation of fibrinolytic factors in the mature adipocytes.
Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss.
Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals.
Regulation of PAI-1 gene expression during adipogenesis.
Relationship between 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene and obesity in Argentinian Hispanic adults.
Relationship of Obesity to Recanalization After Hyperacute Recombinant Tissue-Plasminogen Activator Infusion Therapy in Patients With Middle Cerebral Artery Occlusion.
Resveratrol suppresses PAI-1 gene expression in a human in vitro model of inflamed adipose tissue.
Retinol-binding protein 4 and plasminogen activator inhibitor-1 as potential prognostic biomarkers of non-allergic asthma caused by obesity in adolescents.
Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP).
Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes.
Role of plasminogen activator inhibitor-1 in senescence and aging.
Sarcopenia, obesity, and inflammation--results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study.
Serum Plasminogen Activator Inhibitor-1 (PAI-1) and Tumor Necrosis Factor-Alpha (TNF-?) Levels in Obesity and Periodontal Disease.
Short-term very low-calorie diet in obese females improves the haemostatic balance through the reduction of leptin levels, PAI-1 concentrations and a diminished release of platelet and leukocyte-derived microparticles.
Should obesity be blamed for the high prevalence rates of hypertension in black South African women?
Stimulation in vivo of expression of intra-abdominal adipose tissue plasminogen activator inhibitor Type I by proinsulin.
Stimulation of PAI-1 and adipokines by glucose in human adipose tissue in vitro.
Stochastic sensors designed for assessment of biomarkers specific to obesity.
Strain- and tissue-dependent induction of plasminogen activator inhibitor-1 gene expression in fasted mice.
Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss.
The association between anthropometric measures of adiposity and the progression of carotid atherosclerosis.
The common -675 4G/5G polymorphism in the plasminogen activator inhibitor -1 gene is strongly associated with obesity.
The contribution of different adipose tissue depots to plasma plasminogen activator inhibitor-1 (PAI-1) levels.
The effect of metabolic syndrome and obesity on outcomes of acute ischemic stroke patients treated with systemic thrombolysis.
The effect of obesity on fibrinolytic activity and plasma lipoprotein (a) levels in patients with type 2 diabetes mellitus in Korea.
The effect of plasminogen activator inhibitor-1 -675 4G/5G polymorphism on PAI-1 gene expression and adipocyte differentiation.
The effect of plasminogen activator inhibitor-1 gene 4G/5G polymorphism on glucose and lipid metabolisms in Turkish obese children.
The fat mouse. A powerful genetic model to study hemostatic gene expression in obesity/NIDDM.
The fat mouse: a powerful genetic model to study elevated plasminogen activator inhibitor 1 in obesity/NIDDM.
The matricellular protein SPARC/osteonectin as a newly identified factor up-regulated in obesity.
The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome.
The possible mediatory role of adipokines in the association between low carbohydrate diet and depressive symptoms among overweight and obese women.
The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus.
The role of obesity and its bioclinical correlates in the progression of chronic kidney disease.
The role of vitamin D in asthma.
Thrombosis and occlusion of vascular access in hemodialyzed patients.
Tiplaxtinin impairs nutritionally induced obesity in mice.
Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice.
TISSUE-SPECIFIC PAI-1 GENE EXPRESSION AND GLYCOSYLATION PATTERN IN INSULIN-RESISTANT OLD RATS.
To: J.Hoffstedt et al. (2002) The common -675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity.
Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1.
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance.
Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women.
Weighing in on fistula failure.
[Inflammatory biomarkers: the link between obesity and associated pathologies]
[Life style-related disease]
[Molecular mechanism in the development of the complications associated with obesity--the physiological and pathological role of adipocytokines]
[Polycystic ovary syndrome and miscarriage].
[Research advances in association between pediatric obesity and bronchial asthma].
[The correlation between the activity of tissue plasminogen activator (TPA), levels of tissue plasminogen activator inhibitor (PAI-1) antigen and serum lipids in healthy subjects]
[Thrombus in transit - two cases of patients with massive pulmonary embolism treated with thrombolysis]
Obesity, Abdominal
Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1.
Adipokine Profiling in Adult Women With Central Obesity and Hypertension.
Altered Daytime Fluctuation Pattern of Plasminogen Activator Inhibitor 1 in Type 2 Diabetes Patients with Coronary Artery Disease: A Strong Association with Persistently Elevated Plasma Insulin, Increased Insulin Resistance, and Abdominal Obesity.
Androgens and coronary artery disease.
Birth weight and the insulin resistance syndrome: association of low birth weight with truncal obesity and raised plasminogen activator inhibitor-1 but not with abdominal obesity or plasma lipid disturbances.
Cardiovascular risk continuum: implications of insulin resistance and diabetes.
Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1 in young adults.
Coagulation, fibrinolysis and haemorheology in premenopausal obese women with different body fat distribution.
Comparable Enhanced Prothrombogenesis in Simple Central Obesity and Metabolic Syndrome.
Coronary artery disease in South asians: an emerging risk group.
Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity.
Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
Hemostatic and metabolic variables in women with polycystic ovary syndrome.
High Prevalence of Diabetes and Prediabetes and Their Coexistence with Cardiovascular Risk Factors in a Hispanic Community.
Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes.
Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome.
Influence of free testosterone on antigen levels of plasminogen activator inhibitor-1 in premenopausal women with central obesity.
Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity.
Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men.
Plasminogen activator inhibitor 1 and visceral obesity during pronounced weight loss after bariatric surgery.
Psychosocial stress and the insulin resistance syndrome.
Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP).
Testosterone and atherosclerosis.
The association between anthropometric measures of adiposity and the progression of carotid atherosclerosis.
The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance.
The relation of adipose tissue to cardiometabolic risk.
Thrombotic tendency in diabetes mellitus. Revisiting and revising a study initiated 30 years ago.
Visceral fat as a determinant of fibrinolysis and hemostasis.
Obesity, Metabolically Benign
Does Inflammation Determine Metabolic Health Status in Obese and Nonobese Adults?
Obesity, Morbid
FACTORS AFFECTING THE FUNCTIONAL OUTCOME OF OXFORD PHASE 3 UNICOMPARTMENTAL KNEE ARTHROPLASTY.
Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.
Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity.
Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism.
Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity.
Obstetric Labor, Premature
Progestin inhibits and thrombin stimulates the plasminogen activator/inhibitor system in term decidual stromal cells: implications for parturition.
Ocular Motility Disorders
Acute onset internuclear ophthalmoplegia responsive to treatment with intravenous alteplase.
Odontogenic Tumors
Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
Oligodendroglioma
Amplification of the epidermal growth factor receptor gene in human gliomas.
Plasminogen activators and inhibitors in gliomas: an immunohistochemical study.
Oligospermia
Biomarkers for demographic research: sperm counts and other male infertility biomarkers.
[Source of plasminogen activator in rhesus monkey semen and its possible role in sperm capacitation]
Opportunistic Infections
Production of plasminogen activator and plasminogen activator inhibitors by alveolar macrophages in control subjects and AIDS patients.
Oral Submucous Fibrosis
Increased plasminogen activator inhibitor-1/tissue type plasminogen activator ratio in oral submucous fibrosis.
The upregulation of type I plasminogen activator inhibitor in oral submucous fibrosis.
Osteoarthritis
Activities of plasminogen activator, plasmin and kallikrein in synovial fluid from patients with temporomandibular joint disorders.
Clinical Correlation with the PA/Plasmin System in Septic Arthritis of the Knee.
Control of the chondrocyte fibrinolytic balance by the drug piroxicam: relevance to the osteoarthritic process.
Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis.
Effect of urinary trypsin inhibitor on osteoarthritis.
Effects of different molecular weight hyaluronan products on the expression of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis.
Effects of intra-articular administration of sodium hyaluronate on plasminogen activator system in temporomandibular joints with osteoarthritis.
Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium.
Elevations in synovial fluid plasminogen activator in patients with rheumatoid arthritis.
Glucosamine sulfate suppresses the expressions of urokinase plasminogen activator and inhibitor and gelatinases during the early stage of osteoarthritis.
Interleukin-1 beta, plasminogen activator and inhibitor of plasminogen activator in synovial fluid of rheumatoid arthritis, psoriatic arthritis and osteoarthritis.
Irreversible Inhibition of Serine Proteases - Design and In Vivo Activity of Diaryl alpha-Aminophosphonate Derivatives.
Lack of association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism and osteoarthritis.
Naproxen, meloxicam and methylprednisolone inhibit urokinase plasminogen activator and inhibitor and gelatinases expression during the early stage of osteoarthritis.
Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints.
Plasminogen activator and receptor in osteoarthritis.
Plasminogen activator in synovial fluid from patients with rheumatoid arthritis.
Plasminogen activator inhibitor-1 deficiency enhances subchondral osteopenia after induction of osteoarthritis in mice.
Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis.
Regulation of plasminogen activator activity and expression by cyclic mechanical stress in rat mandibular condylar chondrocytes.
Significance of serine proteinase and matrix metalloproteinase systems in the destruction of human articular cartilage.
Study of an inhibitor of plasminogen activator (tranexamic acid) in the treatment of experimental osteoarthritis.
Synoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptors on their surface.
The distribution of enzyme inhibitors in the joint in rheumatoid and experimental arthritis.
Two NSAIDs, nimesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAI-1, in human OA synovial fibroblasts.
[Activity of plasminogen activators and plasmin inhibitors in the joint capsule in various articular diseases (author's transl)]
[Plasminogen activator activity of the synovial fluid as an indicator of activation phenomena in degenerative joint diseases]
Osteoarthropathy, Primary Hypertrophic
Synthesis and degradation of connective tissue macromolecules in pachydermoperiostosis (PDP): evidence for altered processing of plasminogen activator inhibitor-1 (PAI-1).
Osteogenesis Imperfecta
Intraparenchymal hemorrhage in a patient with osteogenesis imperfecta and plasminogen activator inhibitor-1 deficiency.
Osteomyelitis
tPA Alu (I/D) polymorphism associates with bacterial osteomyelitis.
Osteonecrosis
Association between PAI-1 4G/5G Polymorphisms and osteonecrosis of femoral head: A Meta-analysis.
Association between plasminogen activator inhibitor gene polymorphisms and osteonecrosis of the femoral head susceptibility: A case-control study.
Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients.
Bone marrow mesenchymal stem cell-derived exosomes promote plasminogen activator inhibitor 1 expression in vascular cells in the local microenvironment during rabbit osteonecrosis of the femoral head.
Dexamethasone-induced plasminogen activator inhibitor-1 expression in human primary bone marrow adipocytes.
Familial idiopathic osteonecrosis mediated by familial hypofibrinolysis with high levels of plasminogen activator inhibitor.
Genetic polymorphism of vitamin D receptors and plasminogen activator inhibitor-1 and osteonecrosis risk in childhood acute lymphoblastic leukemia.
Genetic polymorphisms in plasminogen activator inhibitor-1 predict susceptibility to steroid-induced osteonecrosis of the femoral head in Chinese population.
Hypofibrinolysis: a common, major cause of osteonecrosis.
Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with Stanozolol.
Massive subperiosteal hemorrhage and femoral shaft osteonecrosis: a complication of tissue plasminogen activator therapy for purpura fulminans.
Plasminogen Activator Inhibitor-1 4G/5G Polymorphism Contributes to Osteonecrosis of the Femoral Head Susceptibility: Evidence from a Systematic Review and Meta-analysis.
Relation between osteonecrosis of the femoral head and PAI-1 4G/5G gene polymorphism: a meta-analysis.
Relationship between post-SARS osteonecrosis and PAI-1 4G/5G gene polymorphisms.
The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis.
Thrombophilia and hypofibrinolysis: pathophysiologies of osteonecrosis.
Osteoporosis
Bone assessment via thermal photo-acoustic measurements.
Dosing time-dependent effect of raloxifene on plasma plasminogen activator inhibitor-1 concentrations in post-menopausal women with osteoporosis.
Plasminogen activator inhibitor-1 is involved in streptozotocin-induced bone loss in female mice.
Relationship between plasminogen activator inhibitor type-1 (PAI-1) gene polymorphisms and osteoporosis in Turkish women.
Role of Plasminogen Activator Inhibitor-1 in Glucocorticoid-Induced Diabetes and Osteopenia in Mice.
Role of plasminogen activator inhibitor-1 in glucocorticoid-induced muscle change in mice.
Osteoporosis, Postmenopausal
Genetic polymorphisms of TGF-beta, PAI-1, and COL1A-1, and determination of bone mineral density in Caucasian females.
No associations between genetic polymorphisms of TGF-beta, PAI-1, and COL1A1, and bone mineral density in Caucasian females.
Osteosarcoma
AP-1 regulation of the rat bone sialoprotein gene transcription is mediated through a TPA response element within a glucocorticoid response unit in the gene promoter.
Characterization of tissue plasminogen activator binding proteins isolated from endothelial cells and other cell types.
Coordinate regulation of fibronectin matrix assembly by the plasminogen activator system and vitronectin in human osteosarcoma cells.
Cyclic AMP-dependent and -independent effects on tissue-type plasminogen activator activity in osteogenic sarcoma cells; evidence from phosphodiesterase inhibition and parathyroid hormone antagonists.
Effects of interleukin-1, tumor necrosis factor -beta, and forskolin on tissue plasminogen activator activity in human osteoblastic osteosarcoma cells.
Gene expression in periodontal tissues following treatment.
Osteoblasts display receptors for and responses to leukemia-inhibitory factor.
Parathyroid hormone-related protein of malignancy: active synthetic fragments.
Plasminogen activator regulation in osteoblasts: parathyroid hormone inhibition of type-1 plasminogen activator inhibitor and its mRNA.
Production and release of matrix vesicles in the cell processes of TPA-treated human osteoblast-like cells.
Production of plasminogen activator by cells transformed by herpesviruses.
Protease expression in dedifferentiated parosteal osteosarcoma.
Protein kinase C activating phorbolesters enhance the cyclic AMP response to parathyroid hormone, forskolin and choleratoxin in mouse calvarial bones and rat osteosarcoma cells.
Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha.
Regulation of plasminogen activator inhibitor-1 (PAI-1) expression by 1,25-dihydroxyvitamin D-3 in normal and malignant rat osteoblasts.
Regulation of plasminogen activator production by bone-resorbing hormones in normal and malignant osteoblasts.
Signal transduction pathways involved in the stimulation of tissue type plasminogen activator by interleukin-1alpha and Porphyromonas gingivalis in human osteosarcoma cells.
SK-216, a Novel Inhibitor of Plasminogen Activator Inhibitor-1, Suppresses Lung Metastasis of Human Osteosarcoma.
Stimulation of collagenase production by rat osteosarcoma cells can occur in a subpopulation of cells.
Stimulation of plasminogen activator in osteoblast-like cells by bone-resorbing hormones.
The course of fibrinolytic proteins in children with malignant bone tumours.
The effect of IL-1alpha on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in osteoblastic ROS 17/2.8 cells.
The effect of transforming growth factor beta on the plasminogen activator activity of normal human osteoblast-like cells and a human osteosarcoma cell line MG-63.
Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells.
Tumour interstitial fluid pressure may regulate angiogenic factors in osteosarcoma.
Up-regulation of osteolytic mediators in human osteosarcoma cells stimulated with nicotine.
Otitis
A Glycosaminoglycan-Rich Fraction from Sea Cucumber Isostichopus badionotus Has Potent Anti-Inflammatory Properties In Vitro and In Vivo.
Anti-inflammatory agents from Sandoricum koetjape Merr.
Assessment of the anti-inflammatory activity and free radical scavenger activity of tiliroside.
Comparison of the effect of sn-1,2-didecanoylglycerol and 12-O-tetradecanoylphorbol-13-acetate on cutaneous morphology, inflammation and tumor promotion in CD-1 mice.
Effects of CGRP in different models of mouse ear inflammation.
The ethanol extract of Leonurus sibiricus L. induces antioxidant, antinociceptive and topical anti-inflammatory effects.
Topical anti-inflammatory activity of Polygonum cuspidatum extract in the TPA model of mouse ear inflammation.
Otitis Media
Fibrinolytic activity of middle ear fluid in otitis media with effusion.
PAI-1 inhibits development of chronic otitis media and tympanosclerosis in a mouse model of otitis media.
The 4G/4G plasminogen activator inhibitor-1 genotype is associated with frequent recurrence of acute otitis media.
[The role of fibrinolysis in pathogenesis of middle ears adhesions]
Otitis Media with Effusion
Fibrinolytic activity of middle ear fluid in otitis media with effusion.
Out-of-Hospital Cardiac Arrest
Assessment of reperfusion following thrombolysis with mean fibrillation and amplitude spectrum area in patients with sustained ventricular fibrillation.
Long-term survival and neurological outcome of patients who received recombinant tissue plasminogen activator during out-of-hospital cardiac arrest.
Outcome of out-of-hospital cardiac arrest after fibrinolysis with reteplase in comparison to the return of spontaneous circulation after cardiac arrest score in a geographic region without emergency coronary intervention.
Recombinant tissue plasminogen activator during cardiopulmonary resuscitation in 108 patients with out-of-hospital cardiac arrest.
Relationship Between Severity of Fibrinolysis Based on Rotational Thromboelastometry and Conventional Fibrinolysis Markers.
Thrombolysis using recombinant tissue-type plasminogen activator during cardiopulmonary resuscitation in patients with out-of-hospital cardiac arrest.
Ovarian Diseases
Relation between serum levels of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125) and their immunohistochemical identification in benign and malignant gynecological disease.
Ovarian Hyperstimulation Syndrome
Stroke in ovarian hyperstimulation syndrome in early pregnancy treated with intra-arterial rt-PA.
Ovarian Neoplasms
A kunitz-type protease inhibitor bikunin disrupts ligand-induced oligomerization of receptors for transforming growth factor (TGF)-beta and subsequently suppresses TGF-beta signalings.
A tumour-marker combination versus second-look surgery in ovarian cancer. I. Clinical experience.
Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.
Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer.
Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta-chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma.
Clinical significance of different serum tumor markers in gynecological malignancies.
Clinical tumour markers in ovarian cancer.
Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin.
Collagenase expression in ovarian cancer cell lines.
Combination assay of CA125, TPA, IAP, CEA, and ferritin in serum for ovarian cancer.
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
Expression of plasminogen activator inhibitor-2 in epithelial ovarian cancer: a favorable prognostic factor related to the actions of CSF-1.
Expression of the jun family of genes in human ovarian cancer and normal ovarian surface epithelium.
Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer Network.
High preoperative plasma concentration of tissue plasminogen activator (tPA) is an independent marker for shorter overall survival in patients with ovarian cancer.
Immunological effects of tumor vaccines: III. Influenza virus oncolysates inhibit the TPA induced activation of peripheral blood mononuclear cells.
Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.
Ovarian cancer G protein-coupled receptor 1-dependent and -independent vascular actions to acidic pH in human aortic smooth muscle cells.
PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination.
Phorbol ester exposure activates an AP-1-mediated increase in ERCC-1 messenger RNA expression in human ovarian tumor cells.
Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
Plasminogen Activator Inhibitor Type 1 in Blood at Onset of Chemotherapy Unfavorably Affects Survival in Primary Ovarian Cancer.
Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination.
Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer.
Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2.
Prognostic value of tissue plasminogen activator (tPA) in patients with epithelial ovarian cancer undergoing chemotherapy.
Protein C and its inhibitor in malignancy.
pS2 and PAI-1 in ovarian cancer: correlation to pathohistological parameters.
RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene.
Selective decrease in serum immunoglobulin G1. A tissue nonspecific tumor marker detecting early stages of gynecologic malignant disease with high efficiency.
Serum levels of six tumor markers in patients with benign and malignant gynecological disease.
The effects of gemcitabine and TPA on PKC signaling in BG-1 human ovarian cancer cells.
The mechanism and significance of synergistic induction of the expression of plasminogen activator inhibitor-1 by glucocorticoid and transforming growth factor beta in human ovarian cancer cells.
The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma.
Transforming growth factor-beta1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells.
[A study on tumor marker of tissue-polypeptide-antigen (TPA) in gynecologic malignancies]
[Clinical relevance of tumor markers]
[Clinical significances of tissue polypeptide antigen in patients with gynecological malignancies]
[Field trial of the early detection in patients with ovarian cancer]
[Measurement of serum tissue polypeptide antigen (TPA) in patients with malignant tumor using prolifigen TPA-M "Daiichi" kit]
[New prospects in the combined use of tumor markers in epithelial neoplasms of the ovary]
[Preliminary experience with TPA (tissue polypeptide antigen) in ovarian cancer]
[Serodiagnostic tests by factor analysis and stepwise discriminating analysis with tumor markers for the detection of ovarian cancer]
[Serum levels of CA 125, CA 19-9, TPA, CEA and CA 50: useful evaluation parameters in the diagnosis of ovarian cancer]
[Significance of tumor markers in the treatment of patients with ovarian malignancies]
[Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer]
[Study on the plasma plasminogen activators in patients with malignant gynecologic tumors]
[The accuracy of CT and tumor markers in the detection of a recurrent ovarian carcinoma]
[The clinical significance of tissue polypeptide antigen (TPA) in the patients with gynecologic tumor]
[The role of D-dimer in diagnosis of ovarian cancer]
[Tissue polypeptide antigen in gynecological cancer]
[Tumor marker combination versus second-look operation in ovarian cancer]
Overnutrition
Postnatal early overnutrition dysregulates the intrarenal renin-angiotensin system and extracellular matrix-linked molecules in juvenile male rats.
Overweight
A low-glycemic-index diet reduces plasma plasminogen activator inhibitor-1 activity, but not tissue inhibitor of proteinases-1 or plasminogen activator inhibitor-1 protein, in overweight women.
Adipose tissue activity in relation to overweight or obesity.
Comprehensive Assessment of the Hemostatic System in Polycystic Ovarian Syndrome.
Effect of obesity on endogenous fibrinolytic activity in diabetes mellitus.
Estimating Maximal Oxygen Uptake from the Ratio of Heart Rate at Maximal Exercise to Heart Rate at Rest in Middle-Aged Men.
Glycemic index, glycemic load, and thrombogenesis.
Hemostatic status and fibrinolytic response potential at different phases of the menstrual cycle.
Human gender differences in fibrinolytic responses to exercise training and their determinants.
Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults.
Increased Systolic and Diastolic Blood Pressure Is Associated With Altered Gut Microbiota Composition and Butyrate Production in Early Pregnancy.
Insulin resistance but not visceral adipose tissue is associated with plasminogen activator inhibitor type 1 levels in overweight and obese premenopausal African-American women.
Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation.
Is visceral adipose tissue a determinant of von Willebrand factor in overweight and obese premenopausal women?
Maternal body mass index, change in weight status from childhood to late adulthood and physical activity in older age.
Maternal gestational weight gain and objectively measured physical activity among offspring.
NASH predicts plasma inflammatory biomarkers independently of visceral fat in men.
Overweight across the life course and adipokines, inflammatory and endothelial markers at age 60-64 years: Evidence from the 1946 birth cohort.
Physical activity in the prevention and treatment of a thrombogenic profile in the obese: current evidence and research issues.
Plasma insulin, plasminogen activator inhibitor, and ankle-brachial systolic blood pressure ratio in overweight hypertensive subjects.
Plasma markers of inflammation and hemostatic and endothelial activity in naturally overweight and obese dogs.
Plasminogen activator inhibitor-1, tissue-type plasminogen activator, and fibrinogen: Effect of dieting with or without exercise in overweight postmenopausal women.
Sudden sensorineural hearing loss and hemostatic mechanisms.
The weight of tissue plasminogen activator dose in overweight patients with strokes.
Thrombolysis Outcomes among Obese and Overweight Stroke Patients: An Age-and National Institutes of Health Stroke Scale-matched Comparison.
[Prothrombotic and prethrombotic markers in obese diabetic and non-diabetic subjects]
Pancreatic Cyst
Proliferation tissue polypeptide antigen distinguishes malignant mucinous cystadenocarcinomas from benign cystic tumors and pseudocysts.
Pancreatic Diseases
Is tissue polypeptide antigen more accurate than serum CEA for diagnosing pancreatic cancer?
Pancreatic Neoplasms
A prospective study of serum tumour markers carcinoembryonic antigen, carbohydrate antigens 50 and 242, tissue polypeptide antigen and tissue polypeptide specific antigen in the diagnosis of pancreatic cancer with special reference to multivariate diagnostic score.
A proteomic approach to the identification of new tPA receptors in pancreatic cancer cells.
Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer.
Activation of peroxisome proliferator-activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system.
Activation of the epidermal growth factor signalling pathway by tissue plasminogen activator in pancreas cancer cells.
Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer.
Combination of 12-O-tetradecanoylphorbol-13-acetate with diethyldithiocarbamate markedly inhibits pancreatic cancer cell growth in 3D culture and in immunodeficient mice.
Combined determination of serum CA 19-9 and tissue polypeptide antigen: why no improvement in pancreatic cancer diagnosis?
Different role of liver dysfunction and damage in increasing serum CA 19-9, TPA, and CEA in patients with pancreatic cancer.
Effects of 12-O-tetradecanoylphorbol-13-acetate in combination with gemcitabine on Panc-1 pancreatic cancer cells cultured in vitro or Panc-1 tumors grown in immunodeficient mice.
Galectin-1 is a novel functional receptor for tissue plasminogen activator in pancreatic cancer.
Identification and in silico characterization of a novel gene: TPA induced trans-membrane protein.
Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy.
Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Is tissue polypeptide antigen more accurate than serum CEA for diagnosing pancreatic cancer?
Isolation of tissue-type plasminogen activator, cathepsin H, and non-specific cross-reacting antigen from SK-PC-1 pancreas cancer cells using subtractive hybridization.
Pancreatic cancer and thromboembolic disease, 150 years after Trousseau.
Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer.
Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma.
Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis.
Pre-clinical Study of (213)Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer.
Selective activation of PPARgamma inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator.
Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
Specific interaction of tissue-type plasminogen activator (t-PA) with annexin II on the membrane of pancreatic cancer cells activates plasminogen and promotes invasion in vitro.
Synthesis and functionalization of protease-activated nanoparticles with tissue plasminogen activator peptides as targeting moiety and diagnostic tool for pancreatic cancer.
The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.
Thrombospondin-1 and transforming growth factor beta-1 upregulate plasminogen activator inhibitor type 1 in pancreatic cancer.
Tissue plasminogen activator in murine exocrine pancreas cancer: selective expression in ductal tumors and contribution to cancer progression.
Tissue plasminogen activator induces pancreatic cancer cell proliferation by a non-catalytic mechanism that requires extracellular signal-regulated kinase 1/2 activation through epidermal growth factor receptor and annexin A2.
Tissue polypeptide antigen, galactosyltransferase isoenzyme II and pancreatic oncofetal antigen serum determination: role in pancreatic cancer diagnosis.
Transcriptional regulation of claudin-18 via specific protein kinase C signaling pathways and modification of DNA-methylation in human pancreatic cancer cells.
Tumour markers in pancreatic cancer.
[CEA, TPA and APP as a guide in the surgical therapy and follow-up of pancreatic cancer]
[Clinical relevance of tumor markers]
[Measurement of serum tissue polypeptide antigen (TPA) in patients with malignant tumor using prolifigen TPA-M "Daiichi" kit]
[The L.A.I. test and tumor markers (Ca 19-9 and TPA) in the diagnosis of pancreatic carcinoma]
[The role of CEA, CA 19-9 and TPA in the diagnosis of pancreatic cancer. Evaluation by discriminant analysis]
[Tumor markers of pancreatic cancer]
[Tumoral markers and acute-phase reactants in the diagnosis of pancreatic cancer]
Pancreatitis
Acute pancreatitis is a very rare comorbidity of acute ischemic stroke.
The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
Tissue plasminogen activator, plasminogen activator inhibitor, and other parameters of fibrinolysis in the early stages of taurocholate acute pancreatitis in rats.
[Hemostatic indices of oncological patients with different forms of jaundice]
Pancreatitis, Acute Necrotizing
The plasminogen activator/plasmin system is up-regulated after acute necrotizing pancreatitis in human beings.
Pancreatitis, Chronic
Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer.
Combined determination of serum CA 19-9 and tissue polypeptide antigen: why no improvement in pancreatic cancer diagnosis?
Is tissue polypeptide antigen more accurate than serum CEA for diagnosing pancreatic cancer?
The role of the tissue plasminogen activator as a prognostic and differentiation factor in patients with pancreatic canceer and chronic pancreatitis.
Tissue polypeptide antigen, galactosyltransferase isoenzyme II and pancreatic oncofetal antigen serum determination: role in pancreatic cancer diagnosis.
[Serum tissue polypeptide antigen in the differential diagnosis of chronic pancreatitis and exocrine pancreatic tumors. Preliminary results]
[The role of CEA, CA 19-9 and TPA in the diagnosis of pancreatic cancer. Evaluation by discriminant analysis]
[Tumoral markers and acute-phase reactants in the diagnosis of pancreatic cancer]
Papilloma
12-O-tetradecanoylphorbol-13-acetate and UV radiation-induced nucleoside diphosphate protein kinase B mediates neoplastic transformation of epidermal cells.
12-O-tetradecanoylphorbol-13-acetate promotion of transgenic mice expressing epidermal-targeted v-fos induces rasHA-activated papillomas and carcinomas without p53 mutation: association of v-fos expression with promotion and tumor autonomy.
12-O-tetradecanoylphorbol-13-acetate promotion of transgenic mouse epidermis coexpressing transforming growth factor-alpha and v-fos: acceleration of autonomous papilloma formation and malignant conversion via c-Ha-ras activation.
12-O-tetradecanoylphorbol-13-acetate-mediated systemic co-promotion in the murine skin multistage carcinogenesis protocol.
2-year carcinogenicity study in the male NMRI mouse with 2-ethylhexyl acrylate by epicutaneous administration.
26-Week dermal oncogenicity study evaluating pure trans-capsaicin in Tg.AC hemizygous mice (FBV/N).
3,3'-diindolylmethane suppresses 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and tumor promotion in mouse skin via the downregulation of inflammatory mediators.
A derivative of chrysin suppresses two-stage skin carcinogenesis by inhibiting mitogen- and stress-activated kinase 1.
A farnesyl transferase inhibitor suppresses TPA-mediated skin tumor development without altering hyperplasia in the ras transgenic Tg.AC mouse.
A genetic variant of Aurora kinase A promotes genomic instability leading to highly malignant skin tumors.
A novel mechanism of skin tumor promotion involving interferon-gamma (IFN?)/signal transducer and activator of transcription-1 (Stat1) signaling.
A simple phenolic antioxidant protocatechuic acid enhances tumor promotion and oxidative stress in female ICR mouse skin: dose-and timing-dependent enhancement and involvement of bioactivation by tyrosinase.
A subpopulation of 12-O-tetradecanoylphorbol-13-acetate-induced papillomas is not inhibited by retinoic acid.
Aberrant expression during two-stage mouse skin carcinogenesis of a type I 47-kDa keratin, K13, normally associated with terminal differentiation of internal stratified epithelia.
Activation of the rasHa gene in urethane-initiated papillomas induced by protocols with high and low frequencies of malignant conversion.
All-trans retinoic acid protects against conversion of chemically induced and ultraviolet B radiation-induced skin papillomas to carcinomas.
alpha-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin.
Alterations in protein kinase C isozymes alpha and beta 2 in activated Ha-ras containing papillomas in the absence of an increase in diacylglycerol.
Anti-tumor-Promoting activity of tibolone and its metabolites.
Antitumor activity of combination therapy with traditional Chinese medicine and OK432 or MMC.
Antitumor promotional effects of a novel intestinal bacterial metabolite (IH-901) derived from the protopanaxadiol-type ginsenosides in mouse skin.
Arsenic can mediate skin neoplasia by chronic stimulation of keratinocyte-derived growth factors.
Arsenic enhancement of skin neoplasia by chronic stimulation of growth factors.
Arsenic exposure in utero exacerbates skin cancer response in adulthood with contemporaneous distortion of tumor stem cell dynamics.
Assessment of the antioxidant/prooxidant status of murine skin following topical treatment with 12-O-tetradecanoylphorbol-13-acetate and throughout the ontogeny of skin cancer. Part I: Quantitation of superoxide dismutase, catalase, glutathione peroxidase and xanthine oxidase.
Assessment of the antioxidant/prooxidant status of murine skin following topical treatment with 12-O-tetradecanoylphorbol-13-acetate and throughout the ontogeny of skin cancer. Part II: Quantitation of glutathione and glutathione disulfide.
Benzyl isothiocyanate inhibits excessive superoxide generation in inflammatory leukocytes: implication for prevention against inflammation-related carcinogenesis.
beta-Carotene fails to act as a tumor promoter, induces RAR expression, and prevents carcinoma formation in a two-stage model of skin carcinogenesis in male Sencar mice.
Beta-radiation-induced resistance to MNNG initiation of papilloma but not carcinoma formation in mouse skin.
Biological properties of hybrid plasminogen activators.
Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis.
Blue light inhibits the growth of skin tumors in the v-Ha-ras transgenic mouse.
Bryostatin 1 causes attenuation of TPA?mediated tumor promotion in mouse skin.
Characteristics of neoplastic progression and tumor behavior in skin carcinogenesis by different methods: an experimental study.
Characterization of an inbred strain of the SENCAR mouse that is highly sensitive to phorbol esters.
Characterization of skin tumor promotion and progression by chrysarobin in SENCAR mice.
Characterization of the tumor-promoting activity of thapsigargin in cf-1 mouse skin.
Chemical skin carcinogenesis is prevented in mice by the induced expression of a TGF-beta related transgene.
Chemically induced skin carcinogenesis in a transgenic mouse line (TG.AC) carrying a v-Ha-ras gene.
Chemomodulatory Effect of Trigonella foenum graecum (L.) Seed Extract on Two Stage Mouse Skin Carcinogenesis.
Chemopreventive effect of 4'-demethyl epipodophyllotoxin on DMBA/TPA-induced mouse skin carcinogenesis.
Chemopreventive effect of resveratrol, sesamol, sesame oil and sunflower oil in the Epstein-Barr virus early antigen activation assay and the mouse skin two-stage carcinogenesis.
Comparative two-stage cancer tests of ethylene oxide, N-(2-hydroxyethyl)-N-nitrosourea and X-rays.
Comparison of octahydromezerein and mezerein as protein kinase C activators and as mouse skin tumor promoters.
Comparison of the effects of 3-isobutyl-1-methylxanthine and adenosine cyclic 3':5'-monophosphate on the induction of skin tumors by the initiation-promotion protocol and by the complete carcinogenesis process.
Comparison of the tumorigenic response of SENCAR and C57BL/6 mice to benzo(a)pyrene and the inter-experimental variability over a three-year period.
Cultivation and characterization of cells derived from mouse skin papillomas induced by an initiation-promotion protocol.
Cutaneous changes during prolonged application of 12-O-tetradecanoylphorbol-13-acetate on mouse skin and residual effects after cessation of treatment.
Decreases in phorbol ester-induced papilloma development in v-Ha-ras transgenic TG.AC mice during reduced gene dosage of bcl-2.
Defective responses of transformed keratinocytes to terminal differentiation stimuli. Their role in epidermal tumour promotion by phorbol esters and by deep skin wounding.
Dermal carcinogenicity in transgenic mice: effect of vehicle on responsiveness of hemizygous Tg.AC mice to phorbol 12-myristate 13-acetate (TPA).
Development of spontaneous hyperplastic skin lesions and chemically induced skin papillomas in transgenic mice expressing human papillomavirus type 16 E6/E7 genes.
Dietary fat effects on the initiation and promotion of two-stage skin tumorigenesis in the SENCAR mouse.
Differential co-promoting activities of alpha, beta and gamma interferons in the murine skin two-stage carcinogenesis model.
Differential down-regulation of epidermal protein kinase C by 12-O-tetradecanoylphorbol-13-acetate and diacylglycerol: association with epidermal hyperplasia and tumor promotion.
Differential effects of dietary beta-carotene on papilloma and carcinoma formation induced by an initiation-promotion protocol in SENCAR mouse skin.
Differential expression of prostaglandin H synthase isozymes during multistage carcinogenesis in mouse epidermis.
DNA adducts, cell proliferation and papilloma latency time in mouse skin after repeated dermal application of DMBA and TPA.
Dose and frequency effect in mouse skin tumor promotion.
Dose-time response in mouse skin tumor induction by 7, 12-dimethylbenz[a]anthracene and 12-O-tetradecanoyl-phorbol-13-acetate.
Early epidermal destruction with subsequent epidermal hyperplasia is a unique feature of the papilloma-independent squamous cell carcinoma phenotype in PKCepsilon overexpressing transgenic mice.
Effect of the viable-yellow (A(vy)) agouti allele on skin tumorigenesis and humoral hypercalcemia in v-Ha-ras transgenic TGxAC mice.
Effects of beta-carotene on chemically-induced skin tumors in HRA/Skh hairless mice.
Effects of dose and duration of treatment with the tumor-promoting agent, 12-O-tetradecanoylphorbol-13-acetate on mouse skin carcinogenesis.
Effects of N-acyl dehydroalanines on phorbol ester-elicited tumor development and other events in mouse skin.
Effects of oral administration of ciclosporin A on skin carcinogenesis: a study using the two-stage carcinogenesis protocol in mice.
Effects of oral versus topical administration of cyclosporine on phorbol ester promotion of murine epidermal carcinogenesis.
Effects of short-term exposure to the tumor promoter, 12-O-tetradecanoylphorbol-13-acetate on skin carcinogenesis in SENCAR mice.
Effects of the antiandrogen, cyproterone acetate, on the induction of papillomas, DNA synthesis and ornithine decarboxylase activity in mouse skin.
Effects of type of dietary fat on phorbol ester-elicited tumor promotion and other events in mouse skin.
Elevated expression and point mutation of the Ha-ras proto-oncogene in mouse skin tumors promoted by benzoyl peroxide and other promoting agents.
Enhanced sensitivity to tumor growth and development in multistage skin carcinogenesis by transforming growth factor-alpha-induced epidermal growth factor receptor activation but not p53 inactivation.
Enhancement of mezerein-promoted papilloma formation by treatment with 12-O-tetradecanoylphorbol-13-acetate or mezerein prior to initiation.
Epidermal expression of transforming growth factor-alpha in transgenic mice: induction of spontaneous and 12-O-tetradecanoylphorbol-13-acetate-induced papillomas via a mechanism independent of Ha-ras activation or overexpression.
Evaluation of the Tg.AC assay: specificity testing with three noncarcinogenic pharmaceuticals that induce selected stress gene promoters in vitro and the inhibitory effects of solvent components.
Evidence that mirex promotes a unique population of epidermal cells that cannot be distinguished by their mutant Ha-ras genotype.
Evidence that weak promotion of carcinogen-initiated cells prevents their progression to malignancy.
Focal transgene expression associated with papilloma development in v-Ha-ras-transgenic TG.AC mice.
Free radical generating agents lead to the rapid progression of benign skin tumors to carcinoma in iron-overloaded mice.
Frequent codon 12 Ki-ras mutations in mouse skin tumors initiated by N-methyl-N'-nitro-N-nitrosoguanidine and promoted by mezerein.
Further characterization of skin tumor promotion and progression by mezerein in SENCAR mice.
Further studies on the influence of initiation dose on papilloma growth and progression during two-stage carcinogenesis in SENCAR mice.
FVB/N mice: an inbred strain sensitive to the chemical induction of squamous cell carcinomas in the skin.
Genetics of chemical carcinogenesis--II. Papilloma induction and malignant conversion in susceptible (Car-s) and resistant (Car-R) lines of mice produced by bidirectional selective breeding and in their (Car-S X Car-R) F1 hybrids.
Genetics of chemical carcinogenesis: analysis of bidirectional selective breeding inducing maximal resistance or maximal susceptibility to 2-stage skin tumorigenesis in the mouse.
Heterogeneity of ornithine decarboxylase expression in 12-O-tetradecanoylphorbol-13-acetate-treated mouse skin and in epidermal tumors.
High dietary retinoic acid prevents malignant conversion of skin papillomas induced by a two-stage carcinogenesis protocol in female SENCAR mice.
Histologic alterations produced by chrysarobin (1,8-dihydroxy-3-methyl-9-anthrone) in SENCAR mouse skin: relationship to skin tumor promoting activity.
Human keratin-1.bcl-2 transgenic mice aberrantly express keratin 6, exhibit reduced sensitivity to keratinocyte cell death induction, and are susceptible to skin tumor formation.
Human papilloma virus transformed CaSki cells constitutively express high levels of functional SerpinB2.
Human papillomavirus 16 E5 oncogene contributes to two stages of skin carcinogenesis.
Hydrolyzable tannins: potent inhibitors of hydroperoxide production and tumor promotion in mouse skin treated with 12-O-tetradecanoylphorbol-13-acetate in vivo.
Hyperthermia and phorbol ester tumor promotion in mouse skin.
Identification of cembratriene-4,6-diol as antitumor-promoting agent from cigarette smoke condensate.
Identification of epidermal cell subpopulations with increased ornithine decarboxylase activity following treatment of murine epidermis with 12-O-tetradecanoylphorbol-13-acetate.
Immunohistochemical analysis for cell regulatory proteins in bladder carcinogenesis induced by N-methyl-N-nitrosourea-terephthalic acid.
In vivo long-term effects of retinoic acid exposure in utero on induced hyperplastic epidermal foci in murine skin.
Increased sensitivity to two-stage skin carcinogenesis of mice heterozygous for the repeated epilation mutation (Er).
Inducible cutaneous inflammation reveals a protumorigenic role for keratinocyte CXCR2 in skin carcinogenesis.
Inducible nitric oxide synthase mRNA is upregulated in skin tumors of v-ha-ras transgenic TG-AC mice treated with 12-o-tetradecanoylphorbol-13-acetate.
Induction of melanoma in TPras transgenic mice.
Induction of metallothionein mRNA by tumor promoters in mouse skin and its constitutive expression in papillomas.
Induction of PA2.26, a cell-surface antigen expressed by active fibroblasts, in mouse epidermal keratinocytes during carcinogenesis.
Induction of papillomas with a high probability of conversion to malignancy.
Induction of terminal differentiation-resistant epidermal cells in mouse skin and in papillomas by different initiators during two-stage carcinogenesis.
Influence of diet restriction and tumor promoter dose on cell proliferation, oxidative DNA damage and rate of papilloma appearance in the mouse skin after initiation with DMBA and promotion with TPA.
Influence of dose of initiator on two-stage skin carcinogenesis in BALB/c mice with cellular mosaicism.
Influences of sphingosine on two-stage skin tumorigenesis in Sencar mice.
Inhibition by putrescine of the induction of epidermal ornithine decarboxylase activity and tumor promotion caused by 12-O-tetradecanoylphorbol-13-acetate.
Inhibition of both stage I and stage II mouse skin tumour promotion by retinoic acid and the dependence of inhibition of tumor promotion on the duration of retinoic acid treatment.
Inhibition of both stage I and stage II skin tumor promotion in SENCAR mice by a polyphenolic fraction isolated from green tea: inhibition depends on the duration of polyphenol treatment.
Inhibition of mouse skin tumor promotion and of promoter-induced epidermal polyamine biosynthesis by methylglyoxal bis(butylamidinohydrazone).
Inhibition of mouse skin tumor promotion and of promoter-stimulated epidermal polyamine biosynthesis by alpha-difluoromethylornithine.
Inhibitory effects of caffeic acid phenethyl ester (CAPE) on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion in mouse skin and the synthesis of DNA, RNA and protein in HeLa cells.
Inhibitory effects of licochalcone A isolated from Glycyrrhiza inflata root on inflammatory ear edema and tumour promotion in mice.
Inhibitory effects of oligonol on phorbol ester-induced tumor promotion and COX-2 expression in mouse skin: NF-kappaB and C/EBP as potential targets.
Integrin A6 Cleavage in Mouse Skin Tumors.
Interaction between bovine papillomavirus type 4 and cocarcinogens in the production of malignant tumours.
Ionizing radiation as an initiator in the mouse two-stage model of skin tumor formation.
Ionizing radiation as an initiator: effects of proliferation and promotion time on tumor incidence in mice.
Ionizing radiation enhances malignant progression of mouse skin tumors.
Lack of initiating capacity of the genotoxic air pollutant 2-nitrofluorene in the mouse skin two-stage carcinogenesis system.
Malignant conversion and metastasis of mouse skin tumors: a comparison of SENCAR and CD-1 mice.
Malignant conversion of mouse skin tumours is increased by tumour initiators and unaffected by tumour promoters.
Malignant conversion, the first stage in progression, is distinct from phorbol ester promotion in mouse skin.
Malignant progression of papillomas induced by the initiation--promotion protocol in NMRI mouse skin.
Manganese superoxide dismutase is a p53-regulated gene that switches cancers between early and advanced stages.
Mathematical modeling of skin papilloma data in SENCAR mice.
Mechanism of mouse skin tumor promotion by chrysarobin.
Moderate enhancement of the promotion phase of skin tumorigenesis in hairless mice by topical pretreatment with a mitosis-inhibiting epidermal pentapeptide.
Modification of N-Methyl-N-Nitrosourea initiated bladder carcinogenesis in Wistar rats by terephthalic acid.
Modulation by adriamycin, daunomycin, verapamil, and trifluoperazine of the biochemical processes linked to mouse skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Modulation of chemically initiated and promoted skin tumorigenesis in CD-1 mice by dietary glucarate.
Modulation of mouse skin tumor promotion by dietary 13-cis-retinoic acid and alpha-difluoromethylornithine.
Modulation of the co-promoting activity of gamma interferon in SENCAR and C57BL/6 mouse skin by difluoromethylornithine and the scheduling and duration of interferon treatment.
New strains of inbred SENCAR mice with increased susceptibility to induction of papillomas and squamous cell carcinomas in skin.
Nitric oxide induces expression of cyclooxygenase-2 in mouse skin through activation of NF-kappaB.
Non-melanoma skin cancer in mouse and man.
NTP Toxicology and Carcinogenesis Studies of 1,2-Dihydro-2,2,4-Trimethylquinoline (CAS No. 147-47-7) in F344/N Rats and B6C3F1 Mice (Dermal Studies) and the Dermal Initiation/Promotion Study in Female Sencar Mice.
NTP Toxicology and Carcinogenesis Studies of Diethylphthalate (CAS No. 84-66-2) in F344/N Rats and B6C3F1 Mice (Dermal Studies) with Dermal Initiation/ Promotion Study of Diethylphthalate and Dimethylphthalate (CAS No. 131-11-3) in Male Swiss (CD-1(R)) Mice.
Okadaic acid induces the expression of both early and secondary response genes in mouse keratinocytes.
Only a subset of 12-O-tetradecanoylphorbol-13-acetate-promoted mouse skin papillomas are promotable by benzoyl peroxide.
Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice.
Oxymetholone: II. Evaluation in the Tg-AC transgenic mouse model for detection of carcinogens.
p44 mitogen-activated protein kinase (extracellular signal-regulated kinase 1)-dependent signaling contributes to epithelial skin carcinogenesis.
Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha.
Polymeric black tea polyphenols inhibit mouse skin chemical carcinogenesis by decreasing cell proliferation.
Possible dissociation of the phorbol ester-induced oxidant response and tumor promotion in the F1 offspring of SSIN x C57BL/6J mice.
Potentiation of tumor formation by topical administration of 15-deoxy-delta12,14-prostaglandin J2 in a model of skin carcinogenesis.
Pro/antioxidant status in murine skin following topical exposure to cumene hydroperoxide throughout the ontogeny of skin cancer.
Promoter independence as a feature of most skin papillomas in SENCAR mice.
Promotion of skin tumors by 12-O-tetradecanoylphorbol-13-acetate in two generations of descendants of male mice exposed to X-ray irradiation.
Promutagenic etheno-DNA adducts in multistage mouse skin carcinogenesis: correlation with lipoxygenase-catalyzed arachidonic acid metabolism.
Protection against 12-O-tetradecanoylphorbol-13-acetate induced skin-hyperplasia and tumor promotion, in a two-stage carcinogenesis mouse model, by the 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-[2,3-b]quinoxaline analogue of ellipticine.
Protection against induction of mouse skin papillomas with low and high risk of conversion to malignancy by green tea polyphenols.
Protective effect of all trans retinoic acid against tumor promotion and progression in low- and high-risk protocols of mouse skin chemical carcinogenesis.
Protective role of cathepsin L in mouse skin carcinogenesis.
Raised expression of the antiapoptotic protein ped/pea-15 increases susceptibility to chemically induced skin tumor development.
Rapid induction of skin and mammary tumors in human c-Ha-ras proto-oncogene transgenic rats by treatment with 7,12-dimethylbenz[a]anthracene followed by 12-O-tetradecanoylphorbol 13-acetate.
REG? is critical for skin carcinogenesis by modulating the Wnt/?-catenin pathway.
Regression and progression characteristics of papillomas induced by chrysarobin in SENCAR mice.
Regulation of ornithine decarboxylase gene expression in mouse epidermis and epidermal tumors during two-stage tumorigenesis.
Relation of the induction of epidermal ornithine decarboxylase and hyperplasia to the different skin tumor-promotion susceptibilities of protein kinase C alpha, -delta and -epsilon transgenic mice.
Reversal of food restriction-induced inhibition of mouse skin tumor promotion by adrenalectomy.
Sandalwood oil prevent skin tumour development in CD1 mice.
SENCAR mouse skin tumors produced by promotion alone have A to G mutations in codon 61 of the c-rasHa gene.
Sensitivity of HRA/Skh hairless mice to initiation/promotion of skin tumors by chemical treatment.
Sensitivity of subpopulations of mouse skin papillomas to malignant conversion by urethane or 4-nitroquinoline N-oxide.
Sequential studies of skin tumorigenesis in PGK mosaic mice: the effect of repeated exposure to a carcinogen on regressed mouse skin papillomas.
Sequential studies of skin tumorigenesis in phosphoglycerate kinase mosaic mice: effect of resumption of promotion on regressed papillomas.
Skin carcinomas and micronucleus induction in epidermal keratinocytes following 12-O-tetradecanoylphorbol-13-acetate and mezerein treatment.
Skin tumorigenesis by initiators and promoters of different chemical structures in lines of mice selectively bred for resistance (Car-r) or susceptibility (Car-s) to two-stage skin carcinogenesis.
Squamous cell hyperplastic foci: precursors of cutaneous papillomas induced in SENCAR mice by a two-stage carcinogenesis regimen.
Susceptibility of 129/SvEv mice in two-stage carcinogenesis protocols to 12-O-tetradecanoylphorbol-13-acetate promotion.
Synergistic interaction between the non-phorbol ester-type promoter mirex and 12-O-tetradecanoylphorbol-13-acetate in mouse skin tumor promotion.
Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis.
Terminal differentiation-resistant epidermal cells in mice undergoing two-stage carcinogenesis.
TGF alpha is dispensable for skin tumorigenesis in Tg.AC mice.
The chemotherapeutic effect of ?-2-himachalen-6-ol in chemically induced skin tumorigenesis.
The effect of the level of dietary corn oil on mouse skin carcinogenesis.
The genetic control of chemically and radiation-induced skin tumorigenesis: a study with carcinogenesis-susceptible and carcinogenesis-resistant mice.
The influence of a hyperthermia treatment on chemically induced tumor initiation and progression in mouse skin.
The tumor-initiating and -promoting effects of ionizing radiations in mouse skin.
Topical retinoic acid reduces skin papilloma formation but resistant papillomas are at high risk for malignant conversion.
Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition.
Transforming Growth Factor {beta}1 Enhances Tumor Promotion in Mouse Skin Carcinogenesis.
Transgenic coexpression of v-Ha-ras and transforming growth factor alpha increases epidermal hyperproliferation and tumorigenesis and predisposes to malignant conversion via endogenous c-Ha-ras activation.
Transmaternal variation of the Berenblum experiment with NMRI-mice: tumour initiation with DMBA via mothers milk followed by promotion with the phorbol ester TPA.
Transplacental carcinogenicity of cisplatin: initiation of skin tumors and induction of other preneoplastic and neoplastic lesions in SENCAR mice.
Tumor copromoting activity of gamma-interferon in the murine skin multistage carcinogenesis model.
Tumor initiating activities of 1-nitropyrene and its nitrated products in SENCAR mice.
Tumor progression in Sencar mouse skin as a function of initiator dose and promoter dose, duration, and type.
Tumor progression of murine epidermal cells after treatment in vitro with 12-O-tetradecanoylphorbol-13-acetate or retinoic acid.
Tumorigenesis and carcinogenesis in mouse skin treated with hyperthermia during stage I or stage II of tumor promotion.
Tumorigenesis facilitated by Pten deficiency in the skin: evidence of p53-Pten complex formation on the initiation phase.
v-ras genes from Harvey and BALB murine sarcoma viruses can act as initiators of two-stage mouse skin carcinogenesis.
Vitamin E is a complete tumor promoter in mouse skin.
[Factors controlling tumor promotion induced by TPA]
[Skin carcinogenesis induced be neonatal administration of 5-bromo-2'-deoxyuridine and subsequent treatment with 12-O-tetradecanoylphorbol-13-acetate in mice]
[Study on the anti-carcinogenic effects of three compounds in Kaempferia galanga L]
[The effect of the irradiation of male mice on the sensitivity of 2 generations of progeny to the action of the skin tumor promoter 12-0-tetradecanoylphorbol-13-acetate]
Papillomavirus Infections
Up-regulation of plasminogen activator inhibitor-2 is associated with high-risk HPV and grade of cervical lesion at baseline but does not predict outcomes of high-risk HPV infections or incident CIN.
Paralysis
Fibrinolysis and spinal injury. Relationship to post-traumatic deep vein thrombosis.
Hemorrhagic upper extremity complications from tissue plasminogen activator.
Pathogenesis of venous thromboembolism: when the cup runneth over.
Paraparesis
Spinal Epidural Hematoma as a Complication of Intravenous Thrombolysis in an Acute Ischemic Stroke Patient.
Paraplegia
Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators.
Paraplegia subsequent to administration of tissue plasminogen activator and intravenous heparin following myocardial infarction--a case report.
Parasitemia
Macrophage activation in murine African trypanosomiasis.
Paresis
A case of intracranial arterial dolichoectasia with 4 repeated cerebral infarctions in 6 months and enlargement of basilar artery.
A spontaneous cervical epidural hematoma mimicking a stroke - A case report.
Acute ischemic stroke successfully treated using sequenced intravenous and intra-arterial thrombolysis and argatroban anticoagulation: a case study.
Angioedema After tPA: What Neurointensivists Should Know.
Cardiac Papillary Fibroelastoma: Source of Cerebral Embolism Treated With Intravenous Thrombolysis.
Effective and safe conditions of low-frequency transcranial ultrasonic thrombolysis for acute ischemic stroke: neurologic and histologic evaluation in a rat middle cerebral artery stroke model.
Emergent Double-barrel Bypass Shortly after Intravenous Administration of Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke.
Evidence of anaphylaxy after alteplase infusion.
Imaging Evidence for Cerebral Hyperperfusion Syndrome after Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke.
Impaired volitional closure of the left eyelid after right anterior cerebral artery infarction: apraxia due to interhemispheric disconnection?
Improper Use of Thrombolytic Agents in Acute Hemiparesis Following Misdiagnosis of Acute Ischemic Stroke.
Pulmonary Embolism in a Stroke Patient after Systemic Thrombolysis: Clinical Decisions and Literature Review.
Spinal epidural hematoma: an important stroke mimic.
Stroke and Cardiac Papillary Fibroelastoma: Mechanical Thrombectomy after Thrombolytic Therapy.
Stroke secondary to calcific bicuspid aortic valve: Case report and literature review.
Successful Intravenous Alteplase for a Centenarian Woman with Acute Ischaemic Stroke.
Successful thrombolysis without hemorrhage in a patient with cardioembolic stroke under dabigatran treatment-a case report and review of literature.
Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report.
The Role of Angioplasty Alone in Intracranial Atherosclerosis: 2-Dimensional Operative Video.
Unruptured Cerebral Aneurysm Detected after Intravenous Tissue Plasminogen Activator for Stroke.
Use of Emergency department transcranial doppler assessment of reperfusion after intravenous tPA for ischemic stroke.
Worsening Cervical Epidural Hematoma After Tissue Plasminogen Activator Administration for Stroke Like Symptoms.
[Clinical Manifestations of Spinal Epidural Hematoma-Stroke Mimic and Pitfalls in Diagnosis].
[Intracerebral and subarachnoid hemorrhages after administration of recombinant tissue plasminogen activator in a patient with acute ischemicstroke due to anterior cerebral artery dissection: a case report].
[Takotsubo Cardiomyopathy and Neurogenic Pulmonary Edema Following Fibrinolytic Therapy for Embolic Stroke:A Case Report].
Parkinson Disease
Role of plasminogen activator inhibitor-1 in the diagnosis and prognosis of patients with Parkinson's disease.
Synergy between plasminogen activator inhibitor-1, ?-synuclein, and neuroinflammation in Parkinson's disease.
Pediatric Obesity
Childhood obesity: evidence of an association between plasminogen activator inhibitor-1 levels and visceral adiposity.
Elevated circulating tissue factor procoagulant activity, factor VII, and plasminogen activator inhibitor-1 in childhood obesity: evidence of a procoagulant state.
Maternal body mass index, change in weight status from childhood to late adulthood and physical activity in older age.
Metabolic syndrome in youths.
Pelvic Inflammatory Disease
Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
Pelvic Neoplasms
Establishment of a human renal pelvic cancer cell line producing tissue thromboplastin and plasminogen activator.
Pemphigoid Gestationis
An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid.
Pemphigoid, Bullous
Determination of plasminogen activator activities in normal and pathological human tears. The significance of tear plasminogen activators in the inflammatory and traumatic lesions of the cornea and the conjunctiva.
Interleukin-1 beta upregulates tissue-type plasminogen activator in a keratinocyte cell line (HaCaT).
mRNA for tissue-type plasminogen activator is present in lesional epidermis from patients with psoriasis, pemphigus, or bullous pemphigoid, but is not detected in normal epidermis.
Plasminogen activation in bullous pemphigoid immunohistology reveals urokinase type plasminogen activator, its receptor and plasminogen activator inhibitor type-2 in lesional epidermis.
Serum is a potent stimulator of keratinocyte tissue plasminogen activator expression.
Transmembrane signaling for adhesive regulation of desmosomes and hemidesmosomes, and for cell-cell datachment induced by pemphigus IgG in cultured keratinocytes: involvement of protein kinase C.
Pemphigus
A possible mechanism for phenol-induced pemphigus.
Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation.
Calcium-independent increases in pericellular plasminogen activator activity in pemphigus vulgaris.
Characterization of keratinocyte plasminogen activator inhibitors and demonstration of the prevention of pemphigus IgG-induced acantholysis by a purified plasminogen activator inhibitor.
Dexamethasone inhibits plasminogen activator activity in experimental pemphigus in vivo but does not block acantholysis.
Interleukin-1 beta upregulates tissue-type plasminogen activator in a keratinocyte cell line (HaCaT).
mRNA for tissue-type plasminogen activator is present in lesional epidermis from patients with psoriasis, pemphigus, or bullous pemphigoid, but is not detected in normal epidermis.
Pemphigus can be induced by topical phenol as well as by foods and drugs that contain phenols or thiols.
Pemphigus IgG activates and translocates protein kinase C from the cytosol to the particulate/cytoskeleton fractions in human keratinocytes.
Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice.
Penicillamine-induced pemphigus. Immunoglobulin from this patient induces plasminogen activator synthesis by human epidermal cells in culture: mechanism for acantholysis in pemphigus.
Pharmacologic evidence for involvement of phospholipase C in pemphigus IgG-induced inositol 1,4,5-trisphosphate generation, intracellular calcium increase, and plasminogen activator secretion in DJM-1 cells, a squamous cell carcinoma line.
Plasmin induces acantholysis in skin organ cultures.
Plasminogen activation in lesional skin of Pemphigus vulgaris type Neumann.
Plasminogen activator system in pemphigus vulgaris.
Protease inhibitors prevent plasminogen-mediated, but not pemphigus vulgaris-induced, acantholysis in human epidermis.
Role of plasminogen activator in pemphigus vulgaris.
Serum is a potent stimulator of keratinocyte tissue plasminogen activator expression.
The effect of corticosteroids, dapsone and gold upon plasminogen activator synthesis and secretion by human epidermal cells cultured with pemphigus antibody.
Pemphigus, Benign Familial
Serum is a potent stimulator of keratinocyte tissue plasminogen activator expression.
Penile Induration
Peyronie's disease associated with increase in plasminogen activator inhibitor in fibrotic plaque.
Peptic Ulcer
Mucoadhesive gastroretentive microparticulate system for programmed delivery of famotidine and clarithromycin.
Mucosal plasminogen activator activity in peptic ulcer disease.
Reduced tissue type plasminogen activator activity of the gastroduodenal mucosa in peptic ulcer disease.
Tissue plasminogen activator and plasminogen activator inhibitor type 1 gene polymorphism in patients with gastric ulcer complicated with bleeding.
[Clinical study on tissue polypeptide antigen (TPA) in gastric cancer]
Peri-Implantitis
Associations between peri-implant crevicular fluid volume, concentrations of crevicular inflammatory mediators, and composite IL-1A -889 and IL-1B +3954 genotype. A cross-sectional study on implant recall patients with and without clinical signs of peri-implantitis.
Pericardial Effusion
Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease.
Hemopericardium and cardiac tamponade after thrombolysis for acute ischemic stroke.
Left atrial thrombus in a 10-month-old boy--successful thrombolysis with recombinant tissue-type plasminogen activator after open-heart surgery: review of the literature.
Pericardial effusion after intravenous recombinant tissue-type plasminogen activator for acute myocardial infarction.
Therapeutic application of intrapericardial tissue plasminogen activator in a 4-month-old child with complex fibropurulent pericarditis.
[A case of advanced gastric cancer with carcinomatous pericarditis effectively treated by S-1/CDDP combined therapy].
[Two separate surgical repairs of post-infarction blowout rupture of the left ventricular free wall and subsequently developed subepicardial aneurysm]
Pericarditis
Intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series.
Lessons from the European Cooperative recombinant tissue-type plasminogen activator (rt-PA) versus placebo trial.
Pericardial infusion of tissue plasminogen activator in fibropurulent pericarditis.
Successful therapy of transplant-associated veno-occlusive disease with a combination of tissue plasminogen activator and defibrotide.
Therapeutic application of intrapericardial tissue plasminogen activator in a 4-month-old child with complex fibropurulent pericarditis.
Pericarditis, Constrictive
Intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series.
Periodontal Diseases
A clinical study of plasminogen activator activity in gingival tissue in dogs with gingivitis and periodontitis.
Association of gene polymorphisms for plasminogen activators with alveolar bone loss.
Evaluation of gingival crevicular fluid levels of tissue plasminogen activator, plasminogen activator inhibitor 2, matrix metalloproteinase-3 and interleukin 1-? in patients with different periodontal diseases.
Molecular characterization of plasminogen activator in human supragingival plaque.
Periodontal disease and biomarkers related to cardiovascular disease.
Plasminogen activator system in smokers and non-smokers with and without periodontal disease.
Serum Plasminogen Activator Inhibitor-1 (PAI-1) and Tumor Necrosis Factor-Alpha (TNF-?) Levels in Obesity and Periodontal Disease.
Signal transduction pathways involved in the stimulation of tissue type plasminogen activator by interleukin-1alpha and Porphyromonas gingivalis in human osteosarcoma cells.
Up-regulation of osteolytic mediators in human osteosarcoma cells stimulated with nicotine.
Periodontal Pocket
Periodontal disease is associated with carotid plaque area: the Malmö Offspring Dental Study (MODS).
Periodontitis
A clinical study of plasminogen activator activity in gingival tissue in dogs with gingivitis and periodontitis.
Comparing periodontitis biomarkers in saliva, oral rinse and gingival crevicular fluid: A pilot study.
Detection of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor 2(PAI-2) in gingival crevicular fluid from healthy, gingivitis and periodontitis patients.
Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in Turkish patients with generalized aggressive periodontitis.
Gingival crevicular fluid tissue/blood vessel-type plasminogen activator and plasminogen activator inhibitor-2 levels in patients with rheumatoid arthritis: effects of nonsurgical periodontal therapy.
Periodontitis contributes to aberrant metabolism in type 2 diabetes mellitus rats by stimulating the expression of adipokines.
Plasminogen activator in human periodontal health and disease.
Plasminogen activator inhibitor type 1 expression induced by lipopolysaccharide of Porphyromonas gingivalis in human gingival fibroblast.
Plasminogen activator inhibitor-1 polymorphisms as a risk factor for chronic periodontitis in North Indian population.
Tissue plasminogen activator and plasminogen activator inhibitor-1 gene polymorphisms in patients with chronic periodontitis.
Peripheral Arterial Disease
Ankle-brachial index and hemostatic markers in the Atherosclerosis Risk in Communities (ARIC) study cohort.
Association between physical activity and endogenous fibrinolysis in peripheral arterial disease: a cross-sectional study.
Brain Natriuretic Peptide Is a Powerful Predictor of Outcome in Stroke Patients with Atrial Fibrillation?.
Cost-effectiveness of urokinase and alteplase for treatment of acute peripheral artery disease: comparison in a decision analysis model.
Fibrinogen and plasminogen activator inhibitor-1 level in peripheral arterial disease of type 2 diabetes patients.
Hypercoagulability Markers in Patients With Peripheral Arterial Disease: Association to Ankle-brachial Index.
Progressive intermittent claudication is associated with impaired fibrinolysis.
Relation of haemostatic, fibrinolytic, and rheological variables to the angiographic extent of peripheral arterial occlusive disease.
Smoking, haemostatic factors and lipid peroxides in a population case control study of peripheral arterial disease.
Tissue plasminogen activator, tissue plasminogen activator inhibitor and lipoprotein(a) in patients with coronary, epiaortic and peripheral occlusive artery disease.
Tissue-plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease.
Peripheral Nerve Injuries
Crohn's disease but not chronic ulcerative colitis induces the expression of PAI-1 in enteric neurons.
Exogenous tissue plasminogen activator enhances peripheral nerve regeneration and functional recovery after injury in mice.
Induction of plasminogen activator inhibitor-1 and -2 in dorsal root ganglion neurons after peripheral nerve injury.
Tissue plasminogen activator in primary afferents induces dorsal horn excitability and pain response after peripheral nerve injury.
Tissue plasminogen activator promotes axonal outgrowth on CNS myelin after conditioned injury.
Peripheral Nervous System Diseases
Associations of serum anti-ganglioside antibodies and inflammatory markers in diabetic peripheral neuropathy.
Interactions between and Shared Molecular Mechanisms of Diabetic Peripheral Neuropathy and Obstructive Sleep Apnea in Type 2 Diabetes Patients.
Peripheral Vascular Diseases
Alteplase: descendancy in myocardial infarction, ascendancy in stroke.
Metformin in noninsulin-dependent diabetes mellitus.
Pharmacologic therapies in the treatment of peripheral vascular disease: clinical experience with reteplase, a third-generation thrombolytic.
Short- and long-term treatments with iloprost in diabetic patients with peripheral vascular disease: effects on the cardiovascular risk factor plasminogen activator inhibitor type-1.
Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab. The SCVIR Consultants' Conference; May 22, 2000; Orlando, FL. Society for Cardiovascular and Interventional Radiology.
Using efficacy, safety, and cost data to support a formulary decision regarding thrombolytic therapy.
von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis.
[Local low dosage thrombolysis with rt-PA. Systemic effects on the fibrinolytic system--data on the assessment of the value and risk of this method]
Peritoneal Fibrosis
Peritoneal Effluent MMP-2 and PAI-1 in Encapsulating Peritoneal Sclerosis.
Poly(ADP-ribose) polymerase-1 in high glucose-induced epithelial-mesenchymal transition during peritoneal fibrosis.
The impact of gene polymorphisms in angiotensin receptor 1 and aldosterone synthase in peritoneal dialysis patients.
Tissue-type plasminogen activator (tPA) and its inhibitor (PAI-1) in patients treated with continuous ambulatory peritoneal dialysis.
Tissue-type plasminogen activator deficiency attenuates peritoneal fibrosis in mice.
Peritoneal Neoplasms
Role of CEA, TPA, and Ca 19-9 in the early detection of localized and diffuse recurrent rectal cancer.
Peritonitis
Both tissue-type plasminogen activator and urokinase prevent intraabdominal abscess formation after surgical treatment of peritonitis in the rat.
Candidate host marker for peritoneal dissemination.
Effect of recombinant tissue plasminogen activator on intra-abdominal abscess formation in rats with generalized peritonitis.
Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
Effects of tissue plasminogen activator in experimentally induced peritonitis.
Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice.
Fibrinolytic activity in the abdominal cavity of rats with faecal peritonitis.
Gentamycin reduces bacteremia and mortality rates associated with the treatment of experimental peritonitis with recombinant tissue plasminogen activator.
Intraperitoneal hypercoagulation and hypofibrinolysis is present in childhood peritonitis.
PAI-1 secretion and matrix deposition in human peritoneal mesothelial cell cultures: transcriptional regulation by TGF-beta 1.
Peritoneal fibrinolytic activity in peritonitis.
Pharmacokinetics of human recombinant tissue-type plasminogen activator, administered intra-abdominally, in a rat peritonitis model.
Plasminogen activator, but not systemic antibiotic therapy, prevents abscess formation in an experimental model of secondary peritonitis.
Preclinical Assessment of Adjunctive tPA and DNase for Peritoneal Dialysis Associated Peritonitis.
Prevention of intraperitoneal adhesions and abscesses by polysaccharides isolated from Phellinus spp in a rat peritonitis model.
Protein C as an early marker of severe septic complications in diffuse secondary peritonitis.
Successful use of recombinant tissue plasminogen activator in a patient with relapsing peritonitis.
The role of fibrinolysis in adhesion formation.
Time course of peritoneal tissue plasminogen activator after experimental colonic surgery: effect of hyaluronan-based antiadhesive agents and bacterial peritonitis.
Timing and dose of tissue plasminogen activator to prevent abscess formation after surgical treatment of secondary peritonitis in the rat.
Tissue-type plasminogen activator prevents abscess formation but does not affect healing of bowel anastomoses and laparotomy wounds in rats with secondary peritonitis.
Tissue-type plasminogen activator prevents formation of intra-abdominal abscesses after surgical treatment of secondary peritonitis in a rat model.
Use of tissue plasminogen activator in peritoneal dialysis catheters: a literature review and one center's experience.
[Changes in tissue plasminogen activator in experimental peritonitis caused by pathogenic factors]
[Studies on fibrinolysis and ascites accumulation associated with peritonitis carcinomatosa--inducer of plasminogen activator (IPA) in malignant ascites tumor]
Pheochromocytoma
Expression of nerve growth factor-induced type 1 plasminogen activator inhibitor (PAI-1) mRNA is inhibited by genistein and wortmannin.
Hemodynamic stability during adrenalectomy for pheochromocytoma: A case control study of posterior retroperitoneal vs lateral transperitoneal approaches.
Neuroserpin regulates N-cadherin-mediated cell adhesion independently of its activity as an inhibitor of tissue plasminogen activator.
Plasminogen activator inhibitor-1 aids nerve growth factor-induced differentiation and survival of pheochromocytoma cells by activating both the extracellular signal-regulated kinase and c-Jun pathways.
Plasminogen activator inhibitor-1 aids survival of neurites on neurons derived from pheochromocytoma (PC-12) cells.
Phlebitis
[Treatment of blue phlebitis by in situ thrombolysis with a plasminogen activator]
Photosensitivity Disorders
Augmentation of 12-O-tetradecanoyl 13-phorbol acetate-mediated tumor promoting response by the porphyrin photosensitization of 7,12-dimethyl benz[a]anthracene-initiated murine skin: role of in situ generated reactive oxygen species.
Pituitary ACTH Hypersecretion
Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Pituitary Neoplasms
12-O-tetradecanoyl-phorbol-13-acetate-induced ACTH secretion in pituitary tumor cells.
Bryostatins selectively regulate protein kinase C-mediated effects on GH4 cell proliferation.
Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
Growth hormone secretion in human acromegalic pituitary adenomas: cyclic adenosine monophosphate and protein kinase C responses.
Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications.
Placenta Accreta
Placenta accreta spectrum: biomarker discovery using plasma proteomics.
[Placenta accreta: epidemiology, molecular mechanism (hypothesis) and some clinical remarks]
Placental Insufficiency
Adverse obstetric and neonatal outcomes in women with mental disorders.
Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia.
The 4G/4G polymorphism of the plasminogen activator inhibitor-1 (PAI-1) gene as an independent risk factor for placental insufficiency, which triggers fetal hemodynamic centralization.
Plague
A dual role for the Plasminogen activator protease during the pre-inflammatory phase of primary pneumonic plague.
Characterization of Yersinia Using MALDI-TOF Mass Spectrometry and Chemometrics.
Detection of Yersinia pestis using branched DNA.
Direct transcriptional control of the plasminogen activator gene of Yersinia pestis by the cyclic AMP receptor protein.
Evaluation of the role of the Yersinia pestis plasminogen activator and other plasmid-encoded factors in temperature-dependent blockage of the flea.
Expression of the low calcium response in Yersinia pestis.
Expression of the plague plasminogen activator in Yersinia pseudotuberculosis and Escherichia coli.
Functional characterization and biological significance of Yersinia pestis lipopolysaccharide biosynthesis genes.
Modeling Pneumonic Plague in Human Precision-Cut Lung Slices Highlights a Role for the Plasminogen Activator Protease in Facilitating Type 3 Secretion.
Neurovascular proteases in brain injury, hemorrhage and remodeling after stroke.
Protein regions important for plasminogen activation and inactivation of alpha2-antiplasmin in the surface protease Pla of Yersinia pestis.
Proteolysis of plasminogen activator inhibitor-1 by Yersinia pestis remodulates the host environment to promote virulence.
Relative immunogenicity and protection potential of candidate Yersinia Pestis antigens against lethal mucosal plague challenge in Balb/C mice.
Role of the Yersinia pestis plasminogen activator in the incidence of distinct septicemic and bubonic forms of flea-borne plague.
Structural basis for activation of an integral membrane protease by lipopolysaccharide.
The omptin family of enterobacterial surface proteases/adhesins: from housekeeping in Escherichia coli to systemic spread of Yersinia pestis.
Plasmacytoma
Expression of intermediate filament proteins in TPA-induced MPC-11 and HL-60 cells.
Expression of nuclear lamins in mammalian somatic cells lacking cytoplasmic intermediate filament proteins.
Role of microRNA 1207-5P and its host gene, the long non-coding RNA Pvt1, as mediators of extracellular matrix accumulation in the kidney: implications for diabetic nephropathy.
TPA induces apoptosis in MPC-11 mouse plasmacytoma cells grown in serum-free medium.
plasmin deficiency
Clinical disorders of fibrinolysis: a critical review.
Development and application of global assays of hyper- and hypofibrinolysis.
Dysfunctional fibrinolysis and cerebral venous thrombosis.
Hypercoagulable states.
Serine proteases, inhibitors and receptors in renal fibrosis.
Type 1 Plasminogen Deficiency With Pulmonary Involvement: Novel Treatment and Novel Mutation.
Pleural Diseases
[Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma]
Pleural Effusion
A 22-year-old man with pleural tuberculosis associated hydropneumothorax: Case report and literature review.
Alteplase: pleural effusion (parapneumonic) and empyema in children.
Analysis of Cytokine Levers in Pleural Effusions of Tuberculous Pleurisy and Tuberculous Empyema.
Computed Tomography Angiography Findings in Pulmonary Embolism Patients Vary Following Thrombolytic Treatment.
Current use of intrapleural tissue plasminogen activator in the treatment of complex pleural processes: a review of the literature and report of 9 cases.
Dose De-Escalation of Intrapleural Tissue Plasminogen Activator Therapy for Pleural Infection: The ADAPT Project.
Dose dependency of outcomes of intrapleural fibrinolytic therapy in new rabbit empyema models.
Efficacy and safety of intrapleural instillation of alteplase in the management of complicated pleural effusion or empyema.
Extended Dwell Time Improves Results of Fibrinolytic Therapy for Complex Pleural Effusions.
Fibrinolysis treatment for loculated parapneumonic pleural effusion secondary to right lower lobe pneumonia.
Fibrinolytic and inflammatory processes in pleural effusions.
Intrapleural alteplase decreases parapneumonic effusion volume in children more than saline irrigation.
Intrapleural alteplase in a patient with complicated pleural effusion.
Intrapleural Fibrinolysis with Urokinase Versus Alteplase in Complicated Parapneumonic Pleural Effusions and Empyemas: A Prospective Randomized Study.
Intrapleural hemorrhage after administration of tPA: a case report and review of the literature.
Intrapleural hemorrhage due to alteplase use in a 6-year-old boy with pleural effusion.
Intrapleural tissue plasminogen activator for complicated pleural effusions.
Mixing It Up: Coadministration of tPA/DNase in Complicated Parapneumonic Pleural Effusions and Empyema.
Proinflammatory cytokines and fibrinolytic enzymes in tuberculous and malignant pleural effusions.
Proinflammatory cytokines, transforming growth factor-beta1, and fibrinolytic enzymes in loculated and free-flowing pleural exudates.
Recombinant tissue plasminogen activator in the treatment of pleural infections in adults.
Relationships among tumor burden, tumor size, and the changing concentrations of fibrin degradation products and fibrinolytic factors in the pleural effusions of rabbits with VX2 lung tumors.
Rethinking the Doses of Tissue Plasminogen Activator and Deoxyribonuclease Administrated Concurrently for Intrapleural Therapy for Complicated Pleural Effusion and Empyema.
Safe administration of intrapleural alteplase during pregnancy.
Safety and Efficacy of Tissue Plasminogen Activator and DNase for Complicated Pleural Effusions Secondary to Abdominal Pathology.
Thrombin Upregulates PAI-1 and Mesothelial-Mesenchymal Transition Through PAR-1 and Contributes to Tuberculous Pleural Fibrosis.
Tissue Plasminogen Activator Potently Stimulates Pleural Effusion via an MCP-1 Dependent Mechanism.
Tissue polypeptide antigen (TPA) in pleural effusions.
Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment.
[A case of advanced gastric cancer with carcinomatous pericarditis effectively treated by S-1/CDDP combined therapy].
[A clinical study on CEA, TPA, ADA, ferritin, beta 2 microglobulin and sialic acid levels in pleural effusion]
[Clinical evaluation of various tumor markers in pleural effusion and in the serum]
[Diagnositic values of combined determination of carbohydrate antigen and tissue polypeptide antigen and neuron-specific enolase and carcinoembryonic antigen in the malignant pleural effusion.]
[Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma]
[Lysis therapy in aortic dissection: by hypertrophic cardiomyopathy simulated myocardial infarct]
[The effect of intrapleural pingyangmycin administration on activity of fibrinolytic system and transforming growth factor-beta1 in malignant pleural effusion]
[Tissue polypeptide antigen and tumor trypsin inhibitor in pleural effusions of various etiologies]
Pleural Effusion, Malignant
Effect of repeated thoracenteses on fluid characteristics, cytokines, and fibrinolytic activity in malignant pleural effusion.
Intrapleural Fibrinolytic Therapy in Patients With Nondraining Indwelling Pleural Catheters.
Proinflammatory cytokines and fibrinolytic enzymes in tuberculous and malignant pleural effusions.
Successful drainage of complex haemoserous malignant pleural effusion with a single modified low-dose intrapleural alteplase and dornase alfa.
Successful treatment of a complex malignant pleural effusion with 1 mg alteplase instilled through a non-draining indwelling pleural catheter.
[Diagnositic values of combined determination of carbohydrate antigen and tissue polypeptide antigen and neuron-specific enolase and carcinoembryonic antigen in the malignant pleural effusion.]
[Tissue polypeptide antigen and tumor trypsin inhibitor in pleural effusions of various etiologies]
Pleurisy
Local production of plasminogen activator inhibitor-1 in carcinomatous pleuritis.
Properties of urokinase type-plasminogen activator found in chest fluid.
[Assessment of the activity of plasminogen activators in the differential diagnosis of pleural effusion]
[Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma]
Pleuropneumonia
The Use of Recombinant Tissue Plasminogen Activator (rTPA) in The Treatment of Fibrinous Pleuropneumonia in Horses: 25 Cases (2007-2012).
Pneumoconiosis
Gene polymorphisms of fibrinolytic enzymes in coal workers' pneumoconiosis.
Pneumonia
4G/5G plasminogen activator inhibitor-1 polymorphisms and haplotypes are associated with pneumonia.
4G/5G polymorphism of plasminogen activator inhibitor-1 gene is associated with mortality in intensive care unit patients with severe pneumonia.
Alveolar plasminogen activator inhibitor-1 predicts ARDS in aspiration pneumonitis.
Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.
Bronchoalveolar levels of plasminogen activator inhibitor-1 and soluble tissue factor are sensitive and specific markers of pulmonary inflammation.
Changes of serum parameters of TiO? nanoparticle-induced atherosclerosis in mice.
COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis.
COVID-19 Critical Illness Pathophysiology Driven by Diffuse Pulmonary Thrombi and Pulmonary Endothelial Dysfunction Responsive to Thrombolysis.
Gender differences in stroke examined in a 10-year cohort of patients admitted to a Canadian teaching hospital.
Hospital mortality from atrial fibrillation associated with ischemic stroke: a national data report.
Impact of Polytrauma and Acute Respiratory Distress Syndrome on Markers of Fibrinolysis: A Prospective Pilot Study.
Implementation of Computerized Physician Order Entry Is Associated With Increased Thrombolytic Administration for Emergency Department Patients With Acute Ischemic Stroke.
Infections Increase the Risk of 30-Day Readmissions Among Stroke Survivors.
Modulation of bleomycin-induced lung fibrosis by serotonin receptor antagonists in mice.
Nebulized anticoagulants limit coagulopathy but not inflammation in pseudomonas aeruginosa-induced pneumonia in rats.
PAI-1 is an essential component of the pulmonary host response during Pseudomonas aeruginosa pneumonia in mice.
Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia.
Plasminogen activator production in a rat model of Pneumocystis carinii pneumonia.
Procalcitonin related to stroke-associated pneumonia and clinical outcomes of acute ischemic stroke after IV rt-PA treatment.
Production of plasminogen activator by alveolar macrophages in experimental Pneumocystis carinii pneumonia.
Proinflammatory cytokines, transforming growth factor-beta1, and fibrinolytic enzymes in loculated and free-flowing pleural exudates.
Properties of urokinase type-plasminogen activator found in chest fluid.
Reduced risk of poststroke pneumonia in thrombolyzed stroke patients with continued statin treatment.
Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator Inhibitor-1 through a JNK-mediated pathway.
Rethinking the Doses of Tissue Plasminogen Activator and Deoxyribonuclease Administrated Concurrently for Intrapleural Therapy for Complicated Pleural Effusion and Empyema.
Risk of pneumonia associated with zero-degree head positioning in acute ischemic stroke patients treated with intravenous tissue plasminogen activator.
Stroke-Associated Pneumonia in Thrombolyzed Patients: Incidence and Outcome.
The development of granulomatous pulmonary inflammation in rabbits by aerosol challenge. I. Release of plasminogen activator by alveolar macrophages.
Transgenic tissue-type plasminogen activator expression improves host defense during Klebsiella pneumonia.
Treatment of sepsis-induced acquired protein C deficiency reverses Angiotensin-converting enzyme-2 inhibition and decreases pulmonary inflammatory response.
Using HIS data for health care research.
[Hemostasis system and immune reactivity in patients with acute pneumonia and chronic alcoholism]
[Tissue polypeptide antigen in serum and tissue in patients with lung cancer]
Pneumonia, Bacterial
Procoagulant and fibrinolytic activities in bronchoalveolar fluid of HIV-positive and HIV-negative patients.
Pneumonia, Mycoplasma
M pneumoniae infection, pulmonary thromboembolism and antiphospholipid antibodies.
Pneumonia, Pneumococcal
Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia.
Plasminogen activator inhibitor type-1 deficiency exaggerates LPS-induced acute lung injury through enhancing Toll-like receptor 4 signaling pathway.
Pneumonia, Pneumocystis
Plasminogen activator production in a rat model of Pneumocystis carinii pneumonia.
Production of plasminogen activator by alveolar macrophages in experimental Pneumocystis carinii pneumonia.
Using HIS data for health care research.
Pneumonia, Ventilator-Associated
Increased plasminogen activator inhibitor-1 concentrations in bronchoalveolar lavage fluids are associated with increased mortality in a cohort of patients with Pseudomonas aeruginosa.
Pneumoperitoneum
Prevention of adhesion formation in a laparoscopic mouse model should combine local treatment with peritoneal cavity conditioning.
Role of the plasminogen system in basal adhesion formation and carbon dioxide pneumoperitoneum-enhanced adhesion formation after laparoscopic surgery in transgenic mice.
The effect of pneumoperitoneum on intravascular fibrinolytic activity in rats.
The impact of gas laparoscopy on abdominal plasminogen activator activity.
The plasminogen activator inhibitor system in colon cancer cell lines is influenced by the CO(2) pneumoperitoneum.
[Effect of pneumoperitoneum on plasminogen activator activity in the abdomen]
Pneumothorax
Alteplase for Massive Pulmonary Embolism after Complicated Pericardiocentesis.
Lung Resection in Children with Necrotizing Pneumonia: Outcome and Follow-up.
Poliomyelitis
Applications of cell culture for the improvement of human health.
Polycystic Ovary Syndrome
4G/5G Polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome.
4G/5G polymorphism of plasminogen activator inhibitor-1 gene is associated with polycystic ovary syndrome in Chinese patients: a meta-analysis.
A polymorphism of the plasminogen activator inhibitor-1 gene promoter and the polycystic ovary syndrome.
A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome.
Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system.
Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome.
Angiotensin-converting enzyme D/I and plasminogen activator inhibitor-1 4G/5G gene polymorphisms are associated with increased risk of spontaneous abortions in polycystic ovarian syndrome.
Correlation between plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G polymorphism and metabolic/proinflammatory factors in polycystic ovary syndrome.
Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells.
Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.
Effect of six-month use of oral contraceptive pills on plasminogen activator inhibitor-1 & factor VIII among women with polycystic ovary syndrome: An observational pilot study.
Evaluation of cardiac risk marker levels in obese and non-obese patients with polycystic ovaries.
Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome.
Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy.
Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.
New approaches to insulin resistance in polycystic ovarian syndrome.
PAI-1 in granulosa cells is suppressed directly by statin and indirectly by suppressing TGF-? and TNF-? in mononuclear cells by insulin-sensitizing drugs.
Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome.
Plasminogen activator and plasma activator inhibitor-1 in young women with polycystic ovary syndrome.
Plasminogen Activator Inhibitor 1 and Methylenetetrahydrofolate Reductase Gene mutations in Iranian Women with Polycystic Ovary Syndrome.
Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome.
Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome.
Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome.
Plasminogen Activator Inhibitor Type-1 Gene 4G/5G Polymorphism and Polycystic Ovary Syndrome.
Plasminogen Activator Inhibitor-1 -675 4G/5G Polymorphism and Polycystic Ovary Syndrome Risk: A Meta Analysis.
Plasminogen activator inhibitor-1 4G/5G and 5,10-methylene-tetrahydrofolate reductase C677T polymorphisms in polycystic ovary syndrome.
Plasminogen activator inhibitor-1 4G/5G and the MTHFR 677C/T polymorphisms and susceptibility to polycystic ovary syndrome: a meta-analysis.
Polycystic ovarian syndrome and thrombophilia.
Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss.
Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).
The plasminogen activator inhibitor-1 (PAI-1) gene -844 A/G and -675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome.
The plasminogen activator system in women with polycystic ovary syndrome.
The plasminogen activator system in young and lean women with polycystic ovary syndrome.
The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels.
Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome.
[Correlation between 4G and 5G genetypes distribution of plasminogen activator inhibitor-1 gene polymorphism in its promoter region with polycystic ovarian syndrome]
[Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases]
Polycythemia
Hypercoagulability and Migraine.
Tissue plasminogen activator levels in different types of polycythemia.
[Fibrinolysis studied by an in vitro clot lysis test in polycythemia vera]
Polycythemia Vera
High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.
Tissue plasminogen activator levels in different types of polycythemia.
Polymyalgia Rheumatica
Long-term follow up of von Willebrand factor and plasminogen activator inhibitor-1 in patients with polymyalgia rheumatica.
Plasminogen activator inhibitor and von Willebrand factor in polymyalgia rheumatica.
Polyneuropathies
Reduced levels of tissue plasminogen activator and plasminogen activator inhibitor in plasma of patients with familial amyloidotic polyneuropathy.
Posterior Leukoencephalopathy Syndrome
Neurological Emergencies During Pregnancy.
Postphlebitic Syndrome
Fibrinolytic therapy for idiopathic subclavian-axillary vein thrombosis.
Postthrombotic Syndrome
[Successful partial lysis of a 4-level-thrombosis by rt-PA - case report]
Pre-Eclampsia
A longitudinal study of biochemical variables in women at risk of preeclampsia.
Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease.
Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia.
Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation.
Altered plasma concentrations of leptin, transforming growth factor-beta(1) and plasminogen activator inhibitor type 2 at 18 weeks of gestation in women destined to develop pre-eclampsia. Circulating markers of disturbed placentation?
Are haemostatic and fibrinolytic parameters predictors of preeclampsia in pregnancy-associated hypertension?
Association between plasminogen activator inhibitor 1 gene polymorphisms and preeclampsia.
Association of Plasminogen Activator Inhibitor-Type 1 (-675 4G/5G) Polymorphism with Pre-Eclampsia: Systematic Review.
Biochemical corroboration of endothelial involvement in severe preeclampsia.
Cell-free mRNA concentrations of plasminogen activator inhibitor-1 and tissue-type plasminogen activator are increased in the plasma of pregnant women with preeclampsia.
Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia.
Coagulation and fibrinolysis in preeclampsia and neonates.
Contribution of platelets to increased plasminogen activator inhibitor type 1 in severe preeclampsia.
Correlation between plasminogen activator inhibitor-1 4G/5G polymorphism and pre-eclampsia: an appraisal.
Degradation of fibronectin in association with vascular endothelial disruption in preeclampsia.
Differential release of plasminogen activator inhibitors (PAIs) during dual perfusion of human placenta: implications in preeclampsia.
Early pregnancy plasminogen activator inhibitor-1 levels in Nigerian women and its relationship with preeclampsia.
Efficacy of AT in pre-eclampsia: a case-control prospective trial.
Elevated tissue plasminogen activator as a potential marker of endothelial dysfunction in pre-eclampsia: correlation with proteinuria.
Evaluation of Lp-PLA2 mass, vitronectin and PAI-1 activity levels in patients with preeclampsia.
Evidence of increased oxidative stress and a change in the plasminogen activator inhibitor (PAI)-I to PAI-II ratio in early-onset but not late-onset preeclampsia.
Fetal corticotrophin-releasing hormone mRNA, but not phosphatidylserine-exposing microparticles, in maternal plasma are associated with factor VII activity in pre-eclampsia.
Fibrinolysis during normal pregnancy and severe preeclampsia relationships between plasma levels of plasminogen activators and inhibitors.
Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia.
Fibrinolytic proteins of normal pregnancy and pre-eclamptic patients in North West Nigeria.
Fibrinolytic system and reproductive process with special reference to fibrinolytic failure in pre-eclampsia.
Fibronectin, plasminogen activator inhibitor type 1 (PAI-1) and uterine artery Doppler velocimetry as markers of preeclampsia.
First-trimester trophoblast cell model gene response to hypoxia.
Genetic hypofibrinolysis in complicated pregnancies.
Haemostatic factors in women with history of Preeclampsia.
Hemostatic abnormalities may predict chronic hypertension after preeclampsia.
Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia.
Hyperglycemia impairs cytotrophoblast function via stress signaling.
Increased blood flow resistance in placental circulation and levels of plasminogen activator inhibitors types 1 and 2 in severe preeclampsia.
Increased global fibrinolytic capacity as a clue for activated fibrinolysis in pre-eclampsia.
Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia.
Longitudinal assessment of D-dimer and plasminogen activator inhibitor type-1 plasma levels in pregnant women with risk factors for preeclampsia.
Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation.
Maternal Plasma Plasminogen Activator Inhibitor-2 at 11 to 13 Weeks of Gestation in Hypertensive Disorders of Pregnancy.
Placental plasminogen activator activity in pre-eclampsia.
Placental-type plasminogen activator inhibitor in preeclampsia.
Plasminogen activator inhibitor type 1 (PAI1) and platelet glycoprotein IIIa (PGIIIa) polymorphisms in Black South Africans with pre-eclampsia.
Plasminogen activator inhibitor-1 gene polymorphisms in pre-eclampsia.
Plasminogen activator inhibitor-1 polymorphism in women with pre-eclampsia.
Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, pre-eclampsia and hydatidiform mole.
Plasminogen activators, plasminogen activator inhibitors and markers of intravascular coagulation in pre-eclampsia.
Preeclampsia: the endothelium, circulating factor(s) and vascular endothelial growth factor.
Relationship between polymorphisms in thrombophilic genes and preeclampsia in a Brazilian population.
Studies of blood coagulation-fibrinolysis regarding kallikrein-kinin system in severe preeclampsia.
The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene is associated with severe preeclampsia.
The G20210A prothrombin-gene mutation and the plasminogen activator inhibitor (PAI-1) 5G/5G genotype are associated with early onset of severe preeclampsia.
The imbalance of plasminogen activators and inhibitor in preeclampsia.
The placental syncytium and the pathophysiology of preeclampsia and intrauterine growth restriction: a novel assay to assess syncytial protein expression.
The predictive value of the hemostasis parameters in the development of preeclampsia.
Thrombomodulin, plasminogen activator inhibitor type 1 (PAI-1) and fibronectin as biomarkers of endothelial damage in preeclampsia and eclampsia.
Tumor markers in hypertensive disorders of pregnancy.
Utility of a single mid-trimester measurement of plasminogen activator Type 1 and fibronectin to predict preeclampsia in pregnancy.
[Carriers of thrombophilic factor among women with preeclampsia (preliminary report)]
[Hemostatic system parameters of placental extracts in normal pregnancy and severe preeclampsia]
[Insulin resistance in preeclampsia].
[The role of coagulation and fibrinolysis system in pathogenesis of toxemia of pregnancy]
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Augmentation of mixed lymphocyte response. Stimulatory activity by phorbol ester.
Differentiation of human leukemias in response to 12-0-tetradecanoylphorbol-13-acetate in vitro.
Expression of CD9 (p24) antigen on hematopoietic cells following treatment with phorbol ester.
Functional and phenotypic upregulation of CD13/aminopeptidase-N on precursor-B acute lymphoblastic leukemia after in vitro stimulation.
Genetic polymorphism of vitamin D receptors and plasminogen activator inhibitor-1 and osteonecrosis risk in childhood acute lymphoblastic leukemia.
Heterogenous response of primary cultured bone marrow cells of patients with different varieties of leukemia to differentiation inducers.
Induction of differentiation of African Burkitt's lymphoma cells by phorbol ester: possible relation with early B cells.
Phorbol ester-induced differentiation of a non-T/non-B human leukemic cell line (REH) to macrophage-like cells.
[Activity of procoagulant and fibrinolysis in homogenate of leukemic cells]
[Thrombolysis with rt-PA in children with arterial and venous thromboses--a new therapy concept]
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Acute lymphoblastic leukemia and non-Hodgkin's lymphoma of T lineage: colony-forming cells retain growth factor (interleukin 2) dependence.
Prediabetic State
High Prevalence of Diabetes and Prediabetes and Their Coexistence with Cardiovascular Risk Factors in a Hispanic Community.
Plasminogen activator inhibitor-1 and HbA1c defined prediabetes: the Guangzhou Biobank Cohort Study-CVD.
Pregnancy Complications
Increased Umbilical Cord PAI-1 Levels in Placental Insufficiency Are Associated with Fetal Hypoxia and Angiogenesis.
Procoagulant and anticoagulant mechanisms in human placenta.
The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: an independent risk factor for serious pregnancy complications.
The 4G/4G polymorphism of the plasminogen activator inhibitor-1 (PAI-1) gene as an independent risk factor for placental insufficiency, which triggers fetal hemodynamic centralization.
The Angiotensin-converting Enzyme Insertion/Deletion Polymorphism as a Common Risk Factor for Major Pregnancy Complications.
[Changes in fibrinolysis-associated parameters in HELLP syndrome]
[Impact of inherited thrombophilia on the development of some pregnancy complications]
Pregnancy, Ectopic
Difference in mRNA expression and occurrence of plasminogen activator inhibitors in intrauterine decidua of normal and ectopic human pregnancies.
Immunohistochemical localization of urokinase-type plasminogen activator and the plasminogen activator inhibitors 1 and 2 in early human implantation sites.
Premature Birth
Genetic polymorphisms and spontaneous preterm birth.
Pressure Ulcer
Cultured pressure ulcer fibroblasts show replicative senescence with elevated production of plasmin, plasminogen activator inhibitor-1, and transforming growth factor-beta1.
Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Prediction of healing in Category I pressure ulcers by skin blotting with plasminogen activator inhibitor 1, interleukin-1?, vascular endothelial growth factor C, and heat shock protein 90?: A pilot study.
Priapism
Successful treatment of recalcitrant priapism using intercorporeal injection of tissue plasminogen activator.
Primary Graft Dysfunction
Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction.
Elevated donor plasminogen activator inhibitor-1 levels and the risk of primary graft dysfunction.
Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk.
Primary Ovarian Insufficiency
Association of five common polymorphisms in the plasminogen activator inhibitor-1 gene with primary ovarian insufficiency.
Prion Diseases
Changes in gene expression of kringle domain-containing proteins in murine brains and neuroblastoma cells infected by prions.
Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation.
Tissue plasminogen activator in brain tissues infected with transmissible spongiform encephalopathies.
Prolactinoma
Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
prostaglandin-e synthase deficiency
Gene Deletion of Microsomal Prostaglandin E Synthase-1 Suppresses Chemically Induced Skin Carcinogenesis.
Prostatic Hyperplasia
Effect of urokinase on the proliferation of primary cultures of human prostatic cells.
Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia.
Effects of the nonsteroidal antiandrogen Casodex on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia.
Efficacy of eight serially measured markers for diagnosis of prostatic carcinoma.
Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissue.
Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma.
Post-operative blood loss after transurethral prostatectomy is dependent on in situ fibrinolysis.
Tissue plasminogen activator activity in prostatic cancer.
[Serum tissue polypeptide antigen (TPA) in patients with urogenital cancer]
[Tissue plasminogen activator in urine of patients with prostatic carcinoma and benign prostatic hyperplasia]
Prostatic Neoplasms
213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model.
An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo.
Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer.
Assessment of 54 biomarkers for biopsy-detectable prostate cancer.
Auranofin Suppresses Plasminogen Activator Inhibitor-2 Expression through Annexin A5 Induction in Human Prostate Cancer Cells.
C-Jun N-terminal kinase is required for phorbol ester- and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP.
Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
Elements regulating angiogenesis and correlative microvessel density in benign hyperplastic and malignant prostate tissue.
Evaluation of 12-lipoxygenase (12-LOX) and plasminogen activator inhibitor 1 (PAI-1) as prognostic markers in prostate cancer.
Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer.
Expression of urokinase-type plasminogen activator system in prostate cancer: Correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Functional relevance of D,L-sulforaphane-mediated induction of vimentin and plasminogen activator inhibitor-1 in human prostate cancer cells.
GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system.
Growth control of human prostatic cancer cells by the phorbol ester TPA: possible involvement of protein kinases.
Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior.
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.
In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers.
Increased expression of p21Waf1/Cip1 and JNK with costimulation of prostate cancer cell activation by an siRNA Egr-1 inhibitor.
Induction of plasminogen activator inhibitor-2 is associated with suppression of invasive activity in TPA-mediated differentiation of human prostate cancer cells.
Inhibition of NF-kappaB by (E)3-[(4-methylphenyl)-sulfonyl]-2-propenenitrile (BAY11-7082; BAY) is associated with enhanced 12-O-tetradecanoylphorbol-13-acetate-induced growth suppression and apoptosis in human prostate cancer PC-3 cells.
Inhibitory effect of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans-retinoic acid on the growth of LNCaP prostate tumors in immunodeficient mice.
Injury-specific cytotoxic response of tumor cells and endothelial cells.
Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells.
NFATc1 with AP-3 site binding specificity mediates gene expression of prostate-specific-membrane-antigen.
Nucleotide variations in genes encoding plasminogen activator inhibitor-2 and serine proteinase inhibitor B10 associated with prostate cancer.
Phorbol ester induces differentiation of a human prostatic cancer cell line TSU-Pr1 into cells with characteristics of microglia.
PKCalpha activation downregulates ATM and radio-sensitizes androgen-sensitive human prostate cancer cells in vitro and in vivo.
PKD2 and PKD3 Promote Prostate Cancer Cell Invasion via uPA by Shifting Balance Between NF-?B and HDAC1.
Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms.
Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo.
Plasminogen activator content of neoplastic and benign human prostate tissues; fibrin augmentation of an activator activity.
Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
Plasminogen activator inhibitor-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer.
Preclinical Studies of Bismuth-213 Labeled Plasminogen Activator Inhibitor Type 2 (PAI2) in a Prostate Cancer Nude Mouse Xenograft Model.
Predicting high risk disease using serum and DNA biomarkers.
Protein Kinase C Mediates Prolactin Regulation of Mitochondrial Aspartate Aminotransferase Gene Expression in Prostate Cells.
RB activation and repression of C-MYC transcription precede apoptosis of human prostate epithelial cells.
Regulation of cell growth and the c-myc proto-oncogene expression by phorbol ester 12-0-tetradecanoyl phorbol-13-acetate (TPA) in the androgen-independent human prostatic JCA-1 cells.
Serum tissue polypeptide antigen (TPA) and prostatic acid phosphatase (PAP) in patients with prostatic cancer.
TGF-beta1 and TGF-beta2 Strongly Enhance Secretion of Plasminogen Activator Inhibitor-1 and Matrix Metalloproteinase-9 of the Human Prostate Cancer Cell Line PC-3.
The fibrinolytic system in experimental prostate tumor.
The malignancy index in plasma samples as a prostate cancer biomarker.
The relationship between cardiovascular complications of estrogen therapy and fibrinolysis in patients with prostatic cancer.
Tissue plasminogen activator activity in prostatic cancer.
Tissue polypeptide antigen expression in human prostate tumors.
Up-regulation of p21(WAF1/CIP1) levels leads to growth suppression of prostate cancer cell lines.
[Clinical relevance of tumor markers]
[Clinical studies on the measurement of urinary tissue polypeptide antigen (TPA) levels using Prolifigen TPA kit "Daiichi"-II in urothelial cancers]
[Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer]
[Measurement of serum tissue polypeptide antigen (TPA) in patients with malignant tumor using prolifigen TPA-M "Daiichi" kit]
[Serum and urinary tissue polypeptide antigen (TPA) in patients with urological cancer]
[Serum tissue polypeptide antigen (TPA) in patients with urogenital cancer]
[Tissue plasminogen activator activity in early prostatic cancer and in bone metastases of prostatic cancer]
Prostatitis
[How chronic prostatitis affects plasminogen activator system]
Protein C Deficiency
Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations.
Impaired fibrinolysis in the pathogenesis of dengue hemorrhagic fever.
Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a review and update.
Protein Deficiency
Heterozygous alpha 1-antichymotrypsin deficiency may be associated with cold urticaria.
Protein S Deficiency
A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency.
Association of protein S deficiency with thrombosis in a kindred with increased levels of plasminogen activator inhibitor-1.
Hematological risk factors for coronary heart disease.
Hypercoagulable states.
Inherited and acquired thrombophilia in Indian women experiencing unexplained recurrent pregnancy loss.
Inherited prothrombotic risk factors in children with first ischemic stroke.
Intravenous recombinant tissue plasminogen activator therapy in a 14-week pregnant woman with embolic stroke due to protein S deficiency.
Protein C and S deficiency, thrombophilia, and hypofibrinolysis: pathophysiologic causes of Legg-Perthes disease.
Protein S deficiency manifesting as spontaneous aortic thrombosis in a neonate.
Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a review and update.
Successful delayed thrombolysis with tissue plasminogen activator for recurrent arterial thrombosis secondary to protein S deficiency.
The role of hypercoagulability in the development of osteonecrosis of the femoral head.
The surgical implications of primary hypercoagulable states.
Thrombolysis in pulmonary embolism: an adolescent with protein S deficiency.
protein-glutamine gamma-glutamyltransferase deficiency
Laboratory testing for bleeding disorders: strategic uses of high and low-yield tests.
Proteinuria
Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis.
Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway.
Elevated tissue plasminogen activator as a potential marker of endothelial dysfunction in pre-eclampsia: correlation with proteinuria.
Fingertips ischemia, nephroangiosclerosis, and focal segmental glomerulosclerosis: is genetic thrombophilia the unique explanation?
Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrome.
Moderate alcohol intake has no impact on acute and chronic progressive anti-thy1 glomerulonephritis.
Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril.
Predictive value of increased plasma levels of fibronectin in gestational hypertension.
Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes.
Relationship between autonomic function and plasma fibrinogen, viscosity, and elements of fibrinolytic activity in diabetic nephropathy.
Relationship between maternal and cord blood hemostatic disturbances in preeclamptic pregnancies.
Serial measurements of circulating tissue plasminogen activator and fibrin(ogen) degradation products predict outcome in gestational proteinuric hypertension.
Solitary pancreas transplantation: preliminary findings about early reduction of proteinuria in incipient or evident diabetic type I nephropathy.
Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis.
t-PA promotes glomerular plasmin generation and matrix degradation in experimental glomerulonephritis.
TGF-beta type II receptor deficiency prevents renal injury via decrease in ERK activity in crescentic glomerulonephritis.
Pseudorabies
Pseudorabies virus as a live virus vector for expression of foreign genes.
Pseudoxanthoma Elasticum
Safety and efficacy of rt-PA treatment for acute stroke in pseudoxanthoma elasticum: the first report.
Psoriasis
A peptide derived from phage-display limits psoriasis-like lesions in mice.
Anti-TNF-? treatment modulates SASP and SASP-related microRNAs in endothelial cells and in circulating angiogenic cells.
Antipsoriatic therapies inhibit epidermal plasminogen activator activity.
Biochemical markers of psoriasis as a metabolic disease.
Cell adhesion molecules, plasminogen activator inhibitor type 1, and metabolic syndrome in patients with psoriasis.
Correction to: Cell adhesion molecules, plasminogen activator inhibitor type 1, and metabolic syndrome in patients with psoriasis.
Correlation of epidermal plasminogen activator activity with disease activity in psoriasis.
Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis.
Epidermal plasminogen activator activity, tPA-dependent, is a marker of disease activity in psoriasis.
Expression of plasminogen activator enzymes in psoriatic epidermis.
Human skin proteases. Fractionation of psoriasis scale proteases and separation of a plasminogen activator and a histone hydrolysing protease.
Increased expression of uPA, uPAR, and PAI-1 in psoriatic skin and in basal cell carcinomas.
Increased permeability of psoriatic skin to the protein, plasminogen activator inhibitor 2.
Interleukin-1 beta upregulates tissue-type plasminogen activator in a keratinocyte cell line (HaCaT).
Mangiferin glycethosomes as a new potential adjuvant for the treatment of psoriasis.
mRNA for tissue-type plasminogen activator is present in lesional epidermis from patients with psoriasis, pemphigus, or bullous pemphigoid, but is not detected in normal epidermis.
Plasminogen activator and histone hydrolyzing proteases in psoriasis scales--possible role in increased cell division.
Plasminogen activator in psoriatic scales is of the tissue-type PA as identified by monoclonal antibodies.
Psoriasis and Diabetes, a Dangerous Association: Evaluation of Insulin Resistance, Lipid Abnormalities, and Cardiovascular Risk Biomarkers.
Psoriasis does not worsen outcomes in patients admitted for ischemic stroke: an analysis of the National Inpatient Sample.
Serum is a potent stimulator of keratinocyte tissue plasminogen activator expression.
The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone.
Tissue plasminogen activator in psoriasis.
Tissue-type plasminogen activator concentrations in plasma from patients with psoriasis.
Topical atorvastatin ameliorates 12-O-tetradecanoylphorbol-13-acetate induced skin inflammation by reducing cutaneous cytokine levels and NF-?B activation.
TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: a novel in vivo screening model of psoriasis.
Vitamin D3 and calcipotriol decrease extracellular plasminogen activator activity in cultured keratinocytes.
Psychomotor Agitation
Tissue plasminogen activator for the treatment of thromboembolism in infants and children.
Pterygium
Expression of gelatinase (MMP-2 and MMP-9) in pterygia and pterygium fibroblasts is increased with disease progression and activation of protein kinase C.
Pulmonary Alveolar Proteinosis
[A case of pulmonary alveolar proteinosis with high levels of tumor markers]
Pulmonary Arterial Hypertension
Plasminogen activator inhibitor type 1 inhibits smooth muscle cell proliferation in pulmonary arterial hypertension.
Plasminogen activator Inhibitor-2 inhibits pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension via PI3K/Akt and ERK signaling.
Pulmonary Atelectasis
Alteplase treatment for massive lung atelectasis in a child with severe bronchiolitis obliterans complicating Stevens-Johnson syndrome.
Pulmonary Atresia
Thrombolysis of a modified Blalock-Taussig shunt with recombinant tissue plasminogen activator in a newborn infant with pulmonary atresia and ventricular septal defect.
Pulmonary Disease, Chronic Obstructive
Association Between Plasminogen Activator Inhibitor-1-675 4G/5G Insertion/Deletion Polymorphism and Chronic Obstructive Pulmonary Disease.
Correction to table and text in: sputum plasminogen activator inhibitor-1 elevation by oxidative stress-dependent nuclear factor-?B activation in COPD.
Effect of acute exacerbations on circulating endothelial, clotting and fibrinolytic markers in COPD patients.
Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease.
PAI-1 and tPA gene polymorphisms and susceptibility to chronic obstructive pulmonary disease in a sample of Turkish population.
Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function.
Sputum Plasminogen Activator Inhibitor-1 Elevation by Oxidative Stress-Dependent Nuclear Factor-?B Activation in COPD.
The Prevalence and Impact of Mortality of the Acute Respiratory Distress Syndrome on Admissions of Patients With Ischemic Stroke in the United States.
The SERPINE2 gene is associated with chronic obstructive pulmonary disease in two large populations.
[Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients]
Pulmonary Edema
4G/5G polymorphism of plasminogen activator inhibitor-1 gene is associated with mortality in intensive care unit patients with severe pneumonia.
Coadministration of FTY720 and rt-PA in an experimental model of large hemispheric stroke-no influence on functional outcome and blood-brain barrier disruption.
Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury.
Inhibition of poly(adenosine diphosphate-ribose) polymerase attenuates ventilator-induced lung injury.
Might life-threatening acute pulmonary edema occur after using recombinant tissue plasminogen activator? A case report.
Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome*
Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome.
Successful cricothyrotomy after thrombolytic therapy for acute myocardial infarction: a report of two cases.
Superiority of warfarin over aspirin long term after thrombolytic therapy for acute myocardial infarction.
Pulmonary Embolism
"Real-World" Application of Thrombolysis in Cardiac Arrest.
A Case of Minimally Differentiated Acute Leukemia (AML-M0) Complicated by Ventricle Thrombosis During Remission-induction.
A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency.
A contemporary approach to thrombolytic therapy for pulmonary embolism.
A new short infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease.
A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism.
A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism: The OPTALYSE PE Trial.
Acute adrenal failure following anticoagulation with dabigatran after hip replacement and thrombolysis for massive pulmonary embolism.
Acute and chronic pulmonary thromboembolism: current perspectives. Part I: Glossary of terms, historic evolution and prevalence.
Acute cor pulmonale due to pulmonary tumour thrombotic microangiopathy from renal cell carcinoma.
Acute Massive Pulmonary Embolism with Hemodynamic Compromise Treated Successfully With Thrombolytic Therapy.
Acute pulmonary embolism treated with thrombolytic agents: current status of tPA and future implications for emergency medicine.
Acute pulmonary embolism treated with tissue plasminogen activator.
Alpha 2-antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism.
Alteplase and tenecteplase: applications in the peripheral circulation.
Alteplase for Massive Pulmonary Embolism after Complicated Pericardiocentesis.
Alteplase for the Treatment of Pulmonary Embolism: A Review.
Alteplase treatment of acute pulmonary embolism in the intensive care unit.
Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion.
Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.
Alteplase: descendancy in myocardial infarction, ascendancy in stroke.
Are We Really Doing More With Less: The Value of Half-Dose Alteplase in Pulmonary Embolism Therapy.
Attenuation over 24 hours of the efficacy of thrombolysis of pulmonary embolism among patients with cancer.
Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor.
Bilateral EKOS EndoWave catheter thrombolysis of acute bilateral pulmonary embolism in a hemodynamically unstable patient.
Bivalirudin and Alteplase for Pulmonary Embolism Requiring Veno-Arterial Extracorporeal Membrane Oxygenation in an Adolescent.
Blood coagulation studies in 45 patients with ischemic cerebrovascular disease and 44 patients with venous thromboembolic disease.
Bolus thrombolysis in venous thromboembolism.
Bolus, front-loaded, and accelerated thrombolytic infusions for myocardial infarction and pulmonary embolism.
Bomb Blast and Its Consequences: Successful Intensive Care Management of Massive Pulmonary Embolsim.
Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat.
Can the tandem measurement of age adjusted d-dimer and tissue plasminagen activator improve the clinical utility of a conventional d-dimer in the pulmonary embolism diagnosis?
Cardiac arrest following massive pulmonary embolism during mechanical declotting of thrombosed hemodialysis fistula: successful resuscitation with tPA.
Cardiac findings and long-term thromboembolic outcomes following pulmonary embolism in children: a combined retrospective-prospective inception cohort study.
Catheter-based Therapy for Massive Pulmonary Embolism in an Elderly Woman with Chest Pain and Dyspnea: Case Report.
Catheter-directed clot fragmentation using the Cleaner™ device in a patient presenting with massive pulmonary embolism.
Catheter-directed thrombolysis with recombinant tissue plasminogen activator for acute pulmonary embolism after fontan operation.
Central Venous Catheter-directed Tissue Plasminogen Activator in Massive Pulmonary Embolism.
Characterization of alteplase therapy for presumed or confirmed pulmonary embolism during cardiac arrest.
Choosing the Correct "-ase" in Acute Ischemic Stroke: Alteplase, Tenecteplase, and Reteplase.
Clinical efficacy of low dose recombinant tissue-type plasminogen activator for the treatment of acute intermediate-risk pulmonary embolism.
Clinical safety and efficacy of thrombolytic therapy with low-dose prolonged infusion of tissue type plasminogen activator in patients with intermediate-high risk pulmonary embolism.
Clot penetration and retention by plasminogen activators promote fibrinolysis.
Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up.
Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
Comparative tolerability profiles of thrombolytic agents. A review.
Comparison of alteplase versus heparin for resolution of major pulmonary embolism.
Comparison of long-term outcomes of 50 and 100 mg rt-PA in the management of acute pulmonary thromboembolism.
Comparison of urokinase and reteplase thrombolytic treatment in patients with high-risk pulmonary embolism.
Complete Cognitive Recovery and Survival From Massive Pulmonary Embolism During General Anesthesia after Administration of Alteplase: A Case Report.
Creatinine kinase isoenzyme-MB: A simple prognostic biomarker in patients with pulmonary embolism treated with thrombolytic therapy.
Critical Importance of Low-Dose Tissue Plasminogen Activator Policy for Treating Intraoperative Pulmonary Thromboembolism During Liver Transplantation.
De Winter's pattern: an uncommon but very important electrocardiographic sign in the prompt recognition of spontaneous occlusive coronary artery dissection in young patients with chest pain (a case report).
Desmoteplase in acute massive pulmonary thromboembolism.
Double Bolus Alteplase Therapy during Cardiopulmonary Resuscitation for Cardiac Arrest due to Massive Pulmonary Embolism Guided by Focused Bedside Echocardiography.
Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activator.
Echocardiographic assessment with right ventricular function improvement following ultrasound-accelerated catheter-directed thrombolytic therapy in submassive pulmonary embolism.
Effect of low-molecular-weight heparin on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.
Effect of Recombinant Single-Chain Urokinase-Type Plasminogen Activator on Experimental Pulmonary Embolism.
Effect of tPA on regional lung perfusion in unilobar canine pulmonary thromboembolism.
Effective administration of recombinant tissue plasminogen activator (rt-PA) during resuscitation of a post partum patient with massive pulmonary embolism.
Effectiveness and cost effectiveness of thrombolysis in patients with acute pulmonary embolism.
Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism.
Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism.
Effectiveness of low-dose prolonged infusion of tissue plasminogen activator in a nonagenarian patient with acute pulmonary embolism and main pulmonary artery thrombus.
Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism.
Effects of recombinant tissue-type plasminogen activator on life-threatening acute pulmonary thromboembolism in a canine model: a comparative study of e6010 and alteplase.
Efficacy and Safety of Low Dose rt-PA for the Treatment of Acute Pulmonary Thromboembolism: A Randomized, Multi-Center, Controlled Trial.
Efficacy evaluation of reteplase in a novel canine acute pulmonary thromboembolism model developed by minimally invasive surgery and digital subtraction angiography.
Efficacy of alteplase thrombolysis for ED treatment of pulmonary embolism with shock.
Efficacy of thrombolytic agents in the treatment of pulmonary embolism.
Elevated expression of urokinase-like plasminogen activator and plasminogen activator inhibitor type 1 during the vascular remodeling associated with pulmonary thromboembolism.
Elevated Plasma Hemoglobin Levels Increase Nitric Oxide Consumption in Experimental and Clinical Acute Pulmonary Thromboembolism.
Emergency treatment with recombinant tissue plasminogen activator of pulmonary embolism in a pregnant woman with antithrombin III deficiency.
Endovascular thrombolysis to salvage central venous access in children with catheter-associated upper extremity deep vein thrombosis: technique and initial results.
Engineered Nanoplatelets for Targeted Delivery of Plasminogen Activators to Reverse Thrombus in Multiple Mouse Thrombosis Models.
Epidural hematoma following tissue plasminogen activator (tPA) therapy for pulmonary embolism in a pediatric patient with stage IV Burkitt's lymphoma: a case report.
Evaluation of Fibrinogen Levels during Catheter-Directed Thrombolysis for Acute Pulmonary Embolism.
Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group.
Fibrinolysis by tissue plasminogen activator in a child with pulmonary embolism.
Fibrinolytic treatment with tissue plasminogen activator in a patient with massive pulmonary thromboembolism and bidirectional Glenn procedure.
First trimester use of recombinant tissue plasminogen activator in pulmonary embolism.
Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis.
Half-dose Alteplase for Sub-massive Pulmonary Embolism Directed by Emergency Department Point-of-care Ultrasound.
Half-Dose Versus Full-Dose Alteplase for Treatment of Pulmonary Embolism.
Half-Dose Versus Full-Dose Alteplase Therapy in Pulmonary Embolism: Does Half Dose Really Lose?
Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial.
Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism.
Hemodynamic Effects of Ultrasound-Assisted, Catheter-Directed, Very Low-Dose, Short-Time Duration Thrombolysis in Acute Intermediate-High Risk Pulmonary Embolism (from the EKOS-PL Study).
Hemodynamic management in pulmonary embolism and acute hypoxemic respiratory failure.
Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism.
Heparin plus alteplase reduced morbidity more than heparin alone in submassive pulmonary embolism.
Heparin-induced thrombocytopenia: a critical risk/benefit analysis of patients in intensive care treated with R-hirudin.
High D-dimer levels after stopping anticoagulants in pulmonary embolism with sleep apnoea.
High-dose intra-arterial urokinase for the treatment of hepatic artery thrombosis in liver transplantation.
Human alpha -defensins neutralize fibrinolytic activity exerted by staphylokinase.
Imaging of Pulmonary Embolism and t-PA Therapy Effects Using MDCT and Liposomal Iohexol Blood Pool Agent Preliminary Results in a Rabbit Model.
Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism.
Incidence of increased plasminogen activator inhibitor in patients with deep venous thrombosis and/or pulmonary embolism.
Incidence of Major Bleeding in Patients with Pulmonary Thromboembolism Treated with Fixed Dose Alteplase 100 mg.
Initial Experiences with Endovascular Management of Submassive Pulmonary Embolism: Is It Safe?
Intra-arterial pulmonary thrombolysis at the postoperative period of brain aneurysm clamping: case report.
Intravenous Alteplase for Acute Stroke and Pulmonary Embolism in a Patient With Recent Abdominoplasty.
Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism.
Lack of plasminogen activator inhibitor-1 enhances the preventive effect of DX-9065a, a selective factor Xa inhibitor, on venous thrombus and acute pulmonary embolism in mice.
Life threatening massive pulmonary embolism treated with reteplase: a case report.
Life-threatening pulmonary embolism with right-sided heart thrombus. Rapid recovery with recombinant tissue plasminogen activator.
Long-term results of low-dose tissue plasminogen activator therapy in acute pulmonary embolism.
Low-Dose Alteplase for the Treatment of Submassive Pulmonary Embolism: A Case Series.
Low-Dose Alteplase May Be a Potential Treatment in Some But Not All Submassive Pulmonary Embolism: The Importance of an Abstract Conclusion.
Low-Dose Systemic Alteplase (tPA) for the Treatment of Pulmonary Embolism.
Low-dose tissue plasminogen activator in pulmonary embolism: benefit remains unclear.
Low-dose tissue plasminogen activator in the treatment of a massive pulmonary thromboembolism in a colon cancer patient treated with bevacizumab: A case report.
Low-dose, short course alteplase treatment of submassive pulmonary embolism: a case series from the National Institutes of Health Clinical Center.
Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: a systematic review and meta-analysis.
M pneumoniae infection, pulmonary thromboembolism and antiphospholipid antibodies.
Management of mobile right heart thrombi: a prospective series.
Massive pulmonary embolism during pregnancy successfully treated with recombinant tissue plasminogen activator: a case report and review of treatment options.
Massive pulmonary embolism in a young boy with T-cell leukaemia. Successful thrombolytic therapy by recombinant tissue plasminogen activator (rtPA).
Massive pulmonary embolism in pregnancy treated with catheter-directed tissue plasminogen activator.
Massive pulmonary embolism in pregnancy treated with tissue plasminogen activator.
Massive pulmonary embolism with cardiac arrest in pregnancy: A case report.
Massive pulmonary embolism: treatment with thrombus fragmentation and local fibrinolysis with recombinant human-tissue plasminogen activator.
Mechanical cardiopulmonary resuscitation for venoarterial ECMO implantation in pulmonary embolism complicated by type B aortic dissection and retroperitoneal hemorrhage.
Midterm Results of Endovascular Treatment for Iliac Vein Compression Syndrome from a Single Center.
Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy.
Multiplane transesophageal echocardiography to detect effectiveness of selective pulmonary recombinant tissue-type plasminogen activator thrombolysis in pulmonary embolism and patent foramen ovale.
Multiple boluses of alteplase followed by extracorporeal membrane oxygenation for massive pulmonary embolism.
Neurologically normal survival after fibrinolysis during prolonged cardiac arrest: case report and discussion.
Nursing Assessment of Tissue Plasminogen Activator for Pulmonary Embolism.
Observational Investigation of Thrombolysis With the Tissue-Type Plasminogen Activator Monteplase for Acute Pulmonary Embolism in Japan.
One-Year Echocardiographic, Functional, and Quality of Life Outcomes After Ultrasound-Facilitated Catheter-Based Fibrinolysis for Pulmonary Embolism.
Oropharyngeal angioneurotic edema due to recombinant tissue plasminogen activator following massive pulmonary thromboembolism.
PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2.
Paradoxical embolus illustrating speed of action of recombinant tissue plasminogen activator in massive pulmonary embolism.
Percutaneous catheter and guidewire fragmentation with local administration of recombinant tissue plasminogen activator as a treatment for massive pulmonary embolism.
Perspectives on treatment of acute pulmonary embolism with tissue plasminogen activator.
Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism.
Possible use of monoclonal antibodies to standardize the production and use of human urokinase.
Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism.
Prehospital thrombolytic treatment of massive pulmonary embolism with reteplase during cardiopulmonary resuscitation.
Primary leiomyosarcoma of the pulmonary artery confirmed by catheter suction biopsy.
Principles of thrombolysis in pulmonary embolism.
Pulmonary embolism and heparin-induced thrombocytopenia successfully treated with tissue plasminogen activator and argatroban.
Pulmonary Embolism in a Stroke Patient after Systemic Thrombolysis: Clinical Decisions and Literature Review.
Pulmonary Embolism in COVID-19 Treated with VA-ECLS and Catheter tPA.
Pulmonary embolism with cardiac arrest: a STEMI patient's unexpected course.
Pulmonary perfusion after rt-PA therapy for acute embolism: early improvement assessed with segmental perfusion scanning.
Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism.
Rapid lysis of life-threatening pulmonary thromboembolism following recent abdominal surgery using a modified systemic infusion of rt-PA.
Rapid resolution of acute cor pulmonale with recombinant tissue plasminogen activator.
Rapid resolution of pulmonary embolism by tissue plasminogen activator.
Recombinant tissue plasminogen activator for hemodynamically stable patients experiencing an acute pulmonary embolism: a meta-analysis.
Recombinant tissue plasminogen activator for massive pulmonary thromboembolism.
Recombinant tissue plasminogen activator in patients with pulmonary embolism: correlation of fibrinolytic specificity and efficacy.
Recombinant tissue plasminogen activator plus heparin compared with heparin alone for patients with acute submassive pulmonary embolism: one-year outcome.
Recombinant tissue plasminogen activator treatment of pulmonary embolism also improves deep venous thrombosis.
Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial.
Recurrent Pulmonary Embolism Caused by Superficial Femoral Vein Aneurysm.
Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group.
Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and ?2-Antiplasmin Inactivation.
Repeated thrombolysis for chronologically separated ischemic strokes: a case series.
Resolution of a Mobile Right Atrial Thrombus Complicating Acute Pulmonary Embolism With Low-Dose Tissue Plasminogen Activator in a Patient With Recent Craniotomy.
Reteplase: a review of its use in the management of thrombotic occlusive disorders.
Risk factors associated with bleeding after alteplase administration for pulmonary embolism: a case-control study.
Risk factors for pulmonary emboli after total hip or knee arthroplasty.
Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Consideration of noninvasive management.
Safety, Efficacy of an Accelerated Regimen of Low-Dose Recombinant Tissue-Type Plasminogen Activator for Reperfusion Therapy of Acute Pulmonary Embolism.
Scintigraphic visualization of pulmonary thrombi with 123I-YPACK-TNK-tPA.
Sequential ventilation/perfusion imaging of massive pulmonary embolism treated with recombinant tissue plasminogen activator.
Serial markers of coagulation and inflammation and the occurrence of clinical pulmonary thromboembolism in mechanically ventilated patients with SARS-CoV-2 infection; the prospective Maastricht intensive care COVID cohort.
Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels.
Short term effect of recombinant tissue plasminogen activator in patients with hemodynamically stable acute pulmonary embolism: Results of a meta-analysis involving 464 patients.
SMTP (Stachybotrys microspora triprenyl phenol) enhances clot clearance in a pulmonary embolism model in rats.
Spotlight on reteplase in thrombotic occlusive disorders.
Stability of Alteplase for Catheter-Directed, Ultrasound-Facilitated Thrombolysis.
Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction.
Successful alteplase bolus administration for a presumed massive pulmonary embolism during cardiopulmonary resuscitation.
Successful low-dosage thrombolysis of massive pulmonary embolism in primigravida: A case report.
Successful management of multiple permanent pacemaker complications--infection, 13 year old silent lead perforation and exteriorisation following failed percutaneous extraction, superior vena cava obstruction, tricuspid valve endocarditis, pulmonary embolism and prosthetic tricuspid valve thrombosis.
Successful thrombolysis by prolonged low-dose alteplase in catheter-directed infusion.
Successful thrombolysis of major pulmonary embolism 5 days after lobectomy.
Successful thrombolysis of submassive pulmonary embolism by tissue plasminogen activator.
Successful thrombolysis using recombinant tissue plasminogen activator in cases of severe pulmonary embolism with mobile thrombi in the right atrium.
Successful thrombolysis with rt-PA after syncope and protracted cardiopulmonary resuscitation in massive pulmonary embolism.
Successful thrombolytic therapy with recombinant tissue-type plasminogen activator for massive pulmonary embolism -A case report-.
Successful treatment of a pulmonary embolism with low dose of tissue plasminogen activator after thoracic surgery.
Successful treatment of a pulmonary embolism with low dose prolonged infusion of tissue typed plasminogen activator in a 37 year old female in early postoperative period.
Successful treatment of massive pulmonary embolism in a pregnant woman, with low-dose, slow infusion of tissue plasminogen activator.
Successful treatment of massive pulmonary embolism with low-dose tissue plasminogen activator after meniscus surgery.
Successful treatment of massive pulmonary embolism with recombinant tissue type plasminogen activator (rt-PA) in a pregnant woman with intact gravidity and preterm labour.
Successful treatment of massive pulmonary embolism with reteplase.
Successful Treatment of Massive Pulmonary Thromboembolism with Reteplase: Case Series.
Successful treatment of mobile right atrial thrombus and acute pulmonary embolism with intravenous tissue plasminogen activator.
Successful treatment of pulmonary embolism-induced cardiac arrest by thrombolysis and targeted temperature management during pregnancy.
Successful Treatment of Refractory Massive Pulmonary Embolism with Repeated Administration of Systemic Thrombolysis.
Successful Use of tPA for Saddle Pulmonary Embolism in Perimesencephalic Non-aneurysmal Subarachnoid Hemorrhage: Case Report.
Survival of intraoperative massive pulmonary embolism using alteplase and VA-ECMO.
Systemic Thrombolysis for Treatment of Postpartum Saddle Embolism Complicated by Postpartum Hemorrhage: A Case Report and Brief Literature Review.
Tenecteplase to treat pulmonary embolism in the emergency department.
The association of blood urea nitrogen levels with mortality in acute pulmonary embolism.
The characteristics and outcomes of critically Ill patients with COVID-19 who received systemic thrombolysis for presumed pulmonary embolism: an observational study.
The Efficacy and Safety of Intermittent Low-Dose Urokinase Thrombolysis for the Treatment of Senile Acute Intermediate-High-Risk Pulmonary Embolism: A Pilot Trial.
The role of plasminogen activator inhibitor-1 polymorphism, factor-v-leiden, and prothrombin-20210 mutations in pulmonary thromboembolism.
The role of recombinant human tissue-type plasminogen activator in the treatment of acute pulmonary thromboembolism.
The safety and angiographic efficacy of tissue plasminogen activator in a cerebral embolization model.
The treatment of the pulmonary embolism with tissue plasminogen activator: A case report.
Therapeutic effect evaluation of reteplase on acute pulmonary embolism.
Thrombin-antithrombin III complexes as an additional diagnostic aid in pulmonary embolism.
Thrombolysis and use of argatroban for the treatment of massive pulmonary embolism following anticoagulation failure in a patient with COVID-19.
Thrombolysis by recombinant tissue plasminogen activator during pregnancy: a case of massive pulmonary embolism.
Thrombolysis in pulmonary embolism: a debatable indication.
Thrombolysis in pulmonary embolism: an adolescent with protein S deficiency.
Thrombolysis in venous thromboembolism. An international perspective.
Thrombolysis is an appropriate treatment in lead-associated infective endocarditis with giant vegetations located on the right atrial lead.
Thrombolysis of venous and arterial thrombosis by catheter-directed low-dose infusion of tissue plasminogen activator in children.
Thrombolysis using consecutive high dose bolus and infusion of alteplase in a patient with acute massive pulmonary embolism.
Thrombolysis with a novel modified tissue-type plasminogen activator, monteplase, combined with catheter-based treatment for major pulmonary embolism.
Thrombolysis with recombinant tissue plasminogen activator during cardiopulmonary resuscitation in fulminant pulmonary embolism. A case series.
Thrombolysis with reteplase in acute pulmonary embolism.
Thrombolysis with tissue plasminogen activator in patients with acute pulmonary embolisms in the real world: from the COMMAND VTE registry.
Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model.
Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats.
Thrombolytic Therapy by Tissue Plasminogen Activator for Pulmonary Embolism.
Thrombolytic therapy for massive pulmonary embolism in a patient with a known intracranial tumor.
Thrombolytic therapy for pulmonary embolism.
Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator.
Thrombolytic therapy in pregnancy.
Thrombolytic therapy of acute pulmonary embolism: current status and future potential.
Thrombolytic therapy of massive pulmonary embolism during prolonged cardiac arrest using recombinant tissue-type plasminogen activator.
Thrombolytic therapy: overview of results in major vascular occlusions.
Thrombolytic treatment with recombinant tissue-type plasminogen activator in a patient with massive pulmonary embolism.
Tissue plasminogen activator and acute pulmonary embolism.
Tissue plasminogen activator as a novel diagnostic aid in acute pulmonary embolism.
Tissue plasminogen activator as an alternative to vena cava interruption in recurrent pulmonary thromboembolism.
Tissue plasminogen activator dose and pulmonary artery pressure reduction in catheter directed thrombolysis of submassive pulmonary embolism.
Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators.
Tissue plasminogen activator in acute pulmonary embolism.
Tissue plasminogen activator plasma levels as a potential diagnostic aid in acute pulmonary embolism.
Tissue Plasminogen Activator Use in Cardiac Arrest Secondary to Fulminant Pulmonary Embolism.
Tissue-plasminogen activator for pulmonary embolism resulting in shock: two case reports and discussion of the literature.
tPA regulates pulmonary vascular activity through NMDA receptors.
TPA versus urokinase in acute pulmonary embolism: results of a randomized controlled trial.
Transvenous Catheter-Based Thrombolysis With Continuous Tissue Plasminogen Activator Infusion for Refractory Thrombosis in a Patient With Behcet's Disease.
Treatment of canine embolic pulmonary hypertension with recombinant tissue plasminogen activator. Efficacy of dosing regimes.
Treatment of massive pulmonary embolism with centrally administered tissue-type plasminogen activator.
Treatment of pulmonary embolism during cesarean section with recombinant tissue plasminogen activator.
Treatment of pulmonary embolism with argatroban and ultrasound-assisted catheter-directed thrombolysis with alteplase in a patient with heparin-induced thrombocytopenia.
Treatment of pulmonary embolism with low-dose prolonged infusion of tissue-type plasminogen activator in an 85-year-old woman.
Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor.
Two trials of reduced bolus alteplase in the treatment of pulmonary embolism. An overview.
Ultrasound-assisted lysis using recombinant tissue plasminogen activator and the EKOS EkoSonic endovascular system for treating right atrial thrombus and massive pulmonary embolism: A case study.
Ultrasound-enhanced tissue plasminogen activator thrombolysis in an in vitro porcine clot model.
Upper extremity acute compartment syndrome during tissue plasminogen activator therapy for pulmonary embolism in a morbidly obese patient.
Urokinase versus tissue plasminogen activator in pulmonary embolism.
Use of recombinant tissue-type plasminogen activator to treat massive pulmonary embolism after cesarean section: a case report.
Use of reteplase for thrombolysis in patients with massive pulmonary embolism diagnosed by bedside transthoracic echocardiography: A retrospective study of safety and efficacy.
Use of systemic bivalirudin with catheter-directed thrombolysis in a patient with heparin-induced thrombocytopenia: A case report.
Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism.
[A case of successful thrombolysis by recombinant tissue plasminogen activator for postoperative pulmonary thromboembolism]
[A case of successful tissue plasminogen activator in young-onset pulmonary embolism]
[A clinical case of pulmonary thromboembolism in a patient at risk treated with rt-pA]
[A successful lytic treatment of a perioperative pulmonary embolism necessitating resuscitation using recombinant tissue-type plasminogen activator]
[Acute heart arrest during urologic routine interventions in 2 cases. Interdisciplinary crisis management assures tumor-free survival despite fulminant lung embolism with acute heart arrest during thoraco-abdominal tumor nephrectomy and radical cystoprostatovesiculectomy]
[An economic evaluation of low dose recombinant human tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism]
[Bolus injection of recombinant tissue-type plasminogen activator during cardiopulmonary resuscitation in massive pulmonary embolism complicated with heart arrest. Report of 2 cases and review of the literature]
[Case report. Pulmonary embolism complicated by angioneurotic edema.]
[Chronic effects of 100 mg/2 hours recombinant tissue-type plasminogen activator therapy regimen for patients with acute pulmonary thromboembolism].
[Clinical efficacy and safety of thrombolytic treatment with reteplase in patients with intermediate-risk acute pulmonary embolism].
[Clinical outcome of catheter fragmentation and aspiration therapy in patients with acute pulmonary embolism]
[Comparison of curative effect and thrombolysis time between r-tPA application and urokinase in the interventional thrombectomy and thrombolysis for acute and severe pulmonary embolism].
[Comparison of efficacy and tolerability of a thrombolytic treatment with rt-PA in acute massive pulmonary embolism in the elderly and patients under 75 years of age]
[Cost-benefit study of different thrombolytic strategies in treating 156 patients with symptomatic pulmonary thromboembolism].
[Disseminated coronary occlusions and massive pulmonary embolism in a 40-year-old woman.]
[Dissolution of a right cardiac migrant thromboembolus in pulmonary embolism after treatment with rt-PA. Report of a successfully treated case]
[Early diagnosis of pulmonary embolism in patients with skin and soft tissue defects after trauma].
[Effect of 50 mg alteplase to intermediate-risk pulmonary embolism with right ventricular dysfunction].
[Effects of thrombolysis and anticoagulation on the functions of vascular endothelial cells and coagulation and fibrinolysis in patients with pulmonary thromboembolism]
[Effects of thrombolytic therapy in patients with cardiac arrest from suspected pulmonary thromboembolism].
[Efficacy of treatment with rt-PA of massive pulmonary embolism in patients with contraindications for thrombolytic therapy]
[Heparin-induced thrombocythopenia in a patient with massive pulmonary embolism and dilated cardiomyopathy, successfuly treated with fondaparinux - a case report]
[Ilio-femoral vein thrombosis treated with tissue plasminogen activator in a pregnant woman]
[Intraoperative thrombolysis with rt-PA in massive pulmonary embolism during venous thrombectomy]
[Level of tissue plasminogen activator protein in pulmonary artery in acute pulmonary thromboembolism in rabbit]
[Loco-regional thrombolysis in deep venous thrombosis]
[Lysis therapy with rt-PA in fulminant pulmonary embolism]
[Massive pulmonary embolism during the third trimester of pregnancy: effectiveness of thrombolytic treatment with alteplase]
[Massive pulmonary embolism treated with a reduced dose of alteplase in a patient with acute renal failure.]
[Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism]
[Mobile thrombus in the right atrium and pulmonary embolism: efficacy of thrombolytic treatment with alteplase]
[Oral contraceptives use increases venous thromboembolic risk even for minor surgical procedure - a case report]
[Post-phlebitic leg ulcers and XYY karyotype: fibrinolysis and androgenic function tests. Apropos of 3 cases]
[Recombinant tissue-type plasminogen activator for the emergency treatment of perioperative life-threatening pulmonary embolism (stage IV). Results in 7 patients]
[Relationship between polymorphisms of plasminogen activator inhibitor-1 promoter gene and pulmonary thromboembolism in Chinese Han population]
[Risk factors in chronic thromboembolic pulmonary hypertension]
[Rt-PA thrombolysis in the treatment of massive pulmonary embolism]
[Spontaneous fibrinolysis and possibilities of its acceleration in pulmonary embolism].
[Study of hemostatic molecular marker]
[Successful cardiopulmonary resuscitation with a high-dosage bolus injection of rt-PA after fulminant pulmonary embolism]
[Superselective local infusion therapy with tissue-plasminogen activator for acute massive pulmonary thromboembolism: preliminary clinical experience]
[Systemic lysotherapy using recombinant tissue plasminogen activator for fulminant pulmonary embolism]
[The changes in molecular markers for hemostatic activation after t-PA therapy in case of pulmonary embolism]
[The efficacy of alteplase in pulmonary embolism treatment]
[The thrombolytic treatment of acute and subacute recurrent pulmonary embolism with recombinant tissue plasminogen activator]
[Thrombolytic therapy in the treatment of thromboembolism of the right cardiac cavity during pulmonary embolism: our experience with rt-PA and review of the literature]
[Thrombolytic therapy of pulmonary artery embolism in early pregnancy with recombinant tissue-type plasminogen activator]
[Tissue plasminogen activator (alteplase) in acute massive pulmonary embolism. A pilot study]
[Tissue plasminogen activator after resuscitation in fulminant pulmonary embolism]
[Treatment of pulmonary embolism with tissue plasminogen activator]
[Treatment of pulmonary embolism. Current status and future prospects]
[Treatment of pulmonary thromboembolism with extrinsic plasminogen activator. A case report]
[Very low doses of tissue plasminogen activator in treatment of acute massive pulmonary embolism]
Pulmonary Fibrosis
An Inhibitor of NADPH Oxidase-4 Attenuates Established Pulmonary Fibrosis in a Rodent Disease Model.
Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice.
Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene.
Danggui Buxue Tang ameliorates bleomycin-induced pulmonary fibrosis in rats through inhibiting transforming growth factor-?1/Smad3/ plasminogen activator inhibitor-1 signaling pathway.
Fasudil, a rho-kinase inhibitor, attenuates bleomycin-induced pulmonary fibrosis in mice.
Idiopathic pulmonary fibrosis in relation to gene polymorphisms of transforming growth factor-?1 and plasminogen activator inhibitor 1.
Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts.
Inhibition of Plasminogen Activator Inhibitor-1 Attenuates Transforming Growth Factor-?-Dependent Epithelial Mesenchymal Transition and Differentiation of Fibroblasts to Myofibroblasts.
Local activation of the coagulation and fibrinolysis systems in lung disease.
Plasminogen activator inhibitor-1 serves an important role in radiation-induced pulmonary fibrosis.
Pulmonary delivery of polyplexes for combined PAI-1 gene silencing and CXCR4 inhibition to treat lung fibrosis.
Radiation-induced pulmonary endothelial dysfunction and hydroxyproline accumulation in four strains of mice.
Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1.
Role of the urokinase-fibrinolytic system in epithelial-mesenchymal transition during lung injury.
Serum copper concentration as an index of experimental lung injury.
Silica Induces Plasminogen Activator Inhibitor-1 Expression through a MAPKs/AP-1-Dependent Mechanism in Human Lung Epithelial Cells.
siRNA against plasminogen activator inhibitor-1 ameliorates bleomycin-induced lung fibrosis in rats.
Smad3 signaling involved in pulmonary fibrosis and emphysema.
Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis.
The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system.
The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability.
The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis.
The genetic basis of strain-dependent differences in the early phase of radiation injury in mouse lung.
The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism.
The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice.
tPA promotes the proliferation of lung fibroblasts and activates the Wnt/?-catenin signaling pathway in idiopathic pulmonary fibrosis.
Truncated Plasminogen Activator Inhibitor-1 Protein Protects From Pulmonary Fibrosis Mediated by Irradiation in a Murine Model.
[The effect of plasminogen activator inhibitor-1 on embryonic lung fibroblasts from rats].
Pulmonary Heart Disease
Life-threatening pulmonary embolism with right-sided heart thrombus. Rapid recovery with recombinant tissue plasminogen activator.
Rapid resolution of acute cor pulmonale with recombinant tissue plasminogen activator.
Recombinant tissue plasminogen activator treatment for COVID-19 associated ARDS and acute cor pulmonale.
Pulmonary Infarction
Large right atrial thrombus with pulmonary embolism.
Purpura
Psychogenic purpura with abnormally increased tPA dependent cutaneous fibrinolytic activity.
Recombinant tissue plasminogen activator in children with meningococcal purpura fulminans--role uncertain.
Thrombomodulin, tissue plasminogen activator and plasminogen activator inhibitor-1 in Henoch-Schönlein purpura.
[Abnormalities in coagulation and fibrinolysis in septic shock with purpura]
Purpura Fulminans
Massive subperiosteal hemorrhage and femoral shaft osteonecrosis: a complication of tissue plasminogen activator therapy for purpura fulminans.
Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans.
Use of recombinant tissue plasminogen activator in children with meningococcal purpura fulminans: a retrospective study.
[Recombinant tissue plasminogen activator in treatment of fulminant meningococcal infection]
Purpura, Thrombocytopenic, Idiopathic
Plasma levels of endothelial-derived haemostatic factors in autoimmune thrombocytopenia and haemolytic anaemia.
Purpura, Thrombotic Thrombocytopenic
A role for tissue plasminogen activator in thrombotic thrombocytopenic purpura.
Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura.
Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura.
Plasminogen activator inhibitor (PAI-1) antigen levels in primary TTP and secondary TTP post-bone marrow transplantation.
Stroke due to typical thrombotic thrombocytopenic purpura treated successfully with intravenous thrombolysis and therapeutic plasma exchange.
Stroke in a young patient treated by alteplase heralding an acquired thrombotic thrombocytopenic purpura.
Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome following allogeneic bone marrow transplantation.
Pyelonephritis
Plasminogen activator inhibitor-1 regulates neutrophil influx during acute pyelonephritis.
Quadriplegia
Bilateral internal carotid artery occlusions resulting in near total acute brain infraction.
Impaired circadian variations of haemostatic and fibrinolytic parameters in tetraplegia.
Radiation Pneumonitis
Genetic variants in the plasminogen activator inhibitor-1 gene are associated with an increased risk of radiation pneumonitis in lung cancer patients.
Radicular Cyst
Immunohistochemical localization of tissue-type plasminogen activator and type I plasminogen activator inhibitor in radicular cysts.
Radiculopathy
Tissue type plasminogen activator induced in rat dorsal horn astrocytes contributes to mechanical hypersensitivity following dorsal root injury.
Rectal Neoplasms
Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients.
Role of CEA, TPA, and Ca 19-9 in the early detection of localized and diffuse recurrent rectal cancer.
uPA and PAI-1 in Rectal Cancer-Relationship to Radiotherapy and Clinical Outcome.
[A study of ornithine decarboxylase activity in tumor tissue and rectal mucosa in patients with colorectal cancer or adenoma]
Renal Artery Obstruction
Angiotensinogen and plasminogen activator inhibitor-1 gene polymorphism in relation to renovascular disease.
Renal Insufficiency
Augmentation of phosphate-induced osteo-/chondrogenic transformation of vascular smooth muscle cells by homoarginine.
Cholesterol crystal embolization-associated renal failure after therapy with recombinant tissue-type plasminogen activator.
Combination thrombolytic and anticoagulant therapy for bilateral renal vein thrombosis in a premature infant.
Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure.
Influence of hepatic and renal failure on pharmacokinetic properties of the novel recombinant plasminogen activator BM 06.022 in rats.
Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats.
Psoas muscle size as a frailty measure for open and transcatheter aortic valve replacement.
The Prevalence and Impact of Mortality of the Acute Respiratory Distress Syndrome on Admissions of Patients With Ischemic Stroke in the United States.
The role of medical management for acute intravascular hemolysis in patients supported on axial flow LVAD.
Tissue polypeptide antigen and carcinoembryonic antigen lack diagnostic accuracy in urothelial carcinoma.
Understanding the genetic basis for adverse drug effects: the calcineurin inhibitors.
Urinary plasminogen activator activity in progressive renal failure.
Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment.
[Massive pulmonary embolism treated with a reduced dose of alteplase in a patient with acute renal failure.]
Renal Insufficiency, Chronic
Association analysis of ADPRT1, AKR1B1, RAGE, GFPT2 and PAI-1 gene polymorphisms with chronic renal insufficiency among Asian Indians with type-2 diabetes.
Chronic kidney disease and intravenous thrombolysis in acute stroke: A systematic review and meta-analysis.
Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertension.
Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice.
Novel actions of tissue-type plasminogen activator in chronic kidney disease.
PAI-1 and kidney fibrosis.
Plasminogen activator inhibitor-1 activity in chronic renal disease and dialysis.
Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action.
Sarcopenia predicts poor long-term survival in patients undergoing endovascular aortic aneurysm repair.
The effects of gemfibrozil upon the hypercoagulable state in dyslipidaemic patients with chronic renal failure.
[Effects of Dahuang Zhechong Pill on expressions of tissue inhibitor of metalloproteinase-1 and plasminogen activator inhibitor-1 in rats with glomerulosclerosis]
[Tissue plasminogen activator antigen (t-PA Ag) and tissue plasminogen activator inhibitor (PAI-1) in the course of hemodialysis in patients with chronic renal failure]
Reperfusion Injury
Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial.
Combined tissue plasminogen activator and an NK1 tachykinin receptor antagonist: An effective treatment for reperfusion injury following acute ischemic stroke in rats.
Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group.
Comparative Analysis of Different Methods of Ischemia/Reperfusion in Hyperglycemic Stroke Outcomes: Interaction with tPA.
Depletion of Tissue Plasminogen Activator Attenuates Lung Ischemia-Reperfusion Injury via Inhibition of Neutrophil Extravasation.
Effect of thrombolysis on myocardial injury: recombinant tissue plasminogen activator vs. alfimeprase.
Effects of nitric oxide on reactive oxygen species production and infarction size after brain reperfusion injury.
Effects of pharmacological suppression of plasminogen activator inhibitor-1 in myocardial remodeling after ischemia reperfusion injury.
FUNDC1-dependent mitophagy induced by tPA protects neurons against cerebral ischemia-reperfusion injury.
Graft Neutrophil Sequestration and Concomitant Tissue Plasminogen Activator Release During Reperfusion in Clinical Kidney Transplantation.
Induction of type 1 plasminogen activator inhibitor in human liver ischemia and reperfusion.
Interferon-? Modulates Inflammatory Response in Cerebral Ischemia.
Ischemia-Reperfusion Injury of Sciatic Nerve in Rats: Protective Role of Combination of Vitamin C with E and Tissue Plasminogen Activator.
LEX 032: a novel recombinant human protein for the treatment of ischaemic reperfusion injury.
Mast cell stabilization reduces hemorrhage formation and mortality after administration of thrombolytics in experimental ischemic stroke.
Mild hypothermia markedly reduces ischemia related coronary t-PA release.
Monoacylglycerol Lipase Inhibitor is Safe when Combined with Delayed r-tPA Administration in Treatment of Stroke.
Neurovascular function recovery after focal ischemic stroke by enhancing cerebral collateral circulation via peripheral stimulation-mediated interarterial anastomosis.
Peptide5 attenuates rtPA related brain microvascular endothelial cells reperfusion injury via the Wnt/?-catenin signalling pathway.
Protective Effects and Target Network Analysis of Ginsenoside Rg1 in Cerebral Ischemia and Reperfusion Injury: A Comprehensive Overview of Experimental Studies.
Protective effects of leukopenia and tissue plasminogen activator in microvascular ischemia-reperfusion injury.
Rationale and design of combination of an immune modulator Fingolimod with Alteplase bridging with Mechanical Thrombectomy in Acute Ischemic Stroke (FAMTAIS) trial.
Reactive oxygen intermediates and ischemia-reperfusion injury release tissue plasminogen activator from isolated rat hearts.
Reduction of post-ischemic lung reperfusion injury by fibrinolytic activity suppression.
Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats.
Reperfusion seizures: a manifestation of cerebral reperfusion injury after administration of recombinant tissue plasminogen activator for acute ischemic stroke.
Tirofiban combined with rt-PA intraarterial thrombolysis improves the recanalization rate of acute middle cerebral artery occlusion in rabbits.
Tissue plasminogen activator (tPA) inhibits human neutrophil superoxide anion production in vitro.
Tissue-type plasminogen activator modulates inflammatory responses and renal function in ischemia reperfusion injury.
Transient brain hypothermia reduces the reperfusion injury of delayed tissue plasminogen activator and extends its therapeutic time window in a focal embolic stroke model.
Translational Stroke Research of the Combination of Thrombolysis and Antioxidant Therapy.
Whole body hypothermia extends tissue plasminogen activator treatment window in the rat model of embolic stroke.
[Effects of acupoint-embedment of medicated-thread and acupoint-injection on expression of cortical urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in rats with cerebral ischemia-reperfusion injury].
Respiratory Distress Syndrome
Administration of exogenous tissue plasminogen activator reduces oedema in mice lacking the tissue plasminogen activator gene.
Advantages and pitfalls of combining intravenous antithrombin with nebulized heparin and tissue plasminogen activator in acute respiratory distress syndrome.
Alveolar plasminogen activator inhibitor-1 predicts ARDS in aspiration pneumonitis.
Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model.
Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York.
Cytokines and plasminogen activator inhibitor-1 in posttrauma disseminated intravascular coagulation: relationship to multiple organ dysfunction syndrome.
High concentrations of plasminogen activator inhibitor-1 in lungs of preterm infants with respiratory distress syndrome.
IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Increased neutrophil elastase, persistent intravascular coagulation, and decreased fibrinolytic activity in patients with posttraumatic acute respiratory distress syndrome.
Increased plasminogen activator inhibitor-1 concentrations in bronchoalveolar lavage fluids are associated with increased mortality in a cohort of patients with Pseudomonas aeruginosa.
Lung fluid biomarkers for acute respiratory distress syndrome: a systematic review and meta-analysis.
Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome*
Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome.
Plasma thrombomodulin, plasminogen activator and plasminogen activator inhibitor levels in preterm infants with or without respiratory distress syndrome.
Plasminogen activator activity in preterm infants with respiratory distress syndrome: relationship to the development of bronchopulmonary dysplasia.
Plasminogen activator inhibitor-1 is an inhibitor of factor VII-activating protease in patients with acute respiratory distress syndrome.
Plasminogen activator inhibitor-1 regulates LPS induced inflammation in rat macrophages through autophagy activation.
Prevention of adult respiratory distress syndrome with plasminogen activator in pigs.
Rescue therapy for severe COVID-19-associated acute respiratory distress syndrome with tissue plasminogen activator: A case series.
Rescue therapy with thrombolysis in patients with severe COVID-19-associated acute respiratory distress syndrome.
Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis.
Serum plasminogen activator urokinase receptor predicts elevated risk of acute respiratory distress syndrome in patients with sepsis and is positively associated with disease severity, inflammation and mortality.
The Association between Body Mass Index and Plasma Cytokine Levels in Patients with Acute Lung Injury.
Tissue plasminogen activator (tPA) inhibits human neutrophil superoxide anion production in vitro.
Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak.
Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series.
Tissue plasminogen activator inhibits reactive oxygen species production by macrophages.
Wood Bark Smoke Induces Lung and Pleural Plasminogen Activator Inhibitor 1 and Stabilizes its mRNA in Porcine Lung Cells.
Respiratory Distress Syndrome, Newborn
Increased tissue-type plasminogen activator antigen release is not accompanied by increased systemic fibrinolytic activity in severe neonatal respiratory distress syndrome.
Plasminogen Activator Inhibitor 1 4G/5G Polymorphism in Neonatal Respiratory Distress Syndrome.
Respiratory Insufficiency
Acute cor pulmonale due to pulmonary tumour thrombotic microangiopathy from renal cell carcinoma.
Catheter directed thrombolysis combined with ECMO for massive pulmonary emboli.
Central Venous Catheter-directed Tissue Plasminogen Activator in Massive Pulmonary Embolism.
COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis.
COVID-19 Critical Illness Pathophysiology Driven by Diffuse Pulmonary Thrombi and Pulmonary Endothelial Dysfunction Responsive to Thrombolysis.
Inflammatory Biomarkers Are Associated With a Decline in Functional Status at Discharge in Children With Acute Respiratory Failure: An Exploratory Analysis.
Prospective Evaluation of Right Ventricular Function and Functional Status Six Months After Acute Submassive Pulmonary Embolism: Frequency of Persistent or Subsequent Elevation in Estimated Pulmonary Artery Pressure.
Rescue therapy for severe COVID-19-associated acute respiratory distress syndrome with tissue plasminogen activator: A case series.
STudy of Alteplase for Respiratory failure in SARS-Cov2/COVID-19: Study Design of the Phase IIa STARS Trial.
Successful cricothyrotomy after thrombolytic therapy for acute myocardial infarction: a report of two cases.
Successful use of tPA for thrombolysis in COVID related ARDS: a case series.
Sulfur mustard inhalation: mechanisms of injury, alteration of coagulation, and fibrinolytic therapy.
Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series.
[Pulmonary hemorrhage and acute respiratory failure secondary to thrombolytic treatment with tissue plasminogen activator (rt-PA) in patients with acute myocardial infarction]
Respiratory Tract Infections
An evaluation of tissue polypeptide antigen (TPA) in the two bronchoalveolar lavage fractions of lung cancer patients.
Retinal Arterial Macroaneurysm
Complication associated with intravitreal injection of tissue plasminogen activator for treatment of submacular hemorrhage due to rupture of retinal arterial macroaneurysm.
Intravitreal tissue plasminogen activator and pneumatic displacement of submacular hemorrhage secondary to retinal artery macroaneurysm.
Management of acute submacular hemorrhage using intravitreal injection of tissue plasminogen activator and gas: A case series.
Management of submacular hemorrhage associated with retinal arterial macroaneurysms.
Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator.
Recombinant tissue plasminogen activator, vitrectomy, and gas for recent submacular hemorrhage displacement due to retinal macroaneurysm.
Subretinal injection of recombinant tissue plasminogen activator for submacular hemorrhage associated with ruptured retinal arterial macroaneurysm.
Subretinal Tissue Plasminogen Activator, Bevacizumab and Partial Gas Tamponade for 4-Week-old Submacular Hemorrhage in Retinal Arterial Macroaneurysm.
Treatment of multilevel macular hemorrhage secondary to retinal arterial macroaneurysm with submacular tissue plasminogen activator.
Vitreous hemorrhage after intravitreal tissue plasminogen activator (t-PA) and pneumatic displacement of submacular hemorrhage.
[Findings of Optical Coherence Tomography (OCT) in Submacular Haemorrhage Displacement Due to a Retinal Macroaneurysm by Intravitreal Injection of Gas and Recombinant Tissue Plasminogen Activator (rtPA)].
Retinal Artery Occlusion
Acute Central Retinal Artery Occlusion Treated with Intravenous Recombinant Tissue Plasminogen Activator.
Cardiovascular and thrombophilic risk factors in patients with retinal artery occlusion.
Dramatic recovery of vision in patient with acute central retinal artery occlusion treated with local intra-arterial tissue plasminogen activator.
Efficacy of intravenous tissue-type plasminogen activator in central retinal artery occlusion: report from a randomized, controlled trial.
Intra-arterial thrombolysis for retinal artery occlusion: the Calgary experience.
Intra-Arterial Tissue Plasminogen Activator for Central Retinal Artery Occlusion.
Intravenous Fibrinolysis for Central Retinal Artery Occlusion: A Cohort Study and Updated Patient-Level Meta-Analysis.
Intravenous Recombinant Tissue-Type Plasminogen Activator Thrombolysis for Acute Central Retinal Artery Occlusion.
Intravenous recombinant tissue-type plasminogen activator thrombolysis in treatment of central retinal artery occlusion.
Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in central retinal artery occlusion.
Intravenous tissue plasminogen activator in central retinal artery occlusion.
Management of acute central retinal artery occlusion: Intravenous thrombolysis is feasible and safe.
Observation on therapeutic efficacy of rt-PA intravenous thrombolysis combined with compound anisodine injection on central retinal artery occlusion.
Paracentral Acute Middle Maculopathy as a Presenting Sign of CRAO in Sickle Cell Disease Treated with Tissue Plasminogen Activator.
Peripheral retinal ischemia after intravenous tissue plasminogen activator for central retinal artery occlusion.
Plasminogen activator inhibitor-1 4G/5G polymorphism and dyslipidemia with branch retinal artery occlusion in a young lady.
Retinal Endovascular Surgery with Tissue Plasminogen Activator Injection for Central Retinal Artery Occlusion.
Study of the efficacy of intravenous tissue plasminogen activator in central retinal artery occlusion.
Superselective intraarterial fibrinolysis in central retinal artery occlusion.
Tissue plasminogen activator after retinal artery occlusion.
Varicella Zoster Meningitis, Optic Neuritis Preceding the Development of Posterior Outer Retinal Necrosis, and Central Retinal Artery Occlusion in a HIV Patient.
Visual recovery and OCT evolution following central retinal artery occlusion treated with intra-arterial verapamil and alteplase infusion.
[Intra-retinal vein cannulation without tissue-type plasminogen activator for hemi-central retinal artery occlusion].
[Selective percutaneous transluminal thrombolytic therapy with rt-PA in central retinal artery occlusion]
[Systemic lysis therapy in retinal vascular occlusions]
[Thrombolysis in central retinal artery occlusion using alteplase]
Retinal Degeneration
Fibrinolysis of experimental subretinal haemorrhage without removal using tissue plasminogen activator.
Fibrinolytic-assisted removal of experimental subretinal hemorrhage within seven days reduces outer retinal degeneration.
Tissue plasminogen activator treatment of experimental subretinal hemorrhage.
Retinal Detachment
Complications of tissue plasminogen activator therapy after vitrectomy for diabetes.
Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders.
Direct tissue plasminogen activator administration through a microinjection device in a pig model of retinal vein thrombosis.
Fibrinolytic-assisted removal of experimental subretinal hemorrhage within seven days reduces outer retinal degeneration.
Successful displacement of a traumatic submacular hemorrhage in a 13-year-old boy treated by vitrectomy, subretinal injection of tissue plasminogen activator and intravitreal air tamponade: a case report.
Surgical outcomes of vitrectomy for breakthrough vitreous hemorrhage in eyes with exudative age-related macular degeneration.
Tissue plasminogen activator and Staphylococcus epidermidis endophthalmitis.
Tissue plasminogen activator for postvitrectomy fibrin formation.
Tissue plasminogen activator for preserving inferior peripheral iridectomy patency in eyes with silicone oil.
Tissue-type plasminogen activator in subretinal fluid.
[Treatment of intraocular fibrin formation with tissue plasminogen activator after vitrectomy]
Retinal Perforations
A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits.
Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders.
Macular Hole Following Subretinal Tissue Plasminogen Activator for Submacular Hemorrhage Secondary to Neovascular AMD.
Postoperative Multimodal Analysis in Successful Gas Displacement of a Submacular Hemorrhage.
Subretinal tissue plasminogen-assisted vitrectomy for posttraumatic full-thickness macular hole with submacular hemorrhage.
[Unusual IOL Calcification following Vitreoretinal Surgery with Silicone Oil Endotamponade.]
Retinal Vein Occlusion
Comparison of surgical treatments for central retinal vein occlusion; RON vs. cannulation of tissue plasminogen activator into the retinal vein.
Direct tissue plasminogen activator administration through a microinjection device in a pig model of retinal vein thrombosis.
Fibrinolytic activity in retinal vein occlusion.
Fibrinolytic therapy with low-dose recombinant tissue plasminogen activator in retinal vein occlusion.
Impact of intravitreal injection of tissue plasminogen activator on full-field electroretinogram in patients with macular oedema secondary to retinal vein occlusion.
Increased retinal toxicity of intravitreal tissue plasminogen activator in a central retinal vein occlusion model.
Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion.
Intravitreal and subretinal injection of tissue plasminogen activator (tPA) in the treatment of experimentally created retinal vein occlusion in rabbits.
Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion.
Intravitreal tissue plasminogen activator for acute central retinal vein occlusion.
Intravitreal tissue plasminogen activator for the treatment of central retinal vein occlusion.
Intravitreal tissue plasminogen activator in the management of central retinal vein occlusion.
Intravitreal tissue plasminogen activator to treat macular edema associated with branch retinal vein occlusion.
Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion.
Management of macular edema in branch retinal vein occlusion with sheathotomy and recombinant tissue plasminogen activator.
Multiple Heritable and Acquired Risk Factors in a Case of Recurrent Retinal Vein Occlusion.
Photoreceptor status after resolved macular edema in branch retinal vein occlusion treated with tissue plasminogen activator.
Post-vitrectomy tissue plasminogen activator injection for central retinal vein occlusion.
Retinal surgery for treatment of central retinal vein occlusion.
Retinal vein cannulation with prolonged infusion of tissue plasminogen activator (t-PA) for the treatment of experimental retinal vein occlusion in dogs.
Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion.
Role of angiotensin-converting enzyme insertion/deletion and plasminogen activator inhibitor-1 4G/5G gene polymorphisms in retinal vein occlusion.
Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal vein occlusion.
Sequential treatment of central retinal vein occlusion with intravitreal tissue plasminogen activator and intravitreal triamcinolone.
Short-term results of endovascular surgery with tissue plasminogen activator injection for central retinal vein occlusion.
Simultaneous intravitreal injection of triamcinolone acetonide and tissue plasminogen activator for central retinal vein occlusion: a pilot study.
The role of vitrectomy assisted rt-PA injection for the management of branch retinal vein occlusion: case report.
THREE TREATMENTS FOR MACULAR EDEMA BECAUSE OF BRANCH RETINAL VEIN OCCLUSION: Intravitreous Bevacizumab or Tissue Plasminogen Activator, and Vitrectomy.
Thrombolytic therapy for central retinal vein occlusion: results of a pilot study.
Tissue plasminogen activator in the treatment of experimental retinal vein occlusion.
Treatment of central retinal vein occlusion by injection of tissue plasminogen activator into a retinal vein.
Treatment of central retinal vein occlusion by vitrectomy with lysis of vitreopapillary and epipapillary adhesions, subretinal peripapillary tissue plasminogen activator injection, and photocoagulation.
Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study.
Updated cannulation technique for tissue plasminogen activator injection into peripapillary retinal vein for central retinal vein occlusion.
Visual outcome after treatment with low-dose recombinant tissue plasminogen activator or hemodilution in ischemic central retinal vein occlusion.
[Experiment study of infusing tPA in retinal vein for treatment of retinal vein occlusion]
[Front-loading rt PA thrombolytic therapy in central or venous branch occlusions of the retina]
[Intravitreal tissue plasminogen activator for treatment of central retinal vein occlusion associated with diabetic retinopathy]
[Search for retinal vein occlusion and tissue plasminogen activator]
[Systemic lysis therapy in retinal vascular occlusions]
[Thrombophilia as a risk factor for central retinal vein occlusion]
[Treatment trials of plasminogen activator (rt-PA) in central vein thrombosis of the retina]
Retinoblastoma
Differential effects of 1,25-dihydroxyvitamin D3 and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells and a vitamin D3-resistant variant.
Evidence for the involvement of protein kinase activity in transforming growth factor-beta signal transduction.
Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif.
Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts.
Oncogenic potential in fibroblasts from individuals genetically predisposed to cancer.
Phorbol ester stimulated Cip1 expression in p53-negative leukemic cells.
Rhabdomyosarcoma
12-0-Tetradecanoylphorbol-13-acetate-induced amplification of mesenchymal tumorigenesis in the mouse skin.
12-O-tetradecanoylphorbol-13-acetate and EZH2 inhibition: A novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells.
12-O-tetradecanoylphorbol-13-acetate-induced differentiation of a human rhabdomyosarcoma cell line.
Differentiation dependent expression in muscle cells of ZT3, a novel zinc finger factor differentially expressed in embryonic and adult tissues.
Influence of short-term topical exposure to phorbol ester tumor promoters on subcutaneously induced skin tumorigenesis in S/RVCri mice.
p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
Plasminogen activator inhibitor type-1 protein, mRNA and gene transcription are increased by phorbol esters in human rhabdomyosarcoma cells.
Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
Reactivation of a silenced H19 gene in human rhabdomyosarcoma by demethylation of DNA but not by histone hyperacetylation.
TPA-induced differentiation of human rhabdomyosarcoma cells involves dephosphorylation and nuclear accumulation of mutant P53.
[Immunohistochemical studies in the differential diagnosis of malignant fibrous histiocytoma]
[Thrombolysis with rt-PA in children with arterial and venous thromboses--a new therapy concept]
Rhabdomyosarcoma, Alveolar
p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
Rhabdomyosarcoma, Embryonal
p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
Rheumatic Diseases
Macrophage proteases and rheumatic diseases: regulation of plasminogen activator by thymus-derived lymphocytes.
Rhinitis, Allergic
Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in Turkish children with asthma and allergic rhinitis.
Polymorphism 4G/5G of the plasminogen activator inhibitor 1 gene as a risk factor for the development of allergic rhinitis symptoms in patients with asthma.
The urokinase system in patients with intermittent and persistent allergic rhinitis.
Tissue-type plasminogen activator depletion affects the nasal mucosa matrix reconstruction in allergic rhinitis mice.
Rocky Mountain Spotted Fever
Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by Rickettsia conorii- and Rickettsia rickettsii-infected cultured endothelial cells.
Rubella
Applications of cell culture for the improvement of human health.
Sagittal Sinus Thrombosis
Is heparin treatment the optimal management for cerebral venous thrombosis? Effect of abciximab, recombinant tissue plasminogen activator, and enoxaparin in experimentally induced superior sagittal sinus thrombosis.
Reversibility of severe sagittal sinus thrombosis with open surgical thrombectomy combined with local infusion of tissue plasminogen activator: technical case report.
Sarcoidosis
Increased alveolar plasminogen activator in early asbestosis.
Phagocyte enzymes in bronchoalveolar lavage from patients with pulmonary sarcoidosis and collagen vascular disorders.
Procoagulant and plasminogen activator activities of bronchoalveolar fluid in patients with pulmonary sarcoidosis.
Production of plasminogen activator by alveolar macrophages in normal subjects and patients with interstitial lung disease.
Sarcoidosis, Pulmonary
Phagocyte enzymes in bronchoalveolar lavage from patients with pulmonary sarcoidosis and collagen vascular disorders.
Procoagulant and plasminogen activator activities of bronchoalveolar fluid in patients with pulmonary sarcoidosis.
Sarcoma
Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas.
Clonal variation of expression of the genes coding for plasminogen activators, their inhibitors and the urokinase receptor in HT1080 sarcoma cells.
Cyclic AMP-dependent and -independent effects on tissue-type plasminogen activator activity in osteogenic sarcoma cells; evidence from phosphodiesterase inhibition and parathyroid hormone antagonists.
Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells.
Diverse effects: augmentation, inhibition, and non-efficacy of 12-O-tetradecanoylphorbol-13-acetate (TPA) on retrovirus genome expression in vivo and in vitro.
Functional analysis of the human tissue-type plasminogen activator protein: the light chain.
In vitro and in vivo studies of murine sarcoma cells after prolonged treatment with promoting phorbol ester TPA.
Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2.
Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin.
Isolation and purification of plasminogen activator from Yoshida ascites Sarcoma of rats.
Modulation of plasminogen activator synthesis in chick embryo fibroblasts by cyclic nucleotides and phorobol myristate acetate.
Morphological transformation of cells induced by Kirsten sarcoma virus transforming factor is independent of serine proteases.
Need for tissue plasminogen activator for central venous catheter dysfunction is significantly associated with thrombosis in pediatric cancer patients.
Phenotypic differences between tumor cells derived from different stages of neoplastic growth.
Plasminogen activator in chick embryo muscle cells: induction of enzyme by RSV, PMA and retinoic acid.
Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus.
Plasminogen promotes sarcoma growth and suppresses the accumulation of tumor-infiltrating macrophages.
Proteolytic enzymes in tumor metastasis. I. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma.
Purification and characterization of a plasminogen activator from mouse cells transformed by an oncogenic virus.
Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody.
Tissue polypeptide antigen production in a uterine carcinosarcoma cell line in a serum-free culture.
Two-stage carcinogenesis in NMRI mice: intravaginal application of 7,12-dimethylbenz[a]anthracene as initiator followed by the phorbol ester 12-O-tetradecanoylphorbol-13-acetate as promoter.
Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts.
[Clinical significances of tissue polypeptide antigen in patients with gynecological malignancies]
Sarcoma, Avian
A proenzyme from chicken plasma similar to human plasma prekallikrein.
An anticatalytic monoclonal antibody to avian plasminogen activator: its effect on behavior of RSV-transformed chick fibroblasts.
Association of a protease (plasminogen activator) with a specific membrane fraction isolated from transformed cells.
Direct fluorescent assay of urokinase and plasminogen activators of normal and malignant cells: kinetics and inhibitor profiles.
Effect of tumor promoters on sarc gene expression in normal and transformed chick embryo fibroblasts.
Enhancement of plasminogen activator activity by the culture medium of Rous sarcoma virus-transformed cells.
From Rous sarcoma virus to plasminogen activator, src oncogene and cancer management.
Gene transfer into specific vascular cells.
In vitro transformation with Rous sarcoma virus and the pp60src-associated protein kinase.
Inhibition of plasminogen activator release from transformed chicken fibroblasts by a protease inhibitor.
Lack of correlation between tumorigenicity and level of plasminogen activator in fibroblasts transformed by Rous sarcoma virus.
PC12 cells overexpressing tissue plasminogen activator regenerate neurites to a greater extent and migrate faster than control cells in complex extracellular matrix.
Phorbol ester-induced morphological changes in transformed chick fibroblasts: evidence for direct catalytic involvement of plasminogen activator.
Production of plasminogen activator by synchronized normal and Rous sarcoma virus-transformed chicken fibroblasts in culture.
Purification of plasminogen activator from Rous sarcoma virus transformed chick embryo fibroblasts treated with the tumor promoter phorbol 12-myristate 13-acetate.
Purification of plasminogen activator from Rous sarcoma virus-infected chick embryo fibroblast culture medium.
Receptors for plasminogen activator, urokinase, in normal and Rous sarcoma virus-transformed mouse fibroblasts.
Synergistic effect of tumor virus transformation and tumor promoter treatment on the production of plasminogen activator by chick embryo fibroblasts.
The expression of plasminogen activator in Rous sarcoma virus-transformed cells is controlled both by the virus and the cell.
The extracellular matrix of normal chick embryo fibroblasts: its effect on transformed chick fibroblasts and its proteolytic degradation by the transformants.
Tumor promoters induce changes in the chick embryo fibroblast cytoskeleton.
Sarcoma, Ewing
The course of fibrinolytic proteins in children with malignant bone tumours.
Sarcoma, Yoshida
Characterization of urokinase-type plasminogen activator of rat decidual tissue.
Sarcopenia
Clinical and morphometric parameters of frailty for prediction of mortality following hepatopancreaticobiliary surgery in the elderly.
Comparing the performance of SOFA, TPA combined with SOFA and APACHE-II for predicting ICU mortality in critically ill surgical patients: A secondary analysis.
Does Sarcopenia Impact Complications and Overall Survival in Patients Undergoing Radical Nephrectomy for Stage III and IV Kidney Cancer?
Impact of sarcopenia on clinical outcomes of patients undergoing simultaneous liver and kidney transplantation: a cohort study.
Impact Total Psoas Volume on Short- and Long-Term Outcomes in Patients Undergoing Curative Resection for Pancreatic Adenocarcinoma: a New Tool to Assess Sarcopenia.
Is sarcopenia really a risk factor in the development of postoperative complications?
Morphometric parameters of muscle and bone in critically ill patients : Post hoc analysis of the VITdAL-ICU trial.
Pre-operative volume rather than area of skeletal muscle is a better predictor for post-operative risks for respiratory complications in living-donor liver transplantation.
PREOPERATIVE ASSESSMENT OF MUSCLE MASS USING COMPUTERIZED TOMOGRAPHY SCANS TO PREDICT OUTCOMES FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION.
Preoperative Detection of Sarcopenic Obesity Helps to Predict the Occurrence of Gastric Leak After Sleeve Gastrectomy.
Sarcopenia as independent risk factor of postpneumonectomy respiratory failure, ARDS and mortality.
Sarcopenia in emergency abdominal surgery.
Sarcopenia is Associated with Perioperative Outcomes in Gastric Cancer Patients Undergoing Gastrectomy.
Sarcopenia predicts 90-day mortality in elderly patients undergoing emergency abdominal surgery.
Sarcopenia, obesity, and inflammation--results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study.
Total Psoas Area and Total Muscular Parietal Area Affect Long-Term Survival of Patients Undergoing Pneumonectomy for Non-Small Cell Lung Cancer.
[Morphometry of adipose tissue for prediction of the outcomes of total pancreatectomy with pancreatic islets autotransplantation in patients with chronic pancreatitis].
Schistosomiasis
A case control study on the structural equation model of the mechanism of coagulation and fibrinolysis imbalance in chronic schistosomiasis.
Detection of granuloma-associated plasminogen activator in experimental murine schistosomiasis.
Plasminogen activator activity increases during reversal of hepatic fibrosis in murine schistosomiasis.
Serum TPS versus TPA in Egyptian bladder cancer patients.
The pathogenesis of accelerated fibrinolysis in hepatosplenic schistosomiasis.
Scleroderma, Systemic
A double blind placebo controlled trial of recombinant tissue plasminogen activator in the treatment of digital ischemia in systemic sclerosis.
Antibodies to fibrin bound tissue type plasminogen activator in systemic sclerosis.
L-arginine therapy in Raynaud's phenomenon?
Morphometric evaluation of nitric oxide synthase isoforms and their cytokine regulators predict pulmonary dysfunction and survival in systemic sclerosis.
Prolonged improvement of Raynaud's phenomenon and scleroderma after recombinant tissue plasminogen activator therapy.
The plasminogen activator system in fibroblasts from systemic sclerosis.
The safety and efficacy of low-dose tissue plasminogen activator in the treatment of systemic sclerosis.
Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon.
Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
Scoliosis
A study on platelet function in idiopathic scoliosis.
T1 pelvic angle (TPA) effectively evaluates sagittal deformity and assesses radiographical surgical outcomes longitudinally.
T1 Pelvic Angle Is a Useful Parameter for Postoperative Evaluation in Adult Spinal Deformity Patients.
T1 pelvic angle: a new predictor for postoperative sagittal balance and clinical outcomes in adult scoliosis.
Seizures
A novel approach for imaging brain-behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activator.
Acute ischemic stroke treatment and the occurrence of seizures.
Acute seizures in acute ischemic stroke: does thrombolysis have a role to play?
Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-methyl-D-aspartate receptor signaling.
Brain plasticity: to what extent do aged animals retain the capacity to coordinate gene activity in response to acute challenges.
Catastrophic Secondary Infarctions with Onset Seizure Following Tissue Plasminogen Activator Therapy.
Compartment- and context-specific changes in tissue-type plasminogen activator (tPA) activity following brain injury and pharmacological stimulation.
Decreased neural damage after spinal cord injury in tPA-deficient mice.
Delayed and blunted induction of mRNA for tissue plasminogen activator in the brain of old rats following pentylenetetrazole-induced seizure activity.
Detection of Protein Uptake in In Vitro Cultured Astrocytes Exemplified by the Uptake of the Serine Protease, Tissue Plasminogen Activator.
Dynamics of gene expression for immediate early- and late genes after seizure activity in aged rats.
Early epileptic seizures in ischaemic stroke treated by mechanical thrombectomy: influence of rt-PA.
Early seizures after ischemic stroke: focus on thrombolysis.
Epileptic manifestations in stroke patients treated with intravenous alteplase.
Estimation of seizures prevalence in ischemic strokes after thrombolytic therapy.
Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors.
Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator.
Identification of a neurovascular signaling pathway regulating seizures in mice.
Imaging Evidence for Cerebral Hyperperfusion Syndrome after Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke.
Incidence and Association of Reperfusion Therapies With Poststroke Seizures: A Systematic Review and Meta-Analysis.
Incidence of seizure in stroke patients treated with recombinant tissue plasminogen activator: A systematic review and meta-analysis.
Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations.
Intravenous thrombolysis for acute stroke: current standards and future directions.
Intravenous thrombolysis with tPA and cortical involvement increase the risk of early poststroke seizures: Results of a case-control study.
Kindling status in sprague-dawley rats induced by pentylenetetrazole: involvement of a critical development period.
mRNAs encoding urokinase-type plasminogen activator and plasminogen activator inhibitor-1 are elevated in the mouse brain following kainate-mediated excitation.
Neuroserpin Portland (Ser52Arg) is trapped as an inactive intermediate that rapidly forms polymers: implications for the epilepsy seen in the dementia FENIB.
Neuroserpin: a selective inhibitor of tissue-type plasminogen activator in the central nervous system.
New functions for an old enzyme: nonhemostatic roles for tissue-type plasminogen activator in the central nervous system.
Phospholipase D1-promoted release of tissue plasminogen activator facilitates neurite outgrowth.
Propofol treatment modulates neurite extension regulated by immunologically challenged rat primary astrocytes: a possible role of PAI-1.
Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent.
Reperfusion seizures: a manifestation of cerebral reperfusion injury after administration of recombinant tissue plasminogen activator for acute ischemic stroke.
Role of CT Angiography in Thrombolysis Decision-Making for Patients With Presumed Seizure at Stroke Onset.
Seizures during stroke thrombolysis heralding dramatic neurologic recovery.
Temporal pole signal abnormality on MR imaging in temporal lobe epilepsy with hippocampal sclerosis: a fluid-attenuated inversion-recovery study.
Tissue plasminogen activator and seizures: a clot-buster's secret life.
Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies.
Tissue plasminogen activator, neuroserpin, and seizures.
Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation.
Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system?
Urokinase receptor and tissue plasminogen activator as immediate-early genes in pentylenetetrazole-induced seizures in the mouse brain.
[Treatment of arterial and venous brain ischemia. Experts' recommendations: stroke management in the intensive care unit].
Seminoma
Clinical-evaluation of serum basic fetoprotein as a marker in urogenital malignant-tumors.
p53 expression and tumor proliferative activity in testicular germ-cell tumors.
Sepsis
4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group.
4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia.
4G4G genotype of the plasminogen activator inhibitor-1 promoter polymorphism associates with disseminated intravascular coagulation in children with systemic meningococcemia.
Abrogation of plasminogen activator inhibitor-1-vitronectin interaction ameliorates acute kidney injury in murine endotoxemia.
Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
Activation patterns of coagulation and fibrinolysis in baboons following infusion with lethal or sublethal dose of Escherichia coli.
Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study.
Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice.
Alteplase use for malfunctioning central venous catheters correlates with catheter-associated bloodstream infections.
An ethanol/sodium citrate locking solution compared to heparin to prevent hemodialysis catheter-related infections: a randomized pilot study.
Apolipoprotein M Protects Lipopolysaccharide-Treated Mice from Death and Organ Injury.
Association between PAI-1 polymorphisms and plasma PAI-1 level with sepsis in severely burned patients.
Association between plasminogen activator inhibitor-1 -675 4G/5G polymorphism and sepsis: a meta-analysis.
Beneficial and detrimental effects of plasmin(ogen) during infection and sepsis in mice.
Catheter-related bloodstream infection in end-stage kidney disease: a Canadian narrative review.
Changes of the hemostatic network in critically ill patients--is there a difference between sepsis, trauma, and neurosurgery patients?
Chronic plasminogen activator inhibitor-1 (PAI-1) overexpression dampens CD25+ lymphocyte recruitment after lipopolysaccharide endotoxemia in mouse lung.
Clinical significance of measuring plasminogen activator inhibitor-1 in sepsis.
Coagulation, fibrinolysis, and kallikrein systems in sepsis: relation to outcome.
Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study.
Comparison of the coagulopathies associated with COVID-19 and sepsis.
Compartment-specific expression of plasminogen activator inhibitor-1 correlates with severity/outcome of murine polymicrobial sepsis.
Complexes of factor VII-activating protease with plasminogen activator inhibitor-1 in human sepsis.
Cost-effectiveness of intrapleural use of tissue plasminogen activator and DNase in pleural infection: evidence from the MIST2 randomised controlled trial.
Dysregulation of Inflammatory and Hemostatic Markers in Sepsis and Suspected Disseminated Intravascular Coagulation.
Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients.
Effect of ascorbate on fibrinolytic factors in septic mouse skeletal muscle.
Effect of ascorbate on plasminogen activator inhibitor-1 expression and release from platelets and endothelial cells in an in-vitro model of sepsis.
Effect of various genetic polymorphisms on the incidence and outcome of severe sepsis.
Endogenous tissue-type plasminogen activator impairs host defense during severe experimental Gram-negative sepsis (melioidosis)*.
Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice.
Endothelial Activation and Blood-Brain Barrier Injury as Risk Factors for Delirium in Critically Ill Patients.
Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications.
Etiopathophysiology of disseminated intravascular coagulation.
Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator.
Fibrinolysis and coagulation in patients with infectious disease and sepsis.
Hemostatic parameters in sepsis patients treated with anti-TNF alpha-monoclonal antibodies.
Heparin Versus Normal Saline: Flushing Effectiveness in Managing Central Venous Catheters in Patients Undergoing Blood and Marrow Transplantation
High macrophage migration inhibitory factor levels in disseminated intravascular coagulation patients with systemic inflammation.
Hospital mortality from atrial fibrillation associated with ischemic stroke: a national data report.
HSF1 Alleviates Microthrombosis and Multiple Organ Dysfunction in Mice with Sepsis by Upregulating the Transcription of Tissue-Type Plasminogen Activator.
IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis.
Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis.
Infections Increase the Risk of 30-Day Readmissions Among Stroke Survivors.
Institutional care paths: Development, implementation, and evaluation.
Low dose intrapleural alteplase and pulmozyme (DNase) in two post-surgical patients with pleural sepsis.
Management of Intrapleural Sepsis with Once Daily Use of Tissue Plasminogen Activator and Deoxyribonuclease.
Myeloperoxidase instigates proinflammatory responses in a cecal ligation and puncture rat model of sepsis.
N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1.
Nafamostat Attenuated the Impairment of Fibrinolysis in Animal Sepsis Model by Suppressing the Increase of Plasminogen Activator Inhibitor Type 1.
PAI-1 inhibits neutrophil efferocytosis.
Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans.
Plasminogen activator inhibitor 1 and 2, alpha-2-antiplasmin, plasminogen, and endotoxin levels in systemic meningococcal disease.
Plasminogen Activator Inhibitor 1 for Predicting Sepsis Severity and Mortality Outcomes: A Systematic Review and Meta-Analysis.
Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis.
Plasminogen activator inhibitor type 1 gene polymorphism and sepsis.
Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia.
Plasminogen Activator Inhibitor Type I Contributes to Protective Immunity During Experimental Gram-Negative Sepsis (Melioidosis).
Platelet Drop and Fibrinolytic Shutdown in Patients With Sepsis.
Portal Vein Thrombosis in a Preterm Newborn with Mutation of the MTHFR and PAI-1 Genes and Sepsis by Candida parapsilosis.
PREOPERATIVE ASSESSMENT OF MUSCLE MASS USING COMPUTERIZED TOMOGRAPHY SCANS TO PREDICT OUTCOMES FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION.
Protein C as an early marker of severe septic complications in diffuse secondary peritonitis.
Recent advances in disseminated intravascular coagulation: endothelial cells and fibrinolysis in sepsis-induced DIC.
Redirection of the reaction between activated protein C and a serpin to the substrate pathway.
Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins.
Rethinking the Doses of Tissue Plasminogen Activator and Deoxyribonuclease Administrated Concurrently for Intrapleural Therapy for Complicated Pleural Effusion and Empyema.
Role of 4G/5G promoter polymorphism of Plasminogen Activator Inhibitor-1 (PAI-1) gene in outcome of sepsis.
Sepsis-Induced Adipokine Change with regard to Insulin Resistance.
Serum plasminogen activator urokinase receptor predicts elevated risk of acute respiratory distress syndrome in patients with sepsis and is positively associated with disease severity, inflammation and mortality.
Severe acute myocardial infarction during a staphylococcal septicemia with meningoencephalitis. A possible contraindication to thrombolytic treatment.
Short-Term Dietary Restriction Rescues Mice From Lethal Abdominal Sepsis and Endotoxemia and Reduces the Inflammatory/Coagulant Potential of Adipose Tissue.
Single measurement of plasminogen activator inhibitor-1 in sepsis: is it useful for evaluating the severity or prognosis of sepsis?
Stimulation of tissue type plasminogen activator by leukaemic cell homogenates.
Successful treatment of fulminant pneumococcal sepsis with recombinant tissue plasminogen activator.
Systemic Inhibition and Liver-specific Overexpression of PAI-1 Failed to Improve Survival in All-inclusive Populations or Homogenous Cohorts of CLP Mice.
TAFI and PAI-1 levels in human sepsis.
Template-directed dye-terminator incorporation with fluorescence polarization detection for analysis of single nucleotide polymorphisms implicated in sepsis.
The activation of neutrophil elastase-mediated fibrinolysis is not sufficient to overcome the fibrinolytic shutdown of disseminated intravascular coagulation associated with systemic inflammation.
The association between plasminogen activator inhibitor type-1 and clinical outcome in paediatric sepsis.
The coagulation cascade in sepsis.
The effect of four hemostatic gene polymorphisms on the outcome of septic critically ill patients.
The Prevalence and Impact of Mortality of the Acute Respiratory Distress Syndrome on Admissions of Patients With Ischemic Stroke in the United States.
The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome.
The role of tissue plasminogen activator use and systemic hypercoagulability in central line-associated bloodstream infections.
The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia.
Thrombolytic therapy with tissue plasminogen activator for superior vena cava thrombosis in an infant with sepsis.
Thrombomodulin, Plasminogen Activator Inhibitor-1 and Protein C Levels, and Organ Dysfunction in Sepsis.
Tight glycemic control may favor fibrinolysis in patients with sepsis.
Tissue plasminogen activator reverses the deleterious effect of infection on colonic wound healing.
Tranexamic acid, an inhibitor of plasminogen activation, aggravates staphylococcal septic arthritis and sepsis.
Transgenic tissue-type plasminogen activator expression improves host defense during Klebsiella pneumonia.
Types 1 and 2 plasminogen activator inhibitor and tumor necrosis factor alpha in patients with sepsis.
Usefulness of plasminogen activator inhibitor-1 as a predictive marker of mortality in sepsis.
Validating plasminogen activator inhibitor-1 as a poor prognostic factor in sepsis.
Validation of a modified thromboelastometry approach to detect changes in fibrinolytic activity.
Visceral fat-specific regulation of plasminogen activator inhibitor-1 in aged septic mice.
[Classification and treatment of DIC]
[Infection and hemostasis]
[Relationship between sepsis and 4G/5G polymorphism within the promoter region of plasminogen activator inhibitor-1 gene]
[Relationship of single nucleotide polymorphisms and genetic susceptibility to sepsis].
[Thrombolysis with rt-PA in children with arterial and venous thromboses--a new therapy concept]
Severe Acute Respiratory Syndrome
Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York.
Elevated plasma tissue-type plasminogen activator (t-PA) and soluble thrombomodulin in patients suffering from severe acute respiratory syndrome (SARS) as a possible index for prognosis and treatment strategy.
Severe Combined Immunodeficiency
Analysis of Hepatitis C Virus Particle Heterogeneity in Immunodeficient Human Liver Chimeric fah-/- Mice.
Association between hepatitis B virus and MHC class I polypeptide-related chain A in human hepatocytes derived from human-mouse chimeric mouse liver.
Enzymes approved for human therapy: indications, mechanisms and adverse effects.
Host-specific response to HCV infection in the chimeric SCID-beige/Alb-uPA mouse model: role of the innate antiviral immune response.
Severe Dengue
Impaired fibrinolysis in the pathogenesis of dengue hemorrhagic fever.
Shaken Baby Syndrome
Intravitreal tPA and SF6 promote clearing of premacular subhyaloid hemorrhages in shaken and battered baby syndrome.
Shock, Cardiogenic
A Floating Thrombus in Sinus of Valsalva Complicated with Cardiogenic Shock in a Patient with Plasminogen Activator Inhibitor 1 4G/5G Polymorphism.
Acute diastolic dysfunction due to pneumomediastinum following positive end-expiratory pressure--a case report.
Admission levels of C-reactive protein and plasminogen activator inhibitor-1 in patients with acute myocardial infarction with and without cardiogenic shock or heart failure on admission.
An uncommon case of variant angina.
Cardiogenic shock complicating acute myocardial infarction: predictors of death. GUSTO Investigators. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries.
Catheter directed thrombolysis combined with ECMO for massive pulmonary emboli.
Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
De Winter's pattern: an uncommon but very important electrocardiographic sign in the prompt recognition of spontaneous occlusive coronary artery dissection in young patients with chest pain (a case report).
Efficacy of a two-hour infusion of 150-mg tissue plasminogen activator in acute myocardial infarction.
Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries.
Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study.
Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial.
One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: results from the GUSTO-I trial.
Reversible cardiogenic shock in an angry woman--case report and review of the literature.
Severe acute myocardial infarction during a staphylococcal septicemia with meningoencephalitis. A possible contraindication to thrombolytic treatment.
Thrombelastometry-guided thrombolytic therapy in massive pulmonary artery embolism.
Thrombolytic therapy in cardiogenic shock: effect of increased aortic pressure and rapid tPA administration.
Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Use of Tissue Plasminogen Activator Alteplase Purge Solution in an Impella 5.5 Heart Pump.
[Intra-aortic balloon counterpulsation as percutaneous therapy option in cardiogenic shock]
[Intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction]
[Intravenous thrombolysis by recombinant plasminogen activator (rt-PA) in unstable angina. A randomized multicenter study versus placebo]
[Recombinant tissue-type plasminogen activator for the emergency treatment of perioperative life-threatening pulmonary embolism (stage IV). Results in 7 patients]
[Role of thrombolysis in the treatment of cardiogenic shock following myocardial infarct]
Shock, Septic
A shock toxin that produces disseminated intravascular coagulation and multiple organ failure.
Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study.
Dissemination of extreme levels of extracellular vesicles: tissue factor activity in patients with severe COVID-19.
Enhancement of natural killer cell activity in septic shock patients by a mixture of the calcium ionophore A23187 and the phorbol ester TPA: in vitro studies.
Fibrinolysis and coagulation in patients with infectious disease and sepsis.
Functional determination of tPA, PAI and fibrinogen in endotoxin shock of the pig.
Hemostatic parameters in sepsis patients treated with anti-TNF alpha-monoclonal antibodies.
Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis.
Increased mortality in septic shock with the 4G/4G genotype of plasminogen activator inhibitor 1 in patients of white descent.
Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome.
Institutional care paths: Development, implementation, and evaluation.
Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans.
Plasminogen activator inhibitor 1: a new prognostic marker in septic shock.
Protein C concentrate and recombinant tissue plasminogen activator in meningococcal septic shock.
Suppression of plasminogen activator inhibitor-1 (PAI-1) activity by crocin ameliorates lipopolysaccharide-induced thrombosis in rats.
The 4G/4G Genotype of PAI-1 Polymorphism Is Associated with Higher Plasma PAI-1 Concentrations and Mortality in Patients with Severe Sepsis.
The effect of four hemostatic gene polymorphisms on the outcome of septic critically ill patients.
The relationship between plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock.
tPA Alu (I/D) polymorphism associates with bacterial osteomyelitis.
[Abnormalities in coagulation and fibrinolysis in septic shock with purpura]
Shwartzman Phenomenon
Cutaneous vascular fibrinolytic activity in the local Shwartzman reaction.
Tissue plasminogen activator therapy of glomerular thrombi in the Shwartzman reaction.
Sickle Cell Trait
Triglyceride/HDL-cholesterol ratio and plasminogen activator inhibitor-1 independently predict high pulse pressure in sickle cell trait and disease.
Silicosis
[Effects of silica on the expression of plasminogen activator inhibitor-1 and activator protein-1 in human alveolar epithelial cells type II]
Sinus Thrombosis, Intracranial
A case of worsening deep cerebral venous sinus thrombosis managed by intrasinus thrombolysis.
A Series of Cerebral Venous Sinus Thromboses Treated with Intra-Arterial tPA infused over Ten Hours with a 0.027-inch Catheter and Literature Review.
Acute antithrombotic treatment of ischemic stroke.
Direct endovascular thrombolytic therapy for dural sinus thrombosis: infusion of alteplase.
Dural sinus mechanical thrombectomy and continuous local rt-PA infusion in a child with refractory intracranial hypertension and progressive visual loss: A case report.
Efficacy of tissue plasminogen activator in the lysis of thrombosis of the cerebral venous sinus.
Extensive dural sinus thrombosis: successful recanalization with thrombolysis and a novel thrombectomy device.
Homocystinuria with Cerebral Venous Sinus Thrombosis: Excellent Recovery with Intravenous Recombinant Tissue Plasminogen Activator.
Mechanical thrombectomy combined with recombinant tissue plasminogen activator thrombolysis in the venous sinus for the treatment of severe cerebral venous sinus thrombosis.
Mechanical venous thrombectomy and prolonged infusion of tissue plasminogen activator for cerebral venous sinus thrombosis: Video case report.
Neurological Emergencies During Pregnancy.
Novel use of a double lumen balloon catheter for venous sinus thrombolysis and venoplasty.
Plasminogen Activator Inhibitor-1 (PAI-1) Gene Polymorphisms Associated with Cardiovascular Risk Factors Involved in Cerebral Venous Sinus Thrombosis.
Plasminogen activator inhibitor-1 4G/4G-genotype is associated with cerebral sinus thrombosis in factor V Leiden carriers.
Rheolytic catheter thrombectomy, balloon angioplasty, and direct recombinant tissue plasminogen activator thrombolysis of dural sinus thrombosis with preexisting hemorrhagic infarctions.
Sinusitis
Characteristics of tissue plasminogen activator from paranasal mucous membrane in chronic sinusitis.
Expression of leukotriene C4 synthase and plasminogen activator inhibitor 1 gene promoter polymorphisms in sinusitis.
Fibrin binding, fibrinolytic and fibrinogenolytic activity of plasminogen activator derived from the paranasal mucous membrane of humans.
Fibrinolytic activity in medium from tissue culture of paranasal mucous membrane.
Presence of urokinase-type plasminogen activator (u-PA) in tissue extracts of antrochoanal polyp.
Some chemical properties of tissue plasminogen activator purified from paranasal mucous membrane.
Urokinase-type plasminogen activator and plasminogen activator inhibitor antigen in tissue extracts of paranasal sinus mucous membranes affected by chronic sinusitis and antrochoanal polyps.
Skin Abnormalities
Skin abnormalities in mice transgenic for plasminogen activator inhibitor 1: implications for the regulation of desquamation and follicular neogenesis by plasminogen activator enzymes.
Skin Neoplasms
Arsenic exposure in utero exacerbates skin cancer response in adulthood with contemporaneous distortion of tumor stem cell dynamics.
Chemoprevention of Skin Cancer: Effect of Lawsonia Inermis L. (Henna) Leaf Powder and its Pigment Artifact, Lawsone in the Epstein- Barr Virus Early Antigen Activation Assay and in Two-Stage Mouse Skin Carcinogenesis Models.
Curcumin inhibits TPA induced expression of c-fos, c-jun and c-myc proto-oncogenes messenger RNAs in mouse skin.
Gene Deletion of Microsomal Prostaglandin E Synthase-1 Suppresses Chemically Induced Skin Carcinogenesis.
Inhibition of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mouse skin ornithine decarboxylase and protein kinase C by polyphenolics from grapes.
Inhibition of skin carcinomas but not papillomas by sphingosine, N-methylsphingosine, and N-acetylsphingosine.
Mice defective in the mismatch repair gene Msh2 show increased predisposition to UVB radiation-induced skin cancer.
NTP Toxicology and Carcinogenesis Studies of Diethylphthalate (CAS No. 84-66-2) in F344/N Rats and B6C3F1 Mice (Dermal Studies) with Dermal Initiation/ Promotion Study of Diethylphthalate and Dimethylphthalate (CAS No. 131-11-3) in Male Swiss (CD-1(R)) Mice.
Phorbol ester-induced transcription of a fibroblast growth factor-binding protein is modulated by a complex interplay of positive and negative regulatory promoter elements.
RIP4 Regulates Epidermal Differentiation and Cutaneous Inflammation.
Skin Ulcer
Evaluation of diuron (3-[3,4-dichlorophenyl]-1,1-dimethyl urea) in a two-stage mouse skin carcinogenesis assay.
Sleep Apnea Syndromes
Elevated plasminogen activator inhibitor 1 in sleep apnea and its relation to the metabolic syndrome: an investigation in 2 different study samples.
Feeble awake effects of plasminogen activator inhibitor type-1 in mice.
Increased low-grade inflammation and plasminogen-activator inhibitor-1 level in nondippers with sleep apnea syndrome.
Sleep Apnea, Obstructive
Elevated plasminogen activator inhibitor 1 in sleep apnea and its relation to the metabolic syndrome: an investigation in 2 different study samples.
Pathophysiologic mechanisms, neuroimaging and treatment in wake-up stroke.
Plasminogen activator inhibitor-1 in obstructive sleep apnea patients with and without hypertension.
Sleep Deprivation
Conditions that affect sleep alter the expression of molecules associated with synaptic plasticity.
Negative Influence of Insufficient Sleep on Endothelial Vasodilator and Fibrinolytic Function in Hypertensive Adults.
Small Cell Lung Carcinoma
Diagnostic usefulness of 5 tumor-markers in patients with primary lung-cancer.
Hybrid approach in patients with recurrent brachial artery embolism: adjunctive tissue plasminogen activator infusion following embolectomy.
Macrophages of M1 phenotype have properties that influence lung cancer cell progression.
Serum markers casa, cea, cyfra-21-1, msa, nse, tpa and tps in lung-cancer.
Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
[Tumor markers in bronchus cancer]
Soft Tissue Injuries
Complexing of tissue plasminogen activator with PAI-1, alpha 2-macroglobulin, and C1-inhibitor: studies in patients with defibrination and a fibrinolytic state after electroshock or complicated labor.
Solitary Kidney
Alteplase Instillation for Upper Urinary Tract Clot Dissolution.
Spasm
Arteriographic demonstration of coronary artery spasm during thrombolysis.
Difference in fibrinolytic activity between multivessel coronary spasm and one-vessel coronary spasm.
Increased plasma plasminogen activator inhibitor activity after coronary spasm.
Phase I trial of tissue plasminogen activator for the prevention of vasospasm in patients with aneurysmal subarachnoid hemorrhage.
[Pathophysiology of acute coronary syndromes]
Spinal Cord Diseases
Technical note: Novel use of recombinant tissue plasminogen activator for the evacuation of an acute extensive spinal epidural haematoma in a patient with coagulopathy.
Spinal Cord Injuries
Arm-cranking Exercise Training Reduces Plasminogen Activator Inhibitor 1 in People with Spinal Cord Injury.
Axonal regrowth after spinal cord injury via chondroitinase and the tissue plasminogen activator (tPA)/plasmin system.
Decreased neural damage after spinal cord injury in tPA-deficient mice.
Fibrinolysis and spinal injury. Relationship to post-traumatic deep vein thrombosis.
Plasminogen activator induction facilitates recovery of respiratory function following spinal cord injury.
Plasminogen activator promotes recovery following spinal cord injury.
Role of plasminogen activator in spinal cord remodeling after spinal cord injury.
Stem Cells Downregulate the Elevated Levels of Tissue Plasminogen Activator in Rats After Spinal Cord Injury.
tPA in the injured central nervous system: different scenarios starring the same actor?
tPA promotes ADAMTS-4-induced CSPG degradation, thereby enhancing neuroplasticity following spinal cord injury.
tPA-mediated generation of plasmin is catalyzed by the proteoglycan NG2.
Spinal Cord Ischemia
Acute spinal cord ischemia during aortography treated with intravenous thrombolytic therapy.
Spinocerebellar Ataxias
Compartment- and context-specific changes in tissue-type plasminogen activator (tPA) activity following brain injury and pharmacological stimulation.
Splenic Infarction
The role of medical management for acute intravascular hemolysis in patients supported on axial flow LVAD.
Splenic Rupture
Bedside ultrasound diagnosis of a spontaneous splenic hemorrhage after tissue plasminogen activator administration.
Spontaneous Splenic Rupture Following Intravenous Thrombolysis with Alteplase Applied as Stroke Therapy - Case Report and Review of Literature.
Spondylarthropathies
Mobilization of fibrinolytic enzymes in synovial fluid and plasma of rheumatoid arthritis and spondyloarthropathy and their relation to radiological destruction.
Spondylosis
[Effects of Huoxue Dingxuan Capsule Glare on Vertebral Artery Blood Flow,Plasma PAI and t-PA in CSA Rat Models.]
Spotted Fever Group Rickettsiosis
Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by Rickettsia conorii- and Rickettsia rickettsii-infected cultured endothelial cells.
Squamous Cell Carcinoma of Head and Neck
A novel 3-dimensional culture system as an in vitro model for studying oral cancer cell invasion.
Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Expression of plasminogen activator inhibitor-1, urokinase receptor and laminin gamma-2 chain is an early coordinated event in incipient oral squamous cell carcinoma.
Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Keratinocytes and head and neck squamous cell carcinoma cells regulate urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in fibroblasts.
Localization of plasminogen activators and their inhibitor in squamous cell carcinomas of the head and neck.
PAI-1 expression in intratumoral inflammatory infiltrate contributes to lymph node metastasis in oral cancer: A cross-sectional study.
PAI-1, CAIX, and VEGFA expressions as prognosis markers in oral squamous cell carcinoma.
Plasminogen activator system in oral squamous cell carcinoma.
Plasminogen activators in normal and malignant oral epithelium in vivo and in vitro.
Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma.
Proteinase suppression by E-cadherin-mediated cell-cell attachment in premalignant oral keratinocytes.
uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
Urokinase plasminogen activator receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are potential predictive biomarkers in early stage oral squamous cell carcinomas (OSCC).
Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients.
[Application of serum tumor markers and support vector machine in the diagnosis of oral squamous cell carcinoma]
[Comparison of urokinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in primary resection of oral squamous cell carcinoma]
[Differences in assay sensitivity of selected tumor markers in head and neck neoplasms]
[Growth suppression of squamous cell carcinoma cell lines by PKCs--possible application to gene therapy]
[Immunohistological study of fibrinolytic factors of head and neck squamous cell carcinomas]
[The prognostic importance of urinase type plasminogen activators (uPA) and plasminogen activator inhibitors (PAI-1) in the primary resection of oral squamous cell carcinoma]
ST Elevation Myocardial Infarction
2013 consensus statement for early reperfusion and pharmaco-invasive approach in patients presenting with chest pain diagnosed as STEMI (ST elevation myocardial infarction) in an Indian setting.
Abciximab combined with half-dose reteplase has beneficial effects on inflammatory myocardial response in patients with myocardial infarction.
Alteplase treatment affects circulating matrix metalloproteinase concentrations in patients with ST segment elevation acute myocardial infarction.
Angiographic outcomes in STEMI patients receiving fibrinolysis with guideline directed optimal antithrombotic therapy.
Anti-t-PA antibodies in acute myocardial infarction after thrombolysis with rt-PA.
Assessment of thrombolytic affect of Reteplase in acute STEMI patients.
Association of the Plasminogen Activator Inhibitor-1 Gene 4G/5G Polymorphism With ST Elevation Acute Myocardial Infarction in Young Patients.
B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy.
Cardiac Function, Perfusion, Metabolism, and Innervation following Autologous Stem Cell Therapy for Acute ST-Elevation Myocardial Infarction. A FINCELL-INSIGHT Sub-Study with PET and MRI.
Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York.
Comparative efficacy and safety of reperfusion therapy with fibrinolytic agents in patients with ST-segment elevation myocardial infarction: a systematic review and network meta-analysis.
Comparison of Efficacy and Safety of Recombinant Human Prourokinase and Alteplase in the Treatment of STEMI and Analysis of Influencing Factors of Efficacy.
Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation.
Early ST-segment elevation acute myocardial infarction after thrombolytic therapy for acute ischemic stroke: A case report.
Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction: A Randomized Clinical Trial.
Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction).
Elevated levels of PAI-1 activity and t-PA antigen are associated with newly diagnosed abnormal glucose regulation in patients with ST-elevation myocardial infarction.
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events).
Evaluation of Tpeak to end/QT and Tpeak to end/QTc ratios in patients with STEMI undergoing percutaneous intervention vs. thrombolytic therapy.
Fibrinolytic Agents for the Management of ST-Segment Elevation Myocardial Infarction.
Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways.
Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial.
Impact of type of thrombolytic agent on in-hospital outcomes in ST-segment elevation myocardial infarction patients in the Middle East.
Multiple gene polymorphisms predisposing to the prothrombotic state in an adolescent with acute myocardial infarction.
Outcome of recombinant tissue plasminogen activator in ST-segment elevation myocardial infarction in Buriram Hospital.
Pharmaco-invasive Therapy for STEMI in a Patient with COVID-19: A Case Report.
Pharmacoinvasive therapy for ST elevation myocardial infarction in China: a pilot study.
Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
Post-Reteplase Evaluation of Clinical Safety & Efficacy in Indian Patients (Precise-In Study).
Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudy.
Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) versus alteplase (rt-PA) as fibrinolytic therapy for acute ST-segment elevation myocardial infarction (China TNK STEMI): protocol for a randomised, controlled, non-inferiority trial.
Relationship between therapeutic time intervals and intermediate term left ventricular systolic function in patients treated with facilitated percutaneous coronary intervention for acute myocardial infarction.
Reteplase in ST elevation myocardial infarction.
Reteplase: a review of its use in the management of thrombotic occlusive disorders.
Short- and long-term mortality in patients with ST-elevation myocardial infarction treated with different therapeutic strategies. Results from WIelkopolska REgional 2002 Registry (WIRE Registry).
Spotlight on reteplase in thrombotic occlusive disorders.
ST-elevation myocardial infarction associated with acute ischemic stroke.
ST-segment recovery and prognosis in patients with ST-elevation myocardial infarction reperfused by prehospital combination fibrinolysis, prehospital initiated facilitated percutaneous coronary intervention, or primary percutaneous coronary intervention.
Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis.
The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI-2 trial): outcome after 3 years follow-up.
The relationship of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in peripheral blood with ST-segment resolution and the clinical outcomes of STEMI patients receiving thrombolytic therapy.
Transportation with very long transfer delays (>90 min) for facilitated PCI with reduced-dose fibrinolysis in patients with ST-segment elevation myocardial infarction The Krakow Network.
Utilization of modified diagnostic ultrasound and microbubbles to reduce myocardial infarct size.
[Alteplase in acute coronary syndromes]
[Efficacy and safety comparison between pro-urokinase and reteplase in the treatment of patients with acute ST elevation myocardial infarction].
[Efficacy of thrombolytic therapy using reteplase in cases with acute ST-segment elevation myocardial infarction: results from a multicenter clinical trial].
[Preclinical fibrinolysis in patients with ST-segment elevation myocardial infarction in a rural region].
Starvation
A variety of mild stresses upregulate stanniocalcin-1 (STC-1) and induce mitohormesis in neural crest-derived cells.
Absence of transitory [Ca2+]i flux during early in vitro metacyclogenesis of Trypanosoma cruzi.
Distinct p53-mediated G1/S checkpoint responses in two NIH3T3 subclone cells following treatment with DNA-damaging agents.
Effect of serum starvation on expression and phosphorylation of PKC-alpha and p53 in V79 cells: implications for cell death.
Effects of 5-azacytidine, sodium butyrate, and phorbol esters on amino acid transport system A in a kidney epithelial cell line, MDCK: evidence for multiple mechanisms of regulation.
Induction of a novel damage-specific DNA binding protein correlates with enhanced DNA repair in primate cells.
Redistribution and phosphorylation of occludin during opening and resealing of tight junctions in cultured epithelial cells.
Regulation of hexose transporters in chicken embryo fibroblasts: stimulation by the phorbol ester TPA leads to increased numbers of functioning transporters.
Stress factors affecting expression of O6-methylguanine-DNA methyltransferase mRNA in rat hepatoma cells.
The effect of noise and starvation on the tissue plasminogen activator activity.
The fibroblast mitogenic activity released from human basophilic cell line KU812 is separate from tryptase and PDGF expression.
Tumour-promoting phorbol esters rapidly inhibit bud formation in hydra.
Stevens-Johnson Syndrome
Alteplase treatment for massive lung atelectasis in a child with severe bronchiolitis obliterans complicating Stevens-Johnson syndrome.
Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes.
Stillbirth
Genetic hypofibrinolysis in complicated pregnancies.
Stomach Diseases
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer.
Stomach Neoplasms
12-O-tetradecanoylphorbol-1, 3-acetate induces the negative regulation of protein kinase B by protein kinase Calpha during gastric cancer cell apoptosis.
12-O-tetradecanoylphorbol-1,3-acetate-induced degradation of protein kinase B via ubiquitin- -proteasomal pathway depends on its Ser473 phosphorylation in gastric cancer cells.
Activation of JNK by TPA promotes apoptosis via PKC pathway in gastric cancer cells.
Alteration of haemostasis in non-metastatic gastric cancer.
Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Degradation of retinoid X receptor alpha by TPA through proteasome pathway in gastric cancer cells.
Detection of gastric cancer by a combination of tissue polypeptide antigen (TPA), lipid-bound sialic acid (LBSA) and carcinoembryonic antigen (CEA).
Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer.
Dual roles of Nur77 in selective regulation of apoptosis and cell cycle by TPA and ATRA in gastric cancer cells.
Effect and prognostic significance of the KAI1 gene in human gastric carcinoma.
Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer.
Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Gastrointestinal cancer follow-up: the effectiveness of sequential CEA, TPA and Ca 19-9 evaluation in the early diagnosis of recurrences.
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Identification of plasminogen activator inhibitor-2 as a gastrin-regulated gene: Role of Rho GTPase and menin.
Identification of proteins differentially expressed in gastric cancer cells with high metastatic potential for invasion to lymph nodes.
In vitro activity of probiotic Lactobacillus reuteri against gastric cancer progression by downregulation of urokinase plasminogen activator/urokinase plasminogen activator receptor gene expression.
Induction of apoptosis by TPA and VP-16 is through translocation of TR3.
Invasion and metastases in gastric cancer: in vitro and in vivo models with clinical correlations.
Involvement of hypoxia-inducing factor-1?-dependent plasminogen activator inhibitor-1 up-regulation in Cyr61/CCN1-induced gastric cancer cell invasion.
Involvement of hypoxia-inducing factor-1alpha-dependent plasminogen activator inhibitor-1 up-regulation in Cyr61/CCN1-induced gastric cancer cell invasion.
Levels of tissue polypeptide antigen in serum and the progression of gastric cancer.
miR-30b, down-regulated in gastric cancer, promotes apoptosis and suppresses tumor growth by targeting plasminogen activator inhibitor-1.
Neutrophil gelatinase-associated lipocalin in gastric carcinoma cells and its induction by TPA are controlled by C/EBP?.
Overexpression of Plasminogen Activator Inhibitor-1 in Advanced Gastric Cancer with Aggressive Lymph Node Metastasis.
Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo.
Plasminogen activator inhibitor-1 as a potential marker for the malignancy of gastric cancer.
Plasminogen activators and plasminogen activator inhibitor in malignant and non-malignant ascitic fluid.
Possible role of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissues.
Pre-operative serum levels of tissue polypeptide antigen in patients with gastric cancer.
Prognostic factors in gastric cancer.
Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.
Prognostic significance of tissue-type plasminogen activator (tPA) content in gastric cancer and surrounding mucosa.
Relationship between expression of plasminogen activator system and metastatic ability in human cancers.
Roles of PLC-gamma2 and PKCalpha in TPA-induced apoptosis of gastric cancer cells.
Serum c-erbB-2 oncoprotein in the diagnosis of gastric cancer in comparison with CA 19-9, CEA, TPA, CA 125 and AFP.
Specificity of carcinoembryonic antigen, gastrointestinal cancer-associated antigen, tissue polypeptide antigen, fibrinopeptide A and gamma-glutamyltransferase in the diagnosis and follow-up of gastric cancer.
The expression of protein kinase B in gastric cancer cell apoptosis induced by 12-O-tetradecanoylphorbol-1, 3-acetate.
The tumor markers CEA, TPA and CA 19-9 in gastric cancer.
Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.
Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
[CEA, GICA, TPA, fibrinopeptide-A, gamma-GT and gastric cancer. A contribution to the rationalization of a combined assay]
[Changes in carcinoembryonic antigen and tissue polypeptide antigen in monitoring the post-operative course of some tumor types]
[Clinical effects of PSK on esophageal and gastric cancer patients and usefulness of serum levels of glycoproteins and HLA antigens as prognostic indicators]
[Clinical evaluation of tissue polypeptide antigen in patients with esophageal, stomach and colon cancer]
[Clinical study on tissue polypeptide antigen (TPA) as a tumor marker]
[Clinical study on tissue polypeptide antigen (TPA) in gastric cancer]
[Effectiveness of quarterly assessment of CEA, TPA and GICA serum levels in gastric and colorectal carcinomas: Prospective study of 174 patients undergoing radical surgery]
[Pretreatment evaluation of CA 72.4 in patients with carcinoma of the stomach (0-IV stage) versus CEA, TPA, CA 19-9, FER]
[Protease activities in gastric and colon cancer tissues]
[Studies on the clinical evaluation of tissue polypeptide antigen (TPA) levels in the peripheral and draining venous blood of gastric cancer patients]
[Study of plasminogen activator and trypsin inhibitor in gastric cancer, ulcer and experimental tumor.]
[The changes in tumor markers such as serum CEA, CA 19-9, TPA and CA 125 in the chemotherapy of patients with advanced gastric cancer]
Stomach Ulcer
Antioxidant and anti-inflammatory activities of alpha lipoic acid protect against indomethacin-induced gastric ulcer in rats.
Involvement of superoxide anion and platelet-activating factor in increased tissue-type plasminogen activator during rat gastric microvascular damages.
Reduced tissue type plasminogen activator activity of the gastroduodenal mucosa in peptic ulcer disease.
Tissue plasminogen activator and plasminogen activator inhibitor type 1 gene polymorphism in patients with gastric ulcer complicated with bleeding.
[Clinical study on tissue polypeptide antigen (TPA) as a tumor marker]
Strabismus
Induction of Posterior Vitreous Detachment in Pediatric Vitrectomy by Preoperative Intravitreal Injection of Tissue Plasminogen Activator.
Streptococcal Infections
Characterizing the role of tissue-type plasminogen activator in a mouse model of Group A streptococcal infection.
Stroke
"Hesitating and Puzzling": The Experiences and Decision Process of Acute Ischemic Stroke Patients with Prehospital Delay after the Onset of Symptoms.
"Telestroke" : the application of telemedicine for stroke.
"Time is Brain:" A concept anaiysis.
'Where are we now with intravenous thrombolysis for acute ischaemic stroke'?
12/15-Lipoxygenase Inhibition or Knockout Reduces Warfarin-Associated Hemorrhagic Transformation After Experimental Stroke.
2,7-Bis-(4-amidinobenzylidene)-cycloheptan-1-one dihydrochloride, tPA stop, prevents tPA-enhanced excitotoxicity both in vitro and in vivo.
24-hour blood pressure variability and treatment effect of intravenous alteplase in acute ischaemic stroke.
24/7 Neurocritical Care Nurse Practitioner Coverage Reduced Door-to-Needle Time in Stroke Patients Treated with Tissue Plasminogen Activator.
3alpha-OL-5-beta-pregnan-20-one hemisuccinate, a steroidal low-affinity NMDA receptor antagonist improves clinical rating scores in a rabbit multiple infarct ischemia model: synergism with tissue plasminogen activator.
3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of Tenecteplase.
4.5 Hours. The New Time Window for Tissue Plasminogen Activator in Stroke.
4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke.
5-Fluorouracil associated neurovascular toxicities.
?2-Antiplasmin: New Insights and Opportunities for Ischemic Stroke.
A Case for the Non-Neurologist Telestroke Provider.
A case of cerebral infarction during a hemodialysis procedure successfully treated with recombinant tissue plasminogen activator.
A case report of parenchymal hematoma after intravenous thrombolysis in a rivaroxaban-treated patient: Is it a true rivaroxaban hemorrhagic complication?
A Case Report of Unilateral Orolingual Angioedema Secondary to Alteplase Administration.
A case-control study of the effectiveness of tissue plasminogen activator on 6 month patients--reported outcomes and health care utilization.
A case-control study of tissue plasminogen activator for acute ischemic stroke.
A Citywide Prehospital Protocol Increases Access to Stroke Thrombolysis in Toronto.
A Comparative Case Series of Haitian and non-Haitian Stroke Patients at a Single Center in Miami, Florida.
A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators.
A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators.
A Cost-Utility Analysis of Endovascular Thrombectomy in a Real-World Setting.
A Decade of Improvement in Door-to-Needle Time Among Acute Ischemic Stroke Patients, 2008 to 2017.
A decision analysis of thrombolytic therapy compared with standard therapy in acute ischaemic stroke.
A Four-Year Experience of Symptomatic Intracranial Hemorrhage Following Intravenous Tissue Plasminogen Activator at a Comprehensive Stroke Center.
A graphic reanalysis of the NINDS Trial.
A higher body temperature is associated with hemorrhagic transformation in patients with accute stroke non-treated with recombinant tissue-type plasminogen activator (rtPA).
A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke.
A left MCA territory infarction during intravenous recombinant tissue plasminogen activator therapy for right MCA territory ischaemic stroke.
A Matched Comparison of Eptifibatide Plus RT-PA Versus RT-PA Alone in Acute Ischemic Stroke.
A matching algorithm to address imbalances in study populations: application to the National Institute of Neurological Diseases and Stroke Recombinant Tissue Plasminogen Activator acute stroke trial.
A meta-analysis of the global impact of the COVID-19 pandemic on stroke care & the Houston Experience.
A method to determine stroke trial success using multidimensional pooled control functions.
A Model of Cost-effectiveness of Tissue Plasminogen Activator in Patient Subgroups 3 to 4.5 Hours After Onset of Acute Ischemic Stroke.
A Model to Prevent Fibrinolysis in Patients with Stroke Mimics.
A mouse model of hemorrhagic transformation by delayed tissue plasminogen activator administration after in situ thromboembolic stroke.
A Moving Target? The Fate of Large Vessel Occlusion Strokes Pretreated with Intravenous Tissue Plasminogen Activator in the Era of Mechanical Thrombectomy.
A Multicenter Analysis of "Time to Microcatheter" for Endovascular Therapy in Acute Ischemic Stroke.
A multicenter, randomized, double-blind, placebo-controlled trial to test efficacy and safety of magnetic resonance imaging-based thrombolysis in wake-up stroke (WAKE-UP).
A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND).
A multilevel intervention to increase community hospital use of alteplase for acute stroke (INSTINCT): a cluster-randomised controlled trial.
A Myocardial Infarction During Intravenous Recombinant Tissue Plasminogen Activator Infusion for Evolving Ischemic Stroke.
A National Evaluation of Door-to-Imaging Times among Acute Ischemic Stroke Patients within the Veterans Health Administration.
A novel method to promote behavioral improvement and enhance mitochondrial function following an embolic stroke.
A novel mouse model of thromboembolic stroke.
A panoramic, practice-based view of intravenous alteplase 3-4.5 h after stroke.
A pilot protocol and review of triple neuroprotection with targeted hypothermia, controlled induced hypertension, and barbiturate infusion during emergency carotid endarterectomy for acute stroke after failed tPA or beyond 24-hour window of opportunity.
A pilot randomized clinical safety study of sonothrombolysis augmentation with ultrasound-activated perflutren-lipid microspheres for acute ischemic stroke.
A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke.
A Pilot Trial of Low-Dose Intravenous Abciximab and Unfractionated Heparin for Acute Ischemic Stroke: Translating GP IIb/IIIa Receptor Inhibition to Clinical Practice.
A pragmatic approach to sonothrombolysis in acute ischaemic stroke: the Norwegian randomised controlled sonothrombolysis in acute stroke study (NOR-SASS).
A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke.
A prothrombotic state and denser clot formation in patients following acute limb ischemia of unknown cause.
A qualitative assessment of practices associated with shorter door-to-needle time for thrombolytic therapy in acute ischemic stroke.
A Rapid Decrease in Stroke, Acute Coronary Syndrome, and Corresponding Interventions at 65 United States Hospitals Following Emergence of COVID-19.
A Rare Case of Native Mitral Valve Bacillus Cereus Endocarditis Culminating Into a Cerebrovascular Infarction.
A rat model of studying tissue-type plasminogen activator thrombolysis in ischemic stroke with diabetes.
A Regional System of Stroke Care Provides Thrombolytic Outcomes Comparable With the NINDS Stroke Trial.
A resident boot camp for reducing door-to-needle times at academic medical centers.
A Retrospective Study of thrombolysis with 0.6?mg/kg Recombinant Tissue Plasminogen Activator (rt-PA) in Mild Stroke.
A review of barriers to thrombolytic therapy: implications for nursing care in the emergency department.
A review of oxygen therapy in ischemic stroke.
A Review on Preclinical Models of Ischemic Stroke: Insights Into the Pathomechanisms and New Treatment Strategies.
A risk score to predict intracranial hemorrhage after recombinant tissue plasminogen activator for acute ischemic stroke.
A spontaneous cervical epidural hematoma mimicking a stroke - A case report.
A Stroke Alert Protocol Decreases the Time to Diagnosis of Brain Attack Symptoms in a Pediatric Emergency Department.
A stroke preparedness RCT in a multi-ethnic cohort: design and methods.
A Stroke Registry Data on the Use of Intravenous Recombinant Tissue Plasminogen Activator in Stroke of Unknown Time of Onset.
A systemized stroke code significantly reduced time intervals for using intravenous tissue plasminogen activator under magnetic resonance imaging screening.
A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group.
A unique presentation of four thrombotic events at a time.
A user's guide to the NINDS rt-PA stroke trial database.
A visit to the stroke belt of the United States.
Abnormal haemorheology, endothelial function and thrombogenesis in relation to hypertension in acute (ictus < 12 h) stroke patients: the West Birmingham Stroke Project.
Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke.
About 30% of wake-up stroke patients may be candidate for the tPA therapy using Negative-FLAIR as a "tissue clock".
Absolute and Relative Contraindications to IV rt-PA for Acute Ischemic Stroke.
Absolute blood eosinophil count could be a potential biomarker for predicting haemorrhagic transformation after intravenous thrombolysis for acute ischaemic stroke.
Acceleration of tissue plasminogen activator-mediated thrombolysis by magnetically powered nanomotors.
Access to Expert Stroke Care with Telemedicine: REACH MUSC.
Accessibility to rt-PA in Sub-Saharan Africa, Congolese stroke unit experience: Call for an urgent action.
Accuracy of First Recorded "Last Known Normal" Times of Stroke Code Patients.
Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction : A Secondary Analysis of the TRANSLATE-ACS Study.
Accuracy of stroke diagnosis by registered nurses using the ROSIER tool compared to doctors using neurological assessment on a stroke unit: A prospective audit.
Accuracy of Stroke Diagnosis in Telestroke-Guided Tissue Plasminogen Activator Patients.
Accuracy of the New ICD-9-CM Code for "Drip-and-Ship" Thrombolytic Treatment in Patients with Ischemic Stroke.
Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke.
ACP Journal Club. Alteplase given 3 to 4.5 hours after stroke reduced disability and improved global outcome.
ACP Journal Club. In ischemic stroke, early intraarterial treatment plus alteplase improved reperfusion and functional outcome.
ACP Journal Club: meta-analysis: alteplase improves functional outcomes when given within 4.5 hours of stroke onset.
ACR Appropriateness Criteria(®) on Cerebrovascular Disease.
Activation of complement by tissue plasminogen activator, but not acute cerebral ischemia, in a rabbit model of thromboembolic stroke.
Acute 'strokenomics': efficacy and economic analyses of alteplase for acute ischemic stroke.
Acute administration of rt-PA for acute stroke in Pakistani patients--what does the available evidence teach us?
Acute anterior circulation stroke: recanalization using clot angioplasty.
Acute antithrombotic treatment of ischemic stroke.
Acute changes of coagulation and fibrinolysis parameters after experimental thromboembolic stroke and thrombolytic therapy.
Acute Complement Inhibition Potentiates Neurorehabilitation and Enhances tPA-Mediated Neuroprotection.
Acute endovascular stroke therapy.
Acute endovascular treatment delivery to ischemic stroke patients transferred within a telestroke network: a retrospective observational study.
Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients.
Acute imaging for evidence-based treatment of ischemic stroke.
Acute intravenous--intra-arterial revascularization therapy for severe ischemic stroke.
Acute Ischemic Stroke and COVID-19: Experience From a Comprehensive Stroke Center in Midwest US.
Acute ischemic stroke and thrombolysis location: comparing telemedicine and stroke center treatment outcomes.
Acute ischemic stroke in a child due to basilar artery occlusion treated successfully with a stent retriever.
Acute Ischemic Stroke in Pregnancy.
Acute ischemic stroke management.
Acute Ischemic Stroke Therapy Overview.
Acute ischemic stroke therapy.
Acute ischemic stroke treatment and the occurrence of seizures.
Acute ischemic stroke update.
Acute ischemic stroke what is hidden behind?
Acute Ischemic Stroke with Very Early Clinical Improvement: A National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trials Exploratory Analysis.
Acute Ischemic Stroke: Current Status and Future Directions.
Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window.
Acute ischemic stroke: improving access to intravenous tissue plasminogen activator.
Acute ischemic stroke: new strategies for management and prevention. Interview by Wayne Kuznar.
Acute middle cerebral artery occlusion: reappraisal of the role of endovascular revascularization.
Acute myocardial infarction following intravenous tissue plasminogen activator for acute ischemic stroke: An unknown danger.
Acute pancreatitis is a very rare comorbidity of acute ischemic stroke.
Acute reperfusion therapy and stroke care in Asia after successful endovascular trials.
Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment.
Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator.
Acute stroke reperfusion therapy trends in the expanded treatment window era.
Acute Stroke Symptoms. Comparing Women and Men.
Acute stroke therapy 1981-2009.
Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke.
Acute stroke therapy with tissue plasminogen activator (tPA) since it was approved by the U.S. Food and Drug Administration (FDA).
Acute stroke therapy: beyond i.v. tPA.
Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital.
Acute stroke: prognosis and a prediction of the effect of medical treatment on outcome and health care utilization. The Copenhagen Stroke Study.
Acute Stroke: Shifting From Informed Consent to Informed Refusal of Intravenous Tissue-Type Plasminogen Activator.
Acute stroke: therapeutic transcranial Doppler sonography.
Acute Thrombocytopenia After Tissue Plasminogen Activator for Stroke.
Acute thrombotic occlusion of subclavian artery presenting as a stroke mimic.
Acute Treatment of Stroke (Except Thrombectomy).
Acute [corrected] stroke thrombolysis: an update [corrected]
Adding to the effectiveness of intravenous tissue plasminogen activator for treating acute stroke.
Adenoviral-mediated transfer of tissue plasminogen activator gene into brain capillary endothelial cells in vitro.
Adherence to Acute Care Measures Affects Mortality in Patients with Ischemic Stroke: The Florida Stroke Registry.
Adherence to Guidelines by Emergency Medical Services During Transport of Stroke Patients Receiving Intravenous Thrombolytic Infusion.
Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-hour exclusions and association with outcome: data from Get with the Guidelines-Stroke.
Adjunctive Therapy Approaches for Ischemic Stroke: Innovations to Expand Time Window of Treatment.
Adjuvant therapies using normobaric oxygen with hypothermia or ethanol for reducing hyperglycolysis in thromboembolic cerebral ischemia.
Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke.
Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.
Administration of tissue plasminogen activator for acute ischemic stroke in a rural Wisconsin hospital.
Administration of tissue plasminogen activator without coagulation results in a Chinese population.
Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator.
Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator.
Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial.
Admission hyperglycemia and outcome after intravenous thrombolysis: is there a difference among the stroke-subtypes?
Admission hyperglycemia predicts a worse outcome in stroke patients treated with intravenous thrombolysis.
Adrenal hormones and circulating leukocyte subtypes in stroke patients treated with reperfusion therapy.
Advance hospital notification by EMS in acute stroke is associated with shorter door-to-computed tomography time and increased likelihood of administration of tissue-plasminogen activator.
Advanced Age and Higher National Institutes of Health Stroke Scale Score as Predictors of Poor Outcome in Ischemic Stroke Patients Treated with Alteplase: A Study from a Tertiary Care Centre in Rural North-west India.
Advanced imaging to extend the therapeutic time window of acute ischemic stroke.
Advances in ischemic stroke treatment: neuroprotective and combination therapies.
Advances in medical revascularisation treatments in acute ischemic stroke.
Advances in revascularization for acute ischemic stroke treatment.
Advances in revascularization for acute ischemic stroke treatment: an update.
Advances in stroke medicine.
Age accounts for racial differences in ischemic stroke volume in a population-based study.
Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact.
Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial.
Age differences in utilization and outcomes of tissue-plasminogen activator and mechanical thrombectomy in acute ischemic stroke.
Age Predicts Functional Outcome in Acute Stroke Patients with rt-PA Treatment.
Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase.
Aggressive intervention to treat a young woman with intracranial hemorrhage following unsuccessful intravenous thrombolysis for left middle cerebral artery occlusion.
Agreement Among Stroke Faculty and Fellows in Treating Ischemic Stroke Patients With Tissue-Type Plasminogen Activator and Thrombectomy.
Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy.
Agreement with evidence for tissue Plasminogen Activator use among emergency physicians: a cross-sectional survey.
Alberta Stroke Program early computed tomography score to select patients for endovascular treatment: Interventional Management of Stroke (IMS)-III Trial.
Alberta Stroke Program Early CT Score-Time Score Predicts Outcome after Endovascular Therapy in Patients with Acute Ischemic Stroke: A Retrospective Single-Center Study.
Alcohol Intoxication as a Stroke Mimic and the Incidence of Acute Alcohol Intoxication in Stroke.
Alteplase (r-TPA) vs streptokinase.
Alteplase and Adjuvant Therapies for Acute Ischemic Stroke.
Alteplase and ischaemic stroke: have new reviews of old data helped?
Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT).
Alteplase for Acute Ischemic Stroke in Patients Aged >80 Years: Pooled Analyses of Individual Patient Data.
Alteplase for Acute Ischemic Stroke: Outcomes by Clinically Important Subgroups in the Third International Stroke Trial.
Alteplase for acute stroke revisited: the first 10 years.
Alteplase for Minor Stroke: The AAEM Clinical Practice Advisory is More Accurate Than Other National Guidelines.
Alteplase for stroke. American Heart Association explains how guidelines were formulated.
Alteplase for stroke. Financial information is needed to ensure objectivity.
Alteplase for stroke. Patients and doctors are being misled by promotional pressures.
Alteplase for stroke. Uncertainty remains about efficacy.
Alteplase for stroke. Why were these authors of the commentaries chosen?
Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign.
Alteplase for the Treatment of Acute Ischaemic Stroke: A NICE Single Technology Appraisal; an Evidence Review Group Perspective.
Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal.
Alteplase for the treatment of acute ischemic stroke in patients with low National Institutes of Health Stroke Scale and not clearly disabling deficits (Potential of rtPA for Ischemic Strokes with Mild Symptoms PRISMS): Rationale and design.
Alteplase Inhibits Nerinetide, a Novel Stroke Drug.
Alteplase Reduces Downstream Microvascular Thrombosis and Improves the Benefit of Large Artery Recanalization in Stroke.
Alteplase Treatment in Acute Stroke: Incorporating Food and Drug Administration Prescribing Information into Existing Acute Stroke Management Guide.
Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.
Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.
Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction.
Alteplase: a review of its use in the management of acute ischaemic stroke.
Alteplase: descendancy in myocardial infarction, ascendancy in stroke.
Alteplase: new indication. Inadequately assessed in ischaemic stroke.
Alternate approach to understanding the molecular mechanisms of stroke-induced injury.
An Analysis of EMS and ED Detection of Stroke.
An expedited code stroke protocol is feasible and safe.
An expedited stroke triage pathway: the key to shortening the door-to-needle time in delivery of thrombolysis.
An in vitro Model System for Evaluating Remote Magnetic Nanoparticle Movement and Fibrinolysis.
An Insertion/Deletion polymorphism in the promoter region of the plasminogen activator inhibitor-1 gene is associated with plasma levels but not with stroke risk in the elderly.
An ischemic stroke during intravenous recombinant tissue plasminogen activator infusion for evolving myocardial infarction.
An NO/GSNO-based Neuroregeneration Strategy for Stroke Therapy.
An open, multicenter trial of recombinant tissue plasminogen activator in acute stroke. A progress report. The rt-PA Acute Stroke Study Group.
An Outcome Model for Intravenous rt-PA in Acute Ischemic Stroke.
An overview of the patency and stroke rates following thrombolysis with streptokinase, alteplase, and anistreplase used to treat an acute myocardial infarction.
Analysis of 16,922 patients with acute ischemic stroke and transient ischemic attack in Japan. A hospital-based prospective registration study.
Analysis of Canadian population with potential geographic access to intravenous thrombolysis for acute ischemic stroke.
Analysis of the Association Between Polymorphisms within PAI-1 and ACE genes and Ischemic Stroke Outcome After rt-PA Therapy.
Analysis of the cost-effectiveness of thrombolysis with alteplase in stroke.
Analysis of the National Institute of Neurological Disorders and Stroke tissue plasminogen activator studies following European Cooperative Acute Stroke Study III patient selection criteria.
Analysis of the reasons for exclusion from tPA therapy after early arrival in acute stroke patients.
Analysis of Thrombolysis Process for Acute Ischemic Stroke in Urban and Rural Hospitals in Nova Scotia Canada.
Analysis of tissue plasminogen activator eligibility by sex in the greater cincinnati/northern kentucky stroke study.
Anaphylactoid reactions and angioedema during alteplase treatment of acute ischemic stroke.
And why not thrombolysis in the ambulance (at least for some)?
Aneurysmal subarachnoid hemorrhage models: do they need a fix?
Angioedema after rt-PA treatment in acute ischemic stroke may be attended by shock and worsening of stroke outcome.
Angioedema After tPA: What Neurointensivists Should Know.
Angioedema in the neurointerventional suite.
Angioedema Secondary to tPA Use in Acute Ischemic Stroke Patient with Hypertension: A Case Report.
Angiogenesis in Ischemic Stroke and Angiogenic Effects of Chinese Herbal Medicine.
Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3 Investigators.
Annals of Emergency Medicine Journal Club. rt-PA and Stroke: does IST-3 make it all clear or muddy the waters?
Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy.
Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany-Updated series of 120 cases.
Anti-Inflammatory Targets for the Treatment of Reperfusion Injury in Stroke.
Anti-inflammatory treatments for stroke: from bench to bedside.
Antiactin-targeted immunoliposomes ameliorate tissue plasminogen activator-induced hemorrhage after focal embolic stroke.
Antibodies preventing the interaction of tissue-type plasminogen activator with N-methyl-d-aspartate receptors reduce stroke damages and extend the therapeutic window of thrombolysis.
Antihypertensive therapy in acute ischemic stroke: where do we stand?
Antihypertensive treatment prolongs tissue plasminogen activator door-to-treatment time: secondary analysis of the INSTINCT trial.
Antiphospholipid-protein antibodies and acute ischemic stroke in the NINDS rt-PA Stroke Trial.
Antiplatelet therapy in acute cerebral ischemia.
Antiplatelet therapy within 24 hours of tPA: lessons learned from patients requiring combined thrombectomy and stenting for acute ischemic stroke.
Antiplatelet vs. R-tPA for acute mild ischemic stroke: A prospective, random, and open label multi-center study.
Antithrombotic and thrombolytic therapy for ischemic stroke.
Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Antithrombotic drugs and ischaemic stroke.
Antithrombotic treatments in acute ischemic stroke.
Antithrombotic trials in acute ischaemic stroke: a selective review.
Aortic stent graft leak and aneurysm rupture after alteplase for stroke.
Aortic transgraft hemorrhage after intravenous tissue plasminogen activator therapy in patients with acute ischemic stroke.
Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke.
Apparent diffusion coefficient thresholds do not predict the response to acute stroke thrombolysis.
Application of albumin prior to delayed thrombolysis reduces brain edema and blood brain barrier permeability in an embolic stroke model.
Approval of alteplase in Europe: will it change stroke management?
APX3330 Promotes Neurorestorative Effects after Stroke in Type One Diabetic Rats.
Are all stroke patients eligible for fast alteplase treatment? An analysis of unavoidable delays.
Are EMS bypass policies effective implementation strategies for intravenous alteplase for stroke?
Are patients with acutely recovered cerebral ischemia more unstable?
Are Racial Disparities in Stroke Care Still Prevalent in Certified Stroke Centers?
Are there time-dependent differences in diffusion and perfusion within the first 6 hours after stroke onset?
Are we ready for intravenous thrombolysis in acute stroke treatment in our region?
Argatroban tPA stroke study: study design and results in the first treated cohort.
Arginine 260 of the amino-terminal domain of NR1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of N-methyl-D-aspartate receptor signaling.
Arrhenius temperature dependence of in vitro tissue plasminogen activator thrombolysis.
Arterial Obstruction on Computed Tomographic or Magnetic Resonance Angiography and Response to Intravenous Thrombolytics in Ischemic Stroke.
Arterial occlusion revealed by CT angiography predicts NIH stroke score and acute outcomes after IV tPA treatment.
Arterial occlusion sites on magnetic resonance angiography influence the efficacy of intravenous low-dose (0.6 mg/kg) alteplase therapy for ischaemic stroke.
Arterial occlusive lesions recanalize more frequently in women than in men after intravenous tissue plasminogen activator administration for acute stroke.
Arterial recanalization benefits even neurologically improving stroke patients after intravenous tissue-type plasminogen activator.
Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator.
Arterial Spin Labeling MRI to Measure Cerebral Blood Flow in Untreated Ischemic Stroke.
Arterial status after intravenous TPA therapy for ischaemic stroke. A need for further interventions.
Artery of Percheron Infarct: 12 Cases and Their Complex Clinical Courses.
Artery of Percheron Infarct: An Acute Diagnostic Challenge with a Spectrum of Clinical Presentations.
Ascorbic Acid Reduces the Adverse Effects of Delayed Administration of Tissue Plasminogen Activator in a Rat Stroke Model.
ASPECT scoring to estimate >1/3 middle cerebral artery territory infarction.
ASPECTS-Region-Dependent Functional Outcomes after Endovascular Therapy in Patients with Cardioembolic Stroke.
Aspiration Thrombectomy After Intravenous Alteplase Versus Intravenous Alteplase Alone.
Aspirin Treatment Failure and the Risk of Recurrent Stroke and Death Among Patients with Ischemic Stroke.
Assessing the efficacy of endovascular therapy in stroke treatments: updates from the new generation of trials.
Assessing the impact of thrombolysis on progress through inpatient rehabilitation after stroke: a multivariable approach.
Assessment of healthcare personnel knowledge of stroke care at a large referral hospital in sub-Saharan Africa - A survey based approach.
Assessment of suitability of thrombolysis in middle cerebral artery infarction: a proof of concept study of a stereologically-based technique.
Assessment of the Therapeutic Potential of Metallothionein-II Application in Focal Cerebral Ischemia In Vitro and In Vivo.
Assessment scales for the evaluation of stroke patients.
Association between 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene with stroke or encephalopathy after cardiac surgery.
Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial.
Association between hemorrhagic transformation after endovascular therapy and poststroke seizures.
Association Between Plasminogen Activator Inhibitor-1 Genetic Polymorphisms and Stroke Susceptibility.
Association between platelet activation and fibrinolysis in acute stroke patients.
Association Between the Change of Coagulation Parameters and Clinical Prognosis in Acute Ischemic Stroke Patients After Intravenous Thrombolysis With rt-PA.
Association between the perfusion/diffusion and diffusion/FLAIR mismatch: data from the AXIS2 trial.
Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke.
Association of Clinical, Imaging, and Thrombus Characteristics With Recanalization of Visible Intracranial Occlusion in Patients With Acute Ischemic Stroke.
Association of genetic variants of fibrinolytic system with stroke and stroke subtypes.
Association of geographical factors with administration of tissue plasminogen activator for acute ischemic stroke.
Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.
Association of PAI-1 4G/5G and -844G/A gene polymorphism and changes in PAI-1/tPA levels in stroke: a case-control study.
Association of pretreatment blood pressure with tissue plasminogen activator-induced arterial recanalization in acute ischemic stroke.
Association of Reperfusion After Thrombolysis With Clinical Outcome Across the 4.5- to 9-Hours and Wake-up Stroke Time Window: A Meta-Analysis of the EXTEND and EPITHET Randomized Clinical Trials.
Association of serial biochemical markers with acute ischemic stroke: the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator Stroke Study.
Association of Serum Troponin Obtained During Stroke Codes with Cardioembolic Strokes.
Association of time from last known well to alteplase administration and outcomes in acute stroke.
Asymmetric angioneurotic edema associated with thrombolysis for acute stroke.
Asymmetric dimethylarginine in response to recombinant tissue-type plasminogen activator and erythropoietin in acute stroke.
Asymptomatic hemorrhage after thrombolysis may not be benign: prognosis by hemorrhage type in the Canadian alteplase for stroke effectiveness study registry.
Asymptomatic hemorrhage after thrombolysis may not be benign: prognosis by hemorrhage type of the Canadian alteplase for stroke effectiveness study registry.
Asymptomatic hemorrhagic transformation of cerebral infarction does not worsen long-term outcome.
Atherosclerotic Carotid Artery Occlusion.
Atherosclerotic intracranial internal carotid artery calcification and intravenous thrombolytic therapy for acute ischemic stroke.
ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
Atorvastatin downregulates tissue plasminogen activator-aggravated genes mediating coagulation and vascular permeability in single cerebral endothelial cells captured by laser microdissection.
Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats.
Atrial fibrillation and cardiembolic stroke. Treatment and issue in acute phase.
Atrial fibrillation predicts good functional outcome following intravenous tissue plasminogen activator in patients with severe stroke.
Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger, edaravone: evaluation in a rat thromboembolic stroke model.
Attitudes and beliefs of Michigan emergency physicians toward tissue plasminogen activator use in stroke: baseline survey results from the INcreasing Stroke Treatment through INteractive behavioral Change Tactic (INSTINCT) trial hospitals.
Availability of diagnostic and treatment services for acute stroke in frontier counties in Montana and Northern Wyoming.
B-Type Natriuretic Peptide as a Significant Brain Biomarker for Stroke Triaging Using a Bedside Point-of-Care Monitoring Biosensor.
Ballast and NeuronMax in stroke thrombectomy.
Balloon Angioplasty for Intracranial Atherosclerotic Disease: A Multicenter Study.
Barriers of thrombolysis therapy in developing countries.
Barriers to administering intravenous tissue plasminogen activator (tPA) for acute ischemic stroke in the emergency department: A cross-sectional survey of stroke centers.
Barriers to intravenous tissue plasminogen activator for acute stroke therapy in women.
Barriers to Providing Prehospital Care to Ischemic Stroke Patients: Predictors and Impact on Care.
Barriers to the Use of Intravenous Tissue Plasminogen Activator for In-hospital Strokes.
Baseline computed tomography changes and clinical outcome after thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke.
Baseline magnetic resonance imaging parameters and stroke outcome in patients treated by intravenous tissue plasminogen activator.
Baseline national institutes of health stroke scale-adjusted time window for intravenous tissue-type plasminogen activator in acute ischemic stroke.
Baseline Predictors of Poor Outcome in Patients Too Good to Treat With Intravenous Thrombolysis.
Basilar Artery Thrombosis in a Child Treated With Intravenous Tissue Plasminogen Activator and Endovascular Mechanical Thrombectomy.
Bayesian hierarchical modeling and the integration of heterogeneous information on the effectiveness of cardiovascular therapies.
Bed rest or mobilization after rt-PA? A case-crossover study of factors influencing clinical decision making in stroke services.
Beneficial effects of the 30-minute door-to-needle time standard for alteplase administration.
Benefits of stroke treatment delivered using a mobile stroke unit trial.
Beyond intravenous thrombolysis.
Beyond tissue plasminogen activator: mechanical intervention in acute stroke.
Biology of ischemic cerebral cell death.
Biomarkers for acute diagnosis and management of stroke in neurointensive care units.
Bleeding complications after basilar artery fibrinolysis with tissue plasminogen activator.
Blood pressure declines and less favorable outcomes in the NINDS tPA stroke study.
Blood pressure during the first minutes of focal cerebral ischemia.
Blood Pressure in the First 6 Hours Following Endovascular Treatment for Ischemic Stroke Is Associated With Outcome.
Blood-brain barrier disturbances after rt-PA treatment of thromboembolic stroke in the rat.
Blood-brain barrier permeability and tPA-mediated neurotoxicity.
Body Size Phenotypes and Inflammation in the Women's Health Initiative Observational Study.
Body temperature and major neurological improvement in tPA-treated stroke patients.
Body temperature and outcome after stroke thrombolysis.
Body temperature and response to thrombolytic therapy in acute ischaemic stroke.
Bolus-to-Infusion Time in Stroke Patients Treated with Alteplase on the CT Table: A Clinical Concern.
Brain attack: a new approach to stroke.
Brain capillary tissue plasminogen activator in a diabetes stroke model.
Brain CT signs and the effect of alteplase after stroke.
Brain endothelial cell specific integrins and ischemic stroke.
Brain imaging abnormalities and outcome after acute ischaemic stroke: the ENCHANTED trial.
Brain Imaging Signs and Health-Related Quality of Life after Acute Ischemic Stroke: Analysis of ENCHANTED Alteplase Dose Arm.
Brainstem Hyperperfusion Syndrome After Intravenous Thrombolysis: A Case Report.
Bridging Therapy with i.?v. rtPA in MCA Occlusion Prior to Endovascular Thrombectomy: a Double-Edged Sword?
Bridging-therapy with intravenous recombinant tissue plasminogen activator improves functional outcome in patients with endovascular treatment in acute stroke.
Brief Educational Intervention Improves Emergency Medical Services Stroke Recognition.
Bringing Down the Door-to-needle Time: Patient Thrombolysed in 6 Minutes-A Case Report.
Bringing Emergency Neurology to Ambulances: Mobile Stroke Unit.
Bringing the hospital to the patient: first treatment of stroke patients at the emergency site.
Bryostatin improves survival and reduces ischemic brain injury in aged rats after acute ischemic stroke.
Building a "brain attack" team to administer thrombolytic therapy for acute ischemic stroke.
Bystander Effect Fuels Human Induced Pluripotent Stem Cell-Derived Neural Stem Cells to Quickly Attenuate Early Stage Neurological Deficits After Stroke.
Calculated Decisions: tPA (Tissue Plasminogen Activator) Dosing for Stroke Calculator
Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C.
Can Aspirin Minimize Stroke Risk and New Lesion Formation in Multiple Sclerosis?
Can baseline magnetic resonance angiography (MRA) status become a foremost factor in selecting optimal acute stroke patients for recombinant tissue plasminogen activator (rt-PA) thrombolysis beyond 3 hours?
Can Children Reduce Delayed Hospital Arrival for Ischemic Stroke?: A Systematic Review of School-Based Stroke Education.
Can emergency department physicians safely and effectively initiate thrombolysis for acute ischemic stroke?
Can multivariable risk-benefit profiling be used to select treatment-favorable patients for thrombolysis in stroke in the 3- to 6-hour time window?
Can rt-PA be administered to the wrong patient? Two patients with somatoform disorder.
Can the benefits of rtPA treatment for stroke be improved?
Can the therapeutic window for tissue plasminogen activator be extended to 6 hours after stroke onset?
Canadian guidelines for intravenous thrombolytic treatment in acute stroke. A consensus statement of the Canadian Stroke Consortium.
Candidates for thrombolytic treatment in acute ischaemic stroke--where are our patients in Hong Kong?
Canonical Wnt Pathway Maintains Blood-Brain Barrier Integrity upon Ischemic Stroke and Its Activation Ameliorates Tissue Plasminogen Activator Therapy.
Cardiovascular Instability Preceded by Orolingual Angioedema after Alteplase Treatment.
Carotid Duplex Ultrasonography Can Predict Outcome of Intravenous Alteplase Therapy for Hyperacute Stroke.
Carotid Ultrasonography Can Identify Stroke Patients Ineligible for Intravenous Thrombolysis Therapy due to Acute Aortic Dissection.
Case Files of the Medical Toxicology Fellowship at Banner Good Samaritan Medical Center in Phoenix, AZ: A Non-Warfarin Anticoagulant Overdose.
Catastrophic Intracranial Hemorrhages after IV tPA in a Patient with Insidious Onset of Fever and Back Pain.
Catastrophic Secondary Infarctions with Onset Seizure Following Tissue Plasminogen Activator Therapy.
Causes and Treatment of Acute Ischemic Stroke During Pregnancy.
Causes, Predictors, and Timing of Early Neurological Deterioration and Symptomatic Intracranial Hemorrhage After Administration of IV tPA.
Cell permeable HMGB1-binding heptamer peptide ameliorates neurovascular complications associated with thrombolytic therapy in rats with transient ischemic stroke.
Cell therapy for stroke: remaining issues to address before embarking on clinical trials.
Cell-based and pharmacological neurorestorative therapies for ischemic stroke.
Centenarian stroke treated with tissue-type plasminogen activator.
Cerebral aneurysm as an exacerbating factor in stroke pathology and a therapeutic target for neuroprotection.
Cerebral embolism associated with left atrial myxoma that was treated with thrombolytic therapy.
Cerebral endothelial cell-derived small extracellular vesicles enhance neurovascular function and neurological recovery in rat acute ischemic stroke models of mechanical thrombectomy and embolic stroke treatment with tPA.
Cerebral hemorrhage after systemic fibrinolysis in a patient with severe carotid artery stenosis.
Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits.
Cerebral microbleeds development after stroke thrombolysis: A secondary analysis of the THAWS randomized clinical trial.
Cerebral microbleeds shouldn't dictate treatment of acute stroke: a retrospective cohort study evaluating risk of intracerebral hemorrhage.
Cerebral plasminogen activator activity in spontaneously hypertensive stroke-prone rats.
Cerebral Thrombolysis in Rural Residents Aged ? 80.
Cervicocranial arterial dissection.
CHADS2 score is associated with 3-month clinical outcomes after intravenous rt-PA therapy in stroke patients with atrial fibrillation: SAMURAI rt-PA Registry.
Challenges in Acute Ischemic Stroke Clinical Trials.
Challenges in the Anesthetic and Intensive Care Management of Acute Ischemic Stroke.
Challenges of Decision Making Regarding Futility in a Randomized Trial: The Interventional Management of Stroke III Experience.
Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome.
Changes in Informed Consent Policy and Treatment Delays in Stroke Thrombolysis.
Changes in neutrophil, lymphocyte, platelet ratios and their relationship with NIHSS after rtPA and/or thrombectomy in ischemic stroke.
Characteristics and Outcomes Among Patients Transferred to a Regional Comprehensive Stroke Center for Tertiary Care.
Characteristics and Outcomes of Patients who Refuse Intravenous Thrombolysis for Acute Ischemic Stroke - The San Diego Experience.
Characteristics, management and response to alteplase in China versus non-China participants of the ENCHANTED trial.
Characterization of a severe hypofibrinogenemia induced by alteplase in two patients thrombolysed for stroke.
Chemokine-related gene expression in the brain following ischemic stroke: no role for CXCR2 in outcome.
Chemotherapy induced stroke mimic: 5-Fluorouracil encephalopathy fulfilling criteria for tissue plasminogen activator therapy.
Chinese medicines and bioactive compounds for treatment of stroke.
Choosing the Correct "-ase" in Acute Ischemic Stroke: Alteplase, Tenecteplase, and Reteplase.
Chronic kidney disease and intravenous thrombolysis in acute stroke: A systematic review and meta-analysis.
Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model.
Circadian rhythms may not influence the outcomes of thrombolysis in patients with ischemic stroke: A study from China.
Circadian variation in the effect of intravenous thrombolysis after non-lacunar stroke.
Circulating cell-free DNA is a predictor of short-term neurological outcome in stroke patients treated with intravenous thrombolysis.
Citation bias favoring positive clinical trials of thrombolytics for acute ischemic stroke: a cross-sectional analysis.
Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator.
Clinical and magnetic resonance imaging predictors of very early neurological response to intravenous thrombolysis in patients with middle cerebral artery occlusion.
Clinical and MRI Predictors of No Early Recanalization Within 1 Hour After Tissue-Type Plasminogen Activator Administration.
Clinical and Neuroimaging Outcomes of Direct Thrombectomy vs Bridging Therapy in Large Vessel Occlusion: Analysis of the SELECT Cohort Study.
Clinical and radiological factors associated with unfavorable outcome after intravenous thrombolysis in patients with mild ischemic stroke.
Clinical and sonographic patterns of tandem internal carotid artery/middle cerebral artery occlusion in tissue plasminogen activator-treated patients.
Clinical and tissue response to intravenous thrombolysis in tandem internal carotid artery/middle cerebral artery occlusion: an MRI study.
Clinical and vascular outcome in internal carotid artery versus middle cerebral artery occlusions after intravenous tissue plasminogen activator.
Clinical Characteristics and Outcome of Patients With Hemorrhagic Transformation After Intravenous Thrombolysis in the WAKE-UP Trial.
Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment: a multicenter transcranial Doppler study.
Clinical Deterioration and Early Imaging Changes after Intravenous Tissue Plasminogen Activator Administration in Acute Ischemic Stroke Patients.
Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial.
Clinical Deterioration following Middle Cerebral Artery Hemodynamic Changes after Intravenous Thrombolysis for Acute Ischemic Stroke.
Clinical efficacy and imaging evaluation of recombinant tissue plasminogen activator thrombolytic therapy in patients with wake up stroke: A randomized controlled trial.
Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2).
Clinical features of stroke mimics in the emergency department.
Clinical imaging factors of excellent outcome after thrombolysis in large-vessel stroke: a THRACE subgroup analysis.
Clinical importance of microbleeds in patients receiving IV thrombolysis.
Clinical Outcomes after Intravenous Fibrinolysis in Cryptogenic Strokes with or without Patent Foramen Ovale.
Clinical Outcomes among Stroke Patients Receiving Tissue Plasminogen Activator Therapy Beyond the 3-hour Time Window.
Clinical outcomes of acute stroke patients with atrial fibrillation.
Clinical Outcomes of Endovascular Thrombectomy in Tissue Plasminogen Activator versus Non-Tissue Plasminogen Activator Patients at Primary Stroke Care Centers.
Clinical outcomes of stroke in hemodialysis patients: a retrospective single-center study.
Clinical potential of intra-arterial thrombolytic therapy in patients with acute ischaemic stroke.
Clinical Predictors of Stroke Mimics in Patients Treated with Recombinant Tissue Plasminogen Activator according to a Normal Multimodal Computed Tomography Imaging.
Clinical safety and outcome of recombinant tissue plasminogen activator in patients with stroke attributable to small artery occlusion: A protocol for systematic review and meta-analysis.
Clinical trials in thrombolytic therapy: what do they tell us? INJECT 6-month outcomes data.
Clinical Utility of Electronic Alberta Stroke Program Early Computed Tomography Score Software in the ENCHANTED Trial Database.
Clinical, Biochemical and Neuroimaging Parameters after Thrombolytic Therapy Predict Long-Term Stroke Outcome.
Clinical-Diffusion Mismatch and Benefit From Thrombolysis 3 to 6 Hours After Acute Stroke.
Cloning and purification of an anti-thrombotic, chimeric Staphylokinase in Pichia pastoris.
Closing gaps between evidence-based stroke care guidelines and practices with a collaborative quality improvement project.
Closure of large bore 9 F arterial puncture sites with the AngioSeal STS device in acute stroke patients after intravenous recombinant tissue plasminogen activator (rt-PA).
Clot injection technique affects thrombolytic efficacy in a rat embolic stroke model: implications for translaboratory collaborations.
Clot length does not impact outcome following thrombectomy.
Co-morbid conditions in use of recombinant tissue plasminogen activator (rt-PA) for the treatment of acute ischaemic stroke.
Coadministration of FTY720 and rt-PA in an experimental model of large hemispheric stroke-no influence on functional outcome and blood-brain barrier disruption.
Coagulation activation and organ dysfunction following cardiac surgery.
Coagulation and fibrinolysis markers and risk of dementia. The Dutch Vascular Factors in Dementia Study.
Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke.
Coagulation factor XIII and atherothrombosis. A mini-review.
Coagulation markers and functional outcome in acute ischemic stroke: Impact of intensive versus standard hyperglycemia control.
Code stroke: a mismatch between number of activation and number of thrombolysis.
Code Stroke: rapid transport, triage and treatment using rt-PA therapy. The NINDS rt-PA Stroke Study Group.
Coexistent Sickle Cell Disease Has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke: Findings From Get With The Guidelines-Stroke.
Cognitive and functional outcome after intravenous recombinant tissue plasminogen activator treatment in patients with a first symptomatic brain infarct.
Combination approaches to attenuate hemorrhagic transformation after tPA thrombolytic therapy in patients with poststroke hyperglycemia/diabetes.
Combination Low-Dose Tissue-Type Plasminogen Activator Plus Annexin A2 for Improving Thrombolytic Stroke Therapy.
Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke: A Pilot Trial.
Combination of Thrombolysis and Statins in Acute Stroke Is Safe: Results of the STARS Randomized Trial (Stroke Treatment With Acute Reperfusion and Simvastatin).
Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice.
Combination therapy for ischemic stroke: Novel approaches to lengthen therapeutic window of tissue plasminogen activator.
Combination therapy stroke trial. rt-PA +/- lubeluzole.
Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole.
Combination Therapy Using tPA and Edaravone Improves the Neurotoxic Effect of tPA.
Combination therapy with normobaric oxygen (NBO) plus thrombolysis in experimental ischemic stroke.
Combination therapy with VELCADE and tissue plasminogen activator is neuroprotective in aged rats after stroke and targets microRNA-146a and the toll-like receptor signaling pathway.
Combination tissue plasminogen activator and ticlopidine therapy in a rabbit model of acute thromboembolic stroke.
Combination treatment of r-tPA and an optimized human apyrase reduces mortality rate and hemorrhagic transformation 6h after ischemic stroke in aged female rats.
Combination treatment with dipyridamole, aspirin, and tPA in an embolic model of stroke in rats.
Combination treatment with low-dose Niaspan and tissue plasminogen activator provides neuroprotection after embolic stroke in rats.
Combination treatment with N-acetyl-seryl-aspartyl-lysyl-proline and tissue plasminogen activator provides potent neuroprotection in rats after stroke.
Combination treatment with U0126 and rt-PA prevents adverse effects of the delayed rt-PA treatment after acute ischemic stroke.
Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia.
Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke-Enhanced Regimen Stroke Trial.
Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial.
Combined interventional stroke therapy using intracranial stent and local intraarterial thrombolysis (LIT).
Combined intravenous and intra-arterial approach in acute stroke treatment.
Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial.
Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study.
Combined neuroprotective modalities coupled with thrombolysis in acute ischemic stroke: a pilot study of caffeinol and mild hypothermia.
Combined therapy of intensive statin plus intravenous rt-PA in acute ischemic stroke: the INSPIRE randomized clinical trial.
Combined tissue plasminogen activator and an NK1 tachykinin receptor antagonist: An effective treatment for reperfusion injury following acute ischemic stroke in rats.
Combined Treatment With 2-(2-Benzofu-Ranyl)-2-Imidazoline and Recombinant Tissue Plasminogen Activator Protects Blood-Brain Barrier Integrity in a Rat Model of Embolic Middle Cerebral Artery Occlusion.
Combined treatment with recombinant tissue plasminogen activator and dexamethasone phosphate-containing liposomes improves neurological outcome and restricts lesion progression after embolic stroke in rats.
Combined X-ray angiography and diffusion-perfusion MRI for studying stroke evolution after rt-PA treatment in rats.
Combining Normobaric Oxygen with Ethanol or Hypothermia Prevents Brain Damage from Thromboembolic Stroke via PKC-Akt-NOX Modulation.
Combining statins with tissue plasminogen activator treatment after experimental and human stroke: a safety study on hemorrhagic transformation.
Comment on: A Cost-Utility Analysis of Mechanical Thrombectomy as an Adjunct of Intravenous Tissue-Type Plasminogen Activator for Acute Large-Vessel Ischemic Stroke : Kim AS, Nguyen-Huynh M, Johnston SC. Stroke 2011;42:2013-2018.
Communication between the pharmacy and the emergency department to facilitate alteplase delivery for patients with stroke.
Community Intent to Activate Emergency Medical Services May Be Associated with Regional tPA Treatment.
Community use of intravenous tissue plasminogen activator for acute stroke: results of the brain matters stroke management survey.
Community-based thrombolytic therapy of acute ischemic stroke in Helsinki.
Comparative Analysis of Different Methods of Ischemia/Reperfusion in Hyperglycemic Stroke Outcomes: Interaction with tPA.
Comparative effects of low-dose versus standard-dose alteplase in ischemic patients with prior stroke and/or diabetes mellitus: The ENCHANTED trial.
Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review.
Comparative Sensitivity of Computed Tomography vs. Magnetic Resonance Imaging for Detecting Acute Posterior Fossa Infarct.
Comparative study on the efficacy and safety of alteplase and urokinase in the treatment of acute cerebral infarction.
Comparative tolerability profiles of thrombolytic agents. A review.
Comparing outcome and recanalization results in patients with anterior circulation stroke following endovascular treatment with and without a treatment with rt-PA: A single-center study.
Comparison between MRI screening and CT-plus-MRI screening for thrombolysis within 3h of ischemic stroke.
Comparison of "accelerated" tissue plasminogen activator with streptokinase for treatment of suspected myocardial infarction.
Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign.
Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study.
Comparison of intravenous and intra-arterial urokinase thrombolysis for acute ischaemic stroke.
Comparison of MRI-based thrombolysis for patients with middle cerebral artery occlusion
Comparison of multistate Markov modeling with contemporary outcomes in a reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
Comparison of outcome of patients with acute minor ischaemic stroke treated with intravenous t-PA, DAPT or aspirin.
Comparison of outcomes following thrombolytic therapy amongst patients with prior stroke and diabetes in the Virtual International Stroke Trials Archive (VISTA).
Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits.
Comparison of the post-embolization effects of tissue-plasminogen activator and simvastatin on neurological outcome in a clinically relevant rat model of acute ischemic stroke.
Comparison of the Time Course of Return to Work After Stroke Between Two Cohort Studies in Japan.
Comparison of thrombolysis versus surgery as a first line therapy for prosthetic heart valve thrombosis.
Comparison of thrombolytic agents in treatment of patients with acute ischemic stroke; findings from a single centre follow up study in real-life settings.
Comparison of tissue plasminogen activator administration management between Telestroke Network hospitals and academic stroke centers: the Telemedical Pilot Project for Integrative Stroke Care in Bavaria/Germany.
Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model.
Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
Complex interventional treatment in a patient with atrial fibrillation and stroke caused by large carotid artery thrombus: a case report.
Complex relations between body temperature, tPA action, and stroke outcome.
Complicated orolingual angioedema after recombinant tissue plasminogen activator treatment in stroke patients under angiotensin converting enzyme inhibitor: Report of two cases.
Complications of endovascular therapy for acute ischemic stroke and proposed management approach.
Computed Tomography Angiography in Acute Stroke Patients Receiving Recombinant Tissue Plasminogen Activator: Outcome and Safety Evaluations in an Asian Population.
Computed Tomography Perfusion Derived Blood-Brain Barrier Permeability Does Not Yet Improve Prediction of Hemorrhagic Transformation.
Computer-Aided Diagnosis of Hyperacute Stroke with Thrombolysis Decision Support Using a Contralateral Comparative Method of CT Image Analysis.
Confirmation of tPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-tPA stroke trials.
Conjugate eye deviation as predictor of acute cortical and subcortical ischemic brain lesions.
Consensus statement on the use of intravenous recombinant tissue plasminogen activator to treat acute ischemic stroke by the Chinese Stroke Therapy Expert Panel.
Consent for intravenous thrombolysis in acute stroke: review and future directions.
Continuous EEG Monitoring During Thrombolysis in Acute Hemispheric Stroke Patients Using the Brain Symmetry Index.
Continuous Glibenclamide Prevents Hemorrhagic Transformation in a Rodent Model of Severe Ischemia-Reperfusion.
Contrasting roles of immune cells in tissue injury and repair in stroke: The dark and bright side of immunity in the brain.
Controversies about tissue plasminogen activator: extending the window of therapy.
Controversies in acute stroke treatment.
Controversies in cerebrovascular disease: High or low doses of recombinant tissue plasminogen activator to treat acute stroke? A literature review.
Controversies in Thrombolysis.
Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators.
Correction to: Early Recanalization With Alteplase in Stroke Because of Large Vessel Occlusion in the ESCAPE Trial.
Correction to: Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
Correlation of the L-Arginine Pathway with Thrombo-Inflammation May Contribute to the Outcome of Acute Ischemic Stroke.
Corrigendum to "Comparative Analysis of Fibrinolytic Properties of Alteplase, Tenecteplase and Urokinase in an in Vitro Clot Model of Intracerebral Haemorrhage. [Journal of Stroke and Cerebrovascular Diseases, Vol. 29, No. 9 (September), 2020: 105073]".
Corrigendum to Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient- data meta-analysis of randomized trials.
Cost analysis review of stroke centers, telestroke, and rt-PA.
Cost Burden of Stroke Mimics and Transient Ischemic Attack after Intravenous Tissue Plasminogen Activator Treatment.
Cost-Effectiveness Of Combined Treatment With Alteplase (Rt-Pa) And Cerebrolysin In Acute Ischemic Hemispheric Stroke In Austria.
Cost-effectiveness of CT perfusion for selecting patients for intravenous thrombolysis: a US hospital perspective.
Cost-Effectiveness of Emergent MRI during Stroke Alert to Diagnose Stroke Mimics: Single-Center Experience.
Cost-Effectiveness of Intra-Arterial Treatment as an Adjunct to Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke.
Cost-effectiveness of multimodal CT for evaluating acute stroke.
Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence.
Cost-effectiveness of targeted thrombolytic therapy for stroke patients using multi-modal CT compared to usual practice.
Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: experience from Australian stroke center.
Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group.
Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic Stroke.
Could clinical diffusion-mismatch determined using DWI ASPECTS predict neurological improvement after thrombolysis before 3 h after acute stroke?
COVID-19 Impact on Stroke Presentations.
COVID-19-associated ischaemic stroke due to underlying carotid artery thrombosis in a healthy young woman.
COVID-19-Related Stroke.
Creatine kinase during non-ST-segment elevation acute coronary syndromes is associated with major bleeding.
Creation of an intensive care unit and organizational changes in an adult emergency department: Impact on acute stroke management.
Criteria for Emergency Brain MRI During Stroke-Alert.
Critical Care Management of Acute Ischemic Stroke.
Critical Care Needs in Patients with Diffusion-Weighted Imaging Negative MRI after tPA--Does One Size Fit All?
Critical early thrombolytic and endovascular reperfusion therapy for acute ischemic stroke victims: a call for adjunct neuroprotection.
Cryptogenic stroke in relation to genetic variation in clotting factors and other genetic polymorphisms among young men and women.
Cryptogenic stroke: clinical consideration of a heterogeneous ischemic subtype.
CT Angiography in an Acute Stroke Protocol: Correlation between Occlusion Site and Outcome of Intravenous Thrombolysis.
CT for Treatment Selection in Acute Ischemic Stroke: A Code Stroke Primer.
CT interpretation by ASPECTS in hyperacute ischemic stroke predicting functional outcomes.
CT perfusion identifies increased salvage of tissue in patients receiving intravenous recombinant tissue plasminogen activator within 3 hours of stroke onset.
CT perfusion improves diagnostic accuracy and confidence in acute ischaemic stroke.
CT-based intravenous thrombolysis 3-4·5 hours after acute ischemic stroke in clinical practice.
CTA collateral score predicts infarct volume and clinical outcome after endovascular therapy for acute ischemic stroke: a retrospective chart review.
CTP infarct core may predict poor outcome in stroke patients treated with IV t-PA.
Current and future recanalization strategies for acute ischemic stroke.
Current approaches to glycoprotein analysis.
Current controversies: thrombolysis for patients with acute ischaemic stroke aged over 80.
Current endovascular treatment of acute stroke and future aspects.
Current management of acute ischemic stroke. Part 1: Thrombolytics and the 3-hour window.
Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke.
Current State of Stroke Care in the Philippines.
Cutting through the Complexities of mTOR for the Treatment of Stroke.
Cytoprotective Drug-Tissue Plasminogen Activator Protease Interaction Assays: Screening of Two Novel Cytoprotective Chromones.
Death or nonfatal stroke in patients with acute myocardial infarction treated with tissue plasminogen activator. Participants in the National Registry of Myocardial Infarction 2.
Deciphering the neuroprotective mechanisms of Bu-yang Huan-wu decoction by an integrative neurofunctional and genomic approach in ischemic stroke mice.
Decision Making and the Limits of Evidence: A Case Study of Acute Stroke in Pregnancy.
Decompressive craniectomy after intravenous tissue plasminogen activator administration for stroke.
Defibrinogen Therapy for Acute Ischemic Stroke: 1332 Consecutive Cases.
Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials.
Defining minor symptoms in acute ischemic stroke.
Delay to Tissue Plasminogen Activator in Hypertensive Stroke Patients: An Analysis of Delay Duration Across Agents.
Delayed adjuvant therapy with the 21-aminosteroid U74006F and the anion channel blocker L644-711 does not improve outcome following thrombolytic therapy in a rabbit model of thromboembolic stroke.
Delayed Intravenous Thrombolysis in Patients with Minor Stroke.
Delayed rt-PA treatment in a rat embolic stroke model: diagnosis and prognosis of ischemic injury and hemorrhagic transformation with magnetic resonance imaging.
Delayed tissue-plasminogen activator therapy in a rabbit model of thromboembolic stroke.
Delayed treatment with a novel neurotrophic compound reduces behavioral deficits in rabbit ischemic stroke.
Delays in Door-to-Needle Times and Their Impact on Treatment Time and Outcomes in Get With The Guidelines-Stroke.
Deletion polymorphism in the angiotensin-converting enzyme gene in patients with a history of ischemic stroke.
Depressive symptoms in stroke patients treated and non-treated with intravenous thrombolytic therapy: a 1-year follow-up study.
Derivation and Validation of a Scoring System for Intravenous Tissue Plasminogen Activator Use in Asian Patients.
Derivation of transcranial Doppler criteria for rescue intra-arterial thrombolysis: multicenter experience from the Interventional Management of Stroke study.
Design and validation of a prehospital scale to predict stroke severity: Cincinnati Prehospital Stroke Severity Scale.
Design of a PROspective multi-national CLOTBUST collaboration on reperfusion therapies for stroke (CLOTBUST-PRO).
Design of a standard Iranian protocol of Intravenous thrombolysis with tissue plasminogen activator: A national project.
Desmoteplase 3 to 9 Hours After Major Artery Occlusion Stroke: The DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke).
Desmoteplase for Acute Ischemic Stroke within 3 to 9?Hours after Symptom Onset: Evidence from Randomized Controlled Trials.
Desmoteplase for late treatment of stroke: still in the dark.
Desmoteplase.
Details of a prospective protocol for a collaborative meta-analysis of individual participant data from all randomized trials of intravenous rt-PA vs. control: statistical analysis plan for the Stroke Thrombolysis Trialists' Collaborative meta-analysis.
Determinants of outcome in patients eligible for thrombolysis for ischemic stroke.
Determinants of the impact of blood pressure variability on neurological outcome after acute ischaemic stroke.
Determining intravenous rt-PA eligibility in the Emergency Department.
Detriments of tPA for acute stroke in routine clinical practice.
Developing an emergency department team for treatment of stroke with recombinant tissue plasminogen activator.
Development of a metropolitan matrix of primary stroke centers: the Phoenix experience.
Development of a novel RANKL-based peptide, microglial healing peptide1-AcN (MHP1-AcN), for treatment of ischemic stroke.
Development of regional programs to speed treatment of stroke.
Development of the nitrone-based spin trap agent NXY-059 to treat acute ischemic stroke.
Development of thrombolytic therapy for stroke: a perspective.
Developments in endovascular therapy for acute ischemic stroke.
Developments in mechanical thrombectomy devices for the treatment of acute ischemic stroke.
DEVT: A randomized, controlled, multicenter trial of direct endovascular treatment versus standard bridging therapy for acute stroke patients with large vessel occlusion in the anterior circulation - Protocol.
Diabetes Mellitus/Poststroke Hyperglycemia: a Detrimental Factor for tPA Thrombolytic Stroke Therapy.
Diabetes Worsens Functional Outcomes in Young Female Rats: Comparison of Stroke Models, Tissue Plasminogen Activator Effects, and Sexes.
Diagnosis and treatment of ischemic stroke.
Diagnostic and prognostic value of early MR Imaging vessel signs in hyperacute stroke patients imaged <3 hours and treated with recombinant tissue plasminogen activator.
Dietary Supplementations as Neuroprotective Therapies: Focus on NT-020 Diet Benefits in a Rat Model of Stroke.
Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke.
Different doses of recombinant tissue-type plasminogen activator for acute stroke in Chinese patients.
Different therapy options protecting microvasculature after experimental cerebral ischaemia and reperfusion.
Differential Effect of Baseline Computed Tomographic Angiography Collaterals on Clinical Outcome in Patients Enrolled in the Interventional Management of Stroke III Trial.
Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes.
Diffuse Fluid-Attenuated Inversion Recovery Hyperintensity in Subarachnoid Space Following Cerebral Angiography and Intravenous Thrombolysis.
Digestive and urologic hemorrhage after intravenous thrombolysis for acute ischemic stroke: Data from a Chinese stroke center.
Digital angiographic quantification of blood flow dynamics in embolic stroke treated with tissue-type plasminogen activator.
Dilemma in the emergency setting: hypomagnesemia mimicking acute stroke.
Direct admission to stroke centers reduces treatment delay and improves clinical outcome after intravenous thrombolysis.
Direct Aspiration versus Stent Retriever Thrombectomy for Acute Stroke: A Systematic Review and Meta-Analysis in 9127 Patients.
Direct Imaging of Cerebral Thromboemboli Using Computed Tomography and Fibrin-targeted Gold Nanoparticles.
Direct stroke unit admission of intravenous tissue plasminogen activator: safety, clinical outcome, and hospital cost savings.
Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial.
Direct Thrombus Imaging in Stroke.
Disparities in the Use of Intravenous t-PA among Ischemic Stroke Patients: Population-based Recent Temporal Trends.
Dissociation of severity of stroke and aphasia recovery early after intravenous recombinant tissue plasminogen activator thrombolysis.
Distal hyperintense vessels on FLAIR: an MRI marker for collateral circulation in acute stroke?
Distance to thrombus in acute middle cerebral artery occlusion: a predictor of outcome after intravenous thrombolysis for acute ischemic stroke.
DNA methylation analyses identify an intronic ZDHHC6 locus associated with time to recurrent stroke in the Vitamin Intervention for Stroke Prevention (VISP) clinical trial.
Do All Acute Stroke Patients Receiving tPA Require ICU Admission?
Do billing codes accurately capture intravenous tissue plasminogen activator treatment rates? Justified concern for clinical performance measures based on billing code assignment.
Do efforts to decrease door-to-needle time risk increasing stroke mimic treatment rates?
Do lacunar strokes benefit from thrombolysis? Evidence from the Registry of the Canadian Stroke Network.
Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)? An evaluation of the risks and benefits of TPA from the patient's perspective.
Do silent infarcts modify the effect of thrombolysis for stroke?
Do statins reduce the mortality rate in stroke patients treated with systemic thrombolysis in a 5-year.
Do the Brain Attack Coalition's criteria for stroke centers improve care for ischemic stroke?
Do women benefit more from systemic thrombolysis in acute ischemic stroke? A Serbian experience with thrombolysis in ischemic stroke (SETIS) study.
Dodecafluoropentane Emulsion Extends Window for tPA Therapy in a Rabbit Stroke Model.
Does body weight influence the response to intravenous tissue plasminogen activator in stroke patients?
Does Clinical-CT 'Mismatch' Predict Early Response to Treatment with Recombinant Tissue Plasminogen Activator?
Does current oral antiplatelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen-activator-mediated recanalization rate in patients with acute ischemic stroke?
Does Diffusion Lesion Volume Above 70 mL Preclude Favorable Outcome Despite Post-Thrombolysis Recanalization?
Does Emergency Medical Services Transportation Mitigate Post-stroke Discharge Disability? A Prospective Observational Study.
Does helicopter emergency medical service transfer offer benefit to patients with stroke?
Does ICA Occlusion Frequently Have Intracerebral Hemorrhage after IV Tissue Plasminogen Activator Therapy for Ischemic Stroke?
Does inhibiting Sur1 complement rt-PA in cerebral ischemia?
Does intravenous rtPA benefit patients in the absence of CT angiographically visible intracranial occlusion?
Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator?
Does normobaric hyperoxia increase oxidative stress in acute ischemic stroke? A critical review of the literature.
Does Reducing the Duration from Symptom Onset to Recanalization Improve the Results of Intracranial Mechanical Thrombectomy in the Elderly?
Does smoking influence outcome after intravenous thrombolysis for acute ischaemic stroke?
Does study enrollment delay treatment with intravenous thrombolytics for acute ischemic stroke?
Does the Primary Imaging Modality-Computed Tomography or Magnetic Resonance Imaging-Influence Stroke Physicians' Certainty on Whether or Not to Give Thrombolysis to Randomized Acute Stroke Patients?
Does the sex of acute stroke patients influence the effectiveness of rt-PA?
Door to Intravenous Tissue Plasminogen Activator Time and Hospital Length of Stay in Acute Ischemic Stroke Patients, Georgia, 2007-2013.
Door to needle time and functional outcome for mild ischemic stroke over telestroke.
Door to Needle Time over Telestroke-A Comprehensive Stroke Center Experience.
Door-to-Needle Delays in Minor Stroke: A Causal Inference Approach.
Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset.
Dosing Errors Did Not Have a Major Impact on Outcome in the NINDS t-PA Stroke Study.
Dosing errors may impact the risk of rt-PA for stroke: the Multicenter rt-PA Acute Stroke Survey.
Dosing Tissue Plasminogen Activator on a Mobile Stroke Unit: Comparison Between Estimated and Hospital-Measured Weights.
Doubts, fears and misconceptions. What is the future of thrombolysis in acute stroke?
DRAGON score predicts functional outcomes in acute ischemic stroke patients receiving both intravenous tissue plasminogen activator and endovascular therapy.
Dramatic Changes of a DWI Lesion in a Patient with Acute Ischemic Stroke Treated with IV t-PA.
Drill down analysis of door-to-needle time of acute ischemic stroke patients treated with intravenous tissue plasminogen activator.
Drip 'n Ship Versus Mothership for Endovascular Treatment: Modeling the Best Transportation Options for Optimal Outcomes.
Drip and ship thrombolytic therapy for acute ischemic stroke: use, temporal trends, and outcomes.
Drip-and-ship stroke thrombolysis in the emergency department of a healthcare center - a possibility for those fallen ill in rural settings.
Drip-and-Ship Thrombolytic Therapy for Acute Ischemic Stroke.
Drip-and-Ship Thrombolytic Therapy Supported by the Telestroke System for Acute Ischemic Stroke Patients Living in Medically Under-served Areas.
Drivers of costs associated with reperfusion therapy in acute stroke: the Interventional Management of Stroke III Trial.
Driving stroke quality improvement at scale in EDs across a nationwide network of hospitals: strategies and interventions.
Dual Antiplatelet Therapy after Intravenous Thrombolysis for Acute Minor Ischemic Stroke.
Dual Antiplatelet Therapy Increases Hemorrhagic Transformation Following Thrombolytic Treatment in Experimental Stroke.
DWI-ASPECTS as a predictor of dramatic recovery after intravenous recombinant tissue plasminogen activator administration in patients with middle cerebral artery occlusion.
Dynamic increase in neutrophil levels predicts parenchymal hemorrhage and function outcome of ischemic stroke with r-tPA thrombolysis.
Dysphagia as a predictor of outcome and transition to palliative care among middle cerebral artery ischemic stroke patients.
E-Mail Is an Effective Tool for Rapid Feedback in Acute Stroke.
Early administration of pyrrolidine dithiocarbamate extends the therapeutic time window of tissue plasminogen activator in a male rat model of embolic stroke.
Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial.
Early admission to stroke unit influences clinical outcome.
Early carotid endarterectomy for critical carotid artery stenosis after thrombolysis therapy in acute ischemic stroke in the middle cerebral artery.
Early changes in fibrinogen after administration of alteplase are associated with the short-term efficacy of thrombolysis.
Early changes in tissue perfusion after tissue plasminogen activator administration in hyperacute ischemic stroke: initial experiences with arterial spin labeling perfusion magnetic resonance imaging.
Early computed tomography hypodensity predicts hemorrhage after intravenous tissue plasminogen activator in acute ischemic stroke.
Early CT changes and outcome of ischemic stroke.
Early dramatic recovery during intravenous tissue plasminogen activator infusion: clinical pattern and outcome in acute middle cerebral artery stroke.
Early Endovascular Treatment in Intravenous Tissue Plasminogen Activator-Ineligible Patients.
Early epileptic seizures in ischaemic stroke treated by mechanical thrombectomy: influence of rt-PA.
Early Fibrinogen Depletion and Symptomatic Intracranial Hemorrhage After Reperfusion Therapy.
Early infarct FLAIR hyperintensity is associated with increased hemorrhagic transformation after thrombolysis.
Early infarct growth predicts long-term clinical outcome after thrombolysis.
Early intravenous thrombolysis with recombinant tissue-type plasminogen activator in vertebrobasilar ischemic stroke.
Early Ischemic Blood Brain Barrier Damage: A Potential Indicator for Hemorrhagic Transformation Following Tissue Plasminogen Activator (tPA) Thrombolysis?
Early Ischemic Change on CT Versus Diffusion-Weighted Imaging for Patients With Stroke Receiving Intravenous Recombinant Tissue-Type Plasminogen Activator Therapy: Stroke Acute Management With Urgent Risk-factor Assessment and Improvement (SAMURAI) rt-PA Registry.
Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: Insights into the pathophysiology of acute stroke in the thrombolysis era.
Early metabolic changes following ischemia onset in rats: An in vivo diffusion-weighted imaging and 1H-magnetic resonance spectroscopy study at 7.0 T.
Early Neurologic Improvement Based on the National Institutes of Health Stroke Scale Score Predicts Favorable Outcome within 30 Minutes after Undergoing Intravenous Recombinant Tissue Plasminogen Activator Therapy.
Early Neurological Deterioration within 24 Hours after Intravenous rt-PA Therapy for Stroke Patients: The Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.
Early neurological improvement after intravenous tissue plasminogen activator infusion in patients with ischemic stroke aged 80 years or older.
Early prediction of gross hemorrhagic transformation by noncontrast agent MRI cluster analysis after embolic stroke in rat.
Early Profiles of Clinical Evolution after Intravenous Thrombolysis in an Unselected Stroke Population.
Early recanalization after intravenous administration of recombinant tissue plasminogen activator as assessed by pre- and post-thrombolytic angiography in acute ischemic stroke patients.
Early Recanalization With Alteplase in Stroke Because of Large Vessel Occlusion in the ESCAPE Trial.
Early recurrent ischemic stroke complicating intravenous thrombolysis for stroke: incidence and association with atrial fibrillation.
Early recurrent ischemic stroke in stroke patients undergoing intravenous thrombolysis.
Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study.
Early stroke treatment with IV t-PA associated with early recanalization.
Early Use of Statin in Patients Treated with Alteplase for Acute Ischemic Stroke.
Early [(11)C]Flumazenil/H(2)O positron emission tomography predicts irreversible ischemic cortical damage in stroke patients receiving acute thrombolytic therapy.
Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator.
ECASS II: intravenous alteplase in acute ischaemic stroke. European Co-operative Acute Stroke Study-II.
ECASS-II: intravenous alteplase in acute ischaemic stroke. European Co-operative Acute Stroke Study-II.
Economic Evaluation of a Pre-Hospital Protocol for Patients with Suspected Acute Stroke.
Editorial comment--Remote evaluation of acute ischemic stroke: a reliable tool to extend tissue plasminogen activator use to community and rural stroke patients?
Editorial: Statins and Tissue Plasminogen Activator for Stroke: A Beneficial Combination?
Educating Paramedics on the Finger-to-Nose Test Improves Recognition of Posterior Stroke.
Education to improve stroke awareness and emergent response. The NINDS rt-PA Stroke Study Group.
Effect of a modern stroke unit combined with recombinant human tissue-type plasminogen activator intravenous thrombolysis on ischemic cerebral infarction and its influence on limb motor function and activity of daily living.
Effect of a new inhibitor of the synthesis of 20-HETE on cerebral ischemia reperfusion injury.
Effect of Acute Stroke Care Regionalization on Intravenous Alteplase Use in Two Urban Counties.
Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke.
Effect of alteplase versus aspirin plus clopidogrel in acute minor stroke.
Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
Effect of alteplase within 6 hours of acute ischemic stroke on all-cause mortality (third International Stroke Trial).
Effect of Cardioembolic Etiology on Intravenous Thrombolysis Efficacy for Acute Ischemic Stroke.
Effect of daytime, weekday and year of admission on outcome in acute ischaemic stroke patients treated with thrombolytic therapy.
Effect of Endovascular Treatment Alone vs Intravenous Alteplase Plus Endovascular Treatment on Functional Independence in Patients With Acute Ischemic Stroke: The DEVT Randomized Clinical Trial.
Effect of glycated hemoglobin index and mean arterial pressure on acute ischemic stroke prognosis after intravenous thrombolysis with recombinant tissue plasminogen activator.
Effect of helicopter transport on neurological outcomes in a mouse model of embolic stroke with reperfusion: AIR-MICE pilot study.
Effect of intravenous alteplase on post-stroke depression in the WAKE UP trial.
Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. NINDS; The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group.
Effect of Intravenous Recombinant Tissue-Type Plasminogen Activator in Patients With Mild Stroke in the Third International Stroke Trial-3: Post Hoc Analysis.
Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours.
Effect of IV alteplase on the ischemic brain lesion at 24-48 hours after ischemic stroke.
Effect of selective serotonin re-uptake inhibitors (SSRIs) on functional outcome in patients with acute ischemic stroke treated with tPA.
Effect of Serum Lipid Levels on Stroke Outcome after rt-PA Therapy: SAMURAI rt-PA Registry.
Effect of Stroke Education Pamphlets vs a 12-Minute Culturally Tailored Stroke Film on Stroke Preparedness Among Black and Hispanic Churchgoers: A Cluster Randomized Clinical Trial.
Effect of the Pleiotropic Drug CNB-001 on Tissue Plasminogen Activator (tPA) Protease Activity in vitro: Support for Combination Therapy to Treat Acute Ischemic Stroke.
Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial.
Effect of tissue plasminogen activator dose and interval on stroke severity.
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.
Effect of X-Ray Attenuation of Arterial Obstructions on Intravenous Thrombolysis and Outcome after Ischemic Stroke.
Effective and safe conditions of low-frequency transcranial ultrasonic thrombolysis for acute ischemic stroke: neurologic and histologic evaluation in a rat middle cerebral artery stroke model.
Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries.
Effectiveness of intravenous r-tPA versus UK for acute ischaemic stroke: a nationwide prospective Chinese registry study.
Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke.
Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients.
Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial.
Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials.
Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials.
Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trial.
Effects of alteplase, a thrombolytic agent, in a rat photothrombotic middle cerebral artery occlusion model.
Effects of Blood Pressure and Blood Pressure-Lowering Treatment During the First 24 Hours Among Patients in the Third International Stroke Trial of Thrombolytic Treatment for Acute Ischemic Stroke.
Effects of deferoxamine on brain injury after transient focal cerebral ischemia in rats with hyperglycemia.
Effects of hyperacute blood pressure and heart rate on stroke outcomes after intravenous tissue plasminogen activator.
Effects of labeling human mesenchymal stem cells with superparamagnetic iron oxides on cellular functions and magnetic resonance contrast in hypoxic environments and long-term monitoring.
Effects of Meteorological Conditions on the Risk of Ischemic Stroke Events in Patients Treated with Alteplase--HEWS-tPA.
Effects of ML351 and tissue plasminogen activator combination therapy in a rat model of focal embolic stroke.
Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice.
Effects of public and professional education on reducing the delay in presentation and referral of stroke patients.
Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study.
Effects of the spin trap agent disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator.
Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
Effects on Stroke Metrics and Outcomes of a Nurse-led Stroke Triage Team in Acute Stroke Management.
Efficacy and safety assessment of alteplase in the treatment of stroke - gender differences.
Efficacy and safety of desmoteplase in acute ischemic stroke patients: A systematic review and meta-analysis.
Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke.
Efficacy and safety of i.v. alteplase therapy up to 4.5 hours after acute ischemic stroke onset.
Efficacy and Safety of Intravenous Thrombolysis on Acute Branch Atheromatous Disease: A Retrospective Case-Control Study.
Efficacy and safety of intravenous thrombolysis with alteplase for treating acute ischemic stroke at different time windows: A protocol for systematic review and meta-analysis.
Efficacy and safety of low dose alteplase for intravenous thrombolysis in Asian stroke patients: a meta-analysis.
Efficacy and Safety of Low-Dose Versus Standard-Dose Alteplase Regimens in Patients with Acute Ischaemic Stroke.
Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial.
Efficacy and Safety of Thrombolytic Therapy for Stroke with Unknown Time of Onset: A Meta-Analysis of Observational Studies.
Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis.
Efficacy of Alteplase in a Mouse Model of Acute Ischemic Stroke: A Retrospective Pooled Analysis.
Efficacy of beveled tip aspiration catheter in mechanical thrombectomy for acute ischemic stroke.
Efficacy of IV tissue plasminogen activator in acute stroke: does stroke subtype really matter?
Efficacy of systemic thrombolysis within 4.5 h from stroke symptom onset: a single-centre clinical and diffusion-perfusion 3T MRI study.
Efficacy of Telemedicine for Stroke: Pooled Analysis of the Stroke Team Remote Evaluation Using a Digital Observation Camera (STRokE DOC) and STRokE DOC Arizona Telestroke Trials.
Efficacy of thrombolytic (rt-PA) therapy in old stroke patients: the Perugia Stroke Unit experience.
Efficiency of Enrollment in a Successful Phase II Acute Stroke Clinical Trial.
Egyptian experience in increasing utilization of reperfusion therapies in acute ischemic stroke.
EkoSonicSV endovascular system for recanalization of the basilar artery occlusion.
Elderly patients and intra-arterial stroke therapy.
Elevated fibrinogen levels decrease following treatment of acromegaly.
Elevated international normalized ratio as a manifestation of post-thrombolytic coagulopathy in acute ischemic stroke.
Elevated NT-proBNP is associated with unfavorably altered plasma fibrin clot properties in atrial fibrillation.
Elevated plasma fibrinogen indicates short-term poor outcome in patients with acute ischemic stroke after intravenous thrombolysis.
Elevated tissue plasminogen activator antigen and stroke risk: The Stroke Prevention In Young Women Study.
Elevated urea level is associated with poor clinical outcome and increased mortality post intravenous tissue plasminogen activator in stroke patients.
Eligibility and rate of treatment for recombinant tissue plasminogen activator in acute ischemic stroke using different criteria.
Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial.
Emergency and stroke physician combined consensus statement on thrombolysis for acute stroke.
Emergency brain resuscitation.
Emergency Care of Patients with Acute Ischemic Stroke in the Kaiser Permanente Southern California Integrated Health System.
Emergency management of stroke in the era of mechanical thrombectomy.
Emergency Medical Services Providers' Knowledge, Practices, And Barriers To Stroke Management.
Emergency medical systems education may improve knowledge of pre-hospital stroke triage protocols.
Emergency Medicine Pharmacist Impact on Door-to-Needle Time in Patients With Acute Ischemic Stroke.
Emergency Medicine Physicians Accurately Select Acute Stroke Patients for Tissue-Type Plasminogen Activator Treatment Using a Checklist.
Emergency physician attitudes toward thrombolytic therapy in acute stroke.
Emergency physician survey: recombinant tissue plasminogen activator for stroke.
Emergency physician treatment of acute stroke with recombinant tissue plasminogen activator: a retrospective analysis.
Emergency Superficial Temporal Artery to Middle Cerebral Artery Bypass After Intravenous Administration of Tissue Plasminogen Activator for Stroke.
Emergency transfer of acute stroke patients within the East Saxony telemedicine stroke network: a descriptive analysis.
Emergency transport of stroke suspects in a rural state: opportunities for improvement.
Emergent Loading Dose of Antiplatelets for Stenting after IV rt-PA in Acute Ischemic Stroke: A Feasibility Study.
Emergent mechanical thrombectomy for acute stroke using the Mindframe Capture LP system: initial single-center experience.
Emerging temporal trends in tissue plasminogen activator use: Results from the BASIC project.
Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis.
Empirical characteristics of litigation involving tissue plasminogen activator and ischemic stroke.
Enablers of the implementation of tissue plasminogen activator in acute stroke care: a cross-sectional survey.
Encapsulated Intracerebral Hematoma Presenting as Cerebral Abscess.
Encephalopathy only stroke codes (EoSC) do not result in rt-PA treatments.
Endogenous activated protein C predicts hemorrhagic transformation and mortality after tissue plasminogen activator treatment in stroke patients.
Endogenous regeneration: Engineering growth factors for stroke.
Endogenous tissue plasminogen activator mediates bone marrow stromal cell-induced neurite remodeling after stroke in mice.
Endothelial cells and astrocytes: a concerto en duo in ischemic pathophysiology.
Endothelial progenitor cells: Potential novel therapeutics for ischaemic stroke.
Endovascular equipoise shift in a phase III randomized clinical trial of sonothrombolysis for acute ischemic stroke.
Endovascular Mechanical Thrombectomy in Large-Vessel Occlusion Ischemic Stroke Presenting with Low National Institutes of Health Stroke Scale: Systematic Review and Meta-Analysis.
Endovascular reperfusion therapy in acute ischaemic stroke.
Endovascular revascularization results in IMS III: intracranial ICA and M1 occlusions.
Endovascular stent thrombectomy: the new standard of care for large vessel ischaemic stroke.
Endovascular stroke treatment does not preclude high thrombolysis rates.
Endovascular Therapy Demonstrates Benefit over Intravenous Recombinant Tissue Plasminogen Activator Based on Repeatedly Measured National Institutes of Health Stroke Scale.
Endovascular Therapy for Acute Ischemic Stroke With Occlusion of the Middle Cerebral Artery M2 Segment.
Endovascular therapy for ischemic stroke.
Endovascular therapy in hyperacute ischaemic stroke: history and current status.
Endovascular Therapy Is Effective and Safe for Patients With Severe Ischemic Stroke: Pooled Analysis of Interventional Management of Stroke III and Multicenter Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke in the Netherlands Data.
Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.
Endovascular Thrombectomy for Anterior Circulation Stroke: Systematic Review and Meta-Analysis.
Endovascular Thrombectomy for Mild Strokes: How Low Should We Go?
Endovascular Thrombectomy with or without Intravenous Alteplase in Acute Stroke.
Endovascular Thrombectomy, Platelet Count, and Intracranial Hemorrhage.
Endovascular Treatment for Acute Ischemic Stroke in the Setting of Anticoagulation.
Endovascular treatment for acute stroke: an open field to begin.
Endovascular treatment for Small Core and Anterior circulation Proximal occlusion with Emphasis on minimizing CT to recanalization times (ESCAPE) trial: methodology.
Endovascular treatment of acute intracerebral artery occlusions with the solitaire stent: single-centre experience with 108 recanalization procedures.
Endovascular Treatment of Acute Ischemic Stroke.
Endovascular Treatment of Ischemic Stroke in a Developing Country.
Endovascular treatment versus medical care alone for ischaemic stroke: systematic review and meta-analysis.
Endovascular Treatment versus Sonothrombolysis for Acute Ischemic Stroke.
Endovascular Treatment with Stent-Retriever Devices for Acute Ischemic Stroke: A Meta-Analysis of Randomized Controlled Trials.
Enhanced Detection of Edema in Malignant Anterior Circulation Stroke (EDEMA) Score: A Risk Prediction Tool.
Enhanced dispatch and rendezvous doubles the catchment area and number of patients treated on a mobile stroke unit.
Enhancing community delivery of tissue plasminogen activator in stroke through community-academic collaborative clinical knowledge translation.
Enhancing Recovery after Acute Ischemic Stroke with Donepezil as an Adjuvant Therapy to Standard Medical Care: Results of A Phase IIa Clinical Trial.
Epidemiology and Outcomes of Ischemic Stroke and Transient Ischemic Attack in the Adult and Geriatric Population.
Epidemiology and Registry Studies of Stroke in Japan.
Epidemiology of a large telestroke cohort in the Delaware valley.
Epigallocatechin Gallate Extends Therapeutic Window of Recombinant Tissue Plasminogen Activator Treatment for Brain Ischemic Stroke: A Randomized Double-Blind and Placebo-Controlled Trial.
Epigenetic regulation of inflammation in stroke.
Epigenetic Regulation of Oxidative Stress in Ischemic Stroke.
Epileptic manifestations in stroke patients treated with intravenous alteplase.
EPITHET: Positive Result After Reanalysis Using Baseline Diffusion-Weighted Imaging/Perfusion-Weighted Imaging Co-Registration.
Equivocal roles of tissue-type plasminogen activator in stroke-induced injury.
Erythropoietin in combination of tissue plasminogen activator exacerbates brain hemorrhage when treatment is initiated 6 hours after stroke.
Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma!
Erythropoietin: Powerful protection of ischemic and post-ischemic brain.
Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice.
Essential thrombocythemia-related stroke and improvement with tissue plasminogen activator.
Establishment of stroke treatment plans: one hospital's experience.
Estimating the number of stroke patients eligible for thrombolytic treatment if delay could be avoided.
Estimating Weight of Patients With Acute Stroke When Dosing for Thrombolysis.
Estimation of Iranian stroke patients eligible for intravenous thrombolysis with tPA.
Estimation of seizures prevalence in ischemic strokes after thrombolytic therapy.
Ethic issue in ischemic stroke patients wit thrombolytic therapy.
Ethical Challenges in Acute Evaluation of Suspected Psychogenic Stroke Mimics.
Ethnic Differences in 90-Day Poststroke Medication Adherence.
Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN).
European Cooperative Acute Stroke Study (ECASS): (rt-PA-Thrombolysis in acute stroke) study design and progress report.
European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits ECASS-4: ExTEND.
Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline.
Evaluation of initial diffusion-weighted image findings in acute stroke patients using a semiquantitative score.
Evaluation of the clinical-diffusion and perfusion-diffusion mismatch models in DEFUSE.
Evaluation of the implementation of a 24-hour stroke thrombolysis emergency treatment for patients with acute ischemic stroke.
Evaluation of the recombinant tissue plasminogen activator pretreatment in acute stroke patients with large vessel occlusions treated with the direct bridging approach. Is it worth the effort?
Evolving therapeutic approaches to treating acute ischemic stroke.
Exclusion Criteria for Intravenous Thrombolysis in Stroke Mimics: An Observational Study.
Exogenous stem cells pioneer a biobridge to the advantage of host brain cells following stroke: New insights for clinical applications.
Expanded Indication for Recombinant Tissue Plasminogen Activator from 3 to 4.5 h after Onset of Stroke in Japan.
Expanded modes of tissue plasminogen activator delivery in a comprehensive stroke center increases regional acute stroke interventions.
Expanding Acute Stroke Care in Rural America: A Model for Statewide Success.
Expanding the window for thrombolytic therapy in acute stroke. The potential role of acute MRI for patient selection.
Expansion of Intravenous Tissue Plasminogen Activator Eligibility Beyond National Institute of Neurological Disorders and Stroke and European Cooperative Acute Stroke Study III Criteria.
Expansion of the dimensions in the current management of acute ischemic stroke.
Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association.
Experience with A Direct Aspiration First Pass Technique (ADAPT) for Thrombectomy in Distal Cerebral Artery Occlusions Causing Acute Ischemic Stroke.
Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke.
Expression of the recombinant plasminogen activator (reteplase) by a non-lytic insect cell expression system.
Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data.
Extending tissue plasminogen activator use to community and rural stroke patients.
Extension of Tissue Plasminogen Activator Treatment Window by Granulocyte-Colony Stimulating Factor in a Thromboembolic Rat Model of Stroke.
Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II.
External Validation of the DRAGON Score in an Elderly Spanish Population: Prediction of Stroke Prognosis after IV Thrombolysis.
External validation of the SEDAN score: The real world practice of a single center.
Facial angioedema and stroke.
Facilitating alteplase delivery for patients with stroke.
Facilitating emergency use of alteplase for stroke.
Facilities available in French hospitals treating acute stroke patients: comparison with 24 other European countries.
Factitious stroke presenting for acute treatment.
Factor seven activating protease (FSAP) predicts response to intravenous thrombolysis in acute ischemic stroke.
Factor VIII related antigen, antithrombin III, spontaneous platelet aggregation and plasminogen activator in ischemic cerebrovascular disease: a study of stroke before 55.
Factors affecting the apparent efficacy and safety of tissue plasminogen activator in thrombotic occlusion models of stroke: systematic review and meta-analysis.
Factors Associated with Early Recovery after Intravenous Thrombolytic Therapy in Acute Ischemic Stroke.
Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002.
Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials.
Factors associated with successful revascularization using the aspiration component of ADAPT in the treatment of acute ischemic stroke.
Factors associated with the presence of cerebral microbleeds and its influence on outcomes of stroke not treated with alteplase.
Factors Associated with Thrombolysis Outcome in Ischemic Stroke Patients with Atrial Fibrillation.
Factors associated with timing of early neurological improvement after thrombolysis for ischaemic stroke.
Factors delaying intravenous thrombolytic therapy in acute ischaemic stroke: a systematic review of the literature.
Factors Influencing Acute Stroke Thrombolytic Treatments in Hispanics In the San Diego Region.
Factors predicting hemorrhagic complications after multimodal reperfusion therapy for acute ischemic stroke.
Factors Predicting Outcome in Stroke Patients Treated With 0.6 mg/kg Alteplase: Evidence From the Japan Alteplase Clinical Trial (J-ACT).
Factors predicting the outcome of intravenous thrombolysis in stroke patients before rt-PA administration.
Factors preventing African Americans from seeking early intervention in the treatment of ischemic strokes.
Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke.
Factors that influence clinicians' decisions to offer intravenous alteplase in acute ischemic stroke patients with uncertain treatment indication: Results of a discrete choice experiment.
Factors that Influence Door-to-Needle Administration for Acute Stroke Patients in the Emergency Department.
Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran.
Fatal Intraperitoneal Bleeding after Intravenous Administration of Tissue Plasminogen Activator.
Fatal ischaemic brain oedema after early thrombolysis with tissue plasminogen activator in acute stroke.
Favorable Outcome From A Locked-In State Despite Extensive Pontine Infarction By MRI.
Feasibility and Efficacy of Nurse-Driven Acute Stroke Care.
Feasibility and efficacy of thrombolysis in acute ischemic stroke: A study from National Institute of Neurological and Allied Sciences, Kathmandu, Nepal.
Feasibility of prehospital r-TPA therapy in chest pain patients.
Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy.
Fibrin D-Dimer, Tissue-Type Plasminogen Activator, Von Willebrand Factor, and Risk of Incident Stroke in Older Men.
Fibrin-modifying serine proteases thrombin, tPA, and plasmin in ischemic stroke: a review.
Fibrinogen concentrations predict long-term cognitive outcome in young ischemic stroke patients.
Fibrinolysis induced clinical improvement in a patient with multiple sclerosis exacerbation.
Fibrinolysis with alteplase in a pregnant woman with stroke.
Fibrinolytic gene polymorphism and ischemic stroke.
Fibrinolytic measurements in type 2 diabetic patients with acute cerebral infarction.
Fibrinolytic PLGA nanoparticles for slow clot lysis within abdominal aortic aneurysms attenuate proteolytic loss of vascular elastic matrix.
Fibrinolytic treatment for acute ischaemic stroke.
Field triage for endovascular stroke therapy: a population-based comparison.
Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial.
Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
First case of ischemic stroke which happened during continuous intravenous infusion of rt-PA.
First Food and Drug Administration-Approved Prospective Trial of Primary Intracranial Stenting for Acute Stroke. SARIS (Stent-Assisted Recanalization in Acute Ischemic Stroke).
Fisetin Prolongs Therapy Window of Brain Ischemic Stroke Using Tissue Plasminogen Activator: A Double-Blind Randomized Placebo-Controlled Clinical Trial.
Fixed Dose IV rt-PA and Clinical Outcome in Ischemic Stroke Patients With Body Weight >100 kg: Pooled Data From 3 Randomized Clinical Trials.
FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
Fluctuation of diffusion-weighted imaging and apparent diffusion coefficient in acute stroke following tissue plasminogen activator administration.
Fluoxetine and recovery of motor function after focal ischemia in rats.
Fn-EDA (Fibronectin Containing Extra Domain A) in the Plasma, but Not Endothelial Cells, Exacerbates Stroke Outcome by Promoting Thrombo-Inflammation.
Focal cerebral ischemia and neurovascular protection: a bench-to-bedside update.
Focal embolic cerebral ischemia in the rat.
For how long is brain tissue salvageable? Thrombolysis-based evidence.
Forearm compartment syndrome following intravenous thrombolytic therapy for acute ischemic stroke.
Former antiplatelet drug administration and consequences of intravenous thrombolysis in acute ischemic stroke.
Four evolving strategies in the emergent treatment of acute ischemic stroke.
Frequency of Blood-Brain Barrier Disruption Post-Endovascular Therapy and Multiple Thrombectomy Passes in Acute Ischemic Stroke Patients.
Frequency of Hemorrhage on Follow Up Imaging in Stroke Patients Treated With rt-PA Depending on Clinical Course.
Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: the German Stroke Registers Study Group.
Frequency, determinants, and effects of early seizures after thrombolysis for acute ischemic stroke: The ENCHANTED trial.
Frequency, Risk Factors, and Clinical Significance of Incorrect Dose of Alteplase Due to Weight Estimation in Acute Ischemic Stroke Patients: A Single-Center Retrospective Study.
Full-Dose Thrombolysis for a Right Middle Cerebral Artery Stroke after an Acute Aortic Dissection.
Functional neuroimaging in acute stroke.
Functional Occurrence of the Interaction of Tissue Plasminogen Activator With the NR1 Subunit of N-Methyl-D-Aspartate Receptors During Stroke.
Functional outcome after thrombolytic therapy.
Functional Outcome Following Stroke Thrombectomy in Clinical Practice.
Functional Outcome Measures of Recombinant Tissue Plasminogen Activator-Treated Stroke Patients in the Telestroke Technology.
Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial.
Functional recovery after embolic stroke in rodents by activated protein C.
Functional Recovery at 3 Months in Stroke Patients Not Receiving Thrombolytic Therapy: The Comparison Between Patients Arriving Earlier and Later Than 4.5 Hours.
Further evolution toward effective therapy for acute ischemic stroke.
Future demographic trends decrease the proportion of ischemic stroke patients receiving thrombolytic therapy: a call to set-up therapeutic studies in the very old.
Future directions of acute ischaemic stroke therapy.
Future neurohospitalist: teleneurohospitalist.
Future trends.
G-CSF, rt-PA and combination therapy after experimental thromboembolic stroke.
Gastrointestinal Angioedema as a Side Effect of Alteplase for Acute Stroke.
Gender differences in acute ischemic stroke: etiology, stroke patterns and response to thrombolysis.
Gender Differences in Exclusion Criteria for Recombinant Tissue-Type Plasminogen Activator.
Gender differences in stroke examined in a 10-year cohort of patients admitted to a Canadian teaching hospital.
Gender-Linked Stem Cell Alterations in Stroke and Postpartum Depression.
Gene-drug interaction in stroke.
General Anesthesia During Endovascular Stroke Therapy Does Not Negatively Impact Outcome.
Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial.
Generation and characterization of tissue-type plasminogen activator transgenic rats.
Genetic signatures in the treatment of stroke.
Genetics of coagulation factors in acute lung injury.
Genetics of stroke: a review of recent advances.
Geographic differences in acute stroke care in catalunya: impact of a regional interhospital network.
Ginsenoside Represses Symptomatic Intracerebral Hemorrhage after Recombinant Tissue Plasminogen Activator Therapy by Promoting Transforming Growth Factor-?1.
GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.
GLU298ASP and 4G/5G Polymorphisms and the Risk of Ischemic Stroke in Young Individuals.
Googling Boundaries for Operating Mobile Stroke Unit for Stroke Codes.
Gorlin-Goltz syndrome and stroke: a case report.
Graduating neurology residents' experience with IV tPA for acute stroke.
Graduating US Neurology Residents' Experience With Tissue-Type Plasminogen Activator for Acute Stroke: A 10-Year Comparison.
Granulocyte colony-stimulating factor attenuates delayed tPA-induced hemorrhagic transformation in ischemic stroke rats by enhancing angiogenesis and vasculogenesis.
Greater Cincinnati/Northern Kentucky Stroke Study: volume of first-ever ischemic stroke among blacks in a population-based study.
Groin complications in endovascular mechanical thrombectomy for acute ischemic stroke: a 10-year single center experience.
GRP per capita and hospital characteristics associated with intravenous tissue plasminogen activator adherence rate: evidence from the Chinese Stroke Center Alliance.
Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
Guidelines for the intravenous application of recombinant tissue-type plasminogen activator (alteplase), the second edition, October 2012: a guideline from the Japan Stroke Society.
Haemostatic biomarkers are associated with long-term recurrent vascular events after ischaemic stroke.
Haemostatic variables in Pacific Islanders apparently free from stroke and ischaemic heart disease--the Kitava Study.
Half-dose recombinant tissue plasminogen activator plus abciximab for stroke.
HandiStroke: a handheld tool for the emergent evaluation of acute stroke patients.
Heart Failure in Ischemic Stroke: Relevance for Acute Care and Outcome.
Helicopter Scene Response for Stroke Patients: A 5-Year Experience.
Helicopter transfer offers a potential benefit to patients with acute stroke.
Hematoma expansion in experimental intracerebral hemorrhage is not altered by peracute treatment with recombinant tissue plasminogen activator.
Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke.
Hemifacial angioedema following alteplase for acute stroke.
Hemopericardium and cardiac tamponade after thrombolysis for acute ischemic stroke.
Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm.
Hemorrhage in the interventional management of stroke study.
Hemorrhagic transformation after fibrinolysis with tissue plasminogen activator: evaluation of role of hypertension with rat thromboembolic stroke model.
Hemorrhagic transformation after fibrinolytic therapy with tissue plasminogen activator in a rat thromboembolic model of stroke.
Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment in Acute Ischemic Stroke.
Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group.
Hemorrhagic transformation in focal cerebral ischemia: influence of time to artery reopening and tissue plasminogen activator.
Hemorrhagic transformation induced by acute hyperglycemia in a rat model of transient focal ischemia.
Hemorrhagic transformation is related to the duration of occlusion and treatment with tissue plasminogen activator in a nonembolic stroke model.
Hemorrhagic transformation of ischemic stroke: prediction with CT perfusion.
Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort.
Hemorrhagic upper extremity complications from tissue plasminogen activator.
Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke.
Hemostatic disturbances in acute ischemic stroke: a study of 86 patients.
Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study.
Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA.
High glucose induces plasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-kappaB activation in bovine aortic endothelial cells.
High Plasma D-Dimer Indicates Unfavorable Outcome of Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis.
High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuously monitored with 2-MHz transcranial doppler monitoring.
High-Density Lipoprotein Carries Markers that Track with Recovery from Stroke.
High-density Lipoprotein-based Therapy Reduces the Hemorrhagic Complications Associated With Tissue Plasminogen Activator Treatment in Experimental Stroke.
High-permeability region size on perfusion CT predicts hemorrhagic transformation after intravenous thrombolysis in stroke.
HIV is associated with endothelial activation despite ART, in a sub-Saharan African setting.
Hospital Arrival Time and Intravenous t-PA Use in US Academic Medical Centers, 2001-2004.
Hospital mortality from atrial fibrillation associated with ischemic stroke: a national data report.
Hospital Prenotification of Stroke Patients by Emergency Medical Services Improves Stroke Time Targets.
Hospital presentation after stroke in a community sample: the Mobile Stroke Project.
Hospital resources for urokinase/recombinant tissue-type plasminogen activator therapy for acute stroke in Beijing.
Hospital surveillance of acute stroke treatment in Michigan.
Hospitalization costs of primary stenting versus thrombolysis in acute myocardial infarction: cost analysis of the Canadian STAT Study.
Hot topics in risk management in neurologic practice.
Hourly blood pressure monitoring after intravenous tissue plasminogen activator for ischemic stroke: does everyone need it?
How baseline severity affects efficacy and safety outcomes in acute ischemic stroke intervention trials.
How can we improve stroke thrombolysis rates? A review of health system factors and approaches associated with thrombolysis administration rates in acute stroke care.
How Do Physicians Approach Intravenous Alteplase Treatment in Patients with Acute Ischemic Stroke Who Are Eligible for Intravenous Alteplase and Endovascular Therapy? Insights from UNMASK-EVT.
How important is surrogate consent for stroke research?
How to manage thrombolysis interruptions in acute stroke?
Human neural stem cells improve early stage stroke outcome in delayed tissue plasminogen activator-treated aged stroke brains.
Human recombinant tissue-plasminogen activator (alteplase): why not use the 'human' dose for stroke studies in rats?
Human Umbilical Cord Blood Cell Grafts for Stroke.
Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke.
Hyper-acute stroke patients associated with aortic dissection.
Hyperacute management of ischemic stroke.
Hyperacute stroke therapy with tissue plasminogen activator.
Hyperbaric oxygen-induced attenuation of hemorrhagic transformation after experimental focal transient cerebral ischemia.
Hypercoagulable states and strokes.
Hyperdense artery sign, symptomatic infarct swelling and effect of alteplase in acute ischaemic stroke.
Hyperdense middle cerebral artery sign and outcome after intravenous thrombolysis for acute ischemic stroke.
Hyperglycemia during ischemia rapidly accelerates brain damage in stroke patients treated with tPA.
Hyperglycemia promotes tissue plasminogen activator-induced hemorrhage by Increasing superoxide production.
Hyperglycemia Worsens Outcome After rt-PA Primarily in the Large-Vessel Occlusive Stroke Subtype.
Hyperglycemia, Acute Ischemic Stroke, and Thrombolytic Therapy.
Hypertension and its treatment in the NINDS rt-PA Stroke Trial.
Hypofibrinolytic and atherogenic risk factors for stroke.
Hypointense transcerebral veins at T2*-weighted MRI: a marker of hemorrhagic transformation risk in patients treated with intravenous tissue plasminogen activator.
Hypothermia and Ischemic Stroke.
Identification of nonischemic stroke mimics among 411 code strokes at the University of California, San Diego, Stroke Center.
Identification of novel blood biomarker panels to detect ischemic stroke in patients and their responsiveness to therapeutic intervention.
Identification of Reversible Disruption of the Human Blood-Brain Barrier Following Acute Ischemia.
Identifying errors and safety considerations in patients undergoing thrombolysis for acute ischemic stroke.
Image-Guided Intravenous Alteplase for Stroke - Shattering a Time Window.
Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data.
Imaging in neurointerventional stroke treatment: review of the recent trials and what your neurointerventionalist wants to know from emergency radiologists.
Imaging of the brain in acute ischaemic stroke: comparison of computed tomography and magnetic resonance diffusion-weighted imaging.
Imaging selection for reperfusion therapy in acute ischemic stroke.
Imaging strategy for acute stroke therapy.
Immediate changes in stroke lesion volumes post thrombolysis predict clinical outcome.
Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke.
Immune responses in stroke: how the immune system contributes to damage and healing after stroke and how this knowledge could be translated to better cures?
Immuno-inflammatory and thrombotic/fibrinolytic variables associated with acute ischemic stroke diagnosis.
Immunoinflammatory activation during the acute phase of lacunar and non-lacunar ischemic stroke: association with time of onset and diabetic state.
Impact of a Stay-at-Home Order on Stroke Admission, Subtype, and Metrics during the COVID-19 Pandemic.
Impact of admission hyperglycemia on stroke outcome after thrombolysis: risk stratification in relation to time to reperfusion.
Impact of alcohol consumption on the outcome of ischemic stroke and thrombolysis: role of the hepatic clearance of tissue-type plasminogen activator.
Impact of Bradykinin Generation During Thrombolysis in Ischemic Stroke.
Impact of Computed Tomography Perfusion Imaging on the Response to Tenecteplase in Ischemic Stroke: Analysis of 2 Randomized Controlled Trials.
Impact of COX-2 rs5275 and rs20417 and GPIIIa rs5918 Polymorphisms on 90-Day Ischemic Stroke Functional Outcome: A Novel Finding.
Impact of Early Blood Pressure Variability on Stroke Outcomes After Thrombolysis: The SAMURAI rt-PA Registry.
Impact of establishing a primary stroke center at a community hospital on the use of thrombolytic therapy: the NINDS Suburban Hospital Stroke Center experience.
Impact of estimated-weight-base dose of alteplase in acute stroke treatment on clinical outcome.
Impact of Initial Imaging Protocol on Likelihood of Endovascular Stroke Therapy.
Impact of intravenous alteplase on sub-angiographic emboli in high-resolution diffusion-weighted imaging following successful thrombectomy.
Impact of Mechanical Thrombectomy on the Organization of the Management of Acute Ischemic Stroke.
Impact of Participation in a Telestroke Network on Clinical Outcomes.
Impact of Prehospital Intervention on Delay Time to Thrombolytic Therapy in a Stroke Center with a Systemized Stroke Code Program.
Impact of Primary Stroke Center Certification on Location of Acute Ischemic Stroke Care in Georgia.
Impact of Protocol Deviations in Acute Ischemic Stroke Treated With Intravenous rt-PA Within 4.5 Hours After Symptom Onset.
Impact of stroke center certification on rt-PA thrombolysis after acute ischemic stroke in South China from 2015 to 2020.
Impact of Stroke Center Certification on Thrombolysis Time Metrics in Telestroke Setting.
Impact of the approval of intravenous recombinant tissue plasminogen activator therapy on the processes of acute stroke management in Japan: the Stroke Unit Multicenter Observational (SUMO) Study.
Impact of the Extended Thrombolysis Time Window on the Proportion of Recombinant Tissue-Type Plasminogen Activator-Treated Stroke Patients and on Door-to-Needle Time.
Impact of the neutrophil response to granulocyte colony-stimulating factor on the risk of hemorrhage when used in combination with tissue plasminogen activator during the acute phase of experimental stroke.
Impact of Thrombus Length on Outcomes After Intra-Arterial Aspiration Thrombectomy in the THERAPY Trial.
Impact of Tissue Plasminogen Activator Dosing on Patients Weighing More Than 100?kg on 3-Month Outcomes in Acute Ischemic Stroke.
Impact of transfer status on hospitalization cost and discharge disposition for acute ischemic stroke across the US.
Impacts of tissue-type plasminogen activator (tPA) on neuronal survival.
Impairments of the protein C system and fibrinolysis in infection-associated stroke.
Implementation and outcome of thrombolysis with alteplase 3 to 4.5 h after acute stroke in Chinese patients.
Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR.
Implementation Challenges of Regionalized Acute Stroke Care.
Implementation of a patient selection protocol for intra-arterial therapy increases treatment rates in patients with acute ischemic stroke.
Implementation of a provincial acute stroke pathway and its impact on access to advanced stroke care in Saskatchewan.
Implementation of a stroke alert protocol in the emergency department: a pilot study.
Implementation of a stroke code system in Mobile, Alabama. Diagnostic and therapeutic yield.
Implementation of a telestroke system for general physicians without a nearby stroke center to shorten the time to intravenous thrombolysis for acute cerebral infarction.
Implementation of an institution-wide acute stroke algorithm: Improving stroke quality metrics.
Implementation of Computerized Physician Order Entry Is Associated With Increased Thrombolytic Administration for Emergency Department Patients With Acute Ischemic Stroke.
Implementing a mobile stroke unit program in the United States: why, how, and how much?
Implementing the SNIS recommendations for neurointerventional emergent care in the setting of COVID-19: impact on stroke metrics and patient outcomes.
Implications of immune system in stroke for novel therapeutic approaches.
Implications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic Stroke.
Importance of leukoaraiosis on CT for tissue plasminogen activator decision making: evaluation of the NINDS rt-PA Stroke Study.
Improved clinical outcome 3?months after endovascular treatment, including thrombectomy, in patients with acute ischemic stroke: a meta-analysis.
Improved model of thromboembolic stroke and rt-PA induced reperfusion in the rat.
Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group.
Improvement on detectability of early ischemic changes for acute stroke using nonenhanced computed tomography: Effect of matrix size.
Improving access to acute stroke therapies: a controlled trial of organised pre-hospital and emergency care.
Improving Door to Needle time in Patients for Thrombolysis.
Improving Door-to-Needle Times for Acute Ischemic Stroke: Effect of Rapid Patient Registration, Moving Directly to Computed Tomography, and Giving Alteplase at the Computed Tomography Scanner.
Improving door-to-needle times: a single center validation of the target stroke hypothesis.
Improving reperfusion therapy for acute ischaemic stroke.
Improving Telestroke Treatment Times in an Expanding Network of Hospitals.
Improving the predictive accuracy of recanalization on stroke outcome in patients treated with tissue plasminogen activator.
Improving the translation of animal ischemic stroke studies to humans.
Improving timely treatment with a stroke emergency map: The case of northern China.
In a stroke cohort with incident hypertension; are more women than men likely to be excluded from recombinant tissue-type Plasminogen Activator (rtPA)?
In acute ischemic stroke, are asymptomatic intracranial hemorrhages clinically innocuous?
In imaging-selected ischemic stroke with unknown onset, alteplase increases favorable outcomes and death at 90 d.
In ischemic stroke, thrombectomy alone was noninferior to thrombectomy plus alteplase for functional outcome at 90 days.
In silico and in vivo analyses of the mutated human tissue plasminogen activator (mtPA) and the antithetical effects of P19 silencing suppressor on its expression in two Nicotiana species.
In vitro evaluation of guanidine analogs as sigma receptor ligands for potential anti-stroke therapeutics.
In vitro microscopic imaging of enhanced thrombolysis with 120-kHz ultrasound in a human clot model.
In-hospital delays to stroke thrombolysis: paradoxical effect of early arrival.
In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group.
In-hospital outcomes with thrombolytic therapy in patients with renal dysfunction presenting with acute ischaemic stroke.
In-hospital stroke treated with intravenous tissue plasminogen activator.
In-Transit Telemedicine Speeds Ischemic Stroke Treatment: Preliminary Results.
Incidence and Association of Reperfusion Therapies With Poststroke Seizures: A Systematic Review and Meta-Analysis.
Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected]
Incidence of orolingual angioedema after intravenous thrombolysis for stroke.
Incidence of seizure in stroke patients treated with recombinant tissue plasminogen activator: A systematic review and meta-analysis.
Incidence of space-occupying brain edema following systemic thrombolysis of acute supratentorial ischemia.
Incidental Thrombotic Thrombocytopenic Purpura during Acute Ischemic Stroke and Thrombolytic Treatment.
Including Distal Motor Function within the NIHSS: Correlation with Motor Arm Function and IV rt-PA Treatment Response.
Increase in neutrophils after recombinant tissue plasminogen activator thrombolysis predicts poor functional outcome of ischaemic stroke: a longitudinal study.
Increased Access to and Use of Endovascular Therapy Following Implementation of a 2-Tiered Regional Stroke System.
Increased benefit of alteplase in patients with ischemic stroke and a high body temperature.
Increased blood pressure variability after endovascular thrombectomy for acute stroke is associated with worse clinical outcome.
Increased expression of recombinant human tissue plasminogen activator in Leishmania tarentolae.
Increased levels of tissue plasminogen activator antigen and factor VIII activity in nonvalvular atrial fibrillation: relation to predictors of thromboembolism.
Increased Plasma Matrix Metalloproteinase-9 Levels Contribute to Intracerebral Hemorrhage during Thrombolysis after Concomitant Stroke and Influenza Infection.
Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat.
Increased tissue plasminogen activator levels in patients with nonvalvular atrial fibrillation.
Increasing number of stroke specialists should contribute to utilization of IV rt-PA: results of questionnaires from 1,466 hospitals in Japan.
Increasing tPA activity in astrocytes induced by multipotent mesenchymal stromal cells facilitate neurite outgrowth after stroke in the mouse.
Increasing use of intravenous rt-PA does not affect safety in acute stroke.
Individualized quantification of the benefit from reperfusion therapy using stroke predictive models.
Induced Pluripotent Stem Cells for Ischemic Stroke Treatment.
Induction of plasminogen in rat hippocampal pyramidal neurons by kainic acid.
Infarct Core Expansion on Computed Tomography before and after Intravenous Thrombolysis.
Infections causing stroke or stroke-like syndromes.
Infiltration of tissue plasminogen activator through cerebral vessels: evaluation using a rat thromboembolic stroke model.
Inflammation and hemostasis biomarkers for predicting stroke in postmenopausal women: the Women's Health Initiative Observational Study.
Inflammation following stroke.
Inflammatory and metalloproteinases profiles predict three-month poor outcomes in ischemic stroke treated with thrombolysis.
Inflammatory cytokines in acute ischemic stroke.
Influence of acute myocardial infarction location on in-hospital and late outcome after primary percutaneous transluminal coronary angioplasty versus tissue plasminogen activator therapy.
Influence of intravenous alteplase on endovascular treatment decision-making in acute ischemic stroke due to primary medium-vessel occlusion: a case-based survey study.
Influence of neurologists' experience on the outcome of patients treated by intravenous thrombolysis for cerebral ischaemia.
Influence of on-going treatment with angiotensin-converting enzyme inhibitor or angiotensin receptor blocker on the outcome of patients treated with intravenous rt-PA for ischemic stroke.
Influence of pretreatment MRI parameters on clinical outcome, recanalization and infarct size in 49 stroke patients treated by intravenous tissue plasminogen activator.
Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke: ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) Post Hoc Analysis.
Influence of the site of arterial occlusion on multiple baseline hemodynamic MRI parameters and post-thrombolytic recanalization in acute stroke.
Influence of the stroke code activation source on the outcome of acute ischemic stroke patients.
Influence of Thrombolysis on the Safety and Efficacy of Blocking Platelet Adhesion or Secretory Activity in Acute Ischemic Stroke in Mice.
Influence of tissue plasminogen activator and heparin on cerebral ischemia in a rabbit model.
Informed Consent for Intravenous Tissue Plasminogen Activator in New York State Designated Stroke Centers.
Informed consent for thrombolytic therapy for patients with acute ischemic stroke treated in routine clinical practice.
Inherited prothrombotic risk factors in children with first ischemic stroke.
Inhibiting 12/15-lipoxygenase to treat acute stroke in permanent and tPA induced thrombolysis models.
Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke.
Inhibition of HIF-1? Reduced Blood Brain Barrier Damage by Regulating MMP-2 and VEGF During Acute Cerebral Ischemia.
Inhibition of hypoxia inducible factor 1 by YC-1 attenuates tissue plasminogen activator induced hemorrhagic transformation by suppressing HMGB1/TLR4/NF-?B mediated neutrophil infiltration in thromboembolic stroke rats.
Inhibition of PI3K? by AS605240 plus low-dose tissue plasminogen activator (tPA) combination improves thrombolytic therapy in a rat model of embolic stroke.
Inhibition of tPA-induced hemorrhagic transformation involves adenosine A2b receptor activation after cerebral ischemia.
Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group.
Initial Emergency Room Triage of Acute Ischemic Stroke.
Initial experience with the CatchView thrombectomy device for acute ischemic stroke.
Initial hospital management of patients with emergent large vessel occlusion (ELVO): report of the standards and guidelines committee of the Society of NeuroInterventional Surgery.
Initial Stroke Severity Is the Major Outcome Predictor for Patients Who Do Not Receive Intravenous Thrombolysis due to Mild or Rapidly Improving Symptoms.
Innovations in Care Delivery of Stroke from Emergency Medical Services to the Neurointerventional Operating Room.
Innovative strategies in the management of acute stroke.
Innovative Strategies in the Management of Acute Stroke.
Institutional care paths: Development, implementation, and evaluation.
Institutional Incidence of Severe tPA-Induced Angioedema in Ischemic Cerebral Vascular Accidents.
Insulin resistance and elevated levels of tissue plasminogen activator in first-degree relatives of South Asian patients with ischemic cerebrovascular disease.
Integrated systems may have economic incentive for using alteplase in stroke patients.
Interaction of Blood Pressure Lowering and Alteplase Dose in Acute Ischemic Stroke: Results of the Enhanced Control of Hypertension and Thrombolysis Stroke Study.
Interactions between nitrous oxide and tissue plasminogen activator in a rat model of thromboembolic stroke.
Interdisciplinary rehabilitation outcomes following thrombolysis for acute ischaemic stroke: A case series.
Interhospital transfer on intravenous thrombolysis in patients with acute ischemic stroke in three chinese municipal stroke centers.
Interleukin 1 alpha administration is neuroprotective and neuro-restorative following experimental ischemic stroke.
Intra-arterial delivery of mesenchymal stem cells.
Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.
Intra-Arterial Therapy and Post-Treatment Infarct Volumes: Insights From the ESCAPE Randomized Controlled Trial.
Intra-Arterial Thrombolysis after Full-Dose Intravenous tPA via the "Drip and Ship" Approach in Patients with Acute Ischemic Stroke: Preliminary Report.
Intra-arterial thrombolysis using rt-PA in patients with acute stroke due to vessel occlusion of anterior and/or posterior cerebral circulation.
Intra-arterial versus intravenous tissue-type plasminogen activator treatment in experimental stroke.
Intra-hospital delays in stroke patients treated with rt-PA: impact of preadmission notification.
Intraarterial thrombolytic therapy within 3 hours of the onset of stroke.
Intracarotid regional infusion of recombinant tissue plasminogen activator for acute hemispheric stroke.
Intracerebral hemorrhage after IV tPA for stroke as early symptom of ANCA-associated vasculitis.
Intracerebral transplantation of bone marrow stromal cells ameliorates tissue plasminogen activator-induced brain damage after cerebral ischemia in mice detected by in vivo and ex vivo optical imaging.
Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project.
Intracranial Hemorrhage Following Thrombolytic Use for Stroke Caused by Infective Endocarditis.
Intranasal wnt3a Attenuates Neuronal Apoptosis through Frz1/PIWIL1a/FOXM1 Pathway in MCAO Rats.
Intraosseous Administration of Tissue Plasminogen Activator on a Mobile Stroke Unit.
Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.
Intravenous Alteplase at 0.6 mg/kg for Acute Stroke Patients with Basilar Artery Occlusion: The Stroke Acute Management with Urgent Risk Factor Assessment and Improvement (SAMURAI) Recombinant Tissue Plasminogen Activator Registry.
Intravenous Alteplase for Acute Ischemic Stroke in Taiwan: Can We Expand the National Health Insurance's Reimbursement Criteria?
Intravenous Alteplase for Acute Stroke and Pulmonary Embolism in a Patient With Recent Abdominoplasty.
Intravenous alteplase for Chinese patients with stroke and borderline eligibility.
Intravenous alteplase for stroke in those older than 80 years old.
Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data.
Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations.
Intravenous Alteplase is Associated with First Pass Effect in Stent-retriever but not ADAPT Thrombectomy : Post Hoc Analysis of the SKIP Study.
Intravenous and Arterial Treatments for Acute Ischemic Stroke: Indications and the Role of Imaging.
Intravenous and local intraarterial tissue-plasminogen activator in a rabbit model of acute thromboembolic stroke: angiographic comparison.
Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study.
Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction.
Intravenous recombinant tissue plasminogen activator for acute ischemic stroke: a feasibility and safety study.
Intravenous recombinant tissue plasminogen activator for acute stroke in Poland: an analysis based on the Safe Implementation of Thrombolysis in Stroke (SITS) Registry.
Intravenous recombinant tissue plasminogen activator improves arterial recanalization rates and reduces infarct volumes in patients with hyperdense artery sign on baseline computed tomography.
Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke.
Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience.
Intravenous Recombinant Tissue Plasminogen Activator Therapy for Stroke Patients Receiving Maintenance Hemodialysis: The Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement (SAMURAI) rt-PA Registry.
Intravenous rt-PA for acute stroke: comparing its effectiveness in younger and older patients.
Intravenous rt-PA for stroke.
Intravenous rt-PA: a tenth anniversary reflection.
Intravenous rtPA thrombolysis in acute ischemic stroke.
Intravenous rtPA versus mechanical thrombectomy in acute ischemic stroke: A historical cohort in Joinville, Brazil.
Intravenous t-PA for acute ischemic stroke: therapeutic yield of a stroke code system.
Intravenous Thrombolysis Administration 3-4.5 h After Acute Ischemic Stroke: A Retrospective, Multicenter Study.
Intravenous Thrombolysis and Mechanical Thrombectomy in Patients with Stroke after TAVI: A Report of Two Cases.
Intravenous Thrombolysis and Risk Factors for Ischemic Stroke.
Intravenous Thrombolysis at 3.5 Hours From Onset of Pediatric Acute Ischemic Stroke.
Intravenous Thrombolysis Attenuates Neurologic Deterioration After Ischemic Stroke.
Intravenous Thrombolysis Benefits Mild Stroke Patients With Large-Artery Atherosclerosis but No Tandem Steno-Occlusion.
Intravenous thrombolysis for acute cerebral ischaemia in old stroke patients ?80 years of age.
Intravenous thrombolysis for acute cerebral ischaemia: comparison of outcomes between patients treated at working versus nonworking hours.
Intravenous thrombolysis for acute ischaemic stroke in a hospital without a specialised neuro-intensive care unit.
Intravenous thrombolysis for acute ischaemic stroke in patients not fully adhering to the European licence in Poland.
Intravenous thrombolysis for acute ischaemic stroke in young adult patients.
Intravenous thrombolysis for acute ischemic stroke in centenarians.
Intravenous Thrombolysis for Acute Ischemic Stroke in Patients with Cervicocephalic Dolichoarteriopathy.
Intravenous Thrombolysis for Acute Ischemic Stroke Within 3 Hours Versus Between 3 and 4.5 Hours of Symptom Onset.
Intravenous thrombolysis for acute ischemic stroke--our experiences.
Intravenous thrombolysis for acute ischemic stroke: a bridge between two centuries.
Intravenous Thrombolysis for Acute Ischemic Stroke: Review of 97 Patients.
Intravenous thrombolysis for acute ischemic stroke: the Malabar experience 2003 to 2008.
Intravenous thrombolysis for acute ischemic stroke: the phase IV data.
Intravenous Thrombolysis for Stroke and Presumed Stroke in Human Immunodeficiency Virus-Infected Adults: A Retrospective, Multicenter US Study.
Intravenous thrombolysis for stroke in pregnancy should be administered if the benefit outweighs the risk: A case report and recommended diagnostic workup.
Intravenous thrombolysis for stroke increases over time at primary stroke centers.
Intravenous Thrombolysis for Stroke Patients with G6PD Deficiency.
Intravenous Thrombolysis for Stroke Recurring Within 3 Months From the Previous Event.
Intravenous thrombolysis guided by a telemedicine consultation system for acute ischaemic stroke patients in China: the protocol of a multicentre historically controlled study.
Intravenous Thrombolysis Guided by Perfusion CT with Alteplase in >4.5 Hours from Stroke Onset.
Intravenous thrombolysis in acute ischaemic stroke: optimising its use in routine clinical practice.
Intravenous Thrombolysis in Acute Ischemic Stroke After Idarucizumab Reversal of Dabigatran Effect: Analysis of the Cases From Taiwan.
Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer.
Intravenous Thrombolysis in Chinese Patients with Different Subtype of Mild Stroke: Thrombolysis in Patients with Mild Stroke.
Intravenous thrombolysis in Chinese patients with mild acute ischemic stroke.
Intravenous Thrombolysis in Expanded Time Window (3-4.5 hours) in General Practice with Concurrent Availability of Endovascular Treatment.
Intravenous Thrombolysis in German Stroke Units before and after Regulatory Approval of Recombinant Tissue Plasminogen Activator.
Intravenous thrombolysis in proximal middle cerebral artery occlusion.
Intravenous thrombolysis in stroke patients of > or = 80 versus < 80 years of age--a systematic review across cohort studies.
Intravenous thrombolysis in stroke patients taking novel oral anticoagulants: experience with the low-dose 0.6?mg/kg of recombinant tissue-type plasminogen activator. Case reports.
Intravenous thrombolysis in the emergency department for the treatment of acute ischaemic stroke.
Intravenous Thrombolysis in Unknown-Onset Stroke: Results From the Safe Implementation of Treatment in Stroke-International Stroke Thrombolysis Registry.
Intravenous thrombolysis in wake-up stroke: real-world data from the Austrian Stroke Unit Registry.
Intravenous thrombolysis is more safe and effective for posterior circulation stroke: Data from the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China).
Intravenous Thrombolysis Is Safe and Effective for the Cryptogenic Stroke in China: Data From the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China).
Intravenous Thrombolysis May Not Improve Clinical Outcome of Acute Ischemic Stroke Patients Without a Baseline Vessel Occlusion.
Intravenous thrombolysis of occlusion in the middle cerebral and retinal arteries from presumed ventricular myxoma.
Intravenous thrombolysis on early recurrent cardioembolic stroke: 'Dr Jekyll' or 'Mr Hyde'?
Intravenous Thrombolysis with Neuroprotective Therapy by Edaravone for Ischemic Stroke Patients Older than 80 Years of Age.
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)
Intravenous thrombolysis with recombinant tissue plasminogen activator for ischemic stroke patients over 80 years old: the Fukuoka Stroke Registry.
Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with apixaban.
Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran.
Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with rivaroxaban.
Intravenous Thrombolysis With Recombinant Tissue-Type Plasminogen Activator in a Stroke Patient Receiving Dabigatran Anticoagulant After Antagonization With Idarucizumab.
Intravenous thrombolysis with rt-PA in acute stroke patients aged >or=80 years.
Intravenous thrombolysis with rt-PA in stroke: experience of the moroccan stroke unit.
Intravenous thrombolysis with tPA and cortical involvement increase the risk of early poststroke seizures: Results of a case-control study.
Intravenous thrombolytic therapy for stroke: a review of recent studies and controversies.
Intravenous thrombolytic therapy in acute stroke.
Intravenous thrombolytic therapy in myocardial infarction: an analytical review.
Intravenous thrombolytic therapy in patients with stroke mimics: baseline characteristics and safety profile.
Intravenous thrombolytic treatment in a patient with transient ischemic attack associated with mural carotid thrombi.
Intravenous tissue plasminogen activator administration in community hospitals facilitated by telestroke service.
Intravenous tissue plasminogen activator and flow improvement in acute ischemic stroke patients with internal carotid artery occlusion.
Intravenous tissue plasminogen activator and stroke in the elderly.
Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older : the tPA stroke survey experience.
Intravenous tissue plasminogen activator for acute ischemic stroke in patients with renal dysfunction.
Intravenous tissue plasminogen activator for acute ischemic stroke: A Canadian hospital's experience.
Intravenous tissue plasminogen activator for acute stroke in California: recipients and resources.
Intravenous tissue plasminogen activator for ischemic stroke in early pregnancy dosed by actual body weight.
Intravenous Tissue Plasminogen Activator for Large Vessel Ischemic Stroke - Is There Still a Role?
Intravenous Tissue Plasminogen Activator for Stroke: A Review of the ECASS III Results in Relation to Prior Clinical Trials.
Intravenous Tissue Plasminogen Activator for Wake-Up Stroke: A Propensity Score-Matched Analysis.
Intravenous Tissue Plasminogen Activator in Patients With Cocaine-Associated Acute Ischemic Stroke.
Intravenous tissue plasminogen activator in patients with stroke increases the bioavailability of insulin-like growth factor-1.
Intravenous Tissue Plasminogen Activator in Stroke Mimics.
Intravenous Tissue Plasminogen Activator Thrombolysis in Patients With Diabetes Mellitus and Previous Stroke.
Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.
Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus.
Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000.
Intravenous tissue-type plasminogen activator therapy is an independent risk factor for symptomatic intracerebral hemorrhage after carotid endarterectomy.
Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke.
Intravenous tPA for Acute Ischemic Stroke in Patients with COVID-19.
Intravenous tPA for acute stroke: Any and all hospitals? Any and all docs?
Intravenous TPA for very old stroke patients.
Intravenous tPA in the treatment of acute stroke related to aortic dissection.
Intravenously administered tissue plasminogen activator useful in milder strokes? A meta-analysis.
Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion.
Inverse relationship of baseline body temperature and outcome between ischemic stroke patients treated and not treated with thrombolysis: the Bergen stroke study.
Investigating the utility of previously developed prediction scores in acute ischemic stroke patients in the stroke belt.
Investigation of association between plasminogen activator inhibitor type-1 (PAI-1) gene 4G/5G polymorphism frequency and plasma PAI-1 enzyme activity in patients with acute stroke.
Investigational anti-inflammatory agents for the treatment of ischaemic brain injury.
Investigational use of tPA in acute stroke.
Iron Overload Exacerbates the Risk of Hemorrhagic Transformation After tPA (Tissue-Type Plasminogen Activator) Administration in Thromboembolic Stroke Mice.
Is bridging therapy still required in stroke due to carotid artery terminus occlusions?
Is concurrent intravenous alteplase in patients undergoing endovascular treatment for large vessel occlusion stroke cost-effective even if the cost of alteplase is only US$1?
Is Functional Outcome Different in Posterior and Anterior Circulation Stroke?
Is higher body temperature beneficial in ischemic stroke patients with normal admission CT angiography of the cerebral arteries?
Is hospitalization after TIA cost-effective on the basis of treatment with tPA?
Is Intraarterial tPA Within 3 Hours the Treatment of Choice for Selected Stroke Patients? No.
Is intravenous recombinant plasminogen activator effective up to 4.5 h after onset of ischemic stroke?
Is Intravenous Tissue Plasminogen Activator Still Relevant for Mechanical Embolectomy Stroke Candidates?
Is IV tissue plasminogen activator beneficial in patients with hyperdense artery sign?
Is rt-PA useful for stroke after 3 hours?
Is smoking associated with favourable outcome in tPA-treated stroke patients?
Is spontaneous normalization of systolic blood pressure within 24 hours after ischemic stroke onset related with favorable outcomes?
Is the drip-and-ship approach to delivering thrombolysis for acute ischemic stroke safe?
Is there a bad time for intravenous thrombolysis? The experience of Polish stroke centers.
Is tissue plasminogen activator a threat to neurons?
Ischaemic stroke and the recanalization drug tissue plasminogen activator interfere with antibacterial phagocyte function.
Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin.
Ischemic and Bleeding Risk After Percutaneous Coronary Intervention in Patients With Prior Ischemic and Hemorrhagic Stroke.
Ischemic core thresholds change with time to reperfusion: A case control study.
Ischemic middle cerebral artery stroke missing the tissue plasminogen activator time window: transcranial Doppler evaluation.
Ischemic stroke and excellent recovery after administration of intravenous tissue plasminogen activator.
Ischemic Stroke Symptoms After Warfarin Reversal With 4-Factor Prothrombin Complex Concentrate Case Report.
Ischemic stroke therapy.
Ischemic Stroke Transfer Patterns in the Northeast United States.
Ischemic stroke. Clinical strategies based on mechanisms and risk factors.
ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials.
Isolated Anisocoria as a Presenting Stroke Code Symptom is Unlikely to Result in Alteplase Administration.
Isolated Sulcal Effacement and Response to Intravenous Thrombolysis in Acute Ischemic Stroke.
IV t-PA influences infarct volume in minor stroke: a pilot study.
IV t-PA therapy in acute stroke patients with atrial fibrillation.
IV thrombolysis in very severe and severe ischemic stroke: Results from the SITS-ISTR Registry.
IV tissue plasminogen activator for stroke in the community: what we know and don't know 10 years after FDA approval.
IV tissue plasminogen activator use in acute stroke: experience from a statewide registry.
IV tissue plasminogen activator use in acute stroke: What are neurologists thinking?
IV tPA for acute ischemic stroke: results of the first 101 patients in a community practice.
IV tPA given in the golden hour for emergent large vessel occlusion stroke improves recanalization rates and clinical outcomes.
IV tPA is associated with increase in rates of intracerebral hemorrhage and length of stay in patients with acute stroke treated with endovascular treatment within 4.5 hours: should we bypass IV tPA in large vessel occlusion?
IV vs. IA TPA in Acute Ischemic Stroke with CT Angiographic Evidence of Major Vessel Occlusion: A Feasibility Study.
Joint Commission Primary Stroke Centers Utilize More rt-PA in the Nationwide Inpatient Sample.
Joint modeling of longitudinal ordinal data and competing risks survival times and analysis of the NINDS rt-PA stroke trial.
Knowledge and Attitudes of Saudi Emergency Physicians toward t-PA Use in Stroke.
Knowledge of Tissue Plasminogen Activator for Acute Stroke Among Michigan Adults.
Laboratory factors associated with symptomatic hemorrhagic conversion of acute stroke after systemic thrombolysis.
Lack of association between hyperglycaemia at arrival and clinical outcomes in acute stroke patients treated with tissue plasminogen activator.
Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.
Lack of improvement in patients with acute stroke after treatment with thrombolytic therapy: predictors and association with outcome.
Landmark papers in cerebrovascular neurosurgery 2015.
Language barriers between physicians and patients are not associated with thrombolysis of stroke mimics.
Lanoteplase.
Large Artery Atherosclerotic Clots are Larger than Clots of other Stroke Etiologies and have Poorer Recanalization rates.
Large ischemic lesions on diffusion-weighted imaging done before intravenous tissue plasminogen activator thrombolysis predicts a poor outcome in patients with acute stroke.
Large numbers of stroke physicians should be used to treat large numbers of stroke patients with IV rt-PA.
Large Vessel Occlusion Identification Through Prehospital Administration of Stroke Scales: A County-wide Emergency Medical Services Prospective Research Protocol.
Large Vessel Occlusion Strokes After the DIRECT-MT and SKIP Trials: Is the Alteplase Syringe Half Empty or Half Full?
Large vessel stroke as initial presentation of thrombotic thrombocytopenic purpura.
Large-Vessel Occlusion Is Associated with Poor Outcome in Stroke Patients Aged 80 Years or Older Who Underwent Intravenous Thrombolysis.
Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction.
Late Night Activity Regarding Stroke Codes: LuNAR strokes.
Late resolution of diffusion-weighted MRI changes in a patient with prolonged reversible ischemic neurological deficit after thrombolytic therapy.
LDL receptor blockade reduces mortality in a mouse model of ischaemic stroke without improving tissue-type plasminogen activator-induced brain haemorrhage: towards pre-clinical simulation of symptomatic ICH.
Left Atrial Thrombus Mimicking Myxoma Secondary to Rebound Hypercoagulable State.
Left ventricular apical thrombus after systemic thrombolysis with recombinant tissue plasminogen activator in a patient with acute ischemic stroke.
Length of stay in rehabilitation is associated with admission neurologic deficit and discharge destination.
Lesion patterns in successful and failed thrombolysis in middle cerebral artery stroke.
Less Experienced Telestroke Consultants Are More Likely to Go On-Camera, but Less Likely to Give tPA.
Lessons learned from 2 years experience in intravenous thrombolysis for acute ischemic stroke in a single tertiary medical center.
Letter by Chao et al regarding article, "standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses".
Letter by Dai et al regarding article, "Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the Third International Stroke Trial".
Letter by Katsanos and Tsivgoulis Regarding Article, "Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment".
Letter by Niu et al Regarding Article, "Outcome After Reperfusion Therapies in Patients With Large Baseline Diffusion-Weighted Imaging Stroke Lesions: A THRACE Trial (Mechanical Thrombectomy After Intravenous Alteplase Versus Alteplase Alone After Stroke) Subgroup Analysis".
Letter by Tan and Xu Regarding Article, "Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment".
Letter by turc et Al regarding article, "defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the national institute of neurological disorders and stroke tissue-type plasminogen activator trials".
Letter by Wu et al Regarding Article, "Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus".
Leukoaraiosis and lacunes are associated with poor clinical outcomes in ischemic stroke patients treated with intravenous thrombolysis.
Leukoaraiosis, Cerebral Hemorrhage, and Outcome After Intravenous Thrombolysis for Acute Ischemic Stroke: A Meta-Analysis (v1).
Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke.
Lingual angioedema after alteplase treatment in a patient with acute ischemic stroke.
Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke.
Lipid-Lowering Pretreatment and Outcome Following Intravenous Thrombolysis for Acute Ischaemic Stroke: A Post Hoc Analysis of the Enhanced Control of Hypertension and Thrombolysis Stroke Study Trial.
Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator.
Litigation regarding tPA and stroke.
Local Cerebral Recombinant Tissue Plasminogen Activator Concentrations During Acute Stroke.
Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA).
Locked in and out: a case of emerging basilar artery obstruction secondary to vertebral artery dissection thrombolysed with intravenous rt-PA.
Logistics in acute stroke management.
Long-lasting neuronal loss following experimental focal cerebral ischemia is not affected by combined administration of tissue plasminogen activator and hyperbaric oxygen.
Long-Term Functional Outcome of Telestroke Patients Treated Under Drip-and-Stay Paradigm Compared with Patients Treated in a Comprehensive Stroke Center: A Single Center Experience.
Long-Term Impact of Implementation of a Stroke Protocol on Door-to-Needle Time in the Administration of Intravenous Tissue Plasminogen Activator.
Long-term outcome after thrombolysis in telemedical stroke care.
Long-term outcome as function of blood pressure in acute ischemic stroke and effects of thrombolysis.
Long-term outcomes of post-thrombolytic intracerebral hemorrhage in ischemic stroke patients.
Longer stent retrievers enhance thrombectomy performance in acute stroke.
Low Alberta Stroke Program Early Computed Tomography Score Within 3 Hours of Onset Predicts Subsequent Symptomatic Intracranial Hemorrhage in Patients Treated with 0.6 mg/kg Alteplase.
Low Body Temperature Does Not Compromise the Treatment Effect of Alteplase.
Low dose tPA plus annexin A2 combination attenuates tPA delayed treatment-associated hemorrhage and improves recovery in rat embolic focal stroke.
Low free triiodothyronine levels predict symptomatic intracranial hemorrhage and worse short-term outcome of thrombolysis in patients with acute ischemia stroke.
Low Levels of Caveolin-1 Predict Symptomatic Bleeding After Thrombolytic Therapy in Patients With Acute Ischemic Stroke.
Low serum BDNF may indicate the development of PSD in patients with acute ischemic stroke.
Low- Versus Standard-Dose Alteplase in Patients on Prior Antiplatelet Therapy: The ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study).
Low- versus Standard-Dose Intravenous Alteplase in the Context of Bridging Therapy for Acute Ischemic Stroke: A Korean ENCHANTED Study.
Low-dose intravenous recombinant tissue-type plasminogen activator therapy for patients with stroke outside European indications: Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) rtPA Registry.
Low-dose rt-PA may not decrease the incidence of symptomatic intracranial haemorrhage in patients with high risk of symptomatic intracranial haemorrhage.
Low-Dose Tissue Plasminogen Activator in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis.
Low-dose versus standard-dose alteplase in acute ischemic stroke in Asian stroke registries: an individual patient data pooling study.
Low-dose versus standard-dose intravenous alteplase for octogenerian acute ischemic stroke patients: A multicenter prospective cohort study.
Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke.
Low-Dose vs Standard-Dose Alteplase for Patients With Acute Ischemic Stroke: Secondary Analysis of the ENCHANTED Randomized Clinical Trial.
Low-Dose vs Standard-Dose Alteplase in Acute Lacunar Ischemic Stroke: The ENCHANTED Trial.
Low-Dose vs. Standard-Dose Intravenous Alteplase in Bridging Therapy Among Patients With Acute Ischemic Stroke: Experience From a Stroke Center in Vietnam.
Low-Versus Standard-Dose Alteplase for Ischemic Strokes Within 4.5 Hours: A Comparative Effectiveness and Safety Study.
Lupus anticoagulant and the fibrinolytic system in young patients with stroke.
M1 susceptibility vessel sign on T2* as a strong predictor for no early recanalization after IV-t-PA in acute ischemic stroke.
Magnetic resonance angiography of thromboembolic stroke in rats: indicator of recanalization probability and tissue survival after recombinant tissue plasminogen activator treatment.
Magnetic resonance imaging characterization of hemorrhagic transformation of embolic stroke in the rat.
Magnetic Resonance Imaging in Acute Ischemic Stroke Patients with Mild Symptoms: An Opportunity to Standardize Intravenous Thrombolysis.
Magnetic resonance imaging indexes of therapeutic efficacy of recombinant tissue plasminogen activator treatment of rat at 1 and 4 hours after embolic stroke.
Magnetic Resonance Imaging-DRAGON Score: Three-Month Outcome Prediction After Intravenous Thrombolysis for Anterior Circulation Stroke.
Magnetic Resonance Imaging-Guided Thrombolysis (0.6 mg/kg) Was Beneficial for Unknown Onset Stroke Above a Certain Core Size: THAWS RCT Substudy.
Magnetic resonance prediction of outcome after thrombolytic treatment.
Magnitude of Benefit of Combined Endovascular Thrombectomy and Intravenous Fibrinolysis in Large Vessel Occlusion Ischemic Stroke.
Making a case for acute ischemic stroke.
Making a case for the right "-ase" in acute ischemic stroke: alteplase, tenecteplase, and reteplase.
Making the call: is telestroke cost effective?
Management of acute central retinal artery occlusion: Intravenous thrombolysis is feasible and safe.
Management of Acute Ischemic Stroke-Specific Focus on Anesthetic Management for Mechanical Thrombectomy.
Management of acute ischemic stroke.
Management of acute ischemic stroke. An update for primary care physicians.
Management of acute ischemic stroke. What is the role of tPA and antithrombotic agents?
Management of acute ischemic stroke: time is brain.
Management of ischaemic stroke in the acute setting: review of the current status.
Management of ischemic stroke in the hyperacute phas.
Management of Maternal Stroke and Mitigating Risk.
Management of patients with atherosclerotic carotid occlusion.
Management of Pediatric Strokes With Alteplase (Tissue Plasminogen Activator).
Management of stroke complicating cardiac catheterization with recombinant tissue-type plasminogen activator.
Management of stroke in Auckland Hospital in 1996.
Management protocols and encountered complications among stroke patients admitted to stroke unit of Jimma university medical center, Southwest Ethiopia: Prospective observational study.
Mandatory Neuroendovascular Evolution: Meeting the New Demands.
MANNITOL-ENHANCED DELIVERY OF STEM CELLS AND THEIR GROWTH FACTORS ACROSS THE BLOOD BRAIN BARRIER.
Marked Regional Variation in Acute Stroke Treatment Among Medicare Beneficiaries.
Markedly reduced apparent blood volume on bolus contrast magnetic resonance imaging as a predictor of hemorrhage after thrombolytic therapy for acute ischemic stroke.
Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey.
Mast cell stabilization reduces hemorrhage formation and mortality after administration of thrombolytics in experimental ischemic stroke.
Matrix metalloproteinase (MMP) induction and inhibition at different doses of recombinant tissue plasminogen activator following experimental stroke.
Matrix Metalloproteinase-9 as a Marker for Acute Ischemic Stroke: A Systematic Review.
Matrix Metalloproteinase-9 Expression is Enhanced by Ischemia and Tissue Plasminogen Activator and Induces Hemorrhage, Disability and Mortality in Experimental Stroke.
Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke.
Maximizing the Population Benefit From Thrombolysis in Acute Ischemic Stroke: A Modeling Study of In-Hospital Delays.
Maximum intravenous alteplase dose for obese stroke patients is not associated with greater likelihood of worse outcomes.
Measurement of Length of Hyperdense MCA Sign in Acute Ischemic Stroke Predicts Disappearance after IV tPA.
Measuring outcomes as a function of baseline severity of ischemic stroke.
Mechanical clot disruption following intravenous recombinant tissue plasminogen activator administration in non-responders.
Mechanical disruption of thrombus following intravenous tissue plasminogen activator for ischemic stroke.
Mechanical endovascular recanalization therapies.
Mechanical Recanalization With Flow Restoration in Acute Ischemic Stroke: The Mechanical Recanalization With Flow Restoration in Acute Ischemic Stroke (ReFlow) Study.
Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial.
Mechanical Thrombectomy for Acute Basilar Artery Occlusion in Early Therapeutic Time Window.
Mechanical thrombectomy for acute occlusion of the posterior inferior cerebellar artery: A case report.
Mechanical Thrombectomy for Acute Stroke in Patients with Target and Unrelated Vessel AVMs and AVFs: A Case Series.
Mechanical thrombectomy for ischaemic stroke in the anterior circulation: off-hours effect.
Mechanical thrombectomy for the treatment of acute ischemic stroke.
Mechanical thrombectomy in acute stroke - Five years of experience in Poland.
Mechanical Thrombectomy in Stroke.
Mechanical thrombolysis in ischemic stroke attributable to basilar artery occlusion as first-line treatment.
Mechanisms in blood-brain barrier opening and metabolism-challenged cerebrovascular ischemia with emphasis on ischemic stroke.
Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke.
Medical management of ischaemic stroke.
Medical management of patients with an acute stroke: treatment and prevention.
Medical therapy for acute ischemic stroke.
Medical therapy for ischemic stroke.
Medical treatment strategies: intravenous thrombolysis, neuronal protection, and anti-reperfusion injury agents.
Medical University of South Carolina Telestroke: A Telemedicine Facilitated Network for Stroke Treatment in South Carolina-A Progress Report.
Medicolegal Considerations with Intravenous Tissue Plasminogen Activator in Stroke: A Systematic Review.
Mega-trials and equivalence trials: experience from the INJECT study.
Melatonin and Nitrones As Potential Therapeutic Agents for Stroke.
Memantine for the treatment of ischemic stroke: experimental benefits and clinical lack of studies.
Merci Retriever in acute stroke treatment.
Mesenchymal stem cell-derived extracellular vesicle-based therapies protect against coupled degeneration of the central nervous and vascular systems in stroke.
Mesenchymal stem cells for ischemic stroke: progresses and possibilities.
Mesenchymal Stromal Cells Promote Axonal Outgrowth Alone and Synergistically with Astrocytes via tPA.
Metabolic Syndrome Predicts Refractoriness to Intravenous Thrombolysis in Acute Ischemic Stroke.
Methodological issues for designing and conducting a multicenter, international clinical trial in Acute Stroke: Experience from ARTSS-2 trial.
Methodology for the Canadian Activase for Stroke Effectiveness Study (CASES). CASES Investigators.
Methodology of the Interventional Management of Stroke III Trial.
Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator.
Microbubble-mediated sonothrombolysis with BR38 of a venous full blood thrombus in a rat embolic stroke model.
Microcatheter contrast injections during intra-arterial thrombolysis may increase intracranial hemorrhage risk.
Microglial-mediated PDGF-CC activation increases cerebrovascular permeability during ischemic stroke.
Microplasmin and tissue plasminogen activator: comparison of therapeutic effects in rat stroke model at multiparametric MR imaging.
Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits.
Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating ?2-antiplasmin.
Mild hypothermia of 34degreesC reduces side effects of rt-PA treatment after thromboembolic stroke in rats.
Minimal sufficient balance--a new strategy to balance baseline covariates and preserve randomness of treatment allocation.
Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential.
Minocycline to improve neurologic outcome in stroke (MINOS): a dose-finding study.
MMP-9 Inhibition: a Therapeutic Strategy in Ischemic Stroke.
MMP10 Promotes Efficient Thrombolysis After Ischemic Stroke in Mice with Induced Diabetes.
Mobile device for thrombolysis decisions for telestroke.
Mobile Stroke Units: Current and Future Impact on Stroke Care.
Mobile stroke units: taking stroke care to the patient.
Modeling Stroke Patient Transport for All Patients With Suspected Large-Vessel Occlusion.
Modeling the Cost Effectiveness of Neuroimaging-Based Treatment of Acute Wake-Up Stroke.
Modern medical management of acute ischemic stroke.
Modification of Acute Stroke Pathway in Korea After the Coronavirus Disease 2019 Outbreak.
Modified diffusion-weighted imaging-Alberta Stroke Program Early Computed Tomography Score including deep white matter lesions predicts symptomatic intracerebral hemorrhage following intravenous thrombolysis.
Modulation by the Noble Gas Helium of Tissue Plasminogen Activator: Effects in a Rat Model of Thromboembolic Stroke.
Molecular cloning of Reteplase and its expression in E. coli using tac promoter.
Molecule of the Month. PDGFR-alpha antagonist Gleevec reduces blood vessel leakage and increases the therapeutic window associated with tissue plasminogen activator stroke treatment.
Monoacylglycerol Lipase Inhibitor is Safe when Combined with Delayed r-tPA Administration in Treatment of Stroke.
Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model.
Monte Carlo Simulation Modeling of a Regional Stroke Team's Use of Telemedicine.
More Time Is Taken to Administer Tissue Plasminogen Activator in Ischemic Stroke Patients with Earlier Presentations.
Moving beyond a single perfusion threshold to define penumbra: a novel probabilistic mismatch definition.
MPO is partially associated with neutrophil deleterious effect in acute cerebral ischemia.
MRI evaluation of BBB disruption after adjuvant AcSDKP treatment of stroke with tPA in rat.
MRI evaluation of treatment of embolic stroke in rat with intra-arterial and intravenous rt-PA.
MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study.
MRI-based intravenous thrombolysis in stroke patients with unknown time of symptom onset.
MRI-Based Ultrafast Protocol Thrombolysis with rt-PA for Acute Ischemia Stroke in 12-Hour Time Window.
MRI-Guided High-Intensity Focused Ultrasound as an Emerging Therapy for Stroke: A Review.
MRI-Guided Intravenous Alteplase for Stroke - Still Stuck in Time.
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset.
MT-DRAGON score for outcome prediction in acute ischemic stroke treated by mechanical thrombectomy within 8 hours.
Multicenter Study of Adverse Events After Intravenous Tissue-Type Plasminogen Activator Treatment of Acute Ischemic Stroke.
Multicenter Study of Intravenous Recombinant Tissue Plasminogen Activator Infusion around Hiroshima, Japan: The Hiroshima Acute Stroke Retrospective and Prospective Registry Study.
Multidisciplinary Approach to Decrease In-Hospital Delay for Stroke Thrombolysis.
Multimodal computed tomography evaluation before thrombolysis in acute ischaemic stroke.
Multimodal CT Imaging: Time to Treatment and Outcomes in the IMS III Trial.
Multimodal Imaging Does Not Delay Intravenous Thrombolytic Therapy in Acute Stroke.
Multimodal imaging selection for IV alteplase in unknown time of onset stroke: Are we there yet?
Multimodal MRI for ischemic stroke: from acute therapy to preventive strategies.
Multiparametric iterative self-organizing MR imaging data analysis technique for assessment of tissue viability in acute cerebral ischemia.
Multiple Administrations of Intravenous Thrombolytic Therapy to a Stroke Mimic.
Multiplex Brain Proteomic Analysis Revealed the Molecular Therapeutic Effects of Buyang Huanwu Decoction on Cerebral Ischemic Stroke Mice.
Multipotent mesenchymal stromal cells decrease transforming growth factor ?1 expression in microglia/macrophages and down-regulate plasminogen activator inhibitor 1 expression in astrocytes after stroke.
Multipotent mesenchymal stromal cells increase tPA expression and concomitantly decrease PAI-1 expression in astrocytes through the sonic hedgehog signaling pathway after stroke (in vitro study).
Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat.
Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST).
Munchausen Syndrome by Tissue Plasminogen Activator: Patients Seeking Thrombolytic Administration.
Mutant Prourokinase with Adjunctive C1-Inhibitor Is an Effective and Safer Alternative to tPA in Rat Stroke.
Myocardial infarction following recombinant tissue plasminogen activator treatment for acute ischemic stroke: a dangerous complication.
Myocardial infarction following t-PA for acute stroke.
Myths regarding the NINDS rt-PA Stroke Trial: setting the record straight.
N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Augments Thrombolysis of tPA (Tissue-Type Plasminogen Activator) in Aged Rats After Stroke.
National Practice Patterns of Obtaining Informed Consent for Stroke Thrombolysis.
National trends in outcomes of ischemic stroke and prognostic influence of stroke center capability in Japan, 2010-2016.
National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate.
Negative diffusion-weighted imaging after intravenous tissue-type plasminogen activator is rare and unlikely to indicate averted infarction.
Negative fluid-attenuated inversion recovery-based intravenous thrombolysis using recombinant tissue plasminogen activator in acute stroke patients with unknown onset time.
Neglecting the difference: does right or left matter in stroke outcome after thrombolysis?
Network Mapping of Time to Antithrombotic Therapy Among Patients With Ischemic Stroke and Transient Ischemic Attack (TIA).
Neural stem cell therapy for subacute and chronic ischemic stroke.
Neural Stem Cell Transplantation into a Mouse Model of Stroke.
Neuroendocrinal, Neurodevelopmental, and Embryotoxic Effects of Recombinant Tissue Plasminogen Activator Treatment for Pregnant Women with Acute Ischemic Stroke.
Neuroimmunomodulatory effects of transcranial laser therapy combined with intravenous tPA administration for acute cerebral ischemic injury.
Neuroinflammatory biomarkers: From stroke diagnosis and prognosis to therapy.
Neurological picture. Orolingual angio-oedema after alteplase therapy in a stroke patient concurrently using angiotensin II receptor blocker.
Neurologists' attitudes regarding rt-PA for acute ischemic stroke.
Neuroprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke model.
Neuroprotection and stroke: time for a compromise.
Neuroprotection by human umbilical cord bloodderived progenitors in ischemic brain injuries.
Neuroprotection for acute stroke: making clinical trials work.
Neuroprotection for ischemic stroke: two decades of success and failure.
Neuroprotection in acute ischemic stroke.
Neuroprotection in stroke.
Neuroprotective effect of asiatic acid in rat model of focal embolic stroke.
Neuroprotective effect of masitinib in rats with postischemic stroke.
Neuroprotective effect of neuroserpin in rat primary cortical cultures after oxygen and glucose deprivation and tPA.
Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator.
Neuroprotective mechanisms and translational potential of therapeutic hypothermia in the treatment of ischemic stroke.
Neuroprotective potential of Piroxicam in cerebral ischemia: An in silico evaluation of the hypothesis to explore its therapeutic efficacy by inhibition of aquaporin-4 and acid sensing ion channel1a.
Neuroprotective therapies in stroke.
Neuroproteome changes after ischemia/reperfusion injury and tissue plasminogen activator administration in rats: a quantitative iTRAQ proteomics study.
Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group.
Neuroserpin.
Neurovascular intervention in the acute phase of cerebral infarction.
Neutralizing the neurotoxic effects of exogenous and endogenous tPA.
Neutrophil and Platelet Activity and Quantification Following Delayed tPA Therapy in a Rabbit Model of Thromboembolic Stroke.
Neutrophil-to-Lymphocyte Ratio and Response to Intravenous Thrombolysis in Patients with Acute Ischemic Stroke.
Neutrophils in tPA-induced hemorrhagic transformations: Main culprit, accomplice or innocent bystander?
New antiplatelet agents prescribed to patients with ischemic heart disease: implications for treatment of stroke.
New guidelines on tPA in stroke: putting out fires with gasoline?
New insights on thrombolytic treatment of acute ischemic stroke.
New pathways for evaluating potential acute stroke therapies.
New perspectives on developing acute stroke therapy.
NIHSS-time score easily predicts outcomes in rt-PA patients: The SAMURAI rt-PA registry.
NK cells in cerebral ischemia.
No Impact of Body Mass Index on Outcome in Stroke Patients Treated with IV Thrombolysis BMI and IV Thrombolysis Outcome.
No Weekend or After-Hours Effect in Acute Ischemic Stroke Patients Treated by Telemedicine.
Non-contrast head CT-based thrombolysis for wake-up/unknown onset stroke is safe: A single-center study and meta-analysis.
Normobaric hyperoxia and delayed tPA treatment in a rat embolic stroke model.
Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.
Not only the Sugar, Early infarct sign, hyperDense middle cerebral artery, Age, Neurologic deficit score but also atrial fibrillation is predictive for symptomatic intracranial hemorrhage after intravenous recombinant tissue plasminogen activator.
Novel Algorithm to Help Identify Stroke Mimics.
Novel plasminogen activator inhibitor-1-derived peptide protects against impairment of cerebrovasodilation after photothrombosis through inhibition of JNK MAPK.
Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: Intracranial bleeding associated with the treatment of ischemic stroke: thrombolytic treatment of ischemia-affected endothelial cells with tissue-type plasminogen activator.
Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: Novel mechanism of the expression and amplification of cell surface-associated fibrinolytic activity demonstrated by real-time imaging analysis.
Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development: Protective effects of antiplatelet agents against stroke.
Novel Telestroke Program Improves Thrombolysis for Acute Stroke Across 21 Hospitals of an Integrated Healthcare System.
Novel thrombolytic drugs: will they make a difference in the treatment of ischaemic stroke?
Novel Use of a Nurse-Led Telemedicine Team in Acute Stroke: A Retrospective Review of the Impact on a Regional Health Care System.
Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke.
Number needed to treat: A primer for neurointerventionalists.
Number of stentriever passes and outcome after thrombectomy in stroke.
Nurse-Initiated Acute Stroke Care in Emergency Departments.
Nursing care of acute stroke patients after receiving rt-PA therapy. The NINDS rt-PA Stroke Study Group.
Nursing management of acute complications following rt-PA in acute ischemic stroke. The NINDS rt-PA Stroke Study Group.
NY: Failure to administer TPA to stroke victim: TPA not indicated while in defendants' care. Flanagan v. Catskill Regional Medical Center, 2009-NY-06161 (8/11/2009)-NY.
Observational Study of Telephone Consults by Stroke Experts Supporting Community Tissue Plasminogen Activator Delivery.
Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III.
Obstacles to the use of intravenous tissue plasminogen activator for acute ischemic stroke. Is time the only barrier?
Off-label intravenous thrombolysis in acute stroke.
Off-label thrombolysis versus full adherence to the current European Alteplase license: impact on early clinical outcomes after acute ischemic stroke.
Off-label use of IV t-PA in patients with intracranial neoplasm and cavernoma.
On- versus Off-Hour Patient Cohorts at a Primary Stroke Center: Onset-to-Treatment Duration and Clinical Outcomes after IV Thrombolysis.
One-Year Home-Time and Mortality After Thrombolysis Compared With Nontreated Patients in a Propensity-Matched Analysis.
Open label tissue plasminogen activator for stroke: The oregon experience.
Open trial of intravenous tissue plasminogen activator in acute carotid territory stroke. Correlations of outcome with clinical and radiological data.
Opening the window: Ischemic postconditioning reduces the hyperemic response of delayed tissue plasminogen activator and extends its therapeutic time window in an embolic stroke model.
Optimal Delay Time of CT Perfusion for Predicting Cerebral Parenchymal Hematoma After Intra-Arterial tPA Treatment.
Optimal outcome measures for detecting clinical benefits of early reperfusion: insights from the DEFUSE Study.
Optimal thrombolytic strategies for acute myocardial infarction--bolus administration.
Optimal Tmax threshold for predicting penumbral tissue in acute stroke.
Optimising Clinical Trial Design for Proof of Neuroprotection in Acute Ischaemic Stroke: The SAINT Clinical Trial Programme.
Optimization of Prehospital Triage of Patients With Suspected Ischemic Stroke.
Optimizing discharge planning: clinical predictors of longer stay after recombinant tissue plasminogen activator for acute stroke.
Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).
Organizing regional networks to increase acute stroke intervention.
Orolingual angiodema associated with alteplase treatment of acute stroke: a reappraisal.
Orolingual angioedema associated with olmesartan use after recombinant tissue plasminogen activator treatment of acute stroke.
Outcome After Reperfusion Therapies in Patients With Large Baseline Diffusion-Weighted Imaging Stroke Lesions: A THRACE Trial (Mechanical Thrombectomy After Intravenous Alteplase Versus Alteplase Alone After Stroke) Subgroup Analysis.
Outcome after systemic thrombolysis is predicted by age and stroke severity: an open label experience with recombinant tissue plasminogen activator and tirofiban.
Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or =80 years) stroke patients.
Outcome and Symptomatic Bleeding Complications of Intravenous Thrombolysis Within 6 Hours in MRI-Selected Stroke Patients: Comparison of a German Multicenter Study With the Pooled Data of ATLANTIS, ECASS, and NINDS tPA Trials.
Outcome of acute ischemic stroke after intra-arterial thrombolysis: A study from India.
Outcome of Acute Ischemic Stroke in Very Elderly Patients: Is Intravenous Thrombolysis Beneficial?
Outcome of intravenous recombinant tissue plasminogen activator for acute ischemic stroke in patients aged over 80 years.
Outcome of intravenous rt-PA therapy for a stroke patient during the short-term period after TAVI.
Outcome of Intravenous Thrombolysis in Stroke Patients Weighing over 100 kg.
Outcome of patients with atrial fibrillation after intravenous thrombolysis for cerebral ischaemia.
Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
Outcome of the 'Drip-and-Ship' Paradigm among Patients with Acute Ischemic Stroke: Results of a Statewide Study.
Outcomes after tissue plasminogen activator administration under the drip and ship paradigm may differ according to the regional stroke care system.
Outcomes in Mild Acute Ischemic Stroke Treated With Intravenous Thrombolysis: A Retrospective Analysis of the Get With the Guidelines-Stroke Registry.
Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from get with the guidelines-stroke.
Outcomes of endovascular mechanical thrombectomy and intravenous tissue plasminogen activator for the treatment of vertebrobasilar stroke.
Outcomes of intravenous thrombolytic therapy for acute ischemic stroke with an integrated acute stroke referral network: initial experience of a community-based hospital in a developing country.
Outcomes of intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 90 years or older.
Outcomes of systemic anticoagulation with bivalirudin for Impella 5.0.
Overexpression of tissue-type plasminogen activator in atherosclerotic human coronary arteries.
Overview: hyperacute rt-PA stroke treatment. The NINDS rt-PA Stroke Study Group.
Oxfordshire community stroke project clinical stroke syndrome and appearances of tissue and vascular lesions on pretreatment ct in hyperacute ischemic stroke among the first 510 patients in the Third International Stroke Trial (IST-3).
Oxidative stress after thrombolysis-induced reperfusion in human stroke.
Oxygen glucose deprivation switches the transport of tPA across the blood-brain barrier from an LRP-dependent to an increased LRP-independent process.
Oxygen or cooling, to make a decision after acute ischemia stroke.
PAI-1 derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia.
Pai-1 gene variants and COC use are associated with stroke risk: a case-control study in the Han Chinese women.
PAI-1-derived peptide EEIIMD prevents hypoxia/ischemia-induced aggravation of endothelin- and thromboxane-induced cerebrovasoconstriction.
Paradigm Shift in Intra-Arterial Mechanical Thrombectomy for Acute Ischemic Stroke : A Review of Randomized Controlled Trials after 2015.
Paradoxical Myocardial Infarction After Thrombolytic Therapy for Acute Ischemic Stroke.
Parenchymal hematoma and total lesion volume in combined IV/IA revascularization stroke therapy.
PARP14 inhibits microglial activation via LPAR5 to promote post-stroke functional recovery.
Partial MHC class II constructs as novel immunomodulatory therapy for stroke.
Partial Recanalization of a Large Vessel Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator, Followed by Systemic Anticoagulation, in the Setting of COVID-19-Induced Hypercoagulability: A Case Report.
Participation in Get With the Guidelines-Stroke and Its Association With Quality of Care for Stroke.
Pathophysiology and mechanisms of acute ischemic stroke. The NINDS rt-PA Stroke Study Group.
Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
Patient-Centered Decision Support in Acute Ischemic Stroke: Qualitative Study of Patients' and Providers' Perspectives.
Patients with acute stroke treated with intravenous tPA 3-6 hours after stroke onset: correlations between MR angiography findings and perfusion- and diffusion-weighted imaging in the DEFUSE study.
Patients with Low National Institutes of Health Stroke Scale Scores Have Longer Door-to-Needle Times: Analysis of a Telestroke Network.
Patients with Thrombolysed Stroke in Vietnam have an Excellent Outcome: Results from the Vietnam Thrombolysis Registry.
Patterns and Clinical Impact of Angiographically Visible Distal Emboli During Thrombectomy With Solitaire for Acute Ischemic Stroke.
Paul Coverdell National Acute Stroke Registry Surveillance - four states, 2005-2007.
PDE4 Regulates Tissue Plasminogen Activator Expression of Human Brain Microvascular Endothelial Cells.
Pennsylvania comprehensive stroke center collaborative: Statement on the recently updated IV rt-PA prescriber information for acute ischemic stroke.
Penumbral selection of patients for trials of acute stroke therapy.
Percent change on the National Institutes of Health Stroke Scale: a useful acute stroke outcome measure.
Percutaneous recanalization of acute internal carotid artery occlusions in patients with severe stroke.
Perfusion computed tomography to assist decision making for stroke thrombolysis.
Perfusion Computed Tomography-Guided Intravenous Thrombolysis for Acute Ischemic Stroke beyond 4.5 Hours: A Case-Control Study.
Perfusion CT helps decision making for thrombolysis when there is no clear time of onset.
Perfusion thresholds in acute stroke thrombolysis.
Perfusion-CT guided intravenous thrombolysis in patients with unknown-onset stroke: a randomized, double-blind, placebo-controlled, pilot feasibility trial.
Pericardial Tamponade After Systemic Alteplase in Stroke and Emergent Reversal With Tranexamic Acid.
Peripheral to central: Organ interactions in stroke pathophysiology.
Periprocedural heparin use in acute ischemic stroke endovascular therapy: the TREVO 2 trial.
Periprocedural Risk of Stroke Is Elevated in Patients with End-Stage Renal Disease on Hemodialysis.
Peroxynitrite-Induced Tyrosine Nitration Contributes to Matrix Metalloprotease-3 Activation: Relevance to Hyperglycemic Ischemic Brain Injury and Tissue Plasminogen Activator.
Persistent trigeminal artery in a patient with posterior circulation stroke treated with rt-PA: case report.
Perspectives on reperfusion-induced damage in rodent models of experimental focal ischemia and role of gamma-protein kinase C.
PHANTOM-S: the prehospital acute neurological therapy and optimization of medical care in stroke patients - study.
Pharmacist Participation in Acute Ischemic Stroke Decreases Door-to-Needle Time to Recombinant Tissue Plasminogen Activator.
Pharmacists' role in a hospital's initiative to become a certified primary stroke center.
Pharmacoeconomic impact of an alternative workflow process for stroke.
Pharmacokinetic optimisation of the treatment of embolic disorders.
Pharmacological and non-pharmacological recanalization strategies in acute ischemic stroke.
Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6, 6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator.
Pharmacological Modulation of Neutrophil Extracellular Traps Reverses Thrombotic Stroke tPA (Tissue-Type Plasminogen Activator) Resistance.
Phased changes in strategies can reduce delay of intravenous thrombolysis administration to 15?min.
Phosphorylated recombinant HSP27 protects the brain and attenuates blood-brain barrier disruption following stroke in mice receiving intravenous tissue-plasminogen activator.
Physiologic imaging in acute stroke: Patient selection.
Physiopathology of ischemic stroke and its modulation using memantine: evidence from preclinical stroke.
Physiotherapy in patients in the ICU treated with IV tissue plasminogen activator for stroke.
Phytochemicals in Ischemic Stroke.
PI3K? (Phosphoinositide 3-Kinase-?) Inhibition Attenuates Tissue-Type Plasminogen Activator-Induced Brain Hemorrhage and Improves Microvascular Patency After Embolic Stroke.
Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. The TPA Bridging Study Group.
Pinocembrin attenuates hemorrhagic transformation after delayed t-PA treatment in thromboembolic stroke rats by regulating endogenous metabolites.
Pinocembrin Protects Blood-Brain Barrier Function and Expands the Therapeutic Time Window for Tissue-Type Plasminogen Activator Treatment in a Rat Thromboembolic Stroke Model.
Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke.
Plasma Concentration of Endogenous Tissue Plasminogen Activator and the Occurrence of Future Cardiovascular Events.
Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.
Plasma level of IL-6 and its relationship to procoagulant and fibrinolytic markers in acute ischemic stroke.
Plasma levels of coagulation and fibrinolysis markers in acute ischemic stroke patients with lone atrial fibrillation.
Plasma lipoprotein(a) levels in subjects attending a metabolic ward. Discrimination between individuals with and without a history of ischemic stroke.
Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke.
Plasmin-resistant PSD-95 inhibitors resolve effect-modifying drug-drug interactions between alteplase and nerinetide in acute stroke.
Plasminogen Activation-Based Thrombolysis for Ischaemic Stroke: The Diversity of Targets may Demand New Approaches.
Plasminogen activator inhibitor in acute stroke.
Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke.
Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke.
Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts.
Plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish children with cerebral infarct and effect on factor V 1691 A mutation.
Plasminogen activator system and vascular disease.
Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig.
Pleiotropic Effects of Exosomes as a Therapy for Stroke Recovery.
Polypharmacy, functional outcome and treatment effect of intravenous alteplase for acute ischaemic stroke.
Pooled Assessment of Computed Tomography Interpretation by Vascular Neurologists in the STRokE DOC Telestroke Network.
Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke.
Poor prognosis of acute stroke patients denied thrombolysis due to early CT findings.
Positive impact of stroke unit establishment on patient recovery in Firoozgar hospital.
Post-hoc Analysis of Outcome of Intravenous Thrombolysis in Infarcts of Infratentorial Localization in the WAKE-UP Trial.
Post-licensed 1-year experience of systemic thrombolysis with tissue plasminogen activator for ischemic stroke in a Japanese neuro-unit.
Post-thrombolysis rupture of small lenticulostriate aneurysms: A report of 2 consecutive cases.
Posterior circulation stroke is associated with prolonged door-to-needle time.
Posterior vs. anterior circulation infarction: demography, outcomes, and frequency of hemorrhage after thrombolysis.
Posterior-to-anterior circulation access using the Penumbra Stroke System for mechanical thrombectomy of a right middle cerebral artery thrombus.
Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia.
Postoperative Stroke Following Administration of Intraoperative Recombinant Tissue Plasminogen Activator for the Treatment of Intracardiac Thrombus During Liver Transplantation: A Report of Two Cases.
Postprocedure Subarachnoid Hemorrhage after Endovascular Treatment for Acute Ischemic Stroke.
Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis.
Poststroke Sonic Hedgehog Agonist Treatment Improves Functional Recovery by Enhancing Neurogenesis and Angiogenesis.
Postthrombolysis outcomes in acute ischemic stroke patients of Asian race-ethnicity.
Potential advantages of Chinese medicine Taohong Siwu Decoction () combined with tissue-plasminogen activator for alleviating middle cerebral artery occlusion-induced embolic stroke in rats.
Potential eligibility for recombinant tissue plasminogen activator therapy in children: a population-based study.
Potentially Missed Diagnosis of Ischemic Stroke in the Emergency Department in the Greater Cincinnati/Northern Kentucky Stroke Study.
PPAR-Alpha Agonist Used at the Acute Phase of Experimental Ischemic Stroke Reduces Occurrence of Thrombolysis-Induced Hemorrhage in Rats.
Practical model-based dose finding in early-phase clinical trials: optimizing tissue plasminogen activator dose for treatment of ischemic stroke in children.
Practice variation in the informed consent procedure for thrombolysis in acute ischemic stroke: a survey among neurologists and neurology residents.
Pre-clinical to clinical translational failures and current status of clinical trials in stroke therapy: a brief review.
Pre-hospital Assessment of Large Vessel Occlusion Strokes: Implications for Modeling and Planning Stroke Systems of Care.
Pre-hospital delay in the use of intravenous rt-PA for acute ischemic stroke in Japan.
Preclinical Validation of the Therapeutic Potential of Glasgow Oxygen Level Dependent (GOLD) Technology: a Theranostic for Acute Stroke.
Preclusion of Ischemic Stroke Patients from Intravenous Tissue Plasminogen Activator Treatment for Mild Symptoms Should Not be Based on Low National Institutes of Health Stroke Scale Scores.
Predicting abnormal coagulation in ischemic stroke: reducing delay in rt-PA use.
Predicting Clinical Outcomes After Thrombolysis Using the iScore: Results From the Virtual International Stroke Trials Archive.
Predicting Clinical Outcomes and Response to Thrombolysis in Acute Stroke Patients With Diabetes.
Predicting Independence 6 and 18 Months after Ischemic Stroke Considering Differences in 12 Countries: A Secondary Analysis of the IST-3 Trial.
Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke.
Predicting outcome in hyper-acute stroke: validation of a prognostic model in the Third International Stroke Trial (IST3).
Predicting outcome in ischemic stroke: external validation of predictive risk models.
Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial.
Predicting prognosis in patients with stroke treated with intravenous alteplase through the 24-h trajectory of blood pressure changes.
Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score.
Prediction of hospital disposition after thrombolysis for acute ischemic stroke using the National Institutes of Health Stroke Scale.
Prediction of Thrombolytic Therapy after Stroke-Bypass Transportation: The Maria Prehospital Stroke Scale Score.
Prediction of thrombus resolution after intravenous thrombolysis assessed by CT-based thrombus imaging.
Predictive Ability of an Emergency Medical Dispatch Stroke Diagnostic Tool in Identifying Hospital-Confirmed Strokes.
Predictive value of the Ontario prehospital stroke screening tool for the identification of patients with acute stroke.
Predictive value of thrombus attenuation on thin-slice non-contrast CT for persistent occlusion after intravenous thrombolysis.
Predictors and Outcomes Associated with Rescue Therapy in SWIFT.
Predictors for hemorrhagic transformation with intravenous tissue plasminogen activator in acute ischemic stroke.
Predictors of Acute Neurological Worsening after Endovascular Thrombectomy.
Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke.
Predictors of functional outcome and hemorrhagic complications in acute ischemic stroke patients treated with intravenous thrombolysis - A retrospective analysis?.
Predictors of functional outcome in patients with stroke thrombolysis in a tertiary hospital in Malaysia.
Predictors of good outcome after intravenous tPA for acute ischemic stroke.
Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume.
Predictors of In-Hospital Mortality and the Risk of Symptomatic Intracerebral Hemorrhage after Thrombolytic Therapy with Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke.
Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy.
Predictors of increased intravenous tissue plasminogen activator use among hospitals participating in the Massachusetts Primary Stroke Service Program.
Predictors of Intracerebral Hemorrhage in Acute Stroke Patients Receiving Intravenous Recombinant Tissue Plasminogen Activator.
Predictors of major neurologic improvement after thrombolysis in acute stroke.
Predictors of major neurological improvement after intravenous thrombolysis in acute ischemic stroke: a hospital-based study from south India.
Predictors of malignant middle cerebral artery infarction after mechanical thrombectomy.
Predictors of symptomatic intracranial haemorrhage in off-label thrombolysis: an analysis of the Safe Implementation of Treatments in Stroke registry.
Predictors of symptomatic intracranial haemorrhage in patients with an ischaemic stroke with neurological deterioration after intravenous thrombolysis.
Prehospital delay after acute stroke in Kaohsiung, Taiwan.
Prehospital diagnosis and management of patients with acute stroke.
Prehospital factors determining regional variation in thrombolytic therapy in acute ischemic stroke.
Prehospital notification from the emergency medical service reduces the transfer and intra-hospital processing times for acute stroke patients.
Prehospital stroke care: potential, pitfalls, and future.
Prehospital triage to primary stroke centers and rate of stroke thrombolysis.
Prehospital utility of rapid stroke evaluation using in-ambulance telemedicine: a pilot feasibility study.
PREMISE: Posterior Circulation Results Comparing Embolectomy to Medical Intervention in Stroke Emergencies.
Preprocedure Intravenous Recombinant Tissue Plasminogen Activator and Risk of Distal Embolization with Thrombectomy in Acute Ischemic Stroke.
Presentation and Outcomes of "Wake-Up Strokes" in a Large Randomized Stroke Trial: Analysis of Data from the International Stroke Trial.
Presenting Symptoms and Dysphagia Screen Predict Outcome in Mild and Rapidly Improving Acute Ischemic Stroke Patients.
Prestroke Antiplatelet Effect on Symptomatic Intracranial Hemorrhage and Functional Outcome in Intravenous Thrombolysis.
Prestroke Dementia is Associated with Poor Outcomes after Reperfusion Therapy among Elderly Stroke Patients.
Pretreatment ASPECTS on DWI predicts 3-month outcome following rt-PA: SAMURAI rt-PA Registry.
Pretreatment Blood Pressure is a Simple Predictor of Hemorrhagic Infarction after Intravenous Recombinant Tissue Plasminogen Activator (rt-PA) Therapy.
Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis.
Pretreatment Diffusion-Weighted Imaging Lesion Volume Predicts Favorable Outcome After Intravenous Thrombolysis With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke.
Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator.
Prevalence of Imaging Targets in Patients With Minor Stroke Selected for IV tPA Treatment Using MRI: The Treatment of Minor Stroke With MRI Evaluation Study (TIMES).
Prevention and treatment of perioperative stroke.
Prevention of emergency physician migratory contamination in a cluster randomized trial to increase tissue plasminogen activator use in stroke (the INSTINCT trial).
Primary acute stroke thrombectomy within 3?h for large artery occlusion (PAST3-LAO): a pilot study.
Primary Angioplasty for the Treatment of Acute ST-Segment Elevated Myocardial Infarction: An Evidence-Based Analysis.
Primary intraventricular hemorrhage outcomes in the CLEAR III trial.
Primary Thrombectomy in tPA (Tissue-Type Plasminogen Activator) Eligible Stroke Patients With Proximal Intracranial Occlusions.
Principles and practice of thrombolysis via telestroke.
Prior antiplatelet therapy and haematoma expansion after primary intracerebral haemorrhage: an individual patient-level analysis of CLEAR III, MISTIE III and VISTA-ICH.
Prior statin use may be associated with improved stroke outcome after tissue plasminogen activator.
Pro-inflammatory mediators and apoptosis correlate to rt-PA response in a novel mouse model of thromboembolic stroke.
Pro: Intravenous Tissue Plasminogen Activator in Stroke Patients With Rapid, Complete Recovery During Evaluation (Transient Ischemic Attack) and Evidence of Middle Cerebral Artery Occlusion.
Process evaluation of an implementation trial to improve the triage, treatment and transfer of stroke patients in emergency departments (T3 trial): a qualitative study.
Progesterone attenuates hemorrhagic transformation after delayed tPA treatment in an experimental model of stroke in rats: involvement of the VEGF-MMP pathway.
Prognostic analysis of different therapeutic regimens in patients with acute cardiogenic cerebral embolism.
Prognostic Parameters for Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis in Acute Ischemic Stroke in an Asian Population.
Prognostic significance of blood pressure variability after thrombolysis in acute stroke.
Prognostic Value of the 24-Hour Neurological Examination in Anterior Circulation Ischemic Stroke: A post hoc Analysis of Two Randomized Controlled Stroke Trials.
Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy.
Progression of stroke deficits in patients presenting with mild symptoms: The underlying etiology determines outcome.
Progression of symptomatic intracranial large artery atherosclerosis is associated with a proinflammatory state and impaired fibrinolysis.
Progressive rural-urban disparity in acute stroke care.
Prolyl hydroxylase domain inhibitors: can multiple mechanisms be an opportunity for ischemic stroke?
Promoting Neurovascular Recovery in Aged Mice after Ischemic Stroke - Prophylactic Effect of Omega-3 Polyunsaturated Fatty Acids.
Proof of concept study: relating infarct location to stroke disability in the NINDS rt-PA trial.
Propensity Score Matching in Randomized Clinical Trials.
Proportion of patients treated with thrombolysis in a centralized versus a decentralized acute stroke care setting.
Proportion of single-chain recombinant tissue plasminogen activator and outcome after stroke.
Prospective study of endogenous tissue plasminogen activator and risk of stroke.
Prospective, Multicenter, Controlled Trial of Mobile Stroke Units.
Prospects of Therapeutic Target and Directions for Ischemic Stroke.
Protease-independent action of tissue plasminogen activator in brain plasticity and neurological recovery after ischemic stroke.
Protective effects of 2-(2-benzonfuranyl)-2-imidazoline combined with tissue plasminogen activator after embolic stroke in rats.
Protective effects of non-anticoagulant activated protein C variant (D36A/L38D/A39V) in a murine model of ischaemic stroke.
Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia.
Protective role of tuftsin fragment 1-3 in an animal model of intracerebral hemorrhage.
Proteomic Protease Substrate Profiling of tPA Treatment in Acute Ischemic Stroke Patients: A Step Toward Individualizing Thrombolytic Therapy at the Bedside.
Prothrombolytic action of normobaric oxygen given alone or in combination with recombinant tissue-plasminogen activator in a rat model of thromboembolic stroke.
Prothymosin alpha and its mimetic hexapeptide improve delayed tPA-induced brain damage following cerebral ischemia.
Protocol adherence and safety of intravenous thrombolysis after telephone consultation with a stroke center.
Protocol Deviations before and after Treatment with Intravenous Tissue Plasminogen Activator in Community Hospitals.
Protocol for the perfusion and angiography imaging sub-study of the Third International Stroke Trial (IST-3) of alteplase treatment within six-hours of acute ischemic stroke.
Provider perceptions of barriers to the emergency use of tPA for acute ischemic stroke: a qualitative study.
Psoas muscle size as a frailty measure for open and transcatheter aortic valve replacement.
Puerperium Stroke and Subsequent Tissue-Type Plasminogen Activator-Induced Hemorrhage: A Case Report.
Pulmonary Embolism in a Stroke Patient after Systemic Thrombolysis: Clinical Decisions and Literature Review.
Putaminal haemorrhage after recanalization of an embolic MCA occlusion treated with tissue plasminogen activator.
Pyruvate minimizes rtPA toxicity from in vitro oxygen-glucose deprivation and reoxygenation.
Qualitative data collection and analysis methods: the INSTINCT trial.
Quality assurance monitoring of a citywide transportation protocol improves clinical indicators of intravenous tissue plasminogen activator therapy: a community-based, longitudinal study.
Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update.
Quality improvement for stroke management at the Cleveland Clinic Health System.
Quality improvement in acute stroke: the New York State Stroke Center Designation Project.
Quality of Acute Stroke Care at Primary Stroke Centers Before and After Certification in Comparison to Never-Certified Hospitals.
Quantification of thrombus hounsfield units on noncontrast CT predicts stroke subtype and early recanalization after intravenous recombinant tissue plasminogen activator.
Quantifying the Impact of Acute Stroke System of Care Transfer Protocols on Patient Outcomes.
Quantitative Imaging of Cerebral Thromboemboli In Vivo: The Effects of Tissue-Type Plasminogen Activator.
Quantitative measurement of carotid atherosclerosis in relation to levels of von Willebrand factor and fibrinolytic variables in plasma--a 2-year follow-up study.
Quantitative neuroimaging for the evaluation of the effect of stroke treatment.
Quantitative Signal Intensity in Fluid-Attenuated Inversion Recovery and Treatment Effect in the WAKE-UP Trial.
Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy.
RAcial Disparities in Ich after IV-tPA and Neurointerventional Treatment (RADIANT).
Racial Disparities in Intravenous Recombinant Tissue Plasminogen Activator Use Persist at Primary Stroke Centers.
Racial disparities in tissue plasminogen activator treatment rate for stroke: a population-based study.
Racial-Ethnic Disparities in Acute Stroke Care in the Florida-Puerto Rico Collaboration to Reduce Stroke Disparities Study.
Radiologic evaluation of hyperacute brain infarction: a review.
Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.
Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics.
Randomized assessment of imatinib in patients with acute ischaemic stroke treated with intravenous thrombolysis.
Randomized assessment of rapid endovascular treatment of ischemic stroke.
Randomized trial of argatroban plus recombinant tissue-type plasminogen activator for acute ischemic stroke (ARAIS): Rationale and design.
Rapid Alteplase Administration Improves Functional Outcomes in Patients With Stroke due to Large Vessel Occlusions.
Rapid breakdown of microvascular barriers and subsequent hemorrhagic transformation after delayed recombinant tissue plasminogen activator treatment in a rat embolic stroke model.
Rapid neurological recovery after intravenous tissue plasminogen activator in stroke: prognostic factors and outcome.
Rapid Systematic Review: Intra-Arterial Thrombectomy ("Clot Retrieval") for Selected Patients with Acute Ischemic Stroke.
Rapidly improving stroke symptoms: a pilot, prospective study.
Rare severe hypofibrinogenemia induced by tissue plasminogen activator in stroke patients: Case report.
Rate of intravenous thrombolysis for acute ischaemic stroke in the North-of-France region and evolution over time.
Rate of Symptomatic Intracerebral Hemorrhage Related to Intravenous tPA Administered Over Telestroke Within 4.5-Hour Window.
Rates, Characteristics, and Outcomes of Patients Transferred to Specialized Stroke Centers for Advanced Care.
Rationale and design of combination of an immune modulator Fingolimod with Alteplase bridging with Mechanical Thrombectomy in Acute Ischemic Stroke (FAMTAIS) trial.
Rationale for early intervention in acute stroke.
Rationale, design, and progress of the ENhanced Control of Hypertension ANd Thrombolysis strokE stuDy (ENCHANTED) trial: An international multicenter 2?×?2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment.
RBC-coupled tPA Prevents Whereas tPA Aggravates JNK MAPK-Mediated Impairment of ATP- and Ca-Sensitive K Channel-Mediated Cerebrovasodilation After Cerebral Photothrombosis.
Re-canalization in acute ischemic stroke: the strategies.
Re-examining the exclusion criterion of early recurrent ischemic stroke in intravenous thrombolysis: A meta-analysis.
Re: tPA use for stroke in the registry of the Canadian Stroke Network. Can J Neurol Sci. 2005;32:433-9.
Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator.
Real-World Treatment Trends in Endovascular Stroke Therapy.
Reasons why few patients with acute stroke receive tissue plasminogen activator.
Recanalisation therapies for wake-up stroke.
Recanalization therapies for acute ischemic stroke.
Recanalization within one hour after intravenous tissue plasminogen activator is associated with favorable outcome in acute stroke patients.
Recent advances in stroke management.
Recent advances in stroke therapy.
Recent progress in cell therapy for basal ganglia disorders with emphasis on menstrual blood transplantation in stroke.
Recent progress in drug treatment for acute ischemic stroke.
Recombinant ADAMTS13 reduces tissue plasminogen activator-induced hemorrhage after stroke in mice.
Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke.
Recombinant T cell receptor ligand treatment improves neurological outcome in the presence of tissue plasminogen activator in experimental ischemic stroke.
Recombinant tissue plasminogen activator (rt-PA) utilisation by rural clinicians in acute ischaemic stroke: An audit of current practice and clinical outcomes.
Recombinant tissue plasminogen activator (rtPA) and stroke unit for acute ischaemic stroke in developing countries, are they cost-effective?
Recombinant tissue plasminogen activator (rtPA) for stroke. The perspective at 8 years.
Recombinant tissue plasminogen activator attenuates basal lamina antigen loss after experimental focal cerebral ischemia.
Recombinant tissue plasminogen activator enhances microglial cell recruitment after stroke in mice.
Recombinant tissue plasminogen activator for acute ischemic stroke.
Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
Recombinant Tissue Plasminogen Activator Induces Neurological Side Effects Independent on Thrombolysis in Mechanical Animal Models of Focal Cerebral Infarction: A Systematic Review and Meta-Analysis.
Recombinant tissue plasminogen activator promotes, and progesterone attenuates, microglia/macrophage M1 polarization and recruitment of microglia after MCAO stroke in rats.
Recombinant tissue plasminogen activator reduces infarct size after reversible thread occlusion of middle cerebral artery in mice.
Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
Recombinant tissue-type plasminogen activator (rt-PA) therapy in an acute stroke patient taking dabigatran etexilate: a case report and literature review.
Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis.
Recombinant Tissue-Type Plasminogen Activator Study of Wake-Up Ischemic Strokes Guided by Rapid MRI.
Recombinant tissue-type plasminogen activator transiently enhances blood-brain barrier permeability during cerebral ischemia through vascular endothelial growth factor-mediated endothelial endocytosis in mice.
Recovery after ischemic stroke: criteria for good outcome by level of disability at day 7.
Recovery After Stroke.
Recurrent thrombolysis of a stuttering lacunar infarction captured on serial MRIs.
Red blood cell-coupled tissue plasminogen activator prevents impairment of cerebral vasodilatory responses through inhibition of c-Jun-N-terminal kinase and potentiation of p38 mitogen-activated protein kinase after cerebral photothrombosis in the newborn pig.
Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation.
Redefined Measure of Early Neurological Improvement Shows Treatment Benefit of Alteplase Over Placebo.
Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA receptors by using CP101,606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats.
Reduced estimated glomerular filtration rate is associated with stroke outcome after intravenous rt-PA: the Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement (SAMURAI) rt-PA registry.
Reduced rCBV Ratio in Perfusion-Weighted MR Images Predicts Poor Outcome after Thrombolysis in Acute Ischemic Stroke.
Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents.
Reducing Door-to-Needle Time for Tissue Plasminogen Activator Administration in a Community Hospital: An Operations Study.
Reducing door-to-needle time for tPA use remains an elusive goal in stroke care.
Reducing Door-to-Needle Times for Ischaemic Stroke to a Median of 30 Minutes at a Community Hospital.
Reducing haemorrhagic transformation after thrombolysis for stroke: a strategy utilising minocycline.
Reduction in IV t-PA door to needle times using an Acute Stroke Triage Pathway.
Reduction of infarct volume by thrombolysis with rt-PA in an embolic rat stroke model.
Reduction of infarction volume by bolus injection of pamiteplase, a modified tissue plasminogen activator with a longer half-life.
Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats.
Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats.
Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes.
Referral and care for acute ischemic stroke in a Japanese tertiary emergency hospital.
Refinement of the magnetic resonance diffusion-perfusion mismatch concept for thrombolytic patient selection: insights from the desmoteplase in acute stroke trials.
Refining the Definition of the Malignant Profile: Insights From the DEFUSE-EPITHET Pooled Data Set.
Reflections on 50 Years of Neuroscience Nursing: The Growth of Stroke Nursing.
Regeneration after stroke: Stem cell transplantation and trophic factors.
Regional disparities in the quality of stroke care.
Regional Learning Collaboratives Produce Rapid and Sustainable Improvements in Stroke Thrombolysis Times.
Regional Pediatric Acute Stroke Protocol: Initial Experience During 3 Years and 13 Recanalization Treatments in Children.
Regulatory B cells in experimental stroke.
Regulatory T cells ameliorate tissue plasminogen activator-induced brain haemorrhage after stroke.
Rehabilitation outcomes of stroke patients treated with tissue plasminogen activator.
Related factors with orolingual angioedema after intravenous alteplase in acute ischemic stroke: results from a single-center cohort and meta-analysis.
Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I Investigators.
Relationship between Cardiac Troponin and Thrombo-Inflammatory Molecules in Prediction of Outcome after Acute Ischemic Stroke.
Relationship between chronic atrial fibrillation and worse outcomes in stroke patients after intravenous thrombolysis.
Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes.
Relationships between cerebral perfusion and reversibility of acute diffusion lesions in DEFUSE: insights from RADAR.
Relationships between infarct growth, clinical outcome, and early recanalization in diffusion and perfusion imaging for understanding stroke evolution (DEFUSE).
Release of IL-6 After Stroke Contributes to Impaired Cerebral Autoregulation and Hippocampal Neuronal Necrosis Through NMDA Receptor Activation and Upregulation of ET-1 and JNK.
Relevance of focal cerebral ischemia models. Experience with fibrinolytic agents.
Relevance of Post-Stroke Circulating BDNF Levels as a Prognostic Biomarker of Stroke Outcome. Impact of rt-PA Treatment.
Relevance of the Updated Food and Drug Administration Alteplase Label for Acute Ischemic Stroke: The Estimated Impact and Current Guidelines.
Reliability of the Acutely Estimated Premorbid Modified Rankin Scale for Stroke Treatment Decision Making.
Remote Assessment of Stroke Using the iPhone 4.
Remote evaluation of acute ischemic stroke in rural community hospitals in Georgia.
Remote evaluation of acute ischemic stroke: reliability of National Institutes of Health Stroke Scale via telestroke.
Remote Intracerebral Hemorrhage Following Intravenous Thrombolysis in Pregnancy at 31 Weeks Gestation: A Case Report and Review of the Literature.
Remote ischemic perconditioning in thrombolysed stroke patients: Randomized study of activating endogenous neuroprotection - design and MRI measurements.
Remote supervision of IV-tPA for acute ischemic stroke by telemedicine or telephone before transfer to a regional stroke center is feasible and safe.
Renal Dysfunction and In-Hospital Outcomes in Patients With Acute Ischemic Stroke After Intravenous Thrombolytic Therapy.
Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.
Reocclusion after thrombolytic therapy: strategies for inhibiting thrombin-induced platelet aggregation.
Repeated intravenous thrombolysis in early recurrent stroke secondary to carotid web: Case report.
Repeated Intravenous Treatment with Recombinant Tissue-Type Plasminogen Activator in Patients with Acute Ischemic Stroke.
Repeated tissue plasminogen activator treatment for early stroke recurrence: protocol violation is not an option.
Repeated-Measures Analysis of the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial.
Reperfusion after stroke sonothrombolysis with microbubbles may predict intracranial bleeding.
Reperfusion and outcomes in Penumbra vs. systemic tissue plasminogen activator clinical trials.
Reperfusion Rates Following Intra-Arterial Thrombolysis for Acute Ischemic Stroke: The Influence of the Method for Alteplase Delivery.
Reperfusion seizures: a manifestation of cerebral reperfusion injury after administration of recombinant tissue plasminogen activator for acute ischemic stroke.
Reperfusion therapies of acute ischemic stroke: potentials and failures.
Reperfusion therapy for acute stroke improves outcome by decreasing neuroinflammation.
Reperfusion therapy for minor stroke: A systematic review and meta-analysis.
Reperfusion therapy for stroke.
Reperfusion therapy in patients with acute myocardial infarction and prior coronary artery bypass graft surgery (National Registry of Myocardial Infarction-2).
Reproducibility of ABC/2 Method to Determine Infarct Volume and Mismatch Percentage with CT Perfusion.
Repurposing of Approved Cardiovascular Drugs against Ischemic Cerebrovascular Disease by Disease-Disease Associated Network-Assisted Prediction.
Rescue localized intra-arterial thrombolysis for hyperacute MCA ischemic stroke patients after early non-responsive intravenous tissue plasminogen activator therapy.
Rescue Thrombectomy in Large Vessel Occlusion Strokes Leads to Better Outcomes than Intravenous Thrombolysis Alone: A 'Real World' Applicability of the Recent Trials.
Resident-based acute stroke protocol is expeditious and safe.
Residual flow at the site of intracranial occlusion on transcranial Doppler predicts response to intravenous thrombolysis: a multi-center study.
Residual flow signals predict complete recanalization in stroke patients treated with TPA.
Resolution of acute onset hemichorea-hemiballismus after treatment with intravenous tissue plasminogen activator.
Resource Allocation: Stable Patients Remain Stable 12-24 h Post-tPA.
Resource utilization and outcome at a university versus a community teaching hospital in tPA treated stroke patients: a retrospective cohort study.
Response by Flint et al to Letter Regarding Article, "Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment".
Response by Oppenheim et al to Letter Regarding Article, "Outcome After Reperfusion Therapies in Patients With Large Baseline Diffusion-Weighted Imaging Stroke Lesions: A THRACE Trial (Mechanical Thrombectomy After Intravenous Alteplase Versus Alteplase Alone After Stroke) Subgroup Analysis".
Response of blood pressure and blood glucose to treatment with recombinant tissue-type plasminogen activator in acute ischemic stroke: evidence from the virtual international stroke trials archive.
Response to "Effect of tissue plasminogen activator dose and interval on stroke severity".
Response to ethical challenges in stroke research. The NINDS rt-PA Stroke Study Group.
Response to letter regarding article, "defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the national institute of neurological disorders and stroke tissue-type plasminogen activator trials".
Response to letter regarding article, "standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses".
Response to letter regarding article, "Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the Third International Stroke Trial".
Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect.
Resveratrol improves delayed r-tPA treatment outcome by reducing MMPs.
Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction.
Retrograde transvenous neuroperfusion: a back door treatment for stroke.
Retrospective Multicenter Study of Solitaire FR for Revascularization in the Treatment of Acute Ischemic Stroke.
REVASCAT: a randomized trial of revascularization with SOLITAIRE FR® device vs. best medical therapy in the treatment of acute stroke due to anterior circulation large vessel occlusion presenting within eight-hours of symptom onset.
Revascularization and functional outcomes after mechanical thrombectomy for acute ischemic stroke in elderly patients.
Revascularization and functional outcomes after mechanical thrombectomy: an update to key metrics.
Revascularization end points in stroke interventional trials: recanalization versus reperfusion in IMS-I.
Reversal of acute ischemic stroke after THA using tissue plasminogen activator.
Reversal of warfarin-induced anticoagulation with factor VIIa prior to rt-PA in acute stroke.
Reversing stroke in the 2010s: lessons from Desmoteplase In Acute ischemic Stroke-2 (DIAS-2).
Reversing the deleterious effects of ?2-antiplasmin on tissue plasminogen activator therapy improves outcomes in experimental ischemic stroke.
Review of Stroke Thrombolytics.
Review of the ENCHANTED Trial (Enhanced Control of Hypertension and Thrombolysis Stroke Study): How Low Can We Go With Intravenous Tissue-Type Plasminogen Activator Dose and Blood Pressure Level?
Review of the Mobile Stroke Unit Experience Worldwide.
Review, Historical Context, and Clarifications of the NINDS rt-PA Stroke Trials Exclusion Criteria: Part 1: Rapidly Improving Stroke Symptoms.
Revolution in acute ischaemic stroke care: a practical guide to mechanical thrombectomy.
Rho-kinase mediates hyperglycemia-induced plasminogen activator inhibitor-1 expression in vascular endothelial cells.
Right Hemisphere Ischemia is more likely to Cause Falsely "Mild" Symptoms and Poor Outcomes without Thrombolysis.
Right hemisphere syndromes.
Risk adjustment effect on stroke clinical trials.
Risk factors and outcomes of intravenous tissue plasminogen activator and endovascular thrombectomy utilization amongst pediatrics acute ischemic stroke.
Risk factors for cerebrovascular disease and the role of coagulation and fibrinolysis.
Risk Factors for Early Intracerebral Hemorrhage after Intravenous Thrombolysis with Alteplase.
Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial).
Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).
RISK FACTORS OF rt-PA THERAPY IN PATIENTS WITH ISCHEMIC STROKE.
Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke.
Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2.
Risk of contracting SARS-CoV-2 (COVID-19) from hospital admission and the impact of protection efforts on acute stroke treatment.
Risk of Distal Embolization From tPA (Tissue-Type Plasminogen Activator) Administration Prior to Endovascular Stroke Treatment.
Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis.
Risk of Intracranial Hemorrhage Following Intravenous tPA (Tissue-Type Plasminogen Activator) for Acute Stroke Is Low in Children.
Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator.
Role of Bedside Preparation in Reducing "Door-to-Needle" Tissue-Type Plasminogen Activator (Alteplase) Administration Times and Association with Patient Outcomes.
Role of beta-defensin 2 and interleukin-4 receptor as stroke outcome biomarkers.
Role of CT Angiography in Thrombolysis Decision-Making for Patients With Presumed Seizure at Stroke Onset.
Role of fibrinogen levels and factor XIII V34L polymorphism in thrombolytic therapy in stroke patients.
Role of fibrinolytic markers in acute stroke.
Role of the MMP9 gene in hemorrhagic transformations after tissue-type plasminogen activator treatment in stroke patients.
Role of the S1P pathway and inhibition by fingolimod in preventing hemorrhagic transformation after stroke.
Role of Transporters in Central Nervous System Drug Delivery and Blood-Brain Barrier Protection: Relevance to Treatment of Stroke.
Role of vascular endothelial growth factor and other growth factors in post-stroke recovery.
Role of vasopressin and its antagonism in stroke related edema.
Roles of blood-brain barrier integrins and extracellular matrix in stroke.
Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke.
Rosuvastatin Reduces Neuroinflammation in the Hemorrhagic Transformation After rt-PA Treatment in a Mouse Model of Experimental Stroke.
Routine 24-Hour Computed Tomography Brain Scan is not useful in stable patients Post Intravenous Tissue Plasminogen Activator.
Routine use of FLAIR-negative MRI in the treatment of unknown onset stroke.
Routine Use of Intravenous Low-Dose Recombinant Tissue Plasminogen Activator in Japanese Patients. General Outcomes and Prognostic Factors From the SAMURAI Register.
Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic Stroke.
rt-PA and Stroke: Does IST-3 Make It All Clear or Muddy the Waters?Answers to the November 2012 Journal Club Questions.
rt-PA causes a dose-dependent increase in the extravasation of cellular and non-cellular blood elements after focal cerebral ischemia.
rtPA intravenous thrombolysis in anterior choroidal artery territory stroke.
Ruling Out Brain CT Contraindications prior to Intravenous Thrombolysis: Diagnostic Equivalence between a Primary Interpretation Workstation and a Mobile Tablet Computer.
Safe and effective intravenous thrombolysis for acute ischemic stroke caused by left atrial myxoma.
Safe Readministration of Intravenous Thrombolysis in Recurrent Basilar Thrombosis.
Safe use of alteplase in a 10 months old infant with cardio-embolic stroke.
Safety and clinical outcomes of urgent superficial temporal artery-middle cerebral artery bypass-a single-institution retrospective analysis.
Safety and Effectiveness of Intravenous Thrombolysis for Acute Ischemic Stroke Outside the Coverage of National Health Insurance in Taiwan.
Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial.
Safety and efficacy of intravenous thrombolysis in stroke patients on prior antiplatelet therapy in the WAKE-UP trial.
Safety and Efficacy of Intravenous Thrombolytic Therapy in Patients With Acute Posterior Circulation Stroke: A Single-Center Study.
Safety and efficacy of intravenous thrombolytic treatment in wake-up stroke: Experiences from a single center.
Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke.
Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol.
Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial.
Safety and Efficacy of Mechanical Thrombectomy in Acute Ischemic Stroke of Anticoagulated Patients-A Prospective Observational Study.
Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE-TPA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study.
Safety and Efficacy of Repeated Thrombolysis with Alteplase in Early Recurrent Ischemic Stroke: A Systematic Review.
Safety and efficacy of rt-PA treatment for acute stroke in pseudoxanthoma elasticum: the first report.
Safety and Efficacy of Solitaire Stent Thrombectomy: Individual Patient Data Meta-Analysis of Randomized Trials.
Safety and efficacy of stroke thrombolysis at a secondary provincial hospital in New Zealand.
Safety and efficacy of thrombolysis in telestroke: A systematic review and meta-analysis.
Safety and efficacy of thrombolysis with intravenous alteplase in older stroke patients.
Safety and efficacy of ultrasound-enhanced thrombolysis in the treatment of acute middle cerebral artery infarction: a critically appraised topic.
Safety and feasibility of a lower dose intravenous TPA therapy for ischemic stroke beyond the first three hours.
Safety and Feasibility of Argatroban, Recombinant Tissue Plasminogen Activator, and Intra-Arterial Therapy in Stroke (ARTSS-IA Study).
Safety and feasibility of intravenous rt-PA in the Emergency Department without a neurologist-based stroke unit: an observational study.
Safety and Outcomes following Thrombolytic Treatment in Stroke Patients Who Had Received Prior Treatment with Anticoagulants.
Safety and outcomes in stroke mimics after intravenous tissue plasminogen activator administration: a single-center experience.
Safety and outcomes of intravenous thrombolysis in stroke mimics: a 6-year, single-care center study and a pooled analysis of reported series.
Safety and Outcomes of Intravenous tPA in Acute Ischemic Stroke Patients With Prior Stroke Within 3 Months: Findings From Get With The Guidelines-Stroke.
Safety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke.
Safety and predictors of stroke mimics in The Norwegian Tenecteplase Stroke Trial (NOR-TEST).
Safety and Preliminary Efficacy of Early Tirofiban Treatment After Alteplase in Acute Ischemic Stroke Patients.
Safety and Tolerability of Desmoteplase Within 3 to 9 Hours After Symptoms Onset in Japanese Patients With Ischemic Stroke.
Safety of Early Repeated Thrombolysis: A Case Report.
Safety of Endovascular Intervention for Stroke on Therapeutic Anticoagulation: Multicenter Cohort Study and Meta-Analysis.
Safety of full-dose intravenous recombinant tissue plasminogen activator followed by multimodal endovascular therapy for acute ischemic stroke.
Safety of intravenous alteplase within 4.5 hours for patients awakening with stroke symptoms.
Safety of Intravenous Thrombolysis for Acute Stroke in Patients with an Active Malignancy: Case Series and Review of the Literature.
Safety of intravenous thrombolysis in stroke of unknown time of onset: A systematic review and meta-analysis.
Safety of Intravenous Thrombolysis within 4.5 h of Symptom Onset in Patients with Negative Post-Treatment Stroke Imaging for Cerebral Infarction.
Safety of Intravenous Thrombolytic Use in Four Emergency Departments Without Acute Stroke Teams.
Safety of off-label stroke treatment with tissue plasminogen activator.
Safety of Performing CT-angiography in Stroke Patients Treated with Intravenous Thrombolysis.
Safety of Protocol Violations in Acute Stroke tPA Administration.
Safety of standard-dose (.9-mg/kg) alteplase intravenous thrombolysis for acute ischemic stroke in Afro-Caribbeans, French West Indies.
Safety of tissue plasminogen activator factor in an acute stroke patient with two unruptured cerebral aneurysms.
Safety of tissue plasminogen activator for acute stroke in menstruating women.
Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia.
Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia: swift or sure? The acceptable rate of neurovascular mimics among IV tPA-treated patients.
Safety of Triple Neuroprotection with Targeted Hypothermia, Controlled Induced Hypertension, and Barbiturate Infusion during Emergency Carotid Endarterectomy for Acute Stroke after Missing the 24 Hours Window Opportunity.
Safety of urgent STA-MCA anastomosis after intravenous rt-PA treatment: a report of five cases and literature review.
Safety outcomes of Alteplase among acute ischemic stroke patients with special characteristics.
Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene.
Safety profile of transcranial near-infrared laser therapy administered in combination with thrombolytic therapy to embolized rabbits.
SAFETY, EFFECTIVENESS, AND PRACTICALITY OF ENDOVASCULAR THERAPY WITHIN THE FIRST 3 HOURS OF ACUTE ISCHEMIC STROKE ONSET.
Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.
SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke): A Randomized Controlled Phase 2 Trial.
Scoping review of acute stroke care management and rehabilitation in low and middle-income countries.
Seizures during stroke thrombolysis heralding dramatic neurologic recovery.
Selecting a thrombolytic agent.
Selecting patients for early stroke treatment with penumbra images.
Selection for delayed intravenous alteplase treatment based on a prognostic score.
Sequence-specific MR Imaging Findings That Are Useful in Dating Ischemic Stroke.
Sequential Multiple Assignment Randomized Trials: An Opportunity for Improved Design of Stroke Reperfusion Trials.
Serine protease inhibitors: novel therapeutic targets for stroke?
Serum creatinine may indicate risk of symptomatic intracranial hemorrhage after intravenous tissue plasminogen activator (IV tPA).
Serum uric acid is neuroprotective in Chinese patients with acute ischemic stroke treated with intravenous recombinant tissue plasminogen activator.
Setting Up a Stroke Team Algorithm and Conducting Simulation-based Training in the Emergency Department - A Practical Guide.
Seven-Day NIHSS Is a Sensitive Outcome Measure for Exploratory Clinical Trials in Acute Stroke: Evidence From the Virtual International Stroke Trials Archive.
Severe heat stroke associated with high plasma levels of plasminogen activator inhibitor 1.
Sex as a predictor of outcomes in patients treated with thrombolysis for acute stroke.
Sex differences in ischaemic stroke: potential cellular mechanisms.
Sex differences in IV thrombolysis treatment for acute ischemic stroke: A systematic review and meta-analysis.
Sex Differences in rt-PA Utilization at Hospitals Treating Stroke: The National Inpatient Sample.
Sex differences in stroke therapies.
Sex differences in the impact of acute stroke treatment in a population-based study: a sex-specific propensity score approach.
Sex differences in the use of intravenous rt-PA thrombolysis treatment for acute ischemic stroke: a meta-analysis.
Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials.
Sex-Based Differences in Symptom Perception and Care-Seeking Behavior in Acute Stroke.
Sex-Related Differences in Management and Outcome of Acute Ischemic Stroke in Eligible Patients to Thrombolysis.
Sexual dimorphism in stroke.
Shenzhen stroke emergency map improves access to rt-PA for patients with acute ischaemic stroke.
Short- and Long-Term Reduction of Door-to-Needle Time in Thrombolysis for Acute Stroke.
Shortening time to stroke treatment using ambulance telemedicine: TeleBAT.
Shorter Intensive Care Unit Stays? The Majority of Post-Intravenous tPA (Tissue-Type Plasminogen Activator) Symptomatic Hemorrhages Occur Within 12 Hours of Treatment.
Should all patients with mild ischemic stroke be excluded from therapeutic stroke trials?
Should all stroke patients receive tissue plasminogen activator therapy, despite mild or improving symptoms?
Should physicians give tPA to patients with acute ischemic stroke? Against: and just what is the emperor of stroke wearing?
Should physicians give tPA to patients with acute ischemic stroke? For: thrombolytics in stroke: whose risk is it anyway?
Should stroke patients with mild or improving symptoms receive tissue plasminogen activator therapy?
Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?
Sickle Mice Are Sensitive to Hypoxia/Ischemia-Induced Stroke but Respond to Tissue-Type Plasminogen Activator Treatment.
Sigma receptor activation reduces infarct size at 24 hours after permanent middle cerebral artery occlusion in rats.
Silver Jubilee of Stroke Thrombolysis With Alteplase: Evolution of the Therapeutic Window.
Similar thrombolysis outcomes in acute stroke patients with and without atrial fibrillation if pre-stroke CHA2DS2-VASc score is low: A retrospective study.
Simple clinical predictors of stroke outcome based on National Institutes of Health Stroke scale score during 1-h recombinant tissue-type plasminogen activator infusion.
Simulation training for emergency teams to manage acute ischemic stroke by telemedicine.
Simultaneous administration of recombinant tissue plasminogen activator and edaravone in acute cerebral ischemic stroke patients.
Simultaneous cardiocerebral infarctions: a five-year retrospective case series reviewing natural history.
Simultaneous treatment of ischaemic bowel and ischaemic stroke with intravenous thrombolysis therapy.
Single nucleotide variations in ZBTB46 are associated with post-thrombolytic parenchymal haematoma.
Single- and two- chain tissue type plasminogen activator treatments differentially influence cerebral recovery after stroke.
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators.
Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke.
Smad3-dependent induction of plasminogen activator inhibitor-1 in astrocytes mediates neuroprotective activity of transforming growth factor-beta 1 against NMDA-induced necrosis.
Small Rural Hospitals Have a Harder Time Achieving Success in Continuous Quality Improvement: An Example From a Stroke Care Network.
Smart Acute Stroke Quality Registry Design-Data Elements Identification.
Sodium Tanshinone IIA Sulfonate Enhances Effectiveness Rt-PA Treatment in Acute Ischemic Stroke Patients Associated with Ameliorating Blood-Brain Barrier Damage.
SOLITAIRE™ with the intention for thrombectomy (SWIFT) trial: design of a randomized, controlled, multicenter study comparing the SOLITAIRE™ Flow Restoration device and the MERCI Retriever in acute ischaemic stroke.
Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke.
Soluble expression of active recombinant human tissue plasminogen activator derivative (K2S) in Escherichia coli.
Some suggest wider therapeutic window for offering alteplase to treat stroke.
Sonothrombolysis in ischemic stroke.
Sonothrombolysis in the management of acute ischemic stroke.
Sonothrombolysis with transcranial color-coded sonography and recombinant tissue-type plasminogen activator in acute middle cerebral artery main stem occlusion: results from a randomized study.
Spatio-temporal course of macrophage-like cell accumulation after experimental embolic stroke depending on treatment with tissue plasminogen activator and its combination with hyperbaric oxygenation.
Specific Needs for Telestroke Networks for Thrombolytic Therapy in Japan.
Speed of intracranial clot lysis with intravenous tissue plasminogen activator therapy: sonographic classification and short-term improvement.
Speed of tPA-induced clot lysis predicts DWI lesion evolution in acute stroke.
Spin Trap Agents: A New Approach to Stroke Therapy.
Spontaneous cerebral calcific embolus from the aortic arch.
Spontaneous Splenic Rupture Following Intravenous Thrombolysis with Alteplase Applied as Stroke Therapy - Case Report and Review of Literature.
Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses.
Statin use and functional outcome after tissue plasminogen activator treatment in acute ischaemic stroke.
Statistical analysis plan for evaluating different intensities of blood pressure control in the ENhanced Control of Hypertension And Thrombolysis strokE stuDy.
Statistical analysis plan for evaluating low- vs. standard-dose alteplase in the ENhanced Control of Hypertension and Thrombolysis strokE stuDy (ENCHANTED).
Status of prehospital delay and intravenous thrombolysis in the management of acute ischemic stroke in Nepal.
Stem cell-paved biobridges facilitate stem transplant and host brain cell interactions for stroke therapy.
Stent retriever thrombectomy with aneurysm in target vessel: Technical note.
Stent Retriever-Assisted Mechanical Thrombectomy for Acute Basilar Artery Occlusion: Single US Institution Experience.
Stenting versus endarterectomy and the impact of ultra-early revascularization for emergent admissions of carotid artery stenosis.
Stop Stroke© Acute Care Coordination Medical Application: A Brief Report on Postimplementation Performance at a Primary Stroke Center.
Strategies to Extend Thrombolytic Time Window for Ischemic Stroke Treatment: An Unmet Clinical Need.
Strategies to prevent hemorrhagic transformation after reperfusion therapies for acute ischemic stroke: A literature review.
Streamlining the Process for Intravenous Tissue Plasminogen Activator.
Streptokinase. A pharmacoeconomic appraisal of its use in the management of acute myocardial infarction.
Streptokinase. A review of its pharmacology and therapeutic efficacy in acute myocardial infarction in older patients.
Stressed neurons protect themselves by a tissue-type plasminogen activator-mediated EGFR-dependent mechanism.
Striking rural-urban disparities observed in acute stroke care capacity and services in the pacific northwest: implications and recommendations.
Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long-term prognosis.
Stroke and Drug Delivery-In Vitro Models of the Ischemic Blood-Brain Barrier.
Stroke and immunotherapy: Potential mechanisms and its implications as immune-therapeutics.
Stroke and the aging of the brain and the arteries.
Stroke as the initial presentation of Takayasu's arteritis: A case report.
Stroke biomarkers: Can they help us to guide stroke thrombolysis?
Stroke biomarkers: can they help us to guide stroke thrombolysis?
Stroke care: Room for improvement.
Stroke center characteristics which influence the administration of thrombolytic therapy for acute ischemic stroke: a national survey of stroke centers in Taiwan.
Stroke code improves intravenous thrombolysis administration in acute ischemic stroke.
Stroke complicating acute myocardial infarction. A meta-analysis of risk modification by anticoagulation and thrombolytic therapy.
Stroke Fast Track Reduces Time Delay to Neuroimaging and Increases Use of Thrombolysis in an Academic Medical Center in Thailand.
Stroke following internal carotid artery occlusion - a contra-indication for intravenous thrombolysis?
Stroke guideline supports expanded alteplase use.
Stroke in a Child Safely Treated with Intravenous Tissue Plasminogen Activator and Edaravone, a Free Radical Scavenger.
Stroke in a young patient treated by alteplase heralding an acquired thrombotic thrombocytopenic purpura.
Stroke in children: recognition, treatment, and future directions.
Stroke in ovarian hyperstimulation syndrome in early pregnancy treated with intra-arterial rt-PA.
Stroke in patients with cancer in the era of hyper-acute stroke intervention.
Stroke in South Asian countries.
Stroke in the patient with diabetes (Part 2) - Prevention and the effects of glucose lowering therapies.
Stroke in the puerperium treated with intra-arterial rt-PA.
Stroke in Women: Risk Factors and Clinical Biomarkers.
Stroke information reported on local television news: a national perspective.
Stroke initiative speeds time of tPA administration.
Stroke knowledge among urban and frontier first responders and emergency medical technicians in Montana.
Stroke Mimics and Acute Stroke Evaluation: Clinical Differentiation and Complications after Intravenous Tissue Plasminogen Activator.
Stroke Mimics in a Stroke Care Pathway Based on MRI Screening.
Stroke Mimics: An Important Source of Bias in Acute Ischemic Stroke Research.
Stroke Neurologist's Perspective on the New Endovascular Trials.
Stroke onset time using sodium MRI in rat focal cerebral ischemia.
Stroke onset to needle delay: Where these golden hours are lost? An Egyptian center experience.
Stroke Presenting as a Complication of Sarcoidosis in an Otherwise Asymptomatic Patient.
Stroke Prognostication using Age and NIH Stroke Scale: SPAN-100.
Stroke Quality Measures in Mexican Americans and Non-Hispanic Whites.
Stroke Ready: a multi-level program that combines implementation science and community-based participatory research approaches to increase acute stroke treatment: protocol for a stepped wedge trial.
Stroke salvage using a suction thrombectomy device and tissue plasminogen activator.
Stroke Scale Items Associated with Neurologic Deterioration within 24 Hours after Recombinant Tissue Plasminogen Activator Therapy.
Stroke service: how can we improve and measure outcomes? Consensus summary from a global stroke forum.
Stroke symptoms and the decision to call for an ambulance.
Stroke Systems of Care During the COVID-19 Epidemic in Kobe City.
Stroke thrombolysis complicated by ST elevation myocardial infarction (STEMI).
Stroke thrombolysis in England: an age stratified analysis of practice and outcome.
Stroke Thrombolysis in Patients Taking Ticagrelor -Two Successful Cases and a Review of the Literature.
Stroke Thrombolysis With Tenecteplase to Reduce Emergency Department Spread of Coronavirus Disease 2019 and Shortages of Alteplase.
Stroke thrombolysis: is tissue plasminogen activator a defibrillator for the brain?
Stroke Treatment Using Intravenous and Intra-Arterial Tissue Plasminogen Activator.
Stroke treatment window widens, but a fast response is still crucial. Research shows the clotbusting drug rt-PA can work if given after four and a half hours, but its more effective the sooner it is administered.
Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.
Stroke Treatment With Intravenous Tissue-Type Plasminogen Activator: More Proof That Time Is Brain.
Stroke Treatment With PAR-1 Agents to Decrease Hemorrhagic Transformation.
Stroke treatment with tissue plasminogen activator in the setting of aortic dissection.
Stroke treatment: beyond the three-hour window and in the pregnant patient.
Stroke trials: what have we learned?
Stroke units in Hungary - the Debrecen experience.
Stroke units in Italy: engaging the public in optimizing existing resources.
Stroke units, tissue plasminogen activator, aspirin and neuroprotection: which stroke intervention could provide the greatest community benefit?
Stroke warning syndrome: 18 new cases.
Stroke, tPA, and physician decision-making.
Stroke-Associated Pneumonia in Thrombolyzed Patients: Incidence and Outcome.
Stroke.
Stroke: a double-edged sword for cleaving clots?
Stroke: acute stroke receiving facilities and management.
Stroke: call 911. Nursing recognition & response.
Stroke: current concepts of care.
Stroke: Effect of implementing an evaluation and treatment protocol compliant with NINDS recommendations.
Stroke: New study vindicates use of low-dose alteplase in East Asia.
Stroke: part II. Management of acute ischemic stroke.
Stroke: Support for IV tPA in ischaemic stroke in elderly people.
Stroke: The question of alteplase dose for stroke is not resolved.
Stroke: validation of the ABCD2 score, safety of tPA in stroke mimics and effects of robot-assisted therapy.
Strokes and net clinical benefit.
Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials.
Study of the efficacy of intravenous tissue plasminogen activator in central retinal artery occlusion.
Subacute intranasal administration of tissue plasminogen activator improves stroke recovery by inducing axonal remodeling in mice.
Subacute intranasal administration of tissue plasminogen activator increases functional recovery and axonal remodeling after stroke in rats.
Subcortical Magnetic Resonance Imaging Changes in a Healthy Elderly Population; Stroke Risk Factors, Ultrasound, and Hemostasis Findings.
Successful Emergency Carotid Endarterectomy after Thrombolysis with Intravenous Recombinant Tissue-Type Plasminogen Activator.
Successful intravenous thrombolysis in a 14-year-old boy with ischemic stroke.
Successful intravenous thrombolysis in a stroke patient with hemiballism.
Successful recanalization post endovascular therapy is associated with a decreased risk of intracranial haemorrhage: a retrospective study.
Successful Systemic Thrombolysis in an Adolescent With Acute Ischemic Stroke.
Successful thrombolysis of stroke with intravenous alteplase in the third trimester of pregnancy.
Successful thrombolysis with recombinant tissue plasminogen activator after antagonizing dabigatran by idarucizumab: a case report.
Successful Tissue Plasminogen Activator for a Patient with Stroke After Stanford Type A Aortic Dissection Treatment.
Successful treatment for stroke in a child using recombinant tissue plasminogen activator.
Successful treatment of ischemic stroke associated with brachiocephalic artery stenosis using alteplase.
Successful treatment of pediatric stroke with recombinant tissue plasminogen activator (rt-PA): a case report and review of the literature.
Successful treatment with intravenous recombinant tissue plasminogen activator in an acute stroke patient presenting with hemiballism.
Successful use of rt-PA in pediatric stroke.
Suppression of NLRP3 attenuates hemorrhagic transformation after delayed rtPA treatment in thromboembolic stroke rats: Involvement of neutrophil recruitment.
Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure.
Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke.
Susceptibility-weighted Imaging in Thrombolytic Therapy of Acute Ischemic Stroke.
Sustained benefit of a community and professional intervention to increase acute stroke therapy.
Sustained Opening of the Blood-Brain Barrier with Progressive Accumulation of White Matter Hyperintensities Following Ischemic Stroke.
Switching to Tenecteplase for Stroke Thrombolysis: Real-World Experience and Outcomes in a Regional Stroke Network.
Symptomatic intracerebral hemorrhage after intravenous thrombolysis in Chinese patients: comparison of prediction models.
Symptomatic intracerebral hemorrhage and recanalization after IV rt-PA: a multicenter study.
Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors.
SYNTHESIS expansion: design of a nonprofit, pragmatic, randomized, controlled trial on the best fast-track endovascular treatment vs. standard intravenous alteplase for acute ischemic stroke.
Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke.
Systemic augmentation of {alpha}B-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation.
Systemic thrombolysis in clinical practice: what have we learned after the safe implementation of thrombolysis in stroke monitoring study?
Systemic thrombolysis with rt-PA in patients under 40 years of age: a subgroup analysis of the Cologne Stroke Experience.
t-PA reduces ischemic impairment of blood-brain barrier by strengthening endothelium junction.
Tandem internal carotid artery/middle cerebral artery occlusion: an independent predictor of poor outcome after systemic thrombolysis.
Target Door-to-Needle Time for Tissue Plasminogen Activator Treatment with Magnetic Resonance Imaging Screening Can Be Reduced to 45 min.
Target: tPA. Educational efforts help prehospital providers get stroke patients to the appropriate destinations and treatment.
Targeted tPA overexpression in denervated spinal motor neurons promotes stroke recovery in mice.
Targeting extracellular matrix proteolysis for hemorrhagic complications of tPA stroke therapy.
Targeting histone deacetylases as a multifaceted approach to treat the diverse outcomes of stroke.
Targeting neuroprotection clinical trials to ischemic stroke patients with potential to benefit from therapy.
Targeting Platelet GPVI Plus rt-PA Administration but Not ?2?1-Mediated Collagen Binding Protects against Ischemic Brain Damage in Mice.
Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial.
Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat.
Telehealth for Remote Stroke Management.
Telemedicine Can Replace the Neurologist on a Mobile Stroke Unit.
Telemedicine for acute stroke: triumphs and pitfalls.
Telemedicine for safe and extended use of thrombolysis in stroke: the Telemedic Pilot Project for Integrative Stroke Care (TEMPiS) in Bavaria.
Telemedicine in acute stroke management: systematic review.
Telemedicine in emergency neurological service provision in Singapore: using technology to overcome limitations.
Telemedicine Interest for Routine Follow-Up Care Among Neurology Patients in Arkansas.
Telemedicine physician providers: augmented acute stroke care delivery in rural Texas: an initial experience.
Telemedicine versus face-to-face evaluation in the delivery of thrombolysis for acute ischaemic stroke: a single centre experience.
Telephone consultations for tissue plasminogen activator administration in acute stroke.
Telephonic guidance of systemic thrombolysis in acute ischemic stroke: safety outcome in rural hospitals.
Teleradiology Assessment of Computerized Tomographs Online Reliability Study (TRACTORS) for acute stroke evaluation.
Telestroke Imaging: A Review.
Telestroke in South Carolina.
Telestroke in the Time of COVID-19: The Mayo Clinic Experience.
Telestroke-guided intravenous tissue-type plasminogen activator treatment achieves a similar clinical outcome as thrombolysis at a comprehensive stroke center.
Telestroke.
Telestroke: extending stroke expertise into underserved areas.
Telestroke: Variations in Intravenous Thrombolysis by Spoke Hospitals.
Temporal Trends in Patient Characteristics and Treatment With Intravenous Thrombolysis Among Acute Ischemic Stroke Patients at Get With the Guidelines-Stroke Hospitals.
Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at get with the guidelines-stroke hospitals.
Ten-Year Evaluation of the TOYOTA Prehospital Stroke Scale for Tissue Plasminogen Activator Intravenous Therapy in the Real World.
Ten-Year Trend in Age, Sex, and Racial Disparity in tPA (Alteplase) and Thrombectomy Use Following Stroke in the United States.
Tenecteplase for Acute Ischemic Stroke: Current Evidence and Practical Considerations.
Tenecteplase for the treatment of acute ischemic stroke: A review of completed and ongoing randomized controlled trials.
Tenecteplase for thrombolysis in stroke patients: Systematic review with meta-analysis.
Tenecteplase Thrombolysis for Acute Ischemic Stroke.
Tenecteplase versus alteplase after acute ischemic stroke at high age.
Tenecteplase Versus Alteplase Between 3 and 4.5 Hours in Low National Institutes of Health Stroke Scale.
Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.
Tenecteplase versus alteplase in stroke thrombolysis: An individual patient data meta-analysis of randomized controlled trials.
Tenecteplase Versus Reteplase in Acute Myocardial Infarction: A Network Meta-Analysis of Randomized Clinical Trials.
Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction.
Tensions remain over tPA for stroke.
TESPI (Thrombolysis in Elderly Stroke Patients in Italy): a randomized controlled trial of alteplase (rt-PA) versus standard treatment in acute ischaemic stroke in patients aged more than 80 years where thrombolysis is initiated within three hours after stroke onset.
Text-message-driven intervention, real time feedback slashes time-to-treatment for stroke patients.
The "drip-and-ship" approach: starting IV t-PA for acute ischemic stroke at outside hospitals prior to transfer to a regional stroke center.
The 4G/4G genotype at nucleotide position -675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls.
The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--II: neurologic outcome and efficacy analysis.
The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.
The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study.
The Association Between an Antecedent of Transient Ischemic Attack Prior to Onset of Stroke and Functional Ambulatory Outcome.
The Association between Presentation by EMS and EMS Prenotification with Receipt of Intravenous Tissue-type Plasminogen Activator in a State Implementing Stroke Systems of Care.
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.
The brain-specific tissue-type plasminogen activator inhibitor, neuroserpin, protects neurons against excitotoxicity both in vitro and in vivo.
The Burden of Diabetes and the Chance of a Previous Stroke: Thrombolysis for Recurrent Stroke in Diabetics.
The chain of care enabling tPA treatment in acute ischemic stroke: a comprehensive review of organisational models.
The challenge of acute-stroke management: does telemedicine offer a solution?
The clomethiazole acute stroke study in ischemic, hemorrhagic, and t-PA treated stroke: Design of a phase III trial in the united states and canada.
The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results.
The CLOQS trial protocol: a cluster-randomized trial evaluating a simple, low-cost intervention to reduce treatment times in acute stroke.
The clot thickens--thrombolysis and combination therapies.
The coagulopathy of heat stroke: alterations in coagulation and fibrinolysis in heat stroke patients during the pilgrimage (Haj) to Makkah.
The Combination of Clinical Features, Transcranial Doppler, and Alberta Stroke Program Early Computed Tomography Score (Computed Tomography Angiography) in Predicting Outcome in Intravenous Recombinant Tissue Plasminogen Activator-Treated Patients.
The combination of elevated BNP and AF as a predictor of no early recanalization after IV-t-PA in acute ischemic stroke.
The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial.
The complexities of acute stroke decision-making: A survey of neurologists.
The complexity of tissue-type plasminogen activator: can serine protease inhibitors help in stroke management?
The concept of ischemic penumbra in acute stroke and therapeutic opportunities.
The cost of stroke in a public hospital in Brazil: a one-year prospective study.
The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.
The development of stroke therapeutics: promising mechanisms and translational challenges.
The diagnostic utility of S-100B protein and TPA in patients with ischemic stroke.
The Door to Needle Time Metric Can Be Achieved via Telestroke.
The Early Outcomes of Nurse Case Management in Patients with Acute Ischemic Stroke Treated with Intravenous Recombinant Tissue Plasminogen Activator: A Prospective Randomized Controlled Trial.
The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study.
The Effect of Age and Sex on Clinical Outcome after Intravenous Recombinant Tissue Plasminogen Activator Treatment in Patients with Acute Ischemic Stroke.
The effect of anticonvulsant drugs on the fibrinolytic activity of tissue plasminogen activator.
The effect of physiologic derangement in patients with stroke treated with thrombolysis.
The effect of race and gender on patterns of rt-PA use within a population.
The effect of recombinant tissue plasminogen activator on MMP-2 and MMP-9 activities in vitro.
The Effect of tPA on Inpatient Rehabilitation after Stroke: A Cost Comparison.
The Effects and Underlying Mechanisms of Cell Therapy on Blood-Brain Barrier Integrity After Ischemic Stroke.
The effects of a new tissue plasminogen activator analogue, Fb-Fb-CF, on cerebral reperfusion in a rabbit embolic stroke model.
The effects of alteplase 3 to 6 hours after stroke in the EPITHET-DEFUSE combined dataset: post hoc case-control study.
The effects of citicoline on acute ischemic stroke: a review.
The efficacy and safety of tissue plasminogen activator in acute ischemic strokes.
The Efficacy of IV Tissue Plasminogen Activator for Restoring Cerebral Blood Flow in the Hours Immediately after Administration in Patients with Acute Stroke.
The Emergency Medicine Debate on tPA for Stroke: What Is Best for Our Patients? Efficacy in the First Three Hours.
The FAST-ED App: A Smartphone Platform for the Field Triage of Patients With Stroke.
The first 100 thrombolysis cases in a novel Scottish mesh telestroke system.
The future of stroke thrombolysis.
The gender effect in stroke thrombolysis: of CASES, controls, and treatment-effect modification.
The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis.
The hemodynamic status within 24 h after intravenous thrombolysis predicts infarct growth in acute ischemic stroke.
The hemorrhagic transformation index score: a prediction tool in middle cerebral artery ischemic stroke.
The Hyperdense Middle Cerebral Artery Sign in Drip-and-Ship Models of Acute Stroke Management.
The immune response of T cells and therapeutic targets related to regulating the levels of T helper cells after ischaemic stroke.
The impact of acute kidney injury on in-hospital mortality in acute ischemic stroke patients undergoing intravenous thrombolysis.
The impact of ambulance practice on acute stroke care.
The Impact of Discrepancy between Measured versus Stated Weight on Hemorrhagic Transformation and Clinical Outcomes after Intravenous Alteplase Thrombolysis.
The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study.
The Impact of Intracranial Carotid Artery Calcification on the Development of Thrombolysis-Induced Intracerebral Hemorrhage.
The impact of intravenous alteplase on long-term patient survival: The Georgia Coverdell acute stroke registry's experience.
The impact of lesion side on acute stroke treatment.
The Impact of Loading Dose on Outcome in Stroke Patients Receiving Low-Dose Tissue Plasminogen Activator Thrombolytic Therapy.
The impact of tele-neurologists on acute stroke care at an advanced primary stroke centre.
The impact of the DWI-FLAIR-mismatch in the ECASS-4 trial - A post hoc analysis.
The implementation of intravenous tissue plasminogen activator in acute ischaemic stroke--a scientific position statement from the National Stroke Foundation and the Stroke Society of Australasia.
The influence of dehydration on the prognosis of acute ischemic stroke for patients treated with tissue plasminogen activator.
The influence of stroke risk factors and comorbidities on assessment of stroke therapies in humans and animals.
The Interventional Management of Stroke (IMS) II Study.
The intranigral injection of tissue plasminogen activator induced blood-brain barrier disruption, inflammatory process and degeneration of the dopaminergic system of the rat.
The investigational use of tPA for stroke.
The iScore Predicts Clinical Response to Tissue Plasminogen Activator in Korean Stroke Patients.
The iScore Predicts Efficacy and Risk of Bleeding in the National Institute of Neurological Disorders and Stroke Tissue Plasminogen Activator Stroke Trial.
The lack of documentation of preferences in a cohort of adults who died after ischemic stroke.
The Magic Touch: A Case Report of How Smartphone Fingerprint Technology Was Utilized to Establish a Last Known Well Time for Recanalization Treatment in a Patient With Acute Ischemic Stroke.
The main components of stroke unit care: results of a European expert survey.
The Mild and Rapidly Improving Stroke Study (MaRISS): Rationale and design.
The molecular basis of thrombolysis and its clinical application in stroke.
The MRA-DWI mismatch identifies patients with stroke who are likely to benefit from reperfusion.
The multiarm optimization of stroke thrombolysis phase 3 acute stroke randomized clinical trial: Rationale and methods.
The need for a population-based, dose optimization study for recombinant tissue plasminogen activator in acute ischemic stroke: A study from a tertiary care teaching hospital from South India.
The neuroprotective mechanisms of ginkgolides and bilobalide in cerebral ischemic injury: a literature review.
The neurovascular unit and combination treatment strategies for stroke.
The nonpeptide glycoprotein IIb/IIIa platelet receptor antagonist SM-20302 reduces tissue plasminogen activator-induced intracerebral hemorrhage after thromboembolic stroke.
The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke.
The Number of Stroke Physicians Is the Key to Preparing IV rt-PA.
The objectives of the Banca Dati Italiana Ictus Acuto (BADIA) Project.
The Oxfordshire Community Stroke Project classification system predicts clinical outcomes following intravenous thrombolysis: a prospective cohort study.
The pattern of leptomeningeal collaterals on CT angiography is a strong predictor of long-term functional outcome in stroke patients with large vessel intracranial occlusion.
The Penumbra Stroke System: a technical review.
The PI3K/Akt pathway mediates the neuroprotective effect of atorvastatin in extending thrombolytic therapy after embolic stroke in the rat.
The plasminogen activator inhibitor (PAI)-1 promoter 4G/4G genotype is not associated with ischemic stroke in a population of German children. Childhood Stroke Study Group.
The pleiotropic effects of tissue plasminogen activator in the brain: implications for stroke recovery.
The Potential Impact of Maintaining a 3-Hour IV Thrombolysis Window: How Many More Patients can we Safely Treat?
The practice and predictors of early mobilization of patients post-acute admission to a specialized stroke center.
The predictive value of red cell distribution width for stroke severity and outcome.
The presence of a right-to-left shunt is associated with dramatic improvement after thrombolytic therapy in patients with acute ischemic stroke.
The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling.
The randomized study of endovascular therapy with versus without intravenous tissue plasminogen activator in acute stroke with ICA and M1 occlusion (SKIP study).
The ratio of d-dimer to brain natriuretic peptide may help to differentiate between cerebral infarction with and without acute aortic dissection.
The Relationship Between Admission Systolic Blood Pressure and Mortality in Telestroke Patients.
The response to IV rt-PA in very old stroke patients.
The Risk Factors for Death within 6 Months After Ischemic Stroke in Patients with Cancer.
The risk factors of early hemorrhage after emergency intravenous thrombolysis in patients with acute ischemic stroke.
The risk of delayed intracranial hemorrhage with direct acting oral anticoagulants after trauma: A two-center study.
The Risk of Hemorrhagic Transformation After Thrombolysis for Acute Ischemic Stroke in Chinese Versus North Americans: A Comparative Study.
The risk of intravenous thrombolysis-induced intracranial hemorrhage in Taiwanese patients with unruptured intracranial aneurysm.
The Role for Cardiologists in Stroke Intervention.
The role of Akt (protein kinase B) and protein kinase C in ischemia-reperfusion injury.
The role of astrocytes in mediating exogenous cell-based restorative therapy for stroke.
The Role of Biomarkers in Atherothrombotic Stroke-A Systematic Review.
The role of classic risk factors and prothrombotic factor gene mutations in ischemic stroke risk development in young and middle-aged individuals.
The role of diffusion- and perfusion-weighted magnetic resonance imaging in drug development for ischemic stroke: from laboratory to clinics.
The role of endogenous tissue-type plasminogen activator in neuronal survival after ischemic stroke: friend or foe?
The role of histamine in the increased cardiac output in hyperdynamic endotoxemia.
The Role of Informed Consent for Thrombolysis in Acute Ischemic Stroke.
The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia.
The Role of PAI-1 4G/5G Promoter Polymorphism and Its Levels in the Development of Ischemic Stroke in Young Indian Population.
The Role of Small Vessel Disease in Re-exacerbation of Stroke Symptoms within 24 Hours after Tissue Plasminogen Activator Infusion.
The Role of Stem Cell Factor and Granulocyte-Colony Stimulating Factor in Treatment of Stroke.
The role of stroke nurses in thrombolysis administration in Australia and the United Kingdom: A cross-sectional survey of current practice.
The safety and angiographic efficacy of tissue plasminogen activator in a cerebral embolization model.
The Safety and Effectiveness of Low-Dose Recombinant Tissue Plasminogen Activator (0.6 mg/kg) Therapy for Elderly Acute Ischemic Stroke Patients (? 80 Years Old) in the Pre-endovascular Era.
The safety and efficacy of tPA intravenous thrombolysis for treating acute ischemic stroke patients with a history of cerebral hemorrhage.
The secretome of endothelial progenitor cells: a potential therapeutic strategy for ischemic stroke.
The silver effect of admission glucose level on excellent outcome in thrombolysed stroke patients.
The SITS-UTMOST: A registry-based prospective study in Europe investigating the impact of regulatory approval of intravenous Actilyse in the extended time window (3-4.5?h) in acute ischaemic stroke.
The sonic hedgehog pathway mediates brain plasticity and subsequent functional recovery after bone marrow stromal cell treatment of stroke in mice.
The story of an exceptional serine protease, tissue-type plasminogen activator (tPA).
The STRokE DOC trial technique: 'video clip, drip, and/or ship'.
The Stroke Practice Improvement Network: a quasiexperimental trial of a multifaceted intervention to improve quality.
The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke.
The susceptibility vessel sign at the proximal M1: a strong predictor for poor outcome after intravenous thrombolysis.
The THRIVE score predicts symptomatic intracerebral hemorrhage after intravenous tPA administration in SITS-MOST.
The THRIVE score strongly predicts outcomes in patients treated with the Solitaire device in the SWIFT and STAR trials.
The Totaled Health Risks in Vascular Events (THRIVE) Score Predicts Ischemic Stroke Outcomes Independent of Thrombolytic Therapy in the NINDS tPA Trial.
The transcriptome of cerebral ischemia.
The Use of Antiplatelet Agents and Heparin in the 24-Hour Postintravenous Alteplase Window for Neurointervention.
The use of recombinant tissue plasminogen activator in in acute ischemic stroke is associated with increased level of BDNF.
The very acute stroke treatment: fibrinolysis and after.
The weight of tissue plasminogen activator dose in overweight patients with strokes.
The Year Embolectomy Won: a Review of Five Trials Assessing the Efficacy of Mechanical Intervention in Acute Stroke.
The yield of expanding the therapeutic time window for tPA.
Therapeutic applications of bone marrow-derived stem cells in ischemic stroke.
Therapeutic effect of tPA in ischemic stroke is enhanced by its combination with normobaric oxygen and hypothermia or ethanol.
Therapeutic potential of herbal drugs in cerebral ischemia.
Therapeutic Potential of Platelet Glycoprotein IIb/IIIa Receptor Antagonists in the Management of Ischemic Stroke.
Therapeutic potential of TACE inhibitors in stroke.
Therapeutic strategies for the treatment of stroke.
Therapeutic Strategies to Attenuate Hemorrhagic Transformation After Tissue Plasminogen Activator Treatment for Acute Ischemic Stroke.
Therapeutic time window for ischemic stroke.
Therapeutic time window of tacrolimus (FK506) in a nonhuman primate stroke model: comparison with tissue plasminogen activator.
Therapeutic yield and outcomes of a community teaching hospital code stroke protocol.
Therapy for acute ischemic stroke: the door opens. Interpreting the NINDS rt-PA stroke study.
Therapy of acute basilar artery occlusion: intraarterial thrombolysis alone vs bridging therapy.
Therapy of postoperative stroke: report of intra-arterial thrombolysis of a hyperacute embolic stroke 5 days following CABG.
Third International Stroke Trial 3: an update.
Thirty Years After the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Trial: A New Era for Stroke Therapy.
THR-18, a 18-mer peptide derived from PAI-1, is neuroprotective and improves thrombolysis by tPA in rat stroke models.
THRIVE Score Predicts Ischemic Stroke Outcomes and Thrombolytic Hemorrhage Risk in VISTA.
Thrombectomy for acute basilar artery occlusion by using double Merci retriever devices and bilateral temporary vertebral artery flow reversal.
Thromboelastography in patients with acute ischemic stroke.
Thrombolysis (tissue plasminogen activator) in stroke: a medicolegal quagmire.
Thrombolysis 2004: the good, the bad, and the ugly.
Thrombolysis acute ischemic stroke.
Thrombolysis and stroke. Past and future.
Thrombolysis and Thrombectomy for Acute Ischemic Stroke: Strengths and Synergies.
Thrombolysis at 3-4.5 hours after acute ischemic stroke onset--evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry.
Thrombolysis by PLAT/tPA increases serum free IGF1 leading to a decrease of deleterious autophagy following brain ischemia.
Thrombolysis despite recent stroke: a case series.
Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW).
Thrombolysis for acute ischaemic stroke.
Thrombolysis for acute ischaemic stroke: core nursing requirements.
Thrombolysis for Acute Ischemic Stroke Following Transcatheter Aortic Valve Replacement: Case Report and Literature Review.
Thrombolysis for acute ischemic stroke.
Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study.
Thrombolysis for Acute Minor Stroke: Outcome and Barriers to Management. Results from the RESUVAL Stroke Network.
Thrombolysis for acute stroke in Australia: outcomes from the Safe Implementation of Thrombolysis in Stroke registry (2002-2008).
Thrombolysis for acute stroke in routine clinical practice.
Thrombolysis for acute stroke in the United Kingdom.
Thrombolysis for acute stroke with special emphasis on the very old: experience from a single Dutch centre.
Thrombolysis for acute stroke.
Thrombolysis for acute stroke: is it for everyone?
THrombolysis for Acute Wake-up and unclear-onset Strokes with alteplase at 0·6?mg/kg (THAWS) Trial.
Thrombolysis for Central Retinal Artery Occlusion in 2020: Time Is Vision!
Thrombolysis for ischemic stroke in patients with old microbleeds on pretreatment MRI.
Thrombolysis for patients with acute ischaemic stroke.
Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke.
Thrombolysis ImPlementation in Stroke (TIPS): evaluating the effectiveness of a strategy to increase the adoption of best evidence practice - protocol for a cluster randomised controlled trial in acute stroke care.
Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases.
Thrombolysis in acute childhood stroke: design and challenges of the thrombolysis in pediatric stroke clinical trial.
Thrombolysis in acute ischaemic stroke within 3 hours of symptom onset: a report of the first 100 cases.
Thrombolysis in acute ischaemic stroke: a guide to patient selection.
Thrombolysis in acute ischemic stroke: successes, failures, and new hopes.
Thrombolysis in acute stroke.
Thrombolysis in acute stroke: ongoing challenges based on a tertiary hospital audit and comparisons with other Australian studies.
Thrombolysis in an acute ischemic stroke patient with rivaroxaban anticoagulation: A case report.
Thrombolysis in brain ischemia (TIBI) transcranial Doppler flow grades predict clinical severity, early recovery, and mortality in patients treated with intravenous tissue plasminogen activator.
Thrombolysis in cerebral ischemia. A review of clinical and experimental data.
Thrombolysis in ischemic stroke without arterial occlusion at presentation.
Thrombolysis in Mild Stroke: A Comparative Analysis of the PRISMS and MaRISS Studies.
Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study.
Thrombolysis in patients with transient neurologic deficits.
Thrombolysis in recurrent stroke-beyond guidelines: a case report.
Thrombolysis in right versus left hemispheric stroke.
Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis.
Thrombolysis in stroke.
Thrombolysis in Young Adults With Ischemic Stroke.
Thrombolysis on ischemic stroke patients with decreased level of consciousness within 4.5 h.
Thrombolysis outcomes according to arterial characteristics of acute ischemic stroke by alteplase dose and blood pressure target.
Thrombolysis Outcomes among Obese and Overweight Stroke Patients: An Age-and National Institutes of Health Stroke Scale-matched Comparison.
Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus.
Thrombolysis risk prediction: applying the SITS-SICH and SEDAN scores in South African patients.
Thrombolysis safety and effectiveness in acute ischemic stroke patients with pre-morbid disability.
Thrombolysis targeting MRI defined tissue at risk in minor stroke.
Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice: the Japan post-Marketing Alteplase Registration Study (J-MARS).
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: the first multicentre, phase III trial in China.
Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: trial reanalysis adjusted for baseline imbalances.
Thrombolysis with alteplase after stroke: extending outcomes.
Thrombolysis With Alteplase at 0.6 mg/kg for Stroke With Unknown Time of Onset: A Randomized Controlled Trial.
Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.
Thrombolysis with alteplase for acute ischemic stroke: review of SITS-MOST and other Phase IV studies.
Thrombolysis with alteplase for acute ischemic stroke: safe and effective outside the 3-hour time window?
Thrombolysis with Low-Dose Tissue Plasminogen Activator 3-4.5 h After Acute Ischemic Stroke in Five Hospital Groups in Japan.
Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke: preliminary observations.
Thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: evaluation with rCBF-SPECT.
Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke.
Thrombolysis with reteplase, an unglycosylated plasminogen activator variant, in experimental embolic stroke.
Thrombolysis, stroke units and other strategies for reducing acute stroke costs.
Thrombolysis, stroke-unit admission and early rehabilitation in elderly patients.
Thrombolysis-related hemorrhagic infarction: a marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion.
Thrombolysis.
Thrombolysis: Improving door-to-needle times for ischemic stroke treatment - A narrative review.
Thrombolytic and newer mechanical device treatment for acute ischemic stroke.
Thrombolytic efficacy of tissue plasminogen activator-loaded echogenic liposomes in a rabbit thrombus model.
Thrombolytic Recanalization of Carotid Arteries Is Highly Dependent on Degree of Stenosis, Despite Sonothrombolysis.
Thrombolytic Refusal Over Telestroke.
Thrombolytic stroke therapy: past, present, and future.
Thrombolytic therapy for acute ischaemic stroke.
Thrombolytic therapy for acute ischaemic stroke: successful implementation in an Australian tertiary hospital.
Thrombolytic therapy for acute ischaemic stroke: what can we do to improve outcomes?
Thrombolytic therapy for acute ischemic stroke : issues and answers.
Thrombolytic therapy for acute ischemic stroke.
Thrombolytic therapy for acute stroke in Austria: data from the Safe Implementation of Thrombolysis in Stroke (SITS) register.
Thrombolytic therapy for acute stroke in late pregnancy with intra-arterial recombinant tissue plasminogen activator.
Thrombolytic therapy for acute stroke in the United Kingdom: experience from the safe implementation of thrombolysis in stroke (SITS) register.
Thrombolytic therapy for ischemic stroke--a review. Part I--Intravenous thrombolysis.
Thrombolytic therapy for stroke in patients with preexisting cognitive impairment.
Thrombolytic therapy for stroke: a review with particular reference to elderly patients.
Thrombolytic therapy for stroke: the new paradigm.
Thrombolytic therapy for wake-up stroke: A systematic review and meta-analysis.
Thrombolytic therapy in a patient with acute ischemic stroke caused by aortic dissection.
Thrombolytic therapy in acute ischaemic stroke.
Thrombolytic therapy in acute ischemic stroke - basic concepts.
Thrombolytic therapy in acute ischemic stroke patients with cardiac thrombus.
Thrombolytic therapy in acute myocardial infarction.
Thrombolytic therapy in cerebrovascular disorders.
Thrombolytic therapy in older acute ischemic stroke patients with gastrointestinal malignancy or recent bleeding.
Thrombolytic therapy in patients of female gender.
Thrombolytic therapy in pregnancy.
Thrombolytic Therapy in Severe Cardioembolic Stroke After Reversal of Dabigatran with Idarucizumab: Case Report and Literature Review.
Thrombolytic therapy in the treatment of stroke.
Thrombolytic Therapy in Wake-Up Stroke Patients.
Thrombolytic Therapy of Acute Ischemic Stroke during Early Pregnancy.
Thrombolytic therapy with intravenous recombinant tissue plasminogen activator in Japanese older patients with acute ischemic stroke: Fukuoka Stroke Registry.
Thrombolytic therapy with streptokinase and tissue plasminogen activator in a patient with suspected acute myocardial infarction: A decision analysis.
Thrombolytic therapy. From myocardial to cerebral infarction. The MAST-I Group. Multicentre Acute Stroke Trial.
Thrombolytic therapy: pre- and post-GISSI-2, ISIS-3, and GUSTO-1.
Thrombolytic treatment for acute ischemic stroke: a 2 year-experience at King Chulalongkorn Memorial Hospital.
Thrombolytic Treatment for Ischaemic Stroke: Could the Crisis of Confidence Have Been Avoided by Better Analysis of Trial Data?
Thrombolytic treatment of acute cerebral infarction.
Thrombolytic treatment of clot embolism in rat: comparison of intra-arterial and intravenous application of recombinant tissue plasminogen activator.
Thrombolytics for hyperacute stroke in children.
Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities.
Thrombotic Thrombocytopenic Purpura Masquerading as Acute Ischemic Stroke.
Thrombus localization with emergency cerebral CT.
Thrombus Migration and Fragmentation After Intravenous Alteplase Treatment: The INTERRSeCT Study.
Thymosin ?4 for the treatment of acute stroke: neurorestorative or neuroprotective?
Time and diffusion lesion size in major anterior circulation ischemic strokes.
Time Extended for Use of Image-Guided Intravenous Alteplase After Stroke.
Time from stroke onset to groin puncture affects rate of recanalisation after mechanical thrombectomy: a real-life single centre experience.
Time Intervals for Direct Versus Transfer Cases of Thrombectomy for Stroke in a Primarily Rural System of Care.
Time is brain--acute stroke management.
Time of day, outcome, and response to thrombolytic therapy: the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trial experience.
Time of hospital presentation in patients with acute stroke.
Time to Decision and Treatment With tPA (Tissue-Type Plasminogen Activator) Using Telemedicine Versus an Onboard Neurologist on a Mobile Stroke Unit.
Time to Stop Looking at Alteplase for Stroke Through a Prism.
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.
Time to treatment with recombinant tissue plasminogen activator and outcome of stroke in clinical practice: retrospective analysis of hospital quality assurance data with comparison with results from randomised clinical trials.
TIME TO WAKE-UP: EXTENDING THE WINDOW FOR MANAGEMENT OF UNKNOWN-ONSET STROKES.
Time Trends in Systemic Thrombolysis in a Large Hospital-Based Stroke Registry.
Time-Dependent Thrombus Resolution After Tissue-Type Plasminogen Activator in Patients With Stroke and Mice.
Time-resolved CT assessment of collaterals as imaging biomarkers to predict clinical outcomes in acute ischemic stroke.
Timeliness of Nursing Care Delivered by Stroke Certified Registered Nurses as Compared to Non-Stroke Certified Registered Nurses to Hyperacute Stroke Patients.
Timing of alteplase for acute stroke.
Timing of arrival to a tertiary hospital after acute ischaemic stroke - A follow-up survey 5 years later.
Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke.
Timing of Recanalization and Functional Recovery in Acute Ischemic Stroke.
Timing of Symptomatic Infarct Swelling Following Intravenous Thrombolysis in Acute Middle Cerebral Artery Infarction: A Case-Control Study.
Tissue at risk of infarction rescued by early reperfusion: a positron emission tomography study in systemic recombinant tissue plasminogen activator thrombolysis of acute stroke.
Tissue plasminogen activator (rt-PA) in acute ischemic stroke: Outcomes associated with ambulation.
Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release.
Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies.
Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background.
Tissue plasminogen activator (tPA) for stroke.
Tissue plasminogen activator (tPA) in acute ischaemic stroke: time for collegiate communication and consensus.
Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice.
Tissue plasminogen activator -7351C/T enhancer polymorphism is a risk factor for lacunar stroke.
Tissue plasminogen activator and plasminogen activator inhibitor in patients with acute ischemic stroke: relation to stroke etiology.
Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
Tissue Plasminogen Activator and Stroke: Review of the Literature for the Clinician.
Tissue plasminogen activator approved for stroke.
Tissue Plasminogen Activator Causes Brain Microvascular Endothelial Cell Injury After Oxygen Glucose Deprivation by Inhibiting Sonic Hedgehog Signaling.
Tissue plasminogen activator contributes to morphine tolerance and induces mechanical allodynia via astrocytic IL-1? and ERK signaling in the spinal cord of mice.
Tissue plasminogen activator does not benefit most eligible patients with stroke.
Tissue Plasminogen Activator Expression Is Restricted to Subsets of Excitatory Pyramidal Glutamatergic Neurons.
Tissue plasminogen activator extravasated through the cerebral vessels: evaluation using a rat thromboembolic stroke model.
Tissue plasminogen activator followed by antioxidant-loaded nanoparticle delivery promotes activation/mobilization of progenitor cells in infarcted rat brain.
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
Tissue plasminogen activator for acute stroke in everyday clinical practice.
Tissue Plasminogen Activator for Cortical Embolism Stroke with Magnetic Resonance Perfusion Imaging: A Report of Two Cases.
Tissue Plasminogen Activator for preclinical stroke research: Neither "rat" nor "human" dose mimics clinical recanalization in a carotid occlusion model.
Tissue plasminogen activator for stroke and concomitant influenza infection: is this a dangerous combination?
Tissue plasminogen activator for stroke in Israel: the time has finally come.
Tissue plasminogen activator in acute stroke.
Tissue plasminogen activator induced fibrinolysis: standardization of method using thromboelastography.
Tissue plasminogen activator is elevated in women with ischemic stroke.
Tissue plasminogen activator mediates deleterious complement cascade activation in stroke.
Tissue Plasminogen Activator Neurotoxicity is Neutralized by Recombinant ADAMTS 13.
Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C.
Tissue Plasminogen Activator Prescription and Administration Errors within a Regional Stroke System.
Tissue plasminogen activator prevents white matter damage following stroke.
Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia.
Tissue Plasminogen Activator Promotes TXNIP-NLRP3 Inflammasome Activation after Hyperglycemic Stroke in Mice.
Tissue plasminogen activator reduces brain injury in a rabbit model of thromboembolic stroke.
Tissue Plasminogen Activator Thrombolytic Therapy for Acute Ischemic Stroke in 4 Hospital Groups in Japan.
Tissue Plasminogen Activator to Treat a Stroke after Foam Sclerotherapy in a Woman with a Patent Foramen Ovale.
Tissue plasminogen activator treatment of stroke in type-1 diabetes rats.
Tissue plasminogen activator use: evaluation and initial management of ischemic stroke from an iowa hospital perspective.
Tissue plasminogen activator via cross-collateralization for tandem internal carotid and middle cerebral artery occlusion.
Tissue plasminogen activator, fibrin D-dimer, and insulin resistance in the relatives of patients with premature coronary artery disease.
Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke.
Tissue plasminogen activator-based nanothrombolysis for ischemic stroke.
Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke.
Tissue plasminogen activator: comparison of dose and route of administration in a rabbit model of thromboembolic stroke.
Tissue type plasminogen activator amplifies hemoglobin-induced neurotoxicity in rat neuronal cultures.
Tissue-type plasminogen activator as a therapeutic target in stroke.
Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis.
Tissue-type plasminogen activator for stroke mimics: continuing to be swift rather than delaying treatment to be sure.
Tissue-type plasminogen activator improves neurological functions in a rat model of thromboembolic stroke.
Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic.
Tissue-type plasminogen activator regulates macrophage activation and innate immunity.
Tissue-Type Plasminogen Activator-A296-299 Prevents Impairment of Cerebral Autoregulation After Stroke Through Lipoprotein-Related Receptor-Dependent Increase in cAMP and p38.
To tPA or Not to tPA: Two Medical-Legal Misadventures of Diagnosing a Cerebrovascular Accident as a Stroke Mimic.
To Treat or Not to Treat M2 Occlusions? The Question (and Answer) From a Single Institution.
To Treat or Not to Treat? Exploring Factors Influencing Intravenous Thrombolysis Treatment Decisions for Minor Stroke.
To treat or not to treat? Pilot survey for minor and rapidly improving stroke.
Toll-Like Receptor 4 Mediates Hemorrhagic Transformation After Delayed Tissue Plasminogen Activator Administration in In Situ Thromboembolic Stroke.
Total mismatch: negative diffusion-weighted imaging but extensive perfusion defect in acute stroke.
Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
Total Transfer Time for Ground vs. Air Transport for Interhospital and Scene Transfers of Acute Stroke Patients.
Toward a multimodal neuroprotective treatment of stroke.
tPA after stroke: the sooner the better: clinical benefit is gone by six hours.
tPA Alu (I/D) polymorphism associates with bacterial osteomyelitis.
tPA by telephone: extending the benefits of a comprehensive stroke center.
tPA contributes to impairment of ATP and Ca sensitive K channel mediated cerebrovasodilation after hypoxia/ischemia through upregulation of ERK MAPK.
tPA Deficiency in Mice Leads to Rearrangement in the Cerebrovascular Tree and Cerebroventricular Malformations.
tPA for Acute Ischemic Stroke and Its Controversies: A Review.
tPA for acute stroke: balancing baseline imbalances.
tPA for stroke.
tPA for stroke: important progress in achieving faster treatment.
tPA Helpers in the Treatment of Acute Ischemic Stroke: Are They Ready for Clinical Use?
tPA in acute ischemic stroke: United States experience and issues for the future.
tPA in acute stroke--risk or reprieve?
TPA in acute stroke.
TPA in stroke.
tPA Mobilizes Immune Cells That Exacerbate Hemorrhagic Transformation in Stroke.
TPA use for stroke in the Registry of the Canadian Stroke Network.
tPA variant tPA-A(296-299) Prevents impairment of cerebral autoregulation and necrosis of hippocampal neurons after stroke by inhibiting upregulation of ET-1.
tPA-associated reperfusion after acute stroke demonstrated by SPECT.
Traditional Chinese herbal medicine and cerebral ischemia.
Traditional Chinese medicine, Xue-Fu-Zhu-Yu decoction, potentiates tissue plasminogen activator against thromboembolic stroke in rats.
Tranexamic acid for treatment of pulmonary hemorrhage after tissue plasminogen activator administration for intubated patient.
Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial.
Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial.
Transcranial ultrasound-improved thrombolysis: diagnostic vs. therapeutic ultrasound.
Transfusion of Resting Platelets Reduces Brain Hemorrhage After Intracerebral Hemorrhage and tPA-Induced Hemorrhage After Cerebral Ischemia.
Transient ischemic attack after tissue plasminogen activator: aborted stroke or unnecessary stroke therapy?
Transition of European Cooperative Acute Stroke Study III Results to Clinical Practice: Ninety-Day Outcomes in a US Cohort.
Translational Stroke Research of the Combination of Thrombolysis and Antioxidant Therapy.
Translational Stroke Research Using a Rabbit Embolic Stroke Model: A Correlative Analysis Hypothesis for Novel Therapy Development.
Treating acute ischemic stroke.
Treating acute stroke patients with intravenous tPA. The OSF stroke network experience.
Treating ischemic stroke as an emergency.
Treatment and Outcome of Hemorrhagic Transformation After Intravenous Alteplase in Acute Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.
Treatment Delays for Patients With Acute Ischemic Stroke in an Iranian Emergency Department: A Retrospective Chart Review.
Treatment in patients who are not eligible for intravenous alteplase: MR CLEAN subgroup analysis.
Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment.
Treatment of acute ischemic stroke.
Treatment of acute ischemic stroke: systemic or local?
Treatment of acute stroke with recombinant tissue plasminogen activator and abciximab.
Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator.
Treatment patterns and short-term outcomes in ischemic stroke in pregnancy or postpartum period.
Treatment results of stroke patients aged >80 years receiving intravenous rt-PA.
Treatment Time-Specific Number Needed to Treat Estimates for Tissue Plasminogen Activator Therapy in Acute Stroke Based on Shifts Over the Entire Range of the Modified Rankin Scale.
Treatment with rtPA of stroke associated with intravenous immunoglobulins perfusion.
Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals.
Treatment with tissue plasminogen activator is not associated with increased use of neurosurgery.
Treatment with tPA predicts better outcome even if MCA occlusion persists.
Trends Among Rural and Urban Medicare Beneficiaries in Care Delivery and Outcomes for Acute Stroke and Transient Ischemic Attacks, 2008-2017.
Trends in mechanical thrombectomy and decompressive hemicraniectomy for stroke: A multicenter study.
Trends in New Zealand stroke thrombolysis treatment rates.
Trends of Acute Ischemic Stroke Reperfusion Therapies from 2012 to 2016 in the United States.
Trends of r-tPA (Recombinant Tissue-Type Plasminogen Activator) Treatment and Treatment-Influencing Factors in Acute Ischemic Stroke.
Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial.
Triage, treatment and transfer of patients with stroke in emergency department trial (the T(3) Trial): a cluster randomised trial protocol.
Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).
Trimming the fat in acute ischemic stroke: an assessment of 24-h CT scans in tPA patients.
TRUST-tPA trial: Telemedicine for remote collaboration with urgentists for stroke-tPA treatment.
Turning a stroke into a TIA: curative thrombolysis with combined intravenous and intra-arterial tPA.
Twenty-Year History of the Evolution of Stroke Thrombolysis With Intravenous Alteplase to Reduce Long-Term Disability.
Two in One: Endovascular Treatment of Acute Tandem Occlusions in the Anterior Circulation.
Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours.
Two-Hour Improvement of Patients in the National Institute of Neurological Disorders and Stroke Trials and Prediction of Final Outcome.
Types of intraparenchymal hematoma as a predictor after revascularization in patients with anterior circulation acute ischemic stroke.
UK drug agency announces review of use of alteplase after stroke.
Ultrasound Acceleration of rt-PA Thrombolysis Depends on Acoustic Intensity.
Ultrasound enhanced thrombolysis for stroke.
Ultrasound enhanced thrombolysis: applications in acute cerebral ischemia.
Ultrasound identification and lysis of clots.
Ultrasound in the treatment of ischaemic stroke.
Ultrasound-enhanced thrombolysis for acute ischemic stroke: phase I. Findings of the CLOTBUST trial.
Ultrasound-enhanced thrombolysis for stroke: clinical significance.
Ultrasound-enhanced thrombolysis in acute ischemic stroke: potential, failures, and safety.
Unanswered questions in thrombolytic therapy for acute ischemic stroke.
Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators.
Understanding delays in acute stroke care: a systematic review of reviews.
Understanding the functions of endogenous and exogenous tissue-type plasminogen activator during stroke.
Unique mechanisms of sheng yu decoction ( shèng yù tang) on ischemic stroke mice revealed by an integrated neurofunctional and transcriptome analysis.
Unknown Tetrahydrocannabinol Edible Ingestion Resulting in Acute Stroke Presentation.
Unruptured Cerebral Aneurysm Detected after Intravenous Tissue Plasminogen Activator for Stroke.
Unsuccessful tissue plasminogen activator treatment of acute stroke caused by a calcific embolus.
Unsuspected coagulopathy rarely prevents IV thrombolysis in acute ischemic stroke.
Update of the Korean Clinical Practice Guidelines for Endovascular Recanalization Therapy in Patients with Acute Ischemic Stroke.
Update on intravenous recombinant tissue plasminogen activator for acute ischemic stroke.
Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice.
Update on Neurocritical Care of Stroke.
Update on stroke.
Update on the Serum Biomarkers and Genetic Factors Associated with Safety and Efficacy of rt-PA Treatment in Acute Stroke Patients.
Update on Treatment of Acute Ischemic Stroke.
Updates in Stroke Treatment.
Urgent carotid intervention is safe after thrombolysis for minor to moderate acute ischemic stroke.
Urgent intracranial angioplasty after combined systemic and intra-arterial thrombolysis in acute stroke. An initial experience in indonesia.
Urgent therapy for acute stroke. Effects of a stroke trial on untreated patients.
Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes.
Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset.
Uric acid administration for neuroprotection in patients with acute brain ischemia.
Uric acid administration in patients with acute stroke: a novel approach to neuroprotection.
Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke.
Uric Acid Therapy Improves Clinical Outcome in Women With Acute Ischemic Stroke.
Uric acid therapy improves the outcomes of stroke patients treated with intravenous tissue plasminogen activator and mechanical thrombectomy.
Uric Acid Therapy Prevents Early Ischemic Stroke Progression: A Tertiary Analysis of the URICO-ICTUS Trial (Efficacy Study of Combined Treatment With Uric Acid and r-tPA in Acute Ischemic Stroke).
Use and in-hospital outcomes of recombinant tissue plasminogen activator in pediatric arterial ischemic stroke patients.
Use of a field-to-stroke center helicopter transport program to extend thrombolytic therapy to rural residents.
Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial.
Use of a registry to improve acute stroke care--seven states, 2005-2009.
Use of a spectrophotometric hemoglobin assay to objectively quantify intracerebral hemorrhage in mice.
Use of alteplase beyond 3 hours of ischemic stroke onset.
Use of alteplase in childhood arterial ischaemic stroke: a multicentre, observational, cohort study.
Use of antidepressant medications to improve outcomes after stroke.
Use of Intra-Arterial Tissue Plasminogen Activator in Acute Stroke: Video Case.
Use of intravenous recombinant tissue plasminogen activator in patients outside the defined criteria: safety and feasibility issues.
Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke.
Use of intravenous tissue plasminogen activator and hospital costs for patients with acute ischaemic stroke aged 18-64?years in the USA.
Use of intravenous tissue plasminogen activator in a 16-year-old patient with basilar occlusion.
Use of recombinant tissue plasminogen activator in cancer patients with acute stroke.
Use of self-expanding intracranial stents in the treatment of acute ischemic stroke.
Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke.
Use of telemedicine to increase thrombolysis and advance care in acute ischemic stroke.
Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke.
Use of the New Solitaire (TM) AB Device for Mechanical Thrombectomy when Merci Clot Retriever Has Failed to Remove the Clot. A Case Report.
Use of tissue plasminogen activator in a stroke after radiofrequency ablation of a left-sided accessory pathway.
Use of tissue-type plasminogen activator before and after publication of the European Cooperative Acute Stroke Study III in Get With The Guidelines-Stroke.
Using a quality improvement process to create measurable improvement in care delivery for acute stroke.
Using LEAN methodology to expedite the treatment of acute ischemic stroke in the emergency room.
Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: analysis of the results from the Chinese National Stroke Registry (CNSR).
Using telemedicine to facilitate thrombolytic therapy for patients with acute stroke.
Using the baseline CT scan to select acute stroke patients for IV-IA therapy.
Using the NIH Stroke Scale to assess stroke patients. The NINDS rt-PA Stroke Study Group.
Using tPA for acute stroke in a rural setting.
Utility of Early Post-treatment Single-Photon Emission Computed Tomography Imaging to Predict Outcome in Stroke Patients Treated with Intravenous Tissue Plasminogen Activator.
Utility of Intravenous Alteplase Prior to Endovascular Stroke Treatment: A Systematic Review and Meta-analysis of RCTs.
Utility of Minimum Apparent Diffusion Coefficient Ratios in Alberta Stroke Program Early CT Score Regions for Deciding on Stroke Therapy.
Utility of the Kurashiki Prehospital Stroke Scale for Hyperacute Stroke.
Utility of the stroke-thrombolytic predictive instrument.
Utilization and outcome of thrombolytic therapy for acute stroke in Pakistan.
Utilization of intravenous tissue plasminogen activator for acute ischemic stroke.
Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity.
Utilization rates of tissue plasminogen activator and mechanical thrombectomy in patients with acute stroke and underlying malignancy.
Validated automatic brain extraction of head CT images.
Validation assessment of risk scores to predict postthrombolysis intracerebral haemorrhage.
Validation of a clinical-genetics score to predict hemorrhagic transformations after rtPA.
Validation of a stroke model in rat compatible with rt-PA-induced thrombolysis: new hope for successful translation to the clinic.
Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
Validation of minor stroke definitions for thrombolysis decision making.
Validation of simplified FABS scale to predict stroke mimics in a Chinese population undergoing intravenous thrombolysis.
Validation of the Telestroke Mimic Score in Mayo Clinic population.
Validity of a computerised five-level emergency triage system for patients with acute ischaemic stroke.
Value Utilization of Emergency Medical Services Air Transport in Acute Ischemic Stroke.
Vampire bats yield potent clot buster for ischemic stroke.
Variability in the Use of Intravenous Thrombolysis for Mild Stroke: Experience Across the SPOTRIAS Network.
Variability of the Modified Rankin Scale Score Between Day 90 and 1 Year After Ischemic Stroke.
Variables associated with hospital arrival time after stroke: effect of delay on the clinical efficiency of early treatment.
Vascular closure devices in stroke patients receiving tissue plasminogen activator: A retrospective analysis from an academic tertiary medical center and a teaching community hospital stroke database.
Vascular medicine and thrombectomy in stroke.
Vascular PDGFR-alpha protects against BBB dysfunction after stroke in mice.
Vascular protection and restorative therapy in ischemic stroke.
Vascular protection to increase the safety of tissue plasminogen activator for stroke.
Vascular Risk Factors in Patients with Different Subtypes of Ischemic Stroke May Affect Their Outcome after Intravenous tPA.
Verapamil as an Adjunct Therapy to Reduce tPA Toxicity in Hyperglycemic Stroke: Implication of TXNIP/NLRP3 Inflammasome.
Very early mobilization in stroke patients treated with intravenous recombinant tissue plasminogen activator.
Very Early versus Delayed Rehabilitation for Acute Ischemic Stroke Patients with Intravenous Recombinant Tissue Plasminogen Activator: A Nationwide Retrospective Cohort Study.
Very mild stroke patients benefit from intravenous tissue plasminogen activator without increase of intracranial hemorrhage.
Vessel perforation during withdrawal of Trevo ProVue stent retriever during mechanical thrombectomy for acute ischemic stroke.
Vessel Wall Enhancement and Blood-Cerebrospinal Fluid Barrier Disruption After Mechanical Thrombectomy in Acute Ischemic Stroke.
Views of emergency physicians on thrombolysis for acute ischemic stroke.
Virtual TeleStroke support for the emergency department evaluation of acute stroke.
Volumetric and Spatial Accuracy of Computed Tomography Perfusion Estimated Ischemic Core Volume in Patients With Acute Ischemic Stroke.
Wake-up Stroke Within 3 Hours of Symptom Awareness: Imaging and Clinical Features Compared to Standard Recombinant Tissue Plasminogen Activator Treated Stroke.
Wake-Up Stroke: Clinical Characteristics, Imaging Findings, and Treatment Option - an Update.
Warfarin anticoagulation exacerbates the risk of hemorrhagic transformation after rt-PA treatment in experimental stroke: therapeutic potential of PCC.
What eye-tracking methods can reveal about the role of information format in decision-aid processing: an exploratory study.
What is the value of conducting a trial of r-tPA for the treatment of mild stroke patients?
What's new in stroke prevention and treatment.
What's new in stroke? The top 10 studies of 2009-2011: part I.
What's the "hyper" in hyperacute stroke? Strategies to improve outcomes in ischemic stroke patients presenting within 6 hours.
When is thrombolysis justified in patients with acute ischemic stroke? A bioethical perspective.
When Telestroke Programs Work, Hospital Size Really Does Not Matter.
Where Does the Time Go? The Effect of Protocols for Stroke Last Known Well Documentation on Intravenous Recombinant Tissue Plasminogen Activator Delivery in the Northeast.
Which imaging before reperfusion strategy?
Who may benefit from lower dosages of intravenous tissue plasminogen activator? Results from a cluster data analysis.
Who will benefit more from low-dose alteplase in acute ischemic stroke?
Whole body hypothermia extends tissue plasminogen activator treatment window in the rat model of embolic stroke.
Why are acute ischemic stroke patients not receiving IV tPA? Results from a national registry.
Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility.
Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility.
Why don't more patients receive intravenous rt-PA for acute stroke?
Why emergency XeCT-CBF should become routine in acute ischemic stroke before thrombolytic therapy.
Why Telestroke networks? Rationale, implementation and results of the Stroke Eastern Saxony Network.
Women on Hormone Therapy with Ischemic Stroke, Effects on Deficits and Recovery.
Worldwide reported use of IV tissue plasminogen activator for acute ischemic stroke.
Worse Outcome in Stroke Patients Treated with rt-PA Without Early Reperfusion: Associated Factors.
Worse prognosis in women, compared with men, after thrombolysis: An individual patient data pooling study of Asian acute stroke registries.
Worse stroke outcome in atrial fibrillation is explained by more severe hypoperfusion, infarct growth, and hemorrhagic transformation.
Worsening Cervical Epidural Hematoma After Tissue Plasminogen Activator Administration for Stroke Like Symptoms.
Would a Large tPA Trial for Those 4.5 to 6.0 Hours from Stroke Onset Be Good Value for Information?
Xenon is an inhibitor of tissue-plasminogen activator: adverse and beneficial effects in a rat model of thromboembolic stroke.
Years of disability-adjusted life gained as a result of thrombolytic therapy for acute ischemic stroke.
YiQiFuMai Lyophilized Injection ameliorates tPA-induced hemorrhagic transformation by inhibiting cytoskeletal rearrangement associated with ROCK1 and NF-?B signaling pathways.
Young Stroke Patients Treated with Intravenous Thrombolysis have a More Favorable Outcome and Mortality Compared with Older Patients.
[A case of acute ischemic stroke due to cardiac myxoma treated by intravenous thrombolysis and endovascular therapy].
[A case of basilar artery occlusion successfully treated with tissue plasminogen activator]
[A randomized study of streptokinase and recombinant tissue plasminogen activator, with and without heparin, in patients with acute myocardial infarction. The results of GISSI-2/International tPA/SK Mortality Trial]
[Acute management and secondary prevention of ischemic stroke]
[Acute stroke therapy : Current developments.]
[Acute stroke: early diagnosis, management, and treatment]
[Alteplase treatment for acute stroke 2007: an effective therapeutic option at our disposal]
[Alterations of fibrinolysis in stroke]
[An update on limitations of intravenous thrombolysis to treat acute ischemic stroke.]
[Angioneurotic orolingual edema associated with the use of rt-PA following a stroke.]
[Anticoagulation for patients with non-valvular atrial fibrillation].
[Antithrombotic drugs and stroke: clinical trials and unanswered questions]
[Application of thrombolytic therapy of ischemic stroke in the Russian Federation].
[ASPECTS-DWI, arterial occlusion sites and subtype of acute ischemic stroke have a relation with outcome following intravenous rt-PA therapy].
[Association study of serum uric acid levels with clinical outcome and hemorrhagic transformation in stroke patients with rt-PA intravenous thrombolysis].
[Brain attack in Japan, now and future]
[Carotid TEA and perioperative thrombolysis: a new concept in therapy of acute ischemic stroke]
[Causes of a prolonged prehospital phase in patients admitted to a stroke unit. Can it be influenced by campaigns to educate the public?]
[Cerebral CT perfusion in the diagnosis of acute brain infarction]
[Cerebrovascular accident]
[Clinical study on qingning oral liquid in treating senile chronic obstructive pulmonary disease with pulmonary hypertension]
[Computer tomographic and laboratory predictors of clinical outcomes of acute ischemic stroke patients after the systemic thrombolytic therapy]
[Development and response to intravenous treatment with tissue plasminogen activator with regard to referral hospitals. The experience of a stroke referral unit].
[Early intravenous thrombolysis with recombinant tissue plasminogen activator for acute cerebral infarction]
[Effect of prehospital intervention based on emergency medical services on door-to-needle time of thrombolysis in acute ischemic stroke].
[Effects of statin use on intracranial hemorrhage and clinical outcome after intravenous rt-PA for acute ischemic stroke: SAMURAI rt-PA registry]
[Endovascular thrombectomy for ischemic stroke].
[Endovascular treatment of ischemic strokes : outcomes and practical issues].
[EU-funded treatment study: WAKE-UP: a randomized, placebo-controlled MRI-based trial of thrombolysis in wake-up stroke].
[Factors of good prognosis in stroke treated by intravenous tPA]
[Fibrinolytic treatment with tissue plasminogen activator. Outcomes in clinical practice with a multidisciplinary model of intervention]
[How did the results of ECASS II influence clinical practice of treatment of acute stroke]
[Implementation of thrombolysis in acute stroke--10-year results of the Innsbruck stroke registry]
[INTRA-ARTERIAL STROKE THROMBECTOMY IN SOROKA UNIVERSITY MEDICAL CENTER AS A REFLECTION OF GUIDELINE CHANGES].
[Intravenous administration of a tissue plasminogen activator beyond 3 hours of the onset of acute ischemic stroke--MRI-based decision making]
[Intravenous rt-PA for acute ischemic stroke: 69 consecutive patients managed in an emergency stroke centre]
[Intravenous rt-PA therapy for acute ischemic stroke: efficacy and limitations]
[Intravenous rt-PA therapy: current status and extending therapeutic time window in Japan].
[Intravenous thrombolysis for acute ischemic stroke: past, present and future].
[Intravenous thrombolysis in ischemic stroke: Therapeutic perspectives].
[Intravenous thrombolysis in pediatric arterial ischemic stroke: A case report and a review of the literature.]
[Intravenous thrombolysis with rt-PA in stroke: Experience of the French military hospital of Toulon from September 2003 to June 2009.]
[Intravenous thrombolysis with rt-PA in stroke: Experience of the Nice stroke unit.]
[Intravenous thrombolytic therapy and its unresolved problems in Japan]
[Intravenous thrombolytic treatment in acute ischemic stroke: initial results in the Complejo Hospitalario Universitario de Albacete]
[Intravenous tissue plasminogen activator in the treatment of acute ischemic stroke: feasibility, safety, and efficiency in the 2 first years of the clinical practice]
[Ischemic stroke induced by a left atrial myxoma].
[Ischemic stroke: patients profit from early rt-PA administration].
[IV t-pA thrombolysis in acute stroke patients]
[Lysophosphatidic Acid Receptor Signaling Underlying Chronic Pain and Neuroprotective Mechanisms through Prothymosin ?].
[Major stroke clinical trials in 2006]
[New era has begun since the approval of thrombolytic therapy for acute ischemic stroke in Japan]
[News in neurology 2014].
[Not Available].
[Orolingual angioedema as complication after rt-PA in stroke patient treated with ACE inhibitor]
[Orolingual angioedema secondary to alteplase treatment in cases of stroke]
[Orolingual angioedema under systemic thrombolysis with rt-PA: an underestimated side effect]
[Plasminogen activator inhibitor-1 in the evolution of stroke]
[Primary emergencies: management of acute ischemic stroke].
[Prothymosin?, as a neuroprotective DAMPs/Alarmins molecule].
[Recanalizing therapies in acute stroke]
[Recombinant tissue plasminogen activator therapy for acute ischemic stroke in older patients].
[Relationship between insulin resistance and clustering of risk factors of cerebrovascular disease]
[Repeated treatment of subtotal vertebrobasilar stenosis with tissue plasminogen activator (tPA)]
[Role of endogenous tPA in stroke]
[Stroke code impact on the efficacy of thrombolytic treatment]
[Subtypes of acute ischemic stroke and neurological prognosis].
[Systemic thrombolysis in ischemic stroke]
[Systemic thrombolysis with plasminogen activator in chronic stroke patients]
[Systemic thrombolytic therapy with rt-PA in acute medial territory infarct. Experiences in routine clinical practice]
[The future perspective of acute thrombolytic therapy for acute ischemic stroke].
[The management of cerebrovascular events]
[The prospects of thrombolytic therapy for acute ischemic stroke]
[Therapeutic aspects of cerebral ischemia]
[Thrombolysis and acute cerebral infarction]
[Thrombolysis by intravenous tissue plasminogen activator (t-PA)--current status and future direction]
[Thrombolysis changes the care of stroke]
[Thrombolysis in acute ischemic stroke in basic hospitals. Four cases reports.]
[Thrombolysis in acute stroke with tissue plasminogen activator]
[Thrombolysis in cerebral ischemia]
[Thrombolytic therapy for acute ischemic stroke]
[Thrombolytic therapy in acute myocardial infarct]
[Thrombolytic therapy in arterial disorders other than myocardial infarction]
[Thrombolytic therapy in ischemic infarct]
[Thrombolytic therapy with tPA for the treatment of acute stroke. The Standard Treatment with Alteplase to Reverse Stroke study]
[Thrombolytic therapy]
[Thrombolytic treatment in stroke in patients with intracardiac thrombus: presentation of one case]
[Thrombolytic treatment of acute cerebral infarction]
[Thrombolytic treatment of acute stroke].
[Time is brain : Time management in acute stroke treatment].
[Time is brain]
[Treatment of acute clinical stroke]
[Treatment of arterial and venous brain ischemia. Experts' recommendations: stroke management in the intensive care unit].
[Treatment with intravenous rt-PA in a general hospital context: A review of the Saint-Jean Hospital experience from Perpignan, France]
[Use and results of intravenous fibrinolysis in a stroke unit].
[Use of tissue plasminogen activator factor for acute ischemic stroke]
[VEGF-A therapeutic target against hemorrhagic transformation after t-PA treatment].
Stroke, Lacunar
Does Thrombolysis Benefit Patients with Lacunar Syndrome?
Early neurological deterioration following intravenous recombinant tissue plasminogen activator therapy in patients with acute lacunar stroke.
Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial.
Identification of lacunar infarcts before thrombolysis in the ECASS I study.
Successful thrombolytic therapy with recombinant tissue plasminogen activator in ischemic stroke after idarucizumab administration for reversal of dabigatran: a case report.
Thrombolysis in patients with lacunar stroke is safe: an observational study.
Tissue plasminogen activator -7351C/T enhancer polymorphism is a risk factor for lacunar stroke.
Tissue plasminogen activator -7351C/T polymorphism and lacunar stroke.
Stuttering
Recurrent thrombolysis of a stuttering lacunar infarction captured on serial MRIs.
Subarachnoid Hemorrhage
A phase II clinical trial of recombinant human tissue-type plasminogen activator against cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm.
Acute Lower-Extremity Ischemia in a Patient with COVID-19.
Antisense preproendothelin-oligoDNA therapy for vasospasm in a canine model of subarachnoid hemorrhage.
Association of Plasminogen Activator Inhibitor 1 (SERPINE1) Polymorphisms and Aneurysmal Subarachnoid Hemorrhage.
Comparison of intrathecal administration of urokinase and tissue plasminogen activator on subarachnoid clot and chronic vasospasm in a primate model.
Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs.
Comparison of Intrathecally Administered Urokinase, Tissue-type Plasminogen Activator, and Combination of Urokinase and Lysine-Plasminogen for Clot Lysis after Experimental Subarachnoid Hemorrhage in Dogs.
Early treatment of subarachnoid hemorrhage after preventing rerupture of an aneurysm.
Effect of BQ-123 and tissue plasminogen activator on vasospasm after subarachnoid hemorrhage in monkeys.
Effect of intrathecal fibrinolytic therapy on clot lysis and vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Effect of tissue plasminogen activator on intimal platelet accumulation in cerebral arteries after subarachnoid hemorrhage in cats.
Effects of unilateral intrathecal administrations of low dose tissue-type plasminogen activator on clot lysis, vasospasm and brain phospholipid hydroperoxidation in a primate model of bilateral subarachnoid hemorrhage.
Efficacy of low-dose tissue-plasminogen activator intracisternal administration for the prevention of cerebral vasospasm after subarachnoid hemorrhage.
Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage.
Failure of intracisternal tissue plasminogen activator to prevent vasospasm in certain patients with aneurysmal subarachnoid hemorrhage.
Increased ventriculostomy infection rate with use of intraventricular tissue plasminogen activator: A single-center observation.
Intra-aneurysmal GDC Embolization for Ruptured Aneurysm in the Acute Stage.
Intraaneurysmal GDC Embolization for Ruptured Aneurysm in the Acute Stage. Indication and Results.
Intracisternal administration of tissue plasminogen activator improves cerebrospinal fluid flow and cortical perfusion after subarachnoid hemorrhage in mice.
Intracisternal recombinant tissue plasminogen activator after aneurysmal subarachnoid hemorrhage.
Intracisternal rt-PA during early surgery for aneurysmal subarachnoid hemorrhage: an Italian report.
Intraoperative use of rtPA for subarachnoid hemorrhage.
Intrathecal fibrinolytic therapy after subarachnoid hemorrhage: dosage study in a primate model and review of the literature.
Intraventricular hemorrhage after aneurysmal subarachnoid hemorrhage: pilot study of treatment with intraventricular tissue plasminogen activator.
Intraventricular Tissue Plasminogen Activator and Shunt Dependency in Aneurysmal Subarachnoid Hemorrhage Patients With Cast Ventricles.
Intraventricular tissue plasminogen activator for the prevention of vasospasm and hydrocephalus after aneurysmal subarachnoid hemorrhage.
Intraventricular Tissue Plasminogen Activator in Subarachnoid Hemorrhage Patients: A Prospective, Randomized, Placebo-Controlled Pilot Trial.
Neuroendovascular treatments/procedures: are they efficacious and have they improved patient outcomes poststroke?
Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials.
Outcome of the 'Drip-and-Ship' Paradigm among Patients with Acute Ischemic Stroke: Results of a Statewide Study.
Phase I trial of tissue plasminogen activator for the prevention of vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Plasminogen activator inhibitor-1 4G allele in the 4G/5G promoter polymorphism increases the occurrence of cerebral ischemia after aneurysmal subarachnoid hemorrhage.
Prevention of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage by intraoperative cisternal fibrinolysis using tissue-type plasminogen activator combined with continuous cisternal drainage.
Prevention of vasospasm by clot removal and intrathecal bolus injection of tissue-type plasminogen activator: preliminary report.
Prophylactic thrombosis to prevent new bleeding and to delay aneurysm surgery.
Prospective study on the prevention of cerebral vasospasm by intrathecal fibrinolytic therapy with tissue-type plasminogen activator.
Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
Single intracisternal bolus of recombinant tissue plasminogen activator in patients with aneurysmal subarachnoid hemorrhage: preliminary assessment of efficacy and safety in an open clinical study.
Subacute hydrocephalus after experimental subarachnoid hemorrhage: its prevention by intrathecal fibrinolysis with recombinant tissue plasminogen activator.
Subarachnoid hemorrhage after thrombolytic therapy for acute myocardial infarction: A case report.
Successful intravascular ultrasound thrombolysis of dural sinus thrombosis with pre-existing subarachnoid and intraparenchymal hemorrhages.
Successful Use of tPA for Saddle Pulmonary Embolism in Perimesencephalic Non-aneurysmal Subarachnoid Hemorrhage: Case Report.
Tenecteplase-induced Nonaneurysmal Subarachnoid Hemorrhage in a Patient with Acute Ischemic Stroke: A Case Report and Literature Review.
The effect of timing of intrathecal fibrinolytic therapy on cerebral vasospasm in a primate model of subarachnoid hemorrhage.
The effect of tissue plasminogen activator (t-PA) on cerebral vasospasm in canine subarachnoid hemorrhage.
Thrombolysis for intraventricular hemorrhage after endovascular aneurysmal coiling.
Thrombolytic therapy with tissue plasminogen activator for prevention of vasospasm in experimental subarachnoid hemorrhage: its efficacy and problems.
Tissue plasminogen activator levels after single intracisternal injection in patients with subarachnoid hemorrhage.
[Application of alteplase in prevention of cerebral vasospasm and its sequelae in patients after aneurysmal subarachnoid hemorrhage from ruptured cerebral aneurysm]
[Cerebral vasospasm. Experimental study]
[Intracerebral and subarachnoid hemorrhages after administration of recombinant tissue plasminogen activator in a patient with acute ischemicstroke due to anterior cerebral artery dissection: a case report].
[Preliminary clinical trial of intrathecal rt-PA (TD-2061) for the prevention of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage]
[Role of acute alcohol poisoning and craniocerebral trauma in the mechanism of death caused by subarachnoid hemorrhage].
Superinfection
Differential effect of TPA and n-butyrate on induction of Ii and EBV antigens in the P3HR-1 lymphoblastoid cell line.
Effect of actinomycin D and cycloheximide on Epstein-Barr virus early antigen induction in lymphoblastoid cells.
Immune response to intermediate filament-associated, Epstein-Barr virus-induced early antigen.
TPA-inducible Epstein-Barr virus genes in Raji cells and their regulation.
Superior Vena Cava Syndrome
Thrombolytic therapy with tissue plasminogen activator for superior vena cava thrombosis in an infant with sepsis.
Treatment of superior vena cava syndrome with recombinant tissue plasminogen activator in a sickle cell patient undergoing bone marrow transplantation.
Treatment of superior vena cava thrombosis with recombinant tissue type plasminogen activator.
[Iatrogenic superior vena cava syndrome. Successful thrombolysis with recombinant tissue plasminogen activator (r-tPA)]
Syncope
A Rare Case of Acute Pulmonary Embolism after Coronary Angiography due to Sand Bag Compression.
Safe and effective intravenous thrombolysis for acute ischemic stroke caused by left atrial myxoma.
Successful thrombolysis with rt-PA after syncope and protracted cardiopulmonary resuscitation in massive pulmonary embolism.
Tumor necrosis factor (TNF) stimulates plasminogen activator inhibitor (PAI) production by endothelial cells and decreases blood fibrinolytic activity in the rat.
Syncope, Vasovagal
Successful management of multiple permanent pacemaker complications--infection, 13 year old silent lead perforation and exteriorisation following failed percutaneous extraction, superior vena cava obstruction, tricuspid valve endocarditis, pulmonary embolism and prosthetic tricuspid valve thrombosis.
Synostosis
Fibular osteotomy to facilitate proximal tibial rotation during tibial plateau leveling osteotomy.
Synovitis
Deflazacort modulates the fibrinolytic pattern and reduces uPA-dependent chemioinvasion and proliferation in rheumatoid arthritis synoviocytes.
Multivariate genome-wide association analysis identifies novel and relevant variants associated with anterior cruciate ligament rupture risk in the dog model.
Successful arthroscopic treatment of pigmented villonodular synovitis of the knee in a patient with congenital deficiency of plasminogen activator inhibitor-1 and recurrent haemarthrosis.
Synovitis, Pigmented Villonodular
Successful arthroscopic treatment of pigmented villonodular synovitis of the knee in a patient with congenital deficiency of plasminogen activator inhibitor-1 and recurrent haemarthrosis.
Syphilis
Analysis of Treponema pallidum strains from China using improved methods for whole-genome sequencing from primary syphilis chancres.
Complete genome sequences of two strains of Treponema pallidum subsp. pertenue from Ghana, Africa: Identical genome sequences in samples isolated more than 7 years apart.
Directly Sequenced Genomes of Contemporary Strains of Syphilis Reveal Recombination-Driven Diversity in Genes Encoding Predicted Surface-Exposed Antigens.
Evaluation of different confirmatory algorithms using seven treponemal tests on Architect Syphilis TP-positive/RPR-negative sera.
Evaluation of the VITROS Syphilis TPA chemiluminescence immunoassay as a first-line method for reverse syphilis screening.
Genetics of human and animal uncultivable treponemal pathogens.
Macrolide Resistance in the Syphilis Spirochete, Treponema pallidum ssp. pallidum: Can We Also Expect Macrolide-Resistant Yaws Strains?
Meningovascular syphilis and improvement with tissue-plasminogen activator (T-PA).
Molecular diversity of Treponema pallidum subspecies pallidum isolates in Amsterdam, the Netherlands.
No bejel among Surinamese, Antillean and Dutch syphilis diagnosed patients in Amsterdam between 2006-2018 evidenced by multi-locus sequence typing of Treponema pallidum isolates.
Origin of modern syphilis and emergence of a pandemic Treponema pallidum cluster.
Phylogenetic and genetic characterization of Treponema pallidum strains from syphilis patients in Japan by whole-genome sequence analysis from global perspectives.
Screening for Syphilis with Dual Algorithms: Analysis of Discordant and Concordant Serology Results in a Population with a Low Prevalence of Syphilis.
Tracing the origin of Treponema pallidum in China using next-generation sequencing.
Vitros 5600 Syphilis TPA assay: evaluation of an automated chemiluminescence assay for detection of Treponema pallidum antibodies in a high prevalence setting.
Whole genome sequence of Treponema pallidum ssp. pallidum, strain Mexico A, suggests recombination between yaws and syphilis strains.
Systemic Vasculitis
Plasma levels of TPA, PAI-1 and thrombospondin in patients with systemic vasculitis.
t-plasminogen activator deficiency
Blood protein defects associated with thrombosis. Laboratory assessment.
Collagen dissolution by keratinocytes requires cell surface plasminogen activation and matrix metalloproteinase activity.
Decreased neural damage after spinal cord injury in tPA-deficient mice.
Familial vascular plasminogen activator deficiency: a cause of cerebrovascular thrombosis.
Haematologic disorders and cerebral venous thrombosis.
Hematologic and surgical management of the dental patient with plasminogen activator deficiency.
Hemicentral retinal vein occlusion associated with ocular hypertension and clotting abnormality.
Investigations on the Role of the Fibrinolytic Pathway on Outflow Facility Regulation.
Myocardial infarction and antiphospholipid antibodies in SLE and related disorders.
Myocardial infarction in a young man with systemic lupus erythematosus, deep vein thrombosis, and antibodies to phospholipid.
Peaks in plasma plasminogen activator inhibitor-1 concentration may explain thrombotic events in cases of pancreatic carcinoma.
Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease.
Receptor-independent role of the urokinase-type plasminogen activator during arteriogenesis.
Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a review and update.
Role of the pleiotropic effects of plasminogen deficiency in infection experiments with plasminogen-deficient mice.
Syndromes of hypercoagulability and thrombosis: a review.
The covariation between TpA deficiency, CpG deficiency, and G+C content of human isochores is due to a mathematical artifact.
The surgical implications of primary hypercoagulable states.
Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background.
Tissue plasminogen activator deficiency preserves neurological function and protects against murine acute ischemic stroke.
Tissue plasminogen activator deficiency promotes early phase regeneration in the olfactory epithelium after bulbectomy.
Tissue plasminogen activator promotes the effects of corticotropin-releasing factor on the amygdala and anxiety-like behavior.
Tissue-type plasminogen activator deficiency attenuates peritoneal fibrosis in mice.
Tissue-type plasminogen activator deficiency delays bone repair: roles of osteoblastic proliferation and vascular endothelial growth factor.
Tissue-type plasminogen activator deficiency exacerbates arthritis.
Tissue-type plasminogen activator deficiency exacerbates cholestatic liver injury in mice.
Tissue-type plasminogen activator promotes murine myofibroblast activation through LDL receptor-related protein 1-mediated integrin signaling.
tPA activates LDL receptor-related protein 1-mediated mitogenic signaling involving the p90RSK and GSK3beta pathway.
tPA Deficiency in Mice Leads to Rearrangement in the Cerebrovascular Tree and Cerebroventricular Malformations.
tPA deficiency underlies neurovascular coupling dysfunction by amyloid-?.
[Thrombocytopenia in patients with systemic lupus erythematosis as a risk factor for thrombotic complications and its connection with severity and the course of the disease, systemic lupus erythematosis]
[Thrombophilic states]
Tachycardia
Anaphylactoid reaction to recombinant tissue plasminogen activator.
Effects of cryoablation and radiofrequency ablation on endothelial and blood clotting activation.
Evidence of anaphylaxy after alteplase infusion.
[Fatal central pulmonary embolism under heparin therapy: white-clot syndrome]
Tachycardia, Atrioventricular Nodal Reentry
Effects of cryoablation and radiofrequency ablation on endothelial and blood clotting activation.
Tachycardia, Sinus
Evidence of anaphylaxy after alteplase infusion.
Risk stratification before thrombolytic therapy in patients with acute myocardial infarction. The Thrombolysis in Myocardial Infarction (TIMI) Phase II Co-Investigators.
Tachycardia, Ventricular
Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3 Investigators.
Bolus thrombolytic infusions during CPR for patients with refractory arrest rhythms: outcome of a case series.
Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial.
Pacing-induced myocardial ischemia does not affect the endothelial release of coagulant and fibrinolytic factors into the coronary circulation.
Thrombolytic therapy in acute coronary thrombosis.
Tissue plasminogen activator on admission is an important predictor of 30-day mortality in patients with acute myocardial infarction undergoing primary angioplasty.
Ventricular arrhythmias during treatment with alteplase (recombinant tissue plasminogen activator) in suspected acute myocardial infarction.
Takotsubo Cardiomyopathy
Successful treatment of cerebral emboli with tissue plasminogen activator in a patient with takotsubo cardiomyopathy: A case report.
Telangiectasis
Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis.
Modulation of urokinase-type and tissue-type plasminogen activator occurs at an early stage of progressing stages of chronic venous insufficiency.
von Willebrand factor: clinical features of inherited and acquired disorders.
Temporomandibular Joint Disorders
Activities of plasminogen activator, plasmin and kallikrein in synovial fluid from patients with temporomandibular joint disorders.
Teratocarcinoma
Anti-sense inhibition of tissue plasminogen activator production in differentiated F9 teratocarcinoma cells.
Collagenase expression in ovarian cancer cell lines.
Differentiation of early mouse embryonic and teratocarcinoma cells in vitro: plasminogen activator production.
Differentiation-responsive elements in the 5' region of the mouse tissue plasminogen activator gene confer two-stage regulation by retinoic acid and cyclic AMP in teratocarcinoma cells.
Experimental studies with liarozole (R 75,251): an antitumoral agent which inhibits retinoic acid breakdown.
Isolation of complementary DNA clones for genes exhibiting reduced expression after treatment of mouse teratocarcinoma stem cells with a tumor-promoting phorbol ester.
Molecular cloning of complementary DNA to mouse tissue plasminogen activator mRNA and its expression during F9 teratocarcinoma cell differentiation.
p53 Acts as a Co-Repressor to Regulate Keratin 14 Expression during Epidermal Cell Differentiation.
Plasminogen activator expression in F9 teratocarcinoma embryoid bodies and their endoderm derivatives.
Production, purification and characterization of the plasminogen activator in teratocarcinoma stem cells induced with sodium butyrate.
Selective synthetic ligands for human nuclear retinoic acid receptors.
Suppression of c-mos expression in teratocarcinoma cells with a new type of inducer of differentiation, 3,5-di-tert-butylchalcone 4'-carboxylic acid.
Teratocarcinoma differentiation: plasminogen activator activity associated with embryoid body formation.
Transcription factor Sp1 is important for retinoic acid-induced expression of the tissue plasminogen activator gene during F9 teratocarcinoma cell differentiation.
Tunicamycin reversibly inhibits the terminal differentiation of teratocarcinoma stem cells to endoderm.
Teratoma
In vitro differentiation of teratomas and the distribution of creatine phosphokinase and plasminogen activator in teratocarcinoma-derived cells.
[Studies on marker substances in cell lines derived from various human gynecologic tumors (author's transl)]
Testicular Neoplasms
[Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer]
[Importance of the tissue polypeptide antigen level in neoplastic patients. Its correlation with other tumor markers]
Tetanus
A phorbol ester (TPA) can replace macrophages in human lymphocyte cultures stimulated with a mitogen but not with an antigen.
Plasminogen activator secretion by granule neurons in cultures of developing cerebellum.
Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway.
Tetralogy of Fallot
Successful treatment of prosthetic pulmonary valve thrombosis with reteplase: a case report.
Thalassemia
[Significance of Tissue Factor-Bearing Microparticle Procoagulation Activity and Antithrombin ? Detection in Thalassemia Patients].
Thrombasthenia
Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation.
Observations on optimal conditions for lysis of whole blood clots and use of this assay as a screening assay in clinical investigation.
Thromboangiitis Obliterans
Assessment of plasma prothrombotic factors in patients with Buerger's disease.
Plasminogen activators and plasminogen activator inhibitor 1 before and after venous occlusion of the upper limb in thromboangiitis obliterans (Buerger's disease).
Thromboangitis obliterans with plasminogen activator inhibitor-1 suppression by PGE1.
Thrombocythemia, Essential
Clinical implications of elevated PAI-1 revisited: multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAI-1) levels: a case report and review of the literature.
High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.
Low proteins C and S and activation of fibrinolysis in treated essential thrombocythemia.
[Fibrinolysis studied by an in vitro clot lysis test in polycythemia vera]
Thrombocytopenia
A Case Report of Recombinant Tissue Plasminogen Activator Use in a SPAN-100-Positive Geriatric Patient with Thrombocytopenia.
Activation of coagulation and fibrinolysis during dengue virus infection.
Activation of plasma systems and blood cells by endotoxin in rabbits.
Acute Thrombocytopenia After Tissue Plasminogen Activator for Stroke.
Atypical heparin-induced thrombocytopenia complicated by intracardiac thrombus, effectively treated with ultra-low-dose rt-PA lysis and recombinant hirudin (Lepirudin).
Catheter-directed thrombolysis with alteplase and bivalirudin in a patient with heparin-induced thrombocytopenia.
Catheter-directed Thrombolysis with Argatroban and tPA for Massive Iliac and Femoropopliteal Vein Thrombosis.
Characteristics of blood tests in patients with acute cerebral infarction who developed symptomatic intracranial hemorrhage after intravenous administration of recombinant tissue plasminogen activator.
Endogenous plasminogen activators mediate progressive intracranial hemorrhage after traumatic brain injury.
Genetic polymorphism of murine tissue plasminogen activator associated with antiphospholipid syndrome.
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial.
Increased plasma tissue-type plasminogen activator levels in patients with chronic thrombocytopenia.
Inhibitory effects of lysine analogues on t-PA induced whole blood clot lysis.
Intensive plasma exchange increases a disintegrin and metalloprotease with thrombospondin motifs-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure.
Intensive plasma exchange increases ADAMTS-13 activity and reverses organ dysfunction in children with thrombocytopenia-associated multiple organ failure.
Large vessel stroke as initial presentation of thrombotic thrombocytopenic purpura.
Methylprednisolone prophylaxis protects against endotoxin-induced death in rabbits.
Osteonecrosis induced by a single administration of low-dose lipopolysaccharide in rabbits.
Platelet Drop and Fibrinolytic Shutdown in Patients With Sepsis.
Pulmonary embolism and heparin-induced thrombocytopenia successfully treated with tissue plasminogen activator and argatroban.
Rare thrombophilic conditions.
Successful intravenous thrombolysis in a patient with antiphospholipid syndrome, acute ischemic stroke and severe thrombocytopenia.
The Clinical Conundrum of Managing Ischemic Stroke in Patients with Immune Thrombocytopenia.
The management of filter-related caval thrombosis complicated by heparin-induced thrombocytopenia and thrombosis.
The surgical implications of primary hypercoagulable states.
Toll-like receptors 2 and 7 mediate coagulation activation and coagulopathy in murine sepsis.
Treatment of pulmonary embolism with argatroban and ultrasound-assisted catheter-directed thrombolysis with alteplase in a patient with heparin-induced thrombocytopenia.
Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with heparin-induced thrombocytopenia with thrombosis.
Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome.
[Thrombocytopenia in patients with systemic lupus erythematosis as a risk factor for thrombotic complications and its connection with severity and the course of the disease, systemic lupus erythematosis]
Thrombocytosis
Acute-phase response and the hypercoagulable state in pulmonary tuberculosis.
Hemostatic changes in active pulmonary tuberculosis.
POEMS syndrome with vascular lesions: a role for interleukin-1beta and interleukin-6 increase--a case report.
The Hemostatic Changes in Active Pulmonary Tuberculosis.
The plasma levels of prostanoids and plasminogen activator inhibitor-1 in primary and secondary thrombocytosis.
Thromboembolism
A case of renal artery embolism treated by selective intra-arterial infusion of tissue plasminogen activator.
Accelerated sonothrombolysis with Definity in a xenographic porcine cerebral thromboembolism model.
Antithrombotic therapy in patients with known risk factors for thromboembolism.
Autologous blood transfusion in hip replacement. No effect on blood loss but less increase of plasminogen activator inhibitor in a randomized series of 80 patients.
Binding of tissue plasminogen activator to vascular grafts.
Brachial embolism from mechanical mitral valve thrombosis: multimodality imaging-guided successful thrombolysis.
Dissolution of emboli in rats with experimental cerebral thromboembolism by recombinant human tissue plasminogen activator (TD-2061).
Generation and characterization of tissue-type plasminogen activator transgenic rats.
Hybrid approach in patients with recurrent brachial artery embolism: adjunctive tissue plasminogen activator infusion following embolectomy.
Impaired fibrinolysis and postoperative thromboembolism in orthopedic patients.
Increased D-dimer levels in twin gestation.
Increased levels of tissue plasminogen activator antigen and factor VIII activity in nonvalvular atrial fibrillation: relation to predictors of thromboembolism.
Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating ?2-antiplasmin.
Overview of Cochrane thrombolysis meta-analysis.
Pathogenesis of venous thromboembolism: when the cup runneth over.
Plasminogen activator inhibitor type 1 in platelets induces thrombogenicity by increasing thrombolysis resistance under shear stress in an in-vitro flow chamber model.
Prospective evaluation of tissue plasminogen activator in 11 cats with arterial thromboembolism.
Recent progress in drug treatment for acute ischemic stroke.
Recombinant tissue plasminogen activator treatment of pulmonary embolism also improves deep venous thrombosis.
Recombinant tissue-plasminogen activator-induced thrombolysis after cerebral thromboembolism in mice.
Relevance of focal cerebral ischemia models. Experience with fibrinolytic agents.
Reversing the deleterious effects of ?2-antiplasmin on tissue plasminogen activator therapy improves outcomes in experimental ischemic stroke.
Successful management of acute renal artery thromboembolism by intra-arterial thrombolytic therapy with recombinant tissue plasminogen activator.
Successful treatment of renal artery thromboembolism with low-dose prolonged infusion of tissue-typed plasminogen activator in a patient with mitral mechanical heart valve thrombosis under the guidance of multimodality imaging.
The fibrinolytic system and proteins C and S in treated polycythaemia rubra vera.
The use of desmopressin acetate (DDAVP) as a test of the fibrinolytic capacity of patients--analysis of responders and non-responders.
The Use of Low-Dose Recombinant Tissue Plasminogen Activator to Treat a Preterm Infant with an Intrauterine Spontaneous Arterial Thromboembolism.
Thrombolysis with tissue plasminogen activator (TPA) in feline acute aortic thromboembolism: a retrospective study of 16 cases.
Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator.
Tissue plasminogen activator for the treatment of thromboembolism in infants and children.
Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor.
Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.
[Comparative efficacy of various thrombolytic agents in treatment of pulmonary embolism].
[Efficacy and safety of recombinant tissue plasminogen activator in thrombolytic therapy of vena caval thromboembolism].
[Fibrinolytic therapy of patients with pulmonary artery thromboembolism by tissue plasminogen activator and streptokinase preparations]
[Possibilities and limits of local intra-arterial fibrinolysis in thromboembolic vascular occlusions of the central nervous system]
[Thrombolytic recombinant tissue plasminogen activator (rt-PA) treatment in the acute ischemic stroke with limb arterial embolism; three case reports].
[Thrombolytic therapy in the treatment of thromboembolism of the right cardiac cavity during pulmonary embolism: our experience with rt-PA and review of the literature]
[Use of plasminogen activator (urokinase) in treatment of hemorrhage and thromboembolism of the eye]
Thromboinflammation
Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease.
Thrombophilia
A Case of Unexplained Cerebral Sinus Thrombosis in a 22-Year-Old Obese Caucasian Woman.
Altered preoperative coagulation and fibrinolysis are associated with myocardial injury after non-cardiac surgery.
Anticoagulant Therapy in Pregnant Patients with Metabolic Syndrome: A Review.
Aspirin desensitization in a woman with inherited thrombophilia and recurrent miscarriage.
Assessment of hemostatic risk factors in predicting arterial thrombotic events.
Association of Plasminogen Activator Inhibitor 1 (SERPINE1) Polymorphisms and Aneurysmal Subarachnoid Hemorrhage.
Associations between Maternal and Fetal Inherited Thrombophilias, Placental Characteristics Associated with Vascular Malperfusion, and Fetal Growth.
Autosomal dominant avascular necrosis of femoral head in two Taiwanese pedigrees and linkage to chromosome 12q13.
Can biomarkers of coagulation, platelet activation, and inflammation predict mortality in patients with hematological malignancies?
Cardiovascular and thrombophilic risk factors in patients with retinal artery occlusion.
Cerebral Venous Sinus Thrombosis and Acute Myocardial Infarction in a Patient with PAI-1 4G/4G Homozygosity.
Complicated Lemierre Syndrome Caused by Streptococcus gordonii and Possible Rickettsial Co-Infection in a Patient with Thrombophilia Predisposition.
Degree of hypercoagulability and hyperfibrinolysis is related to organ failure and prognosis after burn trauma.
Effect of bezafibrate on hypercoagulability assessed by fluorogenic prothrombin time in hyperlipidemic patients with non-insulin-dependent diabetes mellitus.
Effect of endotoxin on clotting mechanism. III. On the relationship between hypercoagulability, plasminogen activator activity, and antithrombin activity.
Elevated plasminogen activator inhibitor (PAI), a cause of thrombophilia? A study in 203 patients with familial or sporadic venous thrombophilia.
Evaluation of Cases with Myotonia Congenita for Cardiovascular Risk.
Genetic Background of a Recurrent Unusual Combined Form of Retinal Vein Occlusion: A Case Report.
Genetic factors in fetal growth restriction and miscarriage.
Hemostasis alterations in metabolic syndrome (review).
Hemostasis in Overt and Subclinical Hyperthyroidism.
Hemostatic disturbances in patients with systemic inflammatory response syndrome (SIRS) and associated acute renal failure (ARF).
High F1.2 fragment of prothrombin, thrombin-antithrombin III complex (TAT) and soluble fibrin plasma levels demonstrate hypercoagulability induced during loco-regional thrombolytic therapy with rt-PA.
Hypercoagulability in patients undergoing autologous or allogeneic BMT for hematological malignancies.
Hypercoagulability in working men and women with high levels of panic-like anxiety.
Hypercoagulability panel testing predicts thrombosis in neonates undergoing cardiac surgery.
Hypofibrinolysis in patients with hypercoagulability: the roles of urokinase and of plasminogen activator inhibitor.
Hypofibrinolysis, lipoprotein(a), and plasminogen activator inhibitor.
Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1.
Increased resistance to fibrinolysis activation in patients with coronavirus disease 2019: a case series.
Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
Inherited and acquired thrombophilia in Indian women experiencing unexplained recurrent pregnancy loss.
Is Familial Mediterranean Fever a thrombotic disease or not?
Is there a phase of hypercoagulability when aprotinin is used in cardiac surgery?
Laboratory screening of inherited thrombotic syndromes.
Leg ulcers revealing familial thrombophilia: prothrombin G20210A gene mutation and plasminogen activator inhibitor type 1 (PAI-1) polymorphism.
Metabolic, inflammatory, endothelial and haemostatic markers in a group of Italian obese children and adolescents.
Migraine associated with patent foramen ovale may be caused by reactivation of cerebral toxoplasmosis triggered by arterial blood oxygen desaturation.
Molecular pathophysiology of thrombotic states and their impact to laboratory diagnostics.
Multiple Heritable and Acquired Risk Factors in a Case of Recurrent Retinal Vein Occlusion.
Partial Recanalization of a Large Vessel Acute Ischemic Stroke With Intravenous Tissue Plasminogen Activator, Followed by Systemic Anticoagulation, in the Setting of COVID-19-Induced Hypercoagulability: A Case Report.
Pathophysiological Response to Trauma-Induced Coagulopathy: A Comprehensive Review.
Placental histomorphology in unexplained foetal loss with thrombophilia.
Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease.
Premature coronary artery disease in young (age <45) subjects: Interactions of lipid profile, thrombophilic and haemostatic markers.
Protein C and S deficiency, thrombophilia, and hypofibrinolysis: pathophysiologic causes of Legg-Perthes disease.
Recurrent IVF failure and hereditary thrombophilia.
Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a review and update.
Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins.
Role of Plasminogen Activator Inhibitor Type 1 in Pathologies of Female Reproductive Diseases.
Role of Polymorphisms in Factor V (FV Leiden), Prothrombin, Plasminogen Activator Inhibitor Type-1 (PAI-1), Methylenetetrahydrofolate Reductase (MTHFR) and Cystathionine ?-Synthase (CBS) Genes as Risk Factors for Thrombophilias.
Serial EXTEM, FIBTEM, and tPA Rotational Thromboelastometry Observations in the Maastricht Intensive Care COVID Cohort-Persistence of Hypercoagulability and Hypofibrinolysis Despite Anticoagulation.
The anti-fibrinolytic SERPIN, plasminogen activator inhibitor 1 (PAI-1), is targeted to and released from catecholamine storage vesicles.
The association between IUGR and maternal inherited thrombophilias: A case-control study.
The metabolic syndrome and cardiovascular disease.
The prognostic value of biomarkers after a premature myocardial infarction.
The role of hypercoagulability in the development of osteonecrosis of the femoral head.
The role of tissue plasminogen activator use and systemic hypercoagulability in central line-associated bloodstream infections.
Thrombophilia and hypofibrinolysis: pathophysiologies of osteonecrosis.
Thrombophilia associated gene polymorphisms: Does use of medication, including anti-coagulants, minerals or folic acid, prevent the miscarriages?
Thrombotic risk factors associated with transurethral prostatectomy.
Tissue-type plasminogen activator-induced fibrinolysis is enhanced in patients with breast, lung, pancreas and colon cancer.
Type 2 diabetes: assessment of endothelial lesion and fibrinolytic system markers.
Venous Thromboembolism After Knee Arthroscopy in Undiagnosed Familial Thrombophilia.
Venous thrombosis and procoagulant factors in high-risk neuroblastoma.
Vocal Cord Paralysis as the First Sign of Spontaneous Carotid Dissection in a Patient With Extracranial Internal Carotid Artery Aneurysm.
[Intracardiac Thrombosis in a Child With Hereditary Thrombophilia].
[Mutation and unusual expression of clotting system-related genes and hypercoagulability]
[Myocardial infarction and thromboembolism during pregnancy]
[Pharmacogenetics of the local thrombolysis in patients with deep vein thrombosis]
[Thrombophilia as a risk factor for central retinal vein occlusion]
Thrombophlebitis
A plasma clot lysis assay based on the release of fibrin degradation products: application to the diagnosis of hypofibrinolytic states.
[Comparative studies of the antithrombin III level and plasminogen activator activity in patients with thrombophlebitis]
Thrombosis
111In platelet deposition following peripheral arterial thrombolysis.
3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
99mTc-NC100668, an agent for imaging venous thromboembolism: The effect of anticoagulant or thrombolytic therapy on the uptake and retention of radioactivity in blood clots in vivo.
A biventricular takotsubo cardiomyopathy complication: large thrombus formation to stroke in 150 min.
A case of acute myocardial infarction. Intracoronary thrombosis in two major coronary arteries due to hormone therapy.
A case of intra-arterial thrombolysis with alteplase in a patient with hypothenar hammer syndrome but without underlying aneurysm.
A case of neonatal myocardial infarction: left coronary artery thrombus resolution and normalisation of ventricular function by intracoronary low-dose tissue plasminogen activator.
A case of thrombolytic therapy with recombinant tissue plasminogen activator for mechanical valve thrombosis at 9 weeks of pregnancy in a Japanese woman.
A case of unusual looking prosthetic mitral valve thrombosis treated with low dose slow infusion tPA.
A Case Series of Obstructive Prosthetic Mitral Valve Thrombosis, Successfully Treated with Low-Dose, Slow Infusion Tissue-Type Plasminogen Activator.
A chimeric murine/human antibody Fab fragment directed against the platelet GPIIb/IIIa receptor enhances and sustains arterial thrombolysis with recombinant tissue-type plasminogen activator in baboons.
A collaborative study of a proposed international standard for tissue plasminogen activator (t-PA).
A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency.
A comparative study of captopril and enalapril on endothelial cell function in congestive heart failure patients.
A Direct Aspiration First Pass Technique for Mechanical Thrombectomy in the Setting of a Suspected Cerebral Aneurysm.
A faster-acting and more potent form of tissue plasminogen activator.
A Floating Thrombus in Sinus of Valsalva Complicated with Cardiogenic Shock in a Patient with Plasminogen Activator Inhibitor 1 4G/5G Polymorphism.
A giant thrombus in the right ventricle of a newborn with Down syndrome: successful treatment with rt-PA.
A large and massive abdominal venous thrombosis associated with the presence of a big axillary mass, lupus-like syndrome and antiphospholipid antibodies.
A lethal phenotype associated with tissue plasminogen deficiency in humans.
A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction.
A mathematical model of post-canalization thrombolysis.
A model for the formation, growth, and lysis of clots in quiescent plasma. A comparison between the effects of antithrombin III deficiency and protein C deficiency.
A murine photothrombotic stroke model with an increased fibrin content and improved responses to tPA-lytic treatment.
A Myocardial Infarction During Intravenous Recombinant Tissue Plasminogen Activator Infusion for Evolving Ischemic Stroke.
A neonatal thrombosis patient treated successfully with recombinant tissue plasminogen activator.
A new manifestation and treatment alternative for heparin-induced thrombosis.
A new rat model of thrombotic focal cerebral ischemia.
A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity - a staphylokinase variant. An in-vivo study.
A Novel and Potent Thrombolytic Fusion Protein Consisting of Anti-Insoluble Fibrin Antibody and Mutated Urokinase.
A novel embolic middle cerebral artery occlusion model induced by thrombus formed in common carotid artery in rat.
A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis.
A novel hollow and perforated flexible wire allows the safe and effective local application of thrombolytic therapy in a mouse model of deep vein thrombosis.
A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates.
A novel protocol to reduce bleeding associated with alteplase treatment of HVAD pump thrombosis.
A plasma clot lysis assay based on the release of fibrin degradation products: application to the diagnosis of hypofibrinolytic states.
A population-based study in Ghana to investigate inter-individual variation in plasma t-PA and PAI-1.
A Previously Healthy Premature Infant Treated With Thrombolytic Therapy for Life-threatening Pulmonary Artery Thrombosis.
A pulmonary embolism treated with the Angiojet technique in a patient with double outlet right ventricle.
A randomized, blinded, placebo-controlled trial of recombinant human tissue-type plasminogen activator in patients with unstable angina pectoris.
A rare cause of myocardial infarction: acute inferoposterior myocardial infarction after successful intravenous thrombolytic treatment of mechanical mitral prosthetic valve thrombosis.
A region of tissue plasminogen activator that affects plasminogen activation differentially with various fibrin(ogen)-related stimulators.
A serial fluoroscopy-guided thrombolytic therapy of a mechanical tricuspid prosthetic valve thrombosis with low-dose and ultra-slow infusion of tissue-type plasminogen activator.
A Series of Cerebral Venous Sinus Thromboses Treated with Intra-Arterial tPA infused over Ten Hours with a 0.027-inch Catheter and Literature Review.
A Stepwise Approach to Left Ventricular Assist Device Pump Thrombosis.
A Successful Treatment Strategy for Paradoxical Cerebral Embolism Accompanied by Entrapped Thrombus in Patent Foramen Ovale: A Case Report.
Abciximab is a safe rescue therapy in thromboembolic events complicating cerebral aneurysm coil embolization: single center experience in 42 cases and review of the literature.
Abdominal Aortic Thrombosis in a Healthy Neonate.
Ablation of Angiotensin IV Receptor Attenuates Hypofibrinolysis via PAI-1 Downregulation and Reduces Occlusive Arterial Thrombosis.
Abnormal levels of urokinase plasminogen activator protein and tissue plasminogen activator activity in human aortic aneurysms.
Absence of antibodies to tissue-type plasminogen activator in patients with previous deep vein thrombosis.
Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model.
Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
Accelerated sonothrombolysis with Definity in a xenographic porcine cerebral thromboembolism model.
Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life.
Accelerated TPA for treatment of prosthetic valve thrombosis.
Accelerating thrombolysis using a precision and clot-penetrating drug delivery strategy by nanoparticle-shelled microbubbles.
Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis.
Activated inflammatory cells participate in thrombus size through tissue factor and plasminogen activator inhibitor-1 in acute coronary syndrome: Immunohistochemical analysis.
Activated protein C and antithrombin-III activity during arterial thrombolysis with recombinant tissue-type plasminogen activator in rabbits.
Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs.
Activation of coagulation and fibrinolysis during reconstructive microsurgery in patients with cancer.
Acute and chronic effects of oestrogen on endothelial tissue-type plasminogen activator release in postmenopausal women.
Acute basilar thrombosis: Recanalization following intravenous thrombolysis is dependent on thrombus length.
Acute carotid stent thrombosis.
Acute In-Stent Thrombosis after Carotid Angioplasty and Stenting: A Case Report and Literature Review.
Acute inferior vena cava thrombosis in a patient with membranous nephropathy treated by rt-PA lysis.
Acute intraprocedural thrombus formation during wingspan intracranial stent placement for intracranial atherosclerotic disease.
Acute mechanical prosthetic valve thrombosis after initiating oral anticoagulation therapy. Is bridging anticoagulation with heparin required?
Acute myocardial infarction following intravenous tissue plasminogen activator for acute ischemic stroke: An unknown danger.
Acute psychological stress decreases plasma tissue plasminogen activator (tPA) and tissue plasminogen activator/plasminogen activator inhibitor-1 (tPA/PAI-1) complexes in cardiac patients.
Acute renal artery thrombosis treated with t-PA power-pulse spray rheolytic thrombectomy.
Acute ST-elevation inferior myocardial infarction in a patient with a non-obstructive mechanical mitral valve thrombosis.
Acute stroke management.
Acute stroke: therapeutic transcranial Doppler sonography.
Acute therapy and prevention of stroke in spontaneous carotid dissection.
Acute Thromboembolic Ischemic Stroke From Complex Aortic Arch Plaque.
Acute thrombosis in a contralateral kidney after radical nephrectomy: successful treatment by thrombolytic therapy using a tissue-type plasminogen activator.
ADAMTS13 exerts a thrombolytic effect in microcirculation.
ADAMTS13 Retards Progression of Diabetic Nephropathy by Inhibiting Intrarenal Thrombosis in Mice.
Additive fibrinolysis by recombinant tissue-type plasminogen activator (r-t-PA) and recombinant single-chain urokinase type plasminogen activator (r-scu-PA) in rabbit pulmonary thrombosis.
Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice.
Adipose tissue macrophages: a piece of the PAI of metabolic syndrome.
Adjunctive therapies in the cath lab. Successful thrombolysis using the combination of tissue plasminogen activator and abciximab in an adult with Kawasaki's disease.
Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis.
Adjuvant effect of antibodies against von Willebrand Factor, fibrinogen, and fibronectin on staphylokinase-induced thrombolysis as measured using mural thrombi formed in rat mesenteric venules.
Advances in revascularization for acute ischemic stroke treatment: an update.
Advantages and disadvantages of using intravenous tissue Plasminogen activator as salvage therapy for inoperable HeartWare thrombosis.
Affects of hirudin and heparin on the binding of new fibrin to the thrombus in t-PA treated rabbits.
Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1.
Age-dependent vulnerability to experimental acute pancreatitis is associated with increased systemic inflammation and thrombosis.
Aging accelerates endotoxin-induced thrombosis : increased responses of plasminogen activator inhibitor-1 and lipopolysaccharide signaling with aging.
Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly.
Aging is associated with impaired thrombus resolution in a mouse model of stasis induced thrombosis.
Aging of acute deep vein thrombosis measured by radiolabeled 99mTc-rt-PA.
Albumin therapy augments the effect of thrombolysis on local vascular dynamics in a rat model of arteriolar thrombosis: a two-photon laser-scanning microscopy study.
Algal fucoidan, unlike heparin, has thrombolytic activity in a murine arterial thrombosis model.
Alpha 2-antiplasmin, plasminogen activator inhibitor (PAI) and dilute blood clot lysis time in selected disease states.
alpha-Tocopherol supplementation decreases plasminogen activator inhibitor-1 and P-selectin levels in type 2 diabetic patients.
Alteplase Instillation for Upper Urinary Tract Clot Dissolution.
Alteplase Reduces Downstream Microvascular Thrombosis and Improves the Benefit of Large Artery Recanalization in Stroke.
Alteplase use for malfunctioning central venous catheters correlates with catheter-associated bloodstream infections.
Alteplase versus urokinase in restoring blood flow in hemodialysis-catheter thrombosis.
Alteplase. A reappraisal of its pharmacological properties and therapeutic use in acute myocardial infarction.
Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.
Alteplase: descendancy in myocardial infarction, ascendancy in stroke.
Amediplase. Menarini.
An activated-platelet-sensitive nanocarrier enables targeted delivery of tissue plasminogen activator for effective thrombolytic therapy.
An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1.
An atypical case of pulmonary embolism from a jugular vein.
An enzyme-linked immunosorbent assay for the detection of plasminogen activator-induced fribrin clot lysis in a circulating plasma system.
An in vitro Model System for Evaluating Remote Magnetic Nanoparticle Movement and Fibrinolysis.
An ischemic stroke during intravenous recombinant tissue plasminogen activator infusion for evolving myocardial infarction.
An unusual thrombolytic therapy decision in prosthetic valve thrombosis during early pregnancy.
Anabolic steroids and fibrinolysis.
Angioedema and Hemorrhage After 4.5-Hour tPA (Tissue-Type Plasminogen Activator) Thrombolysis Ameliorated by T541 via Restoring Brain Microvascular Integrity.
Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.
Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus.
Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke.
Antagonism of the platelet 5HT2 receptor in the presence of thrombolysis.
Anti-inflammatory treatments for stroke: from bench to bedside.
Antibodies to fibrin-bound tissue-type plasminogen activator in systemic lupus erythematosus are associated with Raynaud's phenomenon and thrombosis.
Antibodies to tissue-type plasminogen activator (t-PA) in patients with inflammatory bowel disease: high prevalence, interactions with functional domains of t-PA and possible implications in thrombosis.
Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients.
Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator.
Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo.
Anticoagulant and Antithrombotic Properties in Vitro and in Vivo of a Novel Sulfated Polysaccharide from Marine Green Alga Monostroma nitidum.
Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study.
Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist.
Antiplatelet antibody [7E3 F(ab')2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model.
Antithrombotic activity of a monoclonal antibody inducing the substrate form of plasminogen activator inhibitor type 1 in rat models of venous and arterial thrombosis.
Antithrombotic effects and related mechanisms of Salvia deserta Schang root EtOAc extracts.
Antithrombotic effects of DMP 728, a platelet GPIIb/IIIa receptor antagonist, in a canine model of arterial thrombosis.
Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
Antithrombotic efficacy of single subcutaneous administration of a recombinant nematode anticoagulant peptide (rNAP5) in a canine model of coronary artery thrombolysis.
Anxiety-Related Bleeding and Thrombosis.
Aortic thrombosis successfully treated with local recombinant tissue plasminogen activator in a newborn.
Application of long-acting VLHL PAI-1 during sutureless partial nephrectomy in mice reduces bleeding.
Approach to thrombotic occlusion related to long-term catheters of hemodialysis patients: a narrative review.
Are Quality Improvements in the Get With The Guidelines-Stroke Program Related to Better Care or Better Data Documentation?
Are Underlying Assumptions of Current Animal Models of Human Stroke Correct: from STAIRs to High Hurdles?
Argatroban and catheter-directed thrombolysis with alteplase for limb- and graft-threatening thromboses in a patient with a history of HIT.
Arm-cranking Exercise Training Reduces Plasminogen Activator Inhibitor 1 in People with Spinal Cord Injury.
Arterial thrombosis induced by IVIg and its treatment with tPA.
AS3288802, a highly selective antibody to active plasminogen activator inhibitor-1 (PAI-1), exhibits long efficacy duration in cynomolgus monkeys.
Aspiration Thrombectomy After Intravenous Alteplase Versus Intravenous Alteplase Alone.
Assessing the outcome of systemic tissue plasminogen activator for the management of venous and arterial thrombosis in pediatrics.
Assessment of Anti-Tissue Type Plasminogen Activator Antibodies in Patients With Prosthetic Heart Valve Thrombosis: The ATA Trial.
Association between plasma levels of tissue plasminogen activator and postoperative deep vein thrombosis--influence of prophylaxis with a low molecular weight heparin. The Venous Thrombosis Group.
Association of 4G/5G polymorphism in PAI1 promoter with PAI1 level in deep vein thrombosis.
Association of advanced glycoxidation end products and inflammation markers with thrombosis of arteriovenous grafts in hemodialysis patients.
Association of Clinical, Imaging, and Thrombus Characteristics With Recanalization of Visible Intracranial Occlusion in Patients With Acute Ischemic Stroke.
Association of Plasminogen Activator Inhibitor 1 (PAI-1) 4G/5G Polymorphism and Susceptibility to SLE in Egyptian Children and Adolescents: A Multicenter Study.
Association of protein S deficiency with thrombosis in a kindred with increased levels of plasminogen activator inhibitor-1.
Associations of thrombus perviousness derived from entire thrombus segmentation with functional outcome in patients with acute ischemic stroke.
Atheroprotective Mechanisms Activated by Fluid Shear Stress in Endothelial Cells.
Atorvastatin reduces plasminogen activator inhibitor-1 expression in adipose tissue of atherosclerotic rabbits.
Atypical heparin-induced thrombocytopenia complicated by intracardiac thrombus, effectively treated with ultra-low-dose rt-PA lysis and recombinant hirudin (Lepirudin).
Augmentation of plasminogen activator inhibitor type 1 activity in plasma by thrombosis and by thrombolysis.
Augmented arterial wall expression of type-1 plasminogen activator inhibitor induced by thrombosis.
Augmented experimental pulse-spray thrombolysis with tissue plasminogen activator, enabling dose reduction by one or more orders of magnitude.
Augmented pulse-spray thrombolysis with tPA by early pulsed intrathrombic plasminogen enrichment.
Axillary vein thrombosis induced by an increasingly popular oscillating dumbbell exercise device: a case report.
Baseline abnormalities of endothelial function and thrombogenesis in relation to prognosis in essential hypertension.
Basilar Artery Thrombosis in a Child Treated With Intravenous Tissue Plasminogen Activator and Endovascular Mechanical Thrombectomy.
Beneficial actions of prothymosin alpha-mimetic hexapeptide on central post-stroke pain, reduced social activity, learning-deficit and depression following cerebral ischemia in mice.
Beneficial effect of aspirin in maintaining the patency of small-caliber prosthetic grafts after thrombolysis with urokinase or tissue-type plasminogen activator.
Beneficial effect of nitroglycerin on arterial rethrombosis after thrombolysis. Results from a rabbit thrombosis model.
Beneficial Effects of Mineralocorticoid Receptor Pathway Blockade against Endothelial Inflammation Induced by SARS-CoV-2 Spike Protein.
Bilateral Acute Renal Infarction Secondary to Methylene Tetrahydrofolate Reductase A1298C and PAI-1 Mutation.
Bilateral renal vein thrombosis and subsequent acute renal failure due to IVC filter migration and thrombosis.
Bilateral renal venous thrombosis in a neonate associated with resistance to activated protein C.
Binding of human tissue plasminogen activator (t-PA) to blood clots and clot-lytic activity of clot-bound t-PA.
Bio-responsive delivery of tissue plasminogen activator for localized thrombolysis.
Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin.
Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.
Biochemical dynamics relevant to the safety of low-dose, intraclot alteplase for deep vein thrombosis.
Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.
Biological control of tissue plasminogen activator-mediated fibrinolysis.
Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.
Biological properties of hybrid plasminogen activators.
Bivalirudin and thrombolytic therapy: a novel successful treatment of severe aortic arch thrombosis in a term neonate.
Bivalirudin during thrombolysis with catheter-directed tPA in a heparin-refractory patient: A case report.
Bleeding complications after basilar artery fibrinolysis with tissue plasminogen activator.
Blockade of placental growth factor reduces vaso-occlusive complications in murine models of sickle cell disease.
Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs.
Blockade of the platelet P2Y12 receptor by AR-C69931MX sustains coronary artery recanalization and improves the myocardial tissue perfusion in a canine thrombosis model.
Blood Clot Breakdown. Should tPA be used to treat refractory v fib or other OHCA?
Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer.
Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study.
Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
Bolus fibrinolytic therapy in acute myocardial infarction.
Bolus thrombolysis in venous thromboembolism.
Brachial embolism from mechanical mitral valve thrombosis: multimodality imaging-guided successful thrombolysis.
Brain endothelial cell specific integrins and ischemic stroke.
Bryostatin extends tPA time window to 6 h following middle cerebral artery occlusion in aged female rats.
C-reactive protein induces expression of tissue factor and plasminogen activator inhibitor-1 and promotes fibrin accumulation in vein grafts.
Can divergent plasmin-antiplasmin-carbon monoxide interactions in young, healthy tobacco smokers explain the 'smoker's paradox'?
Cangrelor for patients undergoing percutaneous coronary intervention: evidence from a meta-analysis of randomized trials.
Carbon Monoxide Releasing Molecule-2 Improves Protamine-Mediated Hypocoagulation/Hyperfibrinolysis in Human Plasma In Vitro.
Carbon monoxide-releasing molecule-2 decreases fibrinolysis in human plasma.
Cardiac-targeting transfection of tissue-type plasminogen activator gene to prevent the graft thrombosis and vascular anastomotic restenosis after coronary bypass.
Cardioembolic stroke on unaffected side during thrombolysis for acute ischemic stroke.
Cardioprotection and thrombolysis by anistreplase in anesthetized dogs.
Cardiovascular risk factors in relation to cigarette smoking: a population-based survey among Asians in Singapore.
Case study and review: Treatment of tricuspid prosthetic valve thrombosis.
Catheter Placement for Lysis of Spontaneous Intracerebral Hematomas: Is a Navigated Stylet Better Than Pointer-Guided Frameless Stereotaxy for Intrahematomal Catheter Positioning?
Catheter-Directed Low-Dose Tissue Plasminogen Activator for Treatment of Right Atrial Thrombus Caused by a Central Venous Catheter.
Catheter-directed lysis of iliofemoral vein thrombosis with use of rt-PA.
Catheter-directed thrombolysis following vena cava filtration for severe deep venous thrombosis.
Catheter-directed thrombolysis in deep venous thrombosis with use of reteplase: immediate results and complications from a pilot study.
Catheter-directed thrombolysis with alteplase and bivalirudin in a patient with heparin-induced thrombocytopenia.
Catheter-directed Thrombolysis with Argatroban and tPA for Massive Iliac and Femoropopliteal Vein Thrombosis.
Catheter-directed thrombolysis with tPA to restore renal function after iliac venous thrombosis post-renal transplantation.
Catheter-directed thrombolytic therapy for thoracic deep vein thrombosis is safe and effective in selected patients with and without cancer.
Catheter-directed tissue plasminogen activator infusion and concurrent systemic anticoagulation with heparin to treat portal vein thrombosis post orthoptic liver transplantation.
Catheter-induced acute Blalock-Taussig shunt thrombosis and bailout.
Caudal blockade as alternative therapeutic approach in neonatal arterial thrombosis.
Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease.
Caval thrombolysis in neonates using low doses of recombinant human tissue-type plasminogen activator.
Cavitational mechanisms in ultrasound-accelerated thrombolysis at 1 MHz.
Central venous catheter associated thrombosis of major veins: thrombolytic treatment with recombinant tissue plasminogen activator.
Central venous catheter-related thrombosis presenting as superior vena cava syndrome in a haemophilic patient with inhibitors.
Central Venous Catheters for Hemodialysis: How to Overcome the Problems.
Central venous thrombosis after cardiac operations in children.
Cerebral hemorrhagic risk of aspirin or heparin therapy with thrombolytic treatment in rabbits.
Cerebral venous congestion as indication for thrombolytic treatment.
Changes in blood coagulation-fibrinolysis markers by pneumatic tourniquet during total knee joint arthroplasty with venous thromboembolism.
Changes in interstitial collagen metabolism during acute myocardial infarction treated with streptokinase or tissue plasminogen activator.
Characteristic effects of activated human protein C on tissue thromboplastin-induced disseminated intravascular coagulation in rabbits.
Characterization of chitosan magnetic nanoparticles for in situ delivery of tissue plasminogen activator
Chronic allograft nephropathy: expression and localization of PAI-1 and PPAR-gamma.
Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator.
Circadian variation of tissue plasminogen activator and its inhibitor, von Willebrand factor antigen, and prostacyclin stimulating factor in men with ischaemic heart disease.
Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York.
Clinical Course of Acute Ischemic Stroke Due to Medium Vessel Occlusion With and Without Intravenous Alteplase Treatment.
Clinical disorders of fibrinolysis: a critical review.
Clinical experience with alteplase in the management of intracardiac and major cardiac vessels thrombosis in pediatrics: a case series.
Clinical experience with recombinant tissue plasminogen activator in the management of intracardiac and arterial thrombosis in children.
Clinical features and treatment results in preterm infants with intracardiac thrombus.
Clinical implications of elevated PAI-1 revisited: multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAI-1) levels: a case report and review of the literature.
Clinical investigation of the utility of a pair of coagulation-fibrinolysis markers for definite diagnosis of sepsis-induced disseminated intravascular coagulation: A single-center, diagnostic, prospective, observational study.
Cloning and expression of functional full-length human tissue plasminogen activator in Pichia pastoris.
Clot Burden Score and Early Ischemia Predict Intracranial Hemorrhage following Endovascular Therapy.
Clot lysis in a primate model of peripheral arterial occlusive disease with use of systemic or intraarterial reteplase: addition of abciximab results in improved vessel reperfusion.
CLOTBUST-Hands Free: pilot safety study of a novel operator-independent ultrasound device in patients with acute ischemic stroke.
Clots, kinins and coronaries.
Co-administration of liposomal fasudil and tissue plasminogen activator ameliorated ischemic brain damage in occlusion model rats prepared by photochemically induced thrombosis.
Coagulation disorders and aortic stenosis: A chicken and egg question?
Coagulation tests and anti-phospholipid antibodies in patients positive for lupus anticoagulant.
Cognitive Patterns in Relation to Biomarkers of Cerebrovascular Disease and Vascular Risk Factors.
Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase.
Combination of a high bolus dose of tirofiban with half-dose thrombolytics for the treatment of subacute stent thrombosis.
Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke.
Combination thrombolytic and anti-platelet therapies in an infant with incomplete kawasaki disease and coronary aneurysms.
Combination thrombolytic and anticoagulant therapy for bilateral renal vein thrombosis in a premature infant.
Combined glycoprotein IIb/IIIa receptor inhibition and low-dose fibrinolysis for peripheral arterial thrombosis.
Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study.
Combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator for emergent revascularization in acute ischemic stroke (CLOTBUST-ER): design and methodology of a multinational phase 3 trial.
Combined rTPA and aspirin therapy for intracardiac thrombosis in neonates.
Combined thrombolytic therapy for atrial thrombus in a preterm infant.
Comparative analysis of plasminogen activator inhibitor-1 expression in different types of atherosclerotic lesions in coronary arteries from human heart explants.
Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation.
Comparative lytic efficacy of rt-PA and ultrasound in porcine versus human clots.
Comparative results of thrombolysis treatment with rt-PA and urokinase: a pilot study.
Comparative study of a mutant tissue-type plasminogen activator, YM866, with a tissue-type plasminogen activator in a canine model of femoral arterial thrombosis.
Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
Comparative time course of thrombolysis induced by intravenous boluses and infusion of staphylokinase and tissue plasminogen activator in a rabbit arterial thrombosis model.
Comparative tolerability profiles of thrombolytic agents. A review.
Comparison between the clot-protecting activity of a mutant plasminogen activator inhibitor-1 with a very long half-life and 6-aminocaproic acid.
Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
Comparison of alteplase and heparin in maintaining the patency of paediatric central venous haemodialysis lines: a randomised controlled trial.
Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis.
Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.
Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis.
Comparison of retavase and urokinase for management of spontaneous subclavian vein thrombosis.
Comparison of the antithrombotic effects and bleeding risk of fractionated aurin tricarboxylic acid and the GPIIb/IIIa antagonist GR144053 in a hamster model of stenosis.
Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis.
Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin.
Complex Clearance Mechanisms After Intraventricular Hemorrhage and rt-PA Treatment-a Review on Clinical Trials.
Compression-induced HIF-1 enhances thrombosis and PAI-1 expression in mouse skin.
Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease.
Concurrent nitroglycerin administration decreases thrombolytic potential of tissue-type plasminogen activator.
Concurrent nitroglycerin therapy impairs tissue-type plasminogen activator-induced thrombolysis in patients with acute myocardial infarction.
Conjugation of plasminogen activators and fibrin-specific antibodies to improve thrombolytic therapeutic agents.
Conjunctive effects of the 5HT(2) receptor antagonist, sarpogrelate, on thrombolysis with modified tissue plasminogen activator in different laser-induced thrombosis models.
Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
Construction and biological activities of human tPA eukaryotic expression plasmid.
Continuous intraarterial thrombolysis for early hepatic artery thrombosis following liver transplantation: case report.
Controlled localized thrombolysis with the "turbo" trellis to treat acute arterial occlusions following major surgery.
Controlled release of clot-dissolving tissue-type plasminogen activator from a poly(L-glutamic acid) semi-interpenetrating polymer network hydrogel.
Coronary thrombolysis with recombinant tissue plasminogen activator. Intracoronary vs intravenous administration.
Coronary thrombolysis. Comparative effects of intracoronary administration of recombinant tissue plasminogen activator and urokinase.
Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model.
Correlation between plasminogen activator inhibitor-1 4G/5G polymorphism and pre-eclampsia: an appraisal.
COVID-19-Related Stroke.
COVID19: a case report of thrombus in transit.
Current and future recanalization strategies for acute ischemic stroke.
Current status of activity assays for tissue plasminogen activator.
Cutaneous fibrinolytic potential, tPA dependent, is reduced in Behçet's disease.
Cytokines in coagulation and thrombosis: a preclinical and clinical review.
D-dimer in local thrombolytic therapy with low doses of recombinant human tissue-type plasminogen activator (rt-PA) in patients with peripheral arterial occlusive disease.
Daily catheter-directed single dosing of t-PA in treatment of acute deep venous thrombosis of the lower extremity.
Decreased plasminogen activator but normal prostacyclin activity in rat veins during development of experimental thrombosis.
Deep cerebral venous thrombosis and hereditary tissue plasminogen activator (t-PA) deficiency.
Deep vein thrombosis after renal transplantation: a prospective analysis of frequency and risk factors.
Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator release.
Deep vein thrombosis of lower extremity: direct intraclot injection of alteplase once daily with systemic anticoagulation--results of pilot study.
Deficiency of tPA Exacerbates White Matter Damage, Neuroinflammation, Glymphatic Dysfunction and Cognitive Dysfunction in Aging Mice.
Deficient tissue plasminogen activator release and normal tissue plasminogen activator inhibitor in a patient with recurrent deep vein thrombosis.
Delayed fibrinolysis: a cause of thrombosis?
Delivery of anti-platelet-endothelial cell adhesion molecule single-chain variable fragment-urokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema.
Delivery of thrombolytic therapy using rod-shaped plant viral nanoparticles decreases the risk of hemorrhage.
Demonstration of significant resolution of cerebral sino-venous thrombosis associated with intravenous recombinant tissue plasminogen activator.
Dependence of Proximal GC Boxes and Binding Transcription Factors in the Regulation of Basal and Valproic Acid-Induced Expression of t-PA.
Design of a PROspective multi-national CLOTBUST collaboration on reperfusion therapies for stroke (CLOTBUST-PRO).
Detection of extracellular genomic DNA scaffold in human thrombus: implications for the use of deoxyribonuclease enzymes in thrombolysis.
Determinants of tPA antigen and associations with coronary artery disease and acute cerebrovascular disease.
Determination of Biological Activity of Recombinant Reteplase Using Clot Lysis Time and Activated Partial Thromboplastin Time (APTT) Lysis Methods: A Comparative Study.
Development of a new catheter prototype for laser thrombolysis under guidance of optical coherence tomography (OCT): validation of feasibility and efficacy in a preclinical model.
Diagnosis, treatment & management of prosthetic valve thrombosis: the key considerations.
Diagnostic Value of Thrombus Size on T2(*)-weighted Gradient Echo Imaging in Acute Middle Cerebral Artery Occlusion.
Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase- or tissue-type plasminogen activator.
Differential fibrinolytic properties of the recombinant plasminogen activator BM 06.022 in human plasma and blood clot systems in vitro.
Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury.
Direct action on the molecule is one of several mechanisms by which ultrasound enhances the fibrinolytic effects of reteplase.
Direct thrombolytic therapy for intraventricular thrombosis in patients with the Jarvik 2000 left ventricular assist device.
Direct thrombolytic therapy in portal and mesenteric vein thrombosis.
Direct tissue plasminogen activator administration through a microinjection device in a pig model of retinal vein thrombosis.
Disodium disuccinate astaxanthin prevents carotid artery rethrombosis and ex vivo platelet activation.
Disruption of tissue plasminogen activator gene reduces macrophage migration.
Dissolution of a right atrial thrombus attached to pacemaker electrodes: usefulness of recombinant tissue-type plasminogen activator.
Dissolution of emboli in rats with experimental cerebral thromboembolism by recombinant human tissue plasminogen activator (TD-2061).
DNA Aptamers to Thrombin Exosite I. Structure-Function Relationships and Antithrombotic Effects.
DNA, histones and neutrophil extracellular traps exert anti-fibrinolytic effects in a plasma environment.
Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?
Does low protein concentration of tissue-type plasminogen activator predict a low risk of spontaneous deep vein thrombosis?
Does low-dose heparin maintain central venous access device patency?: a comparison of heparin versus saline during a period of heparin shortage.
Does Reducing the Duration from Symptom Onset to Recanalization Improve the Results of Intracranial Mechanical Thrombectomy in the Elderly?
Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: results of the TIMI 31 trial.
Double-blind, randomized comparison of systemic continuous infusion of 0.25 versus 0.50 mg/kg/24 h of alteplase over 3 to 7 days for treatment of deep venous thrombosis in heparinized patients: results of the European Thrombolysis with rt-PA in Venous Thrombosis (ETTT) trial.
Dramatic thrombolysis after rapid injection of tissue plasminogen activator: A case report.
Dual mutation (MTHFR A1298C with PAI (4G) mutation) manifesting with bilateral lower limb gangrene in a neonate.
Duty cycle dependence of ultrasound enhanced thrombolysis in a human clot model.
Dynamic Enhancer Methylation--A Previously Unrecognized Switch for Tissue-Type Plasminogen Activator Expression.
Early hepatic arterial thrombosis in liver transplantation: Systemic intravenous alteplase as a potential rescue treatment after failed surgical revascularization.
Early intracardiac thrombosis in preterm infants and thrombolysis with recombinant tissue type plasminogen activator.
Early thrombolysis by recombinant tissue-plasminogen activator is beneficial to the ischemic myocardium.
Early transcatheter thrombectomy and thrombolytic therapy in acute non-cirrhotic and non-malignant mesenteric vein thrombosis: Case report of two cases and literature review.
Early treatment of subarachnoid hemorrhage after preventing rerupture of an aneurysm.
Effect of a synthetic factor Xa inhibitor, YM-60828, on blood vessel patency in combination with a thrombolytic agent and on blood loss from the operation site in a rat model of arterial thrombosis.
Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke.
Effect of clopidogrel on tissue-plasminogen activator-induced in vitro thrombolysis of feline whole blood thrombi.
Effect of crocin on antioxidant gene expression, fibrinolytic parameters, redox status and blood biochemistry in nicotinamide-streptozotocin-induced diabetic rats.
Effect of dietary docosahexaenoic acid in the rat middle cerebral artery thrombosis model.
Effect of GR144053, a fibrinogen-receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tPA in the injured carotid artery of the hamster.
Effect of intraluminal application of tissue-type plasminogen activator on the fibrinolytic activity of experimental vein grafts.
Effect of intrathecal fibrinolysis on cerebrospinal fluid absorption after experimental subarachnoid hemorrhage.
Effect of locally applied tissue-type plasminogen activator on venous fibrinolytic activity: in vitro and in vivo investigations.
Effect of low-molecular-weight heparin on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.
Effect of oral defibrotide on tissue-plasminogen activator and tissue-plasminogen activator inhibitor balance.
Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV1691 G-A.
Effect of rate of administration of recombinant tissue plasminogen activator on efficacy of coronary thrombolysis.
Effect of recombinant hirudin (LU 52369) on reocclusion rates after thrombolysis in rabbits.
Effect of recombinant plasminogen activator timing on thrombolysis in a novel rat embolic stroke model.
Effect of Recombinant Single-Chain Urokinase-Type Plasminogen Activator on Experimental Pulmonary Embolism.
Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Effect of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on tPA-induced thrombolysis in a rabbit model of femoral arterial thrombosis.
Effect of the lupus anticoagulant on endothelial fibrinolytic activity in vitro.
Effect of thrombolysis on myocardial injury: recombinant tissue plasminogen activator vs. alfimeprase.
Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis.
Effect of time of 7E3 administration on rt-PA-induced reperfusion: study in a canine model of thrombus-based occlusion-reperfusion.
Effect of tissue plasminogen activator on vascular smooth muscle cells.
Effect of wood smoke exposure on vascular function and thrombus formation in healthy fire fighters.
Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits.
Effective treatment with a new protocol using tissue-type plasminogen activator thrombolysis for pump thrombosis with the HVAD device.
Effectiveness of low-dose prolonged infusion of tissue plasminogen activator in a nonagenarian patient with acute pulmonary embolism and main pulmonary artery thrombus.
Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetes.
Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model.
Effects of dietary supplementation with cod liver oil on monocyte thromboplastin synthesis, coagulation and fibrinolysis.
Effects of exercise training on plasminogen activator inhibitor activity.
Effects of High Glucose and Ketosis (Acetoacetate, {beta}-Hydroxybutyrate) on PAI-1 Secretion in Human Umbilical Vascular Endothelial Cells.
Effects of inogatran, a new low-molecular-weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time.
Effects of intrathrombic administration of prostaglandin E1 during pulse-spray thrombolysis with tissue-type plasminogen activator in experimental thrombosis.
Effects of intravenous recombinant tissue-type plasminogen activator therapy on the incidence and associations of left ventricular thrombus in patients with a first acute Q wave anterior myocardial infarction.
Effects of oral stanozolol used in the prevention of postoperative deep vein thrombosis on fibrinolytic activity.
Effects of peptide 6A on coronary blood flow dynamics in canine coronary thrombosis.
Effects of specific chemical suppressors of plasminogen activator inhibitor-1 in cardiovascular diseases.
Effects of therapeutic doses of heparin on thrombolysis with tissue-type plasminogen activator in rabbits.
Effects of vapiprost, a novel thromboxane receptor antagonist, on thrombus formation and vascular patency after thrombolysis by tissue-type plasminogen activator.
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Efficacy evaluation of reteplase in a novel canine acute pulmonary thromboembolism model developed by minimally invasive surgery and digital subtraction angiography.
Efficacy of tissue plasminogen activator and urokinase in a canine model of prosthetic graft thrombosis.
Efficacy of tissue plasminogen activator in the lysis of thrombosis of the cerebral venous sinus.
Efficiency of alteplase in the treatment of venous and arterial thrombosis in neonates.
Elevated plasminogen activator inhibitor (PAI), a cause of thrombophilia? A study in 203 patients with familial or sporadic venous thrombophilia.
Elevated plasminogen activator inhibitor levels found in patients with malignant conditions.
Elevation of plasminogen activators in cerebrospinal fluid of mice with eosinophilic meningitis caused by Angiostrongylus cantonensis.
Embolization of acutely ruptured and unruptured wide-necked cerebral aneurysms using the neuroform2 stent without pretreatment with antiplatelets: a single center experience.
Embolization of ruptured aneurysms in the acute stage: experience at a single institute.
Emerging risk factors for cardiovascular diseases: Indian context.
Encapsulation of a plasminogen activator speeds reperfusion, lessens infarct and reduces blood loss in a canine model of coronary artery thrombosis.
Endocytosis of the recombinant tissue plasminogen activator alteplase by hepatic endothelial cells.
Endogenous and exogenous nitric oxide protect against intracoronary thrombosis and reocclusion after thrombolysis.
Endogenous fibrinolysis in patients with lower extremity ischemia.
Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
Endogenous Tissue Plasminogen Activator Enhances Fibrinolysis and Limits Thrombus Formation in a Clinical Model of Thrombosis.
Endothelial binding of recombinant tissue plasminogen activator: quantification in vivo using a recirculatory model.
Endothelial dysfunction after arterial thrombosis is ameliorated by L-arginine in combination with thrombolysis.
Endothelial fibrinolytic capacity predicts future adverse cardiovascular events in patients with coronary heart disease.
Endothelial Function, Inflammation, Thrombosis, and Basal Ganglia Perivascular Spaces in Patients with Stroke.
Endothelial t-PA release is impaired in overweight and obese adults but can be improved with regular aerobic exercise.
Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis.
Endothelium and inflammation.
Endovascular Thrombectomy for Mild Strokes: How Low Should We Go?
Endovascular treatment of wide necked ruptured saccular aneurysms with flow- diverter stent.
Engineered Nanoplatelets for Targeted Delivery of Plasminogen Activators to Reverse Thrombus in Multiple Mouse Thrombosis Models.
Enhanced clot dissolution in vitro by 1.8-MHz pulsed ultrasound.
Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors.
Enhanced plasminogen activator inhibitor-1 expression in transgenic mice with hepatocyte-specific overexpression of superoxide dismutase or glutathione peroxidase.
Enhanced Thrombolysis by Ultrasound-Assisted Catheter-Directed Thrombolysis and Microbubbles in an In Vitro Model of Iliofemoral Deep Vein Thrombosis.
Enhanced thrombosis in atherosclerosis-prone mice is associated with increased arterial expression of plasminogen activator inhibitor-1.
Enhanced Venous Thrombus Resolution in Plasminogen Activator Inhibitor Type-2 Deficient Mice.
Enhancement of enzymatic fibrinolysis with 2-MHz ultrasound and microbubbles.
Enhancement of fibrinolysis in vitro by ultrasound.
Enhancement of recombinant tissue-type plasminogen activator thrombolysis with a selective factor Xa inhibitor derived from the leech Hirudo medicinalis: comparison with heparin and hirudin in a rabbit thrombosis model.
Enhancement of secretion and extracellular stability of staphylokinase in Bacillus subtilis by wprA gene disruption.
Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin.
Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model.
Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, in a rhesus monkey model of coronary thrombosis.
Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)- ethylidene]-6,11-dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis.
Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels.
Epistatic interactions in genetic regulation of t-PA and PAI-1 levels in a Ghanaian population.
Erythrocyte Fraction Within Retrieved Thrombi Contributes to Thrombolytic Response in Acute Ischemic Stroke.
Erythrocyte-Inspired Discoidal Polymeric Nanoconstructs Carrying Tissue Plasminogen Activator for the Enhanced Lysis of Blood Clots.
Establishing an alteplase dosing protocol for hemodialysis-catheter thrombosis.
Etiopathophysiology of disseminated intravascular coagulation.
Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity.
Evaluation of epithelial tissue plasminogen activator as a thrombolytic agent in a rabbit model of venous thrombosis.
Evaluation of high resolution ultrasound as a tool for assessing the 3D volume of blood clots during in vitro thrombolysis.
Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosis.
Evaluation of the acute hemodynamic effects and pharmacokinetics of coronary thrombolysis produced by intravenous tissue-type plasminogen activator in the anesthetized dog.
Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model.
Evaluation of the in vivo thrombolytic activity of a metalloprotease from Bothrops atrox venom using a model of venous thrombosis.
Evaluation of thrombolytic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis.
Evaluation of thrombotic left main coronary artery occlusions; old problem, different treatment approaches.
Exogenous tissue plasminogen activator enhances peripheral nerve regeneration and functional recovery after injury in mice.
Experimental model of carotid artery thrombosis in rats and the thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator.
Experimental pulmonary embolism: effects of the thrombus and attenuation of pulmonary artery injury by low-molecular-weight heparin.
Experimental study of tissue-type plasminogen activator gene to prevent vein grafts stenosis.
Expression of fibrinolytic antigens in redistributed cardiac mast cells in auricular thrombosis.
Expression of the truncated tissue plasminogen activator (K2S) gene in tobacco chloroplast.
Extended deep vein and inferior vena cava thrombosis in a 15-year-old boy: successful lysis with recombinant tissue-type plasminogen activator 2 weeks after onset of symptoms.
Extended monitoring of hemostatic activation after varicose vein surgery under general anesthesia.
Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs.
Failure of thrombus to resolve in urokinase-type plasminogen activator gene-knockout mice: rescue by normal bone marrow-derived cells.
Familial clustering of defective release of t-PA.
Familial vascular plasminogen activator deficiency: a cause of cerebrovascular thrombosis.
Fast-track thrombolysis protocol for acute limb ischemia.
Fast-track thrombolysis protocol: A single-session approach for acute iliofemoral deep venous thrombosis.
Feasibility of low-dose infusion of alteplase for unsuccessful thrombolysis with urokinase in deep venous thrombosis.
Femoro-popliteal artery thrombolysis with intra-arterial infusion of recombinant tissue-type plasminogen activator--report of a pilot trial.
Fibrin-specific fibrinolysis induced by recombinant staphylokinase.
Fibrinogen and a Triad of Thrombosis, Inflammation, and the Renin-Angiotensin System in Premature Coronary Artery Disease in Women: A New Insight into Sex-Related Differences in the Pathogenesis of the Disease.
Fibrinogen anomalies and disease. A clinical update.
Fibrinogen level as a surrogate for the outcome of thrombolytic therapy using tissue plasminogen activator for acute lower extremity intravascular thrombosis.
Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy.
Fibrinolysis and the risk of venous and arterial thrombosis.
Fibrinolysis in chronic renal failure, dialysis and renal transplantation.
Fibrinolysis inhibits shear stress-induced platelet aggregation.
Fibrinolysis with intrathrombic injection of urokinase and tissue-type plasminogen activator. Results in a new model of subacute venous thrombosis.
Fibrinolysis, antithrombin III, and protein C in neonates during cardiac operations.
Fibrinolysis: from blood to the brain.
Fibrinolytic (rt-PA) therapy for superior vena cava thrombosis in a multiple trauma patient.
Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study.
Fibrinolytic activity after vessel wall injury.
Fibrinolytic activity and d-dimer levels in Behçet's syndrome.
Fibrinolytic properties of lysine-derivatized polyethylene in contact with flowing whole blood (Chandler loop model).
Fibrinolytic therapy for mechanical pulmonary valve thrombosis.
Fibrinolytic therapy in intraventricular hemorrhage.
Fibrinolytic therapy of deep vein thrombosis with continuous intravenous infusion of a recombinant tissue plasminogen activator.
Fibrinolytic Treatment after Transient Ischaemic Attack Caused by Prosthetic Mitral Valve Thrombosis.
Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study.
Findings on the efficacy and safety of thrombolytic therapy. An analysis of key clinical trials.
Flow through clots determines the rate and pattern of fibrinolysis.
Focal embolic cerebral ischemia in the rat.
Free floating right atrial thrombus leading to acute pulmonary embolism.
From Cerius(2) based stereoview to mouse and enzyme: the model systems for discovery of novel urokinase inhibitors.
Fucoidan-functionalized polysaccharide submicroparticles loaded with alteplase for efficient targeted thrombolytic therapy.
Functional magnetic stimulation: a new modality for enhancing systemic fibrinolysis.
Functional plasminogen activator inhibitor 1 is retained on the activated platelet membrane following platelet activation.
Further biocompatibility testing of silica-chitosan complex membrane in the production of tissue plasminogen activator by epithelial and fibroblast cells.
G4120, an Arg-Gly-Asp containing pentapeptide, enhances arterial eversion graft recanalization with recombinant tissue-type plasminogen activator in dogs.
Gastrin stimulates expression of plasminogen activator inhibitor (PAI)-1 in gastric epithelial cells.
Gemfibrozil predictably lowers triglycerides but does not significantly change plasminogen activator inhibitor activity in hypertriglyceridemic patients with a history of thrombosis.
Gene expression of plasminogen activator inhibitor 1 in transplant kidneys complicated by renal vein thrombosis: a combined study by in-situ hybridization and immunohistochemistry.
Gene expression profile of mouse white adipose tissue during inflammatory stress: age-dependent upregulation of major procoagulant factors.
Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies.
Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, neointima formation, and atherosclerosis.
Gene therapy for all aspects of vein-graft disease.
Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model.
Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia.
Genetic variation at the human tissue-type plasminogen activator (tPA) locus: haplotypes and analysis of association to plasma levels of tPA.
Glycoprotein IIb/IIIa receptor antagonist (2S)-2-[(2-Naphthyl-sulfonyl)amino]-3-[[2-([4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl] butanoyl]amino)acetyl]amino]propanoic acid dihydrochloride (CRL42796), in combination with aspirin and/or enoxaparin, prevents coronary artery rethrombosis after successful thrombolytic treatment by recombinant tissue plasminogen activator.
Half-Dose Versus Full-Dose Alteplase for Treatment of Pulmonary Embolism.
Haplotypes of the plasminogen activator gene associated with ischemic stroke.
Hemostatic Abnormalities in Cirrhosis and Tumor-Related Portal Vein Thrombosis.
Hemostatic abnormalities in total artificial heart patients as detected by specific blood markers.
Hemostatic gene polymorphisms in severe acute pancreatitis.
Hemostatic variables in nephrotic patients.
Hemothorax under thrombolytic therapy with recombinant tissue: plasminogen activator (rt-PA) in a 16-year-old girl.
Heparin inhibits spontaneous thrombolysis and the thrombolytic effect of both streptokinase and tissue-type plasminogen activator. An in vitro study of the dislodgement of platelet-rich thrombi formed from native blood.
Heparin-protein C interaction.
Heparin-triggered release of camouflaged tissue plasminogen activator for targeted thrombolysis.
High F1.2 fragment of prothrombin, thrombin-antithrombin III complex (TAT) and soluble fibrin plasma levels demonstrate hypercoagulability induced during loco-regional thrombolytic therapy with rt-PA.
High plasma levels of plasminogen activator inhibitor 1 (PAI-1) in polycythemia vera and essential thrombocythemia are associated with thrombosis.
Hirudin and sulotroban improve coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary artery thrombosis.
Histological observations and the process of ultrasound contrast agent enhancement of tissue plasminogen activator thrombolysis with ultrasound exposure.
Histone deacetylase inhibitors stimulate tissue-type plasminogen activator production in vascular endothelial cells.
Histopathological findings in experimental aneurysms embolized with conventional and thrombogenic/antithrombolytic Guglielmi coils.
How to perform and manage low-dose and slow/ultra-slow tissue type plasminogen activator infusion regimens in patients with prosthetic valve thrombosis.
How to select patients with deep vein thrombosis for tPA therapy.
Human extrinsic plasminogen activator fibrinolytic properties and neutralization in vivo.
Human recombinant tissue type plasminogen activator and its effect on microvascular thrombosis in the rabbit.
Hyperacute Carotid Stent Thrombosis During Emergent Revascularization Treated with Intraarterial Eptifibatide After Systemic Administration of Recombinant Tissue Plasminogen Activator.
Hyperacute direct thrombus imaging using computed tomography and gold nanoparticles.
Identification and Management of Pump Thrombus in the HeartWare Left Ventricular Assist Device System: A Novel Approach Using Log File Analysis.
Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses.
Idiopathic multifocal intracardiac and pulmonary thrombosis: successful treatment with rTPA.
Imidapril, an angiotensin-converting enzyme inhibitor, inhibits thrombosis via reduction in aortic plasminogen activator inhibitor type-1 levels in spontaneously hypertensive rats.
Immunohistochemical detection of uPA, tPA, and PAI-1 in a stasis-induced deep vein thrombosis model and its application to thrombus age estimation.
Immunohistochemical expression of plasminogen activator inhibitor-1 in subcutaneous versus omental adipose tissue in patients after elective abdominal surgery.
Impact of intravenous alteplase on sub-angiographic emboli in high-resolution diffusion-weighted imaging following successful thrombectomy.
Impact of mechanical thrombectomy device on thrombus histology in acute embolic stroke.
Impact of thrombus aspiration on the activity of plasminogen activator inhibitor?1 during acute ST-segment elevation myocardial infarction.
Improving Hemocompatibility: How Can Smart Surfaces Direct Blood To Fight against Thrombi.
In silico and in vivo analyses of the mutated human tissue plasminogen activator (mtPA) and the antithetical effects of P19 silencing suppressor on its expression in two Nicotiana species.
In utero arterial thrombosis treated with recombinant tissue plasminogen activator in an infant of a diabetic mother: A case report and literature review.
In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
In vitro comparison of complementary interactions between synthetic linear/branched oligo/poly-L-lysines and tissue plasminogen activator by means of high-performance monolithic-disk affinity chromatography.
In vitro investigations into enhancement of tPA bioavailability in whole blood clots using pulsed-high intensity focused ultrasound exposures.
In vitro oxidative damage to tissue-type plasminogen activator: a selective modification of the biological functions.
In vitro Simulation of Therapeutic Thrombolysis With Microtiter Plate Clot-Lysis Assay.
In vitro sonothrombolysis with duplex ultrasound: first results using a simplified model.
In vitro testing of a new aspiration thrombus device.
In vitro thrombolytic efficacy of echogenic liposomes loaded with tissue plasminogen activator and octafluoropropane gas.
In vivo distribution of Tc-99m labeled recombinant tissue-type plasminogen activator in control and thrombus-bearing rats.
In vivo retinal vascular cannulation in rabbits.
In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
In vivo thrombolysis with targeted microbubbles loading tissue plasminogen activator in a rabbit femoral artery thrombus model.
Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of a platelet-rich thrombus in rat mesenteric arterioles.
Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected]
Incidence of left ventricular thrombi formation after thrombolytic therapy with recombinant tissue plasminogen activator, heparin, and aspirin in patients with acute myocardial infarction.
Increased expression of plasminogen activator inhibitor-1 with fibrin deposition in a murine model of aging, "Klotho" mouse.
Increased plasma plasminogen activator inhibitor activity after coronary spasm.
Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.
Increased serum vWF and sVCAM-1 levels are associated with late or very late angiographic stent thrombosis after sirolimus-eluting stent implantation.
Indoxyl Sulfate Promotes Arterial Thrombosis in Rat Model via Increased Levels of Complex TF/VII, PAI-1, Platelet Activation as Well as Decreased Contents of SIRT1 and SIRT3.
Inducible carboxypeptidase activity. A role in clot lysis in vivo.
Induction of endothelial cell expression of the plasminogen activator inhibitor type 1 gene by thrombosis in vivo.
Induction of vascular smooth muscle cell expression of plasminogen activator inhibitor-1 by thrombin.
Inertial Cavitation Ultrasound with Microbubbles Improves Reperfusion Efficacy When Combined with Tissue Plasminogen Activator in an In Vitro Model of Microvascular Obstruction.
Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis.
Inflammation, obesity, and thrombosis.
Influence of intraoperative using of recombinant tissue plasminogen activator on the development of cerebral angiospasm after subarachnoid haemorrhage in patients with ruptured intracranial aneurysms.
Influence of selective endoperoxide/thromboxane A2 receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog.
Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components.
Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group.
Inhaled nitric oxide increases coronary artery patency after thrombolysis.
Inherited thrombophilias in pregnant patients: detection and treatment paradigm.
Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis.
Inhibition of clot-bound alpha 2-antiplasmin enhances in vivo thrombolysis.
Inhibition of cyclic flow variations and reocclusion after thrombolysis in dogs by a novel antagonist of platelet-activating factor.
Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator.
Inhibition of Plasminogen Activator Inhibitor-1 Activation Suppresses High Fat Diet-Induced Weight Gain via Alleviation of Hypothalamic Leptin Resistance.
Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis.
Initial clinical experience with tissue plasminogen activator (tPA) assisted removal of submacular haemorrhage.
Insertion of fibrin peptides into urokinase enhances fibrin affinity.
Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system.
Insulin resistance and thrombosis: a cardiologist's view.
Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells.
Interacting hepatic PAI-1/tPA gene regulatory pathways influence impaired fibrinolysis severity in obesity.
Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.
Interleukin 1 alpha administration is neuroprotective and neuro-restorative following experimental ischemic stroke.
Interleukin-4 stimulates human monocytes to produce tissue-type plasminogen activator.
Intermittent regional therapy with rt-PA is not superior to systemic thrombolysis in deep vein thrombosis (DVT)--a German multicenter trial.
Intimatan (dermatan 4,6-O-disulfate) prevents rethrombosis after successful thrombolysis in the canine model of deep vessel wall injury.
Intra-arterial or intravenous thrombolysis for acute ischemic stroke? The SYNTHESIS pilot trial.
Intra-arterial thrombolysis (reteplase) and ReoPro for subacute thrombosis of the distal aorta accomplished by radial arterial access: the radial-kissing-thrombolytic technique.
Intra-arterial thrombolysis using recombinant tissue plasminogen activator (r-TPA): the optimal agent, at the optimal dose?
Intra-arterial Thrombolytic Therapy for Acute Vertebrobasilar Artery Occlusion.
Intra-arterial tissue plasminogen activator for thrombosis complicating cerebral angiography in a 17-year-old girl.
Intra-arterial tPA treatment for basilar artery thrombosis in the combat zone: an example of modern nontrauma medical care in war.
Intra-atrial tissue plasminogen activator infusion for prosthetic valve thrombosis.
Intra-coronary alteplase for extensive coronary artery thrombus.
Intraarterial recombinant tissue plasminogen activator for ischemic stroke: an accelerating dosing regimen.
Intracameral tissue plasminogen activator for blood clot obstructing trabeculectomy ostium.
Intracameral tissue plasminogen activator use in a large series of eyes with valved glaucoma drainage implants.
Intracameral urokinase for dissolution of fibrin or blood clots after glaucoma surgery.
Intracardiac thrombus formation with rapidly progressive heart failure in the neonate: treatment with tissue type plasminogen activator.
Intracardiac thrombus--a rare complication of the steroid resistant nephrotic syndrome.
Intracellular signal transduction modulating expression of plasminogen activator inhibitor-1 in adipocytes.
Intracochlear tPA infusion may reduce fibrosis caused by cochlear implantation surgery.
Intracoronary recombinant tissue plasminogen activator in an infant with hypoplastic left heart syndrome and complete left main coronary artery thrombosis.
Intracoronary recombinant tissue-type plasminogen activator (rt-PA).
Intraluminal thrombus enhances proteolysis in abdominal aortic aneurysms.
Intraoperative lytic therapy: agents and methods of administration.
Intraoperative thrombolytic treatment of microarterial occlusion by selective rt-PA infusion.
Intrauterine Upper Extremity Thrombosis Successfully Treated with Recombinant Tissue Plasminogen Activator, Enoxaparin and Collagenase.
Intravenous abciximab as a rescue therapy for immediate reocclusion after successful mechanical thrombectomy in acute ischemic stroke patients.
Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation.
Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator (rt-PA) in Acute Lower Limb Ischaemia.
Intravenous thrombolytic treatment of mechanical prosthetic valve thrombosis: a study using serial transesophageal echocardiography.
Intravenous tissue plasminogen activator and flow improvement in acute ischemic stroke patients with internal carotid artery occlusion.
Invasive amebiasis: a microcirculatory disorder?
Involvement of Platelets in Cancers.
Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats?
Is it an expected practice for critical care nurses to irrigate an external ventriculostomy drainage (EVD) system with tissue plasminogen activator (tPA) to break up blood clots in the tubing to facilitate drainage, thereby preventing increased intracranial pressure?
Ixonnexin from Tick Saliva Promotes Fibrinolysis by Interacting with Plasminogen and Tissue-Type Plasminogen Activator, and Prevents Arterial Thrombosis.
K1K2Pu, a recombinant t-PA/u-PA chimera with increased thrombolytic potency, consisting of amino acids 1 to 3 and 87 to 274 of human tissue-type plasminogen activator (t-PA) and amino acids 138 to 411 of human single chain urokinase-type plasminogen activator (scu-PA). Purification in centigram quantities and conditioning for use in man.
Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction.
Lack of plasminogen activator inhibitor-1 enhances the preventive effect of DX-9065a, a selective factor Xa inhibitor, on venous thrombus and acute pulmonary embolism in mice.
Latex D-dimer signal in in situ femoral vein thrombus in swine and effect of minidose exogenous tissue plasminogen activator bolus.
Leaf-Inspired Authentically Complex Microvascular Networks for Deciphering Biological Transport Process.
Left atrial thrombus in a 10-month-old boy--successful thrombolysis with recombinant tissue-type plasminogen activator after open-heart surgery: review of the literature.
Left atrium thrombus in an extremely low-birthweight infant with late-onset circulatory dysfunction.
Left ventricular apical thrombus after systemic thrombolysis with recombinant tissue plasminogen activator in a patient with acute ischemic stroke.
Left ventricular thrombus in a 2-year-old boy with cardiomyopathy: lysis with recombinant tissue-type plasminogen activator.
Lesion-directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty.
Leukocyte elastase inhibition and t-PA-induced coronary artery thrombolysis in dogs: beneficial effects on myocardial histology.
Life threatening cavopulmonary thrombus: resolution within 24 h with tissue plasminogen activator.
Life-threatening pulmonary embolism with right-sided heart thrombus. Rapid recovery with recombinant tissue plasminogen activator.
Lipopolysaccharide attenuates thrombolysis in batroxobin-induced lung vasculature fibrin deposition but not in ferrous chloride-induced carotid artery thrombus in rats: role of endogenous PAI-1.
Local in situ fibrinolysis for recanalization of an occluded extracranial-intracranial bypass: Technical note.
Local injection of tissue-plasminogen activator using a pulse spray catheter as a treatment option for proximal deep vein thrombosis: A case report.
Local plasminogen activator inhibitor type 1 overexpression in rat carotid artery enhances thrombosis and endothelial regeneration while inhibiting intimal thickening.
Local Production of Soluble Urokinase Plasminogen Activator Receptor and Plasminogen Activator Inhibitor-1 in the Coronary Circulation Is Associated With Coronary Endothelial Dysfunction in Humans.
Local recombinant tissue plasminogen activator to clear cerebral artery thrombosis developing soon after surgery.
Local Thrombolysis in Acute and Extended Portal Vein and TIPS Thrombosis in a Patient with Decompensated Cirrhosis and Protein S Deficiency.
Localization and identification of thrombin and plasminogen activator activities in model human thrombi by in situ zymography.
Localized left atrial administration of tPA for the treatment of mechanical mitral valve thrombosis.
Locally applied recombinant plasmin results in effective thrombolysis in a porcine model of arteriovenous graft thrombosis.
Locally Deliver the Tissue-Type Plasminogen Activator (tPA) Plasmid for Preventing Thrombosis.
Locoregional fibrinolysis using tissue plasminogen activator in 2 cases of acute thrombosis of the renal artery.
Longitudinal Association Between Endothelial Dysfunction, Inflammation, and Clotting Biomarkers With Subclinical Atherosclerosis in Type 1 Diabetes: An Evaluation of the DCCT/EDIC Cohort.
Low dose tissue plasminogen activator treatment for vascular thrombosis following cardiac catheterization in children - a single center experience.
Low-Dose Alteplase Infusion for the Treatment of Mechanical Aortic Valve Thrombosis: A Spotlight on the Importance of Medication Adherence.
Low-dose intravenous tissue-type plasminogen activator for prosthetic valve thrombosis is better than standard dose streptokinase.
Low-dose tissue plasminogen activator thrombolysis in children.
Lysis of a left ventricular thrombus with recombinant tissue plasminogen activator.
Lysis of intracerebral hematoma with stereotactically implanted tissue plasminogen activator polymers in a rabbit model.
Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody.
Lysis-Assisted Balloon (LAB) Thrombectomy. A Declotting Technique for the Treatment of Thrombosed Arteriovenous Dialysis Grafts. 5-Year Experience of 241 Endovascular Procedures.
Lysophosphatidic acid promotes thrombus stability by inducing rapid formation of neutrophil extracellular traps: A new mechanism of thrombosis.
Maintaining long-term vessel patency in microvascular surgery using tissue-type plasminogen activator.
Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
Male-female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population.
Management of a large organized intraatrial catheter-tip thrombus in a child with acquired immunodeficiency syndrome using escalating tissue plasminogen activator infusions.
Management of Acute Portal Vein Thrombosis With Serial Mechanical Thrombectomy and tPA in a Pediatric Liver Transplant Recipient: A Case Report.
Manual ELISA assays on tPA and PAI-1 automated on Novapath I.S. preliminary report.
Massive pulmonary embolism in pregnancy treated with catheter fragmentation and local thrombolysis.
Massive pulmonary embolism with cardiac arrest in pregnancy: A case report.
Massive pulmonary embolism: treatment with thrombus fragmentation and local fibrinolysis with recombinant human-tissue plasminogen activator.
Mathematical Modelling of Intravenous Thrombolysis in Acute Ischaemic stroke: Effects of Dose Regimens on Levels of Fibrinolytic Proteins and Clot Lysis Time.
Measuring fibrinolysis: from research to routine diagnostic assays.
Mechanical circulatory device thrombosis: a new paradigm linking hypercoagulation and hypofibrinolysis.
Mechanical disruption of thrombus following intravenous tissue plasminogen activator for ischemic stroke.
Mechanical Prosthetic Aortic Valve Thrombosis Treated with Low-dose Ultra Slow Infusion of Tissue-type Plasminogen Activator during Pregnancy.
Mechanical Thrombectomy of Acutely Occluded Flow-Diverters - Neuroendovascular Surgical Technique Demonstration: 2-Dimensional Operative Video.
Mechanical thrombolysis in ischemic stroke attributable to basilar artery occlusion as first-line treatment.
Mechanism of ligustrazini against thrombosis.
Mechanisms linking angiotensin II and atherogenesis.
Mesangial matrix modulation and glomerulosclerosis.
Mesenteric vein thrombosis and vascular plasminogen activator.
Metabolic syndrome and endothelial fibrinolytic capacity in obese adults.
Methodology of the Interventional Management of Stroke III Trial.
Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy.
Microbubble-mediated sonothrombolysis with BR38 of a venous full blood thrombus in a rat embolic stroke model.
Microfluidic Modeling of Thrombolysis.
Microscopic clot fragment evidence of biochemo-mechanical degradation effects in thrombolysis.
Microsurgical repair after crush-avulsion injury of the femoral vein in rats: prevention of microvascular thrombosis with recombinant human tissue-type plasminogen activator (rt-PA).
Microvascular and thrombolytic revascularization of an arm in a 32-week-gestation neonate: case report and review of the literature.
Microvascular thrombolysis to salvage a free flap using human recombinant tissue plasminogen activator.
Microvascular thrombosis, fibrinolysis, ischemic injury, and death after cerebral thromboembolism are affected by levels of circulating ?2-antiplasmin.
Mobile reactive centre of serpins and the control of thrombosis.
Modelling fibrinolysis: a 3D stochastic multiscale model.
Modelling the effect of laminar axially directed blood flow on the dissolution of non-occlusive blood clots.
Moderate Intensity Static Magnetic Fields Prevent Thrombus Formation in Rats and Mice.
Molecular and Physical Mechanisms of Fibrinolysis and Thrombolysis from Mathematical Modeling and Experiments.
Molecular mechanism of action of newer thrombolytic agents.
Monoclonal antibody against tissue factor shortens tissue plasminogen activator lysis time and prevents reocclusion in a rabbit model of carotid artery thrombosis.
Morphological changes following experimental intraventricular haemorrhage and intraventricular fibrinolytic treatment with recombinant tissue plasminogen activator.
Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.
Mouse model of microembolic stroke and reperfusion.
Moyamoya disease and sagittal sinus thrombosis in a child with Down's syndrome.
Multicenter pilot study of the efficacy and safety of systemic rt-PA administration in the treatment of deep vein thrombosis of the lower extremities and/or pelvis.
Multiple treatment algorithms for successful outcomes in venous thoracic outlet syndrome.
Mural thrombus of the aorta in association with homozygous plasminogen activator inhibitor type 1 (PAI-1)-675(4G) and heterozygous GP Ia 807C/T genotypes.
Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor.
Mutant Prourokinase with Adjunctive C1-Inhibitor Is an Effective and Safer Alternative to tPA in Rat Stroke.
Myocardial neutrophil infiltration, lipid peroxidation, and antioxidant activity after coronary artery thrombosis and thrombolysis.
N-methylnicotinamide inhibits arterial thrombosis in hypertensive rats.
Nanodroplet-mediated catheter-directed sonothrombolysis of retracted blood clots.
Nanoscaled ultrasound contrast agents for enhanced sonothrombolysis.
Need for tissue plasminogen activator for central venous catheter dysfunction is significantly associated with thrombosis in pediatric cancer patients.
Neisseria meningitidis lipopolysaccharides in human pathology.
Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1).
Neointimal hyperplasia on a cell-seeded polytetrafluoroethylene graft is promoted by transfer of tissue plasminogen activator gene and inhibited by transfer of nitric oxide synthase gene.
New developments in thrombolytic therapy.
New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody.
New insights into the renin-angiotensin system and hypertensive renal disease.
New insights into the size and stoichiometry of the plasminogen activator inhibitor type-1.vitronectin complex.
Newer insights on the mechanism of heparin-induced thrombocytopenia.
Niacin affects cell adhesion molecules and plasminogen activator inhibitor-1 in HepG2 cells.
Nicotine increases plasminogen activator inhibitor-1 production by human brain endothelial cells via protein kinase C-associated pathway.
No Exacerbation of Perihematomal Edema with Intraventricular Tissue Plasminogen Activator in Patients with Spontaneous Intraventricular Hemorrhage.
Non-invasive imaging techniques for the differentiation of acute and chronic thrombosis.
Noninvasive detection and localization of vulnerable plaque and arterial thrombosis with computed tomography angiography/positron emission tomography.
Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics.
Nonpeptide glycoprotein IIb/IIIa inhibitors. 5. Antithrombotic effects of MK-0383.
Novel and emerging therapies: thrombus-targeted fibrinolysis.
Novel Treatment for Hemorrhagic Descemet Detachment After Canaloplasty.
Nuclear magnetic resonance solution structure of the plasminogen-activator protein staphylokinase.
Obesity enhances the induction of plasminogen activator inhibitor-1 by restraint stress: a possible mechanism of stress-induced renal fibrin deposition in obese mice.
Observations on optimal conditions for lysis of whole blood clots and use of this assay as a screening assay in clinical investigation.
Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans.
Open-angle glaucoma secondary to blood clot in the Schlemm's canal following scleral buckle surgery and its treatment with tPA.
Optimal treatment modality for coexisting acute myocardial infarction and ischemic stroke.
Outcomes of rheolytic thrombectomy in phlegmasia cerulea dolens.
Outcomes of systemic anticoagulation with bivalirudin for Impella 5.0.
Outcomes of Thrombolytic Therapy of Tunnelled Hemodialysis Catheter Dysfunction.
P-selectin inhibition enhances thrombus resolution and decreases vein wall fibrosis in a rat model.
Paediatric acute basilar thrombosis successfully treated with intravenous alteplase.
PAI-1 antagonists: the promise and the peril.
PAI-1 inhibition enhances the lysis of the platelet-rich part of arterial-like thrombi formed in vitro. A comparative study using thrombi prepared from rat and human blood.
PAI-1 Leads to G1-Phase Cell-Cycle Progression through Cyclin D3/cdk4/6 Upregulation.
PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population.
PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects.
Parallel analysis of tissue-type plasminogen activator and type 1 plasminogen activator inhibitor in plasma and endothelial cells derived from patients with chronic pulmonary thromboemboli.
Partial Thrombus Resolution With Trofiban in a Pregnant Woman With Mechanical Prosthetic Mitral Valve Thrombosis.
Patent foramen ovale as lifesaving purging valve.
Pathogenesis of acute myocardial infarction. Novel regulatory systems of bioactive substances in the vessel wall.
Pathophysiology and mechanisms of acute ischemic stroke. The NINDS rt-PA Stroke Study Group.
Pathophysiology of thrombophilic states.
PEGylation of Lumbrokinase improves pharmacokinetic profile and enhances anti?thrombotic effect in a rat carotid artery thrombosis model.
Percutaneous catheter and guidewire fragmentation with local administration of recombinant tissue plasminogen activator as a treatment for massive pulmonary embolism.
Percutaneous portal vein thrombolysis and endovascular stent for management of posttransplant portal venous conduit thrombosis.
Percutaneous Thrombectomy with the JETi8 Peripheral Thrombectomy System for the Treatment of Deep Vein Thrombosis.
Peripheral Nerve Blockade and Neonatal Limb Ischemia: Our Experience and Literature Review.
Perivascular Hyaluronidase With Alteplase as Treatment for Hyaluronic Acid Thrombosis.
Permeable Thrombi Are Associated With Higher Intravenous Recombinant Tissue-Type Plasminogen Activator Treatment Success in Patients With Acute Ischemic Stroke.
Peroxisome proliferator-activated receptor gamma agonists inhibit adipocyte expression of alpha1-acid glycoprotein.
Peroxynitrite inactivates tissue plasminogen activator.
PGE1 accelerates thrombolysis by tissue plasminogen activator.
Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.
Pharmacokinetic properties of a novel tissue-type plasminogen activator pamiteplase after single intravenous administration to rats, dogs, and monkeys.
Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like, and first kringle domains (amino acids 6-173) in a canine model.
Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction.
Pharmacokinetics and thrombolytic properties of a nonglycosylated mutant of human tissue-type plasminogen activator, lacking the finger and growth factor domains, in dogs with copper coil-induced coronary artery thrombosis.
Pharmacological Modulation of Neutrophil Extracellular Traps Reverses Thrombotic Stroke tPA (Tissue-Type Plasminogen Activator) Resistance.
Pharmacology and clinical trial results of lanoteplase in acute myocardial infarction.
Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis.
Pharmacomechanical thrombectomy of acute deep vein thrombosis with the Trellis-8 isolated thrombolysis catheter.
Pharmacomechanical thrombolysis and early stent placement for iliofemoral deep vein thrombosis.
Phospholipase D1 is specifically required for regulated secretion of von Willebrand factor from endothelial cells.
Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model.
Physiological consequences of over- or under-expression of fibrinolytic system components in transgenic mice.
Plasma carboxypeptidases as regulators of the plasminogen system.
Plasma Concentration of Endogenous Tissue Plasminogen Activator and the Occurrence of Future Cardiovascular Events.
Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.
Plasma levels of plasminogen activator inhibitor type 1, factor VIII, prothrombin activation fragment 1+2, anticardiolipin, and antiprothrombin antibodies are risk factors for thrombosis in hemodialysis patients.
Plasmin inhibition increases MMP-9 activity and decreases vein wall stiffness during venous thrombosis resolution.
Plasminogen activation in vivo upon intravenous infusion of DDAVP. Quantitative assessment of plasmin-alpha 2-antiplasmin complex with a novel monoclonal antibody based radioimmunoassay.
Plasminogen activator inhibitor (PA-inhibitor) activity in the blood of patients with deep vein thrombosis.
Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis.
Plasminogen activator inhibitor 1 activity and lipoprotein(a) in nephropathic patients with non-insulin-dependent diabetes mellitus versus patients with nondiabetic nephropathy.
Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer.
Plasminogen activator inhibitor 1 in central serous chorioretinopathy.
Plasminogen Activator Inhibitor 1 Promotes Immunosuppression in Human Non-Small Cell Lung Cancers by Enhancing TGF-?1 Expression in Macrophage.
Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.
Plasminogen activator inhibitor type 1 promotes the self-association of vitronectin into complexes exhibiting altered incorporation into the extracellular matrix.
Plasminogen activator inhibitor type-1 in cardiovascular disease. Status report 2001.
Plasminogen Activator Inhibitor-1 (PAI-1) Gene 4G/5G Promoter Polymorphism is Seen in Higher Frequency in the Indian Patients With Deep Vein Thrombosis.
Plasminogen activator inhibitor-1 (PAI-1) in children and adolescents With Type 1 Diabetes Mellitus: relation to diabetic micro-vascular complications and carotid intima media thickness.
Plasminogen activator inhibitor-1 4G/5G genotype and residual venous occlusion following acute unprovoked deep vein thrombosis of the lower limb: A prospective cohort study.
Plasminogen activator inhibitor-1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction.
Plasminogen activator inhibitor-1 and outcome after femoropopliteal angioplasty: analysis of genotype and plasma levels.
Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice.
Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activator-mediated fibrin dissolution.
Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery.
Plasminogen activator inhibitor-1 gene 4G/5G polymorphism in cancer patients with and without thrombosis.
Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis.
Plasminogen activator inhibitor-1 in vascular thrombosis.
Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals.
Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function.
Plasminogen activator inhibitor-1 levels and polymorphisms.
Plasminogen activator inhibitor-1 removal using dextran sulphate columns. Evidence of PAI-1 homeostasis.
Plasminogen activator inhibitor-1, which is released from blood product transfusions, might be associated with (sub)acute thrombosis after coronary dilatation and stenting: a case report.
Plasminogen activator inhibitor-1: a risk factor for deep vein thrombosis after total hip arthroplasty.
Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents.
Plasminogen activator system in human coronary atherosclerosis.
Plasminogen and tissue-type plasminogen activator deficiency as risk factors for thromboembolic disease.
Plasminogen-activator of the arterial wall in occluded arteries.
Platelet dysfunction in type 2 diabetes.
Platelet inhibition limits TGF-beta overexpression and matrix expansion after induction of anti-thy1 glomerulonephritis.
Platelets and endothelial cells act in concert to delay thrombolysis--evidence from an in vitro model of the human occlusive thrombus.
Platelets synthesize large amounts of active plasminogen activator inhibitor 1.
Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Pneumococcal phosphoglycerate kinase interacts with plasminogen and its tissue activator.
Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis.
Portal vein thrombosis repermeabilization with rt-PA.
Possible role of vascular intima for generation of coagulant activity in patients undergoing coronary thrombolysis with recombinant tissue-type plasminogen activator. A randomized, placebo-controlled study.
Post-transplant IVC occlusion and thrombosis treated with tPA, heparin, and sharp recanalization.
Postinfectious purpura fulminans caused by an autoantibody directed against protein S.
Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor--relationship to deep vein thrombosis and influence of prophylaxis.
Postoperative deep vein thrombosis and plasma levels of tissue plasminogen activator inhibitor.
Postoperative Stroke Following Administration of Intraoperative Recombinant Tissue Plasminogen Activator for the Treatment of Intracardiac Thrombus During Liver Transplantation: A Report of Two Cases.
Postthrombotic syndrome: a 2014 update.
Potential inherited causes of recurrent prosthetic mitral valve thrombosis in a pregnant patient suffering from recurrent miscarriage.
Pravastatin: an antithrombotic effect independent of the cholesterol-lowering effect.
Predicting pharmacodynamic response to tissue plasminogen activator: a preliminary report.
Prediction of the three-dimensional structure of the enzymatic domain of t-PA.
Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores.
Prediction of thrombus resolution after intravenous thrombolysis assessed by CT-based thrombus imaging.
Preparation and characterization of anionic oligopeptide-modified tissue plasminogen activator for triggered delivery: An approach for localized thrombolysis.
Prevalence and Outcomes of Medium Vessel Occlusions With Discrepant Infarct Patterns.
Prevalence of the fibrinogen beta-chain, angiotensin-converting enzyme and plasminogen activator inhibitor-1 polymorphisms in Costa Rican young adults with thrombotic disease.
Prevention and treatment of the post-thrombotic syndrome and of the chronic thromboembolic pulmonary hypertension.
Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis.
Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator.
Prevention of microvascular thrombosis with low-dose tissue plasminogen activator.
Prevention of microvascular thrombosis with short-term infusion of human tissue-type plasminogen activator.
Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.
Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. I. Adjunctive therapy with monoclonal antibody 7E3 F(ab')2 fragment.
Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin.
Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonist.
Prevention, assessment, and treatment of central venous catheter occlusions in neonatal and young pediatric patients.
Primary percutaneous coronary intervention of an unprotected left main using mini-crush drug-eluting stents facilitated by intracoronary reteplase.
Production and characterization of a monoclonal antibody reactive with a specific neoantigenic determinant (comprising B beta 54-118) in degradation products of fibrin and of fibrinogen.
Production of human tissue-type plasminogen activator (htPA) using in vitro cultured transgenic pig mammary gland cells.
Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects.
Properties of a novel plasminogen activator (BM 06.022) produced in Escherichia coli.
Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes.
Prophylactic thrombosis to prevent new bleeding and to delay aneurysm surgery.
Prospective study on the prevention of cerebral vasospasm by intrathecal fibrinolytic therapy with tissue-type plasminogen activator.
Prospects of Therapeutic Target and Directions for Ischemic Stroke.
Prostacyclin analogue, beraprost, sustains recanalization duration after thrombolytic therapy in acute myocardial infarction model.
Prosthetic valve obstruction: thrombolysis versus operation.
Prosthetic valve thrombosis: a regimen of treatment with low-dose and longer-course using recombinant tissue-type plasminogen activator is a promising protocol.
Protein C deficiency and portal thrombosis in liver transplantation in children.
Protein kinase C-beta mediates lipoprotein-induced generation of PAI-1 from vascular endothelial cells.
Protein S deficiency manifesting as spontaneous aortic thrombosis in a neonate.
Protein Z (PZ) and plasminogen activator inhibitor-1 (PAI-1) plasma levels in patients with previously untreated Hodgkin lymphoma (HL).
Prothrombinex-induced thrombosis and its management with regional plasminogen activator in hepatic failure.
Prothrombotic activation of pulmonary arterial endothelial cells in a patient with tuberculosis.
Prothrombotic effects of thrombolytic therapy in a rat (Rattus norvegicus) model of venous thrombolysis.
Prothrombotic State in Patients With a Left Atrial Appendage Thrombus of Unknown Origin and Cerebrovascular Events.
Pulmonary artery thrombus in a premature neonate treated with recombinant tissue plasminogen activator.
Pulmonary microthrombi during left ventricular assist device implantation.
Pulse pressure variability is associated with unfavorable outcomes in acute ischaemic stroke patients treated with intravenous thrombolysis.
Pulse-spray thrombolysis with reteplase: optimization and comparison with tPA in a rabbit model.
Purification of recombinant tissue plasminogen activator (rtPA) protein from transplastomic tobacco plants.
Quality Improvement Initiative Reduces the Occurrence of Complications in Peripherally Inserted Central Catheters.
Quantification of microbubble-induced sonothrombolysis in an ex vivo non-human primate model.
Quantification of thrombus hounsfield units on noncontrast CT predicts stroke subtype and early recanalization after intravenous recombinant tissue plasminogen activator.
Quantifying the effect of locally delivered anticoagulant drugs: modification of an in vivo model of venous thrombosis.
Quantitative effect of intravitreally injected tissue plasminogen activator and gas on subretinal hemorrhage.
Quantitative Imaging of Cerebral Thromboemboli In Vivo: The Effects of Tissue-Type Plasminogen Activator.
Racial-Ethnic Disparities in Acute Stroke Care in the Florida-Puerto Rico Collaboration to Reduce Stroke Disparities Study.
Radiological stenting provides effective palliation in malignant central venous obstruction.
Radiomics-Based Intracranial Thrombus Features on CT and CTA Predict Recanalization with Intravenous Alteplase in Patients with Acute Ischemic Stroke.
Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS).
Randomized comparison of intra-arterial and intravenous thrombolysis in a canine model of acute basilar artery thrombosis.
Randomized, double-blind, placebo-controlled trial of tissue plasminogen activator in unstable angina.
Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation.
Rapid localization of indium-111-labeled inhibited recombinant tissue plasminogen activator in a rabbit thrombosis model.
Rapid resolution of subclavian vein thrombosis by tissue plasminogen activator.
Rates and Quality of Preinterventional Reperfusion in Patients With Direct Access to Endovascular Treatment.
Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo.
Recanalization of an acute middle cerebral artery occlusion using a self-expanding, reconstrainable, intracranial microstent as a temporary endovascular bypass.
Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
Recombinant human tissue-type plasminogen activator is an effective agent for thrombolysis of peripheral arteries and bypass grafts: preliminary report.
Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
Recombinant lys-plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs.
Recombinant plasminogen activator therapy for cerebral vein thrombosis in a child carrier of prothrombin gene mutation.
Recombinant t-PA and platelet activity.
Recombinant tissue plasminogen activator (alteplase) for restoration of flow in occluded central venous access devices: a double-blind placebo-controlled trial--the Cardiovascular Thrombolytic to Open Occluded Lines (COOL) efficacy trial.
Recombinant tissue plasminogen activator (rt-PA) as first-line therapy for declotting of haemodialysis access.
Recombinant tissue plasminogen activator for prosthetic mitral-valve thrombosis.
Recombinant tissue plasminogen activator in patients with pulmonary embolism: correlation of fibrinolytic specificity and efficacy.
Recombinant Tissue Plasminogen Activator in the Treatment of Neonates with Intracardiac and Great Vessels Thrombosis.
Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans.
Recombinant tissue-type plasminogen activator in canine embolic pulmonary hypertension. Effects of bolus versus short-term administration on dynamics of thrombolysis and on pulmonary vascular pressure-flow characteristics.
Recombinant tissue-type plasminogen activator in the treatment of acute renal artery thrombosis after kidney transplantation.
Recombinant tissue-type plasminogen activator therapy in prosthetic mitral valve thrombosis: assessment by transthoracic and transesophageal echocardiography.
Recombinant tissue-type plasminogen activator therapy of thrombosis in 16 neonates.
Recombinant tissue-type plasminogen activator treatment in an extremely low birth weight infant.
Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial.
Recommendations for tPA thrombolysis in children. On behalf of the Scientific Subcommittee on Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.
Recurrent embolization during intravenous administration of tissue plasminogen activator in acute cardioembolic stroke. A case report.
Red blood cells modulate structure and dynamics of venous clot formation in sickle cell disease.
Redistribution of TPA Fluxes in the Presence of PAI-1 Regulates Spatial Thrombolysis.
Redox-Induced Src Kinase and Caveolin-1 Signaling in TGF-?1-Initiated SMAD2/3 Activation and PAI-1 Expression.
Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents.
Reduction in stent and vascular graft thrombosis and enhancement of thrombolysis by recombinant Lys-plasminogen in nonhuman primates.
Reduction of early vein graft thrombosis by tissue plasminogen activator gene transfer.
Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping after embolic focal cerebral ischemia in rats.
Regression of proximal deep venous thrombosis is associated with fibrinolytic enhancement.
Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus.
Regulation of fibrinolysis in aortic surgery.
Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community.
Relationships between tissue plasminogen activator, steroid hormones and deep vein thrombosis.
Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and ?2-Antiplasmin Inactivation.
Repeat reteplase therapy in a patient with recurrent prosthetic tricuspid valve thrombosis after trido multiple valve replacement.
Repeated successful thrombolysis of an acute peripheral arterial thrombosis with tissue plasminogen activator.
Reperfusion and outcomes in Penumbra vs. systemic tissue plasminogen activator clinical trials.
Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs.
Reperfusion Rates Following Intra-Arterial Thrombolysis for Acute Ischemic Stroke: The Influence of the Method for Alteplase Delivery.
Repetitive progressive thermal preconditioning hinders thrombosis by reinforcing phosphatidylinositol 3-kinase/Akt-dependent heat-shock protein/endothelial nitric oxide synthase signaling.
Reply to the Letter to the Editor entitled "Low-dose intravenous tissue-type plasminogen activator for prosthetic valve thrombosis is better than standard dose streptokinase".
Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator.
Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis.
Residual vein thrombosis and onset of post-thrombotic syndrome: influence of the 4G/5G polymorphism of plasminogen activator inhibitor-1 gene.
Resistance of porcine blood clots to lysis relates to poor activation of porcine plasminogen by tissue plasminogen activator.
Resolution of a Mobile Right Atrial Thrombus Complicating Acute Pulmonary Embolism With Low-Dose Tissue Plasminogen Activator in a Patient With Recent Craniotomy.
Resolution of renal artery thrombus with direct administration of tissue plasminogen activator.
Restoration of flow following haemodialysis catheter thrombus. Analysis of rt-PA infusion in tunnelled dialysis catheters.
Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial.
Reteplase thrombolysis for treatment of mechanical valve thrombosis.
Reteplase: a new thrombolytic for the treatment of acute myocardial infarction.
Reteplase: nursing implications for catheter-directed thrombolytic therapy for peripheral vascular occlusions.
Reteplase: Structure, Function, and Production.
Retrograde coronary venous administration of recombinant tissue-type plasminogen activator: a unique and effective approach to coronary artery thrombolysis.
Retroviral gene transfer of tissue-type plasminogen activator targets thrombolysis in vitro and in vivo.
Retrovirus-Mediated Transfection of the Tissue-type Plasminogen Activator Gene Results in Increased Thrombolysis of Blood Clots.
Reversing the deleterious effects of ?2-antiplasmin on tissue plasminogen activator therapy improves outcomes in experimental ischemic stroke.
Right Pulmonary Artery Thrombosis After Hybrid Stage 1 Palliation: Resolution After Direct Tissue Plasminogen Activator Infusion.
Right ventricular pacing wire thrombus presenting as pyrexia of unknown origin.
Right ventricular thrombus in a case of neonatal lupus: case report.
Risk factors for thromboembolic events in renal failure.
Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients.
Rodent-specific hypoxia response elements enhance PAI-1 expression through HIF-1 or HIF-2 in mouse hepatoma cells.
Role of angiotensin II in glomerular injury.
Role of histone acetylation in the stimulatory effect of valproic Acid on vascular endothelial tissue-type plasminogen activator expression.
Role of neutrophil membrane proteases in fibrin degradation.
Role of paf-acether in the mediation of pathophysiological responses to aggregated immunoglobulins. Studies with the platelet-activating factor receptor antagonist BN 52021.
Role of plasminogen activator inhibitor-1 in coronary pathophysiology.
Role of Polymorphisms in Factor V (FV Leiden), Prothrombin, Plasminogen Activator Inhibitor Type-1 (PAI-1), Methylenetetrahydrofolate Reductase (MTHFR) and Cystathionine ?-Synthase (CBS) Genes as Risk Factors for Thrombophilias.
Role of pulsatile perfusion with tissue plasminogen activator in deceased donor kidneys with extensive glomerular thrombosis.
Role of Shear Stress and tPA Concentration in the Fibrinolytic Potential of Thrombi.
Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis evaluation in transgenic animals.
Role of Tissue Plasminogen Activator for Diffuse Pulmonary Microemboli in Coronavirus Disease 2019 Patient.
Roles of blood-brain barrier integrins and extracellular matrix in stroke.
Safe Readministration of Intravenous Thrombolysis in Recurrent Basilar Thrombosis.
Safety and efficacy of reteplase for the treatment of acute arterial occlusion: complexity of underlying lesion predicts outcome.
Safety and efficacy of taurolidine/urokinase versus taurolidine/heparin as a tunneled catheter lock solution in hemodialysis patients: a prospective, randomized, controlled study.
Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children.
Safety Evaluation of a Forward-Viewing Intravascular Transducer for Sonothrombolysis: An in Vitro and ex Vivo Study.
Saving the zone of stasis in burns with recombinant tissue-type plasminogen activator (r-tPA): an experimental study in rats.
Selective embolization and clot dissolution with tPA in the internal carotid artery circulation of the rabbit.
Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis.
Self-reported habitual short sleep duration is associated with endothelial fibrinolytic dysfunction in men: a preliminary report.
Seminars in thrombosis, thrombolysis and vascular biology. 1. The vascular endothelium.
Sequentially Site-Specific Delivery of Thrombolytics and Neuroprotectant for Enhanced Treatment of Ischemic Stroke.
Severe Cerebral Small Vessel Disease Burden Is Associated With Poor Outcomes After Endovascular Thrombectomy in Acute Ischemic Stroke With Large Vessel Occlusion.
Shaken and stirred: mechanisms of ultrasound-enhanced thrombolysis.
Short and long alteplase dwells in dysfunctional hemodialysis catheters.
Short-term High-Dose Effect of Lovastatin on Thrombolysis by rt-PA in a Human Whole-Blood in vitro Clot Model.
Short-term intravenous eptifibatide infusion combined with reduced dose recombinant tissue plasminogen activator inhibits platelet recruitment at sites of coronary artery injury.
Sickle Mice Are Sensitive to Hypoxia/Ischemia-Induced Stroke but Respond to Tissue-Type Plasminogen Activator Treatment.
Significance of microvascular thrombosis in renal allografts: role of ex vivo thrombolytic therapy.
Sildenafil improves coronary artery patency in a canine model of platelet-mediated cyclic coronary occlusion after thrombolysis.
Simulation of Intracranial Acoustic Fields in Clinical Trials of Sonothrombolysis.
Sirtuin 5 promotes arterial thrombosis by blunting the fibrinolytic system.
Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial.
Site-Specific Thiol-mediated PEGylation of Streptokinase Leads to Improved Properties with Clinical Potential.
Sleep and stroke.
Smad6s regulates plasminogen activator inhibitor-1 through a protein kinase C-beta-dependent up-regulation of transforming growth factor-beta.
Small animal thrombosis models for the evaluation of thrombolytic agents.
Snake-like thrombus in the right atrium causing pulmonary embolism.
Sonothrombolysis in ischemic stroke.
Sonothrombolysis is effective with recombinant tissue-type plasminogen activator, but not with Abciximab. Results from an in vitro study with whole blood clots and platelet-rich clots.
Sonothrombolysis: The Contribution of Stable and Inertial Cavitation to Clot Lysis.
Species specificity of the fibrinolytic effects of activated protein C.
Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator.
Spectrophotometric analysis of thrombolytic activity: SATA assay.
Splenectomy for massive splenic infarction unmasks paroxysmal nocturnal hemoglobinuria.
Sputum Plasminogen Activator Inhibitor-1 Elevation by Oxidative Stress-Dependent Nuclear Factor-?B Activation in COPD.
SSR182289A enhances thrombolysis induced by fibrinolytic agents in rabbit models of venous and arterial thrombosis.
Staged interventional management of a massive thrombus related to coronary artery ectasia in acute coronary syndrome.
Statin drugs and dietary isoprenoids as antithrombotic agents.
Statins improve the resolution of established murine venous thrombosis: reductions in thrombus burden and vein wall scarring.
Stent Retriever-Assisted Mechanical Thrombectomy for Acute Basilar Artery Occlusion: Single US Institution Experience.
Stenting for acute cerebral venous sinus thrombosis in the superior sagittal sinus.
Stereotactic treatment of intracerebral hematoma by means of a plasminogen activator: a multicenter randomized controlled trial (SICHPA).
Stimulated tissue plasminogen activator release as a marker of endothelial function in humans.
Streptokinase vs alteplase in massive pulmonary embolism. A randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction.
Streptokinase--a clinically useful thrombolytic agent.
Streptokinase: An Efficient Enzyme in Cardiac Medicine.
Stroke in ovarian hyperstimulation syndrome in early pregnancy treated with intra-arterial rt-PA.
Structure of the complex of the antistasin-type inhibitor bdellastasin with trypsin and modelling of the bdellastasin-microplasmin system.
Study on Construction of nano tPA Plasmid to Prevent Thrombosis After Mechanical Valve Replacement in Dogs.
Subacute stent thrombosis in intracranial stenting.
Subclavian vein thrombosis treated with recombinant tissue plasminogen activator.
Success of delayed thrombolysis for metallic tricuspid valve thrombosis.
Successful delayed thrombolysis with tissue plasminogen activator for recurrent arterial thrombosis secondary to protein S deficiency.
Successful endovascular therapy for acute basilar thrombosis in an adolescent.
Successful fibrinolytic therapy using tissue plasminogen activator in acute renal failure due to acute thrombosis of bilateral renal arteries.
Successful intraoperative use of recombinant tissue plasminogen activator during liver transplantation complicated by massive intracardiac/pulmonary thrombosis.
Successful Low-Dose tPA for Mechanical Mitral Valve Thrombosis in a Patient with Postinfarction Contained Left Ventricular Free Wall Rupture.
Successful lysis of right and left heart thrombus by tissue plasminogen activator.
Successful management of multiple permanent pacemaker complications--infection, 13 year old silent lead perforation and exteriorisation following failed percutaneous extraction, superior vena cava obstruction, tricuspid valve endocarditis, pulmonary embolism and prosthetic tricuspid valve thrombosis.
Successful management of severe chylothorax with argon plasma fulguration and fibrin glue in a premature infant.
Successful recanalization of late portal vein thrombosis after liver transplantation using systemic low-dose recombinant tissue plasminogen activator.
Successful Rescue Utilization of Intraoperative Tissue Plasminogen Activator in the Setting of Massive Thrombosis of Avalon Catheter and Patient in Extremis with Refractory Hypoxemia.
Successful revascularization of coronary artery occluded by massive intracoronary thrombi with alteplase and percutaneous coronary intervention.
Successful salvage of thrombosed arterio-venous fistula with thrombolytic therapy using tissue plasminogen activator.
Successful systemic low-dose lysis of a caval thrombus by rt-PA in a neonate with congenital nephrotic syndrome.
Successful thrombolysis by prolonged low-dose alteplase in catheter-directed infusion.
Successful thrombolysis using recombinant tissue plasminogen activator in cases of severe pulmonary embolism with mobile thrombi in the right atrium.
Successful thrombolytic treatment of a bio-prosthetic mitral valve thrombosis in a pregnant woman.
Successful treatment of a catheter-related right atrial thrombosis with recombinant tissue plasminogen activator and heparin.
Successful treatment of a thrombus in the left aortic coronary sinus in a child with systemic lupus erythematosus.
Successful treatment of acute inferior vena cava and unilateral renal vein thrombosis by local infusion of recombinant tissue plasminogen activator.
Successful treatment of aortic thrombosis after umbilical catheterization with tissue plasminogen activator.
Successful treatment of arterial thrombus in an extremely low-birth-weight preterm neonate.
Successful treatment of basilar artery thrombosis with both heparin and tissue plasminogen activator in the setting of traumatic vertebral artery dissection.
Successful treatment of cerebral emboli with tissue plasminogen activator in a patient with takotsubo cardiomyopathy: A case report.
Successful treatment of massive pulmonary embolism in a pregnant woman, with low-dose, slow infusion of tissue plasminogen activator.
Successful treatment of mobile right atrial thrombus and acute pulmonary embolism with intravenous tissue plasminogen activator.
Successful treatment of neonatal aortic thrombosis with tissue plasminogen activator.
Successful treatment of neonatal arterial thromboses with recombinant tissue plasminogen activator.
Successful treatment of neonatal pulmonary thrombosis in congenital nephrotic syndrome.
Successful treatment of phlegmasia cerulea dolens in a nonagenarian patient with chronic iliac vein occlusion using a Cleaner thrombectomy device.
Successful treatment of prosthetic pulmonary valve thrombosis with reteplase: a case report.
Successful treatment of prosthetic tricuspid valve thrombosis with short-course recombinant tissue-type plasminogen activator.
Successful treatment of renal artery thromboembolism with low-dose prolonged infusion of tissue-typed plasminogen activator in a patient with mitral mechanical heart valve thrombosis under the guidance of multimodality imaging.
Successful Treatment of Severe Mechanical Mitral Valve Thrombosis With Tissue Plasminogen Activator in a 7-Month-Old Infant.
Successful treatment of ventricular assist device associated ventricular thrombus with systemic tenecteplase.
Successful use of recombinant tissue plasminogen activator in the treatment of aortic thrombosis in a premature neonate.
Successful use of tissue plasminogen activator in catheter-related intracardiac thrombus of a premature infant.
Superior mesenteric arterial embolism: treatment by trans-catheter thrombo-aspiration.
Superior vena cava syndrome arising from subclavian vein port catheter implantation and paraneoplastic syndrome.
Superior vena cava thrombus treated with low-dose, peripherally administered recombinant tissue plasminogen activator in a child: case report and review of the literature.
Superoxide dismutase decreases reperfusion arrhythmias and preserves myocardial function during thrombolysis with tissue plasminogen activator.
Suppression of endothelial t-PA expression by prolonged high laminar shear stress.
Suppression of plasminogen activator inhibitor-1 (PAI-1) activity by crocin ameliorates lipopolysaccharide-induced thrombosis in rats.
Suppression of thrombolysis in a canine model of pulmonary embolism.
Surgical treatment versus thrombolysis in acute arterial occlusion: a randomised controlled study.
Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator.
Swim exercise inhibits hemostatic abnormalities in a rat model of obesity and insulin resistance.
Symptomatic Upper-Extremity Deep Venous Thrombosis After Pacemaker Placement in a Pediatric Patient: How to Treat?
Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids.
Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
Synergistic effect of an endothelin type A receptor antagonist, S-0139, with rtPA on the neuroprotection after embolic stroke.
Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke.
Synthetic, organic compound vepoloxamer (P-188) potentiates tissue plasminogen activator.
Systemic and local saphenous vein graft thrombolysis using a tissue plasminogen activator.
Systemic gene therapy for cardiovascular disease.
Systemic or Endoventricular Thrombolysis to Treat HeartWare Left Ventricle Assist Device Thrombosis: A Clinical Dilemma.
Systemic recombinant tissue plasminogen activator lysis for left atrial thrombus formation after single-lung retransplantation.
Systemic thrombolysis of portal vein thrombosis in cirrhotic patients: A pilot study.
Systemic thrombolysis with recombinant tissue plasminogen activator for acute life-threatening Blalock-Taussig shunt obstruction.
T-686, a novel inhibitor of plasminogen activator inhibitor-1, inhibits thrombosis without impairment of hemostasis in rats.
t-PA reduces ischemic impairment of blood-brain barrier by strengthening endothelium junction.
t-plasminogen activator inhibitor-1 polymorphism in idiopathic pulmonary arterial hypertension.
TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots.
Targeted introduction of tissue plasminogen activator (TPA) at the AAVS1 locus in mesenchymal stem cells (MSCs) and its stable and effective expression.
Targeting Thymidine Phosphorylase With Tipiracil Hydrochloride Attenuates Thrombosis Without Increasing Risk of Bleeding in Mice.
Taurine Reduces tPA (Tissue-Type Plasminogen Activator)-Induced Hemorrhage and Microvascular Thrombosis After Embolic Stroke in Rat.
Technetium-99m-labeled recombinant tissue plasminogen activator for the imaging of emboli in vivo.
Technetium-99m-modified recombinant tissue plasminogen activator to detect deep venous thrombosis.
Temperature Affects Thrombolytic Efficacy Using rt-PA and Eptifibatide, an In Vitro Study.
TFC-612, a prostaglandin E1 derivative, enhances fibrinolytic activity in rats.
The 4G/4G polymorphism of the plasminogen activator inhibitor-1 (PAI-1) gene as an independent risk factor for placental insufficiency, which triggers fetal hemodynamic centralization.
The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome.
The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility.
The anti-fibrinolytic SERPIN, plasminogen activator inhibitor 1 (PAI-1), is targeted to and released from catecholamine storage vesicles.
The association between the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor-1 gene and extension of postsurgical calf vein thrombosis.
The cofactor role of protein S in the acceleration of whole blood clot lysis by activated protein C in vitro.
The effect of argatroban on injured endothelial cells by thrombin.
The Effect of Clot Volume and Permeability on Response to Intravenous Tissue Plasminogen Activator in Acute Ischemic Stroke.
The effect of composition, size, and solubility on acute pulmonary injury in rats following exposure to Mexico city ambient particulate matter samples.
The effect of fibrinolytic enzyme FII(a) from Agkistrodon acutus venom on disseminated intravascular coagulation in rabbits.
The effect of red wine on the fibrinolytic system and the cellular activation reactions before and after exercise.
The effects of alcohol on coagulation and fibrinolytic factors: a controlled trial.
The effects of cardiopulmonary bypass on fibrin formation and lysis: is a normal fibrinolytic response essential?
The effects of hydrogen sulfide on platelet-leukocyte aggregation and microvascular thrombolysis.
The effects of pharmacologic plasminogen activator inhibitor-1 inhibition in acute and chronic rejection in murine cardiac allografts.
The effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels are dependent on environmental context.
The evaluation of the role of BMI and insulin resistance on inflammatory markers, PAI-1 levels and arterial stiffness in newly diagnosed type 2 diabetes mellitus patients.
The evolution of the Helsinki frostbite management protocol.
The fast inhibitor of tissue plasminogen activator in plasma during pregnancy.
The fibrinolytic system and proteins C and S in treated polycythaemia rubra vera.
The free-radical scavenger edaravone accelerates thrombolysis with alteplase in an experimental thrombosis model.
The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels.
The impact of alteplase on pulmonary graft function in donation after circulatory death - An experimental study.
The impact of postprandial lipemia in accelerating atherothrombosis.
The influence of hyperestrogenism during in vitro fertilization on the fibrinolytic mechanism.
The influence of transport parameters and enzyme kinetics of the fibrinolytic system on thrombolysis: mathematical modelling of two idealised cases.
The integrated effects of angiotensin II.
The interaction between components of the fibrinolytic system and GPIb/V/IX of platelets thrombus formation in mice.
The Interventional Management of Stroke (IMS) II Study.
The management of filter-related caval thrombosis complicated by heparin-induced thrombocytopenia and thrombosis.
The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy.
The muscle as a possible source of plasminogen activator to the blood and their therapeutic implication in the prevention of deep vein thrombosis.
The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor.
The presence of a right-to-left shunt is associated with dramatic improvement after thrombolytic therapy in patients with acute ischemic stroke.
The prognostic value of Bleeding Academic Research Consortium (BARC) defined bleeding complications in ST-segment elevation myocardial infarction: A Comparison with the Thrombolysis In Myocardial Infarction (TIMI), Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) and International Society of Thrombosis and Haemostasis (ISTH) bleeding classifications.
The Prothrombotic State Associated with SARS-CoV-2 Infection: Pathophysiological Aspects.
The rabbit as a model for studies of fibrinolysis.
The regulation of the inflammatory response through nuclear factor-kappab pathway by angiotensin IV extends the role of the renin angiotensin system in cardiovascular diseases.
The relationship between plasma t-PA and PAI-1 levels is dependent on epistatic effects of the ACE I/D and PAI-1 4G/5G polymorphisms.
The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and PAI-1 in children and adults.
The resolution of carotid arterial thrombus by oral anticoagulation after IV thrombolysis for chemotherapy-induced stroke: A case report.
The response of the vessel wall to thrombosis: the in vivo study of venous thrombolysis.
The risk of dialysis access thrombosis is related to the transforming growth factor-beta1 production haplotype and is modified by polymorphisms in the plasminogen activator inhibitor-type 1 gene.
The role of insulin as an antithrombotic humoral factor.
The role of serotonin in thrombogenesis.
The role of tissue plasminogen activator in the successful treatment of infected cardiac thrombus in children.
The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.
The single-chain form of tissue-type plasminogen activator has catalytic activity: studies with a mutant enzyme that lacks the cleavage site.
The study of gene-environment interactions that influence thrombosis and fibrinolysis. Genetic variation at the loci for factor VII and plasminogen activator inhibitor-1.
The successful use of low-dose recombinant tissue plasminogen activator for treatment of intracardiac/pulmonary thrombosis during liver transplantation.
The TGF-?1/p53/PAI-1 Signaling Axis in Vascular Senescence: Role of Caveolin-1.
The thrombolytic effect of human tissue-type plasminogen activator on the experimental thrombosis in rabbit.
The thrombolytic effect of miniplasmin in a canine model of femoral artery thrombosis.
The thrombolytic effects of native tissue-type plasminogen activator (AK-124) on experimental canine coronary thrombosis.
The tissue plasminogen activator and urokinase response in vivo during natural resolution of venous thrombus.
The tissue-type plasminogen activator story.
The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans.
The use of alteplase in a newborn with an aortic arch thrombus during extracorporeal membrane oxygenation.
The use of intravesicular alteplase for thrombolysis in a dog with urinary bladder thrombi.
The use of recombinant tissue-type plasminogen activator in a newborn with an intracardiac thrombus developed during extracorporeal membrane oxygenation.
The usefulness of systemic administration of recombinant human tissue-type plasminogen activator in femoral arterial thrombolysis of rabbits.
Thigh Compartment Syndrome After Thrombolytic Therapy of an Occluded Lower Extremity Bypass Graft.
Thombolytic therapy in preterm infants: Fifteen-year experience.
Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Thrombin infusion in endotoxin-treated rabbits reduces the plasma levels of plasminogen activator inhibitor: evidence for a protein-C-mediated mechanism.
Thromboembolic events in a severely burned patient.
Thromboembolism related to a Port-a-Cath device in a patient with cystic fibrosis.
Thrombolysis and fibrinolytic parameters during heparin treatment of deep vein thrombosis.
Thrombolysis and mechanical fragmentation to treat massive pulmonary embolism in a patient with an anterior communicating artery aneurysm.
Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.
Thrombolysis by rotational thrombectomy followed by tissue plasminogen activator: evaluation by angioscopy.
Thrombolysis for deep venous thrombosis associated with inferior vena cava agenesis in a young patient.
Thrombolysis for intraventricular hemorrhage after endovascular aneurysmal coiling.
Thrombolysis for lower extremity deep venous thrombosis.
Thrombolysis for obstructed CarboMedics mitral valve prosthesis.
Thrombolysis for prosthetic valve thrombosis: indications and results.
Thrombolysis in microvascular surgery using tissue-type plasminogen activator.
Thrombolysis is an appropriate treatment in lead-associated infective endocarditis with giant vegetations located on the right atrial lead.
Thrombolysis of a neonatal brachial artery thrombosis with tissue plasminogen activator.
Thrombolysis of canine femoral artery thrombus by a novel modified tissue-type plasminogen activator (E6010).
Thrombolysis of prosthetic mitral valve thrombosis in an infant.
Thrombolysis of prosthetic tricuspid valve thrombosis with human recombinant tissue plasminogen activator in an adolescent.
Thrombolysis of venous and arterial thrombosis by catheter-directed low-dose infusion of tissue plasminogen activator in children.
Thrombolysis Using Tissue Plasminogen Activator: Experience from a Critical Care Setting.
Thrombolysis vs. bleeding from hemostatic sites by a prourokinase mutant compared with tissue plasminogen activator.
Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis.
Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis.
Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.
Thrombolysis with intracoronary administration of YM866, a novel modified tissue-type plasminogen activator, in a canine model of coronary artery thrombosis.
Thrombolysis with low dose tissue plasminogen activator.
Thrombolysis With Recombinant Tissue Plasminogen Activator in 7 Children.
Thrombolysis with recombinant tissue plasminogen activator in atherosclerotic thrombotic occlusion.
Thrombolysis with recombinant tissue plasminogen activator in late saphenous vein graft thrombosis.
Thrombolysis with reteplase for recurrent mechanical heartvalve thrombosis.
Thrombolysis with tissue-type plasminogen activator following cardiac surgery in children.
Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis.
Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis.
Thrombolytic activity of BB-10153, a thrombin-activatable plasminogen.
Thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator, in a photochemically induced platelet-rich thrombosis model.
Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728.
Thrombolytic effect of a plasminogen-plasminogen activator chimera in a photochemically induced thrombosis (PIT) model.
Thrombolytic effect of lonomin V in a rabbit jugular vein thrombosis model.
Thrombolytic efficacy of a modified tissue-type plasminogen activator, SUN9216, in the rat middle cerebral artery thrombosis model.
Thrombolytic fucoidans inhibit the tPA-PAI1 complex, indicating activation of plasma tissue-type plasminogen activator is a mechanism of fucoidan-mediated thrombolysis in a mouse thrombosis model.
Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor- and kringle 1-domains.
Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor--and kringle one-domains.
Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.
Thrombolytic Therapy as the Management of Mitral Transcatheter Valve-in-Valve Implantation Early Thrombosis.
Thrombolytic therapy based on fucoidan-functionalized polymer nanoparticles targeting P-selectin.
Thrombolytic Therapy for Acute Myocardial Infarction : A Review.
Thrombolytic therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low-dose, slow infusion of tissue-type plasminogen activator.
Thrombolytic therapy for unstable angina pectoris: rationale and results.
Thrombolytic therapy in acute ischemic stroke patients with cardiac thrombus.
Thrombolytic therapy in pregnancy.
Thrombolytic therapy is effective in paroxysmal nocturnal hemoglobinuria: a series of nine patients and a review of the literature.
Thrombolytic therapy with rt-PA and transcranial color Doppler ultrasound (TCCS) combined with microbubbles for embolic thrombus.
Thrombolytic therapy with tissue plasminogen activator for superior vena cava thrombosis in an infant with sepsis.
Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.
Thrombosis and Haemostasis challenges in COVID-19 - Therapeutic perspectives of heparin and tissue-type plasminogen activator and potential toxicological reactions-a mini review.
Thrombosis in Continuous Flow Left Ventricular Assist Devices: Our Clinical Experience With Medical and Surgical Management.
Thrombosis in newborn infants.
Thrombosis of the deep cerebral veins with excessive bilateral infarction in a premature infant with the thrombogenic 4G/4G genotype of the plasminogen activator inhibitor-1.
Thrombosis of the superior vena cava due to a Hickman catheter: successful management by rt-PA thrombolysis.
Thrombosis recanalization by paeoniflorin through the upregulation of urokinase?type plasminogen activator via the MAPK signaling pathway.
Thrombotic phenotype of mice with a combined deficiency in plasminogen activator inhibitor 1 and vitronectin.
Thrombus age and tissue plasminogen activator mediated thrombolysis in rats.
Thrombus attached to suture materials successfully thrombolysed with low-dose tissue plasminogen activator.
Thrombus characterization with intravascular ultrasound: potential to predict successful thrombolysis.
Thrombus density predicts successful recanalization with Solitaire stent retriever thrombectomy in acute ischemic stroke.
Thrombus Imaging Using 3D Printed Middle Cerebral Artery Model and Preclinical Imaging Techniques: Application to Thrombus Targeting and Thrombolytic Studies.
Thrombus in right atrium in two infants successfully treated with tissue plasminogen activator.
Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI.
Thrombus Migration and Fragmentation After Intravenous Alteplase Treatment: The INTERRSeCT Study.
Thrombus migration following intracoronary tissue plasminogen activator.
Thrombus Migration Paradox in Patients With Acute Ischemic Stroke.
Thrombus Neutrophil Extracellular Traps Content Impair tPA-Induced Thrombolysis in Acute Ischemic Stroke.
Thrombus Removal by Acute-phase Endovascular Reperfusion Therapy to Treat Cerebral Embolism Caused by Thrombus in the Pulmonary Vein Stump after Left Upper Pulmonary Lobectomy: Case Report.
Ticagrelor, but not clopidogrel active metabolite, displays antithrombotic properties in the left atrial endocardium.
Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombosis model.
Time-Dependent Thrombus Resolution After Tissue-Type Plasminogen Activator in Patients With Stroke and Mice.
Time-Restricted Salutary Effects of Blood Flow Restoration on Venous Thrombosis and Vein Wall Injury in Mouse and Human Subjects.
Tissue plasminogen activator (alteplase) treatment for femoral artery thrombosis after cardiac catheterisation in infants and children.
Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial.
Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background.
Tissue plasminogen activator concentrations in major abdominal surgery. Relationship to postoperative deep vein thrombosis.
Tissue plasminogen activator for a left atrial thrombus after Senning repair.
Tissue plasminogen activator for hepatic vein thrombosis in paroxysmal nocturnal haemoglobinuria.
Tissue plasminogen activator in peripheral arterial thrombolysis.
Tissue plasminogen activator in the treatment of superior vena caval thrombosis associated with parenteral nutrition.
Tissue plasminogen activator inhibitor in patients with systemic lupus erythematosus and thrombosis.
Tissue plasminogen activator is a potent activator of PDGF-CC.
Tissue plasminogen activator levels after single intracisternal injection in patients with subarachnoid hemorrhage.
Tissue plasminogen activator lysis of a right ventricular thrombus.
Tissue plasminogen activator production by monocytes in venous thrombolysis.
Tissue plasminogen activator reduces neurological damage after cerebral embolism.
Tissue plasminogen activator thrombolysis and transluminal angioplasty in the treatment of basilar artery thrombosis: case report.
Tissue plasminogen activator thrombolysis during surgical evacuation of experimental subretinal hemorrhage.
Tissue plasminogen activator to prevent central venous access device infections: a systematic review of central venous access catheter thrombosis, infection and thromboprophylaxis.
Tissue plasminogen activator treatment of digital thrombosis in severe Raynaud's phenomenon--a case report.
Tissue Plasminogen Activator Use in Children: Bleeding Complications and Thrombus Resolution.
Tissue plasminogen activator-based clot busting: Controlled delivery approaches.
Tissue plasminogen activator-containing polyurethane surfaces for fibrinolytic activity.
Tissue plasminogen activator-mediated thrombolysis of cerebral emboli and its effect on hemorrhagic infarction in rabbits.
Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy after Ischemic Stroke.
Tissue type plasminogen activator regulates myeloid-cell dependent neoangiogenesis during tissue regeneration.
Tissue-type plasminogen activator (t-PA) and dilute blood clot lysis time in nephrotic patients.
Tissue-type plasminogen activator (t-PA) lysis of aortic and mitral valve thrombosis.
Tissue-type plasminogen activator (tPA) and its inhibitor (PAI-1) in patients treated with continuous ambulatory peritoneal dialysis.
Tissue-type plasminogen activator (tPA) in breast cancer: relationship with clinicopathological parameters and prognostic significance.
Tissue-type plasminogen activator gene is on chromosome 8.
Tissue-type plasminogen activator gene targets thrombolysis in atriums.
Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor.
Tissue-type plasminogen activator-mediated plasminogen activation and contact activation, implications in and beyond haemostasis.
Topology of the fibrinolytic system within the mural thrombus of human abdominal aortic aneurysms.
tPA in the injured central nervous system: different scenarios starring the same actor?
tPA, but not uPA, significantly affects antithrombotic therapy by a glycoprotein IIb/IIIa antagonist, but not by a factor Xa inhibitor.
Transarterial fibrinolysis using tissue plasminogen activator in a patient with acute renal failure due to acute thrombosis of bilateral renal arteries. 3 years' follow-up.
Transcatheter thrombolysis with high-dose bolus tissue plasminogen activator in iatrogenic arterial occlusion after femoral arterial catheterization.
Transhepatic fibrinolysis of mesenteric and portal vein thrombosis in a patient with ulcerative colitis: a case report.
Transhepatic mechanical thrombectomy followed by infusion of TPA into the superior mesenteric artery to treat acute mesenteric vein thrombosis.
Transvenous Catheter-Based Thrombolysis With Continuous Tissue Plasminogen Activator Infusion for Refractory Thrombosis in a Patient With Behcet's Disease.
Treatment of a mobile intracardiac thrombus using ultra-slow low-dose tissue plasminogen activator in combination with heparin.
Treatment of acute basilar artery thrombosis with a combination of systemic alteplase and tirofiban, a nonpeptide platelet glycoprotein IIb/IIIa inhibitor: report of four cases.
Treatment of axillosubclavian vein thrombosis: a novel technique for rapid removal of clot using low-dose thrombolysis.
Treatment of canine embolic pulmonary hypertension with recombinant tissue plasminogen activator. Efficacy of dosing regimes.
Treatment of Carotid Intramural Thrombus With TPA.
Treatment of deep cerebral venous thrombosis by local infusion of tissue plasminogen activator.
Treatment of extensive subacute portal, mesenteric and ileocolic vein thrombosis with recombinant tissue plasminogen activator.
Treatment of Mobile Right Heart Thrombi.
Treatment of neonatal thrombus formation with recombinant tissue plasminogen activator: six years experience and review of the literature.
Treatment of portal vein thrombosis by thrombectomy and regional thrombolysis.
Treatment of post-traumatic trabecular mashwork thrombosis and secondary glaucoma with intracameral tissue plasminogen activator in previously unrecognized sickle cell anemia.
Treatment of prosthetic tricuspid valve thrombosis with low-dose tissue plasminogen activator.
Treatment of prosthetic tricuspid valve thrombosis with recombinant tissue-type plasminogen activator.
Treatment of Recurrent Prosthetic Mitral Valve Thrombosis with Reteplase: A Report of Four Cases.
Treatment of superior mesenteric and portal vein thrombosis with direct thrombolytic infusion via an operatively placed mesenteric catheter.
Treatment of superior vena cava syndrome with recombinant tissue plasminogen activator in a sickle cell patient undergoing bone marrow transplantation.
Treatment of superior vena cava thrombosis with recombinant tissue type plasminogen activator.
Treatment of suprachoroidal hemorrhage with tissue plasminogen activator.
Treatment of thrombus formation associated with the MicroMed DeBakey VAD using recombinant tissue plasminogen activator.
Turbulent axially directed flow of plasma containing rt-PA promotes thrombolysis of non-occlusive whole blood clots in vitro.
Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor.
Two fetal deaths associated with maternal sepsis and with thrombosis of the intervillous space of the placenta.
Ultradelayed Arterial Thrombosis: Critical Flap Ischemia After Phalloplasty.
Ultraslow thrombolytic therapy: A novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: The Ultra-slow PROMETEE trial.
Ultrasound Acceleration of rt-PA Thrombolysis Depends on Acoustic Intensity.
Ultrasound affects distribution of plasminogen and tissue-type plasminogen activator in whole blood clots in vitro.
Ultrasound enhanced thrombolysis for stroke.
Ultrasound enhanced thrombolysis: applications in acute cerebral ischemia.
Ultrasound has synergistic effects in vitro with tirofiban and heparin for thrombus dissolution.
Ultrasound identification and lysis of clots.
Ultrasound-assisted lysis using recombinant tissue plasminogen activator and the EKOS EkoSonic endovascular system for treating right atrial thrombus and massive pulmonary embolism: A case study.
Ultrasound-enhanced thrombolysis for stroke: clinical significance.
Ultrasound-enhanced thrombolysis using Definity as a cavitation nucleation agent.
Ultrasound-enhanced thrombolysis.
Ultrasound-enhanced tissue plasminogen activator thrombolysis in an in vitro porcine clot model.
Ultrasound-induced thermal elevation in clotted blood and cranial bone.
Ultrasound-responsive thrombus treatment with zinc-stabilized gelatin nano-complexes of tissue-type plasminogen activator.
Ultrasound-targeted transfection of tissue-type plasminogen activator gene carried by albumin nanoparticles to dog myocardium to prevent thrombosis after heart mechanical valve replacement.
Uncoupling fibrin from integrin receptors hastens fibrinolysis at the platelet-fibrin interface.
Up-regulation of type 1 plasminogen activator inhibitor messenger RNA with thrombotic changes in renal grafts.
Upper extremity acute compartment syndrome during tissue plasminogen activator therapy for pulmonary embolism in a morbidly obese patient.
Urokinase binding to bovine corneal endothelial cells.
Urokinase in the management of vitreous hemorrhage.
Urokinase plasminogen activator independent early experimental thrombus resolution: MMP2 as an alternative mechanism.
Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double-blinded, randomized trial.
Urokinase, tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in severely stenosed and occluded vein grafts with thrombosis.
Use of a temporary caval filter in a young man with pulmonary embolism to prevent migration of massive caval thrombus during an attempt of caval thrombolysis.
Use of abciximab for mediation of thromboembolic complications of endovascular therapy.
Use of argatroban and catheter-directed thrombolysis with alteplase in an oncology patient with heparin-induced thrombocytopenia with thrombosis.
Use of intraventricular tissue plasminogen activator and Guglielmi detachable coiling for the acute treatment of casted ventricles from cerebral aneurysm hemorrhage: two technical case reports.
Use of recombinant tissue-plasminogen activator in a dog with chylothorax secondary to catheter-associated thrombosis of the cranial vena cava.
Use of rheolytic thrombectomy in treatment of acute massive pulmonary embolism.
Use of Tissue Plasminogen Activator Alteplase for Suspected Impella Thrombosis.
Use of Tissue Plasminogen Activator Alteplase Purge Solution in an Impella 5.5 Heart Pump.
Use of Tissue Plasminogen Activator as a Surrogate Measure for Central Venous Catheter Dysfunction and Survival Outcome in Children with Cancer: A Population-Based Retrospective Cohort Study.
Use of tissue plasminogen activator for femoral artery thrombosis following transcatheter coil occlusion of patent ductus arteriosus.
Use of tissue plasminogen activator for reopening of clotted dialysis catheters.
Use of tissue plasminogen activator to alleviate postoperative subcutaneous ureteral bypass obstruction secondary to blood clot in seven cats.
Use of tissue plasminogen activator to treat intracardiac thrombosis in extremely low-birth-weight infants.
Use of tissue type plasminogen activator in neonates: case reports and review of the literature.
Use of transesophageal echocardiography during thrombolysis with tissue plasminogen activator of a thrombosed prosthetic mitral valve.
Using alteplase nephrostomy tube installation for thrombolysis of ureter tract clot obstruction.
Valproic acid selectively increases vascular endothelial tissue-type plasminogen activator production and reduces thrombus formation in the mouse.
Vampire bat salivary plasminogen activator evokes minimal bleeding relative to tissue-type plasminogen activator as assessed by a rabbit cuticle bleeding time model.
Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis.
Vascular and Cardiac Impairments in Rats Inhaling Ozone and Diesel Exhaust Particles.
Vascular complications and microvascular free flap salvage: The role of thrombolytic agents.
Vascular functions of the plasminogen activation system.
Vascular plasminogen activator and deep vein thrombosis.
Vascular prostacyclin and plasminogen activator activity in experimental and clinical conditions of disturbed haemostasis or thrombosis.
Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice.
Vascular Thoracic Outlet Syndrome.
Vasospasm prevention with postoperative intrathecal thrombolytic therapy: a retrospective comparison of urokinase, tissue plasminogen activator, and cisternal drainage alone.
Venous and arterial thromboembolic disease in women using oral contraceptives.
Venous stasis-induced fibrinolysis prevents thrombosis in mice: role of ?2-antiplasmin.
Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
Ventricular arrhythmias during treatment with alteplase (recombinant tissue plasminogen activator) in suspected acute myocardial infarction.
Ventricular function and cardiac hypertrophy after coronary thrombolysis with tissue-type plasminogen activator (t-PA) in dogs with coronary artery thrombi.
Vepoloxamer Enhances Fibrinolysis of tPA (Tissue-Type Plasminogen Activator) on Acute Ischemic Stroke.
VIDEO MICROSCOPE RECORDING OF THE DYNAMIC COURSE OF THROMBOSIS AND THROMBOLYSIS OF THE RETINAL VEIN IN RABBITS.
Vocal cord haematoma after tenecteplase thrombolysis.
Weighing in on fistula failure.
Whole blood clot dissolution: in vitro study on the effects of permeation pressure.
Whole blood clot lysis in newborns and adults after adding different concentrations of recombinant tissue plasminogen activator (Rt-PA).
Xanthoangelols isolated from Angelica keiskei inhibit inflammatory-induced plasminogen activator inhibitor 1 (PAI-1) production.
YM866, a novel modified tissue-type plasminogen activator, affects left ventricular function and myocardial infarct development in dogs with coronary artery thrombi.
Zebrafish model of photochemical thrombosis for translational research and thrombolytic screening in vivo.
[A case of middle cerebral artery occlusion caused by dissecting aneurysm]
[A family with reduced plasminogen activator activity in the blood associated with recurrent thrombosis]
[A new medical treatment for thrombosis by genetic engineering]
[Activator treatment of acute venous thrombosis (author's transl)]
[Acute deep vein thrombosis of lower limbs treated by thrombolytic therapy with recombinant tissue-type plasminogen activator]
[Acute disfunction from thrombosis of a prosthetic mitral valve: thrombolysis with rt-PA in the clinical emergency phase]
[Acute thrombosis of the portal system. Treatment with alteplase and heparin or with heparin alone in 10 patients]
[An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model]
[Analysis of plasminogen activator in human plasma using the method of fibrin/celite column chromatography--with special reference to the determination of fibrin adsorbable tissue-plasminogen activator by ELISA]
[Antibody mediated thrombolysis. A new therapeutic principle]
[Asymptomatic postoperative thrombosis of a Saint Jude mitral valve prosthesis. Treatment by fibrinolysis with rt-PA]
[Bilateral renal embolism during thrombolytic therapy with tissue-type plasminogen activator in a patient with thrombosis of the left ventricle]
[Catheter-directed thrombolysis of iliofemoral venous thrombosis]
[Cerebral salt wasting syndrome as a complication of subarachnoid hemorrhage in a girl with nephrotic syndrome - a case report].
[Clinical efficacy and safety of thrombolytic treatment with reteplase in patients with intermediate-risk acute pulmonary embolism].
[Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis]
[Direct continuous observation of in situ thrombolysis in the cerebral embolic model of rabbits]
[Disorders of the liberation of tissue-type plasminogen activator (t-PA) from the venous wall as a cause for recurrent thromboses]
[Effect of Xinfeng Capsule on Related Factors of Thrombus Formation and Inflammatory Cytokines in Active Ankylosing Spondylitis Patients].
[Effectiveness of locoregional rt-PA lysis in acute leg and arm vein thrombosis]
[Examinations to detect left atrial thrombus and blood coagulation test analyses in aged patients with atrial fibrillation]
[Experimental therapy of acute thrombosis using a tissue plasminogen activator]
[Fibrinolytic and thrombolytic properties of a plasminogen activator isolated from the culture broth of calf kidney cells]
[Fibrinolytic system and a central retinal vein thrombosis]
[Fibrinolytic treatment with tissue plasminogen activator in a thrombosed modified Blalock-Taussig shunt]
[Giant coronary artery aneurysm in a patient with rheumatoid arthritis].
[Hemostatic status in subjects with deep venous thrombosis]
[High-risk pulmonary embolism in early post-operative period].
[Ilio-femoral vein thrombosis treated with tissue plasminogen activator in a pregnant woman]
[Immunoradiometric determination of blood/tissue plasminogen activators in thrombophilia]
[Intra-arterial lysis therapy in acute limb ischemia. Technical possibilities and limits of indication]
[Intra-arterial thrombolysis in basilar artery thrombosis. Recovery of two patients with locked-in syndrome]
[Intra-arterial thrombolysis using rt-PA for the treatment of occluded infra-inguinal bypasses]
[Intracardiac Thrombosis in a Child With Hereditary Thrombophilia].
[Local intra-arterial thrombolysis. Results in arterial thromboses and graft occlusions]
[Local lysis of peritoneovenous shunt thrombosis with rt-PA]
[Local thrombolysis in the treatment of peripheral arterial vascular diseases]
[Local thrombolysis of sinus thrombosis]
[Local thrombolytic treatment of deep vein thrombosis with small doses of plasminogen activator]
[Low dosage fibrinolytic therapy with r-TPA in thromboses of the deep venous system]
[Low-dose thrombolysis using rt-Pa in extensive peripheral vascular occlusion]
[Lysis of atrial thrombus with in situ injection of rt-PA]
[Lysis of cytostatic drug-associated axillary vein thrombosis]
[Massive endocardial thrombosis in a patient with a peritoneo-jugular shunt for refractory ascites: the therapeutic success of tissue plasminogen activator and defibrotide]
[Massive pulmonary thromboembolism after abdominoplasty and liposuction].
[Mitral prosthesis thrombosis treated by fibrinolysis with accelerated administration of r-TPA]
[Mobile thrombus in the right atrium and pulmonary embolism: efficacy of thrombolytic treatment with alteplase]
[Molecular defects of coagulation factors and of the fibrinolytic system associated with thromboembolism]
[Monitoring drug therapy in venous thrombosis]
[Pathophysiology of acute coronary syndromes]
[Pharmacogenetics of the local thrombolysis in patients with deep vein thrombosis]
[Phlebothrombosis and congenital thrombophilia].
[Plasminogen activator inhibitor 1--a new thrombosis risk marker]
[Polymorphism of the plasminogen activator inhibitor type 1 gene, plasminogen level and thrombosis in patients with antiphospholipid syndrome].
[Post-phlebitic leg ulcers and XYY karyotype: fibrinolysis and androgenic function tests. Apropos of 3 cases]
[Recombinant tissue plasminogen activator for the management of intracardiac thrombi in newborns].
[Recombinant tissue plasminogen activator for thrombolytic therapy of right atrial thrombus in a neonate and infant]
[Refibrinolysis with r-tPA for thrombosis of the mitral prosthesis after an acute myocardial infarct]
[Relation between the blood coagulation status in hemodialyzed patients and arteriovenous fistula thrombosis--prospective study]
[Right atrial thrombus: a rare presentation of plasminogen activator inhibitor deficiency.]
[Risk factors in chronic thromboembolic pulmonary hypertension]
[Septic portal vein thrombosis. Its successful therapy by local fibrinolysis and a transjugular portasystemic stent-shunt (TIPS)]
[Significance of the endothelium of the vascular wall for maintaining hemostasis]
[Spontaneous neonatal arterial thrombosis treated with tissue plasminogen activator]
[Studies on the prevention of postoperative thrombosis with a small dose of recombinant human tissue-type plasminogen activator]
[Study of hemostatic molecular marker]
[Subacute Budd-Chiari syndrome treated with rTPA. Considerations on a case]
[Subtotal thrombosis of the juxta-ductal thoracic aorta in a premature 36-week-old infant. Alteplase therapy]
[Successful catheter-guided local thrombolysis in acute pulmonary embolism in the early postoperative period after pancreatic head resection]
[Successful lysis of a mobile left ventricular thrombus by slow infusion of low-dose tissue plasminogen activator.]
[Successful lysis of a septic thrombosis of the superior vena cava using recombinant tissue-plasminogen activator]
[t-PA activity, antigen and PAI-1 antigen levels in blood obtained from the patients with cerebral infarction]
[t-PA in thrombolytic therapy of acute myocardial infarct]
[The antithrombotic and thrombolytic activity of a plasminogen activator isolated from a monolayer cell culture]
[The efficacy of local T-pa infusion in the treatment of axillary vein thrombosis]
[The experimental study on changes of endothelial nitric oxide synthase and plasminogen activator inhibitor-1 protein in the canine atrial fibrillation model]
[The resolution of a mitral valve prosthesis thrombosis with low-dose plasminogen tissue activator and the role of Doppler echocardiographic monitoring]
[The system of hemostasis in patients with atrial fibrillation: markers of left auricular thrombosis.]
[The use of intravascular nitinol stents in the treatment of subclavian vein compression for thoracic outlet syndrome]
[Thrombi of the right heart. Value of thrombolytic therapy in mobile thrombi]
[Thrombolysis of modified Blalock-Taussig shunts in childhood with recombinant tissue-type plasminogen activator]
[Thrombolysis of prosthetic heart valve thrombosis using recombinant tissue plasminogen activator (rt-PA) in infancy and childhood]
[Thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in 13 children: a case series]
[Thrombolytic therapy in arterial disorders other than myocardial infarction]
[Thrombolytic therapy of deep venous thrombosis with rt-PA]
[Thrombolytic therapy with rt-PA for thrombosis of tricuspid valve prosthesis during pregnancy]
[Thrombolytic therapy with rt-PA of recurrent thrombosis in tricuspid valve prosthesis during pregnancy]
[Thrombolytic treatment in stroke in patients with intracardiac thrombus: presentation of one case]
[Thromboses of the subclavian vein and jugular vein and superior vena cava: sonographic diagnosis and control of treatment using tissue-type plasminogen activator therapy]
[Thrombosis of a Bjork-Shiley mitral valve prosthesis: its thrombolytic treatment with rt-PA]
[Thrombosis of mechanical tricuspid valve prosthesis: treatment by tissue-type plasminogen activator. Success after a 18 month-follow-up]
[Thrombosis of the iliac artery in a premature neonate: thrombolytic therapy using rt-PA]
[Thrombotic tendency and laboratory medicine in metabolic syndrome]
[Thrombus in the right ventricle in an infant--a good result of thrombolytic therapy with recombinant tissue plasminogen activator]
[Thrombus in transit - two cases of patients with massive pulmonary embolism treated with thrombolysis]
[Tissue plasminogen activator and diabetes mellitus]
[Tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI)]
[tPA thrombolytic treatment of aortic thromboses due to umbilical arterial catheterization in newborn infants]
[Traumatic submacular hemorrhage treated with rt-PA and SF6]
[Treatment of pylethrombosis with alteplase. Description of a clinical case]
[Treatment trials of plasminogen activator (rt-PA) in central vein thrombosis of the retina]
[Tumor-associated prognostic factors of the plasminogen activator family: determination and clinical value of u-PA, t-PA, PAI-1, and PAI-2]
[Use of recombinant tissue plasminogen activator (rt-PA) in occluding thrombosis of a Hickman catheter after bone marrow transplantation: clinical and coagulation physiologic aspects]
[Use of tissue plasminogen activator in the treatment of aortic thrombosis in newborn infants]
[Value of thrombolytic therapy in deep venous thrombosis]
[Vitreous hemorrhage after vitrectomy in diabetic retinopathy and tissue plasminogen activator]
Thrombotic Microangiopathies
Comprehensive analysis of glomerular mRNA expression of pro- and antithrombotic genes in atypical haemolytic-uremic syndrome (aHUS).
Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney.
Microvascular thrombosis in pediatric multiple organ failure: Is it a therapeutic target?
Thrombotic Stroke
A Case of Sudden Death: Subarachnoid Hemorrhage, Pheochromocytoma, Berry Aneurysm.
FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
Increased tissue plasminogen activator levels in patients with nonvalvular atrial fibrillation.
Investigational use of tPA in acute stroke.
Microglial-mediated PDGF-CC activation increases cerebrovascular permeability during ischemic stroke.
Mouse model of microembolic stroke and reperfusion.
Neonatal stroke associated with de novo antiphospholipid antibody and homozygous 1298C/C methylenetetrahydrofolate reductase mutation.
Pharmacological Modulation of Neutrophil Extracellular Traps Reverses Thrombotic Stroke tPA (Tissue-Type Plasminogen Activator) Resistance.
Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.
Reactions to alteplase in patients with acute thrombotic stroke.
Releasable vascular plasminogen activator and thrombotic strokes.
Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke.
Tissue plasminogen activator and glial function.
Thymoma
Thrombolysis by PLAT/tPA increases serum free IGF1 leading to a decrease of deleterious autophagy following brain ischemia.
Thyroid Cancer, Papillary
Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
Thyroid Diseases
Molecular biomarkers of Graves' ophthalmopathy.
[Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases]
Thyroid Hormone Resistance Syndrome
Dominant and nondominant negative C-erbA beta 1 receptors associated with thyroid hormone resistance syndromes augment 12-O-tetradecanoyl-phorbol-13-acetate induction of the collagenase promoter and exhibit defective 3,5,3'-triiodothyronine-mediated repression.
Thyroid Neoplasms
Actin architecture of cultured human thyroid cancer cells: predictor of differentiation?
Clinical evaluation of serum tissue polypeptide specific antigen in patients with thyroid carcinoma.
Heterologous desensitization in neoplastic thyroid cells: influence of the phospholipase C signal transduction system on the thyrotropin-adenylate cyclase signal transduction system.
Marker determination for response monitoring: radiotherapy and disappearance curves.
Plasminogen activation system in active even in thyroid tumors; an immunohistochemical study.
Serum tissue polypeptide antigen (TPA) in thyroid cancer.
Tissue polypeptide antigen in thyroid tumours of follicular cell origin: an immunohistochemical re-evaluation for diagnostic purposes.
Urokinase plasminogen activator and its inhibitor type-1 as prognostic factors in differentiated thyroid carcinoma patients.
[Clinical relevance of tumor markers]
[Plasminogen activators of urokinase and tissue types and their inhibitor (PAI-1) in cytosol fraction in thyroid diseases]
Thyroid Nodule
Effect of levothyroxine suppression therapy on plasma thrombin activatable fibrinolysis inhibitor antigen levels in benign thyroid nodules.
Thyroid tumors in children and adolescents: preoperative study.
Thyrotoxicosis
The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: a systematic review and meta-analysis.
Tonsillitis
Plasminogen activator derived from tonsillar lymphocytes of rabbits with arthus tonsillitis.
Toxemia
[The role of coagulation and fibrinolysis system in pathogenesis of toxemia of pregnancy]
Toxic Optic Neuropathy
Chemical injury to an in vitro ocular system: differential release of plasminogen activator.
Transfusion-Related Acute Lung Injury
Transfusion-related acute lung injury in cardiac surgery patients is characterized by pulmonary inflammation and coagulopathy: A prospective nested case-control study.
Trauma, Nervous System
Neuron-specific enolase and S-100B are associated with neurologic outcome after pediatric cardiac arrest.
Novel plasminogen activator inhibitor-1-derived peptide protects against impairment of cerebrovasodilation after photothrombosis through inhibition of JNK MAPK.
Treponemal Infections
No bejel among Surinamese, Antillean and Dutch syphilis diagnosed patients in Amsterdam between 2006-2018 evidenced by multi-locus sequence typing of Treponema pallidum isolates.
Triple Negative Breast Neoplasms
Plasminogen activator inhibitor 1 (PAI1) promotes actin cytoskeleton reorganization and glycolytic metabolism in triple negative breast cancer.
Trophoblastic Neoplasms
Relation between serum levels of tissue polypeptide antigen (TPA) and cancer antigen 125 (CA125) and their immunohistochemical identification in benign and malignant gynecological disease.
Tuberculoma
[Higher levels of urokinase plasminogen activator system components in the airways of chronic obstructive pulmonary disease patients]
Tuberculosis
DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis.
Fibrinolytic characteristics and their significance in malignant, tuberculous and cirrhotic pleural and ascitic fluids.
Identification of novel host biomarkers in plasma as candidates for the immunodiagnosis of tuberculosis disease and monitoring of tuberculosis treatment response.
Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences.
Plasminogen activator inhibitor type I may contribute to transient, non-specific changes in immunity in the subacute phase of murine tuberculosis.
Proinflammatory cytokines and fibrinolytic enzymes in tuberculous and malignant pleural effusions.
Proinflammatory cytokines, transforming growth factor-beta1, and fibrinolytic enzymes in loculated and free-flowing pleural exudates.
Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis.
Vaccinia expression of Mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85.
Tuberculosis, Pleural
Analysis of Cytokine Levers in Pleural Effusions of Tuberculous Pleurisy and Tuberculous Empyema.
Intrapleural alteplase and DNase for complex tuberculous pleurisy: a medical approach.
Proinflammatory cytokines and fibrinolytic enzymes in tuberculous and malignant pleural effusions.
[Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma]
Tuberculosis, Pulmonary
DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis.
Haemostatic Abnormalities in Patients with a Clinical Predisposition to Venous Thromboembolism.
[Clinical significance of serum tumor markers (CEA, TPA, IAP and ferritin) in pulmonary tuberculosis]
[Tissue polypeptide antigen in serum and tissue in patients with lung cancer]
Tuberous Sclerosis
Enhancement of plasminogen activator activities by N-methyl-N'-nitro-N-nitrosoguanidine in tuberous sclerosis fibroblasts.
Serum factors responsible for unusual induction of plasminogen activator activity in tuberous sclerosis.
Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies.
Tumor Lysis Syndrome
Enzymes approved for human therapy: indications, mechanisms and adverse effects.
Turner Syndrome
Serum lipids, lipoprotein lp(a), and plasminogen activator inhibitor-1 in patients with Turner's syndrome before and during growth hormone and estrogen therapy.
Unconsciousness
Evidence of anaphylaxy after alteplase infusion.
Secondary hemorrhage after intraventricular fibrinolysis: a cautionary note: a report of two cases.
Uremia
Does uremia cause vascular dysfunction?
Plasma parameters of the prothrombotic state in chronic uremia.
Ureteral Obstruction
Clusterin attenuates the development of renal fibrosis.
Delayed treatment with plasminogen activator inhibitor-1 decoys reduces tubulointerstitial fibrosis.
Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy.
Erythropoietin protects the tubular basement membrane by promoting the bone marrow to release extracellular vesicles containing tPA-targeting miR-144.
Fibroblast-specific plasminogen activator inhibitor-1 depletion ameliorates renal interstitial fibrosis after unilateral ureteral obstruction.
Plasminogen activator inhibitor-1 and tissue-type plasminogen activator are up-regulated during unilateral ureteral obstruction in adult rats.
Serine proteases, inhibitors and receptors in renal fibrosis.
Upregulated expression of transforming growth factor-beta, type IV collagen, and plasminogen activator inhibitor-1 mRNA are decreased after release of unilateral ureteral obstruction.
Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.
Ureterolithiasis
Alteplase Instillation for Upper Urinary Tract Clot Dissolution.
Urinary Bladder Calculi
Bladder epithelial cell proliferation of rats induced by terephthalic acid-calculi.
Deregulation of the p16-cyclin D1/cyclin-dependent kinase 4-retinoblastoma pathway involved in the rat bladder carcinogenesis induced by terephthalic acid-calculi.
Fibrinolysis and the biliary tree.
Modification of N-Methyl-N-Nitrosourea initiated bladder carcinogenesis in Wistar rats by terephthalic acid.
Toxicological review and oral risk assessment of terephthalic acid (TPA) and its esters: A category approach.
Urinary Bladder Diseases
Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS.
Urinary Bladder Neoplasms
A protective effect of chromosome 11 against DNA damage by TPA-activated neutrophils but not TPA acting alone.
Analytical validation of ONCURIA™ a multiplex bead-based immunoassay for the non-invasive bladder cancer detection.
Cell culture studies on the mechanism of action of chemical carcinogens and tumor promoters.
Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen.
Comparison between tissue antigen analysis and plasma determinations for TPA and CEA in transitional cell carcinomas and in tumorfree urothelium of the urinary bladder.
Comparison of CYFRA 21-1, TPA and TPS in lung cancer, urinary bladder cancer and benign diseases.
Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues.
Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS.
Detailed technical analysis of urine RNA-based tumor diagnostics reveals ETS2/urokinase plasminogen activator to be a novel marker for bladder cancer.
Effects of tumor promoters, genotoxic carcinogens and hepatocytotoxins on mouse hepatocyte intercellular communication.
Focus on urinary bladder cancer markers: a review.
Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
Interferon-beta can induce the production of plasminogen activator by cultured human cancer cells.
Intravesical administration of plasminogen activator inhibitor type-1 inhibits in vivo bladder tumor invasion and progression.
Intravesical recombinant tissue plasminogen activator for the prevention of implantation-mediated bladder tumor recurrence.
Is interferon gamma one key of metastatic potential increase in human bladder carcinoma?
Mechanisms of multistage chemical carcinogenesis and their relevance to respiratory tract cancer.
Molecular mechanisms of tumor promotion and multistage carcinogenesis.
Plasminogen activator in bladder tumors.
Plasminogen activator inhibitor-2 (PAI-2) overexpression supports bladder cancer development in PAI-1 knockout mice in N-butyl-N- (4-hydroxybutyl)-nitrosamine- induced bladder cancer mouse model.
Plasminogen- and colony-stimulating factor-1-associated markers in bladder carcinoma: diagnostic value of urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 using immunocytochemical analysis.
Prognostic impact of plasminogen activator inhibitor type 1 expression in bladder cancer.
Prospective evaluation of a urinary biomarker panel to detect and predict recurrence of non-muscle-invasive bladder cancer.
Serum tissue polypeptide antigen (S-TPA) in bladder cancer as a tumor marker. A prospective study.
Serum tissue polypeptide antigen (TPA): monoclonal or polyclonal radio-immunometric assay for the follow-up of bladder cancer.
Serum TPS versus TPA in Egyptian bladder cancer patients.
Simultaneous determination of six tumor markers in patients with prostatic carcinoma and bladder tumors.
Simultaneous determination of urinary CEA, ferritin and TPA in Egyptian bladder cancer patients.
Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model.
Terephthalic acid occupational exposure and its effect on organ functions in fiber workers.
The clinical significance of tissue polypeptide antigen (TPA) in the urine of bladder cancer patients.
The induction of bladder stones by terephthalic acid, dimethyl terephthalate, and melamine (2,4,6-triamino-s-triazine) and its relevance to risk assessment.
The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer.
Tissue and serum TPA in subjects at risk for bladder cancer.
Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Tissue polypeptide antigen and carcinoembryonic antigen lack diagnostic accuracy in urothelial carcinoma.
Tissue polypeptide antigen for monitoring of advanced bladder cancer after MVEC chemotherapy.
Tissue polypeptide antigen in the follow-up of patients with urinary bladder cancer compared with conventional urine cytology.
TPA prognostic value in superficial bladder cancer.
Tumor markers (CEA, TPA and CA 19-9) in urine of bladder cancer patients.
Urokinase and the urokinase receptor: association with in vitro invasiveness of human bladder cancer cell lines.
Usefulness of tissue polypeptide antigen in the follow-up of bladder cancer.
[A study of urinary TPA in bladder cancer]
[A study of urological tumor-associated antigens. IV. Immunocytochemical study of TPA, ABH antigen using urothelial exfoliated cells in bladder tumors]
[Blood and urine determinations of tissue polypeptide antigen in patients with bladder carcinoma]
[Clinical relevance of tumor markers]
[Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer]
[Immunohistochemical study of tissue polypeptide antigen (TPA) in human urinary bladder tumors]
[Serum tissue polypeptide antigen (TPA) in patients with urogenital cancer]
[The investigation on early diagnosis of the bladder tumor. II: A study on urinary cytology, urinary fibrin/fibrinogen degradation products, tissue fibrin deposition and tissue plasminogen activator activity in patients with bladder tumors (author's transl)]
[Therapy and follow-up using TPA in radio-oncologic after-care in bladder cancer]
[Tissue type plasminogen activator antigen in urine of patients with bladder cancer]
[Urine determination of CEA, CA50 and TPA as tumor markers in bladder neoplasms]
[Value of microhematuria, urine cytology, TPA and neopterin in the after care of patients with bladder tumors]
Urinary Bladder, Overactive
Expression of neural plasticity related gene in the pontine tegmental area of rats with overactive bladder after cerebral infarction.
Urinary Tract Infections
Endogenous tissue-type plasminogen activator is protective during ascending urinary tract infection.
Gender differences in stroke examined in a 10-year cohort of patients admitted to a Canadian teaching hospital.
Influence of Plasminogen Activator Inhibitor -1 Gene Polymorphism on Renal Scarring After First Febrile Urinary Tract Infection in Infants.
[Serum and urinary tissue polypeptide antigen (TPA) in patients with urological cancer]
[Serum tissue polypeptide antigen (TPA) in patients with urogenital cancer]
Urogenital Diseases
[Serum tissue polypeptide antigen (TPA) in patients with urogenital cancer]
Urogenital Neoplasms
Tissue polypeptide antigen (TPA) as a predictor for genitourinary cancers and their metastases.
[Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer]
[Serum tissue polypeptide antigen (TPA) in patients with urogenital cancer]
Urolithiasis
Chemical urolithiasis. III. Pharmacokinetics and transplacental transport of terephthalic acid in Fischer-344 rats.
Effects of selected therapeutic agents on urolithiasis induced by terephthalic acid in the male weanling Fischer 344 rat.
Urologic Diseases
Serum TPS versus TPA in Egyptian bladder cancer patients.
[Serum and urinary tissue polypeptide antigen (TPA) in patients with urological cancer]
Urologic Neoplasms
Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer.
Tissue polypeptide antigen (TPA): usefulness in urological neoplasia.
[Serum and urinary tissue polypeptide antigen (TPA) in patients with urological cancer]
Urticaria
Angioedema: A Life-threatening Complication of Tissue Plasminogen Activator.
Blood urokinase plasminogen activator system in chronic urticaria.
Incidence of urticaria, angioedema, and type I hypersensitivity reactions associated with fibrinolytic agents in Thailand using the database of the health product vigilance center.
Uterine Cervical Neoplasms
Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
Clinical significance of different serum tumor markers in gynecological malignancies.
Clinical significance of statistical discrimination employing serum TA-4, TPA, and CEA levels in uterine cervical cancer.
Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Decreased expression of the plasminogen activator inhibitor type 1 is involved in degradation of extracellular matrix surrounding cervical cancer stem cells.
Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.
Genistein and Its Analogue Enhanced Tissue Plasminogen Activator Activity in HeLa S3.
Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway.
Plasminogen activator inhibitor-1 (PAI-1) expression in relation to hypoxia and oncoproteins in clinical cervical tumors.
Prognostic significance of serum tumour markers in carcinoma of the cervix.
Protein kinase C modulates telomerase activity in human cervical cancer cells.
The clinical value of tissue polypeptide antigen in patients with gynecologic tumors.
Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer.
Value of Cyfra 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer.
[Clinical significances of tissue polypeptide antigen in patients with gynecological malignancies]
[New tumour markers useful in diagnostics and monitoring of cervical cancer]
[Study on the plasma plasminogen activators in patients with malignant gynecologic tumors]
[The clinical significance of tissue polypeptide antigen (TPA) in the patients with gynecologic tumor]
[Tissue polypeptide antigen as a tumor marker for gynecologic malignancies]
[Tissue polypeptide antigen in gynecological cancer]
Uterine Diseases
[Diagnosis of ovarian tumor by measuring tumor markers]
Uterine Hemorrhage
Causes and Treatment of Acute Ischemic Stroke During Pregnancy.
Puerperium Stroke and Subsequent Tissue-Type Plasminogen Activator-Induced Hemorrhage: A Case Report.
Tissue-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA and their protein expression levels in human decidua after early pregnancy termination by mifepristone plus misoprostol.
Uterine Neoplasms
[Detection of tumor markers in uterine cancer (plasminogen activators, plasminogen activator inhibitors) using fibrin autography]
Uveitis
Fibrin reaction after uveitic cataract surgery: treatment and prevention.
Regulation of anterior chamber fibrinolysis.
Use of intraocular human recombinant tissue plasminogen activator as an adjunct treatment of posterior synechiae in patients with uveitis.
Use of recombinant tissue plasminogen activator for treatment of recalcitrant anterior uveitis: A case series.
[TPA use in postoperator fibrinoid uveitis treatment]
Uveitis, Anterior
Use of recombinant tissue plasminogen activator for treatment of recalcitrant anterior uveitis: A case series.
Uveomeningoencephalitic Syndrome
Use of recombinant tissue plasminogen activator for treatment of recalcitrant anterior uveitis: A case series.
Vaccinia
Vaccinia expression of Mycobacterium tuberculosis-secreted proteins: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M. tuberculosis Ag85.
Varicocele
Plasminogen activator in cultured cells of human undescended testis.
Varicose Ulcer
Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
Expression of tissue-type and urokinase-type plasminogen activator activities in chronic venous leg ulcers.
Local treatment of venous ulcers with tissue type plasminogen activator containing ointment.
Tissue and urokinase plasminogen activators in the environs of venous and ischaemic leg ulcers.
Topically applied recombinant tissue plasminogen activator for the treatment of venous ulcers. Preliminary report.
Varicose Veins
Fibrinolytic parameters during acute haematemesis in endemic hepatosplenomegaly.
Pathogenesis of venous thromboembolism: when the cup runneth over.
PATHOPHYSIOLOGICAL AND ATHOMORPHOLOGICAL ASPECTS OF RELAPSE OF VARICOSE VEINS AFTER ENDOVASCULAR LASER VEIN COAGULATION.
Plasminogen activator inhibitor-1 levels in patients with primary varicose vein.
Serum concentration of procoagulant, endothelial and oxidative stress markers in early primary varicose veins.
Systemic thrombolysis of portal vein thrombosis in cirrhotic patients: A pilot study.
Vascular complications in Chuvash polycythemia.
[Ambulatory venous thromboembolitic disease. Clinical, etiological and evolutive data]
Vascular Calcification
Augmentation of phosphate-induced osteo-/chondrogenic transformation of vascular smooth muscle cells by homoarginine.
Vascular Diseases
Adipocytokines and metabolic syndrome.
Adipokines in diabetes and cardiovascular diseases.
Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome.
Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta.
Apolipoprotein B vs non-high-density lipoprotein cholesterol: Association with endothelial hemostatic markers and carotid intima-media thickness.
Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperinsulinemic states.
Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis.
Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease.
Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor.
Chemical Antagonists of Plasminogen Activator Inhibitor-1: Mechanisms of Action and Therapeutic Potential in Vascular Disease.
Cutting through the Complexities of mTOR for the Treatment of Stroke.
Delivery of tissue plasminogen activator and streptokinase magnetic nanoparticles to target vascular diseases.
Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNF alpha -induced PAI-1 expression.
Enhancement of PAI-1 mRNA in cardiovascular cells after kainate injection is mediated through the sympathetic nervous system.
Fibrinogen and fibrinolytic activity in CAPD patients with atherosclerosis and its correlation with serum albumin.
Fibrinolysis: a Misunderstood Natural Defense Whose Therapeutic Potential Is Unknown.
Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue.
High factor-VII activity in the elderly is related to vascular disease through activation of the coagulation system.
Homocysteine accelerates endothelial cell senescence.
In-vitro effect of oncostatin M on the release by endothelial cells of von Willebrand factor, tissue-type plasminogen activator and plasminogen activator inhibitor-1.
Increased plasma levels of plasminogen activator inhibitor-1 and soluble vascular cell adhesion molecule after triacylglycerol infusion in man.
Induction of vascular smooth muscle cell expression of plasminogen activator inhibitor-1 by thrombin.
Influence of homocysteine on fibrin network lysis.
Inhibition of plasminogen activator inhibitor-1 expression in vascular smooth muscle cells by protoporphyrins through a heme oxygenase-independent mechanism.
Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances.
Pathogenetic implications of hyaluronan-induced modification of vascular smooth muscle cell fibrinolysis in diabetes.
Phagocyte enzymes in bronchoalveolar lavage from patients with pulmonary sarcoidosis and collagen vascular disorders.
Plasminogen activator inhibitor type 1 in adults with Down syndrome and protection against macrovascular disease.
Plasminogen activator inhibitor-1 in cardiovascular cells: rapid induction after injecting mice with kainate or adrenergic agents.
Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment.
Plasminogen activator inhibitor-1 regulates myoendothelial junction formation.
Plasminogen activator system and vascular disease.
PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease.
Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease.
Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome.
Protein Microarrays for Quantitative Detection of PAI-1 in Serum.
Recombinant plasminogen activator inhibitor-1 inhibits intimal hyperplasia.
Regulatory mutations in human lipoprotein disorders and atherosclerosis.
Retroviral vector-mediated transfer and expression of human tissue plasminogen activator gene in human endothelial and vascular smooth muscle cells.
SIRT1-mediated epigenetic downregulation of plasminogen activator inhibitor-1 prevents vascular endothelial replicative senescence.
TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling.
The metabolic syndrome and adipocytokines.
The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease.
The role of fat topology in the risk of disease.
The Role of PAI-1 4G/5G Promoter Polymorphism and Its Levels in the Development of Ischemic Stroke in Young Indian Population.
Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease.
Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon.
Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: the EPICOR study.
Ultrasound-triggered thrombolysis using urokinase-loaded nanogels.
White adipose tissue and cardiovascular disease.
Young women with advanced aortoiliac occlusive disease: new insights.
[Disorders in the release of plasminogen activators]
[Effects of Danshen injection on the reserve of tissue plasminogen activator and nitric oxide in endothelium and vasodilatation in diabetic patients]
[Molecular mechanism in the development of the complications associated with obesity--the physiological and pathological role of adipocytokines]
Vascular Malformations
[Cerebrovascular malformation revealed during the prethrombolysis workup in acute ischemic stroke. Impact on therapeutic decision making.]
Vascular System Injuries
A 7-day administration of tPA or heparin in the prevention of intimal hyperplasia following vascular injury in atherosclerotic rabbits.
A biological model for the regulation of peri-implantational hemostasis and menstruation.
An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1.
Cilostazol inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor expression in artery wall and neointimal region after vascular injury.
Comparative Analysis of Different Methods of Ischemia/Reperfusion in Hyperglycemic Stroke Outcomes: Interaction with tPA.
Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion.
Damage-Associated Molecular Pattern and Fetal Membrane Vascular Injury and Collagen Disorganization in Lipopolysaccharide-Induced Intra-amniotic Inflammation in Fetal Sheep.
Effect of locally applied tissue-type plasminogen activator on venous fibrinolytic activity: in vitro and in vivo investigations.
Effects and mechanism of tissue-type plasminogen activator and plasminogen activator inhibitor on vascular smooth muscle cell proliferation.
Expression and intein-mediated purification of novel staphylokinase SakSTAR with reduced immunogenicity and antiplatelet and antithrombin activation.
Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes.
Gene transfer of the urokinase-type plasminogen activator receptor-targeted matrix metalloproteinase inhibitor TIMP-1.ATF suppresses neointima formation more efficiently than tissue inhibitor of metalloproteinase-1.
Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke.
In-vitro effect of oncostatin M on the release by endothelial cells of von Willebrand factor, tissue-type plasminogen activator and plasminogen activator inhibitor-1.
Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis.
Low-dose intraocular tissue plasminogen activator treatment for traumatic total hyphema, postcataract, and penetrating keratoplasty fibrinous membranes.
Metabolic endotoxaemia in childhood obesity.
Modulation of expression of monocyte/macrophage plasminogen activator activity and its implications for attenuation of vasculopathy.
Native atherosclerosis and vein graft arterialization: association with increased urokinase receptor expression in vitro and in vivo.
Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1).
Passivating Injured Endothelium with Kinexins in Thrombolytic Therapy.
Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice.
Plasminogen activator inhibitor-1 and its cofactor vitronectin stabilize arterial thrombi after vascular injury in mice.
Plasminogen activator inhibitor-1 from bone marrow-derived cells suppresses neointimal formation after vascular injury in mice.
Plasminogen activator system and vascular disease.
Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7.
Regulation of arterial remodeling and angiogenesis by urokinase-type plasminogen activator.
Serpins, the vasculature, and viral therapeutics.
Sputum Plasminogen Activator Inhibitor-1 Elevation by Oxidative Stress-Dependent Nuclear Factor-?B Activation in COPD.
The fibrin(ogen)olytic properties of cathepsin D.
Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase.
Vitamins C and E attenuate plasminogen activator inhibitor-1 (PAI-1) expression in a hypercholesterolemic porcine model of angioplasty.
Vasculitis
Coagulation abnormalities in rheumatoid disease.
Defective release of tissue plasminogen activator in systemic and cutaneous vasculitis.
Hemorrhagic conversion after alteplase administration in a patient with vasculitis and acute ischemic stroke.
Idiopathic interstitial pneumonia following stem cell transplantation.
Isolation of tissue plasminogen activator from skin lesions with allergic vasculitis.
Mesoglycan treatment restores defective fibrinolytic potential in cutaneous necrotizing venulitis.
Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease.
Vasospasm, Intracranial
A phase II clinical trial of recombinant human tissue-type plasminogen activator against cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm.
Acute haemorrhagic stroke.
Antisense preproendothelin-oligoDNA therapy for vasospasm in a canine model of subarachnoid hemorrhage.
Effect of clot removal and the different incidence of vasospasm between clipping and GDC.
Effect of tissue plasminogen activator on intimal platelet accumulation in cerebral arteries after subarachnoid hemorrhage in cats.
Efficacy of low-dose tissue-plasminogen activator intracisternal administration for the prevention of cerebral vasospasm after subarachnoid hemorrhage.
Efficacy of single intracisternal bolus injection of recombinant tissue plasminogen activator to prevent delayed cerebral vasospasm after experimental subarachnoid hemorrhage.
Influence of intraoperative using of recombinant tissue plasminogen activator on the development of cerebral angiospasm after subarachnoid haemorrhage in patients with ruptured intracranial aneurysms.
Intrathecal fibrinolysis using recombinant tissue plasminogen activator (rTPA) for prevention of cerebral vasospasm and delayed ischaemic deficits after aneurysmal subarachnoid haemorrhage. Experimental and clinical data.
Intrathecal fibrinolytic therapy after subarachnoid hemorrhage: dosage study in a primate model and review of the literature.
Phase I trial of tissue plasminogen activator for the prevention of vasospasm in patients with aneurysmal subarachnoid hemorrhage.
Prevention of vasospasm by clot removal and intrathecal bolus injection of tissue-type plasminogen activator: preliminary report.
Prospective study on the prevention of cerebral vasospasm by intrathecal fibrinolytic therapy with tissue-type plasminogen activator.
The effect of timing of intrathecal fibrinolytic therapy on cerebral vasospasm in a primate model of subarachnoid hemorrhage.
The effect of tissue plasminogen activator (t-PA) on cerebral vasospasm in canine subarachnoid hemorrhage.
[Application of alteplase in prevention of cerebral vasospasm and its sequelae in patients after aneurysmal subarachnoid hemorrhage from ruptured cerebral aneurysm]
[Preliminary clinical trial of intrathecal rt-PA (TD-2061) for the prevention of cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage]
[Prevention of cerebral vasospasm with tissue plasminogen activator]
Venous Insufficiency
Fibrinolytic activity of the arms and legs of patients with lower limb venous disease.
Leg ulcers in Klinefelter's syndrome--further evidence for an involvement of plasminogen activator inhibitor-1.
Modulation of urokinase-type and tissue-type plasminogen activator occurs at an early stage of progressing stages of chronic venous insufficiency.
Type I Plasminogen Activator Inhibitor 4G Allele Frequency is Associated with Chronic Venous Insufficiency.
Venous Thromboembolism
A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency.
A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism.
A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects.
A new short infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease.
A specific immunologic assay for functional plasminogen activator inhibitor 1 in plasma--standardized measurements of the inhibitor and related parameters in patients with venous thromboembolic disease.
Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis.
Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis.
Bolus thrombolysis in venous thromboembolism.
Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York.
Clinical efficacy of low dose recombinant tissue-type plasminogen activator for the treatment of acute intermediate-risk pulmonary embolism.
Clinical utility of biomarkers of endothelial activation and coagulation for prognosis in HIV infection: A systematic review.
Comparison of the plasminogen activator inhibitor-1 4G/5G gene polymorphism in females with venous thromboembolism during pregnancy or spontaneous abortion.
Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism.
Factor V Leiden, prothrombin 20210G --> A, methylenetetrahydrofolate reductase 677C --> T and plasminogen activator inhibitor 4G/5G polymorphism in women with pregnancy-related venous thromboembolism.
Familial association of high levels of histidine-rich glycoprotein and plasminogen activator inhibitor-1 with venous thromboembolism.
Genetic association between plasminogen activator inhibitor-1 rs1799889 polymorphism and venous thromboembolism: Evidence from a comprehensive meta-analysis.
Half-Dose Recombinant Tissue Plasminogen Activator Treatment in Venous Thromboembolism.
High factor VIII activity, high plasminogen activator inhibitor 1 antigen levels and low factor XII activity contribute to a thrombophilic tendency in elderly venous thromboembolism patients.
In patients with deep-vein thrombosis elevated levels of factor VIII correlate only with von Willebrand factor but not other endothelial cell-derived coagulation and fibrinolysis proteins.
Influence of the -675 4G/5G dimorphism of the plasminogen activator inhibitor 1 promoter on thrombotic risk in patients with factor V Leiden.
Is tissue-plasminogen activator gene polymorphism a risk factor for venous thromboembolism in every population?
Nonalcoholic steatohepatitis Fitness Intervention in Thrombosis (NASHFit): Study protocol for a randomized controlled trial of a supervised aerobic exercise program to reduce elevated clotting risk in patients with NASH.
Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism - a meta-analysis and systematic review.
Principles for diagnosis and treatment of pulmonary embolism.
Prospective, randomised, controlled study on the efficacy and safety of different strategies of tranexamic acid with total blood loss, blood transfusion rate and thrombogenic biomarkers in total knee arthroplasty: study protocol.
Prothrombotic risk factors in children with spontaneous venous thrombosis and their asymptomatic parents: a family study.
Successful administration of alteplase in a venous thromboembolism crossing through a patent foramen ovale.
The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.
The relationship between the tissue plasminogen activator Alu I/D polymorphism and venous thromboembolism during pregnancy.
The role of plasminogen activator inhibitor-1 polymorphism, factor-v-leiden, and prothrombin-20210 mutations in pulmonary thromboembolism.
[Fibrinolysis and vascular diseases]
[The investigation of angiotensin converting enzyme I/D and plasminogen activator inhibitor-1 4G/5G polymorphisms in venous thromboembolism patients].
Venous Thrombosis
A family with reduced plasminogen activator activity in blood associated with recurrent venous thrombosis.
A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis.
A plasma clot lysis assay based on the release of fibrin degradation products: application to the diagnosis of hypofibrinolytic states.
Absence of antibodies to tissue-type plasminogen activator in patients with previous deep vein thrombosis.
Absence of potentiation with murine antiplatelet GPIIb/IIIa antibody of thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) in a canine venous thrombosis model.
Accelerating thrombolysis using a precision and clot-penetrating drug delivery strategy by nanoparticle-shelled microbubbles.
ACTA2 Mutation: Microsurgeon Beware!
Aging of acute deep vein thrombosis measured by radiolabeled 99mTc-rt-PA.
Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.
Alteplase: descendancy in myocardial infarction, ascendancy in stroke.
Are Quality Improvements in the Get With The Guidelines-Stroke Program Related to Better Care or Better Data Documentation?
Are Racial Disparities in Stroke Care Still Prevalent in Certified Stroke Centers?
Arm-cranking Exercise Training Reduces Plasminogen Activator Inhibitor 1 in People with Spinal Cord Injury.
Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men.
Association between plasma levels of tissue plasminogen activator and postoperative deep vein thrombosis--influence of prophylaxis with a low molecular weight heparin. The Venous Thrombosis Group.
Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis.
Association of 4G/5G polymorphism in PAI1 promoter with PAI1 level in deep vein thrombosis.
Association of protein S deficiency with thrombosis in a kindred with increased levels of plasminogen activator inhibitor-1.
Autoantibodies to receptor induced neoepitopes of fibrinolytic proteins in rheumatic and vascular diseases.
Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor.
Benchmarks and determinants of adherence to stroke performance measures.
Biochemical dynamics relevant to the safety of low-dose, intraclot alteplase for deep vein thrombosis.
Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer.
Blood coagulation studies in 45 patients with ischemic cerebrovascular disease and 44 patients with venous thromboembolic disease.
Bolus thrombolysis in venous thromboembolism.
Cardiac findings and long-term thromboembolic outcomes following pulmonary embolism in children: a combined retrospective-prospective inception cohort study.
Catheter-directed thrombolysis in deep venous thrombosis with use of reteplase: immediate results and complications from a pilot study.
Catheter-directed thrombolysis of inferior vena cava thrombosis in a 13-day-old neonate and review of literature.
Catheter-Directed Thrombolysis With a Continuous Infusion of Low-Dose Alteplase for Subacute Proximal Venous Thrombosis: Efficacy and Safety Compared to Urokinase.
Catheter-directed thrombolysis with tPA to restore renal function after iliac venous thrombosis post-renal transplantation.
Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York.
Clinical features and molecular analysis of a family with multiple colon tumours and reduced plasminogen activator activity.
Cloning and expression of functional full-length human tissue plasminogen activator in Pichia pastoris.
Coagulation, fibrinolysis, and recanalization after acute deep venous thrombosis.
Comparative effects of enoxaparin and heparin on arterial and venous clot lysis with alteplase in dogs.
Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis.
Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis.
COVID-19 and Stroke: Casual or Causal Role?
Daily catheter-directed single dosing of t-PA in treatment of acute deep venous thrombosis of the lower extremity.
Decreased Plasma Fibrinolytic Potential As a Risk for Venous and Arterial Thrombosis.
Deep cerebral venous thrombosis and hereditary tissue plasminogen activator (t-PA) deficiency.
Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator release.
Deep vein thrombosis of lower extremity: direct intraclot injection of alteplase once daily with systemic anticoagulation--results of pilot study.
Deficient tissue plasminogen activator release and normal tissue plasminogen activator inhibitor in a patient with recurrent deep vein thrombosis.
Detection of deep venous thrombosis with indium 111-labelled monoclonal antibody against tissue plasminogen activator.
Detection of genomic polymorphisms associated with venous thrombosis using the invader biplex assay.
Detection of postoperative deep-venous thrombosis using technetium-99m-labeled tissue plasminogen activator.
Does low protein concentration of tissue-type plasminogen activator predict a low risk of spontaneous deep vein thrombosis?
Double-blind, randomized comparison of systemic continuous infusion of 0.25 versus 0.50 mg/kg/24 h of alteplase over 3 to 7 days for treatment of deep venous thrombosis in heparinized patients: results of the European Thrombolysis with rt-PA in Venous Thrombosis (ETTT) trial.
Dual-reporter high-throughput screen for small-molecule in vivo inhibitors of plasminogen activator inhibitor type-1 yields a clinical lead candidate.
Dysfunction in the coagulation system and schizophrenia.
Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV1691 G-A.
Effects of oral stanozolol used in the prevention of postoperative deep vein thrombosis on fibrinolytic activity.
Efficacy and safety of recombinant tissue plasminogen activator for venous thrombosis after paediatric heart surgery.
Endovascular thrombolysis for pediatric cerebral sinus venous thrombosis with tissue plasminogen activator and abciximab.
Enhanced Thrombolysis by Ultrasound-Assisted Catheter-Directed Thrombolysis and Microbubbles in an In Vitro Model of Iliofemoral Deep Vein Thrombosis.
Evaluation of epithelial tissue plasminogen activator as a thrombolytic agent in a rabbit model of venous thrombosis.
Evaluation of thrombolysis using tissue plasminogen activator in lower extremity deep venous thrombosis with concomitant femoral-popliteal venous segment involvement.
Evidence that postoperative fibrinolytic shutdown is mediated by plasma factors that stimulate endothelial cell type I plasminogen activator inhibitor biosynthesis.
Familial association of high levels of histidine-rich glycoprotein and plasminogen activator inhibitor-1 with venous thromboembolism.
Familial clustering of defective release of t-PA.
Feasibility of low-dose infusion of alteplase for unsuccessful thrombolysis with urokinase in deep venous thrombosis.
Fibrinolysis and the risk of venous and arterial thrombosis.
Fibrinolysis with intrathrombic injection of urokinase and tissue-type plasminogen activator. Results in a new model of subacute venous thrombosis.
Fibrinolytic therapy of deep vein thrombosis with continuous intravenous infusion of a recombinant tissue plasminogen activator.
Free flap salvage with subcutaneous injection of tissue plasminogen activator in head and neck patients.
Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis.
G4120, an Arg-Gly-Asp containing pentapeptide, enhances arterial eversion graft recanalization with recombinant tissue-type plasminogen activator in dogs.
Gemfibrozil predictably lowers triglycerides but does not significantly change plasminogen activator inhibitor activity in hypertriglyceridemic patients with a history of thrombosis.
Gene polymorphisms of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with antiphospholipid antibodies.
Genetics of coagulation factors in acute lung injury.
Hemostatic changes and postoperative deep-vein thrombosis associated with use of a pneumatic tourniquet.
Heparin-induced thrombocytopenia: a critical risk/benefit analysis of patients in intensive care treated with R-hirudin.
Homocystinuria with Cerebral Venous Sinus Thrombosis: Excellent Recovery with Intravenous Recombinant Tissue Plasminogen Activator.
How to select patients with deep vein thrombosis for tPA therapy.
Immunohistochemical detection of uPA, tPA, and PAI-1 in a stasis-induced deep vein thrombosis model and its application to thrombus age estimation.
Impact of acute phase on concentrations of tissue plasminogen activator and plasminogen activator inhibitor in plasma after deep-vein thrombosis or open-heart surgery.
Incidence of increased plasminogen activator inhibitor in patients with deep venous thrombosis and/or pulmonary embolism.
Increased concentration of the fast-acting plasminogen activator inhibitor in plasma associated with familial venous thrombosis.
Influence of decreased fibrinolytic activity and plasminogen activator inhibitor-1 4G/5G polymorphism on the risk of venous thrombosis.
Intermittent regional therapy with rt-PA is not superior to systemic thrombolysis in deep vein thrombosis (DVT)--a German multicenter trial.
Intra-arterial tissue plasminogen activator: an effective adjunct following microsurgical venous thrombosis.
Intraclot recombinant tissue plasminogen activator in the treatment of deep venous thrombosis of the lower and upper extremities.
Intraventricular hemorrhage in a full-term neonate associated with sinus venous thrombosis and homozygosity for the plasminogen activator inhibitor-1 4G/4G polymorphism.
Investigation of Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G promoter polymorphism in Indian venous thrombosis patients: A case-control study.
Islet autotransplantation in a patient with hypercoagulable disorder.
Late results of catheter-directed recombinant tissue plasminogen activator fibrinolytic therapy of iliofemoral deep venous thrombosis.
Latex D-dimer signal in in situ femoral vein thrombus in swine and effect of minidose exogenous tissue plasminogen activator bolus.
Local injection of tissue-plasminogen activator using a pulse spray catheter as a treatment option for proximal deep vein thrombosis: A case report.
Long-term stability of recombinant tissue plasminogen activator at -80 C.
Low-dose, once-daily, intraclot injections of alteplase for treatment of acute deep venous thrombosis.
Major and potential prothrombotic genotypes in patients with venous thrombosis and in healthy subjects from Slovenia.
Mesenteric vein thrombosis and vascular plasminogen activator.
Moyamoya disease and sagittal sinus thrombosis in a child with Down's syndrome.
Multicenter pilot study of the efficacy and safety of systemic rt-PA administration in the treatment of deep vein thrombosis of the lower extremities and/or pelvis.
Newer thrombolytic drugs for acute myocardial infarction.
No evidence for plasminogen activator inhibitor 1 4G/4G genotype as risk factor for cerebral venous thrombosis.
Non-invasive imaging techniques for the differentiation of acute and chronic thrombosis.
Novel bis-arylsulfonamides and aryl sulfonimides as inactivators of plasminogen activator inhibitor-1 (PAI-1).
Observations on optimal conditions for lysis of whole blood clots and use of this assay as a screening assay in clinical investigation.
PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects.
Paradoxical Brain Embolism Caused by Isolated Pulmonary Arteriovenous Fistula Successfully Treated with Recombinant Tissue Plasminogen Activator.
Pathophysiology of the plasminogen/plasmin system.
Patient-Level and Hospital-Level Determinants of the Quality of Acute Stroke Care. A Multilevel Modeling Approach.
Paul Coverdell National Acute Stroke Registry Surveillance - four states, 2005-2007.
Pharmacokinetics of pulse-sprayed recombinant tissue plasminogen activator for deep venous thrombosis.
Pharmacokinetics of tissue plasminogen activator in an isolated extracorporeal circuit.
Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis.
Pharmacomechanical thrombectomy of acute deep vein thrombosis with the Trellis-8 isolated thrombolysis catheter.
Pharmacomechanical thrombolysis and early stent placement for iliofemoral deep vein thrombosis.
Plasminogen activator activity of superficial veins in acute deep venous thrombosis.
Plasminogen activator inhibitor (PA-inhibitor) activity in the blood of patients with deep vein thrombosis.
Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer.
Plasminogen activator inhibitor 1 in thrombotic disease.
Plasminogen Activator Inhibitor-1 (PAI-1) Gene 4G/5G Promoter Polymorphism is Seen in Higher Frequency in the Indian Patients With Deep Vein Thrombosis.
Plasminogen activator inhibitor-1 4G/5G genotype and residual venous occlusion following acute unprovoked deep vein thrombosis of the lower limb: A prospective cohort study.
Plasminogen activator inhibitor-1 gene promoter 4G/5G polymorphism and risks of peripherally inserted central catheter-related venous thrombosis in patients with lung cancer: a prospective cohort study.
Plasminogen activator inhibitor-1: a risk factor for deep vein thrombosis after total hip arthroplasty.
Plasminogen activator inhibitors in plasma and platelets from patients with recurrent venous thrombosis and pregnant women.
Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor--relationship to deep vein thrombosis and influence of prophylaxis.
Postoperative deep vein thrombosis and plasma levels of tissue plasminogen activator inhibitor.
Postoperative venous thromboembolism and brain tumors: Part III. Biochemical profile.
Postthrombotic syndrome: a 2014 update.
PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease.
Predictive value for thrombotic disease of plasminogen activator inhibitor-1 plasma levels.
Prevention and treatment of the post-thrombotic syndrome and of the chronic thromboembolic pulmonary hypertension.
Promotor polymorphisms of plasminogen activator inhibitor-1 and other thrombophilic genotypes in cerebral venous thrombosis: a case-control study in adults.
Properties of a novel plasminogen activator (BM 06.022) produced in Escherichia coli.
Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes.
Racial-Ethnic Disparities in Acute Stroke Care in the Florida-Puerto Rico Collaboration to Reduce Stroke Disparities Study.
Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis.
Recombinant tissue plasminogen activator treatment of pulmonary embolism also improves deep venous thrombosis.
Relationships between tissue plasminogen activator, steroid hormones and deep vein thrombosis.
Release of tissue plasminogen activator and its fast-acting inhibitor in defective fibrinolysis.
Remaining perspectives of mutant and chimeric plasminogen activators.
Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator.
Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: a study in 83 patients with confirmed deep vein thrombosis.
Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
Risk factors for peripherally inserted central catheter line-related deep venous thrombosis in critically ill intensive care unit patients.
Role and mechanism of tissue plasminogen activator in venous wall fibrosis remodeling after deep venous thrombosis via the glycogen synthase kinase-3 beta signaling pathway.
Shape anisotropic magnetic thrombolytic actuators: synthesis and systematic behavior study.
Study of recombinant antibody fragments and PAI-1 complexes combining protein-protein docking and results from site-directed mutagenesis.
Subcellular localization of radioactively labelled defibrotide in cultured endothelial cells.
Successful free flap salvage surgery with off-label use of Alteplase: A case report, review of the literature and our free flap salvage algorithm.
Successful intravascular ultrasound thrombolysis of dural sinus thrombosis with pre-existing subarachnoid and intraparenchymal hemorrhages.
Technetium-99m-modified recombinant tissue plasminogen activator to detect deep venous thrombosis.
The impact of the fibrinolytic system on the risk of venous and arterial thrombosis.
The muscle as a possible source of plasminogen activator to the blood and their therapeutic implication in the prevention of deep vein thrombosis.
The predictive value of plasminogen activator inhibitor-1, fibrinogen, and D-dimer for deep venous thrombosis following surgery for traumatic lower limb fracture.
The response of the vessel wall to thrombosis: the in vivo study of venous thrombolysis.
The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis.
The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.
The Stroke Practice Improvement Network: a quasiexperimental trial of a multifaceted intervention to improve quality.
Thrombolysis for lower extremity deep venous thrombosis.
Thrombolysis in venous thromboembolism. An international perspective.
Thrombolysis with recombinant tissue-type plasminogen activator in renal venous thrombosis in infancy.
Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Thrombolytic effect after sequential double-bolus administration of tissue plasminogen activator and urokinase-fibrinogen conjugate into dogs with venous thrombosis.
Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.
Thrombolytic therapy for deep venous thrombosis?
Thrombolytic therapy in pregnancy.
Thrombotic Storm in a Teenager With Previously Undiagnosed Ulcerative Colitis.
Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial.
Tissue plasminogen activator concentrations in major abdominal surgery. Relationship to postoperative deep vein thrombosis.
Tissue plasminogen activator for the treatment of deep venous thrombosis of the lower extremity: a systematic review.
Tissue plasminogen activator production by monocytes in venous thrombolysis.
Tissue plasminogen activator therapy for renal venous thrombosis.
Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor.
Transvenous Catheter-Based Thrombolysis With Continuous Tissue Plasminogen Activator Infusion for Refractory Thrombosis in a Patient With Behcet's Disease.
Treatment of deep cerebral venous thrombosis by local infusion of tissue plasminogen activator.
Treatment of high-risk venous thrombosis patients using low-dose intraclot injections of recombinant tissue plasminogen activator and regional anticoagulation.
Treatment of portal venous thrombosis with selective superior mesenteric artery infusion of recombinant tissue plasminogen activator.
Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor.
Ultrasound-enhanced tissue plasminogen activator thrombolysis in an in vitro porcine clot model.
Unexpected Pulseless Disease Associated With Recurrent Venous Thromboembolisms.
Use of a Trellis Device for Endovascular Treatment of Venous Thrombosis Involving a Duplicated Inferior Vena Cava.
Usefulness of catheter-directed thrombolysis using alteplase in peripheral vascular occlusion.
Vascular plasminogen activator and deep vein thrombosis.
Venous and arterial thromboembolic disease in women using oral contraceptives.
Venous thrombolysis by tissue-type plasminogen activator in conjunction with the urokinase-fibrinogen covalent conjugate. Effects of potentiation and faster action in dogs.
Venous thrombosis and tissue plasminogen activator release deficiency: a family study.
Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand's factor.
Vocal cord haematoma after tenecteplase thrombolysis.
[Activator treatment of acute venous thrombosis (author's transl)]
[Acute deep vein thrombosis of lower limbs treated by thrombolytic therapy with recombinant tissue-type plasminogen activator]
[Catheter-directed thrombolysis of iliofemoral venous thrombosis]
[Deep venous thrombosis; a transient decrease of tissue-type plasminogen activator (t-PA) in the blood]
[Development of new laboratory technics based on monoclonal antibodies in the diagnosis of deep venous thrombosis and in the evaluation of the systemic effects of thrombolytic treatment with tissue-type plasminogen activator]
[Disorders in the release of plasminogen activators]
[Disorders of fibrinolysis and thrombophilic states, risk factors and possibilities of dietary effects]
[Disorders of the liberation of tissue-type plasminogen activator (t-PA) from the venous wall as a cause for recurrent thromboses]
[Hemostatic status in subjects with deep venous thrombosis]
[Ilio-femoral vein thrombosis treated with tissue plasminogen activator in a pregnant woman]
[Local thrombolytic treatment of deep vein thrombosis with small doses of plasminogen activator]
[Loco-regional thrombolysis in deep venous thrombosis]
[Locoregional thrombolytic therapy of deep venous thromboses]
[Non-enzymatic fibrinolytic agents]
[Nursing care of patients with deep venous thrombosis of the lower extremities treated with rt-PA]
[Pharmacogenetics of the local thrombolysis in patients with deep vein thrombosis]
[Phlebothrombosis and congenital thrombophilia].
[Post-phlebitic leg ulcers and XYY karyotype: fibrinolysis and androgenic function tests. Apropos of 3 cases]
[Study of hemostatic molecular marker]
[Successful partial lysis of a 4-level-thrombosis by rt-PA - case report]
[Thrombolysis with rt-PA in children with arterial and venous thromboses--a new therapy concept]
[Thrombolytic therapy in deep venous thrombosis. Initial clinical experience]
[Thrombolytic therapy of deep venous thrombosis with rt-PA]
[Thrombolytic therapy using a low dose of tissue plasminogen activator in children].
[Value of thrombolytic therapy in deep venous thrombosis]
Ventilator-Induced Lung Injury
Captopril decreases plasminogen activator inhibitor-1 in rats with ventilator-induced lung injury.
Plasminogen activator inhibitor-type I gene deficient mice show reduced influx of neutrophils in ventilator-induced lung injury.
Tissue plasminogen activator attenuates ventilator-induced lung injury in rats.
Ventricular Dysfunction
Current theories and therapies relating to acute myocardial infarction and reperfusion injury.
Myocardial Production of Plasminogen Activator Inhibitor-1 is Associated with Coronary Endothelial and Ventricular Dysfunction after Acute Myocardial Infarction.
Ventricular Dysfunction, Left
Does long-term angiotensin converting enzyme inhibition affect the concentration of tissue-type plasminogen activator-plasminogen activator inhibitor-1 in the blood of patients with a previous myocardial infarction.
Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction.
Ventricular Dysfunction, Right
Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activator.
Effect of enoxaparin on plasma fibrin clot properties and fibrin structure in patients with acute pulmonary embolism.
Effectiveness and cost effectiveness of thrombolysis in patients with acute pulmonary embolism.
Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism.
Instructive ECG series in massive bilateral pulmonary embolism.
Rescue therapy with thrombolysis in patients with severe COVID-19-associated acute respiratory distress syndrome.
Ventricular Fibrillation
A double blind placebo controlled study of early and late administration of recombinant tissue plasminogen activator in acute myocardial infarction.
A randomised dose ranging study of recombinant tissue plasminogen activator in acute myocardial infarction.
Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3 Investigators.
Bolus thrombolytic infusions during CPR for patients with refractory arrest rhythms: outcome of a case series.
Large emboli on their way through the heart - first live demonstration of large paradoxical embolisms through a patent foramen ovale.
Lessons from the European Cooperative recombinant tissue-type plasminogen activator (rt-PA) versus placebo trial.
Plasminogen activator inhibitor-1 (PAI-1), toll-like receptor 4 (TLR4), factor II (FII), FXIII and fibrinogen polymorphisms are not associated with the prevalence of sudden death due to ventricular fibrillation during myocardial infarction.
Translational research in acute central nervous system injury: lessons learned and the future.
Ventricular arrhythmias during treatment with alteplase (recombinant tissue plasminogen activator) in suspected acute myocardial infarction.
Ventricular Premature Complexes
Importance of ST-segment depression as a determinant of ventricular premature complex frequency after thrombolysis for acute myocardial infarction. Tissue Plasminogen Activator: Toronto (TPAT) Study Group.
Ventricular arrhythmias during treatment with alteplase (recombinant tissue plasminogen activator) in suspected acute myocardial infarction.
Vertebral Artery Dissection
Locked in and out: a case of emerging basilar artery obstruction secondary to vertebral artery dissection thrombolysed with intravenous rt-PA.
Successful treatment of basilar artery thrombosis with both heparin and tissue plasminogen activator in the setting of traumatic vertebral artery dissection.
The Use of Tissue Plasminogen Activator in the Treatment of Wallenberg Syndrome Caused by Vertebral Artery Dissection.
Thrombectomy using Trevo ProVue Stent Retriever Devices after Recombinant Tissue Plasminogen Activator Thrombolysis for Acute Basilar Artery Occlusion during Vertebral Artery Dissection.
Tissue plasminogen activator in a vertebral artery dissection.
Vertebrobasilar Insufficiency
Successful Treatment of Recurrent Basilar Artery Occlusion with Intra-Arterial Thrombolysis and Vertebral Artery Coiling in a Child.
Vesicular Stomatitis
Multiple preprosomatostatin sorting signals mediate secretion via discrete cAMP- and tetradecanoylphorbolacetate-responsive pathways.
The priming effect of human interferon-alpha is mediated by protein kinase C.
Viremia
Ebola Hemorrhagic Fever: Novel Biomarker Correlates of Clinical Outcome.
Virus Diseases
Coagulation factors, fibrinogen and plasminogen activator inhibitor-1, are differentially regulated by yellow fever virus infection of hepatocytes.
Effects of baculovirus infection on IE1-mediated foreign gene expression in stably transformed insect cells.
Elevation of Plasminogen Activator Inhibitor-1 promotes differentiation of Cancer Stem-like Cell state by Hepatitis C Virus infection.
Factors affecting human cytomegalovirus gene expression in human monocyte cell lines.
Influence of plasminogen activator inhibitor-1 (SERPINE1) 4G/5G polymorphism on circulating SERPINE-1 antigen expression in HCC associated with viral infection.
Interactions between adenovirus, a tumor promoter, and chemical carcinogens in transformation of rat embryo cell cultures.
Production of plasminogen activator by synchronized normal and Rous sarcoma virus-transformed chicken fibroblasts in culture.
Synthetic peptides from the principal neutralizing domain of human immunodeficiency virus type 1 (HIV-1) enhance HIV-1 infection through a CD4-dependent mechanism.
Tissue plasminogen activator induced by dengue virus infection of human endothelial cells.
TPA can overcome the requirement for EIa and together act synergistically in stimulating expression of the adenovirus EIII promoter.
Vision Disorders
Health inequalities with the National Statistics-Socioeconomic classification: disease risk factors and health in the 1958 British birth cohort.
Vitamin D Deficiency
Interactions between and Shared Molecular Mechanisms of Diabetic Peripheral Neuropathy and Obstructive Sleep Apnea in Type 2 Diabetes Patients.
Vitiligo
Functionally stable plasminogen activator inhibitor-1 in a family with cardiovascular disease and vitiligo.
Vitreoretinopathy, Proliferative
Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders.
Tissue plasminogen activator for postvitrectomy fibrin formation.
Vitreous Detachment
Enzymatic vitreolysis with recombinant microplasminogen and tissue plasminogen activator.
Induction of Posterior Vitreous Detachment in Pediatric Vitrectomy by Preoperative Intravitreal Injection of Tissue Plasminogen Activator.
Induction of posterior vitreous detachment in rabbits by intravitreal injection of tissue plasminogen activator following cryopexy.
Intravitreal functional plasminogen in eyes with branch retinal vein occlusion.
Intravitreal functional plasminogen is elevated in central retinal vein occlusion.
Intravitreal tissue plasminogen activator to treat refractory diabetic macular edema by induction of posterior vitreous detachment.
Role of posterior vitreous detachment induced by intravitreal tissue plasminogen activator in macular edema with central retinal vein occlusion.
The effect of tissue plasminogen activator on premacular hemorrhage.
Vitreous Hemorrhage
A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits.
Intravitreal tissue plasminogen activator treatment of experimental vitreous hemorrhage.
Management of postvitrectomy diabetic vitreous hemorrhage with tissue plasminogen activator (t-PA) and volume homeostatic fluid-fluid exchanger.
Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator.
Repetitive low-dose tissue plasminogen activator for the clearance of experimental vitreous hemorrhage.
Repetitive, low-dose tissue plasminogen activator for clearance of experimental vitreous hemorrhage.
Risk factors for breakthrough vitreous hemorrhage after intravitreal tissue plasminogen activator and gas injection for submacular hemorrhage associated with age related macular degeneration.
Successful displacement of a traumatic submacular hemorrhage in a 13-year-old boy treated by vitrectomy, subretinal injection of tissue plasminogen activator and intravitreal air tamponade: a case report.
The effect of tissue plasminogen activator on premacular hemorrhage.
The use of tissue plasminogen activator in postvitrectomy cases.
Tissue plasminogen activator in the treatment of vitreoretinal diseases.
Treatment of experimental vitreous hemorrhage with tissue plasminogen activator.
Treatment of total hyphema with relatively low-dose tissue plasminogen activator.
Vitreous hemorrhage after intravitreal tissue plasminogen activator (t-PA) and pneumatic displacement of submacular hemorrhage.
VITREOUS HEMORRHAGE COMPLICATING INTRAVITREAL TISSUE PLASMINOGEN ACTIVATOR AND PNEUMATIC DISPLACEMENT OF SUBMACULAR HEMORRHAGE.
[Treatment of intraocular fibrin formation with tissue plasminogen activator after vitrectomy]
[Vitreous hemorrhage after vitrectomy in diabetic retinopathy and tissue plasminogen activator]
von Willebrand Diseases
Absence of functional activity of tissue plasminogen activator in patients with severe forms of von Willebrand's disease.
Acquired von Willebrand's syndrome associated with decrease of plasminogen activator and its inhibitor during hypothyroidism.
Endothelial stimulation by DDAVP in von Willebrand's disease and haemophilia.
Factor VII and fibrinolytic response to deamino-8-D-argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease.
Impaired release of tissue plasminogen activator (t-PA) following DDAVP infusion in von Willebrand's disease with low platelet von Willebrand factor content.
Plasma levels of plasminogen activator inhibitor-1 and bleeding phenotype in patients with von Willebrand disease.
Studies of the blood plasminogen activator induced by 1-desamino-8-D-arginine vasopressin with observations in von Willebrand's disease.
von Willebrand factor: clinical features of inherited and acquired disorders.
Vulvar Neoplasms
Serum concentrations of squamous-cell carcinoma antigen and tissue polypeptide antigen in the follow-up of patients with vulvar cancer.
Serum concentrations of tissue polypeptide antigen in patients with vulvar intraepithelial neoplasia and vulvar cancer.
Werner Syndrome
ACE, PAI-1, decorin and Werner helicase genes are not associated with the development of renal disease in European patients with type 1 diabetes.
Increased blood plasminogen activator inhibitor-1 and intercellular adhesion molecule-1 as possible risk factors of atherosclerosis in Werner syndrome.
Overexpression of plasminogen activator inhibitor type-1 in senescent fibroblasts from normal subjects and those with Werner syndrome.
WRN polymorphisms affect expression levels of plasminogen activator inhibitor type 1 in cultured fibroblasts.
White Coat Hypertension
The plasma levels of plasminogen activator inhibitor-1 in subjects with white coat hypertension.
Whooping Cough
Activation of the {beta}-catenin/T-cell-specific transcription factor/lymphoid enhancer factor-1 pathway by plasminogen activators in ECV304 carcinoma cells.
Attenuation of opioid receptor activity by phorbol esters in neuroblastoma x glioma NG108-15 hybrid cells.
Bradykinin induces the bi-phasic production of lysophosphatidyl inositol and diacylglycerol in a dorsal root ganglion X neurotumor hybrid cell line, F-11.
Different roles for Gi and Go proteins in modulation of adenylyl cyclase type-2 activity.
Different sensitivity to phorbol esters and pertussis toxin of bombesin- and platelet-derived growth factor-induced, phospholipase C-mediated hydrolysis of phosphoinositides in NIH/3T3 cells.
Dopamine D(2) receptor-induced COX-2-mediated production of prostaglandin E(2) in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent.
Early PDGF-induced alterations in cytosolic free calcium are required for mitogenesis.
Effect of trifluoperazine on renal epithelioid Madin-Darby canine kidney cells.
Effects of protein kinase C activation on cyclic AMP and testosterone production of rat Leydig cells in vitro.
Enhancement of adenylate cyclase activity in S49 lymphoma cells by phorbol esters. Withdrawal of GTP-dependent inhibition.
Facilitative actions of the protein kinase-C effector system on hormonally stimulated adenosine 3',5'-monophosphate production by swine luteal cells.
Further analysis of ATP-mediated activation of K+ channels in renal epithelioid Madin Darby canine kidney (MDCK) cells.
IL-3 stimulated haemopoietic stem cell proliferation: evidence for G protein independent mitogenic signalling events.
Insulin-like growth factor II inhibits glucose-induced insulin exocytosis.
Involvement of calcium and G proteins in the acute release of tissue-type plasminogen activator and von Willebrand factor from cultured human endothelial cells.
Lipopolysaccharide response is linked to the GTP binding protein, Gi2, in the promonocytic cell line U937.
Mechanism of N-formyl-methionyl-leucyl-phenylalanine- and platelet-activating factor-induced arachidonic acid release in guinea pig alveolar macrophages: involvement of a GTP-binding protein and role of protein kinase A and protein kinase C.
Modulation of adenylate cyclase in human keratinocytes by protein kinase C.
Modulation of islet G-proteins, alpha-glucosidehydrolase inhibition and insulin release stimulated by various secretagogues.
Multiple defects occur in the guanine nucleotide regulatory protein system in liver plasma membranes of obese (fa/fa) but not lean (Fa/Fa) Zucker rats: loss of functional Gi and abnormal Gs function.
Multiple effects of phorbol ester on secretory activity in rabbit gastric glands and parietal cells.
P2Y receptor-mediated Ca2+ signalling in cultured rat aortic smooth muscle cells.
Pertussis toxin inhibits induction of human immunodeficiency virus type 1 in infected monocytes.
Phorbol ester and phospholipase C-induced growth hormone secretion from pituitary somatotroph adenoma cells in culture: effects of somatostatin, bromocriptine, and pertussis toxin.
Phorbol ester modulation of cyclic AMP accumulation in a primary culture of rat aortic smooth muscle cells.
Phorbol ester regulates stimulatory and inhibitory pathways of the hormone-sensitive adenylate cyclase system in rat reticulocytes.
Plasma membrane associated phospholipase C from human platelets: synergistic stimulation of phosphatidylinositol 4,5-bisphosphate hydrolysis by thrombin and guanosine 5'-O-(3-thiotriphosphate).
Platelet-derived growth factor and angiotensin II cause increases in cytosolic free calcium by different mechanisms in vascular smooth muscle cells.
Protein kinase C activation and positive and negative agonist regulation of 3',5'-cyclic adenosine monophosphate levels in cultured rat Sertoli cells.
Protein kinase C activation mimics but does not mediate thyrotropin-induced desensitization of adenylyl cyclase in cultured dog thyroid cells.
Protein kinase C and Gi-protein mediated modulation of cAMP production in different stages of the rat seminiferous epithelium.
Protein kinase C inhibits cyclic adenosine monophosphate generation by histamine and truncated glucagon like peptide 1 in the human gastric cancer cell line HGT-1.
Ras/MAP kinase-dependent and -independent signaling pathways target distinct ternary complex factors.
Sensitization of adrenocortical cell adenylate cyclase activity to ACTH by angiotensin II and activators of protein kinase C.
Studies on the mechanisms of signalling and inhibition by pertussis toxin of fibroblast growth factor-stimulated mitogenesis in Balb/c 3T3 cells.
The inhibitory GTP-binding protein (Gi) occurs in rat Leydig cells and is differentially modified by lutropin and 12-O-tetradecanoylphorbol 13-acetate.
The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue-type plasminogen activator.
Tissue-type plasminogen activator is a potent mitogen for human aortic smooth muscle cells.
Treatment of intact hepatocytes with either the phorbol ester TPA or glucagon elicits the phosphorylation and functional inactivation of the inhibitory guanine nucleotide regulatory protein Gi.
[Mechanism of the activation of extracellular signal-regulated kinase (ERK) in prostate cancer cell lines with different metastatic potential]
Wilms Tumor
Carcinoembryonic proteins produced by Wilms' tumor cells in vitro and in vivo.
Sarcomatous variants of Wilms' tumor. Immunohistochemical and ultrastructural comparison with classical Wilms' tumor.
The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter.
VDR-mediated gene expression patterns in resting human coronary artery smooth muscle cells.
Veno-occlusive disease in pediatric patients affected by Wilms tumor.
Wolff-Parkinson-White Syndrome
How cost-effective are new preventive strategies for cardiovascular disease?
Wound Infection
Psoas muscle size as a frailty measure for open and transcatheter aortic valve replacement.
Xeroderma Pigmentosum
Induction of plasminogen activator by UV light in normal and xeroderma pigmentosum fibroblasts.
[Plasminogen activator inhibitor activity of cultured cancer bearing and non-bearing xeroderma pigmentosum fibroblasts]
Yaws
Complete genome sequences of two strains of Treponema pallidum subsp. pertenue from Ghana, Africa: Identical genome sequences in samples isolated more than 7 years apart.
Macrolide Resistance in the Syphilis Spirochete, Treponema pallidum ssp. pallidum: Can We Also Expect Macrolide-Resistant Yaws Strains?
Yellow Fever
Coagulation factors, fibrinogen and plasminogen activator inhibitor-1, are differentially regulated by yellow fever virus infection of hepatocytes.
Yersinia Infections
Protective Roles for Fibrin, Tissue Factor, Plasminogen Activator Inhibitor-1, and Thrombin Activatable Fibrinolysis Inhibitor, but Not Factor XI, during Defense against the Gram-Negative Bacterium Yersinia enterocolitica.